,Unnamed: 0,nct_id,nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at,source_class,delayed_posting,expanded_access_nctid,expanded_access_status_for_nctid,fdaaa801_violation,baseline_type_units_analyzed
0,1,NCT00006478,,2000-11-06,2010-10-19,,2018-08-02,2003-01-26,2003-01-27,Estimate,2010-10-19,2010-11-17,Estimate,,,,2018-08-02,2018-09-04,Actual,September 2000,,2000-09-30,August 2018,2018-08-31,April 2008,Actual,2008-04-30,March 2008,Actual,2008-03-31,,Interventional,,,Vaccine Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma,Pilot Trial to Evaluate Immune Response Using Idiotype Vaccines Following High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Follicular Lymphoma,Terminated,,Phase 2,19.0,Actual,University of Nebraska,,,,"Genitope suspend drug development by decision made by the FDA March 6, 2008.",False,,,,,,,,,,,,,,,,,2023-06-16 20:46:38,2023-06-16 20:46:38,OTHER,,,,,
2,3,NCT00436007,,2007-02-15,2012-12-19,2012-02-02,2018-07-19,2007-02-15,2007-02-16,Estimate,2013-05-23,2013-05-27,Estimate,2012-02-02,2012-02-07,Estimate,2018-07-19,2018-08-16,Actual,"April 30, 2007",,2007-04-30,April 2017,2017-04-30,"October 7, 2009",Actual,2009-10-07,"September 15, 2008",Actual,2008-09-15,,Interventional,,,"Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen","Safety and Immunogenicity Study of GSK Biologicals' Investigational Vaccination Regimen Malaria Vaccine 257049, When Incorporated Into an Expanded Program on Immunization (EPI) Regimen That Includes Tritanrix HepB/Hib, OPV, Measles and Yellow Fever Vaccination in Infants",Completed,,Phase 2,511.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 20:46:40,2023-06-16 20:46:40,INDUSTRY,,,,,
126,127,NCT00127803,,2005-08-05,2012-03-13,,2012-09-07,2005-08-05,2005-08-09,Estimate,2012-04-19,2012-05-21,Estimate,,,,2012-09-07,2012-09-14,Estimate,July 2005,,2005-07-31,September 2012,2012-09-30,March 2006,Actual,2006-03-31,January 2006,Actual,2006-01-31,,Interventional,,,"Safety, Tolerability, and Immunogenicity Study of a Clostridium Difficile Toxoid Vaccine in Healthy Adult Volunteers","A Phase I Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study of the Safety, Tolerability and Immunogenicity of a Clostridium Difficile Toxoid Vaccine, Alum Adsorbed, in Healthy Adult Volunteers (18-55 Years)",Completed,,Phase 1,50.0,Actual,Sanofi,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 20:48:36,2023-06-16 20:48:36,INDUSTRY,,,,,
131,132,NCT01033409,,2009-11-16,,,2011-11-01,2009-12-15,2009-12-16,Estimate,,,,,,,2011-11-01,2011-11-02,Estimate,August 2009,,2009-08-31,November 2011,2011-11-30,July 2011,Actual,2011-07-31,July 2011,Actual,2011-07-31,,Interventional,,,Recombinant Attenuated Salmonella Typhi Vaccine Vectors Producing Streptococcus Pneumoniae PspA,Comparative Phase I Safety and Immunogenicity in Adult Volunteers of Three Recombinant Attenuated Salmonella Typhi Vaccine Vectors Producing Streptococcus Pneumoniae Surface Protein Antigen PspA,Completed,,Phase 1,60.0,Actual,Arizona State University,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 20:48:40,2023-06-16 20:48:40,OTHER,,,,,
320,321,NCT00718666,,2008-07-17,2017-09-28,2013-12-05,2019-06-11,2008-07-18,2008-07-21,Estimate,2018-07-26,2018-08-23,Actual,2013-12-05,2013-12-30,Estimate,2019-06-11,2019-06-26,Actual,"October 20, 2008",Actual,2008-10-20,June 2019,2019-06-30,"March 28, 2014",Actual,2014-03-28,"November 13, 2013",Actual,2013-11-13,,Interventional,,Baseline Period for Nimenrix 1 Group and Nimenrix 2 Group is considered Year 1 and Baseline Period for Nimenrix Naive Group is considered Year 5.,The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers,Long Term Antibody Persistence Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Administered as 1 or 2 Doses to Healthy Toddlers at 9-12 Months of Age and as a Booster Dose at 5 Years Post-primary Vaccination,Completed,,Phase 2,387.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-16 01:44:27,2023-06-16 01:44:27,INDUSTRY,,,,,
327,328,NCT00772954,,2008-10-10,2012-03-13,,2012-04-19,2008-10-10,2008-10-15,Estimate,2012-04-19,2012-05-21,Estimate,,,,2012-04-19,2012-05-21,Estimate,March 2006,,2006-03-31,April 2012,2012-04-30,June 2006,Actual,2006-06-30,June 2006,Actual,2006-06-30,,Interventional,,,"Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity","A Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study of the Safety, Tolerability and Immunogenicity of Two Doses of a Clostridium Difficile Toxoid Vaccine, Alum Adsorbed, in Healthy Adult Volunteers (18 - 55 Years)",Terminated,,Phase 1,36.0,Actual,Sanofi,,3.0,,Issues with CTM stability.,False,,,,False,,,,,,,,,,,,,2023-06-16 00:58:21,2023-06-16 00:58:21,INDUSTRY,,,,,
407,408,NCT00262028,,2005-12-02,2013-08-30,,2016-01-12,2005-12-02,2005-12-06,Estimate,2016-01-12,2016-02-11,Estimate,,,,2016-01-12,2016-02-11,Estimate,April 2005,,2005-04-30,January 2016,2016-01-31,November 2006,Actual,2006-11-30,November 2006,Actual,2006-11-30,,Interventional,,,Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children,"A Phase 2, Randomized, Single-blind, Controlled, Single-Center Study to Compare the Safety and Immunogenicity of One Dose of Chiron Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Polysaccharide Vaccine Administered to Healthy Children 2-10 Years of Age and an Open-label Study to Assess the Safety and Immunogenicity of One Dose of Chiron Meningococcal ACWY Conjugate Vaccine Administered to Healthy Toddlers 12-23 Months of Age",Completed,,Phase 2,910.0,Actual,Novartis,,5.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 20:51:12,2023-06-16 20:51:12,INDUSTRY,,,,,
416,417,NCT01068509,,2010-02-10,2016-03-29,,2017-04-04,2010-02-11,2010-02-15,Estimate,2016-06-23,2016-08-04,Estimate,,,,2017-04-04,2017-05-11,Actual,July 2010,,2010-07-31,June 2016,2016-06-30,April 2015,Actual,2015-04-30,August 2013,Actual,2013-08-31,,Interventional,,All participants: All participants enrolled in the study.,Ovarian Cancer Vaccine for Patients in Remission,"A Randomized, Open-label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (Cvac) for Epithelial Ovarian Cancer Patients in First or Second Remission",Completed,,Phase 2,63.0,Actual,Prima BioMed Ltd,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 00:58:36,2023-06-16 00:58:36,INDUSTRY,,,,,
547,548,NCT01073306,,2010-02-19,,,2012-12-31,2010-02-19,2010-02-23,Estimate,,,,,,,2012-12-31,2013-01-03,Estimate,February 2010,,2010-02-28,December 2012,2012-12-31,June 2010,Actual,2010-06-30,June 2010,Actual,2010-06-30,,Interventional,,,Safety and Immune Response to an Investigational Dengue Type 2 Vaccine,A Phase I Evaluation of the Safety and Immunogenicity of rDEN2/4 <U+0394>30(ME) Dengue Serotype 2 Vaccine Given at 10^1 PFU in Healthy Flavivirus-naïve Adult Subjects,Completed,,Phase 1,18.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 20:52:38,2023-06-16 20:52:38,NIH,,,,,
719,720,NCT04075201,,2019-08-28,,,2021-07-26,2019-08-28,2019-08-30,Actual,,,,,,,2021-07-26,2021-07-29,Actual,"July 7, 2019",Actual,2019-07-07,July 2021,2021-07-31,"July 25, 2021",Actual,2021-07-25,"May 30, 2021",Actual,2021-05-30,,Interventional,,,"Clinical Trial of Recombinant Hepatitis B Vaccine (Hansenula Polymorpha, 10µg)","A Phase <U+2160>Clinical Trial of Recombinant Hepatitis B Vaccine (Hansenula Polymorpha, 10µg) With an Open-labelled Design in Adults and a Randomized, Double-blinded, Positive Controlled Design in Children and Neonates",Completed,,Phase 1,144.0,Actual,"Sinovac Biotech Co., Ltd",,5.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-16 00:59:21,2023-06-16 00:59:21,INDUSTRY,,,,,
810,811,NCT03942406,,2019-05-02,,,2020-07-08,2019-05-06,2019-05-08,Actual,,,,,,,2020-07-08,2020-07-09,Actual,"June 15, 2019",Actual,2019-06-15,July 2020,2020-07-31,"June 24, 2020",Actual,2020-06-24,"February 14, 2020",Actual,2020-02-14,,Interventional,,,"Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults","Phase 2b Study of BPZE1 Intranasal Pertussis Vaccine in Adults to Assess Immunological Response and Safety Profile of 1-Dose (Prime) and 2-Doses (Prime+Boost) Schedule, Compared to a Boostrix Prime Dose With or Without a BPZE1 Boost Dose",Completed,,Phase 2,300.0,Actual,ILiAD Biotechnologies,,4.0,,,False,,,,True,True,True,True,,,,,,,,No,,2023-06-16 20:54:55,2023-06-16 20:54:55,INDUSTRY,,,,,
1243,1244,NCT01127464,,2010-05-19,,,2014-05-07,2010-05-19,2010-05-20,Estimate,,,,,,,2014-05-07,2014-05-08,Estimate,May 2010,,2010-05-31,May 2014,2014-05-31,November 2012,Actual,2012-11-30,November 2012,Actual,2012-11-30,,Interventional,,,DCVax Plus Poly ICLC in Healthy Volunteers,"A Randomized, Placebo-controlled, Dose-escalating, Double-blinded Phase I Study to Evaluate the Safety and Immunogenicity of Anti-DEC-205 Monoclonal Antibody (Mab) Targeted HIV Gag p24 Vaccine (DCVax-001) With Poly ICLC (Hiltonol) as Adjuvant in HIV-uninfected Healthy Volunteers",Completed,,Phase 1,43.0,Actual,Rockefeller University,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 20:59:03,2023-06-16 20:59:03,OTHER,,,,,
1254,1255,NCT01123954,,2010-03-24,,,2011-12-13,2010-05-13,2010-05-14,Estimate,,,,,,,2011-12-13,2011-12-14,Estimate,January 2010,,2010-01-31,December 2011,2011-12-31,April 2010,Actual,2010-04-30,March 2010,Actual,2010-03-31,,Interventional,,,Evaluating the Safeness of Trivalent Subunit Inactivated Influenza Vaccines in Preventing Flu on Vietnamese Volunteers,Evaluating the Safeness of Trivalent Subunit Inactivated Influenza Vaccines in Preventing Flu on Vietnamese Volunteers,Completed,,Phase 2,33.0,Actual,Novartis,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 20:59:14,2023-06-16 20:59:14,INDUSTRY,,,,,
1305,1306,NCT04341389,,2020-04-07,,,2023-05-22,2020-04-09,2020-04-10,Actual,,,,,,,2023-05-22,2023-05-24,Actual,"April 12, 2020",Actual,2020-04-12,May 2023,2023-05-31,"December 31, 2020",Actual,2020-12-31,"November 30, 2020",Actual,2020-11-30,,Interventional,CTII-nCoV,,A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector),"A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years",Completed,,Phase 2,508.0,Actual,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-19 03:59:47,2023-06-19 03:59:47,OTHER,,,,,
1312,1313,NCT04087252,,2019-09-03,,,2020-04-13,2019-09-11,2019-09-12,Actual,,,,,,,2020-04-13,2020-04-15,Actual,"September 4, 2019",Actual,2019-09-04,August 2019,2019-08-31,"December 30, 2021",Anticipated,2021-12-30,"October 30, 2021",Anticipated,2021-10-30,,Interventional,,,An Immunogenic Personal Neoantigen Vaccine for Cancer Treatment,PhaseI Trial of Tumor Neoantigen Vaccine,Unknown status,Recruiting,Phase 1,30.0,Anticipated,Henan Cancer Hospital,,1.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-16 01:44:41,2023-06-16 01:44:41,OTHER_GOV,,,,,
1424,1425,NCT01226758,,2010-10-21,,,2012-11-01,2010-10-21,2010-10-22,Estimate,,,,,,,2012-11-01,2012-11-02,Estimate,June 2010,,2010-06-30,November 2012,2012-11-30,December 2010,Actual,2010-12-31,December 2010,Actual,2010-12-31,,Interventional,,,Influenza Vaccine Challenge Study in Healthy Subjects,"A Randomised Double-blind, Placebo-controlled, Phase 1b Trial to Evaluate the Safety, Tolerability and Protective Efficacy of the Influenza Vaccine Candidate, FLU-v, in an Influenza Challenge Model",Completed,,Phase 1,32.0,Actual,PepTcell Limited,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 21:00:50,2023-06-16 21:00:50,INDUSTRY,,,,,
1559,1560,NCT03926416,,2019-04-18,,,2020-07-21,2019-04-23,2019-04-24,Actual,,,,,,,2020-07-21,2020-07-23,Actual,"February 21, 2017",Actual,2017-02-21,April 2019,2019-04-30,"September 14, 2018",Actual,2018-09-14,"May 29, 2018",Actual,2018-05-29,,Interventional,,,"Safety Study of Live Attenuated Influenza Vaccine, CodaVax","A Randomised, Double-Blind, Double-Dummy, Active and Placebo Controlled Phase I Trial of the Safety, Tolerability and Immunogenicity of the CodaVax Influenza Vaccine",Completed,,Phase 1,125.0,Actual,"Codagenix, Inc",,4.0,,,False,,,,,True,False,,,True,,,,,,No,,2023-06-16 21:02:11,2023-06-16 21:02:11,INDUSTRY,,,,,
1861,1862,NCT01234012,,2010-10-26,,,2015-03-09,2010-11-03,2010-11-04,Estimate,,,,,,,2015-03-09,2015-03-10,Estimate,May 2011,,2011-05-31,March 2015,2015-03-31,March 2014,Actual,2014-03-31,November 2013,Actual,2013-11-30,,Interventional,,,Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1,A Phase I Study of Therapeutic Cancer Vaccine IMF-001 in Patients With Malignancies Expressing NY-ESO-1,Completed,,Phase 1,23.0,Actual,"ImmunoFrontier, Inc.",,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 21:05:15,2023-06-16 21:05:15,INDUSTRY,,,,,
2106,2107,NCT01142362,,2010-05-27,,,2017-09-11,2010-06-10,2010-06-11,Estimate,,,,,,,2017-09-11,2017-09-13,Actual,June 2010,,2010-06-30,September 2017,2017-09-30,November 2011,Actual,2011-11-30,November 2011,Actual,2011-11-30,,Interventional,,,"Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults","Phase I, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity in Healthy Adults of a DNA Plasmid Vaccine for H5 Avian Influenza (VGX-3400X) Administered by Intramuscular (IM) Injection Followed by Electroporation (EP)",Completed,,Phase 1,32.0,Actual,Inovio Pharmaceuticals,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 21:08:18,2023-06-16 21:08:18,INDUSTRY,,,,,
2145,2146,NCT01236040,,2010-10-28,,,2017-05-09,2010-11-04,2010-11-07,Estimate,,,,,,,2017-05-09,2017-05-10,Actual,"November 29, 2010",Actual,2010-11-29,May 2017,2017-05-31,"August 20, 2012",Actual,2012-08-20,"September 6, 2011",Actual,2011-09-06,,Interventional,,,Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old,Immunogenicity and Safety Study of GSK Biologicals' Cell Culture Derived Pandemic Influenza Vaccines GSK2590066A and GSK2592984A Administered to Healthy Adults 18 - 49 Years Old,Completed,,Phase 1,521.0,Actual,GlaxoSmithKline,,6.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 21:09:01,2023-06-16 21:09:01,INDUSTRY,,,,,
2258,2259,NCT00197028,,2005-09-13,2012-12-13,2009-05-29,2018-07-19,2005-09-13,2005-09-20,Estimate,2012-12-13,2013-01-18,Estimate,2009-10-01,2009-10-02,Estimate,2018-07-19,2018-08-20,Actual,"August 23, 2005",,2005-08-23,April 2017,2017-04-30,"December 27, 2007",Actual,2007-12-27,"December 27, 2007",Actual,2007-12-27,,Interventional,,,Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region,"A Phase I/IIb Randomized, Double-blind, Controlled Study of the Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02D, a Candidate Malaria Vaccine in Infants Living in a Malaria-endemic Region",Completed,,Phase 2,214.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 21:10:13,2023-06-16 21:10:13,INDUSTRY,,,,,
3032,3033,NCT01265914,,2010-12-22,,,2012-03-23,2010-12-22,2010-12-23,Estimate,,,,,,,2012-03-23,2012-03-26,Estimate,August 2010,,2010-08-31,March 2012,2012-03-31,August 2011,Actual,2011-08-31,March 2011,Actual,2011-03-31,,Interventional,,,"A Study to Evaluate the Safety, Tolerability and Immunogenicity of a Universal Influenza A Vaccine","A Randomised, Double-Blind, Placebo-Controlled, Ascending Dose Study to Assess the Safety, Tolerability and Immunogenicity of Repeated Intramuscular Administration of an Influenza A Vaccine (FP-01.1)",Completed,,Phase 1,49.0,Actual,Immune Targeting Systems Ltd,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 21:16:17,2023-06-16 21:16:17,INDUSTRY,,,,,
3095,3096,NCT01266616,,2010-12-23,,,2021-10-28,2010-12-23,2010-12-24,Estimate,,,,,,,2021-10-28,2021-11-01,Actual,March 2011,,2011-03-31,October 2021,2021-10-31,April 2013,Actual,2013-04-30,October 2012,Actual,2012-10-31,,Interventional,,,Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults,"A Phase I Randomized, Partially Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of a Cytokine Enhanced HIV-1 Multi-Antigen (HIV MAG) pDNA Vaccine Delivered Intramuscularly Followed by in Vivo Electroporation (IM/EP) or Intramuscularly in HIV-1 Infected Adults Receiving ART",Completed,,Phase 1,62.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,10.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 21:16:48,2023-06-16 21:16:48,NIH,,,,,
3586,3587,NCT01941056,,2013-09-05,,,2017-07-31,2013-09-09,2013-09-13,Estimate,,,,,,,2017-07-31,2017-08-02,Actual,"January 5, 2014",Actual,2014-01-05,July 2017,2017-07-31,"July 28, 2017",Actual,2017-07-28,"July 28, 2017",Actual,2017-07-28,,Interventional,,,Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus,Phase I Evaluation of a CMV-MVA Triplex Vaccine: Safety and Biologically Effective Dose in Healthy Volunteers With or Without Prior Immunity to CMV and Vaccinia,Completed,,Phase 1,24.0,Actual,City of Hope Medical Center,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 00:46:36,2023-06-15 00:46:36,OTHER,,,,,
3595,3596,NCT01164514,,2010-07-15,,,2014-01-30,2010-07-15,2010-07-16,Estimate,,,,,,,2014-01-30,2014-01-31,Estimate,November 2011,,2011-11-30,August 2012,2012-08-31,February 2013,Actual,2013-02-28,February 2013,Actual,2013-02-28,,Interventional,,,Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant,"A Randomized, Partial-Blinded, Placebo-Controlled, Phase I Safety and Immunogenicity Study in Healthy Subjects of Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram Negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant",Terminated,,Phase 1,20.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 21:21:35,2023-06-16 21:21:35,NIH,,,,,
3649,3650,NCT01175122,,2010-08-03,,,2013-02-08,2010-08-03,2010-08-04,Estimate,,,,,,,2013-02-08,2013-02-11,Estimate,September 2010,,2010-09-30,February 2013,2013-02-28,April 2011,Actual,2011-04-30,April 2011,Actual,2011-04-30,,Interventional,,,Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza,"Phase 1 Evaluation of the Safety and Immunogenicity of Live Influenza A Vaccine H2N3 (6-2) AA ca Recombinant (A/Swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H2N3 Infection in the Event of a Pandemic",Completed,,Phase 1,20.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 21:22:08,2023-06-16 21:22:08,NIH,,,,,
4263,4264,NCT04793620,,2021-03-04,,,2022-10-28,2021-03-10,2021-03-11,Actual,,,,,,,2022-10-28,2022-11-01,Actual,"April 6, 2021",Actual,2021-04-06,October 2022,2022-10-31,"February 14, 2022",Actual,2022-02-14,"August 23, 2021",Actual,2021-08-23,,Interventional,,,Pertussis Acellular Vaccine Adjuvanted With TQL1055,"A Phase 1, Randomized, Double Blind, Active-Controlled Dose-Escalation Study to Assess the Safety and Immunogenicity of Pertussis Acellular Vaccine Adjuvanted With TQL1055 (PAVA)",Terminated,,Phase 1,72.0,Actual,"Adjuvance Technologies, Inc.",,2.0,,financial constraints,False,,,,False,False,False,,,,,,,,,No,,2023-06-16 21:28:42,2023-06-16 21:28:42,INDUSTRY,,,,,
4405,4406,NCT01941758,,2013-09-10,,,2018-07-02,2013-09-12,2013-09-13,Estimate,,,,,,,2018-07-02,2018-07-05,Actual,November 2013,,2013-11-30,July 2018,2018-07-31,November 2014,Actual,2014-11-30,November 2014,Actual,2014-11-30,,Interventional,,,High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors,A Pilot Single Arm Study of High-Dose Influenza Vaccine Immunogenicity in Patients With Central Nervous System Tumors,Completed,,Phase 1,28.0,Actual,Wake Forest University Health Sciences,,1.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-15 00:47:03,2023-06-15 00:47:03,OTHER,,,,,
4574,4575,NCT03813940,,2019-01-09,,,2021-04-07,2019-01-22,2019-01-23,Actual,,,,,,,2021-04-07,2021-04-08,Actual,"January 3, 2019",Actual,2019-01-03,April 2021,2021-04-30,"April 1, 2021",Actual,2021-04-01,"August 18, 2019",Actual,2019-08-18,,Interventional,,,"Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)","An Open-Label, Single-Center Phase I Clinical Trial to Estimate Safety of the Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type) (E.Coli) in Healthy Adults Aged 18 to 45 Years",Completed,,Phase 1,24.0,Actual,Xiamen University,,2.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-16 21:31:59,2023-06-16 21:31:59,OTHER,,,,,
4583,4584,NCT05264974,,2022-02-22,,,2023-01-17,2022-02-22,2022-03-03,Actual,,,,,,,2023-01-17,2023-01-18,Actual,June 2023,Anticipated,2023-06-30,January 2023,2023-01-31,July 2027,Anticipated,2027-07-31,July 2025,Anticipated,2025-07-31,,Interventional,,,Novel RNA-nanoparticle Vaccine for the Treatment of Early Melanoma Recurrence Following Adjuvant Anti-PD-1 Antibody Therapy,Novel RNA-nanoparticle Vaccine for the Treatment of Early Melanoma Recurrence Following Adjuvant Anti-PD-1 Antibody Therapy,Not yet recruiting,,Phase 1,18.0,Anticipated,University of Florida,,1.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-16 21:32:14,2023-06-16 21:32:14,OTHER,,,,,
4640,4641,NCT01302496,,2011-02-23,,,2021-03-24,2011-02-23,2011-02-24,Estimate,,,,,,,2021-03-24,2021-03-29,Actual,February 2011,Actual,2011-02-28,March 2021,2021-03-31,January 2017,Actual,2017-01-31,October 2013,Actual,2013-10-31,,Interventional,TriMix-Ipi,,Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma,A Two-stage Phase II Study of Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma,Completed,,Phase 2,39.0,Actual,Universitair Ziekenhuis Brussel,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 21:32:55,2023-06-16 21:32:55,OTHER,,,,,
4779,4780,NCT04742842,,2021-01-28,,,2022-11-17,2021-02-03,2021-02-08,Actual,,,,,,,2022-11-17,2022-11-21,Actual,"June 21, 2021",Actual,2021-06-21,November 2022,2022-11-30,"July 30, 2023",Anticipated,2023-07-30,"July 30, 2022",Actual,2022-07-30,,Interventional,COVALIA,,The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers,"A Phase I, Double-blind, Dose-ranging, Randomised, Placebo-controlled Trial to Study the Safety and Immunogenicity of a DNA-based Vaccine Against COVID-19 (COVIGEN) in Healthy Participants Aged 18 to 75 Years Old","Active, not recruiting",,Phase 1,68.0,Actual,University of Sydney,,5.0,,,False,,,,True,False,False,,,,,,,,,Undecided,,2023-06-16 21:34:32,2023-06-16 21:34:32,OTHER,,,,,
4834,4835,NCT03799510,,2019-01-08,,,2019-12-05,2019-01-09,2019-01-10,Actual,,,,,,,2019-12-05,2019-12-09,Actual,"December 13, 2018",Actual,2018-12-13,December 2019,2019-12-31,"August 7, 2019",Actual,2019-08-07,"July 1, 2019",Actual,2019-07-01,,Interventional,,,Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children,"Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 Against Schistosomiasis in Senegalese School Children Healthy or Infected With S. Mansoni and/or S. Haematobium. A Comparative, Randomized, Controlled, Open-label Trial",Completed,,Phase 2,95.0,Actual,Oswaldo Cruz Foundation,,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-16 21:35:15,2023-06-16 21:35:15,OTHER,,,,,
4906,4907,NCT01015703,,2009-11-17,2014-06-04,,2014-09-09,2009-11-17,2009-11-18,Estimate,2014-09-09,2014-09-15,Estimate,,,,2014-09-09,2014-09-15,Estimate,November 2009,,2009-11-30,September 2014,2014-09-30,June 2010,Actual,2010-06-30,June 2010,Actual,2010-06-30,,Interventional,,"Safety population, subjects who received at least one dose of test article",Open-label Safety and Tolerability Study of CoVaccine HT in Healthy Volunteers,"A Phase 1, Open-Label, Dose Escalation Study of the Safety and Tolerability of CoVaccine HT in Healthy Adult Volunteers",Completed,,Phase 1,50.0,Actual,BTG International Inc.,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 01:07:51,2023-06-16 01:07:51,OTHER,,,,,
5878,5879,NCT00129116,,2005-08-10,2012-06-15,,2018-07-26,2005-08-10,2005-08-11,Estimate,2012-06-15,2012-07-23,Estimate,,,,2018-07-26,2018-08-27,Actual,"March 1, 2003",,2003-03-01,October 2016,2016-10-31,"December 16, 2003",Actual,2003-12-16,"December 1, 2003",Actual,2003-12-01,,Interventional,,,"3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age","A Phase II, Open (Partially Double-blind), Randomised, Controlled, Multicentre, Primary Vaccination Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Three Different Formulations of GSK Biologicals' Combined Haemophilus Influenzae Type B-meningococcal Serogroups C and Y- Conjugate Vaccine and One Formulation of GSK Biologicals' Haemophilus Influenzae Type B-meningococcal Serogroup C Conjugate Vaccine Each Given Concomitantly With InfanrixTM Penta, Versus MeningitecTM, Given Concomitantly With InfanrixTM Hexa in Infants According to a 2-3-4 Month Schedule",Completed,,Phase 2,388.0,Actual,GlaxoSmithKline,,5.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 21:47:54,2023-06-16 21:47:54,INDUSTRY,,,,,
6128,6129,NCT04090528,,2019-09-12,,,2022-11-21,2019-09-12,2019-09-16,Actual,,,,,,,2022-11-21,2022-11-22,Actual,"October 21, 2019",Actual,2019-10-21,November 2022,2022-11-30,December 2025,Anticipated,2025-12-31,December 2023,Anticipated,2023-12-31,,Interventional,,,"pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer","Phase II Trial of pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer",Recruiting,,Phase 2,60.0,Anticipated,"University of Wisconsin, Madison",,2.0,,,,,,,True,True,False,,,,,,,,,No,,2023-06-16 21:50:45,2023-06-16 21:50:45,OTHER,,,,,
6211,6212,NCT00095576,,2004-11-05,2011-07-20,,2015-10-05,2004-11-05,2004-11-08,Estimate,2011-07-20,2011-08-15,Estimate,,,,2015-10-05,2015-10-06,Estimate,November 2004,,2004-11-30,October 2015,2015-10-31,September 2009,Actual,2009-09-30,September 2007,Actual,2007-09-30,,Interventional,,,Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023),"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase II Proof-of-Concept Study to Evaluate the Safety and Efficacy of a 3-Dose Regimen of the Merck Adenovirus Serotype 5 HIV-1 Gag/Pol/Nef Vaccine (MRK AD5 HIV-1 Gag/Pol/Nef) in Adults at High Risk of HIV-1 Infection",Terminated,,Phase 2,3000.0,Actual,Merck Sharp & Dohme LLC,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 21:51:51,2023-06-16 21:51:51,INDUSTRY,,,,,
6336,6337,NCT03682120,,2018-09-20,2021-04-22,,2021-04-22,2018-09-20,2018-09-24,Actual,2021-04-22,2021-05-17,Actual,,,,2021-04-22,2021-05-17,Actual,"November 2, 2018",Actual,2018-11-02,"September 13, 2018",2018-09-13,"April 30, 2020",Actual,2020-04-30,"April 30, 2020",Actual,2020-04-30,,Interventional,,The baseline analysis population includes all enrolled participants,Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza,"A Phase II Study in Healthy Adults 18-64 Years Old to Assess the Safety, Reactogenicity and Immunogenicity of a Seqirus A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without MF59(R) Adjuvant",Completed,,Phase 2,372.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-16 21:53:19,2023-06-16 21:53:19,NIH,,,,,
6518,6519,NCT00391391,,2006-10-23,2011-10-12,2010-03-30,2011-11-21,2006-10-23,2006-10-24,Estimate,2011-10-12,2011-11-22,Estimate,2010-03-31,2010-04-02,Estimate,2011-11-21,2011-12-01,Estimate,October 2006,,2006-10-31,November 2011,2011-11-30,October 2007,Actual,2007-10-31,March 2007,Actual,2007-03-31,,Interventional,,,"Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children","Immunogenicity and Safety of a Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in Comparison With Intramuscular Vaccination With Standard Fluzone® in Healthy Infants and Young Children.",Completed,,Phase 2,520.0,Actual,Sanofi,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 21:56:03,2023-06-16 21:56:03,INDUSTRY,,,,,
6607,6608,NCT00388583,,2006-10-16,2011-07-14,2010-03-30,2012-04-13,2006-10-16,2006-10-17,Estimate,2011-08-10,2011-09-13,Estimate,2010-03-31,2010-04-02,Estimate,2012-04-13,2012-04-18,Estimate,September 2006,,2006-09-30,April 2012,2012-04-30,September 2008,Actual,2008-09-30,June 2007,Actual,2007-06-30,,Interventional,,,"Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects","Immunogenicity and Safety of The Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in Comparison With Intramuscular Vaccination With Standard Fluzone® in Ambulatory Elderly Subjects",Completed,,Phase 2,817.0,Actual,Sanofi,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 21:57:17,2023-06-16 21:57:17,INDUSTRY,,,,,
6617,6618,NCT00387725,,2006-10-11,2014-11-14,,2014-11-14,2006-10-12,2006-10-13,Estimate,2014-11-14,2014-11-21,Estimate,,,,2014-11-14,2014-11-21,Estimate,November 2006,,2006-11-30,November 2014,2014-11-30,February 2008,Actual,2008-02-29,January 2008,Actual,2008-01-31,,Interventional,,,Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Adolescents,"A Randomized, Observer-blinded, Parallel-group, Active-control, Phase ½ Trial Of The Safety, Immunogenicity, And Tolerability Of 20 Mg, 60 Mg, And 200 Mg Of Meningococcal Group B Rlp2086 Vaccine In Healthy Children And Adolescents Aged 8 To 14 Years",Completed,,Phase 2,127.0,Actual,Pfizer,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 21:57:27,2023-06-16 21:57:27,INDUSTRY,,,,,
6622,6623,NCT01086566,,2010-03-11,,,2015-12-31,2010-03-11,2010-03-15,Estimate,,,,,,,2015-12-31,2016-01-01,Estimate,October 2010,,2010-10-31,May 2012,2012-05-31,February 2012,Actual,2012-02-29,February 2012,Actual,2012-02-29,,Interventional,,,Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines,Evaluation of the Safety and Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines Representing Different Clades,Completed,,Phase 1,95.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 21:57:29,2023-06-16 21:57:29,NIH,,,,,
6687,6688,NCT01091298,,2010-03-17,,,2011-06-07,2010-03-20,2010-03-24,Estimate,,,,,,,2011-06-07,2011-06-08,Estimate,April 2010,,2010-04-30,June 2011,2011-06-30,May 2010,Actual,2010-05-31,May 2010,Actual,2010-05-31,,Interventional,,,A Study to Evaluate the Safety of Tetravalent Rotavirus Vaccine in Healthy Indian Adult Male Volunteers,Phase I Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Tolerability of a Single Administration (10e6.25 FFU of Each Constituent Serotype Per 0.5 ml) of Live Attenuated Tetravalent (G1-G4) Bovine-human Reassortant Rotavirus Vaccine [BRV-TV] Administered to Healthy Indian Adult Males,Completed,,Phase 1,20.0,Anticipated,Shantha Biotechnics Limited,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 21:58:29,2023-06-16 21:58:29,INDUSTRY,,,,,
6838,6839,NCT00380393,,2006-09-25,2017-08-25,2009-09-03,2018-06-04,2006-09-25,2006-09-26,Estimate,2018-06-04,2018-07-03,Actual,2009-09-03,2009-09-04,Estimate,2018-06-04,2018-07-03,Actual,"January 3, 2007",Actual,2007-01-03,November 2017,2017-11-30,"November 11, 2008",Actual,2008-11-11,"August 15, 2008",Actual,2008-08-15,,Interventional,,,"Efficacy of RTS,S/AS01 Vaccine Against Episodes of Malaria Due to P. Falciparum Infection in Children.","A Study of the Efficacy Against Episodes of Clinical Malaria Due to P. Falciparum Infection of GSK Biologicals Candidate Vaccine RTS,S/AS01, Administered According to a 0,1,2-months Schedule in Children Aged 5 to 17 Months Living in Tanzania & Kenya",Completed,,Phase 2,894.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 22:00:59,2023-06-16 22:00:59,INDUSTRY,,,,,
7173,7174,NCT03583606,,2018-06-28,2021-01-07,,2021-05-06,2018-06-28,2018-07-11,Actual,2021-05-06,2021-06-02,Actual,,,,2021-05-06,2021-06-02,Actual,"November 12, 2018",Actual,2018-11-12,"July 15, 2020",2020-07-15,"January 14, 2020",Actual,2020-01-14,"January 14, 2020",Actual,2020-01-14,,Interventional,,,A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z),"A Systems Biology Phase 1 Evaluation of the Safety, Reactogenicity, and Immunogenicity of Chimpanzee Adenovirus Type 3- Vectored Zaire Ebolavirus (ChAd3-EBO-Z) and Modified Vaccinia Ankara- Vectored Multivalent Filovirus (MVA-BN(R)-Filo) Vaccine Candidates",Completed,,Phase 1,61.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-16 22:06:00,2023-06-16 22:06:00,NIH,,,,,
7438,7439,NCT05868733,,2023-05-08,,,2023-05-19,2023-05-19,2023-05-22,Actual,,,,,,,2023-05-19,2023-05-22,Actual,July 2023,Anticipated,2023-07-31,May 2023,2023-05-31,February 2027,Anticipated,2027-02-28,August 2026,Anticipated,2026-08-31,,Interventional,,,A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa,"A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of rVSV<U+2206>G-LASV-GPC Vaccine in Adults and Children Residing in West Africa",Not yet recruiting,,Phase 2,612.0,Anticipated,International AIDS Vaccine Initiative,,10.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-16 22:08:22,2023-06-16 22:08:22,NETWORK,,,,,
7666,7667,NCT05644067,,2022-10-27,,,2023-05-19,2022-12-01,2022-12-09,Actual,,,,,,,2023-05-19,2023-05-22,Actual,July 2023,Anticipated,2023-07-31,October 2022,2022-10-31,May 2024,Anticipated,2024-05-31,May 2024,Anticipated,2024-05-31,,Interventional,SUM-101,,Assessment of the Malaria Vaccine Candidate SumayaVac-1 in Healthy Adults Aged 18-45 Years Living in a Malaria Endemic Country,"A Randomised, Controlled, Double-blind, Parallel Group, Single Center Phase Ib Trial to Assess Safety, Reactogenicity, Immunogenicity and Parasite Growth Rates After Controlled Human Malaria Infection of a Candidate Dual-stage Malaria Vaccine, SumayaVac-1 (MSP-1 With GLA-SE as Adjuvant) in Healthy Malaria Exposed Adults of African Origin Aged 18-45 Years",Not yet recruiting,,Phase 1,40.0,Anticipated,Swiss Tropical & Public Health Institute,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-16 22:10:16,2023-06-16 22:10:16,OTHER,,,,,
7686,7687,NCT05584202,,2022-10-14,,,2023-05-19,2022-10-14,2022-10-18,Actual,,,,,,,2023-05-19,2023-05-22,Actual,"September 30, 2022",Actual,2022-09-30,May 2023,2023-05-31,"March 8, 2025",Anticipated,2025-03-08,"March 8, 2024",Anticipated,2024-03-08,,Interventional,BabyCOVE,,"Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants","A Phase 2, Two-Part Study (Open-Label [Part 1] Followed by Observer-Blind/Randomized [Part 2]) to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 Vaccine in Participants Aged 12 Weeks to < 6 Months",Recruiting,,Phase 2,700.0,Anticipated,"ModernaTX, Inc.",,4.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-16 22:10:27,2023-06-16 22:10:27,INDUSTRY,,,,,
7806,7807,NCT05011123,,2021-08-17,,2023-05-16,2023-05-16,2021-08-17,2021-08-18,Actual,,,,2023-05-16,2023-05-22,Actual,2023-05-16,2023-05-22,Actual,"October 7, 2021",Actual,2021-10-07,January 2023,2023-01-31,"April 25, 2028",Anticipated,2028-04-25,"May 23, 2022",Actual,2022-05-23,,Interventional,,,Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia,Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to Stamaril in Adults,"Active, not recruiting",,Phase 2,690.0,Actual,Sanofi,,2.0,,,False,,,,True,True,False,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-16 22:11:46,2023-06-16 22:11:46,INDUSTRY,,,,,
8095,8096,NCT05409261,,2022-04-01,,,2022-06-07,2022-06-07,2022-06-08,Actual,,,,,,,2022-06-07,2022-06-08,Actual,June 2022,Anticipated,2022-06-30,June 2022,2022-06-30,July 2024,Anticipated,2024-07-31,August 2022,Anticipated,2022-08-31,,Interventional,CoviCompMali,,Evaluation of the Immunogenicity and Safety of COVID-19 Vaccines (Ad26.COV2.S and NVX-CoV2373),Phase II Trial Evaluating the Immunogenicity and Safety of Ad26.COV2.S and NVX-CoV2373 Vaccines in Adult Participants in Mali,Not yet recruiting,,Phase 2,400.0,Anticipated,"ANRS, Emerging Infectious Diseases",,2.0,,,False,,,,,False,False,,,,,,,,,Yes,,2023-06-15 00:50:44,2023-06-15 00:50:44,OTHER_GOV,,,,,
8219,8220,NCT05409196,,2021-10-18,,,2022-06-03,2022-06-03,2022-06-08,Actual,,,,,,,2022-06-03,2022-06-08,Actual,"September 16, 2020",Actual,2020-09-16,June 2022,2022-06-30,"June 21, 2021",Actual,2021-06-21,"June 21, 2021",Actual,2021-06-21,,Interventional,,,"Phase 1 Trial for Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Oral Shigella/ETEC Combination Vaccine to Healthy Adults","Phase 1 Two Stage Randomized, Double-blind, Placebo Controlled Dose- and Schedule Ranging Trial to Assess the Acute Safety, Tolerability, and Immunogenicity of a Live, Attenuated Shigella/ETEC Combination Vaccine Delivered Orally to Healthy Adults Age 18 to 45 Years Old",Completed,,Phase 1,84.0,Actual,Eveliqure Biotechnologies GmbH,,2.0,,,False,,,,,False,False,,,,,,,,,Undecided,,2023-06-15 00:50:47,2023-06-15 00:50:47,INDUSTRY,,,,,
8351,8352,NCT04977479,,2021-07-24,,,2023-03-21,2021-07-24,2021-07-27,Actual,,,,,,,2023-03-21,2023-03-23,Actual,"September 8, 2021",Actual,2021-09-08,January 2023,2023-01-31,"February 22, 2023",Actual,2023-02-22,"June 17, 2022",Actual,2022-06-17,,Interventional,,,The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose,"A Randomized, Placebo-controlled Crossover Study to Assess the Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose",Completed,,Phase 2,17.0,Actual,National Institutes of Health Clinical Center (CC),,2.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-16 22:17:40,2023-06-16 22:17:40,NIH,,,,,
8452,8453,NCT04520659,,2020-08-13,,,2023-03-21,2020-08-18,2020-08-20,Actual,,,,,,,2023-03-21,2023-03-23,Actual,"February 23, 2022",Actual,2022-02-23,March 2023,2023-03-31,December 2024,Anticipated,2024-12-31,June 2024,Anticipated,2024-06-30,,Interventional,,,"Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/<U+0394>M2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age","Phase Ib Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/<U+0394>M2-2/1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age",Recruiting,,Phase 1,81.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,True,True,False,,,,,,After publication,Qualified researchers,,Yes,Qualified researchers may request access to IPD that underlie results in a publication. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants.,2023-06-16 22:18:41,2023-06-16 22:18:41,NIH,,,,,
8660,8661,NCT01893554,,2013-07-02,,,2023-03-21,2013-07-02,2013-07-09,Estimate,,,,,,,2023-03-21,2023-03-23,Actual,"June 1, 2013",Actual,2013-06-01,March 2023,2023-03-31,"October 1, 2025",Anticipated,2025-10-01,"April 30, 2023",Anticipated,2023-04-30,,Interventional,,,Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children,"A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV <U+0394>NS2 <U+0394>1313 I1314L, Lot RSV#006A, Delivered as Nose Drops to RSV-Seropositive Children 12 to 59 Months of Age, RSV-Seronegative Infants and Children 6 to 24 Months of Age, and Infants 4 to 6 Months of Age","Active, not recruiting",,Phase 1,88.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,8.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 22:21:16,2023-06-16 22:21:16,NIH,,,,,
8997,8998,NCT03481816,,2018-03-28,2020-09-25,,2021-04-28,2018-03-28,2018-03-29,Actual,2020-11-30,2020-12-22,Actual,,,,2021-04-28,2021-05-19,Actual,"July 24, 2018",Actual,2018-07-24,April 2021,2021-04-30,"March 9, 2021",Actual,2021-03-09,"January 15, 2020",Actual,2020-01-15,,Interventional,,We did not need to dose de-escalate since none of patient's had dose limiting toxicity (DLT) so all patients received planned higher starting dose in Arm 1/Dose De-escalation Arm/Group.,Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines,Treatment of Patients With Castration Resistant Prostate Cancer Using a Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines,Completed,,Phase 1,18.0,Actual,National Institutes of Health Clinical Center (CC),,2.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-16 22:25:24,2023-06-16 22:25:24,NIH,,,,,
9005,9006,NCT01093664,,2009-09-02,,,2010-10-18,2010-03-25,2010-03-26,Estimate,,,,,,,2010-10-18,2010-10-19,Estimate,October 2009,,2009-10-31,October 2010,2010-10-31,July 2010,Actual,2010-07-31,July 2010,Actual,2010-07-31,,Interventional,,,"Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02","Phase IB Follow-up Study to Assess a Boost Immunization With AFFITOPE AD02 With Regard to Safety/Tolerability, Immunological and Clinical Activity in Alzheimer Patients Who Have Received the Vaccine Within the Clinical Study AFF002",Completed,,Phase 1,20.0,Actual,Affiris AG,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 22:25:30,2023-06-16 22:25:30,INDUSTRY,,,,,
9069,9070,NCT00722839,,2008-07-25,,,2012-06-21,2008-07-25,2008-07-28,Estimate,,,,,,,2012-06-21,2012-06-25,Estimate,December 2006,,2006-12-31,June 2012,2012-06-30,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,,,Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants,A Phase I Dose Escalation Study of Peptide Vaccines With Activity Against Human Cytomegalovirus,Completed,,Phase 1,68.0,Actual,City of Hope Medical Center,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 01:11:54,2023-06-16 01:11:54,OTHER,,,,,
9258,9259,NCT03409276,,2018-01-09,2021-10-25,,2022-03-28,2018-01-17,2018-01-24,Actual,2022-03-28,2022-04-25,Actual,,,,2022-03-28,2022-04-25,Actual,"March 16, 2018",Actual,2018-03-16,March 2022,2022-03-31,"October 22, 2020",Actual,2020-10-22,"May 11, 2020",Actual,2020-05-11,,Interventional,,,"Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults","A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Polyvalent Env (A,B,C,A/E) / Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV-1 Vaccines (PDPHV-201401) as a Prime-boost Regimen or Co-administered in Repeated Doses, in Healthy, HIV-1-Uninfected Adult Participants",Completed,,Phase 1,60.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,6.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-16 22:29:27,2023-06-16 22:29:27,NIH,,,,,
9306,9307,NCT01095848,,2010-03-26,,,2015-12-14,2010-03-26,2010-03-30,Estimate,,,,,,,2015-12-14,2015-12-15,Estimate,March 2010,,2010-03-31,December 2015,2015-12-31,November 2011,Actual,2011-11-30,April 2011,Actual,2011-04-30,,Interventional,,,"A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer","A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer",Completed,,Phase 1,23.0,Actual,"ImmunoVaccine Technologies, Inc. (IMV Inc.)",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 22:30:15,2023-06-16 22:30:15,INDUSTRY,,,,,
9847,9848,NCT04348747,,2020-04-13,,,2023-05-02,2020-04-13,2020-04-16,Actual,,,,,,,2023-05-02,2023-05-03,Actual,"December 19, 2022",Actual,2022-12-19,May 2023,2023-05-31,"April 15, 2025",Anticipated,2025-04-15,"April 15, 2024",Anticipated,2024-04-15,,Interventional,,,Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer,A Phase IIa Study of Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab in Patients With Asymptomatic Brain Metastasis From Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC),Recruiting,,Phase 2,23.0,Anticipated,Roswell Park Cancer Institute,,1.0,,,False,,,,True,True,False,,,True,,,,,,,,2023-06-16 22:37:13,2023-06-16 22:37:13,OTHER,,,,,
10134,10135,NCT00397943,,2006-11-09,2017-08-10,2012-03-09,2019-06-06,2006-11-09,2006-11-10,Estimate,2018-03-12,2018-08-13,Actual,2012-03-09,2012-03-14,Estimate,2019-06-06,2019-06-19,Actual,"November 15, 2006",Actual,2006-11-15,June 2019,2019-06-30,"December 1, 2009",Actual,2009-12-01,"December 1, 2009",Actual,2009-12-01,,Interventional,,,"Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults","Safety, Reactogenicity & Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Administered Intramuscularly According to a Schedule of 0, 1 Month, to Healthy Adults Aged 18 to 50 Years",Completed,,Phase 2,110.0,Actual,GlaxoSmithKline,,5.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 22:43:26,2023-06-16 22:43:26,INDUSTRY,,,,,
10225,10226,NCT03404674,,2018-01-10,2020-12-10,,2020-12-10,2018-01-18,2018-01-19,Actual,2020-12-10,2021-01-06,Actual,,,,2020-12-10,2021-01-06,Actual,"January 16, 2018",Actual,2018-01-16,November 2020,2020-11-30,"March 26, 2019",Actual,2019-03-26,"March 26, 2019",Actual,2019-03-26,,Interventional,,All enrolled participants,Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC),A Phase 1 Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC),Completed,,Phase 1,50.0,Actual,PATH,,6.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-16 22:44:21,2023-06-16 22:44:21,OTHER,,,,,
10394,10395,NCT03384316,,2017-12-23,2019-10-25,,2020-08-25,2017-12-26,2017-12-27,Actual,2019-12-04,2019-12-23,Actual,,,,2020-08-25,2020-09-09,Actual,"January 31, 2018",Actual,2018-01-31,August 2020,2020-08-31,"August 24, 2020",Actual,2020-08-24,"May 22, 2018",Actual,2018-05-22,,Interventional,,,Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer,Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer,Completed,,Phase 1,11.0,Actual,National Institutes of Health Clinical Center (CC),,2.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-16 22:46:59,2023-06-16 22:46:59,NIH,,,,,
10467,10468,NCT00356369,,2006-07-25,2017-04-05,2012-07-26,2018-06-05,2006-07-25,2006-07-26,Estimate,2018-05-08,2018-06-04,Actual,2012-07-26,2012-08-03,Estimate,2018-06-05,2018-07-03,Actual,"December 23, 2006",Actual,2006-12-23,May 2018,2018-05-31,"February 28, 2008",Actual,2008-02-28,"September 7, 2007",Actual,2007-09-07,,Interventional,,,Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine,Phase IIb Primary Vaccination Study to Evaluate Non-Inferiority & Persistence of the Immune Response of GSK Biologicals' MenACWY Conjugate Vaccine (Intramuscularly) vs Mencevax ACWY (Subcutaneously) to Healthy Subjects (11-55 Years of Age),Completed,,Phase 2,500.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 22:47:39,2023-06-16 22:47:39,INDUSTRY,,,,,
10535,10536,NCT01053767,,2010-01-19,,,2020-02-08,2010-01-19,2010-01-21,Estimate,,,,,,,2020-02-08,2020-02-11,Actual,January 2010,,2010-01-31,December 2011,2011-12-31,December 2010,Actual,2010-12-31,August 2010,Actual,2010-08-31,,Interventional,,,A Study to Assess the Persistence of Two GBS Antibodies in Women Previously Immunized With a GBS Vaccine,A Phase I Extension Study to Assess the Long-Term Persistence of GBS Serotypes Ib and III Antibodies in Women Previously Immunized With a GBS Ib and III Crm-Glycoconjugate Vaccine,Completed,,Phase 1,95.0,Actual,Novartis,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 22:48:20,2023-06-16 22:48:20,INDUSTRY,,,,,
10642,10643,NCT03069703,,2017-02-27,,,2022-06-07,2017-02-27,2017-03-03,Actual,,,,,,,2022-06-07,2022-06-08,Actual,"February 5, 2018",Actual,2018-02-05,June 2022,2022-06-30,"November 21, 2021",Actual,2021-11-21,"November 24, 2020",Actual,2020-11-24,,Interventional,PNEUMOVAS,,Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy,Multicenter Randomized Controlled Trial Comparing Immunogenicity and Safety of Two Innovative Anti-pneumococcal Vaccine Strategies to Standard Vaccination Regimen in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy,Completed,,Phase 2,96.0,Actual,Assistance Publique - Hôpitaux de Paris,,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-15 00:52:39,2023-06-15 00:52:39,OTHER,,,,,
10690,10691,NCT02851277,,2016-07-28,,,2022-06-05,2016-07-28,2016-08-01,Estimate,,,,,,,2022-06-05,2022-06-08,Actual,"December 13, 2016",Actual,2016-12-13,May 2022,2022-05-31,"December 6, 2018",Actual,2018-12-06,"December 6, 2018",Actual,2018-12-06,,Interventional,,,"A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine","A Phase 1, Randomized, Placebo Controlled Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA LAMP Vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine",Completed,,Phase 1,31.0,Actual,Astellas Pharma Inc,,5.0,,,False,,,,False,True,False,,,,,,,,,No,"Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under ""Sponsor Specific Details for Astellas.""",2023-06-15 00:52:49,2023-06-15 00:52:49,INDUSTRY,,,,,
10822,10823,NCT00355121,,2006-07-20,2011-07-25,2010-09-02,2011-08-22,2006-07-20,2006-07-21,Estimate,2011-07-25,2011-08-23,Estimate,2010-09-02,2010-09-08,Estimate,2011-08-22,2011-08-24,Estimate,October 2006,,2006-10-31,August 2011,2011-08-31,July 2009,Actual,2009-07-31,June 2009,Actual,2009-06-30,,Interventional,,,Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®,"Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.",Completed,,Phase 2,882.0,Actual,Sanofi,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 22:51:02,2023-06-16 22:51:02,INDUSTRY,,,,,
10972,10973,NCT01110044,,2010-04-22,,,2015-03-26,2010-04-22,2010-04-23,Estimate,,,,,,,2015-03-26,2015-03-27,Estimate,April 2010,,2010-04-30,March 2015,2015-03-31,August 2012,Anticipated,2012-08-31,August 2012,Anticipated,2012-08-31,,Interventional,,,Study of a Birth Dose of GlaxoSmithKline Biologicals' 251154 Vaccine,Immunogenicity and Safety of a Birth Dose of GlaxoSmithKline Biologicals' Reduced-antigen-content Tri-component Pertussis (251154) Vaccine,Withdrawn,,Phase 2,0.0,Actual,GlaxoSmithKline,,2.0,,Study was cancelled before enrolment for reasons not related to vaccine safety or efficacy.,False,,,,,,,,,,,,,,,,,2023-06-16 22:52:22,2023-06-16 22:52:22,INDUSTRY,,,,,
11242,11243,NCT03935204,,2019-04-30,,,2021-04-07,2019-04-30,2019-05-02,Actual,,,,,,,2021-04-07,2021-04-08,Actual,"May 13, 2019",Actual,2019-05-13,April 2021,2021-04-30,"April 1, 2021",Actual,2021-04-01,"October 18, 2019",Actual,2019-10-18,,Interventional,,,"Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)","An Randomized, Double-Blinded, Placebo Controlled Phase II Clinical Trial to Estimate Immunogenicity of the Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type) (E.Coli) in Healthy Adults Aged 18 to 45 Years",Completed,,Phase 2,627.0,Actual,Xiamen University,,2.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-16 22:54:52,2023-06-16 22:54:52,OTHER,,,,,
11300,11301,NCT04006808,,2019-07-01,,,2022-12-06,2019-07-01,2019-07-05,Actual,,,,,,,2022-12-06,2022-12-07,Actual,"October 25, 2019",Actual,2019-10-25,December 2022,2022-12-31,"February 28, 2025",Anticipated,2025-02-28,"March 25, 2024",Anticipated,2024-03-25,,Interventional,,,A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant,"A Reactogenicity, Safety and Immunogenicity Study of GSK's Paediatric Herpes Zoster Subunit Candidate Vaccine (PED-HZ/su) GSK143713A in Immunocompromised Paediatric Renal Transplant Recipients",Recruiting,,Phase 2,184.0,Anticipated,GlaxoSmithKline,,4.0,,,False,,,,True,False,False,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-16 01:13:40,2023-06-16 01:13:40,INDUSTRY,,,,,
11442,11443,NCT02594566,,2015-10-16,,,2018-02-28,2015-10-30,2015-11-03,Estimate,,,,,,,2018-02-28,2018-03-01,Actual,November 2015,,2015-11-30,February 2018,2018-02-28,February 2017,Anticipated,2017-02-28,August 2016,Anticipated,2016-08-31,,Interventional,CM04-101,,"Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA Vaccine","A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Prophylactic Cytomegalovirus Plasmid DNA Vaccine in Healthy Adults",Withdrawn,,Phase 1,0.0,Actual,Virginia Commonwealth University,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 01:38:34,2023-06-16 01:38:34,OTHER,,,,,
11455,11456,NCT01031537,,2009-12-11,2018-04-12,,2018-06-05,2009-12-11,2009-12-14,Estimate,2018-06-05,2018-07-05,Actual,,,,2018-06-05,2018-07-05,Actual,"September 25, 2009",,2009-09-25,April 2018,2018-04-30,"December 23, 2016",Actual,2016-12-23,"December 23, 2016",Actual,2016-12-23,,Interventional,TBEV,,Vaccine Study for Tick-Borne Encephalitis Virus (TBEV),"A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL) Against Tick-Borne Encephalitis (TBE) for NIAID Workers Manipulating Tick-Borne Encephalitis Virus (TBEV) in the Laboratory",Terminated,,Phase 2,69.0,Actual,National Institutes of Health Clinical Center (CC),,1.0,,Manufacturer discontinued support of the study,False,,,,True,True,False,,,False,,,,,,,,2023-06-16 01:42:52,2023-06-16 01:42:52,NIH,,,,,
11484,11485,NCT04927585,,2021-05-29,,,2022-06-08,2021-06-08,2021-06-16,Actual,,,,,,,2022-06-08,2022-06-09,Actual,"July 8, 2021",Actual,2021-07-08,June 2022,2022-06-30,December 2023,Anticipated,2023-12-31,December 2023,Anticipated,2023-12-31,,Interventional,,,"Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults","A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Polyvalent Env (A,B,C,A/E) / Gag (C) DNA and gp120 (A,B,C,A/E) Protein HIV-1 Vaccines (PDPHV-201401) Co-administered With or Without Adjuvant GLA-SE in Repeated Doses, in Healthy, HIV-1 Uninfected Adult Participants","Active, not recruiting",,Phase 1,42.0,Actual,Worcester HIV Vaccine,,4.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-15 00:54:43,2023-06-15 00:54:43,INDUSTRY,,,,,
12005,12006,NCT00748813,,2008-09-08,,,2016-11-30,2008-09-08,2008-09-09,Estimate,,,,,,,2016-11-30,2016-12-01,Estimate,June 2008,,2008-06-30,December 2011,2011-12-31,July 2008,Actual,2008-07-31,July 2008,Actual,2008-07-31,,Interventional,,,"Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2008/2009","A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2008-2009, When Administered to Non-Elderly Adult and Elderly Sub",Completed,,Phase 2,133.0,Actual,Novartis,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 01:43:00,2023-06-16 01:43:00,INDUSTRY,,,,,
12019,12020,NCT05909423,,2023-05-18,,,2023-06-09,2023-06-09,2023-06-19,Estimate,,,,,,,2023-06-09,2023-06-19,Estimate,"September 1, 2023",Anticipated,2023-09-01,June 2023,2023-06-30,"September 1, 2028",Anticipated,2028-09-01,"September 1, 2025",Anticipated,2025-09-01,,Interventional,FLU-IMMUNE,,Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer,Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer - the FLU-IMMUNE Trial.,Not yet recruiting,,Phase 2,21.0,Anticipated,Zealand University Hospital,,1.0,,,False,,,,True,False,False,,,False,,,,,,Undecided,,2023-06-19 04:14:00,2023-06-19 04:14:00,OTHER,,,,,
12108,12109,NCT05401448,,2022-05-19,,,2022-05-27,2022-05-27,2022-06-02,Actual,,,,,,,2022-05-27,2022-06-02,Actual,"May 1, 2021",Actual,2021-05-01,May 2022,2022-05-31,March 2023,Anticipated,2023-03-31,January 2023,Anticipated,2023-01-31,,Interventional,FLUMMR-BRA,,Non-specific Effects of FLU-MMR Vaccines in Adults,"Study of the Non-specific Effects of Influenza and MMR Vaccine on Infectious Diseases in Goiânia, Goiás, Brazil",Recruiting,,Early Phase 1,2000.0,Anticipated,Radboud University Medical Center,,3.0,,,False,,,,,False,False,,,,,,,,,No,,2023-06-16 23:01:57,2023-06-16 23:01:57,OTHER,,,,,
12189,12190,NCT01233362,,2010-10-11,,,2013-09-24,2010-11-02,2010-11-03,Estimate,,,,,,,2013-09-24,2013-09-25,Estimate,December 2010,,2010-12-31,August 2012,2012-08-31,February 2013,Actual,2013-02-28,February 2013,Actual,2013-02-28,,Interventional,,,Study of Alternative Vaccination Schedule of Oral Cholera Vaccine,A Randomized Controlled Trial To Evaluate the Immunogenicity of Two Doses of the Modified Killed Whole-Cell Oral Cholera Vaccine Under Two Alternative Vaccination Schedules.,Completed,,Phase 2,386.0,Actual,International Vaccine Institute,,6.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 23:02:51,2023-06-16 23:02:51,OTHER,,,,,
12465,12466,NCT04119440,,2019-10-06,,,2022-11-06,2019-10-06,2019-10-08,Actual,,,,,,,2022-11-06,2022-11-08,Actual,"April 16, 2021",Actual,2021-04-16,November 2022,2022-11-30,May 2023,Anticipated,2023-05-31,November 2022,Anticipated,2022-11-30,,Interventional,MVA-MERS-S,,Safety and Immunogenicity of the Candidate Vaccine MVA-MERS-S_DF-1 Against MERS,"A Two-center, Randomized, Double-blind, Placebo-controlled, Phase Ib Study to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-MERS-S_DF-1 in Healthy Study Subjects","Active, not recruiting",,Phase 1,145.0,Actual,Universitätsklinikum Hamburg-Eppendorf,,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-16 23:04:42,2023-06-16 23:04:42,OTHER,,,,,
12640,12641,NCT05621655,,2022-11-07,,,2023-05-22,2022-11-14,2022-11-18,Actual,,,,,,,2023-05-22,2023-05-23,Actual,"January 8, 2023",Actual,2023-01-08,May 2023,2023-05-31,April 2024,Anticipated,2024-04-30,"April 29, 2023",Actual,2023-04-29,,Interventional,,,Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers,"A Phase II Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Subunit Rotavirus Vaccine in Healthy Infants Aged 6-12 Weeks and Healthy Toddlers Aged 7-71 Months","Active, not recruiting",,Phase 2,1512.0,Actual,MAXVAX Biotechnology Limited Liability Company,,12.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-18 01:10:05,2023-06-18 01:10:05,INDUSTRY,,,,,
12696,12697,NCT00318149,,2006-04-25,2017-01-27,,2018-02-05,2006-04-25,2006-04-26,Estimate,2018-02-05,2018-08-08,Actual,,,,2018-02-05,2018-08-08,Actual,"October 10, 2005",Actual,2005-10-10,February 2018,2018-02-28,"May 14, 2006",Actual,2006-05-14,"May 14, 2006",Actual,2006-05-14,,Interventional,,,Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population,Demonstrate the Non-inferiority in Term of Cellular Mediated Immune Response of GSK Biologicals' Influenza Candidate Vaccines Containing Various Adjuvants Administered in Elderly Population (Aged 65 Years &Amp; Older) vs Fluarix (Known as Alpha-Rix in Belgium) Administered in Adults (18-40 Years),Completed,,Phase 2,425.0,Actual,GlaxoSmithKline,,6.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 23:07:00,2023-06-16 23:07:00,INDUSTRY,,,,,
12853,12854,NCT00316589,,2006-04-19,2018-12-07,,2018-12-07,2006-04-19,2006-04-21,Estimate,2018-12-07,2019-01-03,Actual,,,,2018-12-07,2019-01-03,Actual,June 2006,,2006-06-30,December 2018,2018-12-31,October 2009,Actual,2009-10-31,March 2009,Actual,2009-03-31,,Interventional,,Full Analysis Set,Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients,"A Multicenter, Open-label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN® (IMVAMUNE) Smallpox Vaccine in 18-55 Year Old Naive and Previously Vaccinated HIV Infected Subjects With CD4 Counts >200 - 750/µl.",Completed,,Phase 2,581.0,Actual,Bavarian Nordic,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 23:08:33,2023-06-16 23:08:33,INDUSTRY,,,,,
13049,13050,NCT03914768,,2019-04-11,,,2020-06-10,2019-04-11,2019-04-16,Actual,,,,,,,2020-06-10,2020-06-12,Actual,"March 31, 2019",Actual,2019-03-31,June 2020,2020-06-30,"December 31, 2022",Anticipated,2022-12-31,"January 31, 2021",Anticipated,2021-01-31,,Interventional,,,Immune Modulatory DC Vaccine Against Brain Tumor,Immune Modulatory DC Vaccine Against Diffuse Intrinsic Pontine Glioma (DIPG) and Glioblastoma (GBM),Unknown status,Enrolling by invitation,Phase 1,10.0,Anticipated,Shenzhen Geno-Immune Medical Institute,,1.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-16 23:10:19,2023-06-16 23:10:19,OTHER,,,,,
13298,13299,NCT05397223,,2022-05-25,,,2023-05-22,2022-05-25,2022-05-31,Actual,,,,,,,2023-05-22,2023-05-23,Actual,"May 24, 2022",Actual,2022-05-24,May 2023,2023-05-31,"March 25, 2024",Anticipated,2024-03-25,"March 25, 2024",Anticipated,2024-03-25,,Interventional,,,A Study of Modified mRNA Vaccines in Healthy Adults,"Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults","Active, not recruiting",,Phase 1,308.0,Actual,"ModernaTX, Inc.",,6.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-18 01:11:10,2023-06-18 01:11:10,INDUSTRY,,,,,
13308,13309,NCT03902054,,2019-04-02,,,2019-04-02,2019-04-02,2019-04-03,Actual,,,,,,,2019-04-02,2019-04-03,Actual,"December 28, 2017",Actual,2017-12-28,April 2019,2019-04-30,"December 28, 2018",Actual,2018-12-28,"May 26, 2018",Actual,2018-05-26,,Interventional,,,Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine.,"A Randomized, Blinded and Controlled Phase II Study to Evaluate the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Vero Cell) in Infants.",Completed,,Phase 2,600.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,5.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-16 23:12:22,2023-06-16 23:12:22,NETWORK,,,,,
13369,13370,NCT00756067,,2008-09-18,,,2017-05-09,2008-09-18,2008-09-19,Estimate,,,,,,,2017-05-09,2017-05-10,Actual,"September 19, 2008",Actual,2008-09-19,May 2017,2017-05-31,"May 28, 2009",Actual,2009-05-28,"May 28, 2009",Actual,2009-05-28,,Interventional,,,Evaluation of Pneumococcal Vaccine Formulations in Elderly,A Study to Evaluate GSK Biologicals' Candidate Formulations of Pneumococcal Vaccines (GSK2189241A) in Elderly Subjects.,Completed,,Phase 1,168.0,Actual,GlaxoSmithKline,,7.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 01:43:18,2023-06-16 01:43:18,INDUSTRY,,,,,
13377,13378,NCT03900572,,2019-03-28,,,2023-04-12,2019-04-02,2019-04-03,Actual,,,,,,,2023-04-12,2023-04-13,Actual,"March 9, 2019",Actual,2019-03-09,April 2023,2023-04-30,"April 30, 2020",Actual,2020-04-30,"April 30, 2020",Actual,2020-04-30,,Interventional,,,A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine,"A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Immunogenicity of a 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Pichia Pastoris) in 9 to 45 Year Old Chinese Females",Completed,,Phase 1,90.0,Actual,"Shanghai Zerun Biotechnology Co.,Ltd",,2.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-16 23:12:50,2023-06-16 23:12:50,INDUSTRY,,,,,
13522,13523,NCT01258868,,2010-12-10,,,2019-11-30,2010-12-10,2010-12-13,Estimate,,,,,,,2019-11-30,2019-12-03,Actual,"December 1, 2010",,2010-12-01,"August 17, 2016",2016-08-17,"June 13, 2016",Actual,2016-06-13,"June 13, 2016",Actual,2016-06-13,,Interventional,,,Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas,"Epigenetically-Modified Autologous Tumor Cell Vaccines With ISCOMATRIX(TM) Adjuvant and Oral Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, Thoracic Sarcomas, and Malignant Pleural Mesotheliomas",Terminated,,Phase 1,44.0,Actual,National Institutes of Health Clinical Center (CC),,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 23:13:54,2023-06-16 23:13:54,NIH,,,,,
13579,13580,NCT01152398,,2010-06-25,,,2019-03-12,2010-06-28,2010-06-29,Estimate,,,,,,,2019-03-12,2019-03-14,Actual,June 2010,,2010-06-30,August 2011,2011-08-31,September 2012,Actual,2012-09-30,September 2012,Actual,2012-09-30,,Interventional,,,A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy,A Phase I Safety and Immunogenicity Trial of MVA-BN®-HER2 Vaccine in HER-2-Positive Breast Cancer Patients Following Adjuvant Therapy,Completed,,Phase 1,15.0,Actual,Bavarian Nordic,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 23:14:15,2023-06-16 23:14:15,INDUSTRY,,,,,
13713,13714,NCT01262300,,2010-12-15,,,2021-06-23,2010-12-15,2010-12-17,Estimate,,,,,,,2021-06-23,2021-06-25,Actual,November 2010,,2010-11-30,June 2021,2021-06-30,"January 23, 2014",Actual,2014-01-23,"January 23, 2014",Actual,2014-01-23,,Interventional,,,Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents,Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Nursing Home Residents,Completed,,Phase 1,33.0,Actual,"University of Colorado, Denver",,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 23:15:22,2023-06-16 23:15:22,OTHER,,,,,
14016,14017,NCT04064905,,2019-08-20,,,2021-04-20,2019-08-20,2019-08-22,Actual,,,,,,,2021-04-20,2021-04-22,Actual,"July 30, 2019",Actual,2019-07-30,April 2021,2021-04-30,"March 22, 2021",Actual,2021-03-22,"March 22, 2021",Actual,2021-03-22,,Interventional,,,"Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults","A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults",Completed,,Phase 1,120.0,Actual,"ModernaTX, Inc.",,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-16 01:17:55,2023-06-16 01:17:55,INDUSTRY,,,,,
14072,14073,NCT00976820,,2009-09-11,2017-07-31,2010-12-23,2017-11-10,2009-09-11,2009-09-14,Estimate,2017-11-10,2017-12-12,Actual,2010-12-23,2010-12-30,Estimate,2017-11-10,2017-12-12,Actual,"October 20, 2009",Actual,2009-10-20,July 2017,2017-07-31,"March 21, 2011",Actual,2011-03-21,"March 21, 2011",Actual,2011-03-21,,Interventional,,,Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age,A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age,Completed,,Phase 2,323.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 01:18:07,2023-06-16 01:18:07,INDUSTRY,,,,,
14074,14075,NCT00729001,,2008-08-04,,,2016-09-15,2008-08-05,2008-08-06,Estimate,,,,,,,2016-09-15,2016-09-16,Estimate,November 2000,,2000-11-30,September 2016,2016-09-30,September 2002,Actual,2002-09-30,September 2002,Actual,2002-09-30,,Interventional,,,Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.,"Phase II, Double-blind, Randomized, Placebo-controlled Study of 2 Doses of GSK Biologicals' Live Attenuated Human Rotavirus Vaccine at Different Virus Concentrations (10 5.2 and 10 6.4 Ffu) in Healthy Infants Following a 0, 2 Month Schedule and Previously Uninfected With Human Rotavirus.",Completed,,Phase 2,529.0,Actual,GlaxoSmithKline,,3.0,,,,,,,False,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 01:18:11,2023-06-16 01:18:11,INDUSTRY,,,,,
14076,14077,NCT00730795,,2008-08-07,,,2008-08-07,2008-08-07,2008-08-08,Estimate,,,,,,,2008-08-07,2008-08-08,Estimate,January 2004,,2004-01-31,August 2008,2008-08-31,,,,December 2004,Actual,2004-12-31,,Interventional,,,Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults,"A Phase I Open Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the Recombinant Mycobacterium Tuberculosis Vaccine, Mtb72F With AS02A Adjuvant, When Administered Intramuscularly to Healthy PPD-Negative Adults",Completed,,Phase 1,12.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 01:18:13,2023-06-16 01:18:13,INDUSTRY,,,,,
14468,14469,NCT03295318,,2017-09-20,2021-08-10,,2021-08-10,2017-09-22,2017-09-27,Actual,2021-08-10,2021-09-05,Actual,,,,2021-08-10,2021-09-05,Actual,"November 15, 2017",Actual,2017-11-15,August 2021,2021-08-31,"August 31, 2018",Actual,2018-08-31,"August 31, 2018",Actual,2018-08-31,,Interventional,,,"Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds","A Phase 2, Observer-blind, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of Two Formulations of Investigational Meningococcal Groups ACYWX Conjugate Vaccine, Administered to Healthy Malian Children 12-16 Months of Age",Completed,,Phase 2,375.0,Actual,Serum Institute of India Pvt. Ltd.,,3.0,,,False,,,,True,False,False,,,,,,,,,Undecided,,2023-06-16 23:21:41,2023-06-16 23:21:41,INDUSTRY,,,,,
14741,14742,NCT00310817,,2006-04-03,2013-08-29,,2015-10-06,2006-04-03,2006-04-05,Estimate,2015-10-06,2015-11-06,Estimate,,,,2015-10-06,2015-11-06,Estimate,March 2005,,2005-03-31,October 2015,2015-10-31,May 2006,Actual,2006-05-31,May 2006,Actual,2006-05-31,,Interventional,,,Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.,"A Phase II, Randomized, Observer Blind, Multi-Center, Active Controlled Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.",Completed,,Phase 2,623.0,Actual,Novartis,,4.0,,,,,,,,,,,,,,,,,,,,2023-06-16 23:23:33,2023-06-16 23:23:33,INDUSTRY,,,,,
14805,14806,NCT01172054,,2010-07-26,,,2012-07-30,2010-07-27,2010-07-29,Estimate,,,,,,,2012-07-30,2012-07-31,Estimate,July 2010,,2010-07-31,July 2012,2012-07-31,November 2011,Actual,2011-11-30,December 2010,Actual,2010-12-31,,Interventional,VAX128-01,,"Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults","A Phase I Escalating Dose Ranging Study to Evaluate the Safety and Immunogenicity of the VAX128 A, B, and C Novel H1N1 Influenza Vaccine Constructs in Healthy Adults 18-49 Years of Age and in Community Living Adults =65 Years of Age",Completed,,Phase 1,292.0,Actual,VaxInnate Corporation,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 23:23:49,2023-06-16 23:23:49,INDUSTRY,,,,,
15014,15015,NCT01181336,,2010-08-12,,,2010-10-14,2010-08-12,2010-08-13,Estimate,,,,,,,2010-10-14,2010-10-15,Estimate,April 2010,,2010-04-30,October 2010,2010-10-31,July 2010,Actual,2010-07-31,July 2010,Actual,2010-07-31,,Interventional,,,Phase 1b Influenza Vaccine Study in Healthy Subjects,"A Single Centre, Randomised, Double Blind, Phase 1 Study of the Safety, Tolerability, and Immunogenicity of an Influenza Vaccine Candidate (FLU-v)",Completed,,Phase 1,48.0,Anticipated,PepTcell Limited,,5.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 23:25:10,2023-06-16 23:25:10,INDUSTRY,,,,,
15245,15246,NCT01177202,,2010-08-05,,,2016-07-22,2010-08-05,2010-08-06,Estimate,,,,,,,2016-07-22,2016-07-26,Estimate,September 2010,,2010-09-30,July 2016,2016-07-31,October 2012,Actual,2012-10-31,May 2011,Actual,2011-05-31,,Interventional,,,Study of the Safety and Immunogenicity of H1N1 Vaccine,A Phase I Dose-Escalation Study to Investigate the Safety and Immunogenicity of the Fusion Protein Recombinant Influenza A (HAC1) Vaccine Derived From Influenza A/California/04/09 (H1N1) in Healthy Adults,Completed,,Phase 1,80.0,Actual,"Fraunhofer, Center for Molecular Biotechnology",,8.0,,,False,,,,False,,,,,,,,,,,Undecided,,2023-06-16 23:26:59,2023-06-16 23:26:59,INDUSTRY,,,,,
15270,15271,NCT03300817,,2017-10-03,2022-11-25,,2023-04-29,2017-10-03,2017-10-04,Actual,2023-03-27,2023-04-19,Actual,,,,2023-04-29,2023-05-23,Actual,"December 27, 2017",Actual,2017-12-27,October 2022,2022-10-31,"December 1, 2023",Anticipated,2023-12-01,"September 23, 2021",Actual,2021-09-23,,Interventional,,,MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer,A Pilot Study of MUC1 Vaccine in Current and Former Smokers at High Risk for Lung Cancer,"Active, not recruiting",,Phase 1,50.0,Actual,National Cancer Institute (NCI),,1.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-18 01:16:17,2023-06-18 01:16:17,NIH,,,,,
15308,15309,NCT01089660,,2010-03-17,,,2014-01-10,2010-03-17,2010-03-18,Estimate,,,,,,,2014-01-10,2014-01-14,Estimate,March 2010,,2010-03-31,January 2014,2014-01-31,December 2010,Actual,2010-12-31,September 2010,Actual,2010-09-30,,Interventional,,,A Study of the Immunogenicity of Swine-origin A/H1N1 Influenza Vaccine in Healthy Adults,"Immunogenicity of the Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine Without Adjuvant in Healthy Adult Subjects",Completed,,Phase 2,202.0,Actual,Sanofi,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 23:27:14,2023-06-16 23:27:14,INDUSTRY,,,,,
15760,15761,NCT01296386,,2011-01-21,,,2014-09-24,2011-02-14,2011-02-15,Estimate,,,,,,,2014-09-24,2014-09-25,Estimate,December 2010,,2010-12-31,September 2014,2014-09-30,April 2013,Actual,2013-04-30,April 2013,Actual,2013-04-30,,Interventional,,,"An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84","An Open-label Phase 1 Study Assessing the Safety, Immunogenicity and Dose Response of IC84, a New Vaccine Against Clostridium Difficile, in Healthy Subjects",Completed,,Phase 1,82.0,Actual,Valneva Austria GmbH,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 23:30:22,2023-06-16 23:30:22,INDUSTRY,,,,,
15841,15842,NCT03953196,,2019-04-01,,,2020-01-27,2019-05-15,2019-05-16,Actual,,,,,,,2020-01-27,2020-01-29,Actual,"April 8, 2019",Actual,2019-04-08,January 2020,2020-01-31,"December 26, 2019",Actual,2019-12-26,"December 26, 2019",Actual,2019-12-26,,Interventional,,,A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants,A Phase 0 Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Volunteers,Completed,,Early Phase 1,48.0,Actual,"Janssen Research & Development, LLC",,5.0,,,False,,,,False,True,False,,,True,,,,,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2023-06-16 23:31:03,2023-06-16 23:31:03,INDUSTRY,,,,,
15932,15933,NCT05599802,,2022-10-26,,,2022-10-30,2022-10-26,2022-10-31,Actual,,,,,,,2022-10-30,2022-11-01,Actual,February 2023,Anticipated,2023-02-28,September 2022,2022-09-30,May 2024,Anticipated,2024-05-31,May 2023,Anticipated,2023-05-31,,Interventional,,,Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants,"An Open-Label, Phase 1 Clinical Study to Determine the Safety and Preliminary Immunogenicity of SARS-CoV-2 Variant mRNA Vaccine (LVRNA010) in Healthy Participants Aged 18 Years and Older",Not yet recruiting,,Phase 1,144.0,Anticipated,"AIM Vaccine Co., Ltd.",,6.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-16 23:31:59,2023-06-16 23:31:59,INDUSTRY,,,,,
16324,16325,NCT04957485,,2021-06-23,,,2022-12-22,2021-06-30,2021-07-12,Actual,,,,,,,2022-12-22,2022-12-23,Actual,"January 5, 2022",Actual,2022-01-05,June 2022,2022-06-30,"May 5, 2023",Anticipated,2023-05-05,"May 1, 2023",Anticipated,2023-05-01,,Interventional,,,Study to Assess the Safety and Pharmacokinetics of TPOXX® When Administered Orally for 28 Days,"A Phase 1, Open-Label (JYNNEOS®), Double-Blind (TPOXX® And Placebo), Multicenter, Randomized, Placebo-Controlled, Drug-Vaccine Interaction Study To Evaluate the Impact of TPOXX on JYNNEOS Immunogenicity","Active, not recruiting",,Phase 2,100.0,Actual,SIGA Technologies,,2.0,,,True,,,,True,True,False,,,,,,,,,No,,2023-06-16 01:21:58,2023-06-16 01:21:58,INDUSTRY,,NCT02080767,Available,,
16559,16560,NCT01064141,,2010-02-05,,,2013-02-05,2010-02-05,2010-02-08,Estimate,,,,,,,2013-02-05,2013-02-06,Estimate,January 2010,,2010-01-31,February 2013,2013-02-28,November 2012,Actual,2012-11-30,September 2012,Actual,2012-09-30,,Interventional,,,A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines,Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines,Completed,,Phase 2,210.0,Actual,Sanofi,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 23:35:27,2023-06-16 23:35:27,INDUSTRY,,,,,
16608,16609,NCT00306995,,2006-02-16,2017-09-22,,2020-02-06,2006-03-24,2006-03-27,Estimate,2020-02-06,2020-02-10,Actual,,,,2020-02-06,2020-02-10,Actual,"May 11, 2005",Actual,2005-05-11,February 2020,2020-02-29,"July 4, 2006",Actual,2006-07-04,"July 4, 2006",Actual,2006-07-04,,Interventional,,,Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population,"A Phase III, Open, Randomized, Multicenter, Comparative Vaccination Study to Evaluate the Immunogenicity and Reactogenicity of Various Formulations of a Monovalent Candidate Pandemic Influenza A Vaccine in Individuals Over 60 Years of Age",Completed,,Phase 2,385.0,Actual,GlaxoSmithKline,,7.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 23:35:47,2023-06-16 23:35:47,INDUSTRY,,,,,
17127,17128,NCT02934178,,2016-08-30,2018-10-16,,2020-03-18,2016-10-12,2016-10-14,Estimate,2020-03-18,2020-03-31,Actual,,,,2020-03-18,2020-03-31,Actual,"February 23, 2017",Actual,2017-02-23,March 2020,2020-03-31,"January 10, 2018",Actual,2018-01-10,"January 10, 2018",Actual,2018-01-10,,Interventional,,,Shigella WRSS1 Vaccine Trial in Bangladesh,"A Phase 1 Randomized, Double-Blinded, Placebo-controlled, Dose-Escalation Study to Assess the Safety, Tolerability and Immunogenicity of Live Attenuated, Oral Shigella WRSS1 Vaccine in Bangladeshi Toddlers (12 to 24 Months Old)",Completed,,Phase 1,16.0,Actual,PATH,,8.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-16 23:39:55,2023-06-16 23:39:55,OTHER,,,,,
17392,17393,NCT01069601,,2010-02-15,,,2012-04-13,2010-02-16,2010-02-17,Estimate,,,,,,,2012-04-13,2012-04-16,Estimate,February 2010,,2010-02-28,April 2012,2012-04-30,April 2012,Actual,2012-04-30,April 2011,Actual,2011-04-30,,Interventional,,,H1N1sw Vaccine in Adult Transplant Recipients,"A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a H1N1 Influenza Vaccine in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers",Terminated,,Phase 2,13.0,Actual,"HepNet Study House, German Liverfoundation",,1.0,,End of H1N1 Swine Flu Pandemic,False,,,,True,,,,,,,,,,,,,2023-06-16 23:41:53,2023-06-16 23:41:53,NETWORK,,,,,
17517,17518,NCT02057263,,2014-02-04,,,2016-10-20,2014-02-05,2014-02-07,Estimate,,,,,,,2016-10-20,2016-10-21,Estimate,April 2014,,2014-04-30,October 2016,2016-10-31,February 2016,Actual,2016-02-29,February 2016,Actual,2016-02-29,,Interventional,,,The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults,The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults - a Randomized Placebo-controlled Pilot Study,Completed,,Phase 1,28.0,Actual,Massachusetts General Hospital,,2.0,,,False,,,,False,,,,,,,,,,,Yes,Available upon request,2023-06-18 01:26:02,2023-06-18 01:26:02,OTHER,,,,,
17692,17693,NCT04813562,,2021-03-19,,,2022-03-28,2021-03-23,2021-03-24,Actual,,,,,,,2022-03-28,2022-03-31,Actual,"March 23, 2021",Actual,2021-03-23,March 2022,2022-03-31,"July 30, 2022",Anticipated,2022-07-30,"July 30, 2022",Anticipated,2022-07-30,,Interventional,,,Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells),"A Single-center, Randomized, Double Blinded, Placebo Controlled, Phase 2 Clinical Trial of Recombinant COVID-19 Vaccine (CHO Cells), in the Subjects From Healthy Aged 18 Years and Above",Recruiting,,Phase 2,480.0,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,,8.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 01:26:59,2023-06-18 01:26:59,NETWORK,,,,,
17736,17737,NCT04942210,,2021-06-25,,,2023-01-03,2021-06-25,2021-06-28,Actual,,,,,,,2023-01-03,2023-01-04,Actual,"July 1, 2021",Actual,2021-07-01,January 2023,2023-01-31,"June 29, 2028",Anticipated,2028-06-29,"June 24, 2022",Actual,2022-06-24,,Interventional,VYF02,,Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA,Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults,"Active, not recruiting",,Phase 2,567.0,Actual,Sanofi,,2.0,,,False,,,,True,True,False,,,False,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-16 23:44:33,2023-06-16 23:44:33,INDUSTRY,,,,,
17748,17749,NCT00740155,,2008-05-07,,,2015-03-02,2008-08-21,2008-08-22,Estimate,,,,,,,2015-03-02,2015-03-03,Estimate,August 2008,,2008-08-31,March 2015,2015-03-31,January 2010,Actual,2010-01-31,October 2009,Actual,2009-10-31,,Interventional,,,Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults,Safety and Immunogenicity of Bivalent and Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Flavivirus-Naïve Adults Aged 18 to 45 Years,Completed,,Phase 2,154.0,Actual,Sanofi,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 01:23:44,2023-06-16 01:23:44,INDUSTRY,,,,,
18052,18053,NCT01949909,,2013-08-29,,,2018-07-16,2013-09-21,2013-09-25,Estimate,,,,,,,2018-07-16,2018-07-18,Actual,March 2014,,2014-03-31,July 2018,2018-07-31,July 2015,Actual,2015-07-31,July 2015,Actual,2015-07-31,,Interventional,P27A,,Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib,"Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A With Alhydrogel® Or GLA-SE As Adjuvant: A Staggered, Antigen And Adjuvant Dose-Finding, Randomized, Multi-Centre Phase Ia/Ib Trial",Completed,,Phase 1,56.0,Actual,Centre Hospitalier Universitaire Vaudois,,7.0,,,False,,,,True,,,,,,,,,,,Yes,,2023-06-15 01:03:58,2023-06-15 01:03:58,OTHER,,,,,
18106,18107,NCT03561181,,2018-06-07,,,2018-10-15,2018-06-07,2018-06-19,Actual,,,,,,,2018-10-15,2018-10-17,Actual,"July 18, 2017",Actual,2017-07-18,October 2018,2018-10-31,"February 8, 2018",Actual,2018-02-08,"January 28, 2018",Actual,2018-01-28,,Interventional,,,Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months,"A Single-center, Open, Phase I Clinical Trial to Evaluate Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months",Completed,,Phase 1,180.0,Actual,"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd",,2.0,,,False,,,,False,False,False,,,False,,,,,,No,,2023-06-18 01:29:10,2023-06-18 01:29:10,INDUSTRY,,,,,
18613,18614,NCT05654467,,2022-12-07,,,2022-12-14,2022-12-14,2022-12-16,Actual,,,,,,,2022-12-14,2022-12-16,Actual,"May 29, 2023",Anticipated,2023-05-29,November 2022,2022-11-30,"January 31, 2024",Anticipated,2024-01-31,"January 31, 2024",Anticipated,2024-01-31,,Interventional,,,Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama,"A Phase 2, Randomized, Observer-Blind, Controlled, Age De-escalation, Dosage Escalation Study to Assess the Safety and Immunogenicity of a Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine in Healthy Young Children, Infants, and Neonates in Panama",Not yet recruiting,,Phase 2,1532.0,Anticipated,PATH,,12.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 01:32:22,2023-06-18 01:32:22,OTHER,,,,,
18936,18937,NCT01951677,,2013-09-16,,,2019-05-06,2013-09-23,2013-09-27,Estimate,,,,,,,2019-05-06,2019-05-07,Actual,July 2013,Actual,2013-07-31,May 2019,2019-05-31,May 2019,Actual,2019-05-31,October 2017,Actual,2017-10-31,,Interventional,,,Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine,"Phase 1 Randomized, Controlled, Double-blind Study to Compare the Safety and Effectiveness of Hepatitis B Vaccines in Individuals With Renal Impairment, Diabetes Mellitus or Age Greater Than 40 Years",Completed,,Phase 1,240.0,Anticipated,Vaxine Pty Ltd,,12.0,,,False,,,,True,,,,,,,,,,,No,Currently no plan,2023-06-15 01:05:17,2023-06-15 01:05:17,INDUSTRY,,,,,
19044,19045,NCT02719743,,2016-03-21,2018-08-10,,2019-06-13,2016-03-21,2016-03-25,Estimate,2019-02-22,2019-06-03,Actual,,,,2019-06-13,2019-06-27,Actual,"July 7, 2016",Actual,2016-07-07,June 2019,2019-06-30,"February 13, 2018",Actual,2018-02-13,"February 13, 2018",Actual,2018-02-13,,Interventional,,,A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age,"An Observer-blind, Dose Ranging Safety and Immunogenicity Study of GSK Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age",Completed,,Phase 2,185.0,Actual,GlaxoSmithKline,,5.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-18 01:34:09,2023-06-18 01:34:09,INDUSTRY,,,,,
19086,19087,NCT05694728,,2022-12-12,,,2023-01-12,2023-01-12,2023-01-23,Actual,,,,,,,2023-01-12,2023-01-23,Actual,"May 23, 2020",Actual,2020-05-23,December 2022,2022-12-31,"January 27, 2021",Actual,2021-01-27,"December 11, 2020",Actual,2020-12-11,,Interventional,,,A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine,A Phase II Trial in Healthy Chinese Women Ages 20-45 to Evaluate the Immunogenicity and Safety Profile of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli),Completed,,Phase 2,780.0,Actual,"Beijing Health Guard Biotechnology, Inc",,2.0,,,False,,,,False,False,False,,,,,,,,,No,No informed consent was obtained to disclose the subject's data and sample test results,2023-06-16 23:52:42,2023-06-16 23:52:42,INDUSTRY,,,,,
19220,19221,NCT03776786,,2018-12-12,,,2019-10-24,2018-12-12,2018-12-17,Actual,,,,,,,2019-10-24,2019-10-25,Actual,"December 6, 2018",Actual,2018-12-06,October 2019,2019-10-31,"October 10, 2019",Actual,2019-10-10,"July 1, 2019",Actual,2019-07-01,,Interventional,,,Safety and Tolerability of an Antibody Against Yellow Fever Virus (TY014) in Humans,"Phase 1 First-in-Human, Time Lagged, Single Ascending Dose Study of TY014 in Healthy Adult Volunteers (Safety Arm - 1A) and Sequential Time Lagged, Parallel-Group, Randomised, Placebo-Controlled, Double-Blind, Single Ascending Dose Study of TY014 in YF-17D Vaccine Strain-Challenged Healthy Adult Volunteers (Efficacy Arm - 1B)",Completed,,Phase 1,37.0,Actual,Tysana Pte Ltd,,14.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-16 23:53:29,2023-06-16 23:53:29,INDUSTRY,,,,,
19296,19297,NCT03784040,,2018-12-20,,,2019-04-05,2018-12-20,2018-12-21,Actual,,,,,,,2019-04-05,2019-04-08,Actual,"February 21, 2019",Actual,2019-02-21,April 2019,2019-04-30,"March 1, 2024",Anticipated,2024-03-01,"March 1, 2023",Anticipated,2023-03-01,,Interventional,da VINci,,"Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.","da VINci Study (OTSGC-A24 Therapeutic Peptide Vaccine + Ipilimumab + Nivolumab) Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.",Recruiting,,Phase 1,40.0,Anticipated,"National University Hospital, Singapore",,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-16 23:54:10,2023-06-16 23:54:10,OTHER,,,,,
19314,19315,NCT01320176,,2011-03-21,,,2012-02-13,2011-03-21,2011-03-22,Estimate,,,,,,,2012-02-13,2012-02-14,Estimate,October 2010,,2010-10-31,February 2012,2012-02-29,November 2011,Actual,2011-11-30,November 2011,Actual,2011-11-30,,Interventional,,,Study to Evaluate the Dosage and Safety of Two Intramuscular Injections of an Investigational Clade B HIV Vaccine,"An Open-label, Phase I, Dose-escalation and Safety Study of Two Intramuscular Injections of a Dose of 2.9 Log or 4 Log CCID50 of the Recombinant HIV I Clade B Measles Vaccine Vector in Healthy Adults.",Completed,,Phase 1,36.0,Actual,Institut Pasteur,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 23:54:28,2023-06-16 23:54:28,INDUSTRY,,,,,
19432,19433,NCT03773744,,2018-12-10,,,2021-04-01,2018-12-11,2018-12-12,Actual,,,,,,,2021-04-01,2021-04-06,Actual,"February 15, 2020",Actual,2020-02-15,April 2021,2021-04-30,"December 31, 2021",Anticipated,2021-12-31,"October 30, 2020",Anticipated,2020-10-30,,Interventional,Pelican,,MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma,"A Phase 1b, Multicenter, Open-label Trial of Oncolytic MG1 Expressing MAGE-A3 (MG1-MAGEA3) With Adenovirus Vaccine Expressing MAGE-A3 (Ad-MAGEA3), in Combination With Immune Modulating Therapy in Patients With Metastatic Melanoma or Previously Treated Cutaneous Squamous Cell Carcinoma",Withdrawn,,Phase 1,0.0,Actual,"Turnstone Biologics, Corp.",,2.0,,insufficient suitable drug supply,False,,,,True,True,False,,,,,,,,,No,,2023-06-16 23:55:11,2023-06-16 23:55:11,INDUSTRY,,,,,
19457,19458,NCT05254184,,2022-02-14,,,2023-01-19,2022-02-14,2022-02-24,Actual,,,,,,,2023-01-19,2023-01-23,Actual,"November 1, 2022",Actual,2022-11-01,January 2023,2023-01-31,"April 1, 2026",Anticipated,2026-04-01,"April 1, 2024",Anticipated,2024-04-01,,Interventional,,,KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC,Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Advanced KRAS Mutated Non-Small Cell Lung Cancer,Recruiting,,Phase 1,12.0,Anticipated,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,1.0,,,False,,,,,True,False,,,,,,,,,No,,2023-06-16 23:55:30,2023-06-16 23:55:30,OTHER,,,,,
19490,19491,NCT00186927,,2005-09-12,,,2023-02-10,2005-09-12,2005-09-16,Estimate,,,,,,,2023-02-10,2023-02-14,Actual,"May 5, 2005",Actual,2005-05-05,February 2023,2023-02-28,January 2026,Anticipated,2026-01-31,January 2025,Anticipated,2025-01-31,,Interventional,,,A Study to Assess the Safety of Live Intranasal Sendai Virus Vaccine in Children and Toddlers,A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity,Suspended,,Phase 1,54.0,Anticipated,St. Jude Children's Research Hospital,,1.0,,"voluntary Hold because of COVID-19, all participants were off study prior to the hold.",False,,,,True,True,False,,,,,,,,,,,2023-06-18 01:36:30,2023-06-18 01:36:30,OTHER,,,,,
19661,19662,NCT00652275,,2008-03-18,,,2008-05-06,2008-04-02,2008-04-03,Estimate,,,,,,,2008-05-06,2008-05-07,Estimate,May 2008,,2008-05-31,April 2008,2008-04-30,December 2010,Anticipated,2010-12-31,November 2010,Anticipated,2010-11-30,,Interventional,,,"Immunogenicity, Efficacy and Safety Study of an MSP3-LSP (Long Synthetic Peptide) Malaria Vaccine","Phase IIb Immunogenicity, Efficacy and Safety Study of P. Falciparum Vaccine Candidate, MSP3-LSP Adjuvanted in Aluminium Hydroxide Versus Verorab Control in Healthy Children Aged 12-48 Months in Mali.",Unknown status,Recruiting,Phase 2,378.0,Anticipated,African Malaria Network Trust,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 01:25:59,2023-06-16 01:25:59,NETWORK,,,,,
19813,19814,NCT00710593,,2008-07-02,2013-11-15,,2017-06-01,2008-07-02,2008-07-04,Estimate,2017-04-13,2017-05-22,Actual,,,,2017-06-01,2017-07-02,Actual,February 2008,,2008-02-29,April 2017,2017-04-30,February 2011,Actual,2011-02-28,February 2011,Actual,2011-02-28,,Interventional,,,Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women,"Immunogenicity, Safety, Tolerability, and Behavioral Consequences of an HPV-6, -11, -16, -18 Vaccine in HIV-Infected Young Women",Completed,,Phase 2,99.0,Actual,"University of North Carolina, Chapel Hill",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 01:26:07,2023-06-16 01:26:07,OTHER,,,,,
20167,20168,NCT03412786,,2018-01-02,,,2022-01-10,2018-01-25,2018-01-26,Actual,,,,,,,2022-01-10,2022-01-11,Actual,"May 1, 2018",Actual,2018-05-01,January 2022,2022-01-31,"December 8, 2021",Actual,2021-12-08,"December 8, 2021",Actual,2021-12-08,,Interventional,,,Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases,A Phase I Study of the Bcl-XL_42-CAF09b Vaccine to Test Safety and Immunological Effect in Patients With Prostate Cancer With Lymph Node Metastases,Completed,,Phase 1,20.0,Actual,Herlev Hospital,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-17 00:01:01,2023-06-17 00:01:01,OTHER,,,,,
20203,20204,NCT01072799,,2010-02-19,,,2012-04-23,2010-02-19,2010-02-22,Estimate,,,,,,,2012-04-23,2012-04-25,Estimate,October 2009,,2009-10-31,April 2012,2012-04-30,March 2012,Actual,2012-03-31,March 2012,Actual,2012-03-31,,Interventional,,,Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine,A Phase 2 Study to Assess the Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine,Completed,,Phase 2,4560.0,Actual,Novavax,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 00:01:29,2023-06-17 00:01:29,INDUSTRY,,,,,
20259,20260,NCT01351948,,2011-05-09,,,2013-03-13,2011-05-10,2011-05-11,Estimate,,,,,,,2013-03-13,2013-03-14,Estimate,June 2011,,2011-06-30,March 2013,2013-03-31,March 2013,Actual,2013-03-31,March 2013,Actual,2013-03-31,,Interventional,,,"Safety and Immunogenicity of Malaria Vaccines AdCh63 AMA1, MVA AMA1 and AMA1-C1/Alhydrogel®+/- CPG 7909","A Phase Ia Study to Assess the Safety and Immunogenicity of Novel Schedules for Vaccination With the Candidate Malaria Vaccines; AdCh63 AMA1, MVA AMA1 & AMA1-C1/Alhydrogel® +/- CPG 7909",Completed,,Phase 1,35.0,Actual,University of Oxford,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 00:02:07,2023-06-17 00:02:07,OTHER,,,,,
20384,20385,NCT05876364,,2023-05-01,,,2023-05-24,2023-05-24,2023-05-25,Actual,,,,,,,2023-05-24,2023-05-25,Actual,"November 19, 2021",Actual,2021-11-19,May 2023,2023-05-31,"August 30, 2023",Anticipated,2023-08-30,"June 13, 2022",Actual,2022-06-13,,Interventional,,,"Study to Assess Safety, Reactogenicity and Immunogenicity of the repRNA(QTP104) Vaccine Against SARS-CoV-2(COVID-19)","A Phase 1, Dose-escalation, Multi-center, Open-label, Study to Evaluate the Safety, Reactogenicity and Immunogenicity of a Preventive SARS-CoV-2 Vaccine (QTP104) in Healthy Adults","Active, not recruiting",,Phase 1,36.0,Anticipated,Quratis Inc.,,3.0,,,False,,,,False,True,False,,,True,,,,,,,,2023-06-15 01:06:14,2023-06-15 01:06:14,INDUSTRY,,,,,
20942,20943,NCT02640404,,2015-12-22,2017-12-06,,2017-12-06,2015-12-22,2015-12-29,Estimate,2017-12-06,2018-01-08,Actual,,,,2017-12-06,2018-01-08,Actual,"June 6, 2016",,2016-06-06,December 2017,2017-12-31,"December 5, 2016",Actual,2016-12-05,"December 5, 2016",Actual,2016-12-05,,Interventional,,Safety analysis set included all participants who received at least 1 dose of study vaccine.,"Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam","Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Healthy Subjects Aged 9 Months to 55 Years in Vietnam",Completed,,Phase 2,224.0,Actual,Sanofi,,2.0,,,False,,,,False,True,False,,,True,,,,,,,,2023-06-18 01:42:44,2023-06-18 01:42:44,INDUSTRY,,,,,
21020,21021,NCT00231413,,2005-10-03,2019-11-25,,2019-11-25,2005-10-03,2005-10-04,Estimate,2019-11-25,2019-12-12,Actual,,,,2019-11-25,2019-12-12,Actual,"March 4, 2005",Actual,2005-03-04,November 2019,2019-11-30,"March 27, 2006",Actual,2006-03-27,"March 27, 2006",Actual,2006-03-27,,Interventional,,,Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.,"A Dose-range Study to Assess the Safety and Immunogenicity of a Novel HPV Vaccine When Administered Intramuscularly According to a 3-dose Schedule (0,1,6-month) in Healthy Adult Females (18-25 Years of Age)",Completed,,Phase 2,383.0,Actual,GlaxoSmithKline,,7.0,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below).,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://www.clinicalstudydatarequest.com/Posting.aspx?ID=1504,Yes,IPD is available via the Clinical Study Data Request site (click on the link provided below).,2023-06-17 00:07:51,2023-06-17 00:07:51,INDUSTRY,,,,,
21207,21208,NCT04528641,,2020-08-19,2022-01-17,,2022-02-07,2020-08-25,2020-08-27,Actual,2022-02-07,2022-02-08,Actual,,,,2022-02-07,2022-02-08,Actual,"August 10, 2020",Actual,2020-08-10,January 2022,2022-01-31,"May 19, 2021",Actual,2021-05-19,"May 19, 2021",Actual,2021-05-19,,Interventional,,,Phase I Study to Assess the Safety and Immunology of a COVID-19 Vaccine With GRAd-COV2 Vaccine,"A Phase 1, Dosage-Escalation Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine GRAd-COV2 in Healthy Adults and Elderly Subjects",Completed,,Phase 1,98.0,Actual,ReiThera Srl,,6.0,,,False,,,,,False,False,,,,,,,,,No,,2023-06-17 03:56:18,2023-06-17 03:56:18,INDUSTRY,,,,,
21420,21421,NCT01111968,,2010-04-14,,,2013-02-05,2010-04-27,2010-04-28,Estimate,,,,,,,2013-02-05,2013-02-06,Estimate,January 2010,,2010-01-31,February 2013,2013-02-28,March 2011,Actual,2011-03-31,December 2010,Actual,2010-12-31,,Interventional,,,Evaluation of Pandemic Influenza A (H1N1)Candidate Vaccines,"Evaluation of Safety, Tolerability and Immunogenicity of Adjuvanted Candidate Vaccines Against Pandemic Influenza A (H1N1)",Completed,,Phase 1,266.0,Actual,Butantan Institute,,10.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 00:11:01,2023-06-17 00:11:01,OTHER_GOV,,,,,
21672,21673,NCT00960752,,2009-08-17,2021-07-20,,2021-07-20,2009-08-17,2009-08-18,Estimate,2021-07-20,2021-08-13,Actual,,,,2021-07-20,2021-08-13,Actual,"May 20, 2010",Actual,2010-05-20,July 2021,2021-07-31,"July 20, 2020",Actual,2020-07-20,"July 20, 2020",Actual,2020-07-20,,Interventional,,,Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist,Activation of pDCs at the Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist,Completed,,Phase 2,47.0,Actual,M.D. Anderson Cancer Center,,3.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-16 01:28:28,2023-06-16 01:28:28,OTHER,,,,,
22034,22035,NCT05035238,,2021-09-01,,,2021-09-01,2021-09-01,2021-09-05,Actual,,,,,,,2021-09-01,2021-09-05,Actual,"September 20, 2021",Anticipated,2021-09-20,September 2021,2021-09-30,"September 20, 2022",Anticipated,2022-09-20,"September 20, 2022",Anticipated,2022-09-20,,Interventional,,,"Evaluation of the Efficacy, Safety and Immunogenicity of Inactivated COVID 19 Vaccine(TURKOVAC) in Healthy Population of 18 and 64 Years of Age (Both Inclusive):a Randomized, Double-blind, Phase IIb Clinical Trial","Evaluation of the Efficacy, Safety and Immunogenicity of Inactivated COVID 19 Vaccine (TURKOVAC Inactive) in Healthy Population of 18 and 64 Years of Age (Both Inclusive): a Randomized, Double-blind, Phase IIb Clinical Trial",Not yet recruiting,,Phase 2,200.0,Anticipated,Health Institutes of Turkey,,2.0,,,False,,,,True,False,False,,,False,,,,,,No,,2023-06-18 01:47:39,2023-06-18 01:47:39,OTHER_GOV,,,,,
22054,22055,NCT01585350,,2012-04-24,,,2016-08-11,2012-04-24,2012-04-25,Estimate,,,,,,,2016-08-11,2016-08-12,Estimate,October 2012,,2012-10-31,August 2016,2016-08-31,October 2014,Actual,2014-10-31,July 2014,Actual,2014-07-31,,Interventional,MEL58,,A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients,"A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients, With Evaluation of the Injection Site Microenvironment",Completed,,Phase 1,53.0,Actual,University of Virginia,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 00:15:14,2023-06-17 00:15:14,OTHER,,,,,
22076,22077,NCT05871541,,2023-05-03,,,2023-05-23,2023-05-12,2023-05-23,Actual,,,,,,,2023-05-23,2023-05-25,Actual,May 2023,Anticipated,2023-05-31,May 2023,2023-05-31,"March 21, 2024",Anticipated,2024-03-21,"February 23, 2024",Anticipated,2024-02-23,,Interventional,JCXH-105,,"A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine","A Phase 1 Randomized, Double-Blinded, Active-Controlled, 2-Dose Study to Assess the Safety and Immunogenicity of a Herpes Zoster (HZ) Vaccine, JCXH-105, in Healthy Subjects 50 to 69 Years of Age.",Recruiting,,Phase 1,75.0,Anticipated,"Immorna Biotherapeutics, Inc.",,2.0,,,False,,,,,True,False,,,,,,,,,No,,2023-06-15 01:07:44,2023-06-15 01:07:44,INDUSTRY,,,,,
22351,22352,NCT04162600,,2019-11-11,,,2022-05-06,2019-11-13,2019-11-14,Actual,,,,,,,2022-05-06,2022-05-09,Actual,"January 2, 2020",Actual,2020-01-02,May 2022,2022-05-31,September 2023,Anticipated,2023-09-30,September 2023,Anticipated,2023-09-30,,Interventional,,,Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG,A Phase I Clinical Trial to Determine the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG in UK Healthy Adult Volunteer,"Active, not recruiting",,Phase 1,18.0,Actual,University of Oxford,,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-17 00:17:08,2023-06-17 00:17:08,OTHER,,,,,
22502,22503,NCT05023928,,2021-08-21,,,2021-08-21,2021-08-21,2021-08-27,Actual,,,,,,,2021-08-21,2021-08-27,Actual,"September 1, 2021",Anticipated,2021-09-01,August 2021,2021-08-31,"September 1, 2023",Anticipated,2023-09-01,"March 1, 2023",Anticipated,2023-03-01,,Interventional,,,Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for Esophagus Cancer,Research on the Transformation of Postoperative Adjuvant Therapy of Tumor Antigen-sensitized DC Vaccine Applied to Esophagus Cancer,Not yet recruiting,,Phase 1,20.0,Anticipated,Sichuan University,,1.0,,,False,,,,False,False,False,,,,,,,,,Yes,,2023-06-18 01:49:23,2023-06-18 01:49:23,OTHER,,,,,
22865,22866,NCT02859350,,2016-07-27,,,2018-10-10,2016-08-03,2016-08-09,Estimate,,,,,,,2018-10-10,2018-10-15,Actual,November 2016,Actual,2016-11-30,October 2018,2018-10-31,February 2018,Actual,2018-02-28,December 2017,Actual,2017-12-31,,Interventional,,,"Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea.","Age Escalation / De-escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of a Radiation-attenuated Plasmodium Falciparum (Pf) Sporozoite Vaccine (PfSPZ Vaccine) in Equatoguinean Adults, Children and Infants, and Comparison With Non-attenuated Pf Sporozoites (PfSPZ Challenge) Administered Under Chloroquine Prophylaxis (PfSPZ-CVac Approach) for Efficacy Against Controlled Human Malaria Infection.",Completed,,Phase 1,135.0,Actual,Sanaria Inc.,,15.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 01:29:41,2023-06-16 01:29:41,INDUSTRY,,,,,
23040,23041,NCT05027672,,2021-08-18,,,2021-08-24,2021-08-24,2021-08-30,Actual,,,,,,,2021-08-24,2021-08-30,Actual,"July 30, 2021",Actual,2021-07-30,August 2021,2021-08-31,"September 6, 2021",Anticipated,2021-09-06,"August 30, 2021",Anticipated,2021-08-30,,Interventional,,,Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines.,"Randomised Phase II Study to Assess the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schedules (rAd26-rAd5, rAd26-rAd26, rAd26-ChAdOx1 and rAd26-mRNA-1273).","Active, not recruiting",,Phase 2,348.0,Actual,Ministerio de Salud de Ciudad Autónoma de Buenos Aires,,4.0,,,False,,,,True,False,False,,,False,,,,,,No,,2023-06-18 01:51:30,2023-06-18 01:51:30,OTHER_GOV,,,,,
23051,23052,NCT03102034,,2017-03-23,2019-05-23,,2022-01-13,2017-03-29,2017-04-05,Actual,2019-05-23,2019-06-14,Actual,,,,2022-01-13,2022-02-08,Actual,"April 6, 2017",Actual,2017-04-06,January 2022,2022-01-31,"May 25, 2018",Actual,2018-05-25,"May 25, 2018",Actual,2018-05-25,,Interventional,,Baseline analysis population was participants who received inoculation.,"Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/<U+0394>M2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age","Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, D46/NS2/N/<U+0394>M2-2-HindIII, Lot RSV#011B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age",Completed,,Phase 1,32.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-17 00:21:57,2023-06-17 00:21:57,NIH,,,,,
23249,23250,NCT03929172,,2019-04-12,,,2020-06-29,2019-04-24,2019-04-26,Actual,,,,,,,2020-06-29,2020-07-01,Actual,"February 28, 2019",Actual,2019-02-28,June 2020,2020-06-30,"May 29, 2020",Actual,2020-05-29,"May 29, 2020",Actual,2020-05-29,,Interventional,,,"A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects","A First-in-Human, Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety and Tolerability, and to Explore Immunological Effects of I.M. Administered AAVLP-HPV Vaccine in Healthy Adult Male and Female Subjects",Completed,,Phase 1,20.0,Actual,2A Pharma AB,,2.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-17 00:23:14,2023-06-17 00:23:14,INDUSTRY,,,,,
23265,23266,NCT01132014,,2010-05-26,,,2018-06-08,2010-05-26,2010-05-27,Estimate,,,,,,,2018-06-08,2018-06-11,Actual,May 2010,,2010-05-31,April 2018,2018-04-30,"May 30, 2018",Actual,2018-05-30,"May 30, 2018",Actual,2018-05-30,,Interventional,,,Autologous OC-DC Vaccine in Ovarian Cancer,"A Pilot Clinical Trial of Dendritic Cell Vaccine Loaded With Autologous Tumor for Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer",Completed,,Early Phase 1,67.0,Actual,Abramson Cancer Center at Penn Medicine,,,,,False,,,,True,True,,,,,,,,,,,,2023-06-17 00:23:17,2023-06-17 00:23:17,OTHER,,,,,
23491,23492,NCT02126761,,2014-04-28,,,2016-07-28,2014-04-28,2014-04-30,Estimate,,,,,,,2016-07-28,2016-07-29,Estimate,June 2014,,2014-06-30,December 2015,2015-12-31,November 2015,Actual,2015-11-30,November 2015,Actual,2015-11-30,,Interventional,,,"Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above","A Phase 1, Randomized, Observer Blind, Antigen and Adjuvant Dosage-Finding Study to Evaluate the Safety and Immunogenicity of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects =65 Years of Age",Completed,,Phase 1,196.0,Actual,Seqirus,,7.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 01:53:36,2023-06-18 01:53:36,INDUSTRY,,,,,
24226,24227,NCT04985760,,2021-07-21,,,2023-05-23,2021-07-21,2021-08-02,Actual,,,,,,,2023-05-23,2023-05-25,Actual,"September 30, 2021",Actual,2021-09-30,May 2023,2023-05-31,"January 31, 2025",Anticipated,2025-01-31,"June 30, 2024",Anticipated,2024-06-30,,Interventional,NETI,,Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy,"Safety, Tolerability and Immunogenicity of Recombinant HIV Envelope Protein VRC-HIVRGP096-00-VP (Trimer 4571) Vaccine, in HIV-1 Infected Adults on Suppressive ART",Recruiting,,Phase 1,32.0,Anticipated,University of Pittsburgh,,4.0,,,,,,,True,True,False,,,,,,,,,No,,2023-06-15 01:10:58,2023-06-15 01:10:58,OTHER,,,,,
24302,24303,NCT02132299,,2014-04-29,,,2016-04-25,2014-05-06,2014-05-07,Estimate,,,,,,,2016-04-25,2016-04-27,Estimate,April 2014,,2014-04-30,April 2016,2016-04-30,August 2015,Actual,2015-08-31,July 2015,Actual,2015-07-31,,Interventional,,,"Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults","Phase 1, Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults",Completed,,Phase 1,67.0,Actual,Sanaria Inc.,,7.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 01:57:57,2023-06-18 01:57:57,INDUSTRY,,,,,
24499,24500,NCT05844423,,2023-04-24,,,2023-05-04,2023-04-24,2023-05-06,Actual,,,,,,,2023-05-04,2023-05-08,Actual,"March 29, 2023",Actual,2023-03-29,May 2023,2023-05-31,December 2025,Anticipated,2025-12-31,December 2025,Anticipated,2025-12-31,,Interventional,,,"Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants","Randomized, Observer-Blind, Active-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, and Immunogenicity of 24-Valent PCV (VAX-24) in Infants Given 4 Doses at 2, 4, 6, and 12-15 Months of Age With Pediatric Vaccines",Recruiting,,Phase 2,800.0,Anticipated,"Vaxcyte, Inc.",,4.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-17 00:30:32,2023-06-17 00:30:32,INDUSTRY,,,,,
24524,24525,NCT05844202,,2023-05-02,,,2023-05-02,2023-05-02,2023-05-06,Actual,,,,,,,2023-05-02,2023-05-06,Actual,"June 27, 2022",Actual,2022-06-27,May 2023,2023-05-31,"March 2, 2023",Actual,2023-03-02,"March 2, 2023",Actual,2023-03-02,,Interventional,,,"Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 Prevention","A Phase 1 Open-label, Active-controlled, Randomized Dose-finding Study to Evaluate Safety, Tolerability, and Immunogenicity of Intradermal and Subcutaneous Application of the Plasmid DNA SARS-CoV-2 Omicron BA.2 Vaccine Alveavax-v1.2 in Primary Ad26.COV2.S Vaccinated Healthy Individuals",Completed,,Phase 1,130.0,Actual,"Alvea Holdings, LLC",,5.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-17 00:30:42,2023-06-17 00:30:42,INDUSTRY,,,,,
24904,24905,NCT05801913,,2023-03-24,,,2023-05-02,2023-04-05,2023-04-06,Actual,,,,,,,2023-05-02,2023-05-06,Actual,"September 13, 2023",Anticipated,2023-09-13,May 2023,2023-05-31,"September 30, 2026",Anticipated,2026-09-30,"September 30, 2026",Anticipated,2026-09-30,,Interventional,,,Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma,A Pilot / Feasibility Study of Autologous CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine in Patients With Intermediate or High Grade B-Lineage Non-Hodgkin Lymphoma,Recruiting,,Phase 1,15.0,Anticipated,City of Hope Medical Center,,1.0,,,,,,,True,True,False,,,,,,,,,,,2023-06-17 00:33:32,2023-06-17 00:33:32,OTHER,,,,,
24939,24940,NCT05784701,,2023-02-07,,,2023-05-02,2023-03-13,2023-03-27,Actual,,,,,,,2023-05-02,2023-05-06,Actual,"April 5, 2023",Actual,2023-04-05,May 2023,2023-05-31,"December 30, 2026",Anticipated,2026-12-30,"April 5, 2025",Anticipated,2025-04-05,,Interventional,,,Trivalent Salmonella Conjugate Vaccine (TSCV),"Age-descending, Randomized, Placebo-controlled Phase 2 Trial in Three Sites in Sub-Saharan Africa to Assess the Safety and Immunogenicity of a Parenteral Trivalent Salmonella (S. Enteritidis/S. Typhimurium/S. Typhi Vi) Conjugate Vaccine (TSCV) Versus Placebo",Recruiting,,Phase 2,800.0,Anticipated,"University of Maryland, Baltimore",,4.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 00:33:44,2023-06-17 00:33:44,OTHER,,,,,
24978,24979,NCT05770180,,2023-03-10,,,2023-05-04,2023-03-10,2023-03-15,Actual,,,,,,,2023-05-04,2023-05-08,Actual,"March 30, 2023",Actual,2023-03-30,March 2023,2023-03-31,May 2024,Anticipated,2024-05-31,July 2023,Anticipated,2023-07-31,,Interventional,,,Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell),"A Single-center, Randomized, Double-blind, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Booster Vaccination of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) in Healthy People Aged 18 Years and Older","Active, not recruiting",,Phase 2,450.0,Actual,"WestVac Biopharma Co., Ltd.",,4.0,,,False,,,,,False,False,,,,,,,,,No,,2023-06-17 00:33:59,2023-06-17 00:33:59,INDUSTRY,,,,,
25003,25004,NCT05765604,,2023-03-10,,,2023-05-04,2023-03-10,2023-03-13,Actual,,,,,,,2023-05-04,2023-05-08,Actual,"March 14, 2023",Actual,2023-03-14,March 2023,2023-03-31,July 2024,Anticipated,2024-07-31,July 2023,Anticipated,2023-07-31,,Interventional,,,Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (WSK-V102),"A Randomized, Parallel Controlled, Double-blind, Single-center Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)(WSK-V102) in People Aged 18 Years or Older","Active, not recruiting",,Phase 1,72.0,Actual,"WestVac Biopharma Co., Ltd.",,2.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-17 00:34:06,2023-06-17 00:34:06,INDUSTRY,,,,,
25146,25147,NCT02564575,,2015-09-29,,,2017-01-31,2015-09-29,2015-09-30,Estimate,,,,,,,2017-01-31,2017-02-01,Estimate,August 2015,,2015-08-31,January 2017,2017-01-31,November 2016,Actual,2016-11-30,November 2016,Actual,2016-11-30,,Interventional,,,Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults,Phase 1 Evaluation of a Live Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein,Completed,,Phase 1,30.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 01:33:02,2023-06-16 01:33:02,NIH,,,,,
25210,25211,NCT05652504,,2022-12-14,,,2023-05-04,2022-12-14,2022-12-15,Actual,,,,,,,2023-05-04,2023-05-06,Actual,"September 1, 2023",Anticipated,2023-09-01,"February 2, 2023",2023-02-02,"November 30, 2024",Anticipated,2024-11-30,"November 30, 2024",Anticipated,2024-11-30,,Interventional,,,Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1),Phase 1 Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1),Suspended,,Phase 1,120.0,Anticipated,National Institutes of Health Clinical Center (CC),,2.0,,The FDA has placed a clinical hold on the IND under which this research is to be conducted.,False,,,,,True,False,,,,,,,,,No,,2023-06-17 00:35:28,2023-06-17 00:35:28,NIH,,,,,
25259,25260,NCT05613205,,2022-11-04,,,2023-05-03,2022-11-04,2022-11-14,Actual,,,,,,,2023-05-03,2023-05-06,Actual,"December 5, 2022",Actual,2022-12-05,May 2023,2023-05-31,"February 7, 2024",Anticipated,2024-02-07,"June 1, 2023",Anticipated,2023-06-01,,Interventional,,,Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults,"A Phase 1, Observer-blind, Randomised, Controlled, Single-centre Study to Evaluate the Safety, Reactogenicity, and Immune Responses to an Adjuvanted and Non-adjuvanted Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults 18 to 50 Years of Age in Europe",Recruiting,,Phase 1,96.0,Anticipated,GlaxoSmithKline,,7.0,,,False,,,,False,False,False,,,False,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-17 00:35:58,2023-06-17 00:35:58,INDUSTRY,,,,,
25367,25368,NCT05496231,,2022-08-03,,,2023-05-02,2022-08-10,2022-08-11,Actual,,,,,,,2023-05-02,2023-05-06,Actual,"August 22, 2022",Actual,2022-08-22,May 2023,2023-05-31,"March 29, 2024",Anticipated,2024-03-29,"March 29, 2024",Anticipated,2024-03-29,,Interventional,,,A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age,"A Phase 1/2 Randomized, Observer-blinded, Multi-country Study to Evaluate Safety and Immunogenicity of Investigational Adjuvanted Human Papillomavirus Vaccine in Females (16 to 26 Years of Age)","Active, not recruiting",,Phase 2,1080.0,Anticipated,GlaxoSmithKline,,4.0,,,False,,,,False,True,False,,,True,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-17 00:36:42,2023-06-17 00:36:42,INDUSTRY,,,,,
25639,25640,NCT05291676,,2022-03-07,,,2023-05-02,2022-03-15,2022-03-23,Actual,,,,,,,2023-05-02,2023-05-06,Actual,September 2023,Anticipated,2023-09-30,May 2023,2023-05-31,April 2027,Anticipated,2027-04-30,April 2027,Anticipated,2027-04-30,,Interventional,,,Systems Investigation of Vaccine Responses in Aging and Frailty,Systems Investigation of Vaccine Responses in Aging and Frailty,Not yet recruiting,,Phase 2,96.0,Anticipated,Yale University,,4.0,,,False,,,,True,True,False,,,False,,,,,,Yes,"Data with Protected Health Information (PHI) removed on participant demographics and health conditions, and primary and secondary outcome data will be uploaded to the NIH ImmPort as required by the NIH Human Immunology Project Consortium.

Publicly available data will be released after publication. Registration on ImmPort required by the NIH. Timeframe for data upload will be approximately 6-12 months after each influenza vaccine season during the study.",2023-06-17 00:38:40,2023-06-17 00:38:40,OTHER,,,,,
25907,25908,NCT05183854,,2021-12-21,,,2023-05-04,2021-12-21,2022-01-11,Actual,,,,,,,2023-05-04,2023-05-06,Actual,"January 7, 2022",Actual,2022-01-07,May 2023,2023-05-31,"January 7, 2027",Anticipated,2027-01-07,"January 7, 2025",Anticipated,2025-01-07,,Interventional,,,"Pneumococcal Pneumonia Vaccine Series (PCV13 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial",Phase II Study of the Efficacy of the Pneumococcal Pneumonia Vaccine Series in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency (PROTECT CLL),Recruiting,,Phase 2,60.0,Anticipated,University of Utah,,2.0,,,False,,,,True,True,False,,,False,,,,,,No,,2023-06-17 00:39:35,2023-06-17 00:39:35,OTHER,,,,,
26104,26105,NCT05000216,,2021-08-06,,,2023-05-05,2021-08-06,2021-08-11,Actual,,,,,,,2023-05-05,2023-05-08,Actual,"August 13, 2021",Actual,2021-08-13,May 2023,2023-05-31,November 2024,Anticipated,2024-11-30,December 2023,Anticipated,2023-12-31,,Interventional,,,COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders,Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccine (ACV01),"Active, not recruiting",,Phase 2,2340.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,43.0,,,False,,,,True,True,False,,,,,,"On average, within 24 months after database lock for the trial.",Open access.,https://www.immport.org/home,Yes,"The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.",2023-06-17 00:41:06,2023-06-17 00:41:06,NIH,,,,,
26487,26488,NCT04579510,,2020-09-22,,,2023-05-02,2020-10-05,2020-10-08,Actual,,,,,,,2023-05-02,2023-05-06,Actual,"February 8, 2021",Actual,2021-02-08,May 2023,2023-05-31,"December 23, 2021",Actual,2021-12-23,"December 23, 2021",Actual,2021-12-23,,Interventional,,,Immunogenicity nOPV2 With and Without bOPV,Immunogenicity of Novel Monovalent Oral Poliovirus Vaccine Type 2 (nOPV2) With and Without Bivalent OPV,Completed,,Phase 2,795.0,Actual,Centers for Disease Control and Prevention,,3.0,,,False,,,,True,False,False,,,,,,,,,No,"Aggregated data will be added to the registration with publication. In accordance with the protocol, icddr,b investigators will have access to participant data with identifiers. External investigators will have access to deidentified participant data. Deidentified data may be shared with national and international vaccine manufacturers and regulatory authorities upon request.",2023-06-17 00:44:04,2023-06-17 00:44:04,FED,,,,,
26649,26650,NCT05518201,,2022-08-25,,,2022-10-12,2022-08-25,2022-08-26,Actual,,,,,,,2022-10-12,2022-10-13,Actual,"September 23, 2022",Actual,2022-09-23,October 2022,2022-10-31,September 2024,Anticipated,2024-09-30,September 2024,Anticipated,2024-09-30,,Interventional,,,Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old,"Evaluate the Safety and Immunogenicity of the 9-valent Human Papillomavirus Recombinant Vaccine (Hansenula Polymorpha) in Chinese Male Aged 9-45 Years: A Randomized, Blinded and Placebo-Controlled Phase I Study",Recruiting,,Phase 1,90.0,Anticipated,"Shanghai Bovax Biotechnology Co., Ltd.",,2.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-18 02:12:22,2023-06-18 02:12:22,INDUSTRY,,,,,
26825,26826,NCT04117087,,2019-10-03,,,2023-05-03,2019-10-03,2019-10-07,Actual,,,,,,,2023-05-03,2023-05-06,Actual,"May 28, 2020",Actual,2020-05-28,May 2023,2023-05-31,"December 8, 2024",Anticipated,2024-12-08,"December 8, 2024",Anticipated,2024-12-08,,Interventional,,,Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer,Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer,Recruiting,,Phase 1,30.0,Anticipated,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,1.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 00:47:06,2023-06-17 00:47:06,OTHER,,,,,
27031,27032,NCT03758625,,2018-11-20,,,2023-05-02,2018-11-28,2018-11-29,Actual,,,,,,,2023-05-02,2023-05-06,Actual,"November 30, 2018",Actual,2018-11-30,May 2023,2023-05-31,June 2024,Anticipated,2024-06-30,September 2023,Anticipated,2023-09-30,,Interventional,DC-HIV04,,Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure,"A Phase I Study to Evaluate the Safety, Tolerability and Immunogenicity of a Therapeutic HIV Vaccine Composed of Autologous Dendritic Cells Loaded With Autologous Inactivated Whole Virus or Conserved Peptides in ART-treated HIV-infected Adults",Recruiting,,Phase 1,40.0,Anticipated,University of Pittsburgh,,6.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-17 00:48:48,2023-06-17 00:48:48,OTHER,,,,,
27198,27199,NCT03387553,,2017-12-19,,,2023-05-03,2017-12-22,2018-01-02,Actual,,,,,,,2023-05-03,2023-05-06,Actual,"June 6, 2018",Actual,2018-06-06,April 2023,2023-04-30,"August 29, 2026",Anticipated,2026-08-29,"August 29, 2026",Anticipated,2026-08-29,,Interventional,,,HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer,A Pilot Study Utilizing a HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+ Breast Cancer,"Active, not recruiting",,Early Phase 1,31.0,Actual,H. Lee Moffitt Cancer Center and Research Institute,,3.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-17 00:50:39,2023-06-17 00:50:39,OTHER,,,,,
27298,27299,NCT03179761,,2017-06-01,2022-10-24,,2023-05-02,2017-06-05,2017-06-07,Actual,2022-12-19,2023-01-12,Actual,,,,2023-05-02,2023-05-06,Actual,"October 9, 2017",Actual,2017-10-09,May 2023,2023-05-31,"March 31, 2024",Anticipated,2024-03-31,"February 15, 2022",Actual,2022-02-15,,Interventional,,All participants who received at least one dose of their assigned vaccine,High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients,High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients,"Active, not recruiting",,Phase 2,124.0,Actual,Vanderbilt-Ingram Cancer Center,,2.0,,,False,,,,True,True,False,,,,,,,,,Undecided,,2023-06-17 00:51:30,2023-06-17 00:51:30,OTHER,,,,,
27404,27405,NCT02860039,,2016-08-04,2022-02-02,,2023-05-02,2016-08-04,2016-08-09,Estimate,2022-03-21,2022-04-14,Actual,,,,2023-05-02,2023-05-06,Actual,September 2016,Actual,2016-09-30,May 2023,2023-05-31,September 2024,Anticipated,2024-09-30,"December 1, 2021",Actual,2021-12-01,,Interventional,,All participants who received at least one dose of their assigned vaccine,High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant,Comparison of High vs. Standard Dose Flu Vaccine in Pediatric Stem Cell Transplant Recipients,"Active, not recruiting",,Phase 2,170.0,Actual,Vanderbilt-Ingram Cancer Center,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 00:52:42,2023-06-17 00:52:42,OTHER,,,,,
27620,27621,NCT01814813,,2013-03-18,2019-04-08,,2023-05-02,2013-03-18,2013-03-20,Estimate,2019-05-17,2019-06-12,Actual,,,,2023-05-02,2023-05-06,Actual,May 2013,Actual,2013-05-31,May 2023,2023-05-31,"May 1, 2023",Actual,2023-05-01,"April 3, 2017",Actual,2017-04-03,,Interventional,,,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,"A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)",Terminated,,Phase 2,90.0,Actual,Alliance for Clinical Trials in Oncology,,3.0,,DSMB futility analysis,False,,,,True,,,,,,,,,,,,,2023-06-17 00:54:54,2023-06-17 00:54:54,OTHER,,,,,
27674,27675,NCT01405521,,2011-07-28,,,2023-05-03,2011-07-28,2011-07-29,Estimate,,,,,,,2023-05-03,2023-05-06,Actual,"October 7, 2011",Actual,2011-10-07,December 2020,2020-12-31,"May 6, 2022",Actual,2022-05-06,December 2015,Actual,2015-12-31,,Interventional,,,Understanding Typhoid Disease After Vaccination,"Understanding Typhoid Disease After Vaccination: a Single Centre, Randomised, Doubleblind, Placebo Controlled Study to Evaluate M01ZH09 in a Healthy Adult Challenge Model, Using Ty21a Vaccine as a Positive Control.",Completed,,Phase 2,99.0,Actual,University of Oxford,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 00:55:30,2023-06-17 00:55:30,OTHER,,,,,
27848,27849,NCT05794659,,2023-03-07,,,2023-03-20,2023-03-20,2023-04-03,Actual,,,,,,,2023-03-20,2023-04-03,Actual,"August 15, 2023",Anticipated,2023-08-15,March 2023,2023-03-31,"August 15, 2027",Anticipated,2027-08-15,"October 15, 2025",Anticipated,2025-10-15,,Interventional,Cornerstone4,,"Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer","A Randomized Phase 2 Study to Evaluate the Efficacy and Safety for Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer (Cornerstone-004)",Not yet recruiting,,Phase 2,98.0,Anticipated,Aston Sci. Inc.,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 00:57:09,2023-06-17 00:57:09,INDUSTRY,,,,,
28136,28137,NCT02063555,,2014-02-13,,,2016-08-01,2014-02-13,2014-02-14,Estimate,,,,,,,2016-08-01,2016-08-02,Estimate,February 2014,,2014-02-28,August 2016,2016-08-31,June 2016,Actual,2016-06-30,March 2016,Actual,2016-03-31,,Interventional,,,Phase I Trial of DAR-901,"A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose, Dose-Ranging Study of the Safety and Immunogenicity of DAR-901, a Killed, Non-Tuberculous Mycobacterial Vaccine, in HIV-negative and HIV-positive Adults Who Have Previously Received BCG",Completed,,Phase 1,59.0,Actual,Dartmouth-Hitchcock Medical Center,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 02:19:54,2023-06-18 02:19:54,OTHER,,,,,
29271,29272,NCT05038618,,2021-08-25,,,2022-06-10,2021-08-31,2021-09-09,Actual,,,,,,,2022-06-10,2022-06-13,Actual,"August 2, 2021",Actual,2021-08-02,October 2021,2021-10-31,"March 11, 2022",Actual,2022-03-11,"October 14, 2021",Actual,2021-10-14,,Interventional,,,"A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study","A Phase II, Prospective, Open-Label, Single-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine Candidate MVC-COV1901, CT-COV-21 Sub-study",Completed,,Phase 2,399.0,Actual,Medigen Vaccine Biologics Corp.,,1.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-17 01:08:21,2023-06-17 01:08:21,INDUSTRY,,,,,
29339,29340,NCT03237663,,2017-07-31,,,2017-08-01,2017-08-01,2017-08-02,Actual,,,,,,,2017-08-01,2017-08-02,Actual,"March 30, 2015",Actual,2015-03-30,August 2017,2017-08-31,"June 23, 2017",Actual,2017-06-23,"November 5, 2016",Actual,2016-11-05,,Interventional,,,Safety of An Oral O1 / O139 Cholera Vaccine (Enteric Capsules),Safety of An Oral O1 / O139 Cholera Vaccine (Enteric Capsules) Through Phase I Clinical Trial in China,Completed,,Phase 1,60.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,2.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-18 02:26:50,2023-06-18 02:26:50,NETWORK,,,,,
29375,29376,NCT00700713,,2008-05-07,2016-01-16,2010-09-02,2016-01-16,2008-06-18,2008-06-19,Estimate,2016-01-16,2016-02-15,Estimate,2010-09-02,2010-09-08,Estimate,2016-01-16,2016-02-15,Estimate,June 2008,,2008-06-30,January 2016,2016-01-31,March 2009,Actual,2009-03-31,February 2009,Actual,2009-02-28,,Interventional,,,Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26,"Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) Three Years Earlier in Study MTA26",Completed,,Phase 2,181.0,Actual,Sanofi,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 02:27:10,2023-06-18 02:27:10,INDUSTRY,,,,,
29607,29608,NCT04082182,,2019-06-20,,,2021-03-29,2019-09-06,2019-09-09,Actual,,,,,,,2021-03-29,2021-03-30,Actual,"August 26, 2019",Actual,2019-08-26,March 2021,2021-03-31,"December 31, 2021",Anticipated,2021-12-31,"June 7, 2021",Anticipated,2021-06-07,,Interventional,MIDRIX4-LUNG,,MIDRIX4-LUNG Dendritic Cell Vaccine in Patients With Metastatic Non-small Cell Lung Cancer,"Phase Ia Study of MIDRIX4-LUNG, a Tetravalent Autologous Dendritic Cell Vaccine, in Patients With Metastatic Non-small Cell Lung Cancer",Unknown status,"Active, not recruiting",Phase 1,7.0,Actual,"University Hospital, Ghent",,1.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-16 01:47:52,2023-06-16 01:47:52,OTHER,,,,,
29878,29879,NCT00921973,,2009-06-15,,,2014-09-22,2009-06-16,2009-06-17,Estimate,,,,,,,2014-09-22,2014-09-23,Estimate,June 2009,,2009-06-30,September 2014,2014-09-30,September 2009,Actual,2009-09-30,July 2009,Actual,2009-07-31,,Interventional,,,Safety of VAX102 Vaccine Given With Seasonal Flu Vaccine in Healthy Adults,"A Multicenter, Double-Blinded, Randomized, Placebo Controlled Study to Investigate the Safety and Immunogenicity of VAX102 When Given in the Same Arm With the Standard Influenza Vaccine in Healthy Adults",Completed,,Phase 1,80.0,Actual,VaxInnate Corporation,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 01:48:04,2023-06-16 01:48:04,INDUSTRY,,,,,
29999,30000,NCT01255410,,2010-12-06,,,2015-12-14,2010-12-06,2010-12-07,Estimate,,,,,,,2015-12-14,2015-12-15,Estimate,January 2011,,2011-01-31,December 2015,2015-12-31,January 2015,Actual,2015-01-31,October 2014,Actual,2014-10-31,,Interventional,,,Evaluation of the Safety and Immunogenicity of a Live Attenuated Human Metapneumovirus Vaccine,"A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Human Metapneumovirus Vaccine, rHMPV-Pa Lot HMPV #101A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HMPV-Seropositive Children 12 to 59 Months of Age, and HMPV-Seronegative Infants and Children 6 to 59 Months of Age",Completed,,Phase 1,60.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,7.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 01:13:10,2023-06-17 01:13:10,NIH,,,,,
30061,30062,NCT01258062,,2010-12-06,,,2017-02-01,2010-12-09,2010-12-10,Estimate,,,,,,,2017-02-01,2017-02-02,Estimate,September 2010,,2010-09-30,February 2017,2017-02-28,April 2011,Actual,2011-04-30,April 2011,Actual,2011-04-30,,Interventional,,,Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults,"Phase 1, Double Blind, Randomized, Placebo Controlled Study to Assess Safety and Immunogenicity of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults.",Completed,,Phase 1,7.0,Actual,Ology Bioservices,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 01:13:47,2023-06-17 01:13:47,INDUSTRY,,,,,
30129,30130,NCT03888924,,2018-09-04,,,2021-06-04,2019-03-21,2019-03-25,Actual,,,,,,,2021-06-04,2021-06-09,Actual,"June 17, 2019",Actual,2019-06-17,June 2021,2021-06-30,"October 1, 2023",Anticipated,2023-10-01,"July 1, 2023",Anticipated,2023-07-01,,Interventional,,,Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS),Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS),Recruiting,,Phase 2,100.0,Anticipated,S. Andrea Hospital,,2.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-17 01:14:10,2023-06-17 01:14:10,OTHER,,,,,
30484,30485,NCT01954563,,2013-09-26,,,2016-01-27,2013-09-26,2013-10-01,Estimate,,,,,,,2016-01-27,2016-01-28,Estimate,October 2013,,2013-10-31,January 2016,2016-01-31,January 2016,Actual,2016-01-31,January 2016,Actual,2016-01-31,,Interventional,,,"Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA85A, as a Way to Increase Immune Response and Avoid Anti-vector Immunity","A Phase I Trial Evaluating Mucosal Administration of a Candidate TB Vaccine, MVA85A, as a Way to Induce Potent Local Cellular Immune Responses and Avoid Anti-vector Immunity",Completed,,Phase 1,37.0,Actual,University of Oxford,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 01:17:21,2023-06-15 01:17:21,OTHER,,,,,
30587,30588,NCT01160172,,2010-07-01,,,2017-05-24,2010-07-08,2010-07-12,Estimate,,,,,,,2017-05-24,2017-05-30,Actual,"July 19, 2010",Actual,2010-07-19,May 2017,2017-05-31,"August 23, 2012",Actual,2012-08-23,"August 23, 2012",Actual,2012-08-23,,Interventional,,,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults","A Partially Blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal 4-component Investigational Vaccine (GSK2392102A) in Healthy Adults",Completed,,Phase 1,88.0,Actual,GlaxoSmithKline,,6.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 01:17:29,2023-06-17 01:17:29,INDUSTRY,,,,,
30590,30591,NCT01266720,,2010-12-23,,,2010-12-23,2010-12-23,2010-12-24,Estimate,,,,,,,2010-12-23,2010-12-24,Estimate,April 2008,,2008-04-30,December 2010,2010-12-31,March 2012,Anticipated,2012-03-31,March 2010,Actual,2010-03-31,,Interventional,,,HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1),"Phase 1 Study of HLA-A*0201 Restricted Antiangiogenic Peptide Vaccine Therapy Using Epitope Peptide Derived From VEGFR1 and VEGFR2 With Gemcitabine in Treating Patients With Unresectable, Recurrent, or Metastatic Pancreatic Cancer",Unknown status,"Active, not recruiting",Phase 1,6.0,Actual,Fukushima Medical University,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 01:17:32,2023-06-17 01:17:32,OTHER,,,,,
30605,30606,NCT01162590,,2010-07-13,,,2017-05-18,2010-07-13,2010-07-14,Estimate,,,,,,,2017-05-18,2017-05-19,Actual,"March 1, 2010",Actual,2010-03-01,May 2017,2017-05-31,"March 31, 2010",Actual,2010-03-31,"March 31, 2010",Actual,2010-03-31,,Interventional,,,Study to Evaluate the Reactogenicity and Safety of Rotarix in Chinese Adults,Reactogenicity and Safety of a Single Dose of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563) in Healthy Adults,Completed,,Phase 1,52.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-17 01:17:43,2023-06-17 01:17:43,INDUSTRY,,,,,
30655,30656,NCT03878004,,2019-03-14,,,2020-06-16,2019-03-15,2019-03-18,Actual,,,,,,,2020-06-16,2020-06-17,Actual,"December 1, 2018",Actual,2018-12-01,March 2019,2019-03-31,"May 31, 2020",Actual,2020-05-31,"December 31, 2019",Actual,2019-12-31,,Interventional,,,Phase II Clinical Trial of Safety and Immunogenicity of Recombinant Subunit Tuberculosis Vaccine GamTBvac,"A Double-blind, Randomized, Multicentre, Placebo-controlled Phase II Clinical Trial of Safety and Immunogenicity of Recombinant Subunit Tuberculosis Vaccine GamTBvac in Healthy Adults",Completed,,Phase 2,180.0,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,2.0,,,False,,,,False,False,False,,,,,,,,,Undecided,,2023-06-17 01:18:10,2023-06-17 01:18:10,OTHER,,,,,
31796,31797,NCT00584194,,2007-12-20,2017-02-22,2017-02-02,2019-12-30,2007-12-31,2008-01-02,Estimate,2017-06-16,2017-07-14,Actual,2017-02-02,2017-02-03,Estimate,2019-12-30,2020-01-03,Actual,June 2004,Actual,2004-06-30,December 2019,2019-12-31,May 2010,Actual,2010-05-31,May 2010,Actual,2010-05-31,,Interventional,RVF,"Baseline includes all subjects vaccinated and doesn't account for drop outs, deviations, and withdraws. Demographics weren't given in Final Clinical Study Report. Numbers are reliant on numbers of females and males receiving vaccination.",Safety and Immunogenicity Study of Rift Valley Fever Vaccine,"Parts A&B: Evaluation of the Safety and Immunogenicity of Rift Valley Fever Vaccine, Inactivated, Dried (TSI-GSD 200), A Phase 2 Study",Completed,,Phase 2,278.0,Actual,U.S. Army Medical Research and Development Command,,1.0,,,False,,,,False,,,,,,,,,,,No,,2023-06-16 01:49:54,2023-06-16 01:49:54,FED,,,,,
32284,32285,NCT03051386,,2017-02-09,,,2021-02-10,2017-02-09,2017-02-13,Actual,,,,,,,2021-02-10,2021-02-11,Actual,"May 30, 2018",Actual,2018-05-30,February 2021,2021-02-28,"April 1, 2023",Anticipated,2023-04-01,"April 1, 2022",Anticipated,2022-04-01,,Interventional,VEE,,Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine in Healthy Adults,"Phase 2 Open-Label Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis (VEE) Vaccine, Live Attenuated, Dried, TC-83, NDBR 102, Lot 4, Run 3, as Primary Vaccination in Healthy Adult Subjects at Risk of Exposure to VEE Virus",Unknown status,"Active, not recruiting",Phase 2,500.0,Anticipated,U.S. Army Medical Research and Development Command,,1.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-18 02:41:40,2023-06-18 02:41:40,FED,,,,,
32309,32310,NCT00604058,,2008-01-17,,,2014-01-20,2008-01-28,2008-01-29,Estimate,,,,,,,2014-01-20,2014-01-22,Estimate,January 2008,,2008-01-31,January 2014,2014-01-31,December 2008,Actual,2008-12-31,September 2008,Actual,2008-09-30,,Interventional,,,Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly,Immunogenicity and Safety of Fractional Doses of Sanofi Pasteur's Inactivated Poliomyelitis Vaccine Administered Intradermally vs Full Doses of Inactivated Poliomyelitis Vaccine Administered Intramuscularly in Healthy Philippines Infants,Completed,,Phase 2,236.0,Actual,Sanofi,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 01:50:32,2023-06-16 01:50:32,INDUSTRY,,,,,
32385,32386,NCT04090658,,2019-09-12,2021-12-07,,2021-12-07,2019-09-12,2019-09-16,Actual,2021-12-07,2022-02-25,Actual,,,,2021-12-07,2022-02-25,Actual,"September 25, 2019",Actual,2019-09-25,December 2021,2021-12-31,"December 11, 2020",Actual,2020-12-11,"January 10, 2020",Actual,2020-01-10,,Interventional,,,A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults,"Phase I, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK's Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Japanese Subjects Aged 60-80 Years",Completed,,Phase 1,40.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,False,False,False,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-18 02:42:25,2023-06-18 02:42:25,INDUSTRY,,,,,
32737,32738,NCT02362464,,2015-02-12,2022-08-17,,2023-04-05,2015-02-12,2015-02-13,Estimate,2022-08-17,2022-09-15,Actual,,,,2023-04-05,2023-04-28,Actual,"May 12, 2015",Actual,2015-05-12,April 2023,2023-04-30,"March 25, 2022",Actual,2022-03-25,"March 25, 2022",Actual,2022-03-25,,Interventional,,,Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139,A Pilot Study of Long Term TARP Vaccination Using A Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccine in Previously Vaccinated Men on NCI 09-C-0139.,Completed,,Phase 2,14.0,Actual,National Institutes of Health Clinical Center (CC),,1.0,,,False,,,,,True,False,,,,,,Clinical data available during the study and indefinitely.,Clinical data will be made available via subscription to Biomedical Translational Research Information System (BTRIS) and with the permission of the study principal investigator (PI).,,Yes,All individual participant data (IPD) recorded in the medical record will be shared with intramural investigators upon request. All collected IPD will be shared with collaborators under the terms of collaborative agreements.,2023-06-17 01:28:01,2023-06-17 01:28:01,NIH,,,,,
32764,32765,NCT01344057,,2011-04-21,2015-12-21,,2023-04-27,2011-04-27,2011-04-28,Estimate,2015-12-21,2016-01-28,Estimate,,,,2023-04-27,2023-04-28,Actual,May 2011,,2011-05-31,April 2023,2023-04-30,June 2011,Actual,2011-06-30,June 2011,Actual,2011-06-30,,Interventional,,Baseline analysis population was defined as all participants who were enrolled into the study.,"Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012","A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2011-2012, When Administered to Elderly Subjects",Completed,,Phase 2,63.0,Actual,Novartis,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 01:28:32,2023-06-17 01:28:32,INDUSTRY,,,,,
32773,32774,NCT00583024,,2007-12-20,2023-02-01,,2023-04-26,2007-12-20,2007-12-31,Estimate,2023-04-26,2023-04-28,Actual,,,,2023-04-26,2023-04-28,Actual,December 2007,Actual,2007-12-31,April 2023,2023-04-30,"January 31, 2023",Actual,2023-01-31,"December 31, 2020",Actual,2020-12-31,,Interventional,APP22,,Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer,Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer,Completed,,Phase 2,32.0,Actual,University of Iowa,,1.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 01:28:38,2023-06-17 01:28:38,OTHER,,,,,
32939,32940,NCT03867162,,2019-02-14,,,2021-02-10,2019-03-06,2019-03-07,Actual,,,,,,,2021-02-10,2021-02-11,Actual,"June 9, 2021",Anticipated,2021-06-09,February 2021,2021-02-28,"June 4, 2025",Anticipated,2025-06-04,"June 4, 2024",Anticipated,2024-06-04,,Interventional,NDBR,,FY15-14: Tularemia Vaccine Protocol (NDBR Lot 4),"Phase 2 Open-Label Safety and Immunogenicity Study of Tularemia Vaccine, Live, Attenuated (NDBR 101, Lot 4) in Adult Subjects at Risk of Exposure to Tularemia Bacteria",Not yet recruiting,,Phase 2,500.0,Anticipated,U.S. Army Medical Research and Development Command,,1.0,,,False,,,,,True,False,,,,,,,,,No,,2023-06-17 01:30:36,2023-06-17 01:30:36,FED,,,,,
32958,32959,NCT01284582,,2011-01-25,,,2012-10-04,2011-01-26,2011-01-27,Estimate,,,,,,,2012-10-04,2012-10-05,Estimate,May 2011,,2011-05-31,October 2012,2012-10-31,July 2012,Actual,2012-07-31,July 2012,Actual,2012-07-31,,Interventional,,,"Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)","Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP), in Healthy Male Subjects With High Density Lipoprotein Cholesterol (HDLc) Blood Concentrations Equal or Below 80 mg/dl",Completed,,Phase 1,36.0,Actual,Affiris AG,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 01:30:48,2023-06-17 01:30:48,INDUSTRY,,,,,
33340,33341,NCT01184976,,2010-08-16,,,2015-03-16,2010-08-18,2010-08-19,Estimate,,,,,,,2015-03-16,2015-03-17,Estimate,August 2010,,2010-08-31,March 2015,2015-03-31,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,,,"Study Of VGX-3400, H5N1 Avian Flu Virus Plasmid DNA With Electroporation Device In Healthy Adult Males","Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity in Healthy Adult Males of a DNA Plasmid Vaccine for HS Avian Influenza (VGX-3400) Administered by Intramuscular (IM) Injection Followed by Electroporation (EP)",Completed,,Phase 1,30.0,Actual,"GeneOne Life Science, Inc.",,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 01:35:00,2023-06-17 01:35:00,INDUSTRY,,,,,
33347,33348,NCT01181856,,2010-08-11,,,2011-03-25,2010-08-11,2010-08-13,Estimate,,,,,,,2011-03-25,2011-03-28,Estimate,January 2010,,2010-01-31,March 2011,2011-03-31,January 2011,Actual,2011-01-31,January 2011,Actual,2011-01-31,,Interventional,,,"Safety of Tuberculosis Vaccine, MVA85A, Administered by the Intramuscular Route and the Intradermal Route",Safety and Immunogenicity of Candidate Tuberculosis (TB) Vaccine MVA85A Administered by the Intramuscular Route and the Intradermal Route: a Phase I Randomised Active Controlled Trial,Completed,,Phase 1,24.0,Anticipated,University of Oxford,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 01:35:06,2023-06-17 01:35:06,OTHER,,,,,
33609,33610,NCT01189656,,2010-08-25,,,2010-08-26,2010-08-26,2010-08-27,Estimate,,,,,,,2010-08-26,2010-08-27,Estimate,January 2009,,2009-01-31,February 2009,2009-02-28,December 2010,Anticipated,2010-12-31,November 2010,Anticipated,2010-11-30,,Interventional,,,A Clinical Study on Therapeutic Double-plasmid Hepatitis B Virus (HBV) DNA Vaccine in Patients With HBeAg-positive Chronic Hepatitis B,"A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study on Specific-Population to Evaluate the Safety and Efficacy of Therapeutic Double-plasmid HBV DNA Vaccine in HBeAg-positive Patients With Chronic Hepatitis B",Unknown status,"Active, not recruiting",Phase 2,33.0,Actual,The 458 Hospital of Chinese PLA,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 01:37:44,2023-06-17 01:37:44,OTHER,,,,,
33638,33639,NCT01194180,,2010-08-31,,,2012-08-29,2010-09-01,2010-09-02,Estimate,,,,,,,2012-08-29,2012-08-30,Estimate,May 2010,,2010-05-31,October 2011,2011-10-31,January 2012,Actual,2012-01-31,January 2012,Actual,2012-01-31,,Interventional,,,"A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A","A Phase 1 Study to Evaluate a BCG Challenge Model as a Method of Assessing Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A, Alone and in Combination",Completed,,Phase 1,48.0,Actual,University of Oxford,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 01:38:02,2023-06-17 01:38:02,OTHER,,,,,
33665,33666,NCT00363077,,2006-08-07,2013-03-21,,2018-05-09,2006-08-11,2006-08-15,Estimate,2013-03-21,2013-05-07,Estimate,,,,2018-05-09,2018-06-08,Actual,"October 2, 2006",,2006-10-02,October 2016,2016-10-31,"November 17, 2006",Actual,2006-11-17,"November 1, 2006",Actual,2006-11-01,,Interventional,,,Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate,"A Study to Evaluate the Immunogenicity, Safety and Reactogenicity of Adjuvanted Influenza Vaccine Candidate Compared to Fluarix (GlaxoSmithKline Biologicals) Administered Intramuscularly in Elderly Aged 60 Years and Older.",Completed,,Phase 2,150.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-14 00:31:43,2023-06-14 00:31:43,INDUSTRY,,,,,
33718,33719,NCT01191684,,2010-08-27,,,2017-07-28,2010-08-30,2010-08-31,Estimate,,,,,,,2017-07-28,2017-08-01,Actual,October 2011,,2011-10-31,July 2017,2017-07-31,August 2013,Actual,2013-08-31,August 2013,Actual,2013-08-31,,Interventional,,,"Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer",A Phase I Study of an MVA Vaccine Targeting P53 in Cancer,Completed,,Phase 1,12.0,Actual,City of Hope Medical Center,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 01:38:45,2023-06-17 01:38:45,OTHER,,,,,
33752,33753,NCT01195038,,2010-09-02,,,2011-02-07,2010-09-02,2010-09-03,Estimate,,,,,,,2011-02-07,2011-02-08,Estimate,October 2010,,2010-10-31,February 2011,2011-02-28,January 2011,Actual,2011-01-31,January 2011,Actual,2011-01-31,,Interventional,,,Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults,"A Multicenter, Open-Label Study to Assess the Immunogenicity and Safety of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Healthy Young Adults Primed With a Two-Vaccination of a Recombinant H5N1 Influenza HA Vaccine",Completed,,Phase 2,87.0,Anticipated,UMN Pharma Inc.,,,,,False,,,,False,,,,,,,,,,,,,2023-06-17 01:39:06,2023-06-17 01:39:06,INDUSTRY,,,,,
34498,34499,NCT01381744,,2011-06-23,,,2016-01-28,2011-06-23,2011-06-27,Estimate,,,,,,,2016-01-28,2016-01-29,Estimate,February 2012,,2012-02-29,October 2014,2014-10-31,August 2014,Actual,2014-08-31,August 2014,Actual,2014-08-31,,Interventional,,,"Dose Escalation Trial of a Plague Vaccine, Flagellin/F1/V, in Healthy Adult Volunteers","A Phase I Safety and Immunogenicity Dose Escalation Trial of Plague Vaccine, Flagellin/F1/V, In Healthy Adult Volunteers",Completed,,Phase 1,48.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 01:48:19,2023-06-17 01:48:19,NIH,,,,,
34757,34758,NCT01302990,,2011-02-11,,,2013-08-15,2011-02-23,2011-02-24,Estimate,,,,,,,2013-08-15,2013-08-16,Estimate,February 2011,,2011-02-28,August 2013,2013-08-31,November 2011,Actual,2011-11-30,July 2011,Actual,2011-07-31,,Interventional,,,"Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in Adults","Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in Adults",Completed,,Phase 1,100.0,Actual,Medicago,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 01:51:22,2023-06-17 01:51:22,INDUSTRY,,,,,
35283,35284,NCT02111135,,2014-04-08,,,2015-07-16,2014-04-08,2014-04-10,Estimate,,,,,,,2015-07-16,2015-07-20,Estimate,April 2014,,2014-04-30,July 2015,2015-07-31,March 2015,Actual,2015-03-31,September 2014,Actual,2014-09-30,,Interventional,IPV005,,Safety Study of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) in Infants Early in Life,"Phase II, Observer-blind, Randomized Study on the Safety, Reactogenicity, Immunogenicity and Impact on Intestinal Shedding of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) or a Single Dose of Standard Trivalent Inactivated Poliovirus Vaccine (t-IPV) When Given Concomitantly With the Third Dose of Bivalent Oral Poliovirus Vaccine (b-OPV) to Infants Early in Life",Completed,,Phase 2,240.0,Actual,Vaxtrials S.A.,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 02:50:38,2023-06-18 02:50:38,OTHER,,,,,
35286,35287,NCT05065983,,2021-09-23,2023-01-30,,2023-01-30,2021-09-23,2021-10-04,Actual,2023-01-30,2023-02-28,Actual,,,,2023-01-30,2023-02-28,Actual,"October 11, 2021",Actual,2021-10-11,January 2023,2023-01-31,"May 5, 2022",Actual,2022-05-05,"May 5, 2022",Actual,2022-05-05,,Interventional,CHIKV VLP,,A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine,"A Phase 2 Open-Label Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV VLP], Aluminum Hydroxide Adjuvanted)",Completed,,Phase 2,25.0,Actual,Emergent BioSolutions,,1.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-14 00:31:53,2023-06-14 00:31:53,INDUSTRY,,,,,
35439,35440,NCT05856084,,2023-05-04,,,2023-05-04,2023-05-04,2023-05-12,Actual,,,,,,,2023-05-04,2023-05-12,Actual,May 2023,Anticipated,2023-05-31,April 2023,2023-04-30,September 2025,Anticipated,2025-09-30,September 2025,Anticipated,2025-09-30,,Interventional,,,Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above,"A Phase II, Single Center, Randomized, Blind, Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above",Not yet recruiting,,Phase 2,924.0,Anticipated,MAXVAX Biotechnology Limited Liability Company,,7.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-16 01:52:35,2023-06-16 01:52:35,INDUSTRY,,,,,
35489,35490,NCT03776994,,2018-11-07,,,2021-02-19,2018-12-13,2018-12-17,Actual,,,,,,,2021-02-19,2021-02-23,Actual,"July 17, 2018",Actual,2018-07-17,February 2021,2021-02-28,April 2021,Anticipated,2021-04-30,"July 27, 2020",Actual,2020-07-27,,Interventional,VEEV,,Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine,A Phase 1 Dose Escalation Study to Assess the Safety and Immunogenicity of a Monovalent Virus-Like Particle (VLP) Venezuelan Equine Encephalitis Vaccine in Healthy Adults,Unknown status,"Active, not recruiting",Phase 1,48.0,Actual,SRI International,,6.0,,,False,,,,True,True,False,,,,,,,,,Undecided,,2023-06-17 01:56:21,2023-06-17 01:56:21,INDUSTRY,,,,,
36165,36166,NCT02114333,,2014-04-11,,,2020-07-07,2014-04-14,2014-04-15,Estimate,,,,,,,2020-07-07,2020-07-08,Actual,May 2014,,2014-05-31,July 2020,2020-07-31,May 2020,Actual,2020-05-31,March 2016,Actual,2016-03-31,,Interventional,,,Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds,A Comparison of the Immunogenicity and Descriptive Safety of a Live Attenuated Herpes Zoster Vaccine and the Glaxo Smith Kline (GSK) Herpes Zoster Recombinant HZ/su Candidate Vaccine in 50-59 Year Old and 70-85 Year Old Vaccine Recipients,Completed,,Phase 1,160.0,Actual,"University of Colorado, Denver",,4.0,,,False,,,,False,True,,,,,,,,,,No,,2023-06-18 02:57:58,2023-06-18 02:57:58,OTHER,,,,,
36197,36198,NCT02302066,,2014-11-24,2020-02-10,2019-08-13,2020-02-10,2014-11-24,2014-11-26,Estimate,2020-02-10,2020-02-24,Actual,2019-08-13,2019-08-19,Actual,2020-02-10,2020-02-24,Actual,"December 5, 2014",Actual,2014-12-05,February 2020,2020-02-29,"February 18, 2019",Actual,2019-02-18,"February 18, 2019",Actual,2019-02-18,,Interventional,,Safety Analysis Set included all participants who received at least 1 dose of trial vaccine.,Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants,"A Phase II, Double-Blind, Controlled Trial to Assess the Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Subjects Aged Between 2 and <18 Years and Living in Dengue Endemic Countries in Asia and Latin America",Completed,,Phase 2,1800.0,Actual,Takeda,,4.0,,,False,,,,True,,,,,,,,,,,Yes,"Takeda makes patient/subject-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.",2023-06-18 02:58:16,2023-06-18 02:58:16,INDUSTRY,,,,,
36884,36885,NCT00383071,,2006-09-29,2012-04-26,,2018-07-02,2006-09-29,2006-10-02,Estimate,2013-04-04,2013-05-27,Estimate,,,,2018-07-02,2018-07-31,Actual,August 2006,,2006-08-31,April 2016,2016-04-30,December 2014,Actual,2014-12-31,March 2010,Actual,2010-03-31,,Interventional,,All subjects enrolled into the study,Development of Immune Globulin Treatment for Avian Flu,A Phase II Vaccine Dose Finding Pilot Study for Development of an Anti-Influenza A (H5N1) Intravenous Hyper-Immune Globulin,Terminated,,Phase 2,126.0,Actual,National Institutes of Health Clinical Center (CC),,4.0,,Cannot get enough plasma to manufacture IVIG for human trials,False,,,,True,,,,,,,,,,,,,2023-06-14 00:32:19,2023-06-14 00:32:19,NIH,,,,,
37502,37503,NCT01666652,,2012-08-08,2018-08-08,,2018-08-08,2012-08-10,2012-08-16,Estimate,2018-08-08,2019-01-25,Actual,,,,2018-08-08,2019-01-25,Actual,September 2012,Actual,2012-09-30,August 2018,2018-08-31,November 2017,Actual,2017-11-30,September 2015,Actual,2015-09-30,,Interventional,DPIV-001,,A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults,"A Phase I, Randomized, Placebo-Controlled, Observer-blind, Two-dose (0-28 Day Schedule) Primary Vaccination Study of Walter Reed Army Institute of Research (WRAIR) Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) in Healthy Adults in a Non-Endemic Region",Completed,,Phase 1,100.0,Actual,U.S. Army Medical Research and Development Command,,5.0,,,False,,,,True,,,,,,,,,,,Undecided,,2023-06-18 03:10:36,2023-06-18 03:10:36,FED,,,,,
37556,37557,NCT05904054,,2023-06-02,,,2023-06-16,2023-06-12,2023-06-15,Actual,,,,,,,2023-06-16,2023-06-19,Estimate,"June 15, 2023",Actual,2023-06-15,June 2023,2023-06-30,"October 31, 2023",Anticipated,2023-10-31,"September 30, 2023",Anticipated,2023-09-30,,Interventional,,,Immunogenicity and Safety Study of SARS-CoV-2 DNA Vaccine (ICCOV),An Open-label and Single-center Phase IIa Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 DNA Vaccine (ICCOV) in Healthy Subjects Aged 18-75 Years,Recruiting,,Phase 2,60.0,Anticipated,Immuno Cure Holding (HK) Limited,,4.0,,,False,,,,False,False,False,,,,,,,,,Undecided,,2023-06-19 04:17:44,2023-06-19 04:17:44,INDUSTRY,,,,,
37726,37727,NCT02764333,,2016-05-04,2021-11-01,,2021-11-01,2016-05-04,2016-05-06,Estimate,2021-11-01,2021-11-30,Actual,,,,2021-11-01,2021-11-30,Actual,"May 6, 2016",Actual,2016-05-06,January 2021,2021-01-31,"January 20, 2021",Actual,2021-01-20,"January 20, 2021",Actual,2021-01-20,,Interventional,,,TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer,A Phase II Trial of TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer,Completed,,Phase 2,29.0,Actual,Memorial Sloan Kettering Cancer Center,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-18 03:12:38,2023-06-18 03:12:38,OTHER,,,,,
37979,37980,NCT02408913,,2015-04-03,,,2019-04-10,2015-04-03,2015-04-06,Estimate,,,,,,,2019-04-10,2019-04-11,Actual,"March 26, 2015",,2015-03-26,"April 6, 2017",2017-04-06,"April 6, 2017",Actual,2017-04-06,"April 6, 2017",Actual,2017-04-06,,Interventional,,,"VRC 208: Dose, Safety and Immunogenicity of a Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine, VRC-EBOMVA079-00-VP (MVA-EbolaZ), Administered Alone or as a Boost to cAd3-Ebola Vaccines in Healthy Adults","VRC 208: Phase 1/1b Open-Label Clinical Trial to Evaluate Dose, Safety and Immunogenicity of Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine,VRC-EBOMVA079-00-VP, Administered Alone or as Boost to cAd3-Ebola Vaccines in Healthy Adults",Completed,,Phase 1,140.0,Actual,National Institutes of Health Clinical Center (CC),,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-18 03:14:53,2023-06-18 03:14:53,NIH,,,,,
38726,38727,NCT00101101,,2005-01-07,2013-06-20,,2022-08-03,2005-01-07,2005-01-10,Estimate,2013-06-20,2013-09-04,Estimate,,,,2022-08-03,2022-08-05,Actual,July 2004,Actual,2004-07-31,August 2022,2022-08-31,July 2023,Anticipated,2023-07-31,October 2012,Actual,2012-10-31,,Interventional,,All participants who started the study.,Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma,A Phase II Trial Using a Universal GM-CSF-Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-Based Vaccines for Patients With Mantle Cell Lymphoma,"Active, not recruiting",,Phase 2,43.0,Actual,H. Lee Moffitt Cancer Center and Research Institute,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 03:21:24,2023-06-18 03:21:24,OTHER,,,,,
38868,38869,NCT01322802,,2011-03-07,,,2021-02-22,2011-03-23,2011-03-25,Estimate,,,,,,,2021-02-22,2021-02-25,Actual,"March 6, 2012",Actual,2012-03-06,February 2021,2021-02-28,"December 1, 2020",Actual,2020-12-01,"January 9, 2015",Actual,2015-01-09,,Interventional,,,Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer,A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine Encoding the Amino Acids 1-163 of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in Patients With Advanced Ovarian Cancer,Completed,,Phase 1,25.0,Actual,University of Washington,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 02:05:40,2023-06-17 02:05:40,OTHER,,,,,
39081,39082,NCT03999554,,2019-06-18,2021-08-11,,2021-12-10,2019-06-25,2019-06-26,Actual,2021-12-10,2022-03-04,Actual,,,,2021-12-10,2022-03-04,Actual,"September 3, 2019",Actual,2019-09-03,December 2021,2021-12-31,"July 1, 2020",Actual,2020-07-01,"July 1, 2020",Actual,2020-07-01,,Interventional,,,Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines,Phase 1b Clinical Study to Investigate the Safety and Immunogenicity of the Bris10 (A/Brisbane/10/2007) M2SR and Sing2016 (A/Singapore/INFIMH-16-0019/2016) M2SR H3N2 Monovalent Influenza Vaccines,Completed,,Phase 1,206.0,Actual,FluGen Inc,,5.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-17 02:06:25,2023-06-17 02:06:25,INDUSTRY,,,,,
39252,39253,NCT05903183,,2023-06-05,,,2023-06-05,2023-06-05,2023-06-15,Actual,,,,,,,2023-06-05,2023-06-15,Actual,"May 15, 2023",Actual,2023-05-15,June 2023,2023-06-30,"September 30, 2024",Anticipated,2024-09-30,"October 28, 2023",Anticipated,2023-10-28,,Interventional,,,A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age,"A Phase 2a Randomized, Observer-blind, Placebo-controlled, Dosage Optimization, Multi-center Clinical Trial to Evaluate the Safety and Immunogenicity of IVX-A12, a Respiratory Syncytial Virus and Human Metapneumovirus Bivalent Combination Virus-like Particle Protein Subunit Vaccine, in Adults 60 to 85 Years of Age",Recruiting,,Phase 2,250.0,Anticipated,"Icosavax, Inc.",,3.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-19 04:18:35,2023-06-19 04:18:35,INDUSTRY,,,,,
39440,39441,NCT05875961,,2023-05-05,,,2023-06-16,2023-05-16,2023-05-25,Actual,,,,,,,2023-06-16,2023-06-19,Estimate,"June 15, 2023",Actual,2023-06-15,June 2023,2023-06-30,November 2024,Anticipated,2024-11-30,November 2024,Anticipated,2024-11-30,,Interventional,,,"Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults","A Phase 1, Randomized, Observer-Blind, Multi-Center, Dose Ranging Study to Evaluate the Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted or Non-Adjuvanted Cell Culture-derived A/H2N3 Subunit Influenza Virus Vaccine in Healthy Subjects 18 Years and Above",Recruiting,,Phase 1,600.0,Anticipated,Seqirus,,6.0,,,False,,,,False,True,False,,,,,,,,,Undecided,,2023-06-19 04:20:55,2023-06-19 04:20:55,INDUSTRY,,,,,
39517,39518,NCT05831111,,2023-04-14,,,2023-06-12,2023-04-14,2023-04-26,Actual,,,,,,,2023-06-12,2023-06-15,Actual,"April 5, 2023",Actual,2023-04-05,June 2023,2023-06-30,"February 4, 2026",Anticipated,2026-02-04,"February 4, 2026",Anticipated,2026-02-04,,Interventional,,,"A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Adults","A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, 2-Part, Dose-Ranging Study of an EBV Candidate Vaccine, mRNA-1195, in Healthy Adults 18 to 55 Years of Age",Recruiting,,Phase 1,500.0,Anticipated,"ModernaTX, Inc.",,15.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-19 04:21:48,2023-06-19 04:21:48,INDUSTRY,,,,,
39603,39604,NCT05740982,,2023-02-13,,,2023-06-15,2023-02-13,2023-02-23,Actual,,,,,,,2023-06-15,2023-06-16,Estimate,"March 22, 2023",Actual,2023-03-22,"March 9, 2023",2023-03-09,"December 1, 2024",Anticipated,2024-12-01,"July 1, 2024",Anticipated,2024-07-01,,Interventional,,,A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox,"A Phase 2 Randomized, Open-Label, Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox",Recruiting,,Phase 2,400.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-19 04:23:08,2023-06-19 04:23:08,NIH,,,,,
39649,39650,NCT01966289,,2013-10-10,,,2021-03-26,2013-10-16,2013-10-21,Estimate,,,,,,,2021-03-26,2021-03-30,Actual,"April 14, 2014",Actual,2014-04-14,March 2021,2021-03-31,"June 6, 2020",Actual,2020-06-06,"June 6, 2020",Actual,2020-06-06,,Interventional,,,SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC),A Pilot Study of SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC) as Maintenance Therapy,Completed,,Phase 1,18.0,Actual,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 01:25:23,2023-06-15 01:25:23,OTHER,,,,,
39723,39724,NCT05664334,,2022-12-07,,,2023-06-15,2022-12-22,2022-12-23,Actual,,,,,,,2023-06-15,2023-06-16,Estimate,"September 21, 2022",Actual,2022-09-21,March 2023,2023-03-31,"December 3, 2023",Anticipated,2023-12-03,"January 17, 2023",Actual,2023-01-17,,Interventional,,,Safety and Immunogenicity of IVX-A12 in Healthy Older Adults,"A Phase 1 Randomized, Observer-blind, Placebo-controlled, Multi-center Trial to Evaluate the Safety and Immunogenicity of IVX-A12, a Respiratory Syncytial Virus and Human Metapneumovirus Bivalent Combination Virus-like Particle Protein Subunit Vaccine, in Healthy Adults, 60 to 75 Years of Age","Active, not recruiting",,Phase 1,120.0,Anticipated,"Icosavax, Inc.",,6.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-19 04:24:53,2023-06-19 04:24:53,INDUSTRY,,,,,
39782,39783,NCT05622942,,2022-11-03,,,2023-06-12,2022-11-10,2022-11-21,Actual,,,,,,,2023-06-12,2023-06-15,Actual,"March 11, 2023",Actual,2023-03-11,June 2023,2023-06-30,"September 11, 2023",Anticipated,2023-09-11,"September 11, 2023",Anticipated,2023-09-11,,Interventional,,,Clinical Trial of Recombinant Pneumococcal Protein Vaccine,"Randomized, Blinded, Positive-controlled Phase Ib Clinical Trial for Preliminary Evaluation of Safety and Immunogenicity of Recombinant Pneumococcal Protein Vaccine in Adults Aged 50 Years and Older After Vaccination","Active, not recruiting",,Phase 1,60.0,Anticipated,CanSino Biologics Inc.,,2.0,,,False,,,,False,False,False,,,,,,,,,No,"In order to maintain the rights of the subject, do not open the Individual Participant Data (IPD)",2023-06-19 04:25:39,2023-06-19 04:25:39,INDUSTRY,,,,,
39882,39883,NCT05541861,,2022-09-14,,,2023-06-13,2022-09-14,2022-09-15,Actual,,,,,,,2023-06-13,2023-06-15,Actual,"November 8, 2022",Actual,2022-11-08,June 2023,2023-06-30,November 2023,Anticipated,2023-11-30,November 2023,Anticipated,2023-11-30,,Interventional,,,Safety and Effects of an Investigational COVID-19 Vaccine as a Booster in Healthy People,"An Exploratory Phase I, Randomized, Observer-blind, Active-controlled Dose Escalation Trial Evaluating the Safety, Tolerability, and Immunogenicity of an Investigational RNA-based SARS-CoV-2 Vaccine in COVID-19 Vaccine Experienced Healthy Adults",Recruiting,,Phase 1,240.0,Anticipated,BioNTech SE,,6.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-19 04:27:05,2023-06-19 04:27:05,INDUSTRY,,,,,
39910,39911,NCT05512949,,2022-08-20,,,2023-06-15,2022-08-20,2022-08-23,Actual,,,,,,,2023-06-15,2023-06-16,Estimate,"September 7, 2022",Actual,2022-09-07,"August 23, 2022",2022-08-23,"December 13, 2023",Anticipated,2023-12-13,"September 13, 2023",Anticipated,2023-09-13,,Interventional,,,Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine,"A Phase 2 Randomized, Open-Label, Multisite Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Vaccine","Active, not recruiting",,Phase 2,229.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-19 04:27:24,2023-06-19 04:27:24,NIH,,,,,
39925,39926,NCT05500417,,2022-08-11,,,2023-06-15,2022-08-11,2022-08-15,Actual,,,,,,,2023-06-15,2023-06-16,Estimate,"August 22, 2022",Actual,2022-08-22,June 2023,2023-06-30,"August 21, 2024",Anticipated,2024-08-21,"August 21, 2024",Anticipated,2024-08-21,,Interventional,,,Safety and Immunogenicity of CJCV2 With and Without ALFQ,First-in-Human Safety and Immunogenicity Evaluation of an Intramuscular Campylobacter Jejuni Conjugate Vaccine (CJCV2) With and Without Army Liposome Formulation Containing QS-21 (ALFQ),Recruiting,,Phase 1,60.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,6.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-19 04:27:33,2023-06-19 04:27:33,NIH,,,,,
39997,39998,NCT05445882,,2022-07-02,,,2023-06-16,2022-07-05,2022-07-06,Actual,,,,,,,2023-06-16,2023-06-19,Estimate,"June 22, 2023",Anticipated,2023-06-22,"May 31, 2023",2023-05-31,"August 1, 2026",Anticipated,2026-08-01,"November 1, 2023",Anticipated,2023-11-01,,Interventional,,,N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer,A Phase II Study of N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer,Not yet recruiting,,Phase 2,28.0,Anticipated,National Institutes of Health Clinical Center (CC),,3.0,,,False,,,,,True,False,,,,,,Clinical data available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.,Clinical data will be made available via subscription to BTRIS and with the permission of the study PI. Genomic data are made available via dbGaP through requests to the data custodians.,,Yes,".All IPD recorded in the medical record will be shared with intramural investigators upon request. In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP.",2023-06-19 04:28:18,2023-06-19 04:28:18,NIH,,,,,
40035,40036,NCT05423418,,2022-06-06,,,2023-06-15,2022-06-14,2022-06-21,Actual,,,,,,,2023-06-15,2023-06-19,Estimate,"August 29, 2022",Actual,2022-08-29,June 2023,2023-06-30,"October 23, 2028",Anticipated,2028-10-23,"October 23, 2023",Anticipated,2023-10-23,,Interventional,RV575,,"Safety, Tolerability, and Immunogenicity of ALFQ in a HIV Vaccine Containing A244 and B.65321 in Healthy Adults","A Phase 1 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Ranging Doses of ALFQ Adjuvant in a Candidate HIV Vaccine Containing A244 and B.65321",Recruiting,,Phase 1,60.0,Anticipated,U.S. Army Medical Research and Development Command,,3.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-19 04:28:41,2023-06-19 04:28:41,FED,,,,,
40087,40088,NCT05380388,,2022-04-13,,,2023-06-15,2022-05-17,2022-05-18,Actual,,,,,,,2023-06-15,2023-06-16,Estimate,September 2023,Anticipated,2023-09-30,June 2023,2023-06-30,"May 30, 2024",Anticipated,2024-05-30,May 2024,Anticipated,2024-05-31,,Interventional,MIST3,,"A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 )","A Phase II Clinical Study to Assess the Safety, Immunogenicity, and Efficacy of Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvRII/Matrix-M in Healthy Thai Adults Living in Thailand",Not yet recruiting,,Phase 2,36.0,Anticipated,University of Oxford,,2.0,,,False,,,,True,False,False,,,,,,,,,Yes,"With participant's consent, suitably anonymised clinical data and results from blood analyses stored in the database may be shared according to the terms defined in the MORU data sharing policy with other researchers to use in the future.",2023-06-19 04:29:11,2023-06-19 04:29:11,OTHER,,,,,
40233,40234,NCT05252845,,2022-01-10,,,2023-06-15,2022-02-22,2022-02-23,Actual,,,,,,,2023-06-15,2023-06-16,Estimate,"January 4, 2023",Actual,2023-01-04,January 2023,2023-01-31,September 2023,Anticipated,2023-09-30,"June 8, 2023",Actual,2023-06-08,,Interventional,R21/Matrix-M,,"Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults","A Randomized, Open Label, Single Centre, Phase 2 Trial of the Malaria Vaccine, R21/Matrix-M, to Assess Safety and Immunogenicity of the Vaccine in Thai Adults",Recruiting,,Phase 2,120.0,Anticipated,University of Oxford,,3.0,,,False,,,,True,False,False,,,,,,,,,Yes,All personal details of participants will be de-identified. These data including laboratory investigation results will be stored and may be shared with other researchers to apply in their research in accordance with the MORU data sharing policy.,2023-06-19 04:31:33,2023-06-19 04:31:33,OTHER,,,,,
40343,40344,NCT05127824,,2021-10-22,,,2023-06-14,2021-11-09,2021-11-19,Actual,,,,,,,2023-06-14,2023-06-16,Estimate,"July 15, 2023",Anticipated,2023-07-15,June 2023,2023-06-30,December 2026,Anticipated,2026-12-31,December 2026,Anticipated,2026-12-31,,Interventional,,,Autologous Dendritic Cell Vaccine in Kidney Cancer,A Phase 2a Study to Type I-Polarized Autologous Dendritic Cell Vaccines Incorporating Tumor Blood Vessel Antigen (TBVA)-Derived Peptides in Combination With Cabozantinib in Patients With Localized Clear Cell Renal Cancer.,Not yet recruiting,,Phase 2,42.0,Anticipated,University of Pittsburgh,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-19 04:33:15,2023-06-19 04:33:15,OTHER,,,,,
40457,40458,NCT05027932,,2021-08-28,,,2023-06-16,2021-08-28,2021-08-31,Actual,,,,,,,2023-06-16,2023-06-19,Estimate,"June 27, 2022",Actual,2022-06-27,"June 15, 2023",2023-06-15,"March 1, 2024",Anticipated,2024-03-01,"March 1, 2024",Anticipated,2024-03-01,,Interventional,,,"Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine","Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of the Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine","Active, not recruiting",,Phase 1,45.0,Actual,National Institutes of Health Clinical Center (CC),,3.0,,,False,,,,,True,False,,,,,,,,,No,.We are not working with any outside collaborators that require this information.,2023-06-19 04:34:44,2023-06-19 04:34:44,NIH,,,,,
40479,40480,NCT05016622,,2021-08-16,,,2023-06-15,2021-08-16,2021-08-23,Actual,,,,,,,2023-06-15,2023-06-16,Estimate,"August 10, 2021",Actual,2021-08-10,June 2023,2023-06-30,August 2023,Anticipated,2023-08-31,August 2023,Anticipated,2023-08-31,,Interventional,,,Booster Dose Trial,Safety and Efficacy of Booster Doses of BNT162b2 Vaccine in Immunocompromised Patients With a Cancer Diagnosis,Recruiting,,Phase 2,250.0,Anticipated,Montefiore Medical Center,,1.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-19 04:35:00,2023-06-19 04:35:00,OTHER,,,,,
40507,40508,NCT01967758,,2013-10-18,,,2018-08-15,2013-10-18,2013-10-23,Estimate,,,,,,,2018-08-15,2018-08-17,Actual,"January 8, 2014",Actual,2014-01-08,August 2018,2018-08-31,"August 15, 2018",Actual,2018-08-15,"June 18, 2018",Actual,2018-06-18,,Interventional,,,Phase I Study of Safety and Immunogenicity of ADU-623,"Phase I Study of Safety and Immunogenicity of ADU-623, a Live-attenuated Listeria Monocytogenes Strain (<U+0394>actA/<U+0394>inlB) Expressing the EGFRvIII-NY-ESO-1 Vaccine, in Patients With Treated and Recurrent WHO Grade III/IV Astrocytomas",Completed,,Phase 1,11.0,Actual,Providence Health & Services,,3.0,,,False,,,,False,,,,,,,,Data has been available from study start-up through the end of data analysis. Anticipated August 2018.,De-identified data will be made available to Aduro BioTech.,,Yes,"Data generated by this study will be shared with the collaborator, Aduro BioTech.",2023-06-15 01:26:21,2023-06-15 01:26:21,OTHER,,,,,
40509,40510,NCT04977024,,2021-06-11,,,2023-06-13,2021-07-22,2021-07-26,Actual,,,,,,,2023-06-13,2023-06-15,Actual,"September 27, 2021",Actual,2021-09-27,June 2023,2023-06-30,"January 31, 2025",Anticipated,2025-01-31,"March 31, 2024",Anticipated,2024-03-31,,Interventional,,,SARS-CoV-2 Vaccine (COH04S1) Versus EUA SARS-COV-2 Vaccine for the Treatment of COVID-19 in Patients With Blood Cancer,"A Multi-Center, Observer-Blinded, EUA Vaccine-Controlled, Randomized Phase II Study to Evaluate the Biological Activity of COH04S1 (SARS-CoV-2 Vaccine) Compared to EUA SARS-CoV-2 Vaccines in Hematology Patients Who Have Received Cellular Therapy (HCT or CAR-T)",Recruiting,,Phase 2,240.0,Anticipated,"GeoVax, Inc.",,2.0,,,,,,,True,True,False,,,False,,,,,,,,2023-06-19 04:35:33,2023-06-19 04:35:33,INDUSTRY,,,,,
40658,40659,NCT04776317,,2021-02-25,,,2023-06-15,2021-02-25,2021-03-01,Actual,,,,,,,2023-06-15,2023-06-16,Estimate,"March 18, 2021",Actual,2021-03-18,June 2023,2023-06-30,"October 29, 2023",Anticipated,2023-10-29,"October 29, 2023",Anticipated,2023-10-29,,Interventional,,,Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults,"A Phase 1 Trial to Evaluate the Safety, Immunogenicity, and Reactogenicity of Heterologous and Homologous Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults","Active, not recruiting",,Phase 1,81.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,15.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-19 04:37:41,2023-06-19 04:37:41,NIH,,,,,
40736,40737,NCT04658667,,2020-11-23,,,2023-06-15,2020-12-01,2020-12-08,Actual,,,,,,,2023-06-15,2023-06-19,Estimate,"January 18, 2022",Actual,2022-01-18,June 2023,2023-06-30,May 2027,Anticipated,2027-05-31,"May 30, 2024",Anticipated,2024-05-30,,Interventional,RV546,,HIV Vaccine in HIV-uninfected Adults,"Randomized, Double Blind Evaluation of Late Boost Strategies With IHV01 (FLSC in Aluminum Phosphate) and A244 With or Without ALFQ for HIV-uninfected Participants in the HIV Vaccine Trial RV306 / WRAIR 1920",Recruiting,,Phase 1,120.0,Anticipated,U.S. Army Medical Research and Development Command,,5.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-19 04:38:56,2023-06-19 04:38:56,FED,,,,,
40773,40774,NCT01968083,,2013-10-18,,,2021-07-19,2013-10-18,2013-10-23,Estimate,,,,,,,2021-07-19,2021-07-26,Actual,"October 3, 2013",Actual,2013-10-03,January 2017,2017-01-31,May 2015,Actual,2015-05-31,May 2015,Actual,2015-05-31,,Interventional,,,Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children,"A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV cps2, Lot RSV#005A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age",Completed,,Phase 1,51.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 01:26:32,2023-06-15 01:26:32,NIH,,,,,
40787,40788,NCT04573140,,2020-09-14,,,2023-06-12,2020-09-28,2020-10-05,Actual,,,,,,,2023-06-12,2023-06-15,Actual,"October 26, 2021",Actual,2021-10-26,June 2023,2023-06-30,July 2027,Anticipated,2027-07-31,July 2026,Anticipated,2026-07-31,,Interventional,PNOC020,,A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM),A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM),Recruiting,,Phase 1,28.0,Anticipated,University of Florida,,1.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-19 04:39:46,2023-06-19 04:39:46,OTHER,,,,,
40892,40893,NCT04350138,,2020-04-15,,,2023-06-15,2020-04-15,2020-04-16,Actual,,,,,,,2023-06-15,2023-06-16,Estimate,"December 29, 2020",Actual,2020-12-29,May 2023,2023-05-31,"September 30, 2023",Anticipated,2023-09-30,"September 30, 2023",Anticipated,2023-09-30,,Interventional,,,Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection,"A Phase II Randomized, Observer-Blind, Placebo-Controlled Study, to Assess the Efficacy of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) in Preventing Gonococcal Infection",Recruiting,,Phase 2,2200.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-19 04:41:52,2023-06-19 04:41:52,NIH,,,,,
40936,40937,NCT04266730,,2020-02-10,,,2023-06-16,2020-02-10,2020-02-12,Actual,,,,,,,2023-06-16,2023-06-19,Estimate,"April 22, 2024",Anticipated,2024-04-22,June 2023,2023-06-30,"June 1, 2033",Anticipated,2033-06-01,"June 1, 2024",Anticipated,2024-06-01,,Interventional,PANDA-VAC,,Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab,Phase I Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Administered Concurrently With Pembrolizumab,Not yet recruiting,,Phase 1,6.0,Anticipated,UNC Lineberger Comprehensive Cancer Center,,1.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-19 04:43:13,2023-06-19 04:43:13,OTHER,,,,,
40954,40955,NCT04242264,,2020-01-23,,,2023-06-15,2020-01-23,2020-01-27,Actual,,,,,,,2023-06-15,2023-06-16,Estimate,"October 12, 2022",Actual,2022-10-12,"December 8, 2022",2022-12-08,"June 30, 2023",Anticipated,2023-06-30,"June 30, 2023",Anticipated,2023-06-30,,Interventional,,,Phase 2 Shigella Vaccine and Challenge,"A Double-Blind Placebo Controlled Randomized Phase 2 Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of a Live-Attenuated Shigella Sonnei Vaccine, WRSs2 and Determine Its Efficacy in a Challenge Model of S. Sonnei 53G in Healthy Adults",Recruiting,,Phase 2,120.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-19 04:43:26,2023-06-19 04:43:26,NIH,,,,,
41065,41066,NCT04054752,,2019-08-10,,,2023-06-15,2019-08-10,2019-08-13,Actual,,,,,,,2023-06-15,2023-06-16,Estimate,"June 21, 2023",Anticipated,2023-06-21,"June 12, 2023",2023-06-12,"May 19, 2025",Anticipated,2025-05-19,"May 19, 2024",Anticipated,2024-05-19,,Interventional,,,Vaccine Response With NT-I7,A Phase 1/1b Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Recombinant Human IL-7-hyFc (NT-I7) in Older Subjects Following Chemotherapy,Recruiting,,Phase 1,68.0,Anticipated,National Institutes of Health Clinical Center (CC),,3.0,,,False,,,,,True,False,,,,,,Clinical data available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.,Clinical data will be made available via subscription to BTRIS and with the permission of the study PI. Genomic data are made available via dbGaP through requests to the data custodians.,,Yes,".All IPD recorded in the medical record will be shared with intramural investigators upon request. In addition, all large scale genomic sequencing data will be shared with subscribers to dbGAP.",2023-06-19 04:45:49,2023-06-19 04:45:49,NIH,,,,,
41261,41262,NCT03679650,,2018-09-17,,,2023-06-16,2018-09-17,2018-09-20,Actual,,,,,,,2023-06-16,2023-06-19,Estimate,"October 11, 2018",Actual,2018-10-11,June 2023,2023-06-30,"August 31, 2026",Anticipated,2026-08-31,"August 31, 2023",Anticipated,2023-08-31,,Interventional,,,Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients,A Phase I Clinical Trial of Dendritic Cell/AML Fusion Cell Vaccine Alone and in Conjunction With Decitabine Following Allogeneic Transplantation in AML Patients,Recruiting,,Phase 1,45.0,Anticipated,Beth Israel Deaconess Medical Center,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-19 04:50:33,2023-06-19 04:50:33,OTHER,,,,,
41291,41292,NCT03631043,,2018-08-10,,,2023-06-12,2018-08-14,2018-08-15,Actual,,,,,,,2023-06-12,2023-06-15,Actual,"December 21, 2018",Actual,2018-12-21,June 2023,2023-06-30,"September 30, 2023",Anticipated,2023-09-30,"September 30, 2023",Anticipated,2023-09-30,,Interventional,,,Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma,A Personalized Vaccine for the Immune Prevention of Multiple Myeloma,Recruiting,,Early Phase 1,30.0,Anticipated,M.D. Anderson Cancer Center,,2.0,,,,,,,False,True,False,,,False,,,,,,,,2023-06-19 04:51:02,2023-06-19 04:51:02,OTHER,,,,,
41431,41432,NCT03199040,,2017-06-22,,,2023-06-14,2017-06-22,2017-06-26,Actual,,,,,,,2023-06-14,2023-06-16,Estimate,"August 8, 2019",Actual,2019-08-08,June 2023,2023-06-30,"August 23, 2023",Anticipated,2023-08-23,"November 21, 2022",Actual,2022-11-21,,Interventional,,,Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy,A Randomized Phase 1 Trial of Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy,"Active, not recruiting",,Phase 1,18.0,Actual,Washington University School of Medicine,,2.0,,,False,,,,True,True,False,,,False,,,,,,No,,2023-06-19 04:54:13,2023-06-19 04:54:13,OTHER,,,,,
41467,41468,NCT03059485,,2017-02-15,,,2023-06-16,2017-02-16,2017-02-23,Actual,,,,,,,2023-06-16,2023-06-19,Estimate,"June 1, 2017",Actual,2017-06-01,June 2023,2023-06-30,"August 31, 2025",Anticipated,2025-08-31,"May 31, 2025",Anticipated,2025-05-31,,Interventional,,,DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission,A Randomized Phase II Clinical Trial of Dendritic Cell/AML Fusion Cell Vaccine Versus Observation in Patients Who Achieve a Chemotherapy-induced Remission,Recruiting,,Phase 2,75.0,Anticipated,Beth Israel Deaconess Medical Center,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-19 04:55:36,2023-06-19 04:55:36,OTHER,,,,,
41476,41477,NCT03029403,,2017-01-20,,,2023-06-15,2017-01-20,2017-01-24,Estimate,,,,,,,2023-06-15,2023-06-19,Estimate,"February 12, 2018",Actual,2018-02-12,June 2023,2023-06-30,"February 12, 2024",Anticipated,2024-02-12,"December 12, 2023",Anticipated,2023-12-12,,Interventional,,,"Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer","A Phase 2 Study of Pembrolizumab (MK-3475), DPX-Survivac Vaccine and Low Dose of Cyclophosphamide Combination in Patients With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer","Active, not recruiting",,Phase 2,47.0,Actual,"University Health Network, Toronto",,4.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-19 04:55:41,2023-06-19 04:55:41,OTHER,,,,,
41502,41503,NCT05609994,,2022-11-02,,,2023-05-11,2022-11-02,2022-11-08,Actual,,,,,,,2023-05-11,2023-05-12,Actual,July 2023,Anticipated,2023-07-31,May 2023,2023-05-31,August 2027,Anticipated,2027-08-31,August 2025,Anticipated,2025-08-31,,Interventional,ViCToRy,,ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas,ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas,Not yet recruiting,,Phase 1,48.0,Anticipated,Duke University,,1.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-16 01:54:42,2023-06-16 01:54:42,OTHER,,,,,
41545,41546,NCT02788227,,2016-05-28,,,2023-06-13,2016-06-01,2016-06-02,Estimate,,,,,,,2023-06-13,2023-06-15,Actual,"October 14, 2016",Actual,2016-10-14,"April 3, 2023",2023-04-03,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2023",Anticipated,2023-12-31,,Interventional,,,Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure,A Multicenter Study of the Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSVdeltaG-ZEBOV GP) for Pre-Exposure Prophylaxis in Individuals at Potential Occupational Risk for Ebola Virus Exposure (PREPARE),"Active, not recruiting",,Phase 2,99.0,Actual,National Institutes of Health Clinical Center (CC),,2.0,,,False,,,,,True,False,,,,,,,,,Undecided,".Individual (coded with Participant ID only) data and antibody titer levels are shared with the University of Minnesota Data Center for statistical evaluation. The study team is blinded to the titers after Month 18 timepoint for all subjects. When the endpoint of the study is reached (i.e. when a statistically significant number of subject have reached Month 36/end-of-study), data will likely be shared with other study sites.",2023-06-19 04:57:36,2023-06-19 04:57:36,NIH,,,,,
41553,41554,NCT02700841,,2016-03-02,,,2023-06-13,2016-03-02,2016-03-07,Estimate,,,,,,,2023-06-13,2023-06-16,Estimate,May 2016,Actual,2016-05-31,June 2023,2023-06-30,"December 21, 2022",Actual,2022-12-21,"December 21, 2022",Actual,2022-12-21,,Interventional,,,Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation,A Phase II Study of Enhancing Anti-Tetanus Vaccine Response After Autologous Stem Cell Transplantation,Terminated,,Phase 2,8.0,Actual,University of Nebraska,,2.0,,Study terminated prematurely due to poor recruitment.,False,,,,True,,,,,,,,,,,No,,2023-06-19 04:57:45,2023-06-19 04:57:45,OTHER,,,,,
41634,41635,NCT02232191,,2014-09-02,,,2023-06-15,2014-09-04,2014-09-05,Estimate,,,,,,,2023-06-15,2023-06-16,Estimate,December 2014,,2014-12-31,June 2023,2023-06-30,"March 2, 2024",Anticipated,2024-03-02,"March 1, 2024",Anticipated,2024-03-01,,Interventional,,,Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients,Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients,Recruiting,,Phase 2,90.0,Anticipated,"University of California, Davis",,3.0,,,False,,,,False,True,False,,,False,,,,,,No,,2023-06-19 04:59:52,2023-06-19 04:59:52,OTHER,,,,,
41668,41669,NCT01970358,,2013-10-09,,,2020-12-07,2013-10-22,2013-10-28,Estimate,,,,,,,2020-12-07,2020-12-09,Actual,January 2014,Actual,2014-01-31,December 2020,2020-12-31,June 2018,Actual,2018-06-30,September 2015,Actual,2015-09-30,,Interventional,,,A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma,A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma,Completed,,Phase 1,20.0,Anticipated,Dana-Farber Cancer Institute,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 01:28:23,2023-06-15 01:28:23,OTHER,,,,,
41672,41673,NCT01970449,,2013-10-22,,,2021-10-13,2013-10-22,2013-10-28,Estimate,,,,,,,2021-10-13,2021-10-15,Actual,,,,October 2021,2021-10-31,,,,August 2018,Anticipated,2018-08-31,,Interventional,,,"Evaluating the Safety and Immune Response to Three Different Prime-Boost HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults","A Phase 1 Randomized, Double-blind, Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of DNA Prime and NYVAC Boost With 3 Different HIV-1 Envelope Inserts (Nat-B Env, CON-S Env, and Mosaic Env) in Healthy, HIV-1-uninfected Adults",Withdrawn,,Phase 1,0.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 01:28:26,2023-06-15 01:28:26,NIH,,,,,
41798,41799,NCT01096602,,2010-03-29,,,2023-06-16,2010-03-30,2010-03-31,Estimate,,,,,,,2023-06-16,2023-06-19,Estimate,May 2010,,2010-05-31,June 2023,2023-06-30,June 2024,Anticipated,2024-06-30,December 2023,Anticipated,2023-12-31,,Interventional,,,Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission,Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission,"Active, not recruiting",,Phase 2,63.0,Actual,Beth Israel Deaconess Medical Center,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-19 05:03:30,2023-06-19 05:03:30,OTHER,,,,,
42101,42102,NCT01972737,,2013-10-24,,,2017-04-04,2013-10-29,2013-10-30,Estimate,,,,,,,2017-04-04,2017-04-05,Actual,October 2013,,2013-10-31,April 2017,2017-04-30,"January 13, 2016",Actual,2016-01-13,"June 3, 2014",Actual,2014-06-03,,Interventional,,,Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer,A Phase I Study of Guanylyl Cyclase C (GCC)-Encoding Replication-Deficient Human Type 5 Recombinant Adenovirus Vaccine (Ad5-hGCC-PADRE) in Stage I and II Colon Cancer Patients,Completed,,Phase 1,10.0,Actual,Thomas Jefferson University,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 01:30:13,2023-06-15 01:30:13,OTHER,,,,,
42182,42183,NCT05724472,,2023-01-05,,,2023-03-08,2023-02-10,2023-02-13,Actual,,,,,,,2023-03-08,2023-03-09,Actual,May 2023,Anticipated,2023-05-31,March 2023,2023-03-31,November 2023,Anticipated,2023-11-30,November 2023,Anticipated,2023-11-30,,Interventional,,,Evaluation of Safety and Immunogenicity of rVSV<U+0394>G-SEBOV-GP Vaccine in Adults With Good General Health,"A Phase 1, Single-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV<U+0394>G-SEBOV-GP Vaccine at 3 Dose Levels in Adults in Good General Health",Not yet recruiting,,Phase 1,36.0,Anticipated,International AIDS Vaccine Initiative,,3.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-17 02:10:13,2023-06-17 02:10:13,NETWORK,,,,,
42208,42209,NCT03281876,,2017-09-05,2020-11-17,,2021-01-08,2017-09-11,2017-09-13,Actual,2021-01-08,2021-01-11,Actual,,,,2021-01-08,2021-01-11,Actual,"November 27, 2017",Actual,2017-11-27,January 2021,2021-01-31,"March 26, 2020",Actual,2020-03-26,"March 26, 2020",Actual,2020-03-26,,Interventional,,,A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.,"An Observer-blind Study to Evaluate the Efficacy, Safety, Reactogenicity and Immunogenicity of the GSK Biologicals' Investigational Vaccine GSK3277511A When Administered to COPD Patients",Completed,,Phase 2,606.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,False,True,False,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-17 03:40:57,2023-06-17 03:40:57,INDUSTRY,,,,,
42320,42321,NCT00428077,,2007-01-25,2011-05-26,,2011-08-31,2007-01-25,2007-01-29,Estimate,2011-08-01,2011-08-31,Estimate,,,,2011-08-31,2011-09-02,Estimate,October 2005,,2005-10-31,August 2011,2011-08-31,April 2009,Actual,2009-04-30,April 2009,Actual,2009-04-30,,Interventional,,,Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia,A Multi-Center Pilot Phase II Trial of a Synthetic Tumor-Specific Breakpoint Peptide Vaccine in Patients With Chronic Myeloid Leukemia (CML) and Minimal Residual Disease,Terminated,,Phase 2,4.0,Actual,OHSU Knight Cancer Institute,,,,"Withdrawn because there were no dramatic changes in the main endpoint, as well as low enrollment numbers. The data are not interpretable in terms of efficacy.",False,,,,True,,,,,,,,,,,,,2023-06-14 00:32:40,2023-06-14 00:32:40,OTHER,,,,,
42422,42423,NCT00441259,,2007-02-27,2012-06-06,,2012-07-24,2007-02-27,2007-02-28,Estimate,2012-07-24,2012-08-27,Estimate,,,,2012-07-24,2012-08-27,Estimate,January 2007,,2007-01-31,July 2012,2012-07-31,December 2011,Actual,2011-12-31,February 2011,Actual,2011-02-28,,Interventional,,,Safety and Efficacy Study of ChimeriVax-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age,"Randomised, Double Blind, Controlled, Safety, Tolerability and Immunogenicity Phase II Trial of ChimeriVax-JE and Japanese Encephalitis Inactivated Mouse Brain Vaccine in Children of Descending Age.",Completed,,Phase 2,96.0,Actual,Sanofi,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 00:33:56,2023-06-14 00:33:56,INDUSTRY,,,,,
42427,42428,NCT00460525,,2007-04-12,2010-07-02,,2018-10-11,2007-04-12,2007-04-16,Estimate,2010-08-04,2010-08-10,Estimate,,,,2018-10-11,2018-11-09,Actual,May 2007,,2007-05-31,October 2018,2018-10-31,July 2009,Actual,2009-07-31,July 2009,Actual,2009-07-31,,Interventional,,,Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali,"Randomized, Controlled Phase II Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the AMA-1 Malaria Vaccine FMP2.1/AS02A Versus Rabies Vaccine in 1-6 Year Old Children in Bandiagara, Mali",Completed,,Phase 2,400.0,Actual,U.S. Army Medical Research and Development Command,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 00:34:02,2023-06-14 00:34:02,FED,,,,,
42510,42511,NCT00450463,,2007-03-20,2018-06-19,,2018-11-27,2007-03-20,2007-03-22,Estimate,2018-10-26,2018-11-26,Actual,,,,2018-11-27,2018-11-29,Actual,"February 23, 2007",Actual,2007-02-23,November 2018,2018-11-30,"June 8, 2017",Actual,2017-06-08,"April 27, 2017",Actual,2017-04-27,,Interventional,,,Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer,"A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC/TRICOM and Flutamide vs. Flutamide Alone in Men With Androgen Insensitive, Non-Metastatic (D0.5) Prostate Cancer",Completed,,Phase 2,64.0,Actual,National Institutes of Health Clinical Center (CC),,2.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-14 00:35:16,2023-06-14 00:35:16,NIH,,,,,
42764,42765,NCT00538213,,2007-10-01,2012-04-05,2009-05-20,2018-05-09,2007-10-01,2007-10-02,Estimate,2012-08-02,2012-09-05,Estimate,2009-09-28,2009-09-30,Estimate,2018-05-09,2018-06-08,Actual,"October 15, 2007",,2007-10-15,November 2016,2016-11-30,"November 28, 2007",Actual,2007-11-28,"November 1, 2007",Actual,2007-11-01,,Interventional,,,Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults,Reactogenicity and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK576389A in Elderly Adults (=66 Years) Previously Vaccinated With the Same Candidate Vaccine. Fluarix Will be Used as Reference,Completed,,Phase 2,133.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-14 00:38:56,2023-06-14 00:38:56,INDUSTRY,,,,,
42797,42798,NCT03591614,,2018-07-09,,,2022-11-04,2018-07-09,2018-07-19,Actual,,,,,,,2022-11-04,2022-11-07,Actual,June 2023,Anticipated,2023-06-30,November 2022,2022-11-30,April 2024,Anticipated,2024-04-30,December 2023,Anticipated,2023-12-31,,Interventional,,,Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma,A Pilot Study of Dendritic Cell DKK1 Vaccine for Patients With Monoclonal Gammopathy and Stable or Smoldering Myeloma,Not yet recruiting,,Early Phase 1,18.0,Anticipated,Case Comprehensive Cancer Center,,1.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-14 00:39:23,2023-06-14 00:39:23,OTHER,,,,,
42867,42868,NCT01867333,,2013-05-30,,,2022-11-08,2013-05-30,2013-06-04,Estimate,,,,,,,2022-11-08,2022-11-09,Actual,"August 12, 2013",Actual,2013-08-12,"November 1, 2022",2022-11-01,"October 26, 2022",Actual,2022-10-26,"September 28, 2022",Actual,2022-09-28,,Interventional,,,Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer,A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men With Metastatic Castration Resistant Prostate Cancer,Completed,,Phase 2,57.0,Actual,National Institutes of Health Clinical Center (CC),,2.0,,,False,,,,,True,False,,,,,,Clinical data available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as the database is active.,Clinical data will be made available via subscription to BTRIS and with permission of the study PI. Genomic data are made available via dbGaP through requests to the data custodians,,Yes,".All IPD recorded in the medical record will be shared with intramural investigators upon request. In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP",2023-06-14 00:40:12,2023-06-14 00:40:12,NIH,,,,,
42922,42923,NCT05630846,,2022-11-24,,,2023-01-16,2022-11-24,2022-11-30,Actual,,,,,,,2023-01-16,2023-01-18,Actual,"December 14, 2022",Actual,2022-12-14,January 2023,2023-01-31,"June 17, 2024",Anticipated,2024-06-17,"January 31, 2024",Anticipated,2024-01-31,,Interventional,,,"A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age","A Phase II, Single-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of a Measles, Mumps, Rubella, Varicella Vaccine Compared With ProQuad, Administered in Healthy Children 4-6 Years of Age",Recruiting,,Phase 2,800.0,Anticipated,GlaxoSmithKline,,4.0,,,False,,,,True,True,False,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-14 00:40:54,2023-06-14 00:40:54,INDUSTRY,,,,,
43010,43011,NCT00442169,,2007-02-27,2011-01-21,,2016-04-12,2007-02-28,2007-03-01,Estimate,2011-01-21,2011-02-14,Estimate,,,,2016-04-12,2016-04-14,Estimate,December 2005,,2005-12-31,April 2016,2016-04-30,April 2009,Actual,2009-04-30,June 2008,Actual,2008-06-30,,Interventional,,,Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults,"Randomized, Double-blind, Placebo Controlled Phase II Trial of the Safety, Tolerability and Immunogenicity of Lyophilized ChimeriVax-WN02 West Nile Vaccine in Healthy Adults",Completed,,Phase 2,208.0,Actual,Sanofi,,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 00:42:03,2023-06-14 00:42:03,INDUSTRY,,,,,
43201,43202,NCT01976520,,2013-10-29,,,2021-04-07,2013-10-29,2013-11-05,Estimate,,,,,,,2021-04-07,2021-04-08,Actual,October 2013,,2013-10-31,April 2021,2021-04-30,January 2024,Anticipated,2024-01-31,January 2024,Anticipated,2024-01-31,,Interventional,,,Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL),NU 13H05: A Phase Ib Trial of Oncoquest-CLL Vaccine for Treatment-Naive Patients With Chronic Lymphocytic Leukemia,"Active, not recruiting",,Phase 1,30.0,Actual,XEME Biopharma Inc.,,1.0,,,False,,,,True,,,,,,,,,,,Undecided,,2023-06-15 01:32:43,2023-06-15 01:32:43,INDUSTRY,,,,,
43251,43252,NCT03159975,,2017-05-14,,,2019-01-09,2017-05-18,2017-05-19,Actual,,,,,,,2019-01-09,2019-01-11,Actual,March 2018,Anticipated,2018-03-31,January 2019,2019-01-31,August 2018,Anticipated,2018-08-31,August 2018,Anticipated,2018-08-31,,Interventional,,,Safety and Immunogenicity Study of GX-70 in TB Patient,"A Open-label, Dose Escalation, Phase 1 Clinical Trial to Evaluate the Tolerability, Safety and Immunogenicity of GX-70, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation (EP) in Patients With Pulmonary Tuberculosis Who Have High Risk Factors for Relapse or Treatment Failure",Withdrawn,,Phase 1,0.0,Actual,Yonsei University,,3.0,,Unconfirmed research expenses,False,,,,False,False,False,,,,,,,,,No,,2023-06-18 06:32:03,2023-06-18 06:32:03,OTHER,,,,,
43370,43371,NCT04961359,,2021-07-08,,,2023-04-23,2021-07-08,2021-07-14,Actual,,,,,,,2023-04-23,2023-04-25,Actual,"July 3, 2021",Actual,2021-07-03,April 2023,2023-04-30,"April 6, 2023",Actual,2023-04-06,"December 12, 2021",Actual,2021-12-12,,Interventional,,,Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2(COVID-19) Phase I Clinical Trial (3~17 Years Old),"A Randomized, Blinded, Placebo-controlled Phase <U+2160> Clinical Trial of Recombinant New Coronavirus Vaccine (CHO Cells) in the Safety and Tolerability of Healthy People Aged 3 to 17 Years of Age",Completed,,Phase 1,75.0,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,6.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-14 00:46:19,2023-06-14 00:46:19,INDUSTRY,,,,,
43436,43437,NCT02572388,,2015-10-01,2019-07-16,,2019-11-08,2015-10-07,2015-10-08,Estimate,2019-11-08,2019-11-12,Actual,,,,2019-11-08,2019-11-12,Actual,"October 15, 2015",Actual,2015-10-15,January 2018,2018-01-31,"August 29, 2017",Actual,2017-08-29,"August 29, 2017",Actual,2017-08-29,,Interventional,,,"A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1","Safety and Immunogenicity of a Protein Particle Malaria Vaccine Candidate, R21, Administered With and Without Matrix-M1 in Healthy UK Volunteers",Completed,,Phase 1,31.0,Actual,University of Oxford,,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-18 03:26:10,2023-06-18 03:26:10,OTHER,,,,,
43463,43464,NCT01977170,,2013-10-29,,,2013-11-05,2013-11-05,2013-11-06,Estimate,,,,,,,2013-11-05,2013-11-06,Estimate,November 2010,,2010-11-30,October 2013,2013-10-31,December 2010,Actual,2010-12-31,December 2010,Actual,2010-12-31,,Interventional,,,Safety of Hib Vaccine (Bio Farma),Phase 1 Study of Hib Vaccine (Bio Farma),Completed,,Phase 1,25.0,Actual,PT Bio Farma,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 01:33:11,2023-06-15 01:33:11,INDUSTRY,,,,,
43467,43468,NCT01977196,,2013-10-30,,,2013-11-05,2013-11-05,2013-11-06,Estimate,,,,,,,2013-11-05,2013-11-06,Estimate,April 2011,,2011-04-30,October 2013,2013-10-31,July 2011,Actual,2011-07-31,July 2011,Actual,2011-07-31,,Interventional,,,The Safety and Immunogenicity of DTP/Hepatitis B 10ug Hib Vaccine (Bio Farma),Phase 1 of DTP/Hepatitis B 10ug Hib Vaccine,Completed,,Phase 1,30.0,Actual,PT Bio Farma,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 01:33:12,2023-06-15 01:33:12,INDUSTRY,,,,,
43501,43502,NCT03674827,,2018-08-29,,,2022-04-29,2018-09-14,2018-09-18,Actual,,,,,,,2022-04-29,2022-05-05,Actual,"November 27, 2018",Actual,2018-11-27,April 2022,2022-04-30,"September 27, 2021",Actual,2021-09-27,"September 27, 2021",Actual,2021-09-27,,Interventional,,,Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC,"A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of a Vaccine-based Immunotherapy Regimen-2 (VBIR-2) (PF-06936308) for Advanced Non-small Cell Lung Cancer and Metastatic Triple-negative Breast Cancer",Terminated,,Phase 1,36.0,Actual,Pfizer,,2.0,,The study was terminated due to the review of the asset (VBIR-2) within the Sponsor's oncology portfolio; the study was not terminated because of safety concerns.,False,,,,False,True,False,,,,,,,,,No,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2023-06-14 00:47:51,2023-06-14 00:47:51,INDUSTRY,,,,,
43902,43903,NCT01978964,,2013-11-01,,,2018-05-14,2013-11-07,2013-11-08,Estimate,,,,,,,2018-05-14,2018-05-17,Actual,November 2012,,2012-11-30,March 2016,2016-03-31,March 2016,Actual,2016-03-31,March 2016,Actual,2016-03-31,,Interventional,,,Phase 1b Maintenance Therapy Study of ONT-10 in Patients With Solid Tumors,"Maintenance Therapy With ONT-10, a Liposomal MUC1 Cancer Vaccine, in Patients Who Have Previously Received ONT-10",Completed,,Phase 1,90.0,Anticipated,Seagen Inc.,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 01:34:33,2023-06-15 01:34:33,INDUSTRY,,,,,
43932,43933,NCT01979406,,2013-10-16,,,2020-03-03,2013-11-03,2013-11-08,Estimate,,,,,,,2020-03-03,2020-03-04,Actual,November 2013,,2013-11-30,March 2020,2020-03-31,September 2015,Actual,2015-09-30,October 2014,Actual,2014-10-31,,Interventional,,,A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines,A Phase 1 Randomized Double-Blind Positive-Controlled Ascending Dose Study to Evaluate the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4 Anthrax Vector Candidate Vaccines - Ad4-PA (Protective Antigen)and Ad4-PA-GPI (Glycosylphosphatidylinositol),Completed,,Phase 1,120.0,Actual,Emergent BioSolutions,,7.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 01:34:49,2023-06-15 01:34:49,INDUSTRY,,,,,
44007,44008,NCT03676634,,2018-09-17,2021-08-20,,2021-09-22,2018-09-17,2018-09-19,Actual,2021-09-22,2021-10-19,Actual,,,,2021-09-22,2021-10-19,Actual,"March 7, 2019",Actual,2019-03-07,January 2020,2020-01-31,"July 3, 2020",Actual,2020-07-03,"April 25, 2020",Actual,2020-04-25,,Interventional,,,Tolerability and Immunogenicity of rBV A/B for the Production of BabyBIG®,Tolerability and Immunogenicity of a Single 40-µg Dose of Recombinant Botulinum Vaccine A/B (rBV A/B) for the Production of BabyBIG® in Volunteers With Existing Botulinum Immunity,Completed,,Phase 2,32.0,Actual,California Department of Public Health,,1.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-17 02:11:36,2023-06-17 02:11:36,OTHER,,,,,
44261,44262,NCT01984983,,2013-09-23,,,2015-08-24,2013-11-07,2013-11-15,Estimate,,,,,,,2015-08-24,2015-08-26,Estimate,December 2013,,2013-12-31,August 2015,2015-08-31,May 2015,Actual,2015-05-31,June 2014,Actual,2014-06-30,,Interventional,,,Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers,"A Phase I, Randomized, Observer-blind, Placebo Controlled Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered Intramuscularly or Intradermally by Electroporation to Healthy Adults",Completed,,Phase 1,42.0,Actual,Ichor Medical Systems Incorporated,,5.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 01:39:07,2023-06-15 01:39:07,INDUSTRY,,,,,
44344,44345,NCT01986322,,2013-10-30,,,2013-11-11,2013-11-11,2013-11-18,Estimate,,,,,,,2013-11-11,2013-11-18,Estimate,July 2011,,2011-07-31,November 2013,2013-11-30,January 2012,Actual,2012-01-31,January 2012,Actual,2012-01-31,,Interventional,,,Immunogenicity and Safety of DTP/HB/Hib (Bio Farma)Compared to DTP/HB Given Simultaneously With Hib(Registered)Vaccine,Phase 2 Study of Immunogenicity and Safety of DPT/HB/Hib (Bio Farma) Vaccine Compared to DTP/HB (Bio Farma) Vaccine Given Simultaneously With Hib (Registered) Vaccine in Indonesian Infants,Completed,,Phase 2,220.0,Actual,PT Bio Farma,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 01:40:08,2023-06-15 01:40:08,INDUSTRY,,,,,
44469,44470,NCT01988636,,2013-11-09,,,2019-11-30,2013-11-14,2013-11-20,Estimate,,,,,,,2019-11-30,2019-12-03,Actual,"October 29, 2013",,2013-10-29,"August 20, 2015",2015-08-20,"August 20, 2015",Actual,2015-08-20,"August 20, 2015",Actual,2015-08-20,,Interventional,,,Study of Safety and Effectiveness of Intravenous Immunization With PfSPZ Vaccine in Healthy African Adults,Assessment of Safety and Immunogenicity of Intravenous Immunization With Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) in Healthy African Adults,Completed,,Phase 1,296.0,Actual,National Institutes of Health Clinical Center (CC),,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 01:41:39,2023-06-15 01:41:39,NIH,,,,,
44528,44529,NCT01989533,,2013-11-19,,,2019-12-14,2013-11-19,2013-11-21,Estimate,,,,,,,2019-12-14,2019-12-17,Actual,"November 19, 2013",,2013-11-19,"April 24, 2019",2019-04-24,"April 8, 2019",Actual,2019-04-08,"April 8, 2019",Actual,2019-04-08,,Interventional,,,Study of Safety and Immunogenicity of HIV Vaccines in Healthy Volunteers,Phase I Study of Safety and Immunogenicity of Ad4-HIV Vaccine Vectors in Healthy Volunteers,Completed,,Phase 1,62.0,Actual,National Institutes of Health Clinical Center (CC),,4.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-15 01:42:20,2023-06-15 01:42:20,NIH,,,,,
44529,44530,NCT01989559,,2013-11-18,,,2015-01-23,2013-11-18,2013-11-21,Estimate,,,,,,,2015-01-23,2015-01-26,Estimate,October 2002,,2002-10-31,November 2013,2013-11-30,September 2013,Actual,2013-09-30,September 2013,Actual,2013-09-30,,Interventional,,,Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery,A Pilot Study to Assess the Immunologic Response to Booster Vaccination With a Modified gp100 Melanoma Peptide (209-2M) Vaccine in Previously Vaccinated HLA-A2.1+ Patients With Melanoma,Completed,,Phase 1,30.0,Actual,National Cancer Institute (NCI),,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 01:42:21,2023-06-15 01:42:21,NIH,,,,,
44641,44642,NCT01991561,,2013-09-18,,,2020-06-08,2013-11-18,2013-11-25,Estimate,,,,,,,2020-06-08,2020-06-11,Actual,June 2013,,2013-06-30,September 2015,2015-09-30,November 2014,Actual,2014-11-30,July 2014,Actual,2014-07-31,,Interventional,,,"Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine.","Immunogenicity, Safety, Tolerability of a Plant-made H5 VLP Influenza Vaccine.",Completed,,Phase 2,390.0,Actual,Medicago,,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 01:43:47,2023-06-15 01:43:47,INDUSTRY,,,,,
44741,44742,NCT04695652,,2020-12-31,,,2022-01-27,2021-01-04,2021-01-05,Actual,,,,,,,2022-01-27,2022-01-31,Actual,"December 30, 2020",Actual,2020-12-30,December 2020,2020-12-31,"October 29, 2021",Actual,2021-10-29,"May 15, 2021",Actual,2021-05-15,,Interventional,COVID-19,,A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult,"A Phase II, Prospective, Double-blinded, Multi-Center, Multi-Regional Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS-CoV-2 Vaccine Candidate MVC-COV1901",Completed,,Phase 2,3854.0,Actual,Medigen Vaccine Biologics Corp.,,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-17 02:12:01,2023-06-17 02:12:01,INDUSTRY,,,,,
44885,44886,NCT01995617,,2013-11-19,,,2015-12-10,2013-11-21,2013-11-26,Estimate,,,,,,,2015-12-10,2015-12-11,Estimate,November 2013,,2013-11-30,November 2015,2015-11-30,February 2015,Actual,2015-02-28,February 2015,Actual,2015-02-28,,Interventional,,,Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of GEN-004, a Streptococcus Pneumoniae Protein Subunit Vaccine, in Adult Subjects",Completed,,Phase 1,90.0,Actual,"Genocea Biosciences, Inc.",,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 01:46:42,2023-06-15 01:46:42,INDUSTRY,,,,,
44890,44891,NCT01995695,,2013-11-21,,,2016-07-26,2013-11-21,2013-11-26,Estimate,,,,,,,2016-07-26,2016-07-27,Estimate,October 2013,,2013-10-31,July 2016,2016-07-31,,,,January 2016,Actual,2016-01-31,,Interventional,,,Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults,"Phase 1 Evaluation of the Safety and Immunogenicity of Live Influenza A Vaccine H7N9 (6-2) AA ca Recombinant (A/Anhui/1/2013 (H7N9) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H7N9 Disease in the Event of a Pandemic",Completed,,Phase 1,48.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 01:46:46,2023-06-15 01:46:46,NIH,,,,,
45004,45005,NCT01997632,,2013-11-22,,,2015-11-09,2013-11-27,2013-11-28,Estimate,,,,,,,2015-11-09,2015-11-10,Estimate,November 2013,,2013-11-30,November 2015,2015-11-30,May 2014,Actual,2014-05-31,May 2014,Actual,2014-05-31,,Interventional,IPV-004,,Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults,Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults,Completed,,Phase 1,120.0,Actual,"University Hospital, Ghent",,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 01:48:02,2023-06-15 01:48:02,OTHER,,,,,
45063,45064,NCT01998542,,2013-11-21,,,2020-01-21,2013-11-25,2013-11-29,Estimate,,,,,,,2020-01-21,2020-01-23,Actual,January 2016,Actual,2016-01-31,August 2016,2016-08-31,November 2017,Actual,2017-11-30,"June 1, 2017",Actual,2017-06-01,,Interventional,HNC,,Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck,Phase II Study Designed To Evaluate Safety and Tumor Debulking Mechanism of an Individualized Cancer Vaccine (AllovaxTM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck.,Completed,,Phase 2,12.0,Actual,"Immunovative Therapies, Ltd.",,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 01:48:40,2023-06-15 01:48:40,INDUSTRY,,,,,
45131,45132,NCT01999699,,2013-11-26,,,2019-03-18,2013-12-02,2013-12-03,Estimate,,,,,,,2019-03-18,2019-03-20,Actual,November 2013,,2013-11-30,March 2019,2019-03-31,March 2015,Actual,2015-03-31,February 2015,Actual,2015-02-28,,Interventional,,,A Study of the Immune Response to Heplisav in Healthy Older Adults,A Phase 1 Systems Biology Study to Investigate Immune Correlates of the Response to an Experimental Hepatitis B Vaccine (HEPLISAV) in Healthy Adults 50 to 70 Years of Age.,Completed,,Phase 1,25.0,Actual,Dynavax Technologies Corporation,,1.0,,,False,,,,False,,,,,,,,,,,Undecided,"a/o August 2016, decision still pending.",2023-06-15 01:49:23,2023-06-15 01:49:23,INDUSTRY,,,,,
45141,45142,NCT01999842,,2013-11-21,,,2017-05-26,2013-11-26,2013-12-03,Estimate,,,,,,,2017-05-26,2017-05-30,Actual,"November 25, 2013",Actual,2013-11-25,May 2017,2017-05-31,"January 19, 2015",Actual,2015-01-19,"February 1, 2014",Actual,2014-02-01,,Interventional,,,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age,An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age,Completed,,Phase 1,424.0,Actual,GlaxoSmithKline,,6.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 01:49:30,2023-06-15 01:49:30,INDUSTRY,,,,,
45658,45659,NCT05663086,,2022-12-22,,,2023-03-09,2022-12-22,2022-12-23,Actual,,,,,,,2023-03-09,2023-03-10,Actual,"June 30, 2023",Anticipated,2023-06-30,December 2022,2022-12-31,"June 30, 2024",Anticipated,2024-06-30,"December 30, 2023",Anticipated,2023-12-30,,Interventional,,,Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above,"A Randomized, Blinded, Positive-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in Population Aged 18 Years and Above(Negative for Antibody Against COVID-19)",Not yet recruiting,,Phase 2,720.0,Anticipated,"Guangzhou Patronus Biotech Co., Ltd.",,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-17 02:12:31,2023-06-17 02:12:31,INDUSTRY,,,,,
45970,45971,NCT04886154,,2021-05-10,,,2023-03-17,2021-05-10,2021-05-13,Actual,,,,,,,2023-03-17,2023-03-21,Actual,"June 14, 2021",Actual,2021-06-14,March 2023,2023-03-31,"January 19, 2024",Anticipated,2024-01-19,"January 19, 2024",Anticipated,2024-01-19,,Interventional,,,"A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults","A Phase I/II, Randomised, Controlled Study to Assess the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine When Administered to Healthy Adults (Phase I) and to Healthy Adolescents and Adults (Phase II)","Active, not recruiting",,Phase 1,1258.0,Anticipated,GlaxoSmithKline,,15.0,,,False,,,,False,True,False,,,True,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-15 01:59:27,2023-06-15 01:59:27,INDUSTRY,,,,,
46132,46133,NCT03361852,,2017-11-29,,,2023-03-20,2017-11-29,2017-12-05,Actual,,,,,,,2023-03-20,2023-03-21,Actual,"March 14, 2022",Actual,2022-03-14,March 2023,2023-03-31,"March 14, 2026",Anticipated,2026-03-14,"March 14, 2024",Anticipated,2024-03-14,,Interventional,,,Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma,A Pilot Study of a Personalized Neoantigen Cancer Vaccine in Combination With Pembrolizumab Following Front-Line Rituximab in Follicular Lymphoma,Recruiting,,Phase 1,20.0,Anticipated,Dana-Farber Cancer Institute,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-15 02:02:04,2023-06-15 02:02:04,OTHER,,,,,
46188,46189,NCT02432963,,2015-04-29,,,2023-03-17,2015-05-01,2015-05-04,Estimate,,,,,,,2023-03-17,2023-03-21,Actual,"June 14, 2016",Actual,2016-06-14,March 2023,2023-03-31,"December 31, 2023",Anticipated,2023-12-31,"December 4, 2017",Actual,2017-12-04,,Interventional,,,Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy,A Phase I Study of a p53MVA Vaccine in Combination With Pembrolizumab,"Active, not recruiting",,Phase 1,11.0,Actual,City of Hope Medical Center,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 02:02:58,2023-06-15 02:02:58,OTHER,,,,,
46520,46521,NCT02014168,,2013-11-08,,,2014-04-29,2013-12-11,2013-12-18,Estimate,,,,,,,2014-04-29,2014-04-30,Estimate,January 2014,,2014-01-31,April 2014,2014-04-30,April 2014,Actual,2014-04-30,April 2014,Actual,2014-04-30,,Interventional,,,Safety and Immunogenicity of Co-administration of Candidate Influenza Vaccine MVA-NP+M1 and Viroflu® Seasonal Influenza Vaccine,A Phase I Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NP+M1 and the Viroflu® Seasonal Influenza Vaccine,Terminated,,Phase 1,3.0,Actual,University of Oxford,,2.0,,Futility,False,,,,False,,,,,,,,,,,,,2023-06-15 02:07:28,2023-06-15 02:07:28,OTHER,,,,,
46551,46552,NCT02014727,,2013-12-12,,,2016-02-01,2013-12-12,2013-12-18,Estimate,,,,,,,2016-02-01,2016-02-02,Estimate,January 2014,,2014-01-31,September 2015,2015-09-30,July 2015,Actual,2015-07-31,March 2015,Actual,2015-03-31,,Interventional,AMA1-DiCo,,Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults,"Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults:a Staggered Phase Ia/Ib, Randomised, Double-blind, Multi-Centre Trial",Completed,,Phase 1,66.0,Actual,"Institut National de la Santé Et de la Recherche Médicale, France",,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 02:07:53,2023-06-15 02:07:53,OTHER_GOV,,,,,
46572,46573,NCT02015091,,2013-12-18,,,2019-12-14,2013-12-18,2013-12-19,Estimate,,,,,,,2019-12-14,2019-12-17,Actual,"December 12, 2013",,2013-12-12,"September 8, 2016",2016-09-08,"September 8, 2016",Actual,2016-09-08,"May 1, 2015",Actual,2015-05-01,,Interventional,,,Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults,"VRC 314: A Phase 1, Open-Label, Clinical Trial With Experimental Controlled Human Malaria Infections (CHMI) to Evaluate Safety and Durability of Protection Following Intravenous and Intramuscular Administration of PFSPZ Vaccine in Malaria-Naive Adults",Completed,,Phase 1,141.0,Actual,National Institutes of Health Clinical Center (CC),,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 02:08:07,2023-06-15 02:08:07,NIH,,,,,
46594,46595,NCT02015494,,2013-12-09,,,2015-03-05,2013-12-12,2013-12-19,Estimate,,,,,,,2015-03-05,2015-03-06,Estimate,March 2014,,2014-03-31,March 2015,2015-03-31,December 2015,Anticipated,2015-12-31,December 2014,Actual,2014-12-31,,Interventional,,,Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention,Phase 1 Study of the Safety and Immunogenicity of VAX2012Q: A Quadrivalent Influenza Vaccine in Healthy Adults Age 18-40 Years,Unknown status,"Active, not recruiting",Phase 1,316.0,Actual,VaxInnate Corporation,,7.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 02:08:22,2023-06-15 02:08:22,INDUSTRY,,,,,
46833,46834,NCT02019524,,2013-11-25,,,2020-03-16,2013-12-18,2013-12-24,Estimate,,,,,,,2020-03-16,2020-03-18,Actual,"September 30, 2013",,2013-09-30,March 2020,2020-03-31,"December 6, 2016",Actual,2016-12-06,"December 6, 2016",Actual,2016-12-06,,Interventional,J65,,Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients,Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients,Completed,,Phase 1,39.0,Actual,San Antonio Military Medical Center,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 02:11:07,2023-06-15 02:11:07,FED,,,,,
46960,46961,NCT02021968,,2013-12-20,,,2015-12-14,2013-12-20,2013-12-27,Estimate,,,,,,,2015-12-14,2015-12-15,Estimate,November 2013,,2013-11-30,December 2015,2015-12-31,December 2015,Actual,2015-12-31,March 2015,Actual,2015-03-31,,Interventional,,,Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults,"A Phase 1 Evaluation of the Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV003 to Protect Against Infection With Attenuated DENV-2, rDEN2<U+2206>30-7169",Completed,,Phase 1,48.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 02:12:42,2023-06-15 02:12:42,NIH,,,,,
46968,46969,NCT02022163,,2013-12-20,,,2015-09-24,2013-12-20,2013-12-27,Estimate,,,,,,,2015-09-24,2015-09-25,Estimate,December 2013,,2013-12-31,September 2015,2015-09-30,December 2014,Actual,2014-12-31,September 2014,Actual,2014-09-30,,Interventional,,,"Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.","Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.",Completed,,Phase 1,100.0,Actual,Medicago,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 02:12:47,2023-06-15 02:12:47,INDUSTRY,,,,,
47168,47169,NCT05507450,,2022-08-17,,,2023-05-11,2022-08-17,2022-08-19,Actual,,,,,,,2023-05-11,2023-05-12,Actual,"September 7, 2022",Actual,2022-09-07,May 2023,2023-05-31,"June 24, 2024",Anticipated,2024-06-24,"June 8, 2023",Anticipated,2023-06-08,,Interventional,,,Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003),"A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Three Different Potency Levels of V181 (Dengue Quadrivalent Vaccine rDENV<U+0394>30 [Live, Attenuated]) in Healthy Adults","Active, not recruiting",,Phase 2,1265.0,Anticipated,Merck Sharp & Dohme LLC,,4.0,,,False,,,,True,True,False,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2023-06-16 01:55:13,2023-06-16 01:55:13,INDUSTRY,,,,,
47488,47489,NCT02035956,,2014-01-10,,,2020-01-14,2014-01-13,2014-01-14,Estimate,,,,,,,2020-01-14,2020-01-18,Actual,December 2013,Actual,2013-12-31,January 2020,2020-01-31,October 2019,Actual,2019-10-31,"February 14, 2017",Actual,2017-02-14,,Interventional,,,IVAC MUTANOME Phase I Clinical Trial,"First-in-human Study Evaluating the Safety, Tolerability and Immunogenicity of i.n. Administration of a Personalized Vaccination With IVAC MUTANOME Vaccine w/o Initial Treatment With RBL001/RBL002 Vaccine in Patients With Advanced Melanoma",Completed,,Phase 1,15.0,Actual,BioNTech SE,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 02:18:47,2023-06-15 02:18:47,INDUSTRY,,,,,
47548,47549,NCT02040636,,2014-01-16,,,2015-03-24,2014-01-16,2014-01-20,Estimate,,,,,,,2015-03-24,2015-03-25,Estimate,January 1999,,1999-01-31,March 2015,2015-03-31,May 2000,Actual,2000-05-31,May 2000,Actual,2000-05-31,,Interventional,,,Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis,Safety and Immunogenicity of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis Vaccine (TdcP-IPV) Compared to Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis Vaccine (TdcP-IPV) and Hepatitis B Vaccine Given Concurrently In Adolescents 11-14 Years of Age,Completed,,Phase 2,277.0,Actual,Sanofi,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 02:19:32,2023-06-15 02:19:32,INDUSTRY,,,,,
47558,47559,NCT02040831,,2014-01-17,,,2016-12-20,2014-01-17,2014-01-20,Estimate,,,,,,,2016-12-20,2016-12-21,Estimate,September 2014,,2014-09-30,December 2016,2016-12-31,April 2015,Actual,2015-04-30,April 2015,Actual,2015-04-30,,Interventional,,,Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children,"A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID <U+0394>M2-2, Lot RSV#007A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age",Completed,,Phase 1,3.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 02:19:38,2023-06-15 02:19:38,NIH,,,,,
47925,47926,NCT00005841,,2000-06-02,,,2014-05-20,2004-05-25,2004-05-26,Estimate,,,,,,,2014-05-20,2014-05-22,Estimate,June 2000,,2000-06-30,May 2014,2014-05-31,October 2002,Actual,2002-10-31,December 2000,Actual,2000-12-31,,Interventional,,,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,A Phase I Trial of a Vaccine Combining Tyrosinase/GP100/Mart-1 Peptides Emulsified With Montanide ISA 51 With ProGP for Patients With Resected Stages III and IV Melanoma,Terminated,,Phase 1,15.0,Actual,University of Southern California,,,,Toxicity/Side Effects,False,,,,True,,,,,,,,,,,,,2023-06-15 02:24:06,2023-06-15 02:24:06,OTHER,,,,,
47946,47947,NCT00005916,,2006-06-30,,,2017-06-30,2000-06-16,2000-06-19,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"June 13, 2000",,2000-06-13,"December 22, 2005",2005-12-22,"December 22, 2005",Actual,2005-12-22,,,,,Interventional,,,PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer,A Randomized Phase II Study of a PSA-Based Vaccine in Patients With Localized Prostate Cancer Receiving Standard Radiotherapy,Completed,,Phase 2,48.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 02:24:21,2023-06-15 02:24:21,NIH,,,,,
47960,47961,NCT00005949,,2000-07-05,,,2013-01-15,2003-01-26,2003-01-27,Estimate,,,,,,,2013-01-15,2013-01-16,Estimate,March 2001,,2001-03-31,January 2013,2013-01-31,,,,March 2006,Actual,2006-03-31,,Interventional,,,Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma,"Phase II Study of Melanoma Vaccine (NSC #683472/675756, IND #6123) and Low-Dose, Subcutaneous Interleukin-2 in Advanced Melanoma",Completed,,Phase 2,50.0,Actual,National Cancer Institute (NCI),,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 02:24:36,2023-06-15 02:24:36,NIH,,,,,
48269,48270,NCT03748524,,2018-11-15,,,2021-01-05,2018-11-16,2018-11-21,Actual,,,,,,,2021-01-05,2021-01-06,Actual,"October 29, 2018",Actual,2018-10-29,January 2021,2021-01-31,"October 29, 2021",Anticipated,2021-10-29,"September 30, 2021",Anticipated,2021-09-30,,Interventional,,,Analysis of Antigen Specific B Cell Responses to Immunization With Influenza Virus Vaccine,Washington University (WU) 321: Analysis of Antigen Specific B Cell Responses to Immunization With Influenza Virus Vaccine: Fine Needle Aspiration (FNA) and Bone Marrow Aspiration (BMA),Unknown status,"Active, not recruiting",Early Phase 1,11.0,Actual,Washington University School of Medicine,,1.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-17 02:13:27,2023-06-17 02:13:27,OTHER,,,,,
48342,48343,NCT00386698,,2006-10-09,,,2016-10-06,2006-10-09,2006-10-11,Estimate,,,,,,,2016-10-06,2016-10-07,Estimate,October 2006,,2006-10-31,October 2016,2016-10-31,December 2006,Actual,2006-12-31,,,,,Interventional,,,Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly Adults,Evaluate Reactogenicity & Immunogenicity of Adjuvanted Influenza Vaccine in Elderly Adults Previously Vaccinated With the Same Candidate Vaccine. Fluarix Administered in Young & Elderly Adults Will be Used as Reference,Completed,,Phase 2,200.0,Actual,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 02:29:23,2023-06-15 02:29:23,INDUSTRY,,,,,
48388,48389,NCT05679466,,2023-01-09,,,2023-01-09,2023-01-09,2023-01-11,Actual,,,,,,,2023-01-09,2023-01-11,Actual,"December 27, 2022",Actual,2022-12-27,January 2023,2023-01-31,"December 31, 2023",Anticipated,2023-12-31,"June 30, 2023",Anticipated,2023-06-30,,Interventional,,,"An Investigator Initiated, Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older","An Investigator Initiated, Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older","Active, not recruiting",,Early Phase 1,3300.0,Actual,West China Second University Hospital,,2.0,,,False,,,,,False,False,,,,,,,,,No,,2023-06-15 02:29:53,2023-06-15 02:29:53,OTHER,,,,,
48500,48501,NCT04852978,,2021-04-19,,,2023-01-09,2021-04-19,2021-04-21,Actual,,,,,,,2023-01-09,2023-01-11,Actual,"April 29, 2021",Actual,2021-04-29,December 2022,2022-12-31,"November 21, 2022",Actual,2022-11-21,"November 21, 2022",Actual,2022-11-21,,Interventional,,,"COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers","A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers",Completed,,Phase 2,295.0,Actual,Regeneron Pharmaceuticals,,12.0,,,True,,,,False,True,False,,,,,,"When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.",Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf,https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2023-06-15 02:31:09,2023-06-15 02:31:09,INDUSTRY,,NCT04617535,Available,,
48508,48509,NCT03384914,,2017-12-20,,,2023-01-10,2017-12-20,2017-12-28,Actual,,,,,,,2023-01-10,2023-01-12,Actual,"February 19, 2018",Actual,2018-02-19,January 2023,2023-01-31,December 2026,Anticipated,2026-12-31,December 2025,Anticipated,2025-12-31,,Interventional,,,Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer,A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer,"Active, not recruiting",,Phase 2,119.0,Actual,H. Lee Moffitt Cancer Center and Research Institute,,2.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-17 03:41:46,2023-06-17 03:41:46,OTHER,,,,,
48548,48549,NCT03771157,,2018-12-07,,,2023-01-09,2018-12-07,2018-12-10,Actual,,,,,,,2023-01-09,2023-01-11,Actual,"February 1, 2019",Actual,2019-02-01,January 2023,2023-01-31,"August 3, 2022",Actual,2022-08-03,"September 1, 2020",Actual,2020-09-01,,Interventional,,,Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors,"Serologic Response to a New Recombinant, Adjuvanted Herpes Zoster Vaccine in Patients With Chronic Lymphocytic Leukemia and Waldenström Macroglobulinemia Treated With First-Line BTK Inhibitors - A Pilot Study",Completed,,Early Phase 1,33.0,Actual,University of Rochester,,1.0,,,False,,,,True,True,False,,,False,,,,,,,,2023-06-15 02:31:40,2023-06-15 02:31:40,OTHER,,,,,
48595,48596,NCT00006630,,2000-12-06,,,2021-10-28,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-28,2021-11-01,Actual,,,,October 2021,2021-10-31,,,,,,,,Interventional,,,Vaccinia Immune Globulin in Treating or Preventing Vaccinal Infection,"Open-Label, Multi-Site Study for the Administration of Vaccinia Immune Globulin (Human) To Subjects Who Experience Complications From Vaccinia Virus Vaccinations or To Unprotected Individuals Accidentally Exposed To Vaccinia Virus or Related Orthopox Viruses [During HIV Vaccine Research]",Withdrawn,,Phase 1,0.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 02:32:17,2023-06-15 02:32:17,NIH,,,,,
48750,48751,NCT00006385,,2000-10-04,,,2011-11-05,2003-01-26,2003-01-27,Estimate,,,,,,,2011-11-05,2011-11-08,Estimate,September 2000,,2000-09-30,December 2002,2002-12-31,,,,October 2006,Actual,2006-10-31,,Interventional,,,Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma,"Phase II Evaluation of Immunization With an HLA-A2 Multi-Epitope Peptide Vaccine Containing MART-1 (NSC #672643), gp100 (NSC #683472), and Tyrosinase (NSC #699048) Peptides Alone or in Combination With GM-CSF, IFN Alpha-2b, or GM-CSF + IFN Alpha-2b in Patients With Metastatic Melanoma",Completed,,Phase 2,,,National Cancer Institute (NCI),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 02:34:11,2023-06-15 02:34:11,NIH,,,,,
48972,48973,NCT03582085,,2018-06-18,,,2022-04-05,2018-06-27,2018-07-10,Actual,,,,,,,2022-04-05,2022-04-06,Actual,"January 1, 2022",Anticipated,2022-01-01,April 2022,2022-04-30,"January 1, 2023",Anticipated,2023-01-01,"January 1, 2023",Anticipated,2023-01-01,,Interventional,,,Phase II Clinical Trial: Multi-dosing the BCG Vaccine for Fibromyalgia,Phase II Clinical Trial: Multi-dosing the BCG Vaccine for Fibromyalgia,Withdrawn,,Phase 2,0.0,Actual,Massachusetts General Hospital,,2.0,,No funding at the current time.,False,,,,True,True,False,,,,,,,,,Undecided,,2023-06-15 02:36:56,2023-06-15 02:36:56,OTHER,,,,,
49045,49046,NCT00000631,,1999-11-02,,,2021-10-26,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-26,2021-11-02,Actual,,,,October 2021,2021-10-31,December 1992,Actual,1992-12-31,,,,,Interventional,,,A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn),A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn),Completed,,Phase 1,13.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 02:37:51,2023-06-15 02:37:51,NIH,,,,,
49089,49090,NCT00000904,,1999-11-02,,,2021-10-27,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-27,2021-11-04,Actual,,,,October 2021,2021-10-31,August 1999,Actual,1999-08-31,,,,,Interventional,,,Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults,"A Phase I Trial to Compare the Safety and Immunogenicity of the Live Recombinant Canarypox ALVAC-HIV Vaccines, vCP205, vCP1433, and vCP1452, in HIV-1 Uninfected Adult Volunteers",Completed,,Phase 1,100.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 02:38:19,2023-06-15 02:38:19,NIH,,,,,
49108,49109,NCT00001021,,1999-11-02,,,2005-06-23,2001-08-30,2001-08-31,Estimate,,,,,,,2005-06-23,2005-06-24,Estimate,,,,October 2002,2002-10-31,,,,,,,,Interventional,,,A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009),A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009),Completed,,Phase 1,57.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 02:38:31,2023-06-15 02:38:31,NIH,,,,,
49288,49289,NCT05639998,,2022-08-17,,,2022-11-25,2022-11-25,2022-12-07,Actual,,,,,,,2022-11-25,2022-12-07,Actual,"September 1, 2021",Actual,2021-09-01,November 2022,2022-11-30,"July 31, 2022",Actual,2022-07-31,"March 1, 2022",Actual,2022-03-01,,Interventional,BBV152BBV154,,BBV152/BBV154 Heterologus Prime-Boost Study,"Phase 2 Randomized, Multi-centric of Heterologus Prime-Boost Combination of SARS-CoV-2 Vaccines to Evaluate the Immunogenicity and Safety of BBV152 (COVAXIN®) With BBV154 (Adenoviral Intranasal COVID-19 Vaccine) in Healthy Volunteers",Completed,,Phase 2,608.0,Actual,Bharat Biotech International Limited,,4.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-15 02:40:41,2023-06-15 02:40:41,INDUSTRY,,,,,
49479,49480,NCT04713514,,2021-01-14,,,2022-12-02,2021-01-15,2021-01-19,Actual,,,,,,,2022-12-02,2022-12-05,Actual,"August 5, 2021",Actual,2021-08-05,December 2022,2022-12-31,June 2025,Anticipated,2025-06-30,June 2025,Anticipated,2025-06-30,,Interventional,TEDOVA,,OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC,Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy,Recruiting,,Phase 2,180.0,Anticipated,ARCAGY/ GINECO GROUP,,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-15 02:42:54,2023-06-15 02:42:54,OTHER,,,,,
49513,49514,NCT00389103,,2006-10-16,,,2014-01-17,2006-10-17,2006-10-18,Estimate,,,,,,,2014-01-17,2014-01-22,Estimate,October 2006,,2006-10-31,January 2014,2014-01-31,January 2007,Actual,2007-01-31,January 2007,Actual,2007-01-31,,Interventional,,,Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD),"A Phase 1, Placebo-Controlled, Double-Blind Study of the Safety and Immunogenicity of Two Injections of MVA3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Vaccinia Naive Adult Subjects With a History of Atopic Dermatitis (AD)",Withdrawn,,Phase 1,0.0,Actual,Sanofi,,1.0,,Senior management decision,False,,,,True,,,,,,,,,,,,,2023-06-15 02:43:17,2023-06-15 02:43:17,INDUSTRY,,,,,
49600,49601,NCT00000822,,1999-11-02,,,2021-10-27,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-27,2021-10-29,Actual,,,,October 2021,2021-10-31,May 1999,Actual,1999-05-31,,,,,Interventional,,,A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells,A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells,Completed,,Phase 1,46.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 02:44:25,2023-06-15 02:44:25,NIH,,,,,
49640,49641,NCT00000879,,1999-11-02,,,2021-10-27,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-27,2021-10-29,Actual,,,,October 2021,2021-10-31,April 2005,Actual,2005-04-30,,,,,Interventional,,,A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers,A Phase I/II Study to Evaluate the Safety and Immunogenicity of ALVAC HIV Vaccines Alone and With AIDSVAX B/B in Children Born to HIV-Infected Mothers,Completed,,Phase 1,48.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 02:44:54,2023-06-15 02:44:54,NIH,,,,,
49717,49718,NCT00001020,,1999-11-02,,,2012-05-16,2001-08-30,2001-08-31,Estimate,,,,,,,2012-05-16,2012-05-18,Estimate,,,,May 2012,2012-05-31,February 1995,Actual,1995-02-28,,,,,Interventional,,,A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study),A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study),Completed,,Phase 1,28.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 02:45:53,2023-06-15 02:45:53,NIH,,,,,
49725,49726,NCT00001041,,1999-11-02,,,2021-10-28,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-28,2021-11-01,Actual,,,,October 2021,2021-10-31,July 1998,Actual,1998-07-31,,,,,Interventional,,,"Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)","Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)",Completed,,Phase 1,24.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 02:46:01,2023-06-15 02:46:01,NIH,,,,,
49763,49764,NCT00009685,,2001-02-02,,,2008-03-03,2001-02-02,2001-02-05,Estimate,,,,,,,2008-03-03,2008-03-04,Estimate,January 2001,,2001-01-31,March 2005,2005-03-31,March 2005,,2005-03-31,,,,,Interventional,,,HIV-1 Vaccine Test in Uninfected Adult Volunteers,Evaluation of an HIV-1 DNA Vaccine Encoding a Modified Gag-Pol Protein in Uninfected Adult Volunteers,Completed,,Phase 1,21.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 02:46:28,2023-06-15 02:46:28,NIH,,,,,
50035,50036,NCT00386633,,2006-10-09,,,2015-01-26,2006-10-09,2006-10-11,Estimate,,,,,,,2015-01-26,2015-01-27,Estimate,October 2006,,2006-10-31,January 2015,2015-01-31,November 2007,Actual,2007-11-30,,,,,Interventional,,,Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection,"Phase I, Open, Sequential Vaccination Study on Safety and Tolerability of Two Different Doses of a Recombinant MVA HIV Polytope Vaccine (MVA-mBN32) in HIV-negative 18-50 Year Old Healthy Volunteers",Completed,,Phase 1,36.0,Anticipated,Bavarian Nordic,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 02:49:40,2023-06-15 02:49:40,INDUSTRY,,,,,
50110,50111,NCT00001566,,1999-11-03,2012-03-28,,2012-06-12,1999-11-03,1999-11-04,Estimate,2012-05-08,2012-06-12,Estimate,,,,2012-06-12,2012-06-15,Estimate,December 1996,,1996-12-31,June 2012,2012-06-30,September 2008,Actual,2008-09-30,September 2008,Actual,2008-09-30,,Interventional,,,A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas,A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas,Completed,,Phase 2,42.0,Actual,National Institutes of Health Clinical Center (CC),,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 02:50:33,2023-06-15 02:50:33,NIH,,,,,
50132,50133,NCT00001605,,1999-11-03,,,2008-03-03,2002-12-09,2002-12-10,Estimate,,,,,,,2008-03-03,2008-03-04,Estimate,May 1997,,1997-05-31,April 2000,2000-04-30,April 2001,,2001-04-30,,,,,Interventional,,,Vaccination for Middle Ear Infection,Phase I Study to Evaluate the Safety and Immunogenicity of a Nontypeable Haemophilus Influenzae Vaccine for Otitis Media,Completed,,Phase 1,40.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 02:50:51,2023-06-15 02:50:51,NIH,,,,,
50307,50308,NCT05641545,,2022-05-02,,,2022-11-30,2022-11-30,2022-12-07,Actual,,,,,,,2022-11-30,2022-12-07,Actual,"October 17, 2022",Actual,2022-10-17,November 2022,2022-11-30,November 2025,Anticipated,2025-11-30,December 2024,Anticipated,2024-12-31,,Interventional,,,IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients,IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients,Recruiting,,Phase 1,10.0,Anticipated,SLK Kliniken Heilbronn GmbH,,1.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-15 02:52:46,2023-06-15 02:52:46,OTHER,,,,,
50477,50478,NCT05154578,,2021-11-09,,,2023-01-10,2021-11-29,2021-12-13,Actual,,,,,,,2023-01-10,2023-01-11,Actual,"February 17, 2022",Actual,2022-02-17,January 2023,2023-01-31,November 2023,Anticipated,2023-11-30,April 2023,Anticipated,2023-04-30,,Interventional,,,Immunogenicity and Safety of GBS-NN/NN2 in Pregnant Women,"A Multicentre, Multinational, Parallel Group, Observer-blind, Randomised, Placebo-controlled Study on the Group B Streptococcus Vaccine (GBS-NN/NN2), Investigating the Immunogenicity and Safety of Four Vaccination Regimens in Pregnant Woman, Assessing IgG Specific to AlpN Proteins in Cord Blood and Maternal Blood, and the Safety Profile in Mother and Infant up to 6 Months Post-delivery","Active, not recruiting",,Phase 2,272.0,Actual,Minervax ApS,,5.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-15 02:54:40,2023-06-15 02:54:40,OTHER,,,,,
50746,50747,NCT04083950,,2019-09-05,,,2023-01-10,2019-09-05,2019-09-10,Actual,,,,,,,2023-01-10,2023-01-11,Actual,"December 4, 2019",Actual,2019-12-04,January 2023,2023-01-31,"September 30, 2023",Anticipated,2023-09-30,"January 31, 2022",Actual,2022-01-31,,Interventional,,,Induction of Gut Permeability by an Oral Vaccine,Induction of Gut Permeability by an Oral Vaccine,"Active, not recruiting",,Early Phase 1,10.0,Actual,"USDA, Western Human Nutrition Research Center",,1.0,,,False,,,,False,True,False,,,False,,,,,,No,,2023-06-15 02:58:13,2023-06-15 02:58:13,FED,,,,,
50752,50753,NCT05352867,,2022-04-25,,,2022-12-01,2022-04-25,2022-04-29,Actual,,,,,,,2022-12-01,2022-12-05,Actual,"March 16, 2022",Actual,2022-03-16,November 2022,2022-11-30,May 2023,Anticipated,2023-05-31,"June 23, 2022",Actual,2022-06-23,,Interventional,,,Clinical Trial of SARS-CoV-2 mRNA Vaccine in Chinese People,Phase <U+2161> Clinical Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) in Chinese People Aged 18~59 Years,"Active, not recruiting",,Phase 2,420.0,Actual,"AIM Vaccine Co., Ltd.",,3.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-15 02:58:16,2023-06-15 02:58:16,INDUSTRY,,,,,
50790,50791,NCT00847171,,2009-02-18,2018-08-28,,2018-09-25,2009-02-18,2009-02-19,Estimate,2018-09-25,2018-09-26,Actual,,,,2018-09-25,2018-09-26,Actual,December 2008,,2008-12-31,September 2018,2018-09-30,June 2013,Actual,2013-06-30,June 2013,Actual,2013-06-30,,Interventional,,,"Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer","A Safety and Bioactivity Study of Combination Therapy With Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for the Treatment of Patients With High Risk/ Metastatic HER-2/Neu- Overexpressing Breast Cancer With No Evidence of Disease",Completed,,Phase 2,20.0,Actual,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 02:58:45,2023-06-15 02:58:45,OTHER,,,,,
50849,50850,NCT03519464,,2018-05-08,,,2023-01-10,2018-05-08,2018-05-09,Actual,,,,,,,2023-01-10,2023-01-11,Actual,"February 4, 2019",Actual,2019-02-04,"January 6, 2023",2023-01-06,"February 28, 2024",Anticipated,2024-02-28,"February 28, 2024",Anticipated,2024-02-28,,Interventional,,,Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia,"A Phase 2, Open-Label Study to Assess the Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in Patients With Idiopathic CD4 T Cell Lymphocytopenia",Recruiting,,Phase 2,100.0,Anticipated,National Institutes of Health Clinical Center (CC),,1.0,,,False,,,,,True,False,,,,,,,,,No,.No plan to make IPD available at this time.,2023-06-15 02:59:28,2023-06-15 02:59:28,NIH,,,,,
51020,51021,NCT04935801,,2021-06-09,,,2022-11-28,2021-06-15,2021-06-23,Actual,,,,,,,2022-11-28,2022-12-05,Actual,"August 2, 2021",Actual,2021-08-02,November 2022,2022-11-30,"September 15, 2022",Actual,2022-09-15,"March 11, 2022",Actual,2022-03-11,,Interventional,,,A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against Dengue Virus,"naNO-DENGUE: A Phase I Double-blind, Randomized, Vehicle-controlled, Dose-finding, Safety Study of a Synthetic Nanoparticle-based, T-Cell Priming Peptide Vaccine Against Dengue Virus in Healthy Adults in Switzerland",Completed,,Phase 1,26.0,Actual,Emergex Vaccines Holding Ltd.,,4.0,,,False,,,,True,False,False,,,,,,Within 12 months of study completion,Peer-reviewed publication,,Yes,"The Investigators will be involved in writing and/or reviewing drafts of the manuscripts, abstracts, press releases and any other publications arising from the study.

Apart from obvious flaws to the conduct of the study, which may preclude data publication, safety and efficacy data will be published under the supervision and authorization of PI and Sponsor.

Publication will include as much individual level data as possible to ensure reproducibility of results without compromising participant privacy.",2023-06-15 03:01:28,2023-06-15 03:01:28,INDUSTRY,,,,,
51130,51131,NCT00387569,,2006-10-11,,,2008-05-06,2006-10-12,2006-10-13,Estimate,,,,,,,2008-05-06,2008-05-08,Estimate,October 2006,,2006-10-31,May 2008,2008-05-31,March 2008,Actual,2008-03-31,March 2008,Actual,2008-03-31,,Interventional,,,Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Healthy Toddlers,"A Randomized, Observer-Blinded, Parallel-Group, Active-Control, Phase 1/2 Trial of the Safety, Immunogenicity, and Tolerability of 20 µg, 60 µg, and 200 µg of Meningococcal Group B rLP2086 Vaccine in Healthy Adolescents Aged 10 to 12 Years",Completed,,Phase 1,99.0,Anticipated,Wyeth is now a wholly owned subsidiary of Pfizer,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 03:02:45,2023-06-15 03:02:45,INDUSTRY,,,,,
51145,51146,NCT00006113,,2000-08-03,,,2014-05-20,2003-01-26,2003-01-27,Estimate,,,,,,,2014-05-20,2014-05-22,Estimate,June 1999,,1999-06-30,May 2014,2014-05-31,April 2006,Actual,2006-04-30,May 2003,Actual,2003-05-31,,Interventional,,,Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma,A Phase II Trial of a MART-1/gp100/Tyrosinase Peptide-Pulsed Dendritic Cell Vaccine Treated With CD40 Ligand/Gamma Interferon With Subcutaneous IL-2 for Patients With Metastatic Melanoma,Terminated,,Phase 2,25.0,Actual,University of Southern California,,,,Lack of efficacy,False,,,,True,,,,,,,,,,,,,2023-06-15 03:02:55,2023-06-15 03:02:55,OTHER,,,,,
51200,51201,NCT00006146,,2000-08-07,,,2010-08-26,2001-08-30,2001-08-31,Estimate,,,,,,,2010-08-26,2010-08-27,Estimate,August 2000,,2000-08-31,November 2005,2005-11-30,September 2000,,2000-09-30,,,,,Interventional,,,Half-Dose Flu Vaccine Study in Healthy Adults,Evaluation of the Immunogenicity of Low Dose Trivalent Inactivated Influenza Vaccine in Healthy Adults,Completed,,Phase 2,840.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 03:03:35,2023-06-15 03:03:35,NIH,,,,,
51240,51241,NCT00089908,,2004-08-17,,,2008-01-17,2004-08-18,2004-08-19,Estimate,,,,,,,2008-01-17,2008-01-18,Estimate,September 2004,,2004-09-30,January 2008,2008-01-31,November 2005,Actual,2005-11-30,November 2005,Actual,2005-11-30,,Interventional,,,Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults,"Phase I Study of the Safety and Immunogenicity of rDEN1delta30, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 1",Completed,,Phase 1,28.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 03:03:59,2023-06-15 03:03:59,NIH,,,,,
51256,51257,NCT00090688,,2004-09-02,,,2016-12-27,2004-09-02,2004-09-03,Estimate,,,,,,,2016-12-27,2016-12-28,Estimate,August 2004,,2004-08-31,January 2006,2006-01-31,,,,,,,,Interventional,,,Phase 1 meCS6 + LT(R192G) Vaccine Study,Safety and Immunogenicity of Oral Microencapsulated CS6 Vaccine and LT(R192G) Adjuvant in Volunteers,Withdrawn,,Phase 1,0.0,Actual,U.S. Army Medical Research and Development Command,,,,IND was terminated for being inactive for more than five years,,,,,,,,,,,,,,,,,,2023-06-15 03:04:11,2023-06-15 03:04:11,FED,,,,,
51366,51367,NCT00094705,,2004-10-21,,,2008-01-18,2004-10-21,2004-10-22,Estimate,,,,,,,2008-01-18,2008-01-21,Estimate,January 2005,,2005-01-31,January 2008,2008-01-31,April 2006,Actual,2006-04-30,April 2006,Actual,2006-04-30,,Interventional,,,Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults,"Phase 1 Study of the Safety and Immunogenicity of rDEN2/4delta30(ME), a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 2",Completed,,Phase 1,28.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 03:05:31,2023-06-15 03:05:31,NIH,,,,,
51455,51456,NCT00097396,,2004-11-23,,,2011-06-29,2004-11-23,2004-11-24,Estimate,,,,,,,2011-06-29,2011-06-30,Estimate,November 2004,,2004-11-30,June 2011,2011-06-30,September 2006,Actual,2006-09-30,July 2006,Actual,2006-07-31,,Interventional,,,"Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V","A Phase 1, Open-Label, Dose-Escalating Study to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant Plague Vaccine rF1V in Healthy Volunteers",Completed,,Phase 1,40.0,,"DynPort Vaccine Company LLC, A GDIT Company",,,,,False,,,,True,,,,,,,,,,,,,2023-06-15 03:06:35,2023-06-15 03:06:35,INDUSTRY,,,,,
51480,51481,NCT00098098,,2004-12-03,,,2012-08-22,2004-12-03,2004-12-06,Estimate,,,,,,,2012-08-22,2012-08-23,Estimate,August 2004,,2004-08-31,August 2012,2012-08-31,August 2005,Actual,2005-08-31,,,,,Interventional,,,"Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults","A Phase 1, Open-Label, Dose-Escalating Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults",Completed,,Phase 1,44.0,Anticipated,"DynPort Vaccine Company LLC, A GDIT Company",,,,,,,,,,,,,,,,,,,,,,2023-06-15 03:06:54,2023-06-15 03:06:54,INDUSTRY,,,,,
51518,51519,NCT05292391,,2022-03-03,,,2023-05-10,2022-03-22,2022-03-23,Actual,,,,,,,2023-05-10,2023-05-12,Actual,"May 23, 2022",Actual,2022-05-23,January 2023,2023-01-31,"April 30, 2024",Anticipated,2024-04-30,"October 31, 2023",Anticipated,2023-10-31,,Interventional,,,"Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults","A Phase 1, Open-Label, Dose-Escalation Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults","Active, not recruiting",,Phase 1,45.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,,False,,,,,False,False,,,False,,,,,,,,2023-06-16 01:56:07,2023-06-16 01:56:07,NIH,,,,,
51618,51619,NCT04960397,,2021-07-08,,,2023-05-11,2021-07-08,2021-07-13,Actual,,,,,,,2023-05-11,2023-05-12,Actual,"September 10, 2021",Actual,2021-09-10,"October 3, 2022",2022-10-03,"November 1, 2023",Anticipated,2023-11-01,"November 1, 2023",Anticipated,2023-11-01,,Interventional,,,Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine,"A Phase 1b, Double-Blind, Randomized, Dose-Escalating, Age De-Escalating, Placebo-Controlled Study to Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine Delivered Intranasally In a Healthy Pediatric Population 6 Months Through 17 Years of Age.",Recruiting,,Phase 1,200.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,7.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-16 01:57:21,2023-06-16 01:57:21,NIH,,,,,
51702,51703,NCT04528719,,2020-08-20,,,2023-05-11,2020-08-24,2020-08-27,Actual,,,,,,,2023-05-11,2023-05-12,Actual,"September 30, 2020",Actual,2020-09-30,May 2023,2023-05-31,"September 30, 2023",Anticipated,2023-09-30,"September 30, 2023",Anticipated,2023-09-30,,Interventional,,,"A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive","A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Healthy Younger Adults Aged 18 to 49 Years, Women of Child-Bearing Potential Aged 18 to 40 Years, Healthy Older Adults Aged 65 to 79 Years, Japanese Older Adults Aged = 60 Years, and RSV-Seropositive Children Aged 12 to 59 Months","Active, not recruiting",,Phase 1,651.0,Actual,"ModernaTX, Inc.",,15.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-16 01:58:39,2023-06-16 01:58:39,INDUSTRY,,,,,
51752,51753,NCT04197687,,2019-12-05,,,2023-05-10,2019-12-11,2019-12-13,Actual,,,,,,,2023-05-10,2023-05-12,Actual,"February 20, 2020",Actual,2020-02-20,May 2023,2023-05-31,"January 15, 2025",Anticipated,2025-01-15,"January 15, 2025",Anticipated,2025-01-15,,Interventional,,,"TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery",Phase II Trial to Evaluate Immune-Related Biomarkers for Pathological Response in Stage II-III HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Subsequent Randomization to Multi-Epitope HER2 Vaccine vs. Placebo in Patients With Residual Disease Post-Neoadjuvant Chemotherapy,Recruiting,,Phase 2,480.0,Anticipated,Academic and Community Cancer Research United,,3.0,,,,,,,True,True,False,,,,,,,,,,,2023-06-16 01:59:22,2023-06-16 01:59:22,OTHER,,,,,
51849,51850,NCT00099463,,2004-12-14,,,2017-06-30,2004-12-14,2004-12-15,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"December 9, 2004",,2004-12-09,"August 22, 2007",2007-08-22,"August 22, 2007",,2007-08-22,,,,,Interventional,,,Phase I Study of a Vaccine for Severe Acute Respiratory Syndrome (SARS),"A Phase I Study of the Safety and Immunogenicity of a SARS Recombinant DNA Plasmid Vaccine, VRC-SRSDNA015-00-VP, in Healthy Adult Volunteers",Completed,,Phase 1,10.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 03:07:22,2023-06-15 03:07:22,NIH,,,,,
52009,52010,NCT00505063,,2007-07-18,,,2023-05-11,2007-07-19,2007-07-20,Estimate,,,,,,,2023-05-11,2023-05-12,Actual,July 2007,,2007-07-31,May 2023,2023-05-31,July 2023,Anticipated,2023-07-31,July 2023,Anticipated,2023-07-31,,Interventional,,,Prospective Trial of Vaccine Responses in Childhood Cancer Survivors,Phase II Prospective Trial of Vaccine Responses in Childhood Cancer Survivors,"Active, not recruiting",,Phase 2,75.0,Anticipated,Memorial Sloan Kettering Cancer Center,,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 02:03:03,2023-06-16 02:03:03,OTHER,,,,,
52047,52048,NCT05593042,,2022-10-20,,,2023-01-12,2022-10-20,2022-10-25,Actual,,,,,,,2023-01-12,2023-01-13,Actual,"November 28, 2022",Actual,2022-11-28,September 2022,2022-09-30,September 2023,Anticipated,2023-09-30,June 2023,Anticipated,2023-06-30,,Interventional,CoronaVarCL,,Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile,"Phase 2, Randomized, Double-blind Study to Evaluate Immunogenicity Superiority of a Booster Dose With an Omicron or a Trivalent Vaccine Compared to CoronaVac, in Adults Immunized With Different Vaccine Schedules Against SARS-CoV-2 in Chile",Recruiting,,Phase 2,826.0,Anticipated,Pontificia Universidad Catolica de Chile,,5.0,,,False,,,,True,False,False,,,False,,,,,,,,2023-06-16 02:03:23,2023-06-16 02:03:23,OTHER,,,,,
52097,52098,NCT05269381,,2022-02-25,,,2023-05-25,2022-02-25,2022-03-08,Actual,,,,,,,2023-05-25,2023-05-26,Actual,"March 31, 2022",Actual,2022-03-31,May 2023,2023-05-31,"February 24, 2025",Anticipated,2025-02-24,"February 24, 2024",Anticipated,2024-02-24,,Interventional,,,"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study",A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA),Recruiting,,Phase 1,36.0,Anticipated,Mayo Clinic,,1.0,,,,,,,True,True,False,,,,,,,,,,,2023-06-16 02:04:02,2023-06-16 02:04:02,OTHER,,,,,
52168,52169,NCT04264598,,2020-02-09,,,2020-02-10,2020-02-10,2020-02-11,Actual,,,,,,,2020-02-10,2020-02-11,Actual,"August 21, 2017",Actual,2017-08-21,February 2020,2020-02-29,"December 28, 2018",Actual,2018-12-28,"December 19, 2017",Actual,2017-12-19,,Interventional,,,Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine,A Phase I Study to Evaluate the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Vero Cell),Completed,,Phase 1,100.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,5.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-16 02:04:55,2023-06-16 02:04:55,NETWORK,,,,,
52175,52176,NCT00766285,,2008-10-02,,,2015-07-30,2008-10-02,2008-10-03,Estimate,,,,,,,2015-07-30,2015-08-03,Estimate,,,,December 2009,2009-12-31,September 2010,Actual,2010-09-30,September 2010,Actual,2010-09-30,,Interventional,,,High Dose Influenza in Immunosuppressed Subjects,Safety and Immunogenicity of High Dose Baculovirus-Expressed Recombinant Trivalent HA Influenza Vaccine in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: Phase II Double-Blind Trial,Withdrawn,,Phase 2,0.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 02:05:01,2023-06-16 02:05:01,NIH,,,,,
52963,52964,NCT05330624,,2022-04-08,,,2022-04-08,2022-04-08,2022-04-15,Actual,,,,,,,2022-04-08,2022-04-15,Actual,"May 8, 2020",Actual,2020-05-08,April 2022,2022-04-30,"September 20, 2022",Anticipated,2022-09-20,"May 20, 2022",Anticipated,2022-05-20,,Interventional,,,Immunogenicity and Safety of Subunit Vaccine of Plague Vaccine With Two Immunization Regimens,Immunogenicity and Safety of Subunit Vaccine of Plague Vaccine (F1+ rV) With Two Immunization Regimens: A Random Phase 2b Clinical Trial,"Active, not recruiting",,Phase 2,720.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,2.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-16 02:15:24,2023-06-16 02:15:24,NETWORK,,,,,
53169,53170,NCT00801697,,2008-12-02,,,2021-10-13,2008-12-02,2008-12-03,Estimate,,,,,,,2021-10-13,2021-10-14,Actual,February 2009,,2009-02-28,October 2021,2021-10-31,April 2015,Actual,2015-04-30,February 2011,Actual,2011-02-28,,Interventional,,,Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector,"A Phase 1B Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Adenoviral Subtype 35 (rAd35) and Subtype 5 (rAd5) HIV-1 Vaccines When Given as a Heterologous Prime-boost Regimen or as Boosts to a Recombinant DNA Vaccine in Healthy, Ad5-Naïve and Ad5-Exposed, Low Risk, HIV-1 Uninfected Adult Participants",Completed,,Phase 1,192.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,8.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 02:17:55,2023-06-16 02:17:55,NIH,,,,,
53244,53245,NCT04161755,,2019-11-12,,,2022-12-06,2019-11-12,2019-11-13,Actual,,,,,,,2022-12-06,2022-12-08,Actual,"December 13, 2019",Actual,2019-12-13,December 2022,2022-12-31,"November 11, 2023",Anticipated,2023-11-11,"November 11, 2023",Anticipated,2023-11-11,,Interventional,,,Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery,Phase 1 Clinical Trial of Personalized Neoantigen Tumor Vaccines and Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Surgically Resected Pancreatic Cancer,"Active, not recruiting",,Phase 1,29.0,Actual,Memorial Sloan Kettering Cancer Center,,1.0,,,False,,,,,True,False,,,,,,,,,Yes,"Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.",2023-06-16 02:18:50,2023-06-16 02:18:50,OTHER,,,,,
53264,53265,NCT04041570,,2019-07-25,2021-09-07,,2022-11-10,2019-07-30,2019-08-01,Actual,2021-10-27,2021-11-24,Actual,,,,2022-11-10,2022-12-06,Actual,"July 2, 2019",Actual,2019-07-02,November 2022,2022-11-30,"September 7, 2020",Actual,2020-09-07,"September 7, 2020",Actual,2020-09-07,,Interventional,,Population includes all enrolled participants.,Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults,"A Phase I Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of an Ebola Sudan Chimpanzee Adenovirus Vector Vaccine, VRC-EBOADC086-00-VP (cAd3-EBO S), in Healthy Adults",Completed,,Phase 1,40.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-15 03:08:28,2023-06-15 03:08:28,NIH,,,,,
53606,53607,NCT05366296,,2022-05-03,,,2023-04-25,2022-05-05,2022-05-09,Actual,,,,,,,2023-04-25,2023-04-27,Actual,July 2022,Anticipated,2022-07-31,April 2023,2023-04-30,January 2023,Anticipated,2023-01-31,September 2022,Anticipated,2022-09-30,,Interventional,,,"Safety, Reactogenicity, and Immunogenicity Study of a Lyophilized COVID-19 mRNA Vaccine","A Randomized, Observer-Blinded, Placebo-Controlled Phase I Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of One Dose Booster by A Lyophilized COVID-19 mRNA Vaccine in Adults Aged 18 to 60 Years",Withdrawn,,Phase 1,0.0,Actual,"Wuhan Recogen Biotechnology Co., Ltd.",,2.0,,business stragety,False,,,,,False,False,,,,,,,,,No,There is not a plan to make individual participant data (IPD) available,2023-06-16 02:23:04,2023-06-16 02:23:04,INDUSTRY,,,,,
54047,54048,NCT00695877,,2008-06-10,,,2021-10-28,2008-06-10,2008-06-12,Estimate,,,,,,,2021-10-28,2021-11-01,Actual,"February 8, 2009",Actual,2009-02-08,October 2021,2021-10-31,"October 14, 2016",Actual,2016-10-14,"December 11, 2012",Actual,2012-12-11,,Interventional,,,Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults,"A Phase I Randomized, Double-blind, Placebo Controlled Dose Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Adenovirus Serotype 5 HVR48 HIV-1 Vaccine (Ad5HVR48.ENVA.01) in Healthy, HIV-1 Uninfected Adults (Ad5HVR48.ENVA.01 (rAd5HVR48) HIV-1/IPCAVD-002 Vaccine Study)",Completed,,Phase 1,48.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 02:28:56,2023-06-16 02:28:56,NIH,,,,,
54244,54245,NCT00697125,,2008-06-11,,,2008-06-11,2008-06-11,2008-06-13,Estimate,,,,,,,2008-06-11,2008-06-13,Estimate,June 1993,,1993-06-30,June 2008,2008-06-30,July 1994,Actual,1994-07-31,July 1994,Actual,1994-07-31,,Interventional,,,Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants,Study to Evaluate the Immunogenicity and Reactogenicity of Various Formulations of GSK Biologicals' (Previously SmithKline Beecham Biologicals') Recombinant Hepatitis B Vaccine With Different Adjuvants in Healthy Adult Volunteers,Completed,,Phase 2,60.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 02:31:10,2023-06-16 02:31:10,INDUSTRY,,,,,
54293,54294,NCT00970307,,2009-08-27,2017-03-03,2010-12-10,2019-12-31,2009-09-01,2009-09-02,Estimate,2017-03-03,2017-04-14,Actual,2010-12-10,2010-12-16,Estimate,2019-12-31,2020-01-03,Actual,"August 13, 2009",Actual,2009-08-13,December 2019,2019-12-31,"January 27, 2010",Actual,2010-01-27,"January 27, 2010",Actual,2010-01-27,,Interventional,,,"Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age","Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age",Completed,,Phase 2,421.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=136,Yes,IPD is available via the Clinical Study Data Request site (click on the link provided below),2023-06-16 02:31:40,2023-06-16 02:31:40,INDUSTRY,,,,,
54312,54313,NCT03039790,,2017-01-31,2022-07-21,,2022-11-07,2017-01-31,2017-02-01,Estimate,2022-09-08,2022-10-06,Actual,,,,2022-11-07,2022-11-09,Actual,"February 21, 2017",Actual,2017-02-21,November 2022,2022-11-30,"July 22, 2021",Actual,2021-07-22,"July 22, 2021",Actual,2021-07-22,,Interventional,,Full Analysis Set (FAS) included all participants with data from at least 1 follow-up time point.,Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults,"A Phase 2, Long-Term Immunogenicity Follow-up Trial of Adult and Elderly Subjects Who Have Previously Received an Intramuscular Injection of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine",Completed,,Phase 2,528.0,Actual,Takeda,,20.0,,,False,,,,False,True,False,,,,,,,"IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.",https://vivli.org/ourmember/takeda/,Yes,"Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.",2023-06-17 02:17:31,2023-06-17 02:17:31,INDUSTRY,,,,,
54496,54497,NCT05218070,,2022-01-25,,,2022-02-06,2022-01-31,2022-02-01,Actual,,,,,,,2022-02-06,2022-02-23,Actual,"February 6, 2022",Actual,2022-02-06,January 2022,2022-01-31,June 2023,Anticipated,2023-06-30,October 2022,Anticipated,2022-10-31,,Interventional,Sphinx,,Safety and Immunogenicity Study of EgyVax Vaccine Candidate for Prophylaxis of COVID-19 Infection,Safety and Immunogenicity Study of EgyVax Vaccine Candidate for Prophylaxis of Severe Acute Respiratory Syndrome (SARS) - Coronavirus 2 (CoV-2) Infection (COVID-19),Recruiting,,Phase 1,45.0,Anticipated,Eva Pharma,,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-16 02:34:09,2023-06-16 02:34:09,INDUSTRY,,,,,
54521,54522,NCT00699231,,2008-06-13,,,2008-06-16,2008-06-16,2008-06-17,Estimate,,,,,,,2008-06-16,2008-06-17,Estimate,February 1992,,1992-02-29,June 2008,2008-06-30,December 1992,Actual,1992-12-31,December 1992,Actual,1992-12-31,,Interventional,,,"Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix-B, in Haemodialysis Patients","Study to Evaluate the Immunogenicity, Reactogenicity and Safety of GSK Biologicals' (Previously SmithKline Beecham Biologicals') MPL-Adjuvanted Recombinant Hepatitis B Vaccine Versus Engerix-B, in Haemodialysis Patients",Completed,,Phase 1,30.0,Actual,GlaxoSmithKline,,8.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 02:34:33,2023-06-16 02:34:33,INDUSTRY,,,,,
54572,54573,NCT00701649,,2008-06-18,,,2009-12-01,2008-06-18,2008-06-19,Estimate,,,,,,,2009-12-01,2009-12-02,Estimate,March 2008,,2008-03-31,December 2009,2009-12-31,November 2009,Actual,2009-11-30,March 2009,Actual,2009-03-31,,Interventional,,,"Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of a Vaccine Against Essential Hypertension","A Double Blind, Randomized, Placebo Controlled, Parallel Group Phase IIa Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of an Anti-Angiotensin II Vaccine (CYT006-AngQb) in Patients With Mild to Moderate Essential Hypertension",Completed,,Phase 2,60.0,Anticipated,Cytos Biotechnology AG,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 02:35:24,2023-06-16 02:35:24,INDUSTRY,,,,,
54587,54588,NCT00807781,,2008-12-11,,,2015-01-02,2008-12-11,2008-12-12,Estimate,,,,,,,2015-01-02,2015-01-05,Estimate,October 2009,,2009-10-31,January 2015,2015-01-31,December 2014,Actual,2014-12-31,March 2014,Actual,2014-03-31,,Interventional,,,Mammaglobin-A DNA Vaccine for Metastatic Breast Cancer,A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Mammaglobin-A DNA Vaccine in Breast Cancer Patients With Metastatic Disease,Completed,,Phase 1,15.0,Actual,Washington University School of Medicine,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 02:35:36,2023-06-16 02:35:36,OTHER,,,,,
54916,54917,NCT03718130,,2018-10-18,,,2022-05-16,2018-10-22,2018-10-24,Actual,,,,,,,2022-05-16,2022-05-18,Actual,"October 11, 2019",Actual,2019-10-11,May 2022,2022-05-31,"April 30, 2023",Anticipated,2023-04-30,"December 30, 2022",Anticipated,2022-12-30,,Interventional,,,Combination HTNV and PUUV DNA Vaccine,"A Phase 1, Randomized Trial to Assess the Safety, Reactogenicity, and Immunogenicity of a Combination HTNV and PUUV DNA Vaccine Candidate Administered by Electroporation","Active, not recruiting",,Phase 1,72.0,Anticipated,U.S. Army Medical Research and Development Command,,6.0,,,False,,,,True,True,False,,,False,,,,,,No,,2023-06-16 02:39:30,2023-06-16 02:39:30,FED,,,,,
54962,54963,NCT00922363,,2009-06-16,,,2013-01-18,2009-06-16,2009-06-17,Estimate,,,,,,,2013-01-18,2013-01-21,Estimate,October 2009,,2009-10-31,January 2013,2013-01-31,October 2011,Actual,2011-10-31,October 2011,Actual,2011-10-31,,Interventional,,,"Trial on the Safety of a New Liposomal Adjuvant System, CAF01, When Given With the Tuberculosis Subunit Vaccine Ag85B-ESAT-6 as Two Injections With Two Months Interval to Healthy Adult Volunteers","An Open Phase I, Dose-escalating, Clinical Trial on the Safety of a New Liposomal Adjuvant System, CAF01, When Given With the Tuberculosis Subunit Vaccine Ag85B-ESAT-6 as Two Injections With Two Months Interval to Healthy Adult Volunteers",Completed,,Phase 1,38.0,Actual,Statens Serum Institut,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 02:40:11,2023-06-16 02:40:11,OTHER,,,,,
54989,54990,NCT00971321,,2009-08-27,2017-09-29,2010-12-10,2018-10-11,2009-09-02,2009-09-03,Estimate,2018-10-11,2019-02-25,Actual,2010-12-10,2010-12-16,Estimate,2018-10-11,2019-02-25,Actual,"September 10, 2009",,2009-09-10,August 2018,2018-08-31,"November 24, 2010",Actual,2010-11-24,"November 24, 2010",Actual,2010-11-24,,Interventional,,,"Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)",Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 6 to 35 Months,Completed,,Phase 2,157.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 02:40:34,2023-06-16 02:40:34,INDUSTRY,,,,,
55472,55473,NCT00006509,,2000-11-17,,,2015-03-05,2001-08-30,2001-08-31,Estimate,,,,,,,2015-03-05,2015-03-09,Estimate,,,,March 2015,2015-03-31,June 2007,Actual,2007-06-30,,,,,Interventional,,,A Study of the Safety and Effectiveness of an HIV Vaccine for HIV-Positive Patients Receiving Anti-HIV Drugs for at Least 2 Years,A Phase I/II Safety and Immunogenicity Evaluation of a Prime/Boost Vaccine Using ALVAC-HIV (vCP 1452) With Recombinant gp160 LAI/MN-2 in HIV-Infected Subjects Treated With Antiretroviral Therapy for a Minimum of 2 Years,Completed,,Phase 1,12.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,,,,,,,,,,,,,,,,,,2023-06-15 03:10:51,2023-06-15 03:10:51,NIH,,,,,
55601,55602,NCT02833506,,2016-07-08,,,2018-04-27,2016-07-12,2016-07-14,Estimate,,,,,,,2018-04-27,2018-05-01,Actual,"December 8, 2017",Actual,2017-12-08,April 2018,2018-04-30,"August 15, 2019",Anticipated,2019-08-15,"August 15, 2018",Anticipated,2018-08-15,,Interventional,,,"Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing NY-ESO-1 Protein With MIS416 Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube and Primary Peritoneal Cancer",Withdrawn,,Phase 1,0.0,Actual,Roswell Park Cancer Institute,,2.0,,production of adjuvant to be used with vaccine was discontinued by sponsor,False,,,,True,True,False,,,,,,,,,,,2023-06-16 02:48:05,2023-06-16 02:48:05,OTHER,,,,,
55672,55673,NCT03652610,,2018-08-28,2021-01-20,2020-01-17,2021-01-20,2018-08-28,2018-08-29,Actual,2021-01-20,2021-02-09,Actual,2020-02-18,2020-02-25,Actual,2021-01-20,2021-02-09,Actual,"September 7, 2018",Actual,2018-09-07,January 2021,2021-01-31,"June 11, 2019",Actual,2019-06-11,"January 17, 2019",Actual,2019-01-17,,Interventional,,,A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age,"Immunogenicity, Reactogenicity and Safety of Two Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) in Healthy Adults 18 to 40 Years of Age",Completed,,Phase 2,996.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,True,False,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-17 02:19:23,2023-06-17 02:19:23,INDUSTRY,,,,,
55673,55674,NCT03615404,,2018-07-30,2020-11-30,,2021-01-26,2018-08-02,2018-08-03,Actual,2021-01-26,2021-01-28,Actual,,,,2021-01-26,2021-01-28,Actual,"October 5, 2018",Actual,2018-10-05,January 2021,2021-01-31,"July 2, 2020",Actual,2020-07-02,"November 19, 2019",Actual,2019-11-19,,Interventional,ATTAC-P,,"Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma","A Phase 1 Trial of CMV RNA-Pulsed Dendritic Cells With Tetanus-Diphtheria Toxoid Vaccine in Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma",Completed,,Phase 1,11.0,Actual,Duke University,,1.0,,,,,,,True,True,False,,,,,,,,,,,2023-06-17 02:19:24,2023-06-17 02:19:24,OTHER,,,,,
55802,55803,NCT04009824,,2019-07-01,2022-03-22,,2022-04-25,2019-07-03,2019-07-05,Actual,2022-04-25,2022-04-28,Actual,,,,2022-04-25,2022-04-28,Actual,"July 8, 2019",Actual,2019-07-08,March 2022,2022-03-31,"February 23, 2021",Actual,2021-02-23,"March 3, 2020",Actual,2020-03-03,,Interventional,,,"Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine","Randomized, Double-Blind, Placebo-Controlled, Single-Center, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine",Completed,,Phase 1,51.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-17 02:21:31,2023-06-17 02:21:31,NIH,,,,,
55950,55951,NCT01086657,,2010-03-12,,,2017-06-30,2010-03-12,2010-03-15,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"February 25, 2010",,2010-02-25,"December 12, 2011",2011-12-12,"December 12, 2011",Actual,2011-12-12,"December 12, 2011",Actual,2011-12-12,,Interventional,,,"An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...","VRC 310: An Open-Label, Randomized Ph I: Healthy Adults of Prime-Boost Intervals w/Monovalent Influenza Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc), Administered Alone or Following Recombinant H5 DNA Vaccine",Completed,,Phase 1,64.0,Actual,National Institutes of Health Clinical Center (CC),,6.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 02:23:47,2023-06-17 02:23:47,NIH,,,,,
56079,56080,NCT05198752,,2022-01-05,,,2022-10-12,2022-01-19,2022-01-20,Actual,,,,,,,2022-10-12,2022-10-17,Actual,"March 18, 2022",Actual,2022-03-18,October 2022,2022-10-31,"June 12, 2024",Anticipated,2024-06-12,"December 22, 2023",Anticipated,2023-12-22,,Interventional,,,A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors,"A Phase 1 Clinical Study to Evaluate the Tolerability, Safety,Immunogenicity and Efficacy of the Neoantigen mRNA Personalised Cancer Vaccine SW1115C3 in Patients With Advanced Malignant Solid Tumours",Recruiting,,Phase 1,30.0,Anticipated,Stemirna Therapeutics,,1.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-17 02:25:53,2023-06-17 02:25:53,INDUSTRY,,,,,
56115,56116,NCT03807843,,2019-01-15,2022-04-20,,2022-09-06,2019-01-15,2019-01-17,Actual,2022-04-20,2022-05-16,Actual,,,,2022-09-06,2022-09-08,Actual,"July 16, 2019",Actual,2019-07-16,September 2022,2022-09-30,"May 13, 2021",Actual,2021-05-13,"May 13, 2021",Actual,2021-05-13,,Interventional,,,Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006),Phase 2 Study of a Live Attenuated Measles Virus-Vectored Chikungunya Vaccine in Previously Exposed Adults,Completed,,Phase 2,41.0,Actual,Themis Bioscience GmbH,,2.0,,,False,,,,True,True,False,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2023-06-17 02:26:24,2023-06-17 02:26:24,INDUSTRY,,,,,
57242,57243,NCT02981524,,2016-12-01,2019-08-29,,2021-02-08,2016-12-01,2016-12-05,Estimate,2019-09-16,2019-10-08,Actual,,,,2021-02-08,2021-02-10,Actual,"May 26, 2017",Actual,2017-05-26,February 2020,2020-02-29,"March 20, 2018",Actual,2018-03-20,"March 20, 2018",Actual,2018-03-20,,Interventional,,,Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer,A Phase 2 Study of GVAX Colon Vaccine (With Cyclophosphamide) and Pembrolizumab in Patients With Mismatch Repair-Proficient (MMR-p) Advanced Colorectal Cancer,Completed,,Phase 2,17.0,Actual,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,1.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 02:44:36,2023-06-17 02:44:36,OTHER,,,,,
57299,57300,NCT04186000,,2019-12-01,,,2023-01-03,2019-12-03,2019-12-04,Actual,,,,,,,2023-01-03,2023-01-04,Actual,"December 18, 2019",Actual,2019-12-18,January 2023,2023-01-31,"October 12, 2022",Actual,2022-10-12,"April 25, 2020",Actual,2020-04-25,,Interventional,EBOVAC3DRC,,Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola,Open-label Phase 2 Study to Evaluate the Immunogenicity and Safety of a Prophylactic Vaccination of Health Care Providers by Administration of a Heterologous Vaccine Regimen Against Ebola in the Democratic Republic of the Congo,Completed,,Phase 2,699.0,Actual,Universiteit Antwerpen,,2.0,,,False,,,,False,False,False,,,False,,,,,,No,,2023-06-17 02:45:31,2023-06-17 02:45:31,OTHER,,,,,
57374,57375,NCT03651544,,2018-08-24,,,2019-03-14,2018-08-28,2018-08-29,Actual,,,,,,,2019-03-14,2019-03-15,Actual,"October 15, 2018",Actual,2018-10-15,July 2018,2018-07-31,"March 14, 2019",Actual,2019-03-14,"December 24, 2018",Actual,2018-12-24,,Interventional,,,"The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac","An Open Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac Vector Vaccine Against Influenza A in Healthy Volunteers in 3 Groups With a Dose Escalation",Completed,,Phase 1,36.0,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,3.0,,,False,,,,False,False,False,,,,,,,,,Undecided,,2023-06-17 02:46:41,2023-06-17 02:46:41,OTHER,,,,,
57739,57740,NCT02562482,,2015-09-21,2019-03-05,,2020-10-20,2015-09-28,2015-09-29,Estimate,2019-04-25,2019-05-14,Actual,,,,2020-10-20,2020-10-22,Actual,"November 18, 2015",Actual,2015-11-18,October 2020,2020-10-31,"March 6, 2018",Actual,2018-03-06,"March 6, 2018",Actual,2018-03-06,,Interventional,,Population includes all enrolled subjects.,"Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults","Phase 2 Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Chikungunya Virus-Like Particle Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults",Completed,,Phase 2,400.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-18 03:30:17,2023-06-18 03:30:17,NIH,,,,,
58155,58156,NCT00700635,,2008-05-07,2010-12-11,2010-09-02,2016-04-12,2008-06-18,2008-06-19,Estimate,2010-12-11,2010-12-23,Estimate,2010-10-04,2010-10-06,Estimate,2016-04-12,2016-04-14,Estimate,June 2008,,2008-06-30,April 2016,2016-04-30,October 2009,Actual,2009-10-31,May 2009,Actual,2009-05-31,,Interventional,,,Dose Comparison Study of Menactra® in US Children,"Exploratory Evaluation of a Two-dose Schedule Versus a One-dose Schedule of Menactra® (Meningococcal [Groups A, C, Y and W 135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) in Children in the US",Completed,,Phase 2,333.0,Actual,Sanofi,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 03:35:07,2023-06-18 03:35:07,INDUSTRY,,,,,
58326,58327,NCT02145377,,2014-05-20,,,2019-09-24,2014-05-21,2014-05-22,Estimate,,,,,,,2019-09-24,2019-09-26,Actual,July 2014,,2014-07-31,September 2019,2019-09-30,March 2015,Actual,2015-03-31,March 2015,Actual,2015-03-31,,Interventional,,,PXVX0200 (CVD103-HgR) vs Shanchol in Mali,"A Phase 2 Randomized, Double-Blinded Study to Compare in Malian Adults the Immunogenicity, Clinical Acceptability and Excretion Pattern Following the Ingestion of a Single Dose of PXVX0200 (CVD 103-HgR) Live Oral Cholera Vaccine Containing Either 108 Colony Forming Units [Cfu] or 109 Cfu Using Shanchol Killed Whole Cell Oral Cholera Vaccine as an Immunological Comparator",Completed,,Phase 2,150.0,Actual,"University of Maryland, Baltimore",,5.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 03:37:01,2023-06-18 03:37:01,OTHER,,,,,
58892,58893,NCT02553343,,2015-09-15,,2017-04-25,2018-02-05,2015-09-15,2015-09-17,Estimate,,,,2017-04-25,2017-04-26,Actual,2018-02-05,2018-02-09,Actual,September 2015,,2015-09-30,February 2018,2018-02-28,"April 4, 2016",Actual,2016-04-04,"April 4, 2016",Actual,2016-04-04,,Interventional,,,A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older,Safety and Immunogenicity Trial of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Subjects Aged 65 Years and Older,Completed,,Phase 2,792.0,Actual,Sanofi,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 03:43:52,2023-06-18 03:43:52,INDUSTRY,,,,,
59027,59028,NCT02555618,,2015-09-17,2016-11-02,,2016-11-02,2015-09-17,2015-09-21,Estimate,2016-11-02,2016-12-29,Estimate,,,,2016-11-02,2016-12-29,Estimate,September 2015,,2015-09-30,November 2016,2016-11-30,December 2015,Actual,2015-12-31,December 2015,Actual,2015-12-31,,Interventional,,Randomized Set included all randomized participants.,Phase 2 Study of TAK-850 in Comparison With Influenza Hemagglutinin (HA) Vaccine in Healthy Adult Participants,A Randomized Double-Blind Parallel-Group Comparative Phase 2 Study to Evaluate the Immunogenicity and Safety of a Single Subcutaneous Injection of TAK-850 in Comparison With Influenza HA Vaccine in Healthy Adult Subjects,Completed,,Phase 2,400.0,Actual,Takeda,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 03:45:37,2023-06-18 03:45:37,INDUSTRY,,,,,
59372,59373,NCT05228613,,2022-02-07,,,2023-02-23,2022-02-07,2022-02-08,Actual,,,,,,,2023-02-23,2023-02-27,Actual,"February 16, 2022",Actual,2022-02-16,February 2023,2023-02-28,"January 24, 2023",Actual,2023-01-24,"August 2, 2022",Actual,2022-08-02,,Interventional,,,Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018,"A Phase I, Observer-Blind, Randomized, Controlled Study of the Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine (Adjuvanted With Alum+CpG 1018) in Healthy Populations Aged 18 Years and Above in Indonesia",Completed,,Phase 1,175.0,Actual,PT Bio Farma,,5.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 03:50:02,2023-06-18 03:50:02,INDUSTRY,,,,,
59443,59444,NCT02547974,,2015-08-27,2018-03-02,,2018-08-03,2015-09-10,2015-09-14,Estimate,2018-03-02,2018-07-23,Actual,,,,2018-08-03,2018-08-31,Actual,"August 31, 2015",Actual,2015-08-31,March 2018,2018-03-31,"March 31, 2017",Actual,2017-03-31,"March 31, 2017",Actual,2017-03-31,,Interventional,,,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults.","An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults.",Completed,,Phase 1,120.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-18 03:50:57,2023-06-18 03:50:57,INDUSTRY,,,,,
59745,59746,NCT04739527,,2021-01-08,,,2022-11-25,2021-02-03,2021-02-04,Actual,,,,,,,2022-11-25,2022-11-28,Actual,"June 10, 2021",Actual,2021-06-10,November 2022,2022-11-30,"June 1, 2026",Anticipated,2026-06-01,"June 1, 2025",Anticipated,2025-06-01,,Interventional,ALISON,,"Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment","An Open Label, Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment",Recruiting,,Phase 1,17.0,Anticipated,University Medical Center Groningen,,1.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 03:54:54,2023-06-18 03:54:54,OTHER,,,,,
59762,59763,NCT05652543,,2022-12-12,,,2023-01-05,2022-12-14,2022-12-15,Actual,,,,,,,2023-01-05,2023-01-09,Actual,"January 5, 2023",Actual,2023-01-05,January 2023,2023-01-31,August 2023,Anticipated,2023-08-31,June 2023,Anticipated,2023-06-30,,Interventional,SCTV01E,,A Phase<U+2161> Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine,"Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants S Trimer Protein Vaccine (SCTV01E) in a Vaccinated Population",Recruiting,,Phase 2,750.0,Anticipated,Sinocelltech Ltd.,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 03:55:07,2023-06-18 03:55:07,INDUSTRY,,,,,
60174,60175,NCT01222221,,2010-10-14,,,2015-10-13,2010-10-14,2010-10-18,Estimate,,,,,,,2015-10-13,2015-10-14,Estimate,July 2010,,2010-07-31,October 2015,2015-10-31,February 2015,Actual,2015-02-28,February 2015,Actual,2015-02-28,,Interventional,,,"Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",A Cancer Research UK Phase I Trial of IMA950 (A Novel Multi-Peptide Vaccine) Plus GM-CSF in Patients With Newly Diagnosed Glioblastoma,Completed,,Phase 1,45.0,Actual,Cancer Research UK,,,,,False,,,,,,,,,,,,,,,,,2023-06-17 02:53:03,2023-06-17 02:53:03,OTHER,,,,,
60607,60608,NCT05401305,,2022-05-27,,,2022-05-27,2022-05-27,2022-06-02,Actual,,,,,,,2022-05-27,2022-06-02,Actual,"January 14, 2020",Actual,2020-01-14,May 2022,2022-05-31,"June 17, 2020",Actual,2020-06-17,"March 30, 2020",Actual,2020-03-30,,Interventional,,,Safety and Reactogenicity Trial of Vaccine for the Prevention of Infections Caused by Haemophilus Influenzae Type b,"Simple Blind, Placebo Controlled, Randomized Safety and Reactogenicity Trial of ""Baby-Hib [Vaccine for the Prevention of Infections Caused by Haemophilus Influenzae Type b], Lyophilizate for Preparation of Intramuscular Injection Solution, 0.5 mL/Dose"", FSUE SPbSRIVS FMBA of Russia, in Volunteers Aged 18-50",Completed,,Phase 1,60.0,Actual,St. Petersburg Research Institute of Vaccines and Sera,,2.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-17 02:59:15,2023-06-17 02:59:15,OTHER_GOV,,,,,
60908,60909,NCT01140009,,2010-06-07,,,2015-04-14,2010-06-07,2010-06-09,Estimate,,,,,,,2015-04-14,2015-04-15,Estimate,August 2010,,2010-08-31,April 2015,2015-04-30,September 2010,Actual,2010-09-30,September 2010,Actual,2010-09-30,,Interventional,PCIRNRT06,,Safety and Protectiveness of the Seasonal Influenza Vaccine for 2010-2011,"A Randomized, Blinded, Placebo-controlled, Cross-over Study of the Safety and Immunogenicity of Trivalent, Inactivated Influenza Vaccine for 2010-2011",Completed,,Phase 2,324.0,Actual,University of British Columbia,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 03:03:28,2023-06-17 03:03:28,OTHER,,,,,
61185,61186,NCT04333459,,2020-03-31,,,2022-02-16,2020-03-31,2020-04-03,Actual,,,,,,,2022-02-16,2022-02-18,Actual,"August 23, 2021",Actual,2021-08-23,February 2022,2022-02-28,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2022",Anticipated,2022-12-31,,Interventional,,,"Safety and Immunogenicity of a Hantaan Virus DNA Vaccine and a Puumala Virus DNA Vaccine, For The Prevention of Hemorrhagic Fever With Renal Syndrome","A Phase 2A, Randomized, Double-Blind Study To Evaluate The Safety And Immunogenicity Of A Hantaan Virus DNA Vaccine And A Puumala Virus DNA Vaccine, For The Prevention Of Hemorrhagic Fever With Renal Syndrome, Administered To Healthy Adult Volunteers Using The Pharmajet Stratis® Needle-Free Jet Injection Delivery Device",Recruiting,,Phase 2,132.0,Anticipated,U.S. Army Medical Research and Development Command,,4.0,,,,,,,False,True,False,,,,,,,,,Undecided,,2023-06-14 00:55:44,2023-06-14 00:55:44,FED,,,,,
61343,61344,NCT03833271,,2019-01-21,,,2020-06-15,2019-02-05,2019-02-06,Actual,,,,,,,2020-06-15,2020-06-17,Actual,"October 28, 2018",Actual,2018-10-28,June 2020,2020-06-30,"September 30, 2019",Actual,2019-09-30,"September 30, 2019",Actual,2019-09-30,,Interventional,,,The Efficacy of Influenza Vaccine Program in Children With Juvenile Idiopathic Arthritis. A Single Centre Results From Hungary,The Investigation of Immune Function and the Effectiveness of Influenza Vaccine in Children With Juvenile Idiopathic Arthritis Compared to Healthy Control,Completed,,Early Phase 1,62.0,Actual,University of Pecs,,3.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-14 00:57:51,2023-06-14 00:57:51,OTHER,,,,,
61544,61545,NCT03594890,,2018-06-20,,,2022-09-20,2018-07-19,2018-07-20,Actual,,,,,,,2022-09-20,2022-09-22,Actual,"June 12, 2018",Actual,2018-06-12,September 2022,2022-09-30,"August 7, 2019",Actual,2019-08-07,"August 7, 2019",Actual,2019-08-07,,Interventional,,,Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects,"A First-in-human Phase I, Single Center, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Safety and Immune Response of Increasing Doses of OVX836 Vaccine After Intramuscular (IM) or Intranasal (IN) Administrations in Healthy Subjects Aged 18-49 Years.",Completed,,Phase 1,72.0,Actual,Osivax,,4.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-14 01:00:34,2023-06-14 01:00:34,INDUSTRY,,,,,
61569,61570,NCT01799161,,2013-02-22,,,2014-11-14,2013-02-22,2013-02-26,Estimate,,,,,,,2014-11-14,2014-11-17,Estimate,December 2014,,2014-12-31,November 2014,2014-11-30,,,,April 2018,Anticipated,2018-04-30,,Interventional,,,"Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung Cancer","Phase 1 Study of the Combination of gp96-Ig Cell Based Lung Cancer Vaccine With Suppression of Adenosinergic Pathways With Theophylline and Oxygen for the Treatment of Non-Small Cell Lung Cancer (NSCLC) Patients With Advanced (Stage IIIB), Relapsed or Metastatic (Stage IV) Disease Who Have Failed Palliative Therapy.",Withdrawn,,Phase 1,0.0,Actual,University of Miami,,3.0,,Insufficient funding,False,,,,True,,,,,,,,,,,,,2023-06-14 01:00:56,2023-06-14 01:00:56,OTHER,,,,,
61640,61641,NCT02996461,,2016-12-16,,,2019-12-14,2016-12-16,2016-12-19,Estimate,,,,,,,2019-12-14,2019-12-17,Actual,"December 12, 2016",,2016-12-12,"September 3, 2019",2019-09-03,"September 3, 2019",Actual,2019-09-03,"September 3, 2019",Actual,2019-09-03,,Interventional,,,"VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults","VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, in Healthy Adults",Completed,,Phase 1,45.0,Actual,National Institutes of Health Clinical Center (CC),,3.0,,,False,,,,,True,,,,,,,,,,,,2023-06-14 01:02:06,2023-06-14 01:02:06,NIH,,,,,
61660,61661,NCT02129075,,2014-04-30,2021-05-25,,2021-11-10,2014-04-30,2014-05-02,Estimate,2021-11-10,2021-11-16,Actual,,,,2021-11-10,2021-11-16,Actual,"April 9, 2014",Actual,2014-04-09,November 2021,2021-11-30,"May 18, 2018",Actual,2018-05-18,"March 28, 2016",Actual,2016-03-28,,Interventional,,,A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma,"A Phase II, Open-Label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients With Malignant Melanoma Pre-Treated With Recombinant CDX-301, a Recombinant Human Flt3 Ligand",Completed,,Phase 2,60.0,Actual,National Cancer Institute (NCI),,2.0,,,False,,,,False,True,False,,,False,,,,,,,,2023-06-14 01:02:22,2023-06-14 01:02:22,NIH,,,,,
61765,61766,NCT04576702,,2020-09-17,,2022-03-11,2022-03-15,2020-10-02,2020-10-06,Actual,,,,2022-03-15,2022-03-17,Actual,2022-03-15,2022-03-17,Actual,"October 8, 2020",Actual,2020-10-08,March 2022,2022-03-31,"October 6, 2021",Actual,2021-10-06,"March 19, 2021",Actual,2021-03-19,,Interventional,,,Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults,"A Phase 2, Randomized, Stratified, Observer-Blind Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine in Older Adults",Completed,,Phase 2,471.0,Actual,Seqirus,,4.0,,,False,,,,True,True,False,,,,,,SEQIRUS discloses results from clinical studies within 12 months of last patient last visit (LPLV) unless otherwise mandated by local laws or regulations.,"SEQIRUS will consider requests from qualified scientific and medical researchers to disclose protocols, anonymized subject-level data and study-level data when there is medical, scientific and/or public health interest to ensure the safe use of a Seqirus product licensed on or after 1 January 2014 in the United States (US) and/or the European Union (EU). This applies to Seqirus-sponsored interventional studies initiated after 27 September 2007 and ongoing as of 26 December 2007, that have been included as part of a US or EU submission package which received approval in US and EU on or after 1 January 2014 and have been accepted for publication",http://ClinicalTrials.gov,Yes,"SEQIRUS supports the release of anonymized subject-level and study-level data in compliance with regulatory requirements, including Clinical Documents which are part of the CTD modules submitted to regulatory agencies for public release.

Summary results disclosure is either in document form (e.g., ICH E3 Clinical Study Report synopsis) or structured data form (such as summary results in ClinicalTrials.gov (United States) or eudract.ema.europa.eu (EU Clinical Trial Registry [EU CTR])",2023-06-17 03:05:43,2023-06-17 03:05:43,INDUSTRY,,,,,
61771,61772,NCT02862106,,2016-08-06,2016-11-20,,2019-08-11,2016-08-06,2016-08-10,Estimate,2016-11-20,2017-01-18,Estimate,,,,2019-08-11,2019-08-20,Actual,September 2010,,2010-09-30,November 2016,2016-11-30,March 2013,Actual,2013-03-31,March 2013,Actual,2013-03-31,,Interventional,,The safety population,Second Stage:Open-label Study of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B,Second Stage:Open-label Study of Therapeutic Hepatitis B Vaccine (Mimogen-based) in Treating Chronic Hepatitis B Patients,Completed,,Phase 2,209.0,Actual,Chongqing Jiachen Biotechnology Ltd.,,6.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-17 03:05:48,2023-06-17 03:05:48,INDUSTRY,,,,,
61923,61924,NCT02237638,,2014-08-15,,,2021-04-14,2014-09-09,2014-09-11,Estimate,,,,,,,2021-04-14,2021-04-19,Actual,April 2014,,2014-04-30,April 2021,2021-04-30,"January 1, 2020",Actual,2020-01-01,January 2020,Actual,2020-01-31,,Interventional,,,Phase I Study on VEGF Vaccination in Metastatic Solid Tumors,"A Phase I Open-label Clinical Trial, Evaluating the Therapeutic Vaccine hVEGF26-104/RFASE in Patients With Advanced Solid Tumors",Completed,,Phase 1,30.0,Actual,"Amsterdam UMC, location VUmc",,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 03:08:02,2023-06-17 03:08:02,OTHER,,,,,
62490,62491,NCT01341652,,2011-03-24,2020-10-30,,2021-01-15,2011-04-22,2011-04-26,Estimate,2020-10-30,2020-11-25,Actual,,,,2021-01-15,2021-01-20,Actual,"May 23, 2011",Actual,2011-05-23,January 2021,2021-01-31,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,,Interventional,,Baseline characteristics include those who completed the study.,Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer,Randomized Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) Versus GM-CSF Adjuvant in Patients With Non-Metastatic Prostate Cancer,Completed,,Phase 2,99.0,Actual,"University of Wisconsin, Madison",,2.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-17 03:15:32,2023-06-17 03:15:32,OTHER,,,,,
62530,62531,NCT05116917,,2021-10-23,,,2022-03-15,2021-11-02,2021-11-11,Actual,,,,,,,2022-03-15,2022-03-16,Actual,"November 5, 2021",Actual,2021-11-05,March 2022,2022-03-31,"December 1, 2024",Anticipated,2024-12-01,"December 1, 2023",Anticipated,2023-12-01,,Interventional,INFLUENCE,,Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.,"Nivolumab, Ipilimumab and Radiation in Combination With Influenza Vaccine in Patients With Pancreatic Cancer (INFLUENCE)",Recruiting,,Phase 2,30.0,Anticipated,Herlev Hospital,,1.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-17 03:15:59,2023-06-17 03:15:59,OTHER,,,,,
62589,62590,NCT01256853,,2010-12-08,,,2011-12-21,2010-12-08,2010-12-09,Estimate,,,,,,,2011-12-21,2011-12-22,Estimate,September 2006,,2006-09-30,December 2011,2011-12-31,September 2010,Actual,2010-09-30,September 2010,Actual,2010-09-30,,Interventional,,,Modified Vaccinia Ankara (MVA) Vaccine Study,"A Phase I, Dose Escalation Trial of Recombinant Modified Vaccinia Ankara (MVA)-Based Vaccine Encoding Epstein-Barr Virus Target Antigens",Completed,,Phase 1,18.0,Actual,Chinese University of Hong Kong,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 03:16:44,2023-06-17 03:16:44,OTHER,,,,,
62674,62675,NCT01154049,,2010-06-29,,,2016-08-09,2010-06-29,2010-06-30,Estimate,,,,,,,2016-08-09,2016-08-10,Estimate,March 2011,,2011-03-31,August 2016,2016-08-31,April 2014,Actual,2014-04-30,April 2014,Actual,2014-04-30,,Interventional,,,Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis,Phase 1 Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis,Completed,,Phase 1,20.0,Actual,Oswaldo Cruz Foundation,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 03:17:41,2023-06-17 03:17:41,OTHER,,,,,
62692,62693,NCT05175950,,2022-01-03,,,2023-02-12,2022-01-03,2022-01-04,Actual,,,,,,,2023-02-12,2023-02-14,Actual,"January 24, 2022",Actual,2022-01-24,February 2023,2023-02-28,November 2023,Anticipated,2023-11-30,August 2023,Anticipated,2023-08-31,,Interventional,,,"Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)","A Placebo-controlled, Randomized, Observer-blinded, Multi-center Study to Assess the Safety, Reactogenicity, and Immunogenicity of Booster Vaccination of A SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)","Active, not recruiting",,Phase 2,770.0,Anticipated,Korea University Guro Hospital,,14.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-17 03:17:53,2023-06-17 03:17:53,OTHER,,,,,
62721,62722,NCT01312376,,2011-03-09,,,2020-04-22,2011-03-09,2011-03-10,Estimate,,,,,,,2020-04-22,2020-04-24,Actual,March 2011,,2011-03-31,April 2020,2020-04-30,January 2019,Actual,2019-01-31,October 2015,Actual,2015-10-31,,Interventional,,,Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer,A Phase-1 Trial of Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Combined With Vaccine Boost and Bevacizumab for Recurrent Ovarian Fallopian Tube or Primary Peritoneal Cancer Previously Vaccinated With Autologous Tumor Vaccine,Terminated,,Phase 1,18.0,Actual,Abramson Cancer Center at Penn Medicine,,,,,False,,,,True,,,,,,,,,,,,,2023-06-17 03:18:16,2023-06-17 03:18:16,OTHER,,,,,
62751,62752,NCT01151319,,2010-06-24,,,2014-04-29,2010-06-25,2010-06-28,Estimate,,,,,,,2014-04-29,2014-04-30,Estimate,October 2010,,2010-10-31,April 2014,2014-04-30,April 2014,Actual,2014-04-30,April 2014,Actual,2014-04-30,,Interventional,HIV-CORE 002,,"Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults","A Randomized Single-blind Placebo-controlled Study to Evaluate the Safety and Immunogenicity of Three Candidate HIV-1 Vaccines, pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv, Administered in Combination to Healthy HIV 1 Uninfected Adults",Completed,,Phase 1,32.0,Actual,University of Oxford,,7.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 03:18:36,2023-06-17 03:18:36,OTHER,,,,,
62758,62759,NCT01259505,,2010-12-11,,,2014-11-13,2010-12-13,2010-12-14,Estimate,,,,,,,2014-11-13,2014-11-17,Estimate,December 2009,,2009-12-31,November 2014,2014-11-30,November 2014,Actual,2014-11-30,June 2012,Actual,2012-06-30,,Interventional,,,Safety Study of Multiple-Vaccine to Treat Metastatic Breast Cancer,Phase I Study of Multiple-Vaccine Therapy Using Epitope Peptides Restricted to HLA-A*2402 in Treating Patients With Refractory Breast Cancer,Completed,,Phase 1,10.0,Actual,Tokyo Medical University,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 03:18:41,2023-06-17 03:18:41,OTHER,,,,,
62780,62781,NCT01258023,,2010-11-18,,,2012-04-13,2010-12-09,2010-12-10,Estimate,,,,,,,2012-04-13,2012-04-16,Estimate,November 2010,,2010-11-30,April 2012,2012-04-30,April 2012,Actual,2012-04-30,February 2012,Actual,2012-02-29,,Interventional,Fluad Tx,,Seasonal Flu Vaccine in Adult Transplant Recipients,"A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a Seasonal Influenza Vaccine Including H1N1 in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers",Completed,,Phase 2,122.0,Actual,"HepNet Study House, German Liverfoundation",,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 03:18:57,2023-06-17 03:18:57,NETWORK,,,,,
62850,62851,NCT01265433,,2010-12-21,,,2018-11-01,2010-12-22,2010-12-23,Estimate,,,,,,,2018-11-01,2018-11-05,Actual,"December 21, 2010",Actual,2010-12-21,November 2018,2018-11-30,"July 25, 2017",Actual,2017-07-25,"July 25, 2017",Actual,2017-07-25,,Interventional,,,WT-1 Analog Peptide Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy,Randomized Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy,Completed,,Phase 2,31.0,Actual,Sellas Life Sciences Group,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 03:19:43,2023-06-17 03:19:43,INDUSTRY,,,,,
63010,63011,NCT01263327,,2010-12-17,,,2020-07-09,2010-12-17,2010-12-20,Estimate,,,,,,,2020-07-09,2020-07-10,Actual,December 2010,,2010-12-31,July 2020,2020-07-31,July 2011,Actual,2011-07-31,July 2011,Actual,2011-07-31,,Interventional,,,Clinical Trial of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine,"An Open-Label, Single-dose, Non-Randomized, Safety and Tolerability Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine (E.Coli)in Healthy Female Subjects Aged 18 to 55 Years",Completed,,Phase 1,38.0,Actual,Xiamen University,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 03:21:47,2023-06-17 03:21:47,OTHER,,,,,
63066,63067,NCT03205358,,2017-06-28,2020-05-20,2017-09-06,2022-03-24,2017-06-28,2017-07-02,Actual,2020-05-20,2020-06-05,Actual,2017-09-06,2017-09-14,Actual,2022-03-24,2022-04-04,Actual,"March 31, 2015",Actual,2015-03-31,March 2022,2022-03-31,"August 19, 2015",Actual,2015-08-19,"August 19, 2015",Actual,2015-08-19,,Interventional,,The analysis was performed on safety analysis set which included those participants who had received at least 1 dose of the study vaccine and had any safety data available.,Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers,A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers,Completed,,Phase 2,188.0,Actual,Sanofi,,2.0,,,False,,,,False,True,False,,,True,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-17 03:22:24,2023-06-17 03:22:24,INDUSTRY,,,,,
63199,63200,NCT01268787,,2010-12-30,,,2015-04-15,2010-12-30,2010-12-31,Estimate,,,,,,,2015-04-15,2015-04-16,Estimate,December 2010,,2010-12-31,October 2013,2013-10-31,September 2012,Actual,2012-09-30,March 2012,Actual,2012-03-31,,Interventional,,,A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine,"A Phase I, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine Administrated With Adjuvant AlPO4 in Health Volunteers",Completed,,Phase 1,60.0,Actual,"National Health Research Institutes, Taiwan",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 03:24:04,2023-06-17 03:24:04,OTHER,,,,,
63269,63270,NCT01339000,,2011-04-19,2016-05-16,,2016-05-16,2011-04-19,2011-04-20,Estimate,2016-05-16,2016-06-22,Estimate,,,,2016-05-16,2016-06-22,Estimate,April 2011,,2011-04-30,May 2016,2016-05-31,April 2016,Actual,2016-04-30,April 2016,Actual,2016-04-30,,Interventional,,,Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy,A Multicenter Phase II Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Glyco-Recombinant Human IL-7(CYT107) in Older Subjects Following Chemotherapy,Terminated,,Phase 2,1.0,Actual,National Institutes of Health Clinical Center (CC),,2.0,,"Company supplying drug declared bankruptcy, thus there was no drug supply.",False,,,,False,,,,,,,,,,,No,,2023-06-17 03:25:04,2023-06-17 03:25:04,NIH,,,,,
63617,63618,NCT01678352,,2012-08-30,,,2020-02-20,2012-09-04,2012-09-05,Estimate,,,,,,,2020-02-20,2020-02-24,Actual,October 2012,,2012-10-31,February 2020,2020-02-29,"November 8, 2018",Actual,2018-11-08,"November 8, 2017",Actual,2017-11-08,,Interventional,,,Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas,A Pilot Study to Evaluate the Effects of Imiquimod and Tumor Lysate Vaccine Immunotherapy for Adults With High Risk or Recurrent/Post-Chemotherapy WHO Grade II Gliomas,Completed,,Early Phase 1,19.0,Actual,University of Pittsburgh,,3.0,,,False,,,,True,,False,,,,,,,,,,,2023-06-14 01:04:19,2023-06-14 01:04:19,OTHER,,,,,
63917,63918,NCT03814720,,2019-01-23,2022-04-04,,2022-04-04,2019-01-23,2019-01-24,Actual,2022-04-04,2022-04-29,Actual,,,,2022-04-04,2022-04-29,Actual,"April 1, 2019",Actual,2019-04-01,April 2022,2022-04-30,"April 6, 2021",Actual,2021-04-06,"April 6, 2021",Actual,2021-04-06,,Interventional,,Population includes all enrolled participants.,"Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults","VRC 321: A Phase I Open-Label Clinical Trial to Evaluate Dose, Safety, Tolerability, and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine, VRCFLUNPF099-00-VP, in Healthy Adults",Completed,,Phase 1,52.0,Actual,National Institutes of Health Clinical Center (CC),,5.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-17 03:30:29,2023-06-17 03:30:29,NIH,,,,,
64070,64071,NCT00726739,,2008-07-31,2012-08-29,,2017-12-03,2008-07-31,2008-08-01,Estimate,2012-11-07,2012-12-13,Estimate,,,,2017-12-03,2017-12-28,Actual,June 2008,,2008-06-30,December 2017,2017-12-31,June 2011,Actual,2011-06-30,June 2011,Actual,2011-06-30,,Interventional,,,Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma,A Randomized Phase II Study of IL-2 With or Without an Allogeneic Large Multivalent Immunogen (LMI) Vaccine for the Treatment of Stage IV Melanoma,Completed,,Phase 2,21.0,Actual,"Masonic Cancer Center, University of Minnesota",,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 01:08:20,2023-06-14 01:08:20,OTHER,,,,,
64175,64176,NCT00751777,,2008-09-11,2014-01-30,,2020-01-16,2008-09-11,2008-09-12,Estimate,2014-03-17,2014-04-21,Estimate,,,,2020-01-16,2020-01-29,Actual,September 2008,,2008-09-30,January 2020,2020-01-31,November 2009,Actual,2009-11-30,November 2009,Actual,2009-11-30,,Interventional,,"Intent-to-Treat (ITT) Population: all study subjects who were consented, randomized, and had a baseline serology",Traveler's Diarrhea (TD) Automated Process,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Two Vaccination Regimen With an LT Vaccine Patch in Healthy Adults",Completed,,Phase 2,120.0,Actual,"Intercell USA, Inc.",,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 01:09:41,2023-06-14 01:09:41,INDUSTRY,,,,,
64384,64385,NCT00248833,,2005-11-02,2017-03-30,,2018-01-29,2005-11-02,2005-11-04,Estimate,2018-01-29,2018-10-29,Actual,,,,2018-01-29,2018-10-29,Actual,"December 5, 2005",Actual,2005-12-05,January 2018,2018-01-31,December 2007,Actual,2007-12-31,"November 30, 2006",Actual,2006-11-30,,Interventional,,,Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.,"Phase 1 Dose Esc Study of Safety and Immun of 3 Injections, Given at 0, 6 and 24 Wks, of Grp B Meningococcal 44/76 MOS NOMV 5D Vaccine Admin to Healthy Subjs IM With and Without Adjuvant",Completed,,Phase 1,34.0,Actual,U.S. Army Medical Research and Development Command,,3.0,,,False,,,,False,True,False,,,,,,,,,Yes,WRAIR,2023-06-14 01:12:56,2023-06-14 01:12:56,FED,,,,,
64500,64501,NCT05281263,,2022-03-07,,,2023-02-17,2022-03-15,2022-03-16,Actual,,,,,,,2023-02-17,2023-02-21,Actual,"July 20, 2022",Actual,2022-07-20,February 2023,2023-02-28,"June 2, 2023",Anticipated,2023-06-02,"June 2, 2023",Anticipated,2023-06-02,,Interventional,,,Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults,"A Phase 1 Trial of the Safety, Tolerability, and Immunogenicity of BLB-201 Vaccine in Healthy Young Adults and Older Adults","Active, not recruiting",,Phase 1,30.0,Actual,Blue Lake Biotechnology Inc.,,2.0,,,False,,,,True,True,False,,,,,,"5 years, beginning as soon as possible (but no later than 12 months) after article publication.",Data will be made available to investigators and institutions upon request. Requests should be directed to the CyanVac authors of the publication(s).,,Yes,"De-identified IPD underlying the results reported in any published articles (text, tables, figures, appendices) will be shared.",2023-06-14 01:14:40,2023-06-14 01:14:40,INDUSTRY,,,,,
64587,64588,NCT04954287,,2021-06-30,,,2023-02-17,2021-06-30,2021-07-08,Actual,,,,,,,2023-02-17,2023-02-21,Actual,"August 6, 2021",Actual,2021-08-06,February 2023,2023-02-28,"June 16, 2024",Anticipated,2024-06-16,"December 16, 2023",Anticipated,2023-12-16,,Interventional,CVXGA1-001,,Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents,"A Phase 1 Open-Label, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of Intranasal Parainfluenza Virus Type 5- SARS CoV-2 S Vaccine (CVXGA1) in Healthy Adults Aged 18 to 55 Years and Adolescents Aged 12 to 17 Years","Active, not recruiting",,Phase 1,80.0,Anticipated,CyanVac LLC,,4.0,,,False,,,,True,True,False,,,,,,"5 years, beginning as soon as possible (but no later than 12 months) after article publication",Data will be made available to investigators and institutions upon request. Requests should be directed to the CyanVac authors of the publication(s).,,Yes,"De-identified IPD underlying the results reported in any published articles (text, tables, figures, appendices) will be shared.",2023-06-14 01:15:03,2023-06-14 01:15:03,INDUSTRY,,,,,
64618,64619,NCT05680454,,2022-12-12,,,2023-01-12,2022-12-23,2023-01-11,Actual,,,,,,,2023-01-12,2023-01-17,Actual,"September 1, 2019",Actual,2019-09-01,December 2022,2022-12-31,"May 10, 2022",Actual,2022-05-10,"April 6, 2020",Actual,2020-04-06,,Interventional,,,A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine,A Phase I Trial in Healthy Chinese Women Ages 18-45 to Evaluate the Safety and Tolerability Profile of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli),Completed,,Phase 1,160.0,Actual,"Beijing Health Guard Biotechnology, Inc",,2.0,,,False,,,,False,False,False,,,,,,,,,No,No informed consent was obtained to disclose the subject's data and sample test results.,2023-06-14 01:15:27,2023-06-14 01:15:27,INDUSTRY,,,,,
64759,64760,NCT00111514,,2005-05-20,,,2007-02-13,2005-05-20,2005-05-23,Estimate,,,,,,,2007-02-13,2007-02-15,Estimate,July 2004,,2004-07-31,February 2007,2007-02-28,May 2006,,2006-05-31,,,,,Interventional,,,Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate Safety, Tolerability, and Immunogenicity of Leish-111f + MPL-SE Vaccine in Combination With Pentavalent Antimony in Treatment of Mucosal Leishmaniasis",Completed,,Phase 1,48.0,,Access to Advanced Health Institute (AAHI),,,,,,,,,,,,,,,,,,,,,,2023-06-15 03:12:34,2023-06-15 03:12:34,OTHER,,,,,
64760,64761,NCT00111553,,2005-05-23,,,2007-02-13,2005-05-23,2005-05-24,Estimate,,,,,,,2007-02-13,2007-02-15,Estimate,October 2004,,2004-10-31,February 2007,2007-02-28,August 2006,,2006-08-31,,,,,Interventional,,,Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis,"Randomized, Double-Blind, Adjuvant- and Placebo-Controlled, Dose-Escalating Study to Evaluate Safety, Tolerability, and Immunogenicity of Leish-111f + MPL-SE Vaccine With Meglumine Antimoniate (Glucantime) in Cutaneous Leishmaniasis",Completed,,Phase 1,45.0,,Access to Advanced Health Institute (AAHI),,,,,,,,,,,,,,,,,,,,,,2023-06-15 03:12:34,2023-06-15 03:12:34,OTHER,,,,,
64789,64790,NCT00112216,,2005-05-31,,,2013-04-23,2005-05-31,2005-06-01,Estimate,,,,,,,2013-04-23,2013-04-24,Estimate,May 1999,,1999-05-31,March 2009,2009-03-31,June 2007,Actual,2007-06-30,June 2007,Actual,2007-06-30,,Interventional,,,Immunotherapy of Melanoma Patients,Specific Immunotherapy of Skin Melanoma Patients With Antigenic Peptides and Immunological Analysis of the Vaccine Site Sentinel Lymph Node,Completed,,Phase 1,9.0,Actual,Centre Hospitalier Universitaire Vaudois,,,,,False,,,,False,,,,,,,,,,,,,2023-06-15 03:12:52,2023-06-15 03:12:52,OTHER,,,,,
64844,64845,NCT00114010,,2005-06-11,,,2017-06-30,2005-06-11,2005-06-13,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"April 1, 2005",,2005-04-01,"August 19, 2010",2010-08-19,"December 22, 2006",Actual,2006-12-22,"December 22, 2006",Actual,2006-12-22,,Interventional,,,Experimental Vaccine for Malaria,"Phase 1 Study of the Safety of Immunization of Naive Individuals With AMA1-C1/Alhydrogel [R], an Asexual Blood-Stage Vaccine for Plasmodium Falciparum Malaria, and the Effect of Immunization on Antigen-specific Memory and Plasma B Cells and T Cells",Completed,,Phase 1,13.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 03:13:33,2023-06-15 03:13:33,NIH,,,,,
64887,64888,NCT03945825,,2019-05-09,2021-09-09,,2023-02-23,2019-05-09,2019-05-10,Actual,2021-12-02,2022-01-03,Actual,,,,2023-02-23,2023-02-27,Actual,"June 10, 2019",Actual,2019-06-10,"February 19, 2021",2021-02-19,"September 18, 2020",Actual,2020-09-18,"September 18, 2020",Actual,2020-09-18,,Interventional,,The baseline analysis population includes all participants that were enrolled.,Flublok or Fluzone With Advax-CpG55.2 or AF03,"A Phase I Study to Assess the Safety, Reactogenicity and Immunogenicity of Two Quadrivalent Seasonal Influenza Vaccines (Fluzone(R) or Flublok(R)) With or Without One of Two Adjuvants (AF03 or Advax-CpG55.2) in Healthy Adults 18-45 Years of Age",Completed,,Phase 1,241.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,6.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-18 03:57:49,2023-06-18 03:57:49,NIH,,,,,
64893,64894,NCT00115531,,2005-06-22,,,2014-12-18,2005-06-22,2005-06-23,Estimate,,,,,,,2014-12-18,2014-12-19,Estimate,April 2005,,2005-04-30,February 2007,2007-02-28,November 2005,,2005-11-30,,,,,Interventional,,,Eldery High Dose TIV 2005,Comparisons of the Reactogenicity and Immunogenicity in Ambulatory Elderly Subjects of a Standard-Dose Fluzone® (15 µg HA/Virus Strain) and a High-Dose (60 µg HA/Virus Strain) of a Trivalent Inactivated Influenza Virus Vaccine,Completed,,Phase 2,414.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 03:14:14,2023-06-15 03:14:14,NIH,,,,,
64908,64909,NCT00115960,,2005-06-26,,,2021-10-13,2005-06-26,2005-06-27,Estimate,,,,,,,2021-10-13,2021-10-14,Actual,,,,October 2021,2021-10-31,July 2008,Actual,2008-07-31,,,,,Interventional,,,Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults,"A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Gag DNA Vaccine Alone or With IL-15 DNA, Boosted With HIV-1 Gag DNA + IL-15 DNA or HIV-1 Gag DNA + IL-12 DNA, in Healthy, HIV-1 Uninfected Adult Participants",Completed,,Phase 1,120.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,6.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 03:14:23,2023-06-15 03:14:23,NIH,,,,,
64945,64946,NCT02743455,,2016-04-14,,,2022-12-01,2016-04-14,2016-04-19,Estimate,,,,,,,2022-12-01,2022-12-05,Actual,"July 5, 2016",Actual,2016-07-05,"February 1, 2019",2019-02-01,"March 22, 2018",Actual,2018-03-22,"March 22, 2018",Actual,2018-03-22,,Interventional,,,"A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers","A Phase I, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA 720 Adjuvant in 18-45 Year Old Healthy Adults",Completed,,Phase 1,92.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,6.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-15 03:14:48,2023-06-15 03:14:48,NIH,,,,,
65001,65002,NCT00118924,,2005-07-08,,,2008-01-18,2005-07-08,2005-07-12,Estimate,,,,,,,2008-01-18,2008-01-21,Estimate,July 2005,,2005-07-31,January 2008,2008-01-31,July 2007,Actual,2007-07-31,July 2007,Actual,2007-07-31,,Interventional,,,Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults,"Phase 1 Study of the Safety and Immunogenicity of Tick-Borne Langat/Dengue 4 Chimera (LGT(TP21)/DEN4), a Live Attenuated Vaccine for Tick-Borne Encephalitis",Completed,,Phase 1,28.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 03:15:35,2023-06-15 03:15:35,NIH,,,,,
65008,65009,NCT00119197,,2005-07-04,,,2008-06-26,2005-07-04,2005-07-13,Estimate,,,,,,,2008-06-26,2008-07-04,Estimate,August 2005,,2005-08-31,June 2008,2008-06-30,July 2006,Actual,2006-07-31,June 2006,Actual,2006-06-30,,Interventional,,,Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata,"Safety and Immunogenicity of a Killed, Oral Cholera Vaccine in Indian Subjects in Eastern Kolkata, West Bengal",Completed,,Phase 2,200.0,Actual,International Vaccine Institute,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 03:15:39,2023-06-15 03:15:39,OTHER,,,,,
65098,65099,NCT00121771,,2005-07-18,,,2017-01-11,2005-07-18,2005-07-21,Estimate,,,,,,,2017-01-11,2017-01-12,Estimate,January 2004,,2004-01-31,January 2017,2017-01-31,July 2004,,2004-07-31,,,,,Interventional,,,Malaria Candidate Vaccines FP9 Circumsporozoite (CS) and MVA CS in Adult Gambian Men,A Phase 1 Trial of the Malaria Candidate Vaccines FP9 CS and MVA CS in Adult Gambian Men Aged 18 - 45 Years,Completed,,Phase 1,32.0,,London School of Hygiene and Tropical Medicine,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 03:16:44,2023-06-15 03:16:44,OTHER,,,,,
65099,65100,NCT00121849,,2005-07-15,,,2006-05-04,2005-07-15,2005-07-21,Estimate,,,,,,,2006-05-04,2006-05-05,Estimate,August 2005,,2005-08-31,May 2006,2006-05-31,February 2006,,2006-02-28,,,,,Interventional,,,Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite,"A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Leish-111f + MPL-SE Vaccine in Montenegro Skin Test-Positive Healthy Adults",Completed,,Phase 1,12.0,,Access to Advanced Health Institute (AAHI),,,,,,,,,,,,,,,,,,,,,,2023-06-15 03:16:44,2023-06-15 03:16:44,OTHER,,,,,
65165,65166,NCT00008853,,2001-01-18,,,2010-08-26,2001-08-30,2001-08-31,Estimate,,,,,,,2010-08-26,2010-08-27,Estimate,,,,November 2005,2005-11-30,November 2005,,2005-11-30,,,,,Interventional,,,Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines,Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines,Completed,,Phase 1,65.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 03:17:30,2023-06-15 03:17:30,NIH,,,,,
65210,65211,NCT00019006,,2007-03-01,,,2015-04-27,2007-03-01,2007-03-02,Estimate,,,,,,,2015-04-27,2015-04-28,Estimate,March 1995,,1995-03-31,May 2005,2005-05-31,,,,,,,,Interventional,,,"Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer","Phase I Pilot Study of Vaccine Therapy With Tumor-Specific Mutated Ras Peptides in the Adjuvant Setting in Patients With Colorectal, Pancreatic, or Lung Cancer",Completed,,Phase 1,,,National Cancer Institute (NCI),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 03:18:01,2023-06-15 03:18:01,NIH,,,,,
65392,65393,NCT02669121,,2016-01-27,2021-05-14,2019-05-30,2021-05-14,2016-01-27,2016-01-29,Estimate,2021-05-14,2021-06-10,Actual,2019-05-30,2019-06-05,Actual,2021-05-14,2021-06-10,Actual,"June 14, 2016",Actual,2016-06-14,May 2021,2021-05-31,"June 16, 2018",Actual,2018-06-16,"June 16, 2018",Actual,2018-06-16,,Interventional,,Randomized Set included all enrolled participants.,Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults,"Phase 2b, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Healthy Adults Aged 18 - 49 Years",Completed,,Phase 2,4748.0,Actual,Takeda,,2.0,,,False,,,,True,True,False,,,,,,,"IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.",https://vivli.org/ourmember/takeda/,Yes,"Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.",2023-06-18 03:59:26,2023-06-18 03:59:26,INDUSTRY,,,,,
65573,65574,NCT02388009,,2015-02-23,,,2015-12-21,2015-03-09,2015-03-13,Estimate,,,,,,,2015-12-21,2015-12-22,Estimate,February 2015,,2015-02-28,December 2015,2015-12-31,September 2015,Actual,2015-09-30,May 2015,Actual,2015-05-31,,Interventional,,,Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a,Safety and Tolerability of a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a When Administered to Adult Volunteers,Completed,,Phase 1,30.0,Actual,LimmaTech Biologics AG,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 06:06:12,2023-06-18 06:06:12,INDUSTRY,,,,,
65800,65801,NCT05096481,,2021-10-15,,,2023-02-15,2021-10-15,2021-10-27,Actual,,,,,,,2023-02-15,2023-02-21,Actual,"May 15, 2023",Anticipated,2023-05-15,February 2023,2023-02-28,"May 15, 2029",Anticipated,2029-05-15,"May 15, 2027",Anticipated,2027-05-15,,Interventional,,,PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma,Phase 2 Trial of a Novel Peptide Vaccine (PEP-CMV) Targeting CMV Antigen for Newly Diagnosed Pediatric High-grade Glioma and Diffuse Intrinsic Pontine Glioma and Recurrent Medulloblastoma,Not yet recruiting,,Phase 2,120.0,Anticipated,Nationwide Children's Hospital,,1.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-14 01:16:44,2023-06-14 01:16:44,OTHER,,,,,
65946,65947,NCT00643097,,2008-03-25,2014-01-06,,2016-12-02,2008-03-25,2008-03-26,Estimate,2014-01-06,2014-02-17,Estimate,,,,2016-12-02,2017-02-01,Estimate,September 2007,,2007-09-30,December 2016,2016-12-31,November 2016,Actual,2016-11-30,January 2012,Actual,2012-01-31,,Interventional,ACTIVATe,,Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,A Complementary Trial of an Immunotherapy Vaccine Against Tumor-Specific EGFRvIII,Completed,,Phase 2,40.0,Actual,Duke University,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 01:19:09,2023-06-14 01:19:09,OTHER,,,,,
65958,65959,NCT05208710,,2022-01-12,,,2023-01-17,2022-01-12,2022-01-26,Actual,,,,,,,2023-01-17,2023-01-18,Actual,"April 1, 2023",Anticipated,2023-04-01,January 2023,2023-01-31,August 2023,Anticipated,2023-08-31,August 2023,Anticipated,2023-08-31,,Interventional,PANHPVAX,,"PANHPVAX, Study of a New HPV Vaccine in Healthy Volunteers","A First-in-human, Phase I, Single-center, Open-label, Dose-escalation Trial in Healthy Volunteers to Assess Safety, Tolerability, and Immunogenicity of PANHPVAX, a Vaccine Targeting Human Papilloma L2 Antigen Formulated With Cyclic Di-AMP",Not yet recruiting,,Early Phase 1,45.0,Anticipated,German Cancer Research Center,,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-14 01:19:19,2023-06-14 01:19:19,OTHER,,,,,
65981,65982,NCT04349553,,2020-01-11,,,2021-03-10,2020-04-15,2020-04-16,Actual,,,,,,,2021-03-10,2021-03-11,Actual,"December 16, 2019",Actual,2019-12-16,April 2020,2020-04-30,"February 15, 2021",Actual,2021-02-15,"September 28, 2020",Actual,2020-09-28,,Interventional,,,"Study to Evaluate the Safety, Tolerability and Immunogenicity of a Potential Enteric Fever Vaccine","A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Dose Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of a Potential Oral Enteric Fever Vaccine (ZH9 + ZH9PA) in Healthy Participants",Completed,,Phase 1,46.0,Actual,Prokarium Ltd,,4.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-14 01:19:44,2023-06-14 01:19:44,INDUSTRY,,,,,
66171,66172,NCT00026611,,2001-11-12,,,2010-08-26,2001-11-12,2001-11-13,Estimate,,,,,,,2010-08-26,2010-08-27,Estimate,,,,March 2010,2010-03-31,December 2001,Actual,2001-12-31,December 2001,Actual,2001-12-31,,Interventional,,,A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults,"A Multicenter, Double-Blind, Randomized Dose-Response Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults",Completed,,Phase 2,,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 03:21:14,2023-06-15 03:21:14,NIH,,,,,
66357,66358,NCT00031564,,2002-03-08,,,2012-09-26,2003-01-26,2003-01-27,Estimate,,,,,,,2012-09-26,2012-09-27,Estimate,May 2000,,2000-05-31,September 2012,2012-09-30,June 2012,Actual,2012-06-30,June 2005,Actual,2005-06-30,,Interventional,,,Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2,Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2 for Patients With Stage IV Renal Cell Carcinoma,Completed,,Phase 2,49.0,Actual,H. Lee Moffitt Cancer Center and Research Institute,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 03:23:24,2023-06-15 03:23:24,OTHER,,,,,
66448,66449,NCT00033748,,2002-04-09,,,2016-07-15,2003-01-26,2003-01-27,Estimate,,,,,,,2016-07-15,2016-07-19,Estimate,December 2001,,2001-12-31,July 2016,2016-07-31,June 2010,Actual,2010-06-30,March 2007,Actual,2007-03-31,,Interventional,,,Vaccine Therapy in Treating Patients With Colorectal Cancer Metastatic to the Liver,Sequential Phase II Study of the Anti-Idiotype Monoclonal Antibody Vaccine CeaVac and TriAb in Patients With Minimal Metastatic Colorectal Cancer,Completed,,Phase 2,56.0,Actual,Alliance for Clinical Trials in Oncology,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 03:24:23,2023-06-15 03:24:23,OTHER,,,,,
66536,66537,NCT00000746,,1999-11-02,,,2021-10-27,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-27,2021-11-04,Actual,,,,October 2021,2021-10-31,July 1994,Actual,1994-07-31,,,,,Interventional,,,"A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines","A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines",Completed,,Phase 1,56.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 03:25:30,2023-06-15 03:25:30,NIH,,,,,
66545,66546,NCT00000755,,1999-11-02,,,2021-10-27,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-27,2021-11-04,Actual,,,,October 2021,2021-10-31,March 1993,Actual,1993-03-31,,,,,Interventional,,,A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3,A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3,Completed,,Phase 1,168.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 03:25:36,2023-06-15 03:25:36,NIH,,,,,
66783,66784,NCT00001076,,1999-11-02,,,2021-10-28,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-28,2021-11-04,Actual,,,,October 2021,2021-10-31,December 1997,Actual,1997-12-31,,,,,Interventional,,,A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules,A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules,Completed,,Phase 1,34.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 03:28:18,2023-06-15 03:28:18,NIH,,,,,
66797,66798,NCT00016146,,2001-05-06,,,2013-03-18,2003-01-26,2003-01-27,Estimate,,,,,,,2013-03-18,2013-03-19,Estimate,July 2000,,2000-07-31,March 2013,2013-03-31,March 2009,Actual,2009-03-31,March 2009,Actual,2009-03-31,,Interventional,,,Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer,Vaccination Of Prostate Cancer Patients With A Bivalent Vaccine Containing MUC-2 Glycopeptide And Globo H Conjugates: A Dose-Escalating Trial Studying The Immunogenicity And Safety Of The Immunological Adjuvant GPI-0100,Completed,,Phase 1,34.0,Actual,Memorial Sloan Kettering Cancer Center,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 03:28:26,2023-06-15 03:28:26,OTHER,,,,,
66882,66883,NCT00039091,,2002-06-06,,,2018-09-04,2003-01-26,2003-01-27,Estimate,,,,,,,2018-09-04,2018-09-05,Actual,March 2002,,2002-03-31,September 2018,2018-09-30,"November 21, 2007",Actual,2007-11-21,November 2007,Actual,2007-11-30,,Interventional,,,"Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer","Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 (Anti-CTLA-4) Humanized Monoclonal Antibody (MDX-CTLA-4 NSC# 732442, Previously 720801) in Patients Previously Vaccinated With GM-CSF-Based Autologous Tumor Vaccines (CTEP Protocol Number P-5708) and Patients With Acute Myelogenous Leukemia/ Myelodysplasia, and Non-Small Cell Lung Cancer Who Have Not Received a Prior Vaccine",Terminated,,Phase 1,26.0,Actual,National Cancer Institute (NCI),,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 03:29:28,2023-06-15 03:29:28,NIH,,,,,
66971,66972,NCT02385825,,2015-02-26,,,2019-12-30,2015-03-05,2015-03-11,Estimate,,,,,,,2019-12-30,2020-01-02,Actual,April 2016,,2016-04-30,December 2019,2019-12-31,December 2017,Anticipated,2017-12-31,June 2017,Anticipated,2017-06-30,,Interventional,,,IM Recombinant Ricin Toxin Vaccine (RVEc) - 3-Dose Primary Series With Boost,Phase 1b Escalating Study to Evaluate the Safety and Immunogenicity of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc) Administered Intramuscularly to Healthy Adults as a 3-Dose Primary Series and Booster,Withdrawn,,Phase 1,0.0,Actual,U.S. Army Medical Research and Development Command,,3.0,,lack of funding,False,,,,False,,,,,,,,,,,,,2023-06-18 06:09:21,2023-06-18 06:09:21,FED,,,,,
67040,67041,NCT00413725,,2006-12-18,,2015-05-28,2021-10-13,2006-12-18,2006-12-20,Estimate,,,,2015-07-02,2015-07-24,Estimate,2021-10-13,2021-10-15,Actual,January 2007,,2007-01-31,October 2021,2021-10-31,August 2012,Actual,2012-08-31,August 2012,Actual,2012-08-31,,Interventional,,,Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African Adults,A Multicenter Double-Blind Randomized Placebo-Controlled Phase IIB Test-of-Concept Study to Evaluate the Safety and Efficacy of a Three-Dose Regimen of the Clade B-based Merck Adenovirus Serotype 5 HIV-1 Gag/Pol/Nef Vaccine in HIV-1 Uninfected Adults in South Africa,Completed,,Phase 2,801.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-18 06:10:18,2023-06-18 06:10:18,NIH,,,,,
67194,67195,NCT02285413,,2013-05-11,,,2016-05-03,2014-11-04,2014-11-07,Estimate,,,,,,,2016-05-03,2016-05-04,Estimate,February 2011,,2011-02-28,May 2016,2016-05-31,April 2016,Actual,2016-04-30,October 2015,Actual,2015-10-31,,Interventional,,,Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients,Immunochemotherapy: Do Platin-based Chemotherapeutics Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients?,Completed,,Phase 2,54.0,Actual,Radboud University Medical Center,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 06:12:25,2023-06-18 06:12:25,OTHER,,,,,
67312,67313,NCT02380443,,2015-03-02,,,2020-01-17,2015-03-04,2015-03-05,Estimate,,,,,,,2020-01-17,2020-01-22,Actual,September 2016,Actual,2016-09-30,October 2016,2016-10-31,September 2018,Actual,2018-09-30,March 2018,Actual,2018-03-31,,Interventional,,,AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer,"In-Situ Cancer Vaccine: Phase IIA, Open-Label Study to Assess the Safety of AlloStim® Immunotherapy Alone and in Combination With Cryoablation as Third Line Therapy for Metastatic Colorectal Cancer",Completed,,Phase 2,12.0,Actual,"Immunovative Therapies, Ltd.",,4.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-18 06:13:55,2023-06-18 06:13:55,INDUSTRY,,,,,
67625,67626,NCT00285259,,2006-01-30,,2013-07-31,2013-07-31,2006-01-30,2006-02-01,Estimate,,,,2013-07-31,2013-08-07,Estimate,2013-07-31,2013-08-07,Estimate,January 2006,,2006-01-31,July 2013,2013-07-31,November 2010,Actual,2010-11-30,November 2009,Actual,2009-11-30,,Interventional,,,Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT),"A Phase 2 Clinical Trial to Evaluate the Safety, Immunogenicity, and Clinical Benefit of a CMV Immunotherapeutic Vaccine in Donors and CMV-Seropositive Recipients Undergoing Allogeneic, Matched Hematopoietic Cell Transplant (HCT)",Completed,,Phase 2,108.0,Actual,Astellas Pharma Inc,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 06:14:22,2023-06-18 06:14:22,INDUSTRY,,,,,
67860,67861,NCT05245838,,2022-01-27,,,2022-11-03,2022-02-08,2022-02-18,Actual,,,,,,,2022-11-03,2022-11-07,Actual,"January 10, 2022",Actual,2022-01-10,November 2022,2022-11-30,"October 20, 2022",Actual,2022-10-20,"October 20, 2022",Actual,2022-10-20,,Interventional,,,"Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers","A Phase 1 Randomized, Subject-Blinded, Active-Controlled, Dose Escalation, Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers Between the Ages of 50 and 69 Years",Completed,,Phase 1,150.0,Actual,Dynavax Technologies Corporation,,5.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-14 01:26:49,2023-06-14 01:26:49,INDUSTRY,,,,,
67924,67925,NCT02194751,,2014-07-14,,,2021-04-07,2014-07-16,2014-07-18,Estimate,,,,,,,2021-04-07,2021-04-08,Actual,July 2021,Anticipated,2021-07-31,July 2020,2020-07-31,June 2026,Anticipated,2026-06-30,June 2024,Anticipated,2024-06-30,,Interventional,,,"Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma","Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma",Not yet recruiting,,Phase 2,30.0,Anticipated,XEME Biopharma Inc.,,1.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-18 06:15:47,2023-06-18 06:15:47,INDUSTRY,,,,,
68278,68279,NCT00735839,,2008-08-13,2012-05-23,,2015-12-18,2008-08-13,2008-08-15,Estimate,2012-05-23,2012-06-26,Estimate,,,,2015-12-18,2015-12-21,Estimate,March 2008,,2008-03-31,December 2015,2015-12-31,June 2008,Actual,2008-06-30,June 2008,Actual,2008-06-30,,Interventional,,,V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED),"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Single Dose of Merck S. Aureus Vaccine (V710) in Healthy Male Japanese Subjects",Completed,,Phase 1,40.0,Actual,Merck Sharp & Dohme LLC,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 01:28:49,2023-06-14 01:28:49,INDUSTRY,,,,,
68733,68734,NCT05357560,,2022-04-13,,,2023-03-29,2022-04-26,2022-05-03,Actual,,,,,,,2023-03-29,2023-03-30,Actual,April 2023,Anticipated,2023-04-30,October 2022,2022-10-31,July 2025,Anticipated,2025-07-31,July 2025,Anticipated,2025-07-31,,Interventional,,,A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21,"A Phase Ib Multi-stage Plasmodium Falciparum Malaria Vaccine Study to Assess the Safety and Immunogenicity of the Blood-stage Vaccine Candidate RH5.2 Virus-like Particle (VLP) in Matrix-M and the Pre-erythrocytic Stage Vaccine Candidate R21 in Matrix-M, Both Alone and in Combination, in Adults and Infants in the Gambia",Not yet recruiting,,Phase 1,96.0,Anticipated,University of Oxford,,9.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 06:21:51,2023-06-18 06:21:51,OTHER,,,,,
68832,68833,NCT04826094,,2021-03-30,,,2023-03-28,2021-03-30,2021-04-01,Actual,,,,,,,2023-03-28,2023-03-30,Actual,"March 15, 2021",Actual,2021-03-15,March 2023,2023-03-31,"October 10, 2024",Anticipated,2024-10-10,"January 31, 2024",Anticipated,2024-01-31,,Interventional,,,A Study to Assess the Safety and Immune Response to Env-C DNA and Protein Vaccines in Kenya,"A Randomized, Double-Blind Phase 1 Trial to Evaluate the Safety and Immunogenicity of Priming With Env-C Plasmid DNA Vaccine Alone, With Different Adjuvants, or With an Adjuvanted HIV Env gp145 C.6980 Protein Vaccine and Boosting With the Adjuvanted HIV Env gp145 C.6980 Protein Vaccine With or Without the Env-C Plasmid DNA Vaccine in Healthy HIV Uninfected Adults in Kenya","Active, not recruiting",,Phase 1,126.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,7.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-18 06:23:01,2023-06-18 06:23:01,NIH,,,,,
68984,68985,NCT03406715,,2018-01-16,2023-02-02,,2023-03-29,2018-01-16,2018-01-23,Actual,2023-03-29,2023-03-30,Actual,,,,2023-03-29,2023-03-30,Actual,"March 15, 2018",Actual,2018-03-15,March 2023,2023-03-31,"May 16, 2022",Actual,2022-05-16,"March 23, 2022",Actual,2022-03-23,,Interventional,,,Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC),Combination Immunotherapy With Ipilimumab and Nivolumab Plus a Dendritic Cell Based p53 Vaccine (Ad.p53-DC) in Patients With Relapsed Small Cell Lung Cancer (SCLC),Terminated,,Phase 2,14.0,Actual,H. Lee Moffitt Cancer Center and Research Institute,,1.0,,Sponsor closed study,False,,,,False,True,False,,,,,,,,,,,2023-06-18 06:25:08,2023-06-18 06:25:08,OTHER,,,,,
69102,69103,NCT03806699,,2019-01-14,,,2019-07-22,2019-01-14,2019-01-16,Actual,,,,,,,2019-07-22,2019-07-23,Actual,"April 2, 2019",Actual,2019-04-02,July 2019,2019-07-31,December 2020,Anticipated,2020-12-31,September 2020,Anticipated,2020-09-30,,Interventional,,,Phase 1 Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Adolescent,"A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Explore the Immunogenicity of ID93+GLA-SE Vaccine in BCG-Vaccinated Healthy Adolescent",Unknown status,"Active, not recruiting",Phase 1,36.0,Actual,Quratis Inc.,,3.0,,,False,,,,False,True,False,,,True,,,,,,No,,2023-06-14 01:34:00,2023-06-14 01:34:00,INDUSTRY,,,,,
69327,69328,NCT00822757,,2009-01-13,2011-06-22,,2015-10-01,2009-01-13,2009-01-14,Estimate,2011-10-13,2011-11-21,Estimate,,,,2015-10-01,2015-10-02,Estimate,August 2007,,2007-08-31,October 2015,2015-10-31,December 2007,Actual,2007-12-31,October 2007,Actual,2007-10-31,,Interventional,,,Safety and Immunogenicity Study of V710 Lyophilized Formulation (V710-004),"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Single Dose of the Lyophilized Formulation of Merck Staphylococcus Aureus Vaccine (V710) in Healthy Adults",Completed,,Phase 1,51.0,Actual,Merck Sharp & Dohme LLC,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 01:37:53,2023-06-14 01:37:53,INDUSTRY,,,,,
69335,69336,NCT02344407,,2015-01-22,2017-05-25,,2021-03-17,2015-01-22,2015-01-26,Estimate,2017-05-25,2017-08-01,Actual,,,,2021-03-17,2021-04-08,Actual,"January 20, 2015",,2015-01-20,March 2021,2021-03-31,"November 1, 2020",Actual,2020-11-01,"June 1, 2016",Actual,2016-06-01,,Interventional,,,Partnership for Research on Ebola Vaccines in Liberia (PREVAIL),Partnership for Research on Ebola Vaccines in Liberia (PREVAIL),Completed,,Phase 2,1500.0,Actual,National Institutes of Health Clinical Center (CC),,3.0,,,,,,,True,,,,,,,,,,,,,2023-06-14 01:38:01,2023-06-14 01:38:01,NIH,,,,,
69352,69353,NCT02153671,,2014-05-23,2018-08-07,,2019-02-14,2014-05-30,2014-06-03,Estimate,2019-02-14,2019-02-18,Actual,,,,2019-02-14,2019-02-18,Actual,May 2014,,2014-05-31,February 2019,2019-02-28,September 2014,Actual,2014-09-30,September 2014,Actual,2014-09-30,,Interventional,,,Immunogenicity of H5N1 Vaccine Following H5N2,Immunogenicity of OrniFlu® Inactivated Influenza Vaccine in Subjects Previously Immunized With Live Attenuated H5N2 Influenza Vaccine and in Non-vaccinated Subjects,Completed,,Phase 2,43.0,Actual,PATH,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 01:38:18,2023-06-14 01:38:18,OTHER,,,,,
69362,69363,NCT00849121,,2009-02-19,2014-08-29,,2019-11-13,2009-02-20,2009-02-23,Estimate,2014-09-10,2014-09-11,Estimate,,,,2019-11-13,2019-11-21,Actual,"March 16, 2009",Actual,2009-03-16,March 2019,2019-03-31,"February 17, 2014",Actual,2014-02-17,"February 17, 2014",Actual,2014-02-17,,Interventional,,,Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer,A Pilot Randomized Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer,Completed,,Phase 2,17.0,Actual,"University of Wisconsin, Madison",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 01:38:28,2023-06-14 01:38:28,OTHER,,,,,
69448,69449,NCT00042094,,2002-07-23,,,2011-06-29,2002-07-25,2002-07-26,Estimate,,,,,,,2011-06-29,2011-06-30,Estimate,March 2002,,2002-03-31,June 2011,2011-06-30,March 2003,,2003-03-31,,,,,Interventional,,,"Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax®","A Phase 1 Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation (Take Rate) of a Cell-Cultured Smallpox Vaccine (CCSV) Compared to a Calf Lymph Vaccine (Dryvax®)",Completed,,Phase 1,350.0,,"DynPort Vaccine Company LLC, A GDIT Company",,,,,,,,,,,,,,,,,,,,,,2023-06-15 03:30:38,2023-06-15 03:30:38,INDUSTRY,,,,,
69488,69489,NCT05743595,,2023-02-14,,,2023-02-14,2023-02-14,2023-02-24,Actual,,,,,,,2023-02-14,2023-02-24,Actual,"June 30, 2023",Anticipated,2023-06-30,February 2023,2023-02-28,"June 30, 2027",Anticipated,2027-06-30,"September 30, 2024",Anticipated,2024-09-30,,Interventional,,,"Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma","A Pilot Study to Assess the Safety and Immunogenicity of a Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma",Not yet recruiting,,Phase 1,12.0,Anticipated,Washington University School of Medicine,,2.0,,,False,,,,True,True,True,,,False,,,,,,Yes,,2023-06-14 01:39:27,2023-06-14 01:39:27,OTHER,,,,,
69608,69609,NCT00001703,,1999-11-03,2011-05-17,,2014-07-16,1999-11-03,1999-11-04,Estimate,2012-05-11,2012-06-14,Estimate,,,,2014-07-16,2014-07-25,Estimate,August 1998,,1998-08-31,July 2014,2014-07-31,November 2008,Actual,2008-11-30,November 2008,Actual,2008-11-30,,Interventional,,,Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma,Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma,Terminated,,Phase 2,6.0,Actual,National Institutes of Health Clinical Center (CC),,1.0,,Due to poor accrual and lack of peptide vaccine,False,,,,False,,,,,,,,,,,,,2023-06-15 03:32:23,2023-06-15 03:32:23,NIH,,,,,
69610,69611,NCT00045838,,2002-09-10,,,2015-09-30,2002-09-10,2002-09-11,Estimate,,,,,,,2015-09-30,2015-10-02,Estimate,August 2002,,2002-08-31,September 2015,2015-09-30,April 2003,Actual,2003-04-30,April 2003,Anticipated,2003-04-30,,Interventional,,,HIV-1 Vaccine Test in Uninfected Adult Volunteers,"A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA006-00-VP, In Uninfected Adult Volunteers",Withdrawn,,Phase 1,0.0,Actual,National Institutes of Health Clinical Center (CC),,,,The study product was revised. PI withdrew the study without enrolling participants..,False,,,,,,,,,,,,,,,,,2023-06-15 03:32:25,2023-06-15 03:32:25,NIH,,,,,
69770,69771,NCT00050518,,2002-12-11,,,2010-08-26,2002-12-12,2002-12-13,Estimate,,,,,,,2010-08-26,2010-08-27,Estimate,,,,March 2010,2010-03-31,February 2003,Actual,2003-02-28,February 2003,Actual,2003-02-28,,Interventional,,,APSV in Vaccinia Naive Adults,"A Multicenter, Double-Blind, Randomized Study of the Safety and Efficacy of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-Naive Adults.",Completed,,Phase 2,444.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,,,,,,,,,,,,,,,,,,2023-06-15 03:34:18,2023-06-15 03:34:18,NIH,,,,,
69822,69823,NCT00051922,,2003-01-17,,,2011-06-06,2003-01-21,2003-01-22,Estimate,,,,,,,2011-06-06,2011-06-08,Estimate,October 1997,,1997-10-31,June 2011,2011-06-30,June 2009,Actual,2009-06-30,July 2006,Actual,2006-07-31,,Interventional,,,Development of a New HIV Vaccine,Evaluation of the Safety of a Polyvalent Vaccinia Virus HIV-1 Envelope Recombinant Vaccine (PolyEnv1) in Healthy Adults,Completed,,Phase 1,24.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 03:34:51,2023-06-15 03:34:51,NIH,,,,,
70150,70151,NCT02366013,,2015-02-04,,,2016-11-18,2015-02-11,2015-02-19,Estimate,,,,,,,2016-11-18,2016-11-21,Estimate,January 2015,,2015-01-31,November 2016,2016-11-30,June 2016,Actual,2016-06-30,June 2016,Actual,2016-06-30,,Interventional,,,"Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine","A Phase 1 Clinical Trial of the Safety and Immunogenicity of an Oral, Replicating Adenovirus 26 Vector Vaccine for HIV-1 (rcAd26.MOS1.HIV-Env) in Healthy HIV-1-uninfected Adults",Completed,,Phase 1,22.0,Actual,International AIDS Vaccine Initiative,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 06:29:50,2023-06-18 06:29:50,NETWORK,,,,,
70598,70599,NCT03300050,,2017-09-28,2020-11-17,,2021-02-01,2017-09-28,2017-10-03,Actual,2021-02-01,2021-02-21,Actual,,,,2021-02-01,2021-02-21,Actual,"October 10, 2017",Actual,2017-10-10,July 2020,2020-07-31,"August 9, 2019",Actual,2019-08-09,"April 24, 2018",Actual,2018-04-24,,Interventional,,All enrolled participants,Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine,"A Phase 1, Randomized, Controlled, Observer-blind Study to Assess the Reactogenicity, Safety, and Immunogenicity of a Live Attenuated Universal Influenza Vaccine (cH8/1N1 LAIV) Administered as a Single Priming Dose Followed Three Months Later by a Single Booster Dose of an Inactivated Universal Influenza Vaccine (cH5/1N1 IIV) (Adjuvanted With AS03A or Unadjuvanted) in 18 Through 39 Year-old Healthy Subjects, Contrasted With a Two Dose Schedule of an Inactivated Universal Influenza Vaccine (cH8/1N1 IIV + AS03A Followed Three Months Later by cH5/1N1 IIV + AS03A)",Completed,,Phase 1,65.0,Actual,PATH,,5.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 03:37:50,2023-06-17 03:37:50,OTHER,,,,,
71141,71142,NCT05260437,,2022-02-25,,,2023-04-07,2022-02-25,2022-03-02,Actual,,,,,,,2023-04-07,2023-04-10,Actual,"March 24, 2022",Actual,2022-03-24,April 2023,2023-04-30,"March 7, 2023",Actual,2023-03-07,"March 7, 2023",Actual,2023-03-07,,Interventional,,,"Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants","A Phase 1, Open-label, Safety, Reactogenicity, and Immunogenicity Trial of the CV2CoV mRNA Vaccine Against SARS CoV 2 in Seropositive Adult Participants",Completed,,Phase 1,98.0,Actual,GlaxoSmithKline,,5.0,,,False,,,,,True,False,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-14 02:26:47,2023-06-14 02:26:47,INDUSTRY,,,,,
71198,71199,NCT00971737,,2009-09-03,2019-02-15,,2019-04-10,2009-09-03,2009-09-04,Estimate,2019-02-15,2019-03-12,Actual,,,,2019-04-10,2019-04-24,Actual,July 2009,,2009-07-31,April 2019,2019-04-30,March 2016,Actual,2016-03-31,March 2016,Actual,2016-03-31,,Interventional,,"63 subjects were deemed eligible for this study. 2 were taken off-study prior to vaccination due to the development of new medical problems. 1 subject was taken off due to anxiety and non-compliance. 60 research subjects went on to receive at least 1 vaccination, where 30 subjects were randomized to Arm A and 30 subjects were randomized to Arm B.",Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer,"A Randomized, Open-Label Comparative Study of Combination Therapy With Cyclophosphamide and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine With or Without Trastuzumab for the Treatment of Metastatic Breast Cancer That Does NOT Over-express HER-2/Neu",Completed,,Phase 2,63.0,Actual,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 02:27:27,2023-06-14 02:27:27,OTHER,,,,,
71234,71235,NCT00703521,,2008-06-20,,,2008-10-23,2008-06-20,2008-06-23,Estimate,,,,,,,2008-10-23,2008-10-24,Estimate,August 2002,,2002-08-31,June 2008,2008-06-30,September 2005,Actual,2005-09-30,October 2002,Actual,2002-10-31,,Interventional,,,Rabies Immunization Concomitant With JEV in Children,"A Three-Year Clinical Study on Immunogenicity, Safety and Booster Response of Purified Chick Embryo Cell Rabies Vaccine (Pcecv) Administered Intramuscularly or Intradermally to 12- to 18-Month-Old Thai Children Concomitantly With Japanese Encephalitis Vaccine",Completed,,Phase 2,200.0,Anticipated,Mahidol University,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 02:48:29,2023-06-16 02:48:29,OTHER,,,,,
71532,71533,NCT05364047,,2022-04-22,,,2022-12-01,2022-05-05,2022-05-06,Actual,,,,,,,2022-12-01,2022-12-05,Actual,"July 31, 2021",Actual,2021-07-31,November 2022,2022-11-30,October 2023,Anticipated,2023-10-31,"October 14, 2022",Actual,2022-10-14,,Interventional,,,Clinical Trial of SARS-CoV-2 mRNA Vaccine in China,"Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) in Chinese People Aged 18 Years and Over","Active, not recruiting",,Phase 1,144.0,Actual,"AIM Vaccine Co., Ltd.",,6.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-15 03:38:07,2023-06-15 03:38:07,INDUSTRY,,,,,
71604,71605,NCT00061243,,2003-05-22,,,2008-09-25,2003-05-22,2003-05-23,Estimate,,,,,,,2008-09-25,2008-09-26,Estimate,April 2004,,2004-04-30,December 2005,2005-12-31,April 2010,Anticipated,2010-04-30,April 2005,Actual,2005-04-30,,Interventional,,,Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults,"A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Multi-Gene, Polyvalent HIV-1 DNA Plasmid Prime/Env Protein Boost Vaccine Formulation, DP6-001 in Healthy Volunteers",Unknown status,"Active, not recruiting",Phase 1,36.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 03:38:57,2023-06-15 03:38:57,NIH,,,,,
71669,71670,NCT00062530,,2003-06-09,,,2008-09-25,2003-06-11,2003-06-12,Estimate,,,,,,,2008-09-25,2008-09-26,Estimate,,,,September 2008,2008-09-30,,,,,,,,Interventional,,,Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers,Development of an Oral Prime-Boost AIDS Vaccine to Elicit Broadly Neutralizing Antibodies Against HIV-1,Unknown status,Not yet recruiting,Phase 1,38.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 03:39:44,2023-06-15 03:39:44,NIH,,,,,
71708,71709,NCT00063778,,2003-07-07,,,2012-06-27,2003-07-07,2003-07-08,Estimate,,,,,,,2012-06-27,2012-07-02,Estimate,July 2003,,2003-07-31,June 2012,2012-06-30,July 2005,Actual,2005-07-31,July 2005,Actual,2005-07-31,,Interventional,,,Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa,"A Phase I Safety and Immunogenicity Trial of an Alphavirus Replicon HIV Subtype C Gag Vaccine (AVX101, Alphavax, Inc.) in Healthy HIV-1 Uninfected Adult Volunteers",Completed,,Phase 1,48.0,Actual,"AlphaVax, Inc.",,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 03:40:13,2023-06-15 03:40:13,INDUSTRY,,,,,
71769,71770,NCT05105048,,2021-10-22,,,2022-12-03,2021-10-22,2021-11-03,Actual,,,,,,,2022-12-03,2022-12-06,Actual,"November 8, 2021",Actual,2021-11-08,December 2022,2022-12-31,"August 7, 2023",Anticipated,2023-08-07,"August 7, 2023",Anticipated,2023-08-07,,Interventional,,,"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647","A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccine mRNA-1647 When Administered to Healthy Japanese Adults (18-40 Years of Age) in the United States","Active, not recruiting",,Phase 1,9.0,Actual,"ModernaTX, Inc.",,2.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-15 03:40:57,2023-06-15 03:40:57,INDUSTRY,,,,,
71952,71953,NCT03055000,,2017-02-14,2020-03-05,,2020-08-03,2017-02-14,2017-02-16,Actual,2020-07-21,2020-08-03,Actual,,,,2020-08-03,2020-08-11,Actual,"February 15, 2017",Actual,2017-02-15,December 2018,2018-12-31,"December 28, 2018",Actual,2018-12-28,"December 28, 2018",Actual,2018-12-28,,Interventional,,,Safety and Immunogenicity of a First-in-Human Mosquito Saliva Peptide Vaccine,"Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease Vaccine",Completed,,Phase 1,49.0,Actual,National Institutes of Health Clinical Center (CC),,3.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-14 02:29:31,2023-06-14 02:29:31,NIH,,,,,
72029,72030,NCT00073216,,2003-11-18,,,2021-10-13,2003-11-18,2003-11-19,Estimate,,,,,,,2021-10-13,2021-10-14,Actual,,,,October 2021,2021-10-31,September 2007,Actual,2007-09-30,,,,,Interventional,,,Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults,"A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Clade B Gag DNA/PLG and Env DNA/PLG Microparticles Vaccine and a Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant Vaccine in Healthy, HIV-1 Uninfected Adult Participants",Completed,,Phase 1,96.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 03:43:55,2023-06-15 03:43:55,NIH,,,,,
72734,72735,NCT03969134,,2019-05-22,,,2023-05-25,2019-05-28,2019-05-31,Actual,,,,,,,2023-05-25,2023-05-26,Actual,"April 6, 2020",Actual,2020-04-06,May 2023,2023-05-31,"February 28, 2023",Actual,2023-02-28,"August 31, 2022",Actual,2022-08-31,,Interventional,,,"A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL","A Phase IIb Study to Assess the Safety, Efficacy and Immunogenicity of the Leishmania Vaccine ChAd63-KH in Post-kala Azar Dermal Leishmaniasis",Completed,,Phase 2,86.0,Actual,University of York,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-16 02:55:27,2023-06-16 02:55:27,OTHER,,,,,
72736,72737,NCT03946358,,2019-05-07,,,2023-05-25,2019-05-09,2019-05-10,Actual,,,,,,,2023-05-25,2023-05-26,Actual,"February 18, 2020",Actual,2020-02-18,May 2023,2023-05-31,October 2025,Anticipated,2025-10-31,September 2024,Anticipated,2024-09-30,,Interventional,VolATIL,,Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL),A Phase II Study Evaluating the Interest to Combine UCPVax a CD4 TH1-inducer Cancer Vaccine and Atezolizumab for the Treatment of Human PapillomaVirus Positive Cancers,"Active, not recruiting",,Phase 2,47.0,Anticipated,Centre Hospitalier Universitaire de Besancon,,1.0,,,False,,,,True,False,False,,,False,,,,,,No,,2023-06-16 02:55:28,2023-06-16 02:55:28,OTHER,,,,,
72855,72856,NCT05525208,,2022-08-30,,,2022-09-06,2022-08-30,2022-09-01,Actual,,,,,,,2022-09-06,2022-09-09,Actual,"September 1, 2022",Actual,2022-09-01,September 2022,2022-09-30,"March 30, 2023",Anticipated,2023-03-30,"February 28, 2023",Anticipated,2023-02-28,,Interventional,,,Booster Study of COVID-19 Protein Subunit Recombinant Vaccine,"Observer-Blind, Randomized, Controlled Study of Immunogenicity and Safety of SARS-Cov-2 Protein Subunit Recombinant Vaccine (Bio Farma) as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older",Recruiting,,Phase 2,900.0,Anticipated,PT Bio Farma,,6.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-14 02:07:11,2023-06-14 02:07:11,INDUSTRY,,,,,
72982,72983,NCT03816878,,2019-01-23,,,2022-02-15,2019-01-23,2019-01-25,Actual,,,,,,,2022-02-15,2022-02-16,Actual,"January 8, 2019",Actual,2019-01-08,February 2022,2022-02-28,"March 17, 2020",Actual,2020-03-17,"April 18, 2019",Actual,2019-04-18,,Interventional,,,"Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals","An Exploration of a Prime-Boost Approach for Universal Influenza Vaccination: Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals",Completed,,Phase 1,32.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-16 02:58:45,2023-06-16 02:58:45,NIH,,,,,
73176,73177,NCT02830932,,2016-03-23,,,2018-08-14,2016-07-09,2016-07-13,Estimate,,,,,,,2018-08-14,2018-08-16,Actual,"June 22, 2016",Actual,2016-06-22,August 2018,2018-08-31,"September 20, 2017",Actual,2017-09-20,"September 16, 2016",Actual,2016-09-16,,Interventional,,,Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f),"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Respiratory Syncytial Virus (RSV) F Protein Vaccine (VXA-RSV-f) Expressing Protein F and dsRNA Adjuvant Administered Orally to Healthy Volunteers",Completed,,Phase 1,66.0,Actual,Vaxart,,3.0,,,False,,,,True,,,,,,,,,,,Undecided,Data may be made available to subjects following the 1 year safety follow-up period.,2023-06-16 03:01:18,2023-06-16 03:01:18,INDUSTRY,,,,,
73390,73391,NCT00845611,,2009-02-17,,,2012-04-04,2009-02-17,2009-02-18,Estimate,,,,,,,2012-04-04,2012-04-06,Estimate,September 2008,,2008-09-30,April 2012,2012-04-30,September 2010,Actual,2010-09-30,September 2010,Actual,2010-09-30,,Interventional,,,Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer,Tumor Vaccine Therapy Against Advanced Gastric Cancer Using HLA-A*2402 Restricted Epitope Peptides Drived From URLC10,Completed,,Phase 1,9.0,Actual,Kinki University,,,,,False,,,,True,,,,,,,,,,,,,2023-06-16 03:03:45,2023-06-16 03:03:45,OTHER,,,,,
73431,73432,NCT00840931,,2009-02-04,,,2019-12-10,2009-02-10,2009-02-11,Estimate,,,,,,,2019-12-10,2019-12-11,Actual,"February 2, 2009",Actual,2009-02-02,December 2019,2019-12-31,December 2019,Actual,2019-12-31,"February 17, 2014",Actual,2014-02-17,,Interventional,,,Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS),"A Phase I Pilot Study of Immunotherapy Using Lenalidomide Plus ""Bystander"" Vaccine in Patients With High-Risk Myelodysplastic Syndrome (MDS)",Completed,,Phase 1,22.0,Actual,H. Lee Moffitt Cancer Center and Research Institute,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 03:04:18,2023-06-16 03:04:18,OTHER,,,,,
73490,73491,NCT00841399,,2009-02-10,,,2020-03-28,2009-02-10,2009-02-11,Estimate,,,,,,,2020-03-28,2020-03-31,Actual,July 2001,,2001-07-31,March 2020,2020-03-31,March 2013,Actual,2013-03-31,September 2012,Actual,2012-09-30,,Interventional,,,Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Node-Positive Breast Cancer Patients,Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Breast Cancer Patients at Risk for Recurrence After Surgical and Medical Therapies,Completed,,Phase 1,100.0,Actual,Walter Reed Army Medical Center,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 03:04:59,2023-06-16 03:04:59,FED,,,,,
73495,73496,NCT00848887,,2009-02-19,,,2014-01-23,2009-02-19,2009-02-20,Estimate,,,,,,,2014-01-23,2014-01-24,Estimate,October 2008,,2008-10-31,January 2014,2014-01-31,May 2009,Actual,2009-05-31,May 2009,Actual,2009-05-31,,Interventional,,,A Dose Ranging Study Comparing Different Combinations of Adjuvanted and Non-adjuvanted Influenza Vaccines in Healthy Children 6 to <36 Months of Age,"A Phase Ib, Randomized, Observer-Blind, Multicenter, Factorial-Design Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Injections of Trivalent Inactivated Influenza Vaccine With or Without a Second Influenza B Strain in Combination With or Without One of Three Different Doses of Adjuvant in Healthy Children, Aged 6 to <36 Months",Completed,,Phase 1,410.0,Actual,Novartis,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 03:05:01,2023-06-16 03:05:01,INDUSTRY,,,,,
73641,73642,NCT00620815,,2008-02-12,2011-07-04,,2016-03-03,2008-02-21,2008-02-22,Estimate,2012-09-17,2012-09-19,Estimate,,,,2016-03-03,2016-03-28,Estimate,November 2007,,2007-11-30,March 2016,2016-03-31,December 2008,Actual,2008-12-31,January 2008,Actual,2008-01-31,,Interventional,,,Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above,"A Phase II, Randomized, Placebo-controlled, Observer-blind, Multi Center Study on the Safety and Immunogenicity of Novartis Tetravalent Influenza Vaccine (Containing Both Interpandemic Strains and H5N1) in Adults Aged 18 Years and Above",Completed,,Phase 2,601.0,Actual,Novartis,,6.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 03:06:41,2023-06-16 03:06:41,INDUSTRY,,,,,
73756,73757,NCT00851383,,2009-02-24,,,2012-04-23,2009-02-24,2009-02-25,Estimate,,,,,,,2012-04-23,2012-04-25,Estimate,March 2009,,2009-03-31,April 2012,2012-04-30,August 2011,Actual,2011-08-31,August 2011,Actual,2011-08-31,,Interventional,,,A Trial to Evaluate Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers,"A Phase I Placebo-controlled, Double-blinded (in Terms of Vaccine or Placebo), Randomized Dose-escalation Trial to Evaluate the Safety and Immunogenicity of Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers. (IAVI B001)",Completed,,Phase 1,56.0,Actual,International AIDS Vaccine Initiative,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 03:08:02,2023-06-16 03:08:02,NETWORK,,,,,
73870,73871,NCT04236960,,2018-07-05,,,2020-01-16,2020-01-16,2020-01-22,Actual,,,,,,,2020-01-16,2020-01-22,Actual,"July 17, 2018",Actual,2018-07-17,January 2020,2020-01-31,"November 28, 2019",Actual,2019-11-28,"September 16, 2019",Actual,2019-09-16,,Interventional,,,Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.,Phase I Clinical Study of Meningococcal Group ACYW135 Conjugate Vaccine,Completed,,Phase 1,100.0,Actual,"Walvax Biotechnology Co., Ltd.",,5.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-16 03:09:28,2023-06-16 03:09:28,INDUSTRY,,,,,
73952,73953,NCT00853255,,2009-02-26,,,2012-12-31,2009-02-27,2009-03-02,Estimate,,,,,,,2012-12-31,2013-01-03,Estimate,July 2010,,2010-07-31,December 2012,2012-12-31,December 2011,Actual,2011-12-31,August 2011,Actual,2011-08-31,,Interventional,,,Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy Adults,"Phase 1 Inpatient Study of the Safety and Immunogenicity of One Dose of Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/Chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H7N3 Infection in the Event of a Pandemic",Completed,,Phase 1,20.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 03:10:31,2023-06-16 03:10:31,NIH,,,,,
74294,74295,NCT02797236,,2016-04-18,,,2018-04-10,2016-06-10,2016-06-13,Estimate,,,,,,,2018-04-10,2018-04-11,Actual,September 2016,Actual,2016-09-30,April 2018,2018-04-30,December 2017,Actual,2017-12-31,June 2017,Actual,2017-06-30,,Interventional,,,SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers,A Phase I Dose Escalation Study to Assess the Safety and Immunogenicity of the SF2a-TT15 Conjugate Vaccine Against S. Flexneri 2a in Healthy Adult Volunteers,Completed,,Phase 1,64.0,Actual,Institut Pasteur,,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 03:14:34,2023-06-16 03:14:34,INDUSTRY,,,,,
74667,74668,NCT02234921,,2014-09-04,,,2018-10-09,2014-09-04,2014-09-09,Estimate,,,,,,,2018-10-09,2018-10-11,Actual,"October 24, 2014",Actual,2014-10-24,October 2018,2018-10-31,"August 15, 2018",Actual,2018-08-15,"August 15, 2018",Actual,2018-08-15,,Interventional,DRibble,,Pilot Study of DRibble Vaccine for Prostate Cancer Patients,A Pilot Study of DPV-001 DRibble Vaccine With Imiquimod in Advanced Prostate Cancer,Completed,,Phase 1,3.0,Actual,UbiVac,,1.0,,,False,,,,False,,,,,,,,,,,No,,2023-06-18 06:47:38,2023-06-18 06:47:38,INDUSTRY,,,,,
75208,75209,NCT01561768,,2012-03-02,,2013-07-16,2013-07-16,2012-03-22,2012-03-23,Estimate,,,,2013-07-16,2013-07-18,Estimate,2013-07-16,2013-07-18,Estimate,March 2012,,2012-03-31,July 2013,2013-07-31,January 2013,Actual,2013-01-31,January 2013,Actual,2013-01-31,,Interventional,,,A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults,"A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-64) Adults",Completed,,Phase 2,500.0,Actual,Novavax,,5.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 06:12:20,2023-06-17 06:12:20,INDUSTRY,,,,,
75232,75233,NCT00374998,,2006-09-10,,,2007-02-28,2006-09-10,2006-09-12,Estimate,,,,,,,2007-02-28,2007-03-01,Estimate,April 2006,,2006-04-30,February 2007,2007-02-28,January 2007,,2007-01-31,,,,,Interventional,,,Safety and Immunogenicity Study of the Malaria Vaccines FP9 PP and MVA PP,A Phase I Study to Assess the Safety and Immunogenicity of the Polyprotein Malaria Vaccine Candidates FP9 PP and MVA PP in Healthy Adults Using a Prime-Boost Delivery Schedule,Completed,,Phase 1,35.0,,European Malaria Vaccine Initiative,,,,,False,,,,,,,,,,,,,,,,,2023-06-14 02:32:05,2023-06-14 02:32:05,OTHER,,,,,
75268,75269,NCT02140138,,2014-04-07,,,2016-06-10,2014-05-15,2014-05-16,Estimate,,,,,,,2016-06-10,2016-06-13,Estimate,June 2014,,2014-06-30,June 2016,2016-06-30,April 2016,Actual,2016-04-30,April 2016,Actual,2016-04-30,,Interventional,,,An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer,An Open Label Randomised Phase II Trial of RNActive® Cancer Vaccine (CV9104) in High Risk and Intermediate Risk Patients With Prostate Cancer,Terminated,,Phase 2,35.0,Actual,CureVac,,3.0,,Recruitment was terminated after enrolment of 35 instead of 36 evaluable patients for administrative reasons.,False,,,,False,,,,,,,,,,,,,2023-06-17 06:13:00,2023-06-17 06:13:00,INDUSTRY,,,,,
75287,75288,NCT03549208,,2018-05-25,,,2018-06-11,2018-05-25,2018-06-07,Actual,,,,,,,2018-06-11,2018-06-13,Actual,"July 1, 2018",Anticipated,2018-07-01,May 2018,2018-05-31,"July 25, 2019",Anticipated,2019-07-25,"April 1, 2019",Anticipated,2019-04-01,,Interventional,,,A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults,"Single-blind, Single-center, Randomized, Active-controlled, Parallel Group, Phase I Study to Evaluate the Safety and Immunogenicity of Intramuscular Single Injection With Pneumococcal Conjugate Vaccine or Prevnar13 in Healthy Adults",Unknown status,Not yet recruiting,Phase 1,60.0,Anticipated,LG Chem,,3.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-17 06:13:15,2023-06-17 06:13:15,INDUSTRY,,,,,
75695,75696,NCT02140996,,2014-05-08,,,2016-10-12,2014-05-14,2014-05-16,Estimate,,,,,,,2016-10-12,2016-10-14,Estimate,September 2014,,2014-09-30,October 2016,2016-10-31,June 2017,Anticipated,2017-06-30,March 2017,Anticipated,2017-03-31,,Interventional,MUC-1,,Safety Study of Human MUC-1 (Mucin-1) Adenoviral Vector Vaccine for Immunotherapy of Epithelial Cancers,Ad-sig-hMUC-1/ecdCD40L Vector Vaccine for Immunotherapy of Epithelial Cancers,Unknown status,Recruiting,Phase 1,24.0,Anticipated,Singapore Clinical Research Institute,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 06:17:02,2023-06-17 06:17:02,OTHER,,,,,
75739,75740,NCT02148328,,2014-05-23,,,2014-10-23,2014-05-23,2014-05-28,Estimate,,,,,,,2014-10-23,2014-10-24,Estimate,May 2014,,2014-05-31,October 2014,2014-10-31,October 2014,Actual,2014-10-31,October 2014,Actual,2014-10-31,,Interventional,,,"Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults","A Phase 1, Double-blind, Active-controlled, Randomized Study in Healthy Adults to Evaluate Safety, Tolerability, and Immunogenicity of a Trivalent and Quadrivalent Cell-based Virosomal Subunit Influenza Vaccine",Completed,,Phase 1,240.0,Actual,Crucell Holland BV,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 06:17:27,2023-06-17 06:17:27,INDUSTRY,,,,,
75742,75743,NCT05456165,,2022-07-08,,,2022-11-21,2022-07-08,2022-07-13,Actual,,,,,,,2022-11-21,2022-11-25,Actual,"May 19, 2022",Actual,2022-05-19,November 2022,2022-11-30,"September 1, 2022",Actual,2022-09-01,"September 1, 2022",Actual,2022-09-01,,Interventional,,,Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer,"A Randomized, Open-Label, Phase 2 Study of a Patient-Specific Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer With Minimal Residual Disease Following Surgical Resection and Standard Adjuvant Chemotherapy",Terminated,,Phase 2,1.0,Actual,"Gritstone bio, Inc.",,2.0,,terminated due to reprioritization,False,,,,False,True,False,,,,,,,,,,,2023-06-18 06:59:38,2023-06-18 06:59:38,INDUSTRY,,,,,
75790,75791,NCT02775942,,2016-05-05,,,2017-06-28,2016-05-15,2016-05-18,Estimate,,,,,,,2017-06-28,2017-06-29,Actual,November 2015,,2015-11-30,May 2016,2016-05-31,"October 31, 2016",Actual,2016-10-31,"July 25, 2016",Actual,2016-07-25,,Interventional,,,Safety and Immunogenicity of IPOVAC in Young Children,Safety and Immunogenicity of an Inactivated Poliomyelitis Vaccine (IPOVAC) in Vietnamese Children,Completed,,Phase 2,240.0,Actual,"National Institute of Hygiene and Epidemiology, Vietnam",,4.0,,,False,,,,True,,,,,,,,,,,No,"Individual data with identification removed are to be available for Ethical committee, Ministry of Health and National Foundation of Science and Technology Development to avoid misuse of data.

Public shared data will be in the form of summarised tables and figures.",2023-06-16 03:25:06,2023-06-16 03:25:06,OTHER,,,,,
75873,75874,NCT02153320,,2014-05-22,,,2017-05-24,2014-05-29,2014-06-03,Estimate,,,,,,,2017-05-24,2017-05-30,Actual,"September 5, 2005",Actual,2005-09-05,May 2017,2017-05-31,"October 28, 2005",Actual,2005-10-28,"October 28, 2005",Actual,2005-10-28,,Interventional,,,Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers,A Long-term Follow-up of a Phase I/II Study to Compare the Persistence and to Perform in Depth Characterisation of the Cellular and Humoral Immune Response Following Vaccinations With GSK Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers,Completed,,Phase 1,93.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 06:18:43,2023-06-17 06:18:43,INDUSTRY,,,,,
76039,76040,NCT03729219,,2017-10-16,,,2019-11-06,2018-11-01,2018-11-02,Actual,,,,,,,2019-11-06,2019-11-08,Actual,"June 12, 2017",Actual,2017-06-12,November 2019,2019-11-30,"April 15, 2019",Actual,2019-04-15,"April 15, 2019",Actual,2019-04-15,,Interventional,,,Prevention of Diarrheal Disease Due to Infection With Enterotoxigenic E. Coli (ETEC),"A Randomized, Placebo-controlled Phase II b(OEV 123) Study to Evaluate Safety, Immunogenicity, Diagnostic Methodology, and Estimate Vaccine Efficacy of an Oral Enterotoxigenic Escherichia Coli(ETEC) Vaccine(ETVAX) for Prevention of Clinically Significant ETEC Diarrhea in Healthy Adult Travelers Visiting West Africa",Completed,,Phase 2,749.0,Actual,Scandinavian Biopharma AB,,2.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-17 06:20:35,2023-06-17 06:20:35,INDUSTRY,,,,,
76196,76197,NCT04227210,,2020-01-06,,,2020-09-13,2020-01-09,2020-01-13,Actual,,,,,,,2020-09-13,2020-09-16,Actual,"January 14, 2020",Actual,2020-01-14,September 2020,2020-09-30,"August 27, 2020",Actual,2020-08-27,"August 27, 2020",Actual,2020-08-27,,Interventional,,,Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults,A Phase 1 Study to Evaluate the Safety and Immunogenicity of an Intranasal Live Attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Adults,Completed,,Phase 1,20.0,Actual,"Meissa Vaccines, Inc.",,2.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-16 03:25:30,2023-06-16 03:25:30,INDUSTRY,,,,,
76685,76686,NCT02178748,,2014-06-03,,,2015-01-29,2014-06-27,2014-07-01,Estimate,,,,,,,2015-01-29,2015-01-30,Estimate,June 2014,,2014-06-30,January 2015,2015-01-31,January 2015,Actual,2015-01-31,January 2015,Actual,2015-01-31,,Interventional,TB036,,Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African Adolescents,"A Phase II Open Label Trial to Investigate the Effect of Schistosoma Mansoni (Sm) Infection on the Immunogenicity of a Candidate TB Vaccine, MVA85A, in BCG-vaccinated African Adolescents",Completed,,Phase 2,36.0,Actual,University of Oxford,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 06:28:07,2023-06-17 06:28:07,OTHER,,,,,
76819,76820,NCT00992719,,2009-10-08,2012-01-19,,2013-08-01,2009-10-08,2009-10-09,Estimate,2012-02-02,2012-03-05,Estimate,,,,2013-08-01,2013-08-07,Estimate,November 2009,,2009-11-30,July 2010,2010-07-31,February 2011,Actual,2011-02-28,February 2011,Actual,2011-02-28,,Interventional,,,Novartis H1N1 Vaccine in Pregnant Women,A Phase II Study In Pregnant Women to Assess the Safety and Immunogenicity of an Unadjuvanted Novartis H1N1 Inactivated Influenza Vaccine Administered at Two Dose Levels,Completed,,Phase 2,84.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 02:34:29,2023-06-14 02:34:29,NIH,,,,,
76837,76838,NCT02177734,,2014-06-19,,,2016-06-16,2014-06-26,2014-06-30,Estimate,,,,,,,2016-06-16,2016-06-20,Estimate,March 2016,,2016-03-31,June 2016,2016-06-30,May 2017,Anticipated,2017-05-31,June 2016,Anticipated,2016-06-30,,Interventional,,,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age,An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A Administered in Adults 18 to 60 Years of Age,Withdrawn,,Phase 1,0.0,Actual,GlaxoSmithKline,,6.0,,The study was cancelled for scientifically legitimate reasons not related to safety or efficacy of the vaccine.,False,,,,,,,,,,,,,,,,,2023-06-17 06:29:31,2023-06-17 06:29:31,INDUSTRY,,,,,
76845,76846,NCT02181088,,2014-07-01,,,2015-12-02,2014-07-01,2014-07-03,Estimate,,,,,,,2015-12-02,2015-12-03,Estimate,August 2014,,2014-08-31,December 2015,2015-12-31,October 2015,Actual,2015-10-31,October 2015,Actual,2015-10-31,,Interventional,,,A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5,A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5,Completed,,Phase 1,26.0,Actual,University of Oxford,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 06:29:35,2023-06-17 06:29:35,OTHER,,,,,
76995,76996,NCT02186626,,2014-07-08,,,2017-01-31,2014-07-08,2014-07-10,Estimate,,,,,,,2017-01-31,2017-02-01,Estimate,February 2014,,2014-02-28,January 2017,2017-01-31,July 2016,Actual,2016-07-31,July 2016,Actual,2016-07-31,,Interventional,,,Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age,"Phase 1 Study of the Safety and Immunogenicity of a 2-Dose Regimen of West Nile/Dengue 4-3´<U+0394>30 Chimeric Virus Vaccine (WN/DEN4<U+0394>30), a Live Attenuated Vaccine for West Nile Encephalitis, in Flavivirus-naïve Adults 50-65 Years of Age",Completed,,Phase 1,28.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 06:31:03,2023-06-17 06:31:03,NIH,,,,,
77214,77215,NCT01084343,,2010-03-09,,,2012-07-12,2010-03-09,2010-03-10,Estimate,,,,,,,2012-07-12,2012-07-13,Estimate,November 2009,,2009-11-30,October 2009,2009-10-31,September 2010,Actual,2010-09-30,September 2010,Actual,2010-09-30,,Interventional,,,Investigation of the Safety of an HIV-1 Vaccine Given Intra-muscularly and Intra-nasally to Healthy Female Subjects,"A Dose Escalating Phase I Study, Double-blind, Randomized, Placebo-controlled for Examining the Safety and Tolerability to a Prophylactic HIV-1 Vaccine Called MYM-V101, Administered i.m. in Combination With i.n. Administrations to Healthy Female Subjects.",Completed,,Phase 1,24.0,Actual,Mymetics Corporation,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 06:32:50,2023-06-17 06:32:50,INDUSTRY,,,,,
77333,77334,NCT02203864,,2014-07-29,,,2014-07-30,2014-07-29,2014-07-30,Estimate,,,,,,,2014-07-30,2014-07-31,Estimate,August 1998,,1998-08-31,July 2014,2014-07-31,,,,February 2001,Actual,2001-02-28,,Interventional,,,Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma,"An Open-label, Multicenter, Controlled, Combined Parallel Group and Dose Escalation (0, 0.12, 1.2, 12.0 µg IL-2/10**8 Cells/24 Hours) Study, to Evaluate the Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 Containing Melanoma Cells Transfected With the Human IL-2 Gene in Patients With Advanced Malignant Melanoma",Completed,,Phase 1,49.0,Actual,Boehringer Ingelheim,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 06:33:54,2023-06-17 06:33:54,INDUSTRY,,,,,
77363,77364,NCT05238454,,2022-02-11,,,2022-02-14,2022-02-11,2022-02-14,Actual,,,,,,,2022-02-14,2022-03-02,Actual,"March 20, 2022",Anticipated,2022-03-20,February 2022,2022-02-28,"December 1, 2022",Anticipated,2022-12-01,"July 1, 2022",Anticipated,2022-07-01,,Interventional,,,A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged =18 Years and Previously Fully Vaccinated With COVID-19 Vaccine,"A Randomized, Double-blind, Positive-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C (A Bivalent SARS-CoV-2 Trimeric Spike Protein Vaccine) in Population Aged =18 Years Previously Fully Vaccinated With Either Inactivated or mRNA COVID-19 Vaccine or Previously Diagnosed With COVID-19",Not yet recruiting,,Phase 2,600.0,Anticipated,Sinocelltech Ltd.,,4.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-17 06:34:12,2023-06-17 06:34:12,INDUSTRY,,,,,
77513,77514,NCT02231866,,2014-09-03,,,2018-07-03,2014-09-03,2014-09-04,Estimate,,,,,,,2018-07-03,2018-07-05,Actual,"August 27, 2014",,2014-08-27,"April 5, 2017",2017-04-05,"April 5, 2017",Actual,2017-04-05,"April 5, 2017",Actual,2017-04-05,,Interventional,,,"Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults","VRC 207: A Phase I/1b, Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccines, VRC-EBOADC069-00-VP (cAd3-EBO) and VRC-EBOADC076-00-VP (cAd3-EBOZ), in Healthy Adults",Completed,,Phase 1,143.0,Actual,National Institutes of Health Clinical Center (CC),,6.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 06:35:39,2023-06-17 06:35:39,NIH,,,,,
77542,77543,NCT04453852,,2020-06-03,,,2022-02-12,2020-06-30,2020-07-01,Actual,,,,,,,2022-02-12,2022-03-02,Actual,"June 30, 2020",Actual,2020-06-30,February 2022,2022-02-28,"April 14, 2021",Actual,2021-04-14,"February 1, 2021",Actual,2021-02-01,,Interventional,COVAX19,,Monovalent Recombinant COVID19 Vaccine,"A Randomised, Controlled, Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult Subjects",Completed,,Phase 1,40.0,Actual,Vaxine Pty Ltd,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-17 06:35:58,2023-06-17 06:35:58,INDUSTRY,,,,,
77640,77641,NCT01081847,,2010-03-03,,,2010-03-05,2010-03-04,2010-03-05,Estimate,,,,,,,2010-03-05,2010-03-08,Estimate,July 2005,,2005-07-31,March 2010,2010-03-31,April 2006,Actual,2006-04-30,March 2006,Actual,2006-03-31,,Interventional,Fase1B,,Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants,Malaria Vaccine Phase IB Clinical Trial: Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants,Completed,,Phase 1,40.0,Actual,Malaria Vaccine and Drug Development Center,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 06:37:10,2023-06-17 06:37:10,OTHER,,,,,
77724,77725,NCT03992872,,2019-06-18,,2021-12-15,2022-01-04,2019-06-18,2019-06-20,Actual,,,,2022-01-04,2022-01-06,Actual,2022-01-04,2022-01-06,Actual,"November 20, 2019",Actual,2019-11-20,January 2022,2022-01-31,"January 19, 2021",Actual,2021-01-19,"January 19, 2021",Actual,2021-01-19,,Interventional,WRAIR,,Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317),A Phase 2 Open-label Study to Assess the Safety and Immunogenicity of an Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) in Prior Recipients of Other Alphavirus Vaccines Versus Alphavirus Naïve Controls.,Completed,,Phase 2,60.0,Actual,Emergent BioSolutions,,2.0,,,False,,,,,True,False,,,,,,,,,No,,2023-06-17 06:37:46,2023-06-17 06:37:46,INDUSTRY,,,,,
77800,77801,NCT01086449,,2010-03-04,,,2018-03-08,2010-03-11,2010-03-15,Estimate,,,,,,,2018-03-08,2018-03-09,Actual,"March 4, 2010",Actual,2010-03-04,March 2018,2018-03-31,"November 25, 2010",Actual,2010-11-25,"June 25, 2010",Actual,2010-06-25,,Interventional,,,Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults,Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults,Completed,,Phase 1,20.0,Actual,GlaxoSmithKline,,1.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-17 06:38:43,2023-06-17 06:38:43,INDUSTRY,,,,,
77862,77863,NCT02233816,,2014-09-04,,,2019-11-11,2014-09-04,2014-09-08,Estimate,,,,,,,2019-11-11,2019-11-13,Actual,"July 28, 2014",Actual,2014-07-28,November 2019,2019-11-30,"June 22, 2015",Actual,2015-06-22,"June 22, 2015",Actual,2015-06-22,,Interventional,,,"Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults","Immunogenicity, Safety, and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults",Completed,,Phase 2,300.0,Actual,Medicago,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 06:39:26,2023-06-17 06:39:26,INDUSTRY,,,,,
77933,77934,NCT01094405,,2010-03-26,,,2021-07-26,2010-03-26,2010-03-29,Estimate,,,,,,,2021-07-26,2021-07-28,Actual,"March 31, 2010",Actual,2010-03-31,July 2021,2021-07-31,"August 27, 2020",Actual,2020-08-27,"August 27, 2020",Actual,2020-08-27,,Interventional,,,Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy,Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy,Completed,,Phase 2,25.0,Actual,Chinese University of Hong Kong,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 06:40:03,2023-06-17 06:40:03,OTHER,,,,,
78066,78067,NCT00633074,,2008-02-29,2012-04-26,2009-05-20,2018-05-09,2008-03-10,2008-03-11,Estimate,2012-04-26,2012-05-28,Estimate,2009-05-21,2009-09-30,Estimate,2018-05-09,2018-06-08,Actual,"March 3, 2008",,2008-03-03,November 2016,2016-11-30,"April 11, 2008",Actual,2008-04-11,"April 11, 2008",Actual,2008-04-11,,Interventional,,,Non-inferiority Study of GSK Biologicals' Influenza Vaccine GSK576389A Using Different Formulations,Non-inferiority Study of GlaxoSmithKline Biologicals' Influenza Vaccine GSK576389A Using Different Formulations.,Completed,,Phase 2,720.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-14 02:38:11,2023-06-14 02:38:11,INDUSTRY,,,,,
78079,78080,NCT04447898,,2020-05-04,,,2022-04-25,2020-06-23,2020-06-25,Actual,,,,,,,2022-04-25,2022-04-26,Actual,"February 18, 2021",Actual,2021-02-18,April 2022,2022-04-30,"February 28, 2023",Anticipated,2023-02-28,"February 28, 2023",Anticipated,2023-02-28,,Interventional,,,Dose Escalation Study Assessing the Safety and Immune Response of PPV-06 Vaccine,"A Randomized, Double-blind, Placebo-controlled, Dose Escalation Phase I Study Assessing the Safety and Immune Response of PPV-06 Vaccine in Patient With Inflammatory Knee Osteoarthritis (KOA)",Recruiting,,Phase 1,24.0,Anticipated,Peptinov SAS,,2.0,,,False,,,,False,False,False,,,,,,,,,Undecided,,2023-06-14 02:38:18,2023-06-14 02:38:18,INDUSTRY,,,,,
78082,78083,NCT01092611,,2010-03-22,,,2018-03-01,2010-03-23,2010-03-25,Estimate,,,,,,,2018-03-01,2018-03-02,Actual,"March 22, 2010",Actual,2010-03-22,March 2018,2018-03-31,"May 19, 2014",Actual,2014-05-19,"March 17, 2014",Actual,2014-03-17,,Interventional,,,Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine,Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462,Completed,,Phase 1,190.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 06:41:29,2023-06-17 06:41:29,INDUSTRY,,,,,
78221,78222,NCT01304524,,2011-02-16,,2018-05-23,2018-09-05,2011-02-24,2011-02-25,Estimate,,,,2018-05-23,2018-05-25,Actual,2018-09-05,2018-09-07,Actual,April 2011,,2011-04-30,September 2018,2018-09-30,April 2015,Actual,2015-04-30,May 2014,Actual,2014-05-31,,Interventional,HPV-003,,A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3,"Phase II Placebo Controlled Study of VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA Vaccine) Delivered IM Followed by Electroporation With CELLECTRA-5P for the Treatment of Biopsy-proven CIN 2/3 or CIN 3 With Documented HPV 16 or 18.",Completed,,Phase 2,167.0,Actual,Inovio Pharmaceuticals,,2.0,,,False,,,,True,True,True,True,,,,,,,,,,2023-06-17 06:42:44,2023-06-17 06:42:44,INDUSTRY,,,,,
78383,78384,NCT02771730,,2016-05-05,,,2018-07-03,2016-05-10,2016-05-13,Estimate,,,,,,,2018-07-03,2018-07-05,Actual,March 2015,,2015-03-31,July 2018,2018-07-31,February 2019,Anticipated,2019-02-28,November 2015,Actual,2015-11-30,,Interventional,,,"Study to Evaluate the Safety and Immunogenicity of Orally-administered HIV Vaccine in Healthy, HIV-uninfected Adult Participants","A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Orally-administered Replication-competent Adenovirus Type-4 HIV Vaccine Regimens in Combination With an AIDSVAX® B/E Boost in Healthy, HIV-uninfected Adult Participants",Unknown status,"Active, not recruiting",Phase 1,60.0,Anticipated,Emergent BioSolutions,,5.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-16 03:27:09,2023-06-16 03:27:09,INDUSTRY,,,,,
78507,78508,NCT00985790,,2009-09-24,2012-11-28,2010-07-02,2018-08-22,2009-09-24,2009-09-28,Estimate,2013-02-07,2013-03-12,Estimate,2010-07-02,2010-07-07,Estimate,2018-08-22,2018-09-21,Actual,"October 8, 2009",,2009-10-08,September 2016,2016-09-30,"May 21, 2010",Actual,2010-05-21,"May 21, 2010",Actual,2010-05-21,,Interventional,,,Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine in Healthy Children,Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine GSK2321138A in Healthy Children,Completed,,Phase 2,599.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-14 02:40:33,2023-06-14 02:40:33,INDUSTRY,,,,,
78645,78646,NCT01122784,,2010-05-07,,2013-08-14,2020-07-28,2010-05-11,2010-05-13,Estimate,,,,2013-08-14,2013-08-22,Estimate,2020-07-28,2020-07-30,Actual,July 2010,,2010-07-31,July 2020,2020-07-31,July 2012,Actual,2012-07-31,May 2012,Actual,2012-05-31,,Interventional,,,Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant,"A Phase 2b Randomized, Single-Blinded Study to Evaluate the Safety and Immunogenicity of 80 µg Recombinant Plague Vaccine (rF1V) With and Without Adjuvant at Two Vaccination Schedules in Healthy Adult Volunteers",Completed,,Phase 2,402.0,Actual,"DynPort Vaccine Company LLC, A GDIT Company",,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 06:45:49,2023-06-17 06:45:49,INDUSTRY,,,,,
78768,78769,NCT00866476,,2009-03-19,,2017-04-20,2021-04-27,2009-03-19,2009-03-20,Estimate,,,,2017-04-20,2017-04-21,Actual,2021-04-27,2021-04-29,Actual,January 2010,,2010-01-31,April 2021,2021-04-30,February 2010,Actual,2010-02-28,February 2010,Actual,2010-02-28,,Interventional,,,"Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa","Safety, Immunogenicity, and Efficacy Following Experimental Challenge of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set Shigella Flexneri 2a Live, Oral Vaccine: Phase IIa Vaccination Study",Terminated,,Phase 2,20.0,Actual,"University of Maryland, Baltimore",,2.0,,Reactogenicity met study halting criteria,False,,,,True,,,,,,,,,,,,,2023-06-17 06:46:45,2023-06-17 06:46:45,OTHER,,,,,
78771,78772,NCT00866242,,2009-03-19,,2017-04-20,2021-04-27,2009-03-19,2009-03-20,Estimate,,,,2017-04-20,2017-04-21,Actual,2021-04-27,2021-04-29,Actual,January 2010,,2010-01-31,April 2021,2021-04-30,February 2010,Actual,2010-02-28,February 2010,Actual,2010-02-28,,Interventional,,,"Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIb","Safety, Immunogenicity, and Efficacy Following Experimental Challenge of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set Shigella Flexneri 2a Live, Oral Vaccine: Phase IIb Challenge Study",Terminated,,Phase 2,20.0,Actual,"University of Maryland, Baltimore",,1.0,,Reactogenicity met study halting criteria,False,,,,True,,,,,,,,,,,,,2023-06-17 06:46:46,2023-06-17 06:46:46,OTHER,,,,,
79003,79004,NCT00390338,,2006-10-18,,,2017-09-25,2006-10-18,2006-10-19,Estimate,,,,,,,2017-09-25,2017-09-26,Actual,October 2006,,2006-10-31,September 2017,2017-09-30,January 2015,Actual,2015-01-31,May 2012,Actual,2012-05-31,,Interventional,,,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,Phase I Evaluation of Alpha-Type-1 DC-Based and cDC-Based Intralymphatic Vaccines in Patients With Metastatic Melanoma,Completed,,Phase 1,22.0,Actual,University of Pittsburgh,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 03:47:20,2023-06-15 03:47:20,OTHER,,,,,
79034,79035,NCT00082069,,2004-04-28,,,2015-04-28,2004-04-29,2004-04-30,Estimate,,,,,,,2015-04-28,2015-04-30,Estimate,April 2004,,2004-04-30,April 2015,2015-04-30,November 2006,Actual,2006-11-30,November 2006,Actual,2006-11-30,,Interventional,,,Invaplex 50 Vaccine Dose-Ranging,Safety and Immunogenicity Study of an Intranasal Shigella Flexneri 2a Invaplex 50 Vaccine,Completed,,Phase 1,32.0,Actual,U.S. Army Medical Research and Development Command,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 03:47:27,2023-06-15 03:47:27,FED,,,,,
79289,79290,NCT03162614,,2017-05-15,2019-07-01,,2020-10-05,2017-05-18,2017-05-22,Actual,2019-07-01,2019-07-24,Actual,,,,2020-10-05,2020-10-27,Actual,"May 24, 2017",Actual,2017-05-24,October 2020,2020-10-31,"September 24, 2018",Actual,2018-09-24,"July 9, 2018",Actual,2018-07-09,,Interventional,,,"Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults","Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Various Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults",Completed,,Phase 2,154.0,Actual,GlaxoSmithKline,,6.0,,,False,,,,,True,False,,,,,,IPD is available via the Clinical Study Data Request site (copy the URL below to your browser),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://www.clinicalstudydatarequest.com/Posting.aspx?ID=20719,Yes,IPD for this study is available via the Clinical Study Data Request site.,2023-06-17 06:50:00,2023-06-17 06:50:00,INDUSTRY,,,,,
79340,79341,NCT00137917,,2005-08-26,,,2016-09-15,2005-08-26,2005-08-30,Estimate,,,,,,,2016-09-15,2016-09-16,Estimate,July 2002,,2002-07-31,September 2016,2016-09-30,June 2003,Actual,2003-06-30,June 2003,Actual,2003-06-30,,Interventional,,,Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs,"A Primary Vaccination Study to Evaluate Immunogenicity, Safety and Reactogenicity of 3 Doses of GSK Biologicals/Finlay's Meningococcal B Candidate Vaccine Given Intramuscularly Using Either 0-2-4 Month or 0-1-6 Month Schedule to Healthy Subjects Aged 12-18 Years",Completed,,Phase 2,478.0,Actual,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 03:49:26,2023-06-15 03:49:26,INDUSTRY,,,,,
79588,79589,NCT00003895,,1999-11-01,2015-04-28,,2016-12-28,2003-07-17,2003-07-18,Estimate,2016-12-28,2017-02-20,Actual,,,,2016-12-28,2017-02-20,Actual,April 1999,,1999-04-30,December 2016,2016-12-31,September 2013,Actual,2013-09-30,September 2013,Actual,2013-09-30,,Interventional,,,Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma,A Randomized Phase II Trial to Determine the Immune Response to a Mutated gp100 Melanoma Peptide (209-2M) Vaccine in HLA-A2 Positive Patients With a &gt;1mm Melanoma on Initial Biopsy,Completed,,Phase 2,36.0,Actual,National Cancer Institute (NCI),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 06:52:59,2023-06-17 06:52:59,NIH,,,,,
79735,79736,NCT00393276,,2006-10-25,,,2021-10-28,2006-10-25,2006-10-27,Estimate,,,,,,,2021-10-28,2021-11-01,Actual,August 2007,,2007-08-31,October 2021,2021-10-31,July 2009,Actual,2009-07-31,July 2009,Actual,2009-07-31,,Interventional,,,Determining Responses to Two Different Vaccines in HIV and HCV Infected Individuals,Optimizing Vaccine Responsiveness in HIV-1 and HCV Infections by Identifying Determinants of Responsiveness: A Pilot Study,Completed,,Phase 1,29.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 03:51:49,2023-06-15 03:51:49,NIH,,,,,
80019,80020,NCT00885157,,2009-04-20,,,2014-01-20,2009-04-20,2009-04-21,Estimate,,,,,,,2014-01-20,2014-01-22,Estimate,April 2009,,2009-04-30,January 2014,2014-01-31,December 2009,Actual,2009-12-31,October 2009,Actual,2009-10-31,,Interventional,,,Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose Intramuscularly,Immunogenicity and Safety of Fractional Booster Dose of Sanofi Pasteur's Inactivated Poliomyelitis Vaccine (IMOVAX Polio) Administered Intradermally Versus Full Booster Dose of Inactivated Poliomyelitis Vaccine (IMOVAX Polio) Administered Intramuscularly at 15 to 18 Months of Age in Healthy Toddlers in The Philippines,Completed,,Phase 2,225.0,Actual,Sanofi,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 03:28:22,2023-06-16 03:28:22,INDUSTRY,,,,,
80071,80072,NCT05215327,,2022-01-18,,,2022-11-18,2022-01-18,2022-01-31,Actual,,,,,,,2022-11-18,2022-11-23,Actual,"November 7, 2022",Actual,2022-11-07,November 2022,2022-11-30,December 2027,Anticipated,2027-12-31,July 2027,Anticipated,2027-07-31,,Interventional,,,High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients,Comparison of High Dose vs. Standard Dose Influenza Vaccines in Lung Allograft Recipients,Recruiting,,Phase 2,270.0,Anticipated,Vanderbilt University Medical Center,,2.0,,,False,,,,True,True,False,,,True,,,,,,No,,2023-06-17 06:56:12,2023-06-17 06:56:12,OTHER,,,,,
80253,80254,NCT02281396,,2014-10-30,,,2016-01-19,2014-10-31,2014-11-02,Estimate,,,,,,,2016-01-19,2016-01-20,Estimate,November 2014,,2014-11-30,October 2014,2014-10-31,May 2015,Actual,2015-05-31,January 2015,Actual,2015-01-31,,Interventional,,,The Safety Research of Freeze-dried Rabies Vaccine(MRC-5 Cell) in Chinese Humans,A Safety Study of Freeze-dried Rabies Vaccine(MRC-5 Cell)in Chinese Humans From 10-60 Years Old,Completed,,Phase 1,40.0,Actual,Beijing Center for Disease Control and Prevention,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 06:57:22,2023-06-17 06:57:22,OTHER_GOV,,,,,
80473,80474,NCT01341704,,2011-04-23,,,2015-08-27,2011-04-25,2011-04-26,Estimate,,,,,,,2015-08-27,2015-08-31,Estimate,May 2011,,2011-05-31,August 2015,2015-08-31,March 2013,Actual,2013-03-31,December 2011,Actual,2011-12-31,,Interventional,MSP3-POC,,Proof-of-Concept Study of MSP3-LSP Vaccine to Protect Against Malaria in Africa,"Phase 2B Double Blind, Randomized, Controlled Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of MSP3-LSP Vaccine Candidate Adjuvanted in Aluminium Hydroxide (AIOH) Against Plasmodium Falciparum Clinical Malaria in Healthy Children Aged 12-48 Months in Mali",Completed,,Phase 2,800.0,Actual,Vac4All,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 06:59:16,2023-06-17 06:59:16,INDUSTRY,,,,,
80479,80480,NCT00892567,,2009-04-30,,,2016-12-15,2009-05-01,2009-05-04,Estimate,,,,,,,2016-12-15,2016-12-16,Estimate,May 2009,,2009-05-31,December 2016,2016-12-31,February 2012,Actual,2012-02-29,December 2011,Actual,2011-12-31,,Interventional,Breast 37,,Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer,Evaluation of CD8+ T Cell Activation and Infiltration Into Primary Breast Tumors Following Administration of a Peptide Vaccine,Completed,,Phase 1,9.0,Actual,University of Virginia,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 03:28:48,2023-06-16 03:28:48,OTHER,,,,,
80529,80530,NCT01465035,,2011-10-21,,,2012-11-28,2011-11-01,2011-11-04,Estimate,,,,,,,2012-11-28,2012-11-29,Estimate,October 2011,,2011-10-31,November 2012,2012-11-30,November 2012,Actual,2012-11-30,November 2012,Actual,2012-11-30,,Interventional,,,A Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NP+M1 and Seasonal Influenza Vaccine,A Phase I Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NP+M1 and Seasonal Influenza Vaccine,Completed,,Phase 1,24.0,Actual,University of Oxford,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 03:56:28,2023-06-15 03:56:28,OTHER,,,,,
80772,80773,NCT00332956,,2006-06-01,,2011-06-29,2011-11-28,2006-06-01,2006-06-02,Estimate,,,,2011-06-29,2011-07-01,Estimate,2011-11-28,2011-12-02,Estimate,May 2006,,2006-05-31,November 2011,2011-11-30,October 2008,Actual,2008-10-31,February 2008,Actual,2008-02-29,,Interventional,,,Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers,"A Phase 2 (a), Dose-Blinded, Block-Randomized, Dose and Schedule Selection Study to Evaluate the Immunogenicity and Safety of the Recombinant Plague Vaccine rF1V in Healthy Volunteers",Completed,,Phase 2,400.0,Actual,"DynPort Vaccine Company LLC, A GDIT Company",,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 07:00:55,2023-06-17 07:00:55,INDUSTRY,,,,,
81459,81460,NCT00021762,,2001-08-04,,,2021-10-28,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-28,2021-11-01,Actual,,,,October 2021,2021-10-31,,,,,,,,Interventional,,,Effects of Immunization With HIV-1 Immunogen Plus Anti-HIV Treatment Interruption on the Levels of HIV,"A Pilot Phase II Evaluation of the Effects on HIV Replication of Immunization With a gp120-Depleted, Inactivated Whole Virus Vaccine Combined With Exposures to Replicating Autologous HIV by Scheduled Treatment Interruptions, a Rollover Study of A5057",Withdrawn,,Phase 2,0.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 05:54:44,2023-06-15 05:54:44,NIH,,,,,
81612,81613,NCT00023634,,2001-09-13,,,2015-03-05,2003-01-26,2003-01-27,Estimate,,,,,,,2015-03-05,2015-03-06,Estimate,June 2001,,2001-06-30,March 2015,2015-03-31,November 2008,Actual,2008-11-30,November 2008,Actual,2008-11-30,,Interventional,,,"S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer",An Early Phase Study of an EGFRvIII Peptide Based Vaccine in Patients With EGFRvIII Expressing Cancers,Terminated,,Phase 1,14.0,Actual,SWOG Cancer Research Network,,2.0,,lack of accrual,False,,,,True,,,,,,,,,,,,,2023-06-15 05:55:51,2023-06-15 05:55:51,NETWORK,,,,,
81750,81751,NCT03145766,,2017-05-03,2021-01-07,2019-01-24,2022-03-30,2017-05-05,2017-05-09,Actual,2021-01-07,2021-01-28,Actual,2019-01-24,2019-01-28,Actual,2022-03-30,2022-04-19,Actual,"April 17, 2017",Actual,2017-04-17,March 2022,2022-03-31,"January 8, 2018",Actual,2018-01-08,"January 8, 2018",Actual,2018-01-08,,Interventional,,Analysis was performed on all randomized participants.,Immunogenicity and Safety of a Purified Vero Rabies Vaccine,Immunogenicity and Safety of a Purified Vero Rabies Vaccine - Serum Free When Administered According to a Simulated Rabies Post-exposure Regimen in Healthy Adults,Completed,,Phase 2,320.0,Actual,Sanofi,,5.0,,,False,,,,False,True,False,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-17 07:07:06,2023-06-17 07:07:06,INDUSTRY,,,,,
81942,81943,NCT00027261,,2001-11-29,,,2021-10-13,2001-11-29,2001-11-30,Estimate,,,,,,,2021-10-13,2021-10-14,Actual,,,,October 2021,2021-10-31,December 2005,Actual,2005-12-31,,,,,Interventional,,,"Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults","A Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of High-Dose Live Recombinant Canarypox ALVAC-HIV Vaccine (vCP1452) in Healthy, HIV-1 Uninfected Adult Participants",Completed,,Phase 1,110.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 05:57:36,2023-06-15 05:57:36,NIH,,,,,
82147,82148,NCT03958799,,2019-05-20,,,2022-04-21,2019-05-20,2019-05-22,Actual,,,,,,,2022-04-21,2022-04-25,Actual,"June 26, 2019",Actual,2019-06-26,April 2022,2022-04-30,"April 6, 2021",Actual,2021-04-06,"April 6, 2021",Actual,2021-04-06,,Interventional,,,A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada,"Safety and Immunogenicity of an Investigational Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Adsorbed (Tdap) Vaccine in Young Adults",Completed,,Phase 1,71.0,Actual,Sanofi,,9.0,,,False,,,,False,False,False,,,False,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-15 05:58:47,2023-06-15 05:58:47,INDUSTRY,,,,,
82238,82239,NCT00030693,,2002-02-14,,,2013-01-23,2003-01-26,2003-01-27,Estimate,,,,,,,2013-01-23,2013-01-24,Estimate,December 2001,,2001-12-31,January 2013,2013-01-31,,,,April 2010,Actual,2010-04-30,,Interventional,,,Vaccine Therapy in Treating Patients With Metastatic Solid Tumors,Intra-Lesional rF-B7.1 Versus rF-Tricom Vaccine In The Treatment Of Metastatic Cancer,Terminated,,Phase 1,42.0,Actual,National Cancer Institute (NCI),,2.0,,Administratively complete.,False,,,,,,,,,,,,,,,,,2023-06-15 05:59:23,2023-06-15 05:59:23,NIH,,,,,
82540,82541,NCT00376402,,2006-09-11,,,2016-07-17,2006-09-13,2006-09-14,Estimate,,,,,,,2016-07-17,2016-07-19,Estimate,October 2006,,2006-10-31,November 2008,2008-11-30,June 2007,,2007-06-30,,,,,Interventional,,,Study of a Pandemic Influenza Vaccine in Elderly Participants,Phase II Study of a Pandemic Influenza Vaccine in Elderly Participants,Completed,,Phase 2,200.0,,Seqirus,,,,,False,,,,,,,,,,,,,,,,,2023-06-14 02:42:44,2023-06-14 02:42:44,INDUSTRY,,,,,
82738,82739,NCT00891007,,2009-04-29,,,2012-07-26,2009-04-29,2009-04-30,Estimate,,,,,,,2012-07-26,2012-07-27,Estimate,June 2009,,2009-06-30,July 2012,2012-07-31,August 2010,Actual,2010-08-31,July 2010,Actual,2010-07-31,,Interventional,,,"Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years","Partially Randomized, Controlled Phase II Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years",Completed,,Phase 2,90.0,Actual,Bavarian Nordic,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 03:30:12,2023-06-16 03:30:12,INDUSTRY,,,,,
82768,82769,NCT02204098,,2014-07-23,,,2023-04-13,2014-07-28,2014-07-30,Estimate,,,,,,,2023-04-13,2023-04-18,Actual,"January 7, 2015",Actual,2015-01-07,April 2023,2023-04-30,"August 31, 2028",Anticipated,2028-08-31,"April 6, 2022",Actual,2022-04-06,,Interventional,,,Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy,"A Phase 1B Clinical Trial to Evaluate the Safety and Immune Response to a Mammaglobin-A DNA Vaccine in ER+, HER2- Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy or Chemotherapy","Active, not recruiting",,Phase 1,27.0,Actual,Washington University School of Medicine,,4.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 07:14:31,2023-06-17 07:14:31,OTHER,,,,,
82796,82797,NCT01129453,,2010-05-21,,,2021-04-27,2010-05-21,2010-05-24,Estimate,,,,,,,2021-04-27,2021-04-30,Actual,May 2010,,2010-05-31,April 2021,2021-04-30,April 2013,Actual,2013-04-30,December 2012,Actual,2012-12-31,,Interventional,,,Safety and Immunogenicity of CVD 1902 Oral Attenuated Vaccine to Prevent S. Paratyphi A Infection,Phase I Trial of a Live Oral Salmonella Enterica Serovar Paratyphi A Vaccine Harboring Mutations in guaBA and clpX,Completed,,Phase 1,51.0,Actual,"University of Maryland, Baltimore",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 07:14:43,2023-06-17 07:14:43,OTHER,,,,,
82840,82841,NCT00034554,,2002-04-30,,,2010-04-08,2002-04-30,2002-05-01,Estimate,,,,,,,2010-04-08,2010-04-09,Estimate,March 2002,,2002-03-31,December 2009,2009-12-31,September 2004,Actual,2004-09-30,September 2004,Actual,2004-09-30,,Interventional,,,Study of gp75 Vaccine in Patients With Stage III and IV Melanoma,Phase I Study of gp75 DNA Vaccine in Patients With AJCC Stage III and IV Melanoma,Completed,,Phase 1,31.0,Actual,Eli Lilly and Company,,5.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 06:01:46,2023-06-15 06:01:46,INDUSTRY,,,,,
83060,83061,NCT00951041,,2009-07-31,2017-04-25,2010-12-23,2018-05-29,2009-07-31,2009-08-04,Estimate,2018-05-29,2018-11-26,Actual,2010-12-23,2010-12-30,Estimate,2018-05-29,2018-11-26,Actual,"August 11, 2009",Actual,2009-08-11,April 2017,2017-04-30,"August 30, 2010",Actual,2010-08-30,"August 30, 2010",Actual,2010-08-30,,Interventional,,,Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults,Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 to 60 Years,Completed,,Phase 2,130.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 03:32:20,2023-06-16 03:32:20,INDUSTRY,,,,,
83334,83335,NCT00900991,,2009-05-12,,,2009-05-13,2009-05-12,2009-05-13,Estimate,,,,,,,2009-05-13,2009-05-14,Estimate,,,,May 2009,2009-05-31,,,,,,,,Interventional,,,Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Children,Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Children,Completed,,Phase 2,,,"Sinovac Biotech Co., Ltd",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 03:34:03,2023-06-16 03:34:03,INDUSTRY,,,,,
83355,83356,NCT05350501,,2022-04-06,,,2023-03-27,2022-04-26,2022-04-28,Actual,,,,,,,2023-03-27,2023-03-29,Actual,March 2023,Anticipated,2023-03-31,March 2023,2023-03-31,January 2028,Anticipated,2028-01-31,June 2025,Anticipated,2025-06-30,,Interventional,CLAUDE,,"EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer","A Phase 2 Trial of EO2040, a miCrobiaL-derived Peptide therApeUtic Vaccine, in Combination With Nivolumab, for Treatment of Patients With Circulating Tumor DNA-dEfined Minimal Residual Disease of Colorectal Cancer Stage II, III, or IV After Completion of Curative Therapy (the ""CLAUDE"" Study)",Recruiting,,Phase 2,34.0,Anticipated,Enterome,,1.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 07:18:07,2023-06-17 07:18:07,INDUSTRY,,,,,
83368,83369,NCT04108845,,2019-09-25,,,2019-09-26,2019-09-26,2019-09-30,Actual,,,,,,,2019-09-26,2019-09-30,Actual,"June 5, 2019",Actual,2019-06-05,September 2019,2019-09-30,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,,Interventional,,,Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in Healthy Volunteers Aged Above 2 Months,"A Single-center, Open, Phase I Clinical Trial to Evaluate Safety of 15-Valent Pneumococcal Conjugate Vaccine in Healthy Volunteers Aged Above 2 Months",Unknown status,Recruiting,Phase 1,80.0,Anticipated,"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd",,1.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-16 03:34:12,2023-06-16 03:34:12,INDUSTRY,,,,,
83528,83529,NCT02751528,,2016-04-11,,,2019-08-23,2016-04-25,2016-04-26,Estimate,,,,,,,2019-08-23,2019-08-28,Actual,December 2016,,2016-12-31,September 2018,2018-09-30,December 2020,Anticipated,2020-12-31,July 2020,Anticipated,2020-07-31,,Interventional,,,"QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer","Phase I Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Low-Expressing (IHC 1+/2+) Breast Cancer",Unknown status,"Active, not recruiting",Phase 1,3.0,Actual,"NantBioScience, Inc.",,1.0,,,False,,,,False,,,,,,,,,,,No,,2023-06-16 03:35:04,2023-06-16 03:35:04,INDUSTRY,,,,,
83628,83629,NCT04894435,,2021-05-18,,,2023-03-27,2021-05-19,2021-05-20,Actual,,,,,,,2023-03-27,2023-03-29,Actual,"May 20, 2021",Actual,2021-05-20,March 2023,2023-03-31,September 2023,Anticipated,2023-09-30,March 2023,Anticipated,2023-03-31,,Interventional,MOSAIC,,Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity,"Immunogenicity and Adverse Events Following Immunization (AEFI) With Alternate Schedules of COVID-19 Vaccines in Canada: is ""Mix and Match"" of the Second Dose (MOSAIC-1;CT24a) and Additional Doses (MOSAIC-2 and MOSAIC-3;CT24b and CT24c) Safe and Immunogenic?","Active, not recruiting",,Phase 2,669.0,Actual,Canadian Immunization Research Network,,28.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-17 07:20:07,2023-06-17 07:20:07,NETWORK,,,,,
83813,83814,NCT01805921,,2013-03-05,,,2016-04-24,2013-03-05,2013-03-06,Estimate,,,,,,,2016-04-24,2016-04-26,Estimate,May 2013,,2013-05-31,April 2016,2016-04-30,August 2015,Actual,2015-08-31,August 2015,Actual,2015-08-31,,Interventional,,,RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections.,"A Phase I Study to Assess Safety and Immunogenicity of a New Respiratory Syncytial Virus (RSV) Vaccine Based on the RSV Viral Proteins F, N and M2-1 Encoded by Simian Adenovirus (PanAd3-RSV) and Modified Vaccinia Virus Ankara (MVA-RSV)",Completed,,Phase 1,72.0,Actual,ReiThera Srl,,9.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 06:02:28,2023-06-15 06:02:28,INDUSTRY,,,,,
83836,83837,NCT00938639,,2009-07-13,2013-07-24,,2018-04-25,2009-07-13,2009-07-14,Estimate,2013-10-28,2013-11-21,Estimate,,,,2018-04-25,2018-06-28,Actual,July 2009,,2009-07-31,April 2018,2018-04-30,March 2010,Actual,2010-03-31,September 2009,Actual,2009-09-30,,Interventional,,,A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults,"A Phase II, Single-centre, Randomised, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's Monovalent H1N1 Influenza Virus Vaccine in Healthy Adults Aged 18 to < 65 Years.",Completed,,Phase 2,240.0,Actual,Seqirus,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 03:36:54,2023-06-16 03:36:54,INDUSTRY,,,,,
84238,84239,NCT04951388,,2021-06-30,,,2022-04-19,2021-07-01,2021-07-06,Actual,,,,,,,2022-04-19,2022-04-20,Actual,"July 22, 2021",Actual,2021-07-22,August 2021,2021-08-31,"March 21, 2022",Actual,2022-03-21,"October 25, 2021",Actual,2021-10-25,,Interventional,,,A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents,"A Phase II, Prospective, Double-blinded, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS CoV 2 Vaccine Candidate MVC COV1901 in Adolescents",Completed,,Phase 2,399.0,Actual,Medigen Vaccine Biologics Corp.,,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-16 03:39:36,2023-06-16 03:39:36,INDUSTRY,,,,,
84295,84296,NCT03031912,,2016-12-22,,,2023-03-27,2017-01-23,2017-01-26,Estimate,,,,,,,2023-03-27,2023-03-29,Actual,"August 1, 2017",Actual,2017-08-01,March 2023,2023-03-31,March 2023,Anticipated,2023-03-31,March 2023,Anticipated,2023-03-31,,Interventional,,,African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola,"A Phase 2 Randomized, Multi-Center Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of the V920 (rVSV<U+0394>G-ZEBOV-GP) Ebola Virus Vaccine Candidate in HIV-Infected Adults and Adolescents","Active, not recruiting",,Phase 2,250.0,Anticipated,Canadian Immunization Research Network,,5.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-17 07:23:55,2023-06-17 07:23:55,NETWORK,,,,,
84430,84431,NCT00036933,,2002-05-13,,,2013-03-22,2003-01-26,2003-01-27,Estimate,,,,,,,2013-03-22,2013-03-25,Estimate,March 2002,,2002-03-31,March 2013,2013-03-31,March 2009,Actual,2009-03-31,March 2009,Actual,2009-03-31,,Interventional,,,Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer,Vaccination Of Prostate Cancer Patients With A Bivalent Vaccine Containing MUC-2 Glycopeptide And Globo H Conjugates Plus The Immunological Adjuvant QS21,Completed,,Phase 1,9.0,Actual,Memorial Sloan Kettering Cancer Center,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 06:03:21,2023-06-15 06:03:21,OTHER,,,,,
84636,84637,NCT00606359,,2008-01-21,,,2014-01-10,2008-01-31,2008-02-01,Estimate,,,,,,,2014-01-10,2014-01-14,Estimate,November 2007,,2007-11-30,January 2014,2014-01-31,June 2008,Actual,2008-06-30,February 2008,Actual,2008-02-29,,Interventional,,,Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects,Immunogenicity of the Inactivated Split-Virion Influenza Vaccine Administered by the Intradermal Route in Renal Transplant Subjects,Completed,,Phase 2,62.0,Actual,Sanofi,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 03:41:50,2023-06-16 03:41:50,INDUSTRY,,,,,
84744,84745,NCT02289196,,2014-10-30,,,2019-06-18,2014-11-12,2014-11-13,Estimate,,,,,,,2019-06-18,2019-06-19,Actual,March 2014,,2014-03-31,June 2019,2019-06-30,May 2017,Actual,2017-05-31,October 2014,Actual,2014-10-31,,Interventional,,,Safety Study of Vx006 Vaccine in Solid Tumor Patients,"A Multicenter, Open Label, Uncontrolled Phase I Trial to Compare Safety, Tolerability and Immunogenicity of Vx-006 Vaccine at 0.5mg, 1mg, 5mg and 10mg Doses in Human Leukocyte Antigen-A02 (HLA-A02) Positive Patients With Solid Tumours",Completed,,Phase 1,23.0,Actual,Vaxon Biotech,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 07:26:46,2023-06-17 07:26:46,INDUSTRY,,,,,
84985,84986,NCT05658614,,2021-11-10,,,2022-12-13,2022-12-13,2022-12-21,Actual,,,,,,,2022-12-13,2022-12-21,Actual,"July 1, 2022",Actual,2022-07-01,December 2022,2022-12-31,"December 31, 2023",Anticipated,2023-12-31,"September 15, 2023",Anticipated,2023-09-15,,Interventional,,,Anti-Schistosomiasis Sm14-vaccine in Senegal,Evaluation of Immunogenicity and Safety of a New Vaccine Schedule Using the Vaccine Candidate Sm14 Against Schistosomiasis in Adults With a History of S. Mansoni and / or S. Haematobium Infection.,Recruiting,,Phase 2,120.0,Anticipated,Oswaldo Cruz Foundation,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-16 03:44:04,2023-06-16 03:44:04,OTHER,,,,,
85184,85185,NCT02742558,,2016-04-07,,,2017-06-15,2016-04-13,2016-04-19,Estimate,,,,,,,2017-06-15,2017-06-16,Actual,April 2016,Actual,2016-04-30,October 2016,2016-10-31,June 2017,Actual,2017-06-30,June 2017,Actual,2017-06-30,,Interventional,,,Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine,A Randomized Observer Blinded Controlled Non Inferiority Trial to Evaluate the Safety and Immunogenicity of Locally Manufactured Inactivated Bivalent Whole Cell-oral Cholera Vaccine (WC-OCV) 'Cholvax' in Bangladeshi Healthy Adults and Children,Completed,,Phase 2,2052.0,Actual,"International Centre for Diarrhoeal Disease Research, Bangladesh",,2.0,,,False,,,,True,,,,,,,,,,,Yes,Data will be shared with International Vaccine Institute,2023-06-16 03:45:33,2023-06-16 03:45:33,OTHER,,,,,
85321,85322,NCT05112848,,2021-10-25,,,2023-03-14,2021-11-03,2021-11-09,Actual,,,,,,,2023-03-14,2023-03-16,Actual,"February 28, 2022",Actual,2022-02-28,March 2023,2023-03-31,"November 30, 2022",Actual,2022-11-30,"May 23, 2022",Actual,2022-05-23,,Interventional,COVID-19,,A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19),"A Phase 2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M Adjuvant in People Living With HIV",Completed,,Phase 2,384.0,Actual,Novavax,,5.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-15 06:19:51,2023-06-15 06:19:51,INDUSTRY,,,,,
85326,85327,NCT00773097,,2008-10-15,2013-07-17,,2019-01-03,2008-10-15,2008-10-16,Estimate,2013-12-13,2014-02-03,Estimate,,,,2019-01-03,2019-01-07,Actual,October 2008,,2008-10-31,January 2019,2019-01-31,October 2012,Actual,2012-10-31,October 2011,Actual,2011-10-31,,Interventional,,A total of 39 subjects completed the 52 weeks of the study.,Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma,Study of the MUC1 Peptide - Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma,Completed,,Phase 2,46.0,Actual,University of Pittsburgh,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 03:46:48,2023-06-16 03:46:48,OTHER,,,,,
85425,85426,NCT00772629,,2008-10-13,2009-03-16,,2014-01-21,2008-10-13,2008-10-15,Estimate,2009-03-16,2009-04-27,Estimate,,,,2014-01-21,2014-02-14,Estimate,January 2004,,2004-01-31,January 2014,2014-01-31,April 2004,Actual,2004-04-30,April 2004,Actual,2004-04-30,,Interventional,,,"Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults","Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults Who Were Either Previously Vaccinated With Unconjugated Meningococcal Polysaccharide (Serogroups A, C or Serogroups A, C, Y, and W-135) Vaccine or Not Vaccinated With Meningococcal Vaccine",Terminated,,Phase 2,18.0,Actual,Sanofi,,2.0,,See detailed description for termination reason,False,,,,False,,,,,,,,,,,,,2023-06-16 03:47:28,2023-06-16 03:47:28,INDUSTRY,,,,,
85691,85692,NCT05786937,,2023-03-14,,,2023-03-14,2023-03-14,2023-03-28,Actual,,,,,,,2023-03-14,2023-03-28,Actual,June 2023,Anticipated,2023-06-30,March 2023,2023-03-31,December 2023,Anticipated,2023-12-31,December 2023,Anticipated,2023-12-31,,Interventional,,,Therapeutic Vaccine Based on aDC1 Dendritic Cells for the Control of Viremia After ATI in HIV Infected Individuals,Therapeutic Vaccine Based on aDC1 Dendritic Cells for the Control of Viremia After Antiretroviral Therapy Interruption in HIV Infected Individuals,Not yet recruiting,,Phase 1,30.0,Anticipated,University of Sao Paulo General Hospital,,3.0,,,False,,,,,False,False,,,,,,,,,No,,2023-06-16 03:49:11,2023-06-16 03:49:11,OTHER,,,,,
86392,86393,NCT03669627,,2018-09-05,,,2023-03-27,2018-09-11,2018-09-13,Actual,,,,,,,2023-03-27,2023-03-28,Actual,"November 1, 2018",Actual,2018-11-01,March 2023,2023-03-31,"July 21, 2021",Actual,2021-07-21,"July 21, 2021",Actual,2021-07-21,,Interventional,,,CT18 Infant Influenza Priming Study in Vaccine Naive Infants,A Randomized Controlled Observer Blind Trial to Compare the Immunogenicity and Acceptability of a MF59-adjuvanted Influenza Vaccine Compared to an Inactivated Influenza Vaccine as a Preferred Influenza Vaccine Priming Strategy for Naive Infants 6 to <24 Months of Age,Completed,,Phase 2,159.0,Actual,Canadian Immunization Research Network,,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-16 03:54:58,2023-06-16 03:54:58,NETWORK,,,,,
86455,86456,NCT03153410,,2017-05-11,,,2023-03-24,2017-05-11,2017-05-15,Actual,,,,,,,2023-03-24,2023-03-28,Actual,"September 27, 2018",Actual,2018-09-27,March 2023,2023-03-31,December 2023,Anticipated,2023-12-31,December 2023,Anticipated,2023-12-31,,Interventional,,,"Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas",A Pilot Study of a GVAX Pancreas Vaccine (With Cyclophosphamide) in Combination With a PD-1 Blockade Antibody (Pembrolizumab) and a Macrophage Targeting Agent (CSF1R Inhibitor) for the Treatment of Patients With Borderline Resectable Adenocarcinoma of the Pancreas,"Active, not recruiting",,Early Phase 1,12.0,Anticipated,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,1.0,,,False,,,,True,True,False,,,,,,,,,Undecided,,2023-06-16 03:55:37,2023-06-16 03:55:37,OTHER,,,,,
86495,86496,NCT01136161,,2010-05-31,,,2013-01-23,2010-06-02,2010-06-03,Estimate,,,,,,,2013-01-23,2013-01-24,Estimate,June 2010,,2010-06-30,January 2013,2013-01-31,May 2011,Actual,2011-05-31,May 2011,Actual,2011-05-31,,Interventional,,,"Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection","Double-Blind, Randomized, Placebo-Controlled Phase II Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection",Completed,,Phase 2,95.0,Actual,Archivel Farma S.L.,,8.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 07:33:54,2023-06-17 07:33:54,INDUSTRY,,,,,
86505,86506,NCT02772003,,2016-04-27,,,2023-03-25,2016-05-12,2016-05-13,Estimate,,,,,,,2023-03-25,2023-03-28,Actual,"June 6, 2016",Actual,2016-06-06,March 2023,2023-03-31,,,,"March 4, 2020",Actual,2020-03-04,,Interventional,,,DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection,Phase I Trial of a Therapeutic DNA Vaccine for Chronic Hepatitis C Virus (HCV) Infection,"Active, not recruiting",,Phase 1,33.0,Actual,National Cancer Institute (NCI),,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 03:55:56,2023-06-16 03:55:56,NIH,,,,,
86694,86695,NCT01139437,,2010-06-07,,,2017-03-31,2010-06-07,2010-06-08,Estimate,,,,,,,2017-03-31,2017-04-04,Actual,June 2010,,2010-06-30,March 2017,2017-03-31,September 2015,Actual,2015-09-30,September 2015,Actual,2015-09-30,,Interventional,,,"Safety of a Live Attenuated Human Parainfluenza Virus Type 2 (HPIV2) Vaccine for Adults, Children, and Infants","A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Human Parainfluenza Type 2 Virus Vaccine, rHPIV2 15C/948L/<U+0394>1724 Lot PIV2#109C, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV2-Seropositive Children 15 to 59 Months of Age, and HPIV2-Seronegative Infants and Children 6 to 59 Months of Age",Completed,,Phase 1,45.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,7.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 07:35:33,2023-06-17 07:35:33,NIH,,,,,
87329,87330,NCT02317900,,2014-12-15,,,2017-01-31,2014-12-15,2014-12-17,Estimate,,,,,,,2017-01-31,2017-02-01,Estimate,December 2014,,2014-12-31,January 2017,2017-01-31,,,,November 2016,Actual,2016-11-30,,Interventional,,,Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults,"A Phase 1 Evaluation of the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With Attenuated DENV-2, rDEN2<U+2206>30-7169",Completed,,Phase 1,48.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 07:39:40,2023-06-17 07:39:40,NIH,,,,,
87410,87411,NCT01317758,,2011-03-16,,,2013-01-17,2011-03-16,2011-03-17,Estimate,,,,,,,2013-01-17,2013-01-18,Estimate,May 2011,,2011-05-31,January 2013,2013-01-31,September 2012,Actual,2012-09-30,September 2012,Actual,2012-09-30,,Interventional,,,H5N1 Mix and Match With AS03,"A Randomized, Double-Blinded, Controlled, Phase I Study in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of Intramuscular Subvirion Inactivated Monovalent Influenza A/H5N1 Virus Vaccine Administered at Different Dose Levels Given With and Without AS03 Adjuvant",Completed,,Phase 1,245.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,6.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 07:40:17,2023-06-17 07:40:17,NIH,,,,,
87543,87544,NCT05905432,,2023-06-07,,,2023-06-07,2023-06-07,2023-06-15,Estimate,,,,,,,2023-06-07,2023-06-15,Estimate,"July 25, 2023",Anticipated,2023-07-25,June 2023,2023-06-30,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2023",Anticipated,2023-12-31,,Interventional,PamTBVac,,Pan-Malaria Transmission-Blocking Vaccine AnAPN1,"A Randomized Double-blinded Phase 1 Clinical Trial to Assess Safety, Tolerability and Reactogenicity of the Pan-Malaria Transmission-Blocking Vaccine AnAPN1 in Healthy Adults Living in Gabon",Not yet recruiting,,Phase 1,33.0,Anticipated,Centre de Recherche Médicale de Lambaréné,,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-16 04:11:48,2023-06-16 04:11:48,OTHER,,,,,
87903,87904,NCT05902624,,2023-04-03,,,2023-06-13,2023-06-10,2023-06-14,Estimate,,,,,,,2023-06-13,2023-06-15,Estimate,"June 10, 2023",Anticipated,2023-06-10,June 2023,2023-06-30,"August 20, 2024",Anticipated,2024-08-20,"May 20, 2024",Anticipated,2024-05-20,,Interventional,,,Efficacy and Safety of Hepatitis B Virus Vaccine(HBV) in Treatment of Cutaneous Warts,Efficacy and Safety of Hepatitis B Virus Vaccine(HBV) in Treatment of Cutaneous Warts,Not yet recruiting,,Early Phase 1,66.0,Anticipated,Assiut University,,3.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-16 04:14:10,2023-06-16 04:14:10,OTHER,,,,,
88468,88469,NCT02269007,,2014-10-16,,,2015-10-11,2014-10-16,2014-10-20,Estimate,,,,,,,2015-10-11,2015-10-14,Estimate,May 2015,,2015-05-31,October 2015,2015-10-31,September 2015,Actual,2015-09-30,July 2015,Actual,2015-07-31,,Interventional,,,A Phase I Clinical Trial for Inactivated Quadrivalent Influenza Vaccine (Split Virion) in Healthy Adults in China,A Phase I Clinical Trial for Inactivated Quadrivalent Influenza Vaccine (Split Virion) in Healthy Adults in China,Completed,,Phase 1,110.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 06:51:28,2023-06-18 06:51:28,NETWORK,,,,,
88594,88595,NCT01376726,,2011-06-16,,,2021-10-13,2011-06-16,2011-06-20,Estimate,,,,,,,2021-10-13,2021-10-15,Actual,July 2011,,2011-07-31,October 2021,2021-10-31,December 2014,Actual,2014-12-31,December 2014,Actual,2014-12-31,,Interventional,,,"Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials","A Phase I Open-Label Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Subtype C gp140 Vaccine With MF59 Adjuvant in Healthy, HIV-1 Uninfected Adult Participants Previously Primed or Unprimed With HIV-1 Subtype B Envelope Subunit Vaccines With MF59",Completed,,Phase 1,36.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 07:50:03,2023-06-17 07:50:03,NIH,,,,,
88829,88830,NCT05592223,,2022-10-13,,,2023-06-13,2022-10-19,2022-10-24,Actual,,,,,,,2023-06-13,2023-06-15,Estimate,"December 6, 2022",Actual,2022-12-06,June 2023,2023-06-30,"November 15, 2023",Anticipated,2023-11-15,"August 22, 2023",Anticipated,2023-08-22,,Interventional,,,Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines,A Phase I Single Site Open Label Clinical Trial for the Development of a Human BCG Challenge Model to Assess TB Drugs and Vaccines.,Suspended,,Phase 1,20.0,Anticipated,Fred Hutchinson Cancer Center,,3.0,,Enrollment temporarily on hold while preparing for part 2 of the study.,False,,,,False,True,False,,,False,,,During the participants active study period.,,,Yes,Sharing de-identified AE's/SAE's from all individual participants with Merck & Co during the trial.,2023-06-16 04:18:53,2023-06-16 04:18:53,OTHER,,,,,
88879,88880,NCT05581641,,2022-10-12,,,2023-06-14,2022-10-12,2022-10-14,Actual,,,,,,,2023-06-14,2023-06-15,Estimate,"December 15, 2022",Actual,2022-12-15,June 2023,2023-06-30,September 2024,Anticipated,2024-09-30,February 2024,Anticipated,2024-02-29,,Interventional,,,Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria,"An Exploratory Phase I, Randomized, Observer-blind, Placebo-controlled Dose Escalation Trial Evaluating the Safety, Tolerability and Immunogenicity of an Investigational RNA-based Vaccine for Active Immunization Against Malaria","Active, not recruiting",,Phase 1,60.0,Actual,BioNTech SE,,2.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-16 04:18:58,2023-06-16 04:18:58,INDUSTRY,,,,,
88925,88926,NCT03475056,,2018-03-14,2020-12-18,,2022-08-09,2018-03-22,2018-03-23,Actual,2020-12-18,2021-01-14,Actual,,,,2022-08-09,2022-08-11,Actual,"October 9, 2018",Actual,2018-10-09,August 2022,2022-08-31,"December 19, 2019",Actual,2019-12-19,"December 19, 2019",Actual,2019-12-19,,Interventional,,Population includes all enrolled participants.,cAd3-Marburg Vaccine in Healthy Adults,"RV 507: A Phase I Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Marburg Chimpanzee Adenovirus Vector Vaccine, VRC-MARADC087-00-VP (cAd3-Marburg), in Healthy Adults",Completed,,Phase 1,40.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-17 07:52:37,2023-06-17 07:52:37,NIH,,,,,
88955,88956,NCT03722472,,2018-10-25,2023-05-05,,2023-05-05,2018-10-25,2018-10-29,Actual,2023-05-05,2023-06-01,Actual,,,,2023-05-05,2023-06-01,Actual,"October 2, 2018",Actual,2018-10-02,May 2023,2023-05-31,"June 15, 2020",Actual,2020-06-15,"June 15, 2020",Actual,2020-06-15,,Interventional,,"males and females, ages 18-55 inclusive",Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults,"A Phase 1, Double-Blind, Randomized Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the Single-Vial Lyophilized ID93 + GLA-SE Vaccine Administered Intramuscularly in Healthy Adult Subjects",Completed,,Phase 1,48.0,Actual,Access to Advanced Health Institute (AAHI),,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 07:52:53,2023-06-17 07:52:53,OTHER,,,,,
89107,89108,NCT01254175,,2010-12-02,,,2014-12-02,2010-12-02,2010-12-06,Estimate,,,,,,,2014-12-02,2014-12-03,Estimate,December 2010,,2010-12-31,December 2014,2014-12-31,February 2012,Actual,2012-02-29,February 2012,Actual,2012-02-29,,Interventional,,,Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children,"Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval",Completed,,Phase 1,28.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 07:54:24,2023-06-17 07:54:24,NIH,,,,,
89118,89119,NCT03486834,,2018-03-28,2021-10-01,,2021-10-13,2018-03-28,2018-04-03,Actual,2021-10-13,2021-11-10,Actual,,,,2021-10-13,2021-11-10,Actual,"April 30, 2018",Actual,2018-04-30,October 2021,2021-10-31,"June 30, 2021",Actual,2021-06-30,"October 30, 2020",Actual,2020-10-30,,Interventional,,,V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002),"Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 (Cytomegalovirus [CMV] Vaccine) in Healthy Seronegative Women, 16 to 35 Years of Age",Completed,,Phase 2,2200.0,Actual,Merck Sharp & Dohme LLC,,3.0,,,False,,,,True,True,False,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2023-06-17 07:54:31,2023-06-17 07:54:31,INDUSTRY,,,,,
89384,89385,NCT01151059,,2010-06-23,,,2012-03-27,2010-06-24,2010-06-25,Estimate,,,,,,,2012-03-27,2012-03-28,Estimate,June 2010,,2010-06-30,March 2012,2012-03-31,July 2010,Actual,2010-07-31,June 2010,Actual,2010-06-30,,Interventional,,,Safety and Immunogenicity of One Dose of Inactivated Trivalent Flu Vaccine Administered to Non-elderly Adult and Elderly Subjects,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL® S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2010-2011, When Administered to Non-elderly Adult and Elderly Subjects",Completed,,Phase 2,138.0,Actual,Novartis,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 07:57:01,2023-06-17 07:57:01,INDUSTRY,,,,,
89409,89410,NCT05373485,,2022-05-12,,,2023-06-14,2022-05-12,2022-05-13,Actual,,,,,,,2023-06-14,2023-06-15,Estimate,"May 20, 2022",Actual,2022-05-20,June 2023,2023-06-30,"September 20, 2023",Anticipated,2023-09-20,"August 21, 2023",Anticipated,2023-08-21,,Interventional,,,Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older,"A Randomized, Double-blind, Dose-exploring, Placebo-controlled, Multi-center Phase I Clinical Trial Evaluating the Safety and Immunogenicity of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older","Active, not recruiting",,Phase 1,43.0,Actual,CanSino Biologics Inc.,,8.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-16 04:20:57,2023-06-16 04:20:57,INDUSTRY,,,,,
89411,89412,NCT05373472,,2022-05-12,,,2023-06-14,2022-05-12,2022-05-13,Actual,,,,,,,2023-06-14,2023-06-15,Estimate,"July 6, 2022",Actual,2022-07-06,June 2023,2023-06-30,November 2023,Anticipated,2023-11-30,July 2023,Anticipated,2023-07-31,,Interventional,,,Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older,"A Randomized, Double-blind, Dose-exploring, Placebo-controlled, Multi-center Phase II Clinical Trial Evaluating the Safety and Immunogenicity of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older","Active, not recruiting",,Phase 2,150.0,Anticipated,CanSino Biologics Inc.,,8.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-16 04:20:58,2023-06-16 04:20:58,INDUSTRY,,,,,
89671,89672,NCT03433482,,2018-02-08,2021-01-27,2020-06-19,2021-01-27,2018-02-08,2018-02-14,Actual,2021-01-27,2021-02-17,Actual,2020-06-19,2020-07-02,Actual,2021-01-27,2021-02-17,Actual,"August 30, 2018",Actual,2018-08-30,January 2021,2021-01-31,"December 17, 2019",Actual,2019-12-17,"July 26, 2019",Actual,2019-07-26,,Interventional,,,A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age,"Immunogenicity, Reactogenicity and Safety Study of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) When Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age",Completed,,Phase 2,1707.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,True,False,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-17 07:59:38,2023-06-17 07:59:38,INDUSTRY,,,,,
89741,89742,NCT01155037,,2010-06-29,,,2018-07-17,2010-06-29,2010-07-01,Estimate,,,,,,,2018-07-17,2018-07-18,Actual,March 2010,,2010-03-31,July 2018,2018-07-31,April 2012,Actual,2012-04-30,March 2012,Actual,2012-03-31,,Interventional,VIP-H1N1,,Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults,Phase 2 Study to Evaluate the Safety of and the Immunogenicity to an Adjuvanted A(H1N1)v Influenza Vaccine in HIV-Infected Adults,Completed,,Phase 2,450.0,Actual,Oswaldo Cruz Foundation,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 08:00:21,2023-06-17 08:00:21,OTHER,,,,,
89792,89793,NCT01159561,,2010-07-08,,,2019-04-25,2010-07-08,2010-07-09,Estimate,,,,,,,2019-04-25,2019-04-29,Actual,February 2010,,2010-02-28,April 2019,2019-04-30,March 2012,Actual,2012-03-31,August 2011,Actual,2011-08-31,,Interventional,WEE,,"Western Equine Encephalitis Vaccine, Inactivated","Phase 1 Study to Evaluate the Safety and Immunogenicity of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, TSI-GSD 210, Lot 3-1-92, In Healthy Adults",Completed,,Phase 1,20.0,Actual,U.S. Army Medical Research and Development Command,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 08:00:58,2023-06-17 08:00:58,FED,,,,,
90001,90002,NCT01267903,,2010-12-28,,,2011-06-09,2010-12-28,2010-12-29,Estimate,,,,,,,2011-06-09,2011-06-10,Estimate,January 2011,,2011-01-31,January 2011,2011-01-31,June 2011,Actual,2011-06-30,May 2011,Actual,2011-05-31,,Interventional,,,A Clinical Trial for Inactivated Vaccine(Vero Cell) Against EV71 in Chinese Healthy Young Adults and Children,A Phase Ia Clinical Trial for Inactivated Vaccine(Vero Cell) Against EV71 in Chinese Healthy Young Adults and Children,Completed,,Phase 1,100.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 08:03:19,2023-06-17 08:03:19,NETWORK,,,,,
90221,90222,NCT05067933,,2021-09-16,,,2023-06-14,2021-10-01,2021-10-05,Actual,,,,,,,2023-06-14,2023-06-15,Estimate,"October 1, 2021",Actual,2021-10-01,September 2022,2022-09-30,"October 1, 2023",Anticipated,2023-10-01,"May 1, 2022",Actual,2022-05-01,,Interventional,,,A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine,"A Phase 2, Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety, Immunogenicity and Efficacy of an Adenoviral-Vector Based Vaccine Expressing Severe Acute Respiratory Syndrome (SARS-CoV-2) and dsRNA Adjuvant Administered Orally","Active, not recruiting",,Phase 2,66.0,Actual,Vaxart,,10.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-16 04:23:44,2023-06-16 04:23:44,INDUSTRY,,,,,
90229,90230,NCT01164553,,2010-07-15,,,2013-04-25,2010-07-15,2010-07-16,Estimate,,,,,,,2013-04-25,2013-04-29,Estimate,October 2010,,2010-10-31,October 2012,2012-10-31,October 2012,Actual,2012-10-31,October 2012,Actual,2012-10-31,,Interventional,,,Comparison of Flu Vaccine Doses in Children,"A Randomized, Double-Blind, Phase I Study Comparing an Increased Dose(s) (0.5 ml) of Trivalent Inactivated Influenza Vaccine (TIV) With Standard Dose(s) (0.25 ml) TIV in Children 6-35 Months of Age",Completed,,Phase 1,243.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 08:05:31,2023-06-17 08:05:31,NIH,,,,,
90417,90418,NCT01169077,,2010-07-22,,,2012-11-15,2010-07-22,2010-07-23,Estimate,,,,,,,2012-11-15,2012-11-16,Estimate,August 2010,,2010-08-31,November 2012,2012-11-30,July 2012,Actual,2012-07-31,July 2012,Actual,2012-07-31,,Interventional,,,EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria,"A Phase I, Randomized, Controlled Dosage-Escalation Study of the Safety and Reactogenicity of the EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria Administered Via Electroporation to Healthy Adults",Completed,,Phase 1,39.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 08:07:12,2023-06-17 08:07:12,NIH,,,,,
90578,90579,NCT04785794,,2021-03-03,2023-03-13,,2023-05-22,2021-03-03,2021-03-08,Actual,2023-05-22,2023-06-15,Estimate,,,,2023-05-22,2023-06-15,Estimate,"June 30, 2021",Actual,2021-06-30,May 2023,2023-05-31,"November 30, 2021",Actual,2021-11-30,"November 30, 2021",Actual,2021-11-30,,Interventional,,"Within each cohort, subjects were to be stratified based on a prescreening antibody titer to HA (by hemagglutinin inhibition [HAI] assay) from Sing2016 H3N2 influenza virus. Subjects were stratified into groups that had a pre-dose HAI titer of <40 and an HAI titer from 40 to <320.",Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old,Phase 1b Clinical Study to Investigate the Safety and Immunogenicity of the Sing2016 (A/Singapore/INFIMH-16-0019/2016) M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old.,Completed,,Phase 1,122.0,Actual,FluGen Inc,,4.0,,,,,,,,True,False,,,,,,,,,,,2023-06-16 04:25:47,2023-06-16 04:25:47,INDUSTRY,,,,,
90603,90604,NCT01285141,,2011-01-26,,,2012-12-04,2011-01-26,2011-01-27,Estimate,,,,,,,2012-12-04,2012-12-05,Estimate,July 2011,,2011-07-31,December 2012,2012-12-31,December 2012,Actual,2012-12-31,January 2012,Actual,2012-01-31,,Interventional,TL01,,Reactogenicity and Immunogenicity of Cervico-vaginal CN54gp140-hsp70 Conjugate Vaccine,Phase I Clinical Trial in Healthy Female Volunteers of Reactogenicity and Immunogenicity of Three Cervico-vaginal Topical Immunisations With a Fixed Dose of HIV CN54gp140 Glycoprotein-hsp70 Conjugate Vaccine,Completed,,Phase 1,8.0,Actual,"St George's, University of London",,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 08:08:40,2023-06-17 08:08:40,OTHER,,,,,
90693,90694,NCT04639466,,2020-11-04,,,2023-06-13,2020-11-19,2020-11-20,Actual,,,,,,,2023-06-13,2023-06-15,Estimate,"November 19, 2020",Actual,2020-11-19,June 2023,2023-06-30,"September 30, 2024",Anticipated,2024-09-30,"October 31, 2023",Anticipated,2023-10-31,,Interventional,,,"A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19 Infection","Phase 1/2 Dose Escalation Study to Evaluate the Safety and Biologically Effective Dose of COH04S1, a Synthetic MVA-Based SARS-CoV-2 Vaccine, Administered as One or Two Injections or as a Booster to Healthy Adult Volunteers",Recruiting,,Phase 1,189.0,Anticipated,"GeoVax, Inc.",,5.0,,,False,,,,True,True,False,,,False,,,,,,,,2023-06-16 04:26:49,2023-06-16 04:26:49,INDUSTRY,,,,,
90828,90829,NCT00943631,,2009-07-21,2011-03-17,,2012-10-25,2009-07-21,2009-07-22,Estimate,2011-03-17,2011-04-13,Estimate,,,,2012-10-25,2012-10-31,Estimate,August 2009,,2009-08-31,March 2010,2010-03-31,March 2010,Actual,2010-03-31,March 2010,Actual,2010-03-31,,Interventional,,,Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations,A Phase II Study in Healthy Adult and Elderly Populations to Assess the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine Administered at Two Dose Levels,Completed,,Phase 2,406.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 02:44:43,2023-06-14 02:44:43,NIH,,,,,
90849,90850,NCT01103687,,2010-04-13,,,2017-09-05,2010-04-13,2010-04-15,Estimate,,,,,,,2017-09-05,2017-09-08,Actual,July 2010,,2010-07-31,September 2017,2017-09-30,May 2016,Actual,2016-05-31,September 2012,Actual,2012-09-30,,Interventional,,,Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults,"A Phase 1 Randomized, Double-Blind, Placebo Controlled Clinical Trial to Evaluate the Safety, Mucosal Immunogenicity and Innate Immune Responses of Recombinant Adenovirus Serotype 26 HIV-1 Vaccine (Ad26.ENVA.01) in Healthy, HIV-1 Uninfected Adults (Ad26.ENVA.01 (rAd26) HIV-1 Mucosal/IPCAVD-003 Vaccine Study)",Completed,,Phase 1,24.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 08:11:03,2023-06-17 08:11:03,NIH,,,,,
91184,91185,NCT01180621,,2010-08-11,,,2011-06-21,2010-08-11,2010-08-12,Estimate,,,,,,,2011-06-21,2011-06-22,Estimate,September 2010,,2010-09-30,June 2011,2011-06-30,April 2011,Actual,2011-04-30,October 2010,Actual,2010-10-31,,Interventional,,,Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children,PCIRN Evaluation of Seasonal Trivalent Influenza Vaccine for 2010-2011 in Young Children in the First Year After the H1N1 Pandemic,Completed,,Phase 2,200.0,Actual,Dalhousie University,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 08:14:08,2023-06-17 08:14:08,OTHER,,,,,
91247,91248,NCT05243862,,2022-01-26,,,2022-09-30,2022-02-07,2022-02-17,Actual,,,,,,,2022-09-30,2022-10-03,Actual,"June 2, 2022",Actual,2022-06-02,September 2022,2022-09-30,"June 2, 2026",Anticipated,2026-06-02,"June 2, 2024",Anticipated,2024-06-02,,Interventional,,,Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.,Phase II Study of PolyPEPI1018 Vaccine in Combination With Atezolizumab in Participants With Relapsed or Refractory Microsatellite-stable Metastatic Colorectal Cancer.,Recruiting,,Phase 2,28.0,Anticipated,Treos Bio Limited,,1.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-14 03:02:25,2023-06-14 03:02:25,INDUSTRY,,,,,
91294,91295,NCT02719379,,2016-03-14,,,2017-10-09,2016-03-21,2016-03-25,Estimate,,,,,,,2017-10-09,2017-10-11,Actual,April 2016,,2016-04-30,October 2017,2017-10-31,June 2017,Actual,2017-06-30,June 2017,Actual,2017-06-30,,Interventional,,,Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma,Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma,Completed,,Phase 1,60.0,Actual,Mayo Clinic,,3.0,,,False,,,,False,,,,,,,,,,,No,,2023-06-16 08:48:33,2023-06-16 08:48:33,OTHER,,,,,
91454,91455,NCT03343626,,2017-11-13,2021-11-24,,2021-11-24,2017-11-13,2017-11-17,Actual,2021-11-24,2022-02-11,Actual,,,,2021-11-24,2022-02-11,Actual,"November 13, 2017",Actual,2017-11-13,November 2021,2021-11-30,"November 24, 2020",Actual,2020-11-24,"December 28, 2018",Actual,2018-12-28,,Interventional,,Safety Analysis Set included all participants who received at least one (1) dose of PIZV or placebo.,"Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants","A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Safety, Immunogenicity, and Dose Ranging Study of Purified Inactivated Zika Virus Vaccine (PIZV) Candidate in Flavivirus Naïve and Primed Healthy Adults Aged 18 to 49 Years",Completed,,Phase 1,271.0,Actual,Takeda,,8.0,,,False,,,,True,True,False,,,,,,,"IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.",https://vivli.org/ourmember/takeda/,Yes,"Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.",2023-06-17 08:16:29,2023-06-17 08:16:29,INDUSTRY,,,,,
91510,91511,NCT01107587,,2010-04-20,,,2017-05-18,2010-04-20,2010-04-21,Estimate,,,,,,,2017-05-18,2017-05-19,Actual,"April 13, 2010",Actual,2010-04-13,May 2017,2017-05-31,"June 28, 2010",Actual,2010-06-28,"June 28, 2010",Actual,2010-06-28,,Interventional,,,Study to Assess the Safety of GSK Biologicals' Liquid Human Rotavirus Vaccine in Healthy Infants,"Reactogenicity and Safety of Two Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Liquid Human Rotavirus (HRV) Vaccine 444563, in Healthy Infants",Completed,,Phase 1,50.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-17 08:17:22,2023-06-17 08:17:22,INDUSTRY,,,,,
91550,91551,NCT01450280,,2011-10-03,,,2012-11-28,2011-10-07,2011-10-12,Estimate,,,,,,,2012-11-28,2012-11-29,Estimate,December 2011,,2011-12-31,November 2012,2012-11-30,October 2012,Actual,2012-10-31,October 2012,Actual,2012-10-31,,Interventional,,,Safety and Immunogenicity of New Malaria Vaccine Candidate ChAd63 CS Administered Alone and With MVA CS,A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and With MVA CS,Completed,,Phase 1,24.0,Actual,University of Oxford,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 03:02:31,2023-06-14 03:02:31,OTHER,,,,,
91724,91725,NCT01585181,,2012-04-23,,,2020-03-03,2012-04-24,2012-04-25,Estimate,,,,,,,2020-03-03,2020-03-04,Actual,April 2012,,2012-04-30,March 2020,2020-03-31,January 2013,Actual,2013-01-31,August 2012,Actual,2012-08-31,,Interventional,,,Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200,"A Phase 1 Randomized, Double-Blind Placebo Controlled Study to Evaluate the Safety and Immunogenicity of the LIve Oral Cholera Vaccine Candidate PXVX0200 Vibrio Cholerae Serotype 01 Inaba CVD 103-HgR Vaccine Strain",Completed,,Phase 1,66.0,Actual,Emergent BioSolutions,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 08:19:53,2023-06-17 08:19:53,INDUSTRY,,,,,
91743,91744,NCT03473002,,2018-03-15,,,2019-02-28,2018-03-15,2018-03-21,Actual,,,,,,,2019-02-28,2019-03-01,Actual,"May 16, 2018",Actual,2018-05-16,"March 5, 2018",2018-03-05,"February 14, 2019",Actual,2019-02-14,"February 14, 2019",Actual,2019-02-14,,Interventional,,,A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults,A Phase I Double-Blind Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults,Completed,,Phase 1,21.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-17 08:20:02,2023-06-17 08:20:02,NIH,,,,,
91760,91761,NCT03012100,,2016-12-29,,,2023-01-12,2017-01-04,2017-01-06,Estimate,,,,,,,2023-01-12,2023-01-13,Actual,"March 31, 2017",Actual,2017-03-31,December 2022,2022-12-31,"July 31, 2026",Anticipated,2026-07-31,"August 30, 2022",Actual,2022-08-30,,Interventional,,,"Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer","Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer","Active, not recruiting",,Phase 2,280.0,Actual,Academic and Community Cancer Research United,,2.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-16 08:48:42,2023-06-16 08:48:42,OTHER,,,,,
91769,91770,NCT03738241,,2018-11-08,2021-06-10,,2021-07-08,2018-11-08,2018-11-13,Actual,2021-06-10,2021-07-01,Actual,,,,2021-07-08,2021-07-30,Actual,"December 18, 2018",Actual,2018-12-18,"November 8, 2018",2018-11-08,"June 19, 2020",Actual,2020-06-19,"June 19, 2020",Actual,2020-06-19,,Interventional,,The baseline analysis population includes all enrolled participants,2017 A/H7N9 IIV Revaccination,"A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects",Completed,,Phase 2,304.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-17 08:20:22,2023-06-17 08:20:22,NIH,,,,,
92127,92128,NCT00730288,,2008-08-06,,,2018-02-23,2008-08-06,2008-08-08,Estimate,,,,,,,2018-02-23,2018-02-27,Actual,August 2006,,2006-08-31,February 2018,2018-02-28,January 2008,Actual,2008-01-31,August 2007,Actual,2007-08-31,,Interventional,,,Study of ChimeriVax Dengue Tetravalent Vaccine in Adult Subjects,Safety of ChimeriVax Dengue Tetravalent Vaccine in Adult Subjects Previously Immunised With an Investigational Dengue or Yellow Fever Vaccine,Completed,,Phase 2,35.0,Actual,Sanofi,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 08:48:55,2023-06-16 08:48:55,INDUSTRY,,,,,
92189,92190,NCT01110551,,2010-04-22,,,2013-01-31,2010-04-22,2010-04-26,Estimate,,,,,,,2013-01-31,2013-02-04,Estimate,May 2010,,2010-05-31,January 2013,2013-01-31,December 2012,Actual,2012-12-31,April 2012,Actual,2012-04-30,,Interventional,,,Tetravalent Chimeric Dengue Vaccine Trial,"A Double-Blind Randomized, Placebo-Controlled, Phase I Dose Escalation Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Adult Volunteers",Completed,,Phase 1,72.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 08:24:23,2023-06-17 08:24:23,NIH,,,,,
92485,92486,NCT01215149,,2010-10-04,,,2012-12-13,2010-10-05,2010-10-06,Estimate,,,,,,,2012-12-13,2012-12-17,Estimate,October 2010,,2010-10-31,December 2012,2012-12-31,December 2012,Actual,2012-12-31,December 2012,Actual,2012-12-31,,Interventional,,,Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults,"A Phase 1 Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Safety and Immunogenicity of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adult Volunteers",Completed,,Phase 1,218.0,Actual,International AIDS Vaccine Initiative,,12.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 08:27:46,2023-06-17 08:27:46,NETWORK,,,,,
92601,92602,NCT02710851,,2016-01-27,,,2023-06-14,2016-03-12,2016-03-17,Estimate,,,,,,,2023-06-14,2023-06-15,Estimate,"March 24, 2016",Actual,2016-03-24,June 2023,2023-06-30,"December 30, 2023",Anticipated,2023-12-30,"December 30, 2023",Anticipated,2023-12-30,,Interventional,,,Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine,"A Phase<U+2161> Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Immunogenicity of the Recombinant (E.Coli) Human Papillomavirus Type 6/11 Bivalent Vaccine in Healthy Volunteers Aged 18-55 Years","Active, not recruiting",,Phase 2,640.0,Actual,Xiamen University,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 04:35:30,2023-06-16 04:35:30,OTHER,,,,,
92698,92699,NCT02287428,,2014-10-29,,,2023-06-14,2014-11-06,2014-11-10,Estimate,,,,,,,2023-06-14,2023-06-15,Estimate,November 2014,Actual,2014-11-30,June 2023,2023-06-30,January 2026,Anticipated,2026-01-31,January 2025,Anticipated,2025-01-31,,Interventional,,,Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM,A Phase I Study of a Personalized NeoAntigen Cancer Vaccine With Radiotherapy Plus Pembrolizumab/MK-3475 Among Newly Diagnosed Glioblastoma Patients,Recruiting,,Phase 1,56.0,Anticipated,Dana-Farber Cancer Institute,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 04:36:47,2023-06-16 04:36:47,OTHER,,,,,
92704,92705,NCT02255227,,2014-09-26,,,2023-06-13,2014-10-01,2014-10-02,Estimate,,,,,,,2023-06-13,2023-06-15,Estimate,"April 13, 2015",Actual,2015-04-13,June 2023,2023-06-30,"July 6, 2022",Actual,2022-07-06,"August 6, 2019",Actual,2019-08-06,,Interventional,PneumoMICI,,Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD,Phase IIb Multicenter Randomized Comparative Study of Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for Chronic Inflammatory Bowel Disease,Terminated,,Phase 2,104.0,Actual,Centre Hospitalier Universitaire de Saint Etienne,,2.0,,low inclusion rates,False,,,,False,False,False,,,,,,,,,,,2023-06-16 04:36:51,2023-06-16 04:36:51,OTHER,,,,,
92786,92787,NCT03443427,,2018-02-14,2020-09-14,,2021-08-04,2018-02-21,2018-02-23,Actual,2020-10-20,2020-11-12,Actual,,,,2021-08-04,2021-08-31,Actual,"March 20, 2018",Actual,2018-03-20,July 2021,2021-07-31,"September 23, 2020",Actual,2020-09-23,"December 31, 2019",Actual,2019-12-31,,Interventional,,,A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine,"An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' COPD Vaccine (GSK3277511A) in Adults",Completed,,Phase 2,200.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,False,True,False,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-17 08:31:06,2023-06-17 08:31:06,INDUSTRY,,,,,
92994,92995,NCT01219907,,2010-09-22,,,2013-05-15,2010-10-11,2010-10-13,Estimate,,,,,,,2013-05-15,2013-05-17,Estimate,June 2012,,2012-06-30,May 2013,2013-05-31,,,,June 2014,Anticipated,2014-06-30,,Interventional,,,Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer,Phase I Study of Adoptive T-Cell Therapy With HER-2/Neu (HER-2)-Specific Memory CD8+ T Lymphocytes Obtained Following In Vivo Priming With a Peptide Vaccine in Patients With Advanced Stage HER-2-Positive Breast Cancer,Withdrawn,,Phase 1,0.0,Actual,University of Washington,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 08:32:39,2023-06-17 08:32:39,OTHER,,,,,
93393,93394,NCT03014089,,2017-01-05,,,2019-12-06,2017-01-05,2017-01-09,Estimate,,,,,,,2019-12-06,2019-12-09,Actual,"December 21, 2016",,2016-12-21,December 2019,2019-12-31,July 2019,Actual,2019-07-31,July 2019,Actual,2019-07-31,,Interventional,,,"Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects","A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA 1325 Zika Vaccine in Healthy Adults in a Non-endemic Zika Region",Completed,,Phase 1,90.0,Actual,"ModernaTX, Inc.",,2.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-14 02:46:40,2023-06-14 02:46:40,INDUSTRY,,,,,
93725,93726,NCT00771849,,2008-10-13,2009-03-16,,2016-04-12,2008-10-13,2008-10-15,Estimate,2009-03-16,2009-04-24,Estimate,,,,2016-04-12,2016-04-14,Estimate,August 2003,,2003-08-31,April 2016,2016-04-30,May 2004,Actual,2004-05-31,March 2004,Actual,2004-03-31,,Interventional,,,Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children,"Antibody Responses for Serogroup C After One Dose of an Experimental Tetravalent (A, C, Y, and W-135) Meningococcal Diphtheria Toxoid Conjugate Vaccine Versus a Non-meningococcal Control Vaccine in Children Who Have Previously Received a Monovalent Meningococcal C Conjugate Vaccine",Completed,,Phase 2,103.0,Actual,Sanofi,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 06:48:36,2023-06-16 06:48:36,INDUSTRY,,,,,
93744,93745,NCT05205746,,2022-01-22,,,2022-09-27,2022-01-22,2022-01-25,Actual,,,,,,,2022-09-27,2022-09-28,Actual,"November 23, 2021",Actual,2021-11-23,September 2022,2022-09-30,"January 23, 2023",Anticipated,2023-01-23,"August 9, 2022",Actual,2022-08-09,,Interventional,,,Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence,Phase II Study to Evaluate Immunogenicity and Safety in Subjects With Evidence of Prior Immunity to SARS-CoV-2 of a Single Intramuscular or Intranasal Dose of the Live Recombinant Newcastle Disease Virus Based AVX/COVID-12 Vaccine,"Active, not recruiting",,Phase 2,158.0,Actual,"Laboratorio Avi-Mex, S.A. de C.V.",,4.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 07:00:26,2023-06-18 07:00:26,INDUSTRY,,,,,
93763,93764,NCT05477186,,2022-07-27,,,2023-04-11,2022-07-27,2022-07-28,Actual,,,,,,,2023-04-11,2023-04-12,Actual,"August 12, 2022",Actual,2022-08-12,April 2023,2023-04-30,"August 14, 2023",Anticipated,2023-08-14,"August 14, 2023",Anticipated,2023-08-14,,Interventional,,,Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old,"A Phase 1, Open-label, Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old","Active, not recruiting",,Phase 1,180.0,Actual,GlaxoSmithKline,,7.0,,,False,,,,,True,False,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-16 06:48:53,2023-06-16 06:48:53,INDUSTRY,,,,,
93846,93847,NCT00771615,,2008-10-10,2013-12-19,2010-07-02,2018-08-22,2008-10-10,2008-10-13,Estimate,2014-08-21,2014-09-04,Estimate,2010-07-02,2010-07-07,Estimate,2018-08-22,2018-09-21,Actual,"October 16, 2008",,2008-10-16,October 2016,2016-10-31,"December 4, 2009",Actual,2009-12-04,"May 26, 2009",Actual,2009-05-26,,Interventional,,,Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years,A Trial to Evaluate the Safety & Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age,Completed,,Phase 2,469.0,Actual,GlaxoSmithKline,,9.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 06:49:31,2023-06-16 06:49:31,INDUSTRY,,,,,
94192,94193,NCT04096911,,2019-09-18,,,2019-09-18,2019-09-18,2019-09-20,Actual,,,,,,,2019-09-18,2019-09-20,Actual,"July 31, 2019",Actual,2019-07-31,September 2019,2019-09-30,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,,Interventional,,,Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer,"A Single-arm, Single-center, Phase II Clinical Study Evaluating Efficacy of PD-1 Monoclonal Antibody Combined With HPV Vaccine in the Patients With Cervical Cancer(CC)Who Fails in or Can Not Endure the Standard Treatment",Unknown status,Recruiting,Phase 2,20.0,Anticipated,Northern Jiangsu Province People's Hospital,,1.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-16 06:52:19,2023-06-16 06:52:19,OTHER,,,,,
94328,94329,NCT02718443,,2016-03-16,,,2018-10-17,2016-03-18,2016-03-24,Estimate,,,,,,,2018-10-17,2018-10-19,Actual,May 2016,,2016-05-31,October 2018,2018-10-31,July 2018,Actual,2018-07-31,August 2017,Actual,2017-08-31,,Interventional,,,VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma,"VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma to Examine Safety, Tolerability, Immune and Biomarker Response to the Investigational VEGFR-2 DNA Vaccine VXM01",Completed,,Phase 1,14.0,Actual,Vaximm GmbH,,1.0,,,False,,,,True,,,,,,,,,,,Yes,,2023-06-16 08:49:20,2023-06-16 08:49:20,INDUSTRY,,,,,
94459,94460,NCT04138056,,2019-10-22,2022-11-18,2021-01-28,2022-11-18,2019-10-22,2019-10-24,Actual,2022-11-18,2022-12-19,Actual,2021-02-08,2021-02-09,Actual,2022-11-18,2022-12-19,Actual,"November 5, 2019",Actual,2019-11-05,November 2022,2022-11-30,"November 22, 2021",Actual,2021-11-22,"February 25, 2020",Actual,2020-02-25,,Interventional,,,"A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women","A Phase II Study of a Primary Dose of Investigational RSV Maternal Vaccine, Given Alone or With Boostrix, With a 2nd Dose Investigational RSV Maternal Vaccine",Completed,,Phase 2,509.0,Actual,GlaxoSmithKline,,5.0,,,False,,,,False,True,False,,,False,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-16 06:54:01,2023-06-16 06:54:01,INDUSTRY,,,,,
94515,94516,NCT02722512,,2016-03-17,,,2020-07-24,2016-03-24,2016-03-30,Estimate,,,,,,,2020-07-24,2020-07-28,Actual,July 2016,,2016-07-31,July 2020,2020-07-31,"November 13, 2019",Actual,2019-11-13,"November 13, 2019",Actual,2019-11-13,,Interventional,,,Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine,A Phase I and Feasibility Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine for Pediatric Patients With Newly Diagnosed Intracranial High Grade Glioma and Recurrent Resectable Intracranial High Grade Glioma and Ependymoma,Terminated,,Phase 1,10.0,Actual,Ann & Robert H Lurie Children's Hospital of Chicago,,2.0,,Lack of substantial evidence for immune responses in response to vaccination.,False,,,,True,,,,,,,,,,,Undecided,,2023-06-16 06:54:28,2023-06-16 06:54:28,OTHER,,,,,
94563,94564,NCT05769049,,2023-01-27,,,2023-03-13,2023-03-13,2023-03-15,Actual,,,,,,,2023-03-13,2023-03-15,Actual,"February 9, 2023",Actual,2023-02-09,March 2023,2023-03-31,"March 31, 2024",Anticipated,2024-03-31,"December 25, 2023",Anticipated,2023-12-25,,Interventional,,,The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell),"A Randomized, Observer-Blinded, Active-Controlled, Phase I Study to Evaluate the Safety and Immunogenicity of the Recombinant Zoster Vaccine (CHO Cell) in Healthy Adults Aged 40 Years and Older",Recruiting,,Phase 1,48.0,Anticipated,"Jiangsu Rec-Biotechnology Co., Ltd.",,2.0,,,False,,,,True,False,False,,,,,,,,,No,There is not a plan to make individual participant data (IPD) available.,2023-06-15 06:08:25,2023-06-15 06:08:25,INDUSTRY,,,,,
94642,94643,NCT00923195,,2009-06-17,2012-10-04,,2015-10-06,2009-06-17,2009-06-18,Estimate,2012-10-04,2012-11-04,Estimate,,,,2015-10-06,2015-10-28,Estimate,December 2008,,2008-12-31,October 2015,2015-10-31,August 2011,Actual,2011-08-31,August 2011,Actual,2011-08-31,,Interventional,,,"Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma",Phase II Study of Metastatic Melanoma Using a Chemoradiation Lymphodepleting Conditioning Regimen Followed by Infusion of Anti-Mart-1 and Anti-gp100 TCR-Gene Engineered Lymphocytes and Peptide Vaccines,Completed,,Phase 2,4.0,Actual,National Institutes of Health Clinical Center (CC),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 06:55:22,2023-06-16 06:55:22,NIH,,,,,
94660,94661,NCT03922061,,2019-04-16,,,2020-08-04,2019-04-16,2019-04-19,Actual,,,,,,,2020-08-04,2020-08-05,Actual,"March 19, 2019",Actual,2019-03-19,August 2020,2020-08-31,"June 4, 2020",Actual,2020-06-04,"July 18, 2019",Actual,2019-07-18,,Interventional,,,"Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant","Phase I Evaluation of the Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant [LT(R192G/L211A)] Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant",Completed,,Phase 1,29.0,Actual,University of Vermont,,2.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-17 08:41:22,2023-06-17 08:41:22,OTHER,,,,,
94769,94770,NCT05385991,,2022-05-17,,,2022-11-16,2022-05-20,2022-05-23,Actual,,,,,,,2022-11-16,2022-11-21,Actual,"July 1, 2022",Actual,2022-07-01,July 2022,2022-07-31,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2022",Anticipated,2022-12-31,,Interventional,,,Booster Dose Study to Assess the Safety and Immunogenicity of ACM-001 Administered Intramuscularly or Intranasally.,"An Open Label, Randomized, Dose and Route of Administration Comparison Phase 1 Study to Evaluate the Safety and Immunogenicity of the ACM-SARS-CoV-2-beta With ACM-CpG Vaccine Candidate (ACM-001), Administered Intramuscularly or Intranasally as a Booster Dose in Healthy Adults Aged 18 to 55 Years, Who Were Previously Vaccinated Against SARS-CoV-2.",Recruiting,,Phase 1,80.0,Anticipated,ACM Biolabs,,8.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-17 08:41:54,2023-06-17 08:41:54,INDUSTRY,,,,,
94978,94979,NCT04344054,,2020-04-06,,,2022-11-28,2020-04-10,2020-04-14,Actual,,,,,,,2022-11-28,2022-11-29,Actual,"February 22, 2021",Actual,2021-02-22,November 2022,2022-11-30,"September 9, 2022",Actual,2022-09-09,"September 6, 2022",Actual,2022-09-06,,Interventional,,,Mixed Schedule Study of Live Oral Rotavirus Vaccines and Trivalent P2-VP8 Subunit Rotavirus Vaccine,"A Phase II, Observer-blinded, Randomized, Active-controlled Study to Examine the Immunogenicity and Safety of Rotarix® and RV3-BB When Co-administered/Boosted With Trivalent P2-VP8 Subunit Rotavirus Vaccine Candidate in Healthy Infants in South Africa",Completed,,Phase 2,850.0,Actual,PATH,,6.0,,,False,,,,True,False,False,,,,,,Within 12 months of completion of study,Researchers who provide a methodologically sound proposal may be provided access after sponsor permission.,,Yes,Summary results for primary and secondary objectives to be posted at CT.gov.,2023-06-16 06:57:40,2023-06-16 06:57:40,OTHER,,,,,
95342,95343,NCT00693966,,2008-06-05,,,2016-09-15,2008-06-05,2008-06-09,Estimate,,,,,,,2016-09-15,2016-09-16,Estimate,October 1999,,1999-10-31,September 2016,2016-09-30,September 2004,Actual,2004-09-30,September 2004,Actual,2004-09-30,,Interventional,,,Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females,"A Phase II Double-Blind, Randomized, Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine Against Human Papillomavirus Types 16 and 18, in Healthy Adult Female Volunteers",Completed,,Phase 2,210.0,Actual,GlaxoSmithKline,,4.0,,,,,,,False,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 08:49:25,2023-06-16 08:49:25,INDUSTRY,,,,,
95439,95440,NCT04816019,,2021-03-15,,,2022-10-21,2021-03-24,2021-03-25,Actual,,,,,,,2022-10-21,2022-10-24,Actual,"April 1, 2021",Actual,2021-04-01,November 2021,2021-11-30,"September 30, 2022",Actual,2022-09-30,"September 30, 2022",Actual,2022-09-30,,Interventional,,,A Study of Intranasal ChAdOx1 nCOV-19,"A Phase I Study to Determine Safety, Tolerability and Immunogenicity of Intranasal Administration of the COVID Vaccine ChAdOx1 nCOV-19 in Healthy UK Adults",Completed,,Phase 1,42.0,Actual,University of Oxford,,7.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-16 07:01:03,2023-06-16 07:01:03,OTHER,,,,,
95966,95967,NCT02673255,,2016-01-29,,,2021-07-19,2016-02-01,2016-02-03,Estimate,,,,,,,2021-07-19,2021-07-20,Actual,"August 22, 2016",Actual,2016-08-22,December 2019,2019-12-31,"July 29, 2019",Actual,2019-07-29,"July 29, 2019",Actual,2019-07-29,,Interventional,,,Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program,Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program,Completed,,Phase 1,300.0,Actual,"Biomat USA, Inc.",,2.0,,,False,,,,True,,,,,,,,,,,Yes,,2023-06-16 07:03:59,2023-06-16 07:03:59,INDUSTRY,,,,,
96369,96370,NCT04613206,,2020-10-13,,,2022-05-27,2020-10-27,2020-11-03,Actual,,,,,,,2022-05-27,2022-05-31,Actual,"February 2, 2021",Actual,2021-02-02,May 2022,2022-05-31,"April 30, 2025",Anticipated,2025-04-30,"December 31, 2024",Anticipated,2024-12-31,,Interventional,,,High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients,Comparison of High vs. Standard Dose Influenza Vaccines in Adult Solid Organ Transplant Recipients,Recruiting,,Phase 2,396.0,Anticipated,Vanderbilt University Medical Center,,3.0,,,False,,,,True,True,False,,,True,,,,,,Undecided,,2023-06-17 08:52:21,2023-06-17 08:52:21,OTHER,,,,,
96533,96534,NCT05089630,,2021-10-11,,,2023-01-24,2021-10-11,2021-10-22,Actual,,,,,,,2023-01-24,2023-01-25,Actual,"October 14, 2021",Actual,2021-10-14,January 2023,2023-01-31,"March 23, 2029",Anticipated,2029-03-23,"February 23, 2024",Anticipated,2024-02-23,,Interventional,,,A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults,"A Phase 1/2, First-Time-in Human (FTiH), Randomized, Observer-blind, Placebo-controlled, Dose Escalation Study to Assess Safety, Reactogenicity and Immunogenicity of a Candidate Cytomegalovirus (CMV) Vaccine Comprising Recombinant Protein and Adjuvant When Administered Intramuscularly in Healthy Adults",Recruiting,,Phase 1,320.0,Anticipated,GlaxoSmithKline,,5.0,,,False,,,,False,True,False,,,True,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-17 08:53:55,2023-06-17 08:53:55,INDUSTRY,,,,,
96592,96593,NCT03784885,,2018-12-20,,,2018-12-21,2018-12-20,2018-12-24,Actual,,,,,,,2018-12-21,2018-12-26,Actual,"September 1, 2017",Actual,2017-09-01,December 2018,2018-12-31,"October 30, 2018",Actual,2018-10-30,"January 7, 2018",Actual,2018-01-07,,Interventional,,,"A Phase 2, Double-blind Study to Evaluate Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult","A Phase 2, Double-blind, Randomized Controlled Study to Evaluate Immunogenicity and Safety of Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult V Olunteers",Completed,,Phase 2,345.0,Actual,Advagene Biopharma Co. Ltd.,,3.0,,,False,,,,False,False,False,,,,,,,,,Undecided,,2023-06-17 08:54:28,2023-06-17 08:54:28,INDUSTRY,,,,,
96738,96739,NCT04889274,,2021-05-06,,,2023-01-22,2021-05-14,2021-05-17,Actual,,,,,,,2023-01-22,2023-01-25,Actual,"May 10, 2021",Actual,2021-05-10,January 2023,2023-01-31,"December 30, 2023",Anticipated,2023-12-30,"March 30, 2023",Anticipated,2023-03-30,,Interventional,,,Investigation of the Effects of Dietary Nitrate and Sex on COVID-19 Vaccine Induced Vascular Dysfunction in Healthy Men and Women (DiNOVasc-COVID-19),"A Double-blind, Randomised, Placebo-controlled Parallel Study to Investigate the Effect of Dietary Nitrate and Sex on COVID-19 Vaccine Induced Vascular Dysfunction in Healthy Men and Women",Recruiting,,Phase 1,98.0,Anticipated,Queen Mary University of London,,4.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-14 02:47:55,2023-06-14 02:47:55,OTHER,,,,,
97035,97036,NCT01560793,,2012-02-14,,,2014-09-22,2012-03-20,2012-03-22,Estimate,,,,,,,2014-09-22,2014-09-23,Estimate,June 2012,,2012-06-30,September 2014,2014-09-30,November 2013,Actual,2013-11-30,June 2013,Actual,2013-06-30,,Interventional,,,Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years,Phase I Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years,Completed,,Phase 1,224.0,Actual,VaxInnate Corporation,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 08:58:36,2023-06-17 08:58:36,INDUSTRY,,,,,
97129,97130,NCT00956449,,2009-08-08,,,2017-03-24,2009-08-10,2009-08-11,Estimate,,,,,,,2017-03-24,2017-03-28,Actual,June 2009,,2009-06-30,March 2017,2017-03-31,July 2009,Actual,2009-07-31,July 2009,Actual,2009-07-31,,Interventional,,,"Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects","A Phase II, Single Center, Uncontrolled, Open-Label Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine [Ph.Eur], Formulation 2009/2010, When Administered to Non-Elderly Adult and Elderly Subjects",Completed,,Phase 2,126.0,Actual,Novartis,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 07:08:20,2023-06-16 07:08:20,INDUSTRY,,,,,
97570,97571,NCT05092386,,2021-10-13,,,2023-01-11,2021-10-13,2021-10-25,Actual,,,,,,,2023-01-11,2023-01-12,Actual,"January 3, 2023",Actual,2023-01-03,January 2023,2023-01-31,"December 30, 2023",Anticipated,2023-12-30,"December 30, 2023",Anticipated,2023-12-30,,Interventional,,,Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine,"An Open-label Combined Randomized Double-blind, Positive Control Clinical Trial in Subjects Aged 2 Months (Minimum 6 Weeks) and Above to Preliminary Evaluate the Safety and Immunogenicity of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine",Recruiting,,Phase 1,310.0,Anticipated,"Sinovac Biotech Co., Ltd",,8.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-17 09:02:59,2023-06-17 09:02:59,INDUSTRY,,,,,
97863,97864,NCT03109600,,2016-11-01,,,2018-03-04,2017-04-05,2017-04-12,Actual,,,,,,,2018-03-04,2018-03-06,Actual,"April 18, 2017",Actual,2017-04-18,July 2017,2017-07-31,"February 19, 2018",Actual,2018-02-19,"September 28, 2017",Actual,2017-09-28,,Interventional,,,Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I),"A Randomized, Observer Blinded, Comparative, Phase I Safety Study in Two Age De-escalating Cohorts to Assess the Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)",Completed,,Phase 1,100.0,Actual,PT Bio Farma,,4.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-17 09:06:35,2023-06-17 09:06:35,INDUSTRY,,,,,
97916,97917,NCT02758730,,2016-04-26,,,2016-08-04,2016-04-28,2016-05-02,Estimate,,,,,,,2016-08-04,2016-08-05,Estimate,,,,August 2016,2016-08-31,,,,October 2017,Anticipated,2017-10-31,,Interventional,,,Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients,"A Randomized, Placebo-controlled, Parallel Group, Patient-blind, Single-center Phase I Pilot Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A, a New Vaccine Against Alpha-synuclein, in Patients With PD-GBA",Withdrawn,,Phase 1,0.0,Actual,Affiris AG,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 07:11:15,2023-06-16 07:11:15,INDUSTRY,,,,,
98349,98350,NCT03318315,,2017-10-19,2020-07-16,,2020-07-16,2017-10-19,2017-10-23,Actual,2020-07-16,2020-08-06,Actual,,,,2020-07-16,2020-08-06,Actual,"February 20, 2018",Actual,2018-02-20,"February 14, 2018",2018-02-14,"July 25, 2019",Actual,2019-07-25,"July 25, 2019",Actual,2019-07-25,,Interventional,,The baseline analysis population includes all randomized participants.,Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4,"A Phase II Study in Healthy Adults (19-64 Years of Age) to Assess the Safety, Reactogenicity and Immunogenicity of Sequential or Simultaneous Intramuscular Administration of an AS03-adjuvanted A/H7N9 Inactivated Influenza Vaccine With Seasonal Influenza Vaccine",Completed,,Phase 2,149.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-17 09:09:48,2023-06-17 09:09:48,NIH,,,,,
98471,98472,NCT01143545,,2010-06-11,,,2020-03-02,2010-06-11,2010-06-14,Estimate,,,,,,,2020-03-02,2020-03-03,Actual,"December 7, 2010",Actual,2010-12-07,March 2020,2020-03-31,"February 26, 2020",Actual,2020-02-26,"February 9, 2015",Actual,2015-02-09,,Interventional,,,"Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas","Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib as Adjuvant Therapy for Lung and Esophageal Cancers, Thymic Neoplasms, Thoracic Sarcomas, and Malignant Pleural Mesotheliomas",Terminated,,Phase 1,10.0,Actual,National Institutes of Health Clinical Center (CC),,1.0,,Closed accrual due to unpromising results and the opening of study 14C0053 targeting the same population.,False,,,,,True,False,,,,,,,,,,,2023-06-17 09:11:03,2023-06-17 09:11:03,NIH,,,,,
98786,98787,NCT04953078,,2021-06-14,,,2023-01-11,2021-07-06,2021-07-07,Actual,,,,,,,2023-01-11,2023-01-12,Actual,"September 11, 2021",Actual,2021-09-11,January 2023,2023-01-31,"November 4, 2022",Actual,2022-11-04,"December 2, 2021",Actual,2021-12-02,,Interventional,,,"A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19","A Phase 1, Randomized, Open-label, Dose-Finding Study to Evaluate the Safety, Tolerability, and Reactogenicity of Escalating Doses of the Baiya SARS-CoV-2 Vax 1 Vaccine in Healthy Adults",Completed,,Phase 1,48.0,Actual,"Baiya Phytopharm Co., Ltd.",,6.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-17 09:13:46,2023-06-17 09:13:46,INDUSTRY,,,,,
98859,98860,NCT05307835,,2022-03-23,,,2022-03-23,2022-03-23,2022-04-01,Actual,,,,,,,2022-03-23,2022-04-01,Actual,"December 2, 2021",Actual,2021-12-02,December 2021,2021-12-31,"December 3, 2025",Anticipated,2025-12-03,"December 2, 2025",Anticipated,2025-12-02,,Interventional,,,Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection,Clinical Study of a Personalized Neoantigen Vaccine in Esophagus Cancer Patients Who Have Completed Adjuvant Therapy Following Neoadjuvant Therapy and Surgical Resection,Recruiting,,Phase 1,40.0,Anticipated,"Second Affiliated Hospital, School of Medicine, Zhejiang University",,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-14 02:48:56,2023-06-14 02:48:56,OTHER,,,,,
98904,98905,NCT05308602,,2022-02-15,,,2022-04-01,2022-04-01,2022-04-04,Actual,,,,,,,2022-04-01,2022-04-04,Actual,"April 1, 2022",Anticipated,2022-04-01,March 2022,2022-03-31,"August 1, 2023",Anticipated,2023-08-01,"August 1, 2022",Anticipated,2022-08-01,,Interventional,,,A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged =12 Years,"A Randomized, Double-blinded, Active-controlled Phase II Clinical Study to Evaluate the Immunogenicity and Safety of SCTV01C (A Bivalent SARS-CoV-2 Trimeric Spike Protein Vaccine) and SCTV01E (A COVID-19 Alpha/Beta/Delta/Omicron Variants S-Trimer Vaccine) in Population Aged =12 Years and Previously Unvaccinated",Not yet recruiting,,Phase 2,480.0,Anticipated,Sinocelltech Ltd.,,4.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-17 09:14:46,2023-06-17 09:14:46,INDUSTRY,,,,,
98940,98941,NCT00632333,,2008-02-29,,,2011-07-20,2008-03-07,2008-03-10,Estimate,,,,,,,2011-07-20,2011-07-21,Estimate,February 2008,,2008-02-29,September 2009,2009-09-30,March 2012,Anticipated,2012-03-31,December 2011,Anticipated,2011-12-31,,Interventional,,,Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer,"Phase I Study of Chemoradiation Therapy With Epitope Peptide Vaccine Therapy in Treating Patients With Unresectable, Advanced or Recurrent Esophageal Cancer",Unknown status,Recruiting,Phase 1,9.0,Anticipated,Teikyo University,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 07:16:24,2023-06-16 07:16:24,OTHER,,,,,
98993,98994,NCT01146119,,2010-06-13,,,2012-07-30,2010-06-16,2010-06-17,Estimate,,,,,,,2012-07-30,2012-07-31,Estimate,July 2010,,2010-07-31,July 2012,2012-07-31,June 2011,Actual,2011-06-30,May 2011,Actual,2011-05-31,,Interventional,,,Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001),"A Phase II, Randomized, Two Stage, Double-Blind, Placebo-Controlled, Safety and Immunogenicity Study of an Intramuscular Influenza Vaccine (Multimeric-001) Injected to Healthy Volunteers",Completed,,Phase 2,200.0,Actual,BiondVax Pharmaceuticals ltd.,,6.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 09:15:17,2023-06-17 09:15:17,INDUSTRY,,,,,
99250,99251,NCT03312231,,2017-10-12,2020-09-17,,2020-09-17,2017-10-12,2017-10-17,Actual,2020-09-17,2020-10-12,Actual,,,,2020-09-17,2020-10-12,Actual,"February 14, 2018",Actual,2018-02-14,September 2019,2019-09-30,"September 26, 2019",Actual,2019-09-26,"September 26, 2019",Actual,2019-09-26,,Interventional,,The baseline analysis population includes all participants who received at least one dose of study vaccine.,Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly,"A Phase II Study in Healthy Adults 19 Years and Older to Assess the Safety, Reactogenicity and Immunogenicity of a Sanofi Pasteur A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without AS03 Adjuvant",Completed,,Phase 2,720.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-17 09:17:29,2023-06-17 09:17:29,NIH,,,,,
99252,99253,NCT04232280,,2020-01-09,,,2023-01-11,2020-01-14,2020-01-18,Actual,,,,,,,2023-01-11,2023-01-12,Actual,"January 9, 2020",Actual,2020-01-09,January 2023,2023-01-31,"January 4, 2023",Actual,2023-01-04,"January 4, 2023",Actual,2023-01-04,,Interventional,,,Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults,"A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults",Completed,,Phase 2,315.0,Actual,"ModernaTX, Inc.",,4.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 09:17:32,2023-06-17 09:17:32,INDUSTRY,,,,,
99267,99268,NCT03415672,,2018-01-05,,,2019-01-30,2018-01-29,2018-01-30,Actual,,,,,,,2019-01-30,2019-01-31,Actual,"October 11, 2017",Actual,2017-10-11,January 2019,2019-01-31,"January 9, 2019",Actual,2019-01-09,"January 9, 2019",Actual,2019-01-09,,Interventional,,,Hepatitis B Vaccine for Non-responders,Immunogenicity and Safety of HBAI20 Hepatitis B Vaccine in Non-responders,Completed,,Phase 2,133.0,Actual,Maastricht University Medical Center,,2.0,,,False,,,,True,False,False,,,,,,,,,Undecided,,2023-06-17 09:17:38,2023-06-17 09:17:38,OTHER,,,,,
99549,99550,NCT05113862,,2021-11-05,,,2022-11-28,2021-11-08,2021-11-09,Actual,,,,,,,2022-11-28,2022-11-29,Actual,"January 10, 2022",Actual,2022-01-10,November 2022,2022-11-30,"September 15, 2022",Actual,2022-09-15,"September 15, 2022",Actual,2022-09-15,,Interventional,,,A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2,"A Phase-I, Double-blind, Randomized, Vehicle-controlled, Dose-finding, Safety Study of a Synthetic Nanoparticle-based, T Cell Priming Peptide Vaccine Against SARS-CoV-2 in Healthy Adults in Switzerland",Completed,,Phase 1,26.0,Actual,Emergex Vaccines Holding Ltd.,,4.0,,,False,,,,True,False,False,,,,,,Within 12 months of study completion,Peer-reviewed publication,,Yes,"The Investigators will be involved in writing and /or reviewing drafts of the manuscripts, abstracts, press releases and any other publications arising from the study.

Apart from the obvious flaws to conduct of the study, which may preclude data publication, safety and efficacy data will be published under the supervision and authorisation of the PI and Sponsor.

Publication will include as much individual level data as possible to ensure reproducibility of results without compromising participant privacy.",2023-06-16 07:19:55,2023-06-16 07:19:55,INDUSTRY,,,,,
100766,100767,NCT05216601,,2022-01-27,,,2023-03-13,2022-01-27,2022-01-31,Actual,,,,,,,2023-03-13,2023-03-15,Actual,"May 6, 2022",Actual,2022-05-06,June 2022,2022-06-30,"November 30, 2022",Actual,2022-11-30,"July 26, 2022",Actual,2022-07-26,,Interventional,,,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19","A Phase I, Prospective, Randomized, Open-labeled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Booster Dose With MVC-COV1901 or MVC-COV1901(Beta) SARS-CoV-2 Vaccine in Adults",Completed,,Phase 1,107.0,Actual,Medigen Vaccine Biologics Corp.,,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-15 06:10:55,2023-06-15 06:10:55,INDUSTRY,,,,,
100981,100982,NCT05208125,,2021-11-03,,,2023-03-14,2022-01-12,2022-01-26,Actual,,,,,,,2023-03-14,2023-03-15,Actual,"March 30, 2022",Actual,2022-03-30,March 2023,2023-03-31,March 2023,Anticipated,2023-03-31,"March 30, 2022",Actual,2022-03-30,,Interventional,,,"A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals","A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals","Active, not recruiting",,Phase 1,30.0,Anticipated,IrsiCaixa,,2.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-15 06:11:01,2023-06-15 06:11:01,OTHER,,,,,
101018,101019,NCT05239832,,2022-02-10,,,2022-02-15,2022-02-13,2022-02-15,Actual,,,,,,,2022-02-15,2022-03-03,Actual,"August 5, 2021",Actual,2021-08-05,February 2022,2022-02-28,"August 5, 2022",Anticipated,2022-08-05,"September 29, 2021",Actual,2021-09-29,,Interventional,COVID-19,,Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity,A Clinical Study to Evaluate the Safety and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Participants Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines,"Active, not recruiting",,Phase 2,34.0,Actual,Livzon Pharmaceutical Group Inc.,,1.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-16 07:26:16,2023-06-16 07:26:16,INDUSTRY,,,,,
101159,101160,NCT04765436,,2021-02-16,,,2022-04-22,2021-02-19,2021-02-21,Actual,,,,,,,2022-04-22,2022-04-25,Actual,"January 14, 2021",Actual,2021-01-14,April 2022,2022-04-30,"March 30, 2022",Actual,2022-03-30,"March 30, 2022",Actual,2022-03-30,,Interventional,,,"PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64","A Phase I, First-in-Human, Observer-Blinded, Randomized, Placebo Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64",Completed,,Phase 1,60.0,Actual,Providence Therapeutics Holdings Inc.,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-16 07:27:37,2023-06-16 07:27:37,INDUSTRY,,,,,
101276,101277,NCT04451954,,2020-06-25,,,2022-04-21,2020-06-25,2020-06-30,Actual,,,,,,,2022-04-21,2022-04-25,Actual,"July 2, 2020",Actual,2020-07-02,"April 15, 2022",2022-04-15,"September 20, 2021",Actual,2021-09-20,"September 20, 2021",Actual,2021-09-20,,Interventional,FBP00004,,Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects,Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens Without or With Adjuvant in Healthy Adult Subjects,Completed,,Phase 1,210.0,Actual,Sanofi,,7.0,,,False,,,,False,True,False,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-16 07:28:29,2023-06-16 07:28:29,INDUSTRY,,,,,
101281,101282,NCT05197153,,2021-12-13,,,2023-03-13,2022-01-17,2022-01-19,Actual,,,,,,,2023-03-13,2023-03-15,Actual,"January 22, 2022",Actual,2022-01-22,March 2023,2023-03-31,"October 28, 2022",Actual,2022-10-28,"June 1, 2022",Actual,2022-06-01,,Interventional,,,"A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19","A Phase II, Prospective, Randomized, Observer-blinded, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of Heterologous Booster Dose With AZD1222, mRNA-1273, or MVC-COV1901 COVID-19 Vaccine in Adults",Completed,,Phase 2,804.0,Actual,Medigen Vaccine Biologics Corp.,,4.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-15 06:11:04,2023-06-15 06:11:04,INDUSTRY,,,,,
101458,101459,NCT01250795,,2010-11-29,,,2016-05-10,2010-11-30,2010-12-01,Estimate,,,,,,,2016-05-10,2016-05-12,Estimate,November 2010,,2010-11-30,May 2016,2016-05-31,July 2011,Actual,2011-07-31,July 2011,Actual,2011-07-31,,Interventional,,,Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults,"A Phase 1a/b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Reactogenicity, and Immunogenicity of FhCMB HAI-05, a Recombinant Hemagglutinin (rHA) Vaccine Derived From Influenza A/Indonesia/05/2005 (H5N1), in Healthy Adults 18 to 49 Years",Completed,,Phase 1,100.0,Actual,"Fraunhofer, Center for Molecular Biotechnology",,5.0,,,False,,,,True,,,,,,,,,,,Undecided,,2023-06-17 09:36:24,2023-06-17 09:36:24,INDUSTRY,,,,,
101505,101506,NCT01147445,,2010-06-17,,,2014-02-13,2010-06-17,2010-06-22,Estimate,,,,,,,2014-02-13,2014-02-14,Estimate,September 2010,,2010-09-30,June 2012,2012-06-30,June 2012,Actual,2012-06-30,June 2012,Actual,2012-06-30,,Interventional,,,Phase I Study of ETEC Vaccine,"Phase I Study to Determine the Safety and Immunogenicity of an Oral ETEC Candidate Vaccine, Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) From Enterotoxigenic Escherichia Coli",Completed,,Phase 1,36.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 09:36:46,2023-06-17 09:36:46,NIH,,,,,
101658,101659,NCT03880474,,2019-02-21,2021-01-29,,2021-04-23,2019-03-14,2019-03-19,Actual,2021-04-23,2021-04-26,Actual,,,,2021-04-23,2021-04-26,Actual,"March 18, 2019",Actual,2019-03-18,April 2021,2021-04-30,"January 21, 2020",Actual,2020-01-21,"October 15, 2019",Actual,2019-10-15,,Interventional,,,Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults,A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults Aged 18 Years and Over,Terminated,,Phase 2,2364.0,Actual,Vaccitech (UK) Limited,,2.0,,The trial is being stopped for futility. Season 2 cancelled.,False,,,,True,False,False,,,,,,,,,No,,2023-06-14 02:50:27,2023-06-14 02:50:27,INDUSTRY,,,,,
101984,101985,NCT04940130,,2021-06-03,,,2022-04-04,2021-06-17,2021-06-25,Actual,,,,,,,2022-04-04,2022-04-12,Actual,"April 1, 2022",Actual,2022-04-01,April 2022,2022-04-30,June 2023,Anticipated,2023-06-30,April 2023,Anticipated,2023-04-30,,Interventional,,,PfSPZ Vaccine Trial in Malian Children,"Phase 2 Trial of Safety, Immunogenicity, and Efficacy Against Plasmodium Falciparum Malaria of PfSPZ Vaccine in Children in Mali",Recruiting,,Phase 2,268.0,Anticipated,Sanaria Inc.,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-16 07:32:36,2023-06-16 07:32:36,INDUSTRY,,,,,
102005,102006,NCT00620412,,2008-02-11,,,2011-01-16,2008-02-11,2008-02-21,Estimate,,,,,,,2011-01-16,2011-01-19,Estimate,September 2007,,2007-09-30,January 2011,2011-01-31,December 2009,Actual,2009-12-31,June 2008,Actual,2008-06-30,,Interventional,,,Probiotics to Enhance Immunogenicity of Influenza Vaccine in Healthy Adults,Lactobacillus GG to Enhance the Immunogenicity of Influenza Vaccine in Healthy Adults - Proof of Concept Study,Completed,,Phase 1,52.0,Anticipated,Tufts Medical Center,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 07:32:47,2023-06-16 07:32:47,OTHER,,,,,
102318,102319,NCT03893669,,2012-12-12,,,2019-03-25,2019-03-25,2019-03-28,Actual,,,,,,,2019-03-25,2019-03-28,Actual,September 2012,,2012-09-30,October 2012,2012-10-31,November 2012,Actual,2012-11-30,October 2012,Actual,2012-10-31,,Interventional,,,"Safety, Tolerability and Immunogenicity of an Trivalent Inactivated Cell-Culture Influenza Vaccine in Healthy Adults","Randomized, Double-blinded, Controlled, Phase I Trial to Assess Safety, Tolerability and Immunogenicity of 'NBP607(Trivalent Inactivated Cell-Culture Influenza Vaccine)' Compared to Egg-based Influenza Vaccine in Healthy Adult",Completed,,Phase 1,100.0,Actual,"SK Chemicals Co., Ltd.",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 09:41:19,2023-06-17 09:41:19,INDUSTRY,,,,,
102761,102762,NCT01147991,,2010-06-18,,,2012-02-27,2010-06-18,2010-06-22,Estimate,,,,,,,2012-02-27,2012-02-28,Estimate,March 2005,,2005-03-31,February 2012,2012-02-29,April 2011,Actual,2011-04-30,April 2011,Actual,2011-04-30,,Interventional,,,Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer,"A Phase I, Dose Escalation Trial of Recombinant Modified Vaccinia Ankara (MVA)-Based Vaccine Encoding Epstein-Barr Virus Target Antigens",Completed,,Phase 1,16.0,Actual,Cancer Research UK,,,,,False,,,,,,,,,,,,,,,,,2023-06-17 09:44:32,2023-06-17 09:44:32,OTHER,,,,,
103127,103128,NCT01264445,,2010-12-20,,,2013-02-08,2010-12-20,2010-12-21,Estimate,,,,,,,2013-02-08,2013-02-11,Estimate,February 2011,,2011-02-28,February 2013,2013-02-28,November 2012,Actual,2012-11-30,November 2012,Actual,2012-11-30,,Interventional,,,Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines,"A Phase I Double-blinded, Placebo-controlled, Randomized Trial in HIV-uninfected, Healthy Adult Volunteers to Evaluate the Safety and Immunogenicity of an Adjuvanted GSK HIV Vaccine Administered With Ad35-GRIN Investigational Vaccine",Completed,,Phase 1,147.0,Actual,International AIDS Vaccine Initiative,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 09:47:06,2023-06-17 09:47:06,NETWORK,,,,,
103190,103191,NCT05047445,,2021-08-27,,,2022-11-23,2021-09-16,2021-09-17,Actual,,,,,,,2022-11-23,2022-11-25,Actual,"October 1, 2021",Actual,2021-10-01,November 2022,2022-11-30,December 2022,Anticipated,2022-12-31,December 2022,Anticipated,2022-12-31,,Interventional,,,A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection,"A First Time in Human Phase 1 Open-Label Study of the Safety, Tolerability, and Immunogenicity of COVIDITY Vaccine Administered by Needle-free Intradermal Injection or Needle-free Intramuscular Injection in Healthy Adults (COVIDITY-001)","Active, not recruiting",,Phase 1,80.0,Anticipated,Scancell Ltd,,2.0,,,False,,,,False,False,False,,,,,,,,,No,There is not a plan to make individual patient data available.,2023-06-18 07:00:58,2023-06-18 07:00:58,INDUSTRY,,,,,
103293,103294,NCT04649021,,2020-11-17,,,2022-05-09,2020-11-30,2020-12-02,Actual,,,,,,,2022-05-09,2022-05-10,Actual,"December 4, 2020",Actual,2020-12-04,May 2022,2022-05-31,"January 9, 2022",Actual,2022-01-09,"February 7, 2021",Actual,2021-02-07,,Interventional,,,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population,"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population: A Phase II, Randomized, Placebo-controlled, Observer-blinded Study",Completed,,Phase 2,950.0,Actual,BioNTech SE,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-16 07:39:45,2023-06-16 07:39:45,INDUSTRY,,,,,
103320,103321,NCT01266083,,2010-12-21,,,2018-11-28,2010-12-22,2010-12-24,Estimate,,,,,,,2018-11-28,2018-11-30,Actual,December 2010,Actual,2010-12-31,November 2018,2018-11-30,February 2018,Actual,2018-02-28,February 2018,Actual,2018-02-28,,Interventional,,,WT-1 Analog Peptide Vaccine in Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL),Phase II Trial of a WT-1 Analog Peptide Vaccine in Patients in Complete Remission (CR) From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL),Completed,,Phase 2,22.0,Actual,Sellas Life Sciences Group,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 09:48:28,2023-06-17 09:48:28,INDUSTRY,,,,,
103548,103549,NCT00892775,,2009-05-04,2017-05-05,2011-06-01,2019-10-29,2009-05-04,2009-05-05,Estimate,2017-05-05,2017-10-09,Actual,2011-06-01,2011-06-07,Estimate,2019-10-29,2019-11-15,Actual,"June 3, 2009",Actual,2009-06-03,October 2019,2019-10-31,"December 13, 2010",Actual,2010-12-13,"September 17, 2010",Actual,2010-09-17,,Interventional,,,Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds,Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds,Completed,,Phase 2,501.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-16 07:41:17,2023-06-16 07:41:17,INDUSTRY,,,,,
103569,103570,NCT02814708,,2016-06-21,2021-11-10,,2021-12-14,2016-06-23,2016-06-28,Estimate,2021-11-10,2021-12-13,Actual,,,,2021-12-14,2022-01-04,Actual,May 2016,,2016-05-31,December 2021,2021-12-31,January 2021,Actual,2021-01-31,May 2020,Actual,2020-05-31,,Interventional,,,Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults,Phase 2 Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults,Completed,,Phase 2,140.0,Actual,Biomedizinische Forschungs gmbH,,7.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 09:49:52,2023-06-17 09:49:52,INDUSTRY,,,,,
103589,103590,NCT01266707,,2010-12-23,,,2010-12-23,2010-12-23,2010-12-24,Estimate,,,,,,,2010-12-23,2010-12-24,Estimate,March 2007,,2007-03-31,December 2010,2010-12-31,March 2013,Anticipated,2013-03-31,March 2012,Anticipated,2012-03-31,,Interventional,,,Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma,"Phase 1 Study of HLA-A*2402 Restricted Antiangiogenic Peptide Vaccine Therapy Using Epitope Peptide Derived Feom VEGFR1 and VEGFR2 in Treating Patients With Unresectable, Recurrent, or Metastatic Hepatocellular Carcinoma",Unknown status,Recruiting,Phase 1,9.0,Anticipated,Fukushima Medical University,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 09:50:05,2023-06-17 09:50:05,OTHER,,,,,
103792,103793,NCT01313715,,2011-03-10,,,2011-12-30,2011-03-10,2011-03-14,Estimate,,,,,,,2011-12-30,2012-01-02,Estimate,March 2011,,2011-03-31,March 2011,2011-03-31,June 2011,Actual,2011-06-30,June 2011,Actual,2011-06-30,,Interventional,,,A Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants,A Phase Ib Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants,Completed,,Phase 1,360.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,8.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 09:51:27,2023-06-17 09:51:27,NETWORK,,,,,
104010,104011,NCT05085639,,2020-12-23,,,2021-10-18,2021-10-18,2021-10-20,Actual,,,,,,,2021-10-18,2021-10-20,Actual,November 2021,Anticipated,2021-11-30,October 2021,2021-10-31,December 2022,Anticipated,2022-12-31,April 2022,Anticipated,2022-04-30,,Interventional,,,GLS-5310 Vaccine in Healthy Volunteers for the Prevention of SARS-CoV-2 (COVID-19),"Phase I Study of the Safety, Tolerability and Immunogenicity of GLS-5310 DNA Vaccine Against SARS-CoV-2",Not yet recruiting,,Phase 1,30.0,Anticipated,"GeneOne Life Science, Inc.",,4.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-18 07:01:15,2023-06-18 07:01:15,INDUSTRY,,,,,
104103,104104,NCT03713086,,2018-10-18,,,2021-12-22,2018-10-18,2018-10-19,Actual,,,,,,,2021-12-22,2021-12-23,Actual,"October 12, 2018",Actual,2018-10-12,December 2021,2021-12-31,"November 23, 2021",Actual,2021-11-23,"November 23, 2021",Actual,2021-11-23,,Interventional,,,"A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults","A Non-Randomized, Open Label, Controlled, Dose-Escalation, Phase I Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of One or Two Administrations of Candidate Rabies mRNA Vaccine CV7202 in Healthy Adult Subjects",Completed,,Phase 1,53.0,Actual,CureVac,,4.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-17 09:53:17,2023-06-17 09:53:17,INDUSTRY,,,,,
104174,104175,NCT00648102,,2008-03-28,,,2010-07-23,2008-03-31,2008-04-01,Estimate,,,,,,,2010-07-23,2010-07-26,Estimate,January 2006,,2006-01-31,July 2010,2010-07-31,December 2009,Actual,2009-12-31,May 2009,Actual,2009-05-31,,Interventional,CDX1307-02,,"Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer","A Phase I, Open-Label, Dose-Escalation, Multidose Study of CDX-1307, a Mannose Receptor-Targeted hCG-ß Vaccine, in Patients With Incurable Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder and Ovarian Cancer",Completed,,Phase 1,36.0,Anticipated,Celldex Therapeutics,,,,,False,,,,False,,,,,,,,,,,,,2023-06-16 07:44:42,2023-06-16 07:44:42,INDUSTRY,,,,,
104213,104214,NCT01587131,,2012-04-25,,,2015-04-16,2012-04-26,2012-04-27,Estimate,,,,,,,2015-04-16,2015-04-17,Estimate,June 2012,,2012-06-30,January 2013,2013-01-31,March 2015,Actual,2015-03-31,August 2014,Actual,2014-08-31,,Interventional,,,DNA-based Influenza Vaccine in the Elderly,"Phase I, Open Label Study of a DNA Vaccine's Ability to Increase the Immune Response to the Trivalent Seasonal Influenza Vaccine in the Elderly",Completed,,Phase 1,50.0,Actual,University of Manitoba,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 09:54:00,2023-06-17 09:54:00,OTHER,,,,,
104253,104254,NCT02663700,,2016-01-21,,,2019-07-25,2016-01-21,2016-01-26,Estimate,,,,,,,2019-07-25,2019-07-29,Actual,"April 7, 2016",Actual,2016-04-07,"July 12, 2019",2019-07-12,"December 17, 2018",Actual,2018-12-17,"December 17, 2018",Actual,2018-12-17,,Interventional,,,Safety and Immunogenicity of Sanaria's Irradiated Sporozoite Vaccine (PfSPZ Vaccine) in Malaria-Experienced Adults in Burkina Faso,"Dose Escalation Study of Sanaria's Irradiated Sporozoite Vaccine (PFSPZ Vaccine), Followed by a Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PfSPZ Vaccine in Malaria-Experienced Adults in Burkina Faso",Completed,,Phase 1,112.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-16 07:45:05,2023-06-16 07:45:05,NIH,,,,,
104366,104367,NCT03871205,,2019-03-07,,,2019-03-10,2019-03-10,2019-03-12,Actual,,,,,,,2019-03-10,2019-03-12,Actual,"April 1, 2019",Anticipated,2019-04-01,February 2019,2019-02-28,"December 30, 2020",Anticipated,2020-12-30,"June 30, 2020",Anticipated,2020-06-30,,Interventional,,,Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer,A Phase I Study on the Safety and the Efficacy of Personalized Neoantigen-primed Dendritic Cell Vaccines for Refractory Lung Cancer,Unknown status,Not yet recruiting,Phase 1,30.0,Anticipated,Shenzhen People's Hospital,,1.0,,,False,,,,,False,False,,,,,,,,,No,,2023-06-17 09:55:16,2023-06-17 09:55:16,OTHER,,,,,
104783,104784,NCT03870113,,2019-03-08,,,2019-03-12,2019-03-08,2019-03-11,Actual,,,,,,,2019-03-12,2019-03-14,Actual,"April 1, 2019",Anticipated,2019-04-01,March 2019,2019-03-31,"December 30, 2022",Anticipated,2022-12-30,"March 31, 2022",Anticipated,2022-03-31,,Interventional,,,DC Vaccines Targeting HPV16/18 E6/E7 Protein to Regress CINI/CIN2,Clinical Study on the Regress of Cervical Intraepithelial Neoplastic(CIN) 1/CIN2 by Highly Effective DC Vaccines Targeting HPV E6/ E7 Protein,Unknown status,Not yet recruiting,Phase 1,80.0,Anticipated,Shenzhen People's Hospital,,1.0,,,False,,,,,False,False,,,,,,,,,No,,2023-06-17 09:58:17,2023-06-17 09:58:17,OTHER,,,,,
105012,105013,NCT05152017,,2021-11-26,,,2021-12-16,2021-11-26,2021-12-09,Actual,,,,,,,2021-12-16,2022-01-06,Actual,"November 16, 2019",Actual,2019-11-16,November 2021,2021-11-30,"January 24, 2020",Actual,2020-01-24,"January 22, 2020",Actual,2020-01-22,,Interventional,,,"The Objectives of This Study Are Study the Safety, Reactogenicity and Obtain Preliminary Data on the Immunogenicity of Flu-M Quadro, 4-valent Inactivated Split Influenza Vaccine, in Healthy Volunteers","Phase I Simple Blind, Placebo Controlled, Randomized Safety and Reactogenicity Trial of the Flu-M Quadro Tetravalent Inactivated Split Influenza Vaccine, Solution for Intramuscular Injection, Produced by FSUE SPbSRIVS FMBA, vs. Placebo in Healthy Volunteers",Completed,,Phase 1,75.0,Actual,St. Petersburg Research Institute of Vaccines and Sera,,3.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-17 10:00:07,2023-06-17 10:00:07,OTHER_GOV,,,,,
105110,105111,NCT05126979,,2021-09-28,,,2021-12-16,2021-11-08,2021-11-19,Actual,,,,,,,2021-12-16,2022-01-06,Actual,"March 9, 2016",Actual,2016-03-09,October 2021,2021-10-31,"May 13, 2016",Actual,2016-05-13,"April 25, 2016",Actual,2016-04-25,,Interventional,,,"The Objectives of This Study Are Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years","Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years",Completed,,Phase 1,45.0,Actual,St. Petersburg Research Institute of Vaccines and Sera,,3.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-17 10:00:50,2023-06-17 10:00:50,OTHER_GOV,,,,,
105432,105433,NCT03180801,,2017-05-31,2019-03-20,,2020-07-22,2017-06-06,2017-06-08,Actual,2019-04-11,2019-05-01,Actual,,,,2020-07-22,2020-08-05,Actual,"August 18, 2016",Actual,2016-08-18,April 2019,2019-04-30,"May 25, 2017",Actual,2017-05-25,"March 31, 2017",Actual,2017-03-31,,Interventional,,The Intention to treat (ITT) group was used for all analysis. ITT includes those participants who received both vaccination and challenge with an influenza virus.,Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model,"Phase IIb Study of the Efficacy of FLU-v, a Broad Spectrum Influenza Vaccine in an H1N1 Influenza Healthy Human Challenge Model",Completed,,Phase 2,153.0,Actual,PepTcell Limited,,3.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-17 10:04:00,2023-06-17 10:04:00,INDUSTRY,,,,,
105484,105485,NCT03363178,,2017-11-30,,,2017-12-15,2017-11-30,2017-12-06,Actual,,,,,,,2017-12-15,2017-12-18,Actual,"December 14, 2017",Actual,2017-12-14,November 2017,2017-11-30,"March 31, 2018",Anticipated,2018-03-31,"March 31, 2018",Anticipated,2018-03-31,,Interventional,,,Study to Investigate the Safety and Efficacy of GC3107 (BCG Vaccine) in Healthy Adults,"A Single-arm, Open-label, Single-center, Phase 1 Study to Investigate the Safety and Efficacy of GC3107 (BCG Vaccine) After Intradermal Administration in Healthy Adults",Unknown status,Recruiting,Phase 1,20.0,Anticipated,GC Biopharma Corp,,1.0,,,False,,,,,False,False,,,False,,,,,,No,,2023-06-17 10:04:34,2023-06-17 10:04:34,INDUSTRY,,,,,
105825,105826,NCT00886613,,2009-04-22,2011-03-22,,2015-10-05,2009-04-22,2009-04-23,Estimate,2011-03-22,2011-04-13,Estimate,,,,2015-10-05,2015-10-06,Estimate,March 2009,,2009-03-31,October 2015,2015-10-31,December 2009,Actual,2009-12-31,December 2009,Actual,2009-12-31,,Interventional,,,A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003),"A Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Evaluate Biomarkers of Immunity to Varicella Zoster Virus Following Immunization With V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine or With ZOSTAVAX in Healthy Volunteers",Completed,,Phase 1,120.0,Actual,Merck Sharp & Dohme LLC,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 07:52:46,2023-06-16 07:52:46,INDUSTRY,,,,,
106068,106069,NCT04224701,,2019-12-19,,,2022-05-06,2020-01-08,2020-01-13,Actual,,,,,,,2022-05-06,2022-05-10,Actual,"August 1, 2020",Actual,2020-08-01,May 2022,2022-05-31,December 2023,Anticipated,2023-12-31,August 2023,Anticipated,2023-08-31,,Interventional,,,"A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults","A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults","Active, not recruiting",,Phase 1,48.0,Anticipated,International AIDS Vaccine Initiative,,2.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-16 07:53:47,2023-06-16 07:53:47,NETWORK,,,,,
106086,106087,NCT00654108,,2008-04-03,,,2021-07-22,2008-04-03,2008-04-07,Estimate,,,,,,,2021-07-22,2021-07-29,Actual,"June 2, 2008",Actual,2008-06-02,"February 9, 2010",2010-02-09,"December 31, 2010",Actual,2010-12-31,"May 30, 2010",Actual,2010-05-30,,Interventional,,,Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects,"A Randomized, Double-Blind, Placebo-Controlled Dose Escalation, Inpatient Phase I Study to Determine the Safety and Immunogenicity of a Single Oral Dose of a Combined Live, Attenuated, Enterotoxigenic Escherichia Coli (ETEC)-Cholera Vaccine (Peru-15 pCTB) in Healthy Adult Subjects",Completed,,Phase 1,62.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-16 07:53:51,2023-06-16 07:53:51,NIH,,,,,
106184,106185,NCT04445194,,2020-06-16,,,2020-12-01,2020-06-21,2020-06-24,Actual,,,,,,,2020-12-01,2020-12-03,Actual,"June 22, 2020",Actual,2020-06-22,December 2020,2020-12-31,"September 20, 2021",Anticipated,2021-09-20,"October 22, 2020",Actual,2020-10-22,,Interventional,,,Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine,"A Multi-center, Double-blind, Randomized, Placebo Parallel Controlled, Safety and Tolerability Phase I Clinical Trial of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Healthy People Between 18 and 59 Years of Age",Unknown status,"Active, not recruiting",Phase 1,50.0,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,3.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-17 10:10:25,2023-06-17 10:10:25,INDUSTRY,,,,,
106235,106236,NCT02822105,,2016-06-27,,,2020-08-07,2016-06-29,2016-07-04,Estimate,,,,,,,2020-08-07,2020-08-10,Actual,June 2016,Actual,2016-06-30,August 2020,2020-08-31,November 2017,Actual,2017-11-30,April 2017,Actual,2017-04-30,,Interventional,,,Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers,Phase 1 Clinical Study To Investigate The Safety And Immunogenicity Of The H3N2 (A/Brisbane/10/2007) M2SR Monovalent Influenza Vaccine,Completed,,Phase 1,96.0,Actual,FluGen Inc,,2.0,,,False,,,,True,,,,,,,,,,,Undecided,Publications and post to site,2023-06-16 07:54:20,2023-06-16 07:54:20,INDUSTRY,,,,,
106663,106664,NCT01290419,,2011-02-02,,,2012-03-06,2011-02-03,2011-02-07,Estimate,,,,,,,2012-03-06,2012-03-08,Estimate,December 2010,,2010-12-31,March 2012,2012-03-31,December 2011,Actual,2011-12-31,December 2011,Actual,2011-12-31,,Interventional,,,Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine,"A Phase 1 Randomized, Observer-Blinded,Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Recombinant Respiratory Syncytial Virus F Protein Particle Vaccine in Healthy Adults",Completed,,Phase 1,150.0,Actual,Novavax,,7.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 10:15:56,2023-06-17 10:15:56,INDUSTRY,,,,,
106707,106708,NCT00622622,,2008-02-13,,,2009-02-17,2008-02-13,2008-02-25,Estimate,,,,,,,2009-02-17,2009-02-18,Estimate,November 2006,,2006-11-30,February 2009,2009-02-28,February 2009,Actual,2009-02-28,December 2006,Actual,2006-12-31,,Interventional,,,Gemcitabine With Antiangiogenic Peptide Vaccine Therapy in Patients With Pancreatic Cancer,"Phase I Study of Gemcitabine With Antiangiogenic Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*2402 Derived From VEGFR2 in Patients With Unresectable, Locally Advanced, Recurrent or Metastatic Pancreatic Cancer",Completed,,Phase 1,21.0,Actual,Wakayama Medical University,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 07:55:09,2023-06-16 07:55:09,OTHER,,,,,
106758,106759,NCT05480800,,2022-07-27,,,2022-10-17,2022-07-27,2022-07-29,Actual,,,,,,,2022-10-17,2022-10-18,Actual,"September 13, 2022",Actual,2022-09-13,October 2022,2022-10-31,"September 26, 2024",Anticipated,2024-09-26,"September 26, 2024",Anticipated,2024-09-26,,Interventional,,,"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever","A Phase 1/2a, Observer-blind, Randomized, Controlled, Two-stage, Multi-country Study to Evaluate the Safety, Reactogenicity, and Immune Response of the Trivalent Vaccine Against Invasive Nontyphoidal Salmonella (iNTS) and Typhoid Fever in Healthy European and African Adults",Recruiting,,Phase 1,155.0,Anticipated,GlaxoSmithKline,,9.0,,,False,,,,True,False,False,,,False,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-17 10:16:53,2023-06-17 10:16:53,INDUSTRY,,,,,
107205,107206,NCT01195571,,2010-09-02,,,2015-05-18,2010-09-03,2010-09-06,Estimate,,,,,,,2015-05-18,2015-05-19,Estimate,September 2010,,2010-09-30,May 2015,2015-05-31,October 2014,Actual,2014-10-31,October 2014,Actual,2014-10-31,,Interventional,,,Safety Study of Four Chimera Cytomegalovirus (CMV) Vaccines in Healthy Adult Males 30-50 Years of Age,A Dose Escalation Study to Assess the Safety and Immunogenicity of Four Live Attenuated Human Cytomegalovirus(HCMV) Vaccines in Healthy Adults Without Prior Immunity.,Completed,,Phase 1,36.0,Actual,CMV Research Foundation,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 10:22:35,2023-06-17 10:22:35,OTHER,,,,,
107382,107383,NCT03362060,,2017-11-27,,,2022-12-21,2017-12-02,2017-12-05,Actual,,,,,,,2022-12-21,2022-12-22,Actual,"December 12, 2017",Actual,2017-12-12,December 2022,2022-12-31,"December 31, 2024",Anticipated,2024-12-31,"June 30, 2023",Anticipated,2023-06-30,,Interventional,,,PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer,A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination With Pembrolizumab in HLA-A2+ Patients With Metastatic Triple Negative Breast Cancer (TNBC),"Active, not recruiting",,Phase 1,20.0,Anticipated,Massachusetts General Hospital,,1.0,,,False,,,,True,True,False,,,False,,,,,,No,,2023-06-16 07:56:43,2023-06-16 07:56:43,OTHER,,,,,
107454,107455,NCT02685020,,2016-02-12,,,2019-01-22,2016-02-12,2016-02-18,Estimate,,,,,,,2019-01-22,2019-01-23,Actual,"March 28, 2016",Actual,2016-03-28,January 2019,2019-01-31,"January 3, 2019",Actual,2019-01-03,"January 5, 2018",Actual,2018-01-05,,Interventional,,,"Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults","A Randomized, Parallel-group, Placebo-controlled, Double-blind Phase 1 Study in Healthy HIV-uninfected Adults to Evaluate Safety/Tolerability and Immunogenicity of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C gp140",Completed,,Phase 1,36.0,Actual,Janssen Vaccines & Prevention B.V.,,6.0,,,False,,,,False,,False,,,,,,,,,,,2023-06-16 07:57:13,2023-06-16 07:57:13,INDUSTRY,,,,,
107568,107569,NCT00683241,,2008-05-19,,,2013-02-25,2008-05-22,2008-05-23,Estimate,,,,,,,2013-02-25,2013-02-26,Estimate,November 2007,,2007-11-30,February 2013,2013-02-28,December 2009,Actual,2009-12-31,December 2009,Actual,2009-12-31,,Interventional,,,A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer,A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine Leaded With Autologous Tumor Cell Lysate for Recurrent Ovarian or Primary Peritoneal Cancer,Completed,,Phase 1,36.0,Anticipated,Abramson Cancer Center at Penn Medicine,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 07:57:53,2023-06-16 07:57:53,OTHER,,,,,
107574,107575,NCT00985088,,2009-09-24,2017-09-15,2011-11-17,2017-11-13,2009-09-24,2009-09-28,Estimate,2017-11-13,2017-12-12,Actual,2011-11-17,2011-11-21,Estimate,2017-11-13,2017-12-12,Actual,"October 11, 2009",Actual,2009-10-11,November 2017,2017-11-30,"December 16, 2010",Actual,2010-12-16,"November 9, 2009",Actual,2009-11-09,,Interventional,,,Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older,A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older,Completed,,Phase 2,1343.0,Actual,GlaxoSmithKline,,8.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-14 02:52:58,2023-06-14 02:52:58,INDUSTRY,,,,,
107622,107623,NCT03783130,,2018-12-18,2021-06-24,,2021-08-06,2018-12-19,2018-12-20,Actual,2021-08-06,2021-08-12,Actual,,,,2021-08-06,2021-08-12,Actual,"March 7, 2019",Actual,2019-03-07,August 2021,2021-08-31,"June 24, 2020",Actual,2020-06-24,"June 24, 2020",Actual,2020-06-24,,Interventional,,Population includes all enrolled participants.,"Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults","VRC 018: A Phase I Dose Escalation, Randomized, Open-Label Clinical Trial to Evaluate Dose, Safety, Tolerability and Immunogenicity of a HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults",Completed,,Phase 1,16.0,Actual,National Institutes of Health Clinical Center (CC),,4.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-14 02:53:03,2023-06-14 02:53:03,NIH,,,,,
107759,107760,NCT02804711,,2016-06-11,,,2017-10-14,2016-06-16,2016-06-17,Estimate,,,,,,,2017-10-14,2017-10-17,Actual,September 2016,Actual,2016-09-30,October 2017,2017-10-31,September 2017,Actual,2017-09-30,July 2017,Actual,2017-07-31,,Interventional,,,A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults,"A Phase Ia Single-center, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Aged 18-65 Years in China",Completed,,Phase 1,144.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,7.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-16 07:58:55,2023-06-16 07:58:55,NETWORK,,,,,
107881,107882,NCT02826434,,2016-07-05,,,2022-12-21,2016-07-07,2016-07-11,Estimate,,,,,,,2022-12-21,2022-12-22,Actual,August 2016,Actual,2016-08-31,December 2022,2022-12-31,September 2023,Anticipated,2023-09-30,June 2023,Anticipated,2023-06-30,,Interventional,,,Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer,A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination With Durvalumab in Human Leukocyte Antigen (HLA)-A2+ Subjects Following Standard Treatment of Stage II or III Triple Negative Breast Cancer,"Active, not recruiting",,Phase 1,22.0,Anticipated,Massachusetts General Hospital,,1.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-16 07:59:51,2023-06-16 07:59:51,OTHER,,,,,
108015,108016,NCT01173211,,2010-07-29,2012-11-15,,2014-12-04,2010-07-29,2010-07-30,Estimate,2012-12-20,2013-01-31,Estimate,,,,2014-12-04,2014-12-24,Estimate,September 2010,,2010-09-30,March 2013,2013-03-31,November 2011,Actual,2011-11-30,November 2011,Actual,2011-11-30,,Interventional,,,2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women,"A Randomized, Double-Blind Trial on the Safety and Immunogenicity of Seasonal 2010-2011 Inactivated Trivalent Influenza Vaccine in Pregnant Women",Completed,,Phase 2,183.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 02:53:17,2023-06-14 02:53:17,NIH,,,,,
108331,108332,NCT02510950,,2015-07-27,,,2017-11-15,2015-07-27,2015-07-29,Estimate,,,,,,,2017-11-15,2017-11-17,Actual,"December 3, 2015",Actual,2015-12-03,November 2017,2017-11-30,"February 14, 2017",Actual,2017-02-14,"February 14, 2017",Actual,2017-02-14,,Interventional,,,Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma,"A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma",Terminated,,Phase 1,1.0,Actual,Washington University School of Medicine,,1.0,,Low accrual,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 10:29:52,2023-06-17 10:29:52,OTHER,,,,,
108879,108880,NCT02508376,,2015-07-23,,,2017-09-14,2015-07-23,2015-07-24,Estimate,,,,,,,2017-09-14,2017-09-15,Actual,"October 22, 2015",Actual,2015-10-22,"April 5, 2017",2017-04-05,"August 31, 2017",Actual,2017-08-31,"August 31, 2017",Actual,2017-08-31,,Interventional,,,"Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects","A Phase 1, Randomized, Double Blind Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects",Completed,,Phase 1,70.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-17 10:33:24,2023-06-17 10:33:24,NIH,,,,,
109025,109026,NCT00880698,,2009-04-10,2015-06-22,2014-10-30,2021-11-03,2009-04-10,2009-04-14,Estimate,2015-07-17,2015-07-22,Estimate,2014-10-30,2014-11-05,Estimate,2021-11-03,2021-11-05,Actual,December 2009,,2009-12-31,July 2015,2015-07-31,January 2014,Actual,2014-01-31,January 2014,Actual,2014-01-31,,Interventional,,Includes all participants 'as randomized',Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers,"Safety and Immunogenicity of a Live, Attenuated Rotavirus Vaccine (RotaTeq) in HIV-1 Infected and Uninfected Children Born to HIV-1-Infected Mothers",Completed,,Phase 2,202.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 08:07:01,2023-06-16 08:07:01,NIH,,,,,
109063,109064,NCT01181323,,2010-08-12,2014-04-17,,2015-01-15,2010-08-12,2010-08-13,Estimate,2014-04-17,2014-05-16,Estimate,,,,2015-01-15,2015-01-28,Estimate,September 2011,,2011-09-30,April 2013,2013-04-30,May 2013,Actual,2013-05-31,May 2013,Actual,2013-05-31,,Interventional,,All enrolled subjects are included in the baseline analysis population.,Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women,"A Randomized, Double-Blind Trial, Comparing the Safety in Mothers and Their Infants and Immunogenicity in Mothers of Live Attenuated Influenza Vaccine (LAIV) to Inactivated Trivalent Influenza Vaccine (TIV) When Administered to Breast Feeding Women",Completed,,Phase 2,240.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 02:53:53,2023-06-14 02:53:53,NIH,,,,,
109120,109121,NCT03589807,,2018-06-28,2021-06-03,,2021-07-08,2018-07-05,2018-07-18,Actual,2021-07-08,2021-08-02,Actual,,,,2021-07-08,2021-08-02,Actual,"August 21, 2018",Actual,2018-08-21,"June 22, 2018",2018-06-22,"June 14, 2020",Actual,2020-06-14,"June 14, 2020",Actual,2020-06-14,,Interventional,,The baseline analysis population includes all participants who were enrolled in the study.,2013/2017 H7N9 Prime-Boost Interval,"A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A/H7N9 Inactivated Influenza Vaccines Administered Intramuscularly With or Without AS03 Adjuvant in Healthy Adults 19-50 Years of Age",Completed,,Phase 2,180.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,6.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-17 10:35:39,2023-06-17 10:35:39,NIH,,,,,
109215,109216,NCT00964951,,2009-08-20,,,2018-10-11,2009-08-20,2009-08-25,Estimate,,,,,,,2018-10-11,2018-10-16,Actual,,,,October 2009,2009-10-31,November 2010,Anticipated,2010-11-30,November 2010,Anticipated,2010-11-30,,Interventional,,,CSL H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations,A Phase II Study in Healthy Adult and Elderly Populations to Assess the Safety and Immunogenicity of a CSL H1N1 Influenza Vaccine Administered at Different Dose Levels Given With and Without GlaxoSmithKline AS03 Adjuvant,Withdrawn,,Phase 2,0.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 08:07:46,2023-06-16 08:07:46,NIH,,,,,
109579,109580,NCT05238649,,2022-02-10,,,2022-03-12,2022-02-10,2022-02-14,Actual,,,,,,,2022-03-12,2022-03-29,Actual,"November 10, 2021",Actual,2021-11-10,March 2022,2022-03-31,"January 28, 2023",Anticipated,2023-01-28,"November 30, 2022",Anticipated,2022-11-30,,Interventional,COVID-19,,Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine,"A Randomized, Double Blind, Positive Control Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines","Active, not recruiting",,Phase 2,150.0,Actual,Livzon Pharmaceutical Group Inc.,,3.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-16 08:09:33,2023-06-16 08:09:33,INDUSTRY,,,,,
109591,109592,NCT00644540,,2008-03-21,,,2016-11-30,2008-03-25,2008-03-27,Estimate,,,,,,,2016-11-30,2016-12-01,Estimate,November 2007,,2007-11-30,January 2014,2014-01-31,June 2008,Actual,2008-06-30,January 2008,Actual,2008-01-31,,Interventional,,,Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 Study,"A Phase II, Observer-Blind, Parallel Groups, Single Center, Extension Study to Evaluate the Immunogenicity and Safety Following a Single Intramuscular Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine in the Previous V70P2 Study.",Completed,,Phase 2,89.0,Actual,Novartis,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 08:09:39,2023-06-16 08:09:39,INDUSTRY,,,,,
109824,109825,NCT05863585,,2023-04-07,,,2023-05-08,2023-05-08,2023-05-18,Actual,,,,,,,2023-05-08,2023-05-18,Actual,June 2023,Anticipated,2023-06-30,May 2023,2023-05-31,March 2025,Anticipated,2025-03-31,March 2024,Anticipated,2024-03-31,,Interventional,,,A Clinical Trial to Evaluate the Safety and Immunogenicity of a Prophylactic HIV Vaccine Candidate,"An Open-Label Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults in Good General Health Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted",Not yet recruiting,,Phase 1,14.0,Anticipated,International AIDS Vaccine Initiative,,1.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-17 10:41:00,2023-06-17 10:41:00,NETWORK,,,,,
110349,110350,NCT00974935,,2009-09-10,,,2015-06-18,2009-09-10,2009-09-11,Estimate,,,,,,,2015-06-18,2015-06-19,Estimate,February 2011,,2011-02-28,September 2014,2014-09-30,March 2015,Actual,2015-03-31,March 2015,Actual,2015-03-31,,Interventional,,,Phase I STEBVax in Healthy Adults,Phase I Study of the Safety and Immunogenicity of Recombinant Staphylococcal Enterotoxin B Vaccine (STEBVax) in Healthy Adults,Completed,,Phase 1,29.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,7.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 08:14:19,2023-06-16 08:14:19,NIH,,,,,
110395,110396,NCT00693615,,2008-06-05,,,2016-09-15,2008-06-05,2008-06-09,Estimate,,,,,,,2016-09-15,2016-09-16,Estimate,October 2000,,2000-10-31,September 2016,2016-09-30,January 2005,Actual,2005-01-31,January 2005,Actual,2005-01-31,,Interventional,,,Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females,"Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine Against Human Papillomavirus Types 16 and 18, When Formulated With Aluminum Hydroxide, AS04, or Without Adjuvant, in Healthy Adult Female Volunteers",Completed,,Phase 2,60.0,Actual,GlaxoSmithKline,,3.0,,,,,,,False,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 08:14:37,2023-06-16 08:14:37,INDUSTRY,,,,,
110821,110822,NCT00977899,,2009-09-15,,,2018-07-03,2009-09-15,2009-09-16,Estimate,,,,,,,2018-07-03,2018-07-05,Actual,"August 20, 2009",,2009-08-20,"March 5, 2013",2013-03-05,"March 5, 2013",Actual,2013-03-05,"March 5, 2013",Actual,2013-03-05,,Interventional,,,Phase 1 Study of the Safety and Immunogenicity of a Malaria Transmission-blocking Pfs25-Pfs25 Conjugate Vaccine,Malaria Transmission-Blocking Pfs25-Pfs25 Conjugate Vaccine,Withdrawn,,Phase 1,0.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-16 08:17:32,2023-06-16 08:17:32,NIH,,,,,
111063,111064,NCT01367158,,2011-06-03,2014-02-11,,2014-11-17,2011-06-03,2011-06-06,Estimate,2014-11-17,2014-11-19,Estimate,,,,2014-11-17,2014-11-19,Estimate,July 2011,,2011-07-31,November 2014,2014-11-30,July 2012,Actual,2012-07-31,January 2012,Actual,2012-01-31,,Interventional,,,"Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines","Phase 2, Observer-Blind, Controlled, Randomized, Multi-Center Extension Study to Evaluate Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY in Adolescents Who Previously Received the Same Study Vaccines",Completed,,Phase 2,440.0,Actual,Novartis,,11.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 06:11:23,2023-06-17 06:11:23,INDUSTRY,,,,,
111097,111098,NCT00583752,,2007-12-20,2023-02-01,,2023-04-26,2007-12-20,2007-12-31,Estimate,2023-04-26,2023-05-18,Actual,,,,2023-04-26,2023-05-18,Actual,December 2007,Actual,2007-12-31,April 2023,2023-04-30,"January 31, 2023",Actual,2023-01-31,"December 31, 2020",Actual,2020-12-31,,Interventional,APP21,,Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21,Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy,Completed,,Phase 2,50.0,Actual,University of Iowa,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 10:49:19,2023-06-17 10:49:19,OTHER,,,,,
111169,111170,NCT03518125,,2018-04-24,2020-05-18,,2020-07-13,2018-05-04,2018-05-08,Actual,2020-05-18,2020-06-09,Actual,,,,2020-07-13,2020-07-21,Actual,"May 9, 2018",Actual,2018-05-09,July 2020,2020-07-31,"December 9, 2019",Actual,2019-12-09,"January 14, 2019",Actual,2019-01-14,,Interventional,B-SAFE,Safety population includes all randomized participants who received any amount of study vaccination.,BARDA Securing Anthrax Immunity For the Elderly,"Randomized, Active-Comparison, Double-Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Anthrax Vaccine Adsorbed (BioThrax®) Without and With CPG 7909 Adjuvant (AV7909 Anthrax Vaccine), Using a Post-Exposure Prophylaxis Dosing Regimen in Adults 66 Years of Age or Older in Stable Health in Comparison to Adults 18-50 Years of Age in Stable Health",Completed,,Phase 2,305.0,Actual,Biomedical Advanced Research and Development Authority,,6.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 10:50:01,2023-06-17 10:50:01,FED,,,,,
111171,111172,NCT00982579,,2009-09-22,,,2012-02-02,2009-09-22,2009-09-23,Estimate,,,,,,,2012-02-02,2012-02-03,Estimate,November 2009,,2009-11-30,September 2009,2009-09-30,September 2011,Actual,2011-09-30,June 2011,Actual,2011-06-30,,Interventional,PedVacc001,,Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1/2-uninfected Mothers,"An Open Randomized Phase I Study Evaluating Safety and Immunogenicity of a Candidate HIV-1 Vaccine, MVA.HIVA, Administered to Healthy Infants Born to HIV-1/2-uninfected Mothers",Completed,,Phase 1,48.0,Actual,Medical Research Council,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 08:19:36,2023-06-16 08:19:36,OTHER_GOV,,,,,
111193,111194,NCT02777411,,2016-05-16,,,2016-11-28,2016-05-18,2016-05-19,Estimate,,,,,,,2016-11-28,2016-11-30,Estimate,December 2014,,2014-12-31,August 2016,2016-08-31,January 2016,Actual,2016-01-31,January 2016,Actual,2016-01-31,,Interventional,,,A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old,"An Open-label, Dose-finding, Phase II Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old",Completed,,Phase 2,122.0,Actual,Enimmune Corporation,,7.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-16 08:19:43,2023-06-16 08:19:43,INDUSTRY,,,,,
111283,111284,NCT04072900,,2019-07-26,,,2020-04-24,2019-08-26,2019-08-28,Actual,,,,,,,2020-04-24,2020-04-28,Actual,"April 21, 2020",Anticipated,2020-04-21,April 2020,2020-04-30,"September 1, 2022",Anticipated,2022-09-01,"September 1, 2021",Anticipated,2021-09-01,,Interventional,,,A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma,A Phase I Study With a Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Metastatic Melanoma,Unknown status,Recruiting,Phase 1,30.0,Anticipated,Xiangya Hospital of Central South University,,1.0,,,False,,,,,False,False,,,,,,,,,Undecided,,2023-06-16 08:20:07,2023-06-16 08:20:07,OTHER,,,,,
111357,111358,NCT04934111,,2021-06-10,,,2022-04-14,2021-06-19,2021-06-22,Actual,,,,,,,2022-04-14,2022-04-22,Actual,"December 2, 2021",Actual,2021-12-02,April 2022,2022-04-30,"December 31, 2022",Anticipated,2022-12-31,"November 1, 2022",Anticipated,2022-11-01,,Interventional,COVAC-Uganda,,"Safety and Immunogenicity of LNP-nCOV saRNA-02 Vaccine Against SARS-CoV-2, the Causative Agent of COVID-19","A Clinical Trial to Assess the Safety and Immunogenicity of LNP-nCOV saRNA-02, a Self-amplifying Ribonucleic Acid (saRNA) Vaccine, in SARS-CoV-2 Seronegative and Seropositive Uganda Population",Recruiting,,Phase 1,42.0,Anticipated,MRC/UVRI and LSHTM Uganda Research Unit,,1.0,,,False,,,,False,False,False,,,,,,Data will be available for sharing after study completion. Data may be assumed to be indefinitely available after that point until otherwise stated.,Criteria may be accessed through link below,https://www.imperial.ac.uk/research-and-innovation/research-office/research-governance-and-integrity/what-is-research-governance/data-protection---information-for-participants/,Yes,"Data will be shared according to the Imperial College London data sharing policies, adherent to General Data Protection Regulations (https://www.imperial.ac.uk/research-and-innovation/research-office/research-governance-and-integrity/what-is-research-governance-and-integrity/data-protection---information-for-participants/) and the MRC/UVRI & LSHTM Uganda Research Unit Data Sharing Policy (https://www.mrcuganda.org/publications/data-sharing-policy) and controlled access approach.",2023-06-16 08:20:35,2023-06-16 08:20:35,OTHER,,,,,
111520,111521,NCT03527173,,2018-05-04,2020-04-30,,2020-07-16,2018-05-04,2018-05-17,Actual,2020-04-30,2020-05-15,Actual,,,,2020-07-16,2020-07-28,Actual,"August 29, 2018",Actual,2018-08-29,July 2020,2020-07-31,"November 11, 2019",Actual,2019-11-11,"May 8, 2019",Actual,2019-05-08,,Interventional,,,"A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults","Efficacy, Safety and Immunogenicity of GVGH Shigella Sonnei Vaccine (1790GAHB) in a Human Challenge Study of Healthy Non-immune Adults",Completed,,Phase 2,71.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,True,True,False,,,,,,IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-17 10:52:55,2023-06-17 10:52:55,INDUSTRY,,,,,
111806,111807,NCT01304771,,2010-12-03,,,2012-06-19,2011-02-24,2011-02-25,Estimate,,,,,,,2012-06-19,2012-06-20,Estimate,December 2010,,2010-12-31,June 2012,2012-06-30,April 2011,Actual,2011-04-30,April 2011,Actual,2011-04-30,,Interventional,,,Safety of Synbiotics as Adjuvant to Influenza Vaccine in Elderly,A Phase I Trial of the Safety and Efficacy of Adjuvant AKSB (Agri-King Synbiotic) Synbiotic in Patients 65 Years of Age and Older Receiving the Influenza Vaccine,Completed,,Phase 1,22.0,Actual,Mayo Clinic,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 10:56:00,2023-06-17 10:56:00,OTHER,,,,,
111938,111939,NCT03625934,,2018-07-02,,,2021-04-02,2018-08-07,2018-08-10,Actual,,,,,,,2021-04-02,2021-04-06,Actual,"August 6, 2018",Actual,2018-08-06,April 2021,2021-04-30,"December 31, 2023",Anticipated,2023-12-31,"September 30, 2023",Anticipated,2023-09-30,,Interventional,,,Study to Evaluate Induction of HBV Virus Neutralizing Antibodies Using VVX001,Study to Evaluate the Induction of HBV Virus Neutralizing Antibodies in Healthy Vaccine Naive Adults and Non-responders and in Patients Chronically Infected With HBV Using VVX001,Recruiting,,Phase 2,84.0,Anticipated,Viravaxx AG,,2.0,,,False,,,,True,False,False,,,False,,,,,,Undecided,,2023-06-17 10:57:19,2023-06-17 10:57:19,INDUSTRY,,,,,
111987,111988,NCT02767193,,2016-04-22,,,2019-07-25,2016-05-06,2016-05-10,Estimate,,,,,,,2019-07-25,2019-07-26,Actual,May 2016,,2016-05-31,July 2019,2019-07-31,"May 22, 2019",Actual,2019-05-22,"May 22, 2019",Actual,2019-05-22,,Interventional,,,Safety and Immunogenicity of a Vaccine Dendritic Cell-based Pulsed With Autologous Heat-inactivated in HIV-1 Infected Patients,"Safety and Immunogenicity of a Vaccine Dendritic Cell-based Pulsed With Autologous Heat-inactivated HIV in HIV-1 Infected Patients. Prospective, Randomized, Partially Blinded Study",Completed,,Phase 1,36.0,Actual,Fundacion Clinic per a la Recerca Biomédica,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 08:21:40,2023-06-16 08:21:40,OTHER,,,,,
112255,112256,NCT03789539,,2018-12-24,,,2018-12-25,2018-12-25,2018-12-28,Actual,,,,,,,2018-12-25,2018-12-28,Actual,"June 2, 2018",Actual,2018-06-02,December 2018,2018-12-31,"December 31, 2018",Anticipated,2018-12-31,"December 2, 2018",Actual,2018-12-02,,Interventional,,,"Reactogenicity, Safety and Immunogenicity of an Universal Influenza Vaccine Uniflu","Reactogenicity, Safety and Immunogenicity of an Recombinant Universal Influenza Vaccine Uniflu in Healthy Volunteers From 18 to 60 Years Old",Unknown status,"Active, not recruiting",Phase 1,54.0,Actual,VA Pharma Limited Liability Company,,3.0,,,False,,,,True,False,False,,,,,,,,,Undecided,,2023-06-17 11:00:48,2023-06-17 11:00:48,INDUSTRY,,,,,
112610,112611,NCT01313429,,2011-03-10,,,2020-03-02,2011-03-10,2011-03-11,Estimate,,,,,,,2020-03-02,2020-03-03,Actual,"March 4, 2011",Actual,2011-03-04,March 2020,2020-03-31,"February 26, 2020",Actual,2020-02-26,"February 26, 2020",Actual,2020-02-26,,Interventional,,,"Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum","Adjuvant Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura, or Mediastinum",Terminated,,Phase 1,19.0,Actual,National Institutes of Health Clinical Center (CC),,1.0,,"Per stopping rule if 12 patients underwent immune response analysis after 6 vaccinations and none developed a response, the protocol would stop accrual.",False,,,,,True,False,,,,,,,,,,,2023-06-17 11:04:31,2023-06-17 11:04:31,NIH,,,,,
112802,112803,NCT02482636,,2015-06-16,,,2021-09-17,2015-06-23,2015-06-26,Estimate,,,,,,,2021-09-17,2021-09-20,Actual,August 2015,,2015-08-31,September 2021,2021-09-30,June 2021,Actual,2021-06-30,"November 1, 2017",Actual,2017-11-01,,Interventional,,,Baby Vaccine Study (Sched3),Assessment of Post Booster Antibody Responses in UK Infants Given a Reduced Priming Schedule of Meningococcal Serogroup B and 13 Valent Pneumococcal Conjugate Vaccines,Completed,,Phase 2,189.0,Actual,University of Oxford,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 11:07:05,2023-06-17 11:07:05,OTHER,,,,,
112948,112949,NCT03483961,,2018-03-16,2021-09-14,,2021-10-12,2018-03-23,2018-03-30,Actual,2021-10-12,2021-11-09,Actual,,,,2021-10-12,2021-11-09,Actual,"April 18, 2018",Actual,2018-04-18,October 2021,2021-10-31,"September 21, 2020",Actual,2020-09-21,"September 14, 2020",Actual,2020-09-14,,Interventional,,Randomized participants.,"Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults","A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted)",Completed,,Phase 2,445.0,Actual,Emergent BioSolutions,,10.0,,,False,,,,,True,False,,,,,,,,,No,,2023-06-17 11:08:48,2023-06-17 11:08:48,INDUSTRY,,,,,
112974,112975,NCT02481232,,2015-06-23,,,2015-06-23,2015-06-23,2015-06-25,Estimate,,,,,,,2015-06-23,2015-06-25,Estimate,June 2015,,2015-06-30,June 2015,2015-06-30,June 2016,Anticipated,2016-06-30,April 2016,Anticipated,2016-04-30,,Interventional,,,"A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine","A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine",Unknown status,Recruiting,Phase 1,200.0,Anticipated,"Lanzhou Institute of Biological Products Co., Ltd",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 11:09:06,2023-06-17 11:09:06,INDUSTRY,,,,,
113098,113099,NCT02431767,,2015-04-28,,,2021-10-13,2015-04-28,2015-05-01,Estimate,,,,,,,2021-10-13,2021-10-15,Actual,August 2015,,2015-08-31,October 2021,2021-10-31,"December 20, 2017",Actual,2017-12-20,"June 8, 2017",Actual,2017-06-08,,Interventional,,,"Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults","A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX®-GP (Gag, Pol, Env) DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adult Participants",Completed,,Phase 1,94.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,8.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 06:57:31,2023-06-18 06:57:31,NIH,,,,,
113509,113510,NCT05518487,,2022-08-18,,,2023-02-23,2022-08-24,2022-08-26,Actual,,,,,,,2023-02-23,2023-02-24,Actual,"February 20, 2023",Actual,2023-02-20,February 2023,2023-02-28,"July 15, 2024",Anticipated,2024-07-15,"July 15, 2023",Anticipated,2023-07-15,,Interventional,CPAT-SG,,COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study,Safety and Immunogenicity of a Dose of the Sanofi-GSK Monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 Vaccine in Kidney Transplant Recipients With a Persistently Low SARS CoV-2 Antibody Titer (COVID19-TB-04),Recruiting,,Phase 2,80.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,1.0,,,False,,,,True,True,False,,,,,,"On average, within 24 months after database lock for the trial.",Open access.,https://www.immport.org/home,Yes,"The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.",2023-06-14 01:41:47,2023-06-14 01:41:47,NIH,,,,,
113908,113909,NCT03303976,,2017-09-25,,,2018-12-03,2017-10-02,2017-10-06,Actual,,,,,,,2018-12-03,2018-12-04,Actual,"September 7, 2017",Actual,2017-09-07,December 2018,2018-12-31,"September 12, 2018",Actual,2018-09-12,"September 12, 2018",Actual,2018-09-12,,Interventional,,,Phase I to Test a New Pneumococcal Vaccine,Safety and Immunogenicity of a Candidate Bioconjugate Vaccine Against Streptococcus Pneumoniae When Administered to Adult and Elderly Healthy Subjects. A Phase I Randomized Study.,Completed,,Phase 1,72.0,Actual,LimmaTech Biologics AG,,4.0,,,False,,,,False,False,False,,,,,,,,,Undecided,,2023-06-17 11:18:54,2023-06-17 11:18:54,INDUSTRY,,,,,
113960,113961,NCT00913913,,2009-06-02,2014-02-19,,2015-10-28,2009-06-03,2009-06-04,Estimate,2015-10-28,2015-12-01,Estimate,,,,2015-10-28,2015-12-01,Estimate,February 2009,,2009-02-28,February 2014,2014-02-28,January 2013,Actual,2013-01-31,January 2013,Actual,2013-01-31,,Interventional,,Number was the actual number of patients who signed consent and received treatment on study.,"Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNa-2b in Metastatic Renal Cell Carcinoma (RCC) Patients","A Phase II Study of VEGF Blockade With Bevacizumab Combined With Autologous Tumor/Dendritic Cell Vaccine (DC Vaccine), Interleukin-2 (IL-2) and Interferon-a-2b (IFNa-2b) in Patients With Metastatic Renal Cell Carcinoma (RCC)",Terminated,,Phase 2,8.0,Actual,Dartmouth-Hitchcock Medical Center,,1.0,,low accrual not allowing site to meeting statistical endpoints,False,,,,True,,,,,,,,,,,,,2023-06-14 02:17:36,2023-06-14 02:17:36,OTHER,,,,,
113966,113967,NCT02762045,,2016-05-02,,,2016-05-02,2016-05-02,2016-05-04,Estimate,,,,,,,2016-05-02,2016-05-04,Estimate,April 2016,,2016-04-30,May 2016,2016-05-31,December 2017,Anticipated,2017-12-31,December 2016,Anticipated,2016-12-31,,Interventional,,,Clinical Trial of Recombinant Adenovirus Type 5 AIDS Vaccine,Phase I Clinical Trial of Recombinant Adenovirus Type 5 Therapeutic AIDS Vaccine Expressing Gag,Unknown status,Recruiting,Phase 1,36.0,Anticipated,"Centers for Disease Control and Prevention, China",,3.0,,,False,,,,False,,,,,,,,,,,Undecided,,2023-06-16 08:26:17,2023-06-16 08:26:17,OTHER_GOV,,,,,
114198,114199,NCT05414786,,2022-05-26,,,2023-03-08,2022-06-08,2022-06-10,Actual,,,,,,,2023-03-08,2023-03-10,Actual,"May 25, 2022",Actual,2022-05-25,March 2023,2023-03-31,"June 30, 2023",Anticipated,2023-06-30,"June 30, 2023",Anticipated,2023-06-30,,Interventional,,,A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644),A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) in HIV-1 Uninfected Adults in Good General Health,"Active, not recruiting",,Phase 1,18.0,Actual,International AIDS Vaccine Initiative,,1.0,,,False,,,,True,True,False,,,,,,Information will be shared as soon as results are publicly available for the investigational product being used in similar studies conducted in other regions. The existing results and data upon which the G003 study is based is yet to be made fully publicly available.,"Access to data will be determined by the study team, partners and funding agencies.",http://www.iavi.org/newsresources/press-releases/2021/first-in-human-clinicaltrial-confirms-novel-hivvaccine-approachdeveloped-by-iavi-andscripps-research,Yes,"This will be done with the clinical trial team, collaborators and funding agencies. Also, as information becomes available, this will be shared with the site and study participants. Results dissemination plans will be developed and implemented as the study progresses.",2023-06-17 11:22:23,2023-06-17 11:22:23,NETWORK,,,,,
114481,114482,NCT02717494,,2016-03-18,2019-11-06,,2019-12-31,2016-03-22,2016-03-23,Estimate,2019-12-31,2020-01-18,Actual,,,,2019-12-31,2020-01-18,Actual,March 2016,,2016-03-31,December 2019,2019-12-31,May 2019,Actual,2019-05-31,November 2018,Actual,2018-11-30,,Interventional,,Mother participants who received study treatment in Step 1 were included.,Safety and Immunogenicity of Anti-Pneumococcal Vaccines in HIV-Infected Pregnant Women,Safety and Immunogenicity of Anti-Pneumococcal Vaccines in HIV-Infected Pregnant Women,Completed,,Phase 2,347.0,Actual,Westat,,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 11:25:12,2023-06-17 11:25:12,OTHER,,,,,
114533,114534,NCT05772286,,2023-02-15,,,2023-03-15,2023-03-15,2023-03-16,Actual,,,,,,,2023-03-15,2023-03-16,Actual,March 2023,Anticipated,2023-03-31,February 2023,2023-02-28,June 2025,Anticipated,2025-06-30,June 2025,Anticipated,2025-06-30,,Interventional,HIVAC-FOUND,,"Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein SOSIP v8.2 763 Vaccine, Adjuvanted With MPLA Liposomes, in Healthy, HIV-Uninfected Adults","A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein SOSIP v8.2 763 Vaccine, Adjuvanted With MPLA Liposomes, in Healthy, HIV-Uninfected Adults",Not yet recruiting,,Phase 1,12.0,Anticipated,Fundacion Clinic per a la Recerca Biomédica,,1.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-15 06:16:59,2023-06-15 06:16:59,OTHER,,,,,
114616,114617,NCT02575456,,2015-10-11,,,2016-08-30,2015-10-13,2015-10-14,Estimate,,,,,,,2016-08-30,2016-09-01,Estimate,October 2015,,2015-10-31,December 2015,2015-12-31,July 2016,Actual,2016-07-31,June 2016,Actual,2016-06-30,,Interventional,,,A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine,"A Single-Center, Randomized, Blind, Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Adenovirus Type 5 Vector Based Ebola Virus Disease Vaccine (Ad5-EBOV) in Healthy Adults in Sierra Leone",Completed,,Phase 2,500.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 08:28:03,2023-06-16 08:28:03,NETWORK,,,,,
114633,114634,NCT00005780,,2000-06-03,2022-11-02,,2023-01-04,2000-06-03,2000-06-05,Estimate,2023-01-04,2023-01-31,Actual,,,,2023-01-04,2023-01-31,Actual,"June 1, 2000",Actual,2000-06-01,January 2023,2023-01-31,"June 16, 2021",Actual,2021-06-16,"June 9, 2021",Actual,2021-06-09,,Interventional,,,Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma,Pilot Study of Idiotype Vaccine and EPOCH-Rituximab Chemotherapy in Untreated Mantle Cell Lymphoma,Completed,,Phase 2,26.0,Actual,National Institutes of Health Clinical Center (CC),,1.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-17 11:26:49,2023-06-17 11:26:49,NIH,,,,,
115016,115017,NCT00972725,,2009-09-03,2016-11-28,2010-12-23,2018-07-11,2009-09-03,2009-09-07,Estimate,2017-03-02,2017-04-13,Actual,2010-12-23,2010-12-30,Estimate,2018-07-11,2018-08-17,Actual,"December 1, 2009",,2009-12-01,March 2017,2017-03-31,"October 4, 2010",Actual,2010-10-04,"October 4, 2010",Actual,2010-10-04,,Interventional,,,Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine Dose,A Study to Evaluate the Safety and Immunogenicity of a Booster Dose of GSK Biologicals' HIV Candidate Vaccine (732461) After Administration of Chloroquine in Healthy Adults.,Completed,,Phase 2,28.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 02:56:56,2023-06-14 02:56:56,INDUSTRY,,,,,
115100,115101,NCT05771584,,2022-09-06,,,2023-03-14,2023-03-14,2023-03-16,Actual,,,,,,,2023-03-14,2023-03-16,Actual,"June 15, 2023",Anticipated,2023-06-15,March 2023,2023-03-31,"June 15, 2026",Anticipated,2026-06-15,"October 15, 2023",Anticipated,2023-10-15,,Interventional,Conerstone3,,"Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer","A Phase 2 Study to Evaluate the Safety and Immunological Efficacy of Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With HER2 Expressing Gastric Cancer (CORNERSTONE-003)",Not yet recruiting,,Phase 2,24.0,Anticipated,Aston Sci. Inc.,,2.0,,,False,,,,True,True,False,,,True,,,,,,No,,2023-06-15 06:17:24,2023-06-15 06:17:24,INDUSTRY,,,,,
116299,116300,NCT02454634,,2015-05-12,,,2018-11-06,2015-05-26,2015-05-27,Estimate,,,,,,,2018-11-06,2018-11-07,Actual,June 2015,Actual,2015-06-30,September 2017,2017-09-30,"September 19, 2017",Actual,2017-09-19,"September 19, 2017",Actual,2017-09-19,,Interventional,NOA-16,,Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas,"Targeting IDH1R132H in WHO Grade III-IV IDH1R132H-mutated Gliomas by a Peptide Vaccine - a Phase I Safety, Tolerability and Immunogenicity Multicenter Trial (NOA-16)",Completed,,Phase 1,39.0,Actual,"National Center for Tumor Diseases, Heidelberg",,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 11:45:59,2023-06-17 11:45:59,OTHER,,,,,
116848,116849,NCT00709462,,2008-07-01,,,2010-07-23,2008-07-01,2008-07-03,Estimate,,,,,,,2010-07-23,2010-07-26,Estimate,March 2004,,2004-03-31,July 2010,2010-07-31,June 2010,Actual,2010-06-30,May 2010,Actual,2010-05-31,,Interventional,,,"A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)","A Phase I, Open-Label, Dose-Escalation, Multidose Study of CDX-1307, a Mannose Receptor-Targeted hCG-ß Vaccine, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX-1307-01)",Completed,,Phase 1,48.0,Anticipated,Celldex Therapeutics,,,,,False,,,,False,,,,,,,,,,,,,2023-06-16 08:31:32,2023-06-16 08:31:32,INDUSTRY,,,,,
117358,117359,NCT04794218,,2021-03-03,,,2023-03-08,2021-03-09,2021-03-11,Actual,,,,,,,2023-03-08,2023-03-09,Actual,"June 23, 2021",Actual,2021-06-23,March 2023,2023-03-31,January 2024,Anticipated,2024-01-31,December 2023,Anticipated,2023-12-31,,Interventional,,,A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV<U+2206>G-LASV-GPC Vaccine in Adults in Good General Heath,"A Phase 1 Randomized, Double-blinded, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV<U+2206>G-LASV-GPC Vaccine in Adults in Good General Heath","Active, not recruiting",,Phase 1,110.0,Anticipated,International AIDS Vaccine Initiative,,8.0,,,False,,,,,True,False,,,,,,,,,Undecided,,2023-06-17 11:59:12,2023-06-17 11:59:12,NETWORK,,,,,
117466,117467,NCT02434276,,2015-04-16,,,2015-06-25,2015-05-04,2015-05-05,Estimate,,,,,,,2015-06-25,2015-06-26,Estimate,May 2015,,2015-05-31,June 2015,2015-06-30,June 2016,Anticipated,2016-06-30,August 2015,Anticipated,2015-08-31,,Interventional,,,Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years,"A Phase II, Multicenter, Randomized, Double-Blind, Active Comparator Controlled Study of the Immunogenicity and Safety of VAX2012Q, A Quadrivalent Influenza Vaccine in Healthy Adults 18-64 Years",Unknown status,"Active, not recruiting",Phase 2,450.0,Anticipated,VaxInnate Corporation,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 12:01:11,2023-06-17 12:01:11,INDUSTRY,,,,,
117492,117493,NCT04067011,,2019-07-15,2021-05-14,,2023-02-01,2019-08-21,2019-08-26,Actual,2021-06-10,2021-06-30,Actual,,,,2023-02-01,2023-02-03,Actual,"August 12, 2019",Actual,2019-08-12,February 2023,2023-02-28,"March 19, 2020",Actual,2020-03-19,"March 5, 2020",Actual,2020-03-05,,Interventional,,Intent to treat population: all subjects who were randomized.,Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study,A Phase 2 Drug-Vaccine Interaction Study to Examine Whether Co-administering AV7909 With Ciprofloxacin or Doxycycline Affects Antibiotic Pharmacokinetics or AV7909 Immunogenicity in Healthy Adults,Completed,,Phase 2,210.0,Actual,Emergent BioSolutions,,3.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-16 08:32:47,2023-06-16 08:32:47,INDUSTRY,,,,,
117615,117616,NCT02433652,,2015-04-27,,,2018-02-27,2015-04-29,2015-05-05,Estimate,,,,,,,2018-02-27,2018-02-28,Actual,September 2015,,2015-09-30,February 2018,2018-02-28,,,,November 2016,Actual,2016-11-30,,Interventional,,,Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2,A Phase 1 Evaluation of the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2,Completed,,Phase 1,24.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 12:02:34,2023-06-17 12:02:34,NIH,,,,,
117710,117711,NCT03795441,,2019-01-04,,,2019-08-29,2019-01-04,2019-01-07,Actual,,,,,,,2019-08-29,2019-08-30,Actual,"January 7, 2019",Actual,2019-01-07,August 2019,2019-08-31,"July 28, 2019",Actual,2019-07-28,"July 28, 2019",Actual,2019-07-28,,Interventional,,,A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in Adults,"Open Label, Single Arm Phase 1 Study to Evaluate the Shedding, Biodistribution, Safety and Immunogenicity of Ad26.RSV.preF Vaccine in Adults",Completed,,Phase 1,24.0,Actual,Janssen Vaccines & Prevention B.V.,,1.0,,,False,,,,False,True,False,,,True,,,,,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.

As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2023-06-17 03:44:56,2023-06-17 03:44:56,INDUSTRY,,,,,
118300,118301,NCT00889889,,2009-04-28,,2012-01-24,2013-09-27,2009-04-28,2009-04-29,Estimate,,,,2012-01-24,2012-01-30,Estimate,2013-09-27,2013-10-25,Estimate,May 2009,,2009-05-31,September 2013,2013-09-30,January 2011,Actual,2011-01-31,January 2011,Actual,2011-01-31,,Interventional,,,"Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and <= 64, Plus Revaccination","Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Cell-Derived Trivalent Subunit Influenza Vaccine in Subjects Aged >= 18 Years and <= 64 Years During Two Consecutive Years.",Completed,,Phase 2,1270.0,Actual,Abbott,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 06:58:50,2023-06-18 06:58:50,INDUSTRY,,,,,
118375,118376,NCT03122106,,2017-04-17,2022-07-21,,2022-09-22,2017-04-19,2017-04-20,Actual,2022-09-22,2022-10-04,Actual,,,,2022-09-22,2022-10-04,Actual,"January 5, 2018",Actual,2018-01-05,September 2022,2022-09-30,"August 13, 2022",Actual,2022-08-13,"September 3, 2021",Actual,2021-09-03,,Interventional,,,Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy,A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Neoantigen DNA Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy,Terminated,,Phase 1,15.0,Actual,Washington University School of Medicine,,1.0,,Loss of funding,False,,,,True,True,True,,,False,,,,,,No,,2023-06-17 12:12:49,2023-06-17 12:12:49,OTHER,,,,,
118823,118824,NCT03674177,,2018-09-14,2020-03-17,,2021-08-12,2018-09-14,2018-09-17,Actual,2020-04-02,2020-04-15,Actual,,,,2021-08-12,2021-08-13,Actual,"October 30, 2018",Actual,2018-10-30,August 2021,2021-08-31,"September 2, 2019",Actual,2019-09-02,"April 16, 2019",Actual,2019-04-16,,Interventional,,,"A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women","A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational Unadjuvanted RSV Maternal Vaccine Compared to Placebo When Administered to Healthy Non-pregnant Women.",Completed,,Phase 1,502.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,True,False,,,,,,IPD is available via the Clinical Study Data Request site (copy the URL below to your browser),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://www.clinicalstudydatarequest.com/Posting.aspx?ID=20864,Yes,IPD for this study is available via the Clinical Study Data Request site,2023-06-17 12:18:15,2023-06-17 12:18:15,INDUSTRY,,,,,
119220,119221,NCT05554068,,2022-09-21,,,2023-03-07,2022-09-21,2022-09-26,Actual,,,,,,,2023-03-07,2023-03-08,Actual,"March 7, 2023",Actual,2023-03-07,March 2023,2023-03-31,"November 1, 2026",Anticipated,2026-11-01,"March 7, 2025",Anticipated,2025-03-07,,Interventional,,,Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients,"Phase II, Non-randomized, Open-label Study to Assess the Immunogenicity and Clinical Efficacy of the Recombinant Zoster Vaccine for Recipients of an Allogeneic Hematopoietic Stem Cell Transplant",Recruiting,,Phase 2,100.0,Anticipated,Loyola University,,1.0,,,False,,,,True,True,False,,,False,,,,,,No,,2023-06-17 12:21:50,2023-06-17 12:21:50,OTHER,,,,,
119258,119259,NCT03739229,,2018-11-01,,,2018-11-09,2018-11-09,2018-11-13,Actual,,,,,,,2018-11-09,2018-11-13,Actual,"December 3, 2018",Anticipated,2018-12-03,November 2018,2018-11-30,"July 3, 2019",Anticipated,2019-07-03,"June 3, 2019",Anticipated,2019-06-03,,Interventional,,,"Reactogenicity, Safety and Immunogenicity of a LAIV <U+0410>/17/Hong Kong/2017/75108 H7N9 Influenza Vaccine","Reactogenicity, Safety and Immunogenicity of a Live Monovalent <U+0410>/17/Hong Kong/2017/75108 (H7N9) Influenza Vaccine",Unknown status,Not yet recruiting,Phase 1,40.0,Anticipated,"Research Institute of Influenza, Russia",,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-17 12:22:08,2023-06-17 12:22:08,OTHER,,,,,
119280,119281,NCT05528952,,2022-09-01,,,2023-03-06,2022-09-01,2022-09-06,Actual,,,,,,,2023-03-06,2023-03-08,Actual,"September 27, 2022",Actual,2022-09-27,October 2022,2022-10-31,"September 30, 2027",Anticipated,2027-09-30,"April 30, 2025",Anticipated,2025-04-30,,Interventional,TERTIO,,Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma,Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: a Proof of Concept Randomized Phase II Study (TERTIO - Prodige 82),Recruiting,,Phase 2,105.0,Anticipated,Centre Hospitalier Universitaire de Besancon,,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-17 12:22:25,2023-06-17 12:22:25,OTHER,,,,,
119403,119404,NCT03671720,,2018-09-13,,,2019-10-31,2018-09-13,2018-09-14,Actual,,,,,,,2019-10-31,2019-11-04,Actual,"September 11, 2018",Actual,2018-09-11,October 2019,2019-10-31,"December 30, 2022",Anticipated,2022-12-30,"December 30, 2021",Anticipated,2021-12-30,,Interventional,,,Personalized Vaccine Generated by Autologous Dendritic Cells Pulsed With Autologous Whole Tumor Cell Lysate Treat Advanced Solid Tumor Patients With High Tumor Mutation Burden,Personalized Vaccine Generated by Autologous Dendritic Cells Pulsed With Autologous Whole Tumor Cell Lysate Treat Advanced Solid Tumor Patients With High Tumor Mutation Burden,Unknown status,Recruiting,Early Phase 1,10.0,Anticipated,Capital Medical University,,1.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-17 12:23:35,2023-06-17 12:23:35,OTHER,,,,,
119630,119631,NCT02354404,,2015-01-29,,,2017-12-01,2015-02-02,2015-02-03,Estimate,,,,,,,2017-12-01,2017-12-05,Actual,"January 27, 2015",Actual,2015-01-27,September 2017,2017-09-30,"April 19, 2017",Actual,2017-04-19,"April 19, 2017",Actual,2017-04-19,,Interventional,,,"Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda","Phase 1B, Open-Label, Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of the Investigational Ebola Vaccines, VRC-EBOADC069-00-VP, VRC-EBOADC076-00-VP and VRC-EBOMVA079-00-VP in Healthy Adults in Kampala Uganda",Completed,,Phase 1,90.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 12:57:44,2023-06-17 12:57:44,NIH,,,,,
119755,119756,NCT01049035,,2010-01-13,2020-05-19,2013-04-16,2022-03-21,2010-01-13,2010-01-14,Estimate,2020-05-19,2020-06-09,Actual,2013-04-16,2013-04-25,Estimate,2022-03-21,2022-03-28,Actual,"December 16, 2009",Actual,2009-12-16,March 2022,2022-03-31,"February 13, 2012",Actual,2012-02-13,"February 13, 2012",Actual,2012-02-13,,Interventional,,Analysis was performed on all randomized participants.,A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers,Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine Administered in Infants and Toddlers,Completed,,Phase 2,580.0,Actual,Sanofi,,7.0,,,False,,,,False,True,False,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-14 02:05:56,2023-06-14 02:05:56,INDUSTRY,,,,,
119841,119842,NCT05013216,,2021-08-18,,,2023-03-06,2021-08-18,2021-08-19,Actual,,,,,,,2023-03-06,2023-03-08,Actual,"April 11, 2022",Actual,2022-04-11,March 2023,2023-03-31,"May 1, 2026",Anticipated,2026-05-01,"May 1, 2026",Anticipated,2026-05-01,,Interventional,,,Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer,Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer,Recruiting,,Phase 1,25.0,Anticipated,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,1.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 12:29:03,2023-06-17 12:29:03,OTHER,,,,,
120199,120200,NCT00684294,,2008-05-21,,,2020-02-27,2008-05-23,2008-05-26,Estimate,,,,,,,2020-02-27,2020-03-02,Actual,"May 27, 2008",Actual,2008-05-27,February 2020,2020-02-29,"May 28, 2019",Actual,2019-05-28,May 2009,Actual,2009-05-31,,Interventional,Auto TAG,,Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer,Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer,Terminated,,Phase 1,46.0,Actual,Mary Crowley Medical Research Center,,2.0,,"Since no safety issues have been reported to date in association with TAG vaccine, no further survival follow-up will be done.",False,,,,True,,,,,,,,,,,,,2023-06-16 08:38:39,2023-06-16 08:38:39,OTHER,,,,,
120862,120863,NCT05383560,,2022-05-15,,,2022-10-26,2022-05-19,2022-05-20,Actual,,,,,,,2022-10-26,2022-10-28,Actual,"September 5, 2022",Actual,2022-09-05,October 2022,2022-10-31,July 2023,Anticipated,2023-07-31,May 2023,Anticipated,2023-05-31,,Interventional,SH-MO-214,,Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults,"Phase 2, Randomized, Observer-Blind, Investigator-Initiated, Collaborative Study to Evaluate the Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults",Recruiting,,Phase 2,150.0,Anticipated,Sheba Medical Center,,3.0,,,False,,,,True,False,False,,,,,,will be available upon publication of results,Upon request. Requires collaborator's approval as well.,,Yes,Unidentified data will be available after publication of the results.,2023-06-17 12:39:32,2023-06-17 12:39:32,OTHER_GOV,,,,,
120968,120969,NCT02946385,,2016-10-25,2019-02-12,,2019-08-12,2016-10-25,2016-10-27,Estimate,2019-08-12,2019-08-20,Actual,,,,2019-08-12,2019-08-20,Actual,"November 15, 2016",Actual,2016-11-15,August 2019,2019-08-31,"February 13, 2018",Actual,2018-02-13,"February 13, 2018",Actual,2018-02-13,,Interventional,,,Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents,"A Phase 2b Open-Label Multi-Center Study Assessing the Immunological Persistence of Antibodies at Approximately 2 Years After the Last Meningococcal Vaccination in Study V102_15 (NCT02212457) and the Response to a Booster Dose of GSK MenABCWY or Meningococcal Serogroup B Vaccines, in Healthy Adolescents",Completed,,Phase 2,604.0,Actual,GlaxoSmithKline,,6.0,,,False,,,,,False,False,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-17 12:40:34,2023-06-17 12:40:34,INDUSTRY,,,,,
121223,121224,NCT00722098,,2008-07-23,,,2013-07-05,2008-07-24,2008-07-25,Estimate,,,,,,,2013-07-05,2013-07-08,Estimate,June 2008,,2008-06-30,July 2013,2013-07-31,July 2012,Actual,2012-07-31,April 2011,Actual,2011-04-30,,Interventional,,,Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients,Melanoma Peptide-Loaded Dendritic Cell Vaccine in HLA-A*0201 Patients With Stage IV Melanoma: A Phase II Randomized Trial to Compare Vaccination With and Without Cyclophosphamide Treatment.,Terminated,,Phase 2,9.0,Actual,Baylor Research Institute,,2.0,,"Early termination due to lesser accrual, and data analysis not done.",False,,,,True,,,,,,,,,,,,,2023-06-16 08:42:31,2023-06-16 08:42:31,OTHER,,,,,
121306,121307,NCT01379430,,2011-06-10,,,2012-10-02,2011-06-21,2011-06-23,Estimate,,,,,,,2012-10-02,2012-10-03,Estimate,June 2010,,2010-06-30,October 2012,2012-10-31,May 2011,Actual,2011-05-31,May 2011,Actual,2011-05-31,,Interventional,,,Safety and Immunogenicity of AdCh63 ME-TRAP and MVA ME-TRAP Vaccines in Malaria Endemic Areas,Safety and Immunogenicity of Heterologous Prime-boost With the Candidate Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP in Healthy Adults in a Malaria Endemic Area,Completed,,Phase 1,30.0,Actual,University of Oxford,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 12:44:09,2023-06-17 12:44:09,OTHER,,,,,
121501,121502,NCT05435027,,2022-06-24,,,2023-03-15,2022-06-24,2022-06-28,Actual,,,,,,,2023-03-15,2023-03-16,Actual,"February 28, 2022",Actual,2022-02-28,March 2023,2023-03-31,March 2024,Anticipated,2024-03-31,March 2024,Anticipated,2024-03-31,,Interventional,,,Study of Self-Amplifying Messenger Ribonucleic Acid (samRNA) Vaccines Against COVID-19 in Healthy Adults and People Living With Human Immunodeficiency Virus (HIV),"A Phase 1 SARS-CoV-2 Vaccine Study to Assess the Safety and Tolerability of GRT-R912, GRT-R914, and GRT-R918 Administered as Prime and/or Boost in Healthy Adult Participants and People Living With HIV","Active, not recruiting",,Phase 1,342.0,Actual,"Gritstone bio, Inc.",,4.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-15 06:18:54,2023-06-15 06:18:54,INDUSTRY,,,,,
121578,121579,NCT02571166,,2015-08-13,,,2019-01-10,2015-10-07,2015-10-08,Estimate,,,,,,,2019-01-10,2019-01-14,Actual,November 2015,,2015-11-30,January 2019,2019-01-31,"December 1, 2018",Actual,2018-12-01,"December 1, 2018",Actual,2018-12-01,,Interventional,,,HSV529 Vaccine in HSV-2 Seropositive Adults,"Phase I Study of the Genital Immune Response to Live, Attenuated HSV529 Vaccine in HSV-2 Seropositive Adults",Completed,,Phase 1,10.0,Actual,Fred Hutchinson Cancer Center,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 08:43:30,2023-06-16 08:43:30,OTHER,,,,,
121792,121793,NCT02199691,,2014-07-23,2020-05-19,2015-09-29,2022-03-24,2014-07-23,2014-07-24,Estimate,2020-05-19,2020-06-09,Actual,2015-09-29,2015-10-20,Estimate,2022-03-24,2022-04-04,Actual,"July 22, 2014",Actual,2014-07-22,March 2022,2022-03-31,"October 2, 2015",Actual,2015-10-02,"October 2, 2015",Actual,2015-10-02,,Interventional,,Analysis was performed on all randomized participants.,Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents,A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents,Completed,,Phase 2,1715.0,Actual,Sanofi,,4.0,,,False,,,,False,True,False,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-17 12:49:22,2023-06-17 12:49:22,INDUSTRY,,,,,
121896,121897,NCT02386150,,2015-02-26,,,2019-12-30,2015-03-05,2015-03-11,Estimate,,,,,,,2019-12-30,2020-01-02,Actual,October 2017,Anticipated,2017-10-31,December 2019,2019-12-31,December 2018,Anticipated,2018-12-31,December 2017,Anticipated,2017-12-31,,Interventional,,,ID Recombinant Ricin Toxin A-Chain Vaccine RVEc - 3-Dose Primary Series With Boost,Phase 1b Escalating Study to Evaluate the Safety and Immunogenicity of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc) Administered Intradermally to Healthy Adults as a 3-Dose Primary Series and Booster,Withdrawn,,Phase 1,0.0,Actual,U.S. Army Medical Research and Development Command,,2.0,,lack of funding,False,,,,False,True,False,,,,,,,,,,,2023-06-17 12:50:22,2023-06-17 12:50:22,FED,,,,,
121983,121984,NCT01732627,,2012-11-13,2020-05-19,2013-11-11,2022-03-24,2012-11-19,2012-11-26,Estimate,2020-05-19,2020-06-09,Actual,2013-11-11,2013-12-04,Estimate,2022-03-24,2022-04-04,Actual,"November 12, 2012",Actual,2012-11-12,March 2022,2022-03-31,"January 17, 2013",Actual,2013-01-17,"January 17, 2013",Actual,2013-01-17,,Interventional,,Analysis was performed on all randomized participants.,Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older,Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered in Subjects 56 Years of Age and Older,Completed,,Phase 2,301.0,Actual,Sanofi,,2.0,,,False,,,,False,True,False,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-17 12:51:24,2023-06-17 12:51:24,INDUSTRY,,,,,
121998,121999,NCT02661490,,2016-01-08,2020-04-22,,2020-04-22,2016-01-19,2016-01-22,Estimate,2020-04-22,2020-05-18,Actual,,,,2020-04-22,2020-05-18,Actual,"February 1, 2016",Actual,2016-02-01,April 2020,2020-04-30,"September 29, 2017",Actual,2017-09-29,"October 28, 2016",Actual,2016-10-28,,Interventional,,Randomized Set included all randomized participants regardless of whether any study vaccine (NoV VLP vaccine or placebo) was received.,Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population,"A Phase II, Randomized, Double-blind, Safety and Immunogenicity Trial of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in Healthy Elderly Adults",Completed,,Phase 2,320.0,Actual,Takeda,,5.0,,,False,,,,True,,,,,,,,,,,Yes,"Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.",2023-06-17 12:51:34,2023-06-17 12:51:34,INDUSTRY,,,,,
122113,122114,NCT02383498,,2015-03-04,,,2019-10-22,2015-03-06,2015-03-09,Estimate,,,,,,,2019-10-22,2019-10-23,Actual,"April 17, 2015",,2015-04-17,October 2019,2019-10-31,"March 31, 2020",Anticipated,2020-03-31,"March 31, 2020",Anticipated,2020-03-31,,Interventional,,,QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma,"A Randomized, Double-Blind, Phase 2 Trial of GI-6301 (Yeast-Brachyury Vaccine) Versus Placebo in Combination With Standard of Care Definitive Radiotherapy in Locally Advanced, Unresectable, Chordoma",Unknown status,"Active, not recruiting",Phase 2,55.0,Anticipated,"NantCell, Inc.",,2.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-17 12:52:48,2023-06-17 12:52:48,INDUSTRY,,,,,
122152,122153,NCT01364571,,2011-05-31,,,2019-02-28,2011-05-31,2011-06-02,Estimate,,,,,,,2019-02-28,2019-03-04,Actual,August 2011,,2011-08-31,February 2019,2019-02-28,January 2013,Actual,2013-01-31,January 2013,Actual,2013-01-31,,Interventional,,,Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years,"A Phase 1/2 Placebo-controlled, Randomized, Double-blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of 3 Ascending Dose Levels Of A 4-antigen Staphylococcus Aureus Vaccine (sa4ag) In Healthy Adults Aged 18 To <65 Years",Completed,,Phase 1,456.0,Actual,Pfizer,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 12:53:17,2023-06-17 12:53:17,INDUSTRY,,,,,
122178,122179,NCT01364883,,2011-05-31,,,2013-07-26,2011-06-02,2011-06-03,Estimate,,,,,,,2013-07-26,2013-07-29,Estimate,July 2011,,2011-07-31,July 2013,2013-07-31,July 2013,Actual,2013-07-31,July 2013,Actual,2013-07-31,,Interventional,,,Safety and Immunogenicity of Novel Vaccination Schedules With Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP,A Phase I Study to Assess the Safety and Immunogenicity of Novel Schedules for Vaccination With the Candidate Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP,Completed,,Phase 1,39.0,Actual,University of Oxford,,7.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 12:53:33,2023-06-17 12:53:33,OTHER,,,,,
122306,122307,NCT04080245,,2019-09-03,,,2022-12-16,2019-09-05,2019-09-06,Actual,,,,,,,2022-12-16,2022-12-19,Actual,"November 15, 2019",Actual,2019-11-15,December 2022,2022-12-31,"December 1, 2022",Actual,2022-12-01,"June 1, 2020",Actual,2020-06-01,,Interventional,LAIV,,Functional Consequences of T-bet Expression in Flu-specific Memory B Cells After Live Attenuated Influenza Vaccine (LAIV),Functional Consequences of T-bet Expression in Flu-specific Memory B Cells After Live Attenuated Influenza Vaccine (LAIV),Completed,,Early Phase 1,4.0,Actual,University of Alabama at Birmingham,,1.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-16 08:50:39,2023-06-16 08:50:39,OTHER,,,,,
122721,122722,NCT02348320,,2015-01-21,,,2020-06-30,2015-01-27,2015-01-28,Estimate,,,,,,,2020-06-30,2020-07-01,Actual,"June 17, 2015",Actual,2015-06-17,June 2019,2019-06-30,"March 12, 2020",Actual,2020-03-12,"March 12, 2020",Actual,2020-03-12,,Interventional,,,Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy,A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy,Completed,,Phase 1,18.0,Actual,Washington University School of Medicine,,1.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 13:04:12,2023-06-17 13:04:12,OTHER,,,,,
122760,122761,NCT02337868,,2015-01-08,,,2019-01-24,2015-01-08,2015-01-14,Estimate,,,,,,,2019-01-24,2019-01-28,Actual,"March 31, 2015",Actual,2015-03-31,"December 7, 2016",2016-12-07,"December 16, 2016",Actual,2016-12-16,"December 16, 2016",Actual,2016-12-16,,Interventional,,,Phase 1 Trial of Inactivated West Nile Virus Vaccine,"A Double Blind, Randomized, Placebo-Controlled, Phase I Dose Escalation Trial to Evaluate the Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine, HydroVax-001, in Healthy Adults",Completed,,Phase 1,96.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-17 13:04:31,2023-06-17 13:04:31,NIH,,,,,
123497,123498,NCT05202288,,2021-12-15,,,2022-01-07,2022-01-07,2022-01-21,Actual,,,,,,,2022-01-07,2022-01-21,Actual,March 2022,Anticipated,2022-03-31,January 2022,2022-01-31,March 2023,Anticipated,2023-03-31,March 2023,Anticipated,2023-03-31,,Interventional,,,Pilot Study Evaluating the Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers,Phase IIa Pilot Study Evaluating the Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers,Not yet recruiting,,Phase 2,135.0,Anticipated,"ANRS, Emerging Infectious Diseases",,5.0,,,False,,,,False,True,False,,,True,,,,,,No,,2023-06-17 13:12:01,2023-06-17 13:12:01,OTHER_GOV,,,,,
123554,123555,NCT02971670,,2016-11-21,2017-03-28,,2017-05-12,2016-11-21,2016-11-23,Estimate,2017-03-28,2017-05-08,Actual,,,,2017-05-12,2017-06-09,Actual,October 2015,,2015-10-31,May 2017,2017-05-31,May 2016,Actual,2016-05-31,March 2016,Actual,2016-03-31,,Interventional,,,Amendment of rTSST-1 Variant Vaccine Phase 1 Clinical Trial,Amendment of Phase 1 Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults,Completed,,Phase 1,23.0,Actual,Biomedizinische Forschungs gmbH,,4.0,,,False,,,,True,,,,,,,,,,,Yes,,2023-06-17 13:12:30,2023-06-17 13:12:30,INDUSTRY,,,,,
123559,123560,NCT01061840,,2010-02-02,,,2022-03-14,2010-02-02,2010-02-03,Estimate,,,,,,,2022-03-14,2022-03-15,Actual,December 2009,Actual,2009-12-31,March 2022,2022-03-31,January 2019,Actual,2019-01-31,"December 6, 2018",Actual,2018-12-06,,Interventional,,,Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer,Phase I Trial of Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer,Completed,,Phase 1,100.0,Actual,"Gradalis, Inc.",,3.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-17 13:12:34,2023-06-17 13:12:34,INDUSTRY,,,,,
123940,123941,NCT02615574,,2015-11-24,,,2017-09-25,2015-11-25,2015-11-26,Estimate,,,,,,,2017-09-25,2017-09-26,Actual,March 2016,,2016-03-31,September 2017,2017-09-30,December 2018,Anticipated,2018-12-31,June 2018,Anticipated,2018-06-30,,Interventional,,,"A Study of Type-1 Polarized Dendritic Cell (aDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-a2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer","A Phase 2 Study of Type-1 Polarized Dendritic Cell (aDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-a2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer",Withdrawn,,Phase 2,0.0,Actual,University of Pittsburgh,,1.0,,Due to inadequate supply of drug,False,,,,True,,,,,,,,,,,,,2023-06-16 08:55:21,2023-06-16 08:55:21,OTHER,,,,,
123945,123946,NCT01003093,,2009-10-27,,,2013-01-18,2009-10-27,2009-10-28,Estimate,,,,,,,2013-01-18,2013-01-21,Estimate,November 2005,,2005-11-30,January 2013,2013-01-31,June 2008,Actual,2008-06-30,March 2008,Actual,2008-03-31,,Interventional,THYB-01,,A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis(TB) Subunit Vaccine,A Safety and Immunogenicity Phase 1 Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31) Administered at 0 and 2 Months,Completed,,Phase 1,36.0,Actual,Statens Serum Institut,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 08:55:22,2023-06-16 08:55:22,OTHER,,,,,
124204,124205,NCT05060887,,2021-09-20,,,2023-02-20,2021-09-20,2021-09-29,Actual,,,,,,,2023-02-20,2023-02-21,Actual,"November 15, 2021",Actual,2021-11-15,February 2023,2023-02-28,"December 7, 2022",Actual,2022-12-07,"February 1, 2022",Actual,2022-02-01,,Interventional,,,Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers.,"Phase 2a, Single Center, Randomized, Double-blind, Controlled Study to Evaluate the Immunogenicity and the Safety of One Single Administration of OVX836 Influenza Vaccine at Two Dose Levels (300µg and 480µg) Given Intramuscularly (IM), in Comparison to OVX836 Influenza Vaccine at 180µg and Placebo Given IM in Healthy Subjects Aged 18-55 Years and in Healthy Subjects Aged 65 Years and Older.",Completed,,Phase 2,239.0,Actual,Osivax,,4.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-16 08:56:25,2023-06-16 08:56:25,INDUSTRY,,,,,
124253,124254,NCT03893903,,2018-08-16,,,2022-12-20,2019-03-26,2019-03-28,Actual,,,,,,,2022-12-20,2022-12-21,Actual,"October 19, 2018",Actual,2018-10-19,December 2022,2022-12-31,September 2024,Anticipated,2024-09-30,September 2023,Anticipated,2023-09-30,,Interventional,AMPLIFY-NEOVAC,,AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma,"AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma - a Randomized, Open Label, 3 Arm Multicenter Phase I Trial to Assess Safety, Tolerability and Immunogenicity of IDH1R132H-specific Peptide Vaccine in Combination With Checkpoint Inhibitor Avelumab",Recruiting,,Phase 1,60.0,Anticipated,German Cancer Research Center,,3.0,,,False,,,,True,False,False,,,False,,,,,,No,,2023-06-16 08:56:46,2023-06-16 08:56:46,OTHER,,,,,
124271,124272,NCT04968366,,2021-07-06,,,2022-01-13,2021-07-16,2021-07-20,Actual,,,,,,,2022-01-13,2022-01-28,Actual,"July 30, 2021",Actual,2021-07-30,January 2022,2022-01-31,August 2024,Anticipated,2024-08-31,August 2022,Anticipated,2022-08-31,,Interventional,,,Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery,Phase I Clinical Study of Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery,Recruiting,,Phase 1,10.0,Anticipated,Beijing Tiantan Hospital,,1.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-17 13:19:13,2023-06-17 13:19:13,OTHER,,,,,
124306,124307,NCT03058692,,2017-02-09,2020-01-14,,2020-06-02,2017-02-16,2017-02-23,Actual,2020-01-14,2020-02-05,Actual,,,,2020-06-02,2020-06-18,Actual,"April 9, 2018",Actual,2018-04-09,"November 27, 2019",2019-11-27,"January 14, 2019",Actual,2019-01-14,"January 14, 2019",Actual,2019-01-14,,Interventional,,The baseline analysis population includes all subjects.,Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine,"A Phase II, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial to Assess the Safety, Reactogenicity and Immunogenicity of Two Doses of Multimeric-001 (M-001) Followed by Seasonal Quadrivalent Influenza Vaccine",Completed,,Phase 2,120.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-17 13:19:38,2023-06-17 13:19:38,NIH,,,,,
124589,124590,NCT03275389,,2017-08-29,2021-03-16,,2021-04-14,2017-09-05,2017-09-07,Actual,2021-04-14,2021-05-07,Actual,,,,2021-04-14,2021-05-07,Actual,"September 8, 2017",Actual,2017-09-08,April 2021,2021-04-30,"March 26, 2020",Actual,2020-03-26,"March 26, 2020",Actual,2020-03-26,,Interventional,,,"A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years","Reactogenicity, Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults",Completed,,Phase 1,470.0,Actual,GlaxoSmithKline,,10.0,,,False,,,,True,True,False,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-17 13:22:32,2023-06-17 13:22:32,INDUSTRY,,,,,
124763,124764,NCT05638698,,2022-11-16,,,2023-01-30,2022-12-05,2022-12-06,Actual,,,,,,,2023-01-30,2023-01-31,Actual,"December 15, 2022",Actual,2022-12-15,January 2023,2023-01-31,December 2025,Anticipated,2025-12-31,December 2024,Anticipated,2024-12-31,,Interventional,TESLA,,Tg01 Vaccine / Qs-21 Stimulon With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer,Phase II Randomized Trial Combining Tg01 Vaccine / Qs-21 Stimulon With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer(TESLA),Recruiting,,Phase 2,24.0,Anticipated,University of Kansas Medical Center,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 13:24:38,2023-06-17 13:24:38,OTHER,,,,,
124838,124839,NCT05025488,,2021-08-24,,,2023-04-04,2021-08-24,2021-08-27,Actual,,,,,,,2023-04-04,2023-04-06,Actual,"April 4, 2023",Actual,2023-04-04,April 2023,2023-04-30,January 2025,Anticipated,2025-01-31,January 2024,Anticipated,2024-01-31,,Interventional,,,Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm,A Phase I Open Label Peptide Based Vaccine in Patients With Myeloproliferative Neoplasm Harboring CALR Mutations,Recruiting,,Phase 1,10.0,Anticipated,Icahn School of Medicine at Mount Sinai,,1.0,,,False,,,,True,True,False,,,,,,,,,No,Not determined at this time,2023-06-14 03:04:39,2023-06-14 03:04:39,OTHER,,,,,
124973,124974,NCT04134312,,2019-10-18,,,2021-07-08,2019-10-21,2019-10-22,Actual,,,,,,,2021-07-08,2021-07-14,Actual,"January 8, 2020",Actual,2020-01-08,July 2021,2021-07-31,"April 6, 2021",Actual,2021-04-06,"January 12, 2021",Actual,2021-01-12,,Interventional,,,A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer,A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer,Completed,,Phase 1,13.0,Actual,Bavarian Nordic,,1.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-16 08:59:02,2023-06-16 08:59:02,INDUSTRY,,,,,
125064,125065,NCT03049488,,2017-02-09,2020-09-29,,2020-10-21,2017-02-09,2017-02-10,Actual,2020-10-21,2020-10-23,Actual,,,,2020-10-21,2020-10-23,Actual,"February 22, 2017",Actual,2017-02-22,October 2020,2020-10-31,"October 3, 2019",Actual,2019-10-03,"October 3, 2019",Actual,2019-10-03,,Interventional,,Population includes all enrolled subjects.,"Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults","VRC 317: A Phase I Randomized, Open-Label Clinical Trial to Evaluate Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults",Completed,,Phase 1,95.0,Actual,National Institutes of Health Clinical Center (CC),,6.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-17 13:27:27,2023-06-17 13:27:27,NIH,,,,,
125178,125179,NCT00869778,,2009-03-25,2016-11-20,,2019-09-17,2009-03-25,2009-03-26,Estimate,2016-11-20,2017-01-18,Estimate,,,,2019-09-17,2019-10-01,Actual,April 2009,Actual,2009-04-30,September 2019,2019-09-30,May 2013,Actual,2013-05-31,November 2011,Actual,2011-11-30,,Interventional,,FAS,Phase 2 Trial of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine (Mimogen-based) in Treating Chronic Hepatitis B Patients",Completed,,Phase 2,360.0,Actual,Chongqing Jiachen Biotechnology Ltd.,,3.0,,,False,,,,True,,,,,,,,,,,Undecided,,2023-06-16 09:00:02,2023-06-16 09:00:02,INDUSTRY,,,,,
125226,125227,NCT00698100,,2008-06-12,,,2011-09-15,2008-06-13,2008-06-16,Estimate,,,,,,,2011-09-15,2011-09-16,Estimate,June 2002,,2002-06-30,September 2011,2011-09-30,September 2011,Actual,2011-09-30,September 2011,Actual,2011-09-30,,Interventional,,,"Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines","Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines: A Phase I Trial to Assess Safety and Immune Response",Completed,,Phase 1,18.0,Actual,Memorial Sloan Kettering Cancer Center,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 09:00:28,2023-06-16 09:00:28,OTHER,,,,,
125542,125543,NCT00851643,,2009-02-24,2011-02-10,,2016-02-02,2009-02-24,2009-02-26,Estimate,2011-05-20,2011-06-21,Estimate,,,,2016-02-02,2016-02-03,Estimate,April 2006,,2006-04-30,February 2016,2016-02-29,November 2009,Actual,2009-11-30,December 2007,Actual,2007-12-31,,Interventional,,,Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002),"A Randomized, Double-Blind, Multicenter, Biphasic, Controlled With GARDASIL Dose-Escalation Study of Octavalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and ISCOMATRIX (IMX)",Completed,,Phase 1,158.0,Actual,Merck Sharp & Dohme LLC,,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 09:03:08,2023-06-16 09:03:08,INDUSTRY,,,,,
125569,125570,NCT03339713,,2017-11-08,2021-07-22,2019-07-22,2021-07-22,2017-11-08,2017-11-13,Actual,2021-07-22,2021-08-18,Actual,2019-07-22,2019-07-29,Actual,2021-07-22,2021-08-18,Actual,"December 7, 2017",Actual,2017-12-07,July 2021,2021-07-31,"July 23, 2018",Actual,2018-07-23,"July 23, 2018",Actual,2018-07-23,,Interventional,,,"A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health","A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and Ad26.RSV.preF, With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health",Completed,,Phase 2,180.0,Actual,Janssen Vaccines & Prevention B.V.,,2.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-17 13:30:41,2023-06-17 13:30:41,INDUSTRY,,,,,
125611,125612,NCT03630809,,2018-08-10,,,2022-04-15,2018-08-10,2018-08-15,Actual,,,,,,,2022-04-15,2022-04-25,Actual,"January 10, 2019",Actual,2019-01-10,April 2022,2022-04-30,"April 11, 2022",Actual,2022-04-11,"April 11, 2022",Actual,2022-04-11,,Interventional,,,Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1,Immune Response Surveillance and Potential Booster Vaccines for Patients Who Have Received HER2-pulsed DC1 Vaccine,Terminated,,Phase 2,16.0,Actual,H. Lee Moffitt Cancer Center and Research Institute,,4.0,,Quality of the data originating from prior versions of the protocol has been affected by protocol deviations triggered by the COVID-19 pandemics,,,,,False,True,False,,,,,,,,,,,2023-06-16 09:03:33,2023-06-16 09:03:33,OTHER,,,,,
125939,125940,NCT04563702,,2020-09-21,,,2023-01-17,2020-09-23,2020-09-24,Actual,,,,,,,2023-01-17,2023-01-20,Actual,"September 21, 2020",Actual,2020-09-21,September 2022,2022-09-30,"October 10, 2021",Actual,2021-10-10,"October 10, 2021",Actual,2021-10-10,,Interventional,,,Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects,"A Phase 1 Open-Label, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Vaccine (VXA-CoV2-1) Expressing a SARS-CoV-2 Antigen and dsRNA Adjuvant Administered Orally to Healthy Adult Volunteers VXA-CoV2-1.1-S Boost Substudy: Boost at 1 Year Post Initial Vaccination With an Adenoviral-Vector Based Vaccine VXA-CoV2-1.1-S Expressing a SARS-CoV-2 S Protein in a Subset of Subjects",Completed,,Phase 1,35.0,Actual,Vaxart,,2.0,,,False,,,,False,True,False,,,,,,,,,Undecided,A plan on how to share individual subject's outcomes will be defined within the next few months.,2023-06-17 13:33:23,2023-06-17 13:33:23,INDUSTRY,,,,,
126024,126025,NCT00865566,,2009-03-17,2018-10-08,,2021-10-13,2009-03-18,2009-03-19,Estimate,2019-02-01,2019-02-27,Actual,,,,2021-10-13,2021-10-15,Actual,May 2009,,2009-05-31,October 2021,2021-10-31,"October 6, 2017",Actual,2017-10-06,"October 6, 2017",Actual,2017-10-06,,Interventional,,All Enrolled Participants,"Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men","Phase 2b, Randomized, Placebo-Controlled Test-of-Concept Trial to Evaluate the Safety and Efficacy of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by a Multiclade HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Adenovirus Type 5 Neutralizing Antibody Negative, Circumcised Men and Male-to-Female (MTF) Transgender Persons, Who Have Sex With Men",Terminated,,Phase 2,2504.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,The trial was stopped for efficacy futility,False,,,,True,,,,,,,,,,,,,2023-06-16 09:05:58,2023-06-16 09:05:58,NIH,,,,,
126399,126400,NCT03698279,,2018-10-04,2020-05-14,,2022-03-24,2018-10-04,2018-10-05,Actual,2020-05-14,2020-06-01,Actual,,,,2022-03-24,2022-04-04,Actual,"October 9, 2018",Actual,2018-10-09,March 2022,2022-03-31,"October 16, 2019",Actual,2019-10-16,"October 16, 2019",Actual,2019-10-16,,Interventional,QHD04,Analysis was performed on the randomized participants.,Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age,Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age,Completed,,Phase 2,665.0,Actual,Sanofi,,6.0,,,False,,,,False,True,False,,,False,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-17 13:36:57,2023-06-17 13:36:57,INDUSTRY,,,,,
126433,126434,NCT02206464,,2014-07-31,,,2019-12-14,2014-07-31,2014-08-01,Estimate,,,,,,,2019-12-14,2019-12-17,Actual,"July 29, 2014",,2014-07-29,"January 7, 2016",2016-01-07,"January 7, 2016",Actual,2016-01-07,"January 7, 2016",Actual,2016-01-07,,Interventional,,,"H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...","VRC 315: A Phase I Open-Label, Randomized Study of H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boost",Completed,,Phase 1,30.0,Actual,National Institutes of Health Clinical Center (CC),,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 19:03:40,2023-06-17 19:03:40,NIH,,,,,
126613,126614,NCT03227029,,2017-07-20,2020-12-14,,2022-04-20,2017-07-20,2017-07-24,Actual,2020-12-14,2021-01-08,Actual,,,,2022-04-20,2022-04-22,Actual,"September 22, 2017",Actual,2017-09-22,April 2022,2022-04-30,"October 1, 2020",Actual,2020-10-01,"December 19, 2019",Actual,2019-12-19,,Interventional,,Baseline analysis population was participants who received inoculation and were followed on study past Day 0.,"Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV <U+0394>NS2/<U+0394>1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age","Randomized Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV <U+0394>NS2/<U+0394>1313/I1314L or RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age",Completed,,Phase 1,65.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-17 13:38:17,2023-06-17 13:38:17,NIH,,,,,
126771,126772,NCT00377494,,2006-09-14,,,2019-01-18,2006-09-14,2006-09-18,Estimate,,,,,,,2019-01-18,2019-01-23,Actual,,,,February 2007,2007-02-28,July 2008,,2008-07-31,,,,,Interventional,,,"CS DNA MVA Trial in Mampong, Ghana","A Phase I Trial of PFCSP DNA/MVA.CSO Prime/Boost Vaccine in Mampong, Ghana",Withdrawn,,Phase 1,0.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,,,,,,,,,,,,,,,,,,,,,2023-06-14 03:05:48,2023-06-14 03:05:48,NIH,,,,,
126937,126938,NCT00871338,,2009-03-26,2014-06-26,2011-11-17,2018-04-27,2009-03-26,2009-03-30,Estimate,2014-07-24,2014-07-28,Estimate,2011-11-17,2011-11-21,Estimate,2018-04-27,2018-06-06,Actual,"June 24, 2009",,2009-06-24,September 2016,2016-09-30,"December 9, 2010",Actual,2010-12-09,"March 31, 2010",Actual,2010-03-31,,Interventional,,,Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants,"Study in Healthy Children of GSK Biologicals' DTPa-IPV/Hib-MenC-TT Vaccine, GSK2197870A, Co-administered With Prevenar as a Three-dose Primary Vaccination Course in Infancy Followed by a Booster Dose of Menitorix at 12 Months of Age",Completed,,Phase 2,284.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 09:11:21,2023-06-16 09:11:21,INDUSTRY,,,,,
127446,127447,NCT00513409,,2007-08-07,2009-03-11,,2018-06-08,2007-08-07,2007-08-08,Estimate,2009-06-25,2009-08-11,Estimate,,,,2018-06-08,2018-12-19,Actual,"August 22, 2007",,2007-08-22,May 2018,2018-05-31,"August 28, 2008",Actual,2008-08-28,"February 20, 2008",Actual,2008-02-20,,Interventional,,,Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule,"Phase II, Observer-blind Follow-up Study to Assess reacto-and Immunogenicity of GSK Biologicals' Pneumococcal Conjugate Vaccine (GSK1024850A), When Given as Booster in Primed Children or as 2-dose Catch-up in Unprimed Children.",Completed,,Phase 2,163.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 09:13:21,2023-06-16 09:13:21,INDUSTRY,,,,,
127512,127513,NCT03201211,,2017-06-19,2021-03-12,,2021-03-12,2017-06-27,2017-06-28,Actual,2021-03-12,2021-04-08,Actual,,,,2021-03-12,2021-04-08,Actual,"June 22, 2017",Actual,2017-06-22,March 2021,2021-03-31,"March 19, 2020",Actual,2020-03-19,"March 19, 2020",Actual,2020-03-19,,Interventional,,,A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults,A Long-term Follow-up Study of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults,Completed,,Phase 1,81.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,True,False,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-17 13:46:10,2023-06-17 13:46:10,INDUSTRY,,,,,
127666,127667,NCT05212623,,2022-01-16,,,2022-10-27,2022-01-16,2022-01-28,Actual,,,,,,,2022-10-27,2022-10-28,Actual,"October 26, 2021",Actual,2021-10-26,March 2022,2022-03-31,"June 16, 2022",Actual,2022-06-16,"January 17, 2022",Actual,2022-01-17,,Interventional,,,A Clinical Trial of an Quadrivalent Inactivated Influenza Vaccine in Healthy Children Aged 6 to 35 Months,"A Single-center, Randomized, Blinded, Positive Controlled Clinical Trial to Assess the Reactogenicity and Immunogenicity of a Quadrivalent Inactivated Influenza Vaccine in Healthy Participants Aged 6-35 Months",Completed,,Phase 1,120.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,4.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-17 13:47:48,2023-06-17 13:47:48,NETWORK,,,,,
127698,127699,NCT04941261,,2021-06-18,,,2022-10-26,2021-06-18,2021-06-28,Actual,,,,,,,2022-10-26,2022-10-28,Actual,"June 30, 2021",Actual,2021-06-30,May 2022,2022-05-31,"March 30, 2024",Anticipated,2024-03-30,"February 28, 2024",Anticipated,2024-02-28,,Interventional,,,Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha),Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine(Hansenula Polymorpha) in Healthy People Aged Aged From 6 Months to 59 Years,Recruiting,,Phase 2,1716.0,Anticipated,"National Vaccine and Serum Institute, China",,15.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-17 13:48:12,2023-06-17 13:48:12,INDUSTRY,,,,,
127987,127988,NCT03186781,,2017-06-13,2020-09-01,,2021-05-24,2017-06-13,2017-06-14,Actual,2020-10-14,2020-10-19,Actual,,,,2021-05-24,2021-06-16,Actual,"October 25, 2017",Actual,2017-10-25,May 2021,2021-05-31,"September 3, 2019",Actual,2019-09-03,"September 3, 2019",Actual,2019-09-03,,Interventional,,Population includes all enrolled subjects.,"Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults","VRC 316: A Phase I Open-Label Clinical Trial To Evaluate Dose, Safety, Tolerability, And Immunogenicity Of An Influenza HA Ferritin Vaccine, Alone Or In Prime-Boost Regimens With An Influenza DNA Vaccine In Healthy Adults",Completed,,Phase 1,50.0,Actual,National Institutes of Health Clinical Center (CC),,6.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 13:51:00,2023-06-17 13:51:00,NIH,,,,,
128035,128036,NCT03181789,,2017-06-06,2021-07-15,,2022-04-20,2017-06-07,2017-06-09,Actual,2021-09-17,2021-10-14,Actual,,,,2022-04-20,2022-04-22,Actual,"October 18, 2017",Actual,2017-10-18,April 2022,2022-04-30,"April 29, 2020",Actual,2020-04-29,"October 25, 2019",Actual,2019-10-25,,Interventional,HVTN119,,"Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA","A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA, in Healthy, HIV-Uninfected Adult Participants",Completed,,Phase 1,56.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,True,True,True,,,,,,,,,,,2023-06-17 13:51:36,2023-06-17 13:51:36,NIH,,,,,
128186,128187,NCT05239975,,2022-02-14,,,2022-02-14,2022-02-14,2022-02-15,Actual,,,,,,,2022-02-14,2022-02-15,Actual,"February 25, 2022",Anticipated,2022-02-25,February 2022,2022-02-28,"October 1, 2022",Anticipated,2022-10-01,"May 1, 2022",Anticipated,2022-05-01,,Interventional,,,A Phase II Study of the Immunogenicity and Safety of SCTV01C in Population Aged =12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine,"A Randomized, Double-blind Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C (A Bivalent SARS-CoV-2 Trimeric Spike Protein Vaccine) in Population Aged =12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine",Not yet recruiting,,Phase 2,240.0,Anticipated,Sinocelltech Ltd.,,2.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-17 13:53:27,2023-06-17 13:53:27,INDUSTRY,,,,,
128290,128291,NCT04364035,,2020-03-05,,,2021-07-30,2020-04-24,2020-04-27,Actual,,,,,,,2021-07-30,2021-08-02,Actual,"February 20, 2020",Actual,2020-02-20,July 2021,2021-07-31,"December 23, 2022",Anticipated,2022-12-23,"April 15, 2022",Anticipated,2022-04-15,,Interventional,AELIX-003,,"Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients","A Phase IIa Randomised, Double-blind, Placebo-controlled Study of HIV-1 Vaccines MVA.HTI and ChAdOx1.HTI With TLR7 Agonist Vesatolimod (GS-9620) in Early Treated HIV-1 Infection","Active, not recruiting",,Phase 2,57.0,Anticipated,Aelix Therapeutics,,2.0,,,,,,,True,True,False,,,True,,,,,,,,2023-06-14 02:17:55,2023-06-14 02:17:55,INDUSTRY,,,,,
128317,128318,NCT04055454,,2019-07-29,,,2022-01-21,2019-08-12,2019-08-13,Actual,,,,,,,2022-01-21,2022-01-24,Actual,"September 26, 2019",Actual,2019-09-26,January 2022,2022-01-31,"January 15, 2021",Actual,2021-01-15,"March 13, 2020",Actual,2020-03-13,,Interventional,,,A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001),"A Randomized, Placebo-controlled Trial to Evaluate the Optimal Dose of MV-LASV, a New Vaccine Against LASSA Virus Infection, Regarding Safety, Tolerability & Immunogenicity in Healthy Volunteers Consisting of an Unblinded Dose Escalation & an Observer-blinded Treatment Phase",Completed,,Phase 1,60.0,Actual,Themis Bioscience GmbH,,3.0,,,False,,,,True,False,False,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2023-06-17 13:55:16,2023-06-17 13:55:16,INDUSTRY,,,,,
128408,128409,NCT03283319,,2017-09-12,2019-08-28,2019-02-14,2020-04-24,2017-09-12,2017-09-14,Actual,2019-09-23,2019-09-25,Actual,2019-02-14,2019-03-11,Actual,2020-04-24,2020-05-06,Actual,"September 20, 2017",Actual,2017-09-20,April 2020,2020-04-30,"November 9, 2018",Actual,2018-11-09,"December 15, 2017",Actual,2017-12-15,,Interventional,,,Panblok H7 Vaccine Adjuvanted With AS03 or MF59,"Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Panblok H7 Vaccine at Three Antigen Dose Levels Adjuvanted With AS03® or MF59®",Completed,,Phase 2,366.0,Actual,Biomedical Advanced Research and Development Authority,,6.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 13:56:22,2023-06-17 13:56:22,FED,,,,,
128536,128537,NCT02996448,,2016-12-16,2020-06-22,,2020-06-22,2016-12-16,2016-12-19,Estimate,2020-06-22,2020-06-30,Actual,,,,2020-06-22,2020-06-30,Actual,"November 17, 2016",,2016-11-17,October 2018,2018-10-31,"October 9, 2018",Actual,2018-10-09,"July 22, 2018",Actual,2018-07-22,,Interventional,,,"Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome","A Phase 2a Study to Evaluate the Safety, Tolerability, and Immunogenicity of One Dose of NDV-3A Vaccine in Patients With STAT3-Mutated Hyper-IgE Syndrome",Terminated,,Phase 2,3.0,Actual,National Institutes of Health Clinical Center (CC),,1.0,,Safety concerns led to early termination.,False,,,,,True,,,,,,,,,,,,2023-06-17 13:57:50,2023-06-17 13:57:50,NIH,,,,,
128617,128618,NCT04839146,,2021-03-11,,,2022-03-16,2021-04-08,2021-04-09,Actual,,,,,,,2022-03-16,2022-03-17,Actual,"March 11, 2021",Actual,2021-03-11,March 2022,2022-03-31,"February 25, 2022",Actual,2022-02-25,"December 30, 2021",Actual,2021-12-30,,Interventional,COUGH-1,,Safety and Tolerability of COVID-19 Vaccine (ABNCoV2),First-in-human Trial of the Coronavirus Virus-like Particle Subunit Vaccine ABNCoV2 in SARS-CoV-2-naïve Adult Volunteers in Good Health,Completed,,Phase 1,45.0,Actual,Radboud University Medical Center,,7.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-17 13:58:45,2023-06-17 13:58:45,OTHER,,,,,
129252,129253,NCT02627456,,2015-12-09,,,2021-04-19,2015-12-09,2015-12-11,Estimate,,,,,,,2021-04-19,2021-04-21,Actual,"December 9, 2015",,2015-12-09,April 2021,2021-04-30,"July 3, 2018",Actual,2018-07-03,"March 31, 2018",Actual,2018-03-31,,Interventional,,,"Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali","Dose Escalating and Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) in Healthy African Adults in Mali",Completed,,Phase 1,409.0,Actual,National Institutes of Health Clinical Center (CC),,7.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-16 09:16:59,2023-06-16 09:16:59,NIH,,,,,
129349,129350,NCT02270944,,2014-10-08,2016-09-19,2015-04-29,2019-11-19,2014-10-21,2014-10-22,Estimate,2017-06-30,2017-07-28,Actual,2015-04-29,2015-05-18,Estimate,2019-11-19,2019-12-05,Actual,"November 20, 2014",Actual,2014-11-20,November 2019,2019-11-30,"September 22, 2015",Actual,2015-09-22,"April 23, 2015",Actual,2015-04-23,,Interventional,,,Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine,"A Phase II, Randomized, Comparative, Observer-Blind, Multi-Center Study Evaluating the Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine in Healthy Non-Pregnant Women Aged 18 to 40 Years",Completed,,Phase 2,1053.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,False,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below).,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,Yes,IPD is available via the Clinical Study Data Request site (click on the link provided below),2023-06-18 07:03:49,2023-06-18 07:03:49,INDUSTRY,,,,,
129391,129392,NCT03609398,,2018-07-24,,,2021-02-10,2018-07-24,2018-08-01,Actual,,,,,,,2021-02-10,2021-02-11,Actual,"October 4, 2018",Actual,2018-10-04,February 2021,2021-02-28,December 2024,Anticipated,2024-12-31,December 2023,Anticipated,2023-12-31,,Interventional,RVF,,Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine,"A Phase 2 Open Label Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated, Dried, TSI-GSD 200, Lot 7, Run 2, in Adult Subjects at Risk of Exposure to Rift Valley Fever Virus",Recruiting,,Phase 2,500.0,Anticipated,U.S. Army Medical Research and Development Command,,1.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-17 14:08:23,2023-06-17 14:08:23,FED,,,,,
130183,130184,NCT02239172,,2014-08-13,,,2016-05-10,2014-09-10,2014-09-12,Estimate,,,,,,,2016-05-10,2016-05-12,Estimate,August 2014,,2014-08-31,May 2016,2016-05-31,May 2015,Actual,2015-05-31,May 2015,Actual,2015-05-31,,Interventional,,,PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine,A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine in Healthy Adults,Completed,,Phase 1,30.0,Actual,"Fraunhofer, Center for Molecular Biotechnology",,4.0,,,False,,,,False,,,,,,,,,,,Undecided,,2023-06-17 14:17:54,2023-06-17 14:17:54,INDUSTRY,,,,,
130255,130256,NCT05762523,,2023-01-23,,,2023-02-28,2023-02-28,2023-03-09,Actual,,,,,,,2023-02-28,2023-03-09,Actual,"May 18, 2019",Actual,2019-05-18,February 2023,2023-02-28,"January 27, 2020",Actual,2020-01-27,"July 22, 2019",Actual,2019-07-22,,Interventional,,,Safety and Tolerability Study of the VAC<U+2206>6 Vaccine in Volunteers Aged 18-40 Years,"An Open-label Controlled Study of the Safety and Tolerability of the Live Cell-based Vaccine Against Smallpox and Other Orthopoxvirus Infections (VAC<U+2206>6 Vaccine) Based on Vaccinia Virus, in Volunteers Aged 18-40 Years",Completed,,Phase 1,60.0,Actual,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",,4.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-17 14:18:48,2023-06-17 14:18:48,OTHER_GOV,,,,,
130335,130336,NCT05028374,,2021-08-23,,,2022-08-24,2021-08-29,2021-08-31,Actual,,,,,,,2022-08-24,2022-08-29,Actual,"August 17, 2021",Actual,2021-08-17,August 2022,2022-08-31,"July 21, 2023",Anticipated,2023-07-21,"November 2, 2021",Actual,2021-11-02,,Interventional,,,COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies,Phase II Trial Evaluating the Efficacy of Moderna COVID-19 Vaccine Booster Dosing in Patients With Hematologic Malignancies Who Did Not Have an Adequate Response to Prior Vaccination,"Active, not recruiting",,Phase 2,119.0,Actual,Barbara Ann Karmanos Cancer Institute,,1.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-18 07:05:00,2023-06-18 07:05:00,OTHER,,,,,
130678,130679,NCT02962908,,2016-11-07,2018-05-03,,2020-08-27,2016-11-14,2016-11-15,Estimate,2019-04-04,2019-04-08,Actual,,,,2020-08-27,2020-09-16,Actual,August 2016,,2016-08-31,August 2020,2020-08-31,"July 18, 2017",Actual,2017-07-18,"July 18, 2017",Actual,2017-07-18,,Interventional,,"A subject in 1x FLU-v adjuvanted group received 1x non-adjuvanted FLU-v. Subject completed the study but with this treatment, the subject could not be assigned to any group for analysis. This is the reason why 58 subjects were randomised to this group but only 57 were analysed, making the total subject number 174 rather than 175.","A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v Vaccine","A Randomised, Double-blind, Placebo-controlled, Single-centre Phase IIb Trial as Part of the EU-funded UNISEC Project to Assess the Immunogenicity and Safety of Different Formulations and Dosing Regimens of FLU-v Vaccine in Healthy Adults",Completed,,Phase 2,175.0,Actual,PepTcell Limited,,4.0,,,False,,,,False,,,,,,,,,,,No,,2023-06-17 14:23:20,2023-06-17 14:23:20,INDUSTRY,,,,,
130719,130720,NCT03576014,,2018-05-25,,,2018-06-21,2018-06-21,2018-07-03,Actual,,,,,,,2018-06-21,2018-07-03,Actual,"April 27, 2018",Actual,2018-04-27,May 2018,2018-05-31,"July 24, 2019",Anticipated,2019-07-24,"January 30, 2019",Anticipated,2019-01-30,,Interventional,,,Evaluate Tolerability and Safety of BD03 for Prevention of CMV and BKV Reactivation in Kidney Transplant Recipient,"A Prospective, Open, Dose-escalation, Multi-center, Phase 1 Trial to Evaluate Tolerability and Safety of Intramuscularly Administered BD03, a DNA Vaccine for Prevention of CMV and BKV Reactivation in Kidney Transplant Recipient",Unknown status,Recruiting,Phase 1,18.0,Anticipated,SL VAXiGEN,,1.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-17 14:23:52,2023-06-17 14:23:52,INDUSTRY,,,,,
130873,130874,NCT01336699,,2011-04-14,,,2019-01-24,2011-04-14,2011-04-18,Estimate,,,,,,,2019-01-24,2019-01-28,Actual,"January 7, 2013",Actual,2013-01-07,"October 14, 2015",2015-10-14,"May 12, 2015",Actual,2015-05-12,"May 12, 2015",Actual,2015-05-12,,Interventional,,,"Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3","Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3",Completed,,Phase 1,89.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-17 14:25:46,2023-06-17 14:25:46,NIH,,,,,
130885,130886,NCT01335347,,2011-04-10,,,2013-01-02,2011-04-12,2011-04-14,Estimate,,,,,,,2013-01-02,2013-01-03,Estimate,April 2011,,2011-04-30,January 2013,2013-01-31,September 2012,Actual,2012-09-30,August 2012,Actual,2012-08-31,,Interventional,H5N1,,Safety Study of an Oral Vaccine to Prevent Avian Influenza,A Dose Escalation Phase 1 Safety and Immunogenicity Study of an Oral Viral Vector Vaccine Encoding Avian Influenza H5N1 Hemagglutinin Protein and dsRNA Adjuvant in Healthy Adults,Completed,,Phase 1,54.0,Actual,Vaxart,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 14:25:55,2023-06-17 14:25:55,INDUSTRY,,,,,
130993,130994,NCT05010200,,2021-06-18,,,2022-09-08,2021-08-10,2021-08-18,Actual,,,,,,,2022-09-08,2022-09-10,Actual,"January 5, 2022",Actual,2022-01-05,September 2022,2022-09-30,December 2027,Anticipated,2027-12-31,December 2026,Anticipated,2026-12-31,,Interventional,PGV-Prostate,,The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.,"Phase I, Open-label, Single-center Proof of Concept Study Designed to Test the Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in Combination With CDX-301 in Subjects With a History of Prostate Cancer, in the Adjuvant Setting",Recruiting,,Phase 1,27.0,Anticipated,Icahn School of Medicine at Mount Sinai,,3.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-18 07:05:44,2023-06-18 07:05:44,OTHER,,,,,
131304,131305,NCT03563144,,2018-05-25,,,2021-03-17,2018-06-14,2018-06-20,Actual,,,,,,,2021-03-17,2021-03-18,Actual,August 2018,Anticipated,2018-08-31,August 2018,2018-08-31,"December 30, 2019",Anticipated,2019-12-30,"December 30, 2019",Anticipated,2019-12-30,,Interventional,,,QUILT-3.088: NANT Pancreatic Cancer Vaccine,QUILT-3.088 NANT Pancreatic Cancer Vaccine: Phase II Randomized Trial of the NANT Pancreatic Cancer Vaccine vs. Standard-of-Care as First- Line Treatment for Patients With Metastatic Pancreatic Cancer,Withdrawn,,Phase 2,0.0,Actual,"ImmunityBio, Inc.",,3.0,,Trial not initiated,False,,,,True,True,False,,,,,,,,,Undecided,,2023-06-17 14:31:54,2023-06-17 14:31:54,INDUSTRY,,,,,
131326,131327,NCT04697576,,2021-01-05,,,2022-04-28,2021-01-05,2021-01-06,Actual,,,,,,,2022-04-28,2022-04-29,Actual,"October 20, 2021",Actual,2021-10-20,April 2022,2022-04-30,"December 31, 2024",Anticipated,2024-12-31,"December 31, 2023",Anticipated,2023-12-31,,Interventional,,,"Intralesional Influenza Vaccine for the Treatment of Stage I, II, and IV Melanoma",Intralesional Influenza Vaccine for Patients With Melanoma,Recruiting,,Phase 1,36.0,Anticipated,Ohio State University Comprehensive Cancer Center,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 14:32:17,2023-06-17 14:32:17,OTHER,,,,,
131554,131555,NCT01349647,,2011-05-05,,,2016-01-04,2011-05-05,2011-05-06,Estimate,,,,,,,2016-01-04,2016-01-05,Estimate,May 2011,,2011-05-31,January 2016,2016-01-31,July 2015,Actual,2015-07-31,July 2015,Actual,2015-07-31,,Interventional,,,"Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid","Immunization of Small Cell Lung Cancer Patients With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid",Completed,,Phase 1,21.0,Actual,Memorial Sloan Kettering Cancer Center,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 14:35:35,2023-06-17 14:35:35,OTHER,,,,,
131614,131615,NCT05163834,,2021-11-23,,,2022-03-16,2021-12-17,2021-12-20,Actual,,,,,,,2022-03-16,2022-03-17,Actual,"November 17, 2021",Actual,2021-11-17,March 2022,2022-03-31,"March 8, 2022",Actual,2022-03-08,"March 8, 2022",Actual,2022-03-08,,Interventional,,,Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV,"A Randomized, Open-label, Placebo-Controlled, Parallel-Group Study to Evaluate the Immune Response to the Polyvalent Pneumococcal Vaccine (PNEUMOVAX 23) in Healthy Participants Receiving Intravenous Efgartigimod or Placebo",Completed,,Phase 1,36.0,Actual,argenx,,3.0,,,False,,,,False,False,False,,,,,,,,,Undecided,,2023-06-17 14:36:36,2023-06-17 14:36:36,INDUSTRY,,,,,
131716,131717,NCT02058680,,2014-02-04,,,2018-09-07,2014-02-06,2014-02-10,Estimate,,,,,,,2018-09-07,2018-09-10,Actual,April 2012,,2012-04-30,September 2018,2018-09-30,December 2018,Anticipated,2018-12-31,December 2018,Anticipated,2018-12-31,,Interventional,PSA,,Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients,"A Phase 1A/1B, Two-Stage Study of a PSA/IL-2/GM-CSF Vaccine for the Treatment of PSA Recurrent Prostate Cancer in Hormone-Naive and Hormone-Independent Patients",Unknown status,"Active, not recruiting",Phase 1,48.0,Anticipated,OncBioMune Pharmaceuticals,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 14:37:59,2023-06-17 14:37:59,OTHER,,,,,
131817,131818,NCT04686773,,2020-12-25,,,2022-06-02,2020-12-25,2020-12-29,Actual,,,,,,,2022-06-02,2022-06-03,Actual,"March 5, 2021",Actual,2021-03-05,June 2022,2022-06-30,"March 18, 2022",Actual,2022-03-18,"October 30, 2021",Actual,2021-10-30,,Interventional,,,"Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention","Open-label, Non-randomized, Non-comparative, Phase II Study in Adult Subjects to Assess Safety and Immunogenicity of Combination of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, and rAd26-S, a Recombinant Adenovirus Type 26 Component of Gam-COVID-Vac Vaccine, for COVID-19 Prevention",Completed,,Phase 2,100.0,Actual,R-Pharm,,1.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-17 14:39:32,2023-06-17 14:39:32,INDUSTRY,,,,,
132285,132286,NCT05102643,,2021-10-29,,,2022-01-26,2021-10-29,2021-11-01,Actual,,,,,,,2022-01-26,2022-01-27,Actual,"November 18, 2021",Actual,2021-11-18,January 2022,2022-01-31,December 2022,Anticipated,2022-12-31,June 2022,Anticipated,2022-06-30,,Interventional,,,A Study to Evaluate Safety & Immunogenicity of SARS-CoV-2 DNA Vaccine Delivered Intramuscularly Followed by Electroporation for COVID-19,"A Phase 1, Randomized, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 DNA Vaccine Delivered Intramuscularly Followed by Electroporation for COVID-19 in Healthy Adults",Recruiting,,Phase 1,30.0,Anticipated,The University of Hong Kong,,2.0,,,False,,,,,False,False,,,,,,,,,No,"The results of this study will be publicly disseminated by ways of publication(s) in peer-reviewed scientific journal(s), presentation(s) in scientific conference(s), posting on public clinical trial registry(ies) and/or otherwise instead of individual participant data (IPD) sharing.",2023-06-17 14:45:29,2023-06-17 14:45:29,OTHER,,,,,
132294,132295,NCT00618605,,2008-02-18,,,2021-10-28,2008-02-18,2008-02-20,Estimate,,,,,,,2021-10-28,2021-11-01,Actual,February 2008,,2008-02-29,October 2021,2021-10-31,October 2015,Actual,2015-10-31,July 2011,Actual,2011-07-31,,Interventional,,,Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults,"A Phase 1 Randomized, Double-Blind, Placebo Controlled Dose Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Adenovirus Serotype 26 HIV-1 Vaccine (Ad26.ENVA.01) in Healthy, HIV-1 Uninfected Adults",Completed,,Phase 1,60.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 09:21:21,2023-06-16 09:21:21,NIH,,,,,
132438,132439,NCT01317745,,2011-03-16,,,2013-01-24,2011-03-16,2011-03-17,Estimate,,,,,,,2013-01-24,2013-01-25,Estimate,May 2011,,2011-05-31,August 2012,2012-08-31,September 2012,Actual,2012-09-30,September 2012,Actual,2012-09-30,,Interventional,,,H5N1 Mix and Match With MF59,"A Randomized, Double-Blinded, Controlled, Phase I Study in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of Intramuscular Subvirion Inactivated Monovalent Influenza A/H5N1 Virus Vaccine Administered at Different Dose Levels Given With and Without MF59 Adjuvant",Completed,,Phase 1,270.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,6.0,,,,,,,,,,,,,,,,,,,,2023-06-17 14:47:10,2023-06-17 14:47:10,NIH,,,,,
132619,132620,NCT00069030,,2003-09-12,,,2021-10-13,2003-09-15,2003-09-16,Estimate,,,,,,,2021-10-13,2021-10-14,Actual,December 2003,,2003-12-31,October 2021,2021-10-31,December 2006,Actual,2006-12-31,,,,,Interventional,,,Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults,A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of the HIV-1 DNA Vaccine VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade Env) With the Plasmid Cytokine Adjuvant VRC-ADJDNA004-IL2-VP (IL-2/Ig),Completed,,Phase 1,70.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 06:42:41,2023-06-15 06:42:41,NIH,,,,,
132738,132739,NCT01356823,,2011-05-13,,,2016-01-03,2011-05-17,2011-05-20,Estimate,,,,,,,2016-01-03,2016-01-05,Estimate,March 2011,,2011-03-31,February 2014,2014-02-28,October 2013,Actual,2013-10-31,December 2011,Actual,2011-12-31,,Interventional,,,Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine,"A Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine (E.Coli)in Healthy Female Subjects Aged 18 to 25 Years",Completed,,Phase 2,1600.0,Actual,Xiamen University,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 14:49:37,2023-06-17 14:49:37,OTHER,,,,,
132877,132878,NCT01357265,,2011-05-05,,,2011-12-06,2011-05-19,2011-05-20,Estimate,,,,,,,2011-12-06,2011-12-07,Estimate,May 2011,,2011-05-31,December 2011,2011-12-31,June 2011,Actual,2011-06-30,May 2011,Actual,2011-05-31,,Interventional,,,Safety and Immunogenicity of One Dose of an Inactivated Trivalent Sub-unit Influenza Vaccine Administered to Non-elderly Adult and Elderly Subjects,"A Phase II Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface, Antigen, Inactivated, Influenza Vaccine, Formulation 2011/2012, When Administered to Adult and Elderly Subjects",Completed,,Phase 2,125.0,Actual,Novartis,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 14:51:01,2023-06-17 14:51:01,INDUSTRY,,,,,
133051,133052,NCT00019331,,2001-07-11,,,2013-06-19,2003-01-26,2003-01-27,Estimate,,,,,,,2013-06-19,2013-06-20,Estimate,October 1997,,1997-10-31,April 2004,2004-04-30,May 2007,Actual,2007-05-31,,,,,Interventional,,,Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors,Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors,Completed,,Phase 2,,,National Cancer Institute (NCI),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 06:24:36,2023-06-15 06:24:36,NIH,,,,,
133191,133192,NCT01371175,,2011-05-31,,,2011-06-09,2011-06-09,2011-06-10,Estimate,,,,,,,2011-06-09,2011-06-10,Estimate,April 2003,,2003-04-30,June 2011,2011-06-30,,,,May 2005,Actual,2005-05-31,,Interventional,,,A Phase IIA Trial to Evaluate the Safety and Immunogenicity of a DNA HIV-1 Vaccine Followed by an MVA HIV-1 Vaccine in HIV-uninfected Volunteers,"A Randomized, Placebo-Controlled, Dosage-Escalating Phase 2A Study, Double-Blinded With Respect to Assignment to Either Vaccine or Placebo, to Evaluate the Safety and Immunogenicity of a DNA HIV-1 Vaccine Administered Intramuscularly Followed by an MVA HIV-1 Vaccine Administered at Three Different Dosage Levels and by Three Different Routes to HIV-Uninfected, Healthy, Volunteers.",Completed,,Phase 2,115.0,Actual,International AIDS Vaccine Initiative,,9.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 14:54:45,2023-06-17 14:54:45,NETWORK,,,,,
133258,133259,NCT00772343,,2008-10-10,,2012-06-28,2013-09-06,2008-10-14,2008-10-15,Estimate,,,,2012-06-28,2012-07-02,Estimate,2013-09-06,2013-09-17,Estimate,February 2009,,2009-02-28,September 2013,2013-09-30,June 2012,Actual,2012-06-30,July 2011,Actual,2011-07-31,,Interventional,,,Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF) in Subjects With Clostridium Difficile Infection,"A Phase II Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study of A Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF) in Subjects With Clostridium Difficile Infection (CDI)",Completed,,Phase 2,116.0,Actual,Sanofi,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 07:08:36,2023-06-18 07:08:36,INDUSTRY,,,,,
133397,133398,NCT02780401,,2016-04-27,,,2022-01-11,2016-05-20,2016-05-23,Estimate,,,,,,,2022-01-11,2022-01-13,Actual,"September 2, 2016",Actual,2016-09-02,January 2022,2022-01-31,"March 31, 2025",Anticipated,2025-03-31,"March 31, 2025",Anticipated,2025-03-31,,Interventional,WOKVAC,,"Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission","A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine (WOKVAC) Encoding Epitopes Derived From Three Breast Cancer Antigens (IGFBP-2, HER2, and IGF-1R) in Patients With Breast Cancer","Active, not recruiting",,Phase 1,24.0,Actual,University of Washington,,1.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-17 14:56:41,2023-06-17 14:56:41,OTHER,,,,,
133418,133419,NCT02942277,,2016-10-21,2021-08-04,,2022-01-27,2016-10-21,2016-10-24,Estimate,2022-01-27,2022-01-28,Actual,,,,2022-01-27,2022-01-28,Actual,"October 21, 2016",,2016-10-21,"July 29, 2020",2020-07-29,"July 15, 2020",Actual,2020-07-15,"July 15, 2020",Actual,2020-07-15,,Interventional,,,"Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali","Phase 1 Dose Escalating, Double-Blind, Randomized Comparator Controlled Trial of the Safety andImmunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum at Full and Fractional Dosing in Adults in Mali",Completed,,Phase 1,301.0,Actual,National Institutes of Health Clinical Center (CC),,11.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-17 14:56:55,2023-06-17 14:56:55,NIH,,,,,
133460,133461,NCT02921997,,2016-09-29,2021-10-28,2018-08-20,2022-01-25,2016-09-29,2016-10-03,Estimate,2022-01-25,2022-01-26,Actual,2018-08-20,2018-08-22,Actual,2022-01-25,2022-01-26,Actual,"November 7, 2016",Actual,2016-11-07,August 2019,2019-08-31,"February 14, 2018",Actual,2018-02-14,"March 28, 2017",Actual,2017-03-28,,Interventional,,,H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses,A Phase II Study to Evaluate and Compare the Immunogenicity of Monovalent Inactivated Influenza A/H7N9 Virus Vaccine Administered With and Without AS03 Adjuvant and Monovalent Inactivated Influenza A/H3N2v Virus Vaccine Administered Without Adjuvant in Healthy Adults Through Standard and Systems Biology Analyses,Completed,,Phase 2,30.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-17 14:57:35,2023-06-17 14:57:35,NIH,,,,,
133641,133642,NCT02092142,,2014-03-17,,,2019-12-30,2014-03-18,2014-03-20,Estimate,,,,,,,2019-12-30,2020-01-02,Actual,February 2006,,2006-02-28,December 2019,2019-12-31,December 2019,Anticipated,2019-12-31,February 2019,Anticipated,2019-02-28,,Interventional,,,Safety and Immunogenicity of Q Fever Vaccine,"Evaluation of the Safety and Immunogenicity of Q Fever Vaccine, Phase I, Inactivated, Dried, NDBR 105, in Subjects at Risk of Exposure to Coxiella Burnetii",Withdrawn,,Phase 2,0.0,Actual,U.S. Army Medical Research and Development Command,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 14:59:23,2023-06-17 14:59:23,FED,,,,,
133712,133713,NCT02861586,,2016-07-28,2021-03-17,,2021-10-15,2016-08-05,2016-08-10,Estimate,2021-05-11,2021-06-08,Actual,,,,2021-10-15,2021-10-29,Actual,"August 17, 2016",Actual,2016-08-17,October 2021,2021-10-31,"April 16, 2018",Actual,2018-04-16,"September 1, 2017",Actual,2017-09-01,,Interventional,MV-CHIK-202,The Safety Population as well as the Modified Intent-to-treat (mITT) population included all randomized subjects who received at least one vaccination and included 263 participants.,Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine,"Double Blinded, Randomized, Priorix®- and Placebo-controlled, Trial to Evaluate the Optimal Dose of MV-CHIK Vaccine (Against Chikungunya Virus) in Regard to Immunogenicity, Safety and Tolerability in Healthy Volunteers",Completed,,Phase 2,263.0,Actual,Themis Bioscience GmbH,,8.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-17 15:00:18,2023-06-17 15:00:18,INDUSTRY,,,,,
133815,133816,NCT00020267,,2007-03-02,,,2015-04-27,2007-03-02,2007-03-06,Estimate,,,,,,,2015-04-27,2015-04-28,Estimate,July 2000,,2000-07-31,May 2002,2002-05-31,,,,,,,,Interventional,,,Vaccine Therapy in Treating Patients With Metastatic Cancer,Phase I Randomized Study of MAGE-12 Peptide Vaccine in Patients With Refractory Metastatic Cancer Expressing MAGE-12 Antigen,Completed,,Phase 1,,,National Cancer Institute (NCI),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 06:25:01,2023-06-15 06:25:01,NIH,,,,,
133862,133863,NCT04865497,,2018-10-15,,,2021-12-28,2021-04-28,2021-04-29,Actual,,,,,,,2021-12-28,2022-01-13,Actual,"January 19, 2019",Actual,2019-01-19,December 2021,2021-12-31,"December 31, 2020",Actual,2020-12-31,"December 7, 2019",Actual,2019-12-07,,Interventional,,,Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 3 Months to 5 Years Old,"A Randomized, Blinded, Single-center, Parallel Controlled , Phase <U+2161> Clinical Trial to Evaluate Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged From 3 Months to 5 Years Old",Completed,,Phase 2,1050.0,Actual,"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd",,4.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-17 15:01:56,2023-06-17 15:01:56,INDUSTRY,,,,,
133956,133957,NCT01369927,,2011-06-08,,,2019-12-13,2011-06-08,2011-06-09,Estimate,,,,,,,2019-12-13,2019-12-16,Actual,"May 15, 2011",,2011-05-15,"April 24, 2013",2013-04-24,"April 24, 2013",Actual,2013-04-24,"April 24, 2013",Actual,2013-04-24,,Interventional,,,Shigella Sonnel O-SPC/rBRU Conjugate Vaccine,Shigella Sonnel O-SPC/rBRU Conjugate Vaccine,Completed,,Phase 1,60.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-17 15:03:04,2023-06-17 15:03:04,NIH,,,,,
133958,133959,NCT04040231,,2019-07-29,,,2022-11-23,2019-07-29,2019-07-31,Actual,,,,,,,2022-11-23,2022-11-25,Actual,"July 24, 2019",Actual,2019-07-24,November 2022,2022-11-30,July 2023,Anticipated,2023-07-31,July 2023,Anticipated,2023-07-31,,Interventional,,,Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma,Combining a WT1 Cancer Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1-Expressing Malignant Pleural Mesothelioma: A Phase I Study,"Active, not recruiting",,Phase 1,10.0,Actual,Memorial Sloan Kettering Cancer Center,,1.0,,,,,,,,True,False,,,,,,,,,Yes," Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.",2023-06-18 07:09:38,2023-06-18 07:09:38,OTHER,,,,,
134057,134058,NCT00694460,,2008-05-30,,,2008-06-09,2008-06-09,2008-06-10,Estimate,,,,,,,2008-06-09,2008-06-10,Estimate,August 2002,,2002-08-31,June 2008,2008-06-30,September 2004,Actual,2004-09-30,August 2004,Actual,2004-08-31,,Interventional,,,"Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers","A Phase II, Pilot, Randomized, Open-Label, Single-Center Study to Evaluate Immunogenicity, Safety and Booster Response of 3 Full Intramuscular Doses Versus 3 Half Intramuscular Doses Versus 3 Intradermal Doses Versus 2 Intradermal Doses of PCEC Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine as a Pre-Exposure Regimen in 12 to 18 Months Old Toddlers in Thailand.",Completed,,Phase 2,200.0,Actual,Novartis,,5.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 09:24:05,2023-06-16 09:24:05,INDUSTRY,,,,,
134325,134326,NCT01376479,,2011-06-16,,,2015-05-05,2011-06-17,2011-06-20,Estimate,,,,,,,2015-05-05,2015-05-06,Estimate,August 2011,,2011-08-31,May 2015,2015-05-31,April 2012,Actual,2012-04-30,November 2011,Actual,2011-11-30,,Interventional,,,"Safety and Immunogenicity Study of an Inactivated Vaccine Against Hand, Foot and Mouth Disease Caused by Enterovirus 71","Phase I, Double Blind, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety and Immunogenicity of a Prophylactic Vaccine Against Enterovirus Infection in Healthy Adults",Completed,,Phase 1,36.0,Actual,Takeda,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 15:06:48,2023-06-17 15:06:48,INDUSTRY,,,,,
134797,134798,NCT02455479,,2015-05-19,,,2023-01-30,2015-05-26,2015-05-27,Estimate,,,,,,,2023-01-30,2023-01-31,Actual,"June 26, 2012",Actual,2012-06-26,January 2023,2023-01-31,June 2024,Anticipated,2024-06-30,December 2023,Anticipated,2023-12-31,,Interventional,,,Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals,"Phase I Randomized, Double-blind, Placebo Control Study for an Anti-cocaine Vaccine",Recruiting,,Phase 1,150.0,Anticipated,Weill Medical College of Cornell University,,3.0,,,False,,,,True,True,False,,,,,,,,,Undecided,,2023-06-17 15:10:53,2023-06-17 15:10:53,OTHER,,,,,
134960,134961,NCT02126462,,2014-04-28,,,2017-05-30,2014-04-29,2014-04-30,Estimate,,,,,,,2017-05-30,2017-05-31,Actual,November 2014,,2014-11-30,May 2017,2017-05-31,June 2016,Actual,2016-06-30,February 2016,Actual,2016-02-29,,Interventional,,,Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults,"Randomized, Controlled, Phase 1 Study to Assess Safety and Immunogenicity of Co-administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 Adjuvanted With Alhydrogel® and Gluco-pyranosylphospho-lipid A in Gabonese Adults",Completed,,Phase 1,32.0,Actual,Baylor College of Medicine,,3.0,,,False,,,,True,,,,,,,,,,,Undecided,,2023-06-17 15:12:43,2023-06-17 15:12:43,OTHER,,,,,
135034,135035,NCT00569387,,2007-12-05,,2014-08-28,2020-05-26,2007-12-05,2007-12-07,Estimate,,,,2014-08-28,2014-09-01,Estimate,2020-05-26,2020-05-28,Actual,December 2007,,2007-12-31,May 2020,2020-05-31,December 2014,Actual,2014-12-31,March 2011,Actual,2011-03-31,,Interventional,,,Vaccine Study for Surgically Resected Pancreatic Cancer,A Phase II Study of Algenpantucel-L (HyperAcute Pancreas) Cancer Vaccine in Subjects With Surgically Resected Pancreatic Cancer,Completed,,Phase 2,73.0,Actual,Lumos Pharma,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 07:12:27,2023-06-18 07:12:27,INDUSTRY,,,,,
135135,135136,NCT00693706,,2008-06-02,2012-12-19,,2018-05-09,2008-06-02,2008-06-09,Estimate,2013-02-07,2013-03-12,Estimate,,,,2018-05-09,2018-06-08,Actual,"June 2, 2008",,2008-06-02,October 2016,2016-10-31,"March 26, 2009",Actual,2009-03-26,"March 1, 2009",Actual,2009-03-01,,Interventional,,,Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix,Safety and Immunogenicity Study of GSK Biologicals' Cell Culture-based Influenza Virus Vaccine 1388442A Compared With US Licensed TIV in Healthy Adults,Completed,,Phase 1,200.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,False,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 09:26:18,2023-06-16 09:26:18,INDUSTRY,,,,,
135141,135142,NCT00488683,,2007-06-19,2013-05-30,2010-04-16,2014-09-18,2007-06-19,2007-06-20,Estimate,2014-07-24,2014-08-15,Estimate,2010-04-16,2010-04-20,Estimate,2014-09-18,2014-10-01,Estimate,July 2007,,2007-07-31,September 2014,2014-09-30,June 2009,Actual,2009-06-30,May 2009,Actual,2009-05-31,,Interventional,,Analysis was done on all enrolled subjects.,B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants,"A Phase II, Single Center, Open-label, Randomized Study to Investigate Meningococcal Serogroup A, C, W-135 and Y Saccharide Specific B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants",Completed,,Phase 2,216.0,Actual,Novartis,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 09:26:21,2023-06-16 09:26:21,INDUSTRY,,,,,
135209,135210,NCT00746746,,2008-09-03,,,2011-01-12,2008-09-03,2008-09-04,Estimate,,,,,,,2011-01-12,2011-01-13,Estimate,June 2008,,2008-06-30,September 2008,2008-09-30,June 2011,Anticipated,2011-06-30,June 2010,Anticipated,2010-06-30,,Interventional,,,A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma,A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b (PEG-Intron)and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma,Unknown status,"Active, not recruiting",Phase 2,30.0,Anticipated,Ochsner Health System,,,,,False,,,,True,,,,,,,,,,,,,2023-06-16 09:26:48,2023-06-16 09:26:48,OTHER,,,,,
135330,135331,NCT05809752,,2023-03-30,,,2023-04-11,2023-03-30,2023-04-12,Actual,,,,,,,2023-04-11,2023-04-13,Actual,"March 28, 2023",Actual,2023-03-28,April 2023,2023-04-30,March 2026,Anticipated,2026-03-31,March 2026,Anticipated,2026-03-31,,Interventional,,,A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV),A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) Administered Intrathecally (IT) Primed Against HER2/HER3 in Patients With Leptomeningeal Disease (LMD) From Triple-Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC),Recruiting,,Phase 1,18.0,Anticipated,H. Lee Moffitt Cancer Center and Research Institute,,1.0,,,,,,,True,True,False,,,,,,,,,,,2023-06-17 15:15:20,2023-06-17 15:15:20,OTHER,,,,,
135505,135506,NCT04130282,,2019-10-08,,,2020-09-25,2019-10-16,2019-10-17,Actual,,,,,,,2020-09-25,2020-09-29,Actual,"September 27, 2019",Actual,2019-09-27,September 2020,2020-09-30,"September 22, 2020",Actual,2020-09-22,"September 22, 2020",Actual,2020-09-22,,Interventional,,,VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine,A Phase Ia Study to Assess Safety and Immunogenicity of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs25-IMX313 in Matrix-M1 Adjuvant in Healthy Adults Living in the UK,Terminated,,Phase 1,1.0,Actual,University of Oxford,,1.0,,Delays caused by Covid-19,False,,,,True,False,False,,,,,,,,,,,2023-06-16 09:27:33,2023-06-16 09:27:33,OTHER,,,,,
135536,135537,NCT05330871,,2022-04-14,,,2023-04-12,2022-04-14,2022-04-15,Actual,,,,,,,2023-04-12,2023-04-13,Actual,"April 17, 2022",Actual,2022-04-17,March 2023,2023-03-31,"May 30, 2023",Anticipated,2023-05-30,"June 30, 2022",Actual,2022-06-30,,Interventional,,,Evaluate the Safety and Immunogenicity of Ad5 COVID-19 Vaccines for Booster Use in Children Aged 6-17 Years.,"A Single Center, Open-label, Parallel Controlled, Randomized Phase II Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV-IM, Ad5-nCoV-IH or Inactivated COVID-19 Vaccine in Population 6 to 17 Years of Age","Active, not recruiting",,Phase 2,410.0,Actual,Seventh Medical Center of PLA General Hospital,,24.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-17 15:17:35,2023-06-17 15:17:35,OTHER,,,,,
135978,135979,NCT00861744,,2009-03-12,2011-07-14,,2019-12-31,2009-03-12,2009-03-13,Estimate,2011-09-29,2011-11-04,Estimate,,,,2019-12-31,2020-01-03,Actual,"June 3, 2009",Actual,2009-06-03,December 2019,2019-12-31,"June 18, 2012",Actual,2012-06-18,"July 21, 2010",Actual,2010-07-21,,Interventional,,,"Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age","A Phase II, Randomized, Observer Blind, Controlled, Multicenter Study to Assess Immunogenicity and Antibody Persistence Following Vaccination With GSK's Candidate Combined Measles, Mumps, and Rubella Vaccine (MMR) Versus M-M-R® II as a First Dose, Both Administered Subcutaneously at 12-15 Months of Age, Concomitantly With Hepatitis A Vaccine (HAV), Varicella Vaccine (VV) and Pneumococcal Conjugate Vaccine (PCV) But at Separate Sites.",Completed,,Phase 2,1259.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=3669,Yes,IPD is available via the Clinical Study Data Request site (click on the link provided below),2023-06-16 09:28:06,2023-06-16 09:28:06,INDUSTRY,,,,,
136097,136098,NCT02740790,,2016-02-18,,,2023-04-12,2016-04-12,2016-04-15,Estimate,,,,,,,2023-04-12,2023-04-13,Actual,September 2013,Actual,2013-09-30,April 2023,2023-04-30,December 2017,Actual,2017-12-31,September 2015,Actual,2015-09-30,,Interventional,,,Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females,Immunogenicity and Safety of Recombinant Human Papillomavirus Bivalent(Type 16 and 18) Vaccine (Yeast) in Healthy Females,Completed,,Phase 2,1200.0,Actual,"Shanghai Zerun Biotechnology Co.,Ltd",,6.0,,,False,,,,False,,,,,,,,,,,No,,2023-06-17 15:23:21,2023-06-17 15:23:21,INDUSTRY,,,,,
136098,136099,NCT02740777,,2016-04-05,,,2023-04-12,2016-04-12,2016-04-15,Estimate,,,,,,,2023-04-12,2023-04-13,Actual,February 2016,Actual,2016-02-29,April 2023,2023-04-30,July 2019,Actual,2019-07-31,November 2016,Actual,2016-11-30,,Interventional,,,Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females,"Immunogenicity Study of a 2-dose Immunization Schedule of Recombinant Human Papillomavirus Virus-like Particle Vaccine (Type 16 and 18 L1 Proteins, Yeast) in Adolescent Females Aged 9 to 14 Years",Completed,,Phase 2,900.0,Actual,"Shanghai Zerun Biotechnology Co.,Ltd",,3.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-17 15:23:22,2023-06-17 15:23:22,INDUSTRY,,,,,
136251,136252,NCT04385875,,2020-05-08,,,2022-05-03,2020-05-08,2020-05-13,Actual,,,,,,,2022-05-03,2022-05-04,Actual,"June 1, 2020",Actual,2020-06-01,May 2022,2022-05-31,"February 10, 2022",Actual,2022-02-10,"August 30, 2021",Actual,2021-08-30,,Interventional,,,"Study to Assess the Safety and Durability of Viral Control Beyond 24 Weeks of Analytical Treatment Interruption After the Administration of Candidate HIV-1 Vaccines DNA.HTI, MVA.HTI and ChAdOx1.HTI or Placebo in Early Treated HIV-1 Positive Individuals (ATI Extension of AELIX-002 Study)","Study to Assess the Safety and Durability of Viral Control Beyond 24 Weeks of Analytical Treatment Interruption After the Administration of Candidate HIV-1 Vaccines DNA.HTI, MVA.HTI and ChAdOx1.HTI or Placebo in Early Treated HIV-1 Positive Individuals (ATI Extension of AELIX-002 Study)",Completed,,Phase 1,6.0,Actual,"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia",,2.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-16 09:28:42,2023-06-16 09:28:42,OTHER,,,,,
136260,136261,NCT05297994,,2021-10-11,,,2022-03-16,2022-03-16,2022-03-28,Actual,,,,,,,2022-03-16,2022-03-28,Actual,"October 24, 2016",Actual,2016-10-24,October 2021,2021-10-31,"March 9, 2017",Actual,2017-03-09,"December 12, 2016",Actual,2016-12-12,,Interventional,,,"Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA","Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA vs. the Vaxigrip® Inactivated Influenza Split Vaccine Manufactured by Sanofi Pasteur, France, in Volunteers Aged 18-60 Years",Completed,,Phase 2,400.0,Actual,St. Petersburg Research Institute of Vaccines and Sera,,2.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-16 09:28:47,2023-06-16 09:28:47,OTHER_GOV,,,,,
136273,136274,NCT00343109,,2006-06-20,,2017-04-03,2020-02-07,2006-06-20,2006-06-22,Estimate,,,,2017-04-03,2017-04-05,Actual,2020-02-07,2020-02-12,Actual,March 2004,,2004-03-31,May 2019,2019-05-31,,,,June 2015,Actual,2015-06-30,,Interventional,,,Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer,Phase II Study of a HER-2/Neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine Administered to Patients With Locally Advanced or Stage IV HER2 Positive Breast Cancer,Completed,,Phase 2,38.0,Actual,University of Washington,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 07:14:49,2023-06-18 07:14:49,OTHER,,,,,
136633,136634,NCT00390143,,2006-10-17,,2009-09-03,2016-10-21,2006-10-17,2006-10-19,Estimate,,,,2009-09-03,2009-09-04,Estimate,2016-10-21,2016-10-25,Estimate,February 2007,,2007-02-28,October 2016,2016-10-31,May 2009,Actual,2009-05-31,May 2009,Actual,2009-05-31,,Interventional,,,Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612,Assess Long Term Persistence of a Primary Dose of GSK Biologicals' Meningococcal Vaccine 134612 Versus One Dose of Mencevax ACWY in Healthy Adolescents/Young Adults (15 to 19 Years at Vaccination),Completed,,Phase 2,46.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-18 07:15:42,2023-06-18 07:15:42,INDUSTRY,,,,,
136787,136788,NCT05465876,,2022-07-18,,,2023-05-30,2022-07-18,2022-07-20,Actual,,,,,,,2023-05-30,2023-06-01,Actual,October 2023,Anticipated,2023-10-31,May 2023,2023-05-31,October 2025,Anticipated,2025-10-31,October 2024,Anticipated,2024-10-31,,Interventional,PACE-CLL,,Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL,"A Multi-Center, Open-Label, Single-Arm Phase II Trial of Antibody Combination EVUSHELD (Tixagevimab and Cilgavimab) to Provide Passive Immunity Against COVID-19 in Vaccine Non-responsive Chronic Lymphocytic Leukemia",Suspended,,Phase 2,200.0,Anticipated,Sunnybrook Health Sciences Centre,,1.0,,Evusheld is being re-formulated to protect against all strains of Sars-Cov 2,False,,,,True,False,False,,,,,,,,,,,2023-06-17 15:30:30,2023-06-17 15:30:30,OTHER,,,,,
136820,136821,NCT00698906,,2008-06-13,,,2008-06-16,2008-06-16,2008-06-17,Estimate,,,,,,,2008-06-16,2008-06-17,Estimate,June 1997,,1997-06-30,June 2008,2008-06-30,,,,February 1998,Actual,1998-02-28,,Interventional,,,Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix-B in Adults Aged 19-40 y,"Study Comparing the Immunogenicity and Reactogenicity of Different Formulations of GSK Bio's HBV-MPL Vaccine Injected as a 0, 6 Months Schedule With That of Engerix-B Injected as a 0, 1, 6 Months Schedule in Healthy Adults Aged 19-40 Years",Completed,,Phase 2,160.0,Actual,GlaxoSmithKline,,6.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 09:30:11,2023-06-16 09:30:11,INDUSTRY,,,,,
136850,136851,NCT03590340,,2018-06-12,,,2020-01-03,2018-07-05,2018-07-18,Actual,,,,,,,2020-01-03,2020-01-07,Actual,"July 30, 2018",Actual,2018-07-30,January 2020,2020-01-31,"March 12, 2019",Actual,2019-03-12,"March 12, 2019",Actual,2019-03-12,,Interventional,,,Regimen Optimization Trial of PfSPZ Vaccine in Equatorial Guinea,"Randomized, Double-Blind, Placebo-Controlled, Regimen Optimization Study of a Radiation-Attenuated Plasmodium Falciparum (Pf) Sporozoite Vaccine (PfSPZ Vaccine) in Equatoguinean Adults",Completed,,Phase 1,104.0,Actual,Sanaria Inc.,,8.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 15:31:17,2023-06-17 15:31:17,INDUSTRY,,,,,
136921,136922,NCT02238756,,2014-09-04,,,2018-06-05,2014-09-09,2014-09-12,Estimate,,,,,,,2018-06-05,2018-06-06,Actual,September 2014,,2014-09-30,June 2018,2018-06-30,November 2016,Actual,2016-11-30,September 2015,Actual,2015-09-30,,Interventional,,,Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults,Phase I Safety and Tolerability Trial of Single and Repeat Doses of the RNA-based Adjuvant CV8102 Alone and in Combination With a Licensed Rabies Virus Vaccine in Healthy Adults,Completed,,Phase 1,72.0,Anticipated,CureVac,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 15:31:54,2023-06-17 15:31:54,INDUSTRY,,,,,
136978,136979,NCT03579654,,2018-06-06,,,2019-03-05,2018-06-25,2018-07-06,Actual,,,,,,,2019-03-05,2019-03-06,Actual,"February 28, 2019",Anticipated,2019-02-28,March 2019,2019-03-31,"June 30, 2022",Anticipated,2022-06-30,"February 28, 2021",Anticipated,2021-02-28,,Interventional,,,Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance,"A Phase 2, Randomized Study of Proscavax, a PSA/IL-2/GM-CSF Vaccine, in Treatment-naive Patients With Clinically Localized Prostate Cancer Versus an Active Surveillance Strategy",Unknown status,Not yet recruiting,Phase 2,120.0,Anticipated,OncBioMune Pharmaceuticals,,2.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-17 15:32:21,2023-06-17 15:32:21,OTHER,,,,,
137221,137222,NCT02475278,,2015-02-24,2016-09-07,,2018-02-16,2015-06-15,2015-06-18,Estimate,2016-09-07,2016-10-28,Estimate,,,,2018-02-16,2018-02-22,Actual,"February 26, 2015",Actual,2015-02-26,February 2018,2018-02-28,"September 9, 2015",Actual,2015-09-09,"April 7, 2015",Actual,2015-04-07,,Interventional,,"Safety Analysis Set, all participants who received the trial vaccine (NoV Vaccine).","Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine","Phase II, Single Arm, Open Label Trial for Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine",Completed,,Phase 2,50.0,Actual,Takeda,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 07:17:18,2023-06-18 07:17:18,INDUSTRY,,,,,
137286,137287,NCT02239614,,2014-09-10,,,2018-08-14,2014-09-10,2014-09-15,Estimate,,,,,,,2018-08-14,2018-08-15,Actual,December 2014,Actual,2014-12-31,August 2018,2018-08-31,"February 17, 2017",Actual,2017-02-17,"February 17, 2016",Actual,2016-02-17,,Interventional,,,TDENV PIV and LAV Dengue Prime-boost Strategy,"A Phase 1, Randomized, Open-label, Single-center, Study of TDENV-PIV and LAV Dengue Vaccine Platforms as Part of a Heterologous Prime-boost Strategy in Healthy Adults in a Nonendemic Region",Completed,,Phase 1,80.0,Actual,U.S. Army Medical Research and Development Command,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 15:34:52,2023-06-17 15:34:52,FED,,,,,
137356,137357,NCT04944368,,2021-06-19,,,2022-10-11,2021-06-28,2021-06-29,Actual,,,,,,,2022-10-11,2022-10-13,Actual,"May 30, 2021",Actual,2021-05-30,January 2022,2022-01-31,"December 30, 2021",Actual,2021-12-30,"July 19, 2021",Actual,2021-07-19,,Interventional,,,Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen),"A Phase II, Randomized, Two-armed, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine Candidate (SpikoGen)",Completed,,Phase 2,400.0,Actual,Cinnagen,,2.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-17 15:35:38,2023-06-17 15:35:38,INDUSTRY,,,,,
137440,137441,NCT01810016,,2013-03-08,2018-04-17,,2022-10-03,2013-03-12,2013-03-13,Estimate,2018-11-28,2018-11-30,Actual,,,,2022-10-03,2022-10-12,Actual,"January 24, 2014",Actual,2014-01-24,October 2022,2022-10-31,"May 17, 2016",Actual,2016-05-17,"May 17, 2016",Actual,2016-05-17,,Interventional,,The Safety Analysis Set includes all patients who received at least 1 dose of study treatment.,NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma,"Phase I Study of NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma, for Whom Treatment With Ipilimumab is Indicated",Terminated,,Phase 1,8.0,Actual,Ludwig Institute for Cancer Research,,3.0,,Low recruitment due to change in standard of care,False,,,,False,True,False,,,,,,,,,Undecided,,2023-06-17 15:36:28,2023-06-17 15:36:28,OTHER,,,,,
137594,137595,NCT00641615,,2008-03-17,,,2015-05-11,2008-03-17,2008-03-24,Estimate,,,,,,,2015-05-11,2015-05-12,Estimate,May 2007,,2007-05-31,May 2015,2015-05-31,July 2011,Actual,2011-07-31,July 2011,Actual,2011-07-31,,Interventional,,,Peptide Vaccine and S-1/CPT-11 Therapy for Patients With Unresectable Advanced Colorectal Cancer,Phase I Study of Peptide Vaccine and S-1 Plus CPT-11 Chemotherapy in Patients With Unresectable Recurrent or Metastatic Colorectal Cancer,Completed,,Phase 1,18.0,Actual,Tokyo Women's Medical University,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 09:32:50,2023-06-16 09:32:50,OTHER,,,,,
137612,137613,NCT00493285,,2007-06-26,2012-03-12,,2012-07-13,2007-06-27,2007-06-28,Estimate,2012-03-12,2012-04-09,Estimate,,,,2012-07-13,2012-07-19,Estimate,July 2007,,2007-07-31,July 2012,2012-07-31,April 2010,Actual,2010-04-30,November 2009,Actual,2009-11-30,,Interventional,CP149,,Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability,Immunogenicity, and Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV), in Healthy Children 6 to <24 Months of Age",Completed,,Phase 1,49.0,Actual,MedImmune LLC,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 09:32:52,2023-06-16 09:32:52,INDUSTRY,,,,,
137640,137641,NCT00022568,,2001-08-10,,,2013-12-17,2003-01-26,2003-01-27,Estimate,,,,,,,2013-12-17,2013-12-18,Estimate,August 2001,,2001-08-31,December 2003,2003-12-31,,,,,,,,Interventional,,,Vaccine Therapy in Treating Patients With Metastatic Melanoma,A Phase I Trial of Intra Lesional rV-Tricom Vaccine in the Treatment of Malignant Melanoma,Unknown status,"Active, not recruiting",Phase 1,,,National Cancer Institute (NCI),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 06:26:24,2023-06-15 06:26:24,NIH,,,,,
137650,137651,NCT05185817,,2022-01-10,,,2022-05-03,2022-01-10,2022-01-11,Actual,,,,,,,2022-05-03,2022-05-09,Actual,"November 1, 2021",Actual,2021-11-01,October 2021,2021-10-31,"July 1, 2023",Anticipated,2023-07-01,"July 1, 2022",Anticipated,2022-07-01,,Interventional,ESCVHSCT,,Effectiveness of COVID-19 Vaccine in Hematopoietic Stem Cell Transplant Patients,Evaluation of COVID-19 Vaccine Effectiveness and Immunogenicity in Patients Receiving Hematopoietic Stem Cell Transplantation,Recruiting,,Phase 2,100.0,Anticipated,Tehran University of Medical Sciences,,1.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-17 15:38:27,2023-06-17 15:38:27,OTHER,,,,,
137810,137811,NCT03566940,,2018-06-12,,,2020-08-06,2018-06-12,2018-06-25,Actual,,,,,,,2020-08-06,2020-08-07,Actual,"July 31, 2018",Actual,2018-07-31,August 2020,2020-08-31,"October 17, 2019",Actual,2019-10-17,"August 7, 2019",Actual,2019-08-07,,Interventional,,,"A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule","A Phase 2, Observer-blind, Active-controlled, Randomized Dose-finding Study in Healthy Infants to Assess the Safety, Reactogenicity and Immunogenicity of 3 Dose Levels of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains Compared to Conventional Salk IPV, in a 6, 10 and 14 Weeks of Age Immunization Schedule, and Co-administered With Diphtheria, Tetanus, Whole Cell Pertussis, Haemophilus Influenzae Type b, Hepatitis B, Pneumococcal Conjugate and Rotavirus Vaccines",Completed,,Phase 2,302.0,Actual,Janssen Vaccines & Prevention B.V.,,4.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-17 15:39:30,2023-06-17 15:39:30,INDUSTRY,,,,,
137918,137919,NCT01018459,,2009-11-19,,,2014-06-05,2009-11-19,2009-11-23,Estimate,,,,,,,2014-06-05,2014-06-06,Estimate,April 2010,,2010-04-30,February 2012,2012-02-29,December 2011,Actual,2011-12-31,December 2011,Actual,2011-12-31,,Interventional,,,Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkina Faso,"A Phase I Randomized, Controlled, Double-Blinded, Dosage-Escalation Trial to Evaluate the Immunogenicity, Safety, and Reactogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkinabè, Semi-Immune, Healthy Adults 18 to 45 Years of Age",Completed,,Phase 1,48.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 09:33:40,2023-06-16 09:33:40,NIH,,,,,
137969,137970,NCT01368029,,2011-06-02,,,2017-01-10,2011-06-06,2011-06-07,Estimate,,,,,,,2017-01-10,2017-01-11,Estimate,September 2011,,2011-09-30,January 2017,2017-01-31,May 2012,Actual,2012-05-31,May 2012,Actual,2012-05-31,,Interventional,,,Safety of Lactobacillus Rhamnosus GG Vs. Placebo in Elderly Subjects Receiving Trivalent Inactivated Influenza Vaccine,Double Blind Randomized Controlled Trial to Evaluate the Safety of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) Vs. Placebo in Elderly Subjects Receiving Trivalent Inactivated Influenza Vaccine,Completed,,Phase 1,28.0,Actual,Massachusetts General Hospital,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 15:40:47,2023-06-17 15:40:47,OTHER,,,,,
138203,138204,NCT01373879,,2011-06-14,,,2013-03-13,2011-06-14,2011-06-15,Estimate,,,,,,,2013-03-13,2013-03-14,Estimate,June 2010,,2010-06-30,March 2013,2013-03-31,December 2011,Actual,2011-12-31,December 2011,Actual,2011-12-31,,Interventional,,,AdCh63 ME-TRAP and MVA ME-TRAP Malaria Vaccines Evaluation in Healthy Adults and Children in a Malaria Endemic Area,Safety and Immunogenicity of Heterologous Prime-boost With the Candidate Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP in Healthy Adults and Children in a Malaria Endemic Area,Completed,,Phase 1,52.0,Actual,University of Oxford,,8.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 15:43:07,2023-06-17 15:43:07,OTHER,,,,,
138267,138268,NCT01375907,,2011-05-19,,,2016-07-01,2011-06-16,2011-06-17,Estimate,,,,,,,2016-07-01,2016-07-04,Estimate,August 2009,,2009-08-31,July 2016,2016-07-31,October 2009,Actual,2009-10-31,October 2009,Actual,2009-10-31,,Interventional,,,Safety Study of a Rotavirus Vaccine (Rotavin-M1) Among Healthy Adults,A Phase 1 Study to Evaluate Safety and Reactogenicity of a Vietnamese Rotavirus Vaccine (Rotavin-M1 at 10e6.3FFU/Dose) Among Healthy Adults in Vietnam,Completed,,Phase 1,29.0,Actual,"National Institute of Hygiene and Epidemiology, Vietnam",,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 15:43:30,2023-06-17 15:43:30,OTHER,,,,,
138309,138310,NCT03505060,,2018-04-12,,,2021-10-13,2018-04-12,2018-04-23,Actual,,,,,,,2021-10-13,2021-10-15,Actual,"January 1, 2019",Anticipated,2019-01-01,October 2021,2021-10-31,"November 11, 2019",Anticipated,2019-11-11,May 2019,Anticipated,2019-05-31,,Interventional,,,"Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults","A Phase 1b Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adult Participants",Withdrawn,,Phase 1,0.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,One of the study products is no longer available for clinical trial use.,False,,,,True,True,False,,,,,,,,,,,2023-06-17 15:43:46,2023-06-17 15:43:46,NIH,,,,,
138353,138354,NCT02291809,,2014-11-06,,,2016-02-22,2014-11-11,2014-11-14,Estimate,,,,,,,2016-02-22,2016-02-23,Estimate,November 2017,,2017-11-30,February 2016,2016-02-29,November 2019,Anticipated,2019-11-30,November 2019,Anticipated,2019-11-30,,Interventional,,,REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study,REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study,Unknown status,Not yet recruiting,Phase 2,26.0,Anticipated,"Immune Response BioPharma, Inc.",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 06:33:37,2023-06-18 06:33:37,INDUSTRY,,,,,
138369,138370,NCT02654080,,2016-01-11,,,2021-10-13,2016-01-11,2016-01-13,Estimate,,,,,,,2021-10-13,2021-10-15,Actual,March 2016,,2016-03-31,October 2021,2021-10-31,"July 1, 2019",Actual,2019-07-01,"August 24, 2017",Actual,2017-08-24,,Interventional,,,"Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults","A Phase 1 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy HIV-Uninfected Adult Participants",Completed,,Phase 1,14.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 15:44:21,2023-06-17 15:44:21,NIH,,,,,
138450,138451,NCT04842682,,2021-03-24,,,2022-09-09,2021-04-08,2021-04-13,Actual,,,,,,,2022-09-09,2022-09-14,Actual,"March 29, 2021",Actual,2021-03-29,September 2022,2022-09-30,"September 30, 2024",Anticipated,2024-09-30,"September 30, 2023",Anticipated,2023-09-30,,Interventional,,,Dose Escalation Trial of CD40.HIVRI.Env Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers,A Phase I Multicenter Double-blind Placebo Controlled Dose Escalation Trial of an Adjuvanted Anti-CD40 mAb Fused to Env GP140 HIV Clade C ZM-96 (CD40.HIVRI.Env) Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Participants,Recruiting,,Phase 1,72.0,Anticipated,"ANRS, Emerging Infectious Diseases",,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 07:20:47,2023-06-18 07:20:47,OTHER_GOV,,,,,
138473,138474,NCT04969276,,2021-07-16,2022-11-14,,2022-11-14,2021-07-16,2021-07-20,Actual,2022-11-14,2022-12-13,Actual,,,,2022-11-14,2022-12-13,Actual,"July 16, 2021",Actual,2021-07-16,November 2022,2022-11-30,"February 8, 2022",Actual,2022-02-08,"February 8, 2022",Actual,2022-02-08,,Interventional,,Analysis was performed on all randomized participants.,Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine,"A Phase II, Open-label Study to Assess the Safety and Immunogenicity of Fluzone® High-Dose Quadrivalent (Influenza Vaccine), 2021-2022 Formulation and a Third Dose of Moderna COVID-19 Vaccine (mRNA-1273 Vaccine) Administered Either Concomitantly or Singly in Adults 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine",Completed,,Phase 2,306.0,Actual,Sanofi,,3.0,,,False,,,,False,True,False,,,True,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-18 07:20:49,2023-06-18 07:20:49,INDUSTRY,,,,,
138630,138631,NCT05087368,,2021-08-11,,,2021-10-19,2021-10-19,2021-10-21,Actual,,,,,,,2021-10-19,2021-10-21,Actual,"December 1, 2021",Anticipated,2021-12-01,October 2021,2021-10-31,"April 1, 2022",Anticipated,2022-04-01,"April 1, 2022",Anticipated,2022-04-01,,Interventional,TP-SCB-2019001,,Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19),"An Observer-blinded, Randomized, Controlled, Phase 2 Study to Evaluate the Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac COVID-19 Vaccines or One Formulation of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) Determined in a lead-in Formulation Finding in Healthy Adults.",Not yet recruiting,,Phase 2,520.0,Anticipated,D'Or Institute for Research and Education,,10.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-17 15:47:09,2023-06-17 15:47:09,OTHER,,,,,
138967,138968,NCT00050505,,2002-12-10,,,2014-12-04,2002-12-10,2002-12-11,Estimate,,,,,,,2014-12-04,2014-12-05,Estimate,October 2002,,2002-10-31,July 2009,2009-07-31,December 2003,Actual,2003-12-31,,,,,Interventional,,,Expanded Dryvax Dilution Study in Previously Vaccinated Adults,"A Multicenter, Double Blind, Randomized Dose-response Study of Dryvax Vaccine Against Smallpox in Previously Vaccinated Adults",Completed,,Phase 2,927.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 06:26:43,2023-06-15 06:26:43,NIH,,,,,
139074,139075,NCT02826798,,2016-06-23,2019-06-13,,2020-04-16,2016-07-05,2016-07-11,Estimate,2020-04-16,2020-04-20,Actual,,,,2020-04-16,2020-04-20,Actual,"June 23, 2016",Actual,2016-06-23,April 2020,2020-04-30,"August 24, 2017",Actual,2017-08-24,"September 15, 2016",Actual,2016-09-15,,Interventional,,,"Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults","A Phase 1 Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Candidate Human Cytomegalovirus Vaccine (VBI-1501) in Healthy Adults",Completed,,Phase 1,128.0,Actual,VBI Vaccines Inc.,,5.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-17 15:51:17,2023-06-17 15:51:17,INDUSTRY,,,,,
139234,139235,NCT05200741,,2022-01-20,,,2022-10-27,2022-01-20,2022-01-21,Actual,,,,,,,2022-10-27,2022-10-28,Actual,"February 8, 2022",Actual,2022-02-08,January 2022,2022-01-31,February 2024,Anticipated,2024-02-29,February 2024,Anticipated,2024-02-29,,Interventional,,,To Evaluate Safety & Immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 for COVID-19 in Healthy Adults Received 2 Doses of BNT162b2,"A Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 as Booster Vaccine for COVID-19 in Healthy Adults Who Have Received 2 Doses of BNT162b2",Recruiting,,Phase 2,150.0,Anticipated,The University of Hong Kong,,2.0,,,False,,,,,False,False,,,,,,,,,No,"The results of this study will be publicly disseminated by ways of publication(s) in peer-reviewed scientific journal(s), presentation(s) in scientific conference(s), posting on public clinical trial registry(ies) and/or otherwise instead of individual participant data (IPD) sharing.",2023-06-17 15:52:28,2023-06-17 15:52:28,OTHER,,,,,
139283,139284,NCT04283461,,2020-02-21,2023-04-13,,2023-04-13,2020-02-21,2020-02-25,Actual,2023-04-13,2023-05-09,Actual,,,,2023-04-13,2023-05-09,Actual,"March 16, 2020",Actual,2020-03-16,"August 26, 2021",2021-08-26,"April 26, 2022",Actual,2022-04-26,"April 26, 2022",Actual,2022-04-26,,Interventional,,,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19),"Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults",Completed,,Phase 1,120.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,15.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-17 15:53:06,2023-06-17 15:53:06,NIH,,,,,
139447,139448,NCT01376765,,2011-06-16,,,2013-02-14,2011-06-16,2011-06-20,Estimate,,,,,,,2013-02-14,2013-02-15,Estimate,,,,April 2012,2012-04-30,,,,,,,,Interventional,,,"Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study","Phase I, Double-Blinded, Placebo-Controlled, Dose- Escalation Study of the Safety and Immunogenicity of Recombinant SARS-CoV deltaTM S Protein Vaccine Formulated With and Without Alhydrogel® in Healthy Adults When Administered by the Intramuscular Route",Withdrawn,,Phase 1,0.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 15:54:17,2023-06-17 15:54:17,NIH,,,,,
139858,139859,NCT02810340,,2016-06-20,2018-10-16,,2021-05-25,2016-06-21,2016-06-22,Estimate,2021-03-04,2021-03-30,Actual,,,,2021-05-25,2021-06-09,Actual,"August 1, 2016",Actual,2016-08-01,August 2019,2019-08-31,"October 13, 2017",Actual,2017-10-13,"October 13, 2017",Actual,2017-10-13,,Interventional,,,"Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults","A Phase 1, Double Blind, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of a New Meningococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X in Healthy Adults",Completed,,Phase 1,60.0,Actual,PATH,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 15:57:30,2023-06-17 15:57:30,OTHER,,,,,
140024,140025,NCT00649883,,2008-03-25,,,2017-04-05,2008-03-27,2008-04-01,Estimate,,,,,,,2017-04-05,2017-04-07,Actual,January 2008,,2008-01-31,April 2017,2017-04-30,October 2008,Actual,2008-10-31,April 2008,Actual,2008-04-30,,Interventional,,,Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months,"A Phase II, Observer-Blind, Randomized, Multi-center Study to Evaluate the Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Investigational Vaccine and Active Influenza Vaccine in Healthy Children Aged 6 to <60 Months",Completed,,Phase 2,360.0,Actual,Novartis,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 09:39:37,2023-06-16 09:39:37,INDUSTRY,,,,,
140159,140160,NCT03988283,,2019-06-12,,,2023-03-06,2019-06-12,2019-06-17,Actual,,,,,,,2023-03-06,2023-03-08,Actual,"June 30, 2023",Anticipated,2023-06-30,March 2023,2023-03-31,"December 31, 2027",Anticipated,2027-12-31,"January 31, 2026",Anticipated,2026-01-31,,Interventional,,,Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors,"A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors",Not yet recruiting,,Phase 1,10.0,Anticipated,Washington University School of Medicine,,1.0,,,False,,,,True,True,True,True,,False,,,,,,No,,2023-06-17 16:00:12,2023-06-17 16:00:12,OTHER,,,,,
140411,140412,NCT04690387,,2020-12-28,,,2021-12-14,2020-12-29,2020-12-30,Actual,,,,,,,2021-12-14,2021-12-16,Actual,"December 7, 2020",Actual,2020-12-07,December 2021,2021-12-31,"January 15, 2021",Actual,2021-01-15,"January 13, 2021",Actual,2021-01-13,,Interventional,,,"Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection","Adaptive Phase I Clinical Trial of Preventive Vaccine Consisting of Autologous Dendritic Cells Previously Incubated With S-protein From SARS-CoV-2, in Subjects Negative for COVID-19 Infection and Anti-SARS-CoV-2 Antibodies",Completed,,Phase 1,27.0,Actual,"Aivita Biomedical, Inc.",,9.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 07:26:55,2023-06-18 07:26:55,INDUSTRY,,,,,
140516,140517,NCT02661659,,2016-01-20,,,2018-05-07,2016-01-20,2016-01-22,Estimate,,,,,,,2018-05-07,2018-05-14,Actual,"June 12, 2016",Actual,2016-06-12,May 2018,2018-05-31,"October 3, 2017",Actual,2017-10-03,"October 3, 2017",Actual,2017-10-03,,Interventional,,,A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy,A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy,Withdrawn,,Phase 1,0.0,Actual,University of Chicago,,2.0,,PI stopped study due to inability to accrue.,False,,,,False,,,,,,,,,,,,,2023-06-16 09:41:24,2023-06-16 09:41:24,OTHER,,,,,
140539,140540,NCT02149706,,2014-05-24,,,2020-03-09,2014-05-28,2014-05-29,Estimate,,,,,,,2020-03-09,2020-03-11,Actual,"March 9, 2020",Anticipated,2020-03-09,March 2020,2020-03-31,"March 9, 2022",Anticipated,2022-03-09,"March 9, 2022",Anticipated,2022-03-09,,Interventional,,,"A Study of NeuroVax, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis","A Phase IIb Study of NeuroVax, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Slowing Disease Progression Via Vaccination",Unknown status,Not yet recruiting,Phase 2,150.0,Anticipated,"Immune Response BioPharma, Inc.",,2.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-17 16:03:23,2023-06-17 16:03:23,INDUSTRY,,,,,
140543,140544,NCT02151344,,2014-05-28,,,2015-03-26,2014-05-28,2014-05-30,Estimate,,,,,,,2015-03-26,2015-03-30,Estimate,May 2014,,2014-05-31,March 2015,2015-03-31,February 2015,Actual,2015-02-28,February 2015,Actual,2015-02-28,,Interventional,,,"Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals","Phase 1 Evaluation of the Optimal Interval Between Priming With a Live Influenza A Vaccine H7N9 (6-2) AA ca Recombinant (A/Anhui/1/2013 (H7N9) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H7N9 Disease Followed by Boost With a Non-adjuvanted Inactivated H7N9 Influenza Vaccine",Completed,,Phase 1,100.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 16:03:26,2023-06-17 16:03:26,NIH,,,,,
140750,140751,NCT00748150,,2008-09-05,,,2012-01-04,2008-09-05,2008-09-08,Estimate,,,,,,,2012-01-04,2012-01-05,Estimate,July 2008,,2008-07-31,January 2012,2012-01-31,August 2008,Actual,2008-08-31,August 2008,Actual,2008-08-31,,Interventional,,,"Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009, When Administered to Non-Elderly Adult and Elderly Subjects","A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009, When Administered to Non-Elderly Adult and Elderly Subjects",Completed,,Phase 2,143.0,Actual,Novartis,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 09:42:13,2023-06-16 09:42:13,INDUSTRY,,,,,
141070,141071,NCT00001906,,1999-11-03,,,2008-03-03,2002-12-09,2002-12-10,Estimate,,,,,,,2008-03-03,2008-03-04,Estimate,April 1999,,1999-04-30,April 2000,2000-04-30,May 2001,,2001-05-31,,,,,Interventional,,,Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as Adjuvants,Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as Adjuvants,Completed,,Phase 1,50.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 03:14:40,2023-06-14 03:14:40,NIH,,,,,
141098,141099,NCT05082285,,2021-10-07,,,2023-03-08,2021-10-07,2021-10-18,Actual,,,,,,,2023-03-08,2023-03-09,Actual,"November 29, 2021",Actual,2021-11-29,March 2023,2023-03-31,"October 31, 2023",Anticipated,2023-10-31,"October 31, 2023",Anticipated,2023-10-31,,Interventional,,,"A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants","A Phase II, Randomized, Partially Blinded Study to Assess the Safety, Tolerability and Immunogenicity of Meningococcal Combined ABCWY Vaccine When Administered to Healthy Infants",Recruiting,,Phase 2,688.0,Anticipated,GlaxoSmithKline,,4.0,,,False,,,,True,True,False,,,False,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-17 16:08:22,2023-06-17 16:08:22,INDUSTRY,,,,,
141119,141120,NCT00000946,,1999-11-02,,,2021-10-27,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-27,2021-10-29,Actual,,,,October 2021,2021-10-31,March 2001,Actual,2001-03-31,,,,,Interventional,,,A Study to Test the Safety of Three Experimental HIV Vaccines,"A Phase I Trial to Evaluate the HIV-1 SF-2 Recombinant p24 Subunit Vaccine [Chiron Vaccines] Administered as a Novel Boost in ""Prime-Boost"" Vaccination Regimens With ALVAC-HIV vCP205 [Pasteur Merieux Connaught] and HIV-1 SF-2 rgp120 in MF59 [Chiron Vaccines]",Completed,,Phase 1,40.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 03:14:42,2023-06-14 03:14:42,NIH,,,,,
141235,141236,NCT01377571,,2011-05-19,,,2016-06-30,2011-06-20,2011-06-21,Estimate,,,,,,,2016-06-30,2016-07-04,Estimate,October 2009,,2009-10-31,June 2016,2016-06-30,April 2010,Actual,2010-04-30,March 2010,Actual,2010-03-31,,Interventional,,,A Dose-escalating Study to Evaluate the Immunogenicity and Safety of Rotavin-M1 Vaccine in Healthy Infants,"A Phase II, Randomized, Double-blind, Vaccine-controlled Dose-escalating Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Oral Live Attenuated Human Rotavirus (HRV) Vaccine (Rotavin-M1) in Healthy Infants in Vietnam",Completed,,Phase 2,200.0,Actual,"National Institute of Hygiene and Epidemiology, Vietnam",,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 16:09:41,2023-06-17 16:09:41,OTHER,,,,,
141355,141356,NCT02296463,,2014-11-08,,,2016-04-27,2014-11-17,2014-11-20,Estimate,,,,,,,2016-04-27,2016-04-28,Estimate,November 2014,,2014-11-30,April 2016,2016-04-30,April 2016,Actual,2016-04-30,September 2015,Actual,2015-09-30,,Interventional,,,"A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age","A Phase I Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) Recombinant Fusion (F) Nanoparticle Vaccine, With or Without Aluminum Adjuvant, in Healthy Subjects 24 to <72 Months of Age",Completed,,Phase 1,32.0,Actual,Novavax,,5.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 07:29:43,2023-06-18 07:29:43,INDUSTRY,,,,,
141575,141576,NCT00052182,,2003-01-24,,,2007-10-22,2003-01-26,2003-01-27,Estimate,,,,,,,2007-10-22,2007-10-23,Estimate,October 2002,,2002-10-31,September 2007,2007-09-30,,,,,,,,Interventional,,,Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients,A Single Center Phase I Safety and Immunogenicity Study of Epimmune HIV-1 CTL Epitope-Based DNA Vaccine (EP HIV-1090) for Immunotherapy of HIV-1 Infected Individuals Receiving Highly Active Antiretroviral Therapy (HAART),Completed,,Phase 1,40.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 06:27:41,2023-06-15 06:27:41,NIH,,,,,
142422,142423,NCT00001060,,1999-11-02,,,2013-05-03,2001-08-30,2001-08-31,Estimate,,,,,,,2013-05-03,2013-05-06,Estimate,,,,May 2013,2013-05-31,June 2002,Actual,2002-06-30,,,,,Interventional,,,A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons,A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons,Completed,,Phase 1,30.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 03:15:29,2023-06-14 03:15:29,NIH,,,,,
142431,142432,NCT02174978,,2014-06-11,,,2017-10-11,2014-06-24,2014-06-26,Estimate,,,,,,,2017-10-11,2017-10-13,Actual,August 2014,Actual,2014-08-31,October 2017,2017-10-31,October 2015,Actual,2015-10-31,June 2015,Actual,2015-06-30,,Interventional,,,Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults,"Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) Open-label Dose Safety, Reactogenicity, Immunogenicity, and Efficacy of the Vaccine Candidate Plasmodium Falciparum Malaria Protein (FMP012), Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults",Completed,,Phase 1,39.0,Actual,U.S. Army Medical Research and Development Command,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 16:18:56,2023-06-17 16:18:56,FED,,,,,
142669,142670,NCT00707148,,2008-06-26,,,2014-07-24,2008-06-26,2008-06-30,Estimate,,,,,,,2014-07-24,2014-07-25,Estimate,January 2009,,2009-01-31,August 2012,2012-08-31,May 2012,Actual,2012-05-31,May 2012,Actual,2012-05-31,,Interventional,,,Pertussis Vaccine in Healthy Pregnant Women,"Safety and Immunogenicity of Tdap Vaccine in Healthy Pregnant Women, Safety in Their Neonates, and Effect of Maternal Immunization on Infant Immune Responses to DTaP Vaccine",Completed,,Phase 1,80.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 09:46:53,2023-06-16 09:46:53,NIH,,,,,
142806,142807,NCT00656123,,2008-04-09,,,2019-08-12,2008-04-09,2008-04-10,Estimate,,,,,,,2019-08-12,2019-08-14,Actual,March 2008,Actual,2008-03-31,August 2019,2019-08-31,January 2013,Actual,2013-01-31,August 2011,Actual,2011-08-31,,Interventional,,,Study of Colon GVAX and Cyclophosphamide in Patients With Metastatic Colorectal Cancer,A Safety and Feasibility Study of an Allogeneic Colon Cancer Cell Vaccine Administered With a GM-CSF Producing Bystander Cell Line in Patients With Metastatic Colorectal Cancer,Completed,,Phase 1,9.0,Actual,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,1.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-16 09:47:51,2023-06-16 09:47:51,OTHER,,,,,
142951,142952,NCT00657683,,2008-03-27,,,2011-12-07,2008-04-08,2008-04-14,Estimate,,,,,,,2011-12-07,2011-12-08,Estimate,December 2007,,2007-12-31,December 2011,2011-12-31,May 2009,Actual,2009-05-31,April 2009,Actual,2009-04-30,,Interventional,,,"A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of a Monovalent Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18-40 Years of Age","A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of a Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18-40 Years of Age",Completed,,Phase 1,65.0,Actual,Novartis,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 09:48:40,2023-06-16 09:48:40,INDUSTRY,,,,,
143165,143166,NCT02052726,,2013-12-17,,,2018-11-30,2014-01-30,2014-02-03,Estimate,,,,,,,2018-11-30,2018-12-04,Actual,"January 22, 2014",Actual,2014-01-22,November 2018,2018-11-30,"May 5, 2015",Actual,2015-05-05,"May 2, 2015",Actual,2015-05-02,,Interventional,,,"A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.","A Phase 1, Placebo-controlled, Randomized, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of An Adjuvanted Clostridium Difficile Vaccine Administered As A 3-dose Regimen In Healthy Adults Aged 50 To 85 Years",Completed,,Phase 1,184.0,Actual,Pfizer,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 16:23:04,2023-06-17 16:23:04,INDUSTRY,,,,,
143586,143587,NCT03676101,,2018-09-12,,,2020-01-20,2018-09-15,2018-09-18,Actual,,,,,,,2020-01-20,2020-01-22,Actual,"October 10, 2018",Actual,2018-10-10,January 2020,2020-01-31,"January 10, 2020",Actual,2020-01-10,"August 20, 2019",Actual,2019-08-20,,Interventional,,,Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females,"A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Primary Immunogenicity of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years",Completed,,Phase 1,90.0,Actual,"Shanghai Bovax Biotechnology Co., Ltd.",,2.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-17 16:25:52,2023-06-17 16:25:52,INDUSTRY,,,,,
143808,143809,NCT00053508,,2003-01-30,,,2014-01-17,2003-01-30,2003-01-31,Estimate,,,,,,,2014-01-17,2014-01-22,Estimate,September 2002,,2002-09-30,January 2014,2014-01-31,September 2003,Actual,2003-09-30,March 2003,Actual,2003-03-31,,Interventional,,,"Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination","The Effect of Dose On Safety, Tolerability, and Immunogenicity of ACAM1000 Smallpox Vaccine in Adults Without Previous Smallpox Vaccination A Phase 2, Randomized, Double-Blind, Dose-Response Study",Terminated,,Phase 2,274.0,Actual,Sanofi,,4.0,,"CDC's decision to down-select vaccine development to single candidate, ACAM2000",False,,,,True,,,,,,,,,,,,,2023-06-15 06:28:24,2023-06-15 06:28:24,INDUSTRY,,,,,
143881,143882,NCT05672355,,2023-01-03,,,2023-05-15,2023-01-03,2023-01-05,Actual,,,,,,,2023-05-15,2023-05-17,Actual,"September 1, 2023",Anticipated,2023-09-01,May 2023,2023-05-31,"January 9, 2024",Anticipated,2024-01-09,"January 9, 2024",Anticipated,2024-01-09,,Interventional,,,A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia,Randomized Observer-Blinded Phase 2 Trial of COVID-19 Booster With GEO-CM04S1 or mRNA Vaccine in Patients With Chronic Lymphocytic Leukemia,Not yet recruiting,,Phase 2,80.0,Anticipated,City of Hope Medical Center,,2.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-16 09:52:01,2023-06-16 09:52:01,OTHER,,,,,
143900,143901,NCT03161379,,2017-05-18,,,2023-03-08,2017-05-18,2017-05-19,Actual,,,,,,,2023-03-08,2023-03-10,Actual,"February 2, 2018",Actual,2018-02-02,March 2023,2023-03-31,June 2023,Anticipated,2023-06-30,June 2023,Anticipated,2023-06-30,,Interventional,,,GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer,A Phase II Clinical Trial of GVAX Pancreas Vaccine (With Cyclophosphamide) in Combination With Nivolumab and Stereotactic Body Radiation Therapy (SBRT) Followed by Definitive Resection for Patients With Borderline Resectable Pancreatic Adenocarcinoma,"Active, not recruiting",,Phase 2,30.0,Anticipated,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,1.0,,,False,,,,True,True,False,,,,,,,,,Undecided,,2023-06-17 16:28:15,2023-06-17 16:28:15,OTHER,,,,,
143984,143985,NCT03674073,,2018-09-14,,,2018-10-16,2018-09-14,2018-09-17,Actual,,,,,,,2018-10-16,2018-10-18,Actual,"October 15, 2018",Anticipated,2018-10-15,October 2018,2018-10-31,"December 15, 2020",Anticipated,2020-12-15,"October 15, 2020",Anticipated,2020-10-15,,Interventional,,,A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for the Treatment of Hepatocellular Carcinoma,"A Study to Assess the Safety, Feasibility, and Immunogenicity of Personalized Neoantigen-based Dendritic Cell Vaccine in Combination With Microwave Ablation to Treat Hepatocellular Carcinoma",Unknown status,Recruiting,Phase 1,24.0,Anticipated,Chinese PLA General Hospital,,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-17 16:28:48,2023-06-17 16:28:48,OTHER,,,,,
144638,144639,NCT00054912,,2003-02-12,,,2008-04-07,2003-02-13,2003-02-14,Estimate,,,,,,,2008-04-07,2008-04-09,Estimate,February 2003,,2003-02-28,April 2004,2004-04-30,,,,,,,,Interventional,,,An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer,"An Open Label, Multi-Center Safety and Tolerance Study of EP2101 Peptide Vaccine in Patients With Stage III Colon Cancer",Completed,,Phase 1,18.0,,Epimmune,,,,,,,,,,,,,,,,,,,,,,2023-06-15 06:29:17,2023-06-15 06:29:17,INDUSTRY,,,,,
144752,144753,NCT04491877,,2020-07-27,,,2023-05-16,2020-07-27,2020-07-29,Actual,,,,,,,2023-05-16,2023-05-17,Actual,"September 17, 2020",Actual,2020-09-17,May 2023,2023-05-31,"April 13, 2023",Actual,2023-04-13,"April 13, 2023",Actual,2023-04-13,,Interventional,VAD00001,,Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers,"Safety, Immunogenicity, Infectivity, and Dose-Finding Study of an Investigational Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in Infants and Toddlers",Completed,,Phase 2,259.0,Actual,Sanofi,,9.0,,,False,,,,False,True,False,,,False,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-16 09:55:25,2023-06-16 09:55:25,INDUSTRY,,,,,
144895,144896,NCT02200718,,2014-07-17,,,2020-03-30,2014-07-24,2014-07-25,Estimate,,,,,,,2020-03-30,2020-03-31,Actual,"December 31, 2020",Anticipated,2020-12-31,March 2020,2020-03-31,"November 9, 2024",Anticipated,2024-11-09,"November 9, 2024",Anticipated,2024-11-09,,Interventional,,,"A Study of NeuroVax, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis","A Phase I Study of NeuroVax, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis",Not yet recruiting,,Phase 1,12.0,Anticipated,"Immune Response BioPharma, Inc.",,2.0,,,,,,,True,True,False,,,,,,,,,,,2023-06-17 16:33:52,2023-06-17 16:33:52,INDUSTRY,,,,,
145103,145104,NCT02071758,,2014-02-24,,,2016-02-22,2014-02-24,2014-02-26,Estimate,,,,,,,2016-02-22,2016-02-23,Estimate,April 2014,,2014-04-30,February 2016,2016-02-29,December 2015,Actual,2015-12-31,December 2015,Actual,2015-12-31,,Interventional,,,Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers,"A Phase 1, Open-Label Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-F3 + SLA-SE Vaccine Compared to LEISH-F3 + GLA-SE Vaccine in Healthy Adult Subjects",Completed,,Phase 1,39.0,Actual,Access to Advanced Health Institute (AAHI),,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 16:34:46,2023-06-17 16:34:46,OTHER,,,,,
145131,145132,NCT00027365,,2001-12-04,,,2021-10-13,2001-12-04,2001-12-05,Estimate,,,,,,,2021-10-13,2021-10-14,Actual,,,,October 2021,2021-10-31,June 2003,Actual,2003-06-30,,,,,Interventional,,,An Investigational Combination Vaccine Given to People Who Are Not Infected With HIV,A Phase I Safety and Immunogenicity Trial of a Combination Vaccine (NefTat and gp120w61d) Formulated With AS02A (GlaxoSmithKline Biologicals) Given Intramuscularly in HIV-1 Uninfected Adult Participants,Completed,,Phase 1,84.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 06:29:33,2023-06-15 06:29:33,NIH,,,,,
145504,145505,NCT00660257,,2008-04-15,,,2008-04-16,2008-04-16,2008-04-17,Estimate,,,,,,,2008-04-16,2008-04-17,Estimate,January 2007,,2007-01-31,April 2008,2008-04-30,March 2008,Actual,2008-03-31,March 2007,Actual,2007-03-31,,Interventional,,,"Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine","Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza (H5N1)Vaccine in Two-Dose Primed Healthy Adults: A Single Center, Non-Randomized Clinical Trial",Completed,,Phase 1,57.0,Actual,"Sinovac Biotech Co., Ltd",,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 09:58:43,2023-06-16 09:58:43,INDUSTRY,,,,,
145701,145702,NCT00027833,,2001-12-07,,,2014-01-03,2003-01-26,2003-01-27,Estimate,,,,,,,2014-01-03,2014-01-06,Estimate,December 2001,,2001-12-31,September 2003,2003-09-30,,,,,,,,Interventional,,,Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer,"Pilot Phase II Study of Safety and Immunogenicity of an ALVAC-CEA/B7.1 Vaccine Administered With Chemotherapy, Alone or in Combination With Tetanus Toxoid, as Compared to Chemotherapy Alone, in Patients With Metastatic Colorectal Adenocarcinoma",Unknown status,"Active, not recruiting",Phase 2,,,National Cancer Institute (NCI),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 06:29:47,2023-06-15 06:29:47,NIH,,,,,
146015,146016,NCT02083068,,2014-03-05,,,2018-03-21,2014-03-10,2014-03-11,Estimate,,,,,,,2018-03-21,2018-03-23,Actual,August 2014,,2014-08-31,March 2018,2018-03-31,July 2017,Actual,2017-07-31,September 2015,Actual,2015-09-30,,Interventional,,,Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax,Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax,Completed,,Phase 2,32.0,Actual,Malaria Vaccine and Drug Development Center,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 16:40:13,2023-06-17 16:40:13,OTHER,,,,,
146214,146215,NCT04453202,,2020-06-29,,2021-09-23,2021-09-23,2020-06-29,2020-07-01,Actual,,,,2021-09-23,2021-09-28,Actual,2021-09-23,2021-09-28,Actual,"July 16, 2020",Actual,2020-07-16,June 2021,2021-06-30,"April 9, 2021",Actual,2021-04-09,"September 24, 2020",Actual,2020-09-24,,Interventional,,,A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults,"A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate a Range of Dose Levels of an Ad26.RSV.preF-based Vaccine in Adults Aged 60 Years and Older",Completed,,Phase 2,459.0,Actual,Janssen Vaccines & Prevention B.V.,,11.0,,,False,,,,False,True,False,,,,,,,,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2023-06-17 16:41:37,2023-06-17 16:41:37,INDUSTRY,,,,,
146363,146364,NCT00028496,,2002-01-04,,,2013-01-24,2003-01-26,2003-01-27,Estimate,,,,,,,2013-01-24,2013-01-25,Estimate,November 2001,,2001-11-30,January 2013,2013-01-31,,,,November 2005,Actual,2005-11-30,,Interventional,,,Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer,Phase I Study of a Recombinant Fowl Pox Vaccine rF-CEA (6D)/TRICOM Alone or With GM-CSF in Patients With Advanced CEA Expressing Adenocarinomas,Completed,,Phase 1,48.0,Actual,National Cancer Institute (NCI),,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 06:30:04,2023-06-15 06:30:04,NIH,,,,,
146563,146564,NCT00676949,,2008-03-03,,,2011-06-22,2008-05-09,2008-05-13,Estimate,,,,,,,2011-06-22,2011-06-23,Estimate,November 2007,,2007-11-30,April 2011,2011-04-30,March 2010,Actual,2010-03-31,March 2010,Actual,2010-03-31,,Interventional,peptidevac,,"Safety Study of Cancer Specific Epitope Peptides Cocktail for Cervical, GI, and Lung Tumors",Phase I Study of Tumor Specific Potentiated Vaccine Therapy Using Cyclophosphamide Combined Epitope Peptide Cocktail for Progressive/Relapsed Solid Tumors(GI/Lung/Cervical Cancer),Completed,,Phase 1,18.0,Actual,Kyushu University,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 10:01:57,2023-06-16 10:01:57,OTHER,,,,,
146698,146699,NCT02236052,,2014-09-08,,,2019-10-31,2014-09-08,2014-09-10,Estimate,,,,,,,2019-10-31,2019-11-01,Actual,"July 16, 2014",Actual,2014-07-16,October 2019,2019-10-31,"June 17, 2015",Actual,2015-06-17,"June 17, 2015",Actual,2015-06-17,,Interventional,,,"Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly Population","Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like Particles (VLP) Quadrivalent Influenza Vaccine in the Elderly Population",Completed,,Phase 2,450.0,Actual,Medicago,,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 16:44:52,2023-06-17 16:44:52,INDUSTRY,,,,,
146996,146997,NCT04162223,,2019-10-31,,,2019-11-12,2019-11-12,2019-11-14,Actual,,,,,,,2019-11-12,2019-11-14,Actual,"March 29, 2000",Actual,2000-03-29,November 2019,2019-11-30,"May 20, 2003",Actual,2003-05-20,"May 20, 2003",Actual,2003-05-20,,Interventional,,,Hepatitis B Vaccine in Seniors,"Mechanisms of Immunosenescence: A Single-Blinded Comparison of the Location of Vaccine Inoculum, Intramuscular Versus Subcutaneous Adipose Tissue, on the Immune Response of Healthy Elderly Adults to a Recombinant Hepatitis B Surface Antigen Vaccine (Recombivax-HB)",Completed,,Early Phase 1,52.0,Actual,"University of Maryland, Baltimore",,2.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-16 10:02:58,2023-06-16 10:02:58,OTHER,,,,,
147218,147219,NCT00157196,,2005-09-08,2015-07-23,,2015-07-23,2005-09-09,2005-09-12,Estimate,2015-07-23,2015-08-18,Estimate,,,,2015-07-23,2015-08-18,Estimate,April 2005,,2005-04-30,July 2015,2015-07-31,April 2012,Actual,2012-04-30,September 2007,Actual,2007-09-30,,Interventional,,The intention-to-treat (ITT) analysis set included all the enrolled participants who received at least 1 dose of trial treatment.,Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease,"A Multi-center, Non-randomized, Open Label Safety Study of BLP25 Liposome Vaccine (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Patients With Unresectable Stage III Disease",Completed,,Phase 2,22.0,Actual,"Merck KGaA, Darmstadt, Germany",,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 16:48:36,2023-06-17 16:48:36,INDUSTRY,,,,,
147446,147447,NCT00753844,,2008-09-16,,,2012-04-04,2008-09-16,2008-09-17,Estimate,,,,,,,2012-04-04,2012-04-06,Estimate,November 2006,,2006-11-30,April 2012,2012-04-30,July 2009,Actual,2009-07-31,June 2009,Actual,2009-06-30,,Interventional,,,Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer,Tumor Vaccine Therapy Against Advanced Esophageal Cancer Using HLA-A*2402 Restricted Epitope Peptides Drived From URLC10,Completed,,Phase 1,7.0,Actual,Kinki University,,,,,False,,,,,,,,,,,,,,,,,2023-06-16 10:04:42,2023-06-16 10:04:42,OTHER,,,,,
147673,147674,NCT00805389,,2008-12-05,2012-12-19,2012-07-26,2018-07-11,2008-12-05,2008-12-09,Estimate,2012-12-19,2013-01-25,Estimate,2012-07-26,2012-08-03,Estimate,2018-07-11,2018-08-20,Actual,"December 15, 2008",Actual,2008-12-15,June 2018,2018-06-30,"July 14, 2011",Actual,2011-07-14,"September 29, 2010",Actual,2010-09-29,,Interventional,,,Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine,Comparison of the Immunogenicity and Safety of Various Investigational and Licensed Formulations of Hepatitis B Surface Antigen (HBsAg) Vaccines.,Completed,,Phase 2,713.0,Actual,GlaxoSmithKline,,5.0,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-16 10:05:47,2023-06-16 10:05:47,INDUSTRY,,,,,
147707,147708,NCT00678652,,2008-05-08,2016-11-01,,2017-12-15,2008-05-08,2008-05-15,Estimate,2017-12-15,2017-12-18,Actual,,,,2017-12-15,2017-12-18,Actual,April 2008,,2008-04-30,December 2017,2017-12-31,August 2009,Actual,2009-08-31,August 2009,Actual,2009-08-31,,Interventional,HOPS,,Phase 1 Safety and Immunogenicity of Meningococcal Vaccine,"Ph 1 Dose-Escalation Study of Safety and Immunogenicity of 3 Injections, at 0, 6, 2 Wks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Adm Intramuscularly to Healthy Subjects at 10, 25, 50, 75 µg With Adjuvant",Completed,,Phase 1,36.0,Actual,U.S. Army Medical Research and Development Command,,4.0,,,False,,,,True,,,,,,,,,,,Undecided,,2023-06-16 10:06:09,2023-06-16 10:06:09,FED,,,,,
147770,147771,NCT03981952,,2019-06-07,,,2021-10-25,2019-06-07,2019-06-11,Actual,,,,,,,2021-10-25,2021-10-27,Actual,"October 28, 2019",Actual,2019-10-28,October 2021,2021-10-31,"May 7, 2021",Actual,2021-05-07,"May 7, 2021",Actual,2021-05-07,,Interventional,,,Salmonella Conjugates CVD 1000: Study of Responses to Vaccination With Trivalent Invasive Salmonella Disease Vaccine,"Phase 1 Randomized, Placebo-Controlled, Dose-Escalation Study of the Safety, Reactogenicity, and Immunogenicity of Trivalent (S. Enteritidis/S. Typhimurium/S. Typhi Vi) Conjugate Vaccine Against Invasive Salmonella Disease Administered Parenterally to Healthy U.S. Adults",Completed,,Phase 1,96.0,Actual,"University of Maryland, Baltimore",,4.0,,,False,,,,,True,False,,,,,,,,,No,,2023-06-17 16:51:29,2023-06-17 16:51:29,OTHER,,,,,
147813,147814,NCT04627246,,2020-10-15,,,2022-06-23,2020-11-09,2020-11-13,Actual,,,,,,,2022-06-23,2022-06-28,Actual,"September 11, 2020",Actual,2020-09-11,June 2022,2022-06-30,September 2028,Anticipated,2028-09-30,September 2028,Anticipated,2028-09-30,,Interventional,,,Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer,A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine and Standard Of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma,Recruiting,,Phase 1,12.0,Anticipated,Centre Hospitalier Universitaire Vaudois,,1.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-16 10:06:43,2023-06-16 10:06:43,OTHER,,,,,
148120,148121,NCT00908687,,2009-05-22,2014-01-30,,2021-12-09,2009-05-26,2009-05-27,Estimate,2014-01-30,2014-03-13,Estimate,,,,2021-12-09,2021-12-10,Actual,May 2009,,2009-05-31,December 2021,2021-12-31,July 2011,Actual,2011-07-31,January 2010,Actual,2010-01-31,,Interventional,,safety population: all subjects with signed Informed Consent who have received investigational product,A/H5N1/LT Dose Ranging Study,"A Randomized Blinded, LT Dose-ranging Study to Assess the Immunogenicity and Safety of Different Doses of LT Adjuvant Patch Administered in Conjunction With Different Doses of Inactivated Influenza A/H5N1 Vaccine in Healthy Adults",Completed,,Phase 2,500.0,Actual,"Intercell USA, Inc.",,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 07:52:35,2023-06-18 07:52:35,INDUSTRY,,,,,
148336,148337,NCT04602975,,2020-09-24,,,2023-01-03,2020-10-20,2020-10-26,Actual,,,,,,,2023-01-03,2023-01-04,Actual,"October 6, 2020",Actual,2020-10-06,August 2022,2022-08-31,"December 30, 2023",Anticipated,2023-12-30,"December 30, 2023",Anticipated,2023-12-30,,Interventional,GlycoShig3,,A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a,"A Phase 2a Age Descending Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a in Adults, Children, and Infant Target Population in Endemic Countries.","Active, not recruiting",,Phase 2,248.0,Actual,Institut Pasteur,,12.0,,,False,,,,True,False,False,,,,,,,,,No,"This study is a part of a development program, Data will stay confidential and possibly shared only with program partners.",2023-06-17 16:55:55,2023-06-17 16:55:55,INDUSTRY,,,,,
148346,148347,NCT01014806,,2009-11-14,,2013-07-16,2013-07-16,2009-11-16,2009-11-17,Estimate,,,,2013-07-16,2013-07-18,Estimate,2013-07-16,2013-07-18,Estimate,November 2009,,2009-11-30,July 2013,2013-07-31,May 2010,Actual,2010-05-31,May 2010,Actual,2010-05-31,,Interventional,,,Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults,"A Phase 2a Randomized, Double-Blind, Active-Controlled Trial to Evaluate the Safety and Immunogenicity of a Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant) in Older Adults",Completed,,Phase 2,467.0,Actual,Novavax,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 16:55:56,2023-06-17 16:55:56,INDUSTRY,,,,,
148555,148556,NCT00395720,,2006-11-02,,,2011-03-25,2006-11-02,2006-11-03,Estimate,,,,,,,2011-03-25,2011-03-28,Estimate,November 2006,,2006-11-30,March 2011,2011-03-31,July 2010,Actual,2010-07-31,July 2010,Actual,2010-07-31,,Interventional,,,"The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV","A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Infected With HIV",Completed,,Phase 1,20.0,Anticipated,University of Oxford,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 06:30:47,2023-06-15 06:30:47,OTHER,,,,,
148738,148739,NCT04966871,,2021-06-03,,,2022-07-15,2021-07-07,2021-07-19,Actual,,,,,,,2022-07-15,2022-07-18,Actual,"September 27, 2021",Actual,2021-09-27,July 2022,2022-07-31,"June 21, 2022",Actual,2022-06-21,"June 21, 2022",Actual,2022-06-21,,Interventional,,,"Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults","A Clinical Trial of a 3-dose, 28-Day Regimen of PfSPZ Vaccine in Healthy, Malaria-Naïve, Adult Subjects to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI Conducted 14, 42 or 70 Days After Immunization",Completed,,Phase 1,54.0,Actual,Sanaria Inc.,,6.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-17 16:58:32,2023-06-17 16:58:32,INDUSTRY,,,,,
148794,148795,NCT01088789,,2010-03-01,,,2023-03-06,2010-03-16,2010-03-17,Estimate,,,,,,,2023-03-06,2023-03-08,Actual,"April 20, 2010",Actual,2010-04-20,March 2023,2023-03-31,August 2023,Anticipated,2023-08-31,August 2023,Anticipated,2023-08-31,,Interventional,,,A Trial of Boost Vaccinations of Pancreatic Tumor Cell Vaccine,"A Safety and Feasibility Trial of Boost Vaccinations of a Lethally Irradiated, Allogeneic Pancreatic Tumor Cell Vaccine Transfected With the GM-CSF Gene","Active, not recruiting",,Phase 2,71.0,Actual,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,5.0,,,False,,,,True,,,,,,,,,,,No,Data entry and analysis is still ongoing.,2023-06-17 16:58:59,2023-06-17 16:58:59,OTHER,,,,,
148984,148985,NCT03460405,,2018-03-04,,,2020-02-18,2018-03-04,2018-03-09,Actual,,,,,,,2020-02-18,2020-02-20,Actual,"July 16, 2018",Actual,2018-07-16,February 2020,2020-02-29,"January 30, 2020",Actual,2020-01-30,"December 31, 2019",Actual,2019-12-31,,Interventional,,,"Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants","Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Indonesian Adults, Adolescents, Children and Infants (Phase II)",Completed,,Phase 2,600.0,Actual,PT Bio Farma,,6.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 07:55:39,2023-06-18 07:55:39,INDUSTRY,,,,,
149207,149208,NCT03463369,,2018-02-28,,,2021-04-13,2018-03-10,2018-03-13,Actual,,,,,,,2021-04-13,2021-04-14,Actual,"April 18, 2018",Actual,2018-04-18,April 2021,2021-04-30,"March 23, 2021",Actual,2021-03-23,"March 23, 2021",Actual,2021-03-23,,Interventional,,,"A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed","A First-In-Human, Double-Blind, Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(T)Ide Therapy and Virologically Suppressed",Completed,,Phase 1,30.0,Actual,Janssen Sciences Ireland UC,,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 07:56:15,2023-06-18 07:56:15,INDUSTRY,,,,,
149266,149267,NCT03387137,,2017-12-21,,,2022-01-19,2017-12-21,2017-12-29,Actual,,,,,,,2022-01-19,2022-01-20,Actual,"October 13, 2017",Actual,2017-10-13,January 2022,2022-01-31,"May 31, 2021",Actual,2021-05-31,"November 22, 2019",Actual,2019-11-22,,Interventional,,,"Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/<U+2206>NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children","Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, RSV 6120/<U+2206>NS2/1030s, Lot RSV#012A, Delivered as Nose Drops to RSV-Seropositive Children 12 to 59 Months of Age and RSV-Seronegative Infants and Children 6 to 24 Months of Age",Completed,,Phase 1,45.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-17 17:02:33,2023-06-17 17:02:33,NIH,,,,,
149307,149308,NCT00002350,,1999-11-02,,,2005-06-23,2001-08-30,2001-08-31,Estimate,,,,,,,2005-06-23,2005-06-24,Estimate,,,,July 1997,1997-07-31,,,,,,,,Interventional,,,A Phase I Trial of APL 400-003 Vaccine: Safety and Immune Response Evaluations of Multiple Injections at Escalating Doses in Asymptomatic HIV-Infected Patients,A Phase I Trial of APL 400-003 Vaccine: Safety and Immune Response Evaluations of Multiple Injections at Escalating Doses in Asymptomatic HIV-Infected Patients,Completed,,Phase 1,16.0,,NIH AIDS Clinical Trials Information Service,,,,,False,,,,,,,,,,,,,,,,,2023-06-14 03:19:46,2023-06-14 03:19:46,INDUSTRY,,,,,
149312,149313,NCT04800133,,2021-03-01,,,2022-07-14,2021-03-15,2021-03-16,Actual,,,,,,,2022-07-14,2022-07-19,Actual,"May 8, 2021",Actual,2021-05-08,July 2022,2022-07-31,"March 31, 2025",Anticipated,2025-03-31,"March 31, 2025",Anticipated,2025-03-31,,Interventional,COVAC,,Covid-19 Vaccination in Adolescents and Children,To Compare the Reactogenicity and Immunogenicity of Recommended COVID-19 Vaccines in Young Adolescents and Children in Hong Kong,"Active, not recruiting",,Phase 2,1018.0,Actual,The University of Hong Kong,,4.0,,,False,,,,,False,False,,,False,,,,,,No,,2023-06-18 07:56:49,2023-06-18 07:56:49,OTHER,,,,,
149654,149655,NCT04818281,,2021-03-24,,,2022-05-24,2021-03-24,2021-03-26,Actual,,,,,,,2022-05-24,2022-05-25,Actual,"March 27, 2021",Actual,2021-03-27,May 2022,2022-05-31,"December 29, 2021",Actual,2021-12-29,"December 29, 2021",Actual,2021-12-29,,Interventional,COVID-19,,Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults,"Phase I Study Evaluating the Basic Pharmacological and Toxicological Effects of the Protective VLP Vaccine Developed Against SARS-CoV-2 in Healthy Participants, Administered as Two Injections Subcutaneously, in Two Different Dosages.",Completed,,Phase 1,38.0,Actual,The Scientific and Technological Research Council of Turkey,,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 07:58:19,2023-06-18 07:58:19,OTHER,,,,,
149690,149691,NCT05396573,,2022-05-25,,,2022-05-26,2022-05-26,2022-05-31,Actual,,,,,,,2022-05-26,2022-05-31,Actual,July 2022,Anticipated,2022-07-31,May 2022,2022-05-31,July 2023,Anticipated,2023-07-31,August 2022,Anticipated,2022-08-31,,Interventional,,,A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19,"A Randomized, Blinded, Positive Control Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine (RQ3013) in Healthy Adults Completed a Two-dose Primary Series of Inactivated Vaccine",Not yet recruiting,,Phase 1,120.0,Anticipated,"Walvax Biotechnology Co., Ltd.",,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 07:58:29,2023-06-18 07:58:29,INDUSTRY,,,,,
149723,149724,NCT00798265,,2008-11-25,,,2022-01-26,2008-11-25,2008-11-26,Estimate,,,,,,,2022-01-26,2022-01-27,Actual,"June 29, 2009",Actual,2009-06-29,"June 4, 2021",2021-06-04,"February 4, 2013",Actual,2013-02-04,"September 22, 2012",Actual,2012-09-22,,Interventional,,,"A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults","A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents and Young Adults",Completed,,Phase 1,26.0,Actual,National Institutes of Health Clinical Center (CC),,3.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-17 17:04:43,2023-06-17 17:04:43,NIH,,,,,
149948,149949,NCT00057525,,2003-04-03,,,2011-06-29,2003-04-04,2003-04-07,Estimate,,,,,,,2011-06-29,2011-06-30,Estimate,April 2003,,2003-04-30,June 2011,2011-06-30,August 2004,Actual,2004-08-31,April 2004,Actual,2004-04-30,,Interventional,,,A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults,"A Phase 1 Study of Safety and Immunogenicity of E. Coli-Derived Recombinant Protective Antigen (rPA), a New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults",Completed,,Phase 1,70.0,Actual,"DynPort Vaccine Company LLC, A GDIT Company",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 06:31:05,2023-06-15 06:31:05,INDUSTRY,,,,,
150161,150162,NCT00689741,,2008-05-30,,,2016-09-09,2008-05-30,2008-06-04,Estimate,,,,,,,2016-09-09,2016-09-12,Estimate,January 2001,,2001-01-31,September 2016,2016-09-30,April 2003,Actual,2003-04-30,April 2003,Actual,2003-04-30,,Interventional,,,Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women,"A Double-blind, Placebo-controlled, Randomised Study of the Efficacy of an HPV-16/18 VLP Vaccine in the Prevention of HPV-16 and/or HPV-18 Cervical Infection in Healthy Adolescent and Young Adult Women in North America and Brazil.",Completed,,Phase 2,1113.0,Actual,GlaxoSmithKline,,2.0,,,,,,,False,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 10:14:17,2023-06-16 10:14:17,INDUSTRY,,,,,
150223,150224,NCT02624219,,2015-11-25,,,2019-10-22,2015-12-03,2015-12-08,Estimate,,,,,,,2019-10-22,2019-10-23,Actual,"August 16, 2016",Actual,2016-08-16,October 2019,2019-10-31,"January 30, 2018",Actual,2018-01-30,"January 30, 2018",Actual,2018-01-30,,Interventional,,,H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults,"A Phase I Randomized, Double-Blind, Controlled Trial in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of a Monovalent Inactivated Influenza A/H5N8 Virus Vaccine Administered Intramuscularly at Different Dosages Given With or Without AS03 or MF59 Adjuvants",Completed,,Phase 1,276.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-16 10:14:26,2023-06-16 10:14:26,NIH,,,,,
150415,150416,NCT03268083,,2016-08-04,,,2021-10-18,2017-08-29,2017-08-31,Actual,,,,,,,2021-10-18,2021-10-26,Actual,July 2016,Actual,2016-07-31,October 2021,2021-10-31,December 2017,Actual,2017-12-31,August 2017,Actual,2017-08-31,,Interventional,,,A Study to Evaluate the Immunogenicity and Safety of EV71 Vaccine in Pediatric Subjects,"An Open-Label, Dose-Finding, Phase II Study to Evaluate the Immunogenicity and Safety of the Bioreactor-generated EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 2 to 35 Months Old",Completed,,Phase 2,140.0,Actual,Enimmune Corporation,,6.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-18 08:01:13,2023-06-18 08:01:13,INDUSTRY,,,,,
150503,150504,NCT00851786,,2009-02-25,2012-09-07,,2021-11-02,2009-02-25,2009-02-26,Estimate,2012-09-07,2012-10-10,Estimate,,,,2021-11-02,2021-11-04,Actual,"April 29, 2009",Actual,2009-04-29,January 2018,2018-01-31,"January 3, 2012",Actual,2012-01-03,"September 22, 2011",Actual,2011-09-22,,Interventional,,,Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy,"A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX® (Zoster Vaccine Live) in Human Immunodeficiency Virus (HIV)-1-Infected Adults on Potent Combination ART With Conserved Immune Function",Completed,,Phase 2,395.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 10:15:15,2023-06-16 10:15:15,NIH,,,,,
150536,150537,NCT02624999,,2015-11-29,,,2020-01-17,2015-12-04,2015-12-09,Estimate,,,,,,,2020-01-17,2020-01-22,Actual,December 2016,Anticipated,2016-12-31,July 2016,2016-07-31,May 2017,Actual,2017-05-31,December 2016,Actual,2016-12-31,,Interventional,,,Study Comparing AlloVax to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck,An Individualized Cancer Vaccine for Recurrent/Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN),Withdrawn,,Phase 2,0.0,Actual,"Immunovative Therapies, Ltd.",,2.0,,PI changed institution,False,,,,False,,,,,,,,,,,,,2023-06-16 10:15:27,2023-06-16 10:15:27,INDUSTRY,,,,,
150783,150784,NCT00600782,,2008-01-15,,2009-09-03,2020-10-02,2008-01-24,2008-01-25,Estimate,,,,2009-09-03,2009-09-04,Estimate,2020-10-02,2020-10-12,Actual,"February 5, 2008",Actual,2008-02-05,October 2020,2020-10-31,"December 19, 2008",Actual,2008-12-19,"December 19, 2008",Actual,2008-12-19,,Interventional,,,Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic Region,Immunogenicity and Safety of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342) When Administered to Healthy Adults Aged 21 to 40 Years.,Completed,,Phase 2,45.0,Actual,GlaxoSmithKline,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 17:12:13,2023-06-17 17:12:13,INDUSTRY,,,,,
151308,151309,NCT00002428,,1999-11-02,,,2005-06-23,2001-08-30,2001-08-31,Estimate,,,,,,,2005-06-23,2005-06-24,Estimate,,,,March 1996,1996-03-31,,,,,,,,Interventional,,,A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects,A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects,Completed,,Phase 1,,,NIH AIDS Clinical Trials Information Service,,,,,False,,,,,,,,,,,,,,,,,2023-06-14 03:21:10,2023-06-14 03:21:10,INDUSTRY,,,,,
151320,151321,NCT00697229,,2008-06-11,,,2008-06-11,2008-06-11,2008-06-13,Estimate,,,,,,,2008-06-11,2008-06-13,Estimate,September 1992,,1992-09-30,June 2008,2008-06-30,December 1998,Actual,1998-12-31,May 1996,Actual,1996-05-31,,Interventional,,,Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix-B in Healthy Adults Following 2 Different Schedules,Study to Evaluate the Immunogenicity and Reactogenicity of GSK Biologicals' MPL-Adjuvanted Recombinant Hepatitis B Vaccine in Comparison With Those of Engerix-B in Healthy Adult Volunteers Following 2 Different Schedules,Completed,,Phase 2,99.0,Actual,GlaxoSmithKline,,8.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 10:18:05,2023-06-16 10:18:05,INDUSTRY,,,,,
151977,151978,NCT04962893,,2021-07-12,,,2022-05-24,2021-07-14,2021-07-15,Actual,,,,,,,2022-05-24,2022-05-31,Actual,"June 26, 2021",Actual,2021-06-26,May 2022,2022-05-31,"January 16, 2022",Actual,2022-01-16,"January 16, 2022",Actual,2022-01-16,,Interventional,COVID-19,,Study of a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine,"Phase II Study to Assess the Safety, Efficacy, and Immunogenicity of Authentic SARS-CoV-2 or Alpha Variant Spike Containing VLP Vaccines and Their Combination for the Prevention of COVID-19 in Healthy Adult Volunteers (SAVE STUDY)",Completed,,Phase 2,349.0,Actual,The Scientific and Technological Research Council of Turkey,,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 08:05:56,2023-06-18 08:05:56,OTHER,,,,,
152194,152195,NCT03645148,,2018-08-22,,,2021-11-15,2018-08-22,2018-08-24,Actual,,,,,,,2021-11-15,2021-11-16,Actual,"October 24, 2017",Actual,2017-10-24,November 2021,2021-11-30,"April 1, 2021",Actual,2021-04-01,"November 1, 2020",Actual,2020-11-01,,Interventional,,,Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer,"Safety, Tolerability and Partial Efficacy Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer",Completed,,Phase 1,7.0,Actual,Zhejiang Provincial People's Hospital,,1.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-17 17:21:54,2023-06-17 17:21:54,OTHER,,,,,
152295,152296,NCT00697775,,2008-06-12,,,2008-06-13,2008-06-13,2008-06-16,Estimate,,,,,,,2008-06-13,2008-06-16,Estimate,March 1998,,1998-03-31,June 2008,2008-06-30,,,,May 1999,Actual,1999-05-31,,Interventional,,,"Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix-B, in Healthy Adolescents",Study to Assess the Feasibility of GSK Bio's Candidate HBV / MPL Vaccines Following Different Schedules and Formulations and to Compare Their Safety and Immunogenicity to That of Engerix-B in Healthy Adolescents Aged 11 to 15,Completed,,Phase 2,200.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 10:19:59,2023-06-16 10:19:59,INDUSTRY,,,,,
152330,152331,NCT02111070,,2014-04-08,,,2014-04-09,2014-04-09,2014-04-10,Estimate,,,,,,,2014-04-09,2014-04-10,Estimate,September 2012,,2012-09-30,April 2014,2014-04-30,October 2012,Actual,2012-10-31,October 2012,Actual,2012-10-31,,Interventional,,,Immunogenicity and Safety Study of Inactivated Split Influenza Vaccine' in Healthy Korean Male Subjects,"Open-label, Phase I Clinical Trial to Assess the Immunogenicity and Safety of the 'IL-YANG Inactivated Split Influenza Vaccine' in Healthy Korean Male Subjects",Completed,,Phase 1,44.0,Actual,"Il-Yang Pharm. Co., Ltd.",,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 17:22:45,2023-06-17 17:22:45,INDUSTRY,,,,,
152567,152568,NCT00849680,,2009-02-20,2011-06-09,,2015-01-21,2009-02-20,2009-02-24,Estimate,2011-06-09,2011-07-07,Estimate,,,,2015-01-21,2015-02-02,Estimate,April 2003,,2003-04-30,January 2015,2015-01-31,February 2010,Actual,2010-02-28,March 2005,Actual,2005-03-31,,Interventional,,,"A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)","A Phase I Dose-Ranging Study of the Safety, Tolerability, and Immunogenicity of the Merck Trivalent Adenovirus Serotype 5 HIV-1 Gag/Pol/Nef Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in a Prime-Boost Regimen in Healthy Adults",Completed,,Phase 1,317.0,Actual,Merck Sharp & Dohme LLC,,8.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 10:20:47,2023-06-16 10:20:47,INDUSTRY,,,,,
152616,152617,NCT00697853,,2008-06-12,,,2008-06-13,2008-06-13,2008-06-16,Estimate,,,,,,,2008-06-13,2008-06-16,Estimate,November 1998,,1998-11-30,June 2008,2008-06-30,,,,July 1999,Actual,1999-07-31,,Interventional,,,"Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix-B (3 Doses) in Healthy Adults","Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' Novel Adjuvanted Hepatitis B Vaccine Administered According to a 0, 6 Month Schedule and of Engerix-B Administered According to a 0, 1, 6 Month Schedule in Healthy Adults",Completed,,Phase 2,200.0,Actual,GlaxoSmithKline,,5.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 10:20:56,2023-06-16 10:20:56,INDUSTRY,,,,,
152699,152700,NCT02109354,,2013-12-12,,,2019-06-19,2014-04-04,2014-04-09,Estimate,,,,,,,2019-06-19,2019-06-21,Actual,"June 18, 2013",Actual,2013-06-18,June 2019,2019-06-30,"February 2, 2015",Actual,2015-02-02,"February 2, 2015",Actual,2015-02-02,,Interventional,HVTN 097,,Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults,"Phase 1b Randomized Double Blind Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the Vaccine Regimen ALVAC-HIV (vCP1521) Followed by AIDSVAX® B/E in Healthy, HIV-1 Uninfected Adult Participants in South Africa",Completed,,Phase 1,202.0,Actual,HIV Vaccine Trials Network,,3.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-17 17:24:47,2023-06-17 17:24:47,NETWORK,,,,,
152736,152737,NCT02115126,,2014-04-08,,,2016-10-31,2014-04-14,2014-04-15,Estimate,,,,,,,2016-10-31,2016-11-01,Estimate,December 2016,,2016-12-31,October 2016,2016-10-31,January 2025,Anticipated,2025-01-31,January 2020,Anticipated,2020-01-31,,Interventional,,,Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant,"A Randomized Phase II Trial to Evaluate an EBV Derived Dendritic Cell (DC) Vaccine When Administered Alone or Co-administered With the TLR9 Agonist, DUK-CPG-001, in EBV+ Lymphoma in the Setting of Autologous Stem Cell Transplant",Withdrawn,,Phase 2,0.0,Actual,Duke University,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 17:24:59,2023-06-17 17:24:59,OTHER,,,,,
153163,153164,NCT00707642,,2008-06-29,,,2009-06-13,2008-06-29,2008-07-01,Estimate,,,,,,,2009-06-13,2009-06-16,Estimate,May 2008,,2008-05-31,June 2009,2009-06-30,June 2009,Actual,2009-06-30,June 2009,Actual,2009-06-30,,Interventional,,,Safety Study of HBV-002 West Nile Vaccine in Healthy Adults,"Phase 1, Open-Label, Safety Study of HBV-002 (West Nile Recombinant Subunit Vaccine) in Healthy Adults",Completed,,Phase 1,25.0,Actual,"Hawaii Biotech, Inc.",,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 10:22:49,2023-06-16 10:22:49,INDUSTRY,,,,,
153234,153235,NCT00707798,,2008-06-30,,,2017-05-09,2008-06-30,2008-07-01,Estimate,,,,,,,2017-05-09,2017-05-10,Actual,"June 30, 2008",Actual,2008-06-30,May 2017,2017-05-31,"January 15, 2009",Actual,2009-01-15,"January 15, 2009",Actual,2009-01-15,,Interventional,,,Evaluation of Pneumococcal Vaccine Formulations in Young Adults,A Study to Evaluate GSK Biologicals' Candidate Formulations of Pneumococcal Vaccines (GSK2189242A) in Young Adults.,Completed,,Phase 1,157.0,Actual,GlaxoSmithKline,,7.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 10:23:11,2023-06-16 10:23:11,INDUSTRY,,,,,
153260,153261,NCT00031733,,2002-03-08,,,2014-05-20,2003-01-26,2003-01-27,Estimate,,,,,,,2014-05-20,2014-05-22,Estimate,February 2002,,2002-02-28,May 2014,2014-05-31,November 2007,Actual,2007-11-30,December 2004,Actual,2004-12-31,,Interventional,,,Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma,"A Phase II Randomized Trial of a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With Interleukin-12 With Alum or GM-CSF for Patients With Resected Stages IIB/C, III and IV Melanoma",Completed,,Phase 2,60.0,Actual,University of Southern California,,,,,False,,,,True,,,,,,,,,,,,,2023-06-15 06:32:13,2023-06-15 06:32:13,OTHER,,,,,
153573,153574,NCT03531242,,2018-05-08,,,2021-02-10,2018-05-08,2018-05-21,Actual,,,,,,,2021-02-10,2021-02-16,Actual,June 2021,Anticipated,2021-06-30,February 2021,2021-02-28,December 2024,Anticipated,2024-12-31,December 2023,Anticipated,2023-12-31,,Interventional,VEE,,Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults,"Phase 2 Open-Label Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis (VEE) Vaccine, Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1, as Booster Vaccination in Adult Subjects at Risk of Exposure to VEE Virus",Not yet recruiting,,Phase 2,500.0,Anticipated,U.S. Army Medical Research and Development Command,,2.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-17 17:29:34,2023-06-17 17:29:34,FED,,,,,
153676,153677,NCT00698555,,2008-06-13,,,2008-06-16,2008-06-16,2008-06-17,Estimate,,,,,,,2008-06-16,2008-06-17,Estimate,March 1997,,1997-03-31,June 2008,2008-06-30,,,,May 1998,Actual,1998-05-31,,Interventional,,,Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix-B in Adults Aged 18-40 y,"Study Comparing the Immunogenicity and Reactogenicity of Different Formulations of GSK Bio's HBV-MPL Vaccine Injected as a 0, 6 Months Schedule With That of Engerix-B Injected as a 0, 1, 6 Months Schedule in Healthy Adults Aged 18-40 Years",Completed,,Phase 2,163.0,Actual,GlaxoSmithKline,,6.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 10:25:25,2023-06-16 10:25:25,INDUSTRY,,,,,
153870,153871,NCT04222985,,2020-01-07,,,2022-10-21,2020-01-07,2020-01-10,Actual,,,,,,,2022-10-21,2022-10-25,Actual,"February 18, 2020",Actual,2020-02-18,October 2022,2022-10-31,"May 19, 2021",Actual,2021-05-19,"May 19, 2021",Actual,2021-05-19,,Interventional,HSV15,,Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2,Safety and Efficacy of 4 Investigational HSV 2 Vaccines Administered by Intramuscular Route in Adults With Recurrent Genital Herpes Caused by HSV 2,Terminated,,Phase 1,24.0,Actual,Sanofi,,20.0,,business reasons-Phase 2/Part B not conducted. Study terminated after last patient enrolled in Phase 1/Part A,False,,,,False,True,False,,,False,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-14 03:22:53,2023-06-14 03:22:53,INDUSTRY,,,,,
153956,153957,NCT05606965,,2022-10-31,,,2023-03-07,2022-10-31,2022-11-07,Actual,,,,,,,2023-03-07,2023-03-09,Actual,"November 2, 2022",Actual,2022-11-02,March 2023,2023-03-31,"September 9, 2023",Anticipated,2023-09-09,"September 9, 2023",Anticipated,2023-09-09,,Interventional,,,"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults","Phase 2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 and Comparator Seasonal Influenza Vaccines in Healthy Adults",Recruiting,,Phase 2,125.0,Anticipated,"ModernaTX, Inc.",,5.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-17 17:31:28,2023-06-17 17:31:28,INDUSTRY,,,,,
154349,154350,NCT04083196,,2019-09-06,,,2021-11-23,2019-09-06,2019-09-10,Actual,,,,,,,2021-11-23,2021-11-24,Actual,"September 7, 2019",Actual,2019-09-07,November 2021,2021-11-30,"October 13, 2021",Actual,2021-10-13,"October 13, 2021",Actual,2021-10-13,,Interventional,,,"A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years","A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years",Completed,,Phase 1,90.0,Actual,"National Vaccine and Serum Institute, China",,2.0,,,False,,,,,False,False,,,False,,,,,,No,,2023-06-17 17:33:45,2023-06-17 17:33:45,INDUSTRY,,,,,
154353,154354,NCT02529904,,2015-08-07,,,2021-11-26,2015-08-18,2015-08-20,Estimate,,,,,,,2021-11-26,2021-11-29,Actual,August 2015,,2015-08-31,August 2018,2018-08-31,April 2016,Actual,2016-04-30,April 2016,Actual,2016-04-30,,Interventional,,,ADITEC FLU 2 STUDY: Understanding the Genetics Basis for Immune Responses to Flu Vaccines in Children and Adults,"A Phase II, Open Label Study to Describe Immune & Transcriptional Responses to MF59 Adjuvanted Trivalent Influenza Vaccine (ATIV) in Healthy 13-24 Month Children and Adults 18-65 Years",Completed,,Phase 2,120.0,Actual,University of Oxford,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 17:33:47,2023-06-17 17:33:47,OTHER,,,,,
154385,154386,NCT02316470,,2014-12-09,2017-01-04,,2017-04-25,2014-12-12,2014-12-15,Estimate,2017-04-25,2017-06-08,Actual,,,,2017-04-25,2017-06-08,Actual,December 2014,,2014-12-31,April 2017,2017-04-30,October 2015,Actual,2015-10-31,May 2015,Actual,2015-05-31,,Interventional,,,"Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study","Dose Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Randomized, Controlled, Observer Blind Phase II Study",Completed,,Phase 2,500.0,Actual,Valneva Austria GmbH,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 03:23:13,2023-06-14 03:23:13,INDUSTRY,,,,,
154428,154429,NCT00802464,,2008-12-04,2017-08-10,2009-11-10,2019-06-11,2008-12-04,2008-12-05,Estimate,2017-11-10,2017-12-12,Actual,2009-11-12,2009-11-16,Estimate,2019-06-11,2019-06-26,Actual,"January 12, 2009",Actual,2009-01-12,June 2019,2019-06-30,"July 2, 2010",Actual,2010-07-02,"July 2, 2010",Actual,2010-07-02,,Interventional,,,Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years,Immunogenicity and Safety Study of Different Formulations of GSK Biologicals' Herpes Zoster Vaccine 1437173A When Administered Twice in Adults Aged 50 Years and Older,Completed,,Phase 2,410.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-16 10:28:25,2023-06-16 10:28:25,INDUSTRY,,,,,
154452,154453,NCT00450619,,2007-03-20,2013-05-10,,2016-11-08,2007-03-20,2007-03-22,Estimate,2013-05-10,2013-07-01,Estimate,,,,2016-11-08,2017-01-04,Estimate,February 2007,,2007-02-28,November 2016,2016-11-30,November 2012,Actual,2012-11-30,November 2012,Actual,2012-11-30,,Interventional,,,153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer,A Randomized Phase 2.5 Study of (153)Sm-EDTMP (Quadramet) With or Without a PSA/TRICOM Vaccine in Men With Androgen-Insensitive Metastatic Prostate Cancer,Completed,,Phase 2,44.0,Actual,National Institutes of Health Clinical Center (CC),,2.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-16 10:28:31,2023-06-16 10:28:31,NIH,,,,,
154749,154750,NCT00788151,,2008-11-07,2019-05-24,,2022-03-10,2008-11-07,2008-11-10,Estimate,2019-05-24,2019-07-29,Actual,,,,2022-03-10,2022-04-05,Actual,"September 26, 2008",Actual,2008-09-26,March 2022,2022-03-31,"August 16, 2010",Actual,2010-08-16,"February 16, 2010",Actual,2010-02-16,,Interventional,,Analysis was performed in Full analysis set which included all the participants present at vaccination 1 and received at least 1 dose of vaccine.,Study of ChimeriVax Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years,Immunogenicity and Safety of ChimeriVax Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years Previously Vaccinated Against Yellow Fever in Peru,Completed,,Phase 2,300.0,Actual,Sanofi,,2.0,,,False,,,,False,False,False,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-16 10:29:34,2023-06-16 10:29:34,INDUSTRY,,,,,
154851,154852,NCT00814892,,2008-12-24,2013-05-16,,2013-10-08,2008-12-24,2008-12-25,Estimate,2013-07-26,2013-08-29,Estimate,,,,2013-10-08,2013-11-05,Estimate,January 2009,,2009-01-31,October 2013,2013-10-31,March 2010,Actual,2010-03-31,December 2009,Actual,2009-12-31,,Interventional,,"Since only two participants were accrued, patient confidentiality prevents the reporting of these two participants.",Vaccine Therapy in Treating Patients With Non-Metastatic Prostate Cancer,"A Phase II Trial to Determine the Safety, Tolerability and Efficacy of an Allogeneic Whole Cell Vaccine Administered With Autologous Myeloid Dendritic Cells to Patients With Non-Metastatic Androgen Independent Prostate Carcinoma",Terminated,,Phase 2,2.0,Actual,Mayo Clinic,,1.0,,Study was terminated due to funding issues.,False,,,,True,,,,,,,,,,,,,2023-06-16 10:29:48,2023-06-16 10:29:48,OTHER,,,,,
154918,154919,NCT00032708,,2002-03-28,,,2010-08-26,2002-03-28,2002-03-29,Estimate,,,,,,,2010-08-26,2010-08-27,Estimate,April 2004,,2004-04-30,May 2006,2006-05-31,November 2004,,2004-11-30,,,,,Interventional,,,Dryvax Dilution-Prev Vacc Adults,"A Double Blind, Randomized Dose Response Study of Dryvax Vaccine Against Smallpox in Previously Vaccinated Adults",Completed,,Phase 2,90.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,,,,,,,,,,,,,,,,,,2023-06-15 06:32:48,2023-06-15 06:32:48,NIH,,,,,
154930,154931,NCT03420053,,2017-12-13,,,2019-04-03,2018-01-26,2018-02-05,Actual,,,,,,,2019-04-03,2019-04-05,Actual,"February 7, 2018",Actual,2018-02-07,April 2019,2019-04-30,"August 25, 2018",Actual,2018-08-25,"August 25, 2018",Actual,2018-08-25,,Interventional,,,"Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian Adults","Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of Direct Venous Inoculation of Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in HIV Negative and HIV Positive Tanzanian Adults",Completed,,Phase 1,21.0,Actual,Sanaria Inc.,,5.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-18 08:17:11,2023-06-18 08:17:11,INDUSTRY,,,,,
154941,154942,NCT00806962,,2008-12-10,,,2015-05-05,2008-12-10,2008-12-11,Estimate,,,,,,,2015-05-05,2015-05-06,Estimate,November 2008,,2008-11-30,May 2015,2015-05-31,October 2009,Actual,2009-10-31,October 2009,Actual,2009-10-31,,Interventional,,,Phase 1 Norwalk Vaccine Study,"Randomized Double-Blind Placebo-Controlled Phase 1, Safety and Immunogenicity Study of Two Dosages of Intranasal Norwalk Virus-like Particle Vaccine ( Norwalk VLP Antigen, MPL®, Chitosan, Mannitol, and Sucrose) Compared to Adjuvant/Excipients (MPL®, Chitosan, Mannitol, and Sucrose) and to Placebo (Empty Device",Completed,,Phase 1,61.0,Actual,Takeda,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 10:30:12,2023-06-16 10:30:12,INDUSTRY,,,,,
154958,154959,NCT02603055,,2015-11-10,,,2016-08-30,2015-11-10,2015-11-11,Estimate,,,,,,,2016-08-30,2016-09-01,Estimate,July 2015,,2015-07-31,August 2016,2016-08-31,August 2016,Actual,2016-08-31,April 2016,Actual,2016-04-30,,Interventional,,,A Clinical Trial to Evaluate a Recombinant Hepatitis E Vaccine in Healthy Adults,"A Phase Ib Single Center, Randomized, Blinding, Parallel-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Hepatitis E Vaccine in Healthy Adults Aged 16 to 65 Years Old in China",Completed,,Phase 1,60.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 10:30:22,2023-06-16 10:30:22,NETWORK,,,,,
155059,155060,NCT00301184,,2006-03-08,,,2022-08-04,2006-03-08,2006-03-10,Estimate,,,,,,,2022-08-04,2022-08-08,Actual,April 2006,,2006-04-30,August 2022,2022-08-31,December 2008,Actual,2008-12-31,,,,,Interventional,,,Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults,"A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of pGA2/JS7 DNA Vaccine and Recombinant Modified Vaccinia Ankara/HIV62 Vaccine in Healthy, HIV-1-Uninfected Adult Participants",Completed,,Phase 1,120.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 03:23:33,2023-06-14 03:23:33,NIH,,,,,
155298,155299,NCT04854746,,2021-04-19,,,2023-02-08,2021-04-19,2021-04-22,Actual,,,,,,,2023-02-08,2023-02-13,Actual,"April 26, 2021",Actual,2021-04-26,February 2023,2023-02-28,"January 4, 2022",Actual,2022-01-04,"January 4, 2022",Actual,2022-01-04,,Interventional,VXA-NVV-104,,Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine,"A Phase 1b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Determine the Safety and Immunogenicity of an Adenoviral-vector Based Oral Norovirus Vaccine Expressing GI.1 VP1 Administered Orally to Health Stable Older Adult Volunteers 55-80 Years of Age",Completed,,Phase 1,66.0,Actual,Vaxart,,6.0,,,False,,,,True,True,False,,,,,,,,,No,Study results will be summarized and presented by treatment arm comparisons. Individual subject data will not be shared with other researchers.,2023-06-17 17:39:29,2023-06-17 17:39:29,INDUSTRY,,,,,
155308,155309,NCT03425149,,2018-01-23,,,2019-07-03,2018-02-06,2018-02-07,Actual,,,,,,,2019-07-03,2019-07-05,Actual,"February 24, 2018",Actual,2018-02-24,July 2019,2019-07-31,"November 16, 2018",Actual,2018-11-16,"June 26, 2018",Actual,2018-06-26,,Interventional,,,"Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults","A Randomized, Placebo-controlled, Observer-blinded Phase 1 Study to Assess the Safety and Immunogenicity of Two Different Dose Levels of an Alum Adjuvanted Inactivated Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years",Completed,,Phase 1,67.0,Actual,Valneva Austria GmbH,,5.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-18 08:18:21,2023-06-18 08:18:21,INDUSTRY,,,,,
155338,155339,NCT04523571,,2020-08-18,,,2021-11-05,2020-08-20,2020-08-21,Actual,,,,,,,2021-11-05,2021-11-11,Actual,"July 28, 2020",Actual,2020-07-28,November 2021,2021-11-30,"August 10, 2021",Actual,2021-08-10,"September 30, 2020",Actual,2020-09-30,,Interventional,,,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects,"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects: A Phase I, Randomized, Placebo-controlled, Observer-blind Study",Completed,,Phase 1,144.0,Actual,BioNTech SE,,6.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 08:18:26,2023-06-18 08:18:26,INDUSTRY,,,,,
155412,155413,NCT05284851,,2022-03-09,,,2022-03-09,2022-03-09,2022-03-17,Actual,,,,,,,2022-03-09,2022-03-17,Actual,"April 1, 2022",Anticipated,2022-04-01,March 2022,2022-03-31,"October 1, 2022",Anticipated,2022-10-01,"May 1, 2022",Anticipated,2022-05-01,,Interventional,,,The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine,"A Random, Double-Blind, Multicenter, Positive Control and Placebo Control Phase Two Trail to Evaluate the Safety and Immunogenicity of Live Attenuated Influenza Vaccine in 3-59y Healthy People",Not yet recruiting,,Phase 2,2520.0,Anticipated,Changchun BCHT Biotechnology Co.,,3.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-17 17:40:12,2023-06-17 17:40:12,INDUSTRY,,,,,
155432,155433,NCT00814762,,2008-12-23,,,2018-06-14,2008-12-23,2008-12-25,Estimate,,,,,,,2018-06-14,2018-06-18,Actual,"February 3, 2009",Actual,2009-02-03,June 2018,2018-06-30,"August 18, 2010",Actual,2010-08-18,"August 18, 2010",Actual,2010-08-18,,Interventional,,,Safety of the HIV Vaccine 732462 in HIV Infected Subjects Aged 18 to 55 Years Old,Study to Evaluate the Safety and Reactogenicity of the HIV Vaccine SB732462 in HIV Infected Subjects Aged 18 to 55 Years Old,Completed,,Phase 1,41.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 10:32:10,2023-06-16 10:32:10,INDUSTRY,,,,,
155630,155631,NCT03546426,,2018-05-23,,,2021-02-25,2018-05-23,2018-06-06,Actual,,,,,,,2021-02-25,2021-02-26,Actual,"December 12, 2019",Actual,2019-12-12,February 2021,2021-02-28,January 2024,Anticipated,2024-01-31,January 2022,Anticipated,2022-01-31,,Interventional,MESOVAX,,Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies,Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies,Recruiting,,Phase 1,18.0,Anticipated,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,,1.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-17 17:41:27,2023-06-17 17:41:27,OTHER,,,,,
155780,155781,NCT00061035,,2003-05-20,,,2008-08-26,2003-05-21,2003-05-22,Estimate,,,,,,,2008-08-26,2008-08-28,Estimate,April 2003,,2003-04-30,August 2008,2008-08-31,,,,,,,,Interventional,,,Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma,"A Phase 1, Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma",Completed,,Phase 1,18.0,Anticipated,Cosmo Bioscience,,,,,,,,,,,,,,,,,,,,,,2023-06-15 06:33:16,2023-06-15 06:33:16,INDUSTRY,,,,,
155952,155953,NCT02289794,,2014-11-03,,,2016-02-10,2014-11-10,2014-11-13,Estimate,,,,,,,2016-02-10,2016-02-11,Estimate,January 2014,,2014-01-31,February 2016,2016-02-29,September 2015,Actual,2015-09-30,July 2015,Actual,2015-07-31,,Interventional,,,Vaccine Against Escherichia Coli Infection,Evaluation of a Candidate Vaccine Against Uropathogenic Escherichia Coli in Women With a Clinical History of Recurrent Urinary Tract Infection,Completed,,Phase 1,194.0,Actual,GlycoVaxyn AG,,2.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-17 17:43:50,2023-06-17 17:43:50,INDUSTRY,,,,,
156272,156273,NCT04736147,,2021-01-29,,,2021-12-21,2021-01-29,2021-02-03,Actual,,,,,,,2021-12-21,2021-12-22,Actual,"February 3, 2021",Actual,2021-02-03,December 2021,2021-12-31,"December 7, 2021",Actual,2021-12-07,"December 7, 2021",Actual,2021-12-07,,Interventional,,,A Study of JNJ-64300535 in Healthy Participants,"A Phase 1 Open-label Study to Assess the Immunogenicity, Safety, and Reactogenicity of JNJ-64300535, a DNA Vaccine Administered by Electroporation-mediated Intramuscular Injection, in Healthy Participants",Completed,,Phase 1,14.0,Actual,"Janssen Research & Development, LLC",,1.0,,,False,,,,False,False,False,,,,,,,,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency.

As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2023-06-18 08:21:03,2023-06-18 08:21:03,INDUSTRY,,,,,
156781,156782,NCT03392389,,2018-01-02,,,2020-02-05,2018-01-02,2018-01-08,Actual,,,,,,,2020-02-05,2020-02-06,Actual,"December 4, 2017",Actual,2017-12-04,February 2020,2020-02-29,"July 29, 2019",Actual,2019-07-29,"July 29, 2019",Actual,2019-07-29,,Interventional,,,"Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults","A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus and Human Parainfluenza Virus Type 3 Vaccine, When Administered to Healthy Adults",Completed,,Phase 1,124.0,Actual,"ModernaTX, Inc.",,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-18 08:23:24,2023-06-18 08:23:24,INDUSTRY,,,,,
156827,156828,NCT00820144,,2009-01-02,,,2009-01-09,2009-01-09,2009-01-12,Estimate,,,,,,,2009-01-09,2009-01-12,Estimate,April 2006,,2006-04-30,January 2009,2009-01-31,February 2007,Actual,2007-02-28,April 2006,Actual,2006-04-30,,Interventional,,,Cholera Toxin B Subunit (CTB) Administered by Mucosal Way in Healthy Adult Volunteer,Functional Exploration of the Immune Response Using the B-Subunit of Cholera Toxin Administered by Mucosal Way in Healthy Adult Volunteer: Potential Role in Development of Vaccine Processes,Completed,,Phase 1,40.0,Actual,Centre Hospitalier Universitaire de Nice,,5.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 10:37:52,2023-06-16 10:37:52,OTHER,,,,,
156986,156987,NCT03391375,,2017-12-11,,,2019-02-06,2017-12-29,2018-01-05,Actual,,,,,,,2019-02-06,2019-02-07,Actual,"March 15, 2017",Actual,2017-03-15,December 2017,2017-12-31,"July 31, 2018",Actual,2018-07-31,"January 1, 2018",Actual,2018-01-01,,Interventional,,,Evaluation of the Effect of Late Boost on HIV-uninfected Vaccines From EV06 Trial,An Open Label Phase I Clinical Trial to Evaluate the Effect of Late Boost on HIV-uninfected Vaccinees From EV06 Trial,Completed,,Phase 1,49.0,Actual,EuroVacc Foundation,,1.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 08:24:21,2023-06-18 08:24:21,OTHER,,,,,
157505,157506,NCT00621322,,2008-02-12,2016-12-08,2009-09-03,2018-07-26,2008-02-21,2008-02-22,Estimate,2016-12-08,2017-02-03,Estimate,2009-09-03,2009-09-04,Estimate,2018-07-26,2018-08-24,Actual,"April 3, 2008",Actual,2008-04-03,July 2018,2018-07-31,"April 3, 2009",Actual,2009-04-03,"April 3, 2009",Actual,2009-04-03,,Interventional,,,Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults,Dose Range Study Evaluating Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccines (692342) When Administered to Healthy Adults Aged 18 to 45 Years.,Completed,,Phase 2,180.0,Actual,GlaxoSmithKline,,6.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 10:41:09,2023-06-16 10:41:09,INDUSTRY,,,,,
157806,157807,NCT00845429,,2009-02-13,2012-11-17,,2012-12-13,2009-02-13,2009-02-18,Estimate,2012-11-17,2012-12-17,Estimate,,,,2012-12-13,2012-12-19,Estimate,October 2007,,2007-10-31,December 2012,2012-12-31,November 2008,Actual,2008-11-30,August 2008,Actual,2008-08-31,,Interventional,,,"Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects","Immunogenicity of Two Dosages of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine Administered in Healthy Adult Subjects Aged 18 to 49 Years",Completed,,Phase 2,729.0,Actual,Sanofi,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 10:42:44,2023-06-16 10:42:44,INDUSTRY,,,,,
158228,158229,NCT02601612,,2015-11-09,,,2020-03-26,2015-11-09,2015-11-10,Estimate,,,,,,,2020-03-26,2020-03-30,Actual,October 2015,,2015-10-31,March 2020,2020-03-31,"April 26, 2018",Actual,2018-04-26,"April 26, 2018",Actual,2018-04-26,,Interventional,,,Safety and Immunogenicity of the RSV D46cp<U+0394>M2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children,"A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Live Recombinant RSV D46cp<U+0394>M2-2 Vero Grown Virus Vaccine (Lot RSV #008A), Delivered as Nose Drops to RSV-Seropositive Children 12 to 59 Months of Age and RSV-Seronegative Infants and Children 6 to 24 Months of Age",Completed,,Phase 1,45.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 10:45:04,2023-06-16 10:45:04,NIH,,,,,
158271,158272,NCT01676402,,2012-08-13,,,2022-08-22,2012-08-28,2012-08-30,Estimate,,,,,,,2022-08-22,2022-08-25,Actual,August 2012,,2012-08-31,August 2022,2022-08-31,April 2014,Actual,2014-04-30,April 2014,Actual,2014-04-30,,Interventional,,,Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years,"Open-Label, Randomized Phase 1b Study of the Safety & Immunogenicity of Investigational Seasonal Influenza DNA Vaccine Followed by TIV Administered Intradermally (ID) or Intramuscularly (IM) in Healthy Adults 18-70 Years",Completed,,Phase 1,316.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,6.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 03:26:13,2023-06-14 03:26:13,NIH,,,,,
158595,158596,NCT03125473,,2017-04-14,,,2018-05-29,2017-04-18,2017-04-24,Actual,,,,,,,2018-05-29,2018-05-30,Actual,"April 7, 2017",Actual,2017-04-07,May 2018,2018-05-31,"May 6, 2018",Actual,2018-05-06,"July 1, 2017",Actual,2017-07-01,,Interventional,,,Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers,"A Phase 1b, Open-Label, Dose-Optimization Trial of an Adenoviral-vector Based Norovirus Vaccine (VXA-G1.1-NN) Expressing GI.1 VP1 and dsRNA Adjuvant Administered Orally to Healthy Volunteers",Completed,,Phase 1,66.0,Actual,Vaxart,,4.0,,,False,,,,True,True,False,,,,,,,,,Undecided,,2023-06-18 08:31:43,2023-06-18 08:31:43,INDUSTRY,,,,,
158672,158673,NCT03382405,,2017-12-06,,,2021-01-13,2017-12-18,2017-12-22,Actual,,,,,,,2021-01-13,2021-01-15,Actual,"November 13, 2017",Actual,2017-11-13,January 2021,2021-01-31,"October 28, 2020",Actual,2020-10-28,"October 28, 2020",Actual,2020-10-28,,Interventional,,,"Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults","A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 When Administered to Healthy Adults",Completed,,Phase 1,181.0,Actual,"ModernaTX, Inc.",,3.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-18 08:31:50,2023-06-18 08:31:50,INDUSTRY,,,,,
158915,158916,NCT02540538,,2015-08-25,2018-04-24,,2018-11-29,2015-09-01,2015-09-04,Estimate,2018-04-24,2018-11-29,Actual,,,,2018-11-29,2018-12-19,Actual,September 2015,,2015-09-30,November 2018,2018-11-30,July 2016,Actual,2016-07-31,July 2016,Actual,2016-07-31,,Interventional,,"RCT: 27 participants screened, 3 excluded: 1 with LFTs abnormalities, 1 anti-HBs titre >10 mIU/mL, 1 suspected Cushing's syndrome. 24 included. Open-Label: 10 screened and included.",Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders,Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders,Completed,,Phase 1,34.0,Actual,Maastricht University Medical Center,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 03:26:43,2023-06-14 03:26:43,OTHER,,,,,
158920,158921,NCT00831311,,2009-01-27,2013-09-19,,2013-11-21,2009-01-27,2009-01-28,Estimate,2013-09-19,2013-11-21,Estimate,,,,2013-11-21,2013-12-17,Estimate,October 2004,,2004-10-31,November 2013,2013-11-30,March 2007,Actual,2007-03-31,November 2005,Actual,2005-11-30,,Interventional,,,Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM and ENGERIX B® PEDIATRICO in Argentinean Infants,"Phase-II Immunogenicity Study of a DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age in Healthy Argentinean Infants",Completed,,Phase 2,624.0,Actual,Sanofi,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 10:48:35,2023-06-16 10:48:35,INDUSTRY,,,,,
160339,160340,NCT00063843,,2003-07-07,,,2010-08-26,2003-07-07,2003-07-08,Estimate,,,,,,,2010-08-26,2010-08-27,Estimate,July 2003,,2003-07-31,May 2006,2006-05-31,August 2005,,2005-08-31,,,,,Interventional,,,"Anthrax-rPA: Safety, Tolerability, Immunogenicity","A Phase I, Dose-Escalating Study to Assess the Safety, Tolerability, and Immunogenicity of Recombinant Anthrax Protective Antigen Vaccine (rPA) Administered in Two Intramuscular Doses to Healthy Adults",Completed,,Phase 1,80.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,,,,,,,,,,,,,,,,,,2023-06-15 06:35:18,2023-06-15 06:35:18,NIH,,,,,
160405,160406,NCT00808028,,2008-12-12,2015-03-27,,2015-03-27,2008-12-12,2008-12-15,Estimate,2015-03-27,2015-04-14,Estimate,,,,2015-03-27,2015-04-14,Estimate,February 2009,,2009-02-28,March 2015,2015-03-31,March 2014,Actual,2014-03-31,March 2014,Actual,2014-03-31,,Interventional,,The stage 1 intent-to-treat (ITT) population included all randomized participants who received at least 1 vaccination and have at least 1 valid and determinate assay result from blood samples drawn during stage 1.,A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents,"A Randomized, Single-blind, Placebo-controlled, Phase 2 Trial Of The Safety, Immunogenicity, And Tolerability Of Meningococcal Serogroup B (Mnb) Rlp2086 Vaccine At Doses Of 60 Mug, 120 Mug, And 200 Mug In Healthy Adolescents Aged 11 To 18 Years",Completed,,Phase 2,538.0,Actual,Pfizer,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 10:54:54,2023-06-16 10:54:54,INDUSTRY,,,,,
160722,160723,NCT00037037,,2002-05-13,,,2013-12-17,2003-01-26,2003-01-27,Estimate,,,,,,,2013-12-17,2013-12-18,Estimate,October 2001,,2001-10-31,May 2004,2004-05-31,,,,,,,,Interventional,,,Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma,A Phase I Study of Peptide Based Vaccine Therapy in Patients With High-Risk or Metastatic Melanoma,Unknown status,"Active, not recruiting",Phase 1,,,National Cancer Institute (NCI),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 06:35:23,2023-06-15 06:35:23,NIH,,,,,
160751,160752,NCT02596308,,2015-11-02,,,2015-11-02,2015-11-02,2015-11-04,Estimate,,,,,,,2015-11-02,2015-11-04,Estimate,October 2014,,2014-10-31,November 2015,2015-11-30,January 2015,Actual,2015-01-31,December 2014,Actual,2014-12-31,,Interventional,,,Immunogenicity and Safety of Subunit Plague Vaccine,Immunogenicity and Safety of Subunit Plague Vaccine Comprised by Fraction 1 Capsule (F1) and Virulence-Associated (V) Antigens: A Random Phase 2a Clinical Trial,Completed,,Phase 2,240.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 10:56:11,2023-06-16 10:56:11,NETWORK,,,,,
160890,160891,NCT02958540,,2016-11-04,,,2017-09-07,2016-11-04,2016-11-08,Estimate,,,,,,,2017-09-07,2017-09-08,Actual,October 2016,Actual,2016-10-31,September 2017,2017-09-30,December 2017,Anticipated,2017-12-31,July 2017,Actual,2017-07-31,,Interventional,SynGEM,,"Phase I Study for SynGEM, an Intranasal Respiratory Syncytial Virus (RSV) Prefusion F Subunit Candidate Vaccine","Randomized, Doubleblind, Placebo-controlled Trial in Healthy Adults of Safety and Immunogenicity of 2 Intranasal Doses of SynGEM®, an RSV Candidate Vaccine Containing F Glycoprotein Linked to a Bacterium-like-Particle (BLP) Carrier",Unknown status,"Active, not recruiting",Phase 1,48.0,Actual,Mucosis BV,,3.0,,,False,,,,True,,,,,,,,,,,Undecided,,2023-06-15 06:35:28,2023-06-15 06:35:28,INDUSTRY,,,,,
160902,160903,NCT04568811,,2020-09-28,,,2022-03-28,2020-09-28,2020-09-29,Actual,,,,,,,2022-03-28,2022-03-31,Actual,"September 26, 2020",Actual,2020-09-26,March 2022,2022-03-31,"September 11, 2021",Actual,2021-09-11,"October 25, 2020",Actual,2020-10-25,,Interventional,,,The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine,"The Single-center, Open-label Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine in Healthy Adults Aged 18-60 Years",Completed,,Phase 1,89.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,1.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 08:40:41,2023-06-18 08:40:41,NETWORK,,,,,
161289,161290,NCT00454909,,2007-03-30,2017-03-01,2009-09-03,2018-05-08,2007-03-30,2007-04-02,Estimate,2017-03-01,2017-04-12,Actual,2009-09-03,2009-09-04,Estimate,2018-05-08,2018-06-08,Actual,"April 23, 2007",,2007-04-23,April 2017,2017-04-30,"April 11, 2008",Actual,2008-04-11,"October 31, 2007",Actual,2007-10-31,,Interventional,,,Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.,"Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.",Completed,,Phase 2,873.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 10:58:22,2023-06-16 10:58:22,INDUSTRY,,,,,
161422,161423,NCT02992119,,2016-11-15,2019-01-14,,2022-03-29,2016-12-09,2016-12-14,Estimate,2019-07-26,2019-07-29,Actual,,,,2022-03-29,2022-03-31,Actual,"June 4, 2017",Actual,2017-06-04,July 2019,2019-07-31,"February 20, 2018",Actual,2018-02-20,"February 20, 2018",Actual,2018-02-20,,Interventional,RTSS,,Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults,"Safety and Immunogenicity Evaluation of the Malaria Vaccine, RTS,S/AS01, in Healthy Thai Adults",Completed,,Phase 2,193.0,Actual,University of Oxford,,7.0,,,False,,,,True,False,False,,,,,,,,,Yes,,2023-06-18 08:43:16,2023-06-18 08:43:16,OTHER,,,,,
161547,161548,NCT05252338,,2022-01-26,,,2023-06-05,2022-02-11,2022-02-23,Actual,,,,,,,2023-06-05,2023-06-06,Actual,"February 7, 2022",Actual,2022-02-07,March 2022,2022-03-31,"September 27, 2022",Actual,2022-09-27,"September 27, 2022",Actual,2022-09-27,,Interventional,,,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy Adults","A Phase 1, Open-label, Dose-escalation, First-in-human, Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational Seasonal Quadrivalent Influenza mRNA Vaccine CVSQIV Administered Intramuscularly in Healthy Younger and Older Adults",Completed,,Phase 1,240.0,Actual,CureVac,,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-17 18:07:18,2023-06-17 18:07:18,INDUSTRY,,,,,
161824,161825,NCT04785144,,2021-03-04,,,2023-06-02,2021-03-04,2021-03-05,Actual,,,,,,,2023-06-02,2023-06-06,Actual,"March 31, 2021",Actual,2021-03-31,April 2021,2021-04-30,"July 5, 2022",Actual,2022-07-05,"July 5, 2022",Actual,2022-07-05,,Interventional,,,Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults,"Phase 1, Open-Label, Randomized Study of the Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults",Completed,,Phase 1,135.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,10.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-17 18:08:33,2023-06-17 18:08:33,NIH,,,,,
161873,161874,NCT03121339,,2017-04-14,,,2018-05-29,2017-04-14,2017-04-20,Actual,,,,,,,2018-05-29,2018-05-30,Actual,"March 31, 2017",Actual,2017-03-31,May 2018,2018-05-31,"April 3, 2018",Actual,2018-04-03,"May 5, 2017",Actual,2017-05-05,,Interventional,,,Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults,"A Phase 1, Open-Label, Randomized, 2×2 Crossover Study of Pharmacodynamics Comparing the Impact of Tablet Size and Fasting Status With an Oral Human Influenza A/California/04/2009 (H1N1) HA Adenoviral-Vector Based Vaccine and dsRNA Adjuvant",Completed,,Phase 1,8.0,Actual,Vaxart,,2.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-18 08:45:36,2023-06-18 08:45:36,INDUSTRY,,,,,
162023,162024,NCT04495933,,2020-07-13,,,2021-08-23,2020-07-31,2020-08-03,Actual,,,,,,,2021-08-23,2021-08-27,Actual,"July 13, 2020",Actual,2020-07-13,August 2021,2021-08-31,"February 2, 2022",Anticipated,2022-02-02,"November 6, 2021",Anticipated,2021-11-06,,Interventional,,,"A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults","A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Dosage-Escalation, Single Centre Study to Evaluate the Safety and Immunogenicity of an Adjuvanted SARS-CoV-2 Sclamp Protein Subunit Vaccine in Healthy Adults Aged 18 to 55 Years Old and Healthy Older Adults, Aged 56 Years and Over","Active, not recruiting",,Phase 1,216.0,Actual,The University of Queensland,,3.0,,,False,,,,False,False,False,,,False,,,"Immediately following publication, no end date",Available only to achieve the aims in the approved proposal,,Yes,individual participant data underlying published results only on a case-by-case basis at the discretion of Primary Sponsor,2023-06-18 08:46:02,2023-06-18 08:46:02,OTHER,,,,,
162417,162418,NCT00719043,,2008-07-18,2013-12-19,2010-12-23,2018-06-08,2008-07-18,2008-07-21,Estimate,2013-12-19,2014-02-07,Estimate,2010-12-23,2010-12-30,Estimate,2018-06-08,2018-07-09,Actual,"July 11, 2008",,2008-07-11,May 2018,2018-05-31,"February 18, 2011",Actual,2011-02-18,"April 22, 2010",Actual,2010-04-22,,Interventional,,,Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged =18 Years,A Trial to Evaluate the Safety and Immunogenicity of Monovalent H5N1 Vaccine in Adults >=18 Yrs of Age,Completed,,Phase 2,841.0,Actual,GlaxoSmithKline,,7.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 11:01:54,2023-06-16 11:01:54,INDUSTRY,,,,,
162653,162654,NCT03036930,,2017-01-30,,,2023-06-03,2017-01-30,2017-01-31,Estimate,,,,,,,2023-06-03,2023-06-06,Actual,"June 23, 2017",Actual,2017-06-23,June 2023,2023-06-30,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2023",Anticipated,2023-12-31,,Interventional,,,Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients,"Immunogenicity of Nonavalent HPV Vaccine Administered Prior to Renal Transplantation in Adults: A Prospective, Single-Arm, Multi-Center Clinical Trial","Active, not recruiting",,Phase 2,180.0,Anticipated,National Cancer Institute (NCI),,1.0,,,,,,,True,True,False,,,,,,,,,,,2023-06-17 18:12:03,2023-06-17 18:12:03,NIH,,,,,
162996,162997,NCT03746015,,2018-11-13,,2022-02-23,2022-02-23,2018-11-15,2018-11-19,Actual,,,,2022-02-23,2022-02-25,Actual,2022-02-23,2022-02-25,Actual,"December 28, 2018",Actual,2018-12-28,February 2022,2022-02-28,"March 1, 2021",Actual,2021-03-01,"March 1, 2021",Actual,2021-03-01,,Interventional,,,Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults,"An Open-Label, Phase 2 Trial to Investigate the Humoral and Cell-Mediated Immune Responses and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Flavivirus-Naïve and Dengue-Immune Healthy Adults",Completed,,Phase 2,179.0,Actual,Takeda,,1.0,,,False,,,,True,True,False,,,,,,,"IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.",https://vivli.org/ourmember/takeda/,Yes,"Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.",2023-06-18 06:39:02,2023-06-18 06:39:02,INDUSTRY,,,,,
163042,163043,NCT04888611,,2021-05-12,,,2021-11-28,2021-05-12,2021-05-17,Actual,,,,,,,2021-11-28,2021-11-30,Actual,"October 26, 2021",Actual,2021-10-26,November 2021,2021-11-30,"May 1, 2024",Anticipated,2024-05-01,"May 1, 2023",Anticipated,2023-05-01,,Interventional,,,Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma,"Neoadjuvant PD-1 Antibody Alone or Combined With Autologous Glioblastoma Stem-like Cell Antigens-primed DC Vaccines (GSC-DCV) for Patients With Recurrent Glioblastoma:A Phase II, Randomized Controlled, Double Blind Clinical Trial.",Recruiting,,Phase 2,40.0,Anticipated,Huashan Hospital,,2.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-18 08:52:11,2023-06-18 08:52:11,OTHER,,,,,
163061,163062,NCT04405076,,2020-05-13,2022-10-21,,2022-12-06,2020-05-26,2020-05-28,Actual,2022-12-06,2022-12-30,Actual,,,,2022-12-06,2022-12-30,Actual,"May 29, 2020",Actual,2020-05-29,December 2022,2022-12-31,"October 28, 2021",Actual,2021-10-28,"October 28, 2021",Actual,2021-10-28,,Interventional,,"Safety Set: All participants who received any study injection in their respective part of the study. Note, participants who received placebo in Part A, received 100 ug mRNA-1273 in Part B (N=158). Participants who received 50 or 100 ug mRNA-1273 in Part A, received 50 ug mRNA-1273 in Part B (N=344). Since Baseline Characteristics data for participants in Part B are included in Part A, separate columns are not reported here for Part B.","Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older","A Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine in Adults Aged 18 Years and Older",Completed,,Phase 2,660.0,Actual,"ModernaTX, Inc.",,9.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 04:00:28,2023-06-17 04:00:28,INDUSTRY,,,,,
163210,163211,NCT00736476,,2008-08-13,2016-09-30,,2017-01-09,2008-08-13,2008-08-15,Estimate,2017-01-09,2017-02-28,Actual,,,,2017-01-09,2017-02-28,Actual,October 2008,,2008-10-31,September 2016,2016-09-30,April 2010,Actual,2010-04-30,March 2010,Actual,2010-03-31,,Interventional,,,Efficacy and Safety of an H.Pylori Vaccine in H.Pylori-Negative Adults,"Phase I/II, Randomized, Observer-blind, Placebo-controlled, Single-Center Study of the Tolerability, Immunogenicity, and Efficacy of an Novartis' Investigational H. Pylori Vaccine in H. Pylori-Negative Adults",Completed,,Phase 1,63.0,Actual,Novartis,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 11:03:30,2023-06-16 11:03:30,INDUSTRY,,,,,
163338,163339,NCT02480101,,2015-06-16,,,2015-06-19,2015-06-19,2015-06-24,Estimate,,,,,,,2015-06-19,2015-06-24,Estimate,October 2014,,2014-10-31,June 2015,2015-06-30,April 2015,Actual,2015-04-30,December 2014,Actual,2014-12-31,,Interventional,,,"Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine","Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Anhui/2013/61 (H7N9) Influenza Vaccine",Completed,,Phase 1,40.0,Actual,"Research Institute of Influenza, Russia",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 08:53:05,2023-06-18 08:53:05,OTHER,,,,,
163396,163397,NCT00714285,,2008-07-11,2013-07-11,,2018-05-09,2008-07-11,2008-07-14,Estimate,2013-07-11,2013-09-16,Estimate,,,,2018-05-09,2018-06-08,Actual,"July 14, 2008",,2008-07-14,March 2017,2017-03-31,"January 28, 2009",Actual,2009-01-28,"January 28, 2009",Actual,2009-01-28,,Interventional,,,Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults.,Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate GSK 2115160A in Adults.,Completed,,Phase 1,420.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 11:03:48,2023-06-16 11:03:48,INDUSTRY,,,,,
163397,163398,NCT04533399,,2020-08-28,,,2022-02-14,2020-08-28,2020-08-31,Actual,,,,,,,2022-02-14,2022-02-17,Actual,"August 17, 2020",Actual,2020-08-17,February 2022,2022-02-28,"January 19, 2022",Actual,2022-01-19,"December 7, 2021",Actual,2021-12-07,,Interventional,,,A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults,"A Phase 2A/B, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV",Completed,,Phase 2,4422.0,Actual,Novavax,,4.0,,,False,,,,True,True,False,,,True,,,,,,No,,2023-06-18 08:53:17,2023-06-18 08:53:17,INDUSTRY,,,,,
164068,164069,NCT03099291,,2017-03-28,,,2018-08-30,2017-03-28,2017-04-04,Actual,,,,,,,2018-08-30,2018-08-31,Actual,"April 1, 2017",Actual,2017-04-01,August 2018,2018-08-31,"April 30, 2018",Actual,2018-04-30,"April 30, 2018",Actual,2018-04-30,,Interventional,,,"Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/<U+0394>M2-2-HindIII) in RSV-Seronegative Infants and Children 6 to 24 Months of Age","Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-attenuated Respiratory Syncytial Virus Vaccine, D46/NS2/N/<U+0394>M2-2-HindIII, Lot RSV#011B, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age",Completed,,Phase 1,6.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-18 08:55:51,2023-06-18 08:55:51,NIH,,,,,
164829,164830,NCT00584805,,2007-12-19,2018-10-12,,2019-09-20,2007-12-31,2008-01-02,Estimate,2019-09-20,2019-09-24,Actual,,,,2019-09-20,2019-09-24,Actual,"June 3, 2008",Actual,2008-06-03,October 2018,2018-10-31,June 2017,Actual,2017-06-30,"June 27, 2016",Actual,2016-06-27,,Interventional,EEE,,Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine,"A Multi-Site Phase 2 Open-Label, Safety and Immunogenicity Study of Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104 in Healthy Adults At Risk for Exposure to Eastern Equine Encephalitis Virus",Completed,,Phase 2,138.0,Actual,U.S. Army Medical Research and Development Command,,1.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-16 11:07:00,2023-06-16 11:07:00,FED,,,,,
165095,165096,NCT00914771,,2009-06-04,,,2015-10-08,2009-06-04,2009-06-05,Estimate,,,,,,,2015-10-08,2015-10-12,Estimate,September 2009,,2009-09-30,October 2015,2015-10-31,December 2009,Actual,2009-12-31,December 2009,Actual,2009-12-31,,Interventional,,,"Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects","A Phase II, Randomized, Controlled, Double-blind, Multi-center, Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines Containing 3.75 µg or 7.5 µg of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects",Completed,,Phase 2,722.0,Actual,Novartis,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 11:07:34,2023-06-16 11:07:34,INDUSTRY,,,,,
165352,165353,NCT04691947,,2020-11-14,,,2023-02-10,2020-12-30,2020-12-31,Actual,,,,,,,2023-02-10,2023-02-14,Actual,"November 5, 2020",Actual,2020-11-05,February 2023,2023-02-28,"November 18, 2021",Actual,2021-11-18,"November 18, 2021",Actual,2021-11-18,,Interventional,ERUCOV-VAC,,Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC,"Phase 1 Study for the Determination of Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC, Given Twice Intramuscularly to Healthy Volunteers, in a Placebo Controlled Study Design.",Completed,,Phase 1,44.0,Actual,Health Institutes of Turkey,,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 09:01:08,2023-06-18 09:01:08,OTHER_GOV,,,,,
165657,165658,NCT04824391,,2021-03-25,,,2023-02-10,2021-03-30,2021-04-01,Actual,,,,,,,2023-02-10,2023-02-14,Actual,"February 10, 2021",Actual,2021-02-10,February 2023,2023-02-28,"March 30, 2022",Actual,2022-03-30,"March 11, 2022",Actual,2022-03-11,,Interventional,,,"Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19","Phase 2 Study for the Determination of Efficacy, Immunogenicity and Safety of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC, in a Placebo Controlled, Randomized, Double Blind Study Design.",Completed,,Phase 2,250.0,Actual,Health Institutes of Turkey,,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 09:02:45,2023-06-18 09:02:45,OTHER_GOV,,,,,
165738,165739,NCT05028322,,2021-07-06,,,2021-08-27,2021-08-27,2021-08-31,Actual,,,,,,,2021-08-27,2021-08-31,Actual,"November 1, 2021",Anticipated,2021-11-01,June 2021,2021-06-30,"December 1, 2024",Anticipated,2024-12-01,"December 1, 2024",Anticipated,2024-12-01,,Interventional,IDMODVHB,,"Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD's Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine Regimen","Effectiveness and Safety of Intra-Dermal Hepatitis B Vaccination After Topical Application of IMIQUIMOD, in Cirrhotics Patients, Who Did Not Respond to the Conventional Vaccine Regimen: a Pilot Study",Not yet recruiting,,Phase 2,60.0,Anticipated,"Central Hospital, Nancy, France",,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-17 18:29:58,2023-06-17 18:29:58,OTHER,,,,,
165763,165764,NCT00920517,,2009-06-11,,,2012-12-31,2009-06-11,2009-06-15,Estimate,,,,,,,2012-12-31,2013-01-03,Estimate,January 2009,,2009-01-31,December 2012,2012-12-31,January 2010,Actual,2010-01-31,January 2010,Actual,2010-01-31,,Interventional,,,Safety and Immune Response to Two Doses of rDEN2/4delta30 Dengue Vaccine,Safety and Immunogenicity of a 2-Dose Regimen of rDEN2/4<U+0394>30 Dengue Vaccine With Boosting at 4 Versus 6 Months,Completed,,Phase 1,25.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 11:09:04,2023-06-16 11:09:04,NIH,,,,,
165962,165963,NCT04525859,,2020-08-19,,,2023-06-01,2020-08-21,2020-08-25,Actual,,,,,,,2023-06-01,2023-06-02,Actual,"August 19, 2020",Actual,2020-08-19,May 2023,2023-05-31,"August 31, 2024",Anticipated,2024-08-31,"August 31, 2023",Anticipated,2023-08-31,,Interventional,,,Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma,Direct Injection of Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma,Recruiting,,Phase 1,19.0,Anticipated,"Oncovir, Inc.",,2.0,,,False,,,,True,True,False,,,,,,Duration of the Study,Read/Write access to the protocol Should receive all clinicaltrial.gov notices relating to this study,,Yes,"Rebecca Hernandez is the Administrative Assistant for this study and should have access to the PRS for this study.

Contact Information:

email: rebecca.hernandez@mssm.edu Phone: 212-824-9472.",2023-06-18 09:04:19,2023-06-18 09:04:19,INDUSTRY,,,,,
166185,166186,NCT00741039,,2008-08-22,2015-10-19,,2015-10-19,2008-08-22,2008-08-26,Estimate,2015-10-19,2015-11-20,Estimate,,,,2015-10-19,2015-11-20,Estimate,August 2008,,2008-08-31,October 2015,2015-10-31,August 2012,Actual,2012-08-31,August 2012,Actual,2012-08-31,,Interventional,,,Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older,Phase II Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older,Completed,,Phase 2,126.0,Actual,Memorial Sloan Kettering Cancer Center,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 11:09:45,2023-06-16 11:09:45,OTHER,,,,,
166473,166474,NCT00772070,,2008-10-13,2009-03-26,,2014-01-21,2008-10-14,2008-10-15,Estimate,2009-03-26,2009-05-14,Estimate,,,,2014-01-21,2014-02-14,Estimate,March 2003,,2003-03-31,January 2014,2014-01-31,May 2004,Actual,2004-05-31,August 2003,Actual,2003-08-31,,Interventional,,,Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine,"Antibody Responses to a Reduced Dose of Menomune® in Children Who Previously Received an Experimental Tetravalent (A, C, Y, and W-135) Meningococcal Diphtheria Toxoid Conjugate Vaccine, TetraMenD",Completed,,Phase 2,173.0,Actual,Sanofi,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 11:10:31,2023-06-16 11:10:31,INDUSTRY,,,,,
166493,166494,NCT03361163,,2017-11-14,,,2020-05-16,2017-11-28,2017-12-04,Actual,,,,,,,2020-05-16,2020-05-19,Actual,"July 10, 2018",Actual,2018-07-10,May 2020,2020-05-31,"April 21, 2020",Actual,2020-04-21,"September 28, 2019",Actual,2019-09-28,,Interventional,CHIVAS,,Controlled Human Infection for Vaccination Against Streptococcus Pyogenes,Group A Streptococcal Human Challenge Study: Building a Pharyngitis Model to Accelerate Vaccine Development,Completed,,Phase 1,25.0,Actual,Murdoch Childrens Research Institute,,1.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 09:06:45,2023-06-18 09:06:45,OTHER,,,,,
166619,166620,NCT05007496,,2021-08-11,,,2021-08-16,2021-08-12,2021-08-16,Actual,,,,,,,2021-08-16,2021-08-20,Actual,"April 14, 2021",Actual,2021-04-14,August 2021,2021-08-31,"May 31, 2021",Actual,2021-05-31,"May 31, 2021",Actual,2021-05-31,,Interventional,,,"Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19","Phase II Randomized Double Blind Clinical Trial Three Preventive Vaccine Formulations Consisting of Autologous Dendritic Cells and Lymphocytes Incubated With Different Quantities of Spike Protein Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), in Subjects Not Proven Actively Infected or Never Infected With COVID-19",Completed,,Phase 2,145.0,Actual,"Aivita Biomedical, Inc.",,3.0,,,False,,,,True,False,False,,,,,,,,,Undecided,,2023-06-17 18:35:30,2023-06-17 18:35:30,INDUSTRY,,,,,
166625,166626,NCT00003274,,1999-11-01,,,2014-05-20,2004-03-19,2004-03-22,Estimate,,,,,,,2014-05-20,2014-05-22,Estimate,March 1998,,1998-03-31,May 2014,2014-05-31,November 2002,Actual,2002-11-30,September 2001,Actual,2001-09-30,,Interventional,,,Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery,A Randomized Phase II Trial of a Vaccine Combining Tyrosinase /gp100 Peptides Emulsified With Montanide ISA 51 Alone or With a Block Co-Polymer CRL 1005 or With GM-CSF for Patients With Resected Stages IIA and IIB Melanoma Grant Application Title: MART-1/gp100 Immune Responses to a Melanoma Vaccine,Completed,,Phase 2,48.0,Actual,University of Southern California,,,,,False,,,,True,,,,,,,,,,,,,2023-06-14 03:33:25,2023-06-14 03:33:25,OTHER,,,,,
166744,166745,NCT00085436,,2004-06-10,2013-04-24,,2018-05-29,2004-06-10,2004-06-11,Estimate,2013-04-24,2013-06-10,Estimate,,,,2018-05-29,2018-06-26,Actual,December 2003,,2003-12-31,May 2018,2018-05-31,October 2009,Actual,2009-10-31,October 2009,Actual,2009-10-31,,Interventional,,,DC Vaccine Combined With IL-2 and IFNa-2a in Treating Patients With mRCC,A Phase II Study Of Autologous Tumor/DC Vaccine (DC Vaccine) Combined With Interleukin-2 (IL-2) And Interferon-a-2a (IFNa-2a) In Patients With Metastatic Renal Cell Carcinoma (RCC),Completed,,Phase 2,18.0,Actual,Dartmouth-Hitchcock Medical Center,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 03:33:30,2023-06-14 03:33:30,OTHER,,,,,
166877,166878,NCT05005156,,2021-06-07,,,2021-09-14,2021-08-06,2021-08-13,Actual,,,,,,,2021-09-14,2021-09-21,Actual,"June 24, 2021",Actual,2021-06-24,September 2021,2021-09-30,"September 30, 2022",Anticipated,2022-09-30,"September 30, 2022",Anticipated,2022-09-30,,Interventional,COVID-19,,Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Adults 18 Years of Age and Older.,"A Randomized, Double-blind, Placebo-controlled, Phase IIb Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of One or Two Doses of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Adults 18 Years of Age and Older, Living With HIV, on Stable Treatment, and Virologically Suppressed for at Least 6 Months.",Recruiting,,Phase 2,876.0,Anticipated,Fundación Huésped,,2.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-17 18:37:13,2023-06-17 18:37:13,OTHER,,,,,
167408,167409,NCT05559983,,2022-09-21,,,2023-03-01,2022-09-28,2022-09-29,Actual,,,,,,,2023-03-01,2023-03-03,Actual,"December 5, 2022",Actual,2022-12-05,March 2023,2023-03-31,"January 31, 2024",Anticipated,2024-01-31,"July 31, 2023",Anticipated,2023-07-31,,Interventional,,,Dose Escalation Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Healthy Adults,"A Phase I, Multicenter, Observer-Blinded, Randomized, Placebo-Controlled, Dose Escalation Trial to Evaluate the Safety and Immunogenicity of the OSP:rTTHc Cholera Conjugate Vaccine in 19 to 45 Years Old Healthy Korean Participants",Recruiting,,Phase 1,150.0,Anticipated,International Vaccine Institute,,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-16 11:13:09,2023-06-16 11:13:09,OTHER,,,,,
167510,167511,NCT00792623,,2008-11-17,2017-04-19,,2018-10-11,2008-11-17,2008-11-18,Estimate,2017-04-19,2017-07-06,Actual,,,,2018-10-11,2018-11-08,Actual,"September 8, 2003",Actual,2003-09-08,April 2017,2017-04-30,"September 10, 2007",Actual,2007-09-10,"September 10, 2007",Actual,2007-09-10,,Interventional,,,Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).,"A Phase III, Open-label, Multi-centre Study to Assess the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM), Given as a Primary Vaccination at 4.5 Months and 6.5 Months Post-transplantation, in Autologous Stem Cell/ Bone Marrow Transplant Recipients Aged 18 Years and Older.",Completed,,Phase 2,45.0,Actual,GlaxoSmithKline,,1.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 11:13:18,2023-06-16 11:13:18,INDUSTRY,,,,,
168405,168406,NCT00101166,,2005-01-07,2012-10-18,,2018-01-31,2005-01-07,2005-01-10,Estimate,2012-10-18,2012-11-16,Estimate,,,,2018-01-31,2018-02-28,Actual,October 2004,,2004-10-31,September 2012,2012-09-30,March 2010,Actual,2010-03-31,March 2010,Actual,2010-03-31,,Interventional,,,Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma,A Phase II Trial Using a Universal GM-CSF-Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-Based Vaccines for Patients With Malignant Melanoma,Completed,,Phase 2,43.0,Actual,H. Lee Moffitt Cancer Center and Research Institute,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 18:43:38,2023-06-17 18:43:38,OTHER,,,,,
168711,168712,NCT02601716,,2015-11-06,,,2018-10-11,2015-11-06,2015-11-10,Estimate,,,,,,,2018-10-11,2018-10-16,Actual,January 2016,Actual,2016-01-31,October 2018,2018-10-31,November 2017,Actual,2017-11-30,September 2017,Actual,2017-09-30,,Interventional,,,PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults,Clinical Trial of PfSPZ Vaccine Administered by Direct Venous Inoculation: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults,Completed,,Phase 2,92.0,Actual,Sanaria Inc.,,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 11:16:48,2023-06-16 11:16:48,INDUSTRY,,,,,
169014,169015,NCT05001373,,2021-07-01,,,2023-03-08,2021-08-04,2021-08-11,Actual,,,,,,,2023-03-08,2023-03-09,Actual,"November 12, 2021",Actual,2021-11-12,March 2023,2023-03-31,"July 1, 2023",Anticipated,2023-07-01,"July 1, 2023",Anticipated,2023-07-01,,Interventional,,,A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core),"A Phase 1, Randomized, First-in-human, Open-label Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) in HIV-1 Uninfected Adults in Good General Health","Active, not recruiting",,Phase 1,56.0,Anticipated,International AIDS Vaccine Initiative,,4.0,,,False,,,,True,True,False,,,,,,,,,Undecided,To be Determined,2023-06-17 18:46:01,2023-06-17 18:46:01,NETWORK,,,,,
169287,169288,NCT00746798,,2008-09-02,2011-09-27,,2015-03-17,2008-09-03,2008-09-04,Estimate,2011-09-27,2011-11-02,Estimate,,,,2015-03-17,2015-04-03,Estimate,October 2008,,2008-10-31,March 2015,2015-03-31,December 2009,Actual,2009-12-31,June 2009,Actual,2009-06-30,,Interventional,WinVax004,,Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults,"Randomized, Modified, Double-blind, Placebo-controlled, Phase II, Dose-ranging Study of the Safety and Immunogenicity of Single Dose ChimeriVax-WN02 Vaccine in Healthy Adults.",Completed,,Phase 2,479.0,Actual,Sanofi,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 11:19:20,2023-06-16 11:19:20,INDUSTRY,,,,,
169536,169537,NCT05762393,,2023-02-28,,,2023-03-17,2023-02-28,2023-03-09,Actual,,,,,,,2023-03-17,2023-03-20,Actual,"August 1, 2023",Anticipated,2023-08-01,March 2023,2023-03-31,"December 1, 2024",Anticipated,2024-12-01,"December 1, 2024",Anticipated,2024-12-01,,Interventional,,,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar","A Phase 1b, Multicenter, Randomized, Placebo-controlled, Observer-blinded, Dose-escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar",Not yet recruiting,,Phase 1,120.0,Anticipated,International Vaccine Institute,,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-14 03:36:28,2023-06-14 03:36:28,OTHER,,,,,
169603,169604,NCT00709605,,2008-06-28,,,2019-12-14,2008-07-02,2008-07-03,Estimate,,,,,,,2019-12-14,2019-12-17,Actual,"June 25, 2008",,2008-06-25,"May 20, 2014",2014-05-20,"May 20, 2014",Actual,2014-05-20,"May 20, 2014",Actual,2014-05-20,,Interventional,,,Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection,"A Phase I, Open Label, CT to Evaluate the Safety, Tolerability and Immunogenicity of a Multiclade Recombinant HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP In Uninfected Adults Randomized to Needle or Biojector Methods of Intramuscular Injection",Completed,,Phase 1,31.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-16 11:21:05,2023-06-16 11:21:05,NIH,,,,,
169644,169645,NCT04646005,,2020-11-20,,,2022-12-29,2020-11-20,2020-11-27,Actual,,,,,,,2022-12-29,2023-01-03,Actual,"June 28, 2021",Actual,2021-06-28,December 2022,2022-12-31,"October 22, 2024",Anticipated,2024-10-22,"October 22, 2024",Anticipated,2024-10-22,,Interventional,,,Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy,"A Phase 2 Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients With Recurrent/Metastatic HPV16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy","Active, not recruiting",,Phase 2,113.0,Actual,Regeneron Pharmaceuticals,,1.0,,,False,,,,False,True,False,,,,,,"When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.",Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf,https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2023-06-17 18:49:03,2023-06-17 18:49:03,INDUSTRY,,,,,
170251,170252,NCT03336593,,2017-11-06,,,2019-04-01,2017-11-06,2017-11-08,Actual,,,,,,,2019-04-01,2019-04-02,Actual,"November 21, 2017",Actual,2017-11-21,April 2019,2019-04-30,"November 30, 2018",Actual,2018-11-30,"March 14, 2018",Actual,2018-03-14,,Interventional,,,Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population,A Bridging Study to Assess Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population,Completed,,Phase 2,810.0,Actual,PT Bio Farma,,6.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-18 09:22:01,2023-06-18 09:22:01,INDUSTRY,,,,,
170758,170759,NCT00712803,,2008-07-08,,,2012-12-31,2008-07-08,2008-07-10,Estimate,,,,,,,2012-12-31,2013-01-03,Estimate,December 2008,,2008-12-31,December 2012,2012-12-31,September 2009,Actual,2009-09-30,September 2009,Actual,2009-09-30,,Interventional,,,Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults,"A Phase I Dose Comparison Study of the Safety and Immunogenicity of rDEN3-3'Ddelta30, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3",Completed,,Phase 1,29.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 11:25:49,2023-06-16 11:25:49,NIH,,,,,
171007,171008,NCT00584844,,2007-12-20,2016-12-28,,2019-12-30,2007-12-20,2008-01-02,Estimate,2017-06-05,2017-07-02,Actual,,,,2019-12-30,2020-01-02,Actual,October 2004,,2004-10-31,December 2019,2019-12-31,October 2013,Actual,2013-10-31,October 2009,Actual,2009-10-31,,Interventional,,,Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine,"A Longitudinal Phase 2 Study for the Continued Evaluation of the Safety and Immunogenicity of a Live Francisella Tularensis Vaccine, NDBR 101, Lot 4",Completed,,Phase 2,484.0,Actual,U.S. Army Medical Research and Development Command,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 11:26:36,2023-06-16 11:26:36,FED,,,,,
171196,171197,NCT00584454,,2007-12-20,2016-11-22,2016-11-15,2019-12-30,2007-12-20,2008-01-02,Estimate,2017-01-18,2017-03-09,Actual,2016-11-15,2016-11-16,Estimate,2019-12-30,2020-01-03,Actual,February 2006,,2006-02-28,December 2019,2019-12-31,June 2014,Actual,2014-06-30,July 2009,Actual,2009-07-31,,Interventional,,,"Safety Evaluation of a Q-fever Vaccine, NDBR 105","Continued Evaluation of the Safety of Q Fever Vaccine, Phase I, Inactivated, Freeze Dried, NDBR 105, in Those at Risk of Exposure to Coxiella Burnetii, A Phase 2 Study",Completed,,Phase 2,10.0,Actual,U.S. Army Medical Research and Development Command,,1.0,,,False,,,,False,,,,,,,,,,,No,,2023-06-16 11:27:15,2023-06-16 11:27:15,FED,,,,,
171205,171206,NCT00578175,,2007-12-20,2010-03-05,,2018-09-05,2007-12-20,2007-12-21,Estimate,2010-08-02,2010-08-26,Estimate,,,,2018-09-05,2018-10-09,Actual,"November 20, 2007",,2007-11-20,October 2016,2016-10-31,"March 17, 2009",Actual,2009-03-17,"February 24, 2009",Actual,2009-02-24,,Interventional,,,Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age,"Immunogenicity of GlaxoSmithKline Biologicals' MMRV Vaccine (208136) vs. ProQuad®, When Coadministered With Hepatitis A and Pneumococcal Conjugate Vaccines to Children 12-14 Months of Age.",Completed,,Phase 2,1851.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 11:27:24,2023-06-16 11:27:24,INDUSTRY,,,,,
171391,171392,NCT03063736,,2017-02-21,,,2020-08-28,2017-02-23,2017-02-24,Actual,,,,,,,2020-08-28,2020-09-01,Actual,"December 8, 2017",Actual,2017-12-08,August 2020,2020-08-31,"December 31, 2019",Actual,2019-12-31,"March 9, 2018",Actual,2018-03-09,,Interventional,,,"Entolimod, an Adjuvant for Vaccine Augmentation","Entolimod, an Adjuvant for Vaccine Augmentation",Completed,,Early Phase 1,40.0,Actual,Baylor College of Medicine,,2.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-17 18:57:47,2023-06-17 18:57:47,OTHER,,,,,
171598,171599,NCT04066881,,2019-08-08,,,2022-06-27,2019-08-21,2019-08-26,Actual,,,,,,,2022-06-27,2022-07-01,Actual,"December 15, 2020",Actual,2020-12-15,June 2022,2022-06-30,"December 31, 2024",Anticipated,2024-12-31,"December 31, 2024",Anticipated,2024-12-31,,Interventional,PrEPVacc,,A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP,"A Phase IIb Three-arm, Two-stage HIV Prophylactic Vaccine Trial With a Second Randomisation to Compare TAF/FTC to TDF/FTC as Pre-exposure Prophylaxis",Enrolling by invitation,,Phase 2,1668.0,Anticipated,MRC/UVRI and LSHTM Uganda Research Unit,,6.0,,,False,,,,True,True,False,,,True,,,"The approved versions of the study protocol and global informed consent form will be in the public domain throughout.

The Statistical Analysis Plan will be in the public domain prior to database lock.

The clinical study report will be available a year after the last participant visit.","The approved protocols and final version of the SAP will be in the public domain.

The clinical study report will be available on request.",,Yes,"The investigators will ensure that optimal use is made of the data generated in this trial through a controlled access approach to data sharing. Access will be controlled to ensure that there is a scientific rationale for the data, that no data are released that could compromise the ongoing trial, that the appropriate consent is in place, that an appropriate agreement is in place for secure transfer and storage, and that resources required to process data release are adequate.",2023-06-16 11:28:24,2023-06-16 11:28:24,OTHER,,,,,
172367,172368,NCT00734175,,2008-08-12,,,2009-08-05,2008-08-12,2008-08-14,Estimate,,,,,,,2009-08-05,2009-08-07,Estimate,September 2008,,2008-09-30,September 2008,2008-09-30,,,,December 2008,Actual,2008-12-31,,Interventional,,,Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine,"Phase I Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine H6N1 (6-2) AA ca Recombinant (A/Teal/Hong Kong/W312/1997 (H6N1) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H6N1 Infection in the Event of a Pandemic",Completed,,Phase 1,22.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 11:30:13,2023-06-16 11:30:13,NIH,,,,,
172380,172381,NCT00734565,,2008-08-12,,,2012-02-06,2008-08-12,2008-08-14,Estimate,,,,,,,2012-02-06,2012-02-08,Estimate,July 2008,,2008-07-31,February 2012,2012-02-29,October 2008,Actual,2008-10-31,October 2008,Actual,2008-10-31,,Interventional,,,Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b,"A Phase I, Single-arm, Single-center Study to Investigate Safety and Reactogenicity of Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b in Healthy Children Aged 16 - 20 Months and Infants Aged 2 - 4 Months",Completed,,Phase 1,40.0,Actual,Novartis,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 11:30:20,2023-06-16 11:30:20,INDUSTRY,,,,,
172438,172439,NCT00736047,,2008-08-14,,,2017-03-17,2008-08-14,2008-08-15,Estimate,,,,,,,2017-03-17,2017-03-21,Actual,August 2008,Actual,2008-08-31,March 2017,2017-03-31,October 2009,Actual,2009-10-31,October 2009,Actual,2009-10-31,,Interventional,,,"Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking.","A Double Blind, Placebo-controlled, Multi-centre Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of Repeated s.c Administrations of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking.",Completed,,Phase 2,200.0,Actual,Novartis,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 11:30:50,2023-06-16 11:30:50,INDUSTRY,,,,,
172780,172781,NCT03699241,,2018-10-03,,,2023-03-08,2018-10-04,2018-10-09,Actual,,,,,,,2023-03-08,2023-03-09,Actual,"December 3, 2018",Actual,2018-12-03,March 2023,2023-03-31,"August 30, 2023",Anticipated,2023-08-30,"March 30, 2023",Anticipated,2023-03-30,,Interventional,,,"A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults","A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults","Active, not recruiting",,Phase 1,61.0,Actual,International AIDS Vaccine Initiative,,5.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-17 19:05:35,2023-06-17 19:05:35,NETWORK,,,,,
172789,172790,NCT04983537,,2021-07-28,,,2021-07-28,2021-07-28,2021-07-30,Actual,,,,,,,2021-07-28,2021-07-30,Actual,"July 26, 2021",Actual,2021-07-26,July 2021,2021-07-31,"September 26, 2021",Anticipated,2021-09-26,"September 26, 2021",Anticipated,2021-09-26,,Interventional,,,Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes in an Elderly Population,"Randomised Phase II Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes in an Elderly Population (rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV).",Recruiting,,Phase 2,120.0,Anticipated,Ministerio de Salud de Ciudad Autónoma de Buenos Aires,,3.0,,,False,,,,True,False,False,,,False,,,,,,No,,2023-06-18 09:38:28,2023-06-18 09:38:28,OTHER_GOV,,,,,
173876,173877,NCT00702221,,2008-06-19,2014-09-10,,2016-06-20,2008-06-19,2008-06-20,Estimate,2016-06-20,2016-07-29,Estimate,,,,2016-06-20,2016-07-29,Estimate,June 2008,,2008-06-30,April 2016,2016-04-30,September 2010,Actual,2010-09-30,June 2009,Actual,2009-06-30,,Interventional,,All analyzed subjects,Safety and Efficacy Study of Angiotensin Therapeutic Vaccine in Subjects With Mild to Moderate Hypertension,"A Randomised, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Angiotensin Therapeutic Vaccine (ATV) in Subjects With Mild to Moderate Hypertension",Terminated,,Phase 2,20.0,Actual,BTG International Inc.,,2.0,,Dose limiting adverse effects,False,,,,True,,,,,,,,,,,Yes,Investigators provide information to participants,2023-06-18 09:41:39,2023-06-18 09:41:39,OTHER,,,,,
173977,173978,NCT00924105,,2009-06-16,,,2012-02-10,2009-06-17,2009-06-18,Estimate,,,,,,,2012-02-10,2012-02-13,Estimate,June 2009,,2009-06-30,February 2012,2012-02-29,November 2011,Actual,2011-11-30,November 2011,Actual,2011-11-30,,Interventional,,,"Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes","A Two-Stage Randomized Placebo-controlled Ascending Dose Phase I/ IIa Study to Evaluate Safety, Tolerability, Pharmacodynamic Effects and Preliminary Efficacy of an Anti-Interleukin 1 Beta Vaccine (CYT013-IL1bQb) in Patients With Type 2 Diabetes Mellitus",Completed,,Phase 1,48.0,Actual,Cytos Biotechnology AG,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 13:44:15,2023-06-16 13:44:15,INDUSTRY,,,,,
174545,174546,NCT00755703,,2008-09-17,,,2015-12-31,2008-09-18,2008-09-19,Estimate,,,,,,,2015-12-31,2016-01-01,Estimate,October 2008,,2008-10-31,September 2012,2012-09-30,December 2011,Actual,2011-12-31,September 2009,Actual,2009-09-30,,Interventional,,,"Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.","A Phase I, Dose-Ranging Safety and Immunogenicity Study of an Adenovirus-vectored Intranasal, Pandemic (Hemagglutinin H5) Influenza Vaccine, ADhVN1203/04.H5, in Healthy Adults",Completed,,Phase 1,48.0,Actual,"Altimmune, Inc.",,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 11:43:53,2023-06-16 11:43:53,INDUSTRY,,,,,
174589,174590,NCT00715910,,2008-07-11,2014-04-25,2013-08-22,2014-11-20,2008-07-14,2008-07-15,Estimate,2014-05-01,2014-05-29,Estimate,2013-08-22,2013-08-30,Estimate,2014-11-20,2014-11-27,Estimate,July 2008,,2008-07-31,September 2014,2014-09-30,October 2013,Actual,2013-10-31,April 2013,Actual,2013-04-30,,Interventional,,The overall number of baseline subjects correspond to the subjects at Year 1 persistence phase and another cohort of subjects (naive control group) which was offered a dose of Nimenrix vaccine at Year 5 within the same study.,The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults,Long-term Antibody Persistence of GSK Biologicals' MenACWY-TT Vaccine Versus Menactra® in Healthy Adolescents/Adults Aged 10-25 Years and Booster Response to MenACWY-TT Vaccine Administered at 5 Years Post-primary Vaccination,Completed,,Phase 2,818.0,Actual,GlaxoSmithKline,,6.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 11:44:31,2023-06-16 11:44:31,INDUSTRY,,,,,
174631,174632,NCT00919178,,2009-06-11,,,2012-12-31,2009-06-11,2009-06-12,Estimate,,,,,,,2012-12-31,2013-01-03,Estimate,July 2009,,2009-07-31,December 2012,2012-12-31,May 2010,Actual,2010-05-31,May 2010,Actual,2010-05-31,,Interventional,,,Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus,"Phase I Evaluation of the Safety and Immunogenicity of rDEN4delta30 Lot# 109A, a Live Attenuated DEN4 Vaccine, in Healthy Flavivirus-naïve Adult Volunteers.",Completed,,Phase 1,70.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 11:45:02,2023-06-16 11:45:02,NIH,,,,,
174688,174689,NCT05548439,,2022-09-16,,,2023-02-13,2022-09-16,2022-09-21,Actual,,,,,,,2023-02-13,2023-02-14,Actual,"October 5, 2022",Actual,2022-10-05,February 2023,2023-02-28,February 2024,Anticipated,2024-02-29,February 2024,Anticipated,2024-02-29,,Interventional,,,"Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a","A Phase 1, Randomized Study to Evaluate the Safety and Immunogenicity of VBI-2901a, a Trivalent Coronavirus Vaccine Candidate in Healthy Adults Previously Vaccinated With Licensed COVID-19 Vaccines","Active, not recruiting",,Phase 1,103.0,Actual,VBI Vaccines Inc.,,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 09:43:22,2023-06-18 09:43:22,INDUSTRY,,,,,
175736,175737,NCT03287427,,2017-09-12,,,2023-02-13,2017-09-15,2017-09-19,Actual,,,,,,,2023-02-13,2023-02-15,Actual,"August 22, 2018",Actual,2018-08-22,February 2023,2023-02-28,"December 14, 2022",Actual,2022-12-14,"December 14, 2022",Actual,2022-12-14,,Interventional,MYPHISMO,,MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial,First-in-human Phase I Clinical Trial of a Combined Immune Modulatory Approach Using TetMYB Vaccine and Anti-PD1 Antibody in Patients With Advanced Solid Cancer Including Colorectal or Adenoid Cystic Carcinoma.,Completed,,Phase 1,27.0,Actual,"Peter MacCallum Cancer Centre, Australia",,1.0,,,False,,,,True,False,False,,,False,,,,,,,,2023-06-18 09:48:12,2023-06-18 09:48:12,OTHER,,,,,
176118,176119,NCT03483116,,2018-03-23,,,2021-08-08,2018-03-23,2018-03-30,Actual,,,,,,,2021-08-08,2021-08-16,Actual,"June 15, 2018",Actual,2018-06-15,August 2021,2021-08-31,"January 27, 2020",Actual,2020-01-27,"January 27, 2020",Actual,2020-01-27,,Interventional,,,A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine,"A Phase II Randomized, Double Blind, Parallel Group Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine Administered at a High, Mid and Low Titre as a 3 Dose Neonate Schedule or Administered at a High Titre as a 3 Dose Infant Schedule.",Completed,,Phase 2,688.0,Actual,Murdoch Childrens Research Institute,,4.0,,,False,,,,True,True,False,,,True,,,,,,Yes,"Deidentified group data may be available for sharing on application to the Sponsor. This application must include the relevant proposal detailing the intended use of the data, the Ethics approval for this proposal and requires a signed data sharing agreement. Additional study documents including the study protocol, statistical analysis plan and informed consent are available on application to the Sponsor.",2023-06-17 19:14:27,2023-06-17 19:14:27,OTHER,,,,,
176740,176741,NCT00112112,,2005-05-27,2012-02-27,,2017-06-29,2005-05-27,2005-05-30,Estimate,2012-07-31,2012-09-03,Estimate,,,,2017-06-29,2017-08-14,Actual,"August 1, 2005",Actual,2005-08-01,June 2017,2017-06-30,"May 1, 2008",Actual,2008-05-01,"March 1, 2008",Actual,2008-03-01,,Interventional,,,Safety Study to Evaluate FluMist in Immunocompromised Children,"A Phase I Randomized, Double-Blind Trial of the Safety and Immunogenicity of FluMist® A Live, Intranasal Influenza Virus Vaccine vs. Placebo in Immunocompromised Children Ages 5 Through 17 Years of Age",Completed,,Phase 1,20.0,Actual,MedImmune LLC,,2.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-14 03:46:15,2023-06-14 03:46:15,INDUSTRY,,,,,
176747,176748,NCT02568566,,2015-10-05,2022-01-24,2021-01-11,2022-10-18,2015-10-05,2015-10-06,Estimate,2022-03-14,2022-04-05,Actual,2021-01-11,2021-01-12,Actual,2022-10-18,2022-10-19,Actual,"March 30, 2016",Actual,2016-03-30,October 2022,2022-10-31,,,,"February 6, 2020",Actual,2020-02-06,,Interventional,,,Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants,"A Prospective, Single-Arm, Open-Label, Non-Randomized, Phase IIA Trial of a Nonavalent Prophylactic HPV Vaccine to Assess Immunogenicity of a Prime and Deferred-Booster Dosing Schedule Among 9-11 Year-Old Girls and Boys","Active, not recruiting",,Phase 2,201.0,Actual,National Cancer Institute (NCI),,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 03:46:18,2023-06-14 03:46:18,NIH,,,,,
176809,176810,NCT03472976,,2018-03-15,,,2020-02-20,2018-03-15,2018-03-21,Actual,,,,,,,2020-02-20,2020-02-24,Actual,"June 13, 2018",Actual,2018-06-13,"August 14, 2018",2018-08-14,"March 4, 2019",Actual,2019-03-04,"March 4, 2019",Actual,2019-03-04,,Interventional,,,H5N1 With or Without Topical Aldara in Healthy Adults,A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Inactivated Influenza A/H5N1 Vaccine Administered Intradermally With or Without Topical Aldara(R) in Healthy Young Adults,Completed,,Phase 1,50.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-17 19:17:31,2023-06-17 19:17:31,NIH,,,,,
177005,177006,NCT02171819,,2014-06-20,2018-11-11,,2018-11-11,2014-06-20,2014-06-24,Estimate,2018-11-11,2019-03-14,Actual,,,,2018-11-11,2019-03-14,Actual,June 2014,,2014-06-30,November 2018,2018-11-30,August 2014,Actual,2014-08-31,August 2014,Actual,2014-08-31,,Interventional,,,Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1,"A Phase 1 Double Blinded, Randomized, Placebo-Controlled Study to Examine the Safety and Immunogenicity of an Inactivated A/H5N1 Influenza Vaccine (IVACFLU-A/H5N1) Produced by IVAC in Healthy Adult Volunteers in Vietnam",Completed,,Phase 1,75.0,Actual,"Institute of Vaccines and Medical Biologicals, Vietnam",,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-14 03:46:49,2023-06-14 03:46:49,INDUSTRY,,,,,
177491,177492,NCT00667563,,2008-04-25,2014-01-23,,2016-02-01,2008-04-25,2008-04-28,Estimate,2014-03-07,2014-04-11,Estimate,,,,2016-02-01,2016-02-29,Estimate,August 2009,,2009-08-31,February 2016,2016-02-29,November 2012,Actual,2012-11-30,November 2012,Actual,2012-11-30,,Interventional,,Enrolled in study,Vaccine Therapy in Preventing HPV in HIV-Positive Women in India,"A Single-Arm, Open-Label Pilot Study of the Safety and Immunogenicity of the Merck Quadrivalent Human Papillomavirus Vaccine Among HIV-Positive Women in India",Completed,,Phase 1,150.0,Actual,AIDS Malignancy Consortium,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 11:57:43,2023-06-16 11:57:43,NETWORK,,,,,
177610,177611,NCT00218413,,2005-09-16,,,2017-01-11,2005-09-16,2005-09-22,Estimate,,,,,,,2017-01-11,2017-01-12,Estimate,October 2004,,2004-10-31,November 2008,2008-11-30,August 2006,Actual,2006-08-31,August 2006,Actual,2006-08-31,,Interventional,,,Safety and Effectiveness of NicVAX in Treating Nicotine Dependent Individuals,A Phase 2 Study to Assess Safety and Immunogenicity of Five Doses of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) Administered to Smokers,Completed,,Phase 2,51.0,Actual,National Institute on Drug Abuse (NIDA),,5.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 06:45:38,2023-06-15 06:45:38,NIH,,,,,
177926,177927,NCT01317667,,2011-03-09,2015-01-26,,2019-12-30,2011-03-16,2011-03-17,Estimate,2015-01-26,2015-02-11,Estimate,,,,2019-12-30,2020-01-03,Actual,March 2011,,2011-03-31,December 2019,2019-12-31,December 2014,Actual,2014-12-31,November 2012,Actual,2012-11-30,,Interventional,,,Safety and Immunogenicity Study of Recombinant Ricin Toxin A-Chain Vaccine (RVEc),"Phase 1 Escalating, Multiple-Dose Study to Evaluate the Safety and Immunogenicity of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc) in Healthy Adults",Completed,,Phase 1,30.0,Actual,U.S. Army Medical Research and Development Command,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 03:47:43,2023-06-14 03:47:43,FED,,,,,
178139,178140,NCT04487093,,2020-07-23,,,2020-07-24,2020-07-24,2020-07-27,Actual,,,,,,,2020-07-24,2020-07-27,Actual,"May 17, 2020",Actual,2020-05-17,May 2020,2020-05-31,"December 1, 2022",Anticipated,2022-12-01,"May 17, 2022",Anticipated,2022-05-17,,Interventional,,,Clinical Study of Neoantigen Vaccine Combined With Targeted Drugs in the Treatment of Non-small Cell Lung Cancer,Clinical Study of Personalized Neoantigen Peptide Vaccine Combined With Targeted Drugs in the Treatment of Non-small Cell Lung Cancer,Unknown status,Recruiting,Phase 1,20.0,Anticipated,First Hospital of Shijiazhuang City,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 10:00:34,2023-06-18 10:00:34,OTHER,,,,,
178175,178176,NCT01035749,,2009-12-17,2016-11-28,2012-07-23,2018-07-04,2009-12-17,2009-12-21,Estimate,2016-11-28,2017-01-25,Estimate,2012-07-23,2012-07-31,Estimate,2018-07-04,2018-08-17,Actual,"February 1, 2010",,2010-02-01,November 2016,2016-11-30,"May 10, 2011",Actual,2011-05-10,"September 27, 2010",Actual,2010-09-27,,Interventional,,,Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years,Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine (GSK2340274A) in Children Aged 10 to Less Than 18 Years,Completed,,Phase 2,310.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-14 03:48:05,2023-06-14 03:48:05,INDUSTRY,,,,,
178409,178410,NCT02159482,,2014-06-06,2014-06-17,,2014-07-21,2014-06-06,2014-06-10,Estimate,2014-06-17,2014-07-16,Estimate,,,,2014-07-21,2014-07-25,Estimate,November 2005,,2005-11-30,June 2014,2014-06-30,May 2008,Actual,2008-05-31,May 2008,Actual,2008-05-31,,Interventional,,,Pilot Study of Interferon Alfa for Patients Who Have Received Cancer Vaccines,Pilot Study of Interferon Alfa for Patients Who Have Received Cancer Vaccines,Terminated,,Phase 2,11.0,Actual,Duke University,,1.0,,Low enrollment,False,,,,False,,,,,,,,,,,,,2023-06-18 10:02:18,2023-06-18 10:02:18,OTHER,,,,,
178703,178704,NCT04915989,,2021-06-03,,,2021-06-04,2021-06-04,2021-06-07,Actual,,,,,,,2021-06-04,2021-06-07,Actual,"February 16, 2021",Actual,2021-02-16,June 2021,2021-06-30,"March 31, 2022",Anticipated,2022-03-31,"July 31, 2021",Anticipated,2021-07-31,,Interventional,,,"Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals","A Phase 1, Multicenter, Open-Label, Single Arm Study to Investigate the Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals",Unknown status,"Active, not recruiting",Phase 1,30.0,Actual,"Genexine, Inc.",,1.0,,,False,,,,,False,False,,,,,,,,,No,,2023-06-18 10:04:33,2023-06-18 10:04:33,INDUSTRY,,,,,
179316,179317,NCT00710372,,2008-07-03,,,2010-11-11,2008-07-03,2008-07-04,Estimate,,,,,,,2010-11-11,2010-11-15,Estimate,June 2008,,2008-06-30,November 2010,2010-11-30,November 2010,Actual,2010-11-30,July 2009,Actual,2009-07-31,,Interventional,,,"Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension","A Double Blind, Randomized, Placebo Controlled, Parallel Group, Dose-Titration Phase II Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Efficacy of an Anti-Angiotensin II Vaccine (CYT006-AngQb) in Patients With Mild to Moderate Essential Hypertension",Completed,,Phase 2,83.0,Actual,Cytos Biotechnology AG,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 12:03:31,2023-06-16 12:03:31,INDUSTRY,,,,,
179411,179412,NCT02049489,,2014-01-28,,,2018-08-09,2014-01-28,2014-01-30,Estimate,,,,,,,2018-08-09,2018-08-13,Actual,December 2013,,2013-12-31,August 2018,2018-08-31,March 2017,Actual,2017-03-31,March 2017,Actual,2017-03-31,,Interventional,,,A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma,Immunological Targeting of CD-133 in Recurrent Glioblastoma: A Multi-center Phase I Translational and Clinical Study of an Autologous CD-133 DC Vaccine,Completed,,Phase 1,20.0,Actual,Precision Life Sciences Group,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 19:29:21,2023-06-17 19:29:21,INDUSTRY,,,,,
179700,179701,NCT00712634,,2008-07-09,,,2009-12-18,2008-07-09,2008-07-10,Estimate,,,,,,,2009-12-18,2009-12-21,Estimate,November 1997,,1997-11-30,December 2009,2009-12-31,April 2009,Actual,2009-04-30,April 2009,Actual,2009-04-30,,Interventional,,,Cytomegalovirus Vaccine in Healthy Participants,A Phase I Dose Escalation Study of Lipopeptide Vaccines With Activity Against Human Cytomegalovirus,Completed,,Phase 1,46.0,Anticipated,City of Hope Medical Center,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 12:04:49,2023-06-16 12:04:49,OTHER,,,,,
180162,180163,NCT02452775,,2015-05-21,,,2020-04-23,2015-05-21,2015-05-25,Estimate,,,,,,,2020-04-23,2020-04-24,Actual,May 2015,Actual,2015-05-31,April 2020,2020-04-30,"May 30, 2018",Actual,2018-05-30,"May 30, 2018",Actual,2018-05-30,,Interventional,,,Autologous OC-L Vaccine and Ovarian Cancer,"A Randomized Pilot Trial to Test the Addition of Montanide and Polyiclc to Autologous Oxidized Tumor Cell Lysate Vaccine in Combination With Gmcsf in Primary Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Terminated,,Phase 1,3.0,Actual,Abramson Cancer Center at Penn Medicine,,4.0,,,False,,,,True,True,,,,,,,,,,,,2023-06-18 10:10:15,2023-06-18 10:10:15,OTHER,,,,,
180411,180412,NCT00412477,,2006-12-15,,,2018-10-09,2006-12-15,2006-12-18,Estimate,,,,,,,2018-10-09,2018-10-10,Actual,"August 20, 2004",Actual,2004-08-20,October 2018,2018-10-31,"November 1, 2006",Actual,2006-11-01,"March 13, 2006",Actual,2006-03-13,,Interventional,,,A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine,"RV 151: A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine LFn-p24 Administered by the Intramuscular (IM) Route in Healthy Adults, WRAIR #984, HSRRB Log # A-11905.",Completed,,Phase 1,18.0,Actual,U.S. Army Medical Research and Development Command,,3.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-15 06:46:30,2023-06-15 06:46:30,FED,,,,,
180546,180547,NCT02546752,,2015-09-09,,,2016-05-24,2015-09-10,2015-09-11,Estimate,,,,,,,2016-05-24,2016-05-25,Estimate,September 2015,,2015-09-30,May 2016,2016-05-31,May 2016,Actual,2016-05-31,May 2016,Actual,2016-05-31,,Interventional,,,Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine,Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine,Completed,,Early Phase 1,1306.0,Actual,"Regenstrief Institute, Inc.",,2.0,,,False,,,,False,,,,,,,,,,,No,Individual provider data will not be shared.,2023-06-16 12:09:04,2023-06-16 12:09:04,OTHER,,,,,
180547,180548,NCT00715832,,2008-07-10,,,2009-08-25,2008-07-14,2008-07-15,Estimate,,,,,,,2009-08-25,2009-08-26,Estimate,May 2008,,2008-05-31,August 2009,2009-08-31,February 2015,Anticipated,2015-02-28,February 2010,Anticipated,2010-02-28,,Interventional,,,A Phase I Cancer Vaccine Study for Patients With Metastatic Breast Cancer,A Phase I Vaccine Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast Cancer,Unknown status,Recruiting,Phase 1,25.0,Anticipated,Southern Cancer Center,,,,,False,,,,True,,,,,,,,,,,,,2023-06-16 12:09:05,2023-06-16 12:09:05,OTHER,,,,,
180881,180882,NCT03038776,,2017-01-30,,,2019-05-06,2017-01-31,2017-02-01,Estimate,,,,,,,2019-05-06,2019-05-07,Actual,January 2017,Actual,2017-01-31,May 2019,2019-05-31,May 2019,Actual,2019-05-31,November 2017,Actual,2017-11-30,,Interventional,FLU007,,Recombinant H7 Hemagglutinin Influenza Vaccine Trial,"A Randomised, Controlled, Phase 1 Study in Healthy Adults to Evaluate the Immunogenicity and Safety of a Recombinant H7 Hemagglutinin Influenza Vaccine",Completed,,Phase 1,150.0,Anticipated,Vaxine Pty Ltd,,6.0,,,False,,,,False,,,,,,,,,,,No,,2023-06-17 19:36:25,2023-06-17 19:36:25,INDUSTRY,,,,,
180941,180942,NCT00722774,,2008-07-25,,,2008-11-07,2008-07-25,2008-07-28,Estimate,,,,,,,2008-11-07,2008-11-10,Estimate,,,,July 2008,2008-07-31,,,,September 2008,Actual,2008-09-30,,Interventional,,,Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine,"Phase I Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine H2N2 (A/Ann Arbor/6/60 ca Recombinant), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H2N2 Infection in the Event of a Pandemic",Completed,,Phase 1,22.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 12:10:31,2023-06-16 12:10:31,NIH,,,,,
181028,181029,NCT00851266,,2009-02-23,,,2015-02-11,2009-02-23,2009-02-25,Estimate,,,,,,,2015-02-11,2015-02-12,Estimate,October 2006,,2006-10-31,February 2015,2015-02-28,January 2009,Actual,2009-01-31,August 2007,Actual,2007-08-31,,Interventional,,,A Study of a Bivalent Influenza Peptide Conjugate Vaccine in Healthy Adults,"A Dose-Escalation, Dose-Ranging Study of the Safety, Tolerability, and Immunogenicity of a Bivalent Influenza Peptide Conjugate Vaccine Formulated With Aluminum- and ISCOMATRIX(TM) Containing Adjuvants (BIPCV/IMX) Evaluated in Healthy Adults 18 to 35 Years of Age",Completed,,Phase 1,187.0,Actual,Merck Sharp & Dohme LLC,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 12:11:05,2023-06-16 12:11:05,INDUSTRY,,,,,
181030,181031,NCT04844775,,2021-03-24,,,2021-04-09,2021-04-09,2021-04-14,Actual,,,,,,,2021-04-09,2021-04-14,Actual,June 2021,Anticipated,2021-06-30,March 2021,2021-03-31,June 2023,Anticipated,2023-06-30,June 2022,Anticipated,2022-06-30,,Interventional,,,A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults,EHVA P01 (European HIV Vaccine Alliance Preventative Trial 01/ANRS VRI08) A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults,Unknown status,Not yet recruiting,Phase 1,70.0,Anticipated,"ANRS, Emerging Infectious Diseases",,3.0,,,False,,,,False,False,False,,,True,,,,,,,,2023-06-18 10:15:04,2023-06-18 10:15:04,OTHER_GOV,,,,,
181037,181038,NCT02586792,,2015-10-22,,2018-08-20,2018-08-20,2015-10-22,2015-10-26,Estimate,,,,2018-08-20,2018-08-22,Actual,2018-08-20,2018-08-22,Actual,"January 12, 2016",Actual,2016-01-12,April 2016,2016-04-30,"December 29, 2016",Actual,2016-12-29,"December 29, 2016",Actual,2016-12-29,,Interventional,,,H7N9 Boost in Healthy Adults,"Phase II, Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of a Single Intramuscular Dose of Inactivated Influenza A/H7N9 Vaccine After Priming With Inactivated Influenza A/H7N7 Vaccine",Completed,,Phase 2,27.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 19:36:37,2023-06-17 19:36:37,NIH,,,,,
181350,181351,NCT01668537,,2012-08-14,2020-09-15,,2020-10-09,2012-08-16,2012-08-20,Estimate,2020-10-09,2020-10-12,Actual,,,,2020-10-09,2020-10-12,Actual,March 2013,,2013-03-31,October 2020,2020-10-31,June 2014,Actual,2014-06-30,January 2014,Actual,2014-01-31,,Interventional,,Full Analysis Set,A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects,"A Randomized, Double-blind, Multicenter Phase II Trial to Compare the Immunogenicity and Safety of a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects",Completed,,Phase 2,651.0,Actual,Bavarian Nordic,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 10:16:18,2023-06-18 10:16:18,INDUSTRY,,,,,
181367,181368,NCT00709800,,2008-07-01,,,2009-02-11,2008-07-01,2008-07-03,Estimate,,,,,,,2009-02-11,2009-02-12,Estimate,August 2007,,2007-08-31,February 2009,2009-02-28,,,,September 2008,Actual,2008-09-30,,Interventional,,,Pandemic Influenza Plasmid DNA Vaccines (Needle),"A Phase 1, Double-Blinded Study to Evaluate the Safety, Tolerability, and Immunogenicity of Pandemic Influenza Plasmid DNA Vaccines",Completed,,Phase 1,56.0,Actual,Vical,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 12:12:44,2023-06-16 12:12:44,INDUSTRY,,,,,
181444,181445,NCT04838080,,2021-04-06,,,2021-04-10,2021-04-07,2021-04-08,Actual,,,,,,,2021-04-10,2021-04-13,Actual,"March 19, 2021",Actual,2021-03-19,April 2021,2021-04-30,"October 20, 2021",Anticipated,2021-10-20,"June 1, 2021",Anticipated,2021-06-01,,Interventional,,,Safety and Immunogenicity of the Inactivated Koçak-19 Inaktif Adjuvanli COVID-19 Vaccine Compared to Placebo,"Phase 1 Study for the Determination of Safety and Immunogenicity of Different Strengths of Koçak-19 Inaktif Adjuvanli COVID-19 Vaccine, Given Twice Intramuscularly to Healthy Volunteers, in a Placebo Controlled Study Design.",Unknown status,Recruiting,Phase 1,38.0,Anticipated,Kocak Farma,,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-17 19:38:18,2023-06-17 19:38:18,INDUSTRY,,,,,
181553,181554,NCT03276962,,2017-09-07,,,2023-01-24,2017-09-07,2017-09-08,Actual,,,,,,,2023-01-24,2023-01-25,Actual,"September 28, 2017",Actual,2017-09-28,January 2023,2023-01-31,"November 11, 2022",Actual,2022-11-11,"November 4, 2019",Actual,2019-11-04,,Interventional,,,"Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age","Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or With-out Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age",Completed,,Phase 2,1498.0,Actual,GlaxoSmithKline,,5.0,,,False,,,,,False,False,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-17 19:38:42,2023-06-17 19:38:42,INDUSTRY,,,,,
182356,182357,NCT03204617,,2017-06-13,,,2021-04-07,2017-06-29,2017-07-02,Actual,,,,,,,2021-04-07,2021-04-08,Actual,"July 7, 2017",Actual,2017-07-07,April 2021,2021-04-30,"March 10, 2021",Actual,2021-03-10,"July 1, 2020",Actual,2020-07-01,,Interventional,,,"Safety and Immunogenicity Study of DNA.HTI, MVA.HTI and ChAdOx1.HTI in HIV-1-positive Patients (AELIX-002)","A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines DNA.HTI, MVA.HTI and ChAdOx1.HTI in Early Treated HIV-1 Positive Individuals",Completed,,Phase 1,45.0,Actual,Aelix Therapeutics,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 10:20:52,2023-06-18 10:20:52,INDUSTRY,,,,,
182360,182361,NCT03204227,,2017-06-27,,,2018-09-14,2017-06-28,2017-06-29,Actual,,,,,,,2018-09-14,2018-09-17,Actual,"June 2, 2017",Actual,2017-06-02,September 2018,2018-09-30,"August 12, 2017",Actual,2017-08-12,"August 12, 2017",Actual,2017-08-12,,Interventional,JECEVAX-2B,,Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age,Evaluate the Safety of a Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) Produced by The Company for Vaccine and Biological Production No.1 in Vietnamese Children Aged 9-24 Months,Completed,,Phase 2,220.0,Actual,"National Institute of Hygiene and Epidemiology, Vietnam",,2.0,,,False,,,,True,False,False,,,,,,,,,No,"Individual data with identification removed are to be available for Ethical committee, Ministry of Health and National Foundation of Science and Technology Development to avoid misuse of data.

Public shared data will be in the form of summarised tables and figures.",2023-06-18 10:20:55,2023-06-18 10:20:55,OTHER,,,,,
182570,182571,NCT01094496,,2010-03-25,,2016-02-16,2020-02-10,2010-03-26,2010-03-29,Estimate,,,,2016-02-16,2016-03-15,Estimate,2020-02-10,2020-02-13,Actual,April 2010,,2010-04-30,February 2016,2016-02-29,July 2011,Actual,2011-07-31,July 2011,Actual,2011-07-31,,Interventional,,,"A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The ""N-ABLE"" Study)","A Phase II, Open-Label Study of the CDX-1307 Vaccine Regimen as Neoadjuvant and Adjuvant Therapy in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer Expressing hCG-ß",Terminated,,Phase 2,3.0,Actual,Celldex Therapeutics,,1.0,,Portfolio prioritization due to slow enrollment,False,,,,False,,,,,,,,,,,,,2023-06-17 19:44:33,2023-06-17 19:44:33,INDUSTRY,,,,,
182576,182577,NCT02266992,,2014-10-06,,,2016-03-18,2014-10-16,2014-10-17,Estimate,,,,,,,2016-03-18,2016-03-21,Estimate,September 2014,,2014-09-30,March 2016,2016-03-31,June 2015,Actual,2015-06-30,June 2015,Actual,2015-06-30,,Interventional,LAIV,,Exploring Novel Mechanisms of Vaccine Failure LAIV Pilot Study,Exploring Novel Mechanisms of Vaccine Failure and Induction of Pulmonary Immunity Following Live Attenuated Influenza Vaccination in HIV-infected Individuals: a Pilot Study.,Completed,,Phase 2,28.0,Actual,Sheffield Teaching Hospitals NHS Foundation Trust,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 19:44:38,2023-06-17 19:44:38,OTHER,,,,,
182627,182628,NCT04297917,,2020-02-28,,,2022-07-22,2020-03-03,2020-03-06,Actual,,,,,,,2022-07-22,2022-07-25,Actual,"February 10, 2019",Actual,2019-02-10,March 2022,2022-03-31,"May 26, 2022",Actual,2022-05-26,"May 26, 2022",Actual,2022-05-26,,Interventional,,,First in Human Study of ChAdOx1-HBV,"A Phase 1 Monotherapy Study to Evaluate the Safety, Tolerability & Immunogenicity of Vaccination With Candidate Chimpanzee Adenovirus-vectored HepB Virus Vaccine ChAdOx1 HBV in Healthy Participants & Participants With Chronic HepB Infection",Completed,,Phase 1,47.0,Actual,Vaccitech (UK) Limited,,6.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 10:22:20,2023-06-18 10:22:20,INDUSTRY,,,,,
182905,182906,NCT03467984,,2018-03-12,,,2019-08-21,2018-03-15,2018-03-16,Actual,,,,,,,2019-08-21,2019-08-22,Actual,"May 25, 2018",Actual,2018-05-25,August 2019,2019-08-31,"March 27, 2019",Actual,2019-03-27,"October 5, 2018",Actual,2018-10-05,,Interventional,,,A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants,"A Single-blind, Multi-center, Randomized, Active-controlled, Parallel Group, Phase II Study to Evaluate the Safety and Immunogenicity of Intramuscular Three Injections With LBVE(Multivalent Pneumococcal Conjugate Vaccine) Compared to Prevnar13 in Healthy Infants",Completed,,Phase 2,230.0,Actual,LG Chem,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-17 19:46:43,2023-06-17 19:46:43,INDUSTRY,,,,,
182928,182929,NCT00903552,,2009-05-14,,2013-07-16,2013-07-16,2009-05-15,2009-05-18,Estimate,,,,2013-07-16,2013-07-18,Estimate,2013-07-16,2013-07-18,Estimate,May 2009,,2009-05-31,July 2013,2013-07-31,October 2009,Actual,2009-10-31,October 2009,Actual,2009-10-31,,Interventional,,,Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant),"A Phase 2a Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of a Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant) in Healthy Adults",Completed,,Phase 2,221.0,Actual,Novavax,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 19:46:49,2023-06-17 19:46:49,INDUSTRY,,,,,
183029,183030,NCT05444530,,2022-06-30,,,2023-05-30,2022-06-30,2022-07-06,Actual,,,,,,,2023-05-30,2023-05-31,Actual,"July 21, 2022",Actual,2022-07-21,May 2023,2023-05-31,"July 1, 2027",Anticipated,2027-07-01,"January 16, 2026",Anticipated,2026-01-16,,Interventional,,,"A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms","A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms",Recruiting,,Phase 1,60.0,Anticipated,"Janssen Research & Development, LLC",,2.0,,,False,,,,False,True,False,,,,,,,,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2023-06-16 12:17:26,2023-06-16 12:17:26,INDUSTRY,,,,,
183106,183107,NCT03460730,,2018-02-20,,,2018-03-08,2018-03-02,2018-03-09,Actual,,,,,,,2018-03-08,2018-03-12,Actual,"November 4, 2004",Actual,2004-11-04,March 2018,2018-03-31,"July 3, 2006",Actual,2006-07-03,"July 3, 2006",Actual,2006-07-03,,Interventional,,,Dynamics of the Immune Response in Children to the 23-valent Pneumococcal Capsular Polysaccharide Vaccine (Pneumovax),Dynamics of the Immune Response in Children to the 23-valent Pneumococcal Capsular Polysaccharide Vaccine (Pneumovax),Completed,,Phase 1,100.0,Actual,KEMRI-Wellcome Trust Collaborative Research Program,,1.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-17 19:47:22,2023-06-17 19:47:22,OTHER,,,,,
183336,183337,NCT05238441,,2022-02-11,,,2022-02-14,2022-02-11,2022-02-14,Actual,,,,,,,2022-02-14,2022-03-02,Actual,"March 20, 2022",Anticipated,2022-03-20,February 2022,2022-02-28,"May 1, 2023",Anticipated,2023-05-01,"June 1, 2022",Anticipated,2022-06-01,,Interventional,,,A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged =18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine,"A Randomized, Double-blind, Positive-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E (A COVID-19 Alpha/Beta/Delta/Omicron Variants S-Trimer Vaccine) in Population Aged =18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine",Not yet recruiting,,Phase 2,360.0,Anticipated,Sinocelltech Ltd.,,3.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-17 21:30:36,2023-06-17 21:30:36,INDUSTRY,,,,,
183516,183517,NCT04745559,,2021-02-04,,,2023-04-17,2021-02-04,2021-02-09,Actual,,,,,,,2023-04-17,2023-04-19,Actual,"February 18, 2021",Actual,2021-02-18,April 2023,2023-04-30,February 2025,Anticipated,2025-02-28,February 2024,Anticipated,2024-02-29,,Interventional,,,Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy,Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination With Pneumococcal 13-valent Conjugate Vaccine Before and After CD19-targeted CAR T-cell Immunotherapy,Recruiting,,Phase 2,26.0,Anticipated,H. Lee Moffitt Cancer Center and Research Institute,,1.0,,,False,,,,True,True,False,,,True,,,,,,,,2023-06-18 10:26:16,2023-06-18 10:26:16,OTHER,,,,,
183605,183606,NCT04087460,,2019-09-10,,,2022-11-03,2019-09-10,2019-09-12,Actual,,,,,,,2022-11-03,2022-11-04,Actual,"April 10, 2020",Actual,2020-04-10,October 2022,2022-10-31,"June 30, 2022",Actual,2022-06-30,"May 30, 2021",Actual,2021-05-30,,Interventional,P<U+2160>CTPV,,Phase <U+2160>a Clinical Trial of a Pneumococcal Vaccine,"A Phase <U+2160>a Randomized,Double-Blind, Placebo-controlled Clinical Trial to Preliminary Evaluate the Safety and Immunogenicity of Protein Based Pneumococcal Vaccine(PBPV) in Healthy People Aged Between 18 and 49 Years Old",Completed,,Early Phase 1,120.0,Actual,CanSino Biologics Inc.,,6.0,,,False,,,,True,False,False,,,,,,,,,No,"In order to maintain the rights of the subject, do not open the IPD",2023-06-14 03:53:11,2023-06-14 03:53:11,INDUSTRY,,,,,
183688,183689,NCT04752644,,2021-02-09,,,2022-03-31,2021-02-09,2021-02-12,Actual,,,,,,,2022-03-31,2022-04-01,Actual,"February 22, 2021",Actual,2021-02-22,March 2022,2022-03-31,"November 2, 2021",Actual,2021-11-02,"June 17, 2021",Actual,2021-06-17,,Interventional,,,Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults,"A Phase 2a, Randomised, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Immunogenicity and Efficacy of the Recombinant MVA-BN®-RSV Vaccine Against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Participants",Completed,,Phase 2,73.0,Actual,Bavarian Nordic,,2.0,,,False,,,,False,False,False,,,False,,,,,,No,,2023-06-14 03:53:21,2023-06-14 03:53:21,INDUSTRY,,,,,
183752,183753,NCT02598388,,2015-11-04,2021-12-10,2019-12-11,2022-01-27,2015-11-04,2015-11-05,Estimate,2022-01-27,2022-02-18,Actual,2019-12-11,2019-12-13,Actual,2022-01-27,2022-02-18,Actual,"December 10, 2015",Actual,2015-12-10,January 2022,2022-01-31,"December 12, 2018",Actual,2018-12-12,"December 12, 2018",Actual,2018-12-12,,Interventional,,,"Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo","A Randomized, Observer-blind, Placebo-controlled, Two-part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo",Completed,,Phase 2,578.0,Actual,Janssen Vaccines & Prevention B.V.,,3.0,,,False,,,,True,,False,,,,,,,,,,,2023-06-17 19:50:03,2023-06-17 19:50:03,INDUSTRY,,,,,
183952,183953,NCT04398524,,2020-05-18,,,2023-04-11,2020-05-18,2020-05-21,Actual,,,,,,,2023-04-11,2023-04-12,Actual,"July 1, 2021",Actual,2021-07-01,April 2023,2023-04-30,"December 30, 2024",Anticipated,2024-12-30,"December 30, 2023",Anticipated,2023-12-30,,Interventional,,,A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC,"A Phase II Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients With Recurrent/Metastatic HPV16 Positive Oropharyngeal Cancer Who Have Experienced Disease Progression With Prior Anti-PD-1 Therapy",Recruiting,,Phase 2,86.0,Anticipated,ISA Pharmaceuticals,,1.0,,,,,,,True,True,False,,,,,,,,,,,2023-06-16 12:22:10,2023-06-16 12:22:10,INDUSTRY,,,,,
184112,184113,NCT00764634,,2008-09-30,,2011-06-29,2011-11-28,2008-09-30,2008-10-02,Estimate,,,,2011-06-29,2011-07-01,Estimate,2011-11-28,2011-12-02,Estimate,September 2008,,2008-09-30,November 2011,2011-11-30,December 2010,Actual,2010-12-31,March 2010,Actual,2010-03-31,,Interventional,,,"Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B","A Phase 2, Randomized, Double Blind, Placebo-Controlled, Multicenter Study to Evaluate Safety, Dosing Schedule and Antibody Kinetics of Recombinant Botulinum Vaccine A/B, rBV A/B-40, in Healthy Adults",Completed,,Phase 2,440.0,Actual,"DynPort Vaccine Company LLC, A GDIT Company",,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 19:52:03,2023-06-17 19:52:03,INDUSTRY,,,,,
184380,184381,NCT03438344,,2017-12-29,,,2018-11-19,2018-02-16,2018-02-19,Actual,,,,,,,2018-11-19,2018-11-21,Actual,December 2018,Anticipated,2018-12-31,November 2018,2018-11-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,,Interventional,,,Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant,"A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Protective Function of a CMV-MVA Triplex Vaccine in Recipients of a Haploidentical Hematopoietic Stem Cell Transplant",Withdrawn,,Phase 2,0.0,Actual,City of Hope Medical Center,,2.0,,PI Withdrawal,,,,,True,True,False,,,,,,,,,,,2023-06-17 19:53:10,2023-06-17 19:53:10,OTHER,,,,,
184384,184385,NCT04640402,,2020-11-19,,,2022-05-31,2020-11-20,2020-11-23,Actual,,,,,,,2022-05-31,2022-06-01,Actual,"November 17, 2020",Actual,2020-11-17,March 2022,2022-03-31,"November 23, 2021",Actual,2021-11-23,"February 18, 2021",Actual,2021-02-18,,Interventional,,,A Phase <U+2161> Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells),"A Single-center, Randomized, Double-Blinded, Placebo-Controlled, Phase <U+2161> Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells), in the Subjects From Healthy Aged 18 Years and Above",Completed,,Phase 2,960.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,16.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-17 19:53:13,2023-06-17 19:53:13,NETWORK,,,,,
184462,184463,NCT04530656,,2020-08-27,,,2022-05-31,2020-08-27,2020-08-28,Actual,,,,,,,2022-05-31,2022-06-01,Actual,"August 28, 2020",Actual,2020-08-28,March 2022,2022-03-31,"November 23, 2021",Actual,2021-11-23,"October 28, 2020",Actual,2020-10-28,,Interventional,,,Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell),"Safety, Tolerability and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell) in Chinese Healthy Population Aged 18 Years and Older: A Phase I, Single-center, Randomized, Placebo-controlled, Double-blind Study",Completed,,Phase 1,168.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,12.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-17 19:53:55,2023-06-17 19:53:55,NETWORK,,,,,
185014,185015,NCT01511250,,2011-11-16,2017-11-20,2016-11-29,2023-04-07,2012-01-17,2012-01-18,Estimate,2018-02-27,2018-03-27,Actual,2016-11-29,2016-11-30,Estimate,2023-04-07,2023-04-12,Actual,"November 16, 2011",Actual,2011-11-16,April 2023,2023-04-30,"April 15, 2016",Actual,2016-04-15,"April 1, 2016",Actual,2016-04-01,,Interventional,,The full analysis set (FAS) included all randomized participants who received at least one dose of study vaccine or placebo and for whom valid pre-dosing and at least one valid post-dosing blood sample have been received.,Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years,"A Double-Blind, Randomized, Placebo-Controlled, Age Descending and Expansion Phase 2 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years",Completed,,Phase 2,360.0,Actual,Takeda,,10.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-16 12:26:22,2023-06-16 12:26:22,INDUSTRY,,,,,
185481,185482,NCT02544880,,2015-09-04,,,2021-06-10,2015-09-04,2015-09-09,Estimate,,,,,,,2021-06-10,2021-06-15,Actual,"April 25, 2016",Actual,2016-04-25,June 2021,2021-06-30,"June 8, 2021",Actual,2021-06-08,"June 2, 2019",Actual,2019-06-02,,Interventional,,,PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC,"PDE5 Inhibition Via Tadalafil (Cialis®) to Enhance Anti-Tumor MUC1 Vaccine Efficacy in Patients With Resectable, and Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma (HNSCC): A Phase I/II Clinical Trial",Completed,,Phase 1,16.0,Actual,University of Miami,,5.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-16 12:28:02,2023-06-16 12:28:02,OTHER,,,,,
185704,185705,NCT05522829,,2022-08-30,,,2022-08-30,2022-08-30,2022-08-31,Actual,,,,,,,2022-08-30,2022-08-31,Actual,"October 15, 2022",Anticipated,2022-10-15,August 2022,2022-08-31,"December 15, 2023",Anticipated,2023-12-15,"December 15, 2022",Anticipated,2022-12-15,,Interventional,,,A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years,"A Randomized, Double-blind Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E-1 (Alpha/Beta/Delta/Omicron (BA.1/BA.4/BA.5) Variants S-Trimer COVID-19 Vaccine) in Population Aged 18 Years and Older",Not yet recruiting,,Phase 2,400.0,Anticipated,Sinocelltech Ltd.,,4.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-18 10:37:24,2023-06-18 10:37:24,INDUSTRY,,,,,
185719,185720,NCT05526183,,2022-08-31,,,2022-09-02,2022-08-31,2022-09-02,Actual,,,,,,,2022-09-02,2022-09-06,Actual,"January 21, 2022",Actual,2022-01-21,September 2022,2022-09-30,"March 1, 2023",Anticipated,2023-03-01,"December 30, 2022",Anticipated,2022-12-30,,Interventional,,,Phase I Clinical Trial With New SARS-CoV-2 CoVacHGMix Type 5 Adenoviral Vector Vaccine,Phase I Randomized Double-Blind Clinical Trial With New SARS-CoV-2 CoVacHGMix Type 5 Adenoviral Vector Vaccine in Healthy Volunteers Aged 18-45 Years,Recruiting,,Phase 1,36.0,Anticipated,Ankara City Hospital Bilkent,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 10:37:31,2023-06-18 10:37:31,OTHER,,,,,
186031,186032,NCT02140762,,2014-05-06,2016-02-11,2015-04-17,2018-08-10,2014-05-14,2014-05-16,Estimate,2018-05-17,2018-06-26,Actual,2015-04-17,2015-05-06,Estimate,2018-08-10,2018-09-12,Actual,May 2014,,2014-05-31,August 2018,2018-08-31,February 2015,Actual,2015-02-28,November 2014,Actual,2014-11-30,,Interventional,,,"Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents","A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolescents in the U.S.",Completed,,Phase 2,305.0,Actual,Novartis,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 10:39:23,2023-06-18 10:39:23,INDUSTRY,,,,,
186263,186264,NCT02046148,,2014-01-21,2017-01-31,2016-12-23,2020-12-07,2014-01-23,2014-01-27,Estimate,2017-04-20,2017-05-30,Actual,2016-12-23,2017-01-25,Estimate,2020-12-07,2020-12-29,Actual,"March 18, 2014",Actual,2014-03-18,December 2020,2020-12-31,"March 26, 2016",Actual,2016-03-26,"December 30, 2015",Actual,2015-12-30,,Interventional,,,Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women,"A Phase II, Multicenter, Randomized, Observer-Blind, Controlled Study to Evaluate Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women",Completed,,Phase 2,75.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,True,,,,,,,,IPD is available via the Clinical Study Data Request site (copy the URL below to your browser),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://www.clinicalstudydatarequest.com/Posting.aspx?ID=20751,Yes,IPD for this study is available via the Clinical Study Data Request site.,2023-06-18 10:41:48,2023-06-18 10:41:48,INDUSTRY,,,,,
186281,186282,NCT02419391,,2015-04-07,,,2016-08-09,2015-04-16,2015-04-17,Estimate,,,,,,,2016-08-09,2016-08-10,Estimate,August 2015,,2015-08-31,August 2016,2016-08-31,May 2016,Actual,2016-05-31,December 2015,Actual,2015-12-31,,Interventional,,,"Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine","A Randomized, Single-blind, Placebo-controlled Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine in Healthy Adult Subjects",Completed,,Phase 1,63.0,Actual,Bavarian Nordic,,3.0,,,False,,,,False,,,,,,,,,,,Undecided,,2023-06-18 10:42:00,2023-06-18 10:42:00,INDUSTRY,,,,,
186318,186319,NCT00848848,,2009-02-19,,,2016-05-05,2009-02-19,2009-02-20,Estimate,,,,,,,2016-05-05,2016-05-09,Estimate,October 2008,,2008-10-31,May 2016,2016-05-31,April 2009,Actual,2009-04-30,April 2009,Actual,2009-04-30,,Interventional,,,"Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older","A Phase Ib, Multi-Center, Randomized, Observer-Blind, Proof of Concept, Dose- and Formulation-Ranging Study to Evaluate Safety, Tolerability, and Immunogenicity of One Dose of Trivalent Inactivated Influenza Vaccine in Different Presentations (Intramuscular and Intradermal Delivery), Dosages (Regular or Higher A/H3N2 Content) and Doses of Adjuvant Administered to Healthy Elderly Aged = 65 Years",Completed,,Phase 1,450.0,Actual,Seqirus,,10.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 12:29:07,2023-06-16 12:29:07,INDUSTRY,,,,,
186493,186494,NCT00420732,,2007-01-08,,2014-05-28,2020-05-26,2007-01-08,2007-01-11,Estimate,,,,2014-05-28,2014-06-02,Estimate,2020-05-26,2020-05-28,Actual,January 2007,,2007-01-31,May 2020,2020-05-31,December 2014,Actual,2014-12-31,November 2012,Actual,2012-11-30,,Interventional,,,Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer,A Phase II Study of Tergenpumatucel-L (HyperAcute Lung) Cancer Vaccine in Subjects With Advanced Non-Small Cell Lung Cancer Who Responded to First Line Platinum-Doublet Treatment,Terminated,,Phase 2,6.0,Actual,Lumos Pharma,,1.0,,Enrollment goals unable to be reached.,False,,,,True,,,,,,,,,,,,,2023-06-17 20:03:03,2023-06-17 20:03:03,INDUSTRY,,,,,
186572,186573,NCT02067676,,2014-02-18,2017-03-29,,2018-01-29,2014-02-19,2014-02-20,Estimate,2017-06-19,2018-01-25,Actual,,,,2018-01-29,2018-02-23,Actual,"April 21, 2014",Actual,2014-04-21,January 2018,2018-01-31,"January 22, 2016",Actual,2016-01-22,"September 24, 2014",Actual,2014-09-24,,Interventional,CJCV1-01,,Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea,Safety and Immunogenicity Evaluation of an Intramuscular Capsule-Conjugate Campylobacter Vaccine (CJCV1),Completed,,Phase 1,48.0,Actual,U.S. Army Medical Research and Development Command,,6.0,,,False,,,,False,True,False,,,,,,,,,Yes,WRAIR,2023-06-18 10:44:24,2023-06-18 10:44:24,FED,,,,,
186766,186767,NCT00043511,,2002-08-09,,,2021-10-13,2002-08-09,2002-08-12,Estimate,,,,,,,2021-10-13,2021-10-14,Actual,,,,October 2021,2021-10-31,April 2003,Actual,2003-04-30,,,,,Interventional,,,Safety of an HIV DNA Vaccine Given to HIV Uninfected Adults,A Phase I Trial to Evaluate the Safety and Immunogenicity of the HIV-1 pGA2/JS2 Plasmid DNA Vaccine Given Intramuscularly (IM) in HIV-1 Uninfected Adults,Completed,,Phase 1,30.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 06:48:22,2023-06-15 06:48:22,NIH,,,,,
186908,186909,NCT02083887,,2014-02-28,,,2015-12-02,2014-03-06,2014-03-11,Estimate,,,,,,,2015-12-02,2015-12-03,Estimate,February 2014,,2014-02-28,December 2015,2015-12-31,November 2015,Actual,2015-11-30,November 2015,Actual,2015-11-30,,Interventional,VAC058,,A Phase I Study to Assess the Safety and Immunogenicity of ChAd63 ME-TRAP - MVA ME-TRAP Heterologous Prime-boost Vaccination Co-administered With EPI Vaccines in Gambian Infants,A Phase I Study to Assess the Safety and Immunogenicity of ChAd63 ME-TRAP - MVA ME-TRAP Heterologous Prime-boost Vaccination Co-administered With EPI Vaccines in Gambian Infants,Completed,,Phase 1,65.0,Actual,University of Oxford,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 20:05:16,2023-06-17 20:05:16,OTHER,,,,,
187280,187281,NCT02401373,,2015-03-24,,,2015-07-15,2015-03-26,2015-03-27,Estimate,,,,,,,2015-07-15,2015-07-16,Estimate,March 2015,,2015-03-31,July 2015,2015-07-31,July 2015,Actual,2015-07-31,July 2015,Actual,2015-07-31,,Interventional,,,A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China.,"A Phase 1, Dose-escalation, Open Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of the Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV) in Healthy Adult Africans Aged Between 18-60 Years in China",Completed,,Phase 1,61.0,Actual,First Affiliated Hospital of Zhejiang University,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 10:49:59,2023-06-18 10:49:59,OTHER,,,,,
187947,187948,NCT00074295,,2003-12-10,,,2012-07-20,2003-12-10,2003-12-11,Estimate,,,,,,,2012-07-20,2012-07-24,Estimate,March 2004,,2004-03-31,July 2012,2012-07-31,August 2007,Actual,2007-08-31,August 2007,Actual,2007-08-31,,Interventional,,,S0310: Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Bronchoalveolar Lung Cancer,"Phase II Trial of CG8123, an Autologous Cancer Vaccine (GVAX), in Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)",Terminated,,Phase 2,19.0,Actual,SWOG Cancer Research Network,,1.0,,closed due to lack of availability of vaccine,False,,,,True,,,,,,,,,,,,,2023-06-15 06:48:50,2023-06-15 06:48:50,NETWORK,,,,,
188589,188590,NCT02061423,,2014-02-10,,,2023-01-24,2014-02-11,2014-02-12,Estimate,,,,,,,2023-01-24,2023-01-26,Actual,"April 8, 2014",Actual,2014-04-08,January 2023,2023-01-31,December 2023,Anticipated,2023-12-31,February 2019,Actual,2019-02-28,,Interventional,Neoadjuvant,,HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy,Pilot Phase I HER-2 Pulsed DC Vaccine to Prevent Recurrence for Patients With HER-2 Driven High Risk Invasive Breast Cancer Post Neoadjuvant Chemotherapy,"Active, not recruiting",,Phase 1,7.0,Actual,H. Lee Moffitt Cancer Center and Research Institute,,1.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-18 11:00:08,2023-06-18 11:00:08,OTHER,,,,,
189068,189069,NCT05398796,,2022-05-27,,,2023-04-15,2022-05-31,2022-06-01,Actual,,,,,,,2023-04-15,2023-04-18,Actual,"July 11, 2022",Actual,2022-07-11,"April 14, 2023",2023-04-14,"June 24, 2024",Anticipated,2024-06-24,"June 24, 2024",Anticipated,2024-06-24,,Interventional,,,"Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults","VRC 322/DMID 21-0016: A Phase I, Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults",Recruiting,,Phase 1,50.0,Anticipated,National Institutes of Health Clinical Center (CC),,4.0,,,False,,,,,True,False,,,,,,,,,No,.Only aggregate data will be shared.,2023-06-17 20:13:27,2023-06-17 20:13:27,NIH,,,,,
189140,189141,NCT00389610,,2006-10-18,2022-08-09,,2023-01-20,2006-10-18,2006-10-19,Estimate,2022-08-09,2022-09-02,Actual,,,,2023-01-20,2023-01-25,Actual,"September 11, 2006",Actual,2006-09-11,January 2023,2023-01-31,"December 10, 2022",Actual,2022-12-10,"October 11, 2021",Actual,2021-10-11,,Interventional,,,Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer,A Safety and Efficacy Trial of Vaccine Boosting With Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected With the GM-CSF Gene for the Treatment of Pancreatic Adenocarcinoma,Completed,,Phase 2,56.0,Actual,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 03:59:56,2023-06-14 03:59:56,OTHER,,,,,
189356,189357,NCT02374385,,2015-01-06,,,2016-02-08,2015-02-23,2015-02-27,Estimate,,,,,,,2016-02-08,2016-02-09,Estimate,November 2014,,2014-11-30,February 2016,2016-02-29,June 2015,Actual,2015-06-30,March 2015,Actual,2015-03-31,,Interventional,VSV<U+0394>G-ZEBOV,,"Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine","A Phase 1 Randomized, Single-Center, Double-Blind, Placebo Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of the BPSC-1001 (VSV<U+0394>G-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Subjects",Completed,,Phase 1,40.0,Actual,Dalhousie University,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 11:06:04,2023-06-18 11:06:04,OTHER,,,,,
189503,189504,NCT00128011,,2005-08-08,,,2006-11-08,2005-08-08,2005-08-09,Estimate,,,,,,,2006-11-08,2006-11-10,Estimate,May 2005,,2005-05-31,November 2006,2006-11-30,June 2005,,2005-06-30,,,,,Interventional,,,"Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine","A Safety and Immunogenicity Study of a New Formulation of the Locally-Produced Bivalent Killed, Whole-Cell Oral Cholera Vaccine in Vietnamese Subjects",Completed,,Phase 2,150.0,,International Vaccine Institute,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 06:49:12,2023-06-15 06:49:12,OTHER,,,,,
189562,189563,NCT02362217,,2014-11-06,,,2018-10-10,2015-02-11,2015-02-12,Estimate,,,,,,,2018-10-10,2018-10-11,Actual,October 2014,Actual,2014-10-31,October 2018,2018-10-31,"October 31, 2017",Actual,2017-10-31,August 2016,Actual,2016-08-31,,Interventional,,,A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination,"A Phase I Study to Evaluate the Safety and Immunogenicity of Simultaneous Prime-Boost Immunisations With Candidate HCV and HIV-1 Vaccines, AdCh3NSmut1 / ChAdV63.HIVconsv and MVA-NSmut / MVA.HIVconsv, in Healthy Volunteers",Completed,,Phase 1,33.0,Actual,University of Oxford,,3.0,,,False,,,,True,,,,,,,,,,,Undecided,,2023-06-18 11:08:16,2023-06-18 11:08:16,OTHER,,,,,
189741,189742,NCT04866069,,2021-04-26,,,2023-04-17,2021-04-26,2021-04-29,Actual,,,,,,,2023-04-17,2023-04-18,Actual,"April 25, 2021",Actual,2021-04-25,April 2023,2023-04-30,"September 5, 2021",Actual,2021-09-05,"September 5, 2021",Actual,2021-09-05,,Interventional,COVID-19,,Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults,"Phase I Study Evaluating the Safety and Efficacy of the Protective Adjuvanted Inactivated Vaccine Developed Against SARS-CoV-2 in Healthy Participants, Administered as Two Injections Subcutaneously in Two Different Dosages.",Terminated,,Phase 1,50.0,Actual,The Scientific and Technological Research Council of Turkey,,3.0,,"Although cellular responses to virus were satisfactory, neutralizing titres against virus were lower then expected levels",False,,,,True,False,False,,,,,,,,,No,,2023-06-17 20:15:36,2023-06-17 20:15:36,OTHER,,,,,
189787,189788,NCT00718146,,2008-05-07,,,2014-01-16,2008-07-16,2008-07-18,Estimate,,,,,,,2014-01-16,2014-01-17,Estimate,June 2008,,2008-06-30,January 2014,2014-01-31,September 2008,Actual,2008-09-30,August 2008,Actual,2008-08-31,,Interventional,,,"Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation","Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation (Intramuscular Route)",Completed,,Phase 2,130.0,Actual,Sanofi,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 12:32:21,2023-06-16 12:32:21,INDUSTRY,,,,,
189877,189878,NCT04760743,,2021-02-17,,,2023-04-16,2021-02-17,2021-02-18,Actual,,,,,,,2023-04-16,2023-04-18,Actual,"December 17, 2020",Actual,2020-12-17,April 2023,2023-04-30,"March 2, 2022",Actual,2022-03-02,"April 2, 2021",Actual,2021-04-02,,Interventional,,,Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19),"A Phase I, Placebo-controlled, Randomized, Observer-blinded, Dose-escalation Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults Aged at 19 to 55 Years",Completed,,Phase 1,50.0,Actual,"SK Bioscience Co., Ltd.",,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-17 20:15:55,2023-06-17 20:15:55,INDUSTRY,,,,,
190095,190096,NCT04701021,,2021-01-05,,,2023-04-17,2021-01-07,2021-01-08,Actual,,,,,,,2023-04-17,2023-04-18,Actual,"February 17, 2021",Actual,2021-02-17,April 2023,2023-04-30,"December 31, 2023",Anticipated,2023-12-31,"July 31, 2023",Anticipated,2023-07-31,,Interventional,,,TENDU Vaccine in Patients With Relapse After Primary Radical Prostatectomy,"Safety and Effect of Different Doses of TENDU Vaccine, a Therapeutic Peptide Conjugate Vaccine, in Patients With Relapse After Primary Radical Prostatectomy","Active, not recruiting",,Phase 1,12.0,Actual,Ultimovacs ASA,,1.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-17 20:16:07,2023-06-17 20:16:07,INDUSTRY,,,,,
190236,190237,NCT02330003,,2014-12-29,,,2014-12-30,2014-12-30,2015-01-01,Estimate,,,,,,,2014-12-30,2015-01-01,Estimate,May 2013,,2013-05-31,December 2014,2014-12-31,August 2013,Actual,2013-08-31,August 2013,Actual,2013-08-31,,Interventional,,,Phase 1 Study to Assess the Safety of Inactivated Split Influenza Vaccine and Control Vaccine in Korean Volunteer,"A Randomized, Active-Comparator, Open-Label, Phase 1 Clinical Trial to Assess the Safety of the 'IL-YANG Inactivated Split Influenza Vaccine' and Fluarix Prefilled Syringe in Healthy Korean Male Volunteer",Completed,,Phase 1,100.0,Actual,"Il-Yang Pharm. Co., Ltd.",,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 11:14:31,2023-06-18 11:14:31,INDUSTRY,,,,,
190393,190394,NCT03191383,,2017-06-15,,,2018-10-12,2017-06-15,2017-06-19,Actual,,,,,,,2018-10-12,2018-10-15,Actual,"July 11, 2017",Actual,2017-07-11,October 2018,2018-10-31,"July 14, 2017",Actual,2017-07-14,"July 14, 2017",Actual,2017-07-14,,Interventional,,,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers","An Observer-blind Study to Assess the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Pregnant Women and Infants Born to Vaccinated Mothers",Withdrawn,,Phase 2,0.0,Actual,GlaxoSmithKline,,8.0,,Study was canceled due to instability of the PreF antigen during manufacturing. No safety concern has been identified in past or ongoing studies.,False,,,,,True,False,,,,,,,,,Yes,Patient-level data for this study will be made available through https://www.clinicalstudydatarequest.com/ following the timelines and process described on this site.,2023-06-18 11:16:13,2023-06-18 11:16:13,INDUSTRY,,,,,
190396,190397,NCT02332733,,2015-01-06,,,2018-12-04,2015-01-06,2015-01-07,Estimate,,,,,,,2018-12-04,2018-12-05,Actual,November 2014,,2014-11-30,December 2018,2018-12-31,"October 26, 2018",Actual,2018-10-26,"October 26, 2018",Actual,2018-10-26,,Interventional,,,"Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand","Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Immunogenicity of Two Doses of the LID/NIAID Live-Attenuated Tetravalent Dengue Vaccine, TV003, Administered Six Months Apart, to Healthy Adults, Adolescents, and Children in Thailand",Completed,,Phase 2,266.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 11:16:15,2023-06-18 11:16:15,NIH,,,,,
191081,191082,NCT03137927,,2017-04-25,,,2017-12-27,2017-04-28,2017-05-03,Actual,,,,,,,2017-12-27,2017-12-28,Actual,"June 13, 2017",Actual,2017-06-13,April 2017,2017-04-30,"December 27, 2017",Actual,2017-12-27,"December 19, 2017",Actual,2017-12-19,,Interventional,,,"A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine","A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine; A Randomized Placebo-controlled Dose-escalating Study of Single-use GamLPV Safety and Tolerability in Healthy Human Volunteers",Completed,,Phase 1,36.0,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,6.0,,,False,,,,True,False,False,,,,,,,,,Undecided,,2023-06-18 11:22:43,2023-06-18 11:22:43,OTHER,,,,,
191136,191137,NCT04248569,,2020-01-28,,,2023-04-13,2020-01-28,2020-01-30,Actual,,,,,,,2023-04-13,2023-04-18,Actual,"April 20, 2020",Actual,2020-04-20,April 2023,2023-04-30,"March 1, 2027",Anticipated,2027-03-01,"March 1, 2027",Anticipated,2027-03-01,,Interventional,,,DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma,A Pilot Study of a DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma,Recruiting,,Phase 1,56.0,Anticipated,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,1.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 20:17:43,2023-06-17 20:17:43,OTHER,,,,,
191512,191513,NCT05054621,,2021-09-13,,,2021-10-19,2021-09-22,2021-09-23,Actual,,,,,,,2021-10-19,2021-10-26,Actual,"September 15, 2021",Actual,2021-09-15,August 2021,2021-08-31,"August 31, 2022",Anticipated,2022-08-31,"August 31, 2022",Anticipated,2022-08-31,,Interventional,,,Immunogenicity of COVID-19 Vaccine on Heterologous Schedule,"A Single-blind, Randomized Study to Evaluate the Immunogenicity of Heterologous Prime-boost COVID-19 Vaccine Schedule",Recruiting,,Phase 2,110.0,Anticipated,Chang Gung Memorial Hospital,,2.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-18 11:27:26,2023-06-18 11:27:26,OTHER,,,,,
191639,191640,NCT03888989,,2019-03-20,,,2023-04-17,2019-03-22,2019-03-25,Actual,,,,,,,2023-04-17,2023-04-18,Actual,"September 30, 2019",Actual,2019-09-30,April 2023,2023-04-30,December 2023,Anticipated,2023-12-31,December 2023,Anticipated,2023-12-31,,Interventional,FLU-PG,,Response to Influenza Vaccine During Pregnancy,Response to Influenza Vaccine During Pregnancy,Recruiting,,Phase 1,50.0,Anticipated,Stanford University,,1.0,,,False,,,,False,True,False,,,True,,,,,,No,,2023-06-17 20:18:37,2023-06-17 20:18:37,OTHER,,,,,
191649,191650,NCT00861406,,2009-03-12,,,2017-02-28,2009-03-12,2009-03-13,Estimate,,,,,,,2017-02-28,2017-03-03,Actual,"March 10, 2009",Actual,2009-03-10,February 2017,2017-02-28,"February 24, 2017",Actual,2017-02-24,"February 24, 2017",Actual,2017-02-24,,Interventional,,,Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine,"An Exploratory Study of Adjuvant Therapy of Pegylated Interferon-Alfa 2b Plus Melanoma Peptide Vaccine in Patients With Resected Stage II and III (N1a, N2a) Melanoma",Completed,,Phase 1,38.0,Actual,M.D. Anderson Cancer Center,,3.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-16 12:33:37,2023-06-16 12:33:37,OTHER,,,,,
191760,191761,NCT03196661,,2017-05-19,,,2017-06-20,2017-06-20,2017-06-23,Actual,,,,,,,2017-06-20,2017-06-23,Actual,"November 6, 2015",Actual,2015-11-06,May 2017,2017-05-31,"March 23, 2017",Actual,2017-03-23,"July 5, 2016",Actual,2016-07-05,,Interventional,,,Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population,Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population,Completed,,Phase 1,588.0,Actual,Hualan Biological Bacterin Co. Ltd.,,4.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-18 11:29:05,2023-06-18 11:29:05,INDUSTRY,,,,,
191927,191928,NCT04786457,,2020-11-24,,,2021-10-27,2021-03-03,2021-03-08,Actual,,,,,,,2021-10-27,2021-10-28,Actual,"November 30, 2020",Actual,2020-11-30,October 2021,2021-10-31,"July 9, 2021",Actual,2021-07-09,"July 9, 2021",Actual,2021-07-09,,Interventional,,,ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC),"A Phase 1, Open-Label Clinical Trial With Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC) Assessment of Healthy U.S. Adults Previously Primed With Tetravalent Dengue Virus Purified Inactivated Vaccine (TDEN-PIV) and Boosted With Tetravalent Dengue Virus Live Attenuated Vaccine Formulation (TDEN LAV)",Completed,,Phase 1,17.0,Actual,"University of Maryland, Baltimore",,1.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-18 11:30:53,2023-06-18 11:30:53,OTHER,,,,,
192081,192082,NCT03312699,,2017-10-12,,,2023-04-17,2017-10-12,2017-10-18,Actual,,,,,,,2023-04-17,2023-04-18,Actual,"September 19, 2017",Actual,2017-09-19,April 2023,2023-04-30,December 2023,Anticipated,2023-12-31,December 2023,Anticipated,2023-12-31,,Interventional,SLVP033,,Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort,Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort,"Active, not recruiting",,Phase 1,54.0,Actual,Stanford University,,8.0,,,False,,,,False,True,False,,,False,,,De-identified data will be loaded into ImmPort following completion of all data analysis,De-identified data will be publicly available through ImmPort,,Yes,The NIH Human Immunology Project Consortium (HIPC) data repositories (ImmPORT) may store the results of the research assays results. Genetic data that is developed in this study may be made available to other researchers through the National Center for Biotechnology Information (NCBI) databases. Results from research assays will be labeled with a unique identification code and the volunteer identity (except for age) will not be disclosed.,2023-06-17 20:19:41,2023-06-17 20:19:41,OTHER,,,,,
192209,192210,NCT03219450,,2017-07-06,,,2023-04-17,2017-07-13,2017-07-17,Actual,,,,,,,2023-04-17,2023-04-18,Actual,"August 18, 2021",Actual,2021-08-18,April 2023,2023-04-30,"March 31, 2028",Anticipated,2028-03-31,"March 31, 2026",Anticipated,2026-03-31,,Interventional,,,"A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.","A Pilot Study of a Personalized Neoantigen Cancer Vaccine With and Without Low-Dose Cyclophosphamide or Pembrolizumab in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated Chronic Lymphocytic Leukemia.",Recruiting,,Phase 1,15.0,Anticipated,Dana-Farber Cancer Institute,,3.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 20:19:48,2023-06-17 20:19:48,OTHER,,,,,
192261,192262,NCT05897190,,2023-05-28,,,2023-06-12,2023-05-31,2023-06-09,Actual,,,,,,,2023-06-12,2023-06-13,Estimate,"May 16, 2022",Actual,2022-05-16,June 2023,2023-06-30,November 2023,Anticipated,2023-11-30,"August 20, 2022",Actual,2022-08-20,,Interventional,,,Evaluate the Safety and Preliminary Immunogenicity of a SARS-CoV-2 mRNA Vaccine in Adults,Evaluate the Safety and Preliminary Immunogenicity of a SARS-CoV-2 mRNA Vaccine (RBMRNA) as a Booster Dose in Adults,"Active, not recruiting",,Phase 1,60.0,Actual,"Argorna Pharmaceuticals Co., LTD",,4.0,,,False,,,,,False,False,,,,,,,,,No,,2023-06-14 04:13:24,2023-06-14 04:13:24,INDUSTRY,,,,,
192367,192368,NCT03167593,,2017-05-23,,,2017-05-24,2017-05-24,2017-05-30,Actual,,,,,,,2017-05-24,2017-05-30,Actual,"October 1, 2015",,2015-10-01,May 2017,2017-05-31,"April 30, 2016",Actual,2016-04-30,"January 7, 2016",Actual,2016-01-07,,Interventional,,,Effects of Lactobacillus Coryniformis CECT5711 on Immune Response to Influenza Vaccination in Adults Over 65.,Evaluation of the Effects of Consumption of the Probiotic Strain Lactobacillus Coryniformis CECT5711 on the Immune Response to Influenza Vaccine in Adults Over 65 Years of Age.,Completed,,Phase 2,98.0,Actual,Biosearch S.A.,,2.0,,,False,,,,,,,,,,,,,,,No,,2023-06-18 11:34:51,2023-06-18 11:34:51,INDUSTRY,,,,,
192420,192421,NCT04569383,,2020-09-21,,,2021-11-04,2020-09-28,2020-09-29,Actual,,,,,,,2021-11-04,2021-11-05,Actual,"October 5, 2020",Actual,2020-10-05,November 2021,2021-11-30,"August 24, 2021",Actual,2021-08-24,"August 24, 2021",Actual,2021-08-24,,Interventional,,,Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19,"An Open, Single-center Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-SARS-2-S and Heterologous Booster Vaccinations With a Licensed Vaccine Against COVID-19",Completed,,Phase 1,30.0,Actual,Universitätsklinikum Hamburg-Eppendorf,,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 11:35:13,2023-06-18 11:35:13,OTHER,,,,,
192591,192592,NCT03416036,,2018-01-24,,,2020-01-15,2018-01-24,2018-01-30,Actual,,,,,,,2020-01-15,2020-01-18,Actual,"November 28, 2017",Actual,2017-11-28,January 2020,2020-01-31,"June 4, 2019",Actual,2019-06-04,"January 17, 2019",Actual,2019-01-17,,Interventional,,,Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge,Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge,Completed,,Phase 1,64.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-17 20:21:55,2023-06-17 20:21:55,NIH,,,,,
192601,192602,NCT01986010,,2013-11-11,2021-09-30,,2021-09-30,2013-11-11,2013-11-18,Estimate,2021-09-30,2021-11-01,Actual,,,,2021-09-30,2021-11-01,Actual,"November 25, 2013",Actual,2013-11-25,September 2021,2021-09-30,"March 14, 2017",Actual,2017-03-14,"April 19, 2016",Actual,2016-04-19,,Interventional,,,"Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)","A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults",Completed,,Phase 1,190.0,Actual,Merck Sharp & Dohme LLC,,17.0,,,False,,,,False,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2023-06-18 11:36:19,2023-06-18 11:36:19,INDUSTRY,,,,,
192987,192988,NCT04523246,,2020-08-20,,,2021-12-07,2020-08-20,2020-08-21,Actual,,,,,,,2021-12-07,2021-12-23,Actual,"September 1, 2020",Actual,2020-09-01,December 2021,2021-12-31,"September 30, 2022",Anticipated,2022-09-30,"November 30, 2021",Actual,2021-11-30,,Interventional,NH-Shingrix,,Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents,"Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents: A Randomized, Doubled-Blinded, Comparative Group Observational Study","Active, not recruiting",,Early Phase 1,217.0,Actual,University of Oklahoma,,2.0,,,False,,,,False,True,False,,,True,,,,,,No,,2023-06-17 20:24:01,2023-06-17 20:24:01,OTHER,,,,,
193203,193204,NCT02004262,,2013-10-23,2018-03-09,,2018-05-02,2013-12-06,2013-12-09,Estimate,2018-04-04,2018-05-03,Actual,,,,2018-05-02,2018-06-04,Actual,"February 5, 2014",Actual,2014-02-05,May 2018,2018-05-31,"August 23, 2016",Actual,2016-08-23,January 2016,Actual,2016-01-31,,Interventional,ECLIPSE,Baseline analysis provided for all randomized subjects who were administered at least 1 dose of protocol-specified drug (the Full Analysis Set [FAS]).,Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting,"A Phase 2B, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS 207 Compared to Chemotherapy or to CRS-207 Alone in Adults With Previously-Treated Metastatic Pancreatic Adenocarcinoma",Completed,,Phase 2,303.0,Actual,"Aduro Biotech, Inc.",,6.0,,,False,,,,,,,,,,,,,,,,,2023-06-18 11:39:30,2023-06-18 11:39:30,INDUSTRY,,,,,
193215,193216,NCT04690426,,2020-12-15,,,2022-07-20,2020-12-27,2020-12-30,Actual,,,,,,,2022-07-20,2022-07-25,Actual,"December 14, 2020",Actual,2020-12-14,July 2022,2022-07-31,"December 7, 2021",Actual,2021-12-07,"December 7, 2021",Actual,2021-12-07,,Interventional,PROVENT,,PROtocol for Coxsackievirus VaccinE in Healthy VoluNTteers,"A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of PRV-101, a Coxsackie Virus B (CVB) Vaccine, in Healthy Adult Subjects",Completed,,Phase 1,32.0,Actual,"Provention Bio, Inc.",,4.0,,,False,,,,True,False,False,,,False,,,,,,No,,2023-06-17 20:25:12,2023-06-17 20:25:12,INDUSTRY,,,,,
193361,193362,NCT00617344,,2008-02-06,2019-05-21,2011-02-15,2019-05-21,2008-02-06,2008-02-18,Estimate,2019-05-21,2019-06-11,Actual,2011-02-15,2011-02-18,Estimate,2019-05-21,2019-06-11,Actual,"April 17, 2008",Actual,2008-04-17,May 2019,2019-05-31,February 2010,Actual,2010-02-28,December 2009,Actual,2009-12-31,,Interventional,,The Full Analysis Set (FAS) included all the participants enrolled in the trial who received at least 1 injection of CYD Dengue Vaccine and had any valid immunogenicity result.,Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US,Immunogenicity and Safety of Three Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Adults Aged 18 to 45 Years in the US,Completed,,Phase 2,260.0,Actual,Sanofi,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 12:36:14,2023-06-16 12:36:14,INDUSTRY,,,,,
193368,193369,NCT05475106,,2022-07-22,,,2022-07-22,2022-07-22,2022-07-26,Actual,,,,,,,2022-07-22,2022-07-26,Actual,"May 12, 2022",Actual,2022-05-12,July 2022,2022-07-31,"May 20, 2024",Anticipated,2024-05-20,"November 25, 2023",Anticipated,2023-11-25,,Interventional,,,Pilot Study of Neoantigen Peptides and Leukine for the Treatment of Neoplasms,Pilot Study of Personalized Neoantigen Peptide Vaccines and Leukine for the Treatment of Neoplasms,Recruiting,,Early Phase 1,100.0,Anticipated,Instituto de Medicina Regenerativa,,1.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-17 20:25:41,2023-06-17 20:25:41,INDUSTRY,,,,,
193803,193804,NCT02676895,,2016-02-01,2018-03-09,,2018-10-08,2016-02-03,2016-02-08,Estimate,2018-10-08,2019-02-18,Actual,,,,2018-10-08,2019-02-18,Actual,"August 8, 2016",Actual,2016-08-08,October 2018,2018-10-31,"March 10, 2017",Actual,2017-03-10,"March 10, 2017",Actual,2017-03-10,,Interventional,,,A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults,"A Phase 2a, Observer Blind, Randomized, Controlled, Single Center Study To Evaluate The Safety, Reactogenicity And Immunogenicity Of 2 Doses Of The GVGH 1790GAHB Vaccine Against Shigella Sonnei, Administered Intramuscularly In Adult Subjects From A Country Endemic For Shigellosis",Completed,,Phase 2,74.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,True,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-18 11:43:51,2023-06-18 11:43:51,INDUSTRY,,,,,
193817,193818,NCT02950766,,2016-09-08,,,2023-01-12,2016-10-28,2016-11-01,Estimate,,,,,,,2023-01-12,2023-01-13,Actual,"March 3, 2019",Actual,2019-03-03,January 2023,2023-01-31,"September 30, 2026",Anticipated,2026-09-30,"December 31, 2024",Anticipated,2024-12-31,,Interventional,,,NeoVax Plus Ipilimumab in Renal Cell Carcinoma,"A Phase I Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma",Recruiting,,Phase 1,19.0,Anticipated,Dana-Farber Cancer Institute,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-16 12:37:01,2023-06-16 12:37:01,OTHER,,,,,
193845,193846,NCT05128721,,2021-11-12,,,2021-11-18,2021-11-18,2021-11-22,Actual,,,,,,,2021-11-18,2021-11-22,Actual,"November 14, 2021",Actual,2021-11-14,November 2021,2021-11-30,"May 23, 2023",Anticipated,2023-05-23,"February 23, 2023",Anticipated,2023-02-23,,Interventional,,,Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19),"A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Inactivated Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Vaccine Against COVID-19 in Healthy Adults",Recruiting,,Phase 1,72.0,Anticipated,"National Research Centre, Egypt",,3.0,,,False,,,,True,False,False,,,,,,About one year after completion of the trial,Data will be shared upon individual request by contacting the sponsor of the trial.,,Yes,Data will be shared upon individual request.,2023-06-18 11:44:04,2023-06-18 11:44:04,OTHER,,,,,
193909,193910,NCT05367843,,2022-05-02,,,2023-03-27,2022-05-09,2022-05-10,Actual,,,,,,,2023-03-27,2023-03-30,Actual,"June 20, 2022",Actual,2022-06-20,March 2023,2023-03-31,June 2024,Anticipated,2024-06-30,July 2023,Anticipated,2023-07-31,,Interventional,,,"A Study Assessing the Safety, Tolerability, Immunogenicity of COVID-19 Vaccine Candidate PRIME-2-CoV_Beta, Orf Virus Expressing SARS-CoV_2 Spike and Nucleocapsid Proteins","A Phase 1, Dose Ranging Study Assessing the Safety, Tolerability, Immunogenicity of Vaccine Candidate PRIME-2-CoV_Beta, Orf Virus Expressing SARS-CoV-2 Spike and Nucleocapsid Proteins (ORFEUS Study)",Recruiting,,Phase 1,110.0,Anticipated,Speransa Therapeutics,,3.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-17 20:28:25,2023-06-17 20:28:25,INDUSTRY,,,,,
193970,193971,NCT00727428,,2008-08-01,,,2017-05-05,2008-08-01,2008-08-04,Estimate,,,,,,,2017-05-05,2017-05-08,Actual,"August 5, 2008",Actual,2008-08-05,May 2017,2017-05-31,"February 17, 2009",Actual,2009-02-17,"August 29, 2008",Actual,2008-08-29,,Interventional,,,Immunogenicity and Safety of GSK Biologicals' FluLaval® TF,"Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral®, Thimerosal-free (FluLaval® TF), in Adults 18 to 60 Years of Age.",Completed,,Phase 1,110.0,Actual,GlaxoSmithKline,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 12:37:14,2023-06-16 12:37:14,INDUSTRY,,,,,
194091,194092,NCT04439695,,2020-06-17,,,2021-09-14,2020-06-17,2020-06-19,Actual,,,,,,,2021-09-14,2021-09-16,Actual,"June 25, 2020",Actual,2020-06-25,September 2021,2021-09-30,"July 28, 2021",Actual,2021-07-28,"February 25, 2021",Actual,2021-02-25,,Interventional,,,Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults,"A Phase 1, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults",Completed,,Phase 1,120.0,Actual,KBio Inc,,4.0,,,False,,,,True,True,False,,,,,,,,,No,Plan is to share study data by dosing group in publications,2023-06-18 11:45:20,2023-06-18 11:45:20,INDUSTRY,,,,,
194280,194281,NCT04725877,,2021-01-08,,,2023-02-24,2021-01-21,2021-01-27,Actual,,,,,,,2023-02-24,2023-02-27,Actual,"December 28, 2020",Actual,2020-12-28,February 2023,2023-02-28,"December 5, 2022",Actual,2022-12-05,"December 5, 2022",Actual,2022-12-05,,Interventional,,,VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers,"A Phase 1a, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers",Completed,,Phase 1,27.0,Actual,"Vir Biotechnology, Inc.",,2.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-18 11:46:26,2023-06-18 11:46:26,INDUSTRY,,,,,
194313,194314,NCT05796505,,2023-03-21,,,2023-06-09,2023-03-21,2023-04-03,Actual,,,,,,,2023-06-09,2023-06-13,Estimate,"August 7, 2023",Anticipated,2023-08-07,June 2023,2023-06-30,"June 30, 2026",Anticipated,2026-06-30,"June 30, 2026",Anticipated,2026-06-30,,Interventional,,,Addressing Vaccine Acceptance in Carceral Settings Through Community Engagement,Addressing Vaccine Acceptance in Carceral Settings Through Community Engagement,Not yet recruiting,,Phase 2,37122.0,Anticipated,Yale University,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-14 04:14:26,2023-06-14 04:14:26,OTHER,,,,,
194744,194745,NCT05874713,,2023-05-04,,,2023-06-08,2023-05-15,2023-05-25,Actual,,,,,,,2023-06-08,2023-06-12,Actual,"June 7, 2023",Actual,2023-06-07,June 2023,2023-06-30,October 2024,Anticipated,2024-10-31,May 2024,Anticipated,2024-05-31,,Interventional,,,Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults,"A Phase 2, Multi-Center, Randomized, Observer-Blind Study, to Evaluate Safety and Immunogenicity of Homologous or Heterologous Priming and Booster Vaccinations With H5N8 or H5N6 MF59-adjuvanted, Cell Culture-derived Influenza Vaccine in Healthy Subjects =18 Years of Age",Recruiting,,Phase 2,480.0,Anticipated,Seqirus,,3.0,,,False,,,,False,True,False,,,,,,,,,Undecided,,2023-06-18 11:49:51,2023-06-18 11:49:51,INDUSTRY,,,,,
194778,194779,NCT00080106,,2004-03-23,,2009-08-12,2021-11-04,2004-03-24,2004-03-25,Estimate,,,,2009-08-12,2009-08-14,Estimate,2021-11-04,2021-11-09,Actual,June 2004,,2004-06-30,July 2013,2013-07-31,May 2011,Actual,2011-05-31,September 2007,Actual,2007-09-30,,Interventional,,,Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients,"A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Antiretroviral Effect of Immunization With the MRK Ad5 HIV-1 Gag Vaccine in HIV-1 Infected Individuals Who Interrupt Antiretroviral Therapy",Completed,,Phase 2,114.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 20:31:02,2023-06-17 20:31:02,NIH,,,,,
194853,194854,NCT05734040,,2023-02-09,,,2023-06-09,2023-02-09,2023-02-17,Actual,,,,,,,2023-06-09,2023-06-12,Actual,"May 10, 2023",Actual,2023-05-10,June 2023,2023-06-30,"December 15, 2023",Anticipated,2023-12-15,"July 15, 2023",Anticipated,2023-07-15,,Interventional,,,"Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.","Phase 2a, Randomized, Double-blind (Double-dummy), Double Placebo-controlled, Parallel-group Study to Evaluate the Immunogenicity and the Safety of the Concomitant Administration of OVX836 Influenza Vaccine and Quadrivalent Inactivated Influenza Vaccines (QIVs: Fluarix Tetra and Afluria Quad) Given Intramuscularly as 2 Separate Injections Into Opposite Arms, in Comparison to the Concomitant Administration of Quadrivalent Inactivated Influenza Vaccines and Placebo, and OVX836 and Placebo Given the Same Way in Healthy Subjects Aged 18 to 60 Years.",Recruiting,,Phase 2,600.0,Anticipated,Osivax,,6.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-18 11:50:30,2023-06-18 11:50:30,INDUSTRY,,,,,
194973,194974,NCT00730782,,2008-08-06,,,2008-08-07,2008-08-07,2008-08-08,Estimate,,,,,,,2008-08-07,2008-08-08,Estimate,November 2005,,2005-11-30,August 2008,2008-08-31,August 2008,Actual,2008-08-31,September 2007,Actual,2007-09-30,,Interventional,,,Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers,"Assessment of the Safety and Immunogenicity of Three Formulations of the Recombinant Pichia Pastoris Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545]), Blood-Stage Malaria Vaccine in Healthy Dutch Adult Volunteers : a Phase 1, Single- Blind, Randomised, Dose-Escalating, Unicentre Trial",Completed,,Phase 1,56.0,Actual,European Malaria Vaccine Initiative,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 12:39:20,2023-06-16 12:39:20,OTHER,,,,,
195081,195082,NCT05469802,,2022-07-20,,,2023-06-08,2022-07-20,2022-07-22,Actual,,,,,,,2023-06-08,2023-06-12,Actual,"October 13, 2023",Anticipated,2023-10-13,June 2023,2023-06-30,"July 5, 2024",Anticipated,2024-07-05,"July 5, 2024",Anticipated,2024-07-05,,Interventional,,,A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults,"A Randomized, Observer-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Immunogenicity of the Purified Inactivated Zika Virus Vaccine (PIZV) Administered on Days 1 and 29 in Healthy Participants Aged 18 to 49 Years in the US",Not yet recruiting,,Phase 2,78.0,Anticipated,Takeda,,2.0,,,False,,,,True,True,False,,,False,,,,"IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.",https://vivli.org/ourmember/takeda/,Yes,"Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.",2023-06-18 11:51:44,2023-06-18 11:51:44,INDUSTRY,,,,,
195327,195328,NCT00735020,,2008-08-13,,,2014-01-23,2008-08-13,2008-08-14,Estimate,,,,,,,2014-01-23,2014-01-24,Estimate,June 2008,,2008-06-30,January 2014,2014-01-31,August 2008,Actual,2008-08-31,August 2008,Actual,2008-08-31,,Interventional,,,"Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza Vaccines","A Phase I, Observer-Blind, Randomized, Single-Center Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza Vaccines in Healthy Adults Aged 18 to 39 Years.",Completed,,Phase 1,72.0,Actual,Novartis,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 12:40:14,2023-06-16 12:40:14,INDUSTRY,,,,,
195537,195538,NCT03878121,,2019-03-15,,,2023-06-09,2019-03-15,2019-03-18,Actual,,,,,,,2023-06-09,2023-06-12,Actual,"April 17, 2019",Actual,2019-04-17,"June 8, 2023",2023-06-08,"April 15, 2024",Anticipated,2024-04-15,"April 15, 2024",Anticipated,2024-04-15,,Interventional,,,Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers,Phase I Open-Label Study of Safety and Immunogenicity of AD4-HIV Envelope Vaccine Vectors in Healthy Volunteers,Recruiting,,Phase 1,300.0,Anticipated,National Institutes of Health Clinical Center (CC),,4.0,,,False,,,,,True,False,,,,,,,,,No,,2023-06-18 11:55:47,2023-06-18 11:55:47,NIH,,,,,
195611,195612,NCT03223103,,2017-07-18,,,2023-06-09,2017-07-18,2017-07-19,Actual,,,,,,,2023-06-09,2023-06-12,Actual,"March 1, 2018",Actual,2018-03-01,June 2023,2023-06-30,May 2024,Anticipated,2024-05-31,"July 31, 2020",Actual,2020-07-31,,Interventional,,,Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma,Phase I Study of Tumor Treatment Fields and a Personalized Mutation-derived Tumor Vaccine in Patients With Newly Diagnosed Glioblastoma (GCO 17-0566),"Active, not recruiting",,Phase 1,13.0,Actual,Albert Einstein College of Medicine,,1.0,,,False,,,,False,True,True,,,,,,,,,Undecided,,2023-06-18 11:56:39,2023-06-18 11:56:39,OTHER,,,,,
195667,195668,NCT00740090,,2008-08-21,,,2017-06-30,2008-08-21,2008-08-22,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"August 11, 2008",,2008-08-11,"June 9, 2009",2009-06-09,,,,"June 9, 2009",Actual,2009-06-09,,Interventional,,,Malaria Vaccine for Children in Mali,"Phase 1, Randomized, Double-Blind, Dose-Escalating Study of the Safety, Reactogenicity, and Immunogenicity of the AMA1-C1/Alhydrogel+CPG 7909 Vaccine for Plasmodium Falciparum Malaria in Children in Mali",Completed,,Phase 1,200.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-16 12:41:23,2023-06-16 12:41:23,NIH,,,,,
196578,196579,NCT00125970,,2005-06-30,,2010-01-30,2021-10-13,2005-08-01,2005-08-02,Estimate,,,,2010-01-30,2010-02-02,Estimate,2021-10-13,2021-10-15,Actual,September 2005,,2005-09-30,October 2021,2021-10-31,January 2010,Actual,2010-01-31,February 2008,Actual,2008-02-29,,Interventional,,,"HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants","HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants",Completed,,Phase 2,480.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 20:36:39,2023-06-17 20:36:39,NIH,,,,,
196676,196677,NCT02568332,,2015-09-22,,,2018-10-10,2015-10-01,2015-10-05,Estimate,,,,,,,2018-10-10,2018-10-11,Actual,"July 21, 2015",Actual,2015-07-21,May 2017,2017-05-31,"October 31, 2017",Actual,2017-10-31,"January 26, 2017",Actual,2017-01-26,,Interventional,,,A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive Individuals,A Phase I Study to Assess the Safety and Immunogenicity of Prime-boost Immunisations With Vaccine Candidates AdCh3NSmut1 and MVA-NSmut in HIV-1 Seropositive HCV-uninfected Adults on Antiretroviral Therapy (ART),Completed,,Phase 1,20.0,Actual,University of Oxford,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 12:43:31,2023-06-16 12:43:31,OTHER,,,,,
196997,196998,NCT05229354,,2021-10-18,,,2023-02-08,2022-01-27,2022-02-08,Actual,,,,,,,2023-02-08,2023-02-13,Actual,"December 11, 2021",Actual,2021-12-11,February 2023,2023-02-28,July 2025,Anticipated,2025-07-31,February 2024,Anticipated,2024-02-29,,Interventional,,,"Dengue Controlled Human Infection Model in Dhaka, Bangladesh","Phase II Evaluation of the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TetraVax-DV TV005 to Protect Against Infection With Live, Recombinant DENV-2 (rDEN2<U+2206>30-7169) Attenuated Strain in a Dengue Endemic Population in South Asia","Active, not recruiting",,Phase 2,192.0,Actual,University of Vermont,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 20:37:25,2023-06-17 20:37:25,OTHER,,,,,
197191,197192,NCT03160339,,2017-05-15,,,2020-03-03,2017-05-17,2017-05-19,Actual,,,,,,,2020-03-03,2020-03-04,Actual,"May 1, 2017",Actual,2017-05-01,March 2020,2020-03-31,"November 27, 2017",Actual,2017-11-27,"November 27, 2017",Actual,2017-11-27,,Interventional,,,"A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047","A Phase 1 Two-Arm, Randomized, Double-blind, Active-controlled Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047 (Adenovirus Type 4 and Type 7 Vaccine [A549 Cells], Live, Oral)",Terminated,,Phase 1,25.0,Actual,Emergent BioSolutions,,2.0,,Sponsor Decision,False,,,,False,True,False,,,,,,,,,Undecided,,2023-06-18 12:11:04,2023-06-18 12:11:04,INDUSTRY,,,,,
197235,197236,NCT02139267,,2014-05-13,,,2017-07-11,2014-05-13,2014-05-15,Estimate,,,,,,,2017-07-11,2017-07-12,Actual,July 2014,Actual,2014-07-31,July 2017,2017-07-31,March 2016,Actual,2016-03-31,March 2016,Actual,2016-03-31,,Interventional,,,"Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia","A Randomized, Open-label, Multi-center, Phase 2 Clinical Trial to Determine the Optimal Dose and Evaluate the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation (EP) in HPV Type 16 and/or 18 Positive Patients With Cervical Intraepithelial Neoplasia 3 (CIN 3)",Completed,,Phase 2,72.0,Actual,"Genexine, Inc.",,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 20:38:24,2023-06-17 20:38:24,INDUSTRY,,,,,
197587,197588,NCT02347423,,2015-01-15,,,2018-11-12,2015-01-26,2015-01-27,Estimate,,,,,,,2018-11-12,2018-11-14,Actual,February 2015,,2015-02-28,November 2018,2018-11-30,"September 26, 2015",Actual,2015-09-26,September 2015,Actual,2015-09-30,,Interventional,,,3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants,"Immunogenicity and Safety of 3 Adjuvated Reduced Dose Inactivated Polio Vaccines (IPV-Al SSI) and Non-adjuvated Full Dose IPV SSI, Given as Primary Vaccinations to Infants at 6, 10 and 14 Weeks of Age",Completed,,Phase 2,824.0,Actual,Statens Serum Institut,,4.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-18 12:14:25,2023-06-18 12:14:25,OTHER,,,,,
198123,198124,NCT04107961,,2019-09-23,,,2022-09-29,2019-09-25,2019-09-27,Actual,,,,,,,2022-09-29,2022-09-30,Actual,"October 1, 2023",Anticipated,2023-10-01,September 2022,2022-09-30,July 2025,Anticipated,2025-07-31,December 2024,Anticipated,2024-12-31,,Interventional,LEISH3,,A Study to Assess Safety and Efficacy of a Leishmania Vaccine to Prevent Post Kala Azar Dermal Leishmaniasis (PKDL),A Phase II Study to Assess the Safety and Efficacy of the Leishmania Vaccine ChAd63-KH for the Prevention of Post-kala Azar Dermal Leishmaniasis,Withdrawn,,Phase 2,0.0,Actual,University of York,,2.0,,The trial will be undertaken but the protocol will be substantially revised.,False,,,,True,False,False,,,,,,,,,No,,2023-06-15 06:51:11,2023-06-15 06:51:11,OTHER,,,,,
198158,198159,NCT00045227,,2002-09-06,,,2013-06-18,2003-01-26,2003-01-27,Estimate,,,,,,,2013-06-18,2013-06-19,Estimate,August 2002,,2002-08-31,December 2003,2003-12-31,October 2007,Actual,2007-10-31,,,,,Interventional,,,Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer,A Pilot Trial of Pox Vector PSA Vaccine With Concurrent Docetaxel Versus Pox Vector Vaccine Followed by Docetaxel in Metastatic Androgen Independent Prostate Cancer,Completed,,Phase 2,,,National Cancer Institute (NCI),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 06:51:14,2023-06-15 06:51:14,NIH,,,,,
198202,198203,NCT00415051,,2006-12-21,2016-12-06,2015-06-08,2019-12-30,2006-12-21,2006-12-22,Estimate,2016-12-06,2017-02-01,Estimate,2015-06-08,2015-07-07,Estimate,2019-12-30,2020-01-03,Actual,August 2006,,2006-08-31,December 2019,2019-12-31,May 2009,Actual,2009-05-31,May 2008,Actual,2008-05-31,,Interventional,MP-12,,Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine,"Safety and Immunogenicity of Live-Attenuated MP-12 Rift Valley Fever Vaccine in Humans, and Genetic Characterization of Virus Isolates Recovered From the Blood of Vaccinated Volunteers: A Phase II Study",Completed,,Phase 2,20.0,Actual,U.S. Army Medical Research and Development Command,,1.0,,,False,,,,False,,,,,,,,,,,Undecided,,2023-06-16 12:45:36,2023-06-16 12:45:36,FED,,,,,
198465,198466,NCT00045617,,2002-09-06,,,2012-06-11,2003-01-26,2003-01-27,Estimate,,,,,,,2012-06-11,2012-06-13,Estimate,January 2003,,2003-01-31,June 2012,2012-06-30,May 2003,Actual,2003-05-31,May 2003,Actual,2003-05-31,,Interventional,,,"S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer",A Phase II Trial of Patients With Limited Stage Small Cell Lung Cancer Treated With Thoracic Radiation Therapy and Chemotherapy With Cisplatin/Etoposide Followed by Cisplatin/Etoposide and Anti-Idiotype Monoclonal Antibody Vaccines,Terminated,,Phase 2,9.0,Actual,SWOG Cancer Research Network,,1.0,,Closed due to lack of drug availability.,False,,,,True,,,,,,,,,,,,,2023-06-15 06:51:33,2023-06-15 06:51:33,NETWORK,,,,,
198491,198492,NCT03141463,,2017-03-16,,,2018-05-02,2017-05-02,2017-05-05,Actual,,,,,,,2018-05-02,2018-05-03,Actual,"January 13, 2017",Actual,2017-01-13,November 2017,2017-11-30,"November 28, 2017",Actual,2017-11-28,"November 28, 2017",Actual,2017-11-28,,Interventional,,,Vvax001 Cancer Vaccine in (Pre) Malignant Cervical Lesions,"Immune Modulating Effects and Safety of Vvax001, a Therapeutic Semliki Forest Virus Based Cancer Vaccine, in Patients With a History of (Pre) Malignant Cervical Lesions.",Completed,,Phase 1,12.0,Actual,University Medical Center Groningen,,1.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-18 12:21:46,2023-06-18 12:21:46,OTHER,,,,,
198583,198584,NCT00956761,,2009-08-08,2015-12-21,,2015-12-21,2009-08-10,2009-08-11,Estimate,2015-12-21,2016-01-27,Estimate,,,,2015-12-21,2016-01-27,Estimate,June 2009,,2009-06-30,December 2015,2015-12-31,June 2009,Actual,2009-06-30,June 2009,Actual,2009-06-30,,Interventional,,Baseline analysis population was defined as all participants who were enrolled.,"Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010","A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD® Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2009-2010, When Administered to Elderly Subjects",Completed,,Phase 2,63.0,Actual,Novartis,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 02:21:56,2023-06-14 02:21:56,INDUSTRY,,,,,
198661,198662,NCT00874588,,2009-04-01,,,2013-08-13,2009-04-01,2009-04-02,Estimate,,,,,,,2013-08-13,2013-08-15,Estimate,March 2009,,2009-03-31,August 2013,2013-08-31,June 2012,Actual,2012-06-30,June 2012,Actual,2012-06-30,,Interventional,,,Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer,Phase I Trial in Studying Peptide Vaccine Therapy Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer,Completed,,Phase 1,6.0,Actual,Fukushima Medical University,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 12:46:11,2023-06-16 12:46:11,OTHER,,,,,
199065,199066,NCT05094609,,2021-10-25,,,2022-10-08,2021-10-25,2021-10-26,Actual,,,,,,,2022-10-08,2022-10-12,Actual,"January 3, 2022",Actual,2022-01-03,June 2022,2022-06-30,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2023",Anticipated,2023-12-31,,Interventional,,,Phase 1 Trial of ChAd68 and Ad5 Adenovirus COVID-19 Vaccines Delivered by Aerosol,"Phase 1, Open Label Study to Evaluate the Safety and Immunogenicity of ChAd68 and AdHu5 Vector-based Trivalent COVID-19 Vaccines Delivered Via Inhaled Aerosol",Recruiting,,Phase 1,30.0,Anticipated,McMaster University,,10.0,,,False,,,,True,False,False,,,,,,3 months after publication,Requests will be reviewed by the principal investigator and be judged on the scientific validity of the request and academic qualifications of those requesting access.,,Yes,"On request, individual patient data that underlie the results in a publication will be made to other researchers",2023-06-17 20:42:27,2023-06-17 20:42:27,OTHER,,,,,
199268,199269,NCT05077267,,2021-10-11,,,2022-10-21,2021-10-11,2021-10-14,Actual,,,,,,,2022-10-21,2022-10-24,Actual,"August 19, 2021",Actual,2021-08-19,October 2022,2022-10-31,"February 1, 2024",Anticipated,2024-02-01,"February 2, 2022",Actual,2022-02-02,,Interventional,,,ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects,"An Open Label Phase 2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of the ABNCoV2 Vaccine in SARS-CoV-2 Seronegative and Seropositive Adult Subjects","Active, not recruiting",,Phase 2,197.0,Actual,Bavarian Nordic,,3.0,,,False,,,,True,False,False,,,,,,,,,Undecided,,2023-06-18 12:26:59,2023-06-18 12:26:59,INDUSTRY,,,,,
199321,199322,NCT00884182,,2009-04-16,,,2014-01-10,2009-04-17,2009-04-20,Estimate,,,,,,,2014-01-10,2014-01-14,Estimate,April 2009,,2009-04-30,January 2014,2014-01-31,June 2010,Actual,2010-06-30,March 2010,Actual,2010-03-31,,Interventional,,,"Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children","Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in European Children",Completed,,Phase 2,350.0,Actual,Sanofi,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 12:47:29,2023-06-16 12:47:29,INDUSTRY,,,,,
199492,199493,NCT05736835,,2023-02-17,,,2023-02-17,2023-02-17,2023-02-21,Actual,,,,,,,2023-02-17,2023-02-21,Actual,April 2023,Anticipated,2023-04-30,February 2023,2023-02-28,October 2024,Anticipated,2024-10-31,April 2024,Anticipated,2024-04-30,,Interventional,,,A Phase 2 Trial of the Immunogenicity and Safety of CVXGA1 Intranasal COVID Vaccine in Healthy Adults,A Phase 2 Trial of the Immunogenicity and Safety of CVXGA1 Intranasal COVID Vaccine in Healthy Adults,Not yet recruiting,,Phase 2,400.0,Anticipated,CyanVac LLC,,2.0,,,False,,,,True,True,False,,,,,,,,,Undecided,,2023-06-18 12:28:26,2023-06-18 12:28:26,INDUSTRY,,,,,
199744,199745,NCT04773665,,2021-02-24,,,2023-02-14,2021-02-25,2021-02-26,Actual,,,,,,,2023-02-14,2023-02-15,Actual,"March 15, 2021",Actual,2021-03-15,February 2023,2023-02-28,"November 14, 2022",Actual,2022-11-14,"November 14, 2022",Actual,2022-11-14,,Interventional,,,"Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a","A Phase 1a/1b, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 (SARS-CoV-2) Vaccine Candidates VBI-2902a and VBI-2905a in Healthy Adults",Completed,,Phase 1,114.0,Actual,VBI Vaccines Inc.,,5.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 12:31:11,2023-06-18 12:31:11,INDUSTRY,,,,,
200495,200496,NCT00812019,,2008-12-18,,,2020-08-20,2008-12-18,2008-12-19,Estimate,,,,,,,2020-08-20,2020-08-24,Actual,November 2008,,2008-11-30,August 2020,2020-08-31,November 2010,Actual,2010-11-30,March 2009,Actual,2009-03-31,,Interventional,,,Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old),"A Phase I/II, Randomized, Observer-blind, Multicenter, Dose Ranging Study to Evaluate the Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted or Non-Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine in Healthy Subjects 18 - 40 Years of Age.",Completed,,Phase 1,753.0,Actual,Seqirus,,12.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 12:49:23,2023-06-16 12:49:23,INDUSTRY,,,,,
200843,200844,NCT05113849,,2021-10-29,,,2021-11-08,2021-11-08,2021-11-09,Actual,,,,,,,2021-11-08,2021-11-09,Actual,"September 16, 2021",Actual,2021-09-16,November 2021,2021-11-30,February 2023,Anticipated,2023-02-28,February 2023,Anticipated,2023-02-28,,Interventional,,,Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults (COVID-19),"A Phase 1, Open-label, Dose-escalation Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults Aged at 19 to 55 Years",Recruiting,,Phase 1,40.0,Anticipated,HK inno.N Corporation,,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 12:39:52,2023-06-18 12:39:52,INDUSTRY,,,,,
201321,201322,NCT01273922,,2011-01-07,,,2012-05-21,2011-01-07,2011-01-11,Estimate,,,,,,,2012-05-21,2012-05-22,Estimate,January 2011,,2011-01-31,May 2012,2012-05-31,December 2011,Actual,2011-12-31,October 2011,Actual,2011-10-31,,Interventional,,,Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida,"Phase I Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of NDV-3, a Recombinant Alum-Adjuvanted Vaccine for Staphylococcus Aureus and Candida Infections, Administered Intramuscular to Healthy Adults",Completed,,Phase 1,40.0,Actual,"NovaDigm Therapeutics, Inc.",,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 07:03:29,2023-06-14 07:03:29,INDUSTRY,,,,,
201335,201336,NCT03662815,,2018-09-05,,,2021-11-15,2018-09-05,2018-09-07,Actual,,,,,,,2021-11-15,2021-11-16,Actual,"February 7, 2018",Actual,2018-02-07,November 2021,2021-11-30,"December 30, 2022",Anticipated,2022-12-30,"May 20, 2021",Actual,2021-05-20,,Interventional,,,Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor,"Safety, Tolerability and Partial Efficacy Study of a Personalized Neoantigen Cancer Vaccine inTreating Patients With Advanced Malignant Tumor","Active, not recruiting",,Phase 1,30.0,Anticipated,Sir Run Run Shaw Hospital,,1.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-18 12:43:31,2023-06-18 12:43:31,OTHER,,,,,
201807,201808,NCT02370589,,2015-02-10,,,2021-11-23,2015-02-24,2015-02-25,Estimate,,,,,,,2021-11-23,2021-11-24,Actual,February 2015,,2015-02-28,September 2016,2016-09-30,April 2016,Actual,2016-04-30,April 2016,Actual,2016-04-30,,Interventional,,,Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects,"A Phase 1, Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Nanoparticle Vaccine, With or Without Matrix-M Adjuvant, in Healthy Subjects =18 to <50 Years of Age",Completed,,Phase 1,230.0,Actual,Novavax,,13.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 12:47:59,2023-06-18 12:47:59,INDUSTRY,,,,,
202161,202162,NCT04885361,,2021-05-07,,,2021-06-08,2021-05-12,2021-05-13,Actual,,,,,,,2021-06-08,2021-06-09,Actual,"May 26, 2021",Actual,2021-05-26,June 2021,2021-06-30,"March 31, 2022",Anticipated,2022-03-31,"September 30, 2021",Anticipated,2021-09-30,,Interventional,COVEPIT 3,,"To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults","A Randomized, Open Label, Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of OSE-13E, a Multiepitope-based Vaccine Candidate Against COVID-19, in Healthy Adults (COVEPIT-3)",Unknown status,Recruiting,Phase 1,48.0,Anticipated,OSE Immunotherapeutics,,2.0,,,False,,,,True,False,False,,,,,,,,,Undecided,,2023-06-18 12:51:05,2023-06-18 12:51:05,INDUSTRY,,,,,
202178,202179,NCT03382964,,2017-12-12,,,2019-08-28,2017-12-18,2017-12-26,Actual,,,,,,,2019-08-28,2019-08-29,Actual,"March 5, 2018",Actual,2018-03-05,August 2019,2019-08-31,"July 28, 2019",Actual,2019-07-28,"July 13, 2018",Actual,2018-07-13,,Interventional,,,Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers,"A Randomized, Observer-Blinded, Dose-Escalation Phase 1 Study to Assess the Safety and Immunogenicity of Three Different Dose Levels of a Live-Attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers Aged 18 To 45 Years",Completed,,Phase 1,120.0,Actual,Valneva Austria GmbH,,3.0,,,False,,,,True,True,False,,,,,,,,,Undecided,,2023-06-17 20:50:05,2023-06-17 20:50:05,INDUSTRY,,,,,
202189,202190,NCT04936997,,2021-06-18,,,2022-05-19,2021-06-22,2021-06-23,Actual,,,,,,,2022-05-19,2022-05-20,Actual,"June 7, 2021",Actual,2021-06-07,May 2022,2022-05-31,"May 8, 2022",Actual,2022-05-08,"August 25, 2021",Actual,2021-08-25,,Interventional,,,Immune Response to the COVID-19 Vaccine,Immune Response to the COVID-19 Vaccine,Completed,,Early Phase 1,20.0,Actual,University of Arizona,,1.0,,,False,,,,True,True,False,,,True,,,,,,,,2023-06-18 12:51:22,2023-06-18 12:51:22,OTHER,,,,,
202252,202253,NCT03277703,,2017-08-30,,,2022-02-23,2017-09-06,2017-09-11,Actual,,,,,,,2022-02-23,2022-02-25,Actual,"November 3, 2017",Actual,2017-11-03,February 2022,2022-02-28,"January 1, 2020",Actual,2020-01-01,"January 1, 2020",Actual,2020-01-01,,Interventional,,,Flu Vaccine Response in Patients on Biologic Therapies,Booster Vaccine Strategy to Improve Serologic Responses to Influenza Vaccination in Children With Rheumatic Diseases and Inflammatory Bowel Disease Who Are Receiving Immunosuppressive Therapies,Completed,,Phase 2,30.0,Actual,Stony Brook University,,2.0,,,False,,,,True,True,False,,,False,,,,,,,,2023-06-18 12:52:06,2023-06-18 12:52:06,OTHER,,,,,
202474,202475,NCT00133549,,2005-08-19,,,2014-10-16,2005-08-19,2005-08-23,Estimate,,,,,,,2014-10-16,2014-10-17,Estimate,November 2000,,2000-11-30,May 2011,2011-05-31,December 2002,Actual,2002-12-31,December 2002,Actual,2002-12-31,,Interventional,,,9-valent CRM 197 Pneumococcal,Evaluation of a 9-valent CRM 197- Conjugated Pneumococcal Polysaccharide Vaccine in Elderly Adults,Completed,,Phase 2,180.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 06:53:33,2023-06-15 06:53:33,NIH,,,,,
202559,202560,NCT04636333,,2020-11-17,,,2022-03-28,2020-11-17,2020-11-19,Actual,,,,,,,2022-03-28,2022-03-31,Actual,"October 30, 2020",Actual,2020-10-30,March 2022,2022-03-31,"July 7, 2022",Anticipated,2022-07-07,"December 7, 2021",Actual,2021-12-07,,Interventional,,,Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell),Safety and Immunogenicity of a Recombinant COVID-19 Vaccine (CHO Cell) in Healthy Population Aged 18 Years and Older: A Phase I Study,Recruiting,,Phase 1,216.0,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,,12.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 12:55:24,2023-06-18 12:55:24,NETWORK,,,,,
202654,202655,NCT04864379,,2021-04-25,,,2021-04-25,2021-04-25,2021-04-28,Actual,,,,,,,2021-04-25,2021-04-28,Actual,"September 3, 2020",Actual,2020-09-03,April 2021,2021-04-30,"August 3, 2025",Anticipated,2025-08-03,"August 3, 2025",Anticipated,2025-08-03,,Interventional,,,Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors,"Safety, Tolerability and Immunogenicity of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and Radiofrequency Ablation in Patients With Advanced Solid Tumors",Recruiting,,Phase 1,30.0,Anticipated,Sir Run Run Shaw Hospital,,2.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-18 12:56:19,2023-06-18 12:56:19,OTHER,,,,,
202691,202692,NCT00890422,,2009-04-28,,,2009-04-28,2009-04-28,2009-04-29,Estimate,,,,,,,2009-04-28,2009-04-29,Estimate,March 2007,,2007-03-31,April 2009,2009-04-30,July 2010,Anticipated,2010-07-31,November 2009,Anticipated,2009-11-30,,Interventional,immunisation,,Evaluation of Immunogenicity of Different Tick Borne Encephalitis (TBE) Fast Protective Traveler Schemes With Inactivated TBE Whole Virus Vaccine,Clinical Study to Test the Immunogenicity of Variant Schedules for TBE Rapid Immunisation Using Inactivated TBE (FSME) Vaccine,Unknown status,"Active, not recruiting",Phase 2,99.0,Anticipated,Elisabethinen Hospital,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 12:52:25,2023-06-16 12:52:25,OTHER,,,,,
202968,202969,NCT04851977,,2021-04-13,,,2021-04-19,2021-04-19,2021-04-21,Actual,,,,,,,2021-04-19,2021-04-21,Actual,"October 16, 2018",Actual,2018-10-16,April 2021,2021-04-30,"August 2, 2019",Actual,2019-08-02,"April 7, 2019",Actual,2019-04-07,,Interventional,,,"A First in Human Study to Evaluate the Safety and Immune Response to a Vaccine for the Treatment of a Respiratory Virus, When Administered Into the Arm in Healthy Adult Participants","A Phase I, First in Human (FIH), Randomised, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Recombinant Respiratory Syncytial Virus Vaccines (BARS13) When Administered Intramuscularly (IM) to Healthy Adult Volunteers",Completed,,Phase 1,60.0,Actual,"Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.",,4.0,,,False,,,,True,False,False,,,,,,,,,No,"The results of this clinical trial may be published or presented at scientific meetings. If this is foreseen, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. The Sponsor will comply with the requirements for publication of clinical trial results.",2023-06-18 12:59:48,2023-06-18 12:59:48,INDUSTRY,,,,,
203124,203125,NCT03038243,,2017-01-23,,,2017-11-16,2017-01-26,2017-01-31,Estimate,,,,,,,2017-11-16,2017-11-20,Actual,"August 1, 2017",Anticipated,2017-08-01,November 2017,2017-11-30,"December 31, 2019",Anticipated,2019-12-31,"December 31, 2018",Anticipated,2018-12-31,,Interventional,,,"Safety, Immunogenicity and Efficacy Study of Inactivated Whole Cell Shigella Flexneri 2a Vaccine With and Without dmLT in Adults","A Phase 2a/2b, Randomized, Double-blinded, Placebo-controlled, Trial to Assess the Safety, Immunogenicity and Efficacy of Inactivated Shigella Flexneri 2a Whole Cell (Sf2aWC) Vaccine Administered With and Without Double Mutant E. Coli Heat Labile Toxin (dmLT) in Healthy Adult Subjects",Withdrawn,,Phase 2,0.0,Actual,PATH,,3.0,,Lack of funding,False,,,,True,True,False,,,,,,,,,No,,2023-06-18 13:02:51,2023-06-18 13:02:51,OTHER,,,,,
203415,203416,NCT05056519,,2021-08-31,,,2021-09-23,2021-09-23,2021-09-24,Actual,,,,,,,2021-09-23,2021-09-24,Actual,"September 20, 2021",Anticipated,2021-09-20,September 2021,2021-09-30,"March 30, 2022",Anticipated,2022-03-30,"December 30, 2021",Anticipated,2021-12-30,,Interventional,,,The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine,"A Random, Double -Blind, Placebo Control Phase <U+2160> Trail to Evaluate the Safety and Immunogenicity of Live Attenuated Influenza Vaccine in 3-59y Healthy People",Recruiting,,Phase 1,160.0,Anticipated,Changchun BCHT Biotechnology Co.,,2.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-18 13:06:29,2023-06-18 13:06:29,INDUSTRY,,,,,
203656,203657,NCT04271306,,2020-02-07,,,2022-06-21,2020-02-13,2020-02-17,Actual,,,,,,,2022-06-21,2022-06-22,Actual,"May 25, 2021",Actual,2021-05-25,June 2022,2022-06-30,March 2023,Anticipated,2023-03-31,March 2023,Anticipated,2023-03-31,,Interventional,,,"Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania.","A Phase Ib Age De-escalation and Dose Escalation Open Label Clinical Trial of the Safety, Immunogenicity and ex Vivo Efficacy of a Candidate Malaria Vaccine Pfs25-IMX313/Matrix-M Administered Intramuscularly in Healthy Adults and Young Children in Tanzania.",Recruiting,,Phase 1,52.0,Anticipated,University of Oxford,,6.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-14 07:04:47,2023-06-14 07:04:47,OTHER,,,,,
204461,204462,NCT00399529,,2006-11-13,2020-03-30,2012-11-29,2020-04-21,2006-11-14,2006-11-15,Estimate,2020-03-30,2020-04-13,Actual,2012-12-11,2012-12-13,Estimate,2020-04-21,2020-04-22,Actual,September 2006,,2006-09-30,April 2020,2020-04-30,February 2010,Actual,2010-02-28,February 2010,Actual,2010-02-28,,Interventional,,,"Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer","A Feasibility Study of Combination Therapy With Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for HER-2/Neu-Overexpressing Metastatic Breast Cancer.",Completed,,Phase 2,22.0,Actual,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 12:56:12,2023-06-16 12:56:12,OTHER,,,,,
204711,204712,NCT05003479,,2021-08-10,,,2021-08-11,2021-08-10,2021-08-12,Actual,,,,,,,2021-08-11,2021-08-18,Actual,August 2021,Anticipated,2021-08-31,August 2021,2021-08-31,October 2022,Anticipated,2022-10-31,September 2022,Anticipated,2022-09-30,,Interventional,,,"Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years(COVID-19)","A Randomized, Double-blind, Placebo-controlled Phase <U+2160> Clinical Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years",Not yet recruiting,,Phase 1,84.0,Anticipated,"Shenzhen Kangtai Biological Products Co., LTD",,2.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-18 13:18:16,2023-06-18 13:18:16,INDUSTRY,,,,,
205336,205337,NCT05182125,,2021-12-20,,,2022-07-29,2021-12-20,2022-01-10,Actual,,,,,,,2022-07-29,2022-08-02,Actual,"November 25, 2021",Actual,2021-11-25,July 2022,2022-07-31,"November 6, 2025",Anticipated,2025-11-06,"September 14, 2023",Anticipated,2023-09-14,,Interventional,HVTN139,,"Evaluating the Safety and Immunogenicity of HIV-1 Vaccines Based on Chimpanzee Serotypes of Ad Expressing Clade C gp140 and a CH505TF gp120 Protein Boost in Healthy, HIV- Uninfected Adult Participants","A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Vaccines Based on Chimpanzee Serotypes of Adenovirus Expressing Clade C gp140 and a CH505TF gp120 Protein Boost in Healthy, HIV- Uninfected Adult Participants","Active, not recruiting",,Phase 1,34.0,Actual,HIV Vaccine Trials Network,,6.0,,,False,,,,True,True,False,,,True,,,,,,,,2023-06-18 13:25:18,2023-06-18 13:25:18,NETWORK,,,,,
205607,205608,NCT05048589,,2021-08-31,,,2022-08-20,2021-09-07,2021-09-17,Actual,,,,,,,2022-08-20,2022-08-23,Actual,"October 1, 2021",Actual,2021-10-01,August 2022,2022-08-31,"May 31, 2022",Actual,2022-05-31,"May 31, 2022",Actual,2022-05-31,,Interventional,DANFLU-1,,Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting,Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting,Completed,,Phase 2,12551.0,Actual,Herlev and Gentofte Hospital,,2.0,,,False,,,,False,False,False,,,,,,,,,No,Sharing of individual-level data stemming from Danish administrative registries is illegal according to Danish law.,2023-06-18 13:28:01,2023-06-18 13:28:01,OTHER,,,,,
205775,205776,NCT05059821,,2021-05-11,,,2022-08-10,2021-09-16,2021-09-28,Actual,,,,,,,2022-08-10,2022-08-11,Actual,"April 19, 2021",Actual,2021-04-19,August 2022,2022-08-31,August 2024,Anticipated,2024-08-31,April 2024,Anticipated,2024-04-30,,Interventional,PROVE,,Personalized Cancer Vaccine in Egyptian Cancer Patients,"Phase I Clinical Trial of Alfa-Fetoprotein,Glypican-3 Based Personalized Cancer Vaccine in Egyptian Patients With Hepatocellular Carcinoma: Pilot Study",Recruiting,,Phase 1,10.0,Anticipated,Ain Shams University,,1.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 13:29:41,2023-06-18 13:29:41,OTHER,,,,,
206513,206514,NCT00901654,,2009-05-13,,,2010-01-28,2009-05-13,2009-05-14,Estimate,,,,,,,2010-01-28,2010-01-29,Estimate,June 2009,,2009-06-30,January 2010,2010-01-31,November 2009,Actual,2009-11-30,November 2009,Actual,2009-11-30,,Interventional,,,ACE527 Safety and Immunogenicity Study,"A Phase I, Single Center, Double-Blind, Placebo-controlled Dose Finding Clinical Study to Evaluate the Safety and Immunogenicity of the Live Attenuated, Oral Vaccine ACE527",Completed,,Phase 1,36.0,Anticipated,TD Vaccines A/S,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 13:00:37,2023-06-16 13:00:37,INDUSTRY,,,,,
206919,206920,NCT00902824,,2009-05-13,,,2013-02-08,2009-05-14,2009-05-15,Estimate,,,,,,,2013-02-08,2013-02-11,Estimate,November 2008,,2008-11-30,February 2013,2013-02-28,April 2010,Actual,2010-04-30,April 2010,Actual,2010-04-30,,Interventional,,,"Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine","Phase I Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of TBC-M4 (MVA Based HIV Vaccine) Alone or in a Prime-Boost Regimen With ADVAX, DNA HIV Vaccine",Completed,,Phase 1,32.0,Actual,International AIDS Vaccine Initiative,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 13:01:47,2023-06-16 13:01:47,NETWORK,,,,,
206993,206994,NCT04950751,,2021-06-17,,,2021-09-02,2021-06-25,2021-07-06,Actual,,,,,,,2021-09-02,2021-09-10,Actual,August 2021,Anticipated,2021-08-31,September 2021,2021-09-30,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,,Interventional,,,Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults,"An Observer-blind, Randomized, Controlled, Phase 2 Study to Evaluate the Immunogenicity and Safety of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2020S) in Adults",Withdrawn,,Phase 2,0.0,Actual,Clover Biopharmaceuticals AUS Pty Ltd,,5.0,,sponsor decided to withdrawn the study as development strategy has changed,False,,,,True,False,False,,,,,,,,,,,2023-06-18 13:43:10,2023-06-18 13:43:10,INDUSTRY,,,,,
207094,207095,NCT01042951,,2010-01-05,,,2014-10-29,2010-01-05,2010-01-06,Estimate,,,,,,,2014-10-29,2014-10-30,Estimate,January 2010,,2010-01-31,January 2010,2010-01-31,November 2010,Actual,2010-11-30,August 2010,Actual,2010-08-31,,Interventional,,,To Determine the Safety and Immunogenicity of an Oral Whole Cell ShanChol Cholera Vaccine in Bangladesh,"Randomized, Double-blind, Placebo-controlled Trial, to Evaluate the Safety and Immunogenicity of Orally Administered, Killed, Bivalent Whole-cell, Cholera Vaccine, ShanChol in Bangladeshi Adults and Children",Completed,,Phase 2,330.0,Actual,"International Centre for Diarrhoeal Disease Research, Bangladesh",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 13:02:09,2023-06-16 13:02:09,OTHER,,,,,
207187,207188,NCT03507738,,2018-04-15,,,2019-08-04,2018-04-15,2018-04-25,Actual,,,,,,,2019-08-04,2019-08-06,Actual,"July 3, 2018",Actual,2018-07-03,August 2019,2019-08-31,"June 28, 2019",Actual,2019-06-28,"June 28, 2019",Actual,2019-06-28,,Interventional,,,"Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants","A Phase 1, Randomized, Placebo-controlled, Descending Age, Dose-escalation Study to Assess the Safety and Immunogenicity of an Investigational Non-Replicating Rotavirus Vaccine (MT-5625) in Healthy Adults, Toddlers and Infants",Completed,,Phase 1,110.0,Actual,Mitsubishi Tanabe Pharma Corporation,,8.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-17 20:57:29,2023-06-17 20:57:29,INDUSTRY,,,,,
207647,207648,NCT00048386,,2002-10-30,,,2012-07-26,2002-10-31,2002-11-01,Estimate,,,,,,,2012-07-26,2012-07-27,Estimate,November 1999,,1999-11-30,July 2012,2012-07-31,October 2009,Actual,2009-10-31,December 2004,Actual,2004-12-31,,Interventional,CYCHE2,,Neuroblastoma Vaccine for Treatment of High-Risk Neuroblastoma After Chemotherapy,A Pilot Study of Gene Modified Autologous Neuroblastoma Vaccine for the Post-Chemotherapy Treatment of High-Risk Neuroblastoma,Completed,,Phase 1,13.0,Actual,Baylor College of Medicine,,,,,False,,,,True,,,,,,,,,,,,,2023-06-15 06:55:33,2023-06-15 06:55:33,OTHER,,,,,
207826,207827,NCT04917861,,2021-06-02,,,2022-08-31,2021-06-02,2021-06-08,Actual,,,,,,,2022-08-31,2022-09-02,Actual,"June 8, 2021",Actual,2021-06-08,August 2022,2022-08-31,"April 26, 2024",Anticipated,2024-04-26,"April 26, 2024",Anticipated,2024-04-26,,Interventional,,,A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas,"A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose Confirmation Study to Evaluate the Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Adults Aged 18 Through 65 Years and Living in Endemic and Non-Endemic Flavivirus Areas","Active, not recruiting",,Phase 2,809.0,Actual,"ModernaTX, Inc.",,4.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-18 13:51:26,2023-06-18 13:51:26,INDUSTRY,,,,,
208859,208860,NCT04556981,,2020-09-10,,,2023-06-12,2020-09-17,2020-09-21,Actual,,,,,,,2023-06-12,2023-06-13,Estimate,"November 17, 2020",Actual,2020-11-17,June 2023,2023-06-30,"August 12, 2022",Actual,2022-08-12,"August 12, 2022",Actual,2022-08-12,,Interventional,MESA-TB,,Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV,"A Randomized, Placebo-controlled, Observer-blind, Phase 2 Study to Evaluate Safety and Immunogenicity of the Investigational M72/AS01E Mycobacterium Tuberculosis (Mtb) Vaccine in Virally Suppressed, Antiretroviral-treated Participants With Human Immunodeficiency Virus (HIV)",Completed,,Phase 2,402.0,Actual,Bill & Melinda Gates Medical Research Institute,,2.0,,,False,,,,True,False,False,,,False,,,,,,Yes,,2023-06-14 04:21:33,2023-06-14 04:21:33,OTHER,,,,,
209031,209032,NCT04428073,,2020-06-08,,,2020-06-10,2020-06-10,2020-06-11,Actual,,,,,,,2020-06-10,2020-06-11,Actual,July 2020,Anticipated,2020-07-31,June 2020,2020-06-30,December 2021,Anticipated,2021-12-31,July 2021,Anticipated,2021-07-31,,Interventional,,,Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection,A Phase I Trial of a Therapeutic Vaccine (Covax-19) in SARS-CoV-2 Infected Patients,Unknown status,Not yet recruiting,Phase 1,32.0,Anticipated,GeneCure Biotechnologies,,2.0,,,False,,,,True,True,False,,,,,,,,,No,The final study results will be published in peer reviewed journals.,2023-06-18 14:04:10,2023-06-18 14:04:10,INDUSTRY,,,,,
209560,209561,NCT04784767,,2021-03-03,,,2021-09-13,2021-03-03,2021-03-05,Actual,,,,,,,2021-09-13,2021-09-14,Actual,"April 5, 2021",Actual,2021-04-05,September 2021,2021-09-30,"October 30, 2023",Anticipated,2023-10-30,"October 30, 2022",Anticipated,2022-10-30,,Interventional,,,SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 in Healthy Adults,"A PHASE 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Ranging Doses of SARS-COV-2-Spike-Ferritin-Nanoparticle (SPFN_1B-06-PL) Vaccine With Army Liposomal Formulation QS21 (ALFQ) for Prevention of COVID-19 in Healthy Adults.","Active, not recruiting",,Phase 1,29.0,Actual,U.S. Army Medical Research and Development Command,,6.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-18 14:10:39,2023-06-18 14:10:39,FED,,,,,
209577,209578,NCT05334706,,2022-04-05,,,2023-05-08,2022-04-12,2022-04-19,Actual,,,,,,,2023-05-08,2023-05-09,Actual,"September 13, 2022",Actual,2022-09-13,May 2023,2023-05-31,May 2024,Anticipated,2024-05-31,May 2024,Anticipated,2024-05-31,,Interventional,RIFT-HPV,,A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV),"A Non-Randomized, Open-Label Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV16/18-Positive Women After Vaccination With 9vHPV, a Multivalent L1 Virus-like Particle Vaccine, Evaluated in Cervical, Anal and Oral Samples Obtained After One, Two, and Three Vaccine Doses (RIFT-HPV1/RIFT-HPV2)",Recruiting,,Phase 2,69.0,Anticipated,Institut d'Investigació Biomèdica de Bellvitge,,1.0,,,False,,,,True,True,False,,,True,,,,,,No,,2023-06-17 21:00:26,2023-06-17 21:00:26,OTHER,,,,,
209620,209621,NCT02405221,,2015-03-27,,,2022-07-22,2015-03-31,2015-04-01,Estimate,,,,,,,2022-07-22,2022-07-25,Actual,"April 4, 2019",Actual,2019-04-04,June 2022,2022-06-30,"January 1, 2024",Anticipated,2024-01-01,"December 1, 2023",Anticipated,2023-12-01,,Interventional,,,Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer,A Pilot Clinical Trial Assessing the Safety and Feasibility of Intramuscular Administration of the TA-CIN Vaccine as Adjuvant Therapy for Patients With History of HPV16 Associated Cervical Cancer,"Active, not recruiting",,Phase 1,14.0,Anticipated,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,2.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-18 14:11:27,2023-06-18 14:11:27,OTHER,,,,,
209865,209866,NCT05542693,,2022-08-26,,,2022-09-13,2022-09-13,2022-09-15,Actual,,,,,,,2022-09-13,2022-09-15,Actual,January 2023,Anticipated,2023-01-31,September 2022,2022-09-30,September 2023,Anticipated,2023-09-30,March 2023,Anticipated,2023-03-31,,Interventional,,,Safety and Immunogenicity of the RNA MCTI CIMATEC HDT Vaccine,"Phase IIb, Randomized, Double-blind, Non-inferior, Multicenter Study to Evaluate the Safety and Immunogenicity of the Self-replicating Nanoparticle Carrier Replicon RNA Carrier (repRNA) Vaccine in Adults 18 to 65 Years of Age",Not yet recruiting,,Phase 2,300.0,Anticipated,Azidus Brasil,,4.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 14:14:04,2023-06-18 14:14:04,INDUSTRY,,,,,
210592,210593,NCT05667740,,2022-12-19,,,2023-02-21,2022-12-19,2022-12-29,Actual,,,,,,,2023-02-21,2023-02-23,Actual,"January 16, 2023",Actual,2023-01-16,February 2023,2023-02-28,"September 30, 2023",Anticipated,2023-09-30,"September 30, 2023",Anticipated,2023-09-30,,Interventional,,,"Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.","A Phase 1, Randomised, Placebo-controlled, Double-blind, Sequential Ascending-dose Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine (Gamma-PN3) in Healthy Adults",Recruiting,,Phase 1,117.0,Anticipated,GPN Vaccines,,4.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-16 13:10:38,2023-06-16 13:10:38,INDUSTRY,,,,,
210653,210654,NCT00921206,,2009-06-15,,,2014-09-22,2009-06-15,2009-06-16,Estimate,,,,,,,2014-09-22,2014-09-23,Estimate,June 2009,,2009-06-30,September 2014,2014-09-30,December 2009,Actual,2009-12-31,October 2009,Actual,2009-10-31,,Interventional,,,Study to Investigate the Immune Response to Two Doses of VAX102 Healthy Adults,Open-label Study to Investigate the Humoral and Cellular Immune Response to Two Doses of VAX102 Influenza Vaccine in Healthy Adults,Completed,,Phase 1,21.0,Actual,VaxInnate Corporation,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 13:10:48,2023-06-16 13:10:48,INDUSTRY,,,,,
211018,211019,NCT04754776,,2021-02-05,,,2023-05-17,2021-02-11,2021-02-15,Actual,,,,,,,2023-05-17,2023-05-19,Actual,"June 11, 2021",Actual,2021-06-11,April 2022,2022-04-30,"April 6, 2022",Actual,2022-04-06,"April 6, 2022",Actual,2022-04-06,,Interventional,,,Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001),A Phase I Study to Determine the Safety & Immunogenicity of the Candidate Rift Valley Fever Virus (RVFV) Vaccine ChAdOx1 RVF in UK Healthy Adult Volunteers,Completed,,Early Phase 1,15.0,Actual,University of Oxford,,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 14:25:16,2023-06-18 14:25:16,OTHER,,,,,
211909,211910,NCT05254236,,2022-02-20,,,2022-08-09,2022-02-20,2022-02-24,Actual,,,,,,,2022-08-09,2022-08-11,Actual,"March 10, 2023",Anticipated,2023-03-10,February 2022,2022-02-28,"June 10, 2023",Anticipated,2023-06-10,"March 10, 2023",Anticipated,2023-03-10,,Interventional,,,Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy Adults in in Hong Kong,"A Phase IIb, Randomized, Double-Blinded Trial to Evaluate the Immunogenicity and Safety Study of the Booster Dose Using the High or Medium Dose of COVID- 19 Vaccine (Vero Cell), Inactivated in Healthy Adults Who Have Completed Two Doses of mRNA Vaccine in Hong Kong",Suspended,,Phase 2,150.0,Anticipated,"Sinovac Biotech Co., Ltd",,2.0,,Limited subjects,False,,,,False,False,False,,,,,,,,,,,2023-06-14 06:40:19,2023-06-14 06:40:19,INDUSTRY,,,,,
212060,212061,NCT05226390,,2022-01-31,,,2022-09-06,2022-02-04,2022-02-07,Actual,,,,,,,2022-09-06,2022-09-07,Actual,"February 24, 2022",Actual,2022-02-24,September 2022,2022-09-30,October 2023,Anticipated,2023-10-31,February 2023,Anticipated,2023-02-28,,Interventional,,,"Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate","Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate Administered as Inhalation Boost in SARS-CoV-2 Immunized Adults - Phase I Study",Recruiting,,Phase 1,30.0,Anticipated,Hannover Medical School,,1.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-14 06:41:45,2023-06-14 06:41:45,OTHER,,,,,
212126,212127,NCT00849069,,2009-02-19,,,2017-10-30,2009-02-19,2009-02-23,Estimate,,,,,,,2017-10-30,2017-10-31,Actual,"March 12, 2009",Actual,2009-03-12,October 2017,2017-10-31,"April 7, 2009",Actual,2009-04-07,"April 7, 2009",Actual,2009-04-07,,Interventional,,,Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine,"An Observer-blind, Safety Study of GSK Biologicals' Haemophilus Influenzae and Streptococcus Pneumoniae Candidate Vaccine in Adults.",Terminated,,Phase 1,30.0,Anticipated,GlaxoSmithKline,,2.0,,The study has been stopped for logistic reasons not related to the safety or efficacy of the vaccine.,False,,,,,,,,,,,,,,,,,2023-06-16 13:14:25,2023-06-16 13:14:25,INDUSTRY,,,,,
212300,212301,NCT05150496,,2021-11-25,,,2022-08-09,2021-11-25,2021-12-09,Actual,,,,,,,2022-08-09,2022-08-11,Actual,"December 15, 2022",Anticipated,2022-12-15,November 2021,2021-11-30,"January 15, 2023",Anticipated,2023-01-15,"January 15, 2023",Anticipated,2023-01-15,,Interventional,,,Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey,A Phase IIb Randomized Double-Blinded Positive Controlled Trial to Evaluate the Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults Who Have Completed Two Doses of CoronaVac® or the mRNA Vaccine (Comirnaty) in Turkey,Suspended,,Phase 2,640.0,Anticipated,"Sinovac Biotech Co., Ltd",,4.0,,The plan has changed,False,,,,False,False,False,,,,,,,,,,,2023-06-14 06:44:27,2023-06-14 06:44:27,INDUSTRY,,,,,
212391,212392,NCT00436046,,2007-02-15,2008-10-09,,2011-06-09,2007-02-15,2007-02-16,Estimate,2008-11-12,2008-11-18,Estimate,,,,2011-06-09,2011-06-13,Estimate,March 2007,,2007-03-31,October 2009,2009-10-31,October 2007,Actual,2007-10-31,April 2007,Actual,2007-04-30,,Interventional,,,Interferon as a Mucosal Adjuvant for Influenza Vaccine Given Intranasally,Type 1 Interferon as a Mucosal Adjuvant for Influenza Vaccine Given Intranasally,Completed,,Phase 1,95.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 06:45:28,2023-06-14 06:45:28,NIH,,,,,
212479,212480,NCT05067894,,2021-10-01,,,2022-08-08,2021-10-01,2021-10-05,Actual,,,,,,,2022-08-08,2022-08-09,Actual,"December 10, 2021",Actual,2021-12-10,August 2022,2022-08-31,"August 6, 2022",Actual,2022-08-06,"April 11, 2022",Actual,2022-04-11,,Interventional,,,Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine,"A Phase I, Observer-Blind, Randomized, Controlled Study of the Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Populations Aged 18 Years and Above in Indonesia",Completed,,Phase 1,54.0,Actual,PT Bio Farma,,4.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-14 06:46:39,2023-06-14 06:46:39,INDUSTRY,,,,,
212487,212488,NCT00445484,,2007-03-07,2015-06-26,,2015-08-05,2007-03-07,2007-03-09,Estimate,2015-06-26,2015-07-24,Estimate,,,,2015-08-05,2015-08-24,Estimate,January 2007,,2007-01-31,August 2015,2015-08-31,September 2010,Actual,2010-09-30,April 2009,Actual,2009-04-30,,Interventional,,"A total of 22 patients were enrolled, 11 in each cohort. Patients who showed evidence of disease progression while on study were not included in subsequent analysis.",Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma,Revlimid to Augment Efficacy of Prevnar Vaccines in Patients With Relapsed or Refractory Myeloma,Completed,,Phase 2,22.0,Actual,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 06:46:45,2023-06-14 06:46:45,OTHER,,,,,
212721,212722,NCT05519839,,2022-08-26,,,2023-01-24,2022-08-26,2022-08-29,Actual,,,,,,,2023-01-24,2023-01-26,Actual,"December 30, 2022",Actual,2022-12-30,January 2023,2023-01-31,"December 24, 2023",Anticipated,2023-12-24,"July 25, 2023",Anticipated,2023-07-25,,Interventional,COVID-19,,A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine,"A Phase 2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle and Quadrivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix-M Adjuvant in Healthy Participants = 50 to = 80 Years of Age","Active, not recruiting",,Phase 2,1579.0,Anticipated,Novavax,,22.0,,,False,,,,True,True,False,,,True,,,,,,,,2023-06-18 14:29:52,2023-06-18 14:29:52,INDUSTRY,,,,,
212884,212885,NCT05111353,,2021-10-27,,,2023-01-23,2021-10-27,2021-11-08,Actual,,,,,,,2023-01-23,2023-01-26,Actual,"October 10, 2022",Actual,2022-10-10,January 2023,2023-01-31,"December 31, 2027",Anticipated,2027-12-31,"December 31, 2025",Anticipated,2025-12-31,,Interventional,,,Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery,Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery,Recruiting,,Phase 1,30.0,Anticipated,Washington University School of Medicine,,2.0,,,False,,,,True,True,False,,,False,,,,,,Yes,Sequencing data will be submitted to the database of Genotypes and Phenotypes (dbGap) at the National Cancer Institute.,2023-06-18 14:31:20,2023-06-18 14:31:20,OTHER,,,,,
213000,213001,NCT00050726,,2002-12-17,,,2013-11-19,2002-12-17,2002-12-18,Estimate,,,,,,,2013-11-19,2013-11-21,Estimate,May 2001,,2001-05-31,November 2013,2013-11-30,April 2006,Actual,2006-04-30,April 2006,Actual,2006-04-30,,Interventional,,,Studies of Influenza Vaccine and Tetanus-Pneumococcal Vaccine in HIV-infected Patients Receiving Interleukin-2,Substudies of ESPRIT: ESPRIT Influenza Vaccine Substudy (FLUVAC) and ESPRIT Tetanus-Pneumococcal Vaccine Substudy (TEPVAC),Completed,,Phase 2,620.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 06:58:29,2023-06-15 06:58:29,NIH,,,,,
213010,213011,NCT00850785,,2009-02-23,,,2016-09-26,2009-02-24,2009-02-25,Estimate,,,,,,,2016-09-26,2016-09-27,Estimate,January 2009,,2009-01-31,September 2016,2016-09-30,May 2012,Actual,2012-05-31,May 2012,Actual,2012-05-31,,Interventional,DRibble,,Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer,A Pilot Study of Autologous Tumor DRibble Vaccine With Docetaxel in Stage IIIB and IV Non-Small Cell Lung Cancer,Completed,,Phase 1,6.0,Actual,Providence Health & Services,,,,,False,,,,False,,,,,,,,,,,No,,2023-06-16 13:15:58,2023-06-16 13:15:58,OTHER,,,,,
213097,213098,NCT04144023,,2019-10-28,,,2023-01-11,2019-10-28,2019-10-30,Actual,,,,,,,2023-01-11,2023-01-12,Actual,"April 1, 2019",Actual,2019-04-01,January 2023,2023-01-31,"June 1, 2023",Anticipated,2023-06-01,"June 1, 2023",Anticipated,2023-06-01,,Interventional,,,A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ,A Phase IB Trial of Neoadjuvant Multi-Epitope HER2 Peptide Vaccine in Patients With HER2-Expressing DCIS,Recruiting,,Phase 1,43.0,Anticipated,Mayo Clinic,,1.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-16 13:16:09,2023-06-16 13:16:09,OTHER,,,,,
213254,213255,NCT05506969,,2022-08-10,,,2022-08-16,2022-08-16,2022-08-18,Actual,,,,,,,2022-08-16,2022-08-18,Actual,"August 9, 2022",Actual,2022-08-09,August 2022,2022-08-31,January 2024,Anticipated,2024-01-31,February 2023,Anticipated,2023-02-28,,Interventional,,,"Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age","Phase 2, Randomized, Active-Controlled, Observer-Blinded, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age",Recruiting,,Phase 2,200.0,Anticipated,Dynavax Technologies Corporation,,4.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-18 14:35:06,2023-06-18 14:35:06,INDUSTRY,,,,,
213781,213782,NCT05515042,,2022-07-11,,,2022-08-23,2022-08-23,2022-08-25,Actual,,,,,,,2022-08-23,2022-08-25,Actual,"July 25, 2022",Actual,2022-07-25,August 2022,2022-08-31,"July 31, 2023",Anticipated,2023-07-31,"July 31, 2023",Anticipated,2023-07-31,,Interventional,AUR1-8-341,,Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.,A Phase 2a Trial to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected and HIV-uninfected Adults.,Recruiting,,Phase 2,750.0,Anticipated,The Aurum Institute NPC,,3.0,,,False,,,,True,False,False,,,False,,,Quarter 4 2023,"Publication in Open Access Repositories will ensure that publications are publicly discoverable, accessible, and re-usable as soon as possible. After appropriate data clearance, and where appropriate IP arrangements have been made, we will make use of pre-print archives such as bioRxiv/medRxiv or Zenodo to stimulate immediate exchange and discussion of results, prior to peer-reviewed publication. Any further manuscripts, abstracts, press releases and publications that may arise from the study will be reviewed by all investigators. A full publication plan will be developed with all investigators and the funder once the study results are available.",,Yes,"The applicants are committed to the open science practice and will ensure rapid sharing of research results with scientific communities, policy makers and public of interest through peer-reviewed journal, national and international conferences. All publications will adopt open access principles based on the gold and green models. The study team will prepare a dissemination plan for study updates and results dissemination to high level stakeholders (IECs, Ministries of Health, NDR, government officials and international stakeholders). Study updates will be communicated to participants, CAB, study staff and other key stakeholders (trial networks, health advocates) timeously. The proposed trial will be registered at the Clinicaltrials.gov and South African Clinical Trials Register (SANCTR). Investigators will write and review the interim analysis and final analysis reports and publications.",2023-06-17 21:08:06,2023-06-17 21:08:06,OTHER,,,,,
213936,213937,NCT02323230,,2014-12-12,,,2021-06-16,2014-12-17,2014-12-23,Estimate,,,,,,,2021-06-16,2021-06-22,Actual,January 2015,,2015-01-31,February 2018,2018-02-28,February 2018,Actual,2018-02-28,June 2017,Actual,2017-06-30,,Interventional,,,A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL,"Phase 2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Recurrent Survivin-Expressing Diffuse Large B-Cell Lymphoma (DLBCL)",Terminated,,Phase 2,4.0,Actual,"ImmunoVaccine Technologies, Inc. (IMV Inc.)",,1.0,,new study,False,,,,False,,,,,,,,,,,,,2023-06-17 21:08:09,2023-06-17 21:08:09,INDUSTRY,,,,,
214215,214216,NCT02547649,,2015-09-10,2019-03-08,,2019-04-09,2015-09-10,2015-09-11,Estimate,2019-03-08,2019-04-02,Actual,,,,2019-04-09,2019-04-16,Actual,"October 8, 2015",Actual,2015-10-08,April 2019,2019-04-30,"January 20, 2016",Actual,2016-01-20,"January 20, 2016",Actual,2016-01-20,,Interventional,,The Baseline Analysis Population consists of all vaccinated participants.,"Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)","A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13 in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older",Completed,,Phase 2,690.0,Actual,Merck Sharp & Dohme LLC,,3.0,,,False,,,,True,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2023-06-18 14:46:17,2023-06-18 14:46:17,INDUSTRY,,,,,
215106,215107,NCT02360475,,2015-01-29,2016-11-29,,2018-05-31,2015-02-05,2015-02-10,Estimate,2017-07-14,2017-08-16,Actual,,,,2018-05-31,2018-07-03,Actual,"March 20, 2015",Actual,2015-03-20,May 2018,2018-05-31,"June 21, 2016",Actual,2016-06-21,"July 2, 2015",Actual,2015-07-02,,Interventional,,,"Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women","An Observer-blind Study to Assess the Safety, Reactogenicity and Immunogenicity of Different Formulations of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women",Completed,,Phase 2,507.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-18 14:56:29,2023-06-18 14:56:29,INDUSTRY,,,,,
215157,215158,NCT03929029,,2019-04-02,,,2022-11-15,2019-04-25,2019-04-26,Actual,,,,,,,2022-11-15,2022-11-16,Actual,"November 11, 2020",Actual,2020-11-11,November 2022,2022-11-30,"September 30, 2028",Anticipated,2028-09-30,"December 31, 2023",Anticipated,2023-12-31,,Interventional,,,Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma,A Phase Ib Study of Neoantigen Vaccine (NeoVax Plus Montanide) in Combination With Nivolumab and Locally Administered Ipilimumab in Patients With Advanced Melanoma,Recruiting,,Phase 1,20.0,Anticipated,Dana-Farber Cancer Institute,,1.0,,,False,,,,True,True,False,,,,,,Data can be shared no earlier than 1 year following the date of publication.,Requests may be directed to: [contact information for Sponsor- Investigator or designee].,,Yes,The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor- Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2023-06-18 14:57:20,2023-06-18 14:57:20,OTHER,,,,,
215273,215274,NCT04033068,,2019-07-08,2021-10-28,,2021-10-28,2019-07-24,2019-07-25,Actual,2021-10-28,2021-12-06,Actual,,,,2021-10-28,2021-12-06,Actual,"August 2, 2019",Actual,2019-08-02,October 2021,2021-10-31,"June 10, 2020",Actual,2020-06-10,"January 30, 2020",Actual,2020-01-30,,Interventional,MV-ZIKA-RSP,,Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001),"Observer Blinded, Randomized Trial to Evaluate Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP",Completed,,Phase 1,48.0,Actual,Themis Bioscience GmbH,,4.0,,,False,,,,False,False,False,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2023-06-17 21:11:39,2023-06-17 21:11:39,INDUSTRY,,,,,
215364,215365,NCT05291845,,2022-03-14,,,2022-07-26,2022-03-14,2022-03-23,Actual,,,,,,,2022-07-26,2022-07-29,Actual,"April 3, 2022",Actual,2022-04-03,July 2022,2022-07-31,October 2023,Anticipated,2023-10-31,October 2023,Anticipated,2023-10-31,,Interventional,,,Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts,Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts: Monotherapy Versus Combined Therapy,Recruiting,,Phase 2,75.0,Anticipated,Zagazig University,,3.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-18 14:59:20,2023-06-18 14:59:20,OTHER_GOV,,,,,
215500,215501,NCT04239313,,2020-01-16,,,2022-09-02,2020-01-20,2020-01-27,Actual,,,,,,,2022-09-02,2022-09-06,Actual,"May 27, 2020",Actual,2020-05-27,September 2022,2022-09-30,"June 20, 2022",Actual,2022-06-20,"February 24, 2021",Actual,2021-02-24,,Interventional,,,A Phase Ib Study of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02),Phase Ib Clinical Trial Evaluating the Safety and Immunogenicity of Freeze-dried Recombinant Tuberculosis Vaccine (AEC / BC02) in Healthy Adults,Completed,,Phase 1,30.0,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,3.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-18 15:00:24,2023-06-18 15:00:24,INDUSTRY,,,,,
215714,215715,NCT05172193,,2021-12-23,,,2022-09-04,2021-12-23,2021-12-29,Actual,,,,,,,2022-09-04,2022-09-08,Actual,"December 31, 2021",Actual,2021-12-31,September 2022,2022-09-30,"September 30, 2023",Anticipated,2023-09-30,"September 30, 2023",Anticipated,2023-09-30,,Interventional,,,Safety & Immunogenicity of Booster SARS-CoV-2 Vaccine (Vero Cell),A Phase II Non-Randomized Open Labelled Clinical Trial to Evaluate the Safety & Immunogenicity of SARS-COV-2 Vaccine (Vero Cell) Inactivated as A Booster Dose,Recruiting,,Phase 2,600.0,Anticipated,PT. Kimia Farma (Persero) Tbk,,1.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 15:02:50,2023-06-18 15:02:50,INDUSTRY,,,,,
216122,216123,NCT02508896,,2015-07-24,,,2017-10-19,2015-07-24,2015-07-27,Estimate,,,,,,,2017-10-19,2017-10-20,Actual,July 2015,,2015-07-31,October 2017,2017-10-31,"August 31, 2017",Actual,2017-08-31,May 2016,Actual,2016-05-31,,Interventional,AFF012,,"Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects","A Single-blind Phase 1 Study Assessing the Safety, Immunogenicity and Low Density Lipoprotein Cholesterol (LDLc)-Lowering Activity of 2 Different Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Targeting AFFITOPE® Vaccines in Healthy Subjects",Completed,,Phase 1,72.0,Actual,Affiris AG,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 21:13:26,2023-06-17 21:13:26,INDUSTRY,,,,,
216125,216126,NCT04912765,,2021-05-24,,,2022-08-17,2021-05-31,2021-06-03,Actual,,,,,,,2022-08-17,2022-08-18,Actual,"April 15, 2021",Actual,2021-04-15,August 2022,2022-08-31,May 2025,Anticipated,2025-05-31,May 2025,Anticipated,2025-05-31,,Interventional,,,Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC,"An Open Label, Single-arm, Phase II Neoantigen (NA) Dendritic Cell (DC) Vaccine and Anti-PD1 (Nivolumab) as Adjuvant Treatment in Resected Hepatocellular Carcinoma (HCC) (Group A) and Liver Metastases From Colorectal Cancer (CRLM) (Group B)",Recruiting,,Phase 2,60.0,Anticipated,"National Cancer Centre, Singapore",,1.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-18 15:09:49,2023-06-18 15:09:49,OTHER,,,,,
216143,216144,NCT02416453,,2015-04-10,2021-01-15,2019-01-17,2021-01-15,2015-04-10,2015-04-15,Estimate,2021-01-15,2021-02-08,Actual,2019-01-17,2019-01-22,Actual,2021-01-15,2021-02-08,Actual,"June 15, 2015",Actual,2015-06-15,January 2021,2021-01-31,"January 19, 2018",Actual,2018-01-19,"January 19, 2018",Actual,2018-01-19,,Interventional,,,"A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults","A Randomized, Observer-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Prime-Boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults in Europe",Completed,,Phase 2,423.0,Actual,Janssen Vaccines & Prevention B.V.,,3.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-18 15:10:10,2023-06-18 15:10:10,INDUSTRY,,,,,
216283,216284,NCT02538341,,2015-08-18,2020-10-28,,2021-10-23,2015-08-30,2015-09-02,Estimate,2021-10-23,2021-11-23,Actual,,,,2021-10-23,2021-11-23,Actual,May 2016,Actual,2016-05-31,October 2021,2021-10-31,December 2020,Actual,2020-12-31,December 2019,Actual,2019-12-31,,Interventional,,,Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial),Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial),Completed,,Phase 2,617.0,Actual,University of Alabama at Birmingham,,2.0,,,False,,,,True,,,,,,,,,,,Yes,,2023-06-18 15:12:11,2023-06-18 15:12:11,OTHER,,,,,
216317,216318,NCT00955006,,2009-08-05,,,2021-10-13,2009-08-06,2009-08-07,Estimate,,,,,,,2021-10-13,2021-10-14,Actual,May 2011,,2011-05-31,October 2021,2021-10-31,"November 22, 2017",Actual,2017-11-22,September 2013,Actual,2013-09-30,,Interventional,,,Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals,A Phase 1b Clinical Trial to Evaluate Mucosal Immune Responses to a DNA Plasmid Vaccine Prime Followed by an HIV-1 Adenoviral Vector Boost in Healthy Adenovirus Type 5 Seronegative HIV-1-uninfected Adults,Completed,,Phase 1,17.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 13:22:16,2023-06-16 13:22:16,NIH,,,,,
216331,216332,NCT05397119,,2022-05-13,,,2022-09-21,2022-05-27,2022-05-31,Actual,,,,,,,2022-09-21,2022-09-22,Actual,"July 7, 2022",Actual,2022-07-07,September 2022,2022-09-30,November 2023,Anticipated,2023-11-30,November 2023,Anticipated,2023-11-30,,Interventional,IN-NE-rH5,,A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults,A Ph1 Randomized Double-Blind Controlled Dose-Range Safety Tolerability & Immunogenicity Study of 2 Doses of Intranasal rH5 Flu Vaccine With & Without Nanoemulsion Adjuvant Followed by 1 Boost of Intramuscular H5N1 Vaccine in Healthy Adults,"Active, not recruiting",,Phase 1,40.0,Actual,BlueWillow Biologics,,5.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-18 15:12:34,2023-06-18 15:12:34,INDUSTRY,,,,,
216465,216466,NCT04909021,,2021-05-26,,,2022-08-01,2021-05-26,2021-06-01,Actual,,,,,,,2022-08-01,2022-08-02,Actual,"June 3, 2021",Actual,2021-06-03,August 2022,2022-08-31,October 2023,Anticipated,2023-10-31,October 2023,Anticipated,2023-10-31,,Interventional,,,Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months,"Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Phase 1c Study to Evaluate the Safety and Immunogenicity of an Intranasal Live Attenuated Respiratory Syncytial Virus Vaccine (MV-012-968) in Seronegative Children 6-36 Months",Recruiting,,Phase 1,63.0,Anticipated,"Meissa Vaccines, Inc.",,6.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-18 15:14:10,2023-06-18 15:14:10,INDUSTRY,,,,,
216852,216853,NCT04818801,,2021-03-19,,,2022-09-26,2021-03-23,2021-03-26,Actual,,,,,,,2022-09-26,2022-09-27,Actual,"June 18, 2021",Actual,2021-06-18,September 2022,2022-09-30,"May 5, 2022",Actual,2022-05-05,"May 5, 2022",Actual,2022-05-05,,Interventional,,,"Safety, Reactogenicity and Immunogenicity Study of ReCOV","A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of ReCOV, a Vaccine for COVID-19, in Healthy Adult Subjects",Completed,,Early Phase 1,100.0,Actual,"Jiangsu Rec-Biotechnology Co., Ltd.",,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 15:18:23,2023-06-18 15:18:23,INDUSTRY,,,,,
217401,217402,NCT04619628,,2020-11-05,,,2022-06-24,2020-11-05,2020-11-06,Actual,,,,,,,2022-06-24,2022-06-28,Actual,"December 11, 2020",Actual,2020-12-11,June 2022,2022-06-30,"May 30, 2022",Actual,2022-05-30,"June 26, 2021",Actual,2021-06-26,,Interventional,,,"Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19","First-in-human, Randomised, Double-blind, Placebo-controlled, Dose-escalation Study in Healthy Young Adults Evaluating the Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Candidate for Prevention of COVID-19",Completed,,Phase 1,48.0,Actual,"Codagenix, Inc",,7.0,,,False,,,,False,False,False,,,False,,,,,,No,,2023-06-16 13:24:44,2023-06-16 13:24:44,INDUSTRY,,,,,
217450,217451,NCT02193087,,2014-07-15,2016-05-19,,2019-07-16,2014-07-15,2014-07-17,Estimate,2016-05-19,2016-06-29,Estimate,,,,2019-07-16,2019-07-18,Actual,"August 6, 2014",Actual,2014-08-06,July 2019,2019-07-31,"May 19, 2015",Actual,2015-05-19,"May 19, 2015",Actual,2015-05-19,,Interventional,,All randomized participants.,Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV),"A Randomized, Double Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults",Completed,,Phase 2,1002.0,Actual,Takeda,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 15:25:51,2023-06-18 15:25:51,INDUSTRY,,,,,
217503,217504,NCT04884685,,2021-05-07,,,2022-08-10,2021-05-07,2021-05-13,Actual,,,,,,,2022-08-10,2022-08-12,Actual,"May 3, 2021",Actual,2021-05-03,May 2021,2021-05-31,"June 20, 2022",Actual,2022-06-20,"August 1, 2021",Actual,2021-08-01,,Interventional,,,Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents,"A Randomized, Double-Blinded, Placebo-Controlled, Phase <U+2161>b Clinical Trial, to Evaluate the Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Healthy Population Aged From 3 to 17 Years.",Completed,,Phase 2,500.0,Actual,"Sinovac Biotech Co., Ltd",,2.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-18 15:27:03,2023-06-18 15:27:03,INDUSTRY,,,,,
218020,218021,NCT02179515,,2014-06-28,2020-12-15,,2021-01-11,2014-06-28,2014-07-02,Estimate,2021-01-11,2021-01-26,Actual,,,,2021-01-11,2021-01-26,Actual,"June 28, 2014",Actual,2014-06-28,January 2021,2021-01-31,"February 28, 2018",Actual,2018-02-28,"April 6, 2017",Actual,2017-04-06,,Interventional,,,Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM),An Open Label Phase I Study to Evaluate the Safety and Tolerability of a Modified Vaccinia Ankara (MVA) Based Vaccine Modified to Express Brachyury and T-Cell Costimulatory Molecules (MVA Brachyury-TRICOM),Completed,,Phase 1,38.0,Actual,National Institutes of Health Clinical Center (CC),,1.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-18 15:32:35,2023-06-18 15:32:35,NIH,,,,,
218107,218108,NCT05167253,,2021-12-16,,,2022-08-25,2021-12-21,2021-12-22,Actual,,,,,,,2022-08-25,2022-08-26,Actual,"February 15, 2022",Anticipated,2022-02-15,February 2022,2022-02-28,"October 31, 2022",Anticipated,2022-10-31,"April 15, 2022",Anticipated,2022-04-15,,Interventional,,,A Study to Evaluate the Ability of UB-612 COVID-19 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines.,"A Phase I, Open-label Study to Evaluate the Ability of UB-612 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines",Withdrawn,,Phase 1,0.0,Actual,"United Biomedical Inc., Asia",,1.0,,Regulatory issues raised by the regulatory authority in Taiwan.,False,,,,,False,False,,,,,,,,,,,2023-06-18 15:33:38,2023-06-18 15:33:38,INDUSTRY,,,,,
218316,218317,NCT05135273,,2021-11-17,,,2022-09-07,2021-11-17,2021-11-26,Actual,,,,,,,2022-09-07,2022-09-08,Actual,"October 22, 2021",Actual,2021-10-22,September 2022,2022-09-30,June 2023,Anticipated,2023-06-30,June 2023,Anticipated,2023-06-30,,Interventional,,,Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali,"Phase 1, Dose-Escalating, Double-Blind, Randomized, Comparator-Controlled Trial of the Safety, Tolerability, and Immunogenicity of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Plasmodium Falciparum in Adults in Mali","Active, not recruiting",,Phase 1,80.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,8.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-18 15:35:59,2023-06-18 15:35:59,NIH,,,,,
218444,218445,NCT05048849,,2021-09-03,,,2022-08-23,2021-09-15,2021-09-17,Actual,,,,,,,2022-08-23,2022-08-24,Actual,"July 19, 2021",Actual,2021-07-19,September 2021,2021-09-30,"April 12, 2022",Actual,2022-04-12,"November 8, 2021",Actual,2021-11-08,,Interventional,,,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study","A Phase II, Prospective, Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidate MVC-COV1901, CT-COV-21 Extension Study",Completed,,Phase 2,274.0,Actual,Medigen Vaccine Biologics Corp.,,1.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 15:37:19,2023-06-18 15:37:19,INDUSTRY,,,,,
218559,218560,NCT03332576,,2017-11-02,,,2021-06-16,2017-11-02,2017-11-06,Actual,,,,,,,2021-06-16,2021-06-18,Actual,"August 23, 2013",Actual,2013-08-23,June 2021,2021-06-30,"September 9, 2019",Actual,2019-09-09,"September 8, 2016",Actual,2016-09-08,,Interventional,,,"Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer","Phase 1b Study of Extended Dosing of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer.",Completed,,Phase 1,37.0,Actual,"ImmunoVaccine Technologies, Inc. (IMV Inc.)",,5.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-17 21:19:02,2023-06-17 21:19:02,INDUSTRY,,,,,
218754,218755,NCT05005247,,2021-08-05,,,2022-08-24,2021-08-05,2021-08-13,Actual,,,,,,,2022-08-24,2022-08-25,Actual,"August 17, 2021",Actual,2021-08-17,August 2022,2022-08-31,"August 5, 2022",Actual,2022-08-05,"August 5, 2022",Actual,2022-08-05,,Interventional,,,Study to Assess a Booster Dose of GBS-NN/NN2 Vaccine,"A follow-on Study to Assess the Safety and Immunogenicity of a Booster Dose of GBS-NN/NN2 Vaccine 1 to 5 Years After GBS-NN/NN2 Recipients in Study MVX0002 Have Completed the Primary Vaccination Course, in Comparison With a Single Dose of GBS-NN/NN2 Administered in Placebo Participants From Study MVX0002 or Vaccine naïve Participants",Completed,,Phase 1,27.0,Actual,Minervax ApS,,1.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-18 15:40:10,2023-06-18 15:40:10,OTHER,,,,,
218901,218902,NCT00613509,,2008-01-16,2010-09-14,,2016-04-12,2008-01-30,2008-02-13,Estimate,2010-11-22,2010-12-17,Estimate,,,,2016-04-12,2016-04-14,Estimate,June 2008,,2008-06-30,April 2016,2016-04-30,June 2010,Actual,2010-06-30,April 2010,Actual,2010-04-30,,Interventional,,,Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma,Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma,Terminated,,Phase 2,23.0,Actual,Sanofi,,2.0,,"No safety concerns, the study was terminated due to slow enrollment. All enrolled patients were followed per protocol.",False,,,,True,,,,,,,,,,,,,2023-06-16 13:28:47,2023-06-16 13:28:47,INDUSTRY,,,,,
219303,219304,NCT02491463,,2015-06-29,2017-04-05,,2018-06-11,2015-07-02,2015-07-08,Estimate,2018-06-11,2018-08-20,Actual,,,,2018-06-11,2018-08-20,Actual,"July 23, 2015",Actual,2015-07-23,May 2018,2018-05-31,"January 26, 2017",Actual,2017-01-26,"April 8, 2016",Actual,2016-04-08,,Interventional,,,"A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults","A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in Healthy Adults",Completed,,Phase 1,73.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-18 15:48:19,2023-06-18 15:48:19,INDUSTRY,,,,,
219304,219305,NCT02038881,,2014-01-15,2020-02-13,,2020-03-20,2014-01-15,2014-01-17,Estimate,2020-03-20,2020-04-02,Actual,,,,2020-03-20,2020-04-02,Actual,"April 28, 2014",Actual,2014-04-28,March 2020,2020-03-31,"May 10, 2017",Actual,2017-05-10,"May 10, 2017",Actual,2017-05-10,,Interventional,,,"Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection","Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection",Completed,,Phase 2,87.0,Actual,Bavarian Nordic,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 15:48:22,2023-06-18 15:48:22,INDUSTRY,,,,,
219384,219385,NCT01644565,,2012-07-11,2016-11-30,,2021-02-10,2012-07-16,2012-07-19,Estimate,2019-04-19,2019-07-08,Actual,,,,2021-02-10,2021-02-12,Actual,August 2012,Actual,2012-08-31,February 2021,2021-02-28,June 2015,Actual,2015-06-30,June 2014,Actual,2014-06-30,,Interventional,,Demographics within Final Clinical Study Report were not broken out by groups or cohorts. No randomization was presented to detail which subject was in which group or cohort. Data is presented as it was detailed in the FCSR. No explanation was given as to why groups were combined to report demographic data.,Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea,A Phase 1 Dose Escalating Study of Two Enterotoxigenic Escherichia Coli Prototype Adhesin-based Vaccines With or Without Modified Heat-labile Enterotoxin by Intradermal or Transcutaneous Immunization,Completed,,Phase 1,57.0,Actual,U.S. Army Medical Research and Development Command,,9.0,,,False,,,,True,,,,,,,,,,,Undecided,,2023-06-18 15:49:38,2023-06-18 15:49:38,FED,,,,,
219395,219396,NCT02485301,,2015-06-18,2017-05-16,,2017-12-04,2015-06-25,2015-06-30,Estimate,2017-12-04,2018-01-04,Actual,,,,2017-12-04,2018-01-04,Actual,"July 15, 2015",Actual,2015-07-15,November 2017,2017-11-30,"December 23, 2016",Actual,2016-12-23,"December 23, 2016",Actual,2016-12-23,,Interventional,,,A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults,Safety and Immunogenicity Study of GSK Biologicals' Investigational Recombinant Chimpanzee Adenovirus Type 3-vectored Ebola Zaire Vaccine (GSK3390107A) in Adults in Africa,Completed,,Phase 2,3024.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-18 15:49:52,2023-06-18 15:49:52,INDUSTRY,,,,,
219715,219716,NCT02269423,,2014-10-10,2019-09-13,,2019-10-21,2014-10-16,2014-10-21,Estimate,2019-10-21,2019-10-23,Actual,,,,2019-10-21,2019-10-23,Actual,"October 13, 2014",Actual,2014-10-13,October 2019,2019-10-31,"August 25, 2015",Actual,2015-08-25,"August 25, 2015",Actual,2015-08-25,,Interventional,,,Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001),"A Phase 1 Randomized, Single-Center, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC-1001 (VSV<U+0394>G-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Subjects",Completed,,Phase 1,39.0,Actual,Merck Sharp & Dohme LLC,,4.0,,,False,,,,True,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2023-06-18 15:54:23,2023-06-18 15:54:23,INDUSTRY,,,,,
220339,220340,NCT02017899,,2013-12-17,2017-09-06,,2018-08-10,2013-12-17,2013-12-23,Estimate,2018-08-10,2019-01-23,Actual,,,,2018-08-10,2019-01-23,Actual,February 2014,,2014-02-28,August 2018,2018-08-31,March 2015,Actual,2015-03-31,March 2015,Actual,2015-03-31,,Interventional,,,"A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.","A Phase 1, Randomized, Observer Blinded, Placebo Controlled, Single Center, Dose Escalation Study to Evaluate the Safety and Immunogenicity of 3 Vaccinations With Shigella Sonnei Vaccine (1790GAHB) Administered Intramuscularly in Healthy Adults.",Completed,,Phase 1,50.0,Actual,GSK Vaccines Institute For Global Health S.r.l.,,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 16:04:21,2023-06-18 16:04:21,INDUSTRY,,,,,
220422,220423,NCT02013687,,2013-11-25,2016-11-21,,2017-01-25,2013-12-11,2013-12-17,Estimate,2016-11-21,2017-01-18,Estimate,,,,2017-01-25,2017-03-08,Actual,October 2013,,2013-10-31,January 2017,2017-01-31,January 2015,Actual,2015-01-31,August 2014,Actual,2014-08-31,,Interventional,,,Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults,A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults,Completed,,Phase 1,44.0,Actual,"Fraunhofer, Center for Molecular Biotechnology",,4.0,,,False,,,,True,,,,,,,,,,,Undecided,,2023-06-18 16:05:41,2023-06-18 16:05:41,INDUSTRY,,,,,
220446,220447,NCT05508178,,2022-08-17,,,2022-08-18,2022-08-18,2022-08-19,Actual,,,,,,,2022-08-18,2022-08-19,Actual,"August 17, 2020",Actual,2020-08-17,August 2022,2022-08-31,"October 26, 2021",Actual,2021-10-26,"October 26, 2021",Actual,2021-10-26,,Interventional,,,"Recombinant, Bivalent, Norovirus Vaccine Study","A Phase 1 Randomised, Double-Blind, Placebo-Controlled, Safety and Immunogenicity Study of a Plant-Produced, Bivalent, Recombinant Norovirus-Like Particle Vaccine, Administered Intramuscularly to Healthy Adults Aged 18 to 40 Years",Completed,,Phase 1,60.0,Actual,Icon Genetics GmbH,,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-17 21:21:36,2023-06-17 21:21:36,INDUSTRY,,,,,
220550,220551,NCT01765426,,2012-12-17,2016-11-04,,2019-07-16,2013-01-08,2013-01-10,Estimate,2016-11-04,2017-01-05,Estimate,,,,2019-07-16,2019-07-18,Actual,"February 15, 2013",Actual,2013-02-15,July 2019,2019-07-31,"June 26, 2014",Actual,2014-06-26,"June 26, 2014",Actual,2014-06-26,,Interventional,,Baseline analysis population included all randomized participants.,Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector,"Phase 1b, Partial-Blind, Parallel Group, Randomized Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine (DENVax) Administered Intradermally Using Needle or a Needle-Free PharmaJet® Injector in Healthy Adults",Completed,,Phase 1,67.0,Actual,Takeda,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 16:08:22,2023-06-18 16:08:22,INDUSTRY,,,,,
220628,220629,NCT02075541,,2014-02-27,2018-04-16,,2018-06-14,2014-02-27,2014-03-03,Estimate,2018-06-14,2018-08-01,Actual,,,,2018-06-14,2018-08-01,Actual,"July 8, 2014",Actual,2014-07-08,June 2018,2018-06-30,"April 19, 2017",Actual,2017-04-19,"April 19, 2017",Actual,2017-04-19,,Interventional,,,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.","An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients",Completed,,Phase 2,145.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-18 16:09:56,2023-06-18 16:09:56,INDUSTRY,,,,,
220655,220656,NCT00890019,,2009-04-28,,,2012-08-21,2009-04-28,2009-04-29,Estimate,,,,,,,2012-08-21,2012-08-22,Estimate,July 2007,,2007-07-31,August 2012,2012-08-31,September 2011,Actual,2011-09-30,August 2011,Actual,2011-08-31,,Interventional,,,A Study of AdCh63 ME-TRAP Alone and With MVA ME-TRAP,"A Phase I Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidate AdCh63 ME-TRAP, Alone and With MVA ME-TRAP, Using a Prime-boost Delivery Schedule",Completed,,Phase 1,54.0,Actual,University of Oxford,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 13:33:23,2023-06-16 13:33:23,OTHER,,,,,
220720,220721,NCT01982331,,2013-10-30,2018-09-07,,2019-02-06,2013-11-05,2013-11-13,Estimate,2018-09-07,2019-02-06,Actual,,,,2019-02-06,2019-02-26,Actual,October 2013,,2013-10-31,February 2019,2019-02-28,March 2014,Actual,2014-03-31,January 2014,Actual,2014-01-31,,Interventional,,,"Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/CALIFORNIA/66/395 (H2N2) Influenza Vaccine","Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/California/66/395 (H2N2)Influenza Vaccine",Completed,,Phase 1,38.0,Actual,PATH,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 16:11:36,2023-06-18 16:11:36,OTHER,,,,,
220759,220760,NCT01764256,,2013-01-07,2018-08-08,,2019-02-19,2013-01-08,2013-01-09,Estimate,2018-09-26,2019-02-15,Actual,,,,2019-02-19,2019-03-12,Actual,December 2012,,2012-12-31,February 2019,2019-02-28,September 2013,Actual,2013-09-30,June 2013,Actual,2013-06-30,,Interventional,,,A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine,"A Phase 1 Double Blinded, Randomized, Placebo-controlled Dose Escalation Study to Examine the Safety, Reactogenicity, Tolerability and Immunogenicity of the P2-VP8 Subunit Rotavirus Vaccine in Healthy Adult Volunteers",Completed,,Phase 1,48.0,Actual,PATH,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 16:12:49,2023-06-18 16:12:49,OTHER,,,,,
221171,221172,NCT04627675,,2020-11-06,,,2023-01-04,2020-11-12,2020-11-13,Actual,,,,,,,2023-01-04,2023-01-05,Actual,"December 30, 2020",Actual,2020-12-30,January 2023,2023-01-31,"December 28, 2022",Actual,2022-12-28,"March 11, 2021",Actual,2021-03-11,,Interventional,CORVax12,,CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2),"CORVax12 - a Phase I Trial of SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine (CORVax) +/- pIL-12 (Tavokinogene Telseplasmid) in Healthy Volunteers, With Immunodynamic Biomarker Monitoring of Coordinated Cellular/Humoral Response",Completed,,Phase 1,16.0,Actual,Providence Health & Services,,4.0,,,False,,,,False,True,True,True,,,,,,,,No,,2023-06-14 06:56:08,2023-06-14 06:56:08,OTHER,,,,,
221578,221579,NCT05422326,,2022-06-14,,,2023-04-13,2022-06-14,2022-06-16,Actual,,,,,,,2023-04-13,2023-04-14,Actual,"July 18, 2022",Actual,2022-07-18,April 2023,2023-04-30,"March 24, 2023",Actual,2023-03-24,"October 24, 2022",Actual,2022-10-24,,Interventional,,,A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed,"A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59-adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed",Completed,,Phase 2,260.0,Actual,Seqirus,,3.0,,,False,,,,False,True,False,,,False,,,,,,Undecided,,2023-06-18 16:22:00,2023-06-18 16:22:00,INDUSTRY,,,,,
221631,221632,NCT05137236,,2021-11-24,,,2023-04-13,2021-11-24,2021-11-30,Actual,,,,,,,2023-04-13,2023-04-14,Actual,"December 6, 2021",Actual,2021-12-06,April 2023,2023-04-30,"March 23, 2023",Actual,2023-03-23,"March 23, 2023",Actual,2023-03-23,,Interventional,,,A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters,"A Phase 2A, Randomized, Stratified, Observer-Blind Study to Evaluate the Immunogenicity and Safety of mRNA-1283 Vaccine Boosters for SARS-CoV-2",Completed,,Phase 2,543.0,Actual,"ModernaTX, Inc.",,8.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-18 16:22:51,2023-06-18 16:22:51,INDUSTRY,,,,,
221632,221633,NCT00686582,,2008-05-27,2018-12-19,,2019-02-18,2008-05-29,2008-05-30,Estimate,2019-02-11,2019-02-18,Actual,,,,2019-02-18,2019-03-13,Actual,August 2008,,2008-08-31,February 2019,2019-02-28,June 2009,Actual,2009-06-30,December 2008,Actual,2008-12-31,,Interventional,,Persistence Set i.e. subjects previously vaccinated in study POX-MVA-005 with a blood draw at the screening visit of study POX-MVA-023,An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees,An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees,Completed,,Phase 2,304.0,Actual,Bavarian Nordic,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 06:56:49,2023-06-14 06:56:49,INDUSTRY,,,,,
222020,222021,NCT02506933,,2015-07-21,2023-03-21,,2023-03-21,2015-07-21,2015-07-23,Estimate,2023-03-21,2023-04-14,Actual,,,,2023-03-21,2023-04-14,Actual,"November 5, 2015",Actual,2015-11-05,March 2023,2023-03-31,"December 30, 2023",Anticipated,2023-12-30,"January 25, 2018",Actual,2018-01-25,,Interventional,,,Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant,"A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Protective Function of a CMV-MVA Triplex Vaccine in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant","Active, not recruiting",,Phase 2,102.0,Actual,City of Hope Medical Center,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 16:27:10,2023-06-18 16:27:10,OTHER,,,,,
222111,222112,NCT05163847,,2021-12-07,,,2022-11-11,2021-12-07,2021-12-20,Actual,,,,,,,2022-11-11,2022-11-14,Actual,"June 14, 2022",Actual,2022-06-14,November 2022,2022-11-30,"November 3, 2022",Actual,2022-11-03,"November 3, 2022",Actual,2022-11-03,,Interventional,,,Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults,"Phase 1b Study to Investigate the Safety and Immunogenicity of Cam2020 (A/Cambodia/e0826360/2020) M2SR H3N2 Monovalent Influenza Vaccine Administered Alone or With Licensed, Inactivated Influenza Vaccine in Adults 65 to 85 Years Old",Completed,,Phase 1,303.0,Actual,FluGen Inc,,4.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-18 16:28:24,2023-06-18 16:28:24,INDUSTRY,,,,,
222134,222135,NCT01755598,,2012-12-19,2019-11-12,,2019-11-12,2012-12-19,2012-12-24,Estimate,2019-11-12,2019-12-03,Actual,,,,2019-11-12,2019-12-03,Actual,"August 19, 2014",Actual,2014-08-19,November 2019,2019-11-30,"November 16, 2018",Actual,2018-11-16,"November 16, 2018",Actual,2018-11-16,,Interventional,,,Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults,"Efficacy of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342 Against TB Disease, in Adults Living in a TB Endemic Region",Completed,,Phase 2,3575.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,False,False,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=20104,Yes,IPD is available via the Clinical Study Data Request site (click on the link provided below),2023-06-18 16:28:39,2023-06-18 16:28:39,INDUSTRY,,,,,
222153,222154,NCT01961115,,2013-10-08,2017-10-30,,2018-05-08,2013-10-09,2013-10-11,Estimate,2018-01-09,2018-02-07,Actual,,,,2018-05-08,2018-06-08,Actual,"September 13, 2013",Actual,2013-09-13,May 2018,2018-05-31,"May 18, 2017",Actual,2017-05-18,"October 31, 2016",Actual,2016-10-31,,Interventional,,,Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma,"A Phase II Pilot Trial of an Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients With Advanced Melanoma",Completed,,Phase 2,11.0,Actual,Fred Hutchinson Cancer Center,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-18 16:29:16,2023-06-18 16:29:16,OTHER,,,,,
222247,222248,NCT00397449,,2006-11-08,,,2007-08-09,2006-11-08,2006-11-09,Estimate,,,,,,,2007-08-09,2007-08-10,Estimate,October 2006,,2006-10-31,August 2007,2007-08-31,December 2007,Anticipated,2007-12-31,,,,,Interventional,,,"GMZ2-Aluminum Hydroxide Phase I, Tübingen","Assessment of the Safety and Immunogenicity of the Recombinant Lactococcus Lactis Hybrid GMZ2 [GLURP+MSP3] a Malaria Vaccine in Healthy Adult Volunteers. A Phase I, Double-Blind, Randomised, Dose-Selection, Unicentre Trial",Unknown status,"Active, not recruiting",Phase 1,30.0,Anticipated,European Malaria Vaccine Initiative,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 07:01:32,2023-06-15 07:01:32,OTHER,,,,,
222387,222388,NCT04773067,,2021-02-23,,,2022-08-25,2021-02-24,2021-02-26,Actual,,,,,,,2022-08-25,2022-08-26,Actual,"January 30, 2021",Actual,2021-01-30,June 2022,2022-06-30,"March 8, 2022",Actual,2022-03-08,"March 8, 2022",Actual,2022-03-08,,Interventional,,,"A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers","A Phase II, Placebo-controlled, Randomized, Observer-blind Study to Evaluate the Immunogenicity, Safety, and Tolerability of UB-612 Vaccine Against COVID-19 in Adolescent, Younger and Elderly Adult Volunteers",Terminated,,Phase 2,3877.0,Actual,"United Biomedical Inc., Asia",,2.0,,"Under the limited resources, to re-plan the ongoing clinical trials of this product.",False,,,,True,False,False,,,,,,,,,,,2023-06-18 16:32:29,2023-06-18 16:32:29,INDUSTRY,,,,,
222391,222392,NCT02243371,,2014-09-15,2019-08-06,,2021-03-17,2014-09-16,2014-09-17,Estimate,2019-09-16,2019-10-08,Actual,,,,2021-03-17,2021-04-06,Actual,"January 2, 2015",Actual,2015-01-02,February 2020,2020-02-29,"July 21, 2017",Actual,2017-07-21,"July 21, 2017",Actual,2017-07-21,,Interventional,,,GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab,"A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS-207 With or Without Nivolumab in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma",Completed,,Phase 2,93.0,Actual,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,2.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-18 16:32:33,2023-06-18 16:32:33,OTHER,,,,,
222666,222667,NCT01706458,,2012-10-09,2018-05-17,,2021-06-15,2012-10-11,2012-10-15,Estimate,2018-06-19,2018-07-17,Actual,,,,2021-06-15,2021-06-18,Actual,"May 20, 2013",Actual,2013-05-20,May 2021,2021-05-31,"August 13, 2020",Actual,2020-08-13,"June 12, 2017",Actual,2017-06-12,,Interventional,,"Male patients, histological diagnosis of prostate adenocarcinoma and PSA recurrence following castration were eligible, provided they had evidence of metastatic disease by CT of abdomen/pelvis or bone scintigraphy. Progressive disease following last treatment required, per Prostate Cancer Working Group 2 criteria. 4 weeks from prior treatment.",Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer,"Pilot Trial of Sipuleucel-T, With or Without pTVG-HP DNA Booster Vaccine, in Patients With Castrate-Resistant, Metastatic Prostate Cancer",Completed,,Phase 2,18.0,Actual,"University of Wisconsin, Madison",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 16:37:12,2023-06-18 16:37:12,OTHER,,,,,
222807,222808,NCT02298179,,2014-11-19,2018-03-26,,2018-08-10,2014-11-19,2014-11-21,Estimate,2018-08-10,2018-08-13,Actual,,,,2018-08-10,2018-08-13,Actual,"December 19, 2014",Actual,2014-12-19,August 2018,2018-08-31,"March 27, 2017",Actual,2017-03-27,"March 27, 2017",Actual,2017-03-27,,Interventional,,,A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults,"A Phase 1 Randomized, Observer Blind, Placebo Controlled, Dosage-Escalation Single Center Study to Evaluate the Safety and Immunogenicity of an RSV Fusion Glycoprotein (F) Subunit Vaccine in Healthy Adults",Completed,,Phase 1,288.0,Actual,GlaxoSmithKline,,12.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 16:39:51,2023-06-18 16:39:51,INDUSTRY,,,,,
222820,222821,NCT01058785,,2010-01-27,,,2010-07-28,2010-01-28,2010-01-29,Estimate,,,,,,,2010-07-28,2010-07-29,Estimate,March 2003,,2003-03-31,January 2010,2010-01-31,December 2005,Actual,2005-12-31,December 2005,Actual,2005-12-31,,Interventional,,,Phase II Study of Lucanix in Patients With Stages II-IV Non-Small Cell Lung Cancer,Phase II Study of Lucanix (TGF-beta2 Antisense Gene Modified Allogeneic Tumor Cell Vaccine) in Patients With Stages II-IV Non-Small Cell Lung Cancer,Completed,,Phase 2,75.0,Actual,NovaRx Corporation,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 13:39:36,2023-06-16 13:39:36,INDUSTRY,,,,,
222897,222898,NCT04188223,,2019-11-27,,,2022-07-29,2019-12-03,2019-12-05,Actual,,,,,,,2022-07-29,2022-08-01,Actual,"December 3, 2019",Actual,2019-12-03,July 2022,2022-07-31,"July 16, 2020",Actual,2020-07-16,"July 16, 2020",Actual,2020-07-16,,Interventional,,,Safety and Immunogenicity Following Recombinant Hepatitis B (Bio Farma) Vaccine in Adults & Children,Safety and Preliminary of Immunogenicity Following Recombinant Hepatitis B (Bio Farma) Vaccine in Adults & Children (Phase I),Completed,,Phase 1,100.0,Actual,PT Bio Farma,,2.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-18 16:41:46,2023-06-18 16:41:46,INDUSTRY,,,,,
223055,223056,NCT02285777,,2014-11-05,2017-09-06,2015-04-17,2018-08-22,2014-11-05,2014-11-07,Estimate,2017-10-30,2017-12-06,Actual,2015-04-17,2015-05-06,Estimate,2018-08-22,2018-09-24,Actual,"December 1, 2014",,2014-12-01,May 2018,2018-05-31,"June 11, 2015",Actual,2015-06-11,"March 26, 2015",Actual,2015-03-26,,Interventional,,,"Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents","A Phase 2b, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of the 3rd Dose of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolescents in the U.S.",Completed,,Phase 2,189.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-18 16:43:36,2023-06-18 16:43:36,INDUSTRY,,,,,
223097,223098,NCT01052935,,2010-01-19,,,2017-06-09,2010-01-19,2010-01-21,Estimate,,,,,,,2017-06-09,2017-06-14,Actual,January 2010,,2010-01-31,June 2017,2017-06-30,October 2010,Actual,2010-10-31,January 2010,Actual,2010-01-31,,Interventional,,,A Study to Assess the Persistence of a GBS Antibody in Women Previously Immunized With a GBS Vaccine,A Phase I Extension Study to Assess the Long-Term Persistence of GBS Serotype Ia Antibodies in Women Previously Immunized With a GBS Ia Crm-Glycoconjugate Vaccine,Completed,,Phase 1,50.0,Actual,Novartis,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 13:40:54,2023-06-16 13:40:54,INDUSTRY,,,,,
223326,223327,NCT05400746,,2022-05-26,,,2022-12-13,2022-05-26,2022-06-02,Actual,,,,,,,2022-12-13,2022-12-14,Actual,"November 2, 2022",Actual,2022-11-02,June 2022,2022-06-30,"May 30, 2023",Anticipated,2023-05-30,"May 30, 2023",Anticipated,2023-05-30,,Interventional,,,A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK,A Phase Ia Study to Assess Safety and Immunogenicity of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in Healthy Adults Living in the UK,Recruiting,,Early Phase 1,30.0,Anticipated,University of Oxford,,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 16:46:37,2023-06-18 16:46:37,OTHER,,,,,
223385,223386,NCT00982774,,2009-09-21,,,2011-06-23,2009-09-22,2009-09-23,Estimate,,,,,,,2011-06-23,2011-06-27,Estimate,April 2009,,2009-04-30,June 2011,2011-06-30,April 2011,Actual,2011-04-30,April 2011,Actual,2011-04-30,,Interventional,,,Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDL,"Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine in Combination With SSG in the Treatment of Patients With PKDL",Completed,,Phase 1,42.0,Actual,Access to Advanced Health Institute (AAHI),,,,,False,,,,True,,,,,,,,,,,,,2023-06-16 13:42:05,2023-06-16 13:42:05,OTHER,,,,,
223636,223637,NCT04824638,,2021-03-07,,,2022-09-02,2021-03-30,2021-04-01,Actual,,,,,,,2022-09-02,2022-09-07,Actual,"March 8, 2021",Actual,2021-03-08,September 2022,2022-09-30,"November 30, 2023",Anticipated,2023-11-30,"June 30, 2021",Actual,2021-06-30,,Interventional,CoviCompareP,,BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers,A Phase II Trial Assessing Immunogenicity and Safety of COVID-19 mRNA Vaccine BNT162b2 in Adult Volunteers With no History of SARS-CoV-2 Infection Administered With Two Doses of Vaccine (D1-D29) and in Adult Volunteers With Documented History of SARS-CoV-2 Infection (of More Than 5 Months) Administered With Only One Dose of Vaccine,"Active, not recruiting",,Phase 2,267.0,Actual,"ANRS, Emerging Infectious Diseases",,2.0,,,False,,,,False,False,False,,,,,,,,,Undecided,,2023-06-18 16:49:11,2023-06-18 16:49:11,OTHER_GOV,,,,,
223736,223737,NCT02472548,,2015-06-05,,,2020-01-31,2015-06-15,2015-06-16,Estimate,,,,,,,2020-01-31,2020-02-05,Actual,May 2015,,2015-05-31,January 2020,2020-01-31,"March 14, 2017",Actual,2017-03-14,"March 14, 2017",Actual,2017-03-14,,Interventional,,,"A Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine","A Phase I Randomized, Observer-blind, Controlled, Dose Escalation Trial of the Safety and Tolerability of Two Intramuscular Doses of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine Containing Respiratory Syncytial Virus (RSV) SHe Antigen and a Novel Adjuvant DepoVaxTM, or SHe A Antigen Co-administered With Aluminum Hydroxide, or Placebo to Healthy Adults =50-64 Years of Age",Completed,,Phase 1,40.0,Actual,Dalhousie University,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 21:26:36,2023-06-17 21:26:36,OTHER,,,,,
224142,224143,NCT02196285,,2014-07-16,,,2016-06-21,2014-07-21,2014-07-22,Estimate,,,,,,,2016-06-21,2016-06-22,Estimate,September 2015,,2015-09-30,June 2016,2016-06-30,March 2016,Actual,2016-03-31,December 2015,Actual,2015-12-31,,Interventional,MR,,Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella,"A Phase I, Open, Uncontrolled Study, to Evaluate the Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella in Young Adults",Completed,,Phase 1,30.0,Actual,The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz),,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 21:27:44,2023-06-17 21:27:44,OTHER,,,,,
224272,224273,NCT02147587,,2014-05-22,2016-06-21,,2018-03-13,2014-05-22,2014-05-28,Estimate,2018-03-13,2018-04-11,Actual,,,,2018-03-13,2018-04-11,Actual,June 2014,Actual,2014-06-30,March 2018,2018-03-31,July 2015,Actual,2015-07-31,June 2015,Actual,2015-06-30,,Interventional,,The baseline analysis population included all randomized participants who received at least 1 dose of study drug (tofacitinib or placebo).,A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate,"A Randomized, Double-blind, Placebo-controlled, Phase 2 Study To Assess The Immune Response Following Administration Of Zoster Vaccine To Subjects With Rheumatoid Arthritis Receiving Tofacitinib (Cp-690,550) Or Placebo With Background Methotrexate Treatment",Completed,,Phase 2,112.0,Actual,Pfizer,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 16:58:01,2023-06-18 16:58:01,INDUSTRY,,,,,
224517,224518,NCT05417165,,2022-06-09,,,2022-11-10,2022-06-09,2022-06-14,Actual,,,,,,,2022-11-10,2022-11-14,Actual,"December 31, 2022",Anticipated,2022-12-31,November 2022,2022-11-30,"December 31, 2025",Anticipated,2025-12-31,"December 31, 2024",Anticipated,2024-12-31,,Interventional,,,Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia,Phase II Comparative Study of Anti-Pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia,Not yet recruiting,,Phase 2,70.0,Anticipated,Ohio State University Comprehensive Cancer Center,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-18 17:02:13,2023-06-18 17:02:13,OTHER,,,,,
224548,224549,NCT04591379,,2020-09-07,,,2022-12-12,2020-10-13,2020-10-19,Actual,,,,,,,2022-12-12,2022-12-13,Actual,"February 26, 2021",Actual,2021-02-26,December 2022,2022-12-31,"November 1, 2021",Actual,2021-11-01,"September 22, 2021",Actual,2021-09-22,,Interventional,,,Intratumoral Influenza Vaccine for Early Colorectal Cancer,Intratumoral Influenza Vaccine for Early Colorectal Cancer,Completed,,Phase 2,10.0,Actual,Zealand University Hospital,,1.0,,,False,,,,True,False,False,,,False,,,Study protocol and informed consent form will be available upon start of recruitment of patients,,,Yes,,2023-06-18 17:02:41,2023-06-18 17:02:41,OTHER,,,,,
224675,224676,NCT04060277,,2019-07-29,,,2022-12-08,2019-08-14,2019-08-19,Actual,,,,,,,2022-12-08,2022-12-12,Actual,"November 27, 2019",Actual,2019-11-27,December 2022,2022-12-31,"April 7, 2025",Anticipated,2025-04-07,"April 7, 2025",Anticipated,2025-04-07,,Interventional,,,Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation,"A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Protective Function of CMV-MVA Triplex Vaccine in Adult Recipients of Haploidentical Hematopoietic Stem Cell Transplant","Active, not recruiting",,Phase 2,12.0,Actual,City of Hope Medical Center,,2.0,,,,,,,True,True,False,,,False,,,,,,,,2023-06-18 17:05:52,2023-06-18 17:05:52,OTHER,,,,,
224811,224812,NCT01540474,,2012-02-09,2020-05-22,,2021-05-12,2012-02-27,2012-02-28,Estimate,2021-05-12,2021-06-08,Actual,,,,2021-05-12,2021-06-08,Actual,February 2012,Actual,2012-02-29,May 2021,2021-05-31,December 2012,Actual,2012-12-31,October 2012,Actual,2012-10-31,,Interventional,,,"Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults","Phase 1 Study With the Vaccine Candidate Plasmodium Falciparum Malaria Protein (FMP012), an E.Coli-expressed Cell-Traversal Protein, Administered Intramuscularly in Healthy Malaria-Naive Adults",Completed,,Phase 1,36.0,Actual,U.S. Army Medical Research and Development Command,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 17:07:53,2023-06-18 17:07:53,FED,,,,,
225022,225023,NCT02210780,,2014-08-05,2020-03-20,2017-02-07,2020-04-23,2014-08-05,2014-08-07,Estimate,2020-04-23,2020-05-07,Actual,2017-02-07,2017-02-08,Estimate,2020-04-23,2020-05-07,Actual,"August 5, 2014",Actual,2014-08-05,April 2020,2020-04-30,"September 15, 2015",Actual,2015-09-15,"September 15, 2015",Actual,2015-09-15,,Interventional,,"The safety analysis set (SAF) included all randomized participants who received any study drug, and was analyzed as treated. Any participant given at least 1 dupilumab injection was assigned to the dupilumab group. The safety analysis was based on the SAF.",Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD),"A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab",Completed,,Phase 2,194.0,Actual,Regeneron Pharmaceuticals,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 17:11:14,2023-06-18 17:11:14,INDUSTRY,,,,,
225055,225056,NCT04144348,,2019-10-28,,,2023-02-02,2019-10-28,2019-10-30,Actual,,,,,,,2023-02-02,2023-02-03,Actual,"November 4, 2019",Actual,2019-11-04,January 2023,2023-01-31,"December 20, 2022",Actual,2022-12-20,"December 20, 2022",Actual,2022-12-20,,Interventional,,,"Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure","A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, and to Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure",Completed,,Phase 1,51.0,Actual,"ModernaTX, Inc.",,4.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-16 13:46:48,2023-06-16 13:46:48,INDUSTRY,,,,,
225435,225436,NCT04782323,,2021-03-01,,2022-09-16,2022-09-16,2021-03-01,2021-03-04,Actual,,,,2022-09-16,2022-09-21,Actual,2022-09-16,2022-09-21,Actual,"April 13, 2021",Actual,2021-04-13,September 2022,2022-09-30,"March 3, 2022",Actual,2022-03-03,"September 22, 2021",Actual,2021-09-22,,Interventional,,,Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults,"A Phase 2, Randomized, Observer-blind, Antigen and Adjuvant Dose Ranging Clinical Study to Evaluate Safety and Immunogenicity of Different Formulations of MF59 Adjuvanted Quadrivalent Subunit Inactivated Cell-derived Influenza Vaccine (aQIVc) in Older Adults =50 Years of Age",Completed,,Phase 2,839.0,Actual,Seqirus,,8.0,,,,,,,True,True,False,,,,,,"Time Frame:

SEQIRUS discloses results from clinical studies within 12 months of last patient last visit (LPLV) unless otherwise mandated by local laws or regulations.","SEQIRUS will consider requests from qualified scientific and medical researchers to disclose protocols, anonymized subject-level data and study-level data when there is medical, scientific and/or public health interest to ensure the safe use of a Seqirus product licensed on or after 1 January 2014 in the United States (US) and/or the European Union (EU). This applies to Seqirus-sponsored interventional studies initiated after 27 September 2007 and ongoing as of 26 December 2007, that have been included as part of a US or EU submission package which received approval in US and EU on or after 1 January 2014 and have been accepted for publication",https://www.seqirus.us/partnering,Yes,"SEQIRUS supports the release of anonymized subject-level and study-level data in compliance with regulatory requirements, including Clinical Documents which are part of the CTD modules submitted to regulatory agencies for public release.

Summary results disclosure is either in document form (e.g., ICH E3 Clinical Study Report synopsis) or structured data form (such as summary results in ClinicalTrials.gov (United States) or eudract.ema.europa.eu (EU Clinical Trial Registry [EU CTR])",2023-06-18 17:18:05,2023-06-18 17:18:05,INDUSTRY,,,,,
225451,225452,NCT04798001,,2021-03-09,,,2022-08-01,2021-03-12,2021-03-15,Actual,,,,,,,2022-08-01,2022-08-02,Actual,"April 12, 2021",Actual,2021-04-12,August 2022,2022-08-31,"October 31, 2022",Anticipated,2022-10-31,"October 31, 2022",Anticipated,2022-10-31,,Interventional,,,Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults,"Phase 1, Open-Label, Dose-Escalation Study to Evaluate Tolerability, Safety, and Immunogenicity of an Intranasal Live Attenuated Respiratory Syncytial Virus Vaccine Expressing Spike Protein of SARS-CoV-2 in Healthy Adults Ages 18 - 69 Years",Recruiting,,Phase 1,130.0,Anticipated,"Meissa Vaccines, Inc.",,8.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-18 17:18:17,2023-06-18 17:18:17,INDUSTRY,,,,,
225919,225920,NCT00774384,,2008-10-16,,,2016-11-14,2008-10-16,2008-10-17,Estimate,,,,,,,2016-11-14,2016-11-15,Estimate,September 2009,,2009-09-30,November 2016,2016-11-30,November 2011,Actual,2011-11-30,November 2011,Actual,2011-11-30,,Interventional,,,Regulation of Mucosal Immune Response to Systemic MenB Vaccine,"A Phase II, Open Label, Randomised, Single Centre Study To Evaluate The Importance Of Naturally Induced Immune Regulation On The Mucosal Immune Response To Meningococcal Serogroup B Outer Membrane Vesicle (Omv) Vaccine When Administered Intramuscularly To Adults & Adolescents",Completed,,Phase 2,9.0,Actual,University Hospitals Bristol and Weston NHS Foundation Trust,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 13:48:42,2023-06-16 13:48:42,OTHER,,,,,
225989,225990,NCT02212457,,2014-08-06,2017-03-02,2015-05-29,2019-06-13,2014-08-06,2014-08-08,Estimate,2017-06-22,2017-07-21,Actual,2015-05-29,2015-06-26,Estimate,2019-06-13,2019-06-27,Actual,"August 21, 2014",Actual,2014-08-21,June 2019,2019-06-30,"March 3, 2016",Actual,2016-03-03,"May 22, 2015",Actual,2015-05-22,,Interventional,,,Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents,"A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of GSK Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to GSK Meningococcal Group B Vaccine, in Healthy Adolescents",Completed,,Phase 2,1063.0,Actual,GlaxoSmithKline,,6.0,,,False,,,,,,,,,,,,,,,,,2023-06-18 17:28:52,2023-06-18 17:28:52,INDUSTRY,,,,,
226049,226050,NCT01625689,,2012-06-14,2015-04-28,,2015-05-15,2012-06-19,2012-06-21,Estimate,2015-05-15,2015-06-01,Estimate,,,,2015-05-15,2015-06-01,Estimate,June 2012,,2012-06-30,June 2012,2012-06-30,February 2013,Actual,2013-02-28,February 2013,Actual,2013-02-28,,Interventional,,All participants enrolled who received a single dose of LAIV or placebo.,Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine,Assessment of the Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine Among Children Aged 24 Through 59 Months in Bangladesh,Completed,,Phase 2,309.0,Actual,PATH,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 17:30:25,2023-06-18 17:30:25,OTHER,,,,,
226194,226195,NCT04019444,,2019-07-11,,,2023-03-23,2019-07-11,2019-07-15,Actual,,,,,,,2023-03-23,2023-03-24,Actual,"September 19, 2019",Actual,2019-09-19,February 2023,2023-02-28,"November 4, 2023",Anticipated,2023-11-04,"March 17, 2023",Anticipated,2023-03-17,,Interventional,,,Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects,"A Phase 1, Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects","Active, not recruiting",,Phase 1,50.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-17 21:39:59,2023-06-17 21:39:59,NIH,,,,,
226279,226280,NCT02117570,,2014-04-16,2016-12-05,,2016-12-05,2014-04-16,2014-04-21,Estimate,2016-12-05,2017-01-30,Estimate,,,,2016-12-05,2017-01-30,Estimate,July 2014,,2014-07-31,November 2016,2016-11-30,December 2015,Actual,2015-12-31,December 2015,Actual,2015-12-31,,Interventional,,All participants who received at least 1 vaccination,"A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.","A Phase 2, Placebo-controlled, Randomised, Observer-blinded Trial To Evaluate The Safety, Tolerability And Immunogenicity Of A Clostridium Difficile Vaccine Administered As A 3-dose Regimen In Healthy Adults Aged 50 To 85 Years",Completed,,Phase 2,185.0,Actual,Pfizer,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 17:34:01,2023-06-18 17:34:01,INDUSTRY,,,,,
226310,226311,NCT03917654,,2019-04-16,2022-07-29,,2023-03-22,2019-04-16,2019-04-17,Actual,2022-07-29,2022-08-23,Actual,,,,2023-03-22,2023-03-24,Actual,"April 24, 2019",Actual,2019-04-24,December 2021,2021-12-31,"October 31, 2022",Actual,2022-10-31,"July 30, 2021",Actual,2021-07-30,,Interventional,,,"Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali","Safety, Immunogenicity and Efficacy of Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali",Completed,,Phase 2,1301.0,Actual,National Institutes of Health Clinical Center (CC),,8.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-17 21:40:16,2023-06-17 21:40:16,NIH,,,,,
226510,226511,NCT00054860,,2003-02-11,,,2021-10-13,2003-02-12,2003-02-13,Estimate,,,,,,,2021-10-13,2021-10-14,Actual,,,,October 2021,2021-10-31,September 2005,Actual,2005-09-30,,,,,Interventional,,,Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults,"A Phase I Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of the EP HIV-1090 DNA Vaccine in Healthy, HIV-1-Uninfected Adult Participants",Completed,,Phase 1,42.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:05:30,2023-06-15 07:05:30,NIH,,,,,
226546,226547,NCT00054899,,2003-02-12,,,2010-03-23,2003-02-13,2003-02-14,Estimate,,,,,,,2010-03-23,2010-03-24,Estimate,January 2003,,2003-01-31,April 2004,2004-04-30,,,,,,,,Interventional,,,An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer,"An Open Label, Multi-center Safety and Tolerance Study of EP2101 Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer (NSCLC)",Completed,,Phase 1,18.0,,Epimmune,,,,,,,,,,,,,,,,,,,,,,2023-06-15 07:05:33,2023-06-15 07:05:33,INDUSTRY,,,,,
227024,227025,NCT01309230,,2011-02-25,2023-01-24,,2023-02-28,2011-03-04,2011-03-07,Estimate,2023-02-28,2023-03-24,Actual,,,,2023-02-28,2023-03-24,Actual,"March 8, 2011",Actual,2011-03-08,February 2023,2023-02-28,"February 2, 2022",Actual,2022-02-02,"February 2, 2022",Actual,2022-02-02,,Interventional,,,A Trial of FANG Vaccine for Participants With Ovarian Cancer,Open-label Phase II Trial of Adjuvant bishRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG) for High Risk Stage III/IV Ovarian Cancer,Completed,,Phase 2,145.0,Actual,"Gradalis, Inc.",,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 21:42:10,2023-06-17 21:42:10,INDUSTRY,,,,,
227034,227035,NCT01209871,,2010-09-24,,,2023-03-23,2010-09-24,2010-09-27,Estimate,,,,,,,2023-03-23,2023-03-24,Actual,"February 26, 2015",Actual,2015-02-26,March 2023,2023-03-31,"February 20, 2024",Anticipated,2024-02-20,"February 20, 2024",Anticipated,2024-02-20,,Interventional,,,Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma,Phase I Study of an Active Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma With DNA Vaccines Encoding Antigen-Chemokine Fusion,"Active, not recruiting",,Phase 1,9.0,Actual,M.D. Anderson Cancer Center,,1.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-17 21:42:12,2023-06-17 21:42:12,OTHER,,,,,
227108,227109,NCT00938223,,2009-06-24,,,2018-04-30,2009-07-10,2009-07-13,Estimate,,,,,,,2018-04-30,2018-05-02,Actual,August 2000,,2000-08-31,April 2018,2018-04-30,,,,November 2003,Actual,2003-11-30,,Interventional,MEL39,,"Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma","This is an Open-label, Phase II Study of a Vaccine Comprising Melanoma Peptides and a Tetanus Helper Peptide, Administered in GM-CSF-in-adjuvant. Patients Will be Randomized to Receive One of Two Different Vaccine Regimens. Patients Will be Stratified by Stage of Disease (IIB vs. III vs. IV).",Completed,,Phase 2,51.0,Actual,University of Virginia,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 13:52:41,2023-06-16 13:52:41,OTHER,,,,,
227192,227193,NCT00540592,,2007-10-05,2012-04-26,2009-05-20,2018-05-09,2007-10-05,2007-10-08,Estimate,2012-04-26,2012-05-30,Estimate,2009-05-21,2009-09-30,Estimate,2018-05-09,2018-06-08,Actual,"October 8, 2007",,2007-10-08,October 2016,2016-10-31,"June 10, 2008",Actual,2008-06-10,"June 10, 2008",Actual,2008-06-10,,Interventional,,,Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A,Observer Blind Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Influenza Vaccine GSK576389A With Various Formulations in Adults Aged 65 Years and Above,Completed,,Phase 2,2007.0,Actual,GlaxoSmithKline,,10.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 13:53:06,2023-06-16 13:53:06,INDUSTRY,,,,,
227389,227390,NCT02193347,,2014-07-02,2021-02-19,,2021-02-19,2014-07-16,2014-07-17,Estimate,2021-02-19,2021-03-15,Actual,,,,2021-02-19,2021-03-15,Actual,"January 28, 2016",Actual,2016-01-28,February 2021,2021-02-28,December 2022,Anticipated,2022-12-31,"February 3, 2020",Actual,2020-02-03,,Interventional,RESIST,,IDH1 Peptide Vaccine for Recurrent Grade II Glioma,Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine,Unknown status,"Active, not recruiting",Phase 1,24.0,Actual,Duke University,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 07:08:10,2023-06-14 07:08:10,OTHER,,,,,
227398,227399,NCT04847050,,2021-04-14,,,2023-06-01,2021-04-14,2021-04-15,Actual,,,,,,,2023-06-01,2023-06-02,Actual,"April 28, 2021",Actual,2021-04-28,"May 30, 2023",2023-05-30,"May 25, 2023",Actual,2023-05-25,"May 25, 2023",Actual,2023-05-25,,Interventional,,,"A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Boost...","A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Booster Doses of Vaccine",Completed,,Phase 2,19.0,Actual,National Institutes of Health Clinical Center (CC),,2.0,,,False,,,,,True,False,,,,,,Clinical data available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active,Clinical data will be made available via subscription to BTRIS and with the permission of the study PI. Genomic data are made available via dbGaP through requests to the data custodians,,Yes,".All IPD recorded in the medical record will be shared with intramural investigators upon request. In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP.",2023-06-18 17:45:50,2023-06-18 17:45:50,NIH,,,,,
227633,227634,NCT00170443,,2005-09-09,,,2011-08-11,2005-09-09,2005-09-15,Estimate,,,,,,,2011-08-11,2011-08-12,Estimate,,,,April 2006,2006-04-30,June 2004,,2004-06-30,,,,,Interventional,,,Trivalent rHA Dose Escalation Study in Elderly Subjects,A Phase II Evaluation of the Reactogenicity and Immunogenicity of Different Doses of Intramuscular Trivalent Baculovirus-expressed Influenza HA Vaccine in Healthy Elderly Adults,Completed,,Phase 2,399.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:06:15,2023-06-15 07:06:15,NIH,,,,,
227665,227666,NCT03600350,,2018-07-11,,,2023-06-01,2018-07-24,2018-07-26,Actual,,,,,,,2023-06-01,2023-06-02,Actual,"September 10, 2018",Actual,2018-09-10,June 2023,2023-06-30,November 2023,Anticipated,2023-11-30,"December 5, 2022",Actual,2022-12-05,,Interventional,,,pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer,"Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) and Nivolumab in Patients With Non-Metastatic, PSA-Recurrent Prostate Cancer","Active, not recruiting",,Phase 2,19.0,Actual,"University of Wisconsin, Madison",,1.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-18 17:49:10,2023-06-18 17:49:10,OTHER,,,,,
227739,227740,NCT03251495,,2017-08-14,,,2023-06-01,2017-08-14,2017-08-16,Actual,,,,,,,2023-06-01,2023-06-02,Actual,"August 29, 2017",Actual,2017-08-29,June 2023,2023-06-30,"June 30, 2025",Anticipated,2025-06-30,"June 30, 2024",Anticipated,2024-06-30,,Interventional,,,Immunologic Responses to a Live Attenuated Oral Cholera Vaccine,Immunologic Responses to a Live Attenuated Oral Cholera Vaccine,Recruiting,,Phase 2,50.0,Anticipated,Emory University,,1.0,,,False,,,,False,True,False,,,False,,,,,,No,,2023-06-18 17:49:48,2023-06-18 17:49:48,OTHER,,,,,
227979,227980,NCT02229357,,2014-08-28,,,2015-04-08,2014-08-28,2014-09-01,Estimate,,,,,,,2015-04-08,2015-04-09,Estimate,June 2014,,2014-06-30,April 2015,2015-04-30,September 2014,Actual,2014-09-30,September 2014,Actual,2014-09-30,,Interventional,,,Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine,"Evaluation of Priming Effects by Pandemic Live Attenuated Influenza Vaccine (LAIV Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2)) on the Subsequent Response to Inactivated H5N1 Vaccine in Healthy Thai Volunteers: A Non-Randomized, Open Label Study",Completed,,Phase 2,60.0,Actual,Mahidol University,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 21:43:45,2023-06-17 21:43:45,OTHER,,,,,
228235,228236,NCT04586673,,2020-10-01,,,2022-08-10,2020-10-08,2020-10-14,Actual,,,,,,,2022-08-10,2022-08-11,Actual,"July 3, 2021",Actual,2021-07-03,August 2022,2022-08-31,"August 3, 2022",Actual,2022-08-03,"August 3, 2022",Actual,2022-08-03,,Interventional,,,A Study to Assess Safety and Immunogenicity of Conserved Mosaic HIV-1 Vaccines,"A Phase I Dose Escalation Open Label Trial to Assess Safety and Immunogenicity of Candidate ChAdOx1- and MVA- Vectored Conserved Mosaic HIV-1 Vaccines Given Sequentially to Healthy HIV-1 Negative Adult Volunteers in Oxford, UK",Completed,,Phase 1,13.0,Actual,University of Oxford,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 17:55:03,2023-06-18 17:55:03,OTHER,,,,,
228277,228278,NCT02116205,,2014-04-14,2020-10-14,,2021-02-10,2014-04-15,2014-04-16,Estimate,2020-11-05,2020-12-01,Actual,,,,2021-02-10,2021-02-12,Actual,"July 9, 2014",Actual,2014-07-09,February 2021,2021-02-28,July 2017,Actual,2017-07-31,"December 7, 2016",Actual,2016-12-07,,Interventional,,,Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever,"A Phase 2a Double-Blind, Dose-optimizing Study to Evaluate the Immunogenicity of Hantaan/Puumala Virus DNA Vaccine Administered to Healthy Adult Volunteers by Electroporation for Prevention of Hemorrhagic Fever With Renal Syndrome",Completed,,Phase 2,130.0,Actual,U.S. Army Medical Research and Development Command,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 17:55:25,2023-06-18 17:55:25,FED,,,,,
228284,228285,NCT02115815,,2014-04-03,2016-07-15,,2016-08-29,2014-04-14,2014-04-16,Estimate,2016-08-29,2016-10-21,Estimate,,,,2016-08-29,2016-10-21,Estimate,April 2014,,2014-04-30,August 2016,2016-08-31,June 2015,Actual,2015-06-30,June 2015,Actual,2015-06-30,,Interventional,,As-treated Population (ATP): Participants who received any study investigational product were included in the ATP population.,A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults,A Phase 1a Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults,Completed,,Phase 1,246.0,Actual,MedImmune LLC,,7.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 17:55:28,2023-06-18 17:55:28,INDUSTRY,,,,,
228297,228298,NCT04932824,,2021-04-13,,,2022-01-28,2021-06-17,2021-06-21,Actual,,,,,,,2022-01-28,2022-02-11,Actual,"January 19, 2021",Actual,2021-01-19,January 2022,2022-01-31,"December 16, 2021",Actual,2021-12-16,"November 10, 2021",Actual,2021-11-10,,Interventional,,,Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19.,"A Long-term Follow-up Study to the Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of SCB-2019, a Recombinant SARS-CoV-2 Trimeric S-Protein Subunit Vaccine for COVID-19",Completed,,Phase 1,137.0,Actual,Clover Biopharmaceuticals AUS Pty Ltd,,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-14 07:09:20,2023-06-14 07:09:20,INDUSTRY,,,,,
228410,228411,NCT04693286,,2020-12-14,,,2022-08-29,2020-12-30,2021-01-05,Actual,,,,,,,2022-08-29,2022-08-30,Actual,"September 21, 2020",Actual,2020-09-21,February 2022,2022-02-28,"August 30, 2021",Actual,2021-08-30,"August 30, 2021",Actual,2021-08-30,,Interventional,,,Clinical Trial of Novel OPV2 Vaccine,A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of Novel Oral Polio Type 2 Vaccine Candidate in Healthy Newborns in Bangladesh,Completed,,Phase 2,330.0,Actual,"International Centre for Diarrhoeal Disease Research, Bangladesh",,2.0,,,False,,,,False,False,False,,,,,,July 2021,,,Yes,"IPD will be shared with BMGF, PATH, CDC, WHO",2023-06-18 17:56:42,2023-06-18 17:56:42,OTHER,,,,,
228513,228514,NCT00991354,,2009-10-06,,,2021-10-13,2009-10-06,2009-10-08,Estimate,,,,,,,2021-10-13,2021-10-14,Actual,November 2009,,2009-11-30,October 2021,2021-10-31,March 2011,Actual,2011-03-31,February 2011,Actual,2011-02-28,,Interventional,,,Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected Adults,"A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX-B (Gag, Pol, Env) Vaccine, With or Without IL-12 DNA Plasmid, Delivered Via Electroporation in Healthy, HIV-1-Uninfected Adult Participants",Completed,,Phase 1,48.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 13:57:36,2023-06-16 13:57:36,NIH,,,,,
228516,228517,NCT00800670,,2008-12-01,,,2017-09-05,2008-12-01,2008-12-02,Estimate,,,,,,,2017-09-05,2017-09-08,Actual,June 2009,,2009-06-30,September 2017,2017-09-30,July 2013,Actual,2013-07-31,December 2012,Actual,2012-12-31,,Interventional,,,Study of the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine,Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine,Terminated,,Phase 1,24.0,Actual,McMaster University,,2.0,,Study was terminated after the low dose cohort had been enrolled,False,,,,False,,,,,,,,,,,,,2023-06-16 13:57:37,2023-06-16 13:57:37,OTHER,,,,,
228530,228531,NCT01994629,,2013-11-11,2015-08-05,2014-05-20,2015-10-02,2013-11-20,2013-11-26,Estimate,2015-10-02,2015-11-04,Estimate,2014-05-20,2014-05-30,Estimate,2015-10-02,2015-11-04,Estimate,November 2013,,2013-11-30,October 2015,2015-10-31,October 2014,Actual,2014-10-31,April 2014,Actual,2014-04-30,,Interventional,,,Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers,"A Phase 2, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers",Completed,,Phase 2,202.0,Actual,Novartis,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 17:57:40,2023-06-18 17:57:40,INDUSTRY,,,,,
228541,228542,NCT01992536,,2013-11-15,2016-04-14,2015-04-17,2016-08-31,2013-11-19,2013-11-25,Estimate,2016-08-31,2016-10-25,Estimate,2015-05-07,2015-05-25,Estimate,2016-08-31,2016-10-25,Estimate,December 2013,,2013-12-31,August 2016,2016-08-31,April 2015,Actual,2015-04-30,May 2014,Actual,2014-05-31,,Interventional,,,"Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)","Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)",Completed,,Phase 2,194.0,Actual,Novartis,,9.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 17:57:45,2023-06-18 17:57:45,INDUSTRY,,,,,
228563,228564,NCT05426174,,2022-06-08,,,2023-02-02,2022-06-16,2022-06-21,Actual,,,,,,,2023-02-02,2023-02-03,Actual,"June 9, 2022",Actual,2022-06-09,February 2023,2023-02-28,"December 21, 2023",Anticipated,2023-12-21,"December 21, 2023",Anticipated,2023-12-21,,Interventional,,,"Phase I, Randomized, Modified Double-blind, Parallel-group, Active-controlled, Multi-arm, Dose-escalation Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older",Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older,"Active, not recruiting",,Phase 1,186.0,Actual,Sanofi,,4.0,,,False,,,,False,True,False,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-16 13:57:46,2023-06-16 13:57:46,INDUSTRY,,,,,
228867,228868,NCT00407836,,2006-12-03,,,2009-12-01,2006-12-03,2006-12-05,Estimate,,,,,,,2009-12-01,2009-12-02,Estimate,November 2006,,2006-11-30,November 2006,2006-11-30,November 2008,Actual,2008-11-30,November 2008,Actual,2008-11-30,,Interventional,,,Efficacy Study of T Cell Vaccination in HIV Infection,"Phase II Study of Efficacy, Tolerability and Safety of CD4-Specific T-cell Vaccine in HIV Infection",Completed,,Phase 2,40.0,Anticipated,Soroka University Medical Center,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 07:07:43,2023-06-15 07:07:43,OTHER,,,,,
229194,229195,NCT02038907,,2014-01-15,2016-06-18,,2017-08-04,2014-01-15,2014-01-17,Estimate,2016-06-18,2016-08-01,Estimate,,,,2017-08-04,2017-08-08,Actual,"March 28, 2014",Actual,2014-03-28,August 2017,2017-08-31,"June 19, 2015",Actual,2015-06-19,"June 19, 2015",Actual,2015-06-19,,Interventional,NOR-107,All randomized participants.,Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine,"A Phase II, Randomized, Controlled, Double-Blind, Dosage and Adjuvant Justification, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Adjuvanted With or Without Monophosphoryl Lipid A and Aluminum Hydroxide in Adults",Completed,,Phase 2,420.0,Actual,Takeda,,14.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 18:05:15,2023-06-18 18:05:15,INDUSTRY,,,,,
229340,229341,NCT01974206,,2013-10-28,2021-10-21,2017-05-01,2022-02-16,2013-10-28,2013-11-01,Estimate,2021-12-07,2022-01-04,Actual,2017-05-01,2017-05-02,Actual,2022-02-16,2022-02-17,Actual,"November 20, 2013",Actual,2013-11-20,February 2022,2022-02-28,"November 5, 2020",Actual,2020-11-05,"May 13, 2016",Actual,2016-05-13,,Interventional,,"Randomized population: Age, Gender, Race, Ethnicity Randomized population: Use of ATG, Source of current Transplant, randomization strata","A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor","A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor",Completed,,Phase 2,150.0,Actual,Astellas Pharma Inc,,2.0,,,False,,,,True,True,False,,,,,,Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.,"Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.",https://www.clinicalstudydatarequest.com/,Yes,"Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.",2023-06-18 18:07:45,2023-06-18 18:07:45,INDUSTRY,,,,,
229819,229820,NCT01417000,,2011-08-10,2018-04-06,,2018-04-06,2011-08-12,2011-08-16,Estimate,2018-04-06,2018-05-08,Actual,,,,2018-04-06,2018-05-08,Actual,"September 21, 2011",Actual,2011-09-21,April 2018,2018-04-30,"February 10, 2017",Actual,2017-02-10,October 2016,Actual,2016-10-31,,Interventional,,"Baseline analysis provided for the Full Analysis Set (FAS), defined as those randomized study subjects who were administered at least 1 dose of protocol-specified drug. Baseline analysis is provided for subjects on the basis of their original study arm assignments, prior to any rollover from the Cy/GVAX arm to the Cy/GVAX + CRS-207 arm.",Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer,"A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma",Completed,,Phase 2,93.0,Actual,"Aduro Biotech, Inc.",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 18:13:16,2023-06-18 18:13:16,INDUSTRY,,,,,
229962,229963,NCT01507103,,2012-01-06,2015-09-21,,2017-01-12,2012-01-06,2012-01-10,Estimate,2016-04-26,2016-06-02,Estimate,,,,2017-01-12,2017-01-13,Estimate,February 2012,,2012-02-29,January 2017,2017-01-31,June 2014,Actual,2014-06-30,June 2014,Actual,2014-06-30,,Interventional,SPRINT,Safety analysis set included all subjects who received at least one dose of study treatment (tecemotide [L-BLP25] or CPA).,Tecemotide (L-BLP25) in Rectal Cancer,"A Multi-center, Randomized, Open-label, Mechanism of Action Trial on the Biological Effects of the Therapeutic Cancer Vaccine Stimuvax® (L-BLP25) in Rectal Cancer Subjects Undergoing Neoadjuvant Chemoradiotherapy",Completed,,Phase 2,124.0,Actual,"Merck KGaA, Darmstadt, Germany",,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 07:13:03,2023-06-14 07:13:03,INDUSTRY,,,,,
230074,230075,NCT01974895,,2013-10-23,2015-02-26,,2018-08-09,2013-10-28,2013-11-03,Estimate,2015-04-09,2015-04-13,Estimate,,,,2018-08-09,2018-09-07,Actual,"October 23, 2013",,2013-10-23,August 2016,2016-08-31,"July 3, 2014",Actual,2014-07-03,"February 27, 2014",Actual,2014-02-27,,Interventional,,,Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age,Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) in Children 6 to 35 Months of Age,Completed,,Phase 2,316.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-18 18:16:39,2023-06-18 18:16:39,INDUSTRY,,,,,
230255,230256,NCT01949090,,2013-09-19,2017-08-25,2014-05-29,2017-11-13,2013-09-19,2013-09-24,Estimate,2017-11-13,2017-11-17,Actual,2014-05-29,2014-06-02,Estimate,2017-11-13,2017-11-17,Actual,"September 25, 2013",Actual,2013-09-25,November 2017,2017-11-30,"October 23, 2014",Actual,2014-10-23,"December 4, 2013",Actual,2013-12-04,,Interventional,,,Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older,An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK2789869A Administered in Adults 65 Years of Age and Older,Completed,,Phase 2,363.0,Actual,GlaxoSmithKline,,5.0,,,False,,,,,,,,,,,,,,,,,2023-06-18 18:18:49,2023-06-18 18:18:49,INDUSTRY,,,,,
230390,230391,NCT02479230,,2015-06-19,,,2022-11-21,2015-06-19,2015-06-24,Estimate,,,,,,,2022-11-21,2022-11-22,Actual,"July 17, 2015",Actual,2015-07-17,November 2022,2022-11-30,"July 1, 2022",Actual,2022-07-01,"October 30, 2019",Actual,2019-10-30,,Interventional,,,Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients,Pilot Trial of Type I-Polarized Autologous Dendritic Cell Vaccine Incorporating Tumor Blood Vessel Antigen-Derived Peptides in Patients With Metastatic Breast Cancer,Completed,,Phase 1,18.0,Actual,Case Comprehensive Cancer Center,,1.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-14 07:13:37,2023-06-14 07:13:37,OTHER,,,,,
230432,230433,NCT00323557,,2006-05-05,2012-04-06,,2012-12-03,2006-05-05,2006-05-09,Estimate,2012-04-06,2012-05-02,Estimate,,,,2012-12-03,2012-12-05,Estimate,June 2004,,2004-06-30,December 2012,2012-12-31,May 2011,Actual,2011-05-31,May 2011,Actual,2011-05-31,,Interventional,,,Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients,Immuno-Augmentation With GM-CSF in Patients Receiving Pneumococcal Vaccine While Undergoing Treatment for Advanced Chronic Lymphocytic Leukemia (CLL),Completed,,Phase 2,39.0,Actual,M.D. Anderson Cancer Center,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 14:03:00,2023-06-16 14:03:00,OTHER,,,,,
230446,230447,NCT03300362,,2017-09-26,,,2018-11-20,2017-09-28,2017-10-03,Actual,,,,,,,2018-11-20,2018-11-23,Actual,"October 13, 2017",Actual,2017-10-13,May 2018,2018-05-31,"October 31, 2018",Actual,2018-10-31,"October 31, 2018",Actual,2018-10-31,,Interventional,INVICTUS,,Improved Novel VaccIne CombinaTion InflUenza Study,A Phase IIb Study to Determine the Safety and Efficacy of Candidate INfluenza Vaccine MVA-NP+M1 in Combination With Licensed InaCTivated inflUenza Vaccine in adultS Aged 65 Years and Above,Terminated,,Phase 2,862.0,Actual,Vaccitech (UK) Limited,,2.0,,Change to recommended season flu vaccine in UK,False,,,,True,False,False,,,,,,,,,No,,2023-06-17 21:48:18,2023-06-17 21:48:18,INDUSTRY,,,,,
230449,230450,NCT00176761,,2005-09-09,,,2006-09-06,2005-09-09,2005-09-15,Estimate,,,,,,,2006-09-06,2006-09-11,Estimate,March 2000,,2000-03-31,September 2006,2006-09-30,May 2006,,2006-05-31,,,,,Interventional,,,Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine,"A Phase II Trial Assessing Autologous, Tumor-Pulsed Dendritic Cells as a Tumor Vaccine Administered With IL-2 in Patients With Metastatic Colorectal Cancer",Terminated,,Phase 2,27.0,,University of Michigan Rogel Cancer Center,,,,,,,,,,,,,,,,,,,,,,2023-06-15 07:08:54,2023-06-15 07:08:54,OTHER,,,,,
230482,230483,NCT00350623,,2006-07-07,2010-10-20,,2015-08-11,2006-07-10,2006-07-11,Estimate,2010-10-20,2010-11-04,Estimate,,,,2015-08-11,2015-08-25,Estimate,October 2006,,2006-10-31,August 2015,2015-08-31,May 2008,Actual,2008-05-31,May 2008,Actual,2008-05-31,,Interventional,,,Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED),A Phase IIa Dose-Refinement Study of the Safety and Immunogenicity of a 3-Dose Regimen of the Merck Adenovirus Serotype 5 HIV-1 Gag/Pol/Nef Vaccine in Healthy Adults,Terminated,,Phase 2,210.0,Actual,Merck Sharp & Dohme LLC,,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 14:03:12,2023-06-16 14:03:12,INDUSTRY,,,,,
230537,230538,NCT00679172,,2008-05-14,2017-05-02,,2017-06-06,2008-05-15,2008-05-16,Estimate,2017-06-06,2017-06-07,Actual,,,,2017-06-06,2017-06-07,Actual,May 2008,,2008-05-31,June 2017,2017-06-30,December 2008,Actual,2008-12-31,December 2008,Actual,2008-12-31,,Interventional,,,"Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults","A Randomised, Double-blind, Placebo-controlled, Single Dose, Dose Escalation Study to Determine the Immunogenicity, Safety and Tolerability of S. Typhi (Ty2 aroC-ssaV-) ZH9 at Doses of 5.0 x 10E9 CFU, 7.5 x 10E9 CFU, 1.1 x 10E10 and 1.7 x 10E10 CFU and 1.7 x 10E10 CFU, Following Oral Administration to Healthy, Typhoid Vaccine naïve Subjects in the USA.",Completed,,Phase 2,187.0,Actual,Emergent BioSolutions,,4.0,,,False,,,,False,,,,,,,,,,,No,,2023-06-16 14:03:41,2023-06-16 14:03:41,INDUSTRY,,,,,
230579,230580,NCT00408109,,2006-12-05,,,2017-06-30,2006-12-05,2006-12-06,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"December 4, 2006",,2006-12-04,"August 28, 2008",2008-08-28,"August 28, 2008",,2008-08-28,,,,,Interventional,,,Safety Study of Avian Flu Vaccine,"VRC 304: A Phase I Study of the Safety and Immunogenicity of a Recombinant DNA Plasmid Vaccine (VRC-AVIDNA036-00-VP), Encoding for the Influenza Virus H5 Hemagglutinin Protein in Healthy Adults",Completed,,Phase 1,45.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:09:00,2023-06-15 07:09:00,NIH,,,,,
230606,230607,NCT00423566,,2007-01-17,,,2007-01-17,2007-01-17,2007-01-18,Estimate,,,,,,,2007-01-17,2007-01-18,Estimate,September 2002,,2002-09-30,December 2006,2006-12-31,July 2003,,2003-07-31,,,,,Interventional,,,"A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.","A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.",Completed,,Phase 1,14.0,,University of Oxford,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:09:03,2023-06-15 07:09:03,OTHER,,,,,
230867,230868,NCT05868382,,2023-05-11,,,2023-06-05,2023-05-11,2023-05-22,Actual,,,,,,,2023-06-05,2023-06-07,Actual,"May 15, 2023",Actual,2023-05-15,June 2023,2023-06-30,"February 15, 2024",Anticipated,2024-02-15,"September 15, 2023",Anticipated,2023-09-15,,Interventional,,,"Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults","A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age",Recruiting,,Phase 2,270.0,Anticipated,"ModernaTX, Inc.",,6.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-18 18:24:29,2023-06-18 18:24:29,INDUSTRY,,,,,
231146,231147,NCT05385471,,2022-05-17,,,2023-06-06,2022-05-17,2022-05-23,Actual,,,,,,,2023-06-06,2023-06-07,Actual,"January 13, 2023",Actual,2023-01-13,June 2023,2023-06-30,"July 31, 2024",Anticipated,2024-07-31,"July 31, 2024",Anticipated,2024-07-31,,Interventional,,,A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M in Healthy UK Adults,"A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M, Both Alone and in Combination, in Healthy UK Adults",Recruiting,,Early Phase 1,36.0,Anticipated,University of Oxford,,4.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 18:27:18,2023-06-18 18:27:18,OTHER,,,,,
231302,231303,NCT05130060,,2021-11-10,,,2023-06-06,2021-11-10,2021-11-22,Actual,,,,,,,2023-06-06,2023-06-07,Actual,"January 10, 2022",Actual,2022-01-10,June 2023,2023-06-30,"May 15, 2025",Anticipated,2025-05-15,"May 15, 2024",Anticipated,2024-05-15,,Interventional,,,A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer,"Phase Ib Open-Label Study to Evaluate Safety, Tolerability, Immunogenicity and Efficacy of Multiple Subcutaneous Injections of PolyPEPI1018 Vaccine as an Add-on Immunotherapy to TAS-102 in Late-Stage Metastatic Colorectal Cancer Subjects (OBERTO-201)","Active, not recruiting",,Phase 1,15.0,Anticipated,Mayo Clinic,,1.0,,,,,,,True,True,False,,,,,,,,,,,2023-06-18 18:28:31,2023-06-18 18:28:31,OTHER,,,,,
231364,231365,NCT00046371,,2002-09-27,,,2008-01-22,2002-10-09,2002-10-10,Estimate,,,,,,,2008-01-22,2008-01-23,Estimate,August 2002,,2002-08-31,January 2008,2008-01-31,August 2005,Actual,2005-08-31,,,,,Interventional,,,Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients,"Open-Label, Phase II Trial of Immunological Response Rate, Safety, and Tolerability of THERATOPE® Vaccine in Subjects With Metastatic Breast Cancer Undergoing Treatment With Aromatase Inhibitors or Faslodex®",Completed,,Phase 2,,,Oncothyreon Canada Inc.,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:09:50,2023-06-15 07:09:50,INDUSTRY,,,,,
231386,231387,NCT04975893,,2021-07-09,,,2023-06-05,2021-07-22,2021-07-26,Actual,,,,,,,2023-06-05,2023-06-07,Actual,"June 18, 2021",Actual,2021-06-18,June 2023,2023-06-30,"December 30, 2025",Anticipated,2025-12-30,"December 30, 2025",Anticipated,2025-12-30,,Interventional,,,A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine,"A Phase 2, Non-Randomized, Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus mRNA-1647 Vaccine in Participants Who Completed Study mRNA-1647-P202",Enrolling by invitation,,Phase 2,291.0,Anticipated,"ModernaTX, Inc.",,1.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-18 18:28:55,2023-06-18 18:28:55,INDUSTRY,,,,,
231399,231400,NCT04936529,,2021-06-16,,,2023-06-06,2021-06-16,2021-06-23,Actual,,,,,,,2023-06-06,2023-06-07,Actual,"August 2, 2021",Actual,2021-08-02,June 2023,2023-06-30,"June 15, 2025",Anticipated,2025-06-15,"June 15, 2025",Anticipated,2025-06-15,,Interventional,,,A Study of a Vaccine in Combination With ß-glucan and GM-CSF in People With Neuroblastoma,"Phase II Trial of a Bivalent Vaccine With the Immunological Adjuvant OPT-821 (QS-21), in Combination With Oral ß-glucan and Randomization of GM-CSF, for High-risk Neuroblastoma",Recruiting,,Phase 2,264.0,Anticipated,Memorial Sloan Kettering Cancer Center,,3.0,,,,,,,,True,False,,,,,,,,,Yes,"Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.",2023-06-18 18:29:02,2023-06-18 18:29:02,OTHER,,,,,
231478,231479,NCT00946179,,2009-07-22,,,2014-01-16,2009-07-23,2009-07-24,Estimate,,,,,,,2014-01-16,2014-01-17,Estimate,May 2009,,2009-05-31,January 2014,2014-01-31,July 2009,Actual,2009-07-31,June 2009,Actual,2009-06-30,,Interventional,,,"Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation","Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation (Intramuscular Route)",Completed,,Phase 2,130.0,Actual,Sanofi,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 14:06:36,2023-06-16 14:06:36,INDUSTRY,,,,,
231671,231672,NCT04246671,,2020-01-24,,,2023-06-06,2020-01-28,2020-01-29,Actual,,,,,,,2023-06-06,2023-06-07,Actual,"August 10, 2020",Actual,2020-08-10,June 2023,2023-06-30,June 2026,Anticipated,2026-06-30,June 2024,Anticipated,2024-06-30,,Interventional,,,TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer,Phase 1 Trial of Intravenous Administration of TAEK-VAC-HerBy Vaccine Alone and in Combination With HER2 Antibodies in Patients With Advanced Cancer.,Recruiting,,Phase 1,55.0,Anticipated,Bavarian Nordic,,8.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-18 18:31:21,2023-06-18 18:31:21,INDUSTRY,,,,,
232291,232292,NCT01719783,,2012-10-26,2018-04-09,,2018-11-26,2012-10-30,2012-11-01,Estimate,2018-11-26,2018-11-28,Actual,,,,2018-11-26,2018-11-28,Actual,September 2012,,2012-09-30,November 2018,2018-11-30,January 2013,Actual,2013-01-31,January 2013,Actual,2013-01-31,,Interventional,,,"Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine","Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Turkey/Turkey/05/133 (H5N2) Influenza Vaccine",Completed,,Phase 1,40.0,Actual,PATH,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 18:38:26,2023-06-18 18:38:26,OTHER,,,,,
232438,232439,NCT04009096,,2019-07-03,,,2022-08-16,2019-07-03,2019-07-05,Actual,,,,,,,2022-08-16,2022-08-17,Actual,"July 18, 2019",Actual,2019-07-18,August 2022,2022-08-31,"July 7, 2022",Actual,2022-07-07,"July 7, 2022",Actual,2022-07-07,,Interventional,,,VAC071: A Study to Assess Efficacy of the ChAd63/MVA PvDBP Vaccines,A Phase IIa Challenge Study to Assess Efficacy of the Plasmodium Vivax Malaria Vaccine Candidates ChAd63 PvDBP and MVA PvDBP in Healthy Adults Living in the UK,Completed,,Phase 2,16.0,Actual,University of Oxford,,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 18:40:20,2023-06-18 18:40:20,OTHER,,,,,
232485,232486,NCT03598816,,2018-07-16,,,2020-08-12,2018-07-16,2018-07-26,Actual,,,,,,,2020-08-12,2020-08-13,Actual,"August 31, 2020",Anticipated,2020-08-31,August 2020,2020-08-31,"May 31, 2024",Anticipated,2024-05-31,"December 31, 2022",Anticipated,2022-12-31,,Interventional,PIVOT-RCC,,PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma,A Randomized Phase II PIVOT-RCC (PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma) Trial,Withdrawn,,Phase 2,0.0,Actual,Washington University School of Medicine,,2.0,,FDA Contingencies unresolved,False,,,,True,True,True,,,False,,,,,,No,,2023-06-18 18:40:43,2023-06-18 18:40:43,OTHER,,,,,
232676,232677,NCT03590392,,2018-06-05,,,2019-10-17,2018-07-05,2018-07-18,Actual,,,,,,,2019-10-17,2019-10-18,Actual,"July 31, 2018",Actual,2018-07-31,July 2019,2019-07-31,"September 30, 2019",Actual,2019-09-30,"September 30, 2019",Actual,2019-09-30,,Interventional,,,Safety and Immunogenicity of a Candidate CHIKV Vaccine (CHIK001),A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Chikungunya Virus (CHIKV) Vaccine ChAdOx1 Chik in Healthy Adult Volunteers,Completed,,Phase 1,24.0,Actual,University of Oxford,,3.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-18 18:42:38,2023-06-18 18:42:38,OTHER,,,,,
232874,232875,NCT01230957,,2010-10-28,,2013-12-03,2018-07-13,2010-10-28,2010-10-29,Estimate,,,,2013-12-03,2013-12-27,Estimate,2018-07-13,2018-07-18,Actual,October 2010,,2010-10-31,July 2018,2018-07-31,March 2013,Actual,2013-03-31,November 2012,Actual,2012-11-30,,Interventional,,,Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults,Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection,Completed,,Phase 2,650.0,Actual,Sanofi,,7.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 21:51:38,2023-06-17 21:51:38,INDUSTRY,,,,,
232895,232896,NCT01228383,,2010-10-13,,2013-03-20,2013-04-03,2010-10-25,2010-10-26,Estimate,,,,2013-03-20,2013-03-28,Estimate,2013-04-03,2013-04-10,Estimate,December 2011,,2011-12-31,April 2013,2013-04-30,December 2012,Actual,2012-12-31,October 2012,Actual,2012-10-31,,Interventional,,,"Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults","A Randomized, Single-blind, Active-controlled, Mono-center Phase II Study to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Purified Vero Cell Rabies Vaccine vs. Human Rabies Immune Globulin or Placebo in Combination With Purified Vero Cell Rabies Vaccine vs. CL184 or Placebo in Combination With Human Diploid Cell Rabies Vaccine in Healthy Adult Subjects",Completed,,Phase 2,240.0,Actual,Crucell Holland BV,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 21:51:39,2023-06-17 21:51:39,INDUSTRY,,,,,
232928,232929,NCT04147078,,2019-08-24,,,2019-10-30,2019-10-30,2019-10-31,Actual,,,,,,,2019-10-30,2019-10-31,Actual,"June 1, 2019",Actual,2019-06-01,October 2019,2019-10-31,"June 1, 2023",Anticipated,2023-06-01,"December 31, 2022",Anticipated,2022-12-31,,Interventional,,,Personalized DC Vaccine for Postoperative Cancer,"Adjuvant Treatment in Cancer Patients With Neoantigen-primed DC Vaccine : a Single-arm, Open-label, Prospective Clinical Trial",Unknown status,Recruiting,Phase 1,80.0,Anticipated,Sichuan University,,1.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-18 18:45:39,2023-06-18 18:45:39,OTHER,,,,,
232971,232972,NCT00776438,,2008-10-17,,,2015-06-16,2008-10-17,2008-10-21,Estimate,,,,,,,2015-06-16,2015-06-17,Estimate,September 2007,,2007-09-30,June 2015,2015-06-30,April 2009,Actual,2009-04-30,February 2009,Actual,2009-02-28,,Interventional,,,Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines,"Evaluation of the Cellular, Humoral and Mucosal Immune Response in Adults and Elderly Subjects Vaccinated Either With an Inactivated Influenza Vaccine Administered Via the Intradermal Route or an Inactivated Influenza Vaccine Administered Via the Intramuscular Route",Completed,,Phase 2,160.0,Actual,Sanofi,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 14:11:10,2023-06-16 14:11:10,INDUSTRY,,,,,
233072,233073,NCT00560313,,2007-11-16,2011-06-06,,2016-03-03,2007-11-16,2007-11-19,Estimate,2011-06-06,2011-07-08,Estimate,,,,2016-03-03,2016-04-01,Estimate,July 2007,,2007-07-31,March 2016,2016-03-31,November 2009,Actual,2009-11-30,November 2009,Actual,2009-11-30,,Interventional,,,"Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults","A Phase 2, Multi-Center, Open-label Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2, 6-Month Schedule and of a Single Dose of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy At-risk Adults 18-50 Years of Age",Completed,,Phase 2,54.0,Actual,Novartis,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 14:11:20,2023-06-16 14:11:20,INDUSTRY,,,,,
233301,233302,NCT00321763,,2006-05-03,2013-03-21,,2018-05-09,2006-05-03,2006-05-04,Estimate,2013-05-16,2013-06-24,Estimate,,,,2018-05-09,2018-06-08,Actual,"April 27, 2006",,2006-04-27,September 2016,2016-09-30,"July 7, 2006",Actual,2006-07-07,"July 1, 2006",Actual,2006-07-01,,Interventional,,,Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate,Demonstrate the Lot-to-lot Consistency of 3 Consecutive Production Lots of an Adjuvanted Influenza Vaccine Candidate and Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate Versus Fluarix Administered Intramuscularly in Elderly,Completed,,Phase 2,3124.0,Actual,GlaxoSmithKline,,5.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 14:11:55,2023-06-16 14:11:55,INDUSTRY,,,,,
233541,233542,NCT01671592,,2012-08-20,,,2017-09-25,2012-08-22,2012-08-23,Estimate,,,,,,,2017-09-25,2017-09-26,Actual,January 2013,,2013-01-31,September 2017,2017-09-30,April 2014,Actual,2014-04-30,April 2014,Actual,2014-04-30,,Interventional,,,Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI),Safety and Feasibility Evaluation of the MRI-based Tracking of Alpha-type-1 Dendritic Cell Vaccines in Patients With Colorectal Cancer,Completed,,Phase 1,6.0,Actual,University of Pittsburgh,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 18:50:49,2023-06-18 18:50:49,OTHER,,,,,
233622,233623,NCT00058526,,2003-04-07,,,2017-05-12,2003-04-08,2003-04-09,Estimate,,,,,,,2017-05-12,2017-05-15,Actual,"March 20, 2003",Actual,2003-03-20,May 2017,2017-05-31,"September 6, 2006",Actual,2006-09-06,"September 6, 2006",Actual,2006-09-06,,Interventional,,,A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer,A Multicenter Phase I Open-label Dose-escalation Vaccine Trial of dHER2 Protein With AS15 Adjuvant in HER2-overexpressing Patients With High-risk Breast Cancer,Completed,,Phase 1,61.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:12:10,2023-06-15 07:12:10,INDUSTRY,,,,,
233629,233630,NCT01150695,,2010-06-24,,2013-07-08,2015-12-10,2010-06-24,2010-06-25,Estimate,,,,2013-07-08,2013-07-11,Estimate,2015-12-10,2016-01-13,Estimate,September 2010,,2010-09-30,March 2013,2013-03-31,January 2012,Actual,2012-01-31,January 2012,Actual,2012-01-31,,Interventional,,,Phase II Tularemia Vaccine Comparison,"A Phase II, Multi-Center, Double-Blind, Randomized Trial Comparing the Safety and Immunogenicity of a Francisella Tularensis Live Vaccine Strain (LVS) Vaccine Produced by DynPort Vaccine Company (DVC-LVS) to a LVS Vaccine in Use by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID-LVS)",Completed,,Phase 2,228.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 21:53:01,2023-06-17 21:53:01,NIH,,,,,
233705,233706,NCT05164094,,2021-12-01,,,2023-02-10,2021-12-17,2021-12-20,Actual,,,,,,,2023-02-10,2023-02-14,Actual,"December 28, 2021",Actual,2021-12-28,February 2023,2023-02-28,"June 24, 2023",Anticipated,2023-06-24,"June 24, 2023",Anticipated,2023-06-24,,Interventional,,,"A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-Year-Old Healthy Adults","A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-Year-Old Healthy Adults",Recruiting,,Phase 1,272.0,Anticipated,"ModernaTX, Inc.",,4.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-17 21:53:24,2023-06-17 21:53:24,INDUSTRY,,,,,
233758,233759,NCT02267109,,2014-10-03,,,2019-09-24,2014-10-14,2014-10-17,Estimate,,,,,,,2019-09-24,2019-09-26,Actual,October 2014,Actual,2014-10-31,September 2019,2019-09-30,"April 20, 2016",Actual,2016-04-20,"April 20, 2016",Actual,2016-04-20,,Interventional,,,Phase 1 Trial of Ebola Vaccine in Mali,"A Phase 1b, Dose-escalating Safety and Immunogenicity Trial of the Novel Monovalent Ebola Zaire Candidate Vaccine, cAd3-EBO Z and the Heterologous Prime-boost Candidate Vaccine Regimen of cAD3-EBO Z Followed by MVA-BN® Filo in Malian Adults Aged 18-50 Years.",Completed,,Phase 1,91.0,Actual,"University of Maryland, Baltimore",,5.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-17 21:53:29,2023-06-17 21:53:29,OTHER,,,,,
234012,234013,NCT03629080,,2018-05-29,,,2022-08-10,2018-08-10,2018-08-14,Actual,,,,,,,2022-08-10,2022-08-11,Actual,"December 12, 2018",Actual,2018-12-12,August 2022,2022-08-31,"June 22, 2022",Actual,2022-06-22,"June 22, 2022",Actual,2022-06-22,,Interventional,,,A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients,"A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation From Living CMV-Seropositive Donors (D+).",Completed,,Phase 2,83.0,Actual,Hookipa Biotech GmbH,,6.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-18 18:54:55,2023-06-18 18:54:55,INDUSTRY,,,,,
234028,234029,NCT00321373,,2006-03-16,2013-03-14,,2018-05-08,2006-05-02,2006-05-03,Estimate,2013-03-14,2013-05-01,Estimate,,,,2018-05-08,2018-06-08,Actual,"May 11, 2006",,2006-05-11,September 2016,2016-09-30,"July 18, 2006",Actual,2006-07-18,"July 1, 2006",Actual,2006-07-01,,Interventional,,,Study to Evaluate an Influenza Vaccine Candidate,"A Study to Demonstrate the Non-Inferiority of Influenza Vaccine Candidate, Compared With Fluarix Administered Intramuscularly in Elderly Aged 60 Years Old and Above",Completed,,Phase 2,1220.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 14:14:05,2023-06-16 14:14:05,INDUSTRY,,,,,
234271,234272,NCT02267733,,2014-10-13,,,2016-08-24,2014-10-13,2014-10-17,Estimate,,,,,,,2016-08-24,2016-08-25,Estimate,October 2014,,2014-10-31,August 2016,2016-08-31,December 2015,Actual,2015-12-31,December 2015,Actual,2015-12-31,,Interventional,SHIVERING,,Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients,Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients (SHIVERING Trial),Completed,,Phase 1,51.0,Actual,Yale University,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 21:54:03,2023-06-17 21:54:03,OTHER,,,,,
234371,234372,NCT00992212,,2009-10-08,,,2016-11-30,2009-10-08,2009-10-09,Estimate,,,,,,,2016-11-30,2016-12-01,Estimate,August 2009,,2009-08-31,January 2012,2012-01-31,November 2009,Actual,2009-11-30,October 2009,Actual,2009-10-31,,Interventional,,,"Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10","A Phase II, Open Label Study to Evaluate the Immunogenicity, Tolerability and Safety of an Adjuvanted, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects Aged 18 Years and Above",Completed,,Phase 2,418.0,Actual,Novartis,,5.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 14:14:56,2023-06-16 14:14:56,INDUSTRY,,,,,
234400,234401,NCT01677676,,2012-08-24,,,2013-07-26,2012-08-31,2012-09-03,Estimate,,,,,,,2013-07-26,2013-07-29,Estimate,January 2012,,2012-01-31,July 2013,2013-07-31,September 2012,Actual,2012-09-30,May 2012,Actual,2012-05-31,,Interventional,,,"Safety, Tolerability and Immunogenicity of Two Different Formulations of an Influenza A Vaccine (FP-01.1)","A Randomised, Double-Blind, Double Observer, Study to Assess the Safety, Tolerability and Immunogenicity of Repeated Intramuscular Administration of Two Different Formulations of an Influenza A Vaccine (FP-01.1)",Completed,,Phase 1,48.0,Actual,Immune Targeting Systems Ltd,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 18:59:07,2023-06-18 18:59:07,INDUSTRY,,,,,
234955,234956,NCT00189943,,2005-09-12,,,2005-09-12,2005-09-12,2005-09-19,Estimate,,,,,,,2005-09-12,2005-09-19,Estimate,April 2001,,2001-04-30,September 2005,2005-09-30,July 2003,,2003-07-31,,,,,Interventional,,,"Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy Subjects","Phase I Study on Safety, Tolerability and Immunogenicity of the MVA-BN Vaccine Administered to Healthy Subjects",Completed,,Phase 1,90.0,,Bavarian Nordic,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:13:52,2023-06-15 07:13:52,INDUSTRY,,,,,
234999,235000,NCT05160766,,2021-11-11,,,2023-01-16,2021-12-14,2021-12-16,Actual,,,,,,,2023-01-16,2023-01-18,Actual,"November 8, 2021",Actual,2021-11-08,January 2023,2023-01-31,September 2023,Anticipated,2023-09-30,"October 1, 2022",Actual,2022-10-01,,Interventional,EU-COVAT-1,,Assessing Immune Response of Different COVID-19 Vaccines in Older Adults,"A Multinational, Phase 2, Randomised, Adaptive Protocol to Evaluate Immunogenicity and Reactogenicity of Different COVID-19 Vaccines Administration in Older Adults (=75) Already Vaccinated Against SARS-COV-2 (EU-COVAT-1_AGED)","Active, not recruiting",,Phase 2,323.0,Actual,University of Cologne,,6.0,,,False,,,,True,False,False,,,False,,,,,,,,2023-06-18 19:04:16,2023-06-18 19:04:16,OTHER,,,,,
235080,235081,NCT04583618,,2020-10-05,,2022-08-01,2022-08-01,2020-10-05,2020-10-12,Actual,,,,2022-08-01,2022-08-04,Actual,2022-08-01,2022-08-04,Actual,"October 8, 2020",Actual,2020-10-08,August 2022,2022-08-31,"January 20, 2022",Actual,2022-01-20,"August 9, 2021",Actual,2021-08-09,,Interventional,,,Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.,Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine in Healthy Adults Aged 50 to 84 Years,Completed,,Phase 2,750.0,Actual,Sanofi,,5.0,,,False,,,,True,True,False,,,False,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-18 19:05:02,2023-06-18 19:05:02,INDUSTRY,,,,,
235274,235275,NCT00905060,,2009-05-18,2021-02-25,2018-05-01,2021-03-23,2009-05-19,2009-05-20,Estimate,2021-03-23,2021-03-24,Actual,2018-05-01,2018-05-03,Actual,2021-03-23,2021-03-24,Actual,"June 29, 2009",Actual,2009-06-29,March 2021,2021-03-31,"June 3, 2014",Actual,2014-06-03,"June 3, 2014",Actual,2014-06-03,,Interventional,HeatShock,,HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM,"PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme",Completed,,Phase 2,70.0,Actual,"University of California, San Francisco",,1.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-14 07:18:35,2023-06-14 07:18:35,OTHER,,,,,
235455,235456,NCT01550289,,2012-03-07,2016-09-14,,2022-03-15,2012-03-08,2012-03-09,Estimate,2016-09-14,2016-11-03,Estimate,,,,2022-03-15,2022-04-05,Actual,March 2012,,2012-03-31,March 2022,2022-03-31,February 2014,Actual,2014-02-28,December 2013,Actual,2013-12-31,,Interventional,,,Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India,Immunogenicity and Safety of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India.,Completed,,Phase 2,189.0,Actual,Sanofi,,2.0,,,False,,,,True,,,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-18 19:09:27,2023-06-18 19:09:27,INDUSTRY,,,,,
235538,235539,NCT01545375,,2012-03-01,2017-07-11,,2019-12-17,2012-03-01,2012-03-06,Estimate,2017-08-11,2017-09-12,Actual,,,,2019-12-17,2019-12-27,Actual,"May 21, 2012",Actual,2012-05-21,December 2019,2019-12-31,"July 26, 2016",Actual,2016-07-26,"July 26, 2016",Actual,2016-07-26,,Interventional,,,Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children,Study to Determine Protective Efficacy Against Otitis Media and Assess Safety of an Investigational Pneumococcal Vaccine 2189242A in Healthy Infants,Completed,,Phase 2,1806.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-18 19:10:38,2023-06-18 19:10:38,INDUSTRY,,,,,
235618,235619,NCT01001650,,2009-10-22,,,2014-09-09,2009-10-23,2009-10-26,Estimate,,,,,,,2014-09-09,2014-09-10,Estimate,April 2009,,2009-04-30,September 2014,2014-09-30,September 2010,Actual,2010-09-30,July 2010,Actual,2010-07-31,,Interventional,,,Clinical Trial of the PfSPZ Vaccine,A Phase 1/2a Trial of the PfSPZ Vaccine Administered Subcutaneously or Intradermally to Malaria-Naïve Adult Volunteers,Completed,,Phase 1,80.0,Actual,Sanaria Inc.,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 14:18:39,2023-06-16 14:18:39,INDUSTRY,,,,,
235886,235887,NCT00192166,,2005-09-12,,,2008-12-05,2005-09-12,2005-09-19,Estimate,,,,,,,2008-12-05,2008-12-08,Estimate,October 2002,,2002-10-31,December 2008,2008-12-31,May 2003,Actual,2003-05-31,March 2003,Actual,2003-03-31,,Interventional,,,"Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months","Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months",Completed,,Phase 2,1200.0,,MedImmune LLC,,,,,,,,,,,,,,,,,,,,,,2023-06-15 07:14:54,2023-06-15 07:14:54,INDUSTRY,,,,,
235911,235912,NCT01513551,,2011-12-27,2018-11-26,,2018-11-26,2012-01-16,2012-01-20,Estimate,2018-11-26,2018-12-13,Actual,,,,2018-11-26,2018-12-13,Actual,"March 13, 2012",Actual,2012-03-13,November 2018,2018-11-30,"February 15, 2013",Actual,2013-02-15,"February 15, 2013",Actual,2013-02-15,,Interventional,,The baseline analysis population consisted of all randomized participants who received study vaccine.,"The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)","A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of a Pneumococcal Conjugate Vaccine (V114) Compared to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX® 23) and PREVNAR 13® (Pneumococcal 13-Valent Conjugate Vaccine [Diphtheria CRM197 Protein]) in Healthy Adults 50 Years of Age or Older",Completed,,Phase 2,692.0,Actual,Merck Sharp & Dohme LLC,,3.0,,,False,,,,True,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2023-06-18 19:14:14,2023-06-18 19:14:14,INDUSTRY,,,,,
235932,235933,NCT00192322,,2005-09-12,,,2012-02-15,2005-09-12,2005-09-19,Estimate,,,,,,,2012-02-15,2012-02-17,Estimate,September 2001,,2001-09-30,February 2012,2012-02-29,December 2001,Actual,2001-12-31,December 2001,Actual,2001-12-31,,Interventional,CAIVT,,Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children,"A Randomized, Partially-Blinded, Placebo-Controlled Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent,Types A & B, Live Cold Adapted (CAIV-T) in Healthy Children Aged 6 to Less Than 36 Months",Completed,,Phase 2,173.0,Actual,MedImmune LLC,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 07:14:56,2023-06-15 07:14:56,INDUSTRY,,,,,
236083,236084,NCT05084508,,2021-10-18,,,2023-01-24,2021-10-18,2021-10-19,Actual,,,,,,,2023-01-24,2023-01-25,Actual,"February 3, 2022",Actual,2022-02-03,January 2023,2023-01-31,"March 4, 2024",Anticipated,2024-03-04,"October 2, 2023",Anticipated,2023-10-02,,Interventional,,,"A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age","A Phase II, Observer-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of a Varicella Vaccine at Various Potencies Compared With Varivax, as a First Dose, Administered in Healthy Children in Their Second Year of Life",Recruiting,,Phase 2,800.0,Anticipated,GlaxoSmithKline,,4.0,,,False,,,,True,True,False,,,False,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-17 21:56:09,2023-06-17 21:56:09,INDUSTRY,,,,,
236100,236101,NCT01459198,,2011-10-21,,,2015-12-14,2011-10-21,2011-10-25,Estimate,,,,,,,2015-12-14,2015-12-15,Estimate,August 2011,,2011-08-31,December 2015,2015-12-31,August 2015,Actual,2015-08-31,June 2015,Actual,2015-06-30,,Interventional,,,"Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children","A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, RSV MEDI <U+0394>M2-2 Lot RSV#002A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, RSV-Seropositive Children 12 to 59 Months of Age, and RSV-Seronegative Infants and Children 6 to 24 Months of Age",Completed,,Phase 1,60.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,7.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 19:16:04,2023-06-18 19:16:04,NIH,,,,,
236131,236132,NCT04864418,,2021-04-22,,,2023-02-13,2021-04-27,2021-04-28,Actual,,,,,,,2023-02-13,2023-02-14,Actual,"June 9, 2021",Actual,2021-06-09,February 2023,2023-02-28,July 2023,Anticipated,2023-07-31,March 2023,Anticipated,2023-03-31,,Interventional,,,AST-021p Study in Advanced Solid Tumors,"A Phase 1 Study to Evaluate the Safety, Tolerability and Optimal Immunogenic Dose of Therapeutic Cancer Vaccine (AST-021p) in Patients With Advanced Solid Tumors",Recruiting,,Phase 1,19.0,Anticipated,Aston Sci. Inc.,,1.0,,,False,,,,True,True,False,,,True,,,,,,No,,2023-06-17 21:56:18,2023-06-17 21:56:18,INDUSTRY,,,,,
236381,236382,NCT02996890,,2016-12-15,,,2022-08-17,2016-12-16,2016-12-19,Estimate,,,,,,,2022-08-17,2022-08-18,Actual,"May 3, 2017",Actual,2017-05-03,August 2022,2022-08-31,"April 17, 2018",Actual,2018-04-17,"January 4, 2018",Actual,2018-01-04,,Interventional,,,"Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001)","Double Blinded, Randomized, Placebo Controlled, Dose Finding Trial to Evaluate the Optimal Dose of MV-ZIKA, a New Vaccine Against Zika Virus, in Regard to Immunogenicity, Safety, and Tolerability in Healthy Volunteers",Completed,,Phase 1,48.0,Actual,Themis Bioscience GmbH,,4.0,,,False,,,,False,False,False,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2023-06-18 19:19:11,2023-06-18 19:19:11,INDUSTRY,,,,,
236406,236407,NCT04121494,,2019-08-20,,,2020-09-24,2019-10-08,2019-10-10,Actual,,,,,,,2020-09-24,2020-09-25,Actual,"January 22, 2019",Actual,2019-01-22,September 2020,2020-09-30,"August 24, 2020",Actual,2020-08-24,"August 24, 2020",Actual,2020-08-24,,Interventional,TB039,,ChAdOx1 85A Aerosol Versus Intramuscular Vaccination in Healthy Adults (TB039),A Phase I Clinical Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine ChAdOx1 85A Administered by the Aerosol Inhaled Route and the Intramuscular Route in Healthy Adult Subjects,Completed,,Early Phase 1,39.0,Actual,Centre Hospitalier Universitaire Vaudois,,6.0,,,False,,,,True,False,False,,,,,,immediately without limit in time,,,Yes,availability of study protocol,2023-06-18 19:19:21,2023-06-18 19:19:21,OTHER,,,,,
236497,236498,NCT01006798,,2009-11-02,,,2020-03-16,2009-11-02,2009-11-03,Estimate,,,,,,,2020-03-16,2020-03-18,Actual,October 2009,,2009-10-31,March 2020,2020-03-31,September 2011,Actual,2011-09-30,September 2011,Actual,2011-09-30,,Interventional,,,Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1,Phase 1 Evaluation of the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4-vectored H5N1 Influenza Candidate Vaccine - Ad4-H5-Vtn,Completed,,Phase 1,166.0,Actual,Emergent BioSolutions,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 14:20:22,2023-06-16 14:20:22,INDUSTRY,,,,,
236665,236666,NCT00047931,,2002-10-22,,,2017-06-30,2002-10-22,2002-10-23,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"October 17, 2002",,2002-10-17,"May 5, 2009",2009-05-05,"May 5, 2009",,2009-05-05,,,,,Interventional,,,HIV-1 Vaccine Test in Uninfected Adult Volunteers,"A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA009-00-VP in Uninfected Adult Volunteers",Completed,,Phase 1,50.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:15:54,2023-06-15 07:15:54,NIH,,,,,
236943,236944,NCT00317473,,2006-04-20,2017-01-24,,2017-05-04,2006-04-20,2006-04-24,Estimate,2017-05-04,2017-10-02,Actual,,,,2017-05-04,2017-10-02,Actual,June 2003,,2003-06-30,May 2017,2017-05-31,July 2005,Actual,2005-07-31,July 2004,Actual,2004-07-31,,Interventional,,one subject from FMP1/AS02A Cohort A withdrew after randomization and prior to baseline measurement,Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children,"Double-blind,Randomized,Controlled,Dose Escalation Phase 1 Trial in 12-47 Month Old Children in Western Kenya to Evaluate the Safety and Immunogenicity of WRAIR's MSP-1(FMP1) Malaria Vaccine Adjuvanted in GSK's AS02A Versus Rabies Vaccine.",Completed,,Phase 1,135.0,Actual,U.S. Army Medical Research and Development Command,,4.0,,,False,,,,True,,,,,,,,,,,Yes,Kenya Medical Research Institute; WRAIR; The Path Malaria Vaccine Initiative; United States Agency for International Development; GlaxoSmith Kline,2023-06-16 14:20:58,2023-06-16 14:20:58,FED,,,,,
237024,237025,NCT00316693,,2006-04-19,2009-11-12,,2018-08-30,2006-04-19,2006-04-21,Estimate,2009-11-12,2009-12-16,Estimate,,,,2018-08-30,2018-09-04,Actual,"April 26, 2006",,2006-04-26,August 2018,2018-08-31,"February 10, 2009",Actual,2009-02-10,"February 10, 2009",Actual,2009-02-10,,Interventional,,,"Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine","A Phase II Study to Assess the Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 (Cervarix TM) Vaccine Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Japanese Female Subjects Aged 20 - 25 Years.",Completed,,Phase 2,1046.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 14:21:14,2023-06-16 14:21:14,INDUSTRY,,,,,
237105,237106,NCT05228314,,2021-12-24,,,2022-10-18,2022-01-27,2022-02-08,Actual,,,,,,,2022-10-18,2022-10-19,Actual,"May 30, 2022",Actual,2022-05-30,October 2022,2022-10-31,September 2023,Anticipated,2023-09-30,September 2023,Anticipated,2023-09-30,,Interventional,,,Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults,"A Phase 1, Observer-blind, Randomized, Controlled, Dose-finding Study to Evaluate the Safety and Immunogenicity of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2020S) in Adults 18 to 75 Years of Age","Active, not recruiting",,Phase 1,153.0,Actual,Clover Biopharmaceuticals AUS Pty Ltd,,6.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 19:25:49,2023-06-18 19:25:49,INDUSTRY,,,,,
237255,237256,NCT00820846,,2009-01-08,,2015-05-28,2022-08-04,2009-01-08,2009-01-12,Estimate,,,,2015-07-02,2015-07-24,Estimate,2022-08-04,2022-08-09,Actual,January 2009,,2009-01-31,August 2022,2022-08-31,September 2014,Actual,2014-09-30,August 2012,Actual,2012-08-31,,Interventional,,,Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults,"A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants",Completed,,Phase 2,299.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 19:27:28,2023-06-18 19:27:28,NIH,,,,,
237477,237478,NCT00196963,,2005-09-13,,,2016-09-20,2005-09-13,2005-09-20,Estimate,,,,,,,2016-09-20,2016-09-21,Estimate,March 2005,,2005-03-31,September 2016,2016-09-30,July 2005,Actual,2005-07-31,July 2005,Actual,2005-07-31,,Interventional,,,"Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs","Assess the Immunogenicity, Safety, Reactogenicity of 1 Dose of 4 Different Formulations of GSK Biologicals' Meningococcal Conjugate Vaccine (MenACWY) vs 1 Dose of Mencevax ACWY in Healthy Subjects Aged 15-19 Yrs",Completed,,Phase 2,125.0,Actual,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 07:16:47,2023-06-15 07:16:47,INDUSTRY,,,,,
237486,237487,NCT00197041,,2005-09-13,,,2016-09-20,2005-09-13,2005-09-20,Estimate,,,,,,,2016-09-20,2016-09-21,Estimate,July 2003,,2003-07-31,September 2016,2016-09-30,April 2005,Actual,2005-04-30,April 2005,Actual,2005-04-30,,Interventional,,,"A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, When Administered to Children Aged 1 to 4 Years Living in a Malaria-endemic Region of Mozambique.","A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, Administered Intramuscularly According to a 0, 1 and 2 Month Vaccination Schedule in Toddlers and Children Aged 1 to 4 Years in a Malaria-endemic Region of Mozambique.",Completed,,Phase 2,2022.0,Actual,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 07:16:48,2023-06-15 07:16:48,INDUSTRY,,,,,
237847,237848,NCT03050814,,2017-02-10,2021-11-09,,2021-12-10,2017-02-10,2017-02-13,Actual,2021-11-09,2021-12-09,Actual,,,,2021-12-10,2021-12-20,Actual,"April 5, 2017",Actual,2017-04-05,December 2021,2021-12-31,"August 25, 2021",Actual,2021-08-25,"August 25, 2021",Actual,2021-08-25,,Interventional,,4 participants that were enrolled but not assigned to a treatment arm had baseline data collected and it is reported in this table. These participants were screen failures who were not treated.,Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004,A Randomized Phase II Trial of Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in Patients With Previously Untreated Metastatic or Unresectable Colorectal Cancer,Terminated,,Phase 2,30.0,Actual,National Institutes of Health Clinical Center (CC),,2.0,,Terminated after an unplanned interim efficacy analysis.,False,,,,False,True,False,,,,,,,,,No,,2023-06-17 21:58:37,2023-06-17 21:58:37,NIH,,,,,
237907,237908,NCT05817422,,2023-04-05,,,2023-04-17,2023-04-05,2023-04-18,Actual,,,,,,,2023-04-17,2023-04-19,Actual,"August 15, 2023",Anticipated,2023-08-15,April 2023,2023-04-30,"October 31, 2024",Anticipated,2024-10-31,"December 15, 2023",Anticipated,2023-12-15,,Interventional,,,Phase 2 Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults,"A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults",Not yet recruiting,,Phase 2,125.0,Anticipated,Albert B. Sabin Vaccine Institute,,2.0,,,False,,,,True,True,False,,,False,,,"We will also publish results in a manuscript in a peer reviewed journal, which requires a published study protocol. We expect this will be done either by early 2025.",,,Yes,"The clinic trial results will be published in a peer-reviewed journal, which will include, as feasible, the study protocol. A summary of the study results will be included within the trial registration records in ClinicalTrials.gov.",2023-06-18 19:34:18,2023-06-18 19:34:18,OTHER,,,,,
238024,238025,NCT05815264,,2023-04-03,,,2023-04-13,2023-04-13,2023-04-18,Actual,,,,,,,2023-04-13,2023-04-18,Actual,"September 7, 2020",Actual,2020-09-07,April 2023,2023-04-30,"March 26, 2021",Actual,2021-03-26,"March 26, 2021",Actual,2021-03-26,,Interventional,,,Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above,"A Randomized, Blind, Parallel Controlled Phase I Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Population Aged 2 Years and Older",Completed,,Phase 1,144.0,Actual,"Ab&b Biotechnology Co., Ltd.JS",,6.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-18 19:35:19,2023-06-18 19:35:19,OTHER,,,,,
238265,238266,NCT04967742,,2021-07-12,,,2022-08-25,2021-07-15,2021-07-20,Actual,,,,,,,2022-08-25,2022-08-26,Actual,"August 5, 2021",Actual,2021-08-05,February 2022,2022-02-28,"October 31, 2021",Actual,2021-10-31,"August 22, 2021",Actual,2021-08-22,,Interventional,,,"A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","A Phase I, Open-Label Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 Vaccine in Healthy Adult Volunteers",Completed,,Phase 1,50.0,Actual,"United Biomedical Inc., Asia",,3.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-14 07:21:13,2023-06-14 07:21:13,INDUSTRY,,,,,
238290,238291,NCT05691530,,2023-01-19,,,2023-04-14,2023-01-19,2023-01-20,Actual,,,,,,,2023-04-14,2023-04-18,Actual,"March 7, 2023",Actual,2023-03-07,"April 12, 2023",2023-04-12,"May 1, 2025",Anticipated,2025-05-01,"May 1, 2025",Anticipated,2025-05-01,,Interventional,,,"Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine","Phase 1 Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine",Recruiting,,Phase 1,200.0,Anticipated,National Institutes of Health Clinical Center (CC),,3.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-18 19:36:52,2023-06-18 19:36:52,NIH,,,,,
238309,238310,NCT05683457,,2023-01-04,,,2023-04-15,2023-01-04,2023-01-13,Actual,,,,,,,2023-04-15,2023-04-19,Actual,"April 5, 2023",Actual,2023-04-05,April 2023,2023-04-30,"August 1, 2025",Anticipated,2025-08-01,"February 1, 2025",Anticipated,2025-02-01,,Interventional,,,"A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.","A Phase 2, Observer-Blind, Placebo-Controlled Proof-of-Concept Trial to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus Vaccine in Patients Who Have Undergone Allogeneic Hematopoietic Cell Transplantation (HCT)",Recruiting,,Phase 2,224.0,Anticipated,"ModernaTX, Inc.",,2.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-18 19:36:58,2023-06-18 19:36:58,INDUSTRY,,,,,
238394,238395,NCT05626803,,2022-11-15,,,2023-04-18,2022-11-15,2022-11-25,Actual,,,,,,,2023-04-18,2023-04-19,Actual,"February 28, 2022",Actual,2022-02-28,November 2022,2022-11-30,"February 29, 2024",Anticipated,2024-02-29,"April 14, 2023",Actual,2023-04-14,,Interventional,,,A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Single Dose, Dose-ranging Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccine Administered Orally to Healthy Volunteers Aged Greater Than or Equal to 18 Years and Less Than or Equal to 80 Years Old.","Active, not recruiting",,Phase 2,125.0,Actual,Vaxart,,4.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-18 19:37:34,2023-06-18 19:37:34,INDUSTRY,,,,,
238433,238434,NCT05608005,,2022-10-20,,,2023-04-14,2022-11-04,2022-11-07,Actual,,,,,,,2023-04-14,2023-04-18,Actual,"November 3, 2022",Actual,2022-11-03,April 2023,2023-04-30,"January 26, 2024",Anticipated,2024-01-26,"February 18, 2023",Actual,2023-02-18,,Interventional,,,Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older,"A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older","Active, not recruiting",,Phase 2,582.0,Actual,Sanofi,,3.0,,,True,,,,,True,False,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-18 19:37:44,2023-06-18 19:37:44,INDUSTRY,,,,,
238444,238445,NCT05605470,,2022-10-30,,,2023-04-17,2022-10-30,2022-11-04,Actual,,,,,,,2023-04-17,2023-04-19,Actual,"January 19, 2023",Actual,2023-01-19,April 2023,2023-04-30,"February 29, 2024",Anticipated,2024-02-29,"September 30, 2023",Anticipated,2023-09-30,,Interventional,,,Immunogenicity and Safety of ChulaCov19 BNA159 Vaccine as a Booster Dose in Adults,A Phase 2 Study to Evaluate the Immunogenicity and Safety of ChulaCov19 BNA159 Vaccine as a Booster Dose in Adults Who Have Received a Previous Booster Dose of an Authorized/Approved COVID-19 Vaccine,Recruiting,,Phase 2,150.0,Anticipated,"Technovalia, Pty Ltd",,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 19:37:45,2023-06-18 19:37:45,INDUSTRY,,,,,
238616,238617,NCT05446740,,2022-06-28,,,2023-04-21,2022-07-04,2022-07-07,Actual,,,,,,,2023-04-21,2023-04-24,Actual,"August 9, 2022",Actual,2022-08-09,April 2023,2023-04-30,"January 25, 2024",Anticipated,2024-01-25,"January 25, 2024",Anticipated,2024-01-25,,Interventional,,,"A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults","A Phase 1 Randomized, Observer-blind, Dose-escalation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of an mRNA-based Monovalent Influenza Vaccine Candidate in Healthy Younger and Older Adults",Recruiting,,Phase 1,336.0,Anticipated,GlaxoSmithKline,,12.0,,,False,,,,False,False,False,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-18 19:38:39,2023-06-18 19:38:39,INDUSTRY,,,,,
238662,238663,NCT05378464,,2022-05-12,,,2023-04-17,2022-05-17,2022-05-18,Actual,,,,,,,2023-04-17,2023-04-19,Actual,"May 31, 2022",Actual,2022-05-31,April 2023,2023-04-30,May 2026,Anticipated,2026-05-31,May 2024,Anticipated,2024-05-31,,Interventional,,,Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer,Phase 1 Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab / Trastuzumab in Patients With Metastatic HER2-Positive Breast Cancer,Recruiting,,Phase 1,28.0,Anticipated,H. Lee Moffitt Cancer Center and Research Institute,,4.0,,,,,,,True,True,False,,,,,,,,,No,,2023-06-18 19:38:59,2023-06-18 19:38:59,OTHER,,,,,
238808,238809,NCT05242965,,2022-01-18,,,2023-04-17,2022-02-07,2022-02-16,Actual,,,,,,,2023-04-17,2023-04-19,Actual,"April 6, 2023",Actual,2023-04-06,January 2023,2023-01-31,"January 1, 2026",Anticipated,2026-01-01,"January 1, 2024",Anticipated,2024-01-01,,Interventional,,,A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer,A Phase II Randomized Study of Safety and Efficacy of a Multiple Antigen Vaccine (STEMVAC) in Non-Squamous Non-Small-Cell Lung Cancer Patients,Recruiting,,Phase 2,40.0,Anticipated,University of Washington,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-18 19:39:42,2023-06-18 19:39:42,OTHER,,,,,
238961,238962,NCT05079750,,2021-10-04,,,2023-04-18,2021-10-04,2021-10-15,Actual,,,,,,,2023-04-18,2023-04-19,Actual,"November 11, 2021",Actual,2021-11-11,October 2021,2021-10-31,"March 21, 2023",Actual,2023-03-21,"March 21, 2023",Actual,2023-03-21,,Interventional,,,A Study of a New Vaccine Against Two Types of Ebola,A Phase I Study to Determine the Safety and Immunogenicity of a Bivalent ChAdOx1 Vectored Vaccine Against Zaire and Sudan Ebola Virus Species in UK Healthy Adult Volunteers,Completed,,Phase 1,26.0,Actual,University of Oxford,,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 19:40:28,2023-06-18 19:40:28,OTHER,,,,,
239094,239095,NCT04998240,,2021-07-29,,,2023-04-16,2021-08-09,2021-08-10,Actual,,,,,,,2023-04-16,2023-04-19,Actual,"December 29, 2021",Actual,2021-12-29,April 2023,2023-04-30,"February 28, 2024",Anticipated,2024-02-28,"September 26, 2022",Actual,2022-09-26,,Interventional,,,Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines,"A Phase 2, Observer-blind, Randomized Study to Assess the Safety and Immunogenicity of Heterologous Prime-boost COVID-19 Vaccines Regimens in Individuals Aged 18 to 65 Years in Mozambique and Madagascar.","Active, not recruiting",,Phase 2,360.0,Actual,International Vaccine Institute,,4.0,,,False,,,,True,False,False,,,,,,,,,Undecided,,2023-06-18 19:40:58,2023-06-18 19:40:58,OTHER,,,,,
239107,239108,NCT04990544,,2021-08-02,,,2023-04-18,2021-08-02,2021-08-04,Actual,,,,,,,2023-04-18,2023-04-19,Actual,"July 31, 2021",Actual,2021-07-31,April 2023,2023-04-30,November 2023,Anticipated,2023-11-30,"April 22, 2022",Actual,2022-04-22,,Interventional,,,Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19,"A Randomized, Double-blinded, Placebo-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for the Prevention of COVID-19 in Adults Aged 18 Years and Above","Active, not recruiting",,Phase 2,528.0,Actual,"Shanghai Zerun Biotechnology Co.,Ltd",,8.0,,,False,,,,,False,False,,,,,,,,,Undecided,,2023-06-18 19:41:04,2023-06-18 19:41:04,INDUSTRY,,,,,
239113,239114,NCT04982068,,2021-07-26,,,2023-04-18,2021-07-27,2021-07-29,Actual,,,,,,,2023-04-18,2023-04-19,Actual,"July 12, 2021",Actual,2021-07-12,April 2023,2023-04-30,June 2023,Anticipated,2023-06-30,"October 31, 2021",Actual,2021-10-31,,Interventional,,,Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19,"A Randomized, Double-blinded, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Immunogenicity of the Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy Adults Aged 18 Years and Above","Active, not recruiting",,Phase 1,72.0,Actual,"Shanghai Zerun Biotechnology Co.,Ltd",,8.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 19:41:07,2023-06-18 19:41:07,INDUSTRY,,,,,
239125,239126,NCT04963413,,2021-07-12,,,2023-04-18,2021-07-12,2021-07-15,Actual,,,,,,,2023-04-18,2023-04-19,Actual,"January 13, 2022",Actual,2022-01-13,April 2023,2023-04-30,May 2025,Anticipated,2025-05-31,December 2023,Anticipated,2023-12-31,,Interventional,,,RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.,RENEW: Pilot Study of Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.,"Active, not recruiting",,Phase 1,10.0,Anticipated,University of Florida,,1.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-18 19:41:14,2023-06-18 19:41:14,OTHER,,,,,
239242,239243,NCT00754455,,2008-09-16,,2013-07-16,2013-07-16,2008-09-16,2008-09-18,Estimate,,,,2013-07-16,2013-07-18,Estimate,2013-07-16,2013-07-18,Estimate,September 2008,,2008-09-30,July 2013,2013-07-31,March 2009,Actual,2009-03-31,March 2009,Actual,2009-03-31,,Interventional,,,Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults,"A Phase 2a Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant) in Healthy Adults",Completed,,Phase 2,317.0,Actual,Novavax,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 22:00:19,2023-06-17 22:00:19,INDUSTRY,,,,,
239391,239392,NCT04410900,,2020-05-28,,,2023-04-18,2020-05-28,2020-06-01,Actual,,,,,,,2023-04-18,2023-04-19,Actual,"August 3, 2020",Actual,2020-08-03,April 2023,2023-04-30,"February 1, 2025",Anticipated,2025-02-01,"August 1, 2024",Anticipated,2024-08-01,,Interventional,,,Vaccine Responsiveness After CAR-T Cell Therapy,Rabies Vaccination to Assess Vaccine Responsiveness After B Cell Targeted CAR-T Cell Therapies,Recruiting,,Phase 1,41.0,Anticipated,Fred Hutchinson Cancer Center,,2.0,,,False,,,,True,True,False,,,,,,Data will be shared beginning 3 months and ending 5 years following article publication.,"Data will be shared with researchers who provide a methodologically sound proposal. Data will be shared to achieve aims in the approved proposal. Proposals should be directed to Joshua A. Hill. To gain access, data requestors will need to sign a data access agreement.",,Yes,"Individual participant data that underlie the results reported in a future article will be shared, after deidentification (text, tables, figures, and appendices).",2023-06-18 19:43:27,2023-06-18 19:43:27,OTHER,,,,,
239405,239406,NCT00400101,,2006-11-15,,,2006-11-15,2006-11-15,2006-11-16,Estimate,,,,,,,2006-11-15,2006-11-16,Estimate,November 2003,,2003-11-30,November 2006,2006-11-30,October 2005,,2005-10-31,,,,,Interventional,,,Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Peptides,A Randomized Placebo-Controlled Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Synthetic Peptides in Healthy Adult Volunteers,Terminated,,Phase 1,46.0,,Swiss Tropical & Public Health Institute,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:18:25,2023-06-15 07:18:25,OTHER,,,,,
239600,239601,NCT03804944,,2019-01-09,,,2023-04-18,2019-01-11,2019-01-15,Actual,,,,,,,2023-04-18,2023-04-19,Actual,"March 17, 2020",Actual,2020-03-17,April 2023,2023-04-30,December 2027,Anticipated,2027-12-31,December 2025,Anticipated,2025-12-31,,Interventional,CBCV,,Converting HR+ Breast Cancer Into an Individualized Vaccine,Converting HR+ Breast Cancer Into an Individualized Vaccine,Recruiting,,Phase 2,100.0,Anticipated,Weill Medical College of Cornell University,,4.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-18 19:45:17,2023-06-18 19:45:17,OTHER,,,,,
239757,239758,NCT03060629,,2017-02-17,2023-02-02,,2023-03-24,2017-02-17,2017-02-23,Actual,2023-03-24,2023-04-18,Actual,,,,2023-03-24,2023-04-18,Actual,"November 3, 2017",Actual,2017-11-03,March 2023,2023-03-31,"February 2, 2022",Actual,2022-02-02,"February 2, 2022",Actual,2022-02-02,,Interventional,,,A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Efficacy Study of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-adjuvanted Clade C gp140 in Preventing HIV-1 Infection in Adult Women in Sub-Saharan Africa",Terminated,,Phase 2,2636.0,Actual,Janssen Vaccines & Prevention B.V.,,2.0,,Study was terminated by the sponsor after the last participant completed the Month 24 visit as the pre-specified criteria to continue the study were not met.,False,,,,True,True,False,,,,,,,,,,,2023-06-18 19:46:52,2023-06-18 19:46:52,INDUSTRY,,,,,
239793,239794,NCT01926639,,2013-08-19,,,2014-10-22,2013-08-19,2013-08-21,Estimate,,,,,,,2014-10-22,2014-10-23,Estimate,October 2009,,2009-10-31,October 2014,2014-10-31,October 2014,Actual,2014-10-31,October 2014,Actual,2014-10-31,,Interventional,Lymvac-1,,Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma,Radiotherapy Combined With Intratumoral Injections of Dendritic Cells and Rituximab - a Phase II Cancer Vaccine Trial for Patients With Untreated and Relapsed Indolent Non-Hodgkin's Lymphoma,Completed,,Phase 2,14.0,Actual,Oslo University Hospital,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 21:34:48,2023-06-18 21:34:48,OTHER,,,,,
239860,239861,NCT02063724,,2014-02-06,2018-08-30,,2023-05-22,2014-02-12,2014-02-14,Estimate,2018-08-30,2019-02-15,Actual,,,,2023-05-22,2023-05-24,Actual,"October 1, 2014",Actual,2014-10-01,May 2023,2023-05-31,December 2023,Anticipated,2023-12-31,September 2017,Actual,2017-09-30,,Interventional,Adjuvant,All participants.,HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer,Pilot Phase I HER-2 Pulsed DC Vaccine to Prevent Recurrence for Patients With HER-2 Driven High Risk Invasive Breast Cancer,"Active, not recruiting",,Phase 1,15.0,Actual,H. Lee Moffitt Cancer Center and Research Institute,,1.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-18 19:47:43,2023-06-18 19:47:43,OTHER,,,,,
239947,239948,NCT00053482,,2003-01-30,2011-01-03,,2018-08-09,2003-01-30,2003-01-31,Estimate,2011-01-14,2011-02-11,Estimate,,,,2018-08-09,2018-08-13,Actual,January 2003,,2003-01-31,August 2018,2018-08-31,October 2003,Actual,2003-10-31,April 2003,Actual,2003-04-30,,Interventional,,,Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults,"The Effect of Dose on Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults With Previous Smallpox Vaccination",Completed,,Phase 2,357.0,Actual,Emergent BioSolutions,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 19:48:57,2023-06-18 19:48:57,INDUSTRY,,,,,
240164,240165,NCT00266110,,2005-12-13,2017-03-28,,2018-08-14,2005-12-13,2005-12-15,Estimate,2017-03-28,2017-05-09,Actual,,,,2018-08-14,2018-09-12,Actual,December 2005,Actual,2005-12-31,August 2018,2018-08-31,"October 27, 2017",Actual,2017-10-27,February 2013,Actual,2013-02-28,,Interventional,,,"Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer",Phase II Trial Evaluating the Toxicity and Efficacy of a Multiepitope Dendritic Cell Vaccine Given With Trastuzumab and Vinorelbine Ditartrate for the Treatment of Women With Metastatic Breast Cancer That Express HLA-A0201 and Whose Tumors Overexpress HER-2/NEU,Completed,,Phase 2,17.0,Actual,UNC Lineberger Comprehensive Cancer Center,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 19:51:29,2023-06-18 19:51:29,OTHER,,,,,
240501,240502,NCT01067131,,2010-02-10,,,2012-12-21,2010-02-10,2010-02-11,Estimate,,,,,,,2012-12-21,2012-12-24,Estimate,March 2010,,2010-03-31,December 2012,2012-12-31,December 2012,Actual,2012-12-31,December 2012,Actual,2012-12-31,,Interventional,,,Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection,A Phase I Randomized Placebo Controlled Study of a Virosome Formulated Anti-Candida Vaccine (PEV7) Administered by the Vaginal (PEV7C) or Intramuscular (PEV7B) Route to Healthy Adult Volunteers,Completed,,Phase 1,48.0,Actual,Pevion Biotech Ltd,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 14:31:01,2023-06-16 14:31:01,INDUSTRY,,,,,
240531,240532,NCT01461993,,2011-09-28,2014-11-21,2014-07-25,2018-11-30,2011-10-26,2011-10-28,Estimate,2014-11-21,2014-11-26,Estimate,2014-07-25,2014-07-30,Estimate,2018-11-30,2018-12-19,Actual,"September 28, 2011",Actual,2011-09-28,November 2018,2018-11-30,"July 6, 2013",Actual,2013-07-06,"July 6, 2013",Actual,2013-07-06,,Interventional,,,"A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17","A Phase 2, Randomized, Active-controlled, Observer-blinded Trial, To Assess The Safety, Tolerability, And Immunogenicity Of Gardasil (Registered) (Hpv) Vaccine And Bivalent Rlp2086 Vaccine When Administered Concomitantly In Healthy Subjects Aged >=11 To <18 Years",Completed,,Phase 2,2499.0,Actual,Pfizer,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 19:55:15,2023-06-18 19:55:15,INDUSTRY,,,,,
240575,240576,NCT00778895,,2008-10-23,2012-12-19,2011-11-16,2018-07-02,2008-10-23,2008-10-24,Estimate,2013-07-03,2013-07-09,Estimate,2011-11-16,2011-11-21,Estimate,2018-07-02,2018-08-17,Actual,"November 10, 2008",,2008-11-10,October 2016,2016-10-31,"August 19, 2009",Actual,2009-08-19,"August 19, 2009",Actual,2009-08-19,,Interventional,,,"Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control","Clinical Study in Children, 6 Months to 3 Years of Age, to Assess the Immunogenicity and Safety of Two Dose Levels of Thimerosal-free Fluviral® Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control",Completed,,Phase 2,390.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 14:31:13,2023-06-16 14:31:13,INDUSTRY,,,,,
240685,240686,NCT01437267,,2011-09-19,2014-03-05,,2014-03-05,2011-09-19,2011-09-20,Estimate,2014-03-05,2014-04-10,Estimate,,,,2014-03-05,2014-04-10,Estimate,October 2011,,2011-10-31,March 2014,2014-03-31,August 2012,Actual,2012-08-31,August 2012,Actual,2012-08-31,,Interventional,,Analysis was done on all enrolled subjects.,"Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants","A Phase 2, Randomized, Controlled, Observer Blind, Single Center Study of the Safety, Reactogenicity and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Children, Older Infants and Infants",Completed,,Phase 2,120.0,Actual,Novartis,,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 19:56:45,2023-06-18 19:56:45,INDUSTRY,,,,,
240714,240715,NCT02600975,,2015-11-06,,,2017-06-19,2015-11-06,2015-11-09,Estimate,,,,,,,2017-06-19,2017-06-20,Actual,"December 8, 2015",Actual,2015-12-08,June 2017,2017-06-30,"January 19, 2017",Actual,2017-01-19,"January 19, 2017",Actual,2017-01-19,,Interventional,,,"A Study to Assess the Safety and Immunogenicity of a Malaria Vaccine Candidate, R21, Administered With AS01B","A Phase I Study to Assess the Safety and Immunogenicity of a Protein Particle Malaria Vaccine Candidate, R21, Administered With AS01B in Healthy UK Volunteers",Completed,,Phase 1,20.0,Actual,University of Oxford,,2.0,,,False,,,,True,,,,,,,,,,,Undecided,Yes when manuscript is published,2023-06-16 14:31:38,2023-06-16 14:31:38,OTHER,,,,,
240927,240928,NCT00374842,,2006-09-08,2013-03-07,,2018-05-09,2006-09-08,2006-09-12,Estimate,2013-03-07,2013-04-22,Estimate,,,,2018-05-09,2018-06-08,Actual,"October 3, 2006",,2006-10-03,October 2016,2016-10-31,"November 30, 2006",Actual,2006-11-30,"November 1, 2006",Actual,2006-11-01,,Interventional,,,Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmithKline (GSK) Biologicals' GSK1247446A Low Dose Influenza Vaccine Candidate,"A Study to Evaluate the Immunogenicity, Safety and Reactogenicity of Adjuvanted Influenza Vaccine Candidates Compared to Fluarix Administered Intramuscularly in Subjects Aged 18-59 Years.",Completed,,Phase 2,300.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-18 19:58:39,2023-06-18 19:58:39,INDUSTRY,,,,,
240957,240958,NCT03685708,,2018-09-25,2021-11-17,,2022-01-13,2018-09-25,2018-09-26,Actual,2021-11-17,2021-12-15,Actual,,,,2022-01-13,2022-02-08,Actual,"December 7, 2018",Actual,2018-12-07,June 2021,2021-06-30,"December 16, 2020",Actual,2020-12-16,"December 16, 2020",Actual,2020-12-16,,Interventional,,,HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I),Response to the HEPLISAV-B Hepatitis B Vaccine in Treatment Naive Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's -Tyrosine Kinase Inhibitor (BTK-I),Completed,,Phase 2,78.0,Actual,National Institutes of Health Clinical Center (CC),,3.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-16 14:32:24,2023-06-16 14:32:24,NIH,,,,,
241358,241359,NCT01045460,,2009-12-14,2019-08-08,,2021-03-16,2010-01-07,2010-01-11,Estimate,2019-09-19,2019-10-08,Actual,,,,2021-03-16,2021-04-09,Actual,"January 15, 2010",Actual,2010-01-15,February 2021,2021-02-28,June 2020,Actual,2020-06-30,December 2014,Actual,2014-12-31,,Interventional,aMILs,,Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma,Randomized Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic GM-CSF-based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma,Completed,,Phase 2,36.0,Actual,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-14 07:26:10,2023-06-14 07:26:10,OTHER,,,,,
241472,241473,NCT00831012,,2009-01-27,,,2013-11-13,2009-01-27,2009-01-28,Estimate,,,,,,,2013-11-13,2013-11-15,Estimate,September 2009,,2009-09-30,November 2013,2013-11-30,,,,June 2011,Actual,2011-06-30,,Interventional,,,Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults,"A Phase I Dose Comparison Study of the Safety and Immunogenicity of rDEN3delta30/31-7164, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3",Completed,,Phase 1,56.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 14:35:13,2023-06-16 14:35:13,NIH,,,,,
241559,241560,NCT00513526,,2007-08-06,2011-06-28,,2015-08-27,2007-08-06,2007-08-08,Estimate,2011-06-28,2011-07-26,Estimate,,,,2015-08-27,2015-09-17,Estimate,November 2007,,2007-11-30,August 2015,2015-08-31,October 2011,Actual,2011-10-31,May 2010,Actual,2010-05-31,,Interventional,,,Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection,"A Single-Arm, Open-Label Pilot Trial of the Safety and Immunogenicity of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Men",Completed,,Phase 2,112.0,Actual,AIDS Malignancy Consortium,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 20:03:25,2023-06-18 20:03:25,NETWORK,,,,,
241642,241643,NCT01069471,,2010-02-15,,,2010-10-11,2010-02-16,2010-02-17,Estimate,,,,,,,2010-10-11,2010-10-13,Estimate,February 2010,,2010-02-28,October 2010,2010-10-31,October 2010,Actual,2010-10-31,October 2010,Actual,2010-10-31,,Interventional,,,Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella,Safety and Reactogenicity of a Candidate Vaccine Against S. Dysenteriae When Administered to Healthy Adults,Completed,,Phase 1,40.0,Actual,GlycoVaxyn AG,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 14:36:36,2023-06-16 14:36:36,INDUSTRY,,,,,
241668,241669,NCT03430089,,2018-02-05,,,2022-11-04,2018-02-09,2018-02-12,Actual,,,,,,,2022-11-04,2022-11-09,Actual,"February 22, 2019",Actual,2019-02-22,November 2022,2022-11-30,"June 6, 2019",Actual,2019-06-06,"June 6, 2019",Actual,2019-06-06,,Interventional,,,Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine,"Safety of a Single Dose (Participants Aged 9 Years and Older) or Two Doses Given 28 Days Apart (Participants Aged 6 Months to 8 Years) of the Shenzhen Quadrivalent Influenza Vaccine (Split Virion), Inactivated",Completed,,Phase 1,101.0,Actual,Sanofi,,5.0,,,False,,,,False,False,False,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-18 21:35:22,2023-06-18 21:35:22,INDUSTRY,,,,,
242112,242113,NCT01776554,,2013-01-20,2015-04-02,,2019-01-14,2013-01-23,2013-01-28,Estimate,2015-04-02,2015-04-20,Estimate,,,,2019-01-14,2019-01-16,Actual,January 2013,,2013-01-31,January 2019,2019-01-31,June 2014,Actual,2014-06-30,June 2013,Actual,2013-06-30,,Interventional,,,Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children,"A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Pediatric Subjects.",Completed,,Phase 2,662.0,Actual,Novartis,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 20:07:13,2023-06-18 20:07:13,INDUSTRY,,,,,
242296,242297,NCT00829608,,2009-01-05,,,2016-10-03,2009-01-26,2009-01-27,Estimate,,,,,,,2016-10-03,2016-10-05,Estimate,January 2009,,2009-01-31,October 2016,2016-10-31,June 2010,Anticipated,2010-06-30,December 2009,Anticipated,2009-12-31,,Interventional,,,Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis,Investigator Initiated Study of Effects of Progression of Recurrent Respiratory Papillomatosis in Patients After They Are Given Human Papillomavirus Quadrivalent Vaccine,Withdrawn,,Early Phase 1,0.0,Actual,University of Missouri-Columbia,,1.0,,investigator has left the institution,False,,,,False,,,,,,,,,,,No,,2023-06-16 14:40:16,2023-06-16 14:40:16,OTHER,,,,,
242421,242422,NCT00214461,,2005-09-16,2012-03-13,,2012-04-09,2005-09-16,2005-09-22,Estimate,2012-03-13,2012-04-09,Estimate,,,,2012-04-09,2012-04-11,Estimate,November 2005,,2005-11-30,April 2012,2012-04-30,February 2006,Actual,2006-02-28,February 2006,Actual,2006-02-28,,Interventional,,,"Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers","A Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study of the Safety, Tolerability and Immunogenicity of a Clostridium Difficile Toxoid Vaccine, Alum Adsorbed, in Healthy Elderly Volunteers (> or =65 Years)",Completed,,Phase 1,48.0,Actual,Sanofi,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 20:09:00,2023-06-18 20:09:00,INDUSTRY,,,,,
242472,242473,NCT01855945,,2013-04-02,2015-09-17,,2016-01-19,2013-05-14,2013-05-17,Estimate,2016-01-19,2016-02-17,Estimate,,,,2016-01-19,2016-02-17,Estimate,May 2013,,2013-05-31,January 2016,2016-01-31,September 2014,Actual,2014-09-30,September 2014,Actual,2014-09-30,,Interventional,,Baseline analysis was done on all enrolled set.,"Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.","Phase I Multi-center, Observer-Blind, Randomized, Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated Novel Swine Origin A/H3N2v Monovalent Subunit Influenza Virus Vaccine (H3N2c) in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to < 65 Years and Elderly = 65 Years and Older.",Completed,,Phase 1,627.0,Actual,Novartis,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 20:09:19,2023-06-18 20:09:19,INDUSTRY,,,,,
242499,242500,NCT02492958,,2015-05-29,2017-08-15,,2018-07-27,2015-07-06,2015-07-09,Estimate,2018-07-27,2018-07-30,Actual,,,,2018-07-27,2018-07-30,Actual,June 2015,Actual,2015-06-30,July 2018,2018-07-31,September 2016,Actual,2016-09-30,September 2016,Actual,2016-09-30,,Interventional,,Safety population included all participants who received at least 1 dose of investigational product and had safety data available after vaccination.,"SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults","A Phase 1/2a Placebo-controlled, Randomized, Double-blind, Sponsor-unblinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of Staphylococcus Aureus 4-antigen Vaccine (sa4ag) In Japanese Adults",Completed,,Phase 2,136.0,Actual,Pfizer,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 07:27:33,2023-06-14 07:27:33,INDUSTRY,,,,,
242566,242567,NCT02547792,,2015-09-09,,,2018-05-29,2015-09-10,2015-09-11,Estimate,,,,,,,2018-05-29,2018-05-31,Actual,"October 20, 2015",Actual,2015-10-20,May 2018,2018-05-31,"November 21, 2016",Actual,2016-11-21,"November 21, 2016",Actual,2016-11-21,,Interventional,,,Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults,"Phase 1 , Placebo-Controlled, Dose-Ranging Trial to Determine Safety and Immunogenicity of an Oral Adenoviral-Vector Based Influenza B Vaccine",Completed,,Phase 1,54.0,Actual,Vaxart,,3.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-16 14:42:06,2023-06-16 14:42:06,INDUSTRY,,,,,
242638,242639,NCT00546819,,2007-10-17,2011-07-20,,2017-03-14,2007-10-17,2007-10-19,Estimate,2011-07-20,2011-08-15,Estimate,,,,2017-03-14,2017-04-12,Actual,October 2007,,2007-10-31,March 2017,2017-03-31,August 2010,Actual,2010-08-31,August 2010,Actual,2010-08-31,,Interventional,,,ZOSTAVAX in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED),"A Phase IIb Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids",Completed,,Phase 2,309.0,Actual,Merck Sharp & Dohme LLC,,2.0,,,False,,,,,,,,,,,,,,,Yes,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php",2023-06-16 14:42:35,2023-06-16 14:42:35,INDUSTRY,,,,,
242703,242704,NCT04199715,,2019-12-12,,,2022-02-24,2019-12-12,2019-12-16,Actual,,,,,,,2022-02-24,2022-03-11,Actual,"December 3, 2019",Actual,2019-12-03,February 2022,2022-02-28,"January 20, 2022",Actual,2022-01-20,"January 20, 2022",Actual,2022-01-20,,Interventional,,,Safety and Efficacy of a Hepatitis B Vaccine in Immunosuppressed Patients,Immunologic Efficacy of Heplisav B Vaccine in Patients Undergoing Treatment With Immunosuppressive Medications,Completed,,Phase 1,10.0,Actual,Baylor Research Institute,,1.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-18 20:10:42,2023-06-18 20:10:42,OTHER,,,,,
242748,242749,NCT04026009,,2019-07-16,,,2022-06-09,2019-07-18,2019-07-19,Actual,,,,,,,2022-06-09,2022-06-10,Actual,"August 5, 2019",Actual,2019-08-05,June 2022,2022-06-30,"May 10, 2022",Actual,2022-05-10,"May 10, 2022",Actual,2022-05-10,,Interventional,,,Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years,"A Phase I, Single-center, Randomized, Observer-blind, Placebo-controlled Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK's Clostridium Difficile Investigational Vaccine Based on the F2 Antigen With or Without AS01B Adjuvant, When Administered Intramuscularly According to a 0, 1-month Schedule to Healthy Adults Aged Between 18-45 Years and Between 50-70 Years, Followed by an Additional Dose Administered in a Partial Blind Manner Within an Interval of Approximately 15 Months After Dose 2, in a Subcohort of Subjects Aged 50-70 Years",Completed,,Phase 1,140.0,Actual,GlaxoSmithKline,,5.0,,,False,,,,False,False,False,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-18 20:10:56,2023-06-18 20:10:56,INDUSTRY,,,,,
242785,242786,NCT00844506,,2009-02-13,,,2011-02-24,2009-02-13,2009-02-16,Estimate,,,,,,,2011-02-24,2011-02-25,Estimate,October 2008,,2008-10-31,February 2011,2011-02-28,July 2009,Actual,2009-07-31,July 2009,Actual,2009-07-31,,Interventional,ISA-P53-CTX,,p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer,p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer a Phase II Trial,Completed,,Phase 2,19.0,Anticipated,University Medical Center Groningen,,,,,False,,,,True,,,,,,,,,,,,,2023-06-16 14:43:09,2023-06-16 14:43:09,OTHER,,,,,
242930,242931,NCT04199169,,2019-12-11,,,2022-11-16,2019-12-12,2019-12-13,Actual,,,,,,,2022-11-16,2022-11-17,Actual,"February 18, 2020",Actual,2020-02-18,November 2022,2022-11-30,"May 6, 2022",Actual,2022-05-06,"May 6, 2022",Actual,2022-05-06,,Interventional,,,Safety and Immunogenicity of a Nipah Virus Vaccine,"A Phase 1 Randomized, Placebo-controlled, Observer-blind Trial to Assess the Safety and Immunogenicity of a Nipah Vaccine, HeV-sG-V (Hendra Virus Soluble Glycoprotein Vaccine), in Healthy Adults",Completed,,Phase 1,192.0,Actual,Auro Vaccines LLC,,9.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-18 20:12:06,2023-06-18 20:12:06,INDUSTRY,,,,,
243049,243050,NCT01071031,,2010-02-17,,,2012-09-25,2010-02-17,2010-02-18,Estimate,,,,,,,2012-09-25,2012-09-26,Estimate,November 2009,,2009-11-30,September 2012,2012-09-30,April 2011,Actual,2011-04-30,April 2011,Actual,2011-04-30,,Interventional,,,HIV Vaccine Study in HIV Positive Patients,"A Multicentre, Two Stage, Randomised, Double Blind Study of the Safety, Tolerability and Immunogenicity of a Human Immunodeficiency Virus (HIV) Vaccine Candidate, HIV-v",Completed,,Phase 1,54.0,Actual,PepTcell Limited,,5.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 14:44:40,2023-06-16 14:44:40,INDUSTRY,,,,,
243212,243213,NCT00849732,,2009-02-20,,,2015-02-26,2009-02-20,2009-02-24,Estimate,,,,,,,2015-02-26,2015-02-27,Estimate,June 2003,,2003-06-30,February 2015,2015-02-28,February 2011,Actual,2011-02-28,October 2006,Actual,2006-10-31,,Interventional,,,"A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)","A Worldwide, Phase I, Dose-Escalating Study of Safety, Tolerability, and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 Gag Vaccine in Healthy Adults",Completed,,Phase 1,360.0,Actual,Merck Sharp & Dohme LLC,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 14:45:40,2023-06-16 14:45:40,INDUSTRY,,,,,
243223,243224,NCT01817725,,2013-03-21,2017-02-02,,2017-03-22,2013-03-22,2013-03-25,Estimate,2017-03-22,2017-05-02,Actual,,,,2017-03-22,2017-05-02,Actual,March 2013,,2013-03-31,March 2017,2017-03-31,February 2016,Actual,2016-02-29,February 2016,Actual,2016-02-29,,Interventional,,,Hepatitis B Vaccine in Chronic Hepatitis B Patients With Low Serum HBsAg,Effect of Hepatitis B Vaccine in Chronic Hepatitis B Patients With Low Serum HBsAg-a Pilot Study,Completed,,Phase 1,20.0,Actual,Chang Gung Memorial Hospital,,1.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-18 20:13:31,2023-06-18 20:13:31,OTHER,,,,,
243475,243476,NCT03926728,,2019-04-15,,,2022-05-04,2019-04-23,2019-04-24,Actual,,,,,,,2022-05-04,2022-05-05,Actual,"February 17, 2020",Actual,2020-02-17,May 2022,2022-05-31,"February 22, 2022",Actual,2022-02-22,"February 22, 2022",Actual,2022-02-22,,Interventional,CHLM-02,,Safety and Immunogenicity of a Chlamydia Vaccine CTH522,"A Phase I, Double-blind, Parallel, Randomised and Placebo-controlled Trial Investigating the Safety and Immunogenicity of a Chlamydia Vaccine, CTH522, in Healthy Adults",Completed,,Phase 1,65.0,Actual,Statens Serum Institut,,6.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-18 20:15:31,2023-06-18 20:15:31,OTHER,,,,,
243585,243586,NCT05162482,,2021-12-13,,,2022-02-17,2021-12-16,2021-12-17,Actual,,,,,,,2022-02-17,2022-02-18,Actual,"March 1, 2022",Anticipated,2022-03-01,February 2022,2022-02-28,"June 30, 2024",Anticipated,2024-06-30,"June 30, 2024",Anticipated,2024-06-30,,Interventional,COMBAT-COVID,,Combination Assessment Trial of COVID-19 Vaccines (COMBAT-COVID),Immunogenicity and Safety of Heterologous Combinations of COVID-19 Vaccines Available Under Emergency Use Authorization in Pakistan: A Randomized Phase II Trial,Not yet recruiting,,Phase 2,1680.0,Anticipated,"Aga Khan University Hospital, Pakistan",,9.0,,,False,,,,True,False,False,,,True,,,,,,No,,2023-06-18 20:16:15,2023-06-18 20:16:15,OTHER,,,,,
243662,243663,NCT04497298,,2020-07-31,,,2022-02-03,2020-08-03,2020-08-04,Actual,,,,,,,2022-02-03,2022-02-18,Actual,"August 10, 2020",Actual,2020-08-10,July 2021,2021-07-31,"May 12, 2021",Actual,2021-05-12,"May 12, 2021",Actual,2021-05-12,,Interventional,COVID-19-101,,Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine,"A Randomized, Placebo-controlled Trial, to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine, a Measles Vector-based Vaccine Candidate Against COVID-19 in Healthy Volunteers Consisting of an Unblinded Dose Escalation and a Blinded Treatment Phase",Completed,,Phase 1,90.0,Actual,Institut Pasteur,,4.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 20:16:58,2023-06-18 20:16:58,INDUSTRY,,,,,
243801,243802,NCT00791570,,2008-10-31,,,2012-10-14,2008-11-13,2008-11-14,Estimate,,,,,,,2012-10-14,2012-10-16,Estimate,October 2008,,2008-10-31,October 2012,2012-10-31,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,,,Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy,Histocompatibility Leukocyte Antigen (HLA)-A*2402 and A*0201 Restricted Peptide Vaccine Therapy in Patients With Neovascular Maculopathy,Completed,,Phase 1,17.0,Actual,Osaka University,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 14:49:35,2023-06-16 14:49:35,OTHER,,,,,
243970,243971,NCT00635830,,2008-03-03,2009-03-17,,2015-10-08,2008-03-07,2008-03-14,Estimate,2009-07-10,2009-08-20,Estimate,,,,2015-10-08,2015-10-09,Estimate,March 2008,,2008-03-31,October 2015,2015-10-31,April 2008,Actual,2008-04-30,April 2008,Actual,2008-04-30,,Interventional,,,"An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)","An Open-Label, Single-Dose, Safety and Tolerability Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Chinese Female Subjects Aged 9 to 26 Years",Completed,,Phase 1,40.0,Actual,Merck Sharp & Dohme LLC,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-18 20:19:13,2023-06-18 20:19:13,INDUSTRY,,,,,
244166,244167,NCT02532049,,2015-08-07,,,2017-07-14,2015-08-20,2015-08-25,Estimate,,,,,,,2017-07-14,2017-07-17,Actual,"October 12, 2015",Actual,2015-10-12,July 2017,2017-07-31,"May 25, 2017",Actual,2017-05-25,"May 25, 2017",Actual,2017-05-25,,Interventional,,,A Clinical Trial to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 Pfs25-IMX313 and MVA Pfs25-IMX313,"A Phase Ia Clinical Trial to Assess the Safety, Immunogenicity and Ex-vivo Efficacy of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 Pfs-IMX313 Alone and With MVA Pfs25-IMX313",Completed,,Phase 1,26.0,Actual,University of Oxford,,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 14:50:51,2023-06-16 14:50:51,OTHER,,,,,
244311,244312,NCT00228358,,2005-09-13,,,2014-11-07,2005-09-26,2005-09-28,Estimate,,,,,,,2014-11-07,2014-11-11,Estimate,June 2003,,2003-06-30,November 2014,2014-11-30,,,,May 2011,Actual,2011-05-31,,Interventional,,,"Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine",A Phase I Study of Infusion of HER-2/Neu Specific T Cells in Patients With Advanced Stage HER-2/Neu Expressing Cancers Who Have Received a HER-2/Neu Vaccine,Completed,,Phase 1,8.0,Actual,University of Washington,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 07:22:06,2023-06-15 07:22:06,OTHER,,,,,
244464,244465,NCT01273246,,2011-01-07,,,2021-07-25,2011-01-07,2011-01-10,Estimate,,,,,,,2021-07-25,2021-07-28,Actual,January 2011,,2011-01-31,July 2011,2011-07-31,July 2011,Actual,2011-07-31,June 2011,Actual,2011-06-30,,Interventional,,,Safety of an Inactivated Enterovirus Type 71 Vaccines in Healthy Children,"A Blind, Randomized and Placebo-controlled Clinical Trial With Inactivated Enterovirus Type 71 Vaccines in Healthy Children.",Completed,,Phase 1,132.0,Actual,"Sinovac Biotech Co., Ltd",,10.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 20:23:08,2023-06-18 20:23:08,INDUSTRY,,,,,
244518,244519,NCT00734734,,2008-08-13,2015-12-21,,2015-12-21,2008-08-13,2008-08-14,Estimate,2015-12-21,2016-01-28,Estimate,,,,2015-12-21,2016-01-28,Estimate,June 2008,,2008-06-30,December 2015,2015-12-31,July 2008,Actual,2008-07-31,July 2008,Actual,2008-07-31,,Interventional,,Baseline analysis population was defined as all participants who were enrolled.,"Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009","A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD® Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009, When Administered to Elderly Subjects",Completed,,Phase 2,64.0,Actual,Novartis,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-18 20:23:42,2023-06-18 20:23:42,INDUSTRY,,,,,
244663,244664,NCT05581407,,2022-09-27,,,2022-11-16,2022-10-12,2022-10-14,Actual,,,,,,,2022-11-16,2022-11-17,Actual,"October 3, 2022",Actual,2022-10-03,October 2022,2022-10-31,"December 3, 2023",Anticipated,2023-12-03,"July 3, 2023",Anticipated,2023-07-03,,Interventional,TETRALITE-I,,"Safety, Tolerability, and Immunogenicity of TETRALITE, a Novel Adjuvanted, Low-dose Influenza Vaccin","A Randomized First-in-human, Observer-blind, 3-arm Study to Evaluate Safety, Tolerability, and Immunogenicity of a Single Administration of TETRALITE, a Novel Adjuvanted, Low-dose Influenza Vaccine","Active, not recruiting",,Phase 1,60.0,Actual,LiteVax BV,,3.0,,,False,,,,,False,False,,,,,,,,,Undecided,,2023-06-18 20:24:58,2023-06-18 20:24:58,INDUSTRY,,,,,
244672,244673,NCT03897309,,2019-03-28,,,2022-09-19,2019-03-29,2019-04-01,Actual,,,,,,,2022-09-19,2022-09-21,Actual,"March 20, 2019",Actual,2019-03-20,September 2022,2022-09-30,"April 1, 2021",Actual,2021-04-01,"January 15, 2021",Actual,2021-01-15,,Interventional,VXA-NVV-103,,Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines,"A Ph 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Safety and Immunogenicity Study of Adenoviral-vector Based Oral Norovirus Vaccines Expressing GI.1 or GII.4 VP1 With Monovalent or Bivalent Dosing",Completed,,Phase 1,86.0,Actual,Vaxart,,4.0,,,False,,,,False,True,False,,,,,,,,,No,Study results will be summarized and presented by treatment arm comparisons. Individual subject data will not be shared with other researchers.,2023-06-18 20:25:04,2023-06-18 20:25:04,INDUSTRY,,,,,
244725,244726,NCT00783926,,2008-10-31,,,2015-10-07,2008-10-31,2008-11-02,Estimate,,,,,,,2015-10-07,2015-10-09,Estimate,July 2008,,2008-07-31,July 2009,2009-07-31,July 2009,Actual,2009-07-31,February 2009,Actual,2009-02-28,,Interventional,,,Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant),"Double Blind, Multi-Center, Phase 1 Study of a Vero Cell-Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Subjects Aged 18 to 45 Years",Completed,,Phase 1,422.0,Actual,Ology Bioservices,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 14:52:40,2023-06-16 14:52:40,INDUSTRY,,,,,
244944,244945,NCT01768117,,2013-01-08,2015-02-23,,2018-11-30,2013-01-11,2013-01-15,Estimate,2015-02-23,2015-03-09,Estimate,,,,2018-11-30,2018-12-20,Actual,February 2013,,2013-02-28,November 2018,2018-11-30,February 2014,Actual,2014-02-28,February 2014,Actual,2014-02-28,,Interventional,B1971042,,"Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers =18 To =65 Years Of Age","A Single-arm, Open-label Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers >=18 To < =65 Years Of Age",Completed,,Phase 2,13.0,Actual,Pfizer,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 20:27:33,2023-06-18 20:27:33,INDUSTRY,,,,,
245052,245053,NCT00787826,,2008-11-05,,,2021-04-28,2008-11-06,2008-11-10,Estimate,,,,,,,2021-04-28,2021-04-29,Actual,"August 28, 2009",Actual,2009-08-28,April 2021,2021-04-30,"December 1, 2021",Anticipated,2021-12-01,"November 1, 2019",Actual,2019-11-01,,Interventional,,,Continued Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine,"A Longitudinal Phase 2 Study for the Continued Evaluation of the Safety and Immunogenicity of a Live Francisella Tularensis Vaccine, NDBR 101, Lot 4 in Healthy Adults At-Risk for Exposure to Francisella Tularensis",Unknown status,Enrolling by invitation,Phase 2,1000.0,Anticipated,U.S. Army Medical Research and Development Command,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 14:53:34,2023-06-16 14:53:34,FED,,,,,
245345,245346,NCT01070407,,2010-02-16,,,2015-04-22,2010-02-17,2010-02-18,Estimate,,,,,,,2015-04-22,2015-04-23,Estimate,July 2007,,2007-07-31,April 2015,2015-04-30,February 2011,Actual,2011-02-28,August 2010,Actual,2010-08-31,,Interventional,,,A Study of a New Candidate Vaccine Against Hepatitis C Virus (HCV),A Phase I Study to Assess the Safety and Immunogenicity of New Hepatitis C Virus Vaccine Candidates AdCh3NSmut and Ad6NSmut,Completed,,Phase 1,41.0,Actual,ReiThera Srl,,9.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 14:54:52,2023-06-16 14:54:52,INDUSTRY,,,,,
245352,245353,NCT04669691,,2016-11-30,,,2022-08-22,2020-12-09,2020-12-17,Actual,,,,,,,2022-08-22,2022-08-23,Actual,"December 19, 2020",Actual,2020-12-19,August 2022,2022-08-31,"April 15, 2022",Actual,2022-04-15,"April 15, 2022",Actual,2022-04-15,,Interventional,,,A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine,"A Phase 2, Randomized, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Several Doses of Antigen and MF59 Adjuvant Content in a Monovalent H5N1 Pandemic Influenza Vaccine in Healthy Pediatric Subjects 6 Months to < 9 Years of Age",Completed,,Phase 2,420.0,Actual,Seqirus,,6.0,,,False,,,,False,False,False,,,,,,SEQIRUS discloses results from clinical studies within 12 months of last patient last visit (LPLV) unless otherwise mandated by local laws or regulations.,"SEQIRUS will consider requests from qualified scientific and medical researchers to disclose protocols, anonymized subject-level data and study-level data when there is medical, scientific and/or public health interest to ensure the safe use of a Seqirus product licensed on or after 1 January 2014 in the United States (US) and/or the European Union (EU). This applies to Seqirus-sponsored interventional studies initiated after 27 September 2007 and ongoing as of 26 December 2007, that have been included as part of a US or EU submission package which received approval in US and EU on or after 1 January 2014 and have been accepted for publication",https://www.seqirus.us/partnering,Yes,"SEQIRUS supports the release of anonymized subject-level and study-level data in compliance with regulatory requirements, including Clinical Documents which are part of the CTD modules submitted to regulatory agencies for public release.

Summary results disclosure is either in document form (e.g., ICH E3 Clinical Study Report synopsis) or structured data form (such as summary results in ClinicalTrials.gov (United States) or eudract.ema.europa.eu (EU Clinical Trial Registry [EU CTR])",2023-06-18 20:29:26,2023-06-18 20:29:26,INDUSTRY,,,,,
245424,245425,NCT00506350,,2007-07-24,2017-09-11,2011-02-04,2017-09-11,2007-07-24,2007-07-25,Estimate,2017-09-11,2017-10-04,Actual,2011-02-04,2011-02-09,Estimate,2017-09-11,2017-10-04,Actual,"August 1, 2007",Actual,2007-08-01,September 2017,2017-09-30,"October 12, 2009",Actual,2009-10-12,"October 12, 2009",Actual,2009-10-12,,Interventional,,,Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults,Evaluate the Reactogenicity & Immunogenicity of 1 or 2 Booster Administrations of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults Aged Between 19 & 61 Years,Completed,,Phase 2,350.0,Actual,GlaxoSmithKline,,9.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 14:55:10,2023-06-16 14:55:10,INDUSTRY,,,,,
245488,245489,NCT00231907,,2005-09-30,,,2010-08-26,2005-09-30,2005-10-04,Estimate,,,,,,,2010-08-26,2010-08-27,Estimate,September 2005,,2005-09-30,February 2010,2010-02-28,March 2007,Actual,2007-03-31,March 2007,Actual,2007-03-31,,Interventional,,,A Phase I Safety and Immunogenicity Study of Mix and Match of Licensed Flu Vaccine and Flumist,"Influenza Vaccines: Mix and Match of Trivalent Inactivated Influenza (TIV) and Live Attenuated Influenza Vaccine (LAIV), a Phase I Safety, Immunogenicity, and Viral Shedding Study",Completed,,Phase 1,56.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:23:31,2023-06-15 07:23:31,NIH,,,,,
245496,245497,NCT03806686,,2019-01-14,,,2019-05-29,2019-01-14,2019-01-16,Actual,,,,,,,2019-05-29,2019-05-31,Actual,"May 31, 2018",Actual,2018-05-31,May 2019,2019-05-31,June 2020,Anticipated,2020-06-30,March 2020,Anticipated,2020-03-31,,Interventional,,,Phase 2a Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Healthcare Workers,"A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Explore the Immunogenicity and Efficacy of ID93+GLA-SE Vaccine in BCG-Vaccinated Healthy Healthcare Workers",Unknown status,"Active, not recruiting",Phase 2,107.0,Actual,Quratis Inc.,,3.0,,,False,,,,False,True,False,,,True,,,,,,No,,2023-06-18 20:29:59,2023-06-18 20:29:59,INDUSTRY,,,,,
245607,245608,NCT00510874,,2007-08-01,2013-12-19,,2018-07-02,2007-08-01,2007-08-02,Estimate,2013-12-19,2014-02-07,Estimate,,,,2018-07-02,2018-08-17,Actual,"July 28, 2007",,2007-07-28,October 2016,2016-10-31,"October 24, 2008",Actual,2008-10-24,"June 17, 2008",Actual,2008-06-17,,Interventional,,,Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults,"A Phase I/II, Observer-Blind, Randomized, Active-Controlled Trial to Evaluate the Safety and Immunogenicity of a Two-Dose Series of GSK Biologicals' Candidate Influenza Vaccine GSK 1557484A Antigens With or Without Adjuvant",Completed,,Phase 1,780.0,Actual,GlaxoSmithKline,,7.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 14:56:52,2023-06-16 14:56:52,INDUSTRY,,,,,
245798,245799,NCT00518206,,2007-08-16,2017-04-06,,2022-10-03,2007-08-16,2007-08-20,Estimate,2017-04-06,2017-06-23,Actual,,,,2022-10-03,2022-10-25,Actual,"November 28, 2003",Actual,2003-11-28,October 2022,2022-10-31,"January 22, 2010",Actual,2010-01-22,"January 22, 2010",Actual,2010-01-22,,Interventional,,All enrolled subjects,Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma,A Phase II Study of the Clinical and Immunological Effects of NY-ESO-1 ISCOM® Vaccine in Patients With Measurable Stage III and IV Malignant Melanoma,Completed,,Phase 2,46.0,Actual,Ludwig Institute for Cancer Research,,2.0,,,False,,,,False,False,False,,,,,,,,,Yes,Data have been published,2023-06-16 14:57:58,2023-06-16 14:57:58,OTHER,,,,,
245799,245800,NCT00984945,,2009-09-24,,,2010-11-02,2009-09-24,2009-09-25,Estimate,,,,,,,2010-11-02,2010-11-04,Estimate,September 2009,,2009-09-30,April 2010,2010-04-30,July 2010,Actual,2010-07-31,December 2009,Actual,2009-12-31,,Interventional,,,Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults,"Phase 1 Single Centre, Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of Plant-based H5 VLP (Virus-like Particles), (H5N1) Pandemic Influenza Vaccine Adjuvanted With Aluminium Hydroxide and Administered to Healthy Adults 18-60 Years of Age",Completed,,Phase 1,48.0,Anticipated,Medicago,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 14:57:59,2023-06-16 14:57:59,INDUSTRY,,,,,
246050,246051,NCT00777790,,2008-10-21,2008-12-02,,2014-01-21,2008-10-21,2008-10-22,Estimate,2009-02-18,2009-03-19,Estimate,,,,2014-01-21,2014-02-14,Estimate,February 2004,,2004-02-29,January 2014,2014-01-31,April 2005,Actual,2005-04-30,April 2004,Actual,2004-04-30,,Interventional,,,Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents,"Antibody Responses to a Booster Dose of an Experimental Tetravalent (A, C, Y, and W-135) Meningococcal Diphtheria Toxoid Conjugate Vaccine, Menactra® in Adolescents Who Previously Received Menomune® or Menactra®",Completed,,Phase 2,241.0,Actual,Sanofi,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 20:34:22,2023-06-18 20:34:22,INDUSTRY,,,,,
246152,246153,NCT01776541,,2013-01-20,2015-01-20,,2015-01-20,2013-01-23,2013-01-28,Estimate,2015-01-20,2015-02-03,Estimate,,,,2015-01-20,2015-02-03,Estimate,January 2013,,2013-01-31,January 2015,2015-01-31,May 2014,Actual,2014-05-31,June 2013,Actual,2013-06-30,,Interventional,,,Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults,"A Phase II, Randomized, Observer-Blind,Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult Subjects.",Completed,,Phase 2,979.0,Actual,Novartis,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 20:35:28,2023-06-18 20:35:28,INDUSTRY,,,,,
246235,246236,NCT04661579,,2020-10-26,,,2022-09-12,2020-12-03,2020-12-10,Actual,,,,,,,2022-09-12,2022-09-15,Actual,"November 6, 2020",Actual,2020-11-06,September 2022,2022-09-30,"August 17, 2022",Actual,2022-08-17,"March 18, 2022",Actual,2022-03-18,,Interventional,,,"RTS,S/AS01E Hypo-immuno-responsiveness Study","A Phase 2b Randomized, Open-label, Controlled, Single Center Study in Plasmodium Falciparum-infected and Uninfected Adults Age 18-55 Years Old in Kenya to Evaluate the Efficacy of the Delayed, Fractional Dose RTS,S/AS01E Malaria Vaccine in Subjects Treated With Artemisinin Combination Therapy Plus Primaquine",Completed,,Phase 2,620.0,Actual,PATH,,5.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-18 20:36:07,2023-06-18 20:36:07,OTHER,,,,,
246510,246511,NCT02459262,,2015-05-22,2020-11-30,,2021-01-12,2015-05-28,2015-06-02,Estimate,2021-01-12,2021-01-14,Actual,,,,2021-01-12,2021-01-14,Actual,May 2015,,2015-05-31,November 2020,2020-11-30,"April 21, 2017",Actual,2017-04-21,"April 12, 2017",Actual,2017-04-12,,Interventional,MVX13211,,Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non-pregnant Women 18-40 Years of Age.,"A Two-part, Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability and Immunogenicity of a Dose Range og Group B Streptococcus Vaccine in Healthy Female Volunteers Aged 18 to 40.",Completed,,Phase 1,240.0,Actual,Minervax ApS,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 07:31:44,2023-06-14 07:31:44,OTHER,,,,,
247154,247155,NCT01910519,,2013-07-23,2019-01-02,2014-12-24,2019-01-25,2013-07-25,2013-07-29,Estimate,2019-01-25,2019-02-12,Actual,2014-12-24,2015-01-13,Estimate,2019-01-25,2019-02-12,Actual,July 2013,Actual,2013-07-31,January 2019,2019-01-31,November 2015,Actual,2015-11-30,February 2015,Actual,2015-02-28,,Interventional,,,Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03),Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without AS03 Adjuvant (HIPC: VAX-010),Completed,,Phase 2,50.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 20:44:35,2023-06-18 20:44:35,NIH,,,,,
247336,247337,NCT01616459,,2012-06-07,2014-04-10,2013-08-22,2019-07-02,2012-06-07,2012-06-11,Estimate,2014-05-15,2014-06-16,Estimate,2013-08-22,2013-08-30,Estimate,2019-07-02,2019-07-16,Actual,"July 11, 2012",Actual,2012-07-11,July 2019,2019-07-31,"January 22, 2014",Actual,2014-01-22,"April 25, 2013",Actual,2013-04-25,,Interventional,,,Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants,Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants,Completed,,Phase 2,953.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,False,,,,,,,,IPD will be made available within 6 months of publishing the results of the primary endpoints of the study,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months",http://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site,2023-06-18 20:46:40,2023-06-18 20:46:40,INDUSTRY,,,,,
247647,247648,NCT00943202,,2009-07-21,2011-04-28,,2013-04-11,2009-07-21,2009-07-22,Estimate,2011-04-28,2011-05-26,Estimate,,,,2013-04-11,2013-04-22,Estimate,August 2009,,2009-08-31,December 2010,2010-12-31,May 2010,Actual,2010-05-31,May 2010,Actual,2010-05-31,,Interventional,,,"Sanofi Pasteur, TIV + H1N1, Pediatric Population","Effect of Administration of Licensed TIV Vaccine on the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine in Previously Primed Infants and Toddlers (Greater Than or Equal to 6 - <36 Months), Children (Greater Than or Equal to 36 Months - 9 Years), and Adolescents (10 - 17 Years)",Completed,,Phase 2,531.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 07:33:01,2023-06-14 07:33:01,NIH,,,,,
247724,247725,NCT04111172,,2019-09-20,,,2022-11-16,2019-09-27,2019-10-01,Actual,,,,,,,2022-11-16,2022-11-17,Actual,"November 10, 2020",Actual,2020-11-10,November 2022,2022-11-30,December 2024,Anticipated,2024-12-31,"March 20, 2024",Anticipated,2024-03-20,,Interventional,,,A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma,"A Phase 2A, Dose-Finding Study of Ad5.F35-hGCC-PADRE Vaccine in Adults With Gastrointestinal Adenocarcinomas at Risk of Relapse Post Definitive Surgery and Standard Therapy",Recruiting,,Phase 2,81.0,Anticipated,Thomas Jefferson University,,3.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-14 07:33:20,2023-06-14 07:33:20,OTHER,,,,,
247872,247873,NCT03255278,,2017-06-29,,,2017-12-25,2017-08-16,2017-08-21,Actual,,,,,,,2017-12-25,2017-12-27,Actual,"January 15, 2017",Actual,2017-01-15,August 2017,2017-08-31,"December 13, 2017",Actual,2017-12-13,"December 13, 2017",Actual,2017-12-13,,Interventional,GamTBvac,,"Evaluation of the Safety and Immunogenicity of the Recombinant Subunit Vaccine ""GamTBvac"" Against the Tuberculosis.","Evaluation of the Safety and Immunogenicity of the Recombinant Subunit Vaccine ""GamTBvac"" Against the Tuberculosis. Comparative Placebo-controlled Study With a Two-fold Increase of the Vaccine Dose in Healthy Volunteers Aged 18-49 Years.",Completed,,Phase 1,60.0,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,5.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-17 22:09:05,2023-06-17 22:09:05,OTHER,,,,,
247875,247876,NCT00098085,,2004-12-03,,,2009-03-06,2004-12-03,2004-12-06,Estimate,,,,,,,2009-03-06,2009-03-09,Estimate,September 2003,,2003-09-30,March 2009,2009-03-31,,,,November 2007,Actual,2007-11-30,,Interventional,,,Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer,A Phase II Study of the Feasibility to Derive Autologous Vaccine (HSPPC-96) From Tumor Tissue for Clinical Administration in Patients With Resectable Non-Small Cell Lung Cancer,Completed,,Phase 2,20.0,,Agenus Inc.,,,,,,,,,,,,,,,,,,,,,,2023-06-15 07:26:00,2023-06-15 07:26:00,INDUSTRY,,,,,
247891,247892,NCT00617331,,2008-02-14,,2011-07-20,2011-07-20,2008-02-14,2008-02-18,Estimate,,,,2011-07-20,2011-07-22,Estimate,2011-07-20,2011-07-22,Estimate,February 2008,,2008-02-29,July 2011,2011-07-31,January 2009,Actual,2009-01-31,August 2008,Actual,2008-08-31,,Interventional,,,H9 Priming Study in Healthy Adults,"A Randomized, Double-Blind, Clinical Trial Evaluating the Immunogenicity of an Inactivated Influenza A/H9N2 Vaccine Among Healthy Adults With and Without Prior Exposure to Influenza A/H2N2",Completed,,Phase 2,121.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 22:09:07,2023-06-17 22:09:07,NIH,,,,,
247910,247911,NCT03032588,,2017-01-24,,,2019-07-04,2017-01-24,2017-01-26,Estimate,,,,,,,2019-07-04,2019-07-08,Actual,"October 9, 2017",Actual,2017-10-09,July 2019,2019-07-31,"May 18, 2018",Actual,2018-05-18,"May 18, 2018",Actual,2018-05-18,,Interventional,,,"A First in Human Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy Adults","A First in Human Double-blind, Randomized Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy Adults",Completed,,Phase 1,32.0,Actual,Janssen Vaccines & Prevention B.V.,,2.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-14 07:33:59,2023-06-14 07:33:59,INDUSTRY,,,,,
248019,248020,NCT00614601,,2008-01-31,,2014-05-28,2020-05-26,2008-01-31,2008-02-13,Estimate,,,,2014-05-28,2014-06-02,Estimate,2020-05-26,2020-05-28,Actual,January 2008,,2008-01-31,May 2020,2020-05-31,December 2014,Actual,2014-12-31,May 2010,Actual,2010-05-31,,Interventional,,,Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer,A Phase II Study of Low Dose Algenpantucel-L (HyperAcute Pancreas) Cancer Vaccine in Subjects With Surgically Resected Pancreatic Cancer,Terminated,,Phase 2,9.0,Actual,Lumos Pharma,,2.0,,Sponsor proceeded with a phase III study for same indication.,False,,,,True,,,,,,,,,,,,,2023-06-17 22:09:20,2023-06-17 22:09:20,INDUSTRY,,,,,
248498,248499,NCT00572910,,2007-12-11,2011-07-20,,2015-03-16,2007-12-11,2007-12-13,Estimate,2011-07-20,2011-08-15,Estimate,,,,2015-03-16,2015-04-03,Estimate,August 2008,,2008-08-31,March 2015,2015-03-31,January 2010,Actual,2010-01-31,January 2010,Actual,2010-01-31,,Interventional,,,A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED),"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of Merck Staphylococcus Aureus Vaccine (V710) in Adult Patients With End-Stage Renal Disease on Chronic Hemodialysis",Completed,,Phase 2,206.0,Actual,Merck Sharp & Dohme LLC,,6.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 15:08:45,2023-06-16 15:08:45,INDUSTRY,,,,,
248620,248621,NCT00950612,,2009-07-23,2016-11-09,2010-12-24,2018-06-25,2009-07-30,2009-08-03,Estimate,2016-11-09,2017-01-09,Estimate,2010-12-24,2010-12-30,Estimate,2018-06-25,2018-08-17,Actual,"December 8, 2009",,2009-12-08,November 2016,2016-11-30,"September 30, 2010",Actual,2010-09-30,"September 30, 2010",Actual,2010-09-30,,Interventional,,,Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Healthy HIV Negative Adolescents,Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to Healthy HIV-negative Adolescents Living in a TB Endemic Region,Completed,,Phase 2,60.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 07:34:56,2023-06-14 07:34:56,INDUSTRY,,,,,
249044,249045,NCT02965404,,2016-11-14,,,2017-10-24,2016-11-14,2016-11-16,Estimate,,,,,,,2017-10-24,2017-10-26,Actual,April 2016,,2016-04-30,November 2016,2016-11-30,August 2016,Actual,2016-08-31,May 2016,Actual,2016-05-31,,Interventional,,,"A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and Children","A Blind, Randomized and Controlled Clinical Trial to Evaluate the Safety of Live Attenuated Varicella Vaccines for Healthy Adults, Adolescents and Children",Completed,,Phase 1,270.0,Anticipated,"Sinovac (Dalian) Vaccine Technology Co., Ltd.",,3.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-15 07:27:46,2023-06-15 07:27:46,INDUSTRY,,,,,
249097,249098,NCT00894114,,2009-05-04,,,2015-05-27,2009-05-05,2009-05-06,Estimate,,,,,,,2015-05-27,2015-05-28,Estimate,May 2003,,2003-05-31,May 2015,2015-05-31,June 2009,Actual,2009-06-30,June 2009,Actual,2009-06-30,,Interventional,,,"A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)","A Probe Study of the Safety, Tolerability, and Immunogenicity of a 1-Dose Regimen of the MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC-HIV (vCP205) Vaccine in Healthy Adults Who Previously Received a 3-Dose Regimen of MRKAd5, Ad5, or Placebo in Merck V520 Protocols 007 or 012",Completed,,Phase 1,250.0,Actual,Merck Sharp & Dohme LLC,,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 15:11:42,2023-06-16 15:11:42,INDUSTRY,,,,,
249108,249109,NCT00988767,,2009-10-01,,,2009-10-02,2009-10-01,2009-10-02,Estimate,,,,,,,2009-10-02,2009-10-05,Estimate,February 2001,,2001-02-28,October 2009,2009-10-31,October 2004,Actual,2004-10-31,November 2003,Actual,2003-11-30,,Interventional,RBM99026,,Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B,Specific Vaccine Therapy in Chronic Hepatitis B Using a Naked DNA: Phase I Study Using a GMO,Completed,,Phase 1,10.0,Actual,"Institut National de la Santé Et de la Recherche Médicale, France",,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 15:11:52,2023-06-16 15:11:52,OTHER_GOV,,,,,
249181,249182,NCT03017378,,2017-01-04,,,2017-01-10,2017-01-10,2017-01-11,Estimate,,,,,,,2017-01-10,2017-01-11,Estimate,October 2013,,2013-10-31,January 2017,2017-01-31,February 2015,Actual,2015-02-28,April 2014,Actual,2014-04-30,,Interventional,,,"Reactogenicity, Safety and Immunogenicity of a TB/FLU-01L Tuberculosis Vaccine","A Randomized, Open Clinical Trial Phase 1 Vaccine TB/FLU-01L by Intranasal and Sublingual Application for Specific Immunotherapy Pulmonary Tuberculosis",Completed,,Phase 1,36.0,Actual,Research Institute for Biological Safety Problems,,2.0,,,False,,,,True,,,,,,,,,,,Undecided,,2023-06-14 07:35:39,2023-06-14 07:35:39,OTHER_GOV,,,,,
249279,249280,NCT00076947,,2004-02-06,,,2008-03-20,2004-02-06,2004-02-09,Estimate,,,,,,,2008-03-20,2008-03-21,Estimate,August 2003,,2003-08-31,March 2005,2005-03-31,,,,,,,,Interventional,,,Safety of the EnvPro HIV Vaccine in Healthy Volunteers,Evaluation of Tolerability and Safety of a Recombinant Purified HIV Envelope Vaccine,Completed,,Phase 1,10.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,,,,,,,,,,,,,,,,,,2023-06-15 07:27:59,2023-06-15 07:27:59,NIH,,,,,
249363,249364,NCT03827967,,2018-09-11,,,2022-09-14,2019-01-30,2019-02-04,Actual,,,,,,,2022-09-14,2022-09-16,Actual,"July 20, 2019",Actual,2019-07-20,September 2022,2022-09-30,"May 20, 2023",Anticipated,2023-05-20,"December 20, 2022",Anticipated,2022-12-20,,Interventional,,,Trial of PalloV-CC in Colon Cancer,"A Phase Ib Trial of Neoadjuvant PalloV-CC (Particle-delivered, Allogeneic Tumor Cell Lysate Vaccine for Colon Cancer) in Colon Cancer",Recruiting,,Phase 1,24.0,Anticipated,"Cancer Insight, LLC",,4.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-18 20:57:25,2023-06-18 20:57:25,INDUSTRY,,,,,
249658,249659,NCT00643916,,2008-03-24,2009-09-24,,2014-01-21,2008-03-25,2008-03-26,Estimate,2009-12-04,2010-01-08,Estimate,,,,2014-01-21,2014-02-14,Estimate,December 2004,,2004-12-31,January 2014,2014-01-31,October 2007,Actual,2007-10-31,March 2006,Actual,2006-03-31,,Interventional,,,Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age,"Safety and Immunogenicity of a Tetravalent (A, C, Y, and W-135) Meningococcal Diphtheria Toxoid Conjugate Vaccine (TetraMenD) In Toddlers 9 to 18 Months of Age",Completed,,Phase 2,378.0,Actual,Sanofi,,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 15:13:43,2023-06-16 15:13:43,INDUSTRY,,,,,
249721,249722,NCT00900588,,2009-05-12,,,2009-08-10,2009-05-12,2009-05-13,Estimate,,,,,,,2009-08-10,2009-08-12,Estimate,,,,August 2009,2009-08-31,,,,,,,,Interventional,,,Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescents,Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescent,Completed,,Phase 2,,,"Sinovac Biotech Co., Ltd",,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 15:14:02,2023-06-16 15:14:02,INDUSTRY,,,,,
250022,250023,NCT00627458,,2008-02-20,2017-04-07,2009-05-20,2018-04-27,2008-02-20,2008-03-03,Estimate,2017-04-07,2017-06-26,Actual,2009-05-21,2009-09-30,Estimate,2018-04-27,2018-06-06,Actual,"February 1, 2008",,2008-02-01,April 2017,2017-04-30,"August 18, 2008",Actual,2008-08-18,"August 18, 2008",Actual,2008-08-18,,Interventional,,,Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine,Immunogenicity and Reactogenicity of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine When Given as a Booster Dose,Completed,,Phase 2,403.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 15:14:52,2023-06-16 15:14:52,INDUSTRY,,,,,
250030,250031,NCT00906750,,2009-01-05,,,2011-10-12,2009-05-19,2009-05-21,Estimate,,,,,,,2011-10-12,2011-10-13,Estimate,October 2008,,2008-10-31,October 2011,2011-10-31,July 2011,Actual,2011-07-31,July 2011,Actual,2011-07-31,,Interventional,FMRESP,,A Study of a Live Intranasal Influenza Vaccine in Children With Cancer,"A Pilot Study of Flumist, a Live Attenuated Intranasal Influenza Vaccine, and Inactivated Influenza Vaccine in Children With Cancer",Completed,,Phase 1,56.0,Actual,St. Jude Children's Research Hospital,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 15:14:54,2023-06-16 15:14:54,OTHER,,,,,
250111,250112,NCT05430958,,2022-06-21,,,2022-11-12,2022-06-21,2022-06-24,Actual,,,,,,,2022-11-12,2022-11-17,Actual,October 2022,Anticipated,2022-10-31,November 2022,2022-11-30,March 2024,Anticipated,2024-03-31,March 2024,Anticipated,2024-03-31,,Interventional,,,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers","Phase 1 Open Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Intradermal Booster Dose of INO-4800 Alone or in Combination With INO-9112 Followed by Electroporation, in Adults Who Completed a Primary Immunization Series Against SARS-CoV-2 With mRNA Vaccines",Withdrawn,,Phase 1,0.0,Actual,Inovio Pharmaceuticals,,8.0,,Study was withdrawn due to sponsor decision.,False,,,,True,True,True,True,,,,,,,,No,,2023-06-18 21:03:43,2023-06-18 21:03:43,INDUSTRY,,,,,
250456,250457,NCT01678677,,2012-08-23,,,2017-05-12,2012-08-30,2012-09-05,Estimate,,,,,,,2017-05-12,2017-05-15,Actual,"August 31, 2012",Actual,2012-08-31,May 2017,2017-05-31,"January 30, 2014",Actual,2014-01-30,"January 30, 2014",Actual,2014-01-30,,Interventional,,,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers","An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers",Completed,,Phase 1,272.0,Actual,GlaxoSmithKline,,10.0,,,False,,,,,,,,,,,,,,,,,2023-06-18 21:06:10,2023-06-18 21:06:10,INDUSTRY,,,,,
250608,250609,NCT00963430,,2009-08-20,2011-04-21,,2012-11-29,2009-08-20,2009-08-21,Estimate,2011-04-21,2011-05-16,Estimate,,,,2012-11-29,2012-12-03,Estimate,September 2009,,2009-09-30,April 2010,2010-04-30,May 2010,Actual,2010-05-31,May 2010,Actual,2010-05-31,,Interventional,,,H1N1 Vaccine in Pregnant Women,A Phase II Study in Pregnant Women to Assess the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Inactivated Influenza Vaccine Administered at Two Dose Levels,Completed,,Phase 2,120.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-18 21:07:36,2023-06-18 21:07:36,NIH,,,,,
250675,250676,NCT00966238,,2009-08-24,2011-06-13,,2014-09-22,2009-08-24,2009-08-26,Estimate,2011-06-13,2011-07-14,Estimate,,,,2014-09-22,2014-10-02,Estimate,September 2009,,2009-09-30,September 2014,2014-09-30,March 2011,Actual,2011-03-31,April 2010,Actual,2010-04-30,,Interventional,,,Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of Age,"A Phase II, Open-label, Escalating Dose-ranging Study to Evaluate the Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults =65 Years of Age",Completed,,Phase 2,120.0,Actual,VaxInnate Corporation,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 21:08:04,2023-06-18 21:08:04,INDUSTRY,,,,,
250717,250718,NCT00968890,,2009-08-27,2011-02-17,2010-07-02,2018-07-04,2009-08-27,2009-08-31,Estimate,2011-02-17,2011-03-16,Estimate,2010-07-02,2010-07-07,Estimate,2018-07-04,2018-08-20,Actual,"September 12, 2009",,2009-09-12,September 2016,2016-09-30,"September 23, 2010",Actual,2010-09-23,"September 23, 2010",Actual,2010-09-23,,Interventional,,,Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix Vaccine When Co-administered in Elderly,"Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Influenza GSK2340272A and Fluarix 2009-2010 Vaccines When Co-administered in Elderly Subjects Aged 61 Years and Older",Completed,,Phase 2,168.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-18 21:08:28,2023-06-18 21:08:28,INDUSTRY,,,,,
250728,250729,NCT01686503,,2012-09-13,2015-01-13,,2015-01-22,2012-09-17,2012-09-18,Estimate,2015-01-22,2015-02-05,Estimate,,,,2015-01-22,2015-02-05,Estimate,September 2012,,2012-09-30,January 2015,2015-01-31,August 2013,Actual,2013-08-31,August 2013,Actual,2013-08-31,,Interventional,IDIPV,,Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects,Comparison of the Immunogenicity of Various Inactivated Polio Vaccine Booster Doses by Intradermal vs. Intramuscular Routes in HIV-Infected Subjects,Completed,,Phase 2,231.0,Actual,Eastern Virginia Medical School,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 07:37:27,2023-06-14 07:37:27,OTHER,,,,,
250754,250755,NCT00969878,,2009-08-31,2014-07-17,,2017-02-04,2009-08-31,2009-09-01,Estimate,2014-12-11,2014-12-12,Estimate,,,,2017-02-04,2017-03-15,Actual,August 2010,,2010-08-31,February 2017,2017-02-28,July 2014,Actual,2014-07-31,August 2012,Actual,2012-08-31,,Interventional,TA-CD,,Multisite Controlled Trial of Cocaine Vaccine,"A Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Clinical Efficacy, Safety, and Immunogenicity of a Human Cocaine Vaccine (TA-CD) in the Treatment of Cocaine Dependence",Completed,,Phase 2,300.0,Actual,Baylor College of Medicine,,2.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-14 07:37:29,2023-06-14 07:37:29,OTHER,,,,,
250825,250826,NCT00568334,,2007-12-05,2017-04-13,,2018-05-09,2007-12-05,2007-12-06,Estimate,2017-04-13,2017-06-28,Actual,,,,2018-05-09,2018-06-08,Actual,"November 1, 2007",Actual,2007-11-01,April 2017,2017-04-30,"April 29, 2008",Actual,2008-04-29,"March 18, 2008",Actual,2008-03-18,,Interventional,,,Study of Two Formulations of GSK Biologicals' Varicella Vaccine,Study of Two Formulations of GSK Biologicals' Varicella Vaccine Given as a 2-dose Course in the Second Year of Life,Completed,,Phase 2,244.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,False,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 15:16:33,2023-06-16 15:16:33,INDUSTRY,,,,,
251010,251011,NCT00928902,,2009-06-24,,,2010-10-20,2009-06-25,2009-06-26,Estimate,,,,,,,2010-10-20,2010-10-21,Estimate,November 1999,,1999-11-30,October 2010,2010-10-31,March 2005,Actual,2005-03-31,April 2001,Actual,2001-04-30,,Interventional,MEL36,,"Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma","Pilot Phase II Trial for the Evaluation of the Effect of Systemic Low-dose IL-2 on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With GM-CSF-in-Adjuvant, in Patients With High Risk Melanoma",Completed,,Phase 2,41.0,Actual,University of Virginia,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 15:16:53,2023-06-16 15:16:53,OTHER,,,,,
251028,251029,NCT01896869,,2013-07-08,2020-04-22,,2020-05-05,2013-07-08,2013-07-11,Estimate,2020-04-22,2020-05-06,Actual,,,,2020-05-05,2020-05-19,Actual,November 2013,Actual,2013-11-30,April 2020,2020-04-30,"May 3, 2019",Actual,2019-05-03,"May 3, 2019",Actual,2019-05-03,,Interventional,,,FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer,"A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab in Combination With Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer",Completed,,Phase 2,83.0,Actual,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,2.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-18 21:11:37,2023-06-18 21:11:37,OTHER,,,,,
251130,251131,NCT00249106,,2005-11-03,,,2013-02-08,2005-11-03,2005-11-07,Estimate,,,,,,,2013-02-08,2013-02-11,Estimate,December 2003,,2003-12-31,September 2011,2011-09-30,October 2005,Actual,2005-10-31,October 2005,Actual,2005-10-31,,Interventional,C001,,Safety and Immunogenicity of a Plasmid HIV Vaccine in HIV Uninfected Adults,"Randomized, Placebo-Controlled, Dose-Escalating, Double-Blinded Phase 1 Safety and Immunogenicity Study of Clade C DNA Vaccine ADVAX e/g + ADVAX p/N-t (ADVAX) Administered Intramuscularly to HIV-Uninfected, Healthy Volunteers.",Completed,,Phase 1,45.0,Actual,International AIDS Vaccine Initiative,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 07:30:56,2023-06-15 07:30:56,NETWORK,,,,,
251147,251148,NCT02961595,,2016-11-02,,,2016-11-10,2016-11-10,2016-11-11,Estimate,,,,,,,2016-11-10,2016-11-11,Estimate,October 1999,,1999-10-31,November 2016,2016-11-30,November 2016,Actual,2016-11-30,November 2016,Actual,2016-11-30,,Interventional,,,Live Enterovirus Vaccine and Type 1 Diabetes,Live Enterovirus Vaccine and Type 1 Diabetes,Completed,,Phase 1,315.0,Actual,Tampere University,,2.0,,,False,,,,False,,,,,,,,,,,No,,2023-06-15 07:31:07,2023-06-15 07:31:07,OTHER,,,,,
251162,251163,NCT00068198,,2003-09-09,,,2010-08-26,2003-09-09,2003-09-10,Estimate,,,,,,,2010-08-26,2010-08-27,Estimate,,,,May 2006,2006-05-31,November 2004,,2004-11-30,,,,,Interventional,,,Human Immune Responses Smallpox,Evaluation of Human Immune Response to Smallpox Vaccine (Vaccinia Virus),Completed,,Phase 1,45.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,,,,,,,,,,,,,,,,,,2023-06-15 07:31:16,2023-06-15 07:31:16,NIH,,,,,
251163,251164,NCT00103467,,2005-02-08,,,2005-06-23,2005-02-08,2005-02-09,Estimate,,,,,,,2005-06-23,2005-06-24,Estimate,June 2003,,2003-06-30,February 2005,2005-02-28,,,,,,,,Interventional,,,Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine,A Phase 1 Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine,Completed,,Phase 1,100.0,,VaxGen,,,,,,,,,,,,,,,,,,,,,,2023-06-15 07:31:16,2023-06-15 07:31:16,INDUSTRY,,,,,
251288,251289,NCT00252148,,2005-11-09,,,2013-02-08,2005-11-09,2005-11-11,Estimate,,,,,,,2013-02-08,2013-02-11,Estimate,January 2005,,2005-01-31,June 2010,2010-06-30,August 2007,Actual,2007-08-31,August 2007,Actual,2007-08-31,,Interventional,,,Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults,"Randomized, Placebo-Controlled, Dose-Escalating, Double-Blinded Phase 1 Safety and Immunogenicity Study of a Modified Vaccinia Ankara (MVA) Vectored HIV-1 (ADMVA) Vaccine Administered Intramuscularly to HIV-Uninfected, Healthy Volunteers",Completed,,Phase 1,48.0,Anticipated,International AIDS Vaccine Initiative,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 07:32:34,2023-06-15 07:32:34,NETWORK,,,,,
251562,251563,NCT00100971,,2005-01-07,,,2013-01-03,2005-01-07,2005-01-10,Estimate,,,,,,,2013-01-03,2013-01-04,Estimate,April 2004,,2004-04-30,January 2013,2013-01-31,March 2007,Actual,2007-03-31,March 2007,Actual,2007-03-31,,Interventional,,,Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia,Dendritic/Leukemic Fusion Cell Vaccine Therapy For AML Patients In First Remission; A Phase I Clinical Trial,Terminated,,Phase 1,9.0,,Boston Medical Center,,,,Protocol is withdrawn due to inadequate accrual,False,,,,,,,,,,,,,,,,,2023-06-15 07:34:53,2023-06-15 07:34:53,OTHER,,,,,
251680,251681,NCT00261001,,2005-12-01,,,2009-11-24,2005-12-01,2005-12-02,Estimate,,,,,,,2009-11-24,2009-11-25,Estimate,October 2005,,2005-10-31,November 2009,2009-11-30,September 2009,Actual,2009-09-30,February 2006,Actual,2006-02-28,,Interventional,MANON-05,,Safety Study Comparing a Vaccine Transcutaneous Administration to the Intramuscular Route,A Randomized Comparative Phase I Study to Evaluate and to Compare the Safety and Immunogenicity of a Transcutaneous Mode of Administration of a Licensed Tetanus/Influenza Vaccine to the Conventional Intramuscular Route of Vaccine Administration in Healthy Volunteers and HIV-infected Patients,Completed,,Phase 1,38.0,Actual,Objectif Recherche Vaccins SIDA,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 07:36:02,2023-06-15 07:36:02,OTHER,,,,,
251816,251817,NCT00263692,,2005-12-08,,,2016-09-14,2005-12-08,2005-12-09,Estimate,,,,,,,2016-09-14,2016-09-15,Estimate,November 2002,,2002-11-30,September 2016,2016-09-30,September 2004,Actual,2004-09-30,September 2004,Actual,2004-09-30,,Interventional,,,Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety,"Open, Randomized, Phase II, Clinical Trial to Compare the Immunogenicity and Safety of a Booster Dose of GSK Biologicals' DTaP-IPV Vaccine (Infanrix®-IPV) Co-administered With a Booster Dose of Merck and Company's M-M-R®II, to That of Separate Injections of GSK Biologicals' DTaP Vaccine (Infanrix®), Aventis Pasteur's IPV (IPOL®) and M-M-R®II Administered as Booster Doses to Healthy Children 4 to 6 Years of Age.",Completed,,Phase 2,401.0,Actual,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 07:37:12,2023-06-15 07:37:12,INDUSTRY,,,,,
251817,251818,NCT00072605,,2003-11-04,,,2019-12-16,2003-11-04,2003-11-05,Estimate,,,,,,,2019-12-16,2019-12-17,Actual,"October 30, 2003",,2003-10-30,"August 22, 2007",2007-08-22,"August 22, 2007",,2007-08-22,,,,,Interventional,,,Experimental Ebola Vaccine Trial,"VRC 204 A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiple Strain Ebola DNA Plasmid Vaccine, VRC-EBODNA012-00-VP, in Adult Volunteers",Completed,,Phase 1,27.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:37:13,2023-06-15 07:37:13,NIH,,,,,
251935,251936,NCT00989612,,2009-10-01,2017-04-14,2010-07-02,2018-07-31,2009-10-01,2009-10-05,Estimate,2018-07-31,2019-01-16,Actual,2010-07-02,2010-07-07,Estimate,2018-07-31,2019-01-16,Actual,"October 1, 2009",,2009-10-01,April 2017,2017-04-30,"April 19, 2010",Actual,2010-04-19,"April 19, 2010",Actual,2010-04-19,,Interventional,,,Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1),Immunogenicity and Safety Study of GSK Biologicals' Influenza Candidate Vaccine GSK2340274A,Completed,,Phase 2,100.0,Actual,GlaxoSmithKline,,1.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-14 07:39:00,2023-06-14 07:39:00,INDUSTRY,,,,,
251965,251966,NCT01349569,,2011-05-05,2018-11-29,,2019-01-14,2011-05-05,2011-05-06,Estimate,2019-01-14,2019-01-15,Actual,,,,2019-01-14,2019-01-15,Actual,January 2012,,2012-01-31,January 2019,2019-01-31,October 2016,Actual,2016-10-31,October 2016,Actual,2016-10-31,,Interventional,,"One participant withdrew consent prior to receiving the study intervention, leaving sixteen participants who received at least one day of intervention.",Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission,Administration of an Allogeneic Myeloma GM-CSF Vaccine in Conjunction With a Lenalidomide Containing Regimen in Myeloma Patients With Near Complete Remission,Completed,,Phase 2,19.0,Actual,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,1.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-15 07:38:29,2023-06-15 07:38:29,OTHER,,,,,
252172,252173,NCT00107211,,2005-04-05,,,2014-09-16,2005-04-05,2005-04-06,Estimate,,,,,,,2014-09-16,2014-09-17,Estimate,January 2005,,2005-01-31,September 2014,2014-09-30,July 2008,Actual,2008-07-31,July 2008,Actual,2008-07-31,,Interventional,,,Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carcinoma In Situ of the Breast,A HER-2/Neu Pulsed DC1 Vaccine for Patients With DCIS,Completed,,Phase 1,30.0,Anticipated,Abramson Cancer Center at Penn Medicine,,,,,False,,,,True,,,,,,,,,,,,,2023-06-15 07:40:16,2023-06-15 07:40:16,OTHER,,,,,
252359,252360,NCT00274300,,2006-01-09,,,2007-01-25,2006-01-09,2006-01-10,Estimate,,,,,,,2007-01-25,2007-01-29,Estimate,August 2004,,2004-08-31,January 2006,2006-01-31,July 2005,,2005-07-31,,,,,Interventional,,,Safety Study of HSV2 DNA Vaccine to Treat Patients With Recurrent Genital Herpes Caused by HSV-2,"A Phase I, Two-Center, Open-Label, Dose-Escalating Study to Investigate the Safety, Tolerability and Immunogenicity of pPJV7630, a Therapeutic DNA Vaccine for Herpes Simplex Virus Type 2 (HSV-2), in Patients With Recurrent Genital Herpes Caused by HSV-2",Completed,,Phase 1,36.0,,PowderMed,,,,,,,,,,,,,,,,,,,,,,2023-06-15 07:41:48,2023-06-15 07:41:48,INDUSTRY,,,,,
252380,252381,NCT00108264,,2005-04-14,,,2009-01-20,2005-04-14,2005-04-15,Estimate,,,,,,,2009-01-20,2009-01-21,Estimate,,,,May 2007,2007-05-31,September 2005,,2005-09-30,,,,,Interventional,,,Tumor RNA Transfected Dendritic Cell Vaccines,Tumor RNA Transfected Dendritic Cell Vaccines,Completed,,Phase 1,,,VA Office of Research and Development,,,,,,,,,,,,,,,,,,,,,,2023-06-15 07:41:55,2023-06-15 07:41:55,FED,,,,,
252390,252391,NCT01003418,,2009-10-27,2017-03-03,2010-12-23,2018-09-25,2009-10-27,2009-10-28,Estimate,2018-09-25,2019-02-15,Actual,2010-12-23,2010-12-30,Estimate,2018-09-25,2019-02-15,Actual,"November 17, 2009",Actual,2009-11-17,September 2018,2018-09-30,"November 25, 2010",Actual,2010-11-25,"November 25, 2010",Actual,2010-11-25,,Interventional,,,Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children,Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 8 to 12 Weeks,Terminated,,Phase 2,8.0,Actual,GlaxoSmithKline,,2.0,,"The study was terminated prematurely for logistic reasons, not related to safety or efficacy of the vaccine.",False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-14 07:40:03,2023-06-14 07:40:03,INDUSTRY,,,,,
252399,252400,NCT02808416,,2016-06-17,,,2022-05-23,2016-06-20,2016-06-21,Estimate,,,,,,,2022-05-23,2022-05-27,Actual,"March 1, 2016",Actual,2016-03-01,May 2022,2022-05-31,"June 30, 2019",Actual,2019-06-30,"October 31, 2017",Actual,2017-10-31,,Interventional,PerCellVac3,,Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3),Personalized Cellular Vaccine Therapy in Treating Patients With Brain Metastases From Solid Tumors,Completed,,Phase 1,10.0,Actual,Guangdong 999 Brain Hospital,,1.0,,,False,,,,True,,,,,,,,,,,Undecided,,2023-06-14 07:40:09,2023-06-14 07:40:09,OTHER,,,,,
252407,252408,NCT02266628,,2014-10-13,,2017-05-30,2022-05-25,2014-10-16,2014-10-17,Estimate,,,,2017-05-30,2017-06-06,Actual,2022-05-25,2022-05-27,Actual,October 2014,,2014-10-31,May 2022,2022-05-31,March 2016,Actual,2016-03-31,March 2016,Actual,2016-03-31,,Interventional,,,Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults,"A Phase II Randomized, Observer-Blind, Placebo- Controlled Study to Evaluate the Immunogenicity and Safety of Respiratory Syncytial Virus (RSV) F Vaccine in Healthy Elderly Subjects and to Estimate the Incidence Rate of Medically-attended RSV Disease in Vaccine and Placebo Recipients",Completed,,Phase 2,1599.0,Actual,Novavax,,2.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-14 07:40:18,2023-06-14 07:40:18,INDUSTRY,,,,,
252418,252419,NCT00277147,,2006-01-12,,,2017-06-30,2006-01-12,2006-01-13,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"January 9, 2006",,2006-01-09,"September 17, 2008",2008-09-17,"September 17, 2008",,2008-09-17,,,,,Interventional,,,Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine,"Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine, Phase 1 Trial in Adults at NIH CC",Completed,,Phase 1,25.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:42:06,2023-06-15 07:42:06,NIH,,,,,
252453,252454,NCT00277576,,2006-01-13,,,2008-11-20,2006-01-13,2006-01-16,Estimate,,,,,,,2008-11-20,2008-11-21,Estimate,January 2006,,2006-01-31,November 2008,2008-11-30,December 2007,Actual,2007-12-31,,,,,Interventional,,,Safety Study of HBV DNA Vaccine to Treat Patients With Chronic Hepatitis B Infection,"Phase I, Multi-Centre, Randomised, Placebo-Controlled, Dose Escalation Study to Assess Local & Systemic Tolerability of Therapeutic DNA Plasmid pdpSC18 Vaccine Administered by Particle Mediated Epidermal Delivery Using PowderJect ND10 Delivery System in Subjects With Chronic Hepatitis B Infection",Completed,,Phase 1,48.0,Anticipated,PowderMed,,,,,,,,,,,,,,,,,,,,,,2023-06-15 07:42:17,2023-06-15 07:42:17,INDUSTRY,,,,,
252476,252477,NCT00108654,,2005-04-15,,,2017-06-30,2005-04-15,2005-04-18,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"April 13, 2005",,2005-04-13,"January 15, 2008",2008-01-15,"January 15, 2008",,2008-01-15,,,,,Interventional,,,Vaccine Treatment for HIV-Infection,"A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Booster Dose of a Recombinant Multiclade HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in Uninfected Subjects Who Where Previously Immunized With VRC-HIVDNA016-00-VP in VRC 00",Completed,,Phase 1,14.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:42:31,2023-06-15 07:42:31,NIH,,,,,
252527,252528,NCT00109122,,2005-04-22,,,2017-03-14,2005-04-22,2005-04-25,Estimate,,,,,,,2017-03-14,2017-03-15,Actual,November 2001,,2001-11-30,March 2017,2017-03-31,July 2006,Actual,2006-07-31,February 2003,Actual,2003-02-28,,Interventional,,,"Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)","A Double-Blind, Placebo-Controled, Randomized Study to Evaluate Safety, Tolerability, and Immunogenicity After 1 and 2 Doses of Zoster Vaccine",Completed,,Phase 2,180.0,Actual,Merck Sharp & Dohme LLC,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:43:03,2023-06-15 07:43:03,INDUSTRY,,,,,
252530,252531,NCT00076037,,2004-01-13,,,2021-10-13,2004-01-13,2004-01-14,Estimate,,,,,,,2021-10-13,2021-10-14,Actual,April 2004,,2004-04-30,October 2021,2021-10-31,June 2006,Actual,2006-06-30,,,,,Interventional,,,Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP,"A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a CTL Multi-Epitope Peptide HIV Vaccine Formulated With RC529-SE, With or Without GM-CSF, in Healthy, HIV-1 Uninfected Adult Participants",Completed,,Phase 1,96.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:43:05,2023-06-15 07:43:05,NIH,,,,,
252552,252553,NCT00280111,,2006-01-13,,,2008-07-01,2006-01-19,2006-01-20,Estimate,,,,,,,2008-07-01,2008-07-02,Estimate,January 2005,,2005-01-31,July 2008,2008-07-31,May 2005,Actual,2005-05-31,May 2005,Actual,2005-05-31,,Interventional,,,Safety and Immunogenicity Study of Live Attenuated Indian Rotavirus Vaccine Candidate Strains 116E and I321 in Infants,Reactogenicity and Immunogenicity of Live Attenuated Indian Rotavirus Vaccine Candidate Strains 116E and I321 in Healthy Non-Malnourished Infants 8-12 Weeks of Age,Completed,,Phase 1,90.0,Actual,Society for Applied Studies,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 07:43:20,2023-06-15 07:43:20,OTHER,,,,,
252567,252568,NCT03762291,,2018-09-11,,,2023-02-02,2018-11-30,2018-12-03,Actual,,,,,,,2023-02-02,2023-02-03,Actual,"August 6, 2021",Actual,2021-08-06,February 2023,2023-02-28,"October 5, 2028",Anticipated,2028-10-05,"October 5, 2023",Anticipated,2023-10-05,,Interventional,MAPSS,,Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine,Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine,"Active, not recruiting",,Phase 1,1.0,Actual,Baylor College of Medicine,,1.0,,,False,,,,True,True,False,,,False,,,,,,,,2023-06-16 15:18:33,2023-06-16 15:18:33,OTHER,,,,,
252622,252623,NCT00109629,,2005-04-29,,,2017-06-30,2005-04-29,2005-05-02,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"April 26, 2005",,2005-04-26,"January 22, 2008",2008-01-22,"January 22, 2008",,2008-01-22,,,,,Interventional,,,"""Prime-Boost"" Vaccine Schedule for Prevention of HIV Infection","VRC 008: A Phase I Clinical Trial of a Prime-Boost HIV-1 Vaccination Schedule: Multiclade DNA Vaccine, VRC-HIVDNA016-00-VP, Followed by Multiclade Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in Uninfected Adult Volunteers",Completed,,Phase 1,40.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:43:41,2023-06-15 07:43:41,NIH,,,,,
253159,253160,NCT00111579,,2005-05-23,,,2008-07-22,2005-05-23,2005-05-24,Estimate,,,,,,,2008-07-22,2008-07-24,Estimate,May 2005,,2005-05-31,July 2008,2008-07-31,January 2006,Actual,2006-01-31,January 2006,Actual,2006-01-31,,Interventional,,,Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV),"A Prospective, Randomized, Open-Label Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With Trivalent Inactivated Vaccine (TIV) in Children 6 to <36 Months of Age",Completed,,Phase 2,52.0,,MedImmune LLC,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 07:46:43,2023-06-15 07:46:43,INDUSTRY,,,,,
253330,253331,NCT02960815,,2016-11-08,,,2017-10-09,2016-11-09,2016-11-10,Estimate,,,,,,,2017-10-09,2017-10-10,Actual,November 2016,,2016-11-30,October 2017,2017-10-31,June 2017,Actual,2017-06-30,June 2017,Actual,2017-06-30,,Interventional,IMIFLU,,Imiquimod and Influenza Vaccine for Immunocompromised Patients,Safety and Immunogenicity of Seasonal Influenza Vaccine With Topical Imiquimod in Immunocompromised Patients: A Randomized Controlled Pilot Trial,Completed,,Phase 2,70.0,Actual,University of Lausanne Hospitals,,3.0,,,False,,,,False,,,,,,,,,,,No,,2023-06-15 07:47:38,2023-06-15 07:47:38,OTHER,,,,,
253334,253335,NCT00538473,,2007-10-01,2012-04-19,2009-05-20,2018-05-09,2007-10-01,2007-10-02,Estimate,2012-06-21,2012-07-27,Estimate,2009-09-28,2009-09-30,Estimate,2018-05-09,2018-06-08,Actual,"October 23, 2007",,2007-10-23,November 2016,2016-11-30,"December 12, 2007",Actual,2007-12-12,"December 1, 2007",Actual,2007-12-01,,Interventional,,,Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults,Reactogenicity and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK576389A in Elderly Adults (=67 Years) Previously Vaccinated With the Same Candidate Vaccine. Fluarix Will be Used as Reference.,Completed,,Phase 2,68.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 15:21:22,2023-06-16 15:21:22,INDUSTRY,,,,,
253395,253396,NCT04334980,,2020-03-31,,,2022-10-24,2020-04-02,2020-04-06,Actual,,,,,,,2022-10-24,2022-10-25,Actual,"November 2, 2020",Actual,2020-11-02,May 2022,2022-05-31,"August 31, 2022",Actual,2022-08-31,"August 31, 2022",Actual,2022-08-31,,Interventional,,,"Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19","A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Immunogenicity of the bacTRL-Spike Oral Candidate Vaccine for the Prevention of COVID-19 in Healthy Adults",Completed,,Phase 1,24.0,Actual,Symvivo Corporation,,1.0,,,False,,,,True,False,False,,,,,,,,,Undecided,,2023-06-18 21:13:25,2023-06-18 21:13:25,INDUSTRY,,,,,
253418,253419,NCT00291889,,2006-02-14,,,2017-05-24,2006-02-14,2006-02-15,Estimate,,,,,,,2017-05-24,2017-05-30,Actual,July 2004,,2004-07-31,May 2017,2017-05-31,May 2005,Actual,2005-05-31,May 2005,Actual,2005-05-31,,Interventional,,,Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults.,"Evaluate the Safety, Reactogenicity & Immunogenicity of 2 Antigen Dose Levels of GSK Biologicals' Candidate Tuberculosis Vaccine, Mtb72F/AS02 to Healthy PPD-negative Volunteers Aged 18 to 45 Yrs",Completed,,Phase 1,50.0,Actual,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:48:01,2023-06-15 07:48:01,INDUSTRY,,,,,
253422,253423,NCT00291967,,2006-02-14,,,2006-12-07,2006-02-14,2006-02-15,Estimate,,,,,,,2006-12-07,2006-12-08,Estimate,November 2002,,2002-11-30,December 2006,2006-12-31,,,,,,,,Interventional,,,Assess Immune Response Following Primary Vaccination With Tritanrix-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants,"Evaluate the Feasibility of GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vaccine Administered as a 3 Dose Primary Vaccination Course at 6, 10 & 14 Weeks of Age",Completed,,Phase 2,525.0,,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:48:03,2023-06-15 07:48:03,INDUSTRY,,,,,
253476,253477,NCT05277753,,2022-02-21,,,2022-03-14,2022-03-11,2022-03-14,Actual,,,,,,,2022-03-14,2022-03-15,Actual,"March 15, 2022",Anticipated,2022-03-15,March 2022,2022-03-31,"December 31, 2025",Anticipated,2025-12-31,"December 31, 2024",Anticipated,2024-12-31,,Interventional,,,NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL,NGS-MRD Evaluation of Antigen-specific T Cells and DC Vaccine Combination Targeting T-cell Acute Lymphoblastic Leukemia,Recruiting,,Phase 1,10.0,Anticipated,Shenzhen Geno-Immune Medical Institute,,1.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-16 15:21:59,2023-06-16 15:21:59,OTHER,,,,,
253579,253580,NCT00621764,,2008-02-12,2014-09-09,,2014-09-23,2008-02-21,2008-02-22,Estimate,2014-09-22,2014-09-25,Estimate,,,,2014-09-23,2014-10-02,Estimate,March 2008,,2008-03-31,September 2014,2014-09-30,May 2013,Actual,2013-05-31,December 2009,Actual,2009-12-31,,Interventional,,,Immunogenicity and Safety of ChimeriVax Japanese Encephalitis Vaccine in Thai Toddlers and Children,A Controlled Study of the Safety and Immunogenicity of ChimeriVax Japanese Encephalitis Vaccine in Thai Toddlers and Children,Completed,,Phase 2,300.0,Actual,Sanofi,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 15:22:37,2023-06-16 15:22:37,INDUSTRY,,,,,
253599,253600,NCT02808364,,2016-06-17,,,2022-05-23,2016-06-20,2016-06-21,Estimate,,,,,,,2022-05-23,2022-05-27,Actual,"March 1, 2016",Actual,2016-03-01,May 2022,2022-05-31,"June 30, 2019",Actual,2019-06-30,"October 31, 2017",Actual,2017-10-31,,Interventional,PerCellVac2,,Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2),Personalized Cellular Vaccine Therapy in Treating Patients With Recurrent Glioblastoma (PerCellVac2),Completed,,Phase 1,10.0,Actual,Guangdong 999 Brain Hospital,,1.0,,,False,,,,True,,,,,,,,,,,Undecided,,2023-06-18 21:13:39,2023-06-18 21:13:39,OTHER,,,,,
253638,253639,NCT02709616,,2016-03-07,,,2022-05-23,2016-03-10,2016-03-16,Estimate,,,,,,,2022-05-23,2022-05-27,Actual,"March 1, 2016",Actual,2016-03-01,May 2022,2022-05-31,"June 30, 2019",Actual,2019-06-30,"October 31, 2017",Actual,2017-10-31,,Interventional,PERCELLVAC,,Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC),Personalized Cellular Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma (PerCellVac),Completed,,Phase 1,10.0,Actual,Guangdong 999 Brain Hospital,,1.0,,,False,,,,False,,,,,,,,,,,Undecided,,2023-06-18 21:13:41,2023-06-18 21:13:41,OTHER,,,,,
253657,253658,NCT00299260,,2006-03-03,,,2010-04-16,2006-03-03,2006-03-06,Estimate,,,,,,,2010-04-16,2010-04-19,Estimate,August 2006,,2006-08-31,January 2008,2008-01-31,September 2011,Anticipated,2011-09-30,September 2009,Actual,2009-09-30,,Interventional,,,CMV Glycoprotein B Vaccine in Allograft Recipients,A Phase II Immunogenicity Trial of Cytomegalovirus Glycoprotein B Vaccine in Allograft Candidate Recipients,Unknown status,"Active, not recruiting",Phase 2,140.0,Actual,"University College, London",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 07:49:03,2023-06-15 07:49:03,OTHER,,,,,
253703,253704,NCT00079820,,2004-03-15,,,2014-01-09,2004-03-16,2004-03-17,Estimate,,,,,,,2014-01-09,2014-01-13,Estimate,April 2004,,2004-04-30,January 2014,2014-01-31,October 2006,Actual,2006-10-31,October 2006,Actual,2006-10-31,,Interventional,,,"Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults","The Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine, in Adults Without Previous Smallpox Vaccination",Completed,,Phase 1,110.0,Actual,Sanofi,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 07:49:22,2023-06-15 07:49:22,INDUSTRY,,,,,
253741,253742,NCT04718467,,2021-01-20,,,2021-05-21,2021-01-20,2021-01-22,Actual,,,,,,,2021-05-21,2021-05-25,Actual,"February 1, 2021",Anticipated,2021-02-01,May 2021,2021-05-31,"March 15, 2022",Anticipated,2022-03-15,"May 15, 2021",Anticipated,2021-05-15,,Interventional,,,Phase IIb Clinical Trial of Recombinant Novel Coronavirus Pneumonia (COVID-19) Vaccine (Sf9 Cells),"A Single-center, Randomized, Double-Blinded, Placebo-Controlled, Phase <U+2161>b Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells), in the Subjects From Healthy Aged 18 to 85 Years Old",Withdrawn,,Phase 2,0.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,4.0,,Sponsor decided to cancel this trial.,False,,,,True,False,False,,,,,,,,,,,2023-06-15 07:49:36,2023-06-15 07:49:36,NETWORK,,,,,
253856,253857,NCT00120081,,2005-07-07,,,2017-05-30,2005-07-07,2005-07-15,Estimate,,,,,,,2017-05-30,2017-05-31,Actual,April 2005,,2005-04-30,May 2017,2017-05-31,September 2006,Actual,2006-09-30,September 2006,Actual,2006-09-30,,Interventional,,,Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection,"Phase 1, Single-Center, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study to Compare the Safety, Tolerability, and Immunogenicity of Three Intramuscular Administrations of Na-ASP-2 Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection",Completed,,Phase 1,36.0,Actual,Baylor College of Medicine,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 07:50:28,2023-06-15 07:50:28,OTHER,,,,,
254046,254047,NCT00081848,,2004-04-22,,,2017-06-30,2004-04-21,2004-04-22,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"April 20, 2004",,2004-04-20,"January 25, 2012",2012-01-25,"August 23, 2007",Actual,2007-08-23,"August 23, 2007",Actual,2007-08-23,,Interventional,,,Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors,A Pilot Trial of a CEA-TRICOM Based Vaccine and Radiation to Liver Metastasis in Adults With CEA Positive Solid Tumors,Completed,,Phase 1,12.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:51:38,2023-06-15 07:51:38,NIH,,,,,
254141,254142,NCT00841646,,2009-02-10,,,2016-11-30,2009-02-10,2009-02-11,Estimate,,,,,,,2016-11-30,2016-12-01,Estimate,December 2008,,2008-12-31,December 2011,2011-12-31,November 2009,Actual,2009-11-30,July 2009,Actual,2009-07-31,,Interventional,,,Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects,"A Phase II, Open-label, Multi-center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects",Completed,,Phase 2,343.0,Actual,Novartis,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 15:24:54,2023-06-16 15:24:54,INDUSTRY,,,,,
254421,254422,NCT00307021,,2006-02-16,,,2017-04-24,2006-03-23,2006-03-27,Estimate,,,,,,,2017-04-24,2017-04-25,Actual,"April 7, 2006",,2006-04-07,April 2017,2017-04-30,"August 22, 2007",Actual,2007-08-22,"September 15, 2006",Actual,2006-09-15,,Interventional,,,Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children,"Bridging Safety & Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine RTS,S/AS01E (0.5 mL Dose) to RTS,S/AS02D (0.5 mL Dose) Administered IM According to a 0, 1, 2-Month Schedule in Gabonese Children Aged 18 Months to 4 Years",Completed,,Phase 2,180.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 07:52:44,2023-06-15 07:52:44,INDUSTRY,,,,,
254472,254473,NCT00307177,,2006-03-24,,,2014-12-04,2006-03-24,2006-03-27,Estimate,,,,,,,2014-12-04,2014-12-05,Estimate,August 2004,,2004-08-31,November 2006,2006-11-30,April 2005,,2005-04-30,April 2005,Actual,2005-04-30,,Interventional,,,Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma,"Evaluation of the Reactogenicity and Immunogenicity of Different Doses of Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma: A Phase II, Double-Blind Pilot Study",Completed,,Phase 2,28.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:52:46,2023-06-15 07:52:46,NIH,,,,,
254646,254647,NCT00307528,,2006-03-06,,,2019-10-28,2006-03-23,2006-03-28,Estimate,,,,,,,2019-10-28,2019-10-30,Actual,"January 20, 2004",Actual,2004-01-20,October 2019,2019-10-31,"March 30, 2005",Actual,2005-03-30,"March 30, 2005",Actual,2005-03-30,,Interventional,,,Safety and Efficacy Study of Investigational Pneumococcal Vaccine in Elderly Population,"A Study to Evaluate the Safety, Reactogenicity & Immunogenicity of the GSK Biologicals Candidate Pneumococcal Vaccine Without or With Adjuvant, Administered at 2 Different Concentrations, in Healthy Elderly Subjects",Completed,,Phase 2,146.0,Actual,GlaxoSmithKline,,6.0,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=1980,Yes,IPD is available via the Clinical Study Data Request site (click on the link provided below),2023-06-15 07:52:53,2023-06-15 07:52:53,INDUSTRY,,,,,
254659,254660,NCT00307567,,2006-03-07,,,2016-09-22,2006-03-23,2006-03-28,Estimate,,,,,,,2016-09-22,2016-09-23,Estimate,November 2005,,2005-11-30,September 2016,2016-09-30,March 2006,Actual,2006-03-31,,,,,Interventional,,,"Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488","A Phase II, Multicentre Booster Study to Evaluate Booster Vaccination With GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or to Evaluate the Immune Memory Following the Administration of a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children, Previously Vaccinated in Infancy in the Primary Study 11PN-PD-DIT-002 (103488)",Completed,,Phase 2,689.0,,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 07:52:54,2023-06-15 07:52:54,INDUSTRY,,,,,
254749,254750,NCT00546273,,2007-10-16,2008-10-31,,2009-05-14,2007-10-17,2007-10-18,Estimate,2009-03-24,2009-03-25,Estimate,,,,2009-05-14,2009-05-27,Estimate,April 2007,,2007-04-30,May 2009,2009-05-31,June 2008,Actual,2008-06-30,June 2008,Actual,2008-06-30,,Interventional,,,Clinical Trial to Study 4 Different Doses of the Vaccine RUTI in Healthy Volunteers,"Double-Blind, Randomized, Placebo-Controlled Phase I Study, to Study the Tolerability and Immunogenicity of 4 RUTI Antituberculous Vaccine Different Doses (5, 25, 100 y 200µg of FCMtb) in Healthy Volunteers",Completed,,Phase 1,24.0,Actual,Germans Trias i Pujol Hospital,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 22:17:38,2023-06-17 22:17:38,OTHER,,,,,
254761,254762,NCT00850616,,2009-02-24,,,2015-10-30,2009-02-24,2009-02-25,Estimate,,,,,,,2015-10-30,2015-11-01,Estimate,April 2005,,2005-04-30,October 2015,2015-10-31,March 2011,Actual,2011-03-31,August 2006,Actual,2006-08-31,,Interventional,,,Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED),"A Phase I Dose Ranging Study of the Safety, Tolerability, and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 Trigene and the MRKAd6 HIV-1 Trigene Vaccines Alone and in Combination in Healthy Adults",Completed,,Phase 1,147.0,Actual,Merck Sharp & Dohme LLC,,8.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 15:30:21,2023-06-16 15:30:21,INDUSTRY,,,,,
254857,254858,NCT00083330,,2004-05-20,,,2017-06-30,2004-05-19,2004-05-20,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"May 18, 2004",,2004-05-18,"October 1, 2009",2009-10-01,"October 1, 2009",Actual,2009-10-01,"October 1, 2009",Actual,2009-10-01,,Interventional,,,Safety and Immunogenicity of an HIV Vaccine in Normal Adult Volunteers,"A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Multiclade HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in Uninfected Adult Volunteers",Completed,,Phase 1,36.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:53:22,2023-06-15 07:53:22,NIH,,,,,
254910,254911,NCT00309634,,2006-03-31,,,2017-05-09,2006-03-31,2006-04-03,Estimate,,,,,,,2017-05-09,2017-05-10,Actual,"March 27, 2006",Actual,2006-03-27,May 2017,2017-05-31,"October 28, 2006",Actual,2006-10-28,"October 28, 2006",Actual,2006-10-28,,Interventional,,,Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years,Observer-blind Monocentric Study in Adults Aged Between 18-60 Years to Evaluate Reactogenicity and Immunogenicity of 1 and 2 Administrations of Pandemic Monovalent Influenza Vaccines Administered at Different Antigen Doses and Adjuvanted or Not,Completed,,Phase 1,400.0,Actual,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 07:53:49,2023-06-15 07:53:49,INDUSTRY,,,,,
254921,254922,NCT00083603,,2004-05-26,,,2021-10-13,2004-05-26,2004-05-27,Estimate,,,,,,,2021-10-13,2021-10-14,Actual,September 2004,,2004-09-30,October 2021,2021-10-31,August 2007,Actual,2007-08-31,,,,,Interventional,,,Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults,"A Phase I Trial to Evaluate the Safety and Immunogenicity of rMVA-HIV (rMVA-HIV Env/Gag + rMVA-HIV Tat/Rev/Nef-RT) and rFPV-HIV (rFPV-HIV Env/Gag + rFPV-HIV Tat/Rev/Nef-RT) Vaccines, Alone or in Combination, in Healthy, Vaccinia Naive HIV-1 Negative Participants",Completed,,Phase 1,150.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,16.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:53:53,2023-06-15 07:53:53,NIH,,,,,
255058,255059,NCT00089193,,2004-08-04,,,2014-12-18,2004-08-04,2004-08-05,Estimate,,,,,,,2014-12-18,2014-12-23,Estimate,September 2003,,2003-09-30,December 2014,2014-12-31,,,,February 2007,Actual,2007-02-28,,Interventional,,,"Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma",Evaluation of GM-CSF-in-Adjuvant and the Number of Vaccine Sites on Immunization With Multiple Synthetic Melanoma Peptides,Completed,,Phase 2,,,University of Virginia,,,,,False,,,,True,,,,,,,,,,,,,2023-06-15 07:55:04,2023-06-15 07:55:04,OTHER,,,,,
255157,255158,NCT00121758,,2005-07-18,,,2008-06-05,2005-07-18,2005-07-21,Estimate,,,,,,,2008-06-05,2008-06-06,Estimate,September 2004,,2004-09-30,June 2008,2008-06-30,December 2007,Actual,2007-12-31,November 2007,Actual,2007-11-30,,Interventional,,,AIDS Vaccine Study Comparing Immunogenicity and Safety of 3 Doses of Lipopeptides Versus Placebo in Non Infected HIV Volunteers,Randomised Double Blinded Phase II AIDS Vaccine Study Comparing Immunogenicity and Safety of 3 Doses of Lipopeptide (LIPO-5) Versus Placebo in Non Infected HIV Volunteers (ANRS VAC 18),Completed,,Phase 2,156.0,Anticipated,French National Agency for Research on AIDS and Viral Hepatitis,,,,,False,,,,True,,,,,,,,,,,,,2023-06-15 07:55:58,2023-06-15 07:55:58,OTHER_GOV,,,,,
255266,255267,NCT00297817,,2006-02-27,,,2016-11-30,2006-02-27,2006-03-01,Estimate,,,,,,,2016-11-30,2016-12-01,Estimate,February 2006,,2006-02-28,January 2012,2012-01-31,April 2007,Actual,2007-04-30,April 2007,Actual,2007-04-30,,Interventional,,,Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents,"A Phase 2, Single-Blind, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine ± OMV When Administered at an 0-2-6-Month Schedule in Healthy Adolescents 11-18 Years of Age",Completed,,Phase 2,203.0,Actual,Novartis,,3.0,,,,,,,False,,,,,,,,,,,,,2023-06-15 07:57:06,2023-06-15 07:57:06,INDUSTRY,,,,,
255301,255302,NCT00314041,,2006-04-10,,,2013-02-20,2006-04-11,2006-04-12,Estimate,,,,,,,2013-02-20,2013-02-21,Estimate,June 1997,,1997-06-30,February 2013,2013-02-28,April 1998,Actual,1998-04-30,April 1998,Actual,1998-04-30,,Interventional,,,Study Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in Infants,"A Randomized, Double-blind, Controlled, Active Comparator, Phase II Study to Assess the Tolerance and Immunogenicity of Conjugate Meningococcal C (MnCC) Vaccine in Infants When Administered in Conjunction With Primary DTP/Hib Vaccination at 2, 3, and 4 Months of Age.",Completed,,Phase 2,240.0,,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:57:26,2023-06-15 07:57:26,INDUSTRY,,,,,
255331,255332,NCT02279589,,2014-10-16,,,2021-07-31,2014-10-29,2014-10-31,Estimate,,,,,,,2021-07-31,2021-08-03,Actual,"December 4, 2014",Actual,2014-12-04,July 2021,2021-07-31,"September 6, 2018",Actual,2018-09-06,June 2016,Actual,2016-06-30,,Interventional,HYPOPNEUMO,,Open Randomized Trial Evaluating Four Anti-pneumococcal Vaccine Strategies With Fractionated Doses of Non Conjugate Polysaccharide Vaccine to Prevent Hyporesponse in Healthy Volunteers,Open Randomized Trial Evaluating Four Anti-pneumococcal Vaccine Strategies With Fractionated Doses of Non Conjugate Polysaccharide Vaccine to Prevent Hyporesponse in Healthy Volunteers,Completed,,Phase 2,60.0,Actual,Assistance Publique - Hôpitaux de Paris,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 22:17:59,2023-06-17 22:17:59,OTHER,,,,,
255389,255390,NCT02548078,,2015-09-10,2018-03-30,,2018-05-02,2015-09-10,2015-09-14,Estimate,2018-05-02,2018-05-03,Actual,,,,2018-05-02,2018-05-03,Actual,"November 9, 2015",Actual,2015-11-09,March 2018,2018-03-31,"May 15, 2017",Actual,2017-05-15,"May 15, 2017",Actual,2017-05-15,,Interventional,,,A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children,Safety and Immunogenicity Study of GSK Biologicals' Investigational Recombinant Chimpanzee Adenovirus Type 3-vectored Ebola Zaire Vaccine (GSK3390107A) in Children in Africa,Completed,,Phase 2,600.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 22:18:04,2023-06-17 22:18:04,INDUSTRY,,,,,
255477,255478,NCT00091416,,2004-09-08,,,2021-10-13,2004-09-08,2004-09-09,Estimate,,,,,,,2021-10-13,2021-10-14,Actual,,,,October 2021,2021-10-31,May 2006,Actual,2006-05-31,,,,,Interventional,,,Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052,"A Phase I Clinical Trial to Evaluate the Safety of a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Administered to Healthy, HIV-1 Uninfected, Adult Participants Who Received DNA Plasmid Vaccine or Placebo in the HVTN 052 Clinical Trial",Completed,,Phase 1,70.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 07:59:07,2023-06-15 07:59:07,NIH,,,,,
255595,255596,NCT03719066,,2018-10-23,,,2022-10-04,2018-10-23,2018-10-25,Actual,,,,,,,2022-10-04,2022-10-05,Actual,"October 23, 2018",Actual,2018-10-23,October 2022,2022-10-31,"October 5, 2021",Actual,2021-10-05,"February 27, 2020",Actual,2020-02-27,,Interventional,,,Extended Dose Intervals With Oral Cholera Vaccine in Cameroon,Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine in Cameroon,Completed,,Phase 2,181.0,Actual,Johns Hopkins Bloomberg School of Public Health,,3.0,,,False,,,,False,False,False,,,,,,When the manuscript is published.,Researchers will need to submit a request to the investigators detailing their plans for analysis.,,Yes,We will publish the results of this study in a peer reviewed publication and will make the data available on request after the paper has been published.,2023-06-15 08:00:21,2023-06-15 08:00:21,OTHER,,,,,
255654,255655,NCT00316615,,2006-04-19,,,2006-09-13,2006-04-19,2006-04-21,Estimate,,,,,,,2006-09-13,2006-09-14,Estimate,June 2005,,2005-06-30,September 2006,2006-09-30,,,,,,,,Interventional,,,Safety and Immunogenicity of a Inactivated Influenza Vaccine When Administered to Non Elderly Adults and Elderly Subjects.,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2005-2006, When Administered to Non-Elderly Adult and Elderly Subjects",Completed,,Phase 2,100.0,,Novartis,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 08:00:55,2023-06-15 08:00:55,INDUSTRY,,,,,
255850,255851,NCT00318058,,2006-04-25,,,2017-05-04,2006-04-25,2006-04-26,Estimate,,,,,,,2017-05-04,2017-05-08,Actual,"October 3, 2005",Actual,2005-10-03,May 2017,2017-05-31,"November 4, 2005",Actual,2005-11-04,"November 1, 2005",Actual,2005-11-01,,Interventional,,,Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza Disease in the Elderly Population,"A Phase I/II, Open, Controlled Study in Order to Evaluate the Reactogenicity and the Immunogenicity of GlaxoSmithKline Biologicals Influenza Candidate Adjuvanted Vaccine in an Elderly Population Aged Over 65 Years Previously Vaccinated in 2004 With the Same Candidate Vaccine",Completed,,Phase 1,84.0,Actual,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 08:03:02,2023-06-15 08:03:02,INDUSTRY,,,,,
255997,255998,NCT00326443,,2006-05-12,,,2014-05-08,2006-05-12,2006-05-16,Estimate,,,,,,,2014-05-08,2014-05-09,Estimate,February 2006,,2006-02-28,February 2010,2010-02-28,August 2008,Actual,2008-08-31,September 2007,Actual,2007-09-30,,Interventional,,,CVD 909 Vi Prime Boost Study,"Phase I Randomized, Double-Blind, Heterologous Prime-Boost Study of the Safety and Immunogenicity of Vi Polysaccharide Typhoid Vaccine After Priming by Live Attenuated Oral Vi+ Salmonella Typhi Strain CVD 909",Completed,,Phase 1,21.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 08:04:10,2023-06-15 08:04:10,NIH,,,,,
255998,255999,NCT00093834,,2004-10-06,,,2011-07-19,2004-10-07,2004-10-08,Estimate,,,,,,,2011-07-19,2011-07-20,Estimate,January 2004,,2004-01-31,April 2011,2011-04-30,,,,August 2008,Actual,2008-08-31,,Interventional,,,Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer,A Phase I Vaccine Safety and Chemotherapy Dose-Finding Trial of an Allogeneic GM-CSF-Secreting Breast Cancer Vaccine Given in a Specifically Timed Sequence With Immunomodulatory Doses of Cyclophosphamide and Doxorubicin,Completed,,Phase 1,60.0,Anticipated,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 08:04:11,2023-06-15 08:04:11,OTHER,,,,,
256028,256029,NCT01879553,,2013-06-13,2013-10-31,,2014-02-10,2013-06-13,2013-06-18,Estimate,2014-02-10,2014-03-12,Estimate,,,,2014-02-10,2014-03-12,Estimate,July 2013,,2013-07-31,February 2014,2014-02-28,August 2013,Actual,2013-08-31,August 2013,Actual,2013-08-31,,Interventional,,,"Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above","A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine (Agrippal®) in Healthy Adults",Completed,,Phase 2,126.0,Actual,Novartis,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 21:16:26,2023-06-18 21:16:26,INDUSTRY,,,,,
256057,256058,NCT00656097,,2008-04-04,,2009-06-24,2011-09-15,2008-04-09,2008-04-10,Estimate,,,,2009-07-31,2009-08-10,Estimate,2011-09-15,2011-09-21,Estimate,March 2008,,2008-03-31,September 2011,2011-09-30,July 2008,Actual,2008-07-31,July 2008,Actual,2008-07-31,,Interventional,,,A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects,"A Randomized, Single-blind, Controlled, Monocentric Phase II Trial to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects",Completed,,Phase 2,140.0,Actual,Crucell Holland BV,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 22:18:58,2023-06-17 22:18:58,INDUSTRY,,,,,
256096,256097,NCT02283099,,2014-10-31,,,2017-05-24,2014-11-04,2014-11-05,Estimate,,,,,,,2017-05-24,2017-05-30,Actual,November 2014,,2014-11-30,May 2017,2017-05-31,November 2015,Actual,2015-11-30,November 2015,Actual,2015-11-30,,Interventional,,,"Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSV<U+0394>G-ZEBOV-GP)","An Open Label, Single Center, Dose Escalation Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Single Ascending Dose of the Ebola Virus Vaccine rVSV<U+0394>G-ZEBOV-GP (BPSC1001)",Completed,,Phase 1,30.0,Actual,Universitätsklinikum Hamburg-Eppendorf,,1.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-17 22:19:08,2023-06-17 22:19:08,OTHER,,,,,
256138,256139,NCT00524277,,2007-08-31,,2020-03-23,2020-03-23,2007-08-31,2007-09-03,Estimate,,,,2020-03-23,2020-03-30,Actual,2020-03-23,2020-03-30,Actual,January 2007,,2007-01-31,March 2020,2020-03-31,"March 31, 2017",Actual,2017-03-31,"December 31, 2014",Actual,2014-12-31,,Interventional,,,Vaccine Therapy in Treating Patients With Breast Cancer,Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients,Completed,,Phase 2,456.0,Actual,San Antonio Military Medical Center,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 22:19:17,2023-06-17 22:19:17,FED,,,,,
256147,256148,NCT00321061,,2006-05-02,,,2017-06-30,2006-05-02,2006-05-03,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"April 25, 2006",,2006-04-25,"December 2, 2009",2009-12-02,"December 2, 2009",Actual,2009-12-02,"December 2, 2009",Actual,2009-12-02,,Interventional,,,Phase I Study of Vaccination Schedule of Experimental HIV Vaccines,"VRC 011: A Phase I Clinical Trial of Intramuscular, Subcutaneous and Intradermal Administration of an HIV-1 Multiclade DNA Vaccine, VRC-HIVDNA016-00-VP, and an HIV-1 Multiclade Adenoviral Vector Vaccine,VRC-HIVADV014-00-VP, in Uninfected Adult Volunteers",Completed,,Phase 1,60.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 08:05:08,2023-06-15 08:05:08,NIH,,,,,
256174,256175,NCT05132907,,2021-11-18,,,2023-01-16,2021-11-22,2021-11-24,Actual,,,,,,,2023-01-16,2023-01-18,Actual,"January 24, 2022",Actual,2022-01-24,January 2023,2023-01-31,November 2023,Anticipated,2023-11-30,July 2023,Anticipated,2023-07-31,,Interventional,,,Safety And Immunogenicity Of HDT-301 Targeting A SARS-CoV-2 Variant Spike Protein,"Phase 1, Dose-Escalation Study Of Nanoparticle Carrier-Formulated Self- Replicating Replicon RNA (repRNA) SARS-CoV-2 Vaccine (HDT-301) Targeting A Variant Spike Protein In Unvaccinated Or Previously Vaccinated Healthy Adults","Active, not recruiting",,Phase 1,63.0,Anticipated,HDT Bio,,3.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-18 21:16:38,2023-06-18 21:16:38,INDUSTRY,,,,,
256294,256295,NCT03894969,,2019-03-27,2021-08-30,,2022-05-26,2019-03-27,2019-03-29,Actual,2021-08-30,2021-09-27,Actual,,,,2022-05-26,2022-06-23,Actual,"April 23, 2019",Actual,2019-04-23,May 2022,2022-05-31,"August 13, 2021",Actual,2021-08-13,"August 31, 2020",Actual,2020-08-31,,Interventional,,,Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine,Immunogenicity and Safety Study of GSK's Investigational Vaccine (GSK3277511A) When Administered in Healthy Smokers and Ex-smokers Following Receipt of Shingrix Vaccine,Completed,,Phase 2,541.0,Actual,GlaxoSmithKline,,5.0,,,False,,,,False,True,False,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-16 15:32:41,2023-06-16 15:32:41,INDUSTRY,,,,,
256430,256431,NCT02474901,,2015-06-15,2017-05-01,,2017-10-17,2015-06-15,2015-06-18,Estimate,2017-09-14,2017-10-16,Actual,,,,2017-10-17,2017-11-20,Actual,July 2013,Actual,2013-07-31,October 2017,2017-10-31,December 2016,Actual,2016-12-31,March 2016,Actual,2016-03-31,,Interventional,QLAIV,,"Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults","Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults",Completed,,Phase 2,101.0,Actual,"University of Colorado, Denver",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 07:46:25,2023-06-14 07:46:25,OTHER,,,,,
256800,256801,NCT05609045,,2022-10-28,,,2023-04-25,2022-11-01,2022-11-08,Actual,,,,,,,2023-04-25,2023-04-26,Actual,June 2023,Anticipated,2023-06-30,April 2023,2023-04-30,December 2023,Anticipated,2023-12-31,August 2023,Anticipated,2023-08-31,,Interventional,,,"A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster","A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster for Healthy Adults Who Have Received Homologous or Heterologous Vaccination With 3 Doses of COVID-19 Inactivated and/or mRNA Vaccine(s)",Not yet recruiting,,Phase 1,40.0,Anticipated,"Wuhan Rhegen Biotechnology Co., Ltd.",,2.0,,,False,,,,,False,False,,,,,,,,,No,,2023-06-15 08:09:57,2023-06-15 08:09:57,INDUSTRY,,,,,
256896,256897,NCT03133923,,2017-04-17,,,2018-01-10,2017-04-25,2017-04-28,Actual,,,,,,,2018-01-10,2018-01-11,Actual,"May 20, 2017",Actual,2017-05-20,April 2017,2017-04-30,"July 1, 2018",Anticipated,2018-07-01,"November 10, 2017",Actual,2017-11-10,,Interventional,,,"Phase II of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants",Safety and Efficacy of Attenuated Mumps Vaccine (Human Diploid Cell),Unknown status,"Active, not recruiting",Phase 2,1080.0,Anticipated,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,3.0,,,False,,,,True,False,False,,,,,,,,,Undecided,,2023-06-17 22:20:50,2023-06-17 22:20:50,OTHER,,,,,
256985,256986,NCT02551809,,2015-09-10,2019-12-24,,2020-03-04,2015-09-14,2015-09-16,Estimate,2019-12-24,2020-01-13,Actual,,,,2020-03-04,2020-03-17,Actual,October 2015,Actual,2015-10-31,March 2020,2020-03-31,August 2018,Actual,2018-08-31,August 2018,Actual,2018-08-31,,Interventional,,,"Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients","A Randomized, Double-blind, Placebo-controlled, 3-arm Parallel-group, Multicenter, Phase IIa Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311) in Patients With Mild Alzheimer's Disease",Completed,,Phase 2,43.0,Actual,United Neuroscience Ltd.,,3.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-14 07:46:56,2023-06-14 07:46:56,INDUSTRY,,,,,
257338,257339,NCT03606967,,2018-07-30,,,2023-04-25,2018-07-30,2018-07-31,Actual,,,,,,,2023-04-25,2023-04-26,Actual,"December 14, 2018",Actual,2018-12-14,April 2023,2023-04-30,"December 31, 2024",Anticipated,2024-12-31,"December 31, 2024",Anticipated,2024-12-31,,Interventional,,,"Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer",Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast Cancer,Recruiting,,Phase 2,70.0,Anticipated,National Cancer Institute (NCI),,2.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-15 08:14:47,2023-06-15 08:14:47,NIH,,,,,
257457,257458,NCT02465268,,2015-05-27,,,2023-04-25,2015-06-03,2015-06-08,Estimate,,,,,,,2023-04-25,2023-04-26,Actual,August 2016,,2016-08-31,April 2023,2023-04-30,June 2024,Anticipated,2024-06-30,June 2023,Anticipated,2023-06-30,,Interventional,ATTAC-II,,Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme,"A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-Pulsed Dendritic Cells With Tetanus-Diphtheria Toxoid Vaccine in Patients With Newly-Diagnosed Glioblastoma","Active, not recruiting",,Phase 2,175.0,Anticipated,"Immunomic Therapeutics, Inc.",,3.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-15 08:16:34,2023-06-15 08:16:34,INDUSTRY,,,,,
257584,257585,NCT00126945,,2005-08-04,,,2016-09-20,2005-08-04,2005-08-05,Estimate,,,,,,,2016-09-20,2016-09-21,Estimate,August 2005,,2005-08-31,September 2016,2016-09-30,October 2005,Actual,2005-10-31,,,,,Interventional,,,"Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs","A Primary Vaccination Study to Assess the Immunogenicity, Safety & Reactogenicity of 1 Dose of 4 Different Formulations of GSK Biologicals' Meningococcal Conjugate Vaccine (MenACWY) vs 1 Dose of MENCEVAX ACWY in Healthy Subjects Aged 15-19 Years",Completed,,Phase 2,125.0,Actual,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 08:18:11,2023-06-15 08:18:11,INDUSTRY,,,,,
257698,257699,NCT00089063,,2004-08-04,,,2015-04-14,2004-08-04,2004-08-05,Estimate,,,,,,,2015-04-14,2015-04-15,Estimate,June 2004,,2004-06-30,October 2013,2013-10-31,June 2007,Actual,2007-06-30,June 2007,Actual,2007-06-30,,Interventional,,,Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma,"A Randomized Phase II Continuation Booster Trial After A Vaccine Combining Tyrosinase/GP100/Mart-1 Peptides Emulsified With Montanide ISA 51 and ISA 51 VG With Or Without GM-CSF For Patients With Resected Stages IIB/C, III And IV Melanoma",Completed,,Phase 2,40.0,Actual,National Cancer Institute (NCI),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 08:19:14,2023-06-15 08:19:14,NIH,,,,,
257726,257727,NCT00125502,,2005-07-29,,,2011-09-16,2005-07-29,2005-08-01,Estimate,,,,,,,2011-09-16,2011-09-20,Estimate,August 1999,,1999-08-31,September 2011,2011-09-30,January 2010,Actual,2010-01-31,June 2007,Actual,2007-06-30,,Interventional,,,Recombinant CMV gB Vaccine in Postpartum Women,"A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial of Recombinant CMV gB Vaccine in Postpartum Women",Completed,,Phase 2,464.0,Actual,University of Alabama at Birmingham,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 08:19:25,2023-06-15 08:19:25,OTHER,,,,,
257770,257771,NCT00089531,,2004-08-05,,,2017-06-30,2004-08-05,2004-08-06,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"August 2, 2004",,2004-08-02,"January 15, 2008",2008-01-15,"January 15, 2008",,2008-01-15,,,,,Interventional,,,Candidate HIV Vaccine,"A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a 6-Plasmid Multiclade HIV-1 DNA Vaccine, VRC-HIVDNA016-00-VP, in Uninfected Adult Volunteers",Completed,,Phase 1,15.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 08:19:45,2023-06-15 08:19:45,NIH,,,,,
257783,257784,NCT00342940,,2006-06-20,,,2017-04-19,2006-06-20,2006-06-21,Estimate,,,,,,,2017-04-19,2017-04-20,Actual,October 2006,,2006-10-31,April 2017,2017-04-30,,,,,,,,Interventional,,,Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older,"A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of a Commercially Available Surface Antigen, Inactivated Influenza Vaccine, Formulation 2006-2007, When Administered to Non-Elderly Adult and Elderly Subjects",Withdrawn,,Phase 2,0.0,Actual,Novartis,,,,Lack of Vaccine Supplies,False,,,,,,,,,,,,,,,,,2023-06-15 08:19:58,2023-06-15 08:19:58,INDUSTRY,,,,,
257791,257792,NCT00089726,,2004-08-11,,,2007-12-18,2004-08-11,2004-08-12,Estimate,,,,,,,2007-12-18,2007-12-24,Estimate,March 2003,,2003-03-31,December 2007,2007-12-31,January 2006,Actual,2006-01-31,,,,,Interventional,,,A Cancer Vaccine (CG8123) Given With and Without Cyclophosphamide for Advanced Stage Non-Small Cell Lung Cancer (NSCLC),A Phase II Randomized Study of GM-CSF Gene-Modified Autologous Tumor Vaccine (CG8123) With and Without Low-Dose Cyclophosphamide in Advanced Stage Non-Small Cell Lung Cancer,Completed,,Phase 2,100.0,,Cell Genesys,,,,,,,,,,,,,,,,,,,,,,2023-06-15 08:20:00,2023-06-15 08:20:00,INDUSTRY,,,,,
257840,257841,NCT00343681,,2006-06-21,,,2014-01-16,2006-06-21,2006-06-23,Estimate,,,,,,,2014-01-16,2014-01-17,Estimate,July 2006,,2006-07-31,January 2014,2014-01-31,August 2007,Actual,2007-08-31,August 2007,Actual,2007-08-31,,Interventional,,,A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine,"Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2006-2007 Formulation (Intramuscular Route)",Completed,,Phase 2,120.0,Actual,Sanofi,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 08:20:17,2023-06-15 08:20:17,INDUSTRY,,,,,
257848,257849,NCT00405327,,2006-11-29,,2015-06-29,2017-11-02,2006-11-29,2006-11-30,Estimate,,,,2015-09-11,2015-09-30,Estimate,2017-11-02,2017-11-06,Actual,June 2006,,2006-06-30,November 2017,2017-11-30,June 2010,Actual,2010-06-30,June 2009,Actual,2009-06-30,,Interventional,,,A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation,A Pilot Study of Tumor Lysate-pulsed Dendritic Cell Vaccine for Immune Augmentation for High-risk Solid Tumor Patients Following Autologous Stem Cell Transplantation,Completed,,Phase 2,16.0,Actual,University of Michigan Rogel Cancer Center,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 22:21:49,2023-06-17 22:21:49,OTHER,,,,,
257890,257891,NCT00344539,,2006-06-22,,,2013-05-30,2006-06-22,2006-06-26,Estimate,,,,,,,2013-05-30,2013-06-03,Estimate,May 2005,,2005-05-31,March 2013,2013-03-31,January 2007,Actual,2007-01-31,January 2007,Actual,2007-01-31,,Interventional,,,AMA1-C1/Alhydrogel + CpG 7909 for Malaria,"Phase I Study of the Safety and Immunogenicity of AMA1-C1/Alhydrogel® + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria",Completed,,Phase 1,75.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 08:20:41,2023-06-15 08:20:41,NIH,,,,,
257943,257944,NCT00345670,,2006-06-27,,,2008-09-02,2006-06-27,2006-06-28,Estimate,,,,,,,2008-09-02,2008-09-03,Estimate,June 2006,,2006-06-30,September 2008,2008-09-30,May 2007,Actual,2007-05-31,,,,,Interventional,,,Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children,"A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy RSV and PIV3 Seropositive 1-9 Year-Old Children",Completed,,Phase 1,120.0,,MedImmune LLC,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 08:21:13,2023-06-15 08:21:13,INDUSTRY,,,,,
258036,258037,NCT00091130,,2004-09-07,,,2013-05-31,2004-09-07,2004-09-08,Estimate,,,,,,,2013-05-31,2013-06-03,Estimate,September 2004,,2004-09-30,March 2013,2013-03-31,,,,June 2007,Actual,2007-06-30,,Interventional,,,SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells,"An Exploratory Study to Evaluate the Effect of HPV 16 Vaccine on the Reduction of Viral Load in HPV 16 Positive Women With Persistent Viral Infection, But Low Grade Disease (ASCUS/LSIL)",Completed,,Phase 2,139.0,Actual,National Cancer Institute (NCI),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 08:22:14,2023-06-15 08:22:14,NIH,,,,,
258122,258123,NCT00427453,,2007-01-25,,,2007-01-26,2007-01-26,2007-01-29,Estimate,,,,,,,2007-01-26,2007-01-29,Estimate,June 2003,,2003-06-30,December 2006,2006-12-31,March 2005,,2005-03-31,,,,,Interventional,,,"A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously","A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously",Completed,,Phase 1,12.0,,University of Oxford,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 08:22:58,2023-06-15 08:22:58,OTHER,,,,,
258152,258153,NCT00428233,,2007-01-25,,,2020-04-06,2007-01-25,2007-01-29,Estimate,,,,,,,2020-04-06,2020-04-08,Actual,November 2006,Actual,2006-11-30,April 2020,2020-04-30,June 2014,Actual,2014-06-30,June 2014,Actual,2014-06-30,,Interventional,,,Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation,Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation,Completed,,Phase 1,65.0,Actual,Dana-Farber Cancer Institute,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 08:23:18,2023-06-15 08:23:18,OTHER,,,,,
258260,258261,NCT00094718,,2004-10-21,,,2012-12-31,2004-10-21,2004-10-22,Estimate,,,,,,,2012-12-31,2013-01-03,Estimate,February 2005,,2005-02-28,December 2012,2012-12-31,April 2005,Actual,2005-04-30,April 2005,Actual,2005-04-30,,Interventional,,,Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults,"Phase 1 Study of the Safety and Immunogenicity of West Nile/Dengue-4 3'delta30 Chimeric Virus Vaccine (WN/DEN4-3'delta30), a Live Attenuated Vaccine for West Nile Encephalitis",Completed,,Phase 1,56.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 08:24:39,2023-06-15 08:24:39,NIH,,,,,
258311,258312,NCT00429481,,2007-01-30,,,2016-09-15,2007-01-30,2007-01-31,Estimate,,,,,,,2016-09-15,2016-09-16,Estimate,January 2001,,2001-01-31,September 2016,2016-09-30,April 2003,Actual,2003-04-30,April 2003,Actual,2003-04-30,,Interventional,,,"Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine at Different Viral Concentrations in Healthy Infants","Study to Assess Efficacy, Immunogenicity, Reactogenicity and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus Vaccine at Different Viral Concentrations in Healthy Infants Previously Uninfected With Human Rotavirus and Approximately 3 Months of Age.",Completed,,Phase 2,2464.0,Actual,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 08:25:17,2023-06-15 08:25:17,INDUSTRY,,,,,
258343,258344,NCT00430534,,2007-02-01,,,2007-02-01,2007-02-01,2007-02-02,Estimate,,,,,,,2007-02-01,2007-02-02,Estimate,,,,February 2007,2007-02-28,,,,,,,,Interventional,,,"Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664).","To Evaluate the Safety, Immunogenicity and Efficacy of GSK Biologicals' EBV Vaccine (268664) in Healthy Seronegative Adolescents/Adults When Injected Intramuscularly According to a 0-1-5 Month Schedule in Belgium.",Completed,,Phase 2,200.0,,Henogen,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 08:25:40,2023-06-15 08:25:40,INDUSTRY,,,,,
258357,258358,NCT00096551,,2006-07-07,,,2017-06-30,2004-11-09,2004-11-10,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"November 1, 2004",,2004-11-01,"July 25, 2011",2011-07-25,"July 25, 2011",Actual,2011-07-25,"December 11, 2009",Actual,2009-12-11,,Interventional,,,A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy,A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer and Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy,Completed,,Phase 1,21.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 08:25:52,2023-06-15 08:25:52,NIH,,,,,
258398,258399,NCT02573181,,2015-10-08,2019-07-26,,2019-07-26,2015-10-08,2015-10-09,Estimate,2019-07-26,2019-08-14,Actual,,,,2019-07-26,2019-08-14,Actual,"October 30, 2015",Actual,2015-10-30,July 2019,2019-07-31,"January 28, 2016",Actual,2016-01-28,"January 28, 2016",Actual,2016-01-28,,Interventional,,,"Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13 in PPSV23-vaccinated Healthy Adults =65 Years of Age (V114-007)","A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13 in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine",Completed,,Phase 2,253.0,Actual,Merck Sharp & Dohme LLC,,2.0,,,False,,,,True,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2023-06-14 07:48:51,2023-06-14 07:48:51,INDUSTRY,,,,,
258469,258470,NCT02957656,,2016-11-02,,,2018-10-01,2016-11-03,2016-11-08,Estimate,,,,,,,2018-10-01,2018-10-02,Actual,December 2016,Actual,2016-12-31,October 2018,2018-10-31,,,,June 2018,Actual,2018-06-30,,Interventional,,,Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant,A Phase I Study In Healthy Adults To Assess The Safety And Immunogenicity Of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant,Completed,,Phase 1,53.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 08:27:12,2023-06-15 08:27:12,NIH,,,,,
258481,258482,NCT00097838,,2004-11-30,,,2012-06-27,2004-11-30,2004-12-01,Estimate,,,,,,,2012-06-27,2012-07-02,Estimate,October 2004,,2004-10-31,June 2012,2012-06-30,September 2009,Actual,2009-09-30,September 2009,Actual,2009-09-30,,Interventional,,,Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults,"A Phase I, Dose Escalation, Safety, and Immunogenicity Trial of an Alphavirus Replicon HIV-1 Subtype C Gag Vaccine (AVX101) in Healthy HIV-1 Uninfected Adult Participants",Completed,,Phase 1,96.0,Actual,"AlphaVax, Inc.",,5.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 08:27:20,2023-06-15 08:27:20,INDUSTRY,,,,,
258691,258692,NCT00100724,,2005-01-05,,,2006-01-10,2005-01-05,2005-01-06,Estimate,,,,,,,2006-01-10,2006-01-12,Estimate,April 2004,,2004-04-30,January 2006,2006-01-31,July 2005,,2005-07-31,,,,,Interventional,,,Trial of rPA-102 Vaccine in Healthy Adult Volunteers,"A Phase 2 Multi-Center, Randomized Dose-Finding Trial of rPA-102 Vaccine in Healthy Adult Volunteers",Completed,,Phase 2,480.0,,VaxGen,,,,,,,,,,,,,,,,,,,,,,2023-06-15 08:29:38,2023-06-15 08:29:38,INDUSTRY,,,,,
258728,258729,NCT00135486,,2005-08-25,,,2016-09-15,2005-08-25,2005-08-26,Estimate,,,,,,,2016-09-15,2016-09-16,Estimate,March 2002,,2002-03-31,September 2016,2016-09-30,January 2003,Actual,2003-01-31,January 2003,Actual,2003-01-31,,Interventional,,,Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants,"Evaluate Immunogenicity, Reactogenicity, Safety of GSK Biologicals' MenC-TT Vaccine (2 Formulations) Given With Infanrix Hexa® + GSK Biologicals' Hib MenC-TT Vaccine (2 Formulations) Given With Infanrix Penta® to Infants in Mths 3,4,5 of Life",Completed,,Phase 2,500.0,Actual,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 08:30:05,2023-06-15 08:30:05,INDUSTRY,,,,,
258758,258759,NCT00102089,,2005-01-20,,,2017-06-30,2005-01-20,2005-01-21,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"January 18, 2005",,2005-01-18,"October 10, 2007",2007-10-10,"October 10, 2007",,2007-10-10,,,,,Interventional,,,HIV-1 Vaccine Booster in Previously Immunized Uninfected Adult Volunteers,"A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Booster Dose of a Recombinant Multiclade HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in Uninfected Subjects Who Were Previously Immunized With VRC-HIVDNA009-00-VP in VRC 004",Completed,,Phase 1,32.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 08:30:28,2023-06-15 08:30:28,NIH,,,,,
258903,258904,NCT00104780,,2005-03-03,,,2013-11-05,2005-03-03,2005-03-04,Estimate,,,,,,,2013-11-05,2013-11-06,Estimate,December 2004,,2004-12-31,March 2006,2006-03-31,,,,,,,,Interventional,,,"Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer","A Phase II, Open Label, Multi-center Study of EP2101 Therapeutic Vaccine in Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer (NSCLC)",Unknown status,"Active, not recruiting",Phase 2,,,National Cancer Institute (NCI),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 08:32:00,2023-06-15 08:32:00,NIH,,,,,
259082,259083,NCT00436930,,2007-02-15,,,2014-01-09,2007-02-15,2007-02-19,Estimate,,,,,,,2014-01-09,2014-01-10,Estimate,December 2006,,2006-12-31,June 2009,2009-06-30,October 2012,Actual,2012-10-31,October 2012,Actual,2012-10-31,,Interventional,,,Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma,Randomized Phase II Trial of Autologous Vaccines Consisting of Adjuvant GM-CSF Plus Proliferating Tumor Cells Versus GM-CSF Plus Dendritic Cells Loaded With Proliferating Tumor Cells in Patients With Metastatic Melanoma (MAC-VAC),Completed,,Phase 2,200.0,Anticipated,National Cancer Institute (NCI),,2.0,,,,,,,,,,,,,,,,,,,,2023-06-15 08:34:01,2023-06-15 08:34:01,NIH,,,,,
259141,259142,NCT00106769,,2005-03-29,,,2017-06-30,2005-03-29,2005-03-30,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"March 22, 2005",,2005-03-22,"January 15, 2008",2008-01-15,"January 15, 2008",,2008-01-15,,,,,Interventional,,,Vaccine to Prevent West Nile Virus Disease,"A Phase I Study of the Safety and Immunogenicity of a West Nile Virus Recombinant DNA Plasmid Vaccine, VRC-WNVDNA017-00 VP, in Healthy Adult Volunteers",Completed,,Phase 1,15.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 08:34:38,2023-06-15 08:34:38,NIH,,,,,
259215,259216,NCT00107549,,2005-04-05,,,2021-10-28,2005-04-05,2005-04-06,Estimate,,,,,,,2021-10-28,2021-11-01,Actual,,,,October 2021,2021-10-31,February 2009,Actual,2009-02-28,,,,,Interventional,,,Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy,"A Phase I, Open-Label Study to Evaluate the Safety and Tolerability of Recombinant HIV-1 Vaccines in HIV-1 Infected Young Adults With Control of HIV-1 Replication and on Stable Highly Active Antiretroviral Therapy (HAART)",Completed,,Phase 1,20.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 08:35:24,2023-06-15 08:35:24,NIH,,,,,
259309,259310,NCT00443131,,2007-03-02,,,2017-04-24,2007-03-02,2007-03-05,Estimate,,,,,,,2017-04-24,2017-04-25,Actual,"March 26, 2007",,2007-03-26,April 2017,2017-04-30,"July 13, 2007",Actual,2007-07-13,"July 1, 2007",Actual,2007-07-01,,Interventional,,,Characterisation of the Immune Responses of 2 Experimental Malaria Vaccines,"Adjuvant Justification Study of Candidate Malaria Vaccines (257049), Administered According to a 0, 1, 2 Months Schedule .",Completed,,Phase 2,36.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 08:36:31,2023-06-15 08:36:31,INDUSTRY,,,,,
259444,259445,NCT00109304,,2005-04-27,,,2015-09-17,2005-04-26,2005-04-27,Estimate,,,,,,,2015-09-17,2015-09-18,Estimate,July 2005,,2005-07-31,September 2015,2015-09-30,December 2006,,2006-12-31,,,,,Interventional,,,"Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis (VEE) Attenuated Live-Virus Vaccine","Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis (VEE) Attenuated Live-Virus Vaccine VEE IA/B V3526 in VEE-Naive Healthy Volunteers After Single Dose Subcutaneous Administration",Withdrawn,,Phase 1,0.0,Actual,"DynPort Vaccine Company LLC, A GDIT Company",,,,Funding withdrawn,False,,,,True,,,,,,,,,,,,,2023-06-15 08:38:01,2023-06-15 08:38:01,INDUSTRY,,,,,
259527,259528,NCT00455221,,2007-03-31,,,2012-05-31,2007-03-31,2007-04-03,Estimate,,,,,,,2012-05-31,2012-06-04,Estimate,February 2008,,2008-02-29,May 2012,2012-05-31,November 2011,Actual,2011-11-30,December 2010,Actual,2010-12-31,,Interventional,,,Safety Assessment of a Multipeptide-gene Vaccine in CML,Safety Assessment of a Peptide Vaccine Derived From Bcr-abl Along With Cytokine Genes in CML Patients Undergoing Imatinib Treatment,Completed,,Phase 1,12.0,Actual,Tehran University of Medical Sciences,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 08:38:51,2023-06-15 08:38:51,OTHER,,,,,
259534,259535,NCT00110279,,2005-05-05,,,2008-01-18,2005-05-05,2005-05-06,Estimate,,,,,,,2008-01-18,2008-01-21,Estimate,June 2005,,2005-06-30,January 2008,2008-01-31,September 2005,Actual,2005-09-30,September 2005,Actual,2005-09-30,,Interventional,,,Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A),"Phase I Inpatient Study of the Safety and Immunogenicity of H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H9N2 Infection in the Event of a Pandemic (Study A)",Completed,,Phase 1,30.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 08:38:57,2023-06-15 08:38:57,NIH,,,,,
259755,259756,NCT00111605,,2005-05-23,,,2021-10-13,2005-05-23,2005-05-24,Estimate,,,,,,,2021-10-13,2021-10-14,Actual,,,,October 2021,2021-10-31,May 2008,Actual,2008-05-31,,,,,Interventional,,,Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults,"A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine With or Without IL-12 DNA Adjuvant, Boosted With Homologous Plasmids in Healthy, HIV-1 Uninfected Adult Participants",Completed,,Phase 1,144.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,7.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 08:41:17,2023-06-15 08:41:17,NIH,,,,,
259885,259886,NCT00114621,,2005-06-15,,,2017-06-30,2005-06-15,2005-06-16,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"September 8, 2004",,2004-09-08,"March 16, 2012",2012-03-16,"May 25, 2011",Actual,2011-05-25,,,,,Interventional,,,Anthrax Vaccine Clinical Trials,Anthrax Vaccine Clinical Trials,Completed,,Phase 1,93.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 08:42:38,2023-06-15 08:42:38,NIH,,,,,
259944,259945,NCT00425737,,2007-01-22,,,2016-09-15,2007-01-22,2007-01-23,Estimate,,,,,,,2016-09-15,2016-09-16,Estimate,August 2000,,2000-08-31,September 2016,2016-09-30,July 2001,Actual,2001-07-31,July 2001,Actual,2001-07-31,,Interventional,,,"Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine in Healthy Infants","A Study to Assess the Efficacy, Immunogenicity and Safety of Two Doses of Oral Live Attenuated Human Rotavirus (HRV) Vaccine (Rotarix) in Healthy Infants.",Completed,,Phase 2,405.0,Actual,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 08:43:11,2023-06-15 08:43:11,INDUSTRY,,,,,
260039,260040,NCT00113984,,2005-06-11,,,2019-12-13,2005-06-11,2005-06-13,Estimate,,,,,,,2019-12-13,2019-12-16,Actual,"June 8, 2005",,2005-06-08,"November 7, 2012",2012-11-07,"December 1, 2011",Actual,2011-12-01,"February 1, 2008",Actual,2008-02-01,,Interventional,,,Vaccine and Antibody Treatment of Prostate Cancer,Phase I Trial of a PSA Based Vaccine and an Anti-CTLA-4 Antibody in Adults With Metastatic Androgen Independent Prostrate Cancer,Completed,,Phase 1,30.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 08:44:08,2023-06-15 08:44:08,NIH,,,,,
260080,260081,NCT03277456,,2017-09-01,,,2017-11-10,2017-09-06,2017-09-11,Actual,,,,,,,2017-11-10,2017-11-14,Actual,"September 18, 2017",Actual,2017-09-18,November 2017,2017-11-30,"November 2, 2017",Actual,2017-11-02,"November 2, 2017",Actual,2017-11-02,,Interventional,,,A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1,"A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1, Manufactured on the AGE1.CR.pIX Novel Avian Cell Line, in Healthy Adult Volunteers.",Completed,,Early Phase 1,6.0,Actual,Vaccitech (UK) Limited,,1.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-15 08:44:31,2023-06-15 08:44:31,INDUSTRY,,,,,
260702,260703,NCT00117429,,2005-06-30,,,2010-02-12,2005-07-06,2005-07-07,Estimate,,,,,,,2010-02-12,2010-02-15,Estimate,June 2005,,2005-06-30,February 2010,2010-02-28,January 2010,Actual,2010-01-31,September 2007,Actual,2007-09-30,,Interventional,,,Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART),"A Phase I, Randomized, Double-Blind Clinical Trial of the HIV gp120/NefTat/AS02A Vaccine Candidate in Subjects With Well-Controlled Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)",Completed,,Phase 1,20.0,Anticipated,"Marcus Altfeld, M.D., Ph.D.",,,,,False,,,,,,,,,,,,,,,,,2023-06-15 08:50:26,2023-06-15 08:50:26,INDIV,,,,,
260703,260704,NCT00118313,,2005-07-08,,,2020-03-26,2005-07-08,2005-07-11,Estimate,,,,,,,2020-03-26,2020-03-27,Actual,"November 4, 2004",,2004-11-04,March 2020,2020-03-31,"July 28, 2006",Actual,2006-07-28,"July 28, 2006",Actual,2006-07-28,,Interventional,,,"Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma",Evaluation of Different Adjuvants for the Transdermal Administration of a Peptide-Based Vaccine in Participants With High-Risk Melanoma,Completed,,Phase 1,,,University of Virginia,,,,,False,,,,True,,,,,,,,,,,,,2023-06-15 08:50:26,2023-06-15 08:50:26,OTHER,,,,,
260756,260757,NCT00478621,,2007-05-24,,,2017-05-09,2007-05-24,2007-05-25,Estimate,,,,,,,2017-05-09,2017-05-10,Actual,"May 25, 2007",Actual,2007-05-25,May 2017,2017-05-31,"October 13, 2008",Actual,2008-10-13,"June 30, 2008",Actual,2008-06-30,,Interventional,,,Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1674330A),A Multicentre Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' HPV Vaccine (GSK1674330A) in Healthy Female Subjects Aged 18-25 Years.,Completed,,Phase 1,540.0,Actual,GlaxoSmithKline,,6.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 08:51:01,2023-06-15 08:51:01,INDUSTRY,,,,,
260767,260768,NCT00478816,,2007-05-24,,,2016-11-30,2007-05-24,2007-05-25,Estimate,,,,,,,2016-11-30,2016-12-01,Estimate,May 2007,,2007-05-31,February 2012,2012-02-29,February 2009,Actual,2009-02-28,February 2009,Actual,2009-02-28,,Interventional,,,Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines,"A Phase II, Single Center, Exploratory Study to Evaluate Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With MF59-adjuvanted or Non-adjuvanted H5N3 Influenza Vaccines",Completed,,Phase 2,58.0,Actual,Novartis,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 08:51:07,2023-06-15 08:51:07,INDUSTRY,,,,,
260839,260840,NCT00480454,,2007-05-30,,,2010-02-08,2007-05-30,2007-05-31,Estimate,,,,,,,2010-02-08,2010-02-09,Estimate,October 2006,,2006-10-31,February 2010,2010-02-28,December 2009,Actual,2009-12-31,December 2009,Actual,2009-12-31,,Interventional,,,"Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI Vaccines","An Open Randomized Dose Selection Study Evaluating the Safety, Immunogenicity, and Impact of a TB Vaccine, MVA85A, on the Immunogenicity of EPI Vaccines Administered Simultaneously to Healthy Infants Previously Vaccinated With BCG.",Completed,,Phase 1,214.0,Actual,University of Oxford,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 08:51:45,2023-06-15 08:51:45,OTHER,,,,,
260879,260880,NCT00119873,,2005-07-12,,,2021-10-13,2005-07-12,2005-07-14,Estimate,,,,,,,2021-10-13,2021-10-14,Actual,,,,October 2021,2021-10-31,October 2006,Actual,2006-10-31,,,,,Interventional,,,Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults,"A Phase I Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade, Multivalent Recombinant Adenoviral Vector HIV Vaccine, VRC-HIVADV014-00-VP, in Healthy, HIV-1 Uninfected Adult Participants Who Have Low Titers of Pre-Existing Ad5 Neutralizing Antibodies",Completed,,Phase 1,48.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 08:52:07,2023-06-15 08:52:07,NIH,,,,,
261039,261040,NCT00120848,,2005-07-12,,,2016-11-02,2005-07-18,2005-07-19,Estimate,,,,,,,2016-11-02,2016-11-04,Estimate,November 2003,,2003-11-30,November 2016,2016-11-30,July 2007,Actual,2007-07-31,July 2007,Actual,2007-07-31,,Interventional,,,Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults,Study of the Efficacy of Candidate HPV 16/18 VLP Vaccine in the Prevention of HPV-16 and/or HPV-18 Cervical Infection in Adolescent & Young Adult Women in North America and Brazil Vaccinated in Primary Study 580299/001,Completed,,Phase 2,776.0,Actual,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 08:53:37,2023-06-15 08:53:37,INDUSTRY,,,,,
261079,261080,NCT00121121,,2005-07-13,,,2007-03-14,2005-07-19,2005-07-21,Estimate,,,,,,,2007-03-14,2007-03-15,Estimate,July 2004,,2004-07-31,November 2005,2005-11-30,December 2005,,2005-12-31,,,,,Interventional,,,Safety of Intradermal Versus Intramuscular Administration of HIV Lipopeptides in HIV Uninfected Adult Volunteers,A Phase Ib Vaccine Trial Evaluating the Safety and Immunogenicity of HIV Lipopeptides by Two Administration Routes (Intramuscular And Intradermal) in Healthy Adult Volunteers. ANRS VAC16 Trial,Completed,,Phase 1,70.0,,French National Agency for Research on AIDS and Viral Hepatitis,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 08:54:06,2023-06-15 08:54:06,OTHER_GOV,,,,,
261085,261086,NCT00121160,,2005-07-13,,,2012-03-26,2005-07-19,2005-07-21,Estimate,,,,,,,2012-03-26,2012-03-27,Estimate,September 2005,,2005-09-30,March 2012,2012-03-31,July 2010,Actual,2010-07-31,June 2010,Actual,2010-06-30,,Interventional,,,Health SMART (Stress Management and Relaxation Training) to Improve Vaccine Immune Response,Can Stress Management Improve Vaccine Immune Response,Completed,,Phase 1,126.0,Actual,Fred Hutchinson Cancer Center,,,,,False,,,,True,,,,,,,,,,,,,2023-06-15 08:54:10,2023-06-15 08:54:10,OTHER,,,,,
261123,261124,NCT00486382,,2007-06-12,,,2015-04-01,2007-06-12,2007-06-14,Estimate,,,,,,,2015-04-01,2015-04-03,Estimate,April 2007,,2007-04-30,April 2015,2015-04-30,November 2008,Actual,2008-11-30,November 2008,Actual,2008-11-30,,Interventional,,,Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India,"A Phase 1, Open-Label, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-111F + MPL-SE Vaccine (Recombinant Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE) in Healthy Adults In India",Completed,,Phase 1,36.0,Actual,Access to Advanced Health Institute (AAHI),,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 08:54:25,2023-06-15 08:54:25,OTHER,,,,,
261226,261227,NCT00121862,,2005-07-18,,,2006-05-04,2005-07-18,2005-07-21,Estimate,,,,,,,2006-05-04,2006-05-05,Estimate,August 2005,,2005-08-31,May 2006,2006-05-31,March 2006,,2006-03-31,,,,,Interventional,,,Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Leish-111f + MPL-SE Vaccine Compared to the Leish-111f Protein Alone in Montenegro Skin Test-Negative Healthy Adults",Completed,,Phase 2,60.0,,Access to Advanced Health Institute (AAHI),,,,,,,,,,,,,,,,,,,,,,2023-06-15 08:55:25,2023-06-15 08:55:25,OTHER,,,,,
261265,261266,NCT00489931,,2007-06-20,,,2017-06-30,2007-06-20,2007-06-21,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"June 18, 2007",,2007-06-18,"April 15, 2009",2009-04-15,"April 15, 2009",,2009-04-15,,,,,Interventional,,,"Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally","A Phase I Open-Label Study of the Safety and Immunogenicity of a Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for the Influenza Virus H5 Hemagglutinin Protein Administered Intradermally in Healthy Adults",Completed,,Phase 1,44.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 08:55:46,2023-06-15 08:55:46,NIH,,,,,
261317,261318,NCT00491257,,2007-06-25,,,2014-01-16,2007-06-25,2007-06-26,Estimate,,,,,,,2014-01-16,2014-01-17,Estimate,June 2007,,2007-06-30,January 2014,2014-01-31,July 2007,Actual,2007-07-31,July 2007,Actual,2007-07-31,,Interventional,,,A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine,"Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation (Intramuscular Route)",Completed,,Phase 2,130.0,Actual,Sanofi,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 08:56:21,2023-06-15 08:56:21,INDUSTRY,,,,,
261939,261940,NCT02275039,,2014-10-23,,,2018-04-26,2014-10-23,2014-10-27,Estimate,,,,,,,2018-04-26,2018-04-30,Actual,January 2015,,2015-01-31,April 2018,2018-04-30,"April 23, 2018",Actual,2018-04-23,"April 23, 2018",Actual,2018-04-23,,Interventional,,,p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer,A Phase I Study of a p53MVA Vaccine in Combination With Gemcitabine in Ovarian Cancer,Completed,,Phase 1,12.0,Actual,City of Hope Medical Center,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 09:02:06,2023-06-15 09:02:06,OTHER,,,,,
262289,262290,NCT01245673,,2010-11-19,2020-03-05,,2020-03-19,2010-11-19,2010-11-22,Estimate,2020-03-05,2020-03-19,Actual,,,,2020-03-19,2020-04-06,Actual,"May 10, 2011",Actual,2011-05-10,March 2020,2020-03-31,December 2018,Actual,2018-12-31,December 2015,Actual,2015-12-31,,Interventional,,,Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma,Phase II Combination Immunotherapy After ASCT for Advanced Myeloma to Study MAGE-A3 Immunizations With Hiltonol® (Poly-ICLC) Plus Transfer of Vaccine-Primed Autologous T Cells Followed by Lenalidomide Maintenance,Completed,,Phase 2,28.0,Actual,University of Pennsylvania,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 09:05:13,2023-06-15 09:05:13,OTHER,,,,,
262318,262319,NCT00141024,,2005-08-30,,,2021-10-13,2005-08-30,2005-09-01,Estimate,,,,,,,2021-10-13,2021-10-14,Actual,January 2006,,2006-01-31,October 2021,2021-10-31,December 2007,Actual,2007-12-31,December 2007,Actual,2007-12-31,,Interventional,,,"Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults","A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Protein Vaccine EP-1043 and the DNA Vaccine EP HIV-1090 Given Alone or in Combination in Healthy, HIV-1-Uninfected Adult Participants",Completed,,Phase 1,84.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 09:05:41,2023-06-15 09:05:41,NIH,,,,,
262349,262350,NCT00133445,,2005-08-19,,,2011-11-03,2005-08-22,2005-08-23,Estimate,,,,,,,2011-11-03,2011-11-06,Estimate,December 2005,,2005-12-31,October 2009,2009-10-31,August 2006,Actual,2006-08-31,August 2006,Actual,2006-08-31,,Interventional,,,Pentavalent DTaP-Hep B-IPV,"Randomized, Single Blinded Study of the Safety and Immunogenicity of Pentavalent DTaP-Hep B-IPV Combination Vaccine (Pediarix; GlaxoSmithKline (GSK) Biologicals) Administered to Healthy Neonates and Infants at Birth, 2, and 6 Months of Age Compared to a Routine Infant Schedule at 2, 4, and 6 Months of Age",Completed,,Phase 2,5.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 09:06:05,2023-06-15 09:06:05,NIH,,,,,
262352,262353,NCT00133484,,2005-08-19,,,2010-08-26,2005-08-19,2005-08-23,Estimate,,,,,,,2010-08-26,2010-08-27,Estimate,,,,December 2005,2005-12-31,May 2007,,2007-05-31,,,,,Interventional,,,UMD rPA Regimen Trial in Adults,"A Phase II Study to Assess the Safety, Tolerability, Immunogenicity, and Optimal Primary Schedule of 3 Recombinant Protective Antigen (rPA) Anthrax Vaccines Administered in Two Intramuscular Doses to Healthy Adults",Terminated,,Phase 2,270.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,,,,,,,,,,,,,,,,,,2023-06-15 09:06:06,2023-06-15 09:06:06,NIH,,,,,
262435,262436,NCT03462108,,2017-09-29,,,2019-04-01,2018-03-08,2018-03-12,Actual,,,,,,,2019-04-01,2019-04-03,Actual,"April 9, 2018",Actual,2018-04-09,April 2018,2018-04-30,"March 30, 2019",Actual,2019-03-30,"February 18, 2019",Actual,2019-02-18,,Interventional,,,"Safety and Immunogenicity of Rotavirus (Bio Farma) Vaccine in Adults, Children & Neonates","A Prospective Intervention Phase I Study in Three Age De-escalating Group to Assess the Safety and Immunogenicity of Rotavirus (Bio Farma) Vaccine in Adults, Children & Neonates",Completed,,Phase 1,100.0,Actual,PT Bio Farma,,4.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-18 21:23:42,2023-06-18 21:23:42,INDUSTRY,,,,,
262543,262544,NCT00136331,,2005-08-26,,,2016-07-17,2005-08-26,2005-08-29,Estimate,,,,,,,2016-07-17,2016-07-19,Estimate,October 2005,,2005-10-31,November 2008,2008-11-30,November 2006,,2006-11-30,,,,,Interventional,,,Study of a Pandemic Influenza Vaccine,Phase Ia Study of a Pandemic Influenza Vaccine,Completed,,Phase 1,400.0,,Seqirus,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 09:07:52,2023-06-15 09:07:52,INDUSTRY,,,,,
262602,262603,NCT00153543,,2005-09-08,,,2007-03-19,2005-09-08,2005-09-12,Estimate,,,,,,,2007-03-19,2007-03-20,Estimate,May 2002,,2002-05-31,September 2005,2005-09-30,June 2003,,2003-06-30,,,,,Interventional,,,Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders,Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders,Completed,,Phase 1,90.0,,Centers for Disease Control and Prevention,,,,,,,,,,,,,,,,,,,,,,2023-06-15 09:08:24,2023-06-15 09:08:24,FED,,,,,
262634,262635,NCT00137930,,2005-08-29,,,2016-09-20,2005-08-29,2005-08-30,Estimate,,,,,,,2016-09-20,2016-09-21,Estimate,August 2005,,2005-08-31,September 2016,2016-09-30,November 2005,Actual,2005-11-30,,,,,Interventional,,,Study of Immunogenicity & Safety of 2 Different Formulations of Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis,"Compare the Immunogenicity, Reactogenicity & Safety of 2 Different Formulations of GSK Biologicals' Live Attenuated Human Rotavirus (HRV) Vaccine Given as a Two-dose Primary Vaccination in Healthy Infants Previously Uninfected With HRV",Completed,,Phase 2,250.0,,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 09:08:42,2023-06-15 09:08:42,INDUSTRY,,,,,
262651,262652,NCT01094548,,2010-03-24,2015-10-15,,2016-01-24,2010-03-26,2010-03-29,Estimate,2016-01-24,2016-02-22,Estimate,,,,2016-01-24,2016-02-22,Estimate,January 2008,,2008-01-31,January 2016,2016-01-31,March 2012,Actual,2012-03-31,February 2011,Actual,2011-02-28,,Interventional,,Safety analysis set included all the randomized participants who received at least 1 dose of trial treatment.,Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy,"A Randomized, Open-label, Phase II Study With Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Subjects With Either Chemotherapy-naïve, Slowly Progressive, Asymptomatic Multiple Myeloma or With Stage II/III Multiple Myeloma in Stable Response/Plateau Phase Following Anti-tumor Therapy",Completed,,Phase 2,34.0,Actual,"Merck KGaA, Darmstadt, Germany",,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 21:23:51,2023-06-18 21:23:51,INDUSTRY,,,,,
262723,262724,NCT00139334,,2005-08-30,,,2016-09-20,2005-08-30,2005-08-31,Estimate,,,,,,,2016-09-20,2016-09-21,Estimate,June 2005,,2005-06-30,September 2016,2016-09-30,January 2006,Actual,2006-01-31,,,,,Interventional,,,A Study to Test 2 Doses of the HRV Vaccine Given With or Without OPV in Healthy Infants in Bangladesh,"Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine (RIX4414 at 106.5 CCID50) When Given Concomitantly With OPV Versus Given Alone (HRV Vaccine Dose Given 15 Days After the OPV Dose) in Healthy Infants in Bangladesh",Completed,,Phase 2,300.0,,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 09:09:44,2023-06-15 09:09:44,INDUSTRY,,,,,
263119,263120,NCT02955160,,2016-11-02,,,2018-09-07,2016-11-02,2016-11-04,Estimate,,,,,,,2018-09-07,2018-09-11,Actual,"November 3, 2016",Actual,2016-11-03,September 2018,2018-09-30,"August 1, 2017",Actual,2017-08-01,"August 1, 2017",Actual,2017-08-01,,Interventional,,,"A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years","A Phase 1, Randomized, Controlled, Observer-blinded Trial To Evaluate The Safety And Immunogenicity Of A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults Aged 18 To 49 Years",Completed,,Phase 1,66.0,Actual,Pfizer,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 09:13:38,2023-06-15 09:13:38,INDUSTRY,,,,,
263189,263190,NCT00133497,,2005-08-19,,2017-07-03,2017-07-03,2005-08-19,2005-08-23,Estimate,,,,2017-07-03,2017-07-06,Actual,2017-07-03,2017-07-06,Actual,June 2006,,2006-06-30,September 2013,2013-09-30,June 2013,Actual,2013-06-30,June 2013,Actual,2013-06-30,,Interventional,,,gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females,"A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Safety and Efficacy of the Cytomegalovirus gB/MF59 Vaccine in Preventing Systemic Cytomegalovirus Infection in Healthy Adolescent Females",Completed,,Phase 2,409.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-17 22:25:34,2023-06-17 22:25:34,NIH,,,,,
263564,263565,NCT05304351,,2021-12-07,,,2023-02-09,2022-03-22,2022-03-31,Actual,,,,,,,2023-02-09,2023-02-13,Actual,"February 2, 2022",Actual,2022-02-02,February 2023,2023-02-28,"November 10, 2028",Anticipated,2028-11-10,"November 11, 2022",Actual,2022-11-11,,Interventional,,,Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older,"A Randomized, Observer-Blind, Phase 2 Study To Assess the Safety and Immunogenicity of CRV-101 Vaccine Head-To-Head With SHINGRIX® for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older","Active, not recruiting",,Phase 2,678.0,Actual,Curevo Inc,,3.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 22:25:51,2023-06-17 22:25:51,INDUSTRY,,,,,
263662,263663,NCT00148824,,2005-09-07,,,2008-03-20,2005-09-07,2005-09-08,Estimate,,,,,,,2008-03-20,2008-03-21,Estimate,February 2003,,2003-02-28,March 2008,2008-03-31,January 2006,Actual,2006-01-31,,,,,Interventional,,,Antibody Responses to Pneumococcal Vaccines Among HIV-Infected Adults.,Immunological Efficacy of a Prime-Boost Strategy Combining a 7-Valent Pneumococcal Conjugate Vaccine (PCV) Followed by a 23-Valent Pneumococcal Polysaccharide Vaccine (PPV) Versus PPV Alone in HIV-Infected Adults. ANRS 114 PNEUMOVAC.,Completed,,Phase 2,212.0,,French National Agency for Research on AIDS and Viral Hepatitis,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 09:18:03,2023-06-15 09:18:03,OTHER_GOV,,,,,
263734,263735,NCT00982137,,2009-09-21,2012-07-11,,2012-09-18,2009-09-21,2009-09-22,Estimate,2012-09-18,2012-09-20,Estimate,,,,2012-09-18,2012-09-20,Estimate,July 2004,,2004-07-31,September 2012,2012-09-30,March 2007,Actual,2007-03-31,April 2005,Actual,2005-04-30,,Interventional,,,Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax-JE) and Yellow Fever Vaccine (STAMARIL®),"Randomised, Double-blind, Phase II Evaluation of the Safety and Immunogenicity Following Administration of Live Attenuated JE Vaccine (ChimeriVax-JE) and Yellow Fever Vaccine (STAMARIL®)",Completed,,Phase 2,108.0,Actual,Sanofi,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 21:38:57,2023-06-18 21:38:57,INDUSTRY,,,,,
263780,263781,NCT00469651,,2007-05-03,,,2007-12-13,2007-05-03,2007-05-04,Estimate,,,,,,,2007-12-13,2007-12-14,Estimate,October 2007,,2007-10-31,December 2007,2007-12-31,August 2008,Anticipated,2008-08-31,,,,,Interventional,MSP3TN,,Phase Ib Trial of MSP3 LSP in Children in Tanzania,"A Double Blind, Randomized, Controlled Phase Ib Field Trial in 12 to 24 Month Old Children in Tanzania to Evaluate the Safety and Immunogenicity of Candidate Malaria Vaccine MSP 3 Versus Hepatitis B Vaccine",Unknown status,Recruiting,Phase 1,45.0,Anticipated,African Malaria Network Trust,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 09:19:04,2023-06-15 09:19:04,NETWORK,,,,,
263856,263857,NCT00471133,,2007-05-08,,,2011-06-03,2007-05-08,2007-05-09,Estimate,,,,,,,2011-06-03,2011-06-07,Estimate,April 2007,,2007-04-30,June 2011,2011-06-30,May 2010,Actual,2010-05-31,May 2010,Actual,2010-05-31,,Interventional,,,Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation,A Phase Ia/Ib Study of the Safety and Immunogenicity of a Xenogeneic Tyrosinase DNA Vaccine Melanoma,Completed,,Phase 1,24.0,Actual,Ichor Medical Systems Incorporated,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 09:19:45,2023-06-15 09:19:45,INDUSTRY,,,,,
264137,264138,NCT00158808,,2005-09-08,,,2017-05-24,2005-09-08,2005-09-12,Estimate,,,,,,,2017-05-24,2017-05-30,Actual,January 2005,,2005-01-31,May 2017,2017-05-31,April 2005,Actual,2005-04-30,April 2005,Actual,2005-04-30,,Interventional,,,Immune Memory Foll Pry Vaccination With DTPw-HBV/Hib Vaccine Formulation; Immuno & Reacto of Booster Dose at 15-18 Mths,Assess the Immunogenicity &d Reactogenicity of a Booster Dose of a Formulation of GSK Biologicals' DTPw-HBV/Hib Vaccine at 15-18 Mths of Age in Infants Previously Primed With the Same Vaccine,Completed,,Phase 2,175.0,Actual,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 09:22:26,2023-06-15 09:22:26,INDUSTRY,,,,,
264210,264211,NCT05270265,,2022-01-28,,,2023-02-09,2022-03-07,2022-03-08,Actual,,,,,,,2023-02-09,2023-02-13,Actual,"February 9, 2022",Actual,2022-02-09,February 2023,2023-02-28,"September 30, 2023",Anticipated,2023-09-30,"September 30, 2023",Anticipated,2023-09-30,,Interventional,,,Safety and Immunogenicity of Pvs25-IMX313/Matrix-M1 Vaccine,A Phase Ia Study to Assess Safety and Immunogenicity of the Plasmodium Vivax Malaria Vaccine Candidate Pvs25-IMX313 in Matrix-M1 Adjuvant in Healthy Adults Living in the UK,"Active, not recruiting",,Early Phase 1,25.0,Actual,University of Oxford,,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-17 22:26:08,2023-06-17 22:26:08,OTHER,,,,,
264298,264299,NCT00514072,,2007-08-08,,,2012-08-08,2007-08-08,2007-08-09,Estimate,,,,,,,2012-08-08,2012-08-09,Estimate,March 2007,,2007-03-31,August 2012,2012-08-31,,,,September 2012,Anticipated,2012-09-30,,Interventional,,,Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer,A Double-Blind Randomized Phase 2.5 Trial of ONY-P1 Vaccine Versus Placebo in Men With D0 Prostate Cancer Following Limited Androgen Ablation,Unknown status,"Active, not recruiting",Phase 2,54.0,Anticipated,"Kael-GemVax Co., Ltd.",,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 09:24:02,2023-06-15 09:24:02,INDUSTRY,,,,,
264304,264305,NCT00514189,,2007-08-08,,,2012-07-27,2007-08-08,2007-08-09,Estimate,,,,,,,2012-07-27,2012-07-30,Estimate,July 2007,,2007-07-31,July 2012,2012-07-31,December 2009,Actual,2009-12-31,December 2009,Actual,2009-12-31,,Interventional,,,Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell Vaccines,Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell Vaccines,Terminated,,Phase 1,2.0,Actual,M.D. Anderson Cancer Center,,1.0,,Terminated early due to slow accrual.,False,,,,False,,,,,,,,,,,,,2023-06-15 09:24:06,2023-06-15 09:24:06,OTHER,,,,,
264384,264385,NCT00515983,,2007-08-10,,,2007-08-10,2007-08-10,2007-08-14,Estimate,,,,,,,2007-08-10,2007-08-14,Estimate,October 2004,,2004-10-31,August 2007,2007-08-31,December 2005,Actual,2005-12-31,,,,,Interventional,,,Vaccination of Melanoma Patients With Dendritic Cells Loaded With Allogeneic Apoptotic-Necrotic Melanoma Cells,"Phase I Clinical Trial of a Therapeutic Vaccine Composed of Autologous Dendritic Cells Loaded With Allogeneic Apoptotic Tumor Cells in Patients With Melanoma Stages IIB, IIC, III and IV",Completed,,Phase 1,16.0,Actual,"José Mordoh, M.D., Ph.D.",,,,,False,,,,,,,,,,,,,,,,,2023-06-15 09:24:45,2023-06-15 09:24:45,OTHER,,,,,
264713,264714,NCT00994695,,2009-10-13,,,2009-10-15,2009-10-13,2009-10-14,Estimate,,,,,,,2009-10-15,2009-10-16,Estimate,November 2005,,2005-11-30,October 2009,2009-10-31,November 2007,Actual,2007-11-30,January 2006,Actual,2006-01-31,,Interventional,ETH-TVT,,"Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Vaccine","A Phase II Open and Parallel Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Polysaccharide Vaccine Comparing Three Groups: 2 - 4 Year, 5 - 14 Year and 15 - 29 Year Old Ethiopians",Completed,,Phase 2,412.0,Actual,"Armauer Hansen Research Institute, Ethiopia",,,,,False,,,,True,,,,,,,,,,,,,2023-06-16 15:37:35,2023-06-16 15:37:35,OTHER,,,,,
264759,264760,NCT03527355,,2018-02-12,,,2021-08-26,2018-05-16,2018-05-17,Actual,,,,,,,2021-08-26,2021-08-27,Actual,"April 18, 2018",Actual,2018-04-18,April 2020,2020-04-30,"January 19, 2021",Actual,2021-01-19,"July 28, 2018",Actual,2018-07-28,,Interventional,,,"Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine","A Phase II, Randomized, Dose-scheduling, Observer-Blinded Study to Assess the Safety, Reactogenicity and Immunogenicity of Vi-DT Conjugate Vaccine in 6-23-Month Old Healthy Filipino Infants and Toddlers",Completed,,Phase 2,285.0,Actual,International Vaccine Institute,,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-17 22:26:19,2023-06-17 22:26:19,OTHER,,,,,
264797,264798,NCT05547464,,2022-09-16,,,2023-05-15,2022-09-16,2022-09-21,Actual,,,,,,,2023-05-15,2023-05-16,Actual,July 2023,Anticipated,2023-07-31,May 2023,2023-05-31,April 2025,Anticipated,2025-04-30,October 2024,Anticipated,2024-10-31,,Interventional,,,Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers,"A Phase Ib, Randomized, Placebo-controlled, Observer-blind, Dose-finding Evaluation Trial to Describe the Safety, Reactogenicity, and Immunogenicity of Two Investigational Vaccines Against Active Tuberculosis in BCG Vaccinated, HIV-negative Subjects",Not yet recruiting,,Phase 1,144.0,Anticipated,BioNTech SE,,3.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-15 09:28:33,2023-06-15 09:28:33,INDUSTRY,,,,,
265117,265118,NCT03618056,,2018-08-01,2021-10-13,,2022-01-31,2018-08-01,2018-08-07,Actual,2021-11-30,2021-12-29,Actual,,,,2022-01-31,2022-02-07,Actual,"December 19, 2018",Actual,2018-12-19,January 2022,2022-01-31,"July 17, 2020",Actual,2020-07-17,"July 17, 2020",Actual,2020-07-17,,Interventional,,,Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus,A Phase 1b Open Label Clinical Trial to Evaluate HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus,Completed,,Phase 1,1.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,1.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-17 22:27:14,2023-06-17 22:27:14,NIH,,,,,
265183,265184,NCT04163094,,2019-11-06,,,2022-06-28,2019-11-11,2019-11-14,Actual,,,,,,,2022-06-28,2022-06-30,Actual,"November 25, 2019",Actual,2019-11-25,June 2022,2022-06-30,December 2023,Anticipated,2023-12-31,February 2023,Anticipated,2023-02-28,,Interventional,OLIVIA,,Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy,Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy,"Active, not recruiting",,Phase 1,10.0,Anticipated,University Medical Center Groningen,,1.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 21:26:48,2023-06-18 21:26:48,OTHER,,,,,
265420,265421,NCT03897881,,2019-03-29,,,2023-05-12,2019-03-29,2019-04-01,Actual,,,,,,,2023-05-12,2023-05-16,Actual,"July 18, 2019",Actual,2019-07-18,May 2023,2023-05-31,"September 9, 2029",Anticipated,2029-09-09,"September 9, 2029",Anticipated,2029-09-09,,Interventional,,,An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942),A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942),Recruiting,,Phase 2,257.0,Anticipated,"ModernaTX, Inc.",,2.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-15 09:34:09,2023-06-15 09:34:09,INDUSTRY,,,,,
265586,265587,NCT05239806,,2022-02-14,,,2022-04-01,2022-02-14,2022-02-15,Actual,,,,,,,2022-04-01,2022-04-11,Actual,"April 1, 2022",Anticipated,2022-04-01,February 2022,2022-02-28,"August 1, 2023",Anticipated,2023-08-01,"August 1, 2022",Anticipated,2022-08-01,,Interventional,,,A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged =12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine,"A Randomized, Double-blind Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C (A Bivalent SARS-CoV-2 Trimeric Spike Protein Vaccine) and SCTV01E (A COVID-19 Alpha/Beta/Delta/Omicron Variants S-Trimer Vaccine) in Population Aged =12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine",Not yet recruiting,,Phase 2,400.0,Anticipated,Sinocelltech Ltd.,,4.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-18 21:27:52,2023-06-18 21:27:52,INDUSTRY,,,,,
265597,265598,NCT02636582,,2015-12-18,2023-01-03,2020-07-20,2023-04-25,2015-12-18,2015-12-22,Estimate,2023-04-25,2023-05-16,Actual,2020-07-20,2020-07-23,Actual,2023-04-25,2023-05-16,Actual,"June 14, 2016",Actual,2016-06-14,April 2023,2023-04-30,"March 19, 2024",Anticipated,2024-03-19,"July 22, 2019",Actual,2019-07-22,,Interventional,,Randomized participants.,Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer,VADIS Trial: Phase II Trial of Nelipeimut-S Peptide Vaccine in Women With DCIS of the Breast,"Active, not recruiting",,Phase 2,43.0,Actual,National Cancer Institute (NCI),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 09:36:44,2023-06-15 09:36:44,NIH,,,,,
265912,265913,NCT00521287,,2007-08-24,,,2008-02-29,2007-08-24,2007-08-27,Estimate,,,,,,,2008-02-29,2008-03-03,Estimate,October 2006,,2006-10-31,August 2007,2007-08-31,December 2009,Anticipated,2009-12-31,September 2007,Actual,2007-09-30,,Interventional,,,"Impaired Immunity in Patients With Cancer: Influence of Cancer Stage, Chemotherapy, and Cytomegalovirus Infection",Adjustment of Optimal Immune System by Using Cytokine Cocktails Before Applying DC Vaccine,Unknown status,Recruiting,Phase 2,150.0,Anticipated,Mackay Memorial Hospital,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 09:39:52,2023-06-15 09:39:52,OTHER,,,,,
265940,265941,NCT00522067,,2007-08-28,,,2016-11-30,2007-08-28,2007-08-29,Estimate,,,,,,,2016-11-30,2016-12-01,Estimate,June 2007,,2007-06-30,January 2012,2012-01-31,July 2007,Actual,2007-07-31,July 2007,Actual,2007-07-31,,Interventional,,,"Support Annual Strain Update, Safety and Immunogenicity of an Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Subjects 18-64 Years Affected by Chronic Diseases.","A Phase II, Open Label, Uncontrolled, Multi-Center Study to Support Annual Strain Update and to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Subjects Aged 18-64 Years Affected by Chronic Diseases",Completed,,Phase 2,52.0,Actual,Novartis,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 09:40:10,2023-06-15 09:40:10,INDUSTRY,,,,,
266001,266002,NCT04726553,,2021-01-22,,,2023-03-21,2021-01-22,2021-01-27,Actual,,,,,,,2023-03-21,2023-03-22,Actual,"January 20, 2021",Actual,2021-01-20,March 2023,2023-03-31,"December 31, 2024",Anticipated,2024-12-31,"December 31, 2023",Anticipated,2023-12-31,,Interventional,NAIVE,,Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE,Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in Patients With Moderately to Severely Active Systemic Lupus Erythematosus: A Multi-Centre Open Label Parallel Group Trial:,Recruiting,,Early Phase 1,20.0,Anticipated,Oklahoma Medical Research Foundation,,2.0,,,,,,,False,True,False,,,,,,one year after completion of the study,Our registry requires registry board approval and internal review board approval. Investigators may apply with a description of the planned project,,Yes,de-identified data will be made available for sharing with other researchers upon application to our registry and approval by the internal review board of the Oklahoma Medical Research Foundation,2023-06-15 09:40:42,2023-06-15 09:40:42,OTHER,,,,,
266106,266107,NCT03702231,,2018-10-10,2021-11-17,2021-04-12,2023-02-09,2018-10-10,2018-10-11,Actual,2021-11-17,2021-12-15,Actual,2021-04-21,2021-04-23,Actual,2023-02-09,2023-02-13,Actual,"December 7, 2018",Actual,2018-12-07,February 2023,2023-02-28,"July 12, 2023",Anticipated,2023-07-12,"September 9, 2020",Actual,2020-09-09,,Interventional,,,Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I),Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients That Are Treatment Naive or Receiving Bruton s-Tyrosine Kinase Inhibitor (BTK-I) Therapy,"Active, not recruiting",,Phase 2,116.0,Actual,National Institutes of Health Clinical Center (CC),,3.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-17 22:28:26,2023-06-17 22:28:26,NIH,,,,,
266233,266234,NCT02946190,,2016-10-24,,,2017-05-05,2016-10-24,2016-10-27,Estimate,,,,,,,2017-05-05,2017-05-08,Actual,"October 27, 2016",Actual,2016-10-27,May 2017,2017-05-31,"March 9, 2017",Actual,2017-03-09,"March 9, 2017",Actual,2017-03-09,,Interventional,,,The PertADO Geneva Trial,"A Phase II Randomized, Observer-blind Controlled Pilot Study to Compare the Safety and Immunogenicity of Acellular Pertussis Vaccines Including Chemically or Genetically-detoxified Pertussis Toxin in Adolescents Aged 11-15 Years Previously Immunized With Acellular Pertussis Vaccines",Completed,,Phase 2,60.0,Anticipated,"University Hospital, Geneva",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 09:42:46,2023-06-15 09:42:46,OTHER,,,,,
266635,266636,NCT03523767,,2018-05-01,,,2023-03-31,2018-05-01,2018-05-14,Actual,,,,,,,2023-03-31,2023-04-04,Actual,"February 7, 2018",Actual,2018-02-07,March 2023,2023-03-31,"February 7, 2020",Actual,2020-02-07,"February 7, 2020",Actual,2020-02-07,,Interventional,,,Effect of Systemic Inflammation on Emotion and Cognition in Patients With Mood Disorder - A Vaccine Study,Effect of Systemic Inflammation on Emotion and Cognition in Patients With Mood Disorder - A Vaccine Study,Terminated,,Phase 1,19.0,Actual,"The University of Texas Health Science Center, Houston",,2.0,,Early termination related to COVID pandemic,False,,,,True,True,False,,,False,,,,,,No,,2023-06-17 22:29:04,2023-06-17 22:29:04,OTHER,,,,,
266645,266646,NCT05272605,,2022-03-03,,,2023-05-12,2022-03-08,2022-03-09,Actual,,,,,,,2023-05-12,2023-05-15,Actual,"April 5, 2022",Actual,2022-04-05,May 2023,2023-05-31,"April 19, 2023",Actual,2023-04-19,"April 19, 2023",Actual,2023-04-19,,Interventional,,,Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults,"A Phase I, Randomised, Double-blind, Placebo-controlled, Dose-escalation Study of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults Aged 18 to 64 Years Previously Vaccinated With 3 Doses of Licensed SARS-CoV-2 Ancestral Strain Vaccines",Completed,,Phase 1,76.0,Actual,University of Melbourne,,7.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-14 07:54:57,2023-06-14 07:54:57,OTHER,,,,,
266696,266697,NCT01857869,,2013-05-16,2017-08-25,2014-05-29,2019-06-11,2013-05-16,2013-05-20,Estimate,2018-12-04,2018-12-26,Actual,2014-05-29,2014-06-02,Estimate,2019-06-11,2019-06-26,Actual,"May 20, 2013",Actual,2013-05-20,June 2019,2019-06-30,"December 16, 2014",Actual,2014-12-16,"March 24, 2014",Actual,2014-03-24,,Interventional,,"The number of participants included in the Booster/Rechallenge Phase (0,1,7 M P-NoBo Group; 0,1,7 M P-Bo Group; 0,1,7 NP-Bo Group; 0,1,2 M P-NoBo Group; 0,1,2 M P-Bo Group; 0,1,2 M NP-Bo Group; and Control Group Follow-up) were also in Primary/Challenge Phase (GSK257049-0,1,7M Group; GSK257049-0,1,2M Group; and Infectivity Control Group).","Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults","Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults",Completed,,Phase 2,64.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-18 21:29:52,2023-06-18 21:29:52,INDUSTRY,,,,,
266858,266859,NCT00146744,,2005-09-06,,,2017-05-24,2005-09-06,2005-09-07,Estimate,,,,,,,2017-05-24,2017-05-30,Actual,July 2005,,2005-07-31,May 2017,2017-05-31,May 2006,Actual,2006-05-31,May 2006,Actual,2006-05-31,,Interventional,,,Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02A in Healthy PPD-positive Adults,"Double-blind (Observer-blind), Randomised, Controlled, Phase I/II Study, to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Candidate Tuberculosis Vaccine, Mtb72F/AS02A Administered Intramuscularly at 0, 1, 2 Months to Healthy PPD-positive Volunteers Aged 18 to 50 Years",Completed,,Phase 2,38.0,,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 09:47:44,2023-06-15 09:47:44,INDUSTRY,,,,,
266924,266925,NCT01161160,,2010-07-01,2017-03-03,2011-03-23,2018-08-09,2010-07-12,2010-07-13,Estimate,2017-04-25,2017-08-04,Actual,2011-03-23,2011-03-29,Estimate,2018-08-09,2018-09-06,Actual,"July 1, 2010",,2010-07-01,April 2017,2017-04-30,"January 31, 2011",Actual,2011-01-31,"August 23, 2010",Actual,2010-08-23,,Interventional,,,Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old,An Observer-blind Safety and Immunogenicity Study of GSK Biologicals' A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340272A in Children 3 to Less Than 10 Years Old,Completed,,Phase 2,209.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-18 21:30:13,2023-06-18 21:30:13,INDUSTRY,,,,,
267061,267062,NCT05098210,,2021-10-14,,,2023-05-12,2021-10-26,2021-10-28,Actual,,,,,,,2023-05-12,2023-05-15,Actual,"June 9, 2022",Actual,2022-06-09,May 2023,2023-05-31,"November 1, 2024",Anticipated,2024-11-01,"November 1, 2024",Anticipated,2024-11-01,,Interventional,,,Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer,PNV21-001: A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer and PD1/PD-L1 Inhibitor-Refractory Melanoma,Recruiting,,Phase 1,20.0,Anticipated,Fred Hutchinson Cancer Center,,1.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-14 07:55:26,2023-06-14 07:55:26,OTHER,,,,,
267258,267259,NCT00170469,,2005-09-09,,,2008-09-12,2005-09-09,2005-09-15,Estimate,,,,,,,2008-09-12,2008-09-15,Estimate,March 2005,,2005-03-31,September 2008,2008-09-30,February 2007,Actual,2007-02-28,February 2007,Actual,2007-02-28,,Interventional,,,"Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed","A Phase II, Dose Ranging Multi-Centre, Single Blind, Parallel-Group, Controlled Study of the Safety, Tolerability and Immunogenicity of Recombinant (rPA Based) Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed in a Healthy Population",Completed,,Phase 2,226.0,Actual,PharmAthene UK Limited,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 09:51:04,2023-06-15 09:51:04,INDUSTRY,,,,,
267270,267271,NCT00170547,,2005-09-09,,,2014-12-04,2005-09-09,2005-09-15,Estimate,,,,,,,2014-12-04,2014-12-05,Estimate,September 2005,,2005-09-30,July 2006,2006-07-31,February 2006,,2006-02-28,January 2006,Actual,2006-01-31,,Interventional,,,Comparison of Delivery Routes of Flu Vaccine in Adults,"Immunogenicity and Safety of a Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route Compared to an Intramuscular Vaccination With Fluzone(R) in Healthy Adults",Completed,,Phase 2,1597.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 09:51:12,2023-06-15 09:51:12,NIH,,,,,
267546,267547,NCT05750017,,2023-02-09,,,2023-03-23,2023-02-19,2023-03-01,Actual,,,,,,,2023-03-23,2023-03-27,Actual,"March 23, 2023",Actual,2023-03-23,March 2023,2023-03-31,"March 15, 2024",Anticipated,2024-03-15,"February 1, 2024",Anticipated,2024-02-01,,Interventional,,,A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine,"A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine (LZ901) in Subjects Aged 50 to 70 Years Inclusive",Recruiting,,Phase 1,66.0,Anticipated,"Beijing Luzhu Biotechnology Co., Ltd.",,4.0,,,False,,,,,True,False,,,,,,,,,No,,2023-06-15 09:53:37,2023-06-15 09:53:37,OTHER,,,,,
267757,267758,NCT04969263,,2021-07-16,,,2023-03-23,2021-07-16,2021-07-20,Actual,,,,,,,2023-03-23,2023-03-27,Actual,"August 10, 2021",Actual,2021-08-10,March 2023,2023-03-31,"March 10, 2023",Actual,2023-03-10,"November 10, 2022",Actual,2022-11-10,,Interventional,CPAT,,COVID-19 Protection After Transplant Pilot Study,Immunogenicity of a Third Dose of Either the Moderna COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine in Kidney Transplant Recipients Who Failed to Respond After Two Previous Doses,Completed,,Phase 2,81.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,True,False,,,,,,"On average, within 24 months after database lock for the trial.",Open access.,https://www.immport.org/home,Yes,"The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.",2023-06-15 09:55:34,2023-06-15 09:55:34,NIH,,,,,
268035,268036,NCT02924038,,2016-05-12,,,2023-03-23,2016-10-04,2016-10-05,Estimate,,,,,,,2023-03-23,2023-03-27,Actual,"April 3, 2017",Actual,2017-04-03,March 2023,2023-03-31,"December 31, 2030",Anticipated,2030-12-31,"December 31, 2022",Actual,2022-12-31,,Interventional,,,A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG),Pilot Randomized Neo-adjuvant Evaluation of Agonist Anti-CD27 Monoclonal Antibody Varlilumab on Immunologic Activities of IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG),"Active, not recruiting",,Phase 1,14.0,Anticipated,"University of California, San Francisco",,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-15 09:58:11,2023-06-15 09:58:11,OTHER,,,,,
268404,268405,NCT05552573,,2022-09-15,,,2023-03-09,2022-09-21,2022-09-23,Actual,,,,,,,2023-03-09,2023-03-10,Actual,"July 19, 2022",Actual,2022-07-19,September 2022,2022-09-30,"December 1, 2023",Anticipated,2023-12-01,"January 10, 2023",Actual,2023-01-10,,Interventional,,,Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above,"A Randomized, Blinded, Positive-controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in Population Aged 18 Years and Above","Active, not recruiting",,Phase 1,100.0,Actual,"Guangzhou Patronus Biotech Co., Ltd.",,4.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-17 22:30:52,2023-06-17 22:30:52,INDUSTRY,,,,,
268447,268448,NCT05465902,,2022-07-18,,,2023-02-22,2022-07-18,2022-07-20,Actual,,,,,,,2023-02-22,2023-02-27,Actual,July 2023,Anticipated,2023-07-31,July 2022,2022-07-31,December 2023,Anticipated,2023-12-31,November 2023,Anticipated,2023-11-30,,Interventional,,,Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster,Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster Following Primary Vaccination of Either Inactivated or mRNA or Viral Vector COVID-19 Vaccines,Not yet recruiting,,Phase 2,600.0,Anticipated,"WestVac Biopharma Co., Ltd.",,6.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-15 10:01:59,2023-06-15 10:01:59,INDUSTRY,,,,,
268540,268541,NCT00532792,,2007-09-19,,,2012-03-13,2007-09-19,2007-09-20,Estimate,,,,,,,2012-03-13,2012-03-14,Estimate,August 2007,,2007-08-31,January 2012,2012-01-31,June 2008,Actual,2008-06-30,June 2008,Actual,2008-06-30,,Interventional,,,A/H5N1 Dose Ranging Study With Adjuvant Patch,"A Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine Administered With and Without an Adjuvant Patch in Healthy Adults",Completed,,Phase 1,501.0,Actual,"Intercell USA, Inc.",,10.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 10:02:49,2023-06-15 10:02:49,INDUSTRY,,,,,
268768,268769,NCT01008813,,2009-11-05,,,2011-12-21,2009-11-05,2009-11-06,Estimate,,,,,,,2011-12-21,2011-12-22,Estimate,October 2009,,2009-10-31,December 2011,2011-12-31,December 2010,Actual,2010-12-31,February 2010,Actual,2010-02-28,,Interventional,,,Clinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac),A Randomized Phase II Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac),Completed,,Phase 2,306.0,Actual,French National Agency for Research on AIDS and Viral Hepatitis,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 15:41:40,2023-06-16 15:41:40,OTHER_GOV,,,,,
269226,269227,NCT04658914,,2020-11-18,,,2022-07-19,2020-12-01,2020-12-09,Actual,,,,,,,2022-07-19,2022-07-20,Actual,"April 15, 2021",Actual,2021-04-15,July 2022,2022-07-31,October 2023,Anticipated,2023-10-31,September 2022,Anticipated,2022-09-30,,Interventional,,,Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa,Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa,"Active, not recruiting",,Phase 2,720.0,Actual,Centre for Infectious Disease Research in Zambia,,4.0,,,False,,,,True,False,False,,,,,,after study completion,,,Yes,"Communicate with the participants results of the study and plans to share de-identified data. Disseminate to internal research meetings as well as the Ministry of Health Zambia.

Submit manuscripts, publications, in peer review journal and also present at local and international scientific conferences",2023-06-15 10:09:43,2023-06-15 10:09:43,OTHER,,,,,
269591,269592,NCT00189930,,2005-09-12,,,2012-09-28,2005-09-12,2005-09-19,Estimate,,,,,,,2012-09-28,2012-10-01,Estimate,April 2005,,2005-04-30,September 2012,2012-09-30,December 2006,Actual,2006-12-31,,,,,Interventional,,,An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients,"A Single-blind, Randomized, Controlled, Phase II Study to Evaluate Immunogenicity and Safety of Two Doses of the MVA-nef HIV Vaccine in HIV-1 Infected Patients With CD4 > 250/µl",Completed,,Phase 2,77.0,Actual,Bavarian Nordic,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 10:13:51,2023-06-15 10:13:51,INDUSTRY,,,,,
269597,269598,NCT00189969,,2005-09-13,,,2006-04-20,2005-09-13,2005-09-19,Estimate,,,,,,,2006-04-20,2006-04-21,Estimate,September 2003,,2003-09-30,April 2006,2006-04-30,February 2006,,2006-02-28,,,,,Interventional,,,"Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects","Phase I Study to Evaluate Take Rate, Immunogenicity and Safety of Bavarian Nordic's Smallpox Vaccine Elstree-BN Administered to Healthy Vaccinia-Naive Subjects in the Age of 18-32 Years",Completed,,Phase 1,50.0,,Bavarian Nordic,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 10:13:54,2023-06-15 10:13:54,INDUSTRY,,,,,
269872,269873,NCT00551629,,2007-10-29,,,2015-10-29,2007-10-30,2007-10-31,Estimate,,,,,,,2015-10-29,2015-10-30,Estimate,May 2001,,2001-05-31,October 2015,2015-10-31,March 2003,Actual,2003-03-31,March 2003,Actual,2003-03-31,,Interventional,,,A Study to Test the Safety and Effectiveness of an Investigational Vaccine in Infants (V419-002),"Safety, Tolerability, and Immunogenicity of Four Different Formulations of a Liquid Hexavalent Combination Vaccine, HR5I (Haemophilus Influenzae Type b Conjugate, Recombinant Hepatitis B Surface Antigen, Diphtheria Toxoid, Tetanus Toxoid, 5-Component Acellular Pertussis Vaccine, and Inactivated Poliovirus Type 1, 2, and 3), When Administered to Healthy Hepatitis B Vaccine-Naïve Infants at 2, 3, 4, and 12 to 14 Months of Age",Completed,,Phase 2,708.0,Actual,Merck Sharp & Dohme LLC,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 10:20:27,2023-06-15 10:20:27,INDUSTRY,,,,,
269913,269914,NCT00192153,,2005-09-12,,,2021-09-10,2005-09-12,2005-09-19,Estimate,,,,,,,2021-09-10,2021-09-13,Actual,July 2001,,2001-07-31,October 2006,2006-10-31,October 2001,,2001-10-31,,,,,Interventional,,,Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older,"A Randomized, Partially-Blinded, Placebo-Controlled Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, (CAIV-T) in Healthy Adults 18 to 59 Years and Healthy Adults,60 Years/Older",Completed,,Phase 2,240.0,,MedImmune LLC,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 10:21:00,2023-06-15 10:21:00,INDUSTRY,,,,,
269966,269967,NCT00192270,,2005-09-12,,,2012-03-05,2005-09-12,2005-09-19,Estimate,,,,,,,2012-03-05,2012-03-06,Estimate,October 2000,,2000-10-31,March 2012,2012-03-31,January 2001,Actual,2001-01-31,January 2001,Actual,2001-01-31,,Interventional,FluMist,,"Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-adapted (CAIV-T) in Healthy Children","A Prospective, Open-label, Phase II, Multi-center Study of the Safety, Tolerability and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-adapted (CAIV-T) in Healthy Children, Aged 6 to 17 Years",Completed,,Phase 2,498.0,Actual,MedImmune LLC,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 10:21:31,2023-06-15 10:21:31,INDUSTRY,,,,,
269976,269977,NCT00192309,,2005-09-12,,,2012-02-13,2005-09-12,2005-09-19,Estimate,,,,,,,2012-02-13,2012-02-14,Estimate,September 2001,,2001-09-30,February 2012,2012-02-29,December 2001,Actual,2001-12-31,December 2001,Actual,2001-12-31,,Interventional,,,Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.,"A Randomized, Open-Label, Placebo-Controlled Trial to Investigate the Kinetics of the Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent,Types A & B, Live, Cold-Adapted (CAIV-T) in Healthy Adults Aged 18 to <65 Years.",Completed,,Phase 2,31.0,Actual,MedImmune LLC,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 10:21:39,2023-06-15 10:21:39,INDUSTRY,,,,,
269991,269992,NCT00192348,,2005-09-12,,,2021-09-10,2005-09-12,2005-09-19,Estimate,,,,,,,2021-09-10,2021-09-13,Actual,May 2002,,2002-05-31,October 2006,2006-10-31,December 2002,,2002-12-31,,,,,Interventional,,,"A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants","A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Infants",Completed,,Phase 1,120.0,,MedImmune LLC,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 10:21:49,2023-06-15 10:21:49,INDUSTRY,,,,,
269993,269994,NCT00162500,,2005-09-11,,,2010-11-09,2005-09-11,2005-09-13,Estimate,,,,,,,2010-11-09,2010-11-10,Estimate,,,,September 2005,2005-09-30,,,,,,,,Interventional,,,A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies,A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies,Withdrawn,,Phase 2,15.0,Anticipated,Hadassah Medical Organization,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 10:21:49,2023-06-15 10:21:49,OTHER,,,,,
270007,270008,NCT00192387,,2005-09-13,,,2021-09-10,2005-09-13,2005-09-19,Estimate,,,,,,,2021-09-10,2021-09-13,Actual,September 2001,,2001-09-30,December 2006,2006-12-31,December 2001,,2001-12-31,,,,,Interventional,,,Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T),"A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate Viral Shedding in Healthy Children (6 Mos and Less Than or Equal to 18 Months of Age) Vaccinated With Two Doses of Liquid Formulation of Influenza Virus Vaccine, Live Cold Adapted (CAIV-T)",Completed,,Phase 2,60.0,,MedImmune LLC,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 10:21:55,2023-06-15 10:21:55,INDUSTRY,,,,,
270268,270269,NCT05807035,,2023-03-28,,,2023-04-08,2023-04-07,2023-04-10,Actual,,,,,,,2023-04-08,2023-04-11,Actual,"February 10, 2023",Actual,2023-02-10,April 2023,2023-04-30,"February 10, 2028",Anticipated,2028-02-10,"February 10, 2026",Anticipated,2026-02-10,,Interventional,,,Autologous Tumour Vaccine Trial,A Phase I Trial of Autologous Tumour Vaccine for Advanced Solid Cancers,Recruiting,,Phase 1,10.0,Anticipated,Vaxine Pty Ltd,,1.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-15 10:25:13,2023-06-15 10:25:13,INDUSTRY,,,,,
270311,270312,NCT05642429,,2022-11-30,,,2023-04-07,2022-11-30,2022-12-08,Actual,,,,,,,2023-04-07,2023-04-11,Actual,"February 27, 2023",Actual,2023-02-27,March 2023,2023-03-31,"November 7, 2026",Anticipated,2026-11-07,"February 20, 2026",Anticipated,2026-02-20,,Interventional,,,"Study of AV-1959, an Amyloid Beta Vaccine","A Phase I, Randomized, Double-Blind Study to Evaluate Safety and Tolerability of Amyloid-ß Vaccine, AV-1959D, in Patients With Early Alzheimer's Disease.",Recruiting,,Phase 1,48.0,Anticipated,Institute for Molecular Medicine,,4.0,,,False,,,,True,True,False,,,,,,,,,Undecided,,2023-06-15 10:25:44,2023-06-15 10:25:44,OTHER,,,,,
270706,270707,NCT00936468,,2009-07-09,,,2011-02-10,2009-07-09,2009-07-10,Estimate,,,,,,,2011-02-10,2011-02-14,Estimate,September 2009,,2009-09-30,February 2011,2011-02-28,September 2010,Actual,2010-09-30,June 2010,Actual,2010-06-30,,Interventional,,,"Safety, Tolerability and Immunogenicity of Fluzone® With and Without JVRS-100 in Elderly Subjects","Randomized, Double Blind, Controlled Phase II Trial of the Safety, Tolerability and Immunogenicity of Fluzone® Inactivated Trivalent Influenza Virus Vaccine Administered With and Without JVRS-100 Adjuvant in Subjects 65 Years and Older",Completed,,Phase 2,472.0,Actual,Colby Pharmaceutical Company,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 15:49:14,2023-06-16 15:49:14,INDUSTRY,,,,,
270852,270853,NCT00164411,,2005-09-09,,,2012-03-13,2005-09-09,2005-09-14,Estimate,,,,,,,2012-03-13,2012-03-14,Estimate,January 2004,,2004-01-31,March 2012,2012-03-31,March 2005,,2005-03-31,,,,,Interventional,,,Pneumococcal Conjugate Vaccine With Pneumococcal Polysaccharide Vaccine and Tetanus/Diphtheria Vaccine,Pneumococcal Conjugate Vaccine (Prevnar; Wyeth) With Pneumococcal Polysaccharide Vaccine (23-valent) and Tetanus/Diphtheria Vaccine,Completed,,Phase 1,30.0,,Centers for Disease Control and Prevention,,,,,,,,,,,,,,,,,,,,,,2023-06-15 10:32:41,2023-06-15 10:32:41,FED,,,,,
270884,270885,NCT00889616,,2009-04-28,,,2019-12-14,2009-04-28,2009-04-29,Estimate,,,,,,,2019-12-14,2019-12-17,Actual,"April 23, 2009",,2009-04-23,"July 18, 2012",2012-07-18,"July 18, 2012",Actual,2012-07-18,,,,,Interventional,,,"Phase I Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and Mali","Phase 1 Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and in Bancoumana, Mali",Completed,,Phase 1,154.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-16 15:49:23,2023-06-16 15:49:23,NIH,,,,,
271239,271240,NCT00195234,,2005-09-12,,,2007-12-03,2005-09-12,2005-09-19,Estimate,,,,,,,2007-12-03,2007-12-05,Estimate,December 2004,,2004-12-31,December 2007,2007-12-31,February 2007,Actual,2007-02-28,,,,,Interventional,,,Study Evaluating Vaccine in Adults With HIV,"A Phase 1 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of an HIV CTL Multi-Epitope Peptide Vaccine Formulated With RC529-SE and GM-CSF Given to HIV-1 Positive Adults on Stable HAART.",Completed,,Phase 1,60.0,,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,,,,,,,,,,,,,,,,,2023-06-15 10:36:33,2023-06-15 10:36:33,INDUSTRY,,,,,
271265,271266,NCT00195312,,2005-08-05,,,2007-12-03,2005-09-12,2005-09-19,Estimate,,,,,,,2007-12-03,2007-12-05,Estimate,August 2005,,2005-08-31,December 2007,2007-12-31,August 2007,Actual,2007-08-31,,,,,Interventional,,,Study Evaluating Vaccine in Adults With HIV,"A Phase 1 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine Administered Alone or With Escalating Doses of IL-12 DNA or IL-15 DNA Molecular Adjuvants to HIV-1 Positive Adults Receiving Stable HAART.",Terminated,,Phase 1,91.0,Anticipated,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,,,,,,,,,,,,,,,,,2023-06-15 10:36:46,2023-06-15 10:36:46,INDUSTRY,,,,,
271650,271651,NCT00169481,,2005-09-12,,,2017-01-09,2005-09-12,2005-09-15,Estimate,,,,,,,2017-01-09,2017-01-10,Estimate,October 2004,,2004-10-31,January 2017,2017-01-31,May 2005,Actual,2005-05-31,May 2005,Actual,2005-05-31,,Interventional,,,A Study in Children With Different Formulations of GSK Biologicals' 11 Valent Pneumococcal Conjugate Vaccine,"A Randomized, Controlled, Phase II Study to Evaluate the Safety and Immunogenicity of Different Formulations of GlaxoSmithKline Biologicals' 11-valent Pneumococcal Conjugate Vaccine, When Administered Intramuscularly as a 3-dose Primary Immunization (2-3-4 Month Schedule) Before 6 Months of Age",Completed,,Phase 2,689.0,Actual,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 10:39:57,2023-06-15 10:39:57,INDUSTRY,,,,,
271851,271852,NCT00170456,,2005-09-09,,,2008-09-12,2005-09-09,2005-09-15,Estimate,,,,,,,2008-09-12,2008-09-15,Estimate,March 2005,,2005-03-31,September 2008,2008-09-30,February 2007,Actual,2007-02-28,January 2007,Actual,2007-01-31,,Interventional,,,Phase II Study of Range and Schedule of rPA Doses,"A Double-Blind, Parallel-Group Study of the Safety, Tolerability and Immunogenicity of a Range of Doses and Dosing Schedules of Recombinant (rPA Based) Anthrax Vaccine in Healthy Subjects",Completed,,Phase 2,415.0,Actual,PharmAthene UK Limited,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 10:41:41,2023-06-15 10:41:41,INDUSTRY,,,,,
271888,271889,NCT00170612,,2005-09-13,,,2008-10-20,2005-09-13,2005-09-15,Estimate,,,,,,,2008-10-20,2008-10-21,Estimate,November 2005,,2005-11-30,October 2008,2008-10-31,August 2008,Actual,2008-08-31,January 2008,Actual,2008-01-31,,Interventional,,,Pneumococcal Vaccination of Fiji Infants,"A Single-Blind Open-Label Randomized Phase II Study of the Safety, Immunogenicity and Impact on Pneumococcus (Pnc) Carriage of the Pnc Vaccination Regimens Combining 1, 2, or 3 Doses of 7-Valent Pneumococcal Conjugate Vaccine (PCV) in the First 4 Months of Life Followed by a Single Dose of 23-Valent Pneumococcal Polysaccharide Vaccine (PPS) at 12 Months of Age",Completed,,Phase 2,552.0,Actual,University of Melbourne,,8.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 10:41:56,2023-06-15 10:41:56,OTHER,,,,,
271890,271891,NCT00196950,,2005-09-13,,,2016-09-06,2005-09-13,2005-09-20,Estimate,,,,,,,2016-09-06,2016-09-07,Estimate,September 2003,,2003-09-30,September 2016,2016-09-30,October 2003,Actual,2003-10-31,October 2003,Actual,2003-10-31,,Interventional,,,"Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years","Assess the Safety, Reactogenicity, Immunogenicity & Long-term Persistence of One Intramuscular Dose of GSK Biologicals' MenACWY Conjugate Vaccine vs One Subcutaneous Dose of Mencevax ACWY in Healthy Adults Aged 18-25 Yrs",Completed,,Phase 2,50.0,Actual,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 10:41:57,2023-06-15 10:41:57,INDUSTRY,,,,,
271905,271906,NCT00197067,,2005-09-13,,,2019-12-26,2005-09-13,2005-09-20,Estimate,,,,,,,2019-12-26,2019-12-27,Actual,"March 15, 2004",Actual,2004-03-15,December 2019,2019-12-31,"April 26, 2005",Actual,2005-04-26,"April 26, 2005",Actual,2005-04-26,,Interventional,,,"A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.","A Bridging Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.",Completed,,Phase 1,200.0,Actual,GlaxoSmithKline,,,,,False,,,,,,,,,,,,IPD for this study is available via the Clinical Study Data Request site.,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months",https://www.clinicalstudydatarequest.com/Posting.aspx?ID=19808,Yes,IPD for this study is available via the Clinical Study Data Request site.,2023-06-15 10:42:07,2023-06-15 10:42:07,INDUSTRY,,,,,
271959,271960,NCT01744171,,2012-12-04,,,2022-07-20,2012-12-04,2012-12-06,Estimate,,,,,,,2022-07-20,2022-07-22,Actual,"March 26, 2013",Actual,2013-03-26,July 2022,2022-07-31,"June 11, 2018",Actual,2018-06-11,"June 11, 2018",Actual,2018-06-11,,Interventional,,,Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma,A Phase I Trial of a Recombinant Human hsp110-gp100 Chaperone Complex Vaccine for Advanced Stage IIIB/C or IV Melanoma,Terminated,,Phase 1,10.0,Actual,Roswell Park Cancer Institute,,1.0,,Study was Suspended since 2018; PI decided to terminate.,False,,,,False,,,,,,,,,,,,,2023-06-15 10:42:35,2023-06-15 10:42:35,OTHER,,,,,
272022,272023,NCT01488188,,2011-12-04,2013-07-31,,2013-11-05,2011-12-06,2011-12-08,Estimate,2013-11-05,2013-12-23,Estimate,,,,2013-11-05,2013-12-23,Estimate,December 2011,,2011-12-31,November 2013,2013-11-30,May 2013,Actual,2013-05-31,May 2013,Actual,2013-05-31,,Interventional,,,Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route,A Controlled Study to Determine the Immunogenicity and Safety of Cold-adaptive Live Attenuated Influenza Vaccine (Flumist) Administered by the Nasal and Sublingual Route in Healthy Adult Volunteers,Completed,,Phase 1,40.0,Actual,International Vaccine Institute,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 08:17:35,2023-06-14 08:17:35,OTHER,,,,,
272273,272274,NCT02100436,,2014-03-27,,2017-07-03,2017-07-03,2014-03-27,2014-04-01,Estimate,,,,2017-07-03,2017-07-06,Actual,2017-07-03,2017-07-06,Actual,"June 11, 2014",Actual,2014-06-11,"December 16, 2014",2014-12-16,"March 20, 2015",Actual,2015-03-20,"March 20, 2015",Actual,2015-03-20,,Interventional,,,Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations,"A Phase II Open-Label Study in Healthy Pediatric Populations to Assess the Safety, Reactogenicity, and Immunogenicity of an Intramuscular Unadjuvanted Subvirion Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine",Completed,,Phase 2,270.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-15 10:45:41,2023-06-15 10:45:41,NIH,,,,,
272365,272366,NCT01938742,,2013-09-05,,2015-03-26,2016-12-08,2013-09-05,2013-09-10,Estimate,,,,2015-03-26,2015-04-16,Estimate,2016-12-08,2016-12-12,Estimate,September 2013,,2013-09-30,July 2015,2015-07-31,November 2014,Actual,2014-11-30,November 2014,Actual,2014-11-30,,Interventional,,,H7N9 Mix and Match With MF59 in Healthy Adults,"A Phase II Randomized, Double-Blinded, Controlled Study in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of a Monovalent Influenza A/H7N9 Virus Vaccine Administered at Different Dosages Given With and Without MF59 Adjuvant",Completed,,Phase 2,700.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,7.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 10:46:49,2023-06-15 10:46:49,NIH,,,,,
272367,272368,NCT01930357,,2013-08-22,,2014-11-17,2017-04-24,2013-08-23,2013-08-28,Estimate,,,,2014-11-17,2014-12-03,Estimate,2017-04-24,2017-04-25,Actual,September 2013,,2013-09-30,April 2017,2017-04-30,June 2015,Actual,2015-06-30,August 2014,Actual,2014-08-31,,Interventional,,,Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen,"Immunogenicity and Safety of the Purified Vero Rabies Vaccine - Serum Free (VRVg) in Comparison With the Human Diploid Cell Vaccine, Imovax® Rabies in a Pre-exposure Prophylaxis Regimen in Healthy Children and Adolescents Aged 2 to 17 Years",Completed,,Phase 2,342.0,Actual,Sanofi,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 10:46:50,2023-06-15 10:46:50,INDUSTRY,,,,,
272382,272383,NCT01877395,,2013-06-10,,2014-11-17,2014-11-17,2013-06-11,2013-06-13,Estimate,,,,2014-11-17,2014-12-03,Estimate,2014-11-17,2014-12-03,Estimate,June 2013,,2013-06-30,November 2014,2014-11-30,September 2014,Actual,2014-09-30,May 2014,Actual,2014-05-31,,Interventional,,,Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen,Immunogenicity and Safety of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Rabies Human Diploid Cell Vaccine (Imovax® Rabies) Administered in a Simulated Rabies Post-exposure Regimen in Healthy Adults,Completed,,Phase 2,342.0,Actual,Sanofi,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 10:47:01,2023-06-15 10:47:01,INDUSTRY,,,,,
272462,272463,NCT01746082,,2012-12-06,,2014-01-27,2014-01-27,2012-12-06,2012-12-10,Estimate,,,,2014-01-27,2014-02-28,Estimate,2014-01-27,2014-02-28,Estimate,January 2013,,2013-01-31,January 2014,2014-01-31,August 2013,Actual,2013-08-31,August 2013,Actual,2013-08-31,,Interventional,,,Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Adult and Elderly Populations,"A Phase II Open-Label Study in Healthy Adult and Elderly Populations to Assess the Safety, Reactogenicity, and Immunogenicity of an Intramuscular Unadjuvanted Subvirion Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine",Completed,,Phase 2,211.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 10:47:55,2023-06-15 10:47:55,NIH,,,,,
272530,272531,NCT00944580,,2009-07-21,,,2017-11-21,2009-07-22,2009-07-23,Estimate,,,,,,,2017-11-21,2017-11-24,Actual,June 2009,,2009-06-30,November 2017,2017-11-30,August 2010,Actual,2010-08-31,August 2010,Actual,2010-08-31,,Interventional,,,A Vaccine Study for High Risk Cancers,"A Phase 1 Study to Determine the Immunologic Effects of a MAGE- A1, MAGE- A3, NY-ESO-1 Vaccine in Patients With High Risk Neuroblastoma, Osteogenic Sarcoma, and Rhabdomyosarcoma",Withdrawn,,Phase 1,0.0,Actual,Penn State University,,1.0,,unexpectedly low screening results leading to poor accrual,False,,,,True,,,,,,,,,,,,,2023-06-16 15:50:58,2023-06-16 15:50:58,OTHER,,,,,
272656,272657,NCT04105582,,2019-09-24,,,2022-06-15,2019-09-25,2019-09-26,Actual,,,,,,,2022-06-15,2022-06-21,Actual,"August 1, 2019",Actual,2019-08-01,June 2022,2022-06-30,"February 1, 2022",Actual,2022-02-01,"December 1, 2020",Actual,2020-12-01,,Interventional,,,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,Phase I Clinical Study of Immunotherapy With Personalized Synthetic Vaccines in Patients With Triple Negative Breast Cancer,Completed,,Phase 1,5.0,Actual,Universidad Nacional de Colombia,,1.0,,,False,,,,False,False,False,,,,,,,,,No,We are not going to share individual participant data (IPD),2023-06-15 10:49:56,2023-06-15 10:49:56,OTHER,,,,,
273133,273134,NCT00559975,,2007-11-16,,,2009-11-04,2007-11-16,2007-11-19,Estimate,,,,,,,2009-11-04,2009-11-05,Estimate,October 2007,,2007-10-31,November 2009,2009-11-30,May 2008,Actual,2008-05-31,,,,,Interventional,,,"Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine","A Phase 1, Randomized, Controlled, Observer-Blinded, Dose Escalation Study of the Safety, Tolerability and Immunogenicity of a Single Dose of Adjuvanted Influenza Vaccine Combined With CpG7909 in Healthy Adults",Completed,,Phase 1,60.0,Anticipated,Novartis,,5.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 10:54:30,2023-06-15 10:54:30,INDUSTRY,,,,,
273167,273168,NCT02963909,,2016-11-10,,,2020-09-03,2016-11-10,2016-11-15,Estimate,,,,,,,2020-09-03,2020-09-07,Actual,"November 1, 2016",Actual,2016-11-01,"August 1, 2017",2017-08-01,"October 30, 2018",Actual,2018-10-30,"October 30, 2018",Actual,2018-10-30,,Interventional,,,"A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.","A Phase 1, First-in-Human, Double-blinded, Randomized, Placebo-controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of an Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Healthy Flavivirus-Naïve and Flavivirus-Primed Subjects",Completed,,Phase 1,75.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-15 10:54:47,2023-06-15 10:54:47,NIH,,,,,
273338,273339,NCT00561184,,2007-11-16,,,2016-11-30,2007-11-16,2007-11-20,Estimate,,,,,,,2016-11-30,2016-12-01,Estimate,October 2007,,2007-10-31,February 2012,2012-02-29,June 2008,Actual,2008-06-30,December 2007,Actual,2007-12-31,,Interventional,,,Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine,"A Phase II, Open-label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Booster Dose of -H5N1 (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccine in Non-elderly Adult and Elderly Subjects",Completed,,Phase 2,47.0,Actual,Novartis,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 10:56:29,2023-06-15 10:56:29,INDUSTRY,,,,,
273451,273452,NCT00187044,,2005-09-12,,,2011-09-28,2005-09-12,2005-09-16,Estimate,,,,,,,2011-09-28,2011-09-29,Estimate,October 1997,,1997-10-31,June 2011,2011-06-30,October 2009,Actual,2009-10-31,October 2009,Actual,2009-10-31,,Interventional,,,Evaluation of the Safety of a Polyvalent Virus in Healthy Adults,Evaluation of the Safety of a Polyvalent Vaccinia Virus-HIV-1 Envelope Recombinant Vaccine (PolyEnv1) in Healthy Adults,Completed,,Phase 1,18.0,Actual,St. Jude Children's Research Hospital,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 10:57:37,2023-06-15 10:57:37,OTHER,,,,,
273520,273521,NCT00580060,,2007-12-20,,,2011-06-09,2007-12-21,2007-12-24,Estimate,,,,,,,2011-06-09,2011-06-10,Estimate,December 2003,,2003-12-31,June 2011,2011-06-30,June 2011,Actual,2011-06-30,June 2011,Actual,2011-06-30,,Interventional,,,"Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity","Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity",Completed,,Early Phase 1,20.0,Actual,Memorial Sloan Kettering Cancer Center,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 10:58:16,2023-06-15 10:58:16,OTHER,,,,,
273581,273582,NCT00582088,,2007-12-19,,,2021-02-10,2007-12-27,2007-12-28,Estimate,,,,,,,2021-02-10,2021-02-11,Actual,March 2008,Actual,2008-03-31,February 2021,2021-02-28,December 2021,Anticipated,2021-12-31,June 2021,Anticipated,2021-06-30,,Interventional,VEE C-84,,Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine (VEE C-84) as a Booster to VEE TC-83,"A Phase 2 Open-Label, Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Dried, C-84, TSI-GSD 205 When Used as a Booster After TC-83 Primary Immunization in Healthy Adults At-Risk for Exposure to Virulent Venezuelan Equine Encephalomyelitis Virus",Unknown status,"Active, not recruiting",Phase 2,500.0,Anticipated,U.S. Army Medical Research and Development Command,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 10:58:57,2023-06-15 10:58:57,FED,,,,,
273701,273702,NCT00408395,,2006-12-05,,,2016-11-30,2006-12-05,2006-12-06,Estimate,,,,,,,2016-11-30,2016-12-01,Estimate,November 2006,,2006-11-30,December 2011,2011-12-31,August 2007,Actual,2007-08-31,August 2007,Actual,2007-08-31,,Interventional,,,Safety and Immunogenicity of 2 Commercially Available Influenza Vaccines in Children,"A Phase II, Observer-Blind, Randomized, Parallel Groups, Multicenter, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of One and Two 0.25 mL Intramuscular Doses of a Commercially Available Influenza Vaccine Versus Two 0.25 mL Intramuscular Doses of a Commercially Available Influenza Vaccine in Healthy Children",Completed,,Phase 2,281.0,Actual,Novartis,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 11:00:19,2023-06-15 11:00:19,INDUSTRY,,,,,
273901,273902,NCT00210288,,2005-09-13,,,2018-08-07,2005-09-13,2005-09-21,Estimate,,,,,,,2018-08-07,2018-08-08,Actual,May 2005,,2005-05-31,March 2010,2010-03-31,April 2007,Actual,2007-04-30,September 2006,Actual,2006-09-30,,Interventional,,,Healthy Adult Volunteer Study for Two Doses of a Shigella Vaccine,"A Comparative Double Blind Placebo-Controlled Study of Immunogenicity and Safety of Two Doses 10^5 and 10^7 CFU of SC599 Oral Vaccine, a Live Attenuated Shigella Dysenteriae 1 Vaccine Strain in Healthy Human Adult Volunteers",Completed,,Phase 2,111.0,Anticipated,Institut Pasteur,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 11:02:37,2023-06-15 11:02:37,INDUSTRY,,,,,
273934,273935,NCT00184067,,2005-09-12,,,2014-05-20,2005-09-12,2005-09-16,Estimate,,,,,,,2014-05-20,2014-05-21,Estimate,May 2004,,2004-05-31,January 2014,2014-01-31,September 2009,Actual,2009-09-30,April 2007,Actual,2007-04-30,,Interventional,,,Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma,"A Randomized Phase II Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Resected Stages IIB/C, III, and IV Melanoma",Terminated,,Phase 2,23.0,Actual,University of Southern California,,2.0,,Primary PI left institution,False,,,,,,,,,,,,,,,,,2023-06-15 11:02:57,2023-06-15 11:02:57,OTHER,,,,,
274106,274107,NCT00187148,,2005-09-12,,,2017-04-24,2005-09-12,2005-09-16,Estimate,,,,,,,2017-04-24,2017-04-26,Actual,February 2005,,2005-02-28,June 2011,2011-06-30,November 2009,Actual,2009-11-30,November 2009,Actual,2009-11-30,,Interventional,,,Evaluate Tolerability of a Recombinant DNA HIV-1 Vaccine in Healthy Adults,Evaluation of the Tolerability and Safety of a Recombinant HIV-1 Multi-Envelope DNA Plasmid Vaccine (EnvDNA) in Healthy Adults,Completed,,Phase 1,6.0,Actual,St. Jude Children's Research Hospital,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 11:04:37,2023-06-15 11:04:37,OTHER,,,,,
274284,274285,NCT00189917,,2005-09-11,,,2019-01-08,2005-09-11,2005-09-19,Estimate,,,,,,,2019-01-08,2019-01-10,Actual,April 2004,Actual,2004-04-30,January 2019,2019-01-31,,,,December 2005,Actual,2005-12-31,,Interventional,,,"Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders","An Open-label, Controlled Phase I Pilot Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in 18-40 Year Old Vaccinia-naïve Subjects With Atopic Disorders",Completed,,Phase 1,60.0,Actual,Bavarian Nordic,,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 11:06:14,2023-06-15 11:06:14,INDUSTRY,,,,,
274286,274287,NCT00189956,,2005-09-11,,,2019-01-08,2005-09-11,2005-09-19,Estimate,,,,,,,2019-01-08,2019-01-10,Actual,April 2003,,2003-04-30,December 2018,2018-12-31,December 2005,Actual,2005-12-31,November 2003,Actual,2003-11-30,,Interventional,,,Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.,"Phase II, Double-blind, Randomised, Dose-finding Study to Evaluate the Immunogenicity of Three Different Doses of MVA-BN Smallpox Vaccine in 18-30 Year Old Smallpox naïve Healthy Subjects",Completed,,Phase 2,165.0,Actual,Bavarian Nordic,,3.0,,,False,,,,False,,,,,,,,,,,No,,2023-06-15 11:06:15,2023-06-15 11:06:15,INDUSTRY,,,,,
274454,274455,NCT04232943,,2020-01-13,2022-01-26,,2022-04-05,2020-01-14,2020-01-18,Actual,2022-04-05,2022-09-06,Actual,,,,2022-04-05,2022-09-06,Actual,"January 22, 2020",Actual,2020-01-22,January 2022,2022-01-31,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,,Interventional,,,Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults,"A Phase 1 Randomized Study to Examine the Safety, Tolerability, and Immunogenicity of Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat Labile Toxin (dmLT) and Impact on Poliovirus Shedding Post-bOPV Challenge in Healthy IPV-Primed Adult Subjects",Completed,,Phase 1,87.0,Actual,PATH,,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-17 06:01:56,2023-06-17 06:01:56,OTHER,,,,,
274468,274469,NCT00124007,,2005-07-22,,,2021-10-28,2005-07-22,2005-07-26,Estimate,,,,,,,2021-10-28,2021-11-01,Actual,November 2005,,2005-11-30,October 2021,2021-10-31,April 2007,Actual,2007-04-30,,,,,Interventional,,,Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults,"A Phase I, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by Recombinant, Multiclade HIV-1 Adenoviral Vector Vaccine or the Multiclade HIV-1 Adenoviral Vector Vaccine Alone in Healthy Adult Volunteers Not Infected With HIV",Completed,,Phase 1,114.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 11:08:05,2023-06-15 11:08:05,NIH,,,,,
274484,274485,NCT00192179,,2005-09-12,,,2012-02-29,2005-09-12,2005-09-19,Estimate,,,,,,,2012-02-29,2012-03-02,Estimate,June 2003,,2003-06-30,February 2012,2012-02-29,July 2003,Actual,2003-07-31,July 2003,Actual,2003-07-31,,Interventional,FluMist,,"A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years.","A Phase II, Prospective, Randomized, Double-Blind, Placebo, Controlled Trial, to Assess the Safety and Tolerability of Influenza Virus Vaccine, Trivalent, Types A & B Live Cold-Adapted Liquid Formulation (CAIV-T) in Healthy Children and Adolescents Ages 6 to Less Than 18 Years.",Completed,,Phase 2,240.0,Actual,MedImmune LLC,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 11:08:17,2023-06-15 11:08:17,INDUSTRY,,,,,
274642,274643,NCT00124865,,2005-07-26,,,2017-09-25,2005-07-26,2005-07-28,Estimate,,,,,,,2017-09-25,2017-09-26,Actual,July 2005,,2005-07-31,September 2017,2017-09-30,November 2006,Actual,2006-11-30,November 2006,Actual,2006-11-30,,Interventional,,,Intranasal Recombinant Flagellin Subunit Campylobacter Vaccine (rFla-MBP) Dose-Ranging Study,Safety and Immunogenicity Evaluation of an Intranasal Recombinant Flagellin Subunit Campylobacter Vaccine (rFla-MBP) in Volunteers,Withdrawn,,Phase 1,0.0,Actual,U.S. Army Medical Research and Development Command,,,,Sponsor,False,,,,,,,,,,,,,,,,,2023-06-15 11:09:52,2023-06-15 11:09:52,FED,,,,,
275623,275624,NCT00945438,,2009-07-22,,,2014-01-10,2009-07-23,2009-07-24,Estimate,,,,,,,2014-01-10,2014-01-14,Estimate,May 2009,,2009-05-31,January 2014,2014-01-31,July 2009,Actual,2009-07-31,June 2009,Actual,2009-06-30,,Interventional,,,"Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route)","Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation (Intradermal Route)",Completed,,Phase 2,131.0,Actual,Sanofi,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 15:53:28,2023-06-16 15:53:28,INDUSTRY,,,,,
275836,275837,NCT00414336,,2006-12-20,,,2017-06-30,2006-12-20,2006-12-21,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"December 15, 2006",,2006-12-15,"August 4, 2009",2009-08-04,"December 15, 2006",Actual,2006-12-15,"December 15, 2006",Actual,2006-12-15,,Interventional,,,Phase I Study of Safety and Immunogenicity of AMA1-C1Alhydrogel + CPG 7909 Vaccine for Malaria,"Randomized, Controlled, Phase 1 Study of the Safety and Immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 Vaccine for Plasmodium Falciparum Malaria in Semi-Immune Malian Adults",Completed,,Phase 1,150.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 11:22:51,2023-06-15 11:22:51,NIH,,,,,
276065,276066,NCT00240903,,2005-10-14,,,2011-08-11,2005-10-14,2005-10-18,Estimate,,,,,,,2011-08-11,2011-08-12,Estimate,October 2005,,2005-10-31,March 2007,2007-03-31,March 2006,,2006-03-31,March 2006,Actual,2006-03-31,,Interventional,,,Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine,Revaccination of Healthy Subjects With Intramuscular Inactivated Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine Representing a Drifted Variant,Completed,,Phase 1,37.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 11:25:38,2023-06-15 11:25:38,NIH,,,,,
276072,276073,NCT00134719,,2005-08-10,2012-06-15,,2018-05-24,2005-08-24,2005-08-25,Estimate,2012-06-15,2012-07-20,Estimate,,,,2018-05-24,2018-07-19,Actual,"April 11, 2005",Actual,2005-04-11,May 2018,2018-05-31,"February 21, 2007",Actual,2007-02-21,"July 24, 2006",Actual,2006-07-24,,Interventional,,,Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines,A Multicentre Primary & Booster Vaccination Study of GSK Biologicals' Hib-MenCY-TT Conjugate Vaccine vs ActHIB® & MenC Conjugate Licensed Vaccine When Given According to the 2-4-6 Month Schedule to Healthy Infants With Booster Dose at 12 to 15 Months,Completed,,Phase 2,1104.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 15:53:51,2023-06-16 15:53:51,INDUSTRY,,,,,
276653,276654,NCT00219401,,2005-09-15,,,2011-07-10,2005-09-16,2005-09-22,Estimate,,,,,,,2011-07-10,2011-07-12,Estimate,May 2005,,2005-05-31,July 2011,2011-07-31,May 2010,Actual,2010-05-31,May 2009,Actual,2009-05-31,,Interventional,,,Neonatal Immunization With Pneumococcal Conjugate Vaccine in Papua New Guinea,Neonatal Immunization With Pneumococcal Conjugate Vaccine in Papua New Guinea,Completed,,Phase 2,318.0,Actual,Papua New Guinea Institute of Medical Research,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 11:30:53,2023-06-15 11:30:53,OTHER_GOV,,,,,
276656,276657,NCT04626856,,2020-11-02,,,2020-12-08,2020-11-06,2020-11-13,Actual,,,,,,,2020-12-08,2020-12-10,Actual,"December 3, 2020",Actual,2020-12-03,December 2020,2020-12-31,August 2021,Anticipated,2021-08-31,June 2021,Anticipated,2021-06-30,,Interventional,,,Safety and Preliminary Immunogenicity Study of Inactivated Vaccine for Prevention of Rotavirus Infection,"Evaluation of the Safety and Preliminary Immunogenicity of Inactivated Rotavirus Vaccine (Vero Cell) in Healthy Population: a Randomized, Double-blind, Placebo Parallel-controlled Phase I Clinical Trial",Unknown status,"Active, not recruiting",Phase 1,32.0,Actual,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,17.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-15 11:30:54,2023-06-15 11:30:54,OTHER,,,,,
276764,276765,NCT00562237,,2007-11-20,,,2008-10-24,2007-11-20,2007-11-21,Estimate,,,,,,,2008-10-24,2008-10-27,Estimate,July 2007,,2007-07-31,October 2008,2008-10-31,September 2008,Anticipated,2008-09-30,November 2007,Actual,2007-11-30,,Interventional,,,Immunogenicity and Safety of Two Adjuvant Formulations of an Egg-Derived Pandemic Vaccine,"Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of Two Adjuvant Formulations of an Egg-Derived Pandemic Surface Antigen Influenza Vaccine in Healthy Adults Aged =18 Years and = 49 Years.",Terminated,,Phase 1,400.0,Anticipated,Solvay Pharmaceuticals,,7.0,,This trial discontinued on 20 JUN 2008 because the interim immunogenicity results do not justify these formulations as pandemic vaccine candidates,False,,,,False,,,,,,,,,,,,,2023-06-15 11:32:02,2023-06-15 11:32:02,INDUSTRY,,,,,
277174,277175,NCT01492582,,2011-12-12,2020-02-06,,2021-10-07,2011-12-13,2011-12-15,Estimate,2020-04-17,2020-04-30,Actual,,,,2021-10-07,2021-10-27,Actual,July 2012,,2012-07-31,October 2021,2021-10-31,"July 20, 2020",Actual,2020-07-20,"February 8, 2019",Actual,2019-02-08,,Interventional,,Participants who consented to the study.,Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors,Quadrivalent Human Papillomavirus (qHPV) Vaccine in Cancer Survivors: Cross Sectional Survey and Phase II Open-Label Vaccine Trial,Completed,,Phase 2,1499.0,Actual,University of Alabama at Birmingham,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 21:48:59,2023-06-18 21:48:59,OTHER,,,,,
277420,277421,NCT00127855,,2005-08-08,2012-06-15,,2018-07-26,2005-08-08,2005-08-09,Estimate,2012-06-15,2012-07-23,Estimate,,,,2018-07-26,2018-08-27,Actual,"March 1, 2003",,2003-03-01,October 2016,2016-10-31,"February 12, 2004",Actual,2004-02-12,"February 1, 2004",Actual,2004-02-01,,Interventional,,,Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine,"A Phase II, Open (Partially Double-blind), Randomised, Controlled, Multicentre, Primary Vaccination Study to Evaluate the Immunogenicity (Including Immune Memory), Reactogenicity and Safety of Three Different Formulations of the GSK Biologicals' Combined Haemophilus Influenzae Type B-meningococcal Serogroups CY Conjugate Vaccine Given Concomitantly With Infanrix® Penta and Prevenar®, Versus ActHIB® and Meningitec® Given Concomitantly With Infanrix® Penta and Versus ActHIB® Given Concomitantly With Infanrix® Penta and Prevenar® in Infants According to a 2-4-6 Month Schedule.",Completed,,Phase 2,409.0,Actual,GlaxoSmithKline,,5.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 15:55:13,2023-06-16 15:55:13,INDUSTRY,,,,,
277919,277920,NCT00253734,,2005-11-11,,,2013-05-30,2005-11-11,2005-11-15,Estimate,,,,,,,2013-05-30,2013-06-03,Estimate,November 2005,,2005-11-30,July 2008,2008-07-31,November 2006,Actual,2006-11-30,October 2006,Actual,2006-10-31,,Interventional,,,Immunogenicity and Safety of Different Doses of Fluzone® Influenza,"Immunogenicity and Safety of a Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route Compared to an Intramuscular Vaccination With Fluzone® in Healthy Adults",Completed,,Phase 2,217.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,7.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 11:42:21,2023-06-15 11:42:21,NIH,,,,,
278294,278295,NCT00254826,,2005-11-15,,,2013-12-03,2005-11-15,2005-11-17,Estimate,,,,,,,2013-12-03,2013-12-04,Estimate,June 2006,,2006-06-30,December 2013,2013-12-31,November 2008,Actual,2008-11-30,November 2008,Actual,2008-11-30,,Interventional,,,Yellow Fever Virus Vaccine and Immune Globulin Study,"Randomized Controlled Double-Blind Trial of the Comparative Viremia, Immunogenicity and Safety of a 17-D Live Attenuated Yellow Fever Vaccine (YF-VAX)Given Alone or in Combination With Human Immune Globulin (Gama STAN S/D)",Completed,,Phase 1,80.0,Actual,Emory University,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 11:45:45,2023-06-15 11:45:45,OTHER,,,,,
278360,278361,NCT00574600,,2007-12-13,,,2021-10-13,2007-12-13,2007-12-17,Estimate,,,,,,,2021-10-13,2021-10-14,Actual,November 2008,,2008-11-30,October 2021,2021-10-31,January 2013,Actual,2013-01-31,October 2010,Actual,2010-10-31,,Interventional,,,"Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults","A Phase 1 Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of SAAVI DNA-C2 Vaccine Boosted by SAAVI MVA-C Vaccine, in HIV Uninfected Healthy Vaccinia Naive Adult Participants in South Africa and the United States",Completed,,Phase 1,48.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 11:46:28,2023-06-15 11:46:28,NIH,,,,,
278436,278437,NCT01570036,,2012-03-25,2019-06-17,,2020-11-09,2012-03-30,2012-04-04,Estimate,2020-11-09,2020-12-02,Actual,,,,2020-11-09,2020-12-02,Actual,"May 21, 2013",Actual,2013-05-21,November 2020,2020-11-30,"September 28, 2018",Actual,2018-09-28,"September 28, 2018",Actual,2018-09-28,,Interventional,,,Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax,Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence,Completed,,Phase 2,275.0,Actual,"Cancer Insight, LLC",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 21:51:10,2023-06-18 21:51:10,INDUSTRY,,,,,
278498,278499,NCT02418962,,2015-04-09,,,2016-03-01,2015-04-13,2015-04-17,Estimate,,,,,,,2016-03-01,2016-03-02,Estimate,March 2015,,2015-03-31,March 2016,2016-03-31,February 2016,Actual,2016-02-29,September 2015,Actual,2015-09-30,,Interventional,,,Safety and Immunogenicity of Direct Venous Inoculation of a Radiation-attenuated PfSPZ Vaccine in Equatoguinean Adults,"Phase 1, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety and Immunogenicity of Direct Venous Inoculation of a Radiation-attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Equatoguinean Adults",Completed,,Phase 1,33.0,Actual,Sanaria Inc.,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 22:35:40,2023-06-17 22:35:40,INDUSTRY,,,,,
278548,278549,NCT00199849,,2005-09-12,2021-09-15,,2022-10-03,2005-09-12,2005-09-20,Estimate,2021-09-15,2021-10-08,Actual,,,,2022-10-03,2022-10-10,Actual,"September 27, 2004",Actual,2004-09-27,October 2022,2022-10-31,September 2007,Actual,2007-09-30,"September 11, 2006",Actual,2006-09-11,,Interventional,,All patients who received at least one dose of NY-ESO-1 Plasmid DNA Vaccine.,NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine,Safety and Immunological Evaluation of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Given by Particle-mediated Epidermal Delivery (PMED) in Patients With Tumor Type Known to Express NY-ESO-1 or LAGE-1 Antigen.,Completed,,Phase 1,18.0,Actual,Ludwig Institute for Cancer Research,,3.0,,,False,,,,False,True,,,,,,,,,,No,,2023-06-15 11:48:22,2023-06-15 11:48:22,OTHER,,,,,
278602,278603,NCT00227474,,2005-09-26,,,2013-01-23,2005-09-26,2005-09-28,Estimate,,,,,,,2013-01-23,2013-01-24,Estimate,,,,January 2013,2013-01-31,,,,,,,,Interventional,,,S0348 Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Breast Cancer in Remission,S0348: A Phase II Study of 5T4-Modified Vaccinia Ankara (MVA) Vaccine (TROVAX) in Patients With Advanced Breast Cancer,Withdrawn,,Phase 2,0.0,Actual,SWOG Cancer Research Network,,,,SWOG has decided to not pursue this trial,False,,,,True,,,,,,,,,,,,,2023-06-15 11:48:50,2023-06-15 11:48:50,NETWORK,,,,,
278661,278662,NCT00466726,,2007-04-25,2017-11-21,,2018-08-27,2007-04-25,2007-04-27,Estimate,2018-08-27,2018-08-28,Actual,,,,2018-08-27,2018-08-28,Actual,March 2007,,2007-03-31,August 2018,2018-08-31,July 2014,Actual,2014-07-31,July 2014,Actual,2014-07-31,,Interventional,CML0206,,Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia,Phase II Multicenter Study of P210-B3A2 Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients in Complete Cytogenetic Response With Persistent Molecular Residual Disease During Imatinib Treatment,Completed,,Phase 2,57.0,Actual,Gruppo Italiano Malattie EMatologiche dell'Adulto,,,,,False,,,,False,,,,,,,,,,,,,2023-06-16 15:57:09,2023-06-16 15:57:09,OTHER,,,,,
278957,278958,NCT05007275,,2021-08-12,,,2022-03-11,2021-08-12,2021-08-16,Actual,,,,,,,2022-03-11,2022-03-28,Actual,"October 10, 2021",Actual,2021-10-10,March 2022,2022-03-31,May 2023,Anticipated,2023-05-31,May 2023,Anticipated,2023-05-31,,Interventional,COVAXAER01,,A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers,A Phase I Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers,Recruiting,,Phase 1,30.0,Anticipated,Imperial College London,,1.0,,,False,,,,True,False,False,,,False,,,Data will become available approximately 6 months from the last patient's last visit and remain available indefinitely.,According to study protocol.,,Yes,"The expectation is that after analysis the data from this study will be widely distributed in the medical and scientific community. Facilitated with presentations at local, national and international meetings, the hope is to publish widely in the medical literature. In addition, there is an excellent media department at Imperial College that will publicise research that has public interest when it is published.

The Investigators will be involved in reviewing drafts of the manuscripts, abstracts, press releases and any other publications arising from the study. Data from the study may also be used as part of a thesis for a PhD or MD.

All data will be anonymised and aggregated or pseudonymised; no identifying participant information will be published.",2023-06-16 15:57:16,2023-06-16 15:57:16,OTHER,,,,,
279019,279020,NCT04073459,,2019-08-27,,,2019-09-03,2019-08-27,2019-08-29,Actual,,,,,,,2019-09-03,2019-09-06,Actual,November 2019,Anticipated,2019-11-30,September 2019,2019-09-30,August 2020,Anticipated,2020-08-31,April 2020,Anticipated,2020-04-30,,Interventional,,,Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants,"A Multi-center, Randomized, Active-controlled, Parallel-group, Open-label and Phase II Study to Evaluate Immunogenicity and Safety of LBVD (Fully Liquid Hexavalent Vaccine; Adsorbed Diphtheria-Tetanus-Pertussis-Hepatitis B- Inactivated Poliomyelitis (Sabin) and Haemophilus Influenzae Type b Conjugate Vaccine) Compared to Co-administration of EupentaTM Inj. and Imovax® Polio (Poliomyelitis Vaccine (Inactivated)) in Separate Injections in Healthy Infants at 6-10-14 Weeks of Age as Primary Series",Unknown status,Not yet recruiting,Phase 2,336.0,Anticipated,LG Chem,,4.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-16 15:57:34,2023-06-16 15:57:34,INDUSTRY,,,,,
279156,279157,NCT00231920,,2005-09-30,,,2011-08-11,2005-09-30,2005-10-04,Estimate,,,,,,,2011-08-11,2011-08-12,Estimate,October 2004,,2004-10-31,November 2006,2006-11-30,October 2006,,2006-10-31,August 2006,Actual,2006-08-31,,Interventional,,,Inactivated Influenza Vaccine in Infants 10-22 Weeks of Age,Prospective Pilot Safety Study Administering Two Doses of Inactivated Influenza Vaccine to Infants 10-22 Weeks of Age,Completed,,Phase 1,23.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 11:54:17,2023-06-15 11:54:17,NIH,,,,,
279435,279436,NCT01519817,,2012-01-12,2017-02-27,,2018-01-02,2012-01-26,2012-01-27,Estimate,2017-05-30,2017-07-31,Actual,,,,2018-01-02,2018-01-29,Actual,"January 5, 2012",Actual,2012-01-05,January 2018,2018-01-31,"September 1, 2016",Actual,2016-09-01,"March 3, 2016",Actual,2016-03-03,,Interventional,,,Cancer Vaccine Targeting Brachyury Protein in Tumors,"An Open Label Phase I Study to Evaluate the Safety and Tolerability of GI-6301 Vaccine Consisting of Whole, Heat-Killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express Brachyury Protein in Adults With Solid Tumors",Completed,,Phase 1,34.0,Actual,National Institutes of Health Clinical Center (CC),,1.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-18 23:59:39,2023-06-18 23:59:39,NIH,,,,,
279628,279629,NCT00424944,,2007-01-19,,,2008-04-01,2007-01-19,2007-01-22,Estimate,,,,,,,2008-04-01,2008-04-03,Estimate,June 2007,,2007-06-30,April 2008,2008-04-30,August 2008,Anticipated,2008-08-31,July 2008,Anticipated,2008-07-31,,Interventional,,,Safety of Recombinant Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine,"A Single Centre, Randomised Controlled Trial to Evaluate the Safety and Immunogenicity of Recombinant Lactococcus Lactis Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine Versus Rabies Vaccine in Healthy Gabonese Adult Volunteers",Unknown status,Recruiting,Phase 1,40.0,Anticipated,African Malaria Network Trust,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 11:58:31,2023-06-15 11:58:31,NETWORK,,,,,
279696,279697,NCT02576561,,2015-10-09,,,2017-10-24,2015-10-13,2015-10-15,Estimate,,,,,,,2017-10-24,2017-10-25,Actual,November 2015,,2015-11-30,October 2017,2017-10-31,September 2018,Anticipated,2018-09-30,May 2018,Anticipated,2018-05-31,,Interventional,,,Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL,"Phase 2a Double-Blind, Randomized, Parallel Group, Dose-Ranging Study to Assess the Safety and Efficacy of Three Doses of TVGV-1 Vaccine Compared to Its Adjuvant, GPI-0100, in Subjects With Histologically Confirmed HPV Induced Cervical HSIL",Unknown status,"Active, not recruiting",Phase 2,10.0,Actual,THEVAX Genetics Vaccine,,9.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 15:58:57,2023-06-16 15:58:57,INDUSTRY,,,,,
279916,279917,NCT03541499,,2018-05-17,2021-11-24,2021-04-12,2022-01-06,2018-05-17,2018-05-30,Actual,2022-01-06,2022-02-03,Actual,2022-01-06,2022-02-03,Actual,2022-01-06,2022-02-03,Actual,"October 23, 2018",Actual,2018-10-23,"August 18, 2021",2021-08-18,"May 15, 2020",Actual,2020-05-15,"May 15, 2020",Actual,2020-05-15,,Interventional,,"The study population includes 50 healthy adults, 18-49 years of age, inclusive, who meet all eligibility criteria.",Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults,"A Phase 2A Partially-Blind Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of Live Attenuated, Intranasal B. Pertussis Vaccine (BPZE1) in Healthy Adults",Completed,,Phase 2,50.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-17 22:36:23,2023-06-17 22:36:23,NIH,,,,,
280199,280200,NCT02216188,,2014-08-12,,,2015-08-14,2014-08-12,2014-08-13,Estimate,,,,,,,2015-08-14,2015-08-17,Estimate,August 2014,,2014-08-31,August 2015,2015-08-31,,,,August 2015,Actual,2015-08-31,,Interventional,AFF008A,,Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity,"Phase IB Follow-up, Randomized, Controlled, Parallel Group, Patient-blinded, Single-center Study to Assess One Boost With AFFITOPE® PD01A With Regard to Safety/Tolerability, Immunological + Clinical Activity in Patients Who Have Received the Vaccine Within the Study AFF008",Completed,,Phase 1,28.0,Actual,Affiris AG,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 12:04:37,2023-06-15 12:04:37,INDUSTRY,,,,,
280300,280301,NCT02886065,,2016-08-28,,,2023-01-29,2016-08-31,2016-09-01,Estimate,,,,,,,2023-01-29,2023-01-31,Actual,"March 7, 2017",Actual,2017-03-07,January 2023,2023-01-31,June 2023,Anticipated,2023-06-30,June 2023,Anticipated,2023-06-30,,Interventional,,,"A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM","A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma","Active, not recruiting",,Phase 1,19.0,Actual,Massachusetts General Hospital,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 22:36:34,2023-06-17 22:36:34,OTHER,,,,,
280541,280542,NCT05782179,,2023-02-23,,,2023-06-08,2023-03-21,2023-03-23,Actual,,,,,,,2023-06-08,2023-06-09,Actual,"March 1, 2023",Actual,2023-03-01,February 2023,2023-02-28,"May 16, 2024",Anticipated,2024-05-16,"December 16, 2023",Anticipated,2023-12-16,,Interventional,,,"Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants","A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of Group B Streptococcus Vaccine (GBS NN/NN2 With Alhydrogel®) in Elderly Participants Aged 55 to 75","Active, not recruiting",,Phase 1,90.0,Actual,Minervax ApS,,8.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-15 12:08:20,2023-06-15 12:08:20,OTHER,,,,,
280690,280691,NCT05455658,,2022-06-30,,,2023-06-07,2022-07-07,2022-07-13,Actual,,,,,,,2023-06-07,2023-06-09,Actual,"November 17, 2022",Actual,2022-11-17,January 2023,2023-01-31,"April 30, 2024",Anticipated,2024-04-30,"April 30, 2024",Anticipated,2024-04-30,,Interventional,,,STEMVAC in Patients With Early Stage Triple Negative Breast Cancer,"A Phase II Trial of The Immunogenicity of a DNA Plasmid Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes From Five Antigens Associated With Breast Cancer Stem Cells (MDM2, YB1, SOX2, CDC25B, CD105) in Participants With Early Stage Triple Negative Breast Cancer",Recruiting,,Phase 2,33.0,Anticipated,University of Washington,,1.0,,,,,,,True,True,False,,,,,,,,,No,,2023-06-15 12:09:42,2023-06-15 12:09:42,OTHER,,,,,
280916,280917,NCT04884308,,2021-05-07,,,2023-06-08,2021-05-07,2021-05-12,Actual,,,,,,,2023-06-08,2023-06-09,Actual,"April 28, 2021",Actual,2021-04-28,June 2023,2023-06-30,"December 30, 2023",Anticipated,2023-12-30,"December 30, 2023",Anticipated,2023-12-30,,Interventional,,,Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections,"Effects of BCG Vaccine on the Immune System of Individuals With Cystic Fibrosis, Non-Cystic Fibrosis Bronchiectasis, and Healthy Volunteers",Recruiting,,Phase 2,180.0,Anticipated,Johns Hopkins University,,3.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-15 12:11:49,2023-06-15 12:11:49,OTHER,,,,,
280917,280918,NCT02409524,,2015-04-01,,,2020-01-17,2015-04-06,2015-04-07,Estimate,,,,,,,2020-01-17,2020-01-22,Actual,July 2016,Actual,2016-07-31,November 2017,2017-11-30,March 2019,Actual,2019-03-31,June 2017,Actual,2017-06-30,,Interventional,,,An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects,Phase IIA Clinical Study Of An Individualized Anti-Cancer Vaccine (CRCL-ALLOVAX) in Subjects With Advanced Hepatocellular Carcinoma,Completed,,Phase 2,15.0,Actual,"Immunovative Therapies, Ltd.",,1.0,,,False,,,,False,,,,,,,,,,,No,,2023-06-17 22:37:26,2023-06-17 22:37:26,INDUSTRY,,,,,
281008,281009,NCT04596878,,2020-10-14,,,2023-06-08,2020-10-20,2020-10-22,Actual,,,,,,,2023-06-08,2023-06-09,Actual,"November 19, 2020",Actual,2020-11-19,February 2022,2022-02-28,"May 16, 2023",Actual,2023-05-16,"May 18, 2022",Actual,2022-05-18,,Interventional,,,Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV,"A Multi-centre Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of a Group B Streptococcus Vaccine (GBS-NN/NN2) in Women Who Are Pregnant and Living With HIV and Women Who Are Pregnant and do Not Have HIV",Completed,,Phase 2,205.0,Actual,Minervax ApS,,4.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-15 12:12:52,2023-06-15 12:12:52,OTHER,,,,,
281499,281500,NCT01915212,,2013-07-31,,,2023-06-08,2013-07-31,2013-08-02,Estimate,,,,,,,2023-06-08,2023-06-09,Actual,"September 26, 2013",Actual,2013-09-26,"August 1, 2022",2022-08-01,"March 6, 2017",Actual,2017-03-06,"March 6, 2017",Actual,2017-03-06,,Interventional,,,Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection,"Phase I Study of the Safety of a Replication-Defective Herpes Simplex Virus-2 Vaccine, HSV529, in Adults Aged 18 to 40 Years With or Without HSV Infection",Completed,,Phase 1,69.0,Actual,National Institutes of Health Clinical Center (CC),,2.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-15 12:18:35,2023-06-15 12:18:35,NIH,,,,,
281552,281553,NCT00948480,,2009-07-28,,,2016-07-13,2009-07-28,2009-07-29,Estimate,,,,,,,2016-07-13,2016-07-15,Estimate,October 2000,,2000-10-31,July 2016,2016-07-31,September 2007,Actual,2007-09-30,September 2007,Actual,2007-09-30,,Interventional,DCVaccineMel,,Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells,Vaccine Biotherapy Of Cancer: Autologous Tumor Cells and Dendritic Cells as Active Specific Immunotherapy in Patients With Metastatic Melanoma,Completed,,Phase 2,56.0,Actual,Hoag Memorial Hospital Presbyterian,,,,,False,,,,False,,,,,,,,,,,,,2023-06-16 16:03:10,2023-06-16 16:03:10,OTHER,,,,,
281790,281791,NCT00888446,,2009-04-23,,,2012-12-13,2009-04-24,2009-04-27,Estimate,,,,,,,2012-12-13,2012-12-17,Estimate,October 2005,,2005-10-31,December 2012,2012-12-31,December 2007,Actual,2007-12-31,December 2007,Actual,2007-12-31,,Interventional,TGC14F,,"Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid","Phase II, Placebo-controlled, Double-blind, Dose-escalation/Dose-optimization Trial to Evaluate Safety and Immunogenicity of tgAAC09, an HIV Vaccine Containing Clade C Gag-PR-<U+0394>RT DNA in an Adeno-associated Virus (AAV) Capsid",Completed,,Phase 2,91.0,Actual,International AIDS Vaccine Initiative,,8.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 16:03:55,2023-06-16 16:03:55,NETWORK,,,,,
281856,281857,NCT02411786,,2015-03-27,,,2021-02-02,2015-04-03,2015-04-08,Estimate,,,,,,,2021-02-02,2021-02-04,Actual,"August 24, 2015",Actual,2015-08-24,February 2021,2021-02-28,"November 28, 2020",Actual,2020-11-28,"May 1, 2019",Actual,2019-05-01,,Interventional,,,A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF,"A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD), With or Without Granulocyte Macrophage Colony-Stimulating Factor Adjuvant, in Patients With Metastatic Prostate Cancer",Completed,,Phase 1,40.0,Actual,"University of Wisconsin, Madison",,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 22:39:38,2023-06-17 22:39:38,OTHER,,,,,
281860,281861,NCT03547245,,2018-04-27,,,2022-05-11,2018-06-05,2018-06-06,Actual,,,,,,,2022-05-11,2022-05-12,Actual,"June 15, 2018",Actual,2018-06-15,May 2022,2022-05-31,"August 13, 2021",Actual,2021-08-13,"January 17, 2020",Actual,2020-01-17,,Interventional,,,"A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted","A Phase 1, Randomized, Double-blind, Placebo-controlled Dosage Escalation Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted in HIV-uninfected, Healthy Adult Volunteers",Completed,,Phase 1,46.0,Actual,International AIDS Vaccine Initiative,,2.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-14 08:00:43,2023-06-14 08:00:43,NETWORK,,,,,
281905,281906,NCT04398706,,2020-05-18,,,2023-04-03,2020-05-19,2020-05-21,Actual,,,,,,,2023-04-03,2023-04-05,Actual,"May 22, 2020",Actual,2020-05-22,April 2023,2023-04-30,"August 2, 2023",Anticipated,2023-08-02,"August 2, 2023",Anticipated,2023-08-02,,Interventional,,,Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants,Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants,"Active, not recruiting",,Phase 2,852.0,Actual,Sanofi,,8.0,,,False,,,,True,True,False,,,False,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-18 21:57:19,2023-06-18 21:57:19,INDUSTRY,,,,,
282002,282003,NCT04466085,,2020-07-08,,,2020-12-01,2020-07-08,2020-07-10,Actual,,,,,,,2020-12-01,2020-12-03,Actual,"July 12, 2020",Actual,2020-07-12,December 2020,2020-12-31,"December 15, 2021",Anticipated,2021-12-15,"October 22, 2020",Actual,2020-10-22,,Interventional,,,Clinical Study of Recombinant Novel Coronavirus Vaccine,"A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years",Unknown status,"Active, not recruiting",Phase 2,900.0,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,6.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-17 22:39:47,2023-06-17 22:39:47,INDUSTRY,,,,,
282330,282331,NCT03521973,,2018-04-26,,,2021-10-06,2018-05-09,2018-05-11,Actual,,,,,,,2021-10-06,2021-10-07,Actual,"June 14, 2018",Actual,2018-06-14,October 2021,2021-10-31,"August 3, 2021",Actual,2021-08-03,"May 18, 2021",Actual,2021-05-18,,Interventional,,,"Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in Gabonese Children","Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in 1-12 Year-old Gabonese Children Naturally Exposed to Malaria Parasites",Completed,,Phase 2,200.0,Actual,Sanaria Inc.,,6.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-17 22:40:08,2023-06-17 22:40:08,INDUSTRY,,,,,
282647,282648,NCT00240968,,2005-10-14,,,2013-08-15,2005-10-14,2005-10-18,Estimate,,,,,,,2013-08-15,2013-08-16,Estimate,October 2005,,2005-10-31,July 2008,2008-07-31,July 2006,Actual,2006-07-31,July 2006,Actual,2006-07-31,,Interventional,,,H5 Booster After a Two Dose Schedule,Evaluation of a Booster Dose of A/Vietnam/1203/04 (H5N1) Vaccine Administered at 6 Months to Healthy Adult Subjects After a Two Dose Schedule at 0 and 1 Months,Completed,,Phase 2,337.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 12:24:10,2023-06-15 12:24:10,NIH,,,,,
282782,282783,NCT04444284,,2020-06-12,,,2021-06-26,2020-06-20,2020-06-23,Actual,,,,,,,2021-06-26,2021-06-29,Actual,"June 9, 2020",Actual,2020-06-09,June 2021,2021-06-30,"May 7, 2021",Actual,2021-05-07,"May 7, 2021",Actual,2021-05-07,,Interventional,,,Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children,"A Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Phase 1b Study to Evaluate the Safety and Immunogenicity of an Intranasal Live Attenuated Respiratory Syncytial Virus (RSV) Vaccine in Seropositive Young Children",Completed,,Phase 1,34.0,Actual,"Meissa Vaccines, Inc.",,5.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-18 22:00:47,2023-06-18 22:00:47,INDUSTRY,,,,,
283028,283029,NCT01636102,,2012-07-05,2013-07-11,,2015-11-02,2012-07-05,2012-07-10,Estimate,2013-12-23,2014-01-29,Estimate,,,,2015-11-02,2015-11-30,Estimate,July 2012,,2012-07-31,November 2015,2015-11-30,July 2012,Actual,2012-07-31,July 2012,Actual,2012-07-31,,Interventional,,,Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above,"A Phase II Open Label, Uncontrolled, Multicenter Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Influenza Vaccine (Agrippal®), Formulation 2012/2013, When Administered to Adult and Elderly Subjects",Completed,,Phase 2,126.0,Actual,Novartis,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 22:01:59,2023-06-18 22:01:59,INDUSTRY,,,,,
283477,283478,NCT00246467,,2005-10-27,,,2008-09-12,2005-10-27,2005-10-30,Estimate,,,,,,,2008-09-12,2008-09-15,Estimate,October 2005,,2005-10-31,September 2008,2008-09-30,April 2007,Actual,2007-04-30,April 2007,Actual,2007-04-30,,Interventional,,,One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens),"A Phase 1b, Multi-Centre, Parallel Group, Single Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of a Recombinant Plague Vaccine (rF1 and rV Antigens) in Healthy Subjects",Completed,,Phase 1,123.0,Actual,PharmAthene UK Limited,,,,,False,,,,True,,,,,,,,,,,,,2023-06-15 12:28:08,2023-06-15 12:28:08,INDUSTRY,,,,,
283641,283642,NCT00284973,,2006-01-30,,,2015-04-13,2006-01-30,2006-02-01,Estimate,,,,,,,2015-04-13,2015-04-14,Estimate,January 2006,,2006-01-31,April 2007,2007-04-30,,,,,,,,Interventional,,,A Study of Safety and Immunogenicity of a Malaria Vaccine Candidate,Ph-1 Double-Blind Randomized Control Study-Evaluate Safety & Immunogenicity of Wanxing Bio-Pharmaceuticals AMA-1/MSP-1 Recombinant Malaria Vaccine (PfCP-2.9) Adj. w/ Montanide ISA 720 Compared to Montanide ISA 720 Alone in Adult Volunteers,Completed,,Phase 1,70.0,,PATH,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 12:28:46,2023-06-15 12:28:46,OTHER,,,,,
283863,283864,NCT01960686,,2013-10-08,,2015-10-15,2016-04-27,2013-10-09,2013-10-11,Estimate,,,,2015-10-15,2015-11-06,Estimate,2016-04-27,2016-05-26,Estimate,October 2013,,2013-10-31,April 2016,2016-04-30,April 2014,Actual,2014-04-30,April 2014,Actual,2014-04-30,,Interventional,,,RSV F Dose-Ranging Study in Women,"A Phase II Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Multiple Formulations of an RSV F Particle Vaccine With Aluminum, in Healthy Women of Child-Bearing Age",Completed,,Phase 2,720.0,Actual,Novavax,,8.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 16:12:40,2023-06-15 16:12:40,INDUSTRY,,,,,
284002,284003,NCT02293317,,2014-11-09,,,2016-02-21,2014-11-14,2014-11-18,Estimate,,,,,,,2016-02-21,2016-02-23,Estimate,November 2014,,2014-11-30,November 2014,2014-11-30,June 2015,Actual,2015-06-30,March 2015,Actual,2015-03-31,,Interventional,BVX006,,"Phase II Study to Assess Safety & Immunogenicity of Multimeric-001 Influenza Vaccine, Followed by TIV","A Phase II, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety and Immunogenicity of Multimeric-001 Influenza Vaccine, Followed by a Seasonal Trivalent Influenza Vaccine (TIV)",Completed,,Phase 2,37.0,Actual,BiondVax Pharmaceuticals ltd.,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 22:41:53,2023-06-17 22:41:53,INDUSTRY,,,,,
284230,284231,NCT02500680,,2015-07-10,,,2019-09-04,2015-07-15,2015-07-16,Estimate,,,,,,,2019-09-04,2019-09-06,Actual,July 2015,Actual,2015-07-31,September 2019,2019-09-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,,Interventional,MER4101,,"The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)","A Phase IA/IB Trial to Evaluate the Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101) With Hemagglutinin Dose Escalation Compared to Non-Adjuvanted Comparator Inactivated Influenza Vaccine (IIV) Standard Dose (SD) in Healthy Adults and High Dose (HD) IIV in Ambulatory Elderly Subjects",Unknown status,"Active, not recruiting",Phase 1,102.0,Actual,Nova Immunotherapeutics Limited,,11.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 22:08:32,2023-06-18 22:08:32,INDUSTRY,,,,,
284362,284363,NCT00504231,,2007-07-12,2012-01-11,,2012-06-08,2007-07-18,2007-07-19,Estimate,2012-06-08,2012-07-13,Estimate,,,,2012-06-08,2012-07-13,Estimate,September 2007,,2007-09-30,July 2011,2011-07-31,January 2008,Actual,2008-01-31,January 2008,Actual,2008-01-31,,Interventional,,,Intradermal Influenza Vaccine Study in Elders,Intradermal vs. Intramuscular Delivery of Influenza Vaccine in Immunocompetent Elders,Completed,,Phase 2,257.0,Actual,PATH,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 16:11:32,2023-06-16 16:11:32,OTHER,,,,,
284429,284430,NCT00730457,,2008-08-04,,,2014-09-22,2008-08-04,2008-08-08,Estimate,,,,,,,2014-09-22,2014-09-23,Estimate,July 2008,,2008-07-31,September 2014,2014-09-30,June 2009,Actual,2009-06-30,March 2009,Actual,2009-03-31,,Interventional,,,"Phase 1 Safety and Immunogenicity Study in Healthy Adults of VAX125, a Recombinant HA-flagellin Influenza Vaccine","A Two Part Study to Investigate the Safety and Immunogenicity of the VAX125 Influenza Vaccine in Healthy Adults Age 18-49 Years Part I: Phase I, Open-Label, Escalating Dose-Ranging Study Part II: Phase II, Double-Blind Placebo-Controlled Study",Completed,,Phase 1,56.0,Actual,VaxInnate Corporation,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 16:11:42,2023-06-16 16:11:42,INDUSTRY,,,,,
284498,284499,NCT01669096,,2012-08-16,2017-09-13,2013-04-11,2019-03-20,2012-08-16,2012-08-20,Estimate,2019-03-20,2019-03-22,Actual,2013-04-11,2013-04-18,Estimate,2019-03-20,2019-03-22,Actual,"August 21, 2012",Actual,2012-08-21,March 2019,2019-03-31,"May 24, 2013",Actual,2013-05-24,"December 6, 2012",Actual,2012-12-06,,Interventional,,,Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342,Evaluation of the Kinetics of mRNA Expression After Two Doses of GSK Biologicals' Candidate Tuberculosis (Tuberculosis) Vaccine GSK 692342 in Healthy Adults,Completed,,Phase 2,20.0,Actual,GlaxoSmithKline,,1.0,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-18 22:09:52,2023-06-18 22:09:52,INDUSTRY,,,,,
284612,284613,NCT00924092,,2009-06-17,,,2019-12-11,2009-06-17,2009-06-18,Estimate,,,,,,,2019-12-11,2019-12-12,Actual,"March 13, 2009",,2009-03-13,"May 20, 2014",2014-05-20,"August 2, 2012",Actual,2012-08-02,,,,,Interventional,,,"An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...","Open Label Phase I Study to Evaluate the Safety and Tolerability of Vaccine (GI-6207) Consisting of Whole, Heat-Killed Recombinant Saccharomyces Cerevisiae Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-Expressing Carcinoma",Completed,,Phase 1,25.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-16 16:12:04,2023-06-16 16:12:04,NIH,,,,,
284857,284858,NCT00731471,,2008-08-06,,,2011-03-25,2008-08-08,2008-08-11,Estimate,,,,,,,2011-03-25,2011-03-28,Estimate,August 2008,,2008-08-31,March 2011,2011-03-31,January 2011,Actual,2011-01-31,January 2011,Actual,2011-01-31,,Interventional,,,"A Phase I Study of a New Tuberculosis (TB) Vaccine, MVA85A, in Healthy Volunteers With HIV","A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Infected With HIV",Completed,,Phase 1,24.0,Anticipated,University of Oxford,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 16:12:33,2023-06-16 16:12:33,OTHER,,,,,
284914,284915,NCT03341754,,2017-10-12,,,2020-05-05,2017-11-08,2017-11-14,Actual,,,,,,,2020-05-05,2020-05-06,Actual,"September 15, 2018",Actual,2018-09-15,May 2020,2020-05-31,"March 23, 2020",Actual,2020-03-23,"October 28, 2019",Actual,2019-10-28,,Interventional,,,"Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults","A Phase 1 Trial With Controlled Human Malaria Infection to Evaluate the Safety, Immunogenicity, and Protective Efficacy of Two-Antigen and Three-Antigen Plasmodium Falciparum DNA Prime-Adenovirus Boost Malaria Vaccine Regimens in Healthy Malaria Naïve Adults",Completed,,Phase 1,52.0,Actual,U.S. Army Medical Research and Development Command,,3.0,,,False,,,,False,True,False,,,,,,,,,Undecided,,2023-06-18 22:11:25,2023-06-18 22:11:25,FED,,,,,
285483,285484,NCT00270465,,2005-12-24,,,2017-06-30,2005-12-23,2005-12-26,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"December 21, 2005",,2005-12-21,"June 25, 2009",2009-06-25,"June 25, 2009",Actual,2009-06-25,"June 25, 2009",Actual,2009-06-25,,Interventional,,,Safety and Immune Response to a Prime-Boost Vaccination Schedule in HIV-infected Patients,"VRC101: A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-Boost HIV-1 Vaccination Schedule of a 6-Plasmid Multiclade HIV-1 DNA Vaccine, VRC-HIVDNA016-00-VP, Followed by a Recombinant Multiclade Adenoviral Vector HIV Vaccine",Completed,,Phase 1,17.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 12:39:36,2023-06-15 12:39:36,NIH,,,,,
285549,285550,NCT00270699,,2005-12-27,,,2012-12-31,2005-12-27,2005-12-28,Estimate,,,,,,,2012-12-31,2013-01-03,Estimate,June 2006,,2006-06-30,December 2012,2012-12-31,December 2009,Actual,2009-12-31,December 2009,Actual,2009-12-31,,Interventional,,,"Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults","Phase 1 Study of the Safety and Immunogenicity of rDEN4delta30-200,201, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 4",Completed,,Phase 1,56.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 12:40:14,2023-06-15 12:40:14,NIH,,,,,
285729,285730,NCT02296983,,2014-11-11,,,2016-04-13,2014-11-18,2014-11-21,Estimate,,,,,,,2016-04-13,2016-04-14,Estimate,December 2014,,2014-12-31,April 2016,2016-04-30,September 2016,Anticipated,2016-09-30,February 2016,Actual,2016-02-29,,Interventional,,,"A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.","A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSV<U+0394>G-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Volunteers in Kilifi, Kenya.",Unknown status,"Active, not recruiting",Phase 1,40.0,Anticipated,University of Oxford,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 22:43:32,2023-06-17 22:43:32,OTHER,,,,,
285951,285952,NCT00258947,,2005-11-24,,,2012-01-30,2005-11-24,2005-11-28,Estimate,,,,,,,2012-01-30,2012-02-01,Estimate,September 2005,,2005-09-30,January 2012,2012-01-31,January 2007,Actual,2007-01-31,December 2006,Actual,2006-12-31,,Interventional,,,Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults,Take Evaluation and Safety of Smallpox Vaccine (LISTER Strain) in Naïve Healthy Adults.,Completed,,Phase 2,230.0,Actual,Sanofi,,,,,False,,,,False,,,,,,,,,,,,,2023-06-15 12:43:34,2023-06-15 12:43:34,INDUSTRY,,,,,
286031,286032,NCT00929396,,2009-06-26,,,2013-01-18,2009-06-26,2009-06-29,Estimate,,,,,,,2013-01-18,2013-01-21,Estimate,September 2007,,2007-09-30,January 2013,2013-01-31,June 2009,Actual,2009-06-30,June 2009,Actual,2009-06-30,,Interventional,THYB-02,,A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis (TB) Subunit Vaccine in Purified Protein Derivative (PPD) Positive Volunteers,A Safety and Immunogenicity Phase 1 Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31)Administered in PPD Positive Volunteers at 0 and 2 Months,Completed,,Phase 1,20.0,Actual,Statens Serum Institut,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 16:16:33,2023-06-16 16:16:33,OTHER,,,,,
286042,286043,NCT00272493,,2006-01-04,,,2021-10-15,2006-01-04,2006-01-06,Estimate,,,,,,,2021-10-15,2021-10-25,Actual,,,,May 2012,2012-05-31,September 2008,Actual,2008-09-30,November 2007,Actual,2007-11-30,,Interventional,,,Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals,Improving Immune Response to Hepatitis B Vaccine in HIV-positive Subjects Using Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as a Vaccine Adjuvant: A Phase II Open-Label Pilot Study,Completed,,Phase 2,48.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 12:44:28,2023-06-15 12:44:28,NIH,,,,,
286048,286049,NCT00260039,,2005-11-28,,,2015-06-05,2005-11-28,2005-12-01,Estimate,,,,,,,2015-06-05,2015-06-08,Estimate,December 2005,,2005-12-31,June 2015,2015-06-30,August 2007,Actual,2007-08-31,August 2007,Actual,2007-08-31,,Interventional,,,Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001),"A Randomized, International, Double-Blinded (With In-House Blinding), GARDASIL-Controlled, Dose-Ranging Study of Octavalent Human Papillomavirus (HPV) L1 Virus-like Particle (VLP) Vaccine Administered to 16- to 23- Year-Old Women",Completed,,Phase 2,680.0,Actual,Merck Sharp & Dohme LLC,,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 12:44:31,2023-06-15 12:44:31,INDUSTRY,,,,,
286233,286234,NCT00415649,,2006-12-21,,,2021-10-28,2006-12-21,2006-12-25,Estimate,,,,,,,2021-10-28,2021-11-01,Actual,,,,October 2021,2021-10-31,,,,,,,,Interventional,,,Safety of and Immune Response to an HIV DNA Plasmid Vaccine Followed by HIV Adenoviral Vector Vaccine in Healthy African Adults,"A Phase II, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by Recombinant, Multiclade HIV-1 Adenoviral Vector Vaccine in Healthy Adult Volunteers at Risk for HIV Infection",Withdrawn,,Phase 2,0.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 12:46:11,2023-06-15 12:46:11,NIH,,,,,
286337,286338,NCT00300417,,2006-03-07,,,2017-06-30,2006-03-07,2006-03-08,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"March 3, 2006",,2006-03-03,"December 28, 2007",2007-12-28,"December 28, 2007",,2007-12-28,,,,,Interventional,,,Phase I Study of West Nile Virus Vaccine,"A Phase I Study of the Safety and Immunogenicity of a West Nile Virus Recombinant DNA Plasmid Vaccine, VRC-WNVDNA020-00-VP, in Healthy Adult Subjects",Completed,,Phase 1,30.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 12:47:10,2023-06-15 12:47:10,NIH,,,,,
286439,286440,NCT00295581,,2006-02-23,,,2017-06-30,2006-02-22,2006-02-23,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"March 7, 2005",,2005-03-07,"June 17, 2008",2008-06-17,"June 17, 2008",,2008-06-17,,,,,Interventional,,,PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria,Phase 1 Study of the Safety and Immunogenicity of PpPfs25/ISA51 and ScPvs25/ISA51: Transmission Blocking Vaccines for Plasmodium Falciparum and Plasmodium Vivax Malaria,Completed,,Phase 1,0.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 12:48:13,2023-06-15 12:48:13,NIH,,,,,
286624,286625,NCT00269672,,2005-12-21,,,2010-08-04,2005-12-21,2005-12-23,Estimate,,,,,,,2010-08-04,2010-08-05,Estimate,September 2005,,2005-09-30,August 2010,2010-08-31,February 2007,Actual,2007-02-28,February 2007,Actual,2007-02-28,,Interventional,,,Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects,"A Randomized, Open Label, Controlled Phase II Study to Evaluate Safety, Tolerability and Immunogenicity After Two Different 13-Valent Pneumococcal Conjugate Vaccine Formulations in Elderly Subjects Aged 65 Years and Older Who Are Naive to Previous 23vPS Immunization",Completed,,Phase 2,915.0,Actual,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 12:49:58,2023-06-15 12:49:58,INDUSTRY,,,,,
286660,286661,NCT00270218,,2005-12-21,,,2021-10-13,2005-12-21,2005-12-26,Estimate,,,,,,,2021-10-13,2021-10-14,Actual,February 2006,,2006-02-28,October 2021,2021-10-31,August 2007,Actual,2007-08-31,,,,,Interventional,,,"Safety of and Immune Response to Two Different HIV Vaccines, Each Followed by a Adenoviral Vaccine Boost, in HIV Uninfected Adults","A Phase I Clinical Trial to Evaluate Immune Response Kinetics and Safety of Two Different Primes, Adenoviral Vector Vaccine (VRC-HIVADV014-00-VP) and DNA Vaccine (VRC-HIVDNA009-00-VP), Each Followed by Adenoviral Vector Boost in Healthy, HIV-1 Uninfected Adults",Completed,,Phase 1,66.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 12:50:23,2023-06-15 12:50:23,NIH,,,,,
286664,286665,NCT00297687,,2006-02-24,,,2007-12-03,2006-02-27,2006-02-28,Estimate,,,,,,,2007-12-03,2007-12-05,Estimate,March 2006,,2006-03-31,December 2007,2007-12-31,March 2007,Actual,2007-03-31,,,,,Interventional,,,"Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults","A Randomized, Placebo-Controlled, Double Blind, Phase 1 Trial of the Safety, Immunogenicity, and Tolerability of Ascending Doses of Meningococcal Group B rLP2086 Vaccine in Healthy Adults",Completed,,Phase 1,108.0,,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 12:50:26,2023-06-15 12:50:26,INDUSTRY,,,,,
286753,286754,NCT00307008,,2006-03-24,,,2013-04-11,2006-03-24,2006-03-27,Estimate,,,,,,,2013-04-11,2013-04-15,Estimate,October 2003,,2003-10-31,September 2011,2011-09-30,February 2005,Actual,2005-02-28,February 2005,Actual,2005-02-28,,Interventional,,,Study to Evaluate the Response Rate to the Licensed Pneumovax 23 in Elderly Population.,"An Open, Phase II Study to Evaluate the Response Rate to the Licensed Single-Dose Polysaccharide Pneumococcal Vaccine Pneumovax 23 (MSD Aventis Pasteur) in Elderly Population.",Completed,,Phase 2,1198.0,Actual,GlaxoSmithKline,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 12:51:16,2023-06-15 12:51:16,INDUSTRY,,,,,
286791,286792,NCT00307710,,2006-03-24,,,2012-07-27,2006-03-24,2006-03-28,Estimate,,,,,,,2012-07-27,2012-07-31,Estimate,August 2004,,2004-08-31,July 2012,2012-07-31,February 2007,Actual,2007-02-28,February 2007,Actual,2007-02-28,,Interventional,,,Influenza Vaccination in Patients Receiving Antineoplastic Therapy for Non-Hodgkin's Lymphoma,"Evaluation of the Reactogenicity and Immunogenicity of Different Doses of Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma: A Phase II, Double-Blind Pilot Study - Version 4",Completed,,Phase 2,28.0,Actual,M.D. Anderson Cancer Center,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 12:51:29,2023-06-15 12:51:29,OTHER,,,,,
286883,286884,NCT00308412,,2006-03-28,,,2010-07-15,2006-03-28,2006-03-29,Estimate,,,,,,,2010-07-15,2010-07-16,Estimate,June 2006,,2006-06-30,July 2010,2010-07-31,April 2010,Actual,2010-04-30,April 2010,Actual,2010-04-30,,Interventional,,,Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants,"Phase 1 Study to Determine the Safety, Infectivity, and Tolerability of Two Doses of Live Attenuated Recombinant Cold Passaged (cp) 45 Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3 102A, Delivered as Nose Drops to Infants 6 to 12 Months of Age, and to HPIV3 Seronegative Infants and Children 6 to 36 Months of Age",Completed,,Phase 1,45.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 12:52:28,2023-06-15 12:52:28,NIH,,,,,
286959,286960,NCT00419133,,2007-01-04,,,2009-12-04,2007-01-04,2007-01-08,Estimate,,,,,,,2009-12-04,2009-12-07,Estimate,June 2007,,2007-06-30,December 2009,2009-12-31,August 2007,Actual,2007-08-31,August 2007,Actual,2007-08-31,,Interventional,,,Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine,"Immune Responses Following One Versus Two Doses of Killed Oral Cholera Vaccine in Eastern Kolkata, West Bengal, India",Completed,,Phase 2,160.0,Actual,International Vaccine Institute,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 12:53:14,2023-06-15 12:53:14,OTHER,,,,,
287077,287078,NCT00310206,,2006-03-30,,,2013-05-30,2006-03-30,2006-04-03,Estimate,,,,,,,2013-05-30,2013-06-03,Estimate,July 2005,,2005-07-31,October 2009,2009-10-31,October 2006,Actual,2006-10-31,October 2006,Actual,2006-10-31,,Interventional,,,H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults,"A Randomized, Open-Label, Phase I Clinical Trial Comparing the Safety, Reactogenicity, and Immunogenicity of Immunization With Inactivated Influenza A/H5N1 Vaccine Administered by the Intradermal or the Intramuscular Route Among Healthy Adults",Completed,,Phase 1,100.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 12:54:27,2023-06-15 12:54:27,NIH,,,,,
287215,287216,NCT00282581,,2006-01-26,,,2014-01-17,2006-01-26,2006-01-27,Estimate,,,,,,,2014-01-17,2014-01-22,Estimate,October 2006,,2006-10-31,January 2014,2014-01-31,July 2007,Actual,2007-07-31,July 2007,Actual,2007-07-31,,Interventional,,,Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive,"A Phase 1, Double-Blind, Placebo-Controlled Study to Assess the Safety and Immunogenicity of MVA3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Vaccinia-Naive Human Immunodeficiency Virus (HIV)-Seropositive Subjects",Terminated,,Phase 1,2.0,Actual,Sanofi,,1.0,,Senior managemnt decision,False,,,,True,,,,,,,,,,,,,2023-06-15 12:55:50,2023-06-15 12:55:50,INDUSTRY,,,,,
287469,287470,NCT00320346,,2006-05-01,,,2016-07-17,2006-05-01,2006-05-03,Estimate,,,,,,,2016-07-17,2016-07-19,Estimate,July 2006,,2006-07-31,November 2008,2008-11-30,September 2006,Actual,2006-09-30,,,,,Interventional,,,Phase II Study of Pandemic Influenza Vaccine,"A Double-Blind, Randomised, Multi-Centre Study to Evaluate the Safety, Tolerability, Immunogenicity and Lot to Lot Consistency of Two Formulations of CSL Limited's Inactivated Prototype Pandemic Influenza Vaccine in a Healthy Adult Population (=18 Years to =64 Years of Age).",Completed,,Phase 2,400.0,,Seqirus,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 12:58:08,2023-06-15 12:58:08,INDUSTRY,,,,,
287506,287507,NCT00320658,,2006-05-01,,,2008-01-18,2006-05-01,2006-05-03,Estimate,,,,,,,2008-01-18,2008-01-21,Estimate,March 2006,,2006-03-31,January 2008,2008-01-31,July 2007,Actual,2007-07-31,July 2007,Actual,2007-07-31,,Interventional,,,Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 Adjuvant,"Phase 1 Study of the Safety and Immunogenicity of MSP1 42-C1/Alhydrogel With and Without CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria",Completed,,Phase 1,60.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 12:58:24,2023-06-15 12:58:24,NIH,,,,,
287633,287634,NCT00289796,,2006-02-09,,,2017-02-06,2006-02-09,2006-02-10,Estimate,,,,,,,2017-02-06,2017-02-08,Estimate,July 2004,,2004-07-31,February 2017,2017-02-28,December 2006,Actual,2006-12-31,April 2006,Actual,2006-04-30,,Interventional,,,"Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine","Assess the Feasibility of an Investigational Vaccination Regimen, Compared to a 3-dose Primary Vaccination With GSK Biologicals' Infanrix Hexa (DTPa-HBV-IPV/Hib Vaccine) Following Hepatitis B Vaccination at Birth. Primary Vaccination is Followed in the 2nd Year of Life by a Booster Dose of Infanrix-hexa",Completed,,Phase 2,121.0,Actual,GlaxoSmithKline,,1.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 12:59:39,2023-06-15 12:59:39,INDUSTRY,,,,,
288156,288157,NCT05315830,,2022-03-30,,,2022-04-06,2022-03-30,2022-04-07,Actual,,,,,,,2022-04-06,2022-04-14,Actual,"March 7, 2022",Actual,2022-03-07,March 2022,2022-03-31,"March 1, 2024",Anticipated,2024-03-01,"March 1, 2023",Anticipated,2023-03-01,,Interventional,,,A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric,"A Single-Arm, Open-Label, Exploratory Study to Evaluate the Safety of HER2 Tumor Vaccine Injection Alone/in Combination With Standard of Care Chemotherapy in Patients With her2/Neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction",Recruiting,,Phase 1,10.0,Anticipated,First Affiliated Hospital Bengbu Medical College,,2.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-18 22:15:29,2023-06-18 22:15:29,OTHER,,,,,
288224,288225,NCT00327522,,2006-05-17,,,2008-10-09,2006-05-17,2006-05-18,Estimate,,,,,,,2008-10-09,2008-10-13,Estimate,June 2006,,2006-06-30,October 2008,2008-10-31,,,,,,,,Interventional,,,Safety and Immune Response Study of an Investigational Pneumococcal Vaccine.,"An Open, Phase I/II Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' 11PCV Vaccine Given as a 2-Dose Vaccination in Adults Aged 18-40 Years Old.",Completed,,Phase 2,10.0,,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 13:05:25,2023-06-15 13:05:25,INDUSTRY,,,,,
288429,288430,NCT00303836,,2006-03-15,,,2013-06-05,2006-03-15,2006-03-17,Estimate,,,,,,,2013-06-05,2013-06-06,Estimate,November 2005,,2005-11-30,June 2013,2013-06-30,,,,January 2007,Actual,2007-01-31,,Interventional,,,Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma,A Phase II Study Using a Peptide Vaccine With or Without Aldesleukin Following a Lymphodepleting Chemotherapy and Reinfusion of Autologous Lymphocytes Depleted of T Regulatory Lymphocytes in Metastatic Melanoma,Terminated,,Phase 2,58.0,Actual,National Cancer Institute (NCI),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 13:07:07,2023-06-15 13:07:07,NIH,,,,,
288897,288898,NCT00334776,,2006-06-07,,,2014-05-19,2006-06-07,2006-06-08,Estimate,,,,,,,2014-05-19,2014-05-21,Estimate,October 2003,,2003-10-31,May 2014,2014-05-31,June 2005,Actual,2005-06-30,June 2005,Actual,2005-06-30,,Interventional,,,Vaccine Therapy in Treating Patients With Metastatic Melanoma,A Phase II Trial of an Intradermally Administered MART-1gp100/Tyrosinase Peptide-Pulsed Dendritic Cell Vaccine Matured With a Cytokine Cocktail for Patients With Metastatic Melanoma,Completed,,Phase 2,6.0,Actual,University of Southern California,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 13:09:35,2023-06-15 13:09:35,OTHER,,,,,
288952,288953,NCT00453050,,2007-03-27,,,2015-05-05,2007-03-27,2007-03-28,Estimate,,,,,,,2015-05-05,2015-05-06,Estimate,March 2006,,2006-03-31,November 2008,2008-11-30,,,,March 2009,Actual,2009-03-31,,Interventional,,,Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin,Laser and TLR-Agonist Immunotherapy: A Novel Autologous Melanoma Vaccine Study,Completed,,Phase 1,11.0,Actual,National Cancer Institute (NCI),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 13:09:50,2023-06-15 13:09:50,NIH,,,,,
289240,289241,NCT00340431,,2006-06-19,,,2017-06-30,2006-06-19,2006-06-21,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"June 9, 2004",,2004-06-09,"February 6, 2008",2008-02-06,"February 6, 2008",,2008-02-06,,,,,Interventional,,,Experimental Vaccine for Plasmodium Falciparum Malaria,"Phase 1 Study of the Safety and Immunogenicity of MSP1(42)-FVO/Alhydrogel and MSP1(42)-3D7/Alhydrogel, Asexual Blood-Stage Vaccines for Plasmodium Falciparum Malaria",Completed,,Phase 1,0.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 13:11:16,2023-06-15 13:11:16,NIH,,,,,
289284,289285,NCT00943358,,2009-07-20,,,2012-08-07,2009-07-21,2009-07-22,Estimate,,,,,,,2012-08-07,2012-08-08,Estimate,July 2009,,2009-07-31,August 2012,2012-08-31,December 2009,Actual,2009-12-31,September 2009,Actual,2009-09-30,,Interventional,,,Safety and Immunogenicity of A/H1N1v Vaccines in Healthy Adults,Safety and Immunogenicity of Cell-culture Non-adjuvanted and MF59-adjuvanted Influenza H1N1 Vaccines in Healthy Adults,Completed,,Phase 1,175.0,Actual,"University Hospitals, Leicester",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 16:25:49,2023-06-16 16:25:49,OTHER,,,,,
289540,289541,NCT00954798,,2009-08-03,,,2014-01-10,2009-08-06,2009-08-07,Estimate,,,,,,,2014-01-10,2014-01-14,Estimate,August 2009,,2009-08-31,January 2014,2014-01-31,March 2011,Actual,2011-03-31,December 2010,Actual,2010-12-31,,Interventional,,,A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly,"Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Adult and Elderly Subjects",Completed,,Phase 2,450.0,Actual,Sanofi,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 16:27:31,2023-06-16 16:27:31,INDUSTRY,,,,,
289544,289545,NCT00309647,,2006-03-31,,,2017-05-05,2006-03-31,2006-04-03,Estimate,,,,,,,2017-05-05,2017-05-08,Actual,"March 29, 2006",Actual,2006-03-29,May 2017,2017-05-31,"November 16, 2006",Actual,2006-11-16,"November 1, 2006",Actual,2006-11-01,,Interventional,,,Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age,A Partially-blind Multi-centric Study in Adults Aged Between 18-60 Years Designed to Evaluate the Reactogenicity and Immunogenicity of 1 and 2 Doses of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) Administered at Different Doses and Adjuvanted or Not,Completed,,Phase 1,400.0,Actual,GlaxoSmithKline,,8.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 13:13:40,2023-06-15 13:13:40,INDUSTRY,,,,,
289549,289550,NCT00549900,,2007-10-18,2009-11-12,,2018-05-24,2007-10-25,2007-10-26,Estimate,2009-11-12,2009-12-17,Estimate,,,,2018-05-24,2018-07-20,Actual,"December 2, 2007",,2007-12-02,October 2016,2016-10-31,"July 12, 2008",Actual,2008-07-12,"July 12, 2008",Actual,2008-07-12,,Interventional,,,A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females,"Safety and Immunogenicity Study of the HPV Vaccine (GSK-580299) in Healthy, Chinese, Female Subjects",Completed,,Phase 1,30.0,Actual,GlaxoSmithKline,,1.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 16:27:37,2023-06-16 16:27:37,INDUSTRY,,,,,
289592,289593,NCT00310271,,2006-03-31,,,2008-11-20,2006-03-31,2006-04-03,Estimate,,,,,,,2008-11-20,2008-11-21,Estimate,April 2006,,2006-04-30,November 2008,2008-11-30,December 2006,,2006-12-31,,,,,Interventional,,,A Safety Study to Assess a DNA Vaccine Administered by Particle Mediated Delivery to the Skin in Healthy Subjects,"A Phase I Study Assessing Safety and Tolerability of a DNA Vaccine With a DNA Encoded Immunostimulator , Administered by Particle Mediated Epidermal Delivery Using the PowderMed ND10 Delivery System in HSV-2 Seronegative Healthy Volunteers",Completed,,Phase 1,42.0,,PowderMed,,,,,,,,,,,,,,,,,,,,,,2023-06-15 13:14:00,2023-06-15 13:14:00,INDUSTRY,,,,,
289699,289700,NCT00311480,,2006-04-04,,,2007-03-12,2006-04-04,2006-04-06,Estimate,,,,,,,2007-03-12,2007-03-13,Estimate,March 2006,,2006-03-31,March 2007,2007-03-31,,,,,,,,Interventional,,,"Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects","A Phase II, Randomized, Controlled, Observer-Blind, Multi-Center Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines Containing 7.5 mg or 15 mg of H5N1 Influenza Antigen, in Non-Elderly Adult and Elderly Subjects",Completed,,Phase 2,520.0,,Novartis,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 13:14:32,2023-06-15 13:14:32,INDUSTRY,,,,,
289754,289755,NCT00343005,,2006-06-19,,,2017-06-30,2006-06-19,2006-06-21,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"April 23, 2004",,2004-04-23,"January 22, 2008",2008-01-22,"January 22, 2008",,2008-01-22,,,,,Interventional,,,Experimental Vaccine for Malaria in Adults in Mali,"Double-Blind, Randomized, Controlled, Phase 1 Study of the Safety and Immunogenicity of AMA1-C1/Alhydrogel Vaccine for Plasmodium Falciparum Malaria, in Semi-Immune Adults in Doneguebougou, Mali",Completed,,Phase 1,54.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 13:14:59,2023-06-15 13:14:59,NIH,,,,,
289773,289774,NCT00956046,,2009-08-03,,,2014-01-10,2009-08-10,2009-08-11,Estimate,,,,,,,2014-01-10,2014-01-14,Estimate,September 2009,,2009-09-30,January 2014,2014-01-31,June 2011,Actual,2011-06-30,January 2011,Actual,2011-01-31,,Interventional,,,A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months,"Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Subjects Aged 6 to 35 Months",Completed,,Phase 2,401.0,Actual,Sanofi,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 16:28:26,2023-06-16 16:28:26,INDUSTRY,,,,,
289804,289805,NCT00956202,,2009-08-03,,,2014-01-10,2009-08-10,2009-08-11,Estimate,,,,,,,2014-01-10,2014-01-14,Estimate,August 2009,,2009-08-31,January 2014,2014-01-31,November 2010,Actual,2010-11-30,September 2010,Actual,2010-09-30,,Interventional,,,A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years,"Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-Origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Subjects Aged 3 to 17 Years",Completed,,Phase 2,303.0,Actual,Sanofi,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 16:28:34,2023-06-16 16:28:34,INDUSTRY,,,,,
289936,289937,NCT00695669,,2008-06-10,2013-12-19,2009-05-20,2018-07-02,2008-06-11,2008-06-12,Estimate,2013-12-19,2014-02-07,Estimate,2009-05-21,2009-09-30,Estimate,2018-07-02,2018-07-31,Actual,"June 5, 2008",,2008-06-05,October 2016,2016-10-31,"January 8, 2009",Actual,2009-01-08,"August 13, 2008",Actual,2008-08-13,,Interventional,,,A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64,A Trial to Evaluate the Immunogenicity of Accelerated Primary Vaccination With Monovalent A/Indonesia/5/05 (H5N1) Vaccine Antigen in Association With AS03 Adjuvant in Adults Aged 18-64,Completed,,Phase 2,312.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,False,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 16:29:37,2023-06-16 16:29:37,INDUSTRY,,,,,
289946,289947,NCT02564237,,2015-09-29,,,2017-01-17,2015-09-29,2015-09-30,Estimate,,,,,,,2017-01-17,2017-01-19,Estimate,August 2015,,2015-08-31,January 2017,2017-01-31,December 2017,Anticipated,2017-12-31,March 2017,Anticipated,2017-03-31,,Interventional,,,A Controlled Study to Evaluate the Safety and Immunogenicity of StreptAnova in Healthy Adults,"A Phase I, Randomized, Observer-blind, Comparator-controlled, Study of the Safety and Immunogenicity of StreptAnova Vaccine in Healthy Adults Age = 18 - 50 Years",Unknown status,"Active, not recruiting",Phase 1,39.0,Actual,Dalhousie University,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 16:29:45,2023-06-16 16:29:45,OTHER,,,,,
289947,289948,NCT00434512,,2007-02-12,2019-02-08,2009-06-08,2019-09-04,2007-02-12,2007-02-13,Estimate,2019-09-04,2019-10-01,Actual,2009-09-28,2009-09-30,Estimate,2019-09-04,2019-10-01,Actual,"February 20, 2007",Actual,2007-02-20,September 2019,2019-09-30,"June 13, 2008",Actual,2008-06-13,"June 13, 2008",Actual,2008-06-13,,Interventional,,,Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers,"A Dose-ranging Study to Compare the Safety and Immunogenicity of a Candidate Human Deficiency Virus (HIV) Vaccine 732461, Adjuvanted or Not, Administered According to a 0, 1 Month Schedule to Healthy Adult HIV Seronegative Volunteers.",Completed,,Phase 2,180.0,Actual,GlaxoSmithKline,,6.0,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below).,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,Yes,IPD is available via the Clinical Study Data Request site (click on the link provided below).,2023-06-16 16:29:47,2023-06-16 16:29:47,INDUSTRY,,,,,
290069,290070,NCT00948272,,2009-07-28,,,2014-05-27,2009-07-28,2009-07-29,Estimate,,,,,,,2014-05-27,2014-05-28,Estimate,July 2009,,2009-07-31,May 2014,2014-05-31,August 2011,Actual,2011-08-31,February 2011,Actual,2011-02-28,,Interventional,,,Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults,Immunogenicity of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine in Pre-exposure Use in Healthy Adults,Completed,,Phase 2,384.0,Actual,Sanofi,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 16:31:16,2023-06-16 16:31:16,INDUSTRY,,,,,
290156,290157,NCT01084291,,2010-03-08,,,2012-12-31,2010-03-08,2010-03-10,Estimate,,,,,,,2012-12-31,2013-01-03,Estimate,April 2010,,2010-04-30,December 2012,2012-12-31,June 2010,Actual,2010-06-30,May 2010,Actual,2010-05-31,,Interventional,,,Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine,A Phase I Evaluation of the Safety and Immunogenicity of the rDEN1<U+2206>30 Dengue Serotype 1 Vaccine Given at a Single Dose of 101 PFU in Healthy Flavivirus-naïve Adult Subjects,Completed,,Phase 1,18.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 16:31:40,2023-06-16 16:31:40,NIH,,,,,
290203,290204,NCT00316628,,2006-04-19,,,2006-09-13,2006-04-19,2006-04-21,Estimate,,,,,,,2006-09-13,2006-09-14,Estimate,June 2005,,2005-06-30,September 2006,2006-09-30,,,,,,,,Interventional,,,Safety and Immunogenicity of an Adjuvanted Influenza Vaccine in Subjects Aged 65 Years and Over.,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, (Adjuvanted With MF59C.1) Influenza Vaccine, Formulation 2005-2006, When Administered to Elderly Subjects.",Completed,,Phase 2,50.0,,Novartis,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 13:17:08,2023-06-15 13:17:08,INDUSTRY,,,,,
290416,290417,NCT00318383,,2006-04-24,,,2017-01-11,2006-04-24,2006-04-26,Estimate,,,,,,,2017-01-11,2017-01-12,Estimate,May 2006,,2006-05-31,November 2008,2008-11-30,December 2007,Actual,2007-12-31,September 2007,Actual,2007-09-30,,Interventional,,,Efficacy of NicVAX in Smokers Who Want to Quit Smoking,"A Phase 2, Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Assess Efficacy of 3'-Aminomethylnicotine-P.Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) in Smokers Who Want to Quit Smoking",Completed,,Phase 2,313.0,Actual,National Institute on Drug Abuse (NIDA),,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 13:18:00,2023-06-15 13:18:00,NIH,,,,,
290471,290472,NCT00689351,,2008-05-29,2010-12-10,,2011-06-24,2008-06-02,2008-06-03,Estimate,2010-12-10,2011-01-11,Estimate,,,,2011-06-24,2011-06-28,Estimate,June 2008,,2008-06-30,June 2011,2011-06-30,December 2009,Actual,2009-12-31,December 2009,Actual,2009-12-31,,Interventional,,,Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered To Infants In Korea,"Phase 2, Randomized, Active-Controlled, Double-Blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine In Healthy Infants Given With Routine Pediatric Vaccinations In Korea",Completed,,Phase 2,180.0,Actual,Wyeth is now a wholly owned subsidiary of Pfizer,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 16:33:48,2023-06-16 16:33:48,INDUSTRY,,,,,
290699,290700,NCT00322361,,2006-05-02,,,2017-03-15,2006-05-04,2006-05-05,Estimate,,,,,,,2017-03-15,2017-03-16,Actual,May 2006,,2006-05-31,March 2017,2017-03-31,July 2007,Actual,2007-07-31,July 2007,Actual,2007-07-31,,Interventional,,,Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056),"A Study in Healthy Neonates of Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured Using a Modified Process",Completed,,Phase 2,566.0,Actual,Merck Sharp & Dohme LLC,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 13:19:48,2023-06-15 13:19:48,INDUSTRY,,,,,
290733,290734,NCT00322946,,2006-05-04,,,2009-08-05,2006-05-04,2006-05-08,Estimate,,,,,,,2009-08-05,2009-08-07,Estimate,January 2007,,2007-01-31,November 2008,2008-11-30,,,,August 2009,Actual,2009-08-31,,Interventional,,,Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy Adults,"Phase 1 Study of the Safety and Immunogenicity of rDEN4delta30-4995, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 4",Completed,,Phase 1,84.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 13:20:05,2023-06-15 13:20:05,NIH,,,,,
290894,290895,NCT00962624,,2009-08-19,,,2018-09-17,2009-08-19,2009-08-20,Estimate,,,,,,,2018-09-17,2018-09-19,Actual,July 2010,,2010-07-31,September 2018,2018-09-30,March 2012,Actual,2012-03-31,March 2011,Actual,2011-03-31,,Interventional,MenOccy,,Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults,"A Phase 2, Open-label Study of the Safety, Tolerability and Immunogenicity of a Meningococcal B Vaccine When Administered at a 0, 2, 6 Months and of a Single Dose of Meningococcal ACWY Conjugate Vaccine in Healthy Adults Aged 18-65 Years",Completed,,Phase 2,38.0,Actual,Public Health England,,,,,False,,,,False,,,,,,,,,,,,,2023-06-16 16:36:37,2023-06-16 16:36:37,OTHER_GOV,,,,,
290904,290905,NCT00502593,,2007-07-16,2012-12-20,2012-03-09,2018-09-25,2007-07-16,2007-07-17,Estimate,2014-05-01,2014-06-03,Estimate,2012-03-09,2012-03-14,Estimate,2018-09-25,2018-10-25,Actual,"July 23, 2007",,2007-07-23,June 2017,2017-06-30,"December 4, 2009",Actual,2009-12-04,"December 4, 2009",Actual,2009-12-04,,Interventional,,,Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children,"A Phase II, Randomized, Open, Controlled Study to Evaluate the Safety and Immunogenicity of Different Formulations of a Pandemic Influenza Vaccine Candidate (Split Virus Formulation Adjuvanted With AS03) Given Following a Two-administration Schedule (21 Days Apart) in Children Between 3 and 9 Years of Age.",Completed,,Phase 2,138.0,Actual,GlaxoSmithKline,,12.0,,,False,,,,False,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 16:36:51,2023-06-16 16:36:51,INDUSTRY,,,,,
290946,290947,NCT00546078,,2007-10-17,2009-11-12,,2018-05-24,2007-10-17,2007-10-18,Estimate,2009-11-12,2009-12-15,Estimate,,,,2018-05-24,2018-06-26,Actual,"January 14, 2008",,2008-01-14,October 2016,2016-10-31,"December 1, 2009",Actual,2009-12-01,"December 22, 2008",Actual,2008-12-22,,Interventional,,,Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America,"Safety and Immunogenicity Study of an Additional Dose of HPV Vaccine (580299) in Young, Adult Women in North America.",Completed,,Phase 2,116.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 16:37:17,2023-06-16 16:37:17,INDUSTRY,,,,,
291069,291070,NCT00427167,,2007-01-25,,,2017-06-30,2007-01-25,2007-01-26,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"January 23, 2007",,2007-01-23,"August 3, 2009",2009-08-03,"November 5, 2008",Actual,2008-11-05,"November 5, 2008",Actual,2008-11-05,,Interventional,,,Phase I Study of AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909 Malaria Vaccine,"Phase I Study of the Safety and Immunogenicity of AMA1-C1/Alhydrogel + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria",Completed,,Phase 1,300.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 13:22:18,2023-06-15 13:22:18,NIH,,,,,
291162,291163,NCT05389319,,2022-05-24,,,2022-07-13,2022-05-24,2022-05-25,Actual,,,,,,,2022-07-13,2022-07-14,Actual,"June 24, 2022",Actual,2022-06-24,July 2022,2022-07-31,"February 28, 2023",Anticipated,2023-02-28,"February 28, 2023",Anticipated,2023-02-28,,Interventional,,,A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults,"A Phase Ia, Dose-finding Study to Assess the Safety and Immunogenicity of an Orf Virus-based COVID-19 Vaccine Booster (Prime-2-CoV_Beta) in Healthy Adults",Recruiting,,Phase 1,60.0,Anticipated,University Hospital Tuebingen,,5.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-15 13:22:53,2023-06-15 13:22:53,OTHER,,,,,
291214,291215,NCT00427830,,2007-01-25,,,2007-01-26,2007-01-26,2007-01-29,Estimate,,,,,,,2007-01-26,2007-01-29,Estimate,May 2003,,2003-05-31,December 2006,2006-12-31,January 2005,,2005-01-31,,,,,Interventional,,,"A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG","A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG",Completed,,Phase 1,16.0,,University of Oxford,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 13:23:08,2023-06-15 13:23:08,OTHER,,,,,
291284,291285,NCT00966342,,2009-08-24,,,2009-10-21,2009-08-24,2009-08-26,Estimate,,,,,,,2009-10-21,2009-10-23,Estimate,August 2009,,2009-08-31,October 2009,2009-10-31,November 2009,Anticipated,2009-11-30,October 2009,Anticipated,2009-10-31,,Interventional,,,Rapid Evaluation of Seasonal Influenza Vaccine,Post-marketing Surveillance of Annual Influenza Vaccines: Extended Vaccine Safety and Immunogenicity Evaluation,Withdrawn,,Phase 1,300.0,Anticipated,University of British Columbia,,1.0,,New studies are being offered,False,,,,False,,,,,,,,,,,,,2023-06-16 16:39:30,2023-06-16 16:39:30,OTHER,,,,,
291330,291331,NCT00428337,,2007-01-29,,,2021-10-13,2007-01-29,2007-01-30,Estimate,,,,,,,2021-10-13,2021-10-14,Actual,April 2007,,2007-04-30,October 2021,2021-10-31,August 2008,Actual,2008-08-31,,,,,Interventional,,,"Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults","A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of DNA Vaccine EP-1233 and Recombinant MVA-HIV Polytope Vaccine MVA-mBN32, Separately and in a Combined Prime-boost Regimen, When Given to Healthy, Vaccinia-naive, HIV-1-uninfected Adults",Completed,,Phase 1,36.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 13:23:34,2023-06-15 13:23:34,NIH,,,,,
291397,291398,NCT00980850,,2009-09-18,,,2013-05-07,2009-09-18,2009-09-21,Estimate,,,,,,,2013-05-07,2013-05-09,Estimate,September 2009,,2009-09-30,May 2013,2013-05-31,December 2009,Actual,2009-12-31,December 2009,Actual,2009-12-31,,Interventional,,,Swine Flu (Novel Influenza A H1N1) Vaccine Study,"Open Label, Randomized, Parallel-Group, Multi-Centre Study to Evaluate the Safety, Tolerability and Immunogenicity of Baxter H1N1 Vaccine and GlaxoSmithKline H1N1 Vaccine in Children 6 Months to 12 Years of Age",Completed,,Phase 2,1000.0,Anticipated,University of Oxford,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 16:40:30,2023-06-16 16:40:30,OTHER,,,,,
291590,291591,NCT00327665,,2006-05-17,,,2017-05-05,2006-05-17,2006-05-18,Estimate,,,,,,,2017-05-05,2017-05-08,Actual,"May 1, 2006",Actual,2006-05-01,May 2017,2017-05-31,"January 8, 2007",Actual,2007-01-08,"January 1, 2007",Actual,2007-01-01,,Interventional,,,Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly Population,"A Phase I/II, Randomized, Observer Blinded Study to Evaluate and Compare the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline Biologicals' Investigational Pneumococcal Vaccine Formulations Versus a Licensed Non-GlaxoSmithKline Biologicals' Vaccine and GlaxoSmithKline Biologicals' Aluminum-based 10-valent Pneumococcal Conjugate Vaccine, in Healthy Elderly Subjects",Completed,,Phase 1,335.0,Actual,GlaxoSmithKline,,5.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 13:24:44,2023-06-15 13:24:44,INDUSTRY,,,,,
291736,291737,NCT05714748,,2023-01-27,,,2023-01-27,2023-01-27,2023-02-06,Actual,,,,,,,2023-01-27,2023-02-06,Actual,"November 18, 2022",Actual,2022-11-18,January 2023,2023-01-31,January 2025,Anticipated,2025-01-31,January 2024,Anticipated,2024-01-31,,Interventional,,,Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors,A Phase I Study of mRNA Vaccine for Patients With EBV-positive Advanced Malignant Tumors,Recruiting,,Phase 1,9.0,Anticipated,West China Hospital,,1.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-18 22:19:48,2023-06-18 22:19:48,OTHER,,,,,
291748,291749,NCT00989274,,2009-10-02,,,2012-03-28,2009-10-02,2009-10-05,Estimate,,,,,,,2012-03-28,2012-04-02,Estimate,June 2010,,2010-06-30,March 2012,2012-03-31,July 2010,Anticipated,2010-07-31,June 2010,Anticipated,2010-06-30,,Interventional,,,Clinical Trial to Evaluate the Immunogenicity and Safety of the Vaccine Against Influenza A/H1N1,Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of the Vaccine Against Pandemic Influenza A/H1N1 Produced by Sanofi,Withdrawn,,Phase 2,0.0,Actual,"Instituto Nacional de Salud Publica, Mexico",,3.0,,"Late approval by the Secretariat of Health, and expiration of vaccine",False,,,,True,,,,,,,,,,,,,2023-06-16 16:43:37,2023-06-16 16:43:37,OTHER,,,,,
291795,291796,NCT00540228,,2007-10-04,2013-03-14,2009-05-08,2019-06-13,2007-10-04,2007-10-05,Estimate,2013-03-14,2013-04-30,Estimate,2009-09-25,2009-09-28,Estimate,2019-06-13,2019-06-14,Actual,"October 5, 2007",Actual,2007-10-05,June 2019,2019-06-30,"May 8, 2008",Actual,2008-05-08,"May 8, 2008",Actual,2008-05-08,,Interventional,,,Study to Evaluate an Influenza Vaccine Candidate,"Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Influenza Vaccine GSK1247446A With Various Formulations in Subjects Aged 18-64 Years",Completed,,Phase 2,1006.0,Actual,GlaxoSmithKline,,5.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 16:44:16,2023-06-16 16:44:16,INDUSTRY,,,,,
291870,291871,NCT00329927,,2006-05-23,,,2006-09-13,2006-05-23,2006-05-25,Estimate,,,,,,,2006-09-13,2006-09-14,Estimate,June 2006,,2006-06-30,September 2006,2006-09-30,,,,,,,,Interventional,,,Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Elderly Subjects,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Commercially Available Surface Antigen, Inactivated, (Adjuvanted With MF59C.1) Influenza Vaccine, Formulation 2006-2007, When Administered to Elderly Subjects.",Completed,,Phase 2,60.0,,Novartis,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 13:26:02,2023-06-15 13:26:02,INDUSTRY,,,,,
291933,291934,NCT00329966,,2006-05-23,,,2006-09-13,2006-05-23,2006-05-25,Estimate,,,,,,,2006-09-13,2006-09-14,Estimate,June 2006,,2006-06-30,September 2006,2006-09-30,,,,,,,,Interventional,,,Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Commercially Available Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2006-2007, When Administered to Non-Elderly Adult and Elderly Subjects",Completed,,Phase 2,100.0,,Novartis,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 13:26:04,2023-06-15 13:26:04,INDUSTRY,,,,,
291959,291960,NCT00751595,,2008-09-11,,,2016-03-03,2008-09-11,2008-09-12,Estimate,,,,,,,2016-03-03,2016-03-04,Estimate,September 2008,,2008-09-30,March 2016,2016-03-31,December 2012,Actual,2012-12-31,June 2012,Actual,2012-06-30,,Interventional,ISS T-002,,Immunogenicity and Safety Trial of the HIV-1 Tat Vaccine,"A Phase II Randomized, Open Label, Immunogenicity and Safety Trial of the Vaccine Based on the Recombinant Biologically Active HIV-1 Tat Protein in Anti-Tat Negative HIV-1 Infected HAART-treated Adult Subjects.",Completed,,Phase 2,168.0,Actual,Istituto Superiore di Sanità,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 16:46:24,2023-06-16 16:46:24,OTHER,,,,,
292298,292299,NCT00435396,,2007-02-14,,,2017-05-24,2007-02-14,2007-02-15,Estimate,,,,,,,2017-05-24,2017-05-30,Actual,"February 22, 2007",Actual,2007-02-22,May 2017,2017-05-31,"August 27, 2008",Actual,2008-08-27,"August 27, 2008",Actual,2008-08-27,,Interventional,,,Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects,"A Phase I, Open-label, Vaccination Study to Evaluate the Safety and Immunogenicity of the GSK Biologicals Recombinant CMV gB Sub-unit Vaccine GSK1492903A in CMV-seronegative Healthy Male Adult Subjects",Completed,,Phase 1,40.0,Actual,GlaxoSmithKline,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 13:27:26,2023-06-15 13:27:26,INDUSTRY,,,,,
292521,292522,NCT00335855,,2006-06-08,,,2019-01-18,2006-06-08,2006-06-12,Estimate,,,,,,,2019-01-18,2019-01-23,Actual,,,,April 2009,2009-04-30,October 2006,,2006-10-31,,,,,Interventional,,,Pharma-Pen (Formerly Innoject) Auto-injectory TIV,"Demonstration of Safety, Effectiveness, and Ease-of-Use of an Advanced Self-Delivery System (Pharma-Pen) for IM and SC Administration of Vaccines by Untrained Users - Phase I",Withdrawn,,Phase 1,0.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 13:29:43,2023-06-15 13:29:43,NIH,,,,,
292550,292551,NCT00481065,,2007-05-31,2011-08-26,,2013-12-31,2007-05-31,2007-06-01,Estimate,2013-01-23,2013-02-28,Estimate,,,,2013-12-31,2014-02-03,Estimate,April 2007,,2007-04-30,December 2013,2013-12-31,December 2008,Actual,2008-12-31,December 2008,Actual,2008-12-31,,Interventional,,The demographic characteristics of the randomized population are summarized in this section.,"Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects","A Phase II, Randomized, Controlled, Open Label, Single-Center Study to Evaluate the Immunogenicity, Safety and Tolerability of an H5N1-vaccine and a Seasonal Influenza Vaccine in Adult Subjects",Completed,,Phase 2,405.0,Actual,Novartis,,8.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 16:50:51,2023-06-16 16:50:51,INDUSTRY,,,,,
292570,292571,NCT00347529,,2006-06-30,,,2007-01-25,2006-06-30,2006-07-04,Estimate,,,,,,,2007-01-25,2007-01-29,Estimate,August 2006,,2006-08-31,January 2007,2007-01-31,January 2007,,2007-01-31,,,,,Interventional,,,Safety Study of an Influenza Vaccine Against a Potential Pandemic Strain of Flu,"A Randomised Double Blind Dose-Ranging Study to Assess the Safety, Tolerability and Immunogenicity of a Monovalent H5 DNA Influenza Vaccine (A Vietnam/1194/2004) Administered by Particle Mediated Epidermal Delivery (PMED) to Healthy Adults",Completed,,Phase 1,75.0,,PowderMed,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 13:30:08,2023-06-15 13:30:08,INDUSTRY,,,,,
292763,292764,NCT00338351,,2006-06-16,,,2016-09-27,2006-06-16,2006-06-20,Estimate,,,,,,,2016-09-27,2016-09-28,Estimate,April 2006,,2006-04-30,September 2016,2016-09-30,October 2006,Actual,2006-10-31,,,,,Interventional,,,Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.,"To Assess Reactogenicity and Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine, When Co-administered With GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine (Infanrix Hexa) at 2, 4 and 6 Months of Age.",Completed,,Phase 2,240.0,,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 13:30:58,2023-06-15 13:30:58,INDUSTRY,,,,,
292778,292779,NCT00445419,,2007-03-08,,,2010-02-05,2007-03-08,2007-03-09,Estimate,,,,,,,2010-02-05,2010-02-08,Estimate,December 2006,,2006-12-31,February 2010,2010-02-28,June 2008,Actual,2008-06-30,,,,,Interventional,,,Phase I Hepatitis C Vaccine Trial of Virosome-formulated Peptides,A Phase I Single-blind Randomised Placebo Controlled Dose Escalating Study of One Virosome Formulated CD4 and Two Virosomes Formulated CD8 Hepatitis C Virus (HCV) Vaccine Components (PEV2A and PEV2B) Administered to Healthy Adult Volunteers,Completed,,Phase 1,30.0,Anticipated,Pevion Biotech Ltd,,,,,False,,,,True,,,,,,,,,,,,,2023-06-15 13:31:08,2023-06-15 13:31:08,INDUSTRY,,,,,
292817,292818,NCT00965588,,2009-08-24,,,2011-08-22,2009-08-24,2009-08-25,Estimate,,,,,,,2011-08-22,2011-08-23,Estimate,February 2009,,2009-02-28,August 2011,2011-08-31,April 2011,Actual,2011-04-30,April 2011,Actual,2011-04-30,,Interventional,,,"Study to Evaluate Safety, Tolerability and Immunogenicity of Vaccine (UB 311) in Subjects With Alzheimer's Disease","A Phase I, Open-Label Study to Evaluate the Safety, Tolerability and Immunogenicity of the UBITh AD Immunotherapeutic Vaccine (UB 311) in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 1,19.0,Actual,United Biomedical,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 16:53:10,2023-06-16 16:53:10,INDUSTRY,,,,,
292825,292826,NCT00975572,,2009-09-08,,,2012-09-11,2009-09-09,2009-09-11,Estimate,,,,,,,2012-09-11,2012-09-12,Estimate,July 2009,,2009-07-31,September 2009,2009-09-30,February 2010,Actual,2010-02-28,September 2009,Actual,2009-09-30,,Interventional,,,Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Population Aged 3 Years and Older,"A Double-blind, Randomized, Stratified and Controlled Clinical Trial With Split-virion, Adjuvanted and Non-adjuvanted Influenza A/H1N1 Vaccines in Healthy Adults, Elders, Adolescents and Children",Completed,,Phase 2,2200.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 16:53:16,2023-06-16 16:53:16,NETWORK,,,,,
292839,292840,NCT04822025,,2021-03-25,,,2022-06-27,2021-03-28,2021-03-30,Actual,,,,,,,2022-06-27,2022-06-28,Actual,"May 20, 2021",Actual,2021-05-20,June 2021,2021-06-30,"January 28, 2022",Actual,2022-01-28,"August 25, 2021",Actual,2021-08-25,,Interventional,,,A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults,"A Phase II, Prospective, Randomized, Double-Blind, Dose-Comparison, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS-CoV-2 Vaccine Candidate MVC-COV1901 in Elderly Adults",Completed,,Phase 2,420.0,Actual,Medigen Vaccine Biologics Corp.,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-16 16:53:33,2023-06-16 16:53:33,INDUSTRY,,,,,
292967,292968,NCT00340574,,2006-06-19,,,2017-06-30,2006-06-19,2006-06-21,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"March 8, 2005",,2005-03-08,"July 2, 2008",2008-07-02,"July 2, 2008",,2008-07-02,,,,,Interventional,,,Improving the Efficacy of Experimental Malaria Vaccine AMA1-C1/Alhydrogel® (Registered Trademark),"Phase I Study of the Safety and Immunogenicity of AMA-1-C1/Alhydrogel + CPG 7909, An Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria",Completed,,Phase 1,0.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 13:32:11,2023-06-15 13:32:11,NIH,,,,,
293468,293469,NCT05470400,,2022-06-29,,,2023-02-01,2022-07-19,2022-07-22,Actual,,,,,,,2023-02-01,2023-02-03,Actual,"August 15, 2022",Actual,2022-08-15,February 2023,2023-02-28,July 2025,Anticipated,2025-07-31,"July 1, 2025",Anticipated,2025-07-01,,Interventional,,,"A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults","A Phase 1, Open-Label Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine (VRC-HIVVCP0108-00-VP) Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 (VRC-HIVRGP096-00-VP) and HIV-1 Trimer 6931 (VRC-HIVRGP0106-00-VP) Vaccines in Healthy Adults",Suspended,,Phase 1,60.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,8.0,,Temporarily Closed (Paused) to Accrual,False,,,,,True,False,,,,,,,,,No,,2023-06-16 16:57:43,2023-06-16 16:57:43,NIH,,,,,
293511,293512,NCT00346892,,2006-02-03,,,2016-09-08,2006-06-29,2006-06-30,Estimate,,,,,,,2016-09-08,2016-09-09,Estimate,November 2001,,2001-11-30,September 2016,2016-09-30,,,,March 2003,Actual,2003-03-31,,Interventional,,,To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPV,Reactogenicity & Immunogenicity Study of Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Co-administered With Either OPV or IPV in Healthy Infants (Approximately 5-10 Weeks Old) in South Africa,Completed,,Phase 2,450.0,,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 13:35:41,2023-06-15 13:35:41,INDUSTRY,,,,,
293576,293577,NCT00347555,,2006-06-29,,,2013-04-11,2006-06-29,2006-07-04,Estimate,,,,,,,2013-04-11,2013-04-12,Estimate,May 2006,,2006-05-31,May 2012,2012-05-31,April 2008,Actual,2008-04-30,April 2008,Actual,2008-04-30,,Interventional,,,Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly,"Phase I, Double-Blinded, Placebo-Controlled Dosage-Escalation Study of the Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly",Completed,,Phase 1,80.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 13:36:01,2023-06-15 13:36:01,NIH,,,,,
293600,293601,NCT00541970,,2007-10-09,2012-10-18,,2018-06-28,2007-10-09,2007-10-10,Estimate,2014-03-13,2014-04-17,Estimate,,,,2018-06-28,2018-08-17,Actual,"October 17, 2007",,2007-10-17,August 2016,2016-08-31,"March 18, 2013",Actual,2013-03-18,"March 18, 2013",Actual,2013-03-18,,Interventional,,,Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs,Evaluation of the Safety and Immunogenicity of GSK Biologicals' HPV Vaccine 580299 When Administered in Healthy Females Aged 9 - 25 Years Using an Alternative Schedule and an Alternative Dosing as Compared to the Standard Schedule and Dosing,Completed,,Phase 1,961.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 16:58:50,2023-06-16 16:58:50,INDUSTRY,,,,,
293608,293609,NCT00347672,,2006-07-03,,,2008-01-18,2006-07-03,2006-07-04,Estimate,,,,,,,2008-01-18,2008-01-21,Estimate,June 2006,,2006-06-30,January 2008,2008-01-31,July 2007,Actual,2007-07-31,July 2007,Actual,2007-07-31,,Interventional,,,Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults,"Phase 1 Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca), a Live Attenuated Virus Vaccine Candidate for the Prevention of Avian Influenza H5N1 Infection in the Event of a Pandemic",Completed,,Phase 1,42.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 13:36:04,2023-06-15 13:36:04,NIH,,,,,
293631,293632,NCT00449124,,2007-03-15,,,2019-01-18,2007-03-15,2007-03-19,Estimate,,,,,,,2019-01-18,2019-01-23,Actual,,,,June 2008,2008-06-30,September 2007,Anticipated,2007-09-30,September 2007,Anticipated,2007-09-30,,Interventional,,,TG4040 in Patients With Chronic HCV,"A Phase I, Randomized, Double-Blind, Dose-Ranging, Crossover Trial of HCV Vaccine (TG4040) in Patients With Chronic Hepatitis C to be Conducted in Two Parts",Withdrawn,,Phase 1,0.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,7.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 13:36:10,2023-06-15 13:36:10,NIH,,,,,
293700,293701,NCT00456183,,2007-04-03,,,2007-05-30,2007-04-03,2007-04-04,Estimate,,,,,,,2007-05-30,2007-05-31,Estimate,August 2005,,2005-08-31,May 2007,2007-05-31,April 2007,Actual,2007-04-30,,,,,Interventional,,,Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB.,"A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Latently Infected With Mycobacterium Tuberculosis.",Completed,,Phase 1,12.0,Actual,University of Oxford,,,,,False,,,,True,,,,,,,,,,,,,2023-06-15 13:36:48,2023-06-15 13:36:48,OTHER,,,,,
293708,293709,NCT00349037,,2006-07-05,,,2007-01-25,2006-07-05,2006-07-06,Estimate,,,,,,,2007-01-25,2007-01-29,Estimate,September 2006,,2006-09-30,January 2007,2007-01-31,January 2007,,2007-01-31,,,,,Interventional,,,Study of the Ability of a Flu Vaccine to Prevent Flu Infection,"A Prospective, Randomised, Double Blind, Placebo-Controlled Study to Assess the Efficacy of a Trivalent (A/New Caledonia/20/99, A/Panama/2007/99, B/Jiangsu/10/20) DNA Influenza Vaccine Administered by Particle Mediated Epidermal Delivery (PMED) Against a Controlled Influenza Virus Challenge.",Completed,,Phase 1,105.0,,PowderMed,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 13:36:52,2023-06-15 13:36:52,INDUSTRY,,,,,
293767,293768,NCT04674306,,2020-12-13,,,2023-02-02,2020-12-13,2020-12-19,Actual,,,,,,,2023-02-02,2023-02-06,Actual,"October 1, 2021",Actual,2021-10-01,February 2023,2023-02-28,"September 1, 2023",Anticipated,2023-09-01,"June 1, 2023",Anticipated,2023-06-01,,Interventional,,,Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer,Phase I Trial of Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Patients With Non-Metastatic Triple-Negative Breast Cancer at High Risk of Recurrence,Recruiting,,Early Phase 1,30.0,Anticipated,Case Comprehensive Cancer Center,,2.0,,,False,,,,True,True,False,,,,,,The data will become available during the course of the trial and indefinitely thereafter.,"The data will be available to the FDA and DOD. Otherwise, a confidentiality agreement will need to be in place.",,Yes,"Yes, the data will be shared with the FDA, the Department of Defense (DOD), and Anixa Biosciences who has negotiated rights to the drug, and any pharmaceutical partner who may wish to negotiate rights to the drug. All below may be shared, with patient data anonymized",2023-06-18 22:21:38,2023-06-18 22:21:38,OTHER,,,,,
293816,293817,NCT04672824,,2020-10-19,,,2023-02-03,2020-12-16,2020-12-17,Actual,,,,,,,2023-02-03,2023-02-06,Actual,"May 31, 2022",Actual,2022-05-31,January 2023,2023-01-31,"December 15, 2022",Actual,2022-12-15,"December 15, 2022",Actual,2022-12-15,,Interventional,,,A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults,A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Rift Valley Fever Virus (RVFV) Vaccine ChAdOx1 RVF Among Healthy Adult Volunteers in Uganda,Completed,,Phase 1,30.0,Actual,University of Oxford,,4.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 22:21:46,2023-06-18 22:21:46,OTHER,,,,,
294016,294017,NCT00352898,,2006-07-14,,,2016-10-06,2006-07-14,2006-07-17,Estimate,,,,,,,2016-10-06,2016-10-07,Estimate,April 2006,,2006-04-30,October 2016,2016-10-31,November 2006,Actual,2006-11-30,,,,,Interventional,,,"Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix",Comparative Study Evaluating the Immunogenicity & Safety of MeMuRu-OKA Vaccine & Measles-mumps-rubella Vaccine (Priorix) Co-administered With Varicella Vaccine (Varilrix) in Children Primed With Both Measles-mumps-rubella & Varicella Vaccines,Completed,,Phase 2,400.0,Actual,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 13:38:49,2023-06-15 13:38:49,INDUSTRY,,,,,
294022,294023,NCT00466245,,2007-04-25,,,2014-01-17,2007-04-25,2007-04-27,Estimate,,,,,,,2014-01-17,2014-01-22,Estimate,July 2005,,2005-07-31,January 2014,2014-01-31,June 2006,Actual,2006-06-30,June 2006,Actual,2006-06-30,,Interventional,,,"Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine","Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Study Assessing Safety, Tolerability, Immunogenicity of Three Dose Levels of ACAM3000 Modified Vaccinia Ankara Smallpox Vaccine in Adults With and Without Previous Smallpox Vaccination",Completed,,Phase 2,590.0,Actual,Sanofi,,8.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 13:38:54,2023-06-15 13:38:54,INDUSTRY,,,,,
294033,294034,NCT00353288,,2006-07-17,,,2016-10-06,2006-07-17,2006-07-18,Estimate,,,,,,,2016-10-06,2016-10-07,Estimate,March 2006,,2006-03-31,October 2016,2016-10-31,November 2006,Actual,2006-11-30,November 2006,Actual,2006-11-30,,Interventional,,,"Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix",Comparative Study Evaluating the Immunogenicity and Safety of MeMuRu-OKA Vaccine and Measles-mumps-rubella Vaccine (Priorix) Co-administered With Varicella Vaccine (Varilrix) in Children Primed With Measles-mumps-rubella Vaccine,Completed,,Phase 2,446.0,Actual,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 13:39:03,2023-06-15 13:39:03,INDUSTRY,,,,,
294175,294176,NCT04714229,,2021-01-14,,,2021-10-06,2021-01-14,2021-01-19,Actual,,,,,,,2021-10-06,2021-10-07,Actual,"September 1, 2020",Actual,2020-09-01,January 2021,2021-01-31,"September 1, 2021",Actual,2021-09-01,"November 1, 2020",Actual,2020-11-01,,Interventional,,,Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old,"A Single Center, Randomized, Observer-blinded, Active Comparator Phase I Study to Assess the Safety and Immunogenicity of Meningococcal (Groups A, C, W-135 and Y) Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old",Completed,,Phase 1,60.0,Actual,"EuBiologics Co.,Ltd",,2.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-15 13:39:33,2023-06-15 13:39:33,INDUSTRY,,,,,
294318,294319,NCT00459069,,2007-04-10,,,2010-01-11,2007-04-10,2007-04-11,Estimate,,,,,,,2010-01-11,2010-01-12,Estimate,July 2004,,2004-07-31,January 2010,2010-01-31,November 2009,Actual,2009-11-30,June 2008,Actual,2008-06-30,,Interventional,,,The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma,The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma,Completed,,Phase 1,18.0,Actual,Dana-Farber Cancer Institute,,,,,False,,,,True,,,,,,,,,,,,,2023-06-15 13:40:13,2023-06-15 13:40:13,OTHER,,,,,
294423,294424,NCT01879540,,2013-06-13,2013-10-31,,2014-02-24,2013-06-13,2013-06-18,Estimate,2013-12-23,2014-02-17,Estimate,,,,2014-02-24,2014-03-26,Estimate,July 2013,,2013-07-31,February 2014,2014-02-28,August 2013,Actual,2013-08-31,August 2013,Actual,2013-08-31,,Interventional,,,"Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults =65 Years of Age","A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine Including MF59C.1 Adjuvant (Fluad®) in Healthy Adults =65 Years of Age",Completed,,Phase 2,63.0,Actual,Novartis,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 22:22:39,2023-06-18 22:22:39,INDUSTRY,,,,,
294601,294602,NCT00460590,,2007-04-13,,,2008-08-06,2007-04-13,2007-04-16,Estimate,,,,,,,2008-08-06,2008-08-07,Estimate,October 2005,,2005-10-31,June 2008,2008-06-30,June 2008,Actual,2008-06-30,June 2008,Actual,2008-06-30,,Interventional,,,"Safety and Immunogenicity of MVA85A, in Healthy Volunteers in Cape Town","A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine MVA85A, in Healthy Volunteers With no Evidence of Infection With Mycobacterium Tuberculosis, in Cape Town",Completed,,Phase 1,36.0,Actual,University of Oxford,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 13:41:47,2023-06-15 13:41:47,OTHER,,,,,
294820,294821,NCT02956551,,2016-11-01,,,2018-05-29,2016-11-03,2016-11-06,Estimate,,,,,,,2018-05-29,2018-05-31,Actual,"November 30, 2016",Actual,2016-11-30,May 2018,2018-05-31,"June 1, 2020",Anticipated,2020-06-01,"December 31, 2019",Anticipated,2019-12-31,,Interventional,SKLB1608,,Personalized DC Vaccine for Lung Cancer,Neoantigen-primed DC Vaccine Therapy for Refractory Non-small Cell Lung Cancer,Unknown status,Recruiting,Phase 1,20.0,Anticipated,Sichuan University,,1.0,,,False,,,,False,,,,,,,,,,,Undecided,,2023-06-15 13:43:20,2023-06-15 13:43:20,OTHER,,,,,
294930,294931,NCT00776711,,2008-10-18,,,2017-06-30,2008-10-18,2008-10-21,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"October 16, 2008",,2008-10-16,"January 14, 2011",2011-01-14,"January 14, 2011",Actual,2011-01-14,"January 14, 2011",Actual,2011-01-14,,Interventional,,,Vaccine for Prevention of Bird Flu,"An Open-Label, Randomized Phase I Study in Healthy Adults of 4 Prime-Boost Schedules With Monovalent Influenza Subunit Virion (H5N1) Vaccine (Sanofi Pasteur, Inc), Administered Alone or Following Recombinant DNA Plasmid (H5) Vaccine (VRC, NIAID)",Completed,,Phase 1,60.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-16 17:08:52,2023-06-16 17:08:52,NIH,,,,,
294963,294964,NCT00471471,,2007-05-08,,,2017-06-21,2007-05-08,2007-05-10,Estimate,,,,,,,2017-06-21,2017-06-22,Actual,October 2008,,2008-10-31,June 2017,2017-06-30,December 2011,Actual,2011-12-31,December 2011,Actual,2011-12-31,,Interventional,,,Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,"Safety and Immunogenicity of Vaccination With Multi-Epitope Peptide Vaccine Containing MART-1, gp100, and Tyrosinase Peptides Given With the Combination of GMCSF and CpG Oligonucleotide (CpG 7909) in ISA-Oil Adjuvant for Patients With Recurrent Inoperable Stage III or Stage IV Melanoma",Completed,,Phase 1,22.0,Actual,University of Pittsburgh,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 13:44:18,2023-06-15 13:44:18,OTHER,,,,,
295088,295089,NCT02894008,,2016-08-01,,,2020-01-27,2016-09-02,2016-09-09,Estimate,,,,,,,2020-01-27,2020-01-28,Actual,November 2016,Actual,2016-11-30,January 2020,2020-01-31,"December 31, 2019",Actual,2019-12-31,"September 30, 2019",Actual,2019-09-30,,Interventional,Leish2a,,A Study of a New Leishmania Vaccine Candidate ChAd63-KH,A Phase IIa Safety Study to Assess the Safety and Immunogenicity of a New Leishmania Vaccine Candidate ChAd63-KH,Completed,,Phase 2,24.0,Actual,University of York,,2.0,,,False,,,,True,,,,,,,,,,,Undecided,,2023-06-15 13:45:30,2023-06-15 13:45:30,OTHER,,,,,
295254,295255,NCT00472719,,2007-05-11,,,2021-10-13,2007-05-11,2007-05-14,Estimate,,,,,,,2021-10-13,2021-10-14,Actual,August 2007,,2007-08-31,October 2021,2021-10-31,January 2013,Actual,2013-01-31,July 2008,Actual,2008-07-31,,Interventional,,,Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults,"A Phase 1B Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Adenoviral Serotype 35 (rAd35) and Serotype 5 (rAd5) HIV-1 Vaccines When Given in Heterologous Prime-Boost Regimens or as a Boost to a Recombinant DNA Vaccine in Healthy, HIV-1-Uninfected Adult Participants With Pre-Existing Immunity to Adenovirus Serotype 5 Infection",Completed,,Phase 1,17.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 13:46:36,2023-06-15 13:46:36,NIH,,,,,
295379,295380,NCT00465465,,2007-04-24,,,2008-04-02,2007-04-24,2007-04-25,Estimate,,,,,,,2008-04-02,2008-04-04,Estimate,October 2005,,2005-10-31,March 2008,2008-03-31,September 2007,Actual,2007-09-30,September 2007,Actual,2007-09-30,,Interventional,,,"A Study of 2 Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Previously Vaccinated With BCG","A Dose Selection Study Evaluating the Safety and Immunogenicity of 2 Different Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Have Previously Been Vaccinated With BCG",Completed,,Phase 1,24.0,Actual,University of Oxford,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 13:47:26,2023-06-15 13:47:26,OTHER,,,,,
295467,295468,NCT05317325,,2022-03-30,,,2022-03-30,2022-03-30,2022-04-07,Actual,,,,,,,2022-03-30,2022-04-07,Actual,"April 1, 2022",Anticipated,2022-04-01,March 2022,2022-03-31,"April 1, 2024",Anticipated,2024-04-01,"December 30, 2023",Anticipated,2023-12-30,,Interventional,,,A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC,A Translational Study of Tumor Antigen-pulsed Dendritic Cell Vaccine for Esophageal Squamous Cell Carcinoma,Not yet recruiting,,Phase 1,20.0,Anticipated,Sichuan University,,1.0,,,False,,,,False,False,False,,,,,,,,,Yes,,2023-06-14 08:05:59,2023-06-14 08:05:59,OTHER,,,,,
295487,295488,NCT00473967,,2007-05-14,,,2012-07-06,2007-05-14,2007-05-16,Estimate,,,,,,,2012-07-06,2012-07-09,Estimate,May 2007,,2007-05-31,July 2012,2012-07-31,March 2009,Actual,2009-03-31,March 2008,Actual,2008-03-31,,Interventional,,,Phase 1 Trial of Na-ASP-2 Hookworm Vaccine in Previously Infected Brazilian Adults,"Double-blind, Randomized, Controlled Phase 1 Study of the Safety and Immunogenicity of Na-ASP-2 Hookworm Vaccine in Previously-Infected Brazilian Adults",Terminated,,Phase 1,9.0,Actual,Albert B. Sabin Vaccine Institute,,2.0,,Occurrence of unacceptable adverse events.,False,,,,True,,,,,,,,,,,,,2023-06-15 13:48:05,2023-06-15 13:48:05,OTHER,,,,,
295700,295701,NCT00532298,,2007-09-19,2012-04-23,2009-05-20,2018-05-09,2007-09-19,2007-09-20,Estimate,2012-04-23,2012-05-22,Estimate,2009-09-28,2009-09-30,Estimate,2018-05-09,2018-06-08,Actual,"September 20, 2007",,2007-09-20,November 2016,2016-11-30,"November 2, 2007",Actual,2007-11-02,"November 1, 2007",Actual,2007-11-01,,Interventional,,,Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and Over,Non-Inferiority of GlaxoSmithKline Biologicals' Influenza Vaccine (GSK576389A) 1 Container Over 2 Container Presentation in Adults Aged 65 Years and Over,Completed,,Phase 2,1596.0,Actual,GlaxoSmithKline,,6.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 17:12:58,2023-06-16 17:12:58,INDUSTRY,,,,,
295992,295993,NCT00439803,,2007-02-23,,,2008-11-07,2007-02-23,2007-02-26,Estimate,,,,,,,2008-11-07,2008-11-10,Estimate,April 2007,,2007-04-30,November 2008,2008-11-30,July 2008,Actual,2008-07-31,July 2008,Actual,2008-07-31,,Interventional,CMV,,A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV),"A Single-Site, Phase 1, Double-Blind, Safety and Immunogenicity Trial of an Alphavirus Replicon Vaccine Expressing Cytomegalovirus Genes (AVX601) in Healthy Volunteers",Completed,,Phase 1,40.0,Actual,"AlphaVax, Inc.",,8.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 13:51:46,2023-06-15 13:51:46,INDUSTRY,,,,,
296062,296063,NCT00440544,,2007-02-26,,,2008-10-31,2007-02-26,2007-02-27,Estimate,,,,,,,2008-10-31,2008-11-02,Estimate,January 2007,,2007-01-31,October 2008,2008-10-31,February 2008,Actual,2008-02-29,November 2007,Actual,2007-11-30,,Interventional,TMUVA-01,,A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6),A Phase I Trial of the Safety and Immunogenicity of an Adjuvated TB Subunit Vaccine (Ag85B-ESAT6 + LTK63) Administered at 0 and 2 Months,Terminated,,Phase 1,9.0,Actual,"St George's, University of London",,6.0,,Safety Issues,False,,,,True,,,,,,,,,,,,,2023-06-15 13:52:24,2023-06-15 13:52:24,OTHER,,,,,
296261,296262,NCT01095055,,2010-03-25,,,2011-03-25,2010-03-26,2010-03-29,Estimate,,,,,,,2011-03-25,2011-03-28,Estimate,March 2010,,2010-03-31,March 2011,2011-03-31,October 2010,Actual,2010-10-31,October 2010,Actual,2010-10-31,,Interventional,,,A Study of AdCh63 AMA1 Alone and With MVA AMA1,A Phase I Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates AdCh63 AMA1 Alone and With MVA AMA1,Completed,,Phase 1,16.0,Anticipated,University of Oxford,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 17:16:37,2023-06-16 17:16:37,OTHER,,,,,
296429,296430,NCT00443157,,2007-03-02,,,2018-08-28,2007-03-02,2007-03-05,Estimate,,,,,,,2018-08-28,2018-08-29,Actual,February 2006,,2006-02-28,September 2007,2007-09-30,March 2007,Actual,2007-03-31,,,,,Interventional,MNB3,,Meningococcal B Vaccination in University Students,"A Phase II, Open Label, Randomised, Single Centre Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Three or Four Doses of Meningococcal Serogroup B Outer Membrane Vesicle (OMV) Vaccine MENZBTM When Administered to Healthy Adults (University Students)",Completed,,Phase 2,50.0,,Public Health England,,,,,False,,,,,,,,,,,,,,,,,2023-06-15 13:54:40,2023-06-15 13:54:40,OTHER_GOV,,,,,
296431,296432,NCT00385840,,2006-10-10,2013-03-07,,2018-05-09,2006-10-10,2006-10-11,Estimate,2013-04-25,2013-04-29,Estimate,,,,2018-05-09,2018-06-08,Actual,"October 20, 2006",,2006-10-20,October 2016,2016-10-31,"February 5, 2007",Actual,2007-02-05,"February 1, 2007",Actual,2007-02-01,,Interventional,,,Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate,"A Study to Evaluate the Immunogenicity, Safety and Reactogenicity of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate Compared to Fluarix Administered Intramuscularly in Elderly Aged 60 Years and Above.",Completed,,Phase 2,678.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 17:17:49,2023-06-16 17:17:49,INDUSTRY,,,,,
296470,296471,NCT00480558,,2007-05-30,,,2011-03-25,2007-05-30,2007-05-31,Estimate,,,,,,,2011-03-25,2011-03-28,Estimate,July 2007,,2007-07-31,March 2011,2011-03-31,January 2011,Actual,2011-01-31,January 2011,Actual,2011-01-31,,Interventional,,,"A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both","A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Asymptomatic Volunteers Who Are Infected With Either Mycobacterium Tuberculosis (M.tb.), Human Immunodeficiency Virus (HIV) or Both",Completed,,Phase 1,48.0,Anticipated,University of Oxford,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 13:54:53,2023-06-15 13:54:53,OTHER,,,,,
296609,296610,NCT00458120,,2007-04-06,,,2010-12-13,2007-04-06,2007-04-09,Estimate,,,,,,,2010-12-13,2010-12-14,Estimate,March 2007,,2007-03-31,December 2010,2010-12-31,August 2008,Actual,2008-08-31,August 2008,Actual,2008-08-31,,Interventional,,,Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus,Evaluation of the Safety and Immunogenicity of Heterologous Dengue Vaccine Administration in Dengue Immune Individuals,Completed,,Phase 1,36.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 13:55:49,2023-06-15 13:55:49,NIH,,,,,
296663,296664,NCT00488046,,2007-06-18,,,2007-11-19,2007-06-18,2007-06-19,Estimate,,,,,,,2007-11-19,2007-11-20,Estimate,June 2007,,2007-06-30,November 2007,2007-11-30,September 2007,Actual,2007-09-30,,,,,Interventional,,,Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults,"Phase I Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine Modified H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H5N1 Infection in the Event of a Pandemic",Completed,,Phase 1,16.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 13:56:04,2023-06-15 13:56:04,NIH,,,,,
297295,297296,NCT02314923,,2014-12-08,2019-12-06,,2020-01-21,2014-12-08,2014-12-11,Estimate,2019-12-06,2020-01-02,Actual,,,,2020-01-21,2020-02-05,Actual,"December 5, 2014",Actual,2014-12-05,January 2020,2020-01-31,"June 23, 2016",Actual,2016-06-23,"June 23, 2016",Actual,2016-06-23,,Interventional,,Baseline characteristics were reported for treated participants. 1 participant in 9x10^6 pfu V920: Cohort 2 arm did not receive vaccine,"Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)","A Phase 1 Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Response Study to Evaluate the Safety and Immunogenicity of the BPSC-1001 (VSV<U+0394>G-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Subjects",Completed,,Phase 1,513.0,Actual,Merck Sharp & Dohme LLC,,10.0,,,False,,,,True,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2023-06-17 22:51:45,2023-06-17 22:51:45,INDUSTRY,,,,,
297364,297365,NCT00498654,,2007-07-09,,,2008-06-27,2007-07-09,2007-07-10,Estimate,,,,,,,2008-06-27,2008-07-02,Estimate,July 2007,,2007-07-31,June 2008,2008-06-30,June 2008,Actual,2008-06-30,October 2007,Actual,2007-10-31,,Interventional,,,"Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects","A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of a Single Oral Dose Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects",Completed,,Phase 2,180.0,Anticipated,Avant Immunotherapeutics,,,,,False,,,,True,,,,,,,,,,,,,2023-06-15 14:02:24,2023-06-15 14:02:24,INDUSTRY,,,,,
297698,297699,NCT01366534,,2011-06-02,2017-05-04,2012-11-16,2019-06-04,2011-06-02,2011-06-06,Estimate,2017-05-04,2017-06-09,Actual,2012-11-16,2012-11-21,Estimate,2019-06-04,2019-06-18,Actual,"August 10, 2011",Actual,2011-08-10,June 2019,2019-06-30,"July 3, 2012",Actual,2012-07-03,"February 27, 2012",Actual,2012-02-27,,Interventional,,,"Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults","Safety, Immunogenicity and Efficacy Against Malaria in the Sporozoite Challenge Model of One Dose of Ad35.CS.01 Malaria Vaccine Followed by Two Doses of Malaria 257049 Vaccine in Healthy Malaria-naïve Adults",Completed,,Phase 2,67.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,Patient-level data for this study is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,Yes,Patient-level data for this study is available via the Clinical Study Data Request site (click on the link provided below),2023-06-15 14:05:43,2023-06-15 14:05:43,INDUSTRY,,,,,
298024,298025,NCT00922259,,2009-05-28,,,2013-02-12,2009-06-16,2009-06-17,Estimate,,,,,,,2013-02-12,2013-02-13,Estimate,July 2010,,2010-07-31,February 2013,2013-02-28,January 2012,Actual,2012-01-31,January 2012,Actual,2012-01-31,,Interventional,,,Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7,"Phase 1 Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine H7N7 (6-2) AA ca Recombinant (A/Netherlands/219/03 (H7N7) x A/Ann Arbor/ 6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H7N7 Infection in the Event of a Pandemic",Completed,,Phase 1,25.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 17:22:29,2023-06-16 17:22:29,NIH,,,,,
298124,298125,NCT00469820,,2007-05-03,,,2014-03-20,2007-05-03,2007-05-07,Estimate,,,,,,,2014-03-20,2014-03-21,Estimate,April 2007,,2007-04-30,March 2014,2014-03-31,March 2010,Actual,2010-03-31,March 2010,Actual,2010-03-31,,Interventional,,,"Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant",Posttransplant Immunotherapy With Donor Lymphocyte Infusions and Autologous Tumor Vaccines After HLA-Matched Transplant,Terminated,,Phase 1,1.0,Actual,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,,,low accrual,False,,,,,,,,,,,,,,,,,2023-06-15 14:07:17,2023-06-15 14:07:17,OTHER,,,,,
298146,298147,NCT00814229,,2008-12-23,,,2009-07-20,2008-12-23,2008-12-24,Estimate,,,,,,,2009-07-20,2009-07-21,Estimate,August 2007,,2007-08-31,July 2009,2009-07-31,September 2008,Actual,2008-09-30,January 2008,Actual,2008-01-31,,Interventional,,,Safety and Immunogenicity of Influenza H9 Vaccine in Humans,Randomised Dose Ranging Observer Blind Single Centre Study to Evaluate Safety and Immunogenicity of Adjuvanted and Non-adjuvanted Influenza H9 Influenza Vaccine in Humans,Completed,,Phase 1,353.0,Actual,"University Hospitals, Leicester",,14.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 17:23:38,2023-06-16 17:23:38,OTHER,,,,,
298226,298227,NCT00365716,,2006-08-16,2010-05-19,,2015-10-06,2006-08-16,2006-08-17,Estimate,2010-07-06,2010-08-03,Estimate,,,,2015-10-06,2015-10-07,Estimate,May 2000,,2000-05-31,October 2015,2015-10-31,September 2009,Actual,2009-09-30,May 2004,Actual,2004-05-31,,Interventional,,,"Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)","A Placebo-Controlled, Dose-Ranging Study of Quadrivalent HPV Virus-Like Particle (VLP) Vaccine in 16- to 23-Year-Old Women",Completed,,Phase 2,1158.0,Actual,Merck Sharp & Dohme LLC,,5.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 17:24:24,2023-06-16 17:24:24,INDUSTRY,,,,,
298340,298341,NCT02466750,,2015-06-04,,,2021-02-10,2015-06-08,2015-06-09,Estimate,,,,,,,2021-02-10,2021-02-11,Actual,"December 15, 2015",Actual,2015-12-15,February 2021,2021-02-28,December 2021,Anticipated,2021-12-31,June 2021,Anticipated,2021-06-30,,Interventional,,,Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine,"Phase 2 Open-Label Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, Dried, TSI-GSD 210, Lot 3-1-92, in Healthy Adult Subjects at Risk of Exposure to Western Equine Encephalitis Virus",Unknown status,Recruiting,Phase 2,500.0,Anticipated,U.S. Army Medical Research and Development Command,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 22:28:23,2023-06-18 22:28:23,FED,,,,,
298386,298387,NCT01018641,,2009-11-20,,,2014-04-23,2009-11-20,2009-11-23,Estimate,,,,,,,2014-04-23,2014-04-24,Estimate,January 2010,,2010-01-31,April 2014,2014-04-30,July 2011,Actual,2011-07-31,January 2011,Actual,2011-01-31,,Interventional,,,An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults,"A Phase 1 Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of 3 Ascending Dose Levels Of A 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults",Completed,,Phase 1,449.0,Actual,Pfizer,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 17:26:28,2023-06-16 17:26:28,INDUSTRY,,,,,
298403,298404,NCT01045564,,2010-01-07,,,2015-03-19,2010-01-07,2010-01-11,Estimate,,,,,,,2015-03-19,2015-03-23,Estimate,January 2011,,2011-01-31,March 2015,2015-03-31,February 2013,Anticipated,2013-02-28,February 2013,Anticipated,2013-02-28,,Interventional,,,Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure,Safety and Immunogenicity of GSK 15574484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure,Withdrawn,,Phase 2,0.0,Actual,GlaxoSmithKline,,5.0,,Study was cancelled before enrolment for reasons not related to vaccine safety or efficacy.,False,,,,,,,,,,,,,,,,,2023-06-16 17:26:50,2023-06-16 17:26:50,INDUSTRY,,,,,
298450,298451,NCT00599443,,2008-01-10,,,2008-06-27,2008-01-10,2008-01-23,Estimate,,,,,,,2008-06-27,2008-06-30,Estimate,October 2007,,2007-10-31,June 2008,2008-06-30,May 2008,Actual,2008-05-31,May 2008,Actual,2008-05-31,,Interventional,,,Safety and Tolerability of a Cell-Derived Influenza Vaccine in Healthy Adults Aged =18 Years and = 49 Years,"Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of a Cell-Derived Influenza Vaccine in Healthy Adults Aged =18 Years and = 49 Years.",Completed,,Phase 1,120.0,Actual,Solvay Pharmaceuticals,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 14:07:48,2023-06-15 14:07:48,INDUSTRY,,,,,
298567,298568,NCT00470015,,2007-05-03,,,2019-02-15,2007-05-03,2007-05-07,Estimate,,,,,,,2019-02-15,2019-02-19,Actual,March 2007,Actual,2007-03-31,February 2019,2019-02-28,"January 2, 2013",Actual,2013-01-02,April 2009,Actual,2009-04-30,,Interventional,,,"Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma","Melanoma Peptide Vaccines (MART1 Analog, gp100 and Survivin) With GM-CSF and Low-Dose IL-2 as Immune Adjuvants, A Pilot Study",Completed,,Phase 1,20.0,Anticipated,Mayo Clinic,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 14:08:05,2023-06-15 14:08:05,OTHER,,,,,
298967,298968,NCT01323946,,2011-03-24,2017-08-21,2012-11-16,2019-04-24,2011-03-24,2011-03-28,Estimate,2018-08-31,2019-02-04,Actual,2012-11-16,2012-11-21,Estimate,2019-04-24,2019-05-07,Actual,"April 18, 2011",Actual,2011-04-18,April 2019,2019-04-30,"November 2, 2012",Actual,2012-11-02,"June 22, 2012",Actual,2012-06-22,,Interventional,,,Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children,Safety and Immunogenicity of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine (GSK1562902A) in Children Aged 6 to 35 Months,Completed,,Phase 2,113.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 14:10:53,2023-06-15 14:10:53,INDUSTRY,,,,,
299023,299024,NCT00503568,,2007-07-17,,,2016-12-14,2007-07-17,2007-07-19,Estimate,,,,,,,2016-12-14,2016-12-15,Estimate,May 2007,,2007-05-31,December 2016,2016-12-31,August 2012,Actual,2012-08-31,August 2012,Actual,2012-08-31,,Interventional,,,"Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy","Novel Tumor Vaccine gp96-Ig Fusion Protein in Advanced (Stage IIIB), Relapsed or Metastatic (Stage IV) Non-Small Cell Lung Cancer (NSCLC) Patients Who Have Failed First Line Chemotherapy",Completed,,Phase 1,19.0,Actual,University of Miami,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 14:11:35,2023-06-15 14:11:35,OTHER,,,,,
299166,299167,NCT00473135,,2007-05-11,,,2010-01-11,2007-05-11,2007-05-14,Estimate,,,,,,,2010-01-11,2010-01-13,Estimate,May 2007,,2007-05-31,January 2008,2008-01-31,,,,January 2010,Actual,2010-01-31,,Interventional,,,Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine,Safety and Immunogenicity of a 2-Dose Regimen of rDEN1delta30 Dengue Serotype 1 Vaccine With Boosting at 4 Versus 6 Months,Completed,,Phase 1,60.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 14:13:00,2023-06-15 14:13:00,NIH,,,,,
299248,299249,NCT00479999,,2007-05-26,,,2019-12-13,2007-05-26,2007-05-30,Estimate,,,,,,,2019-12-13,2019-12-16,Actual,"May 24, 2007",,2007-05-24,"May 5, 2014",2014-05-05,"May 5, 2014",Actual,2014-05-05,"May 5, 2014",Actual,2014-05-05,,Interventional,,,Phase 1 Safety Study of Two Experimental HIV Vaccines,VRC 012: A Phase I Clinical Trial of the Safety and Immunogenicity of an HIV-1 Adenoviral Vector Serotype 35 Vaccine: Dose Escalation as a Single Agent and Prime-Boost Schedules With an HIV-1 Adenoviral Vector Serotype 5 Vaccine in Uninfected Adults,Completed,,Phase 1,35.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 14:13:51,2023-06-15 14:13:51,NIH,,,,,
299265,299266,NCT04515147,,2020-08-13,,,2022-03-09,2020-08-13,2020-08-17,Actual,,,,,,,2022-03-09,2022-03-24,Actual,"September 28, 2020",Actual,2020-09-28,December 2021,2021-12-31,"February 21, 2022",Actual,2022-02-21,"February 21, 2022",Actual,2022-02-21,,Interventional,,,"A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19","COVID-19: A Phase 2a, Partially Observer-blind, Multicenter, Controlled, Dose-confirmation Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults >60 Years of Age and 18 to 60 Years of Age",Completed,,Phase 2,674.0,Actual,CureVac,,10.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-15 14:14:06,2023-06-15 14:14:06,INDUSTRY,,,,,
299281,299282,NCT00480155,,2007-05-25,,,2008-12-19,2007-05-25,2007-05-30,Estimate,,,,,,,2008-12-19,2008-12-22,Estimate,May 2007,,2007-05-31,December 2008,2008-12-31,December 2007,Actual,2007-12-31,December 2007,Actual,2007-12-31,,Interventional,,,A Study to Evaluate the Safety of a Monovalent Vaccine in Healthy Adults,"A Prospective, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety of A Monovalent Vaccine in Healthy Adults",Completed,,Phase 2,300.0,Actual,MedImmune LLC,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 14:14:17,2023-06-15 14:14:17,INDUSTRY,,,,,
299317,299318,NCT00482027,,2007-05-31,,,2013-01-14,2007-06-01,2007-06-04,Estimate,,,,,,,2013-01-14,2013-01-16,Estimate,December 2003,,2003-12-31,May 2007,2007-05-31,January 2007,Actual,2007-01-31,December 2006,Actual,2006-12-31,,Interventional,A001,,"Safety and Immunogenicity Study of tgAAC09, a Gag-PR-RT AAV HIV Vaccine","A Phase 1 Randomized, Placebo-controlled, Double-blind Dose-escalation Trial to Evaluate the Safety and Immunogenicity of tgAAC09, a Gag-PR-RT AAV HIV Vaccine",Completed,,Phase 1,80.0,Actual,International AIDS Vaccine Initiative,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 14:14:42,2023-06-15 14:14:42,NETWORK,,,,,
299461,299462,NCT00487916,,2007-06-16,,,2017-06-30,2007-06-16,2007-06-19,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"June 13, 2007",,2007-06-13,"September 22, 2009",2009-09-22,"February 5, 2009",Actual,2009-02-05,"February 5, 2009",Actual,2009-02-05,,Interventional,,,"Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of AMA1-C1/ISA 720: Blood Stage Vaccine for Plasmodium Falciparum","Phase 1 Study of the Safety, Reactogenicity and Immunogenicity of AMA1-C1/ISA 720: A Blood Stage Vaccine for Plasmodium Falciparum",Completed,,Phase 1,150.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 14:16:22,2023-06-15 14:16:22,NIH,,,,,
299507,299508,NCT02956421,,2016-11-03,,,2016-11-06,2016-11-03,2016-11-06,Estimate,,,,,,,2016-11-06,2016-11-08,Estimate,February 2016,,2016-02-29,November 2016,2016-11-30,October 2016,Actual,2016-10-31,October 2016,Actual,2016-10-31,,Interventional,,,Efficacy and Safety of a PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen,Phase II Study to Determine the Efficacy and Safety of PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen,Completed,,Phase 2,126.0,Actual,Yisheng Biopharma (Singapore) Pte. Ltd.,,2.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-15 14:16:56,2023-06-15 14:16:56,INDUSTRY,,,,,
299608,299609,NCT01241162,,2010-11-15,,,2017-05-08,2010-11-15,2010-11-16,Estimate,,,,,,,2017-05-08,2017-05-09,Actual,August 2010,,2010-08-31,May 2017,2017-05-31,October 2016,Actual,2016-10-31,October 2016,Actual,2016-10-31,,Interventional,,,Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma,A Phase I Trial Combining Decitabine and Vaccine Therapy for Patients With Relapsed Neuroblastoma and Sarcoma.,Completed,,Phase 1,19.0,Actual,University of Louisville,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 14:18:10,2023-06-15 14:18:10,OTHER,,,,,
299841,299842,NCT00486408,,2007-06-12,,,2021-10-13,2007-06-12,2007-06-14,Estimate,,,,,,,2021-10-13,2021-10-14,Actual,July 2007,,2007-07-31,October 2021,2021-10-31,November 2012,Actual,2012-11-30,September 2008,Actual,2008-09-30,,Interventional,,,Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults,"A Phase 1B Open-label Clinical Trial to Expand the Characterization of the Immune Responses to the Merck Adenovirus Serotype 5 HIV-1 Gag/Pol/Nef Vaccine in Healthy, HIV-1-uninfected Adult Participants",Completed,,Phase 1,35.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 14:20:57,2023-06-15 14:20:57,NIH,,,,,
300224,300225,NCT00535236,,2007-09-25,2019-01-18,,2019-05-17,2007-09-25,2007-09-26,Estimate,2019-01-18,2019-04-16,Actual,,,,2019-05-17,2019-05-20,Actual,"November 2, 2007",Actual,2007-11-02,May 2019,2019-05-31,"January 26, 2010",Actual,2010-01-26,"January 25, 2010",Actual,2010-01-25,,Interventional,,,A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002),"A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults",Completed,,Phase 1,341.0,Actual,Merck Sharp & Dohme LLC,,10.0,,,False,,,,,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2023-06-16 17:31:43,2023-06-16 17:31:43,INDUSTRY,,,,,
300314,300315,NCT01244867,,2010-11-15,,,2012-07-30,2010-11-18,2010-11-19,Estimate,,,,,,,2012-07-30,2012-07-31,Estimate,November 2010,,2010-11-30,July 2012,2012-07-31,September 2011,Actual,2011-09-30,July 2011,Actual,2011-07-31,,Interventional,,,"Immunogenicity, Safety, Tolerability of a Plant-Made H5 VLP Influenza Vaccine","A Phase 2, Randomized, Observer-blind, Single Center, Dose-Ranging Study to Evaluate the Immunogenicity Safety and Tolerability of the H5 VLP Influenza Vaccine With or Without Alhydrogel in Healthy Adults 18-60 Years of Age.",Completed,,Phase 2,255.0,Actual,Medicago,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 14:25:43,2023-06-15 14:25:43,INDUSTRY,,,,,
300428,300429,NCT00498056,,2007-07-05,,,2021-10-28,2007-07-05,2007-07-09,Estimate,,,,,,,2021-10-28,2021-11-01,Actual,,,,October 2021,2021-10-31,,,,,,,,Interventional,,,Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa,"A Phase IIB Test-of-Concept, Randomized, Double-Blind, Placebo-Controlled, International Clinical Trial to Evaluate the Efficacy, Safety, and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in HIV Uninfected Persons",Withdrawn,,Phase 2,0.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 14:26:46,2023-06-15 14:26:46,NIH,,,,,
300677,300678,NCT00500747,,2007-07-12,,,2011-06-09,2007-07-12,2007-07-13,Estimate,,,,,,,2011-06-09,2011-06-10,Estimate,August 2003,,2003-08-31,April 2010,2010-04-30,August 2005,Actual,2005-08-31,August 2005,Actual,2005-08-31,,Interventional,,,Chiron Corp HCV E1/E2 Vaccine,"A Phase I Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of Chiron Corporation's HCV E1E2/MF59 Vaccine Administered to Healthy HCV-Negative Adults",Completed,,Phase 1,60.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 14:29:20,2023-06-15 14:29:20,NIH,,,,,
300699,300700,NCT02320305,,2014-12-15,,,2020-01-13,2014-12-15,2014-12-19,Estimate,,,,,,,2020-01-13,2020-01-14,Actual,"January 27, 2015",Actual,2015-01-27,February 2019,2019-02-28,"April 11, 2019",Actual,2019-04-11,"December 7, 2015",Actual,2015-12-07,,Interventional,,,MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery,Peptide Vaccine With Glucopyranosyl Lipid A - Stable Oil-in-Water Emulsion (GLA-SE) for Patients With Resected Melanoma: A Pilot Study,Completed,,Early Phase 1,23.0,Actual,Mayo Clinic,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 22:53:50,2023-06-17 22:53:50,OTHER,,,,,
300748,300749,NCT02274545,,2014-10-22,,,2017-04-18,2014-10-22,2014-10-24,Estimate,,,,,,,2017-04-18,2017-04-19,Actual,October 2014,,2014-10-31,April 2017,2017-04-30,,,,May 2016,Actual,2016-05-31,,Interventional,,,Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old,"Phase 1 Evaluation of the Safety and Immunogenicity of Live Influenza A Vaccine H7N9 (6-2) AA ca Recombinant (A/Anhui/1/2013 (H7N9) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H7N9 Disease in 50 to 70 Year Olds in the Event of a Pandemic",Completed,,Phase 1,24.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 14:30:07,2023-06-15 14:30:07,NIH,,,,,
300908,300909,NCT02952339,,2016-10-31,,,2018-02-12,2016-10-31,2016-11-02,Estimate,,,,,,,2018-02-12,2018-02-13,Actual,August 2016,,2016-08-31,February 2018,2018-02-28,July 2017,Actual,2017-07-31,July 2017,Actual,2017-07-31,,Interventional,,,"Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age","Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-attenuated Respiratory Syncytial Virus Vaccine, LID <U+0394>M2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age",Completed,,Phase 1,33.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 14:31:57,2023-06-15 14:31:57,NIH,,,,,
300954,300955,NCT04519073,,2020-08-15,,,2022-03-04,2020-08-16,2020-08-19,Actual,,,,,,,2022-03-04,2022-03-07,Actual,"September 7, 2020",Actual,2020-09-07,March 2022,2022-03-31,"March 2, 2022",Actual,2022-03-02,"March 2, 2022",Actual,2022-03-02,,Interventional,,,Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Vaccine Against Respiratory Syncytial Virus,"Randomized, Placebo-controlled, Double-blind, Phase 1, Dose-escalating Study to Evaluate the Safety and Immunogenicity of a Synthetic Virus Like Particle (SVLP) Vaccine Against Respiratory Syncytial Virus (RSV)",Completed,,Phase 1,60.0,Actual,Virometix,,4.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-15 14:32:33,2023-06-15 14:32:33,INDUSTRY,,,,,
301044,301045,NCT00513669,,2007-08-08,,,2013-03-14,2007-08-08,2007-08-09,Estimate,,,,,,,2013-03-14,2013-03-15,Estimate,January 2008,,2008-01-31,March 2013,2013-03-31,March 2009,Actual,2009-03-31,March 2009,Actual,2009-03-31,,Interventional,PMAL03,,"Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania",A Phase Ib Double-blind Randomized Placebo Controlled Age-deescalating Trial of Two Virosome Formulated Anti-malaria Vaccine Components (PEV 301 and PEV 302) Administered in Combination to Healthy Semi-immune Tanzanian Volunteers,Completed,,Phase 1,50.0,Actual,Swiss Tropical & Public Health Institute,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 14:33:41,2023-06-15 14:33:41,OTHER,,,,,
301057,301058,NCT01248884,,2010-11-24,2014-05-08,2012-07-23,2018-06-28,2010-11-24,2010-11-25,Estimate,2014-05-08,2014-06-06,Estimate,2012-07-23,2012-07-31,Estimate,2018-06-28,2018-08-20,Actual,"December 9, 2010",,2010-12-09,July 2014,2014-07-31,"January 5, 2012",Actual,2012-01-05,"January 5, 2012",Actual,2012-01-05,,Interventional,,,Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744),Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) in Primary Infant Vaccination,Completed,,Phase 2,721.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 14:33:50,2023-06-15 14:33:50,INDUSTRY,,,,,
301479,301480,NCT01897402,,2013-07-09,2015-03-26,,2015-04-16,2013-07-11,2013-07-12,Estimate,2015-04-16,2015-04-23,Estimate,,,,2015-04-16,2015-04-23,Estimate,July 2013,,2013-07-31,April 2015,2015-04-30,December 2014,Actual,2014-12-31,May 2014,Actual,2014-05-31,,Interventional,,"Population contains all randomized subjects. Two randomized subjects could not be vaccinated. Three subjects, one female and 3 males received incorrect vaccine. They are listed according to randomized treatment in the baseline population, but were analyzed according to the actual vaccine received in the safety population (secondary outcomes).","Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine","A Phase 2 Double Blind Study to Evaluate Safety and Immunogenicity of Meningococcal Meningitis Serogroups A, C, Y & W-135 Polysaccharide Diphtheria Toxoid Conjugate Vaccine (NmVac4-A/C/Y/W-135-DT) Compared With a Licensed Vaccine",Completed,,Phase 2,525.0,Actual,JN-International Medical Corporation,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 22:33:36,2023-06-18 22:33:36,INDUSTRY,,,,,
301562,301563,NCT01766921,,2013-01-10,2015-05-05,,2019-01-14,2013-01-10,2013-01-11,Estimate,2015-07-14,2015-08-10,Estimate,,,,2019-01-14,2019-01-30,Actual,January 2013,,2013-01-31,January 2019,2019-01-31,July 2014,Actual,2014-07-31,July 2013,Actual,2013-07-31,,Interventional,,Analysis was done on All Enrolled population.,Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects,"A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.",Completed,,Phase 2,1393.0,Actual,Novartis,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 22:33:56,2023-06-18 22:33:56,INDUSTRY,,,,,
302122,302123,NCT02948127,,2016-10-25,,,2018-08-16,2016-10-26,2016-10-28,Estimate,,,,,,,2018-08-16,2018-08-17,Actual,September 2016,,2016-09-30,August 2018,2018-08-31,"April 30, 2018",Actual,2018-04-30,"April 30, 2017",Actual,2017-04-30,,Interventional,,,"Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp <U+0394>M2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age","Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-attenuated Respiratory Syncytial Virus Vaccine, LID cp <U+0394>M2-2, Lot RSV#009B, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age",Terminated,,Phase 1,8.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 14:42:03,2023-06-15 14:42:03,NIH,,,,,
302193,302194,NCT01450293,,2011-10-03,,,2013-12-11,2011-10-11,2011-10-12,Estimate,,,,,,,2013-12-11,2013-12-12,Estimate,October 2011,,2011-10-31,December 2013,2013-12-31,March 2013,Actual,2013-03-31,March 2013,Actual,2013-03-31,,Interventional,,,AdCh63 ME-TRAP and MVA ME-TRAP Malaria Vaccines Evaluation in Healthy Children in a Malaria Endemic Area,Safety and Immunogenicity of Heterologous Prime-boost Vaccination With the Candidate Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP in Healthy Infants in a Malaria- Endemic Area,Completed,,Phase 1,72.0,Actual,University of Oxford,,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 22:36:43,2023-06-18 22:36:43,OTHER,,,,,
302568,302569,NCT02952833,,2016-10-13,,,2018-12-06,2016-11-01,2016-11-02,Estimate,,,,,,,2018-12-06,2018-12-07,Actual,"October 14, 2016",Actual,2016-10-14,"June 27, 2017",2017-06-27,"December 5, 2018",Actual,2018-12-05,"December 5, 2018",Actual,2018-12-05,,Interventional,,,ZIKA Vaccine in Naive Subjects,"Phase 1, Double-blinded, Placebo-Controlled Study of the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Flavivirus Naïve Adult Subjects",Completed,,Phase 1,91.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-15 14:45:37,2023-06-15 14:45:37,NIH,,,,,
302908,302909,NCT00513968,,2007-08-08,,,2012-08-03,2007-08-08,2007-08-09,Estimate,,,,,,,2012-08-03,2012-08-06,Estimate,July 2007,,2007-07-31,August 2012,2012-08-31,December 2010,Actual,2010-12-31,April 2010,Actual,2010-04-30,,Interventional,,,Phase I Study to Investigate the Safety and Efficacy of HBV DNA Vaccine,"A Single Center, Randomized, Open-label, Dose Escalating Phase I Study to Evaluate the Safety of Intramuscularly Administered DNA Vaccine (HB-110) Combined With Oral Antiviral (Adefovir) in Subjects With Chronic Hepatitis B Over a 48-week Period",Completed,,Phase 1,27.0,Actual,"Genexine, Inc.",,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 14:47:44,2023-06-15 14:47:44,INDUSTRY,,,,,
303125,303126,NCT00516035,,2007-08-13,,,2015-05-15,2007-08-13,2007-08-14,Estimate,,,,,,,2015-05-15,2015-05-18,Estimate,September 2007,,2007-09-30,May 2015,2015-05-31,December 2007,Actual,2007-12-31,December 2007,Actual,2007-12-31,,Interventional,,,Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults,"Phase 1 Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/Chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for the Prevention of Avian Influenza H7N3 Infection in the Event of a Pandemic",Completed,,Phase 1,22.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 14:49:02,2023-06-15 14:49:02,NIH,,,,,
303260,303261,NCT02950688,,2016-10-26,,,2017-11-27,2016-10-28,2016-11-01,Estimate,,,,,,,2017-11-27,2017-11-29,Actual,,,,November 2017,2017-11-30,,,,December 2020,Anticipated,2020-12-31,,Interventional,,,Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus,Evaluation of Correlates of Protective Efficacy of Seasonal Live Attenuated Influenza Vaccine (LAIV) by Utilization of a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus,Withdrawn,,Phase 1,0.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 14:49:57,2023-06-15 14:49:57,NIH,,,,,
303373,303374,NCT05770895,,2023-03-01,,,2023-04-20,2023-03-14,2023-03-16,Actual,,,,,,,2023-04-20,2023-04-24,Actual,"April 3, 2023",Actual,2023-04-03,April 2023,2023-04-30,November 2024,Anticipated,2024-11-30,November 2024,Anticipated,2024-11-30,,Interventional,,,Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B,A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB),Recruiting,,Phase 1,70.0,Anticipated,Gilead Sciences,,7.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-18 22:41:21,2023-06-18 22:41:21,INDUSTRY,,,,,
303395,303396,NCT00518453,,2007-08-17,,,2016-11-30,2007-08-17,2007-08-20,Estimate,,,,,,,2016-11-30,2016-12-01,Estimate,July 2007,,2007-07-31,November 2011,2011-11-30,August 2007,Actual,2007-08-31,August 2007,Actual,2007-08-31,,Interventional,,,"Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Formulation 2007-2008","A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Ph.Eur, Formulation 2007-2008, When Administered to Non-Elderly Adult and Elderly Subjects",Completed,,Phase 2,129.0,Actual,Novartis,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 14:50:43,2023-06-15 14:50:43,INDUSTRY,,,,,
303450,303451,NCT00518726,,2007-08-20,,,2016-11-30,2007-08-20,2007-08-21,Estimate,,,,,,,2016-11-30,2016-12-01,Estimate,June 2007,,2007-06-30,November 2011,2011-11-30,July 2007,Actual,2007-07-31,July 2007,Actual,2007-07-31,,Interventional,,,Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to NON Elderly AND Elderly Subjects,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Surface Antigen, Inactivated, Formulation 2007-2008, When Administered to Non-Elderly Adult and Elderly Subjects",Completed,,Phase 2,125.0,Actual,Novartis,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 14:51:03,2023-06-15 14:51:03,INDUSTRY,,,,,
303538,303539,NCT05393999,,2021-09-01,,,2023-04-21,2022-05-24,2022-05-27,Actual,,,,,,,2023-04-21,2023-04-24,Actual,"November 29, 2021",Actual,2021-11-29,April 2023,2023-04-30,"March 4, 2022",Actual,2022-03-04,"March 4, 2022",Actual,2022-03-04,,Interventional,SABRE,,SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations,"The SABRE Trial: A Single-arm Prospective Study Measuring Safety, Tolerability and Pharmacokinetics of Two SARS-CoV-2 Neutralising Antibodies (C135-LS and C144-LS) Amongst High-risk Special Populations of Vaccine Non-responders.",Withdrawn,,Phase 2,0.0,Actual,Imperial College Healthcare NHS Trust,,1.0,,"The drug was found to be ineffective against Omicron, so the study was terminated and no patients were enrolled.",False,,,,True,False,False,,,,,,,,,No,,2023-06-18 22:42:16,2023-06-18 22:42:16,OTHER,,,,,
303551,303552,NCT05325632,,2022-03-30,,,2023-04-21,2022-04-08,2022-04-13,Actual,,,,,,,2023-04-21,2023-04-24,Actual,"October 28, 2021",Actual,2021-10-28,April 2023,2023-04-30,October 2025,Anticipated,2025-10-31,"October 27, 2024",Anticipated,2024-10-27,,Interventional,,,"Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab","A Phase II Study of Human Epidermal Growth Factor Receptor 2 (HER-2) Directed Dendritic Cell (DC1) Vaccine Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer",Recruiting,,Phase 2,53.0,Anticipated,H. Lee Moffitt Cancer Center and Research Institute,,4.0,,,,,,,True,True,False,,,,,,,,,Undecided,,2023-06-18 22:42:27,2023-06-18 22:42:27,OTHER,,,,,
303628,303629,NCT04748471,,2021-01-24,,,2021-02-06,2021-02-06,2021-02-10,Actual,,,,,,,2021-02-06,2021-02-10,Actual,"February 10, 2021",Anticipated,2021-02-10,January 2021,2021-01-31,"January 25, 2023",Anticipated,2023-01-25,"July 1, 2021",Anticipated,2021-07-01,,Interventional,CoviCompareM,,Immunogenecity and Safety of VaccinemRNA-1273 in Elderly Volunteers (Over 65 y) Compared to Younger Ones (18-45y),A Phase II Trial Assessing Immunogenicity and Safety of SARS-CoV-2 Vaccine mRNA-1273 in Volunteers Aged of 65 Years or More Compared to Participants 18-45 Years Old,Unknown status,Not yet recruiting,Phase 2,180.0,Anticipated,Assistance Publique - Hôpitaux de Paris,,3.0,,,False,,,,False,False,False,,,,,,Beginning 3 months and ending 3 years following article publication. Requests out can also be submitted to the sponsor,Researchers who provide a methodologically sound proposal.,,Yes,"Data are available upon reasonable request The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients.

Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in compliance with the applicable regulations.",2023-06-19 00:01:38,2023-06-19 00:01:38,OTHER,,,,,
303634,303635,NCT05099965,,2021-09-01,,,2023-04-20,2021-10-20,2021-10-29,Actual,,,,,,,2023-04-20,2023-04-24,Actual,"November 2, 2021",Actual,2021-11-02,April 2023,2023-04-30,"September 23, 2025",Anticipated,2025-09-23,"September 23, 2025",Anticipated,2025-09-23,,Interventional,,,Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®),"Phase II, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®), in Adults With Both Human Immunodeficiency Virus (HIV)-1 and CMV Who Are on Potent Combination ART With Conserved Immune Function",Recruiting,,Phase 2,90.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,True,False,,,,,,Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.,"With whom?

Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.

For what types of analyses?

To achieve aims in the proposal approved by the AIDS Clinical Trials Group.

By what mechanism will data be made available?

Researchers may submit a request for access to data using the AIDS Clinical Trials Group ""Data Request"" form at: https://actgnetwork.org/about-actg/templates-and-forms. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.",,Yes,"Individual participant data that underlie results in the publication, after deidentification.",2023-06-18 22:42:55,2023-06-18 22:42:55,NIH,,,,,
303784,303785,NCT00520598,,2007-08-22,,,2015-11-25,2007-08-22,2007-08-24,Estimate,,,,,,,2015-11-25,2015-11-26,Estimate,October 2007,,2007-10-31,November 2015,2015-11-30,May 2011,Actual,2011-05-31,May 2011,Actual,2011-05-31,,Interventional,,,Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001),"A Phase IIa Randomized, Double-Blind Controlled With Gardasil, Clinical Trial to Study theTolerability and Immunogenicity of V505 (a Multivalent Human Papilloma Virus [HPV] L1 Virus Like Particle [VLP] Vaccine) in Healthy 16 to 26 Year Old Women",Completed,,Phase 2,511.0,Actual,Merck Sharp & Dohme LLC,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 14:52:46,2023-06-15 14:52:46,INDUSTRY,,,,,
303935,303936,NCT04131413,,2019-10-16,,,2023-04-20,2019-10-16,2019-10-18,Actual,,,,,,,2023-04-20,2023-04-24,Actual,"September 14, 2020",Actual,2020-09-14,April 2023,2023-04-30,December 2024,Anticipated,2024-12-31,December 2023,Anticipated,2023-12-31,,Interventional,,,HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia,"A Phase I Open Label, Dose Escalation Clinical Trial Assessing the Safety, Tolerability, and Feasibility of pNGVL4aCRTE6E7L2 HPV DNA Vaccine Administration Via Intramuscular TriGridTM Electroporation Delivery System to Patients With HPV16-Positive High-Grade Cervical Intraepithelial Neoplasia",Recruiting,,Phase 1,48.0,Anticipated,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,3.0,,,False,,,,True,True,False,,,,,,Immediately after publication of the study,Sharing is governed by Johns Hopkins University Institutional Guidelines,https://trp.cancer.gov/spores/abstracts/johnshopkins_gyn.htm,Yes,"Per our NCI grant resource sharing plan, this would include all coded data sets, including laboratory analyses of immune responses, as well as, if agreed to by participant, coded human specimens.",2023-06-18 22:44:46,2023-06-18 22:44:46,OTHER,,,,,
303963,303964,NCT00522236,,2007-08-28,,,2012-01-24,2007-08-28,2007-08-29,Estimate,,,,,,,2012-01-24,2012-01-25,Estimate,June 2007,,2007-06-30,January 2012,2012-01-31,July 2007,Actual,2007-07-31,July 2007,Actual,2007-07-31,,Interventional,,,Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to Elderly Subjects,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Elderly Subjects",Completed,,Phase 2,56.0,Actual,Novartis,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 14:53:43,2023-06-15 14:53:43,INDUSTRY,,,,,
304098,304099,NCT03558945,,2018-05-24,,,2023-04-21,2018-06-05,2018-06-15,Actual,,,,,,,2023-04-21,2023-04-24,Actual,"July 12, 2018",Actual,2018-07-12,March 2023,2023-03-31,"December 30, 2023",Anticipated,2023-12-30,"November 30, 2023",Anticipated,2023-11-30,,Interventional,,,Clinical Trial on Personalized Neoantigen Vaccine for Pancreatic Tumor,Clinical Trial to Evaluate Safety and Effect of Personalized Neoantigen Vaccine for Pancreatic Tumor Following Surgical Resection and Adjuvant Chemotherapy,Recruiting,,Phase 1,30.0,Anticipated,"Anda Biopharmaceutical Development (Shenzhen) Co., Ltd.",,1.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 22:45:30,2023-06-18 22:45:30,INDUSTRY,,,,,
304641,304642,NCT00995982,,2009-10-15,,,2017-06-30,2009-10-15,2009-10-16,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"October 8, 2009",,2009-10-08,"September 3, 2010",2010-09-03,"September 3, 2010",Actual,2010-09-03,"September 3, 2010",Actual,2010-09-03,,Interventional,,,"VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years","VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years",Completed,,Phase 1,60.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-16 17:35:06,2023-06-16 17:35:06,NIH,,,,,
304665,304666,NCT01890213,,2013-06-26,,,2019-07-16,2013-06-27,2013-07-01,Estimate,,,,,,,2019-07-16,2019-07-18,Actual,November 2013,Actual,2013-11-30,July 2019,2019-07-31,July 2019,Actual,2019-07-31,June 2017,Actual,2017-06-30,,Interventional,,,Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer,A Pilot Study of Active Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer,Completed,,Phase 1,12.0,Anticipated,Duke University,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-18 22:47:51,2023-06-18 22:47:51,OTHER,,,,,
304831,304832,NCT04758273,,2021-02-09,,,2021-02-16,2021-02-16,2021-02-17,Actual,,,,,,,2021-02-16,2021-02-17,Actual,"October 7, 2020",Actual,2020-10-07,February 2021,2021-02-28,"February 28, 2022",Anticipated,2022-02-28,"June 30, 2021",Anticipated,2021-06-30,,Interventional,,,A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19),"Evaluation of the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above: a Randomized, Double-blind, Placebo Parallel-controlled Phase I Clinical Trial",Unknown status,"Active, not recruiting",Phase 1,180.0,Actual,"Beijing Minhai Biotechnology Co., Ltd",,9.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-18 22:48:34,2023-06-18 22:48:34,INDUSTRY,,,,,
304889,304890,NCT02600949,,2015-11-06,,,2022-08-26,2015-11-06,2015-11-09,Estimate,,,,,,,2022-08-26,2022-08-31,Actual,"May 11, 2016",Actual,2016-05-11,August 2022,2022-08-31,"May 31, 2025",Anticipated,2025-05-31,"May 31, 2025",Anticipated,2025-05-31,,Interventional,,,Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer,Pilot Study of the Feasibility and Safety of a Personalized Peptide Vaccine in Patients With Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma,Recruiting,,Phase 1,150.0,Anticipated,M.D. Anderson Cancer Center,,3.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-18 22:48:49,2023-06-18 22:48:49,OTHER,,,,,
305081,305082,NCT05583357,,2022-10-13,,,2022-10-16,2022-10-13,2022-10-17,Actual,,,,,,,2022-10-16,2022-10-19,Actual,"August 15, 2022",Actual,2022-08-15,October 2022,2022-10-31,"August 10, 2023",Anticipated,2023-08-10,"September 13, 2022",Actual,2022-09-13,,Interventional,COVID-19,,Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351,"A Single Center, Randomized, Open-labeled, Blind Endpoint Evaluation, Exploratory Clinical Study to Evaluate the Safety and Immunogenicity of Bivalent Vaccine V-01D-351 as a Booster Dose in Participants Aged 18 Years and Older Vaccinated 2-dose or 3-dose Inactivated COVID-19 Vaccine","Active, not recruiting",,Early Phase 1,40.0,Actual,Livzon Pharmaceutical Group Inc.,,4.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-18 22:49:57,2023-06-18 22:49:57,INDUSTRY,,,,,
305151,305152,NCT00530660,,2007-09-14,,,2015-10-07,2007-09-14,2007-09-17,Estimate,,,,,,,2015-10-07,2015-10-09,Estimate,September 2007,,2007-09-30,December 2008,2008-12-31,October 2008,Actual,2008-10-31,May 2008,Actual,2008-05-31,,Interventional,,,Safety and Immunogenicity Study of a Booster Vaccination With a Non-Adjuvanted H5N1 Influenza Vaccine (Follow Up to Study 810501),An Open-label Phase II Study to Assess the Immunogenicity and Safety of a Booster Vaccination With a Heterologous Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Healthy Young Adult Population (Follow Up to Study 810501),Completed,,Phase 2,141.0,Anticipated,Ology Bioservices,,,,,False,,,,True,,,,,,,,,,,,,2023-06-15 15:00:22,2023-06-15 15:00:22,INDUSTRY,,,,,
305874,305875,NCT01295320,,2011-02-11,2017-05-11,,2017-10-23,2011-02-11,2011-02-14,Estimate,2017-05-11,2017-10-05,Actual,,,,2017-10-23,2017-11-27,Actual,"February 28, 2011",Actual,2011-02-28,October 2017,2017-10-31,"June 20, 2013",Actual,2013-06-20,"June 20, 2013",Actual,2013-06-20,,Interventional,,,Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects,Long Term Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Subjects,Completed,,Phase 2,129.0,Actual,GlaxoSmithKline,,1.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 15:03:46,2023-06-15 15:03:46,INDUSTRY,,,,,
305998,305999,NCT01048528,,2009-11-03,,,2012-03-26,2010-01-12,2010-01-13,Estimate,,,,,,,2012-03-26,2012-03-27,Estimate,July 2009,,2009-07-31,March 2012,2012-03-31,February 2012,Actual,2012-02-29,February 2012,Actual,2012-02-29,,Interventional,,,Health SMART (Stress Management and Relaxation Training),Phase II Study of Stress Management and Vaccine Response Among Women at Risk for Breast Cancer,Completed,,Phase 2,33.0,Actual,Fred Hutchinson Cancer Center,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 17:37:00,2023-06-16 17:37:00,OTHER,,,,,
306035,306036,NCT04756323,,2021-02-09,,,2021-02-16,2021-02-14,2021-02-16,Actual,,,,,,,2021-02-16,2021-02-17,Actual,"October 27, 2020",Actual,2020-10-27,February 2021,2021-02-28,"February 28, 2022",Anticipated,2022-02-28,"June 30, 2021",Anticipated,2021-06-30,,Interventional,,,A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19),"Evaluation of the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above: a Randomized, Double-blind, Placebo Parallel-controlled Phase II Clinical Trial",Unknown status,"Active, not recruiting",Phase 2,1000.0,Actual,"Beijing Minhai Biotechnology Co., Ltd",,12.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-18 22:54:58,2023-06-18 22:54:58,INDUSTRY,,,,,
306097,306098,NCT02937233,,2016-10-12,,,2018-08-22,2016-10-17,2016-10-18,Estimate,,,,,,,2018-08-22,2018-08-23,Actual,"December 8, 2016",Actual,2016-12-08,August 2018,2018-08-31,"June 4, 2018",Actual,2018-06-04,"June 4, 2018",Actual,2018-06-04,,Interventional,Z001,,Zika Virus Purified Inactivated Vaccine (ZPIV) Accelerated Vaccination Schedule Study,"A Phase 1, Randomized, Double-Blind Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of an Accelerated Vaccination Schedule With a Zika Virus Purified Inactivated Vaccine Plus Alum Adjuvant in Healthy Adults",Completed,,Phase 1,36.0,Actual,Beth Israel Deaconess Medical Center,,3.0,,,False,,,,True,,,,,,,,,,,Undecided,,2023-06-15 15:05:22,2023-06-15 15:05:22,OTHER,,,,,
306790,306791,NCT01390064,,2011-06-29,2018-07-26,,2019-08-07,2011-07-07,2011-07-08,Estimate,2019-02-19,2019-06-03,Actual,,,,2019-08-07,2019-08-20,Actual,July 2011,Actual,2011-07-31,August 2019,2019-08-31,July 2019,Actual,2019-07-31,July 2018,Actual,2018-07-31,,Interventional,,,Vaccination of High Risk Breast Cancer Patients,Phase 1 Safety Study of a Carbohydrate Mimotope Based Vaccine With MONTANIDE ISA 51 VG Adjuvant,Completed,,Phase 1,6.0,Actual,University of Arkansas,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 08:12:17,2023-06-14 08:12:17,OTHER,,,,,
307232,307233,NCT02690181,,2016-02-16,2017-10-30,,2019-06-06,2016-02-19,2016-02-24,Estimate,2018-05-21,2018-07-16,Actual,,,,2019-06-06,2019-06-20,Actual,"March 29, 2016",Actual,2016-03-29,June 2019,2019-06-30,"November 2, 2016",Actual,2016-11-02,"November 2, 2016",Actual,2016-11-02,,Interventional,,,Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.,"A Phase 2, Non-Randomized, Controlled, Open-Label, Parallel-Group, Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-pregnant Subjects.",Completed,,Phase 2,80.0,Actual,GlaxoSmithKline,,6.0,,,False,,,,False,,,,,,,,IPD will be made available within 6 months of publishing the results of the primary endpoints of the study,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months",http://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site,2023-06-14 08:12:38,2023-06-14 08:12:38,INDUSTRY,,,,,
307486,307487,NCT03562377,,2018-06-08,2021-01-14,2020-09-09,2022-10-14,2018-06-08,2018-06-19,Actual,2021-02-15,2021-03-05,Actual,2021-02-15,2021-03-05,Actual,2022-10-14,2022-10-19,Actual,"July 13, 2018",Actual,2018-07-13,January 2021,2021-01-31,"November 22, 2019",Actual,2019-11-22,"September 17, 2019",Actual,2019-09-17,,Interventional,ECZTRA 5,,Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5),"A Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Effect of Tralokinumab on Vaccine Antibody Responses in Adults With Moderate-to-severe Atopic Dermatitis Who Are Candidates for Systemic Therapy",Completed,,Phase 2,215.0,Actual,LEO Pharma,,2.0,,,False,,,,False,True,False,,,,,,Data is available to request after results of the trial are available on leopharmatrials.com,Data-sharing is subject to approved scientifically sound research proposal and signed data-sharing agreement.,http://leopharmatrials.com/for-professionals,Yes,De-identified IPD can be made available to researchers in a closed environment for a specified period of time.,2023-06-18 23:04:27,2023-06-18 23:04:27,INDUSTRY,,,,,
307569,307570,NCT02531698,,2015-08-20,2018-02-28,,2020-10-22,2015-08-20,2015-08-24,Estimate,2018-02-28,2018-03-27,Actual,,,,2020-10-22,2020-10-26,Actual,August 2015,Actual,2015-08-31,October 2020,2020-10-31,March 2017,Actual,2017-03-31,March 2017,Actual,2017-03-31,,Interventional,,"Safety population included all participants who received at least 1 dose of the investigational product (rLP2086, HAV vaccine or saline) and had safety data available.","A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged =24 Months to <10 Years","A Phase 2, Randomized, Controlled, Observer-blinded Study To Describe The Immunogenicity, Safety, And Tolerability Of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent Rlp2086) In Healthy Subjects Aged >/= 24 Months To <10 Years",Completed,,Phase 2,400.0,Actual,Pfizer,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 22:59:10,2023-06-17 22:59:10,INDUSTRY,,,,,
308423,308424,NCT00532974,,2007-09-19,,,2007-12-19,2007-09-20,2007-09-21,Estimate,,,,,,,2007-12-19,2007-12-24,Estimate,October 2006,,2006-10-31,December 2007,2007-12-31,April 2008,Anticipated,2008-04-30,,,,,Interventional,EP1090,,A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART),A Phase 1 Safety and Immunogenicity Study of the Pharmexa-Epimmune HIV-1 CTL Epitope-Based DNA Vaccine (EP HIV-1090) Administered Using a Biojector 2000 Needle Free Immunization Device in HIV-1 Infected Individuals Receiving Potent Combination Antiretroviral Therapy (ART),Unknown status,"Active, not recruiting",Phase 1,32.0,Anticipated,Epimmune,,,,,False,,,,True,,,,,,,,,,,,,2023-06-15 15:16:29,2023-06-15 15:16:29,INDUSTRY,,,,,
308630,308631,NCT01808820,,2013-03-06,,,2022-07-19,2013-03-07,2013-03-11,Estimate,,,,,,,2022-07-19,2022-07-20,Actual,"August 21, 2013",Actual,2013-08-21,July 2022,2022-07-31,"July 16, 2022",Actual,2022-07-16,"November 7, 2018",Actual,2018-11-07,,Interventional,,,Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma,Dendritic Cell Vaccine For Malignant Glioma and Glioblastoma Multiforme in Adult and Pediatric Subjects,Completed,,Phase 1,20.0,Actual,University of Miami,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-15 15:18:14,2023-06-15 15:18:14,OTHER,,,,,
308954,308955,NCT02891980,,2016-09-01,,,2021-02-18,2016-09-01,2016-09-08,Estimate,,,,,,,2021-02-18,2021-02-21,Actual,"March 24, 2017",Actual,2017-03-24,"July 19, 2017",2017-07-19,"March 21, 2019",Actual,2019-03-21,"March 21, 2019",Actual,2019-03-21,,Interventional,,,A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers,"A Phase I Trial to Utilize Systems Biology Approaches to Examine the Safety, Immunogenicity, and 'Omics Response to MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers",Completed,,Phase 1,65.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-15 15:20:25,2023-06-15 15:20:25,NIH,,,,,
309000,309001,NCT00354861,,2006-07-19,,,2008-04-22,2006-07-19,2006-07-20,Estimate,,,,,,,2008-04-22,2008-04-25,Estimate,May 2005,,2005-05-31,April 2008,2008-04-30,February 2006,Actual,2006-02-28,November 2005,Actual,2005-11-30,,Interventional,,,A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321,"A Phase I, Single-Blind Study to Determine the Safety, Tolerability and Pharmacodynamic Profiles of a Hepatitis B Antigen Combined With IMP321 Versus the Hepatitis B Antigen Alone and a Reference Vaccine in Healthy Young Male Volunteers",Completed,,Phase 1,48.0,Actual,Immutep S.A.S.,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 01:42:05,2023-06-14 01:42:05,INDUSTRY,,,,,
309019,309020,NCT02450838,,2015-05-19,,,2016-03-31,2015-05-19,2015-05-21,Estimate,,,,,,,2016-03-31,2016-04-04,Estimate,April 2015,,2015-04-30,March 2016,2016-03-31,October 2015,Actual,2015-10-31,October 2015,Actual,2015-10-31,,Interventional,,,"Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)","A Phase I Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Tetravalent Recombinant Subunit Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)",Completed,,Phase 1,20.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 23:14:57,2023-06-18 23:14:57,NIH,,,,,
309146,309147,NCT02503839,,2015-07-10,,,2022-04-07,2015-07-20,2015-07-21,Estimate,,,,,,,2022-04-07,2022-04-08,Actual,November 2015,Actual,2015-11-30,April 2022,2022-04-30,"March 23, 2020",Actual,2020-03-23,September 2019,Actual,2019-09-30,,Interventional,TBCOX2,,Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic,Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the Multidrug-resistant Tuberculosis Pandemic; an Open Label Phase I Clinical Trial of the Therapeutic TB H56:IC31 Vaccine and Cyclooxygenase-inhibitors,Completed,,Phase 1,39.0,Actual,Oslo University Hospital,,4.0,,,False,,,,True,,,,,,,,Data available as supplementary information in the published manuscript.,The full source datasets generated during and/or analyzed during the current study are available in the repository of the open science framework (https://osf.io/khvf4),https://doi.org/10.1038/s41467-021-27029-6,Yes,The study is published. https://doi.org/10.1038/s41467-021-27029-6,2023-06-15 15:21:23,2023-06-15 15:21:23,OTHER,,,,,
309275,309276,NCT00537524,,2007-09-28,,,2012-02-14,2007-09-28,2007-10-01,Estimate,,,,,,,2012-02-14,2012-02-16,Estimate,September 2007,,2007-09-30,February 2012,2012-02-29,May 2008,Actual,2008-05-31,October 2007,Actual,2007-10-31,,Interventional,,,"Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years","A Phase II, Randomized, Controlled, Observer-blind, Single-center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of an H5N1 Influenza Vaccine in Subjects Aged 6 Months to 17 Years",Completed,,Phase 2,471.0,Actual,Novartis,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 15:22:13,2023-06-15 15:22:13,INDUSTRY,,,,,
309323,309324,NCT04685603,,2020-12-22,,,2020-12-24,2020-12-24,2020-12-28,Actual,,,,,,,2020-12-24,2020-12-29,Actual,"December 7, 2020",Actual,2020-12-07,December 2020,2020-12-31,"January 31, 2022",Anticipated,2022-01-31,"January 31, 2021",Anticipated,2021-01-31,,Interventional,,,Dendritic Cell Vaccine to Prevent COVID-19,"Adaptive Phase I Clinical Trial of Preventive Vaccine Consisting of Autologous Dendritic Cells Previously Incubated With S-protein From SARS-CoV-2, in Subjects Negative for COVID-19 Infection and Anti-SARS-CoV-2 Antibodies",Unknown status,Recruiting,Phase 1,27.0,Anticipated,Indonesia-MoH,,9.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-15 15:22:27,2023-06-15 15:22:27,OTHER_GOV,,,,,
309393,309394,NCT00551915,,2007-10-29,,,2015-10-29,2007-10-29,2007-10-31,Estimate,,,,,,,2015-10-29,2015-10-30,Estimate,May 2001,,2001-05-31,October 2015,2015-10-31,January 2003,Actual,2003-01-31,January 2003,Actual,2003-01-31,,Interventional,,,"A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003)","Safety, Tolerability, and Immunogenicity of 3 Different Formulations of a Liquid Hexavalent Combination Vaccine, HR5I When Administered to Healthy Hepatitis B Vaccine-Naive Infants at 2, 4, 6, and 12-14 Months of Age",Completed,,Phase 2,756.0,Actual,Merck Sharp & Dohme LLC,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 15:22:53,2023-06-15 15:22:53,INDUSTRY,,,,,
309465,309466,NCT04943848,,2021-05-24,,,2023-02-06,2021-06-21,2021-06-29,Actual,,,,,,,2023-02-06,2023-02-08,Actual,"January 10, 2022",Actual,2022-01-10,January 2023,2023-01-31,March 2025,Anticipated,2025-03-31,December 2024,Anticipated,2024-12-31,,Interventional,,,rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG,A Phase I Clinical Trial of Neo-antigen Heat Shock Protein Vaccine (rHSC-DIPGVax) in Combination With Checkpoint Blockade for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma in Childhood,Recruiting,,Phase 1,36.0,Anticipated,Ann & Robert H Lurie Children's Hospital of Chicago,,4.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-18 23:17:54,2023-06-18 23:17:54,OTHER,,,,,
309665,309666,NCT00537147,,2007-09-27,,,2012-12-31,2007-09-27,2007-09-28,Estimate,,,,,,,2012-12-31,2013-01-03,Estimate,March 2008,,2008-03-31,December 2012,2012-12-31,June 2009,Actual,2009-06-30,June 2009,Actual,2009-06-30,,Interventional,,,Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4delta30) in Healthy Adults,"Phase 1 Study of the Safety and Immunogenicity of a 2-Dose Regimen of West Nile/Dengue 4-3'delta30 Chimeric Virus Vaccine (WN/DEN4delta30), a Live Attenuated Vaccine for West Nile Encephalitis",Completed,,Phase 1,26.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 15:24:20,2023-06-15 15:24:20,NIH,,,,,
309872,309873,NCT03989102,,2019-06-14,,,2022-11-01,2019-06-15,2019-06-18,Actual,,,,,,,2022-11-01,2022-11-03,Actual,"July 3, 2019",Actual,2019-07-03,May 2022,2022-05-31,"February 28, 2023",Anticipated,2023-02-28,"April 5, 2022",Actual,2022-04-05,,Interventional,,,"Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Malaria Transmission Season in Healthy African Adult Women of Childbearing Potential in Mali","Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Malaria Transmission Season in Healthy African Adult Women of Childbearing Potential in Mali","Active, not recruiting",,Phase 2,562.0,Actual,National Institutes of Health Clinical Center (CC),,3.0,,,False,,,,,True,False,,,,,,,,,No,,2023-06-15 15:25:50,2023-06-15 15:25:50,NIH,,,,,
309927,309928,NCT05631886,,2022-11-21,,,2023-02-05,2022-11-29,2022-11-30,Actual,,,,,,,2023-02-05,2023-02-08,Actual,"February 6, 2023",Actual,2023-02-06,February 2023,2023-02-28,"December 30, 2026",Anticipated,2026-12-30,"December 30, 2025",Anticipated,2025-12-30,,Interventional,,,Combination of CAR-DC Vaccine and Anti-PD-1 Antibody in Malignant Tumors,A Pilot Clinical Trial of Autologous EphA-2-Targeting Chimeric Antigen Receptor Dendritic Cell Vaccine Loaded With TP53 Mutant Peptide Plus Anti-PD-1 Antibody for Local Advanced/Metastatic Solid Tumors or Relapsed/Refractory Lymphomas.,Recruiting,,Phase 1,10.0,Anticipated,Chinese PLA General Hospital,,1.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 23:21:11,2023-06-18 23:21:11,OTHER,,,,,
310467,310468,NCT03110770,,2017-03-28,2020-10-02,,2023-01-10,2017-04-06,2017-04-12,Actual,2020-11-10,2020-12-04,Actual,,,,2023-01-10,2023-02-08,Actual,"March 29, 2017",Actual,2017-03-29,December 2022,2022-12-31,"October 4, 2019",Actual,2019-10-04,"October 4, 2019",Actual,2019-10-04,,Interventional,DNA,Population includes all randomized subjects.,VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents,"VRC 705: A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents",Completed,,Phase 2,2428.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-18 23:24:41,2023-06-18 23:24:41,NIH,,,,,
310993,310994,NCT01262872,,2010-12-02,2014-03-13,2013-04-11,2019-06-06,2010-12-16,2010-12-17,Estimate,2014-03-13,2014-04-21,Estimate,2013-04-11,2013-04-18,Estimate,2019-06-06,2019-06-19,Actual,"February 9, 2011",Actual,2011-02-09,June 2019,2019-06-30,"March 18, 2013",Actual,2013-03-18,"March 18, 2013",Actual,2013-03-18,,Interventional,,,"Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants","Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety and Immunogenicity When Co-administered With Routine EPI Vaccines in Infants Following Safety Assessment in Children Aged 2-4 Years in The Gambia",Completed,,Phase 2,1320.0,Actual,GlaxoSmithKline,,8.0,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months",http://clinicalstudydatarequest.com,Yes,IPD is available via the Clinical Study Data Request site (click on the link provided below),2023-06-15 15:33:13,2023-06-15 15:33:13,INDUSTRY,,,,,
311352,311353,NCT03455309,,2018-02-13,,,2020-01-28,2018-02-27,2018-03-06,Actual,,,,,,,2020-01-28,2020-01-29,Actual,"January 30, 2018",Actual,2018-01-30,January 2020,2020-01-31,"October 15, 2019",Actual,2019-10-15,"July 19, 2019",Actual,2019-07-19,,Interventional,,,Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization,"A Phase 2 Double-blind Placebo-controlled Study to Evaluate the Safety, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing S. Aureus Colonization",Completed,,Phase 2,382.0,Actual,"NovaDigm Therapeutics, Inc.",,2.0,,,,,,,True,True,False,,,,,,,,,No,,2023-06-15 15:34:40,2023-06-15 15:34:40,INDUSTRY,,,,,
311385,311386,NCT00535665,,2007-09-24,,,2007-11-08,2007-09-24,2007-09-26,Estimate,,,,,,,2007-11-08,2007-11-09,Estimate,September 2007,,2007-09-30,November 2007,2007-11-30,November 2007,Actual,2007-11-30,,,,,Interventional,,,Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine,"The Clinical Trial of Pandemic Influenza Vaccine (Whole-Virion, Inactivated, Adjuvanted) on Healthy Adults by Randomized and Double-Blind Design: a Phase II Study",Completed,,Phase 2,402.0,Actual,"Sinovac Biotech Co., Ltd",,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 15:34:53,2023-06-15 15:34:53,INDUSTRY,,,,,
311668,311669,NCT00708084,,2008-07-01,,2009-07-31,2012-03-19,2008-07-01,2008-07-02,Estimate,,,,2009-07-31,2009-08-10,Estimate,2012-03-19,2012-03-20,Estimate,May 2008,,2008-05-31,March 2012,2012-03-31,October 2008,Actual,2008-10-31,October 2008,Actual,2008-10-31,,Interventional,,,Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents,"A Single-blind, Randomized, Monocentric Phase II Trial to Explore the Safety and Rabies-neutralizing Activity of Combined Administration of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin Plus Rabies Vaccine in Simulated Rabies Post-exposure Prophylaxis in Children and Adolescents",Completed,,Phase 2,48.0,Actual,Crucell Holland BV,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 23:33:12,2023-06-18 23:33:12,INDUSTRY,,,,,
311897,311898,NCT00551187,,2007-10-29,,,2015-06-05,2007-10-29,2007-10-30,Estimate,,,,,,,2015-06-05,2015-06-08,Estimate,October 2007,,2007-10-31,June 2015,2015-06-30,May 2009,Actual,2009-05-31,May 2009,Actual,2009-05-31,,Interventional,,,A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED),"A Randomized, Double-Blinded, Tolerability and Immunogenicity Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered Concomitantly With GARDASIL to 16- to 26- Year-Old Women",Completed,,Phase 2,620.0,Actual,Merck Sharp & Dohme LLC,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 15:37:59,2023-06-15 15:37:59,INDUSTRY,,,,,
312001,312002,NCT03116802,,2017-03-13,,,2020-03-19,2017-04-11,2017-04-17,Actual,,,,,,,2020-03-19,2020-03-23,Actual,"March 8, 2017",Actual,2017-03-08,March 2020,2020-03-31,"April 16, 2018",Actual,2018-04-16,"April 16, 2018",Actual,2018-04-16,,Interventional,,,Yellow Fever Vaccine on Statin/ Non Statin Subjects,Using Systems Vaccinology to Elucidate the Effects of Anti-inflammatory Therapy on Immune Response After Vaccination With a Live Attenuated Vaccine,Completed,,Phase 2,37.0,Actual,Singapore General Hospital,,2.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-18 23:34:47,2023-06-18 23:34:47,OTHER,,,,,
312488,312489,NCT02425098,,2015-04-09,2019-04-10,,2019-07-16,2015-04-20,2015-04-23,Estimate,2019-07-16,2019-08-28,Actual,,,,2019-07-16,2019-08-28,Actual,"June 3, 2015",Actual,2015-06-03,July 2019,2019-07-31,"September 18, 2017",Actual,2017-09-18,"September 18, 2017",Actual,2017-09-18,,Interventional,,Safety set included all randomized participants who received the study vaccine.,Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore,"A Phase II, Double-Blind, Randomized, Controlled Trial to Assess the Safety and Immunogenicity of a Tetravalent Dengue Vaccine With Two Different Serotype 2 Potencies in an Adult Population in Singapore",Completed,,Phase 2,351.0,Actual,Takeda,,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-14 08:19:27,2023-06-14 08:19:27,INDUSTRY,,,,,
312709,312710,NCT02307851,,2014-11-17,,2016-09-20,2016-09-20,2014-12-01,2014-12-04,Estimate,,,,2016-09-20,2016-09-23,Estimate,2016-09-20,2016-09-23,Estimate,November 2014,,2014-11-30,September 2016,2016-09-30,June 2015,Actual,2015-06-30,June 2015,Actual,2015-06-30,,Interventional,,,Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults,"A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and SAfety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-49) Adults",Completed,,Phase 2,400.0,Actual,Novavax,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 15:42:33,2023-06-15 15:42:33,INDUSTRY,,,,,
312812,312813,NCT01209325,,2010-09-24,2020-04-29,,2020-08-06,2010-09-24,2010-09-27,Estimate,2020-05-13,2020-05-27,Actual,,,,2020-08-06,2020-08-11,Actual,"June 28, 2011",Actual,2011-06-28,August 2020,2020-08-31,"December 12, 2017",Actual,2017-12-12,"December 12, 2017",Actual,2017-12-12,,Interventional,,Eligible participants who received at least one dose of vaccine.,Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males,AMC-072: Protective Effect of Quadrivalent Vaccine in Young HIV-Positive Males Who Have Sex With Males,Completed,,Phase 2,149.0,Actual,AIDS Malignancy Consortium,,1.0,,,False,,,,False,True,False,,,False,,,,,,No,,2023-06-15 15:43:50,2023-06-15 15:43:50,NETWORK,,,,,
312880,312881,NCT04665050,,2020-12-08,,,2021-04-16,2020-12-08,2020-12-11,Actual,,,,,,,2021-04-16,2021-04-19,Actual,"February 4, 2021",Actual,2021-02-04,April 2021,2021-04-30,"April 6, 2021",Actual,2021-04-06,"April 6, 2021",Actual,2021-04-06,,Interventional,,,"Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (pPCV) in Japanese Adults (pPCV-002)","A Phase 1, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine in Healthy Japanese Adults.",Completed,,Phase 1,102.0,Actual,Merck Sharp & Dohme LLC,,2.0,,,False,,,,False,True,False,,,True,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2023-06-15 15:44:34,2023-06-15 15:44:34,INDUSTRY,,,,,
313236,313237,NCT01205581,,2010-09-17,2014-07-24,,2016-09-20,2010-09-17,2010-09-20,Estimate,2014-09-05,2014-09-12,Estimate,,,,2016-09-20,2016-09-23,Estimate,September 2010,,2010-09-30,July 2016,2016-07-31,August 2013,Actual,2013-08-31,August 2013,Actual,2013-08-31,,Interventional,,This was an open-label study where participants were randomized at a 1:1 ratio into Fluzone high-dose (HD) and Fluzone standard dose (SD) groups by disease group with the use of a computer-generated randomization schedule.,"Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV","Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV",Completed,,Phase 2,85.0,Actual,St. Jude Children's Research Hospital,,6.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 15:48:22,2023-06-15 15:48:22,OTHER,,,,,
313393,313394,NCT04650971,,2020-11-25,,,2020-11-25,2020-11-25,2020-12-03,Actual,,,,,,,2020-11-25,2020-12-03,Actual,"August 29, 2019",Actual,2019-08-29,November 2020,2020-11-30,"March 31, 2020",Actual,2020-03-31,"March 31, 2020",Actual,2020-03-31,,Interventional,,,"Study to Assess Safety, Tolerability and Reactogenicity of Vaccine ""UniFluVec"" After Two Intranasal Administrations in Healthy Volunteers","Phase I Randomized Double Blind Placebo-controlled Study of Universal Influenza Vector Vaccine ""UniFluVec"" of Two Dose Levels After Two Intranasal Administrations in Healthy Volunteers at the Age From 18 to 49 Years Old",Completed,,Phase 1,60.0,Actual,Pharmenterprises Biotech LLC,,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-15 15:49:59,2023-06-15 15:49:59,OTHER,,,,,
313482,313483,NCT01239043,,2010-11-08,2012-05-14,,2012-06-18,2010-11-09,2010-11-11,Estimate,2012-05-14,2012-06-19,Estimate,,,,2012-06-18,2012-06-25,Estimate,November 2010,,2010-11-30,June 2012,2012-06-30,February 2012,Actual,2012-02-29,April 2011,Actual,2011-04-30,,Interventional,,,Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination,Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® Vaccine Approximately Three Years Following Initial Vaccination in Adults Who Participated in Trial MTA29,Completed,,Phase 2,139.0,Actual,Sanofi,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 15:51:03,2023-06-15 15:51:03,INDUSTRY,,,,,
313741,313742,NCT05721846,,2023-01-30,,,2023-06-02,2023-02-08,2023-02-10,Actual,,,,,,,2023-06-02,2023-06-05,Actual,"May 3, 2023",Actual,2023-05-03,June 2023,2023-06-30,December 2025,Anticipated,2025-12-31,May 2025,Anticipated,2025-05-31,,Interventional,CheckVAC,,Nivolumab With Ipilimumab Combined With TGFß-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer,Phase 1 Study of Nivolumab With Ipilimumab Combined With TGFß-15 Peptide Vaccine and Stereotactic Body Radiotherapy for Refractory Pancreatic Cancer (CheckVAC),Recruiting,,Phase 1,20.0,Anticipated,Herlev Hospital,,1.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-16 17:43:22,2023-06-16 17:43:22,OTHER,,,,,
313936,313937,NCT01229176,,2010-10-25,2014-03-05,,2014-04-11,2010-10-26,2010-10-27,Estimate,2014-03-05,2014-04-10,Estimate,,,,2014-04-11,2014-05-01,Estimate,March 2011,,2011-03-31,April 2014,2014-04-30,June 2012,Actual,2012-06-30,June 2012,Actual,2012-06-30,,Interventional,,All enrolled Set,"Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants","A Phase 2a, Randomized, Controlled, Observer Blind, Age De-Escalation, Multicenter and Multinational Study of the Safety, Reactogenicity and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants",Completed,,Phase 2,200.0,Actual,Novartis,,8.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 15:55:33,2023-06-15 15:55:33,INDUSTRY,,,,,
314230,314231,NCT05525546,,2022-08-30,,,2023-02-24,2022-08-30,2022-09-01,Actual,,,,,,,2023-02-24,2023-02-27,Actual,"August 15, 2022",Actual,2022-08-15,February 2023,2023-02-28,August 2023,Anticipated,2023-08-31,August 2023,Anticipated,2023-08-31,,Interventional,,,Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease,"Phase 1 Randomized, Placebo-Controlled, Study to Compare the Safety, Reactogenicity, and Immunogenicity of a Full-Strength Formulation of Trivalent Salmonella (S. Enteritidis/S. Typhimurium/S. Typhi Vi) Conjugate Vaccine (TSCV), a Half-Strength Formulation of TSCV, and a Dilutional Half-Strength Dose of TSCV Against Invasive Salmonella Disease Administered Parenterally to Healthy U.S. Adults","Active, not recruiting",,Phase 1,80.0,Anticipated,"University of Maryland, Baltimore",,4.0,,,False,,,,,True,False,,,,,,,,,No,,2023-06-17 23:02:24,2023-06-17 23:02:24,OTHER,,,,,
314339,314340,NCT05657782,,2022-11-12,,,2022-12-11,2022-12-11,2022-12-20,Actual,,,,,,,2022-12-11,2022-12-20,Actual,"December 12, 2022",Actual,2022-12-12,December 2022,2022-12-31,"December 1, 2025",Anticipated,2025-12-01,"December 1, 2024",Anticipated,2024-12-01,,Interventional,,,First in Human Phase 1 Ascending Dose Study of PanChol in Healthy Volunteers,PanChol-100: Safety and Immunogenicity of PanChol: First-in-Human Study of a Novel Live Attenuated Oral Cholera Vaccine,Recruiting,,Phase 1,53.0,Anticipated,Brigham and Women's Hospital,,4.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-15 15:59:32,2023-06-15 15:59:32,OTHER,,,,,
315161,315162,NCT03166254,,2017-05-23,,,2019-04-10,2017-05-23,2017-05-25,Actual,,,,,,,2019-04-10,2019-04-12,Actual,"April 30, 2019",Anticipated,2019-04-30,April 2019,2019-04-30,"May 31, 2027",Anticipated,2027-05-31,"June 30, 2022",Anticipated,2022-06-30,,Interventional,,,Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer,Pilot Feasibility Study of the Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer,Withdrawn,,Phase 1,0.0,Actual,Washington University School of Medicine,,2.0,,Lost funding,False,,,,True,True,False,,,False,,,,,,Undecided,,2023-06-18 23:47:53,2023-06-18 23:47:53,OTHER,,,,,
315337,315338,NCT04545749,,2020-09-02,,,2022-08-25,2020-09-10,2020-09-11,Actual,,,,,,,2022-08-25,2022-08-26,Actual,"September 25, 2020",Actual,2020-09-25,February 2022,2022-02-28,"May 24, 2021",Actual,2021-05-24,"January 18, 2021",Actual,2021-01-18,,Interventional,,,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","A Phase I, Open-label Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 Vaccine in Healthy Adult Volunteers",Completed,,Phase 1,60.0,Actual,"United Biomedical Inc., Asia",,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 23:49:29,2023-06-18 23:49:29,INDUSTRY,,,,,
315499,315500,NCT05049226,,2021-09-14,,,2022-07-03,2021-09-16,2021-09-20,Actual,,,,,,,2022-07-03,2022-07-06,Actual,"September 24, 2021",Actual,2021-09-24,July 2022,2022-07-31,"February 22, 2022",Actual,2022-02-22,"February 22, 2022",Actual,2022-02-22,,Interventional,,,Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine,"A Randomized, Observer-blind Trial to Assess the Immunogenicity and Safety of Third Dose Vaccination With AstraZeneca COVID-19 Vaccine or Pfizer/BioNTech COVID-19 Vaccine Among Thai Adults Receiving Two Doses of Sinovac",Completed,,Phase 2,1250.0,Actual,Mahidol University,,3.0,,,False,,,,True,False,False,,,,,,2 years,as document attach when completed study in NCT clinicaltrials.gov,,Yes,data or left over specimen will be shared for future study ONLY subject who consent allow using their data/specimens. Sharing will be done without personnel identification,2023-06-18 23:50:25,2023-06-18 23:50:25,OTHER,,,,,
315875,315876,NCT02741128,,2016-04-08,,,2023-02-06,2016-04-12,2016-04-18,Estimate,,,,,,,2023-02-06,2023-02-08,Actual,"October 28, 2019",Actual,2019-10-28,February 2023,2023-02-28,"January 19, 2023",Actual,2023-01-19,"January 19, 2023",Actual,2023-01-19,,Interventional,,,Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults,Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Aged 18 to 50 Years in Brazil,Completed,,Phase 2,133.0,Actual,Sanofi,,2.0,,,False,,,,True,False,False,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-18 23:52:25,2023-06-18 23:52:25,INDUSTRY,,,,,
315936,315937,NCT02116998,,2014-04-11,,2018-02-13,2018-04-04,2014-04-15,2014-04-17,Estimate,,,,2018-02-13,2018-02-15,Actual,2018-04-04,2018-04-06,Actual,September 2014,,2014-09-30,April 2018,2018-04-30,April 2016,Actual,2016-04-30,April 2016,Actual,2016-04-30,,Interventional,,,"Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GEN-004, a Pneumococcal Protein Subunit Vaccine, on Colonization Following Intranasal Challenge With S. Pneumoniae",Completed,,Phase 2,98.0,Actual,"Genocea Biosciences, Inc.",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 16:08:34,2023-06-15 16:08:34,INDUSTRY,,,,,
316194,316195,NCT00308061,,2006-03-24,2017-01-04,,2017-05-03,2006-03-24,2006-03-28,Estimate,2017-05-03,2017-07-31,Actual,,,,2017-05-03,2017-07-31,Actual,July 2003,,2003-07-31,May 2017,2017-05-31,July 2005,Actual,2005-07-31,September 2004,Actual,2004-09-30,,Interventional,,,"Safety Study of Candidate Malaria Vaccine FMP1/AS02A in Healthy Adults in Bandiagara, Mali","Double Blind Randomized Controlled Phase I Trial to Evaluate the Safety and Immunogenicity of WRAIR's MSP1 Candidate Malaria Vaccine (FMP1) Adjuvant in GSK Bio's AS02A vs. Rabies Vaccine in Semi-immune Adults in Bandiagara, Mali.",Completed,,Phase 1,40.0,Actual,U.S. Army Medical Research and Development Command,,2.0,,,False,,,,False,True,,,,,,,,,,No,,2023-06-19 00:04:59,2023-06-19 00:04:59,FED,,,,,
316214,316215,NCT02680002,,2016-01-26,2019-04-17,,2020-08-14,2016-02-08,2016-02-11,Estimate,2020-08-14,2020-08-31,Actual,,,,2020-08-14,2020-08-31,Actual,March 2016,,2016-03-31,April 2019,2019-04-30,"March 31, 2017",Actual,2017-03-31,"May 13, 2016",Actual,2016-05-13,,Interventional,,Safety Population: Number of participants receiving at least one dose (Dose 1/Day 0) of the investigational product.,Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant,"Randomized, Double-Blinded, Phase 2 Study to Assess Safety & Immunogenicity of Stored Inactivated Monovalent Influenza A/Vietnam/H5N1 Virus Vaccine Administered Intramuscularly at Different Dose Levels Given With & Without Stored MF59® Adjuvant",Completed,,Phase 2,422.0,Actual,Biomedical Advanced Research and Development Authority,,6.0,,,False,,,,True,,,,,,,,,,,Yes,The study results will be posted on publicly available clinical trial registers.,2023-06-18 23:55:51,2023-06-18 23:55:51,FED,,,,,
316346,316347,NCT01529645,,2012-02-06,2014-04-30,,2016-03-03,2012-02-08,2012-02-09,Estimate,2014-09-16,2014-09-18,Estimate,,,,2016-03-03,2016-04-04,Estimate,March 2012,,2012-03-31,March 2016,2016-03-31,July 2013,Actual,2013-07-31,July 2012,Actual,2012-07-31,,Interventional,,"Analysis was done on the all enrolled set, ie, all subjects who have signed an informed consent, undergone screening procedures and were randomized.",Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years,"Phase I, Randomized, Controlled, Observer-Blind, Dose-Ranging Study of Acellular Pertussis and Tetanus-Diptheria-Acellular Pertussis Booster Vaccine in Adults Ages 18 to 40 Years.",Completed,,Phase 1,420.0,Actual,Novartis,,10.0,,,False,,,,,,,,,,,,,,,,,2023-06-18 23:57:13,2023-06-18 23:57:13,INDUSTRY,,,,,
316805,316806,NCT01784874,,2013-02-04,,2014-12-05,2018-02-05,2013-02-04,2013-02-06,Estimate,,,,2014-12-05,2014-12-24,Estimate,2018-02-05,2018-02-09,Actual,February 2013,,2013-02-28,February 2018,2018-02-28,December 2015,Actual,2015-12-31,April 2014,Actual,2014-04-30,,Interventional,,,"Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use","Immunogenicity of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Human Diploid Cell Vaccine, Imovax® Rabies in Pre-exposure Use in Healthy Adults",Completed,,Phase 2,408.0,Actual,Sanofi,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 16:15:08,2023-06-15 16:15:08,INDUSTRY,,,,,
316825,316826,NCT02324751,,2014-12-02,,,2022-06-29,2014-12-18,2014-12-24,Estimate,,,,,,,2022-06-29,2022-07-05,Actual,September 2015,,2015-09-30,February 2018,2018-02-28,"June 27, 2022",Actual,2022-06-27,"December 2, 2017",Actual,2017-12-02,,Interventional,VAST,,Vaccines Against Salmonella Typhi,"A Phase IIb, Observer-blind, Randomised Controlled Trial to Assess the Immunogenicity and Protective Efficacy of Vi Conjugated (Vi-TCV) and Unconjugated (Vi-PS) Polysaccharide Vaccines in Preventing Typhoid Infection Compared to a Control Vaccine (Meningococcal ACWY), Using a Human Challenge Model of Typhoid Infection",Completed,,Phase 2,112.0,Actual,University of Oxford,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 08:20:00,2023-06-14 08:20:00,OTHER,,,,,
316876,316877,NCT05439824,,2022-06-27,,,2023-05-23,2022-06-27,2022-06-30,Actual,,,,,,,2023-05-23,2023-05-24,Actual,"June 28, 2022",Actual,2022-06-28,May 2023,2023-05-31,"June 28, 2023",Anticipated,2023-06-28,"January 12, 2023",Actual,2023-01-12,,Interventional,,,A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More,"A Randomized, Observer-blinded, Placebo-Controlled Phase 2 Clinical Study to Evaluate the Immunogenicity and Safety of a SARS-CoV-2 mRNA Vaccine (SYS6006) in Healthy Participants Aged 18 Years or More","Active, not recruiting",,Phase 2,450.0,Actual,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-19 00:09:04,2023-06-19 00:09:04,INDUSTRY,,,,,
316891,316892,NCT05354089,,2022-04-28,,,2023-05-23,2022-04-28,2022-04-29,Actual,,,,,,,2023-05-23,2023-05-24,Actual,"April 27, 2022",Actual,2022-04-27,May 2023,2023-05-31,"October 1, 2023",Anticipated,2023-10-01,"July 9, 2022",Actual,2022-07-09,,Interventional,,,A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.,"A Phase I, Randomized, Observer-blinded, Placebo-controlled and Dose-escalation Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of a SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.","Active, not recruiting",,Phase 1,40.0,Anticipated,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",,3.0,,,False,,,,,False,False,,,,,,,,,No,,2023-06-19 00:09:16,2023-06-19 00:09:16,INDUSTRY,,,,,
316892,316893,NCT05354063,,2022-04-28,,,2023-05-23,2022-04-28,2022-04-29,Actual,,,,,,,2023-05-23,2023-05-24,Actual,"June 1, 2022",Actual,2022-06-01,May 2023,2023-05-31,"October 1, 2023",Anticipated,2023-10-01,"September 5, 2022",Actual,2022-09-05,,Interventional,,,A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Older Adults.,"A Phase I, Randomized, Observer-blinded, Placebo-controlled and Dose-escalation Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 60 Years and Over.","Active, not recruiting",,Phase 1,40.0,Anticipated,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",,3.0,,,False,,,,,False,False,,,,,,,,,No,,2023-06-19 00:09:16,2023-06-19 00:09:16,INDUSTRY,,,,,
317099,317100,NCT04120415,,2019-09-30,,,2023-04-04,2019-10-07,2019-10-09,Actual,,,,,,,2023-04-04,2023-04-05,Actual,"June 21, 2022",Actual,2022-06-21,April 2023,2023-04-30,December 2023,Anticipated,2023-12-31,June 2023,Anticipated,2023-06-30,,Interventional,,,A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02),"EHVA T02 (European HIV Vaccine Alliance Therapeutic Trial 02)/ANRS VRI07: A Phase II Randomised, Placebo-controlled Trial of Vedolizumab With or Without Therapeutic HIV MVA Vaccine in Individuals Who Started Antiretrovirals During Primary or Chronic Infection","Active, not recruiting",,Phase 2,69.0,Anticipated,"ANRS, Emerging Infectious Diseases",,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-19 00:11:27,2023-06-19 00:11:27,OTHER_GOV,,,,,
317224,317225,NCT03010228,,2016-12-21,,,2023-03-31,2017-01-03,2017-01-04,Estimate,,,,,,,2023-03-31,2023-04-05,Actual,"January 31, 2017",Actual,2017-01-31,March 2023,2023-03-31,"January 16, 2019",Actual,2019-01-16,"September 28, 2017",Actual,2017-09-28,,Interventional,,,"Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis","Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Multivalent Recombinant OspA Vaccine Candidate Against Lyme Borreliosis, In Healthy Adults Aged Below 40 Years",Completed,,Phase 1,179.0,Actual,Pfizer,,6.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-19 00:12:48,2023-06-19 00:12:48,INDUSTRY,,,,,
317225,317226,NCT03006302,,2016-12-28,,,2023-04-03,2016-12-28,2016-12-30,Estimate,,,,,,,2023-04-03,2023-04-05,Actual,"January 31, 2018",Actual,2018-01-31,March 2023,2023-03-31,"December 1, 2023",Anticipated,2023-12-01,"December 1, 2023",Anticipated,2023-12-01,,Interventional,,,"Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer","Phase 2 Study of Epacadostat, Pembrolizumab, and CRS-207, With or Without Cyclophosphamide and GVAX Pancreas Vaccine in Patients With Metastatic Pancreas Cancer","Active, not recruiting",,Phase 2,40.0,Actual,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,2.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-19 00:12:49,2023-06-19 00:12:49,OTHER,,,,,
317344,317345,NCT00349713,,2006-07-06,2016-12-20,,2017-04-25,2006-07-06,2006-07-10,Estimate,2017-04-25,2017-07-24,Actual,,,,2017-04-25,2017-07-24,Actual,November 2004,,2004-11-30,April 2017,2017-04-30,December 2006,Actual,2006-12-31,December 2005,Actual,2005-12-31,,Interventional,,,"FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali","Double Blind Randomized, Controlled Phase 1 Dose Escalation Trial to Evaluate the Safety and Immunogenicity of the WRAIR AMA1 Malaria Antigen (FMP2.1) Adjuvanted in GSK's AS02A Versus Rabies Vaccine in Malaria-experienced Adults in Bandiagara, Mali",Completed,,Phase 1,60.0,Actual,U.S. Army Medical Research and Development Command,,3.0,,,False,,,,False,,,,,,,,,,,Yes,"Plan to share data with

National Institute of Allergy and Infectious Diseases (NIAID)

Walter Reed Army Institute of Research (WRAIR)

GlaxoSmithKline

University of Maryland",2023-06-19 00:14:17,2023-06-19 00:14:17,FED,,,,,
317437,317438,NCT00350337,,2006-07-06,2011-06-06,,2021-02-10,2006-07-06,2006-07-10,Estimate,2018-01-04,2018-10-26,Actual,,,,2021-02-10,2021-02-12,Actual,"April 5, 2006",Actual,2006-04-05,February 2021,2021-02-28,"March 13, 2008",Actual,2008-03-13,"June 20, 2007",Actual,2007-06-20,,Interventional,,,Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults,"Phase II, Randomized, Observer-Blind, Single Center, Controlled Study of Two Doses of Various Formulations of WRAIR Live Attenuated Tetravalent Dengue Vaccine Compared to Placebo Control Administered on 0-6-Month Schedule to Healthy Adults",Completed,,Phase 2,86.0,Actual,U.S. Army Medical Research and Development Command,,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-19 00:15:06,2023-06-19 00:15:06,FED,,,,,
317581,317582,NCT04749641,,2021-02-03,,,2022-07-18,2021-02-07,2021-02-11,Actual,,,,,,,2022-07-18,2022-07-20,Actual,"March 8, 2021",Actual,2021-03-08,July 2022,2022-07-31,"April 1, 2024",Anticipated,2024-04-01,"March 31, 2023",Anticipated,2023-03-31,,Interventional,ENACTING,,Neoantigen Vaccine Therapy Against H3.3-K27M Diffuse Intrinsic Pontine Glioma,Enhanced Histone H3.3-K27M Neoantigen Vaccine Therapy Against Diffuse Intrinsic Pontine Glioma (ENACTING)- A Phase I Clinical Trial,Recruiting,,Phase 1,30.0,Anticipated,Beijing Tiantan Hospital,,2.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-15 16:16:23,2023-06-15 16:16:23,OTHER,,,,,
317638,317639,NCT03028441,,2016-12-29,,,2020-11-25,2017-01-19,2017-01-23,Estimate,,,,,,,2020-11-25,2020-11-27,Actual,"May 30, 2017",Actual,2017-05-30,"October 12, 2017",2017-10-12,"January 17, 2019",Actual,2019-01-17,"January 17, 2019",Actual,2019-01-17,,Interventional,,,Phase I Trial of Measles Vectored Chikungungya Vaccine,"A Phase 1, Double Blinded, Placebo Controlled, Dose Comparison Trial to Evaluate the Safety, Immunogenicity and Schedule of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults",Completed,,Phase 1,180.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,6.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-19 00:17:21,2023-06-19 00:17:21,NIH,,,,,
317779,317780,NCT04668339,,2020-11-25,,,2022-07-07,2020-12-10,2020-12-16,Actual,,,,,,,2022-07-07,2022-07-08,Actual,"January 7, 2021",Actual,2021-01-07,July 2022,2022-07-31,"March 1, 2022",Actual,2022-03-01,"March 1, 2022",Actual,2022-03-01,,Interventional,,,A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults,"A Phase 2 Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety, Reactogenicity, and Immunogenicity of the SARS CoV-2 Vaccine ARCT-021 in Healthy Adult Participants",Terminated,,Phase 2,581.0,Actual,"Arcturus Therapeutics, Inc.",,8.0,,A decision was made to terminate the study for operational/business reasons. The study was not terminated for reasons of safety or immunogenicity.,False,,,,True,True,False,,,,,,,,,No,Individual participant data will only be made available to study investigators at this time.,2023-06-14 08:21:30,2023-06-14 08:21:30,INDUSTRY,,,,,
317801,317802,NCT01551745,,2012-03-01,2018-02-15,,2021-10-15,2012-03-12,2012-03-13,Estimate,2018-03-29,2018-05-01,Actual,,,,2021-10-15,2021-10-19,Actual,March 2012,,2012-03-31,October 2021,2021-10-31,April 2016,Actual,2016-04-30,April 2016,Actual,2016-04-30,,Interventional,,,Salvage Ovarian FANG Vaccine + Bevacizumab,Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG) Integrated With Bevacizumab for Patients With Recurrent/Refractory Ovarian Cancer Participating in Study CL-PTL 105,Completed,,Phase 2,5.0,Actual,"Gradalis, Inc.",,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-19 00:19:12,2023-06-19 00:19:12,INDUSTRY,,,,,
317840,317841,NCT03658629,,2018-08-31,2022-07-27,2019-12-04,2022-11-03,2018-08-31,2018-09-05,Actual,2022-11-03,2022-11-04,Actual,2022-11-03,2022-11-04,Actual,2022-11-03,2022-11-04,Actual,"September 24, 2018",Actual,2018-09-24,November 2022,2022-11-30,"April 26, 2019",Actual,2019-04-26,"April 26, 2019",Actual,2019-04-26,,Interventional,,The population analyzed is the number of participants that are in the Safety Population.,Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults,Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1 Adjuvant in Healthy Adults = 65 Years of Age,Terminated,,Phase 2,1375.0,Actual,Novavax,,7.0,,This study was terminated 182 days after initial dosing.,False,,,,False,True,False,,,,,,,,,Undecided,,2023-06-19 00:19:32,2023-06-19 00:19:32,INDUSTRY,,,,,
317891,317892,NCT00533741,,2007-09-20,,,2012-11-29,2007-09-20,2007-09-21,Estimate,,,,,,,2012-11-29,2012-12-03,Estimate,,,,March 2010,2010-03-31,January 2012,Anticipated,2012-01-31,January 2012,Anticipated,2012-01-31,,Interventional,,,SARS Coronavirus Vaccine (SARS-CoV),"Phase I, Double-Blinded, Placebo-Controlled Dosage Escalation Study of the Safety and Immunogenicity of Adjuvanted and Non-Adjuvanted Inactivated SARS Coronavirus (SARS-CoV) Vaccine Administered by the Intramuscular Route",Withdrawn,,Phase 1,0.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 16:16:58,2023-06-15 16:16:58,NIH,,,,,
318223,318224,NCT02335164,,2015-01-04,,,2019-05-06,2015-01-06,2015-01-09,Estimate,,,,,,,2019-05-06,2019-05-07,Actual,July 2015,Actual,2015-07-31,May 2019,2019-05-31,"May 1, 2019",Actual,2019-05-01,"December 1, 2017",Actual,2017-12-01,,Interventional,FLU003,,A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults,"A Randomised, Controlled, Blinded Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian H5 Influenza Vaccine in Adults",Completed,,Phase 1,270.0,Anticipated,Vaxine Pty Ltd,,9.0,,,False,,,,False,,,,,,,,,,,Undecided,,2023-06-19 00:23:47,2023-06-19 00:23:47,INDUSTRY,,,,,
318252,318253,NCT02334462,,2015-01-07,,,2019-04-10,2015-01-07,2015-01-08,Estimate,,,,,,,2019-04-10,2019-04-11,Actual,"January 7, 2015",,2015-01-07,"October 22, 2018",2018-10-22,"October 22, 2018",Actual,2018-10-22,"March 31, 2016",Actual,2016-03-31,,Interventional,,,"Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali","Phase 1 Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria in Adults in the US and Mali",Completed,,Phase 1,538.0,Actual,National Institutes of Health Clinical Center (CC),,7.0,,,False,,,,,True,,,,,,,,,,,,2023-06-19 00:24:08,2023-06-19 00:24:08,NIH,,,,,
318316,318317,NCT02326194,,2014-12-22,,,2015-08-27,2014-12-22,2014-12-25,Estimate,,,,,,,2015-08-27,2015-08-28,Estimate,December 2014,,2014-12-31,August 2015,2015-08-31,July 2015,Actual,2015-07-31,February 2015,Actual,2015-02-28,,Interventional,,,A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults.,"A Phase 1 Double-blind, Dose-escalation, Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults in China",Completed,,Phase 1,120.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-19 00:24:53,2023-06-19 00:24:53,NETWORK,,,,,
318400,318401,NCT03110952,,2015-04-28,,,2017-04-05,2017-04-05,2017-04-12,Actual,,,,,,,2017-04-05,2017-04-12,Actual,January 2016,,2016-01-31,April 2017,2017-04-30,April 2018,Anticipated,2018-04-30,April 2017,Anticipated,2017-04-30,,Interventional,,,TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant,"A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Single-Center, Study of TDENV-PIV and TDENV-F17 Dengue Vaccine Platforms in a Heterologous Prime Boost Strategy in Healthy Adults in a Non-Endemic Region",Withdrawn,,Phase 1,0.0,Actual,U.S. Army Medical Research and Development Command,,4.0,,"lack of materials, not moving forward",False,,,,False,,,,,,,,,,,,,2023-06-19 00:25:51,2023-06-19 00:25:51,FED,,,,,
318617,318618,NCT01511419,,2012-01-05,2018-07-16,,2019-01-22,2012-01-12,2012-01-18,Estimate,2019-01-22,2019-04-22,Actual,,,,2019-01-22,2019-04-22,Actual,April 2012,,2012-04-30,January 2019,2019-01-31,July 2012,Actual,2012-07-31,June 2012,Actual,2012-06-30,,Interventional,,,Safety Trial of Live Attenuated Influenza (H7N3) Vaccine,"Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Mallard/Netherlands/00/95 (H7N3) Influenza Vaccine",Completed,,Phase 1,40.0,Actual,PATH,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-19 00:28:47,2023-06-19 00:28:47,OTHER,,,,,
318677,318678,NCT03027193,,2017-01-19,,,2020-02-24,2017-01-20,2017-01-23,Estimate,,,,,,,2020-02-24,2020-02-25,Actual,"March 15, 2017",Actual,2017-03-15,May 2019,2019-05-31,"January 16, 2020",Actual,2020-01-16,"January 16, 2020",Actual,2020-01-16,,Interventional,,,A Study to Determine the Safety and Immunogenicity of a Candidate MAP Vaccines ChAdOx2 HAV and MVA in Healthy Adult Volunteers,A Phase I Clinical Trial to Determine the Safety and Immunogenicity of the Candidate Mycobacterium Avium Subspecies Paratuberculosis (MAP) Vaccines ChAdOx2 HAV and MVA HAV in Healthy Adult Volunteers,Completed,,Phase 1,28.0,Actual,University of Oxford,,6.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-19 00:29:38,2023-06-19 00:29:38,OTHER,,,,,
318744,318745,NCT01460719,,2011-10-25,2018-11-15,,2018-11-15,2011-10-25,2011-10-27,Estimate,2018-11-15,2019-03-11,Actual,,,,2018-11-15,2019-03-11,Actual,"January 24, 2012",Actual,2012-01-24,November 2018,2018-11-30,"September 25, 2012",Actual,2012-09-25,"September 25, 2012",Actual,2012-09-25,,Interventional,,,A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies (HM) Receiving Treatment With Anti-Cluster of Differentiation (CD) 20 Monoclonal Antibodies (V212-013),"A Phase I, Open-Label, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of V212/Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies Receiving Treatment With Anti-CD20 Monoclonal Antibodies",Completed,,Phase 1,80.0,Actual,Merck Sharp & Dohme LLC,,1.0,,,False,,,,False,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2023-06-19 00:30:54,2023-06-19 00:30:54,INDUSTRY,,,,,
318891,318892,NCT00545025,,2007-10-15,2013-03-21,2009-05-20,2019-06-13,2007-10-15,2007-10-16,Estimate,2013-03-21,2013-05-07,Estimate,2009-09-28,2009-09-30,Estimate,2019-06-13,2019-06-26,Actual,"October 15, 2007",Actual,2007-10-15,June 2019,2019-06-30,"December 12, 2007",Actual,2007-12-12,"December 12, 2007",Actual,2007-12-12,,Interventional,,,Revaccination With Influenza Vaccine GSK1247446A,Safety and Immunogenicity of a Second Vaccination With GSK Biologicals' Influenza Vaccine GSK1247446A in Subjects 18-60 Years Previously Vaccinated in Study 108656,Completed,,Phase 2,243.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-19 00:33:31,2023-06-19 00:33:31,INDUSTRY,,,,,
319031,319032,NCT01453361,,2011-08-10,2018-02-15,,2018-05-21,2011-10-14,2011-10-17,Estimate,2018-05-08,2018-05-11,Actual,,,,2018-05-21,2018-05-24,Actual,October 2011,,2011-10-31,May 2018,2018-05-31,"March 22, 2016",Actual,2016-03-22,"March 22, 2016",Actual,2016-03-22,,Interventional,,,Phase II FANG in Advanced Melanoma,Phase II Trial of FANG Autologous Tumor Cell Vaccine in Advanced Melanoma,Terminated,,Phase 2,18.0,Actual,"Gradalis, Inc.",,1.0,,Business Decision to pursue other indications,False,,,,True,,,,,,,,,,,,,2023-06-19 00:35:43,2023-06-19 00:35:43,INDUSTRY,,,,,
319077,319078,NCT01685372,,2012-08-27,2017-06-30,2016-10-24,2017-12-21,2012-09-13,2012-09-14,Estimate,2017-10-24,2017-11-30,Actual,2016-10-24,2016-11-28,Estimate,2017-12-21,2018-01-23,Actual,September 2012,,2012-09-30,December 2017,2017-12-31,September 2017,Actual,2017-09-30,September 2015,Actual,2015-09-30,,Interventional,,,Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults,Immunogenicity and Efficacy of High-dose Trivalent Inactivated Seasonal Influenza Vaccine (Fluzone High Dose) in Immunocompromised Children and Young Adults.,Completed,,Phase 2,16.0,Actual,"University of Colorado, Denver",,2.0,,,False,,,,True,,,,,,,,,,,No,There is no plan to share data at the end of the study. Data management at the close of the study will occur according to IRB and FDA regulations.,2023-06-19 00:36:49,2023-06-19 00:36:49,OTHER,,,,,
319126,319127,NCT01542632,,2012-02-27,2014-12-31,,2019-07-16,2012-03-01,2012-03-02,Estimate,2014-12-31,2015-01-09,Estimate,,,,2019-07-16,2019-07-18,Actual,"February 1, 2012",Actual,2012-02-01,July 2019,2019-07-31,"January 10, 2014",Actual,2014-01-10,"January 1, 2014",Actual,2014-01-01,,Interventional,,,A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers,"A Randomized, Phase 1b Study to Investigate the Safety and Immunogenicity of Various Schedules of Tetravalent Chimeric Dengue Vaccine in Healthy Adult Volunteers Between the Ages of 18 - 45 Years",Completed,,Phase 1,140.0,Actual,Takeda,,6.0,,,False,,,,False,,,,,,,,,,,,,2023-06-19 00:37:40,2023-06-19 00:37:40,INDUSTRY,,,,,
319151,319152,NCT01215175,,2010-10-04,2018-10-25,,2019-03-15,2010-10-05,2010-10-06,Estimate,2019-03-15,2019-03-18,Actual,,,,2019-03-15,2019-03-18,Actual,"September 25, 2009",Actual,2009-09-25,March 2019,2019-03-31,"January 5, 2011",Actual,2011-01-05,"April 16, 2010",Actual,2010-04-16,,Interventional,,The baseline analysis population includes all randomized participants receiving study treatment; one toddler participant was enrolled in error.,Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar (V114-001),"A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar in Healthy Adults and Toddlers",Completed,,Phase 1,150.0,Actual,Merck Sharp & Dohme LLC,,5.0,,,False,,,,True,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2023-06-15 16:19:37,2023-06-15 16:19:37,INDUSTRY,,,,,
319315,319316,NCT05559177,,2022-09-26,,,2022-09-26,2022-09-26,2022-09-29,Actual,,,,,,,2022-09-26,2022-09-29,Actual,"September 1, 2022",Actual,2022-09-01,September 2022,2022-09-30,"September 1, 2023",Anticipated,2023-09-01,"June 1, 2023",Anticipated,2023-06-01,,Interventional,,,"An Open, Dose-escalation Clinical Study of Chimeric Exosomal Tumor Vaccines for Recurrent or Metastatic Bladder Cancer","An Open, Dose-escalation Clinical Study of Chimeric Exosomal Tumor Vaccines for Recurrent or Metastatic Bladder Cancer",Recruiting,,Early Phase 1,9.0,Anticipated,Shanghai Pudong Hospital,,1.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-19 00:39:55,2023-06-19 00:39:55,OTHER,,,,,
319441,319442,NCT03121677,,2017-04-17,,,2022-09-28,2017-04-17,2017-04-20,Actual,,,,,,,2022-09-28,2022-09-29,Actual,"October 16, 2018",Actual,2018-10-16,September 2022,2022-09-30,"September 24, 2025",Anticipated,2025-09-24,"September 24, 2020",Actual,2020-09-24,,Interventional,,,Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma,Pilot Study of a Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma,"Active, not recruiting",,Phase 1,4.0,Actual,Washington University School of Medicine,,1.0,,,False,,,,True,True,False,,,False,,,,,,No,,2023-06-19 00:41:10,2023-06-19 00:41:10,OTHER,,,,,
319618,319619,NCT01442675,,2011-09-26,2014-11-11,2012-12-03,2014-11-17,2011-09-27,2011-09-28,Estimate,2014-11-17,2014-11-18,Estimate,2012-12-03,2012-12-05,Estimate,2014-11-17,2014-11-18,Estimate,September 2011,,2011-09-30,November 2014,2014-11-30,December 2012,Actual,2012-12-31,June 2012,Actual,2012-06-30,,Interventional,,,Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine,Safety and Immunogenicity of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine,Completed,,Phase 2,834.0,Actual,Sanofi,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-19 00:43:42,2023-06-19 00:43:42,INDUSTRY,,,,,
319690,319691,NCT00623181,,2008-02-06,2011-07-14,2010-03-31,2016-04-12,2008-02-22,2008-02-25,Estimate,2011-07-14,2011-08-11,Estimate,2010-03-31,2010-04-02,Estimate,2016-04-12,2016-04-14,Estimate,January 2008,,2008-01-31,April 2016,2016-04-30,June 2008,Actual,2008-06-30,May 2008,Actual,2008-05-31,,Interventional,,,Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy Adults,Preference for Fluzone Vaccine Administered Intradermally Versus Intramuscularly in Healthy Adult Subjects 18-49 Years of Age,Completed,,Phase 2,110.0,Actual,Sanofi,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-19 00:44:45,2023-06-19 00:44:45,INDUSTRY,,,,,
319821,319822,NCT01446289,,2011-09-27,2014-06-20,,2014-09-05,2011-10-03,2011-10-05,Estimate,2014-09-05,2014-09-08,Estimate,,,,2014-09-05,2014-09-08,Estimate,September 2011,,2011-09-30,September 2014,2014-09-30,October 2013,Actual,2013-10-31,April 2013,Actual,2013-04-30,,Interventional,,All enrolled population,Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings,"A Phase II Randomized, Observer-Blind, Multi-Center, Controlled Study of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women",Completed,,Phase 2,86.0,Actual,Novartis,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-19 00:46:25,2023-06-19 00:46:25,INDUSTRY,,,,,
319932,319933,NCT01416571,,2011-08-12,2013-12-19,2012-07-26,2018-08-22,2011-08-12,2011-08-15,Estimate,2014-03-20,2014-04-16,Estimate,2012-07-26,2012-08-03,Estimate,2018-08-22,2018-09-21,Actual,"August 12, 2011",,2011-08-12,August 2016,2016-08-31,"September 28, 2012",Actual,2012-09-28,"November 29, 2011",Actual,2011-11-29,,Interventional,,,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults,Immunogenicity and Safety Study of GSK Biologicals' Monovalent Pandemic H5N1 Vaccine 1557484A in Adults Aged 18 - 64 Years,Completed,,Phase 2,78.0,Actual,GlaxoSmithKline,,1.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-19 00:47:56,2023-06-19 00:47:56,INDUSTRY,,,,,
320348,320349,NCT00661557,,2008-04-14,2017-08-25,2009-09-03,2018-06-21,2008-04-15,2008-04-18,Estimate,2018-06-21,2018-12-28,Actual,2009-09-03,2009-09-04,Estimate,2018-06-21,2018-12-28,Actual,"May 19, 2008",Actual,2008-05-19,June 2018,2018-06-30,"December 19, 2008",Actual,2008-12-19,"December 19, 2008",Actual,2008-12-19,,Interventional,,,Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects,Immunogenicity & Safety Study of GSK Biologicals' Meningococcal Vaccine GSK134612 Administered in Healthy Subjects Either Previously Primed With Mencevax ACWY or naïve to Meningococcal Vaccination.,Completed,,Phase 2,271.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-19 00:52:32,2023-06-19 00:52:32,INDUSTRY,,,,,
320380,320381,NCT01412801,,2011-08-08,2014-06-20,,2014-09-05,2011-08-08,2011-08-09,Estimate,2014-09-05,2014-09-12,Estimate,,,,2014-09-05,2014-09-12,Estimate,September 2011,,2011-09-30,September 2014,2014-09-30,December 2012,Actual,2012-12-31,October 2012,Actual,2012-10-31,,Interventional,,,Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings,"A Phase II Open-Label, Multi-Center Study of a Group B Streptococcus Vaccine in HIV Positive and HIV Negative Pregnant Women",Completed,,Phase 2,270.0,Actual,Novartis,,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-19 00:52:49,2023-06-19 00:52:49,INDUSTRY,,,,,
320446,320447,NCT00601731,,2008-01-15,2011-10-28,2011-07-20,2014-10-14,2008-01-25,2008-01-28,Estimate,2012-09-17,2012-09-19,Estimate,2011-07-20,2011-07-25,Estimate,2014-10-14,2014-10-24,Estimate,February 2008,,2008-02-29,October 2014,2014-10-31,September 2010,Actual,2010-09-30,July 2010,Actual,2010-07-31,,Interventional,,,Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months,"A Phase 2, Open-label, Controlled, Multi-center Study to Evaluate Meningococcal ACWY Antibody Response in Children Aged 40 and 60 Months Who Have Previously Received Novartis MenACWY Conjugate Vaccine as Infants",Completed,,Phase 2,382.0,Actual,Novartis,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-19 00:53:36,2023-06-19 00:53:36,INDUSTRY,,,,,
320489,320490,NCT03141138,,2017-04-25,,,2021-03-25,2017-05-03,2017-05-04,Actual,,,,,,,2021-03-25,2021-03-26,Actual,"November 8, 2017",Actual,2017-11-08,March 2021,2021-03-31,"December 31, 2021",Anticipated,2021-12-31,"October 31, 2019",Actual,2019-10-31,,Interventional,,,Comparison of Tetravalent Dengue Virus Purified Inactivated Vaccine and Tetravalent Dengue Virus Live Attenuated Vaccine,"A Phase 1, Randomized, Open-label, Comparison of Heterologous Prime-Boost Vaccination Schedules of Tetravalent Dengue Virus Purified Inactivated Vaccine (PIV) and Tetravalent Dengue Virus Live Attenuated Vaccine (LAV) in Healthy Adults",Unknown status,"Active, not recruiting",Phase 1,40.0,Actual,U.S. Army Medical Research and Development Command,,4.0,,,False,,,,,True,False,,,,,,,,,No,,2023-06-19 00:54:18,2023-06-19 00:54:18,FED,,,,,
320768,320769,NCT00703053,,2008-06-19,2010-06-17,,2013-08-15,2008-06-19,2008-06-23,Estimate,2010-06-17,2010-07-16,Estimate,,,,2013-08-15,2013-08-23,Estimate,September 2008,,2008-09-30,September 2009,2009-09-30,November 2009,Actual,2009-11-30,July 2009,Actual,2009-07-31,,Interventional,,,H5N1 Priming and Boosting Strategies,"A Phase II Randomized Study of the Safety and Immunogenicity of Vaccination Strategies Using One or Two Clades and Different Schedules of H5N1 Unadjuvanted, Inactivated Subvirion Influenza Vaccines in H5 Naïve Healthy Adults",Completed,,Phase 2,505.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,9.0,,,False,,,,,,,,,,,,,,,,,2023-06-19 00:57:22,2023-06-19 00:57:22,NIH,,,,,
320956,320957,NCT00707967,,2008-06-27,2016-11-07,2009-09-03,2018-07-26,2008-06-27,2008-07-01,Estimate,2016-11-07,2017-01-06,Estimate,2009-09-03,2009-09-04,Estimate,2018-07-26,2018-08-24,Actual,"June 30, 2008",,2008-06-30,November 2016,2016-11-30,"May 27, 2009",Actual,2009-05-27,"May 27, 2009",Actual,2009-05-27,,Interventional,,,Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults.,Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine (692342) in HIV-positive Adults.,Completed,,Phase 2,37.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-19 00:59:13,2023-06-19 00:59:13,INDUSTRY,,,,,
321068,321069,NCT02405520,,2015-03-25,,,2022-05-23,2015-03-31,2015-04-01,Estimate,,,,,,,2022-05-23,2022-05-24,Actual,"March 26, 2015",Actual,2015-03-26,May 2022,2022-05-31,"May 20, 2022",Actual,2022-05-20,"June 5, 2019",Actual,2019-06-05,,Interventional,,,Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine,"A Phase I Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Safety and Immunogenicity of the Recombinant (E.Coli) Human Papillomavirus Type 6/11 Bivalent Vaccine in Healthy Volunteers Aged 18-55 Years",Completed,,Phase 1,145.0,Actual,Xiamen University,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-19 01:00:15,2023-06-19 01:00:15,OTHER,,,,,
321110,321111,NCT02992977,,2016-12-09,,,2020-05-29,2016-12-12,2016-12-14,Estimate,,,,,,,2020-05-29,2020-06-02,Actual,January 2017,Actual,2017-01-31,May 2020,2020-05-31,December 2019,Actual,2019-12-31,December 2018,Actual,2018-12-31,,Interventional,,,Safety and Tolerability Study of AutoSynVax Vaccine in Subjects With Advanced Cancer,A Phase 1 Study of Safety and Tolerability of AutoSynVax Vaccine as a Single Agent in Subjects With Advanced Cancer,Terminated,,Phase 1,3.0,Actual,Agenus Inc.,,1.0,,To enable development of an enhanced version of the vaccine.,False,,,,False,,,,,,,,,,,No,,2023-06-19 01:00:41,2023-06-19 01:00:41,INDUSTRY,,,,,
321231,321232,NCT01489358,,2011-12-07,2016-03-11,,2016-06-09,2011-12-08,2011-12-09,Estimate,2016-03-11,2016-04-12,Estimate,,,,2016-06-09,2016-07-25,Estimate,December 2011,,2011-12-31,March 2016,2016-03-31,April 2013,Actual,2013-04-30,April 2013,Actual,2013-04-30,,Interventional,,All enrolled participants,Chikungunya Virus Vaccine Trial in Healthy Adults,"VRC 311: A Phase 1 Open Label, Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Virus-Like Particle (VLP) Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults",Completed,,Phase 1,25.0,Actual,National Institutes of Health Clinical Center (CC),,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-19 01:02:18,2023-06-19 01:02:18,NIH,,,,,
321289,321290,NCT02991417,,2016-12-05,,,2017-07-24,2016-12-09,2016-12-13,Estimate,,,,,,,2017-07-24,2017-07-25,Actual,January 2017,Actual,2017-01-31,July 2017,2017-07-31,"June 8, 2017",Actual,2017-06-08,"March 14, 2017",Actual,2017-03-14,,Interventional,CDVAX,,Oral Vaccination Against Clostridium Difficile Infection,Safety and Immunogenicity Study of a Clostridium Difficile Vaccine in Healthy Adult Volunteers,Terminated,,Phase 1,3.0,Actual,Royal Holloway University,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-19 01:03:10,2023-06-19 01:03:10,OTHER,,,,,
321630,321631,NCT03422094,,2018-01-29,,,2021-10-26,2018-01-29,2018-02-05,Actual,,,,,,,2021-10-26,2021-10-27,Actual,"October 31, 2018",Actual,2018-10-31,October 2021,2021-10-31,"December 31, 2020",Actual,2020-12-31,"April 26, 2020",Actual,2020-04-26,,Interventional,,,"Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma","A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma",Terminated,,Phase 1,3.0,Actual,Washington University School of Medicine,,5.0,,Manufacturer changed focus to cell therapy,False,,,,True,True,False,,,False,,,,,,No,,2023-06-19 01:07:14,2023-06-19 01:07:14,OTHER,,,,,
321663,321664,NCT02794870,,2016-05-24,2018-06-29,,2018-07-27,2016-06-06,2016-06-09,Estimate,2018-07-27,2018-08-27,Actual,,,,2018-07-27,2018-08-27,Actual,"July 15, 2016",Actual,2016-07-15,July 2018,2018-07-31,"July 7, 2017",Actual,2017-07-07,"July 7, 2017",Actual,2017-07-07,,Interventional,,Baseline analysis population was participants who received inoculation.,"Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age","Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID <U+0394>M2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age",Completed,,Phase 1,33.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 03:52:01,2023-06-17 03:52:01,NIH,,,,,
321894,321895,NCT04096820,,2019-09-18,,,2022-07-28,2019-09-18,2019-09-20,Actual,,,,,,,2022-07-28,2022-07-29,Actual,"September 6, 2019",Actual,2019-09-06,July 2022,2022-07-31,"January 1, 2023",Anticipated,2023-01-01,"October 31, 2022",Anticipated,2022-10-31,,Interventional,,,Uromune in Treating Recurrent Urinary Tract Infections in Women,"Protocol 19-01: Canadian, Single Centre, Pilot, Open Label Study to Evaluate the Efficacy and Safety of the Bacterial Vaccine Uromune in Treating Recurrent Urinary Tract Infections in Women.","Active, not recruiting",,Phase 2,62.0,Actual,Queen's University,,1.0,,,False,,,,True,False,False,,,False,,,,,,,,2023-06-19 01:10:15,2023-06-19 01:10:15,OTHER,,,,,
321934,321935,NCT01273233,,2011-01-07,,,2013-03-13,2011-01-07,2011-01-10,Estimate,,,,,,,2013-03-13,2013-03-15,Estimate,December 2010,,2010-12-31,March 2013,2013-03-31,February 2011,Actual,2011-02-28,February 2011,Actual,2011-02-28,,Interventional,,,Safety of an Inactivated Enterovirus Type 71 Vaccine in Healthy Adults,"A Blinded, Randomized and Controlled Clinical Trial of An Inactivated Enterovirus Type 71 Vaccine in Healthy Adults",Completed,,Phase 1,36.0,Actual,"Sinovac Biotech Co., Ltd",,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-19 01:10:48,2023-06-19 01:10:48,INDUSTRY,,,,,
322129,322130,NCT05805618,,2023-02-23,,,2023-04-19,2023-03-27,2023-04-10,Actual,,,,,,,2023-04-19,2023-04-21,Actual,"April 20, 2023",Anticipated,2023-04-20,April 2023,2023-04-30,"December 30, 2024",Anticipated,2024-12-30,"December 30, 2023",Anticipated,2023-12-30,,Interventional,,,Evaluation of Recombinant Norovirus Hexavalent Vaccine in Healthy Subjects,"A Single-center, Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety and Immunogenicity of Recombinant Norovirus Hexavalent Vaccine in Healthy Subjects Aged 18-59 Years",Not yet recruiting,,Early Phase 1,60.0,Anticipated,Syneos Health,,2.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-15 16:26:17,2023-06-15 16:26:17,OTHER,,,,,
322147,322148,NCT02337270,,2014-12-19,,,2021-10-25,2015-01-08,2015-01-13,Estimate,,,,,,,2021-10-25,2021-11-01,Actual,"September 5, 2017",Actual,2017-09-05,October 2021,2021-10-31,"September 7, 2021",Actual,2021-09-07,"September 7, 2021",Actual,2021-09-07,,Interventional,,,Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol,"Phase 1, Open-label Clinical Trial to Evaluate the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine Administered by Aerosol",Completed,,Phase 1,36.0,Actual,McMaster University,,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-19 01:12:49,2023-06-19 01:12:49,OTHER,,,,,
322489,322490,NCT05501561,,2022-08-11,,,2023-04-20,2022-08-11,2022-08-15,Actual,,,,,,,2023-04-20,2023-04-21,Actual,"August 25, 2022",Actual,2022-08-25,April 2023,2023-04-30,"March 31, 2023",Actual,2023-03-31,"March 31, 2023",Actual,2023-03-31,,Interventional,,,Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults =50 Years of Age,"A Phase 2b, Randomized, Observer-Blind, Antigen and Adjuvant Dose-Confirmation Clinical Study to Evaluate Safety and Immunogenicity of Different Formulations of MF59-Adjuvanted Quadrivalent Subunit Inactivated Cell-derived Influenza Vaccine (aQIVc) in Older Adults =50 Years of Age",Completed,,Phase 2,1056.0,Actual,Seqirus,,4.0,,,,,,,False,True,False,,,,,,SEQIRUS discloses results from clinical studies within 12 months of completion of the study unless otherwise mandated by local laws or regulations.,"SEQIRUS will consider requests from qualified scientific and medical researchers to disclose protocols, anonymized subject-level data and study-level data when there is medical, scientific and/or public health interest to ensure the safe use of a Seqirus product licensed on or after 1 January 2014 in the United States (US) and/or the European Union (EU). This applies to Seqirus-sponsored interventional studies initiated after 27 September 2007 and ongoing as of 26 December 2007, that have been included as part of a US or EU submission package which received approval in US and EU on or after 1 January 2014 and have been accepted for publication",http://www.seqirus.us/partnering,Yes,"SEQIRUS supports the release of anonymized subject-level and study-level data in compliance with regulatory requirements, including Clinical Documents which are part of the CTD modules submitted to regulatory agencies for public release.

Summary results disclosure is either in document form (e.g., ICH E3 Clinical Study Report synopsis) or structured data form (such as summary results in ClinicalTrials.gov (United States) or eudract.ema.europa.eu (EU Clinical Trial Registry [EU CTR])",2023-06-15 16:27:11,2023-06-15 16:27:11,INDUSTRY,,,,,
322667,322668,NCT05297578,,2022-03-17,,,2023-04-19,2022-03-17,2022-03-28,Actual,,,,,,,2023-04-19,2023-04-21,Actual,"June 15, 2022",Actual,2022-06-15,April 2023,2023-04-30,"February 15, 2023",Actual,2023-02-15,"February 15, 2023",Actual,2023-02-15,,Interventional,,,"Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults","A Phase 2, Randomized, Observer-Blind, Dose-Finding, Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults 65 Years and Older",Completed,,Phase 2,207.0,Actual,"Vaxcyte, Inc.",,4.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-15 16:27:37,2023-06-15 16:27:37,INDUSTRY,,,,,
323013,323014,NCT05213728,,2022-01-18,,,2022-09-19,2022-01-27,2022-01-28,Actual,,,,,,,2022-09-19,2022-09-21,Actual,"January 24, 2022",Actual,2022-01-24,September 2022,2022-09-30,"February 24, 2022",Actual,2022-02-24,"February 1, 2022",Actual,2022-02-01,,Interventional,(VXA-G1-1-NN),,"A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers","A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Expressing GI.1 VP1 Administered to Healthy Adult Volunteers",Completed,,Phase 1,8.0,Actual,Vaxart,,1.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-17 23:12:12,2023-06-17 23:12:12,INDUSTRY,,,,,
323344,323345,NCT01674205,,2012-08-23,,,2015-12-14,2012-08-23,2012-08-28,Estimate,,,,,,,2015-12-14,2015-12-15,Estimate,September 2012,,2012-09-30,October 2015,2015-10-31,June 2013,Actual,2013-06-30,June 2013,Actual,2013-06-30,,Interventional,,,Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines,Exploratory Evaluation of Host Biomarkers That Predict the Vaccine Virus Replication and Immunogenicity of Seasonal and Pandemic Formulations of Live Attenuated Influenza A Virus Vaccines Based on the A/Ann Arbor/6/60 ca Master Donor Virus (MDV),Completed,,Phase 1,36.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-19 01:24:32,2023-06-19 01:24:32,NIH,,,,,
323426,323427,NCT03755713,,2018-11-26,,,2022-09-18,2018-11-26,2018-11-28,Actual,,,,,,,2022-09-18,2022-09-21,Actual,"March 12, 2019",Actual,2019-03-12,September 2022,2022-09-30,"October 11, 2021",Actual,2021-10-11,"October 11, 2021",Actual,2021-10-11,,Interventional,,,"A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine","A Phase 1, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine",Completed,,Phase 1,20.0,Actual,Astellas Pharma Inc,,3.0,,,False,,,,True,True,False,,,,,,,,,No,"Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on ww.clinicalstudydatarequest.com under ""Sponsor Specific Details for Astellas.""",2023-06-19 01:25:44,2023-06-19 01:25:44,INDUSTRY,,,,,
323838,323839,NCT05125926,,2021-11-12,,,2021-11-14,2021-11-14,2021-11-18,Actual,,,,,,,2021-11-14,2021-11-18,Actual,December 2021,Anticipated,2021-12-31,November 2021,2021-11-30,April 2023,Anticipated,2023-04-30,February 2023,Anticipated,2023-02-28,,Interventional,,,A Phase <U+2160> Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine LYB001,"Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Vaccine LYB001 in Healthy Adults: a Randomized, Double Blinded, Placebo-controlled Phase <U+2160> Trial",Not yet recruiting,,Phase 1,100.0,Anticipated,"Yantai Patronus Biotech Co., Ltd.",,8.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-19 01:30:24,2023-06-19 01:30:24,INDUSTRY,,,,,
323886,323887,NCT04397003,,2020-05-15,,,2023-04-19,2020-05-15,2020-05-21,Actual,,,,,,,2023-04-19,2023-04-21,Actual,"March 30, 2022",Actual,2022-03-30,April 2023,2023-04-30,"June 30, 2026",Anticipated,2026-06-30,"June 30, 2024",Anticipated,2024-06-30,,Interventional,,,Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer,Phase II Study of a Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer,Recruiting,,Phase 2,27.0,Anticipated,Washington University School of Medicine,,1.0,,,False,,,,True,True,False,,,False,,,,,,Yes,All study data will be shared with the study sponsor and will be available from presentations and upon publication.,2023-06-15 16:29:31,2023-06-15 16:29:31,OTHER,,,,,
324018,324019,NCT02251288,,2014-09-25,,,2020-01-23,2014-09-25,2014-09-29,Estimate,,,,,,,2020-01-23,2020-01-27,Actual,"May 18, 2015",Actual,2015-05-18,"July 1, 2018",2018-07-01,"August 17, 2018",Actual,2018-08-17,"August 17, 2018",Actual,2018-08-17,,Interventional,,,A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine,"A Phase I Randomized Study in Healthy Adults to Assess the Safety, Reactogenicity and Immunogenicity of Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine",Completed,,Phase 1,62.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-17 06:05:10,2023-06-17 06:05:10,NIH,,,,,
324021,324022,NCT05142514,,2021-11-17,,,2022-08-02,2021-12-01,2021-12-02,Actual,,,,,,,2022-08-02,2022-08-03,Actual,"November 11, 2021",Actual,2021-11-11,August 2022,2022-08-31,"December 27, 2022",Anticipated,2022-12-27,"December 27, 2021",Actual,2021-12-27,,Interventional,,,"Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)","A Phase IIb Study to Evaluate Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Candidate Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2) in Adult Healthy Volunteers","Active, not recruiting",,Phase 2,256.0,Anticipated,"Hipra Scientific, S.L.U",,2.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-17 23:13:00,2023-06-17 23:13:00,INDUSTRY,,,,,
324423,324424,NCT03961438,,2019-05-22,,,2023-04-20,2019-05-22,2019-05-23,Actual,,,,,,,2023-04-20,2023-04-21,Actual,"November 15, 2019",Actual,2019-11-15,April 2023,2023-04-30,"April 17, 2023",Actual,2023-04-17,"June 6, 2022",Actual,2022-06-06,,Interventional,ACTHIVE-001,,Amsterdam UMC Clinical Trial With a Native-like HIV-1 Envelope Vaccine,"A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes, in Healthy, HIV-Uninfected Adults",Completed,,Phase 1,24.0,Actual,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),,2.0,,,False,,,,False,False,False,,,,,,18 months from when the study officially closes.,Directly from Dr. G.J. de Bree (g.j.debree@amsterdamumc.nl),,Yes,"Results from this study will be disseminated locally and to the wider scientific community at conferences and in published open-access peer-reviewed journals, as appropriate. Any data used for publication will be fully anonymised. We plan to publish the data and hold onto the data for 20 years.",2023-06-15 16:30:35,2023-06-15 16:30:35,OTHER,,,,,
324670,324671,NCT01461980,,2011-09-28,2015-05-07,,2018-11-30,2011-10-26,2011-10-28,Estimate,2015-05-07,2015-05-25,Estimate,,,,2018-11-30,2018-12-20,Actual,"September 28, 2011",Actual,2011-09-28,November 2018,2018-11-30,"May 8, 2014",Actual,2014-05-08,"May 8, 2014",Actual,2014-05-08,,Interventional,,Intent-to-treat (ITT) population included all participants who were randomized.,"A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age","A Phase 2, Randomized, Active-controlled, Observer-blinded Trial, To Assess The Safety, Tolerability, And Immunogenicity Of Mcv4, Tdap Vaccine And Bivalent Rlp2086 Vaccine When Administered Concomitantly In Healthy Subjects Aged > = 10 To <13 Years",Completed,,Phase 2,2648.0,Actual,Pfizer,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-19 01:39:31,2023-06-19 01:39:31,INDUSTRY,,,,,
324679,324680,NCT01424501,,2011-08-25,2016-11-29,,2018-07-17,2011-08-25,2011-08-29,Estimate,2016-11-29,2017-01-24,Estimate,,,,2018-07-17,2018-08-20,Actual,"November 14, 2011",Actual,2011-11-14,July 2018,2018-07-31,"April 10, 2014",Actual,2014-04-10,"April 1, 2014",Actual,2014-04-01,,Interventional,,,Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease,Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342 When Administered to Adults With TB Disease,Terminated,,Phase 2,142.0,Actual,GlaxoSmithKline,,6.0,,"Due to a safety signal found at a planned interim safety review, further conduct of this safety study is not recommended hence the study was terminated.",False,,,,,False,False,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-19 01:39:43,2023-06-19 01:39:43,INDUSTRY,,,,,
324702,324703,NCT03085381,,2017-03-19,,,2018-09-12,2017-03-19,2017-03-21,Actual,,,,,,,2018-09-12,2018-09-14,Actual,December 2016,Actual,2016-12-31,September 2018,2018-09-30,August 2018,Actual,2018-08-31,October 2017,Actual,2017-10-31,,Interventional,,,A Phase I Study of Quadrivalent HPV Recombinant Vaccine,"A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Primary Immunogenicity of the Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years",Completed,,Phase 1,90.0,Actual,"Shanghai Bovax Biotechnology Co., Ltd.",,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-19 01:39:59,2023-06-19 01:39:59,INDUSTRY,,,,,
324706,324707,NCT01679665,,2012-09-01,,,2013-05-07,2012-09-01,2012-09-06,Estimate,,,,,,,2013-05-07,2013-05-08,Estimate,August 2012,,2012-08-31,May 2013,2013-05-31,May 2013,Actual,2013-05-31,May 2013,Actual,2013-05-31,,Interventional,,,Systems Biology of Vaccination for EV71 Vaccine in Humans,Systems Biology of Vaccination for EV71 Vaccine in Chinese Healthy Children Aged From 2 to 5 Years Old,Completed,,Phase 2,72.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-19 01:40:03,2023-06-19 01:40:03,NETWORK,,,,,
324771,324772,NCT03084289,,2017-03-03,,,2020-10-08,2017-03-13,2017-03-20,Actual,,,,,,,2020-10-08,2020-10-09,Actual,"March 28, 2017",Actual,2017-03-28,August 2020,2020-08-31,"July 6, 2020",Actual,2020-07-06,"July 6, 2020",Actual,2020-07-06,,Interventional,,,A Study to Assess the Safety and Immunogenicity of a Candidate Malaria Vaccine Using Novel Routes of Administration,A Phase I Study to Assess the Safety and Immunogenicity of Novel Routes of Administration of Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 and MVA Encoding ME-TRAP.,Completed,,Phase 1,26.0,Actual,University of Oxford,,8.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-19 01:40:45,2023-06-19 01:40:45,OTHER,,,,,
324834,324835,NCT03190265,,2017-06-15,,,2023-03-08,2017-06-15,2017-06-16,Actual,,,,,,,2023-03-08,2023-03-09,Actual,"December 14, 2017",Actual,2017-12-14,March 2023,2023-03-31,"August 1, 2023",Anticipated,2023-08-01,"August 3, 2022",Actual,2022-08-03,,Interventional,,,"Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer","A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cyclophosphamide) in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma","Active, not recruiting",,Phase 2,61.0,Actual,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,2.0,,,False,,,,True,True,False,,,,,,,,,Undecided,,2023-06-17 23:13:27,2023-06-17 23:13:27,OTHER,,,,,
325414,325415,NCT05124340,,2021-10-26,,,2022-09-15,2021-11-07,2021-11-17,Actual,,,,,,,2022-09-15,2022-09-19,Actual,"December 1, 2021",Actual,2021-12-01,September 2022,2022-09-30,"July 30, 2022",Actual,2022-07-30,"May 31, 2022",Actual,2022-05-31,,Interventional,,,Safety and Tuberculin Conversion Following BCG Vaccination,Safety and Tuberculin Conversion Following BCG Vaccine Vial (Bio Farma) Compared to Registered BCG Vaccine (Bio Farma) in Indonesian Infants,Completed,,Phase 2,220.0,Actual,PT Bio Farma,,2.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-17 23:14:04,2023-06-17 23:14:04,INDUSTRY,,,,,
325633,325634,NCT00857493,,2009-03-05,2018-12-07,,2019-01-09,2009-03-05,2009-03-06,Estimate,2019-01-09,2019-01-10,Actual,,,,2019-01-09,2019-01-10,Actual,June 2009,,2009-06-30,January 2019,2019-01-31,August 2010,Actual,2010-08-31,August 2010,Actual,2010-08-31,,Interventional,,Safety Analysis Set,A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects,"A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects",Completed,,Phase 2,120.0,Actual,Bavarian Nordic,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-19 01:48:39,2023-06-19 01:48:39,INDUSTRY,,,,,
325790,325791,NCT04895449,,2021-04-24,,,2023-01-15,2021-05-15,2021-05-20,Actual,,,,,,,2023-01-15,2023-01-18,Actual,"July 16, 2021",Actual,2021-07-16,January 2023,2023-01-31,"November 8, 2022",Actual,2022-11-08,"November 2, 2022",Actual,2022-11-02,,Interventional,MVA-SARS2-ST,,"Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19","A Multi-center Phase Ib Trial to Assess the Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST in Adults",Completed,,Phase 1,43.0,Actual,Universitätsklinikum Hamburg-Eppendorf,,6.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-19 01:50:30,2023-06-19 01:50:30,OTHER,,,,,
325821,325822,NCT00545987,,2007-10-16,,,2011-05-04,2007-10-17,2007-10-18,Estimate,,,,,,,2011-05-04,2011-05-05,Estimate,September 2007,,2007-09-30,May 2011,2011-05-31,April 2011,Actual,2011-04-30,October 2009,Actual,2009-10-31,,Interventional,ADVAX-EP,,Study of a Potential Preventive Vaccine Against HIV in Healthy Volunteers,"Evaluation of Local and Systemic Reactogenicity Following Serial Administration of ADVAX, a Clade C DNA Vaccine, ADVAX e/g + ADVAX p/N-t, by Ichor TriGrid in Vivo Electroporation to HIV-Uninfected, Healthy Volunteers",Completed,,Phase 1,40.0,Anticipated,Rockefeller University,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 16:33:39,2023-06-15 16:33:39,OTHER,,,,,
325896,325897,NCT05155579,,2021-12-09,,,2023-01-12,2021-12-09,2021-12-13,Actual,,,,,,,2023-01-12,2023-01-17,Actual,"May 14, 2022",Actual,2022-05-14,January 2023,2023-01-31,August 2024,Anticipated,2024-08-31,July 2023,Anticipated,2023-07-31,,Interventional,,,Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines,"A Phase Ib Trial to Evaluate the Safety and Immunogenicity of R21/Matrix-M in a Single and Two Vial Presentation, With Different Immunisation Schedules, and When Co-Administered With EPI Vaccines in African Children",Recruiting,,Phase 1,590.0,Anticipated,University of Oxford,,9.0,,,False,,,,True,False,False,,,,,,,,,Undecided,,2023-06-19 01:51:42,2023-06-19 01:51:42,OTHER,,,,,
326115,326116,NCT01376505,,2011-06-09,,,2023-02-22,2011-06-16,2011-06-20,Estimate,,,,,,,2023-02-22,2023-02-24,Actual,"June 21, 2011",Actual,2011-06-21,February 2023,2023-02-28,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2023",Anticipated,2023-12-31,,Interventional,,,Vaccine Therapy in Treating Patients With Metastatic Solid Tumors,Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like)Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid Tumors,Recruiting,,Phase 1,100.0,Anticipated,Ohio State University Comprehensive Cancer Center,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-19 01:53:45,2023-06-19 01:53:45,OTHER,,,,,
326148,326149,NCT03611946,,2018-07-27,,,2022-06-02,2018-08-01,2018-08-02,Actual,,,,,,,2022-06-02,2022-06-03,Actual,"July 6, 2018",Actual,2018-07-06,March 2022,2022-03-31,"March 18, 2022",Actual,2022-03-18,"March 18, 2022",Actual,2022-03-18,,Interventional,,,Evaluation of the Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4<U+0394>30-713 in Flavivirus-naïve Adults,Phase I Evaluation of the Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4<U+0394>30-713 in Flavivirus-naïve Adults,Completed,,Phase 1,56.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-19 01:54:07,2023-06-19 01:54:07,NIH,,,,,
326447,326448,NCT00548054,,2007-10-21,,,2015-05-01,2007-10-21,2007-10-23,Estimate,,,,,,,2015-05-01,2015-05-04,Estimate,December 2015,,2015-12-31,May 2015,2015-05-31,December 2016,Anticipated,2016-12-31,August 2016,Anticipated,2016-08-31,,Interventional,,,Safety and Immunogenicity of a Killed Oral Cholera Vaccine in Infants,Safety and Immunogenicity of a Killed Oral Cholera Vaccine Among Infants 10 Weeks to Less Than 12 Months of Age When Given Concomitantly With EPI Vaccines,Unknown status,Not yet recruiting,Phase 2,300.0,Anticipated,International Vaccine Institute,,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 16:35:12,2023-06-15 16:35:12,OTHER,,,,,
326488,326489,NCT00548444,,2007-10-23,,,2010-01-15,2007-10-23,2007-10-24,Estimate,,,,,,,2010-01-15,2010-01-18,Estimate,October 2007,,2007-10-31,January 2010,2010-01-31,January 2010,Actual,2010-01-31,January 2010,Actual,2010-01-31,,Interventional,,,T-Cell Turnover Following Vaccination With MVA85A,Measurement of Human T-Cell Turnover Following Vaccination With the Tuberculosis Vaccine MVA85A,Completed,,Phase 1,12.0,Actual,University of Oxford,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 16:35:19,2023-06-15 16:35:19,OTHER,,,,,
326640,326641,NCT00893997,,2009-05-04,2011-03-17,,2012-07-10,2009-05-05,2009-05-06,Estimate,2011-03-17,2011-04-12,Estimate,,,,2012-07-10,2012-07-16,Estimate,July 2006,,2006-07-31,July 2012,2012-07-31,March 2009,Actual,2009-03-31,March 2009,Actual,2009-03-31,,Interventional,,,PR1 Vaccination in Myelodysplastic Syndrome (MDS),Phase 2 Study of Proteinase 3 PR1 Peptide Vaccine in Myelodysplastic Syndrome (MDS),Terminated,,Phase 2,12.0,Actual,M.D. Anderson Cancer Center,,1.0,,The trial was ended per sponsor due to slow accrual rates.,False,,,,False,,,,,,,,,,,,,2023-06-19 01:58:31,2023-06-19 01:58:31,OTHER,,,,,
327326,327327,NCT00374049,,2006-09-07,,,2016-07-08,2006-09-07,2006-09-08,Estimate,,,,,,,2016-07-08,2016-07-12,Estimate,June 2006,,2006-06-30,December 2015,2015-12-31,December 2015,Actual,2015-12-31,January 2008,Actual,2008-01-31,,Interventional,,,MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer,A Pilot Dose Finding Study of MUC1 Vaccine in Conjunction With Poly-ICLC (Polyinosinic-polycytidylic Acid Stabilized With Polylysine and Carboxymethylcellulose) or HiltonolTM in Patients With Recurrent and/or Advanced Prostate Cancer,Completed,,Phase 1,14.0,Actual,University of Pittsburgh,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 08:33:36,2023-06-14 08:33:36,OTHER,,,,,
327414,327415,NCT05408312,,2022-06-05,,,2022-07-20,2022-06-05,2022-06-07,Actual,,,,,,,2022-07-20,2022-07-22,Actual,"June 18, 2022",Actual,2022-06-18,July 2022,2022-07-31,December 2023,Anticipated,2023-12-31,December 2023,Anticipated,2023-12-31,,Interventional,,,Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above,"Phase I Clinical Trial of Safety, Tolerance and Immunogenicity of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above","Active, not recruiting",,Phase 1,234.0,Actual,"National Vaccine and Serum Institute, China",,4.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-15 16:37:30,2023-06-15 16:37:30,INDUSTRY,,,,,
327493,327494,NCT01927159,,2013-08-15,,,2018-01-30,2013-08-19,2013-08-22,Estimate,,,,,,,2018-01-30,2018-02-01,Actual,September 2013,,2013-09-30,January 2018,2018-01-31,July 2015,Actual,2015-07-31,July 2015,Actual,2015-07-31,,Interventional,,,Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers,"A Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine in BCG-Vaccinated Healthy Adults",Completed,,Phase 1,66.0,Actual,Access to Advanced Health Institute (AAHI),,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-19 02:06:06,2023-06-19 02:06:06,OTHER,,,,,
327771,327772,NCT02548169,,2015-09-10,,,2019-01-25,2015-09-10,2015-09-14,Estimate,,,,,,,2019-01-25,2019-01-29,Actual,August 2015,Actual,2015-08-31,January 2019,2019-01-31,"April 24, 2017",Actual,2017-04-24,"April 24, 2017",Actual,2017-04-24,,Interventional,PancVax,,Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer,"A Phase I, Safety Trial of Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer",Terminated,,Phase 1,7.0,Actual,Baylor Research Institute,,2.0,,The study was stopped because of loss of funding and no safety issues,False,,,,True,,,,,,,,,,,,,2023-06-16 17:54:40,2023-06-16 17:54:40,OTHER,,,,,
327870,327871,NCT04470024,,2020-07-09,,,2022-09-09,2020-07-09,2020-07-14,Actual,,,,,,,2022-09-09,2022-09-10,Actual,"August 5, 2021",Actual,2021-08-05,September 2022,2022-09-30,"July 31, 2024",Anticipated,2024-07-31,"December 31, 2023",Anticipated,2023-12-31,,Interventional,,,"Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC","A Phase Ib Study of Multivalent Autophagosome Vaccine, With or Without GITR Agonist, With Sequenced Checkpoint Inhibition (Anti-PD-1) - Immunotherapy Trio in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)",Recruiting,,Phase 1,56.0,Anticipated,Providence Health & Services,,2.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-19 02:10:04,2023-06-19 02:10:04,OTHER,,,,,
327900,327901,NCT00981175,,2009-09-21,2011-04-05,,2012-07-11,2009-09-21,2009-09-22,Estimate,2011-04-05,2011-04-29,Estimate,,,,2012-07-11,2012-07-16,Estimate,April 2003,,2003-04-30,July 2012,2012-07-31,February 2008,Actual,2008-02-29,June 2004,Actual,2004-06-30,,Interventional,,,A Study of ChimeriVax-JE Live Attenuated Vaccine in Healthy Adults,"Randomised, Double-blind, Phase 2 Study of the Safety, Immunogenicity and Duration of Immunity of ChimeriVax-JE, Live Attenuated Vaccine in Healthy Adults",Completed,,Phase 2,202.0,Actual,Sanofi,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-19 02:10:27,2023-06-19 02:10:27,INDUSTRY,,,,,
327934,327935,NCT05197751,,2021-11-24,,,2023-02-25,2022-01-05,2022-01-19,Actual,,,,,,,2023-02-25,2023-02-28,Actual,"December 1, 2021",Actual,2021-12-01,February 2023,2023-02-28,"May 9, 2023",Anticipated,2023-05-09,"August 3, 2022",Actual,2022-08-03,,Interventional,MSP3CRMV4All,,MSP3-CRM-Vac4All/ Alhydrogel® Malaria Vaccine,"Phase 1 Randomized, Dose-finding Study to Evaluate the Safety, Tolerability and Immunogenicity of a Novel Malaria Vaccine, MSP3-CRM-Vac4All/ Alhydrogel®, in Healthy Adults","Active, not recruiting",,Phase 1,42.0,Anticipated,Vac4All,,3.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-14 08:35:12,2023-06-14 08:35:12,INDUSTRY,,,,,
328380,328381,NCT02134925,,2014-05-07,2018-03-15,,2023-03-09,2014-05-07,2014-05-09,Estimate,2018-04-19,2018-05-18,Actual,,,,2023-03-09,2023-03-10,Actual,"June 23, 2014",Actual,2014-06-23,March 2023,2023-03-31,,,,"January 27, 2017",Actual,2017-01-27,,Interventional,,,Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps,"Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Vaccine in Patients With Newly Diagnosed Advanced Adenomas","Active, not recruiting",,Phase 2,110.0,Actual,National Cancer Institute (NCI),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-17 23:16:34,2023-06-17 23:16:34,NIH,,,,,
328699,328700,NCT04509167,,2020-08-08,,,2022-07-20,2020-08-08,2020-08-11,Actual,,,,,,,2022-07-20,2022-07-22,Actual,"August 10, 2020",Actual,2020-08-10,November 2021,2021-11-30,"June 24, 2022",Actual,2022-06-24,"June 24, 2022",Actual,2022-06-24,,Interventional,,,Pilot Study of Neoantigen Peptides for the Treatment of Neoplasms,Pilot Study of Personalized Neoantigen Peptide Vaccines for the Treatment of Neoplasms,Completed,,Early Phase 1,30.0,Actual,Instituto de Medicina Regenerativa,,1.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-15 16:39:55,2023-06-15 16:39:55,INDUSTRY,,,,,
328838,328839,NCT00623831,,2008-02-04,2016-09-21,,2022-10-03,2008-02-24,2008-02-26,Estimate,2016-11-10,2017-01-09,Estimate,,,,2022-10-03,2022-10-25,Actual,May 2007,,2007-05-31,October 2022,2022-10-31,May 2013,Actual,2013-05-31,May 2012,Actual,2012-05-31,,Interventional,,All Enrolled Subjects,A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen,A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen.,Completed,,Phase 1,17.0,Actual,Ludwig Institute for Cancer Research,,2.0,,,False,,,,False,,,,,,,,,,,Yes,Data have been published,2023-06-16 17:55:30,2023-06-16 17:55:30,OTHER,,,,,
328904,328905,NCT02241135,,2014-08-22,,,2018-10-25,2014-09-12,2014-09-16,Estimate,,,,,,,2018-10-25,2018-10-29,Actual,October 2013,,2013-10-31,May 2018,2018-05-31,"February 8, 2018",Actual,2018-02-08,"February 8, 2018",Actual,2018-02-08,,Interventional,,,RNActive® Rabies Vaccine (CV7201) in Healthy Adults,Phase I Safety and Immunogenicity Trial of an Investigational RNActive® Rabies Vaccine (CV7201) in Healthy Adults,Completed,,Phase 1,101.0,Actual,CureVac,,8.0,,,False,,,,True,,,,,,,,,,,,,2023-06-19 02:18:28,2023-06-19 02:18:28,INDUSTRY,,,,,
329196,329197,NCT00834665,,2008-01-03,,,2019-10-21,2009-02-02,2009-02-03,Estimate,,,,,,,2019-10-21,2019-10-23,Actual,December 2006,,2006-12-31,October 2019,2019-10-31,December 2017,Actual,2017-12-31,December 2017,Actual,2017-12-31,,Interventional,,,Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma,Phase I/II Combination Immunotherapy After ASCT for Advanced Myeloma to Study HTERT Vaccination Followed by Adoptive Transfer of Vaccine-Primed Autologous T Cells,Completed,,Phase 1,59.0,Actual,University of Pennsylvania,,2.0,,,False,,,,False,,,,,,,,,,,No,,2023-06-16 17:56:15,2023-06-16 17:56:15,OTHER,,,,,
329591,329592,NCT04363359,,2020-04-17,,,2020-04-22,2020-04-22,2020-04-27,Actual,,,,,,,2020-04-22,2020-04-27,Actual,"April 30, 2020",Anticipated,2020-04-30,April 2020,2020-04-30,"March 30, 2021",Anticipated,2021-03-30,"August 30, 2020",Anticipated,2020-08-30,,Interventional,,,Clinical Trial of Quadrivalent Influenza Virus Split Vaccine,"Immunogenicity and Safety of Quadrivalent Influenza Vaccine In 6 to 35 Months Population: a Randomized, Double-blind, Parallel-group <U+2161> Phase of Clinical Trials",Unknown status,Not yet recruiting,Phase 2,1980.0,Anticipated,Shanghai Institute Of Biological Products,,4.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-19 02:21:49,2023-06-19 02:21:49,INDUSTRY,,,,,
329645,329646,NCT04998474,,2021-07-01,,,2021-08-09,2021-08-09,2021-08-10,Actual,,,,,,,2021-08-09,2021-08-10,Actual,January 2022,Anticipated,2022-01-31,August 2021,2021-08-31,July 2024,Anticipated,2024-07-31,January 2024,Anticipated,2024-01-31,,Interventional,,,FRAME-001 Personalized Vaccine in NSCLC,A Phase II Trial of Personalized Tumor Neoantigen Based Vaccine FRAME-001 for Advanced Non-Small Cell Lung Cancer,Not yet recruiting,,Phase 2,15.0,Anticipated,Frame Pharmaceuticals B.V.,,1.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-19 02:22:10,2023-06-19 02:22:10,INDUSTRY,,,,,
329948,329949,NCT05738447,,2023-01-30,,,2023-02-12,2023-02-12,2023-02-22,Actual,,,,,,,2023-02-12,2023-02-22,Actual,"February 15, 2023",Anticipated,2023-02-15,February 2023,2023-02-28,"January 1, 2025",Anticipated,2025-01-01,"January 1, 2024",Anticipated,2024-01-01,,Interventional,,,Application of mRNA Immunotherapy Technology in Hepatitis B Virus-related Refractory Hepatocellular Carcinoma,A Phase I Study of mRNA Vaccine for Patients With HBV-positive Advanced Hepatocellular Carcinoma,Recruiting,,Phase 1,9.0,Anticipated,West China Hospital,,1.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-14 08:41:34,2023-06-14 08:41:34,OTHER,,,,,
330352,330353,NCT04993209,,2021-08-03,,,2022-06-03,2021-08-04,2021-08-06,Actual,,,,,,,2022-06-03,2022-06-06,Actual,"July 9, 2021",Actual,2021-07-09,June 2022,2022-06-30,"November 4, 2022",Anticipated,2022-11-04,"December 10, 2021",Actual,2021-12-10,,Interventional,ADAPTCOV,,"Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil","Double-blind, Randomized, With an Active Control Vaccine, Phase I Clinical Trial for Evaluation of Safety and Immunogenicity of a Recombinant Inactivated COVID-19 Vaccine in Adults in Brazil - ADAPTCOV","Active, not recruiting",,Phase 1,320.0,Actual,Butantan Institute,,4.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-14 08:43:29,2023-06-14 08:43:29,OTHER_GOV,,,,,
330414,330415,NCT00963157,,2009-08-20,2011-11-10,,2014-12-04,2009-08-20,2009-08-21,Estimate,2011-11-10,2011-12-14,Estimate,,,,2014-12-04,2014-12-24,Estimate,September 2009,,2009-09-30,January 2011,2011-01-31,December 2010,Actual,2010-12-31,December 2010,Actual,2010-12-31,,Interventional,,,Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations,A Phase II Study in Healthy Adult and Elderly Populations to Assess the Safety and Immunogenicity of a Sanofi Pasteur H1N1 Influenza Vaccine Administered at Different Dose Levels Given With and Without GlaxoSmithKline AS03 Adjuvant,Completed,,Phase 2,789.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 02:25:28,2023-06-14 02:25:28,NIH,,,,,
330509,330510,NCT04525599,,2020-08-21,,,2022-06-02,2020-08-21,2020-08-25,Actual,,,,,,,2022-06-02,2022-06-06,Actual,"September 22, 2020",Actual,2020-09-22,June 2022,2022-06-30,"April 6, 2022",Actual,2022-04-06,"April 6, 2022",Actual,2022-04-06,,Interventional,,,"A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator","A Phase 1, Randomized, Single Dose, Blinded, Dose-Escalation Study to Assess Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator",Completed,,Phase 1,75.0,Actual,"Affinivax, Inc.",,6.0,,,False,,,,True,True,False,,,,,,,,,No,"Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under ""Sponsor Specific Details for Astellas.""",2023-06-14 08:44:01,2023-06-14 08:44:01,INDUSTRY,,,,,
330547,330548,NCT04146623,,2019-10-28,,,2020-11-28,2019-10-29,2019-10-31,Actual,,,,,,,2020-11-28,2020-12-01,Actual,"May 7, 2019",Actual,2019-05-07,November 2020,2020-11-30,"November 11, 2020",Actual,2020-11-11,"October 11, 2020",Actual,2020-10-11,,Interventional,,,"Safety Study of Live Attenuated Influenza Vaccine, CodaVax, Delivered Via Intranasal Spray","A Randomized Double-Blind, Placebo Controlled, Phase I Study of the Safety, Tolerability and Immunogenicity of a Live Attenuated H1N1 Vaccine in Healthy Individuals",Completed,,Phase 1,33.0,Actual,"Codagenix, Inc",,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-19 02:24:40,2023-06-19 02:24:40,INDUSTRY,,,,,
330827,330828,NCT05631899,,2022-11-21,,,2023-04-03,2022-11-29,2022-11-30,Actual,,,,,,,2023-04-03,2023-04-04,Actual,"April 3, 2023",Actual,2023-04-03,April 2023,2023-04-30,"December 30, 2026",Anticipated,2026-12-30,"December 30, 2025",Anticipated,2025-12-30,,Interventional,,,Combination of CAR-DC Vaccine and Anti-PD-1 Antibody in Local Advanced/Metastatic Solid Tumors,A Pilot Clinical Trial of Autologous EphA-2-Targeting Chimeric Antigen Receptor Dendritic Cell Vaccine Loaded With KRAS Mutant Peptide in Combination With Anti-PD-1 Antibody for Local Advanced/Metastatic Solid Tumors.,Recruiting,,Phase 1,10.0,Anticipated,Chinese PLA General Hospital,,1.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-17 23:20:01,2023-06-17 23:20:01,OTHER,,,,,
330837,330838,NCT05585567,,2022-10-13,,,2022-11-03,2022-10-16,2022-10-19,Actual,,,,,,,2022-11-03,2022-11-07,Actual,"September 16, 2022",Actual,2022-09-16,October 2022,2022-10-31,"September 11, 2023",Anticipated,2023-09-11,"October 14, 2022",Actual,2022-10-14,,Interventional,COVID-19,,A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5,"A Single Center, Randomized, Open-labeled, Exploratory Clinical Study to Evaluate the Safety and Immunogenicity of Bivalent Vaccine V-01-B5 as a Booster Dose in Participants Aged 18-59 Years Vaccinated 3-dose Inactivated COVID-19 Vaccine","Active, not recruiting",,Early Phase 1,48.0,Actual,Livzon Pharmaceutical Group Inc.,,3.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-19 02:25:15,2023-06-19 02:25:15,INDUSTRY,,,,,
330931,330932,NCT00558051,,2007-11-13,,,2016-03-31,2007-11-13,2007-11-14,Estimate,,,,,,,2016-03-31,2016-04-01,Estimate,January 2008,,2008-01-31,March 2016,2016-03-31,April 2014,Actual,2014-04-30,December 2011,Actual,2011-12-31,,Interventional,,,Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer,Phase I Evaluation of Semi-continuous Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer,Completed,,Phase 1,15.0,Actual,University of Pittsburgh,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 16:47:29,2023-06-15 16:47:29,OTHER,,,,,
330975,330976,NCT05614245,,2022-11-02,,,2023-03-30,2022-11-10,2022-11-14,Actual,,,,,,,2023-03-30,2023-04-04,Actual,March 2023,Anticipated,2023-03-31,March 2023,2023-03-31,June 2024,Anticipated,2024-06-30,June 2024,Anticipated,2024-06-30,,Interventional,,,"Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant","A Phase 1, Open-Label, Adjuvant Dose-Escalation, Randomized Study to Evaluate the Safety and Immunogenicity of VBI-2901e, a Trivalent Coronavirus Vaccine Candidate Adjuvanted With Aluminum Phosphate and E6020 in Healthy Adults Previously Vaccinated With Licensed COVID-19 Vaccines",Withdrawn,,Phase 1,0.0,Actual,VBI Vaccines Inc.,,6.0,,Study was halted prematurely prior to enrollment of first participant based on study sponsor's decision to prioritize clinical development of VBI-2901a.,False,,,,True,False,False,,,,,,,,,,,2023-06-17 23:20:10,2023-06-17 23:20:10,INDUSTRY,,,,,
331299,331300,NCT04436133,,2020-06-11,,,2022-05-05,2020-06-16,2020-06-17,Actual,,,,,,,2022-05-05,2022-05-06,Actual,"June 20, 2020",Actual,2020-06-20,May 2022,2022-05-31,"March 1, 2022",Actual,2022-03-01,"March 1, 2022",Actual,2022-03-01,,Interventional,,,Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha),"A Randomized, Blind, and Positive Control Design to Evaluate the Immunization Efficacy of 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 18-26 Years",Completed,,Phase 2,480.0,Actual,"National Vaccine and Serum Institute, China",,2.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-14 08:46:25,2023-06-14 08:46:25,INDUSTRY,,,,,
331402,331403,NCT05003466,,2021-08-10,,,2021-08-11,2021-08-10,2021-08-12,Actual,,,,,,,2021-08-11,2021-08-18,Actual,September 2021,Anticipated,2021-09-30,August 2021,2021-08-31,April 2023,Anticipated,2023-04-30,March 2023,Anticipated,2023-03-31,,Interventional,,,Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 3 to 17 Years(COVID-19),"A Randomized, Double-blind, Placebo-controlled Phase <U+2161> Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 3 to 17 Years",Not yet recruiting,,Phase 2,480.0,Anticipated,"Shenzhen Kangtai Biological Products Co., LTD",,2.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-19 02:26:42,2023-06-19 02:26:42,INDUSTRY,,,,,
331492,331493,NCT03213405,,2017-06-30,2020-10-09,,2020-11-18,2017-07-07,2017-07-11,Actual,2020-11-18,2020-12-11,Actual,,,,2020-11-18,2020-12-11,Actual,"June 27, 2017",Actual,2017-06-27,November 2020,2020-11-30,"June 1, 2018",Actual,2018-06-01,"June 1, 2018",Actual,2018-06-01,,Interventional,EVA-VRS01,,"A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuated hRSV Vaccine rBCG-N-hRSV","A Double Blind, Controlled by Conventional BCG, Dose-escalation Phase I Study, to Evaluate Safety, Tolerability and Immunogenicity of a Mycobacterium Bovis BCG (Bacillus Calmette-Guérin) Vaccine, 1331 Danish Strain, Live Attenuated and Recombinant for the Expression of Human Respiratory Syncytial Virus Nucleoprotein (N) in Healthy Males Within 18 and 50 Years of Age",Completed,,Phase 1,24.0,Actual,Pontificia Universidad Catolica de Chile,,4.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-14 08:46:40,2023-06-14 08:46:40,OTHER,,,,,
331732,331733,NCT03998592,,2019-06-24,,,2021-02-02,2019-06-24,2019-06-26,Actual,,,,,,,2021-02-02,2021-02-04,Actual,May 2021,Anticipated,2021-05-31,February 2021,2021-02-28,October 2023,Anticipated,2023-10-31,March 2022,Anticipated,2022-03-31,,Interventional,,,Clinical Trial to Assess Safety and Immunogenicity of a Synthetic Vaccine Against Streptococcus Pyogenes,Phase I Clinical Trial for Assessment of Safety and Immunogenicity of a Synthetic Vaccine Against Streptococcus Pyogenes in Healthy Volunteers,Withdrawn,,Phase 1,0.0,Actual,Butantan Institute,,4.0,,Agreement between interested partied ended,False,,,,True,False,False,,,,,,,,,No,,2023-06-16 18:01:33,2023-06-16 18:01:33,OTHER_GOV,,,,,
331799,331800,NCT01942265,,2013-09-04,,2017-07-03,2017-07-03,2013-09-12,2013-09-13,Estimate,,,,2017-07-03,2017-07-06,Actual,2017-07-03,2017-07-06,Actual,September 2013,,2013-09-30,September 2014,2014-09-30,January 2015,Actual,2015-01-31,January 2015,Actual,2015-01-31,,Interventional,,,H7N9 Mix and Match With AS03 and MF59 in Healthy Adults,"A Phase II Randomized, Double-Blinded, Controlled Study in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of a Monovalent Influenza A/H7N9 Virus Vaccine Administered at Different Dosages Given With and Without AS03 and MF59 Adjuvants",Completed,,Phase 2,980.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,10.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 16:52:10,2023-06-15 16:52:10,NIH,,,,,
332003,332004,NCT00858611,,2009-03-07,,,2017-06-30,2009-03-07,2009-03-10,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"March 3, 2009",,2009-03-03,"June 21, 2010",2010-06-21,"June 21, 2010",Actual,2010-06-21,"June 21, 2010",Actual,2010-06-21,,Interventional,,,"VRC 307: A Double-Blind, Randomized Phase I Study of the Safety and Immunogenicity of a Prime-Boost Schedule of the Investigational DNA Trivalent Influenza Vaccine, VRC-FLUDNA047-00-VP, Followed by the 2008/2009 Seasonal Influenza Trivalent Inactivat...","VRC 307: A D/B Randomized Ph. I Study of Safety/Immunogenicity of a Prime-Boost Schedule of an Investigational DNA Influenza Vaccine, Followed by the Seasonal Influenza Trivalent Inactivated Vaccine (TIV), Compared to TIV Alone in Healthy Adults",Completed,,Phase 1,51.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-16 18:02:13,2023-06-16 18:02:13,NIH,,,,,
332006,332007,NCT00854789,,2009-03-02,,,2020-03-28,2009-03-02,2009-03-03,Estimate,,,,,,,2020-03-28,2020-03-31,Actual,December 2002,,2002-12-31,March 2020,2020-03-31,March 2013,Actual,2013-03-31,May 2012,Actual,2012-05-31,,Interventional,,,Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Breast Cancer,Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Node Negative Breast Cancer Patients,Completed,,Phase 1,95.0,Actual,Walter Reed Army Medical Center,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 18:02:13,2023-06-16 18:02:13,FED,,,,,
332045,332046,NCT03300843,,2017-10-03,2019-11-19,,2019-11-19,2017-10-03,2017-10-04,Actual,2019-11-19,2019-12-13,Actual,,,,2019-11-19,2019-12-13,Actual,"April 11, 2018",Actual,2018-04-11,November 2019,2019-11-30,"September 16, 2019",Actual,2019-09-16,"July 9, 2019",Actual,2019-07-09,,Interventional,,,Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer,A Phase II Trial to Evaluate the Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer,Terminated,,Phase 2,1.0,Actual,National Institutes of Health Clinical Center (CC),,1.0,,slow accrual,,,,,False,True,False,,,,,,,,,No,,2023-06-14 08:48:08,2023-06-14 08:48:08,NIH,,,,,
332074,332075,NCT00376779,,2006-09-14,,,2016-11-02,2006-09-14,2006-09-15,Estimate,,,,,,,2016-11-02,2016-11-04,Estimate,October 2006,,2006-10-31,November 2016,2016-11-30,May 2007,Actual,2007-05-31,May 2007,Actual,2007-05-31,,Interventional,,,"Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age","A Phase II, Observer-blind, Randomized Study to Evaluate the Immunogenicity, Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Combined DssiTgdPa-HBV-IPV/Hib Vaccine Containing Diphtheria Toxoid From the Statens Serum Institute (SSI) of Denmark and Tetanus Toxoid From GSK Biologicals' Kft [GD], Compared to the Currently Licensed GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine (Infanrix Hexa TM) When Administered to Healthy Infants at 2, 3 and 4 Months of Age.",Completed,,Phase 2,450.0,,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-14 08:48:17,2023-06-14 08:48:17,INDUSTRY,,,,,
332132,332133,NCT00944073,,2009-07-21,2011-03-17,,2015-01-29,2009-07-21,2009-07-22,Estimate,2011-03-17,2011-04-13,Estimate,,,,2015-01-29,2015-02-18,Estimate,August 2009,,2009-08-31,March 2010,2010-03-31,April 2010,Actual,2010-04-30,April 2010,Actual,2010-04-30,,Interventional,,,Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels,"A Phase II Study in Infants (Greater Than or Equal to 6 - Less Than 36 Months), Children (Greater Than or Equal to 36 Months - 9 Years) and Adolescents (10 - 17 Years) to Assess the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine Administered at Two Dose Levels",Completed,,Phase 2,583.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-19 02:29:08,2023-06-19 02:29:08,NIH,,,,,
332220,332221,NCT01704365,,2012-10-08,,2014-02-05,2014-02-05,2012-10-10,2012-10-11,Estimate,,,,2014-02-05,2014-03-07,Estimate,2014-02-05,2014-03-07,Estimate,October 2012,,2012-10-31,February 2014,2014-02-28,May 2013,Actual,2013-05-31,April 2013,Actual,2013-04-30,,Interventional,,,RSV-F Vaccine Dose Ranging Study in Young Women,"A Phase II Randomized, Observer-Blinded, Placebo-Controlled, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of an RSV-F Protein Nanoparticle Vaccine, With or Without Aluminum, in Healthy Women of Child-Bearing Age",Completed,,Phase 2,330.0,Actual,Novavax,,10.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 16:53:47,2023-06-15 16:53:47,INDUSTRY,,,,,
332237,332238,NCT00565461,,2007-11-28,2014-01-30,,2020-03-17,2007-11-29,2007-11-30,Estimate,2014-03-17,2014-04-21,Estimate,,,,2020-03-17,2020-03-30,Actual,November 2007,,2007-11-30,March 2020,2020-03-31,August 2008,Actual,2008-08-31,July 2008,Actual,2008-07-31,,Interventional,,,LT Vaccine Patch Self-Administration Study,"A Phase 2, Randomized, Open-Label Study to Compare the Immunogenicity and Safety of a Self-Administered LT Vaccine Patch With an LT Vaccine Patch Administered by a Clinician",Completed,,Phase 2,160.0,Actual,"Intercell USA, Inc.",,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 16:53:51,2023-06-15 16:53:51,INDUSTRY,,,,,
332300,332301,NCT00434577,,2007-02-12,2017-08-25,2012-03-09,2019-02-22,2007-02-12,2007-02-13,Estimate,2018-06-26,2019-01-08,Actual,2012-03-09,2012-03-14,Estimate,2019-02-22,2019-03-15,Actual,"February 14, 2007",Actual,2007-02-14,February 2019,2019-02-28,"July 14, 2010",Actual,2010-07-14,"October 4, 2007",Actual,2007-10-04,,Interventional,,,Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects,"A Phase II, Single-blind, Randomized, Controlled, Multicentre Vaccination Study to Evaluate the Safety and Immune Response of the GSK Biologicals Zoster Vaccine, gE/AS01B, and to Compare 3 Doses of gE With AS01B Adjuvant in Healthy Elderly Subjects, Aged 60 to 69 Years and 70 Years and Above.",Completed,,Phase 2,715.0,Actual,GlaxoSmithKline,,5.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 18:02:52,2023-06-16 18:02:52,INDUSTRY,,,,,
332484,332485,NCT03581903,,2018-06-26,,,2019-03-22,2018-06-26,2018-07-10,Actual,,,,,,,2019-03-22,2019-03-25,Actual,"September 19, 2017",Actual,2017-09-19,March 2019,2019-03-31,"February 6, 2019",Actual,2019-02-06,"September 14, 2018",Actual,2018-09-14,,Interventional,,,A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine,A Phase I Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine,Completed,,Phase 1,20.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,1.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-19 02:30:27,2023-06-19 02:30:27,NIH,,,,,
332518,332519,NCT05305300,,2022-03-20,,,2022-12-20,2022-03-29,2022-03-31,Actual,,,,,,,2022-12-20,2022-12-22,Actual,"October 18, 2021",Actual,2021-10-18,March 2022,2022-03-31,"September 15, 2022",Actual,2022-09-15,"May 15, 2022",Actual,2022-05-15,,Interventional,,,"A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals","A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Adults Who is COVID-19 naïve or Had Previous COVID-19 Infection or Completed Inactivated or mRNA COVID-19 Vaccination.",Completed,,Phase 1,135.0,Actual,Yisheng Biopharma (Singapore) Pte. Ltd.,,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-15 16:55:17,2023-06-15 16:55:17,INDUSTRY,,,,,
332768,332769,NCT03020771,,2017-01-11,,,2017-10-16,2017-01-12,2017-01-13,Estimate,,,,,,,2017-10-16,2017-10-17,Actual,December 2014,Actual,2014-12-31,October 2017,2017-10-31,June 2017,Actual,2017-06-30,June 2017,Actual,2017-06-30,,Interventional,,,"Phase I Study to Evaluate Basic Pharmacodynamic, Pharmacological and Toxicological Effects of the Newly Developed Crimean-Congo Hemorrhagic Fever Vaccine for Humans","Phase I Study to Evaluate Basic Pharmacodynamic, Pharmacological and Toxicological Effects of the Newly Developed Crimean-Congo Hemorrhagic Fever Vaccine for Humans, Prepared in Cell Culture and Inactivated With Formalin, and Administered Subcutaneously or Intramuscularly With Two Different Doses",Completed,,Phase 1,60.0,Actual,The Scientific and Technological Research Council of Turkey,,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-19 02:31:39,2023-06-19 02:31:39,OTHER,,,,,
332941,332942,NCT03068832,,2017-02-27,,,2021-05-21,2017-02-27,2017-03-03,Actual,,,,,,,2021-05-21,2021-05-25,Actual,"September 30, 2021",Anticipated,2021-09-30,May 2021,2021-05-31,"February 28, 2026",Anticipated,2026-02-28,"March 31, 2023",Anticipated,2023-03-31,,Interventional,,,Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors,"A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors",Withdrawn,,Phase 1,0.0,Actual,Washington University School of Medicine,,1.0,,Made the decision to not go forward with the study,False,,,,True,True,False,,,False,,,,,,No,,2023-06-19 02:32:25,2023-06-19 02:32:25,OTHER,,,,,
333117,333118,NCT00561275,,2007-11-14,,,2008-07-10,2007-11-19,2007-11-20,Estimate,,,,,,,2008-07-10,2008-07-15,Estimate,October 2007,,2007-10-31,July 2008,2008-07-31,June 2008,Actual,2008-06-30,May 2008,Actual,2008-05-31,,Interventional,,,Safety Study of Multiple Peptide Vaccine to Esophageal Cancer,Phase 1 Study of Multiple Peptide Vaccine Therapy and GM-CSF in Treating Patients With Esophageal Cancer,Completed,,Phase 1,6.0,Actual,Japanese Foundation for Cancer Research,,,,,False,,,,False,,,,,,,,,,,,,2023-06-15 16:57:26,2023-06-15 16:57:26,OTHER,,,,,
333221,333222,NCT00873431,,2009-03-31,,,2012-10-18,2009-03-31,2009-04-01,Estimate,,,,,,,2012-10-18,2012-10-19,Estimate,March 2009,,2009-03-31,October 2012,2012-10-31,February 2010,Actual,2010-02-28,February 2010,Actual,2010-02-28,,Interventional,,,"Open-Label Study Assessing The Safety, Immunogenicity and Dose Response of IC47","An Open-Label Phase 1 Study Assessing the Safety, Immunogenicity and Dose Response of IC47, a New Vaccine Against Streptococcus Pneumoniae, in Healthy Subjects.",Completed,,Phase 1,32.0,Actual,Valneva Austria GmbH,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 18:05:28,2023-06-16 18:05:28,INDUSTRY,,,,,
333269,333270,NCT02041325,,2014-01-14,2016-02-09,,2016-04-10,2014-01-17,2014-01-22,Estimate,2016-04-10,2016-05-17,Estimate,,,,2016-04-10,2016-05-17,Estimate,April 2005,,2005-04-30,April 2016,2016-04-30,April 2014,Actual,2014-04-30,January 2011,Actual,2011-01-31,,Interventional,,,Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias,"Investigation of the Enhancement of the Response to Hepatitis B Vaccine by Lenalidomide (RevlimidTM, CC-5013) in Plasma Cell Dyscrasias",Completed,,Phase 2,38.0,Actual,"Boston VA Research Institute, Inc.",,2.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-14 08:52:17,2023-06-14 08:52:17,OTHER,,,,,
333415,333416,NCT04642937,,2020-11-19,,,2023-01-26,2020-11-19,2020-11-24,Actual,,,,,,,2023-01-26,2023-01-27,Actual,"December 1, 2020",Actual,2020-12-01,January 2023,2023-01-31,November 2024,Anticipated,2024-11-30,November 2023,Anticipated,2023-11-30,,Interventional,,,Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma,Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma,"Active, not recruiting",,Phase 1,24.0,Anticipated,OX2 Therapeutics,,1.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-19 02:34:12,2023-06-19 02:34:12,INDUSTRY,,,,,
333585,333586,NCT04603131,,2017-07-17,,,2020-10-26,2020-10-23,2020-10-26,Actual,,,,,,,2020-10-26,2020-10-28,Actual,"April 17, 2017",Actual,2017-04-17,October 2020,2020-10-31,"July 30, 2018",Actual,2018-07-30,"January 30, 2018",Actual,2018-01-30,,Interventional,,,Clinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine,"Phase-I Open Label, Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Chikungunya Vaccine in Healthy Adults of 18 to 50 Years Age",Completed,,Phase 1,60.0,Actual,Bharat Biotech International Limited,,4.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-15 16:58:51,2023-06-15 16:58:51,INDUSTRY,,,,,
333848,333849,NCT00868595,,2009-03-24,,,2019-10-04,2009-03-24,2009-03-25,Estimate,,,,,,,2019-10-04,2019-10-08,Actual,April 2009,,2009-04-30,October 2019,2019-10-31,March 2012,Actual,2012-03-31,July 2011,Actual,2011-07-31,,Interventional,,,MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer,"A Phase I, Non-randomized, Multiple Dose, Dose Escalation Study of the Safety, PK, PD and Efficacy of Therapeutic Vaccine, BP-GMAX-CD1, Plus Activating Agent, AP1903, in Patients With Castrate Resistant Prostate Cancer",Completed,,Phase 1,18.0,Actual,Bellicum Pharmaceuticals,,1.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-16 18:07:06,2023-06-16 18:07:06,INDUSTRY,,,,,
334024,334025,NCT01008956,,2009-11-05,,,2015-03-19,2009-11-05,2009-11-06,Estimate,,,,,,,2015-03-19,2015-03-23,Estimate,April 2010,,2010-04-30,March 2015,2015-03-31,October 2010,Anticipated,2010-10-31,October 2010,Anticipated,2010-10-31,,Interventional,,,Safety and Immune Response of One-Dose of Candidate H1N1 Influenza Vaccine GSK2340274A in Adults,Immunogenicity and Safety Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine GSK2340274A in Adults 18 to 64 Years of Age,Withdrawn,,Phase 2,0.0,Actual,GlaxoSmithKline,,1.0,,Study was cancelled before enrolment for reasons not related to vaccine safety or efficacy.,False,,,,,,,,,,,,,,,,,2023-06-16 18:07:51,2023-06-16 18:07:51,INDUSTRY,,,,,
334059,334060,NCT01676675,,2012-08-29,,,2013-03-14,2012-08-30,2012-08-31,Estimate,,,,,,,2013-03-14,2013-03-15,Estimate,August 2012,,2012-08-31,March 2013,2013-03-31,March 2013,Anticipated,2013-03-31,January 2013,Anticipated,2013-01-31,,Interventional,,,A Phase I Clinical Trial With Whole Virus Inactivated Influenza H5N1 Vaccine in Healthy Adolescents and Adults,"A Single Center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Clinical Trial for Safety and Preliminary Immunogenicity of a Whole Virus Inactivated Influenza H5N1 Vaccine in Healthy Adolescents and Adults, on Day 0 and 21 Intramuscularly",Withdrawn,,Phase 1,0.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,8.0,,,False,,,,False,,,,,,,,,,,,,2023-06-19 02:37:25,2023-06-19 02:37:25,NETWORK,,,,,
334187,334188,NCT00970203,,2009-09-01,2020-04-07,,2020-10-13,2009-09-01,2009-09-02,Estimate,2020-04-23,2020-05-07,Actual,,,,2020-10-13,2020-11-03,Actual,September 2009,,2009-09-30,October 2020,2020-10-31,"October 5, 2019",Actual,2019-10-05,"October 5, 2018",Actual,2018-10-05,,Interventional,,All treated and eligible patients,Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer,"Feasibility, Safety and Efficacy Evaluation of Alpha-Type 1 Dendritic Cell(DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With PSA Progression After Local Therapy for Prostate Cancer",Completed,,Phase 2,13.0,Actual,Roswell Park Cancer Institute,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-19 02:38:14,2023-06-19 02:38:14,OTHER,,,,,
334492,334493,NCT01152814,,2010-06-28,2015-12-21,,2015-12-21,2010-06-28,2010-06-29,Estimate,2015-12-21,2016-01-27,Estimate,,,,2015-12-21,2016-01-27,Estimate,June 2010,,2010-06-30,December 2015,2015-12-31,July 2010,Actual,2010-07-31,June 2010,Actual,2010-06-30,,Interventional,,Baseline analysis population included all participants who were enrolled and randomized into the study.,"Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2010-2011","A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2010-2011, When Administered to Elderly Subjects",Completed,,Phase 2,64.0,Actual,Novartis,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 17:01:11,2023-06-15 17:01:11,INDUSTRY,,,,,
334565,334566,NCT05716347,,2023-01-10,,,2023-01-28,2023-01-28,2023-02-08,Actual,,,,,,,2023-01-28,2023-02-08,Actual,"July 13, 2022",Actual,2022-07-13,January 2023,2023-01-31,"December 9, 2023",Anticipated,2023-12-09,"December 9, 2022",Actual,2022-12-09,,Interventional,,,Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years,Safety and Immunogenicity of a Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cell) as Booster Shots in Healthy Adults Aged 18-59 Years Who Have Completed Two Doses of Inactivated SARS-CoV-2 Vaccine,Recruiting,,Early Phase 1,63.0,Anticipated,"Binhui Biopharmaceutical Co., Ltd.",,4.0,,,False,,,,,False,False,,,,,,,,,Undecided,,2023-06-14 02:23:49,2023-06-14 02:23:49,INDUSTRY,,,,,
334780,334781,NCT04587219,,2020-10-13,,,2021-01-20,2020-10-13,2020-10-14,Actual,,,,,,,2021-01-20,2021-01-22,Actual,"October 22, 2020",Actual,2020-10-22,October 2020,2020-10-31,"April 30, 2021",Anticipated,2021-04-30,"March 30, 2021",Anticipated,2021-03-30,,Interventional,,,"The Study of ""Gam-COVID-Vac"" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older","An Open Study of the Safety, Tolerability and Immunogenicity of the ""Gam-COVID-Vac""Vaccine Against COVID-19 (Solution for Intramuscular Injection) With the Participation of Volunteers in the Age Group Over 60 Years",Unknown status,"Active, not recruiting",Phase 2,110.0,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,1.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-15 17:03:07,2023-06-15 17:03:07,OTHER,,,,,
335129,335130,NCT03576183,,2018-05-15,2020-06-29,,2021-03-29,2018-06-21,2018-07-03,Actual,2021-03-29,2021-04-23,Actual,,,,2021-03-29,2021-04-23,Actual,"June 4, 2018",Actual,2018-06-04,March 2021,2021-03-31,"November 30, 2018",Actual,2018-11-30,"June 26, 2018",Actual,2018-06-26,,Interventional,,Challenge Population = all subjects who received two doses of the vaccine and the challenge dose,Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701,Randomized Double-Blinded Pilot Study Confirming A Human Challenge Model Using LSN03-016011/A Expressing LT And CS17 And Investigating The Safety Of VLA1701 (An Investigational Oral Cholera And ETEC (Enterotoxigenic E Coli) (Vaccine),Completed,,Phase 2,34.0,Actual,Valneva Austria GmbH,,2.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-14 08:59:57,2023-06-14 08:59:57,INDUSTRY,,,,,
335327,335328,NCT04544787,,2020-07-14,2021-09-18,,2021-09-18,2020-09-07,2020-09-10,Actual,2021-09-18,2021-10-15,Actual,,,,2021-09-18,2021-10-15,Actual,"October 22, 2018",Actual,2018-10-22,September 2021,2021-09-30,"May 8, 2019",Actual,2019-05-08,"January 31, 2019",Actual,2019-01-31,,Interventional,,All enrolled participants,A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates,"A Phase 2, Partial Blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Immunogenicity of Two Novel Live Attenuated Serotype 2 Oral Poliovirus Vaccines Candidates, in Healthy Adults Previously Vaccinated With Oral Polio Vaccine (OPV) or Inactivated Polio Vaccine (IPV), Compared With Historical Controls Given Sabin OPV2 or Placebo",Completed,,Phase 2,250.0,Actual,Universiteit Antwerpen,,7.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-14 09:01:06,2023-06-14 09:01:06,OTHER,,,,,
335384,335385,NCT00981669,,2009-09-17,2013-02-04,,2013-03-15,2009-09-21,2009-09-22,Estimate,2013-03-15,2013-04-25,Estimate,,,,2013-03-15,2013-04-25,Estimate,March 2009,,2009-03-31,March 2013,2013-03-31,June 2010,Actual,2010-06-30,March 2010,Actual,2010-03-31,,Interventional,,In the vaccine gorup one volunteer was not considered for the final analysis because He received the second dose of the vaccine in an anapropriate interval.,Rotavirus Vaccine Produced by Butantan Institute,"Evaluation of Rotavirus Vaccine Produced by Butantan Institute. Phase I - Safety, Tolerability and Immunogenicity Evaluation",Completed,,Phase 1,80.0,Actual,Butantan Institute,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-19 02:40:50,2023-06-19 02:40:50,OTHER_GOV,,,,,
335502,335503,NCT04762511,,2021-02-17,,,2021-06-24,2021-02-17,2021-02-21,Actual,,,,,,,2021-06-24,2021-06-28,Actual,"March 2, 2021",Actual,2021-03-02,June 2021,2021-06-30,"May 26, 2021",Actual,2021-05-26,"May 26, 2021",Actual,2021-05-26,,Interventional,,,"A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years","A Phase I, Single-blind, Randomised, Placebo-controlled, Dose Escalation Study to Evaluate the Reactogenicity, Safety and Immune Response of an HSV Vaccine in Healthy Participants Aged 18-40 Years",Terminated,,Phase 1,17.0,Actual,GlaxoSmithKline,,8.0,,To enable development of an enhanced version of the vaccine,False,,,,False,True,False,,,False,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-19 02:41:28,2023-06-19 02:41:28,INDUSTRY,,,,,
335511,335512,NCT00988143,,2009-10-01,2013-07-03,2011-01-03,2013-11-18,2009-10-01,2009-10-02,Estimate,2013-11-18,2013-12-12,Estimate,2011-01-03,2011-01-05,Estimate,2013-11-18,2013-12-12,Estimate,October 2009,,2009-10-31,November 2013,2013-11-30,March 2010,Actual,2010-03-31,December 2009,Actual,2009-12-31,,Interventional,,,A Study of Influenza Virus Vaccines in Children and Adults,"Immunogenicity and Safety Among Children and Adults of the 2009-2010 Trivalent Influenza Vaccine, 2008-2009 Trivalent Influenza Vaccine, and Quadrivalent Influenza Vaccine (Intramuscular Route)",Completed,,Phase 2,600.0,Actual,Sanofi,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-19 02:41:29,2023-06-19 02:41:29,INDUSTRY,,,,,
335884,335885,NCT00992433,,2009-10-08,2011-10-13,,2012-05-10,2009-10-08,2009-10-09,Estimate,2011-10-13,2011-11-17,Estimate,,,,2012-05-10,2012-05-16,Estimate,November 2009,,2009-11-30,February 2011,2011-02-28,November 2010,Actual,2010-11-30,November 2010,Actual,2010-11-30,,Interventional,,,H1N1 Vaccine at Two Dose Levels in HIV Positive Adults,A Phase II Study in HIV-seropositive Adults to Assess the Safety and Immunogenicity of an Unadjuvanted Novartis H1N1 Influenza Vaccine Administered at Two Dose Levels,Completed,,Phase 2,192.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-19 02:42:49,2023-06-19 02:42:49,NIH,,,,,
336004,336005,NCT03879603,,2019-03-08,2021-02-23,,2021-03-23,2019-03-14,2019-03-19,Actual,2021-02-23,2021-03-19,Actual,,,,2021-03-23,2021-03-24,Actual,"April 2, 2019",Actual,2019-04-02,March 2021,2021-03-31,"February 26, 2020",Actual,2020-02-26,"February 26, 2020",Actual,2020-02-26,,Interventional,,Population includes all enrolled subjects.,VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults,"A Phase 1 Open Label, Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Trivalent Virus-Like Particle (VLP) Encephalitis Vaccine, VRC-WEVVLP073-00-VP, in Healthy Adults",Completed,,Phase 1,30.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,6.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-14 09:06:14,2023-06-14 09:06:14,NIH,,,,,
336114,336115,NCT03026348,,2017-01-17,,,2021-12-02,2017-01-17,2017-01-20,Estimate,,,,,,,2021-12-02,2021-12-06,Actual,January 2017,,2017-01-31,December 2021,2021-12-31,"May 18, 2018",Actual,2018-05-18,April 2017,Actual,2017-04-30,,Interventional,,,Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1 Adjuvants In Clinically-Stable Older Adults,Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1 Adjuvants In Clinically-Stable Older Adults,Completed,,Phase 2,300.0,Actual,Novavax,,12.0,,,False,,,,False,,,,,,,,,,,Undecided,,2023-06-14 09:07:03,2023-06-14 09:07:03,INDUSTRY,,,,,
336218,336219,NCT02648282,,2016-01-05,2023-01-31,,2023-02-01,2016-01-06,2016-01-07,Estimate,2023-02-01,2023-02-28,Actual,,,,2023-02-01,2023-02-28,Actual,"July 18, 2016",Actual,2016-07-18,February 2023,2023-02-28,"June 1, 2022",Actual,2022-06-01,"June 1, 2022",Actual,2022-06-01,,Interventional,,,"Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer",A Phase II Study of GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine in Combination With PD-1 Blockade Antibody (Pembrolizumab) and Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Locally Advanced Adenocarcinoma of the Pancreas,Completed,,Phase 2,58.0,Actual,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,1.0,,,False,,,,True,,,,,,,,,,,Undecided,,2023-06-14 09:07:24,2023-06-14 09:07:24,OTHER,,,,,
336537,336538,NCT01150123,,2010-03-31,2014-04-03,,2017-05-08,2010-06-23,2010-06-24,Estimate,2017-05-08,2017-05-15,Actual,,,,2017-05-08,2017-05-15,Actual,May 2010,,2010-05-31,May 2017,2017-05-31,October 2012,Actual,2012-10-31,November 2011,Actual,2011-11-30,,Interventional,,,Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women,"A Phase Ib Randomized, Observer-Blind, Controlled, Single Center, Dose-Ranging Study of a Group B Streptococcus Vaccine in Healthy Women 18-40 Years of Age",Completed,,Phase 1,678.0,Actual,Novartis,,9.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 17:06:53,2023-06-15 17:06:53,INDUSTRY,,,,,
336571,336572,NCT02593071,,2015-10-22,,2017-05-30,2022-05-25,2015-10-29,2015-10-30,Estimate,,,,2017-05-30,2017-06-06,Actual,2022-05-25,2022-05-27,Actual,October 2015,,2015-10-31,May 2022,2022-05-31,November 2016,Actual,2016-11-30,November 2016,Actual,2016-11-30,,Interventional,,,Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.,"A Phase II Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) Recombinant F Nanoparticle Vaccine in Healthy Older Adult Subjects Previously Treated With the Same Vaccine, or Placebo, in the Prior Year; and to Estimate the Incidence Rate of RSV Disease and Vaccine Efficacy in Subjects Based on Their RSV F Vaccine Experience Over Two Consecutive Years.",Completed,,Phase 2,1330.0,Actual,Novavax,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-19 02:44:21,2023-06-19 02:44:21,INDUSTRY,,,,,
336755,336756,NCT02280408,,2014-10-23,2019-06-05,,2019-07-11,2014-10-29,2014-10-31,Estimate,2019-07-11,2019-07-12,Actual,,,,2019-07-11,2019-07-12,Actual,"October 7, 2014",Actual,2014-10-07,July 2019,2019-07-31,"December 10, 2015",Actual,2015-12-10,"December 10, 2015",Actual,2015-12-10,,Interventional,,,Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002),"A Phase 1 Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of Prime-Boost VSV Ebola Vaccine in Healthy Adults",Completed,,Phase 1,39.0,Actual,Merck Sharp & Dohme LLC,,4.0,,,False,,,,False,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2023-06-14 09:09:33,2023-06-14 09:09:33,INDUSTRY,,,,,
336975,336976,NCT02364596,,2015-01-08,,,2015-04-01,2015-02-10,2015-02-18,Estimate,,,,,,,2015-04-01,2015-04-03,Estimate,January 2015,,2015-01-31,April 2015,2015-04-30,February 2015,Actual,2015-02-28,February 2015,Actual,2015-02-28,,Interventional,,,Evaluation of a Single Vaccination With a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years,"A Phase 1, Single-arm, Open-label Study To Confirm The Safety, Tolerability, And Immunogenicity Of A 4-antigen Staphylococcus Aureus Vaccine (sa4ag) In Healthy Adults Aged 18 To <65 Years",Completed,,Phase 1,100.0,Actual,Pfizer,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-17 23:35:43,2023-06-17 23:35:43,INDUSTRY,,,,,
336983,336984,NCT03689192,,2018-09-27,2022-03-01,,2023-02-19,2018-09-27,2018-09-28,Actual,2023-02-19,2023-02-28,Actual,,,,2023-02-19,2023-02-28,Actual,"December 17, 2018",Actual,2018-12-17,February 2023,2023-02-28,"January 19, 2022",Actual,2022-01-19,"January 19, 2022",Actual,2022-01-19,,Interventional,,,Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors,Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors,Completed,,Phase 1,13.0,Actual,Herlev Hospital,,1.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-14 09:10:16,2023-06-14 09:10:16,OTHER,,,,,
337283,337284,NCT01067781,,2010-02-09,2014-01-30,,2020-02-04,2010-02-11,2010-02-12,Estimate,2014-01-30,2014-03-13,Estimate,,,,2020-02-04,2020-02-10,Actual,February 2010,,2010-02-28,February 2020,2020-02-29,March 2012,Actual,2012-03-31,September 2010,Actual,2010-09-30,,Interventional,,"safety population: includes all study subjects that were consented and received investigational study material (i.e., at least one vaccination)",Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine Patch,"A Phase 2, Gender-Stratified, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Two Vaccination Regimen With the Travelers' Diarrhea Vaccine System in Healthy Adults",Completed,,Phase 2,600.0,Actual,"Intercell USA, Inc.",,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-19 02:45:54,2023-06-19 02:45:54,INDUSTRY,,,,,
337454,337455,NCT00573495,,2007-12-12,,,2016-09-27,2007-12-12,2007-12-14,Estimate,,,,,,,2016-09-27,2016-09-29,Estimate,November 2007,,2007-11-30,September 2016,2016-09-30,February 2013,Actual,2013-02-28,July 2011,Actual,2011-07-31,,Interventional,,,Multipeptide Vaccine for Advanced Breast Cancer,A Study of hTERT/Survivin Multi-peptide Vaccine With Daclizumab and Prevnar for Patients With Metastatic Breast Cancer,Completed,,Phase 1,11.0,Actual,University of Pennsylvania,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 17:08:09,2023-06-15 17:08:09,OTHER,,,,,
338049,338050,NCT00000837,,1999-11-02,,,2021-10-27,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-27,2021-10-29,Actual,,,,October 2021,2021-10-31,November 2005,Actual,2005-11-30,,,,,Interventional,,,A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children,Phase I/II Study of the Safety and Immunogenicity of Live-Attenuated Varicella Vaccine (Varivax) in HIV-Infected Children,Completed,,Phase 1,127.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 09:15:54,2023-06-14 09:15:54,NIH,,,,,
338080,338081,NCT00001827,,1999-11-03,,,2017-10-05,1999-11-03,1999-11-04,Estimate,,,,,,,2017-10-05,2017-10-06,Actual,"July 26, 1999",,1999-07-26,"January 25, 2013",2013-01-25,"January 25, 2013",Actual,2013-01-25,"December 17, 2007",Actual,2007-12-17,,Interventional,,,p53 Vaccine for Ovarian Cancer,Vaccine Therapy With Tumor Specific p53 Peptides in Adult Patients With Low Burden Adenocarcinoma of the Ovary,Terminated,,Phase 2,21.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 09:16:10,2023-06-14 09:16:10,NIH,,,,,
338316,338317,NCT00001125,,2000-01-17,,,2021-10-28,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-28,2021-11-01,Actual,,,,October 2021,2021-10-31,March 2004,Actual,2004-03-31,,,,,Interventional,,,Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox,Use of a Live-Attenuated Varicella-Zoster Virus (VZV) Vaccine to Boost Immunity to VZV in HIV-Infected Children Previously Infected With Varicella,Completed,,Phase 1,60.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 09:17:36,2023-06-14 09:17:36,NIH,,,,,
338412,338413,NCT00380679,,2006-09-25,,,2006-09-25,2006-09-25,2006-09-26,Estimate,,,,,,,2006-09-25,2006-09-26,Estimate,December 2005,,2005-12-31,September 2006,2006-09-30,March 2006,,2006-03-31,,,,,Interventional,,,Offering Influenza and Pneumococcal Vaccine to Patients Being Evaluated in the Emergency Department,Offering Influenza and Pneumococcal Vaccine to Patients Being Evaluated in the Emergency Department,Unknown status,"Active, not recruiting",Phase 2,,,Louisiana State University Health Sciences Center in New Orleans,,,,,False,,,,,,,,,,,,,,,,,2023-06-14 09:18:05,2023-06-14 09:18:05,OTHER,,,,,
338454,338455,NCT05231369,,2022-02-07,,,2023-02-08,2022-02-07,2022-02-09,Actual,,,,,,,2023-02-08,2023-02-10,Actual,"December 14, 2022",Actual,2022-12-14,February 2023,2023-02-28,"July 1, 2023",Anticipated,2023-07-01,"July 1, 2023",Anticipated,2023-07-01,,Interventional,,,Safety and Immunogenicity of ChulaCov19 BNA159 mRNA Vaccine,"A Phase 1 Study to Evaluate Safety, Immunogenicity of the ChulaCov19 BNA159 mRNA Vaccine in Healthy Adults",Recruiting,,Phase 1,24.0,Anticipated,Chulalongkorn University,,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-14 09:18:29,2023-06-14 09:18:29,OTHER,,,,,
338486,338487,NCT05217641,,2021-12-30,,,2023-02-06,2022-01-20,2022-02-01,Actual,,,,,,,2023-02-06,2023-02-08,Actual,"February 11, 2022",Actual,2022-02-11,February 2023,2023-02-28,"October 13, 2023",Anticipated,2023-10-13,"July 13, 2023",Anticipated,2023-07-13,,Interventional,,,"A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants","A Phase 1, Randomized, Open-label Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants","Active, not recruiting",,Phase 1,108.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,6.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-14 09:18:44,2023-06-14 09:18:44,NIH,,,,,
338901,338902,NCT04062669,,2019-08-06,,,2023-01-24,2019-08-19,2019-08-20,Actual,,,,,,,2023-01-24,2023-01-25,Actual,"August 13, 2019",Actual,2019-08-13,January 2023,2023-01-31,"July 1, 2022",Actual,2022-07-01,"July 28, 2021",Actual,2021-07-28,,Interventional,,,A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults,Safety and Immunogenicity of GSK's Rabies G SAM (CNE) Vaccine [GSK3903133A] in Healthy Adults.,Completed,,Phase 1,82.0,Actual,GlaxoSmithKline,,6.0,,,False,,,,False,True,False,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an exemption can be granted, when justified, for up to another 12 months.",https://www.clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-17 23:43:35,2023-06-17 23:43:35,INDUSTRY,,,,,
339376,339377,NCT02240875,,2014-09-10,,,2018-07-04,2014-09-15,2014-09-16,Estimate,,,,,,,2018-07-04,2018-07-06,Actual,"September 17, 2014",Actual,2014-09-17,July 2018,2018-07-31,"August 22, 2017",Actual,2017-08-22,"August 22, 2017",Actual,2017-08-22,,Interventional,,,"A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo","A Phase Ia, Dose-Escalating, Safety and Immunogenicity Trial of the Monovalent Zaire Ebola Viral Vector Candidate Vaccine cAd3-EBO Z and the Heterologous Prime-boost Candidate Vaccine Regimen cAd3-EBO Z and MVA-BN® Filo in Healthy UK Adults",Completed,,Phase 1,91.0,Actual,University of Oxford,,13.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 02:11:26,2023-06-14 02:11:26,OTHER,,,,,
339647,339648,NCT00579423,,2007-12-20,,,2009-03-17,2007-12-21,2007-12-24,Estimate,,,,,,,2009-03-17,2009-03-18,Estimate,November 2000,,2000-11-30,March 2009,2009-03-31,March 2009,Actual,2009-03-31,May 2003,Actual,2003-05-31,,Interventional,,,Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate Cancer,A Pilot Multivalent Conjugate Vaccine Trial for Patients With Biochemically Relapsed Prostate Cancer,Completed,,Phase 2,30.0,Actual,Memorial Sloan Kettering Cancer Center,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 17:10:52,2023-06-15 17:10:52,OTHER,,,,,
339660,339661,NCT05831124,,2023-04-14,,,2023-05-30,2023-04-14,2023-04-26,Actual,,,,,,,2023-05-30,2023-05-31,Actual,"April 19, 2023",Actual,2023-04-19,May 2023,2023-05-31,"November 7, 2024",Anticipated,2024-11-07,"November 7, 2024",Anticipated,2024-11-07,,Interventional,,,A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults.,"A Phase 1, Randomized, Double-Blind Study of the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine With a Novel Adjuvant Administered in Adults 50 Through 64 Years of Age",Recruiting,,Phase 1,150.0,Anticipated,Pfizer,,4.0,,,False,,,,,True,False,,,,,,,,,No,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2023-06-16 18:13:38,2023-06-16 18:13:38,INDUSTRY,,,,,
339672,339673,NCT05827874,,2023-04-04,,,2023-05-29,2023-04-24,2023-04-25,Actual,,,,,,,2023-05-29,2023-05-31,Actual,"April 12, 2023",Actual,2023-04-12,May 2023,2023-05-31,"October 9, 2023",Anticipated,2023-10-09,"August 28, 2023",Anticipated,2023-08-28,,Interventional,,,A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants,"A Randomized, Open-Label Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants",Recruiting,,Phase 1,30.0,Anticipated,"Janssen Research & Development, LLC",,2.0,,,False,,,,False,False,False,,,,,,,,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2023-06-16 18:13:39,2023-06-16 18:13:39,INDUSTRY,,,,,
339971,339972,NCT05537038,,2022-09-08,,,2023-05-08,2022-09-08,2022-09-13,Actual,,,,,,,2023-05-08,2023-05-10,Actual,"April 18, 2023",Actual,2023-04-18,May 2023,2023-05-31,February 2026,Anticipated,2026-02-28,August 2025,Anticipated,2025-08-31,,Interventional,,,Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers,"A Phase Ia, Randomized, Placebo-controlled, Double-blind, Dose-finding Evaluation Trial to Describe the Safety, Reactogenicity, and Immunogenicity of Two Investigational Vaccines Against Tuberculosis in IGRA-negative, BCG naïve Subjects",Recruiting,,Phase 1,96.0,Anticipated,BioNTech SE,,3.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-19 02:51:26,2023-06-19 02:51:26,INDUSTRY,,,,,
340128,340129,NCT04589312,,2020-10-01,,,2020-11-02,2020-10-09,2020-10-19,Actual,,,,,,,2020-11-02,2020-11-04,Actual,"October 21, 2020",Actual,2020-10-21,November 2020,2020-11-30,"December 31, 2021",Anticipated,2021-12-31,"September 30, 2021",Anticipated,2021-09-30,,Interventional,WoMANPOWER,,Maternal Pertussis Wholecell Responses,The Safety and imMunogeNicity of Combined Pertussis-cOntaining Vaccine (Tdap) for HIV-infected Pregnant WomEn and Their newboRns - A Randomized Clinical Trial,Unknown status,Recruiting,Phase 2,200.0,Anticipated,"St George's, University of London",,4.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-15 17:12:04,2023-06-15 17:12:04,OTHER,,,,,
340627,340628,NCT00582504,,2007-12-19,,,2021-02-10,2007-12-27,2007-12-28,Estimate,,,,,,,2021-02-10,2021-02-11,Actual,September 2007,Actual,2007-09-30,February 2021,2021-02-28,June 2022,Anticipated,2022-06-30,December 2021,Anticipated,2021-12-31,,Interventional,VEE TC-83,,Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis Vaccine,"A Phase 2 Open-Label, Safety and Immunogenicity Study of a Single Dose of Venezuelan Equine Encephalomyelitis Vaccine, Live, Attenuated, Dried, TC-83, NDBR-102, as Primary Immunization in Healthy Adults At Risk for Exposure to Virulent Venezuelan Equine Encephalomyelitis Virus",Unknown status,"Active, not recruiting",Phase 2,500.0,Anticipated,U.S. Army Medical Research and Development Command,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 17:13:07,2023-06-15 17:13:07,FED,,,,,
340818,340819,NCT05172544,,2021-12-07,,,2023-05-09,2021-12-28,2021-12-29,Actual,,,,,,,2023-05-09,2023-05-10,Actual,"January 13, 2022",Actual,2022-01-13,May 2023,2023-05-31,"April 24, 2023",Actual,2023-04-24,"October 19, 2022",Actual,2022-10-19,,Interventional,,,Trial of an Inactivated Yellow Fever Virus Vaccine,"A Double Blind, Randomized, Placebo-Controlled, Phase 1 Dose Escalation Trial to Evaluate the Safety and Immunogenicity of an Inactivated Yellow Fever Virus Vaccine, HydroVax-002 YFV, in Healthy Adults",Completed,,Phase 1,25.0,Actual,"Najit Technologies, Inc.",,4.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-19 02:54:04,2023-06-19 02:54:04,INDUSTRY,,,,,
341619,341620,NCT05064956,,2021-09-15,,,2023-02-16,2021-09-23,2021-10-01,Actual,,,,,,,2023-02-16,2023-02-21,Actual,"October 6, 2021",Actual,2021-10-06,August 2021,2021-08-31,"October 24, 2022",Actual,2022-10-24,"November 17, 2021",Actual,2021-11-17,,Interventional,,,Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study),"An Open Label, Phase 2 Study to Evaluate the Safety and Immunogenicity of an Ad26.ZEBOV Booster Dose in Human Immunodeficiency Virus Positive (HIV+) Adults Previously Vaccinated With the Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen",Completed,,Phase 2,26.0,Actual,London School of Hygiene and Tropical Medicine,,1.0,,,False,,,,False,False,False,,,,,,Start date: within 12 months of the study completion date End date: 60 months after the sharing start date Sharing period: 5 years,"Study documents, such as the full protocol, statistical codes, Statistical Analytical Plan, Analytic Code, Independent Medical Reviewer's Terms of Reference, will be available upon request by email to Deborah Watson-Jones (Chief Investigator, Deborah.watson-jones@lshtm.ac.uk), Philip Ayieko (Study Statistician, philip.ayieko@lshtm.ac.uk) or Edward Choi (Study Coordinator, edward.choi@lshtm.ac.uk).",https://datacompass.lshtm.ac.uk/,Yes,"The rights of study subjects and partners, the sharing of data between partners and the transfer of data to external third party will be governed by the Data Sharing Agreement. Deidentified participant-level data collected in this trial will be disseminated through a data repository, such as the Data Compass, that complies with the principles of findability, accessibility, interoperability and reusability (FAIR).",2023-06-14 09:39:57,2023-06-14 09:39:57,OTHER,,,,,
341714,341715,NCT00568763,,2007-12-05,,,2018-10-29,2007-12-05,2007-12-06,Estimate,,,,,,,2018-10-29,2018-10-31,Actual,"November 25, 2005",Actual,2005-11-25,October 2018,2018-10-31,"May 24, 2018",Actual,2018-05-24,"May 10, 2010",Actual,2010-05-10,,Interventional,,,Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma,Endogenous Heat-shock Vaccines for Melanoma A Feasibility Study,Completed,,Phase 1,11.0,Actual,Mayo Clinic,,,,,False,,,,True,,,,,,,,,,,,,2023-06-15 17:15:07,2023-06-15 17:15:07,OTHER,,,,,
341754,341755,NCT04579250,,2020-10-07,2023-01-25,,2023-01-25,2020-10-07,2020-10-08,Actual,2023-01-25,2023-02-22,Actual,,,,2023-01-25,2023-02-22,Actual,"October 8, 2020",Actual,2020-10-08,January 2023,2023-01-31,"January 27, 2022",Actual,2022-01-27,"January 27, 2022",Actual,2022-01-27,,Interventional,,Population includes all enrolled participants.,"Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults","VRC 323: A Phase I Open-Label Clinical Trial to Evaluate the Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults",Completed,,Phase 1,25.0,Actual,National Institutes of Health Clinical Center (CC),,3.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-14 09:40:49,2023-06-14 09:40:49,NIH,,,,,
341791,341792,NCT02277392,,2014-10-27,,,2018-09-26,2014-10-27,2014-10-29,Estimate,,,,,,,2018-09-26,2018-09-27,Actual,September 2014,,2014-09-30,July 2018,2018-07-31,,,,June 2015,Actual,2015-06-30,,Interventional,,,"A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer","A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer",Withdrawn,,Phase 1,0.0,Actual,Abramson Cancer Center at Penn Medicine,,,,,False,,,,True,,,,,,,,,,,,,2023-06-15 17:15:17,2023-06-15 17:15:17,OTHER,,,,,
342321,342322,NCT04078022,,2019-07-03,,,2023-05-08,2019-09-03,2019-09-04,Actual,,,,,,,2023-05-08,2023-05-10,Actual,"March 2, 2020",Actual,2020-03-02,May 2023,2023-05-31,January 2024,Anticipated,2024-01-31,"January 24, 2023",Actual,2023-01-24,,Interventional,,,Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine,"Phase 2b Study of the Safety, Immunogenicity, and Efficacy of a Monovalent Synthetic Carbohydrate-based Conjugate Vaccine (SF2a-TT15) for Protection Against Shigella Flexneri 2a Experimental Infection","Active, not recruiting",,Phase 2,58.0,Actual,"University of Maryland, Baltimore",,4.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-19 02:58:59,2023-06-19 02:58:59,OTHER,,,,,
342454,342455,NCT05329051,,2022-04-11,,,2022-04-11,2022-04-11,2022-04-14,Actual,,,,,,,2022-04-11,2022-04-14,Actual,"July 1, 2022",Anticipated,2022-07-01,April 2022,2022-04-30,"March 1, 2023",Anticipated,2023-03-01,"September 1, 2022",Anticipated,2022-09-01,,Interventional,,,A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged =18 Years,"A Randomized, Double-blind, Positive-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E (A COVID-19 Alpha/Beta/Delta/Omicron Variants S-Trimer Vaccine) in Population Aged =18 Years and Previously Fully Vaccinated With mRNA COVID-19",Not yet recruiting,,Phase 2,400.0,Anticipated,Sinocelltech Ltd.,,2.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-14 09:47:27,2023-06-14 09:47:27,INDUSTRY,,,,,
342661,342662,NCT02438423,,2015-05-06,2018-02-27,,2019-04-12,2015-05-07,2015-05-08,Estimate,2019-04-12,2019-07-05,Actual,,,,2019-04-12,2019-07-05,Actual,June 2015,,2015-06-30,April 2019,2019-04-30,"March 23, 2016",Actual,2016-03-23,"March 23, 2016",Actual,2016-03-23,,Interventional,,,Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic Needle,"A Phase I Study of the Safety, Reactogenicity, Acceptability and Immunogenicity of Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic Needle",Completed,,Phase 1,100.0,Actual,Georgia Institute of Technology,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 09:49:47,2023-06-14 09:49:47,OTHER,,,,,
342758,342759,NCT02566265,,2015-09-30,2018-05-31,,2019-01-28,2015-10-01,2015-10-02,Estimate,2019-01-28,2019-01-30,Actual,,,,2019-01-28,2019-01-30,Actual,September 2015,,2015-09-30,January 2019,2019-01-31,June 2018,Actual,2018-06-30,October 2017,Actual,2017-10-31,,Interventional,SHIVERING 2,,Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients,Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients (SHIVERING 2),Completed,,Phase 2,122.0,Actual,Yale University,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 09:50:44,2023-06-14 09:50:44,OTHER,,,,,
342894,342895,NCT03688061,,2018-09-19,,,2023-05-09,2018-09-26,2018-09-27,Actual,,,,,,,2023-05-09,2023-05-10,Actual,"December 4, 2017",Actual,2017-12-04,September 2018,2018-09-30,"August 4, 2022",Actual,2022-08-04,"August 4, 2019",Actual,2019-08-04,,Interventional,,,Class II Invariant Chain HCV Vaccine Study,"A Phase-I Dose-Escalation Study to Evaluate the Safety and Immunogenicity of Prime-Boost Immunisations With Candidate HCV Vaccines, ChAd3-hliNSMut and MVA-hliNSMut in Healthy Volunteers and Patients Previously Chronically Infected With HCV",Completed,,Phase 1,25.0,Actual,University of Oxford,,3.0,,,False,,,,True,False,False,,,False,,,,,,Undecided,,2023-06-19 03:00:25,2023-06-19 03:00:25,OTHER,,,,,
342991,342992,NCT02598089,,2015-10-15,2018-08-14,,2019-01-28,2015-11-04,2015-11-05,Estimate,2018-08-14,2019-01-28,Actual,,,,2019-01-28,2019-02-15,Actual,November 2015,,2015-11-30,January 2019,2019-01-31,February 2016,Actual,2016-02-29,February 2016,Actual,2016-02-29,,Interventional,IVACFLU-S,,Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S),"A Phase 1 Double Blinded, Randomized, Placebo-Controlled Study In Healthy Adult Volunteers In Vietnam To Examine The Safety And Immunogenicity Of A Seasonal Trivalent Inactivated Split Virion Influenza Vaccine (IVACFLU-S) Produced By IVAC",Completed,,Phase 1,60.0,Actual,"Institute of Vaccines and Medical Biologicals, Vietnam",,2.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-14 09:52:36,2023-06-14 09:52:36,INDUSTRY,,,,,
343372,343373,NCT02988739,,2016-12-06,,,2018-03-05,2016-12-06,2016-12-09,Estimate,,,,,,,2018-03-05,2018-03-06,Actual,"February 22, 2017",Actual,2017-02-22,March 2018,2018-03-31,"September 30, 2017",Actual,2017-09-30,"July 31, 2017",Actual,2017-07-31,,Interventional,,,Comparison of Laser Assisted Epidermal to Intradermal Administration of Seasonal Influenza Vaccine,Safety and Immunogenicity of Laser Assisted Epidermally Administered Seasonal Influenza Vaccine in Comparison to Intradermally Administered Seasonal Influenza Vaccine,Completed,,Phase 1,20.0,Actual,Pantec Biosolutions AG,,2.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-14 09:56:01,2023-06-14 09:56:01,INDUSTRY,,,,,
343422,343423,NCT02639351,,2015-12-21,2018-08-21,,2019-06-13,2015-12-21,2015-12-24,Estimate,2019-03-05,2019-06-07,Actual,,,,2019-06-13,2019-06-28,Actual,"March 1, 2016",Actual,2016-03-01,June 2019,2019-06-30,"August 31, 2017",Actual,2017-08-31,"August 31, 2017",Actual,2017-08-31,,Interventional,,,Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine,"A Phase 1, Randomized, Observer-Blind, Dosage-Escalation Study to Evaluate the Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine Compared to Aluminium Hydroxide Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine in Healthy Adults (18-45 Years of Age).",Completed,,Phase 1,80.0,Actual,GlaxoSmithKline,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 09:56:35,2023-06-14 09:56:35,INDUSTRY,,,,,
343572,343573,NCT02646371,,2015-12-23,2020-08-26,2018-02-15,2021-01-07,2016-01-04,2016-01-05,Estimate,2021-01-07,2021-01-27,Actual,2018-02-16,2018-02-22,Actual,2021-01-07,2021-01-27,Actual,December 2015,Actual,2015-12-31,January 2021,2021-01-31,July 2017,Actual,2017-07-31,September 2016,Actual,2016-09-30,,Interventional,,,Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a,"Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a",Completed,,Phase 2,67.0,Actual,LimmaTech Biologics AG,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 09:57:57,2023-06-14 09:57:57,INDUSTRY,,,,,
343689,343690,NCT05644184,,2022-11-10,,,2023-05-26,2022-11-30,2022-12-09,Actual,,,,,,,2023-05-26,2023-05-31,Actual,"March 27, 2023",Actual,2023-03-27,November 2022,2022-11-30,June 2024,Anticipated,2024-06-30,June 2024,Anticipated,2024-06-30,,Interventional,,,Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh,"A Phase 2, Randomized, Observer-blind, Controlled, Age De-escalation, Dosage Escalation Study to Assess Safety and Immunogenicity of a Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine in Healthy Young Children, Infants, and Neonates in Bangladesh",Recruiting,,Phase 2,1683.0,Anticipated,PATH,,12.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-16 18:15:46,2023-06-16 18:15:46,OTHER,,,,,
343807,343808,NCT05411471,,2022-06-07,,,2022-07-04,2022-06-07,2022-06-09,Actual,,,,,,,2022-07-04,2022-07-06,Actual,"June 8, 2022",Actual,2022-06-08,June 2022,2022-06-30,"March 8, 2023",Anticipated,2023-03-08,"March 8, 2023",Anticipated,2023-03-08,,Interventional,,,"Immunogenicity and Safety Study of Booster Vaccine With the COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain","A Phase IIb, Randomized, Open-labeled Trial to Evaluate the Immunogenicity and Safety of One or Two Doses of Booster Vaccine With the COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain in Adults in Hong Kong",Recruiting,,Phase 2,300.0,Anticipated,"Sinovac Biotech Co., Ltd",,4.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-14 09:59:22,2023-06-14 09:59:22,INDUSTRY,,,,,
343998,343999,NCT02410733,,2015-03-24,,,2023-06-12,2015-04-07,2015-04-08,Estimate,,,,,,,2023-06-12,2023-06-13,Actual,March 2015,Actual,2015-03-31,June 2023,2023-06-30,June 2023,Anticipated,2023-06-30,June 2023,Anticipated,2023-06-30,,Interventional,Lipo-MERIT,,Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma,"Clinical First-in-human Dose Escalation Study Evaluating the Safety and Tolerability of Intravenous Administration of a Tetravalent RNA-lipoplex Cancer Vaccine Targeting the Tumor-associated Antigens NY-ESO-1, Tyrosinase, MAGE-A3, and TPTE in Patients With Advanced Melanoma","Active, not recruiting",,Phase 1,119.0,Actual,BioNTech SE,,1.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-19 03:02:51,2023-06-19 03:02:51,INDUSTRY,,,,,
344175,344176,NCT00471081,,2007-05-08,2017-03-09,2009-09-03,2019-06-11,2007-05-08,2007-05-09,Estimate,2018-08-16,2018-09-14,Actual,2009-09-03,2009-09-04,Estimate,2019-06-11,2019-06-25,Actual,"July 5, 2007",Actual,2007-07-05,June 2019,2019-06-30,"November 26, 2008",Actual,2008-11-26,"October 23, 2008",Actual,2008-10-23,,Interventional,,,Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.,"Study to Assess Immunogenicity, Reactogenicity and Safety of Primary Vaccination With GSK Biologicals' MenACWY Vaccine (GSK134612) Given as 1 or 2 Doses to Healthy Toddlers 9-12 Months of Age",Completed,,Phase 2,385.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-15 17:24:29,2023-06-15 17:24:29,INDUSTRY,,,,,
344181,344182,NCT00371189,,2006-08-31,,,2014-09-18,2006-08-31,2006-09-01,Estimate,,,,,,,2014-09-18,2014-09-22,Estimate,January 2007,,2007-01-31,June 2014,2014-06-30,June 2014,Actual,2014-06-30,June 2014,Actual,2014-06-30,,Interventional,,,Adenovirus Vaccine for Malaria,"A Phase I Randomized, Controlled, Dosage-Escalation Trial to Evaluate the Immunogenicity, Safety, and Reactogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Healthy Adults 18 to 45 Years of Age",Completed,,Phase 1,75.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 10:04:32,2023-06-14 10:04:32,NIH,,,,,
344223,344224,NCT02956837,,2016-11-03,2018-08-29,,2019-06-24,2016-11-03,2016-11-06,Estimate,2018-11-12,2018-11-20,Actual,,,,2019-06-24,2019-07-02,Actual,"November 10, 2016",Actual,2016-11-10,June 2019,2019-06-30,"February 5, 2018",Actual,2018-02-05,"August 30, 2017",Actual,2017-08-30,,Interventional,,,"A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women",An Observer-blind Study to Rank Different Formulations of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A) Administered to Healthy Women,Completed,,Phase 2,406.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,,,,,,,,IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-17 23:51:45,2023-06-17 23:51:45,INDUSTRY,,,,,
344637,344638,NCT00342628,,2006-06-19,2012-03-30,,2012-05-22,2006-06-19,2006-06-21,Estimate,2012-05-22,2012-06-27,Estimate,,,,2012-05-22,2012-06-27,Estimate,July 2006,,2006-07-31,May 2012,2012-05-31,January 2011,Actual,2011-01-31,April 2008,Actual,2008-04-30,,Interventional,,,"Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants","Evaluation of the Safety, Immunogenicity and Compatibility With DTP of an Investigational Vi-rEPA Conjugate Vaccine for Typhoid Fever When Administered to Infants in Vietnam Concurrently With DTP",Completed,,Phase 2,301.0,Actual,National Institutes of Health Clinical Center (CC),,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 18:46:24,2023-06-16 18:46:24,NIH,,,,,
344838,344839,NCT00587249,,2008-01-03,,,2013-04-11,2008-01-03,2008-01-07,Estimate,,,,,,,2013-04-11,2013-04-12,Estimate,July 2002,,2002-07-31,March 2013,2013-03-31,July 2005,Actual,2005-07-31,July 2005,Actual,2005-07-31,,Interventional,,,ICC-1132 - Candidate Vaccine Against P Falciparum Malaria,"Phase I Trial of ICC-1132, a Candidate Vaccine Against Plasmodium Falciparum Malaria Based on a Viral-like Particle Comprising Recombinant Hepatitis B Core Antigen and Circumsporozoite Epitopes, to Assess Vaccine Safety and Immunogenicity in Healthy Adult Volunteers",Completed,,Phase 1,75.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 17:26:07,2023-06-15 17:26:07,NIH,,,,,
344964,344965,NCT05182567,,2022-01-05,,,2023-02-21,2022-01-05,2022-01-10,Actual,,,,,,,2023-02-21,2023-02-22,Actual,"May 23, 2022",Actual,2022-05-23,February 2023,2023-02-28,June 2023,Anticipated,2023-06-30,"January 10, 2023",Actual,2023-01-10,,Interventional,,,GLS-5310 Vaccine in Healthy Volunteers as a Booster for SARS-CoV-2 (COVID-19),"Safety, Tolerability and Immunogenicity of GLS-5310 DNA Vaccine Given as a Booster to Those Previously Vaccinated Against SARS-CoV-2","Active, not recruiting",,Phase 1,69.0,Anticipated,"GeneOne Life Science, Inc.",,4.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-14 10:09:51,2023-06-14 10:09:51,INDUSTRY,,,,,
345295,345296,NCT00589394,,2007-12-28,,,2016-01-08,2008-01-08,2008-01-09,Estimate,,,,,,,2016-01-08,2016-01-11,Estimate,July 2007,,2007-07-31,January 2016,2016-01-31,January 2010,Actual,2010-01-31,December 2008,Actual,2008-12-31,,Interventional,,,Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine,Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine,Completed,,Phase 1,100.0,Actual,Mayo Clinic,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 17:26:53,2023-06-15 17:26:53,OTHER,,,,,
345601,345602,NCT04822376,,2021-03-26,,,2021-10-14,2021-03-26,2021-03-30,Actual,,,,,,,2021-10-14,2021-10-15,Actual,"October 17, 2021",Anticipated,2021-10-17,October 2021,2021-10-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,,Interventional,PROVAE,,Prophylaxis Vaccine Antibodies Ebola,Phase IIa Pilot Study Evaluating the Efficacy of a Monoclonal Antibody and Vaccine-based Post-exposure Prophylaxis Strategy in High-risk Contact Cases of Ebola Virus Disease Infection,Not yet recruiting,,Phase 2,250.0,Anticipated,"ANRS, Emerging Infectious Diseases",,3.0,,,False,,,,True,False,False,,,False,,,,,,,,2023-06-18 00:15:04,2023-06-18 00:15:04,OTHER_GOV,,,,,
345643,345644,NCT00374309,,2006-09-08,,,2017-06-30,2006-09-08,2006-09-11,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"September 5, 2006",,2006-09-05,"May 5, 2009",2009-05-05,"May 5, 2009",,2009-05-05,,,,,Interventional,,,Experimental Vaccine for Prevention of Ebola Virus Infection,"A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Ebola Adenoviral Vector Vaccine, VRC-EBOADV018-00-VP, in Healthy Adults",Completed,,Phase 1,48.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 10:16:07,2023-06-14 10:16:07,NIH,,,,,
345738,345739,NCT02340338,,2014-11-21,2016-08-05,,2016-12-01,2015-01-15,2015-01-16,Estimate,2016-12-01,2017-01-31,Estimate,,,,2016-12-01,2017-01-31,Estimate,July 2014,,2014-07-31,December 2016,2016-12-31,July 2015,Actual,2015-07-31,June 2015,Actual,2015-06-30,,Interventional,rTSST-1,,rTSST-1 Variant Vaccine Phase 1 First-in-man Trail,Phase 1 Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults,Completed,,Phase 1,46.0,Actual,Biomedizinische Forschungs gmbH,,7.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-14 10:17:06,2023-06-14 10:17:06,INDUSTRY,,,,,
346110,346111,NCT04906629,,2021-05-25,,,2022-05-22,2021-05-25,2021-05-28,Actual,,,,,,,2022-05-22,2022-05-24,Actual,"September 1, 2021",Actual,2021-09-01,May 2022,2022-05-31,"May 11, 2022",Actual,2022-05-11,"January 5, 2022",Actual,2022-01-05,,Interventional,Boost-EBOV,,INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees,"Phase Ib, Placebo-controlled Randomized Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of INO-4201 Followed by Electroporation as a Booster Vaccination in Healthy Volunteers Who Have Previously Received the VSV-ZEBOV Vaccine",Completed,,Phase 1,46.0,Actual,"University of Geneva, Switzerland",,2.0,,,False,,,,True,True,False,,,True,,,,,,,,2023-06-17 23:54:08,2023-06-17 23:54:08,OTHER,,,,,
346255,346256,NCT05195619,,2021-12-17,,,2023-05-26,2022-01-17,2022-01-19,Actual,,,,,,,2023-05-26,2023-05-30,Actual,"December 10, 2021",Actual,2021-12-10,May 2023,2023-05-31,September 2024,Anticipated,2024-09-30,September 2024,Anticipated,2024-09-30,,Interventional,,,Personalized DC Vaccines in Non Small Cell Lung Cancer,Phase Ib Study to Test the Feasibility and Safety of a Personalized Vaccine in Combination With Low-dose Cyclophosphamide in Patients With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC),Recruiting,,Phase 1,16.0,Anticipated,Centre Hospitalier Universitaire Vaudois,,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-16 18:20:16,2023-06-16 18:20:16,OTHER,,,,,
346398,346399,NCT03089879,,2017-03-21,2018-08-29,,2019-06-13,2017-03-21,2017-03-24,Actual,2019-03-06,2019-03-07,Actual,,,,2019-06-13,2019-06-28,Actual,"March 16, 2017",Actual,2017-03-16,June 2019,2019-06-30,"August 31, 2017",Actual,2017-08-31,"August 31, 2017",Actual,2017-08-31,,Interventional,,,A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vaccine in Healthy Adults Primed With 3 Doses of 1790GAHB Vaccine in Study H03_01TP Compared to 1 Vaccination of 1790GAHB in Either Subjects Who Received Placebo in the Same Study or naïve Subjects Not Part of H03_01TP Study,"A Phase 1, Open Label, Non-randomized, Single Center Study to Evaluate the Safety and Immunogenicity of 1 Booster Vaccination With (GVGH Shigella Sonnei 1790GAHB) Vaccine Administered Intramuscularly in Healthy Adults Previously Primed With Three Doses of the Same Vaccine in Study H03_01TP Compared to 1 Vaccination With (1790GAHB) Administered Intramuscularly Either to Subjects Who Received Placebo in the H03_01TP Study or naïve Subjects Who Were Not Part of H03_01TP Study",Completed,,Phase 1,35.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,False,False,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://www.clinicalstudydatarequest.com/SearchAllPostings.aspx?searchparam=200147,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-14 10:22:21,2023-06-14 10:22:21,INDUSTRY,,,,,
346417,346418,NCT00197054,,2005-09-13,2017-03-27,,2021-02-10,2005-09-13,2005-09-20,Estimate,2020-12-10,2020-12-11,Actual,,,,2021-02-10,2021-02-12,Actual,July 2005,Actual,2005-07-31,February 2021,2021-02-28,September 2006,Actual,2006-09-30,September 2006,Actual,2006-09-30,,Interventional,,,"Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Malaria-experienced Adults.","A Phase IIb Randomized, Double-blind, Controlled Study of the Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02A, and RTS,S/AS01B, Two Candidate Malaria Vaccines in Malaria-experienced Adults Living in Western Kenya.",Completed,,Phase 2,255.0,Actual,U.S. Army Medical Research and Development Command,,3.0,,,False,,,,True,True,False,,,,,,,,,Yes,GSK and WRAIR,2023-06-15 17:29:45,2023-06-15 17:29:45,FED,,,,,
346473,346474,NCT00196976,,2005-09-13,2017-01-11,,2018-05-07,2005-09-13,2005-09-20,Estimate,2017-01-11,2017-03-01,Actual,,,,2018-05-07,2018-06-08,Actual,"March 24, 2005",,2005-03-24,April 2017,2017-04-30,"March 3, 2006",Actual,2006-03-03,"March 1, 2006",Actual,2006-03-01,,Interventional,,,Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old,"Evaluate the Immunogenicity, Reactogenicity, Safety of 4 Different Formulations of GSK Biologicals' Conjugate Vaccine (MenACWY) vs 1 Dose of MenC-CRM197 or Mencevax ACWY in Children Aged 12-14 Months & 3-5 Years",Completed,,Phase 2,461.0,Actual,GlaxoSmithKline,,14.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 17:29:53,2023-06-15 17:29:53,INDUSTRY,,,,,
346593,346594,NCT03101111,,2017-03-29,2021-03-30,,2021-06-28,2017-03-29,2017-04-04,Actual,2021-06-28,2021-07-19,Actual,,,,2021-06-28,2021-07-19,Actual,"August 9, 2017",Actual,2017-08-09,September 2018,2018-09-30,"April 2, 2019",Actual,2019-04-02,"April 2, 2019",Actual,2019-04-02,,Interventional,,"MV-CHIK group: 12 seropositive, 14 seronegative subjects MMR-Placebo: 4 seropositive, 4 seronegative subjects",Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area,Phase 2 Study of a Live Attenuated Measles Virus-Vectored Chikungunya Vaccine in a Previously Epidemic Area,Completed,,Phase 2,34.0,Actual,Themis Bioscience GmbH,,2.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-14 10:23:34,2023-06-14 10:23:34,INDUSTRY,,,,,
346833,346834,NCT00199901,,2005-09-16,2021-03-11,,2022-10-03,2005-09-16,2005-09-20,Estimate,2021-04-06,2021-04-08,Actual,,,,2022-10-03,2022-10-12,Actual,September 2005,,2005-09-30,October 2022,2022-10-31,December 2011,Actual,2011-12-31,December 2008,Actual,2008-12-31,,Interventional,,All patients randomized and received NY-ESO-1 ISCOMATRIX® Vaccine or ISCOMATRIX® adjuvant.,"Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma","Randomized, Double-blind Phase II Trial of NY-ESO-1 ISCOMATRIX® Vaccine and ISCOMATRIX® Adjuvant Alone in Patients With Resected Stage Ilc, Illb, lIIc, or IV Malignant Melanoma",Completed,,Phase 2,111.0,Actual,Ludwig Institute for Cancer Research,,2.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-15 17:30:54,2023-06-15 17:30:54,OTHER,,,,,
346869,346870,NCT04298606,,2020-03-04,,,2023-02-07,2020-03-04,2020-03-06,Actual,,,,,,,2023-02-07,2023-02-08,Actual,"November 22, 2021",Actual,2021-11-22,February 2023,2023-02-28,"April 19, 2024",Anticipated,2024-04-19,"April 19, 2024",Anticipated,2024-04-19,,Interventional,,,A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence,A Phase 0 Study of CIMAvax-EGF Vaccine in Patients Who Are at High Risk for Lung Cancer and Lung Cancer Survivors at Risk for Recurrence,Recruiting,,Early Phase 1,60.0,Anticipated,Roswell Park Cancer Institute,,1.0,,,,,,,True,True,False,,,True,,,,,,,,2023-06-14 10:26:09,2023-06-14 10:26:09,OTHER,,,,,
346923,346924,NCT00356798,,2006-07-25,,,2007-11-08,2006-07-25,2006-07-26,Estimate,,,,,,,2007-11-08,2007-11-09,Estimate,December 2005,,2005-12-31,November 2007,2007-11-30,April 2006,,2006-04-30,,,,,Interventional,,,"Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects",The Phase-I Clinical Trial Protocol for the Pandemic Inactivated Influenza Vaccine,Completed,,Phase 1,120.0,,"Sinovac Biotech Co., Ltd",,,,,False,,,,,,,,,,,,,,,,,2023-06-14 10:26:40,2023-06-14 10:26:40,INDUSTRY,,,,,
347220,347221,NCT02382913,,2015-02-27,2016-01-14,,2016-02-24,2015-03-06,2015-03-09,Estimate,2016-01-14,2016-02-12,Estimate,,,,2016-02-24,2016-03-24,Estimate,April 2015,,2015-04-30,February 2016,2016-02-29,June 2015,Actual,2015-06-30,June 2015,Actual,2015-06-30,,Interventional,,,Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1),Phase 1 Extension Study to Evaluate Antibody Persistence Approximately 3 Years After Administration of Different Dosages of Acellular Pertussis or Tetanus-Diphtheria-acellular Pertussis Booster Vaccines in Healthy Adult Subjects Enrolled in Study V113_01,Completed,,Phase 1,315.0,Actual,Novartis,,10.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 10:29:32,2023-06-14 10:29:32,INDUSTRY,,,,,
347486,347487,NCT03430349,,2018-01-21,2021-01-14,,2021-01-14,2018-02-05,2018-02-12,Actual,2021-01-14,2021-02-04,Actual,,,,2021-01-14,2021-02-04,Actual,"May 16, 2017",Actual,2017-05-16,January 2021,2021-01-31,"October 27, 2017",Actual,2017-10-27,"September 30, 2017",Actual,2017-09-30,,Interventional,nOPV2M4a,All randomized participants who received a dose of study vaccine.,Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in Inactivated Polio Vaccine (IPV) Primed Adults,"A Phase 1, Blinded, Single Center Study to Evaluate the Safety and Immunogenicity of Two Novel Live Attenuated Serotype 2 Oral Poliovirus Vaccines, Derived From a Modified Sabin 2 Infectious cDNA Clone, in Healthy Adults Previously Primed With Inactivated Polio Vaccine (IPV)",Completed,,Phase 1,30.0,Actual,Universiteit Antwerpen,,2.0,,,False,,,,True,False,False,,,,,,,,,No,there is no such plan for the moment,2023-06-14 10:31:39,2023-06-14 10:31:39,OTHER,,,,,
347724,347725,NCT03016143,,2017-01-04,,,2018-06-06,2017-01-08,2017-01-10,Estimate,,,,,,,2018-06-06,2018-06-07,Actual,October 2016,,2016-10-31,January 2017,2017-01-31,December 2016,Actual,2016-12-31,November 2016,Actual,2016-11-30,,Interventional,,,Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI),"A Randomized, Blinded, Comparative Study of Phase II Allantoic Split Inactivated Seasonal Influenza Vaccine in Healthy Adults",Completed,,Phase 2,300.0,Actual,Research Institute for Biological Safety Problems,,4.0,,,False,,,,True,,,,,,,,,,,Undecided,,2023-06-19 03:05:47,2023-06-19 03:05:47,OTHER_GOV,,,,,
347939,347940,NCT05230940,,2022-02-05,,,2023-02-08,2022-02-08,2022-02-09,Actual,,,,,,,2023-02-08,2023-02-10,Actual,"January 15, 2022",Actual,2022-01-15,February 2023,2023-02-28,"July 15, 2023",Anticipated,2023-07-15,"May 15, 2023",Anticipated,2023-05-15,,Interventional,,,"Efficacy, Immunogenicity, and Safety of TURKOVAC Vaccine Versus the CoronaVac Vaccine Against COVID-19 in Healthy Adolescent (12-18 Years)","Multicenter, Randomized, Observational Blind Phase IIB Clinical Trial to Evaluate the Effectiveness, Immunogenicity and Safety of Two Doses of CoronaVac (Sinovac) Vaccine Against Two Doses of Inactivated COVID-19 Vaccine (TURKOVAC) in Healthy Adolescent (12-18 Years) Subjects","Active, not recruiting",,Phase 2,644.0,Anticipated,Health Institutes of Turkey,,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-14 10:35:11,2023-06-14 10:35:11,OTHER_GOV,,,,,
347949,347950,NCT05433194,,2022-06-16,,,2023-02-06,2022-06-24,2022-06-27,Actual,,,,,,,2023-02-06,2023-02-08,Actual,"August 22, 2022",Actual,2022-08-22,August 2022,2022-08-31,"August 25, 2023",Anticipated,2023-08-25,"September 26, 2022",Actual,2022-09-26,,Interventional,,,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)","A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (Omicron) mRNA Vaccine (ABO1009-DP) for Sequential Immunization in the Population Aged 18 Years and Older Who Have Completed the Full Vaccination","Active, not recruiting",,Phase 1,48.0,Anticipated,"Suzhou Abogen Biosciences Co., Ltd.",,1.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-14 10:35:14,2023-06-14 10:35:14,INDUSTRY,,,,,
348047,348048,NCT03587207,,2018-06-29,2019-12-06,,2020-01-30,2018-06-29,2018-07-16,Actual,2019-12-06,2020-01-02,Actual,,,,2020-01-30,2020-02-12,Actual,"July 9, 2018",Actual,2018-07-09,January 2020,2020-01-31,"December 19, 2018",Actual,2018-12-19,"December 19, 2018",Actual,2018-12-19,,Interventional,,,Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years,"Immunogenicity and Safety of Meningococcal MenABCWY Vaccine, and of rMenB+OMV NZ and MenACWY Administered Concomitantly in the Same Arm or in 2 Different Arms, or Alone",Completed,,Phase 2,520.0,Actual,GlaxoSmithKline,,5.0,,,False,,,,,False,False,,,,,,IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://www.clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-14 10:36:04,2023-06-14 10:36:04,INDUSTRY,,,,,
348140,348141,NCT03615911,,2018-07-20,2020-04-28,,2020-10-04,2018-07-30,2018-08-06,Actual,2020-10-04,2020-10-06,Actual,,,,2020-10-04,2020-10-06,Actual,"November 28, 2017",Actual,2017-11-28,October 2020,2020-10-31,"May 10, 2019",Actual,2019-05-10,"April 15, 2019",Actual,2019-04-15,,Interventional,,,"Safety, Tolerability and Immunogenicity of Vaccine Candidate MVA-MERS-S","An Open, Single Center Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-MERS-S",Completed,,Phase 1,26.0,Actual,Universitätsklinikum Hamburg-Eppendorf,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-14 10:37:07,2023-06-14 10:37:07,OTHER,,,,,
348833,348834,NCT04522089,,2020-08-12,,,2022-05-23,2020-08-20,2020-08-21,Actual,,,,,,,2022-05-23,2022-05-24,Actual,"August 24, 2020",Actual,2020-08-24,August 2021,2021-08-31,"May 6, 2021",Actual,2021-05-06,"November 20, 2020",Actual,2020-11-20,,Interventional,,,A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine,"A Randomized, Single Center, Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of Pandemic Virus Vaccine, AdimrSC-2f (SARS-CoV-2), in Healthy Volunteers",Completed,,Phase 1,68.0,Actual,Adimmune Corporation,,4.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-17 23:57:08,2023-06-17 23:57:08,INDUSTRY,,,,,
348874,348875,NCT00604175,,2008-01-17,2013-07-15,2012-12-11,2021-11-02,2008-01-17,2008-01-30,Estimate,2013-08-06,2013-10-17,Estimate,2012-12-28,2013-01-01,Estimate,2021-11-02,2021-11-04,Actual,February 2008,,2008-02-29,August 2015,2015-08-31,November 2012,Actual,2012-11-30,January 2012,Actual,2012-01-31,,Interventional,,"All participants, except 4: one was found to be ineligible after enrollment (Stratum A) and 3 failed to start intervention (2 in Stratum A, 1 in Stratum C).",Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women,A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females,Completed,,Phase 2,319.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 18:48:23,2023-06-16 18:48:23,NIH,,,,,
349059,349060,NCT00316524,,2006-04-19,2018-12-19,,2019-02-11,2006-04-19,2006-04-21,Estimate,2018-12-19,2019-01-09,Actual,,,,2019-02-11,2019-03-06,Actual,April 2006,Actual,2006-04-30,February 2019,2019-02-28,August 2007,Actual,2007-08-31,February 2007,Actual,2007-02-28,,Interventional,,Safety Dataset,"A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE) Smallpox Vaccine in Healthy Subjects","A Partially Randomized, Partially Double-blind, Placebo-controlled Phase II Non-inferiority Study to Evaluate Immunogenicity and Safety of One and Two Doses of MVA-BN® (IMVAMUNE) Smallpox Vaccine in 18-55 Year Old Healthy Subjects",Completed,,Phase 2,745.0,Actual,Bavarian Nordic,,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 15:02:49,2023-06-14 15:02:49,INDUSTRY,,,,,
349188,349189,NCT00377585,,2006-09-14,,,2017-04-20,2006-09-15,2006-09-18,Estimate,,,,,,,2017-04-20,2017-04-24,Actual,"September 22, 2006",,2006-09-22,April 2017,2017-04-30,"January 30, 2007",Actual,2007-01-30,,,,,Interventional,,,Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population,"A Phase II/III, Observer-blind, Multi-Country, Multi-Centre, Randomized Study to Demonstrate the Superiority in Terms of Immunogenicity of Adjuvanted Influenza Vaccine Administered in Adults Aged 50 Years and Older Compared to Fluarix",Completed,,Phase 2,3350.0,,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-14 10:46:14,2023-06-14 10:46:14,INDUSTRY,,,,,
349396,349397,NCT03532217,,2018-04-25,,,2022-08-03,2018-05-09,2018-05-22,Actual,,,,,,,2022-08-03,2022-08-05,Actual,"September 14, 2018",Actual,2018-09-14,August 2022,2022-08-31,"July 25, 2022",Actual,2022-07-25,"April 1, 2022",Actual,2022-04-01,,Interventional,,,Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer,A Pilot Trial of Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer,Completed,,Phase 1,19.0,Actual,Washington University School of Medicine,,1.0,,,False,,,,True,True,True,,,True,,,,,,No,,2023-06-19 03:08:19,2023-06-19 03:08:19,OTHER,,,,,
349576,349577,NCT01193907,,2010-09-01,2012-03-06,,2013-12-16,2010-09-01,2010-09-02,Estimate,2012-03-06,2012-04-03,Estimate,,,,2013-12-16,2014-01-17,Estimate,October 2010,,2010-10-31,December 2013,2013-12-31,November 2010,Actual,2010-11-30,November 2010,Actual,2010-11-30,,Interventional,,,Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old),"A Phase 2, Randomized, Observer-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of Three Formulations of the Novartis Vaccines Institute for Global Health (NVGH) Glycoconjugate Vaccine Against S. Typhi in Adult Subjects 18 to 40 Years of Age",Completed,,Phase 2,88.0,Actual,Novartis,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-19 03:08:43,2023-06-19 03:08:43,INDUSTRY,,,,,
349639,349640,NCT02465216,,2015-06-03,2018-10-11,,2019-02-21,2015-06-04,2015-06-08,Estimate,2018-10-11,2018-11-09,Actual,,,,2019-02-21,2019-03-12,Actual,June 2015,,2015-06-30,February 2019,2019-02-28,January 2017,Actual,2017-01-31,January 2017,Actual,2017-01-31,,Interventional,,,Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion,"A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine in HIV Uninfected Adult TB Patients After Treatment Completion",Completed,,Phase 2,60.0,Actual,Access to Advanced Health Institute (AAHI),,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 10:48:58,2023-06-14 10:48:58,OTHER,,,,,
349651,349652,NCT01195779,,2010-09-03,2012-03-22,,2020-10-08,2010-09-03,2010-09-06,Estimate,2012-03-29,2012-04-24,Estimate,,,,2020-10-08,2020-10-30,Actual,"September 30, 2010",Actual,2010-09-30,October 2020,2020-10-31,"March 22, 2011",Actual,2011-03-22,"March 22, 2011",Actual,2011-03-22,,Interventional,,,Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children,Observer-blind Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Adjuvanted Quadrivalent Influenza Candidate Vaccines (GSK2584786A) in Children Aged 6 to 35 Months,Terminated,,Phase 2,4.0,Actual,GlaxoSmithKline,,14.0,,The study was terminated for logistic reasons not related to safety or efficacy of the vaccine.,False,,,,,,,,,,,,,,,No,,2023-06-19 03:08:57,2023-06-19 03:08:57,INDUSTRY,,,,,
349848,349849,NCT04192500,,2019-12-03,,,2022-09-20,2019-12-06,2019-12-10,Actual,,,,,,,2022-09-20,2022-09-22,Actual,"December 11, 2019",Actual,2019-12-11,September 2022,2022-09-30,"September 7, 2020",Actual,2020-09-07,"September 7, 2020",Actual,2020-09-07,,Interventional,,,"Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years","A Phase 2a, Single Center, Randomized, Double-blind, Controlled Study to Evaluate the Immunogenicity and the Safety of One Dose of OVX836 Influenza Vaccine at Two Dose Levels (90 µg and 180 µg), in Comparison to Influvac TetraTM, Quadrivalent Seasonal Influenza Sub-unit Vaccine, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years",Completed,,Phase 2,300.0,Actual,Osivax,,3.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-14 10:49:48,2023-06-14 10:49:48,INDUSTRY,,,,,
349940,349941,NCT01141491,,2010-06-09,2016-10-14,,2017-03-14,2010-06-09,2010-06-10,Estimate,2016-10-14,2016-12-07,Estimate,,,,2017-03-14,2017-04-12,Actual,June 2010,,2010-06-30,December 2016,2016-12-31,"March 10, 2017",Actual,2017-03-10,September 2013,Actual,2013-09-30,,Interventional,,"Adults (male or female), 16 years of age and older who have metastatic sarcoma at initial presentation or who had relapsed disease and are rendered disease-free following surgical metastectomy",Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free,"A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free",Completed,,Phase 2,136.0,Actual,"MabVax Therapeutics, Inc.",,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-19 03:09:50,2023-06-19 03:09:50,INDUSTRY,,,,,
349981,349982,NCT05434585,,2022-06-20,,,2023-02-06,2022-06-27,2022-06-28,Actual,,,,,,,2023-02-06,2023-02-08,Actual,"July 8, 2022",Actual,2022-07-08,August 2022,2022-08-31,"August 30, 2023",Anticipated,2023-08-30,"October 10, 2022",Actual,2022-10-10,,Interventional,,,"A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines","A Randomized, Double-Blind, and Placebo-Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant mRNA Vaccines (ABO1009-DP and ABO-CoV.617.2) in Indonesian Subjects Aged 18 Years and Older Who Have Not Received SARS-CoV-2 Vaccines","Active, not recruiting",,Phase 1,60.0,Actual,"Suzhou Abogen Biosciences Co., Ltd.",,3.0,,,False,,,,,False,False,,,,,,,,,No,,2023-06-14 10:50:19,2023-06-14 10:50:19,INDUSTRY,,,,,
350593,350594,NCT00003339,,1999-11-01,,,2014-05-20,2004-09-10,2004-09-13,Estimate,,,,,,,2014-05-20,2014-05-22,Estimate,November 1998,,1998-11-30,May 2014,2014-05-31,September 2004,Actual,2004-09-30,November 1999,Actual,1999-11-30,,Interventional,,,Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma,A Randomized Phase II Trial of a Vaccine Combining Tyrosinase/gp100 Peptides Emulsified With Montanide ISA 51 With and Without Interleukin-12 for Patients With Resected Stages III and IV Melanoma,Completed,,Phase 2,48.0,Actual,University of Southern California,,,,,False,,,,True,,,,,,,,,,,,,2023-06-14 10:53:59,2023-06-14 10:53:59,OTHER,,,,,
350671,350672,NCT00370006,,2006-08-28,,,2007-01-10,2006-08-28,2006-08-30,Estimate,,,,,,,2007-01-10,2007-01-11,Estimate,September 2006,,2006-09-30,October 2006,2006-10-31,August 2007,,2007-08-31,,,,,Interventional,,,Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM,"A Phase 1 Clinical Trial to Evaluate the Safety of, and Kinetics and Magnitude of the CMV-Specific Immune Response to, Challenge With a Live Attenuated Strain of CMV (Towne) in Healthy, CMV- Seronegative, Adult Subjects Who Previously Received a CMV Immunotherapeutic Trivalent pDNA Vaccine (VCL CT02) Administered Intradermally or Intramuscularly",Completed,,Phase 1,10.0,,"University of California, San Francisco",,,,,,,,,,,,,,,,,,,,,,2023-06-14 01:57:39,2023-06-14 01:57:39,OTHER,,,,,
350762,350763,NCT04160065,,2019-11-07,,,2023-02-06,2019-11-08,2019-11-12,Actual,,,,,,,2023-02-06,2023-02-08,Actual,"March 3, 2020",Actual,2020-03-03,February 2023,2023-02-28,"September 30, 2023",Anticipated,2023-09-30,"June 30, 2023",Anticipated,2023-06-30,,Interventional,,,Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers,Phase 1 Trial of Intralesional Immunotherapy With IFx-Hu2.0 Vaccine in Patients With Advanced Non-melanoma Skin Cancers,Recruiting,,Phase 1,20.0,Anticipated,"Morphogenesis, Inc.",,1.0,,,True,,,,,True,False,,,,,,,,,No,,2023-06-14 10:55:35,2023-06-14 10:55:35,INDUSTRY,,NCT04853602,Available,,
350770,350771,NCT00004929,,2000-03-07,,,2013-01-30,2004-06-17,2004-06-18,Estimate,,,,,,,2013-01-30,2013-01-31,Estimate,September 1999,,1999-09-30,January 2013,2013-01-31,June 2008,Actual,2008-06-30,June 2008,Actual,2008-06-30,,Interventional,,,Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer,Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21: A Trial Examining the Immunogenicity of Glycosylated MUC-2-KLH Peptide Conjugate Vaccine,Completed,,Phase 1,15.0,Actual,Memorial Sloan Kettering Cancer Center,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 10:55:39,2023-06-14 10:55:39,OTHER,,,,,
350829,350830,NCT03552718,,2018-05-25,,,2019-04-09,2018-06-08,2018-06-12,Actual,,,,,,,2019-04-09,2019-04-11,Actual,"August 10, 2018",Actual,2018-08-10,April 2019,2019-04-30,"December 30, 2020",Anticipated,2020-12-30,"December 30, 2019",Anticipated,2019-12-30,,Interventional,,,QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.,QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.,Unknown status,Recruiting,Phase 1,16.0,Anticipated,"NantBioScience, Inc.",,1.0,,,False,,,,False,True,False,,,,,,,,,Undecided,,2023-06-17 06:08:56,2023-06-17 06:08:56,INDUSTRY,,,,,
351300,351301,NCT05345873,,2022-04-25,,,2022-04-25,2022-04-25,2022-04-26,Actual,,,,,,,2022-04-25,2022-04-26,Actual,"July 1, 2022",Anticipated,2022-07-01,April 2022,2022-04-30,"April 1, 2023",Anticipated,2023-04-01,"October 1, 2022",Anticipated,2022-10-01,,Interventional,,,A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years,"A Randomized, Double-blind, Positive-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E (A COVID-19 Alpha/Beta/Delta/Omicron Variants S-Trimer Vaccine) in Adolescents Aged 12-17 Years and Previously Fully Vaccinated With mRNA COVID-19 Vaccine",Not yet recruiting,,Phase 2,300.0,Anticipated,Sinocelltech Ltd.,,2.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-19 03:11:51,2023-06-19 03:11:51,INDUSTRY,,,,,
351622,351623,NCT04645147,,2020-11-25,,,2023-05-26,2020-11-25,2020-11-27,Actual,,,,,,,2023-05-26,2023-05-30,Actual,"March 29, 2022",Actual,2022-03-29,"May 25, 2023",2023-05-25,"July 1, 2025",Anticipated,2025-07-01,"July 1, 2025",Anticipated,2025-07-01,,Interventional,,,Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection,Phase 1 Study of the Safety and Immunogenicity of an Epstein-Barr Virus (EBV)gp350- Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection,Recruiting,,Phase 1,500.0,Anticipated,National Institutes of Health Clinical Center (CC),,1.0,,,False,,,,,True,False,,,,,,Results from the Clinical Center Laboratory will be available within one to two weeks and will be discussed by the study team.,IPD will be shared with the patient. IPD will also be discussed with the study team. If collaborations are initiated the samples will be coded so that the collaborator does not know the names of the patients.,,Yes,".We will return results from CLIA approved testing done in the department of laboratory medicine to participants. Based on results and clinical judgement, we will manage and refer patients appropriately. Non-FDA approved research assay results will not be shared with patients.",2023-06-16 18:24:19,2023-06-16 18:24:19,NIH,,,,,
351883,351884,NCT02237209,,2014-09-09,,,2015-10-07,2014-09-09,2014-09-11,Estimate,,,,,,,2015-10-07,2015-10-08,Estimate,September 2014,,2014-09-30,October 2015,2015-10-31,April 2015,Actual,2015-04-30,April 2015,Actual,2015-04-30,,Interventional,,,Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children,A Phase I Study of the Safety and Immunogenicity of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID <U+0394>M2-2 in RSV-Seronegative Infants and Children,Completed,,Phase 1,29.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 00:16:04,2023-06-18 00:16:04,NIH,,,,,
351961,351962,NCT04962906,,2021-07-08,,,2021-08-18,2021-07-13,2021-07-15,Actual,,,,,,,2021-08-18,2021-08-20,Actual,"July 5, 2021",Actual,2021-07-05,July 2021,2021-07-31,"August 15, 2021",Actual,2021-08-15,"August 5, 2021",Actual,2021-08-05,,Interventional,,,Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes,"Randomised Phase II Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes (rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV).",Completed,,Phase 2,192.0,Actual,Ministerio de Salud de Ciudad Autónoma de Buenos Aires,,3.0,,,False,,,,True,False,False,,,False,,,,,,No,,2023-06-19 03:40:35,2023-06-19 03:40:35,OTHER_GOV,,,,,
352178,352179,NCT00366782,,2006-08-17,,,2012-02-29,2006-08-17,2006-08-21,Estimate,,,,,,,2012-02-29,2012-03-01,Estimate,March 2007,,2007-03-31,February 2012,2012-02-29,June 2011,Actual,2011-06-30,February 2011,Actual,2011-02-28,,Interventional,,,"Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and Adults","A Phase 1 Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Chimeric Bovine/Human Parainfluenza Type 3 Virus Vaccine, rB/HPIV3, Lot PIV3 #101A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV3-Seropositive Children 15 to 59 Months of Age, and HPIV3-Seronegative Infants and Children 6 to 36 Months of Age",Completed,,Phase 1,51.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 11:09:24,2023-06-14 11:09:24,NIH,,,,,
352213,352214,NCT02215707,,2014-08-01,,,2018-06-28,2014-08-11,2014-08-13,Estimate,,,,,,,2018-06-28,2018-06-29,Actual,June 2014,,2014-06-30,November 2015,2015-11-30,June 2015,Actual,2015-06-30,April 2015,Actual,2015-04-30,,Interventional,,,A Clinical Trial of the PfSPZ Vaccine Administered by Direct Venous Inoculation in Healthy Malaria-Naïve Adults: Heterologous vs. Homologous Controlled Human Malaria Infection and Reduction in Number of Doses,A Clinical Trial of the PfSPZ Vaccine Administered by Direct Venous Inoculation in Healthy Malaria-Naïve Adults: Heterologous vs. Homologous Controlled Human Malaria Infection and Reduction in Number of Doses,Completed,,Phase 1,67.0,Actual,Sanaria Inc.,,7.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 17:39:34,2023-06-15 17:39:34,INDUSTRY,,,,,
352605,352606,NCT03618953,,2018-06-22,,,2023-04-11,2018-08-01,2018-08-07,Actual,,,,,,,2023-04-11,2023-04-14,Actual,"June 21, 2018",Actual,2018-06-21,April 2023,2023-04-30,"March 5, 2021",Actual,2021-03-05,"March 5, 2021",Actual,2021-03-05,,Interventional,Kingfisher,,This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers,"Phase 1/1b, Multicenter, Open-label Trial of Oncolytic MG1 Virus (MG1-E6E7) With Adenovirus Vaccine (Ad-E6E7) Both Expressing Mutant Human Papilloma Virus (HPV) E6 and E7 and Atezolizumab in Pts With HPV Assoc. Cancers",Terminated,,Phase 1,8.0,Actual,"Turnstone Biologics, Corp.",,2.0,,Virus potency titer of drug product as determined by an improved potency assay was lower than originally determined by the assay described in the IND.,False,,,,,True,False,,,,,,,,,,,2023-06-18 00:03:56,2023-06-18 00:03:56,INDUSTRY,,,,,
352683,352684,NCT00309166,,2006-03-28,2016-12-19,,2018-02-05,2006-03-28,2006-03-31,Estimate,2018-02-05,2018-09-17,Actual,,,,2018-02-05,2018-09-17,Actual,"April 5, 2006",Actual,2006-04-05,February 2018,2018-02-28,"June 19, 2007",Actual,2007-06-19,"June 1, 2007",Actual,2007-06-01,,Interventional,,,Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.,"An Observer-blind, Randomized, Controlled Study to Assess the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Male Subjects Aged 10-18 Years",Completed,,Phase 2,270.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 18:55:10,2023-06-16 18:55:10,INDUSTRY,,,,,
352887,352888,NCT03614533,,2018-07-11,,,2021-07-08,2018-08-02,2018-08-03,Actual,,,,,,,2021-07-08,2021-07-15,Actual,"December 3, 2018",Actual,2018-12-03,July 2021,2021-07-31,"August 22, 2019",Actual,2019-08-22,"August 22, 2019",Actual,2019-08-22,,Interventional,,,"Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso","A Phase 2 Randomized, Double-Blind, Controlled Trial of the Safety and Immunogenicity of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso",Completed,,Phase 2,251.0,Actual,"University of Maryland, Baltimore",,2.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-18 00:04:09,2023-06-18 00:04:09,OTHER,,,,,
353322,353323,NCT04739917,,2021-01-25,,,2021-02-25,2021-02-01,2021-02-05,Actual,,,,,,,2021-02-25,2021-03-01,Actual,"June 1, 2021",Anticipated,2021-06-01,February 2021,2021-02-28,"December 1, 2022",Anticipated,2022-12-01,"June 1, 2022",Anticipated,2022-06-01,,Interventional,,,Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Semi-immune Volunteers,"Safety and Protective Efficacy of a Synthetic Vaccine Derived From the CS Protein of Plasmodium Vivax: a Double-blind, Placebo-controlled, Randomized Clinical Trial in naïve and Pre-immune Colombian Volunteers",Unknown status,Not yet recruiting,Phase 2,120.0,Anticipated,Malaria Vaccine and Drug Development Center,,4.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-14 11:21:55,2023-06-14 11:21:55,OTHER,,,,,
353359,353360,NCT04041674,,2019-07-31,,,2021-10-13,2019-07-31,2019-08-01,Actual,,,,,,,2021-10-13,2021-10-15,Actual,"March 1, 2022",Anticipated,2022-03-01,October 2021,2021-10-31,"May 31, 2023",Anticipated,2023-05-31,"September 30, 2022",Anticipated,2022-09-30,,Interventional,,,"Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants","A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants *Imatinib Mesylate Per Oral as a Clinical Therapeutic for TB",Withdrawn,,Phase 1,0.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,Protocol undergoing additional revisions.,False,,,,True,True,False,,,,,,,,,No,,2023-06-18 00:17:43,2023-06-18 00:17:43,NIH,,,,,
353679,353680,NCT04133987,,2019-09-23,,,2023-01-15,2019-10-17,2019-10-21,Actual,,,,,,,2023-01-15,2023-01-18,Actual,"October 15, 2018",Actual,2018-10-15,January 2023,2023-01-31,"September 30, 2022",Actual,2022-09-30,"April 30, 2020",Actual,2020-04-30,,Interventional,,,Clinical Trial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in Taiwan,"Phase II, Randomized, Double-blind, Clinical Tial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in Taiwan",Completed,,Phase 2,252.0,Actual,National Taiwan University Hospital,,2.0,,,False,,,,True,False,False,,,,,,,,,Undecided,,2023-06-19 03:16:49,2023-06-19 03:16:49,OTHER,,,,,
354368,354369,NCT01176461,,2010-08-05,,,2023-01-17,2010-08-05,2010-08-06,Estimate,,,,,,,2023-01-17,2023-01-18,Actual,"August 4, 2010",Actual,2010-08-04,January 2023,2023-01-31,"December 12, 2016",Actual,2016-12-12,"December 12, 2016",Actual,2016-12-12,,Interventional,,,Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558,A Pilot Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG With Escalating Doses of Anti-PD-1 Antibody BMS-936558 for Patients With Unresectable Stages III/IV Melanoma,Completed,,Phase 1,127.0,Actual,H. Lee Moffitt Cancer Center and Research Institute,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-19 03:18:50,2023-06-19 03:18:50,OTHER,,,,,
354617,354618,NCT02753413,,2016-04-21,2017-06-13,,2018-05-29,2016-04-25,2016-04-27,Estimate,2017-06-13,2017-07-11,Actual,,,,2018-05-29,2018-06-26,Actual,"April 1, 2016",,2016-04-01,May 2018,2018-05-31,"June 28, 2016",Actual,2016-06-28,"June 28, 2016",Actual,2016-06-28,,Interventional,,,Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women,An Observer-blind Safety and Reactogenicity Study to Assess GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women,Completed,,Phase 2,102.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-14 11:33:23,2023-06-14 11:33:23,INDUSTRY,,,,,
355176,355177,NCT00373412,,2006-09-06,,,2008-05-05,2006-09-07,2006-09-08,Estimate,,,,,,,2008-05-05,2008-05-08,Estimate,October 2006,,2006-10-31,October 2006,2006-10-31,,,,February 2008,Actual,2008-02-29,,Interventional,,,Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge,"Randomized, Phase 1 Trial to Evaluate Safety and CMV-Specific Immune Response to a pDNA CMV Trivalent Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge in Healthy, CMV- Seronegative Adults",Completed,,Phase 1,16.0,,"University of California, San Francisco",,,,,False,,,,False,,,,,,,,,,,,,2023-06-14 11:38:37,2023-06-14 11:38:37,OTHER,,,,,
355349,355350,NCT02890381,,2016-08-31,2018-04-20,,2021-11-04,2016-08-31,2016-09-07,Estimate,2018-05-31,2018-07-02,Actual,,,,2021-11-04,2021-11-05,Actual,"October 5, 2016",Actual,2016-10-05,May 2018,2018-05-31,"April 24, 2017",Actual,2017-04-24,"April 24, 2017",Actual,2017-04-24,,Interventional,LID,Analysis population was all participants enrolled.,"Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp <U+0394>M2-2) in RSV-Seronegative Infants 6 to 24 Months of Age","Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID cp <U+0394>M2-2, Lot RSV#009B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age",Terminated,,Phase 1,17.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,Interim data indicated this vaccine will not meet the protocol criteria for a good vaccine candidate.,False,,,,True,,,,,,,,,,,,,2023-06-14 11:40:31,2023-06-14 11:40:31,NIH,,,,,
355524,355525,NCT02218125,,2014-08-14,,,2018-11-23,2014-08-14,2014-08-15,Estimate,,,,,,,2018-11-23,2018-11-27,Actual,"September 23, 2014",Actual,2014-09-23,November 2018,2018-11-30,"November 30, 2015",Actual,2015-11-30,"November 30, 2015",Actual,2015-11-30,,Interventional,MENSCH,,"A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults","A Phase I Study of Modified Vaccinia Ankara With Mosaic HIV Inserts in Healthy, HIV-Uninfected Adults, Some of Whom Have Previously Received an Adenovirus Type 26 ENVA.01 Vaccine",Completed,,Phase 1,25.0,Actual,Crucell Holland BV,,4.0,,,False,,,,True,True,,,,,,,,,,,,2023-06-15 17:45:34,2023-06-15 17:45:34,INDUSTRY,,,,,
355860,355861,NCT05727267,,2022-11-06,,,2023-04-22,2023-02-03,2023-02-14,Actual,,,,,,,2023-04-22,2023-04-25,Actual,May 2023,Anticipated,2023-05-31,April 2023,2023-04-30,August 2024,Anticipated,2024-08-31,June 2024,Anticipated,2024-06-30,,Interventional,,,A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate,TherVacB_Phase1a: Open Single Center Phase 1a Trial to Assess the Safety and Immunogenicity of a Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate in Healthy Volunteers,Not yet recruiting,,Phase 1,24.0,Anticipated,Universitätsklinikum Hamburg-Eppendorf,,6.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-14 11:47:39,2023-06-14 11:47:39,OTHER,,,,,
355866,355867,NCT05706324,,2023-01-29,,,2023-04-24,2023-01-29,2023-01-31,Actual,,,,,,,2023-04-24,2023-04-25,Actual,June 2023,Anticipated,2023-06-30,November 2022,2022-11-30,July 2024,Anticipated,2024-07-31,December 2023,Anticipated,2023-12-31,,Interventional,,,Phase <U+2160> Clinical Trial of a Candidate COVID-19 Vaccine,"A Single-arm, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant COVID-19 Vaccine (Adenovirus Vector) for Inhalation in People 21 to 65 Years Old (Previously Primed With Authorized Vaccines)",Not yet recruiting,,Phase 1,60.0,Anticipated,"Wuhan BravoVax Co., Ltd.",,3.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-14 11:47:47,2023-06-14 11:47:47,INDUSTRY,,,,,
356134,356135,NCT00582140,,2007-12-19,,,2019-11-15,2007-12-19,2007-12-28,Estimate,,,,,,,2019-11-15,2019-11-19,Actual,March 2005,,2005-03-31,July 2015,2015-07-31,August 2008,Actual,2008-08-31,August 2008,Actual,2008-08-31,,Interventional,,,Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer,Phase I Study of a DNA-based Vaccine Targeting Prostatic Acid Phosphatase (PAP) in Patients With Stage D0 Prostate Cancer,Completed,,Phase 1,22.0,Actual,"University of Wisconsin, Madison",,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 17:47:38,2023-06-15 17:47:38,OTHER,,,,,
356170,356171,NCT00103116,,2005-02-07,2013-11-07,,2017-03-30,2005-02-07,2005-02-08,Estimate,2017-03-30,2017-04-04,Actual,,,,2017-03-30,2017-04-04,Actual,October 2004,,2004-10-31,March 2017,2017-03-31,April 2008,Actual,2008-04-30,April 2008,Actual,2008-04-30,,Interventional,,,"Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer",Autologous Dendritic Cell Vaccines in Non-small Cell Lung Cancer (NSCLC),Completed,,Phase 2,32.0,Actual,University of Kentucky,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 14:57:34,2023-06-14 14:57:34,OTHER,,,,,
356281,356282,NCT05323435,,2022-04-11,,,2023-04-24,2022-04-11,2022-04-12,Actual,,,,,,,2023-04-24,2023-04-25,Actual,"May 30, 2022",Actual,2022-05-30,April 2023,2023-04-30,"January 16, 2023",Actual,2023-01-16,"July 5, 2022",Actual,2022-07-05,,Interventional,,,Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV),"A Multicenter, Randomized, Observer-Blinded, Active-Controlled Phase II Study to Evaluate the Immunogenicity and Safety of One Dose Booster by Recombinant Two-Component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older",Completed,,Phase 2,300.0,Actual,"Jiangsu Rec-Biotechnology Co., Ltd.",,3.0,,,False,,,,True,False,False,,,,,,,,,No,There is not a plan to make individual participant data (IPD) available,2023-06-14 11:50:23,2023-06-14 11:50:23,INDUSTRY,,,,,
356287,356288,NCT04550351,,2020-08-16,,,2021-01-26,2020-09-14,2020-09-16,Actual,,,,,,,2021-01-26,2021-01-27,Actual,"August 19, 2020",Actual,2020-08-19,August 2020,2020-08-31,"December 31, 2021",Anticipated,2021-12-31,"December 18, 2020",Actual,2020-12-18,,Interventional,,,Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (=60 Years Old),"A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of Recombinant New Coronavirus Vaccines (CHO Cells) in Healthy People Aged 60 Years and Above",Unknown status,"Active, not recruiting",Phase 1,50.0,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-15 17:48:58,2023-06-15 17:48:58,INDUSTRY,,,,,
356289,356290,NCT01640652,,2012-05-23,,,2018-04-06,2012-07-13,2012-07-16,Estimate,,,,,,,2018-04-06,2018-04-09,Actual,August 2012,,2012-08-31,April 2018,2018-04-30,December 2018,Anticipated,2018-12-31,July 2013,Actual,2013-07-31,,Interventional,,,MenPF-1 - A New Vaccine Against Meningococcal Disease,"A Phase I, Single Centre, Open-label Dose-escalation Study to Assess the Safety and Immunogenicity of Three Doses of 25µg or 50 µg of Meningococcal Serogroup B Outer Membrane Vesicle Vaccine MenPF-1",Unknown status,"Active, not recruiting",Phase 1,52.0,Actual,University of Oxford,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 17:49:01,2023-06-15 17:49:01,OTHER,,,,,
356302,356303,NCT00339040,,2006-06-19,2011-09-07,2010-08-03,2021-11-03,2006-06-19,2006-06-20,Estimate,2011-12-12,2012-01-16,Estimate,2010-08-03,2010-08-05,Estimate,2021-11-03,2021-11-05,Actual,October 2006,,2006-10-31,January 2019,2019-01-31,August 2009,Actual,2009-08-31,August 2009,Actual,2009-08-31,,Interventional,,,Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children,"Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age",Completed,,Phase 2,130.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 18:49:25,2023-06-16 18:49:25,NIH,,,,,
356682,356683,NCT05109598,,2021-11-04,,,2023-04-23,2021-11-04,2021-11-05,Actual,,,,,,,2023-04-23,2023-04-25,Actual,"November 4, 2021",Actual,2021-11-04,April 2023,2023-04-30,"April 6, 2023",Actual,2023-04-06,"February 14, 2022",Actual,2022-02-14,,Interventional,,,Clinical Trial of Immunogenicity Bridging of a Recombinant New Coronavirus(COVID-19) Vaccine (CHO Cell),A Clinical Trial Comparing the Immunogenicity of Recombinant New Coronavirus Vaccine (CHO Cells) Among People Aged 3 to 17 and 18 to 59 Years of Age.,Completed,,Phase 2,400.0,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,2.0,,,False,,,,,False,False,,,,,,,,,No,,2023-06-14 11:50:55,2023-06-14 11:50:55,INDUSTRY,,,,,
356724,356725,NCT05084989,,2021-10-14,,,2023-04-24,2021-10-19,2021-10-20,Actual,,,,,,,2023-04-24,2023-04-25,Actual,"January 31, 2022",Actual,2022-01-31,April 2023,2023-04-30,"February 9, 2023",Actual,2023-02-09,"August 18, 2022",Actual,2022-08-18,,Interventional,ReCOV,,"Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)","A Randomized, Blinded, Two-part, Phase II Trial to Evaluate the Safety and Immunogenicity of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults 18 Years and Older",Completed,,Phase 2,948.0,Actual,"Jiangsu Rec-Biotechnology Co., Ltd.",,4.0,,,False,,,,True,False,False,,,,,,,,,No,There is not a plan to make individual participant data (IPD) available,2023-06-14 11:50:59,2023-06-14 11:50:59,INDUSTRY,,,,,
356774,356775,NCT05050474,,2021-09-13,,,2023-04-22,2021-09-13,2021-09-20,Actual,,,,,,,2023-04-22,2023-04-25,Actual,"August 7, 2021",Actual,2021-08-07,April 2023,2023-04-30,"February 18, 2022",Actual,2022-02-18,"February 18, 2022",Actual,2022-02-18,,Interventional,,,Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01),A Clinical Study to Evaluate the Immunogenicity and Safety of the Third Dose Booster Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Participants,Completed,,Phase 1,43.0,Actual,Livzon Pharmaceutical Group Inc.,,1.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-14 11:51:08,2023-06-14 11:51:08,INDUSTRY,,,,,
357032,357033,NCT04537130,,2020-09-02,,,2020-09-22,2020-09-02,2020-09-03,Actual,,,,,,,2020-09-22,2020-09-24,Actual,"December 1, 2020",Anticipated,2020-12-01,September 2020,2020-09-30,June 2022,Anticipated,2022-06-30,June 2021,Anticipated,2021-06-30,,Interventional,COVINVAC,,Vaccination of Ex-acute COVID-19 Patients With Fibrosing Lung Syndrome at Discharge,Phase Ib Controlled Exploratory Trial for Treatment of Fibrosing Interstitial Lung Disease Patients Secondary to SARS-CoV-2 Infection With IN01 Vaccine (COVINVAC),Unknown status,Not yet recruiting,Phase 1,40.0,Anticipated,Instituto Oncológico Dr Rosell,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-15 17:55:35,2023-06-15 17:55:35,OTHER,,,,,
357298,357299,NCT03956056,,2019-05-15,2023-05-01,,2023-05-26,2019-05-15,2019-05-20,Actual,2023-05-26,2023-05-31,Actual,,,,2023-05-26,2023-05-31,Actual,"February 13, 2020",Actual,2020-02-13,May 2023,2023-05-31,"June 21, 2023",Anticipated,2023-06-21,"July 21, 2022",Actual,2022-07-21,,Interventional,,,Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy,A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy,"Active, not recruiting",,Phase 1,12.0,Actual,Washington University School of Medicine,,1.0,,,,,,,True,True,False,,,False,,,,,,No,,2023-06-16 18:28:42,2023-06-16 18:28:42,OTHER,,,,,
357464,357465,NCT02213354,,2014-08-07,,2017-07-03,2017-07-03,2014-08-07,2014-08-11,Estimate,,,,2017-07-03,2017-07-06,Actual,2017-07-03,2017-07-06,Actual,October 2014,,2014-10-31,April 2016,2016-04-30,July 2016,Actual,2016-07-31,July 2016,Actual,2016-07-31,,Interventional,,,H7N9 Mix and Match With MF59 in Healthy Elderly Persons,"A Phase II Randomized, Partially-Blinded, Controlled Trial in Healthy Adults Aged 65 Years and Older to Assess the Safety, Reactogenicity, and Immunogenicity of an MF59-Adjuvanted, Monovalent Inactivated Influenza A/H7N9 Virus Vaccine Administered Intramuscularly at Different Intervals and Dosages",Completed,,Phase 2,479.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,6.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 17:59:07,2023-06-15 17:59:07,NIH,,,,,
357524,357525,NCT04396067,,2020-05-18,,,2020-10-23,2020-05-18,2020-05-20,Actual,,,,,,,2020-10-23,2020-10-27,Actual,October 2020,Anticipated,2020-10-31,October 2020,2020-10-31,December 2020,Anticipated,2020-12-31,October 2020,Anticipated,2020-10-31,,Interventional,Antibodies,,Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment,Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment,Unknown status,Not yet recruiting,Phase 2,360.0,Anticipated,Kafrelsheikh University,,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-19 03:22:56,2023-06-19 03:22:56,OTHER,,,,,
357752,357753,NCT00857545,,2009-03-05,2016-12-20,,2017-09-12,2009-03-05,2009-03-06,Estimate,2017-08-07,2017-09-06,Actual,,,,2017-09-12,2017-09-13,Actual,July 2010,,2010-07-31,December 2016,2016-12-31,,,,September 2015,Actual,2015-09-30,,Interventional,,Enrolled and randomized Participants,"OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission","A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission",Completed,,Phase 2,171.0,Actual,GOG Foundation,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 01:48:39,2023-06-14 01:48:39,NETWORK,,,,,
358281,358282,NCT00369616,,2006-08-25,,,2010-11-11,2006-08-28,2006-08-29,Estimate,,,,,,,2010-11-11,2010-11-15,Estimate,December 2003,,2003-12-31,March 2008,2008-03-31,October 2005,Actual,2005-10-31,March 2005,Actual,2005-03-31,,Interventional,,,Efficacy and Safety of Nicotine-Qbeta Vaccine in Smokers,Evaluation of Efficacy and Safety of Nicotine-Qbeta (NicQb) Vaccine Versus Placebo in Healthy Smokers,Completed,,Phase 2,341.0,Actual,Cytos Biotechnology AG,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 01:58:37,2023-06-14 01:58:37,INDUSTRY,,,,,
358405,358406,NCT00278200,,2006-01-16,2019-01-08,,2023-04-21,2006-01-16,2006-01-18,Estimate,2019-02-05,2019-02-26,Actual,,,,2023-04-21,2023-04-25,Actual,January 2003,Actual,2003-01-31,February 2019,2019-02-28,August 2012,Actual,2012-08-31,August 2012,Actual,2012-08-31,,Interventional,,,Vaccine Therapy For Patients Being Considered For Organ Transplant Who Are at Risk For PTLD,Vaccination of Patients at High Risk for Post-Transplant Lymphoproliferative Disorder With a Photochemically Inactivated EBV-Infected B-Cell Vaccine,Terminated,,Phase 1,23.0,Actual,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,2.0,,Loss of funding,False,,,,,,,,,,,,,,,No,,2023-06-14 11:56:25,2023-06-14 11:56:25,OTHER,,,,,
358442,358443,NCT01682369,,2012-09-06,,,2017-09-29,2012-09-06,2012-09-10,Estimate,,,,,,,2017-09-29,2017-10-02,Actual,September 2012,,2012-09-30,September 2017,2017-09-30,January 2015,Actual,2015-01-31,February 2013,Actual,2013-02-28,,Interventional,,,ADITEC FLU STUDY: Understanding the Genetic Basis for Immune Responses,"A Multi-centre, Phase II, Open Labelled Randomised Control Trial to Describe Immune & Transcriptomic Responses to Trivalent Inactivated Vaccine (TIV) & MF59 Adjuvanted Influenza Vaccine (ATIV) in 14 -26 Month Healthy Children",Completed,,Phase 2,90.0,Actual,University of Oxford,,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 18:04:51,2023-06-15 18:04:51,OTHER,,,,,
358865,358866,NCT04862416,,2021-04-26,,,2022-07-06,2021-04-26,2021-04-28,Actual,,,,,,,2022-07-06,2022-07-07,Actual,"May 17, 2021",Actual,2021-05-17,July 2022,2022-07-31,"June 29, 2022",Actual,2022-06-29,"June 29, 2022",Actual,2022-06-29,,Interventional,STOP-TRANS,,Safety and Efficacy of R0.6C Vaccine,"Safety, Tolerability and Plasmodium Falciparum Transmission-reducing Activity of R0.6C Vaccine Adjuvanted With Alhydrogel Alone or Combined With Matrix-M in Healthy Malaria-naïve Adults in the Netherlands",Completed,,Phase 1,32.0,Actual,Radboud University Medical Center,,8.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-14 01:58:58,2023-06-14 01:58:58,OTHER,,,,,
358974,358975,NCT00375206,,2006-09-11,,,2007-01-25,2006-09-11,2006-09-12,Estimate,,,,,,,2007-01-25,2007-01-29,Estimate,September 2006,,2006-09-30,January 2007,2007-01-31,January 2007,,2007-01-31,,,,,Interventional,,,A Safety and Immunology Study of a DNA Trivalent Influenza Vaccine,"A Phase I Study to Assess Safety, Tolerability and Immunogenicity of a Trivalent Influenza Vaccine Administered by Particle Mediated Epidermal Delivery (PMED) to Healthy Subjects",Completed,,Phase 1,189.0,,PowderMed,,,,,,,,,,,,,,,,,,,,,,2023-06-14 12:01:49,2023-06-14 12:01:49,INDUSTRY,,,,,
359058,359059,NCT01684241,,2012-09-10,,,2020-01-14,2012-09-10,2012-09-12,Estimate,,,,,,,2020-01-14,2020-01-18,Actual,June 2012,,2012-06-30,January 2020,2020-01-31,July 2015,Actual,2015-07-31,May 2015,Actual,2015-05-31,,Interventional,MERIT,,RBL001/RBL002 Phase I Clinical Trial,Clinical First-in-human Dose Escalation Study Evaluating the Safety and Tolerability of Intranodal Administration of an RNA-based Cancer Vaccine Targeting Two Tumor-associated Antigens in Patients With Advanced Melanoma,Completed,,Phase 1,29.0,Actual,BioNTech SE,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 18:06:27,2023-06-15 18:06:27,INDUSTRY,,,,,
359399,359400,NCT00492648,,2007-06-26,2017-09-28,,2019-06-11,2007-06-26,2007-06-27,Estimate,2018-06-25,2018-12-19,Actual,,,,2019-06-11,2019-06-26,Actual,"June 25, 2007",Actual,2007-06-25,June 2019,2019-06-30,"June 23, 2008",Actual,2008-06-23,"June 23, 2008",Actual,2008-06-23,,Interventional,,,Month 30 & 42 Extension Studies of CRD-004 Primary Study,"An Extension Study to Evaluate the Persistence of the Immune Responses Induced by GSK Biologicals Zoster Vaccine, GSK324332A, Administered in Healthy Adult Subjects Aged 18-30 Years and 50-70 Years",Completed,,Phase 2,34.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 18:51:15,2023-06-16 18:51:15,INDUSTRY,,,,,
359537,359538,NCT01609998,,2012-05-30,,,2018-12-04,2012-05-31,2012-06-01,Estimate,,,,,,,2018-12-04,2018-12-06,Actual,June 2012,,2012-06-30,December 2018,2018-12-31,July 2013,Actual,2013-07-31,July 2013,Actual,2013-07-31,,Interventional,,,Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents,"Open-Label, Dose-Escalation, Phase I Study of the Prime-Boost Investigational 2012/13 Seasonal Influenza DNA Vaccine, VRC-FLUDNA063-00-VP, Followed by the 2012/2013 Seasonal TIV Compared to TIV Prime-Boost in Children/Adolescents Ages 6-17",Completed,,Phase 1,75.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 18:07:19,2023-06-15 18:07:19,NIH,,,,,
359907,359908,NCT03531710,,2018-04-06,2020-09-24,,2021-01-07,2018-05-08,2018-05-22,Actual,2020-11-25,2020-12-17,Actual,,,,2021-01-07,2021-01-26,Actual,"August 10, 2018",Actual,2018-08-10,January 2021,2021-01-31,"October 31, 2019",Actual,2019-10-31,"October 31, 2019",Actual,2019-10-31,,Interventional,,,"An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311","An Extension Study of a Phase IIa Study in Patients With Mild Alzheimer's Disease to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311)",Terminated,,Phase 2,34.0,Actual,United Neuroscience Ltd.,,2.0,,United Neuroscience has decided to terminate V203-AD-EXT study based on a treatment assignment error,False,,,,,True,False,,,,,,,,,,,2023-06-14 12:12:11,2023-06-14 12:12:11,INDUSTRY,,,,,
359913,359914,NCT02153112,,2014-05-29,2018-12-20,,2018-12-21,2014-05-29,2014-06-02,Estimate,2018-12-21,2019-04-01,Actual,,,,2018-12-21,2019-04-01,Actual,"June 23, 2015",Actual,2015-06-23,December 2018,2018-12-31,"June 20, 2018",Actual,2018-06-20,"June 20, 2018",Actual,2018-06-20,,Interventional,,Per-Protocol Analysis Set (PPS) included all participants who received the planned vaccination and do not have major protocol violations.,Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Children,"A Phase II, Randomized, Double-Blind, Dosage, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Combined With Aluminum Hydroxide Adjuvant in Children, Toddlers, and Infants",Completed,,Phase 2,840.0,Actual,Takeda,,10.0,,,False,,,,True,False,False,,,,,,,,,Yes,"Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.",2023-06-14 12:12:14,2023-06-14 12:12:14,INDUSTRY,,,,,
359965,359966,NCT03553940,,2018-05-31,2021-08-19,,2021-09-23,2018-05-31,2018-06-12,Actual,2021-09-23,2021-10-21,Actual,,,,2021-09-23,2021-10-21,Actual,"August 15, 2018",Actual,2018-08-15,"March 1, 2021",2021-03-01,"August 27, 2020",Actual,2020-08-27,"August 27, 2020",Actual,2020-08-27,,Interventional,,The baseline analysis population includes all enrolled participants.,H3N2 M2SR in Pediatric Population,A Phase I Trial to Evaluate the Safety and Immunogenicity of an Influenza Vaccination Strategy Including a H3N2 M2SR Prime Followed by a Seasonal Quadrivalent Inactivated Vaccine Boost in a Pediatric Population 9-17 Years Old,Completed,,Phase 1,43.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-14 12:13:02,2023-06-14 12:13:02,NIH,,,,,
360202,360203,NCT03368053,,2017-12-05,2019-04-15,,2020-09-25,2017-12-05,2017-12-11,Actual,2019-11-15,2019-11-18,Actual,,,,2020-09-25,2020-10-20,Actual,"December 14, 2017",Actual,2017-12-14,September 2020,2020-09-30,"January 30, 2018",Actual,2018-01-30,"January 30, 2018",Actual,2018-01-30,,Interventional,,,Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461),Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461),Completed,,Phase 1,36.0,Actual,GlaxoSmithKline,,1.0,,,False,,,,,False,False,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=20331,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-14 12:15:50,2023-06-14 12:15:50,INDUSTRY,,,,,
360270,360271,NCT03497845,,2018-03-13,2020-06-11,,2020-06-30,2018-04-06,2018-04-13,Actual,2020-06-30,2020-07-14,Actual,,,,2020-06-30,2020-07-14,Actual,"March 15, 2018",Actual,2018-03-15,June 2020,2020-06-30,"November 19, 2019",Actual,2019-11-19,"November 19, 2019",Actual,2019-11-19,,Interventional,,,Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59,"Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Homologous and Heterologous Prime-Boost Vaccination Strategies With Stockpiled Inactivated Monovalent Influenza A(H5) Vaccines Administered Intramuscularly With Either AS03 or MF59® as Adjuvant",Completed,,Phase 2,720.0,Actual,Biomedical Advanced Research and Development Authority,,12.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-14 12:16:59,2023-06-14 12:16:59,FED,,,,,
360339,360340,NCT03510481,,2018-04-26,2021-05-07,,2021-08-19,2018-04-26,2018-04-27,Actual,2021-08-19,2021-08-20,Actual,,,,2021-08-19,2021-08-20,Actual,"May 14, 2018",Actual,2018-05-14,May 2021,2021-05-31,"February 13, 2020",Actual,2020-02-13,"November 23, 2019",Actual,2019-11-23,,Interventional,,,"Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali","Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali",Completed,,Phase 1,478.0,Actual,National Institutes of Health Clinical Center (CC),,4.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-14 12:17:43,2023-06-14 12:17:43,NIH,,,,,
360738,360739,NCT01688297,,2012-09-14,,,2017-05-11,2012-09-18,2012-09-19,Estimate,,,,,,,2017-05-11,2017-05-12,Actual,September 2012,,2012-09-30,May 2017,2017-05-31,April 2015,Actual,2015-04-30,May 2014,Actual,2014-05-31,,Interventional,,,Safety Study of an Oral Vaccine to Prevent Seasonal Influenza,Randomized Phase 1 Double-Blinded Placebo Controlled Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Seasonal Influenza A Vaccine and dsRNA Adjuvant Administered Orally to Healthy Volunteers,Completed,,Phase 1,61.0,Actual,Vaxart,,4.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-15 18:09:24,2023-06-15 18:09:24,INDUSTRY,,,,,
361005,361006,NCT03682107,,2018-09-20,2021-09-09,,2022-10-27,2018-09-20,2018-09-24,Actual,2021-09-16,2021-10-14,Actual,,,,2022-10-27,2022-11-22,Actual,"February 19, 2019",Actual,2019-02-19,"April 6, 2021",2021-04-06,"September 23, 2020",Actual,2020-09-23,"September 23, 2020",Actual,2020-09-23,,Interventional,,,Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection Delivery Device,"A Phase I, Randomized, Placebo Controlled, Double-Blind, Dose Escalation Trial to Evaluate the Safety and Immunogenicity of an Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection System in Normal Healthy Adults",Completed,,Phase 1,48.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-17 06:07:16,2023-06-17 06:07:16,NIH,,,,,
361130,361131,NCT00001046,,1999-11-02,,,2021-10-28,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-28,2021-11-01,Actual,,,,October 2021,2021-10-31,,,,,,,,Interventional,,,Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo),Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo),Withdrawn,,Phase 1,0.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 12:26:42,2023-06-14 12:26:42,NIH,,,,,
361142,361143,NCT00001052,,1999-11-02,,,2021-10-28,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-28,2021-11-04,Actual,,,,October 2021,2021-10-31,September 1997,Actual,1997-09-30,,,,,Interventional,,,"A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults","A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults",Completed,,Phase 1,110.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 12:26:51,2023-06-14 12:26:51,NIH,,,,,
361183,361184,NCT00001088,,1999-11-02,,,2008-09-26,2001-08-30,2001-08-31,Estimate,,,,,,,2008-09-26,2008-09-29,Estimate,July 1997,,1997-07-31,September 2008,2008-09-30,February 2001,Actual,2001-02-28,February 2001,Actual,2001-02-28,,Interventional,,,"A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers","A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers",Completed,,Phase 1,40.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 12:27:17,2023-06-14 12:27:17,NIH,,,,,
361231,361232,NCT00001136,,2000-01-25,,,2021-10-28,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-28,2021-11-01,Actual,,,,October 2021,2021-10-31,May 2001,Actual,2001-05-31,,,,,Interventional,,,A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine,A Multi-Centered Phase 1 Trial to Evaluate the Memory Responses to a Single Boosting Vaccination With ALVAC-HIV vCP205 in Volunteers Who Have Previously Received Poxvirus-Based Vaccines,Completed,,Phase 1,60.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 12:27:40,2023-06-14 12:27:40,NIH,,,,,
361404,361405,NCT00002204,,1999-11-02,,,2005-06-23,2001-08-30,2001-08-31,Estimate,,,,,,,2005-06-23,2005-06-24,Estimate,,,,June 1999,1999-06-30,,,,,,,,Interventional,,,"A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults","A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults",Completed,,Phase 1,40.0,,NIH AIDS Clinical Trials Information Service,,,,,False,,,,,,,,,,,,,,,,,2023-06-14 12:29:26,2023-06-14 12:29:26,INDUSTRY,,,,,
361412,361413,NCT00001538,,1999-11-03,,,2008-03-03,2002-12-09,2002-12-10,Estimate,,,,,,,2008-03-03,2008-03-04,Estimate,March 1996,,1996-03-31,February 2000,2000-02-29,April 2001,,2001-04-30,,,,,Interventional,,,"Phase I Study of APL 400-003, a Candidate HIV Vaccine, in HIV-Negative Volunteers","Phase I Study of APL 400-003, a Candidate HIV Vaccine, in HIV-Negative Volunteers",Completed,,Phase 1,41.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 12:29:31,2023-06-14 12:29:31,NIH,,,,,
361504,361505,NCT00002402,,1999-11-02,,,2005-06-23,2001-08-30,2001-08-31,Estimate,,,,,,,2005-06-23,2005-06-24,Estimate,,,,August 1998,1998-08-31,,,,,,,,Interventional,,,"A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines",Phase I/II Trial to Evaluate the Safety and Immunogenicity of AIDSVAX B/B and B/E Vaccines in the United States,Completed,,Phase 1,120.0,,NIH AIDS Clinical Trials Information Service,,,,,False,,,,,,,,,,,,,,,,,2023-06-14 12:30:32,2023-06-14 12:30:32,INDUSTRY,,,,,
361856,361857,NCT04450004,,2020-06-18,,,2022-04-04,2020-06-25,2020-06-29,Actual,,,,,,,2022-04-04,2022-04-06,Actual,"July 10, 2020",Actual,2020-07-10,April 2022,2022-04-30,"August 30, 2021",Actual,2021-08-30,"September 20, 2020",Actual,2020-09-20,,Interventional,,,"Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.","A Randomized, Partially-Blinded, Dose-Ranging Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID 19 Vaccine in Adults 18-55 Years of Age",Completed,,Phase 1,180.0,Actual,Medicago,,9.0,,,False,,,,True,False,False,,,False,,,,,,No,,2023-06-14 12:34:14,2023-06-14 12:34:14,INDUSTRY,,,,,
362239,362240,NCT04099303,,2019-09-18,,,2022-10-28,2019-09-20,2019-09-23,Actual,,,,,,,2022-10-28,2022-10-31,Actual,"April 28, 2020",Actual,2020-04-28,October 2022,2022-10-31,"November 25, 2021",Actual,2021-11-25,"October 27, 2021",Actual,2021-10-27,,Interventional,PCTDTcP,,"Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed .","A Randomized,Blind, Positive-controlled Phase I Clinical Trial to Preliminary Evaluate the Safety of DTcP Vaccine in Healthy Children Aged Between 2 Months and 6 Years",Completed,,Phase 1,400.0,Actual,CanSino Biologics Inc.,,10.0,,,False,,,,False,False,False,,,,,,,,,No,"In order to maintain the rights of the subject, do not open the IPD",2023-06-14 12:37:53,2023-06-14 12:37:53,INDUSTRY,,,,,
362240,362241,NCT00000775,,1999-11-02,,,2005-06-23,2001-08-30,2001-08-31,Estimate,,,,,,,2005-06-23,2005-06-24,Estimate,,,,October 2002,2002-10-31,,,,,,,,Interventional,,,A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine),A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine),Completed,,Phase 1,40.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 12:37:54,2023-06-14 12:37:54,NIH,,,,,
362285,362286,NCT04126213,,2019-10-11,2021-11-12,2021-04-16,2021-11-12,2019-10-11,2019-10-15,Actual,2021-11-12,2021-12-13,Actual,2021-04-16,2021-04-19,Actual,2021-11-12,2021-12-13,Actual,"November 5, 2019",Actual,2019-11-05,November 2021,2021-11-30,"May 14, 2021",Actual,2021-05-14,"July 23, 2020",Actual,2020-07-23,,Interventional,,,"Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants","A Phase II, Randomised, Observer-blind, Placebo Controlled Multi-country Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Intramuscular Dose of GSK Biologicals' Investigational RSV Maternal Unadjuvanted Vaccine (GSK3888550A), in Healthy Pregnant Women Aged 18 to 40 Years and Infants Born to Vaccinated Mothers",Completed,,Phase 2,534.0,Actual,GlaxoSmithKline,,6.0,,,False,,,,True,True,False,,,False,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-19 03:29:02,2023-06-19 03:29:02,INDUSTRY,,,,,
362308,362309,NCT00000829,,1999-11-02,,,2021-10-27,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-27,2021-10-28,Actual,,,,October 2021,2021-10-31,October 1999,Actual,1999-10-31,,,,,Interventional,,,A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants,A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants,Completed,,Phase 1,60.0,,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 12:38:26,2023-06-14 12:38:26,NIH,,,,,
362335,362336,NCT00000853,,1999-11-02,,,2021-10-27,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-27,2021-11-04,Actual,,,,October 2021,2021-10-31,January 1999,Actual,1999-01-31,,,,,Interventional,,,"A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults","A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults",Completed,,Phase 1,37.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 12:38:44,2023-06-14 12:38:44,NIH,,,,,
362496,362497,NCT00003002,,1999-11-01,,,2019-02-25,2004-07-29,2004-07-30,Estimate,,,,,,,2019-02-25,2019-02-27,Actual,April 1996,,1996-04-30,February 2019,2019-02-28,January 2004,Actual,2004-01-31,January 2004,Actual,2004-01-31,,Interventional,,,"HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer",A Phase I Study of a HER-2/Neu Peptide Based Vaccine With GM-CSF as an Adjuvant in Patients With Advanced Stage HER-2/Neu Expressing Cancers,Completed,,Phase 1,60.0,Actual,University of Washington,,,,,False,,,,,,,,,,,,,,,,,2023-06-14 12:40:24,2023-06-14 12:40:24,OTHER,,,,,
362870,362871,NCT00370864,,2006-08-30,,,2016-07-17,2006-08-31,2006-09-01,Estimate,,,,,,,2016-07-17,2016-07-19,Estimate,September 2006,,2006-09-30,November 2008,2008-11-30,July 2007,Actual,2007-07-31,,,,,Interventional,,,Study of a Pandemic Influenza Vaccine in Children,Phase II Study of a Pandemic Influenza Vaccine in Children,Completed,,Phase 2,220.0,Anticipated,Seqirus,,,,,False,,,,,,,,,,,,,,,,,2023-06-14 02:00:37,2023-06-14 02:00:37,INDUSTRY,,,,,
363016,363017,NCT00004052,,1999-12-10,,,2013-06-24,2003-05-07,2003-05-08,Estimate,,,,,,,2013-06-24,2013-06-25,Estimate,March 1999,,1999-03-31,June 2013,2013-06-30,August 2005,Actual,2005-08-31,August 2005,Actual,2005-08-31,,Interventional,,,Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia,"Phase II, Multicenter Vaccination of Patients With Chronic Myelogenous Leukemia With a Multivalent Tumor Specific Breakpoint Peptide Vaccine",Completed,,Phase 2,24.0,Anticipated,Memorial Sloan Kettering Cancer Center,,,,,False,,,,,,,,,,,,,,,,,2023-06-14 12:45:20,2023-06-14 12:45:20,OTHER,,,,,
363090,363091,NCT00003362,,1999-11-01,,,2013-06-24,2004-08-25,2004-08-26,Estimate,,,,,,,2013-06-24,2013-06-25,Estimate,May 1998,,1998-05-31,June 2013,2013-06-30,February 2001,Actual,2001-02-28,February 2001,Actual,2001-02-28,,Interventional,,,Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma,"Pilot Trial of Multi-Epitope Melanoma Peptide Vaccine Using GM-CSF, Montanide and QS-21 as Adjuvants",Completed,,Phase 2,,,Memorial Sloan Kettering Cancer Center,,,,,False,,,,,,,,,,,,,,,,,2023-06-14 12:46:18,2023-06-14 12:46:18,OTHER,,,,,
363092,363093,NCT00004148,,1999-12-10,,,2013-02-08,2004-02-19,2004-02-20,Estimate,,,,,,,2013-02-08,2013-02-11,Estimate,October 1999,,1999-10-31,June 2006,2006-06-30,,,,April 2006,Actual,2006-04-30,,Interventional,,,Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma,A Phase I Trial of Intra Lesional RV-B7.1 Vaccine in the Treatment of Malignant Melanoma,Completed,,Phase 1,12.0,Actual,National Cancer Institute (NCI),,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 12:46:20,2023-06-14 12:46:20,NIH,,,,,
363120,363121,NCT00003386,,1999-11-01,,,2013-04-10,2004-04-22,2004-04-23,Estimate,,,,,,,2013-04-10,2013-04-11,Estimate,July 1999,,1999-07-31,December 2008,2008-12-31,,,,April 2001,Actual,2001-04-30,,Interventional,,,Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer,Treatment of Ovarian Carcinoma With DNP-Modified Autologous Tumor Vaccine,Terminated,,Phase 2,,,GOG Foundation,,,,,False,,,,,,,,,,,,,,,,,2023-06-14 12:46:44,2023-06-14 12:46:44,NETWORK,,,,,
363176,363177,NCT00004880,,2000-03-07,,,2020-07-30,2004-05-19,2004-05-20,Estimate,,,,,,,2020-07-30,2020-08-03,Actual,June 1997,,1997-06-30,July 2012,2012-07-31,,,,April 2001,Actual,2001-04-30,,Interventional,,,Vaccine Therapy in Treating Patients With Advanced Kidney Cancer,A Phase I Pilot Trial of a Multi-Antigen Loaded Dendritic Cell Vaccine for the Treatment of Advanced Renal Cell Carcinoma,Completed,,Phase 1,14.0,Actual,Jonsson Comprehensive Cancer Center,,,,,False,,,,False,,,,,,,,,,,,,2023-06-14 12:47:18,2023-06-14 12:47:18,OTHER,,,,,
363507,363508,NCT03376477,,2017-11-30,,,2023-02-22,2017-12-13,2017-12-18,Actual,,,,,,,2023-02-22,2023-02-24,Actual,"September 23, 2019",Actual,2019-09-23,February 2023,2023-02-28,"September 16, 2024",Anticipated,2024-09-16,"March 17, 2024",Anticipated,2024-03-17,,Interventional,,,Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission,"A Randomized, Double-blind, Placebo-Controlled Phase II Trial of an Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission","Active, not recruiting",,Phase 2,54.0,Anticipated,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,3.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-14 01:52:40,2023-06-14 01:52:40,OTHER,,,,,
363564,363565,NCT05305573,,2022-03-29,,,2023-02-28,2022-03-30,2022-03-31,Actual,,,,,,,2023-02-28,2023-03-01,Actual,"March 25, 2022",Actual,2022-03-25,February 2023,2023-02-28,"October 1, 2022",Actual,2022-10-01,"October 1, 2022",Actual,2022-10-01,,Interventional,,,Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.,"A Phase IIb, Double-Blind, Randomized, Active Controlled, Multi-center, Non-inferiority Trial to Assess Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Fusion Dimer Candidate (PHH-1V) Against SARS-CoV-2, in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19",Completed,,Phase 2,26.0,Actual,"Hipra Scientific, S.L.U",,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-14 12:51:15,2023-06-14 12:51:15,INDUSTRY,,,,,
363889,363890,NCT01588015,,2012-04-26,,,2023-02-28,2012-04-26,2012-04-30,Estimate,,,,,,,2023-02-28,2023-03-01,Actual,"October 29, 2012",Actual,2012-10-29,February 2023,2023-02-28,"November 30, 2023",Anticipated,2023-11-30,"November 30, 2023",Anticipated,2023-11-30,,Interventional,,,Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant,A Phase I Trial to Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell Transplant,"Active, not recruiting",,Phase 1,36.0,Actual,City of Hope Medical Center,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 12:54:31,2023-06-14 12:54:31,OTHER,,,,,
364027,364028,NCT00003715,,1999-11-01,,,2015-12-02,2004-04-22,2004-04-23,Estimate,,,,,,,2015-12-02,2015-12-03,Estimate,December 1998,,1998-12-31,December 2015,2015-12-31,,,,,,,,Interventional,,,Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma,"A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b",Terminated,,Phase 2,425.0,Anticipated,AVAX Technologies,,,,Terminated: recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated,False,,,,,,,,,,,,,,,,,2023-06-14 12:56:20,2023-06-14 12:56:20,INDUSTRY,,,,,
364066,364067,NCT00384787,,2006-10-04,,,2021-10-13,2006-10-05,2006-10-06,Estimate,,,,,,,2021-10-13,2021-10-14,Actual,November 2006,,2006-11-30,October 2021,2021-10-31,December 2012,Actual,2012-12-31,November 2008,Actual,2008-11-30,,Interventional,,,Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults,"A Phase Ib Clinical Trial to Compare the Safety, Tolerability, and Immunogenicity of an HIV-1 Adenoviral Vector Boost Administered Intramuscularly, Intradermally, or Subcutaneously After an HIV-1 DNA Plasmid Vaccine Prime Administered Intramuscularly to Healthy Adenovirus Type 5 Seropositive HIV-1-Uninfected Adults",Completed,,Phase 1,90.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 12:56:46,2023-06-14 12:56:46,NIH,,,,,
364124,364125,NCT00003871,,1999-11-01,,,2010-01-26,2004-06-15,2004-06-16,Estimate,,,,,,,2010-01-26,2010-01-27,Estimate,August 1999,,1999-08-31,January 2010,2010-01-31,,,,June 2002,Actual,2002-06-30,,Interventional,,,PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer,Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer,Completed,,Phase 2,60.0,Anticipated,Eastern Cooperative Oncology Group,,,,,,,,,False,,,,,,,,,,,,,2023-06-14 12:57:19,2023-06-14 12:57:19,NETWORK,,,,,
364218,364219,NCT00005023,,2000-04-06,,,2017-11-28,2004-04-22,2004-04-23,Estimate,,,,,,,2017-11-28,2017-11-30,Actual,March 1999,,1999-03-31,November 2017,2017-11-30,January 2001,Actual,2001-01-31,January 2001,Actual,2001-01-31,,Interventional,,,Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer,A Phase I Vaccine Trial of a HER-2/Neu Peptide Incorporated Into PLG Microspheres in Patients With Advanced Stage HER2-Expressing Cancers,Completed,,Phase 1,,,University of Washington,,,,,False,,,,,,,,,,,,,,,,,2023-06-14 12:58:32,2023-06-14 12:58:32,OTHER,,,,,
364270,364271,NCT00004579,,1999-11-02,,,2005-06-23,2001-08-30,2001-08-31,Estimate,,,,,,,2005-06-23,2005-06-24,Estimate,April 1998,,1998-04-30,June 2003,2003-06-30,,,,,,,,Interventional,,,A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection,"A Phase I, Dose-Ranging Trial of the Pasteur Merieux Connaught (PMC) Oligomeric HIV-1 gp160MN/LAI-2 Vaccine Alone or Primed With Live Recombinant ALVAC-HIV (vCP205) in HIV Seronegative Adults",Completed,,Phase 1,,,NIH AIDS Clinical Trials Information Service,,,,,False,,,,,,,,,,,,,,,,,2023-06-14 12:59:16,2023-06-14 12:59:16,INDUSTRY,,,,,
364367,364368,NCT00386113,,2006-10-09,,,2018-02-22,2006-10-09,2006-10-11,Estimate,,,,,,,2018-02-22,2018-02-26,Actual,"October 16, 2006",Actual,2006-10-16,February 2018,2018-02-28,"November 14, 2006",Actual,2006-11-14,"November 14, 2006",Actual,2006-11-14,,Interventional,,,Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly,"A Phase II, Open, Controlled Study to Evaluate the Reactogenicity and the Immunogenicity of GlaxoSmithKline Biologicals' Adjuvanted Influenza Vaccine in Elderly Adults Previously Vaccinated With Either Fluarix or the Adjuvanted Vaccine.",Completed,,Phase 2,74.0,Actual,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,,,2023-06-14 13:00:43,2023-06-14 13:00:43,INDUSTRY,,,,,
364390,364391,NCT00005779,,2000-06-03,,,2021-10-28,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-28,2021-11-01,Actual,,,,October 2021,2021-10-31,May 2004,Actual,2004-05-31,,,,,Interventional,,,Safety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug Therapy,"A Phase I, Limited-Center, Sequential Cohort Trial of HIV Vaccine (Polyvalent Peptide Vaccine C4-V3) in Conjunction With Interleukin-12 in Subjects With Maximal Suppression of HIV Replication and CD4 Count > 400 Cells/mm3",Completed,,Phase 1,12.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 13:00:59,2023-06-14 13:00:59,NIH,,,,,
364432,364433,NCT03383055,,2017-12-11,,,2021-08-11,2017-12-21,2017-12-26,Actual,,,,,,,2021-08-11,2021-08-17,Actual,"November 16, 2018",Actual,2018-11-16,August 2021,2021-08-31,"July 10, 2021",Actual,2021-07-10,"July 10, 2021",Actual,2021-07-10,,Interventional,,,CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig,CMV-MVA Triplex Vaccine to Enhance Adaptive NK Cell Reconstitution After Autologous Hematopoietic Cell Transplantation in Patients With Lymphoid Malignancies,Completed,,Phase 1,28.0,Actual,"Masonic Cancer Center, University of Minnesota",,2.0,,,,,,,,True,False,,,False,,,,,,,,2023-06-18 00:17:22,2023-06-18 00:17:22,OTHER,,,,,
364449,364450,NCT04751682,,2021-02-08,,,2022-08-17,2021-02-11,2021-02-12,Actual,,,,,,,2022-08-17,2022-08-18,Actual,"March 1, 2021",Actual,2021-03-01,August 2022,2022-08-31,"November 30, 2021",Actual,2021-11-30,"June 25, 2021",Actual,2021-06-25,,Interventional,,,Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19,"A Phase 1, Randomized, Double-blinded, Multicenter Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of an Intranasal Adenovirus Vector COVID-19 Vaccine (BBV154) in Healthy Volunteers",Completed,,Phase 1,175.0,Actual,Bharat Biotech International Limited,,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-14 13:01:56,2023-06-14 13:01:56,INDUSTRY,,,,,
364484,364485,NCT02142504,,2014-05-09,2017-01-03,2016-11-29,2017-08-18,2014-05-15,2014-05-20,Estimate,2017-01-03,2017-02-23,Actual,2016-11-29,2016-11-30,Estimate,2017-08-18,2017-08-21,Actual,"May 15, 2014",Actual,2014-05-15,August 2017,2017-08-31,"January 6, 2016",Actual,2016-01-06,"January 6, 2016",Actual,2016-01-06,,Interventional,,Randomized Set included all randomized participants.,Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults,"Phase II, Randomized, Placebo-controlled, Double-blind, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in Healthy Adults",Completed,,Phase 2,454.0,Actual,Takeda,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 13:02:54,2023-06-14 13:02:54,INDUSTRY,,,,,
364570,364571,NCT04723602,,2020-12-10,,,2022-08-02,2021-01-20,2021-01-26,Actual,,,,,,,2022-08-02,2022-08-03,Actual,"January 6, 2021",Actual,2021-01-06,August 2022,2022-08-31,"December 14, 2021",Actual,2021-12-14,"December 14, 2021",Actual,2021-12-14,,Interventional,,,"Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults","Phase 1b Trial to Evaluate Safety, Tolerability and Immune Responses of 2 Monovalent Chimpanzee Adenoviral Vectored Filovirus (Ebola-S and Marburg) Vaccines to Healthy Adults, Collection of Plasma/Serum for the Purposes of Assay Development",Completed,,Phase 1,32.0,Actual,Albert B. Sabin Vaccine Institute,,2.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-14 13:04:44,2023-06-14 13:04:44,OTHER,,,,,
364864,364865,NCT04711356,,2020-12-09,,,2022-08-04,2021-01-12,2021-01-15,Actual,,,,,,,2022-08-04,2022-08-08,Actual,"July 8, 2021",Actual,2021-07-08,October 2021,2021-10-31,"March 31, 2022",Actual,2022-03-31,"September 17, 2021",Actual,2021-09-17,,Interventional,,,Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study),An Open Label Study to Evaluate the Safety and Immunogenicity of an Ad26.ZEBOV Booster Dose in Children Previously Vaccinated With the Ad26.ZEBOV and MVA-BN-Filo Vaccine Regimen,Completed,,Phase 2,50.0,Actual,London School of Hygiene and Tropical Medicine,,1.0,,,False,,,,False,False,False,,,,,,within 12 months of the study completion date,open,,Yes,"The clinical trial results will be published in an open access, peer-reviewed journal, which will include the study protocol. A summary of the study results will be included within the trial registration record in PACTR and ClinicalTrials.gov

Following publication of the primary and exploratory objectives as detailed in the protocol, individual de-identified participants' data and a data dictionary will be made available upon request via the London School of Hygiene & Tropical Medicine research data repository, LSHTM Data Compass at http://datacompass.lshtm.ac.uk. Requests with a defined analysis plan can be sent via LSHTM Data Compass.",2023-06-14 13:08:43,2023-06-14 13:08:43,OTHER,,,,,
364892,364893,NCT04684914,,2020-12-22,,,2022-09-07,2020-12-22,2020-12-28,Actual,,,,,,,2022-09-07,2022-09-09,Actual,"December 26, 2020",Actual,2020-12-26,September 2022,2022-09-30,July 2023,Anticipated,2023-07-31,April 2023,Anticipated,2023-04-30,,Interventional,,,HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB),"Phase 2, Double-blind, Randomized, Placebo-controlled Study of HepTcell (Adjuvanted FP-02.2) as an Immunotherapeutic Vaccine in Treatment-naïve Patients With Inactive Chronic Hepatitis B (CHB)",Recruiting,,Phase 2,80.0,Anticipated,"Altimmune, Inc.",,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-14 13:08:55,2023-06-14 13:08:55,INDUSTRY,,,,,
365191,365192,NCT01928472,,2013-08-21,2015-05-05,,2019-05-28,2013-08-21,2013-08-26,Estimate,2015-05-05,2015-05-21,Estimate,,,,2019-05-28,2019-06-11,Actual,August 2013,,2013-08-31,May 2019,2019-05-31,September 2014,Actual,2014-09-30,September 2014,Actual,2014-09-30,,Interventional,,,Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years,"Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years",Completed,,Phase 1,402.0,Actual,Novartis,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 13:13:05,2023-06-14 13:13:05,INDUSTRY,,,,,
365361,365362,NCT05419011,,2022-06-14,,,2023-03-30,2022-06-14,2022-06-15,Actual,,,,,,,2023-03-30,2023-03-31,Actual,"March 22, 2023",Actual,2023-03-22,March 2023,2023-03-31,"February 1, 2027",Anticipated,2027-02-01,"February 1, 2027",Anticipated,2027-02-01,,Interventional,,,Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome,A Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury) Vaccine (TRI-AD5) and IL-15 Superagonist N-803 in Lynch Syndrome,Recruiting,,Phase 2,186.0,Anticipated,National Cancer Institute (NCI),,4.0,,,False,,,,True,True,False,,,,,,,,https://grants.nih.gov/policy/sharing.htm,Yes,"'NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page'",2023-06-19 03:33:09,2023-06-19 03:33:09,NIH,,,,,
365441,365442,NCT03807245,,2019-01-09,2020-11-30,,2021-01-30,2019-01-15,2019-01-16,Actual,2020-11-30,2020-12-24,Actual,,,,2021-01-30,2021-02-02,Actual,"January 9, 2019",Actual,2019-01-09,November 2020,2020-11-30,"May 7, 2020",Actual,2020-05-07,"October 14, 2019",Actual,2019-10-14,,Interventional,MVX0002,,Group B Streptococcus Vaccine in Healthy Females,"A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of Group B Streptococcus Vaccine (GBS-NN/NN2 With Alhydrogel®) in Healthy Female Subjects Aged 18 to 40",Completed,,Phase 1,60.0,Actual,Minervax ApS,,4.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-14 13:15:20,2023-06-14 13:15:20,OTHER,,,,,
365590,365591,NCT02482532,,2015-06-18,,,2022-01-20,2015-06-23,2015-06-26,Estimate,,,,,,,2022-01-20,2022-02-04,Actual,"October 6, 2016",Actual,2016-10-06,November 2021,2021-11-30,"September 13, 2021",Actual,2021-09-13,"October 10, 2019",Actual,2019-10-10,,Interventional,MARVSmALo,,"Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma","Phase I Study of Vaccine Enriched, Autologous, Activated T-Cells Redirected to the Tumor Marker GD2 in Patients With Relapsed/Refractory Melanoma",Completed,,Phase 1,7.0,Actual,University of Kansas Medical Center,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 18:16:57,2023-06-15 18:16:57,OTHER,,,,,
365690,365691,NCT00000767,,1999-11-02,,,2021-10-27,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-27,2021-10-28,Actual,,,,October 2021,2021-10-31,July 1996,Actual,1996-07-31,,,,,Interventional,,,"A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)","A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)",Completed,,Phase 1,18.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 13:17:59,2023-06-14 13:17:59,NIH,,,,,
365743,365744,NCT00000845,,1999-11-02,,,2005-06-23,2001-08-30,2001-08-31,Estimate,,,,,,,2005-06-23,2005-06-24,Estimate,,,,October 2002,2002-10-31,,,,,,,,Interventional,,,A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects,A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects,Completed,,Phase 1,30.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 13:18:33,2023-06-14 13:18:33,NIH,,,,,
365832,365833,NCT00001031,,1999-11-02,,,2021-10-28,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-28,2021-11-04,Actual,,,,October 2021,2021-10-31,December 1997,Actual,1997-12-31,,,,,Interventional,,,A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults,A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults,Completed,,Phase 2,296.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 13:19:19,2023-06-14 13:19:19,NIH,,,,,
365881,365882,NCT00380237,,2006-09-22,,,2008-01-18,2006-09-22,2006-09-25,Estimate,,,,,,,2008-01-18,2008-01-21,Estimate,October 2006,,2006-10-31,January 2008,2008-01-31,January 2007,Actual,2007-01-31,January 2007,Actual,2007-01-31,,Interventional,,,Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B),"Phase 1 Inpatient Study of the Safety and Immunogenicity of H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H9N2 Infection in the Event of a Pandemic (Study B)",Completed,,Phase 1,20.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 13:19:45,2023-06-14 13:19:45,NIH,,,,,
366015,366016,NCT05283109,,2022-03-08,,,2023-03-30,2022-03-08,2022-03-16,Actual,,,,,,,2023-03-30,2023-03-31,Actual,June 2023,Anticipated,2023-06-30,March 2023,2023-03-31,February 2028,Anticipated,2028-02-29,April 2025,Anticipated,2025-04-30,,Interventional,ETAPA I,,ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM,"ETAPA I: Evaluation of Tumor Associated P30-Peptide Antigen I; A Pilot Trial of Peptide-based Tumor Associated Antigen Vaccines in Newly Diagnosed, Unmethylated, and Untreated Glioblastoma (GBM)",Not yet recruiting,,Phase 1,36.0,Anticipated,Duke University,,1.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-19 03:33:46,2023-06-19 03:33:46,OTHER,,,,,
366032,366033,NCT00001439,,1999-11-03,,,2008-03-03,2002-12-09,2002-12-10,Estimate,,,,,,,2008-03-03,2008-03-04,Estimate,June 1995,,1995-06-30,May 1999,1999-05-31,April 2000,,2000-04-30,,,,,Interventional,,,A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant,A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant,Completed,,Phase 1,255.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 13:20:49,2023-06-14 13:20:49,NIH,,,,,
366185,366186,NCT00002231,,1999-11-02,,,2005-06-23,2001-08-30,2001-08-31,Estimate,,,,,,,2005-06-23,2005-06-24,Estimate,,,,May 2000,2000-05-31,,,,,,,,Interventional,,,Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative Volunteers,"GENEVAX-HIV (APL 400-003), a Candidate DNA Vaccine: A Pilot Dose Escalation Study of GENEVAX-HIV Delivered Intramuscularly Using the Biojector 2000 in HIV Seronegative Volunteers",Completed,,Phase 1,,,NIH AIDS Clinical Trials Information Service,,,,,False,,,,,,,,,,,,,,,,,2023-06-14 13:22:09,2023-06-14 13:22:09,INDUSTRY,,,,,
366192,366193,NCT00002261,,1999-11-02,,,2007-09-24,2001-08-30,2001-08-31,Estimate,,,,,,,2007-09-24,2007-09-26,Estimate,,,,September 2007,2007-09-30,,,,,,,,Interventional,,,A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers,A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers,Completed,,Phase 1,,,Bristol-Myers Squibb,,,,,,,,,,,,,,,,,,,,,,2023-06-14 13:22:12,2023-06-14 13:22:12,INDUSTRY,,,,,
366249,366250,NCT00382187,,2006-09-27,,,2016-11-30,2006-09-27,2006-09-28,Estimate,,,,,,,2016-11-30,2016-12-01,Estimate,November 2006,,2006-11-30,February 2012,2012-02-29,January 2008,Actual,2008-01-31,January 2008,Actual,2008-01-31,,Interventional,,,Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults,"A Phase II, Randomized, Controlled, Observer-blind, Single-Center Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, and a Six Month Booster Dose of Two Surface Antigen Adjuvanted With MF59C.1 Influenza Vaccines Containing 7.5 Micrograms or 15 Micrograms of A/H5N1 Influenza Antigen and of a Non-adjuvanted Influenza Vaccine Containing 15 Micrograms of A/H5N1 Influenza Antigen, in Adults",Completed,,Phase 2,40.0,Actual,Novartis,,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 13:22:32,2023-06-14 13:22:32,INDUSTRY,,,,,
366279,366280,NCT00381875,,2006-09-26,,,2012-05-01,2006-09-26,2006-09-28,Estimate,,,,,,,2012-05-01,2012-05-02,Estimate,July 2006,,2006-07-31,May 2012,2012-05-31,February 2011,Actual,2011-02-28,February 2011,Actual,2011-02-28,,Interventional,,,"Vaccine Therapy, Incomplete Freund's Adjuvant, and GM-CSF in Treating Patients With HIV",A Pilot Study to Investigate the Safety and Immunogenicity of a Peptide Vaccine for HIV Infected HLA-A2 Individuals Designed to Impede the Development of Antiretroviral Resistance,Completed,,Phase 1,40.0,Anticipated,National Institutes of Health Clinical Center (CC),,,,,,,,,,,,,,,,,,,,,,2023-06-14 13:22:51,2023-06-14 13:22:51,NIH,,,,,
366752,366753,NCT00383903,,2006-10-03,,,2016-09-14,2006-10-03,2006-10-04,Estimate,,,,,,,2016-09-14,2016-09-15,Estimate,September 2003,,2003-09-30,September 2016,2016-09-30,September 2004,Actual,2004-09-30,September 2004,Actual,2004-09-30,,Interventional,,,Evaluate Safety & Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South Africa,"A Phase II, Randomized, Double-blind, Placebo-controlled Study of Safety, Reactogenicity and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus Vaccine at 10E6.5 CCID50 Viral Concentration in Healthy Infants (Approximately 5-10 Weeks Old) in the Republic of South Africa",Completed,,Phase 2,472.0,Actual,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-14 13:26:50,2023-06-14 13:26:50,INDUSTRY,,,,,
366774,366775,NCT01606241,,2012-05-23,,,2020-09-28,2012-05-24,2012-05-25,Estimate,,,,,,,2020-09-28,2020-09-29,Actual,"July 24, 2012",Actual,2012-07-24,September 2018,2018-09-30,"March 9, 2018",Actual,2018-03-09,"September 25, 2014",Actual,2014-09-25,,Interventional,,,"Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope Folate Receptor Alpha Peptide Vaccine Used in Combination With Cyclophosphamide in Subjects Previously Treated for Breast or Ovarian Cancer,Completed,,Phase 1,24.0,Anticipated,Mayo Clinic,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 18:21:15,2023-06-15 18:21:15,OTHER,,,,,
366783,366784,NCT03713801,,2018-10-17,,,2023-02-27,2018-10-19,2018-10-22,Actual,,,,,,,2023-02-27,2023-03-01,Actual,"January 14, 2019",Actual,2019-01-14,February 2023,2023-02-28,December 2024,Anticipated,2024-12-31,July 2023,Anticipated,2023-07-31,,Interventional,,,Impact of Metformin on Immunity,Metformin and Vaccine Response in Older Adults,Suspended,,Phase 1,18.0,Actual,The University of Texas Health Science Center at San Antonio,,2.0,,"Study has been halted due to COVID-19 pandemic, immunity of the subject has been a concern. Modifications are planned for the protocol.",False,,,,True,True,False,,,,,,,,,No,,2023-06-14 13:27:06,2023-06-14 13:27:06,OTHER,,,,,
366921,366922,NCT00003977,,1999-11-01,,,2009-02-06,2003-01-26,2003-01-27,Estimate,,,,,,,2009-02-06,2009-02-09,Estimate,November 1999,,1999-11-30,December 2003,2003-12-31,,,,,,,,Interventional,,,Vaccine Therapy in Treating Patients With Recurrent or Persistent Cervical Cancer,A Phase I Study of Immunization With Alternating Human Papillomavirus E7 Lipopeptide Epitope Vaccine and Dendritic Cells Presenting the E7 Epitope for the Treatment of Recurrent or Persistent Cervical Cancer,Completed,,Phase 1,,,National Cancer Institute (NCI),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 13:28:20,2023-06-14 13:28:20,NIH,,,,,
367080,367081,NCT00005009,,2000-03-28,,,2017-02-14,2001-08-30,2001-08-31,Estimate,,,,,,,2017-02-14,2017-02-16,Actual,February 1998,,1998-02-28,February 2017,2017-02-28,"June 16, 2001",Actual,2001-06-16,"June 16, 2001",Actual,2001-06-16,,Interventional,,,Evaluation of the Safety of Varivax® in Pediatric Renal Transplant Recipients,Evaluation of the Safety and Immunogenicity of Varivax® (Live-Attenuated Varicella-Zoster Virus Vaccine) in Pediatric Renal Transplant Recipients,Terminated,,Phase 1,7.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,1.0,,Slow enrollment,False,,,,True,,,,,,,,,,,Yes,Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.,2023-06-14 13:30:12,2023-06-14 13:30:12,NIH,,,,,
367791,367792,NCT01342796,,2011-04-26,2018-06-05,2012-08-23,2021-04-14,2011-04-26,2011-04-27,Estimate,2021-04-14,2021-04-19,Actual,2012-08-23,2012-08-30,Estimate,2021-04-14,2021-04-19,Actual,May 2011,,2011-05-31,February 2019,2019-02-28,February 2012,Actual,2012-02-29,February 2012,Actual,2012-02-29,,Interventional,,,Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects,"A Phase II, Randomized, Controlled, Observer-Blind, Clinical Study to Evaluate the Humoral and Cell Mediated Immunity and Safety of Two Intramuscular Doses of MF59C.1-adjuvanted Subunit Influenza Vaccine or Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects Aged 6 to <36 Months",Completed,,Phase 2,84.0,Actual,Novartis,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 18:25:56,2023-06-15 18:25:56,INDUSTRY,,,,,
368047,368048,NCT05710224,,2023-01-24,,,2023-06-07,2023-01-24,2023-02-02,Actual,,,,,,,2023-06-07,2023-06-08,Actual,"February 15, 2023",Actual,2023-02-15,May 2023,2023-05-31,"December 22, 2024",Anticipated,2024-12-22,"January 25, 2024",Anticipated,2024-01-25,,Interventional,,,"Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENV<U+0394>30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan-DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181-002)","A Phase 2, Randomized, Double-Blind, Multicenter, Safety and Immunogenicity Clinical Bridging Study to Compare V181 (Dengue Quadrivalent Vaccine rDENV<U+0394>30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan-DV) in Healthy Adults 18 to 50 Years of Age in Brazil",Recruiting,,Phase 2,1240.0,Anticipated,Butantan Institute,,2.0,,,False,,,,True,True,False,,,True,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2023-06-14 13:36:29,2023-06-14 13:36:29,OTHER_GOV,,,,,
368108,368109,NCT01326546,,2011-03-28,2019-03-31,,2019-03-31,2011-03-30,2011-03-31,Estimate,2019-03-31,2019-06-26,Actual,,,,2019-03-31,2019-06-26,Actual,June 2010,Actual,2010-06-30,March 2019,2019-03-31,January 2014,Actual,2014-01-31,January 2014,Actual,2014-01-31,,Interventional,,Population analysis based on intention to treat,Therapeutic Hepatitis B Vaccine (Mimogen-based) Joint Entecavir in Treating Chronic Hepatitis B Patients,"A Randomized, Double-blind, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine (Mimogen-based) Joint Entecavir in Treating HBeAg Positive Chronic Hepatitis B Patients",Completed,,Phase 2,378.0,Actual,Chongqing Jiachen Biotechnology Ltd.,,2.0,,,False,,,,True,,,,,,,,,,,Undecided,,2023-06-15 18:27:07,2023-06-15 18:27:07,INDUSTRY,,,,,
368129,368130,NCT05604521,,2022-10-28,,,2023-06-06,2022-10-28,2022-11-03,Actual,,,,,,,2023-06-06,2023-06-08,Actual,"December 6, 2022",Actual,2022-12-06,June 2023,2023-06-30,"October 25, 2023",Anticipated,2023-10-25,"October 25, 2023",Anticipated,2023-10-25,,Interventional,,,"A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI","A Randomized, Double-blind, Placebo-controlled, Clinical Trial of a 3-dose, 28-day Regimen of PfSPZ Vaccine in Healthy, Adult Participants to Determine Safety, Tolerability and Efficacy Against Heterologous Plasmodium Falciparum Controlled Human Malaria Infection Conducted 3 or 12 Weeks After Immunization","Active, not recruiting",,Phase 1,60.0,Anticipated,Sanaria Inc.,,4.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-14 13:37:04,2023-06-14 13:37:04,INDUSTRY,,,,,
368161,368162,NCT00601770,,2008-01-04,,,2014-02-10,2008-01-15,2008-01-28,Estimate,,,,,,,2014-02-10,2014-02-11,Estimate,February 2006,,2006-02-28,February 2014,2014-02-28,July 2008,Actual,2008-07-31,July 2008,Actual,2008-07-31,,Interventional,,,Virological Response Study of the HCV Vaccine IC41,"Open-label, Multicenter Trial With IC41, a Therapeutic HCV Vaccine in Patients With Chronic HCV",Completed,,Phase 2,71.0,Actual,Valneva Austria GmbH,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 18:27:21,2023-06-15 18:27:21,INDUSTRY,,,,,
368432,368433,NCT05148962,,2021-12-03,,,2023-06-07,2021-12-03,2021-12-08,Actual,,,,,,,2023-06-07,2023-06-08,Actual,"September 16, 2021",Actual,2021-09-16,June 2023,2023-06-30,"May 26, 2023",Actual,2023-05-26,"May 26, 2023",Actual,2023-05-26,,Interventional,,,Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers,"A Phase 1 Trial to Evaluate the Safety, Immunogenicity, and Reactogenicity of a Self-Amplifying mRNA Prophylactic Vaccine Boost Against SARS-CoV-2 in Previously Vaccinated Healthy Adults 18 Years and Older",Completed,,Phase 1,40.0,Actual,"Gritstone bio, Inc.",,5.0,,,False,,,,False,False,False,,,False,,,,,,Undecided,,2023-06-14 13:39:08,2023-06-14 13:39:08,INDUSTRY,,,,,
368543,368544,NCT04813796,,2021-03-22,,,2023-06-07,2021-03-22,2021-03-24,Actual,,,,,,,2023-06-07,2023-06-08,Actual,"March 11, 2021",Actual,2021-03-11,June 2023,2023-06-30,"July 19, 2023",Anticipated,2023-07-19,"July 19, 2023",Anticipated,2023-07-19,,Interventional,,,"A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19","A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years","Active, not recruiting",,Phase 1,104.0,Actual,"ModernaTX, Inc.",,5.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-14 13:40:31,2023-06-14 13:40:31,INDUSTRY,,,,,
368653,368654,NCT02892812,,2016-09-02,,,2017-06-23,2016-09-02,2016-09-08,Estimate,,,,,,,2017-06-23,2017-06-26,Actual,September 2016,,2016-09-30,June 2017,2017-06-30,November 2016,Actual,2016-11-30,November 2016,Actual,2016-11-30,,Interventional,,,A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults,"A Single-blind, Single-center, Randomized, Active-controlled, Parallel Group, Phase I Study to Evaluate the Safety and Immunogenicity of Intramuscular Single Injection With LBVE013 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), LBVE014 (Pneumococcal 14-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) or Prevnar13 in Healthy Adults",Completed,,Phase 1,63.0,Actual,LG Life Sciences,,3.0,,,False,,,,False,,,,,,,,,,,Undecided,,2023-06-15 18:29:27,2023-06-15 18:29:27,INDUSTRY,,,,,
368900,368901,NCT02366728,,2014-10-28,2021-10-20,,2023-06-06,2015-02-12,2015-02-19,Estimate,2022-01-03,2022-02-01,Actual,,,,2023-06-06,2023-06-08,Actual,"October 12, 2015",Actual,2015-10-12,June 2023,2023-06-30,"October 31, 2020",Actual,2020-10-31,"October 31, 2020",Actual,2020-10-31,,Interventional,ELEVATE,Participants who received at least one ppp65 vaccine.,DC Migration Study for Newly-Diagnosed GBM,Evaluation of Overcoming Limited Migration and Enhancing Cytomegalovirus-specific Dendritic Cell Vaccines With Adjuvant TEtanus Pre-conditioning in Patients With Newly-diagnosed Glioblastoma,Completed,,Phase 2,64.0,Actual,Duke University,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 13:44:29,2023-06-14 13:44:29,OTHER,,,,,
368958,368959,NCT00003665,,1999-11-01,,,2013-02-27,2004-02-06,2004-02-09,Estimate,,,,,,,2013-02-27,2013-02-28,Estimate,April 1999,,1999-04-30,February 2013,2013-02-28,November 2002,Actual,2002-11-30,October 2002,Actual,2002-10-31,,Interventional,,,Vaccine Therapy in Treating Patients With Stage IV Melanoma,Phase I Trial of a Dendritic Cell Vaccine for Melanoma,Completed,,Phase 1,40.0,Actual,National Cancer Institute (NCI),,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 13:45:08,2023-06-14 13:45:08,NIH,,,,,
369319,369320,NCT02878291,,2016-08-22,,,2016-08-25,2016-08-22,2016-08-25,Estimate,,,,,,,2016-08-25,2016-08-26,Estimate,June 2016,,2016-06-30,August 2016,2016-08-31,December 2016,Anticipated,2016-12-31,November 2016,Anticipated,2016-11-30,,Interventional,,,Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months,"A Single-center, Open, Phase I Clinical Trial to Evaluate Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months",Unknown status,Recruiting,Phase 1,200.0,Anticipated,"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd",,2.0,,,False,,,,False,,,,,,,,,,,No,,2023-06-15 18:31:27,2023-06-15 18:31:27,INDUSTRY,,,,,
369408,369409,NCT01867086,,2013-05-29,2018-02-15,,2018-05-21,2013-05-29,2013-06-03,Estimate,2018-03-29,2018-05-01,Actual,,,,2018-05-21,2018-06-19,Actual,June 2013,,2013-06-30,May 2018,2018-05-31,"April 8, 2016",Actual,2016-04-08,April 2016,Actual,2016-04-30,,Interventional,,,Salvage Ovarian FANG Vaccine + Carboplatinum,Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG) Integrated With Chemotherapy for Patients With Recurrent Cisplatinum Sensitive Ovarian Cancer Participating in Study CL-PTL 105,Completed,,Phase 2,1.0,Actual,"Gradalis, Inc.",,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 13:50:55,2023-06-14 13:50:55,INDUSTRY,,,,,
369439,369440,NCT01846104,,2013-04-30,2015-12-10,,2019-12-17,2013-04-30,2013-05-03,Estimate,2016-09-29,2016-11-21,Estimate,,,,2019-12-17,2019-12-27,Actual,"April 30, 2013",Actual,2013-04-30,December 2019,2019-12-31,"June 30, 2013",Actual,2013-06-30,"June 30, 2013",Actual,2013-06-30,,Interventional,RVEc,,Booster Dose (50 µg) of Recombinant Ricin Toxin Vaccine (RVEc) in Previously Vaccinated Healthy Adults,Safety and Immunogenicity of a Booster Dose (50 µg) of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc) in Previously Vaccinated Healthy Adults,Completed,,Phase 1,4.0,Actual,U.S. Army Medical Research and Development Command,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 13:51:16,2023-06-14 13:51:16,FED,,,,,
369565,369566,NCT01324440,,2011-02-24,2011-09-09,,2015-03-23,2011-03-28,2011-03-29,Estimate,2011-09-09,2011-10-17,Estimate,,,,2015-03-23,2015-04-10,Estimate,September 2006,,2006-09-30,March 2015,2015-03-31,October 2007,Actual,2007-10-31,October 2007,Actual,2007-10-31,,Interventional,,,"Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)","A Randomized, Multicenter, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With Merck Aluminum Adjuvant or Without Merck Aluminum Adjuvant in Healthy Adults 18 to 70 Years of Age",Completed,,Phase 1,64.0,Actual,Merck Sharp & Dohme LLC,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 18:32:18,2023-06-15 18:32:18,INDUSTRY,,,,,
369611,369612,NCT00518336,,2007-08-17,2010-07-12,,2016-10-27,2007-08-17,2007-08-20,Estimate,2011-09-15,2011-10-25,Estimate,,,,2016-10-27,2016-12-09,Estimate,November 2007,,2007-11-30,October 2016,2016-10-31,September 2010,Actual,2010-09-30,July 2008,Actual,2008-07-31,,Interventional,,,Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil,Follow-up Study to Evaluate the Long-term Efficacy of a HPV Vaccine (580299) in Healthy Young Adult Women in Brazil,Completed,,Phase 2,433.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 18:39:45,2023-06-16 18:39:45,INDUSTRY,,,,,
369741,369742,NCT00623259,,2008-02-19,,,2010-05-19,2008-02-19,2008-02-26,Estimate,,,,,,,2010-05-19,2010-05-20,Estimate,May 2008,,2008-05-31,May 2010,2010-05-31,April 2009,Actual,2009-04-30,February 2009,Actual,2009-02-28,,Interventional,,,Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects,Phase I Vaccination Study Testing the Safety and Reactogenicity of a Recombinant MVA HIV Multiantigen Vaccine (MVA-mBN120B) in HIV-infected Subjects With CD4 Count > 350/µL,Completed,,Phase 1,15.0,Anticipated,Bavarian Nordic,,1.0,,,,,,,True,,,,,,,,,,,,,2023-06-15 18:33:03,2023-06-15 18:33:03,INDUSTRY,,,,,
369824,369825,NCT01730118,,2012-11-17,2022-08-12,,2022-08-12,2012-11-17,2012-11-21,Estimate,2022-08-12,2022-09-10,Actual,,,,2022-08-12,2022-09-10,Actual,"March 4, 2013",Actual,2013-03-04,August 2022,2022-08-31,"December 3, 2019",Actual,2019-12-03,"December 3, 2019",Actual,2019-12-03,,Interventional,,,Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing,A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/Neu ECTM in Adults With Tumors With 1-3+ HER2/Neu Expression,Completed,,Phase 1,33.0,Actual,National Institutes of Health Clinical Center (CC),,5.0,,,False,,,,False,True,False,,,,,,Clinical data available during the study and indefinitely.,Clinical data will be made available via subscription to Biomedical Translational Research Information System (BTRIS) and with the permission of the study principal investigator (PI).,,Yes,All individual participant data (IPD) recorded in the medical record will be shared with intramural investigators upon request. All collected IPD will be shared with collaborators under the terms of collaborative agreements.,2023-06-14 13:56:15,2023-06-14 13:56:15,NIH,,,,,
369836,369837,NCT01728792,,2012-10-16,2016-08-30,,2019-07-16,2012-11-19,2012-11-20,Estimate,2016-11-04,2017-01-04,Estimate,,,,2019-07-16,2019-07-18,Actual,"January 22, 2013",Actual,2013-01-22,July 2019,2019-07-31,"November 21, 2013",Actual,2013-11-21,"November 1, 2013",Actual,2013-11-01,,Interventional,,Safety Analysis Set included all enrolled participants who received at least 1 dose of study vaccine and for whom any post-vaccination safety data has been obtained.,Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity,Impact of Subcutaneous Versus Intramuscular Administration of Inviragen's Live Attenuated Dengue Vaccine on Safety and Immunogenicity,Completed,,Phase 1,80.0,Actual,Takeda,,5.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 13:56:35,2023-06-14 13:56:35,INDUSTRY,,,,,
369883,369884,NCT01723254,,2012-11-05,2016-05-31,,2016-05-31,2012-11-05,2012-11-07,Estimate,2016-05-31,2016-07-11,Estimate,,,,2016-05-31,2016-07-11,Estimate,December 2012,,2012-12-31,May 2016,2016-05-31,June 2015,Actual,2015-06-30,June 2015,Actual,2015-06-30,,Interventional,,,A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis,"A Phase 1, Randomized, Double Blinded, Placebo Controlled Study To Evaluate The Safety, Tolerability, Immunogenicity, And Exploratory Pharmacodynamic Response Of Ascending Dose Levels Of An Anti-ige Vaccine With Two Different Adjuvant Formulations (Pf-06444753 And Pf-06444752) In Generally Healthy Subjects With Allergic Rhinitis",Completed,,Phase 1,190.0,Actual,Pfizer,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 13:57:32,2023-06-14 13:57:32,INDUSTRY,,,,,
370057,370058,NCT03028116,,2017-01-04,,,2017-01-20,2017-01-20,2017-01-23,Estimate,,,,,,,2017-01-20,2017-01-23,Estimate,May 2016,,2016-05-31,December 2016,2016-12-31,July 2016,Actual,2016-07-31,June 2016,Actual,2016-06-30,,Interventional,VSI,,"Reactogenicity, Safety and Immunogenicity Study of a Allantoic Split Inactivated Seasonal Influenza Vaccine","A Randomized, Blinded, Placebo-controlled Study of Phase I Allantoic Split Inactivated Seasonal Influenza Vaccine in Healthy Adults",Completed,,Phase 1,44.0,Actual,Research Institute for Biological Safety Problems,,2.0,,,False,,,,True,False,False,,,,,,,,,Undecided,,2023-06-14 14:01:23,2023-06-14 14:01:23,OTHER_GOV,,,,,
370059,370060,NCT01090453,,2010-03-18,2014-06-19,2011-11-17,2018-06-28,2010-03-18,2010-03-22,Estimate,2014-07-24,2014-08-15,Estimate,2011-11-17,2011-11-21,Estimate,2018-06-28,2018-08-20,Actual,"May 17, 2010",,2010-05-17,August 2016,2016-08-31,"October 11, 2011",Actual,2011-10-11,"October 11, 2011",Actual,2011-10-11,,Interventional,,,Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants,"Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 4 and 12 Months of Age",Completed,,Phase 2,480.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 18:34:21,2023-06-15 18:34:21,INDUSTRY,,,,,
370085,370086,NCT00430521,,2007-02-01,2017-09-21,2009-05-20,2019-10-04,2007-02-01,2007-02-02,Estimate,2019-10-04,2019-10-28,Actual,2009-09-28,2009-09-30,Estimate,2019-10-04,2019-10-28,Actual,"February 5, 2007",Actual,2007-02-05,October 2019,2019-10-31,"October 20, 2008",Actual,2008-10-20,"October 20, 2008",Actual,2008-10-20,,Interventional,,,Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A),Reactogenicity and Immunogenicity Study of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1119711A) Administered According to Different Vaccination Schedules,Completed,,Phase 2,512.0,Actual,GlaxoSmithKline,,8.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 18:40:23,2023-06-16 18:40:23,INDUSTRY,,,,,
370297,370298,NCT01509846,,2012-01-05,2018-07-31,,2021-08-10,2012-01-10,2012-01-13,Estimate,2021-08-10,2021-08-11,Actual,,,,2021-08-10,2021-08-11,Actual,March 2011,,2011-03-31,July 2021,2021-07-31,December 2012,Actual,2012-12-31,December 2012,Actual,2012-12-31,,Interventional,,One subject in Cohort 3 was randomized in error and did not receive the study product.,Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults,"A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Oral Inactivated Whole Cell Shigella Flexneri 2a Vaccine in Healthy Adult Subjects",Completed,,Phase 1,82.0,Actual,PATH,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 14:04:54,2023-06-14 14:04:54,OTHER,,,,,
370384,370385,NCT01453998,,2011-10-06,2014-05-01,2012-11-16,2020-07-03,2011-10-14,2011-10-18,Estimate,2014-07-24,2014-07-28,Estimate,2012-11-16,2012-11-21,Estimate,2020-07-03,2020-07-17,Actual,"October 14, 2011",Actual,2011-10-14,July 2020,2020-07-31,"November 12, 2012",Actual,2012-11-12,"November 12, 2012",Actual,2012-11-12,,Interventional,,,Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744),Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744),Completed,,Phase 2,657.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=20051,Yes,IPD is available via the Clinical Study Data Request site (click on the link provided below),2023-06-14 14:06:29,2023-06-14 14:06:29,INDUSTRY,,,,,
370502,370503,NCT01436370,,2011-09-15,2014-04-17,,2014-12-04,2011-09-15,2011-09-19,Estimate,2014-04-17,2014-05-16,Estimate,,,,2014-12-04,2014-12-24,Estimate,October 2011,,2011-10-31,February 2013,2013-02-28,June 2013,Actual,2013-06-30,February 2013,Actual,2013-02-28,,Interventional,,The baseline analysis population includes all participants who were enrolled and vaccinated.,TIV and High Dose TIV in Subjects With Rheumatoid Arthritis,A Phase II Study in Adults With Rheumatoid Arthritis Receiving TNF-alpha-inhibitor Therapy to Assess the Immunogenicity and Safety of Trivalent Inactivated Vaccine (TIV) and High Dose Trivalent Inactivated Vaccine (High-Dose TIV) Administered at Two Dosage Levels,Completed,,Phase 2,102.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 14:08:46,2023-06-14 14:08:46,NIH,,,,,
370553,370554,NCT04871737,,2021-04-21,,,2022-12-08,2021-04-30,2021-05-04,Actual,,,,,,,2022-12-08,2022-12-09,Actual,"May 20, 2021",Actual,2021-05-20,December 2022,2022-12-31,"September 30, 2022",Actual,2022-09-30,"August 21, 2022",Actual,2022-08-21,,Interventional,,,Study of a Live rNDV Based Vaccine Against COVID-19,"Dose-escalation, Open-label, Non-randomized Phase I Study to Evaluate the Safety and Immunogenicity of Three Concentrations of a rNDV Vaccine Against SARS-CoV-2 Administered by the Intranasal and Intramuscular Route to Healthy Volunteers",Completed,,Phase 1,91.0,Actual,"Laboratorio Avi-Mex, S.A. de C.V.",,9.0,,,False,,,,,False,False,,,,,,,,,No,,2023-06-15 18:36:02,2023-06-15 18:36:02,INDUSTRY,,,,,
371142,371143,NCT02879266,,2016-08-22,,,2018-03-30,2016-08-22,2016-08-25,Estimate,,,,,,,2018-03-30,2018-04-02,Actual,"February 1, 2016",Actual,2016-02-01,March 2018,2018-03-31,,,,"September 7, 2017",Actual,2017-09-07,,Interventional,,,Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age,Phase I Evaluation of the Safety and Immunogenicity of an Investigational Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naïve Adults 50 - 70 Years of Age,Completed,,Phase 1,28.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 18:38:01,2023-06-15 18:38:01,NIH,,,,,
371163,371164,NCT04024800,,2019-06-25,,,2021-05-28,2019-07-17,2019-07-18,Actual,,,,,,,2021-05-28,2021-06-02,Actual,"May 3, 2019",Actual,2019-05-03,May 2021,2021-05-31,"June 30, 2024",Anticipated,2024-06-30,"June 30, 2023",Anticipated,2023-06-30,,Interventional,NSABP FB-14,,Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer,A Phase II Clinical Trial of Pembrolizumab in Combination With the AE37 Peptide Vaccine in Patients With Metastatic Triple-Negative Breast Cancer,"Active, not recruiting",,Phase 2,29.0,Anticipated,NuGenerex Immuno-Oncology,,1.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-14 14:17:14,2023-06-14 14:17:14,INDUSTRY,,,,,
371571,371572,NCT00358332,,2006-07-27,2008-12-09,,2011-10-18,2006-07-27,2006-07-31,Estimate,2009-02-04,2009-03-04,Estimate,,,,2011-10-18,2011-10-24,Estimate,November 2006,,2006-11-30,October 2011,2011-10-31,December 2007,Actual,2007-12-31,December 2007,Actual,2007-12-31,,Interventional,,,Phase I Pediatric FMP2.1/AS02A Trial in Mali,"Randomized, Controlled, Dose Escalation Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of WRAIR's AMA-1 Malaria Vaccine (FMP2.1) Adjuvanted in GSKBio's AS02A Vs. Rabies Vaccine in 1-6 Year Old Children in Bandiagara, Mali",Completed,,Phase 1,100.0,Actual,U.S. Army Medical Research and Development Command,,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 15:01:54,2023-06-14 15:01:54,FED,,,,,
371794,371795,NCT01675284,,2012-08-22,,,2013-10-23,2012-08-26,2012-08-29,Estimate,,,,,,,2013-10-23,2013-10-25,Estimate,August 2012,,2012-08-31,October 2013,2013-10-31,May 2013,Actual,2013-05-31,March 2013,Actual,2013-03-31,,Interventional,,,"A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine","A Phase I, Prospective, Randomized, Open Label, Observer-Blind, Single Center Study to Evaluate the Safety, Reactogenicity and Immunogenicity of an Inactivated H5N1 Influenza Vaccine Produced in Madin-Darby Canine Kidney (MDCK) Cells",Completed,,Phase 1,36.0,Actual,Medigen Biotechnology Corporation,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 14:24:12,2023-06-14 14:24:12,INDUSTRY,,,,,
371818,371819,NCT04747002,,2021-02-05,,,2021-02-28,2021-02-05,2021-02-10,Actual,,,,,,,2021-02-28,2021-03-03,Actual,"June 12, 2020",Actual,2020-06-12,February 2021,2021-02-28,April 2024,Anticipated,2024-04-30,March 2024,Anticipated,2024-03-31,,Interventional,,,"Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine ""Dainippon Sumitomo Phama(DSP)-7888"" for Acute Myeloid Leukemia Patients.","Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine ""DSP-7888"" for Acute Myeloid Leukemia Patients.",Recruiting,,Phase 2,100.0,Anticipated,Osaka University,,2.0,,,False,,,,,False,False,,,,,,,,,No,,2023-06-14 14:24:28,2023-06-14 14:24:28,OTHER,,,,,
371896,371897,NCT03844386,,2019-02-14,2022-07-12,,2022-07-12,2019-02-14,2019-02-18,Actual,2022-07-12,2022-08-09,Actual,,,,2022-07-12,2022-08-09,Actual,"April 22, 2019",Actual,2019-04-22,July 2022,2022-07-31,"April 4, 2022",Actual,2022-04-04,"November 11, 2021",Actual,2021-11-11,,Interventional,M&M,,Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Combination in HIV-infected Adults,A Phase I Pilot Study to Evaluate the Safety and Immunogenicity of the HIV-1 Vaccines MVA.tHIVconsv3 (M3) and MVA.tHIVconsv4 (M4) Given Alone or In Combination in HIV-1-Infected Adults Suppressed on Antiretroviral Therapy - The M&M Study,Completed,,Phase 1,26.0,Actual,"University of North Carolina, Chapel Hill",,4.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-14 14:25:31,2023-06-14 14:25:31,OTHER,,,,,
371973,371974,NCT03589794,,2018-07-05,,,2022-09-15,2018-07-05,2018-07-18,Actual,,,,,,,2022-09-15,2022-09-16,Actual,"December 21, 2018",Actual,2018-12-21,"April 19, 2021",2021-04-19,"July 5, 2022",Actual,2022-07-05,"July 5, 2022",Actual,2022-07-05,,Interventional,,,rCSP/AP10-602 [GLA-LSQ] Vaccine Trial,"A Phase I Challenge Study to Evaluate Safety, Immunogenicity, and Efficacy of a Malaria Vaccine (rCSP Adjuvanted With AP 10-602 [GLA-LSQ]), in Healthy Adults",Completed,,Phase 1,65.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,7.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-14 14:26:35,2023-06-14 14:26:35,NIH,,,,,
372776,372777,NCT01176474,,2010-08-05,,,2023-02-23,2010-08-05,2010-08-06,Estimate,,,,,,,2023-02-23,2023-02-24,Actual,"August 13, 2010",Actual,2010-08-13,February 2023,2023-02-28,December 2023,Anticipated,2023-12-31,August 2020,Actual,2020-08-31,,Interventional,,,Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma,A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma,"Active, not recruiting",,Phase 1,73.0,Actual,H. Lee Moffitt Cancer Center and Research Institute,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 14:35:35,2023-06-14 14:35:35,OTHER,,,,,
373004,373005,NCT01922856,,2013-08-12,,,2017-07-05,2013-08-12,2013-08-14,Estimate,,,,,,,2017-07-05,2017-07-06,Actual,"September 19, 2013",Actual,2013-09-19,July 2017,2017-07-31,"July 14, 2016",Actual,2016-07-14,"February 6, 2016",Actual,2016-02-06,,Interventional,,,Challenge Study of an ETEC Vaccine,A Phase 2b Controlled Efficacy Study of Intradermally Delivered ETEC Fimbrial Tip Adhesin Vaccine Against Experimental Challenge With ETEC H10407 in Healthy Adult Volunteers,Completed,,Phase 2,56.0,Actual,U.S. Army Medical Research and Development Command,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 14:38:11,2023-06-14 14:38:11,FED,,,,,
373208,373209,NCT04553016,,2020-09-10,,,2022-06-21,2020-09-10,2020-09-17,Actual,,,,,,,2022-06-21,2022-06-22,Actual,"August 16, 2021",Actual,2021-08-16,June 2022,2022-06-30,November 2022,Anticipated,2022-11-30,November 2022,Anticipated,2022-11-30,,Interventional,HIV-CORE 006,,A Study to Test Three Experimental HIV Vaccines in Healthy Adults.,"A Phase 1 Trial of ChAdOx1- and MVA-vectored Conserved Mosaic HIV-1 Vaccines in Healthy, Adult HIV-1-negative Volunteers in Eastern and Southern Africa.","Active, not recruiting",,Phase 1,88.0,Actual,University of Oxford,,2.0,,,False,,,,True,False,False,,,,,,Within 12 months of the study completion date we will provide the additional document types as described above.,Aim is to provide a summary of the results or a link to summary results within the trial registration record.,,Yes,"Study information will be made available through an open repository. The information to be made available will be anonymized so that there is no link to participants and will include data on safety, immune responses and any other data generated from samples obtained in this study.",2023-06-14 14:40:34,2023-06-14 14:40:34,OTHER,,,,,
373241,373242,NCT01106092,,2010-04-01,2017-03-01,2010-12-10,2019-09-17,2010-04-14,2010-04-19,Estimate,2017-03-01,2017-04-12,Actual,2010-12-10,2010-12-16,Estimate,2019-09-17,2019-10-01,Actual,"May 13, 2010",Actual,2010-05-13,September 2019,2019-09-30,"September 2, 2010",Actual,2010-09-02,"September 2, 2010",Actual,2010-09-02,,Interventional,,,Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers,Immunogenicity and Reactogenicity of a Booster Dose of GlaxoSmithKline Biologicals' GSK2036874A Vaccine in Healthy Toddlers,Completed,,Phase 2,312.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 18:43:24,2023-06-15 18:43:24,INDUSTRY,,,,,
373658,373659,NCT02851056,,2016-07-28,,,2022-11-10,2016-07-28,2016-08-01,Estimate,,,,,,,2022-11-10,2022-11-14,Actual,"September 27, 2016",Actual,2016-09-27,November 2022,2022-11-30,"August 9, 2018",Actual,2018-08-09,"July 16, 2018",Actual,2018-07-16,,Interventional,,,Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT),Evaluating the Safety and Biological Activity of a Dendritic Cell Survivin Vaccine in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplantation,Completed,,Early Phase 1,14.0,Actual,H. Lee Moffitt Cancer Center and Research Institute,,1.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-14 14:45:24,2023-06-14 14:45:24,OTHER,,,,,
373733,373734,NCT04844268,,2021-04-08,,,2022-03-23,2021-04-13,2021-04-14,Actual,,,,,,,2022-03-23,2022-04-04,Actual,"January 13, 2022",Actual,2022-01-13,March 2022,2022-03-31,October 2022,Anticipated,2022-10-31,September 2022,Anticipated,2022-09-30,,Interventional,,,"Study to Assess Safety, Reactogenicity and Immunogenicity of the VACCINE RNA MCTI CIMATEC HDT (HDT-301) Vaccine Against COVID-19","Phase 1, Randomized, Double-Blind, Dose-Escalation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Nanoparticle Carrier-Formulated Self-Replicating Replicon RNA (repRNA) Vaccine in Healthy Adults",Recruiting,,Phase 1,90.0,Anticipated,SENAI CIMATEC,,4.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-14 14:46:18,2023-06-14 14:46:18,OTHER,,,,,
374347,374348,NCT05171946,,2021-12-07,,,2022-10-16,2021-12-22,2021-12-29,Actual,,,,,,,2022-10-16,2022-10-19,Actual,"November 20, 2022",Anticipated,2022-11-20,October 2022,2022-10-31,"July 1, 2023",Anticipated,2023-07-01,"March 1, 2023",Anticipated,2023-03-01,,Interventional,,,Phase-I Study to Evaluate the Safety and Immunogenicity of a Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults,"Phase-I, Single Center, Randomized, Dosage Finding Study, to Evaluate the Safety, Tolerability, and Immunogenicity of a Prophylactic COVID-19 pDNA Vaccine After Multiple Ascending Doses in Healthy Adults",Not yet recruiting,,Phase 1,30.0,Anticipated,Imam Abdulrahman Bin Faisal University,,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-14 14:53:46,2023-06-14 14:53:46,OTHER,,,,,
374410,374411,NCT00905125,,2009-05-18,2011-02-17,,2012-06-07,2009-05-18,2009-05-20,Estimate,2011-03-03,2011-04-06,Estimate,,,,2012-06-07,2012-06-13,Estimate,June 2009,,2009-06-30,March 2010,2010-03-31,March 2010,Actual,2010-03-31,March 2010,Actual,2010-03-31,,Interventional,,,Influenza Vaccine in Pregnant Women,"A Randomized, Double-Blind Trial on the Safety and Immunogenicity of Inactivated Trivalent Influenza Vaccine in Pregnant Women",Completed,,Phase 2,102.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 01:55:51,2023-06-14 01:55:51,NIH,,,,,
374458,374459,NCT01027351,,2009-12-04,2013-12-18,,2018-09-10,2009-12-04,2009-12-07,Estimate,2014-04-04,2014-05-06,Estimate,,,,2018-09-10,2018-10-09,Actual,January 2010,,2010-01-31,September 2018,2018-09-30,May 2012,Actual,2012-05-31,September 2010,Actual,2010-09-30,,Interventional,,The analysis was done on the all enrolled set.,"Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine","A Phase 2, Open-Label, Single-Center, Extension Study Evaluating Antibody Persistence Compared to Naïve Children and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Novartis Vaccine as Infants in Study V72P6",Completed,,Phase 2,163.0,Actual,Novartis,,6.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 18:46:00,2023-06-15 18:46:00,INDUSTRY,,,,,
374675,374676,NCT00524940,,2007-09-04,2009-02-24,,2016-04-12,2007-09-04,2007-09-05,Estimate,2009-02-24,2009-03-30,Estimate,,,,2016-04-12,2016-04-14,Estimate,August 2007,,2007-08-31,April 2016,2016-04-30,December 2007,Actual,2007-12-31,September 2007,Actual,2007-09-30,,Interventional,,,Trial to Describe the Safety and Immunogenicity of Fluzone®,"Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation (Intramuscular Route)",Completed,,Phase 2,124.0,Actual,Sanofi,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 15:07:31,2023-06-14 15:07:31,INDUSTRY,,,,,
374839,374840,NCT05394012,,2022-05-25,,,2022-11-15,2022-05-25,2022-05-27,Actual,,,,,,,2022-11-15,2022-11-18,Actual,December 2022,Anticipated,2022-12-31,November 2022,2022-11-30,June 2023,Anticipated,2023-06-30,February 2023,Anticipated,2023-02-28,,Interventional,,,A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19,"Randomized, Blinded, Positive Control Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine (RQ3013) in Healthy Adults Aged 18-59 Years",Not yet recruiting,,Phase 1,120.0,Anticipated,"Walvax Biotechnology Co., Ltd.",,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-14 15:09:07,2023-06-14 15:09:07,INDUSTRY,,,,,
375019,375020,NCT00488826,,2007-06-18,2009-03-31,,2010-01-15,2007-06-18,2007-06-20,Estimate,2009-03-31,2009-05-27,Estimate,,,,2010-01-15,2010-01-20,Estimate,October 2005,,2005-10-31,January 2010,2010-01-31,May 2007,Actual,2007-05-31,,,,,Interventional,,,Study Evaluating 7-Valent Pneumococcal Conjugate Vaccine in Healthy Infants,An Open-Label Controlled Phase I/III Study to Evaluate the Safety and Immunogenicity of Pneumococcal 7-Valent Conjugate Vaccine [DIPHTHERIA CRM197 PROTEIN] (PrevenarTM) in Healthy Infants,Completed,,Phase 1,800.0,Actual,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,False,,,,,,,,,,,,,,,,,2023-06-16 18:57:55,2023-06-16 18:57:55,INDUSTRY,,,,,
375054,375055,NCT04405908,,2020-05-25,,,2022-02-17,2020-05-25,2020-05-28,Actual,,,,,,,2022-02-17,2022-02-18,Actual,"June 19, 2020",Actual,2020-06-19,February 2022,2022-02-28,"December 8, 2021",Actual,2021-12-08,"October 20, 2021",Actual,2021-10-20,,Interventional,,,SCB-2019 as COVID-19 Vaccine,"A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers.",Completed,,Phase 1,166.0,Actual,Clover Biopharmaceuticals AUS Pty Ltd,,27.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-14 15:11:13,2023-06-14 15:11:13,INDUSTRY,,,,,
375071,375072,NCT01011049,,2009-11-09,2011-07-14,2010-03-31,2016-04-12,2009-11-10,2009-11-11,Estimate,2011-07-14,2011-08-11,Estimate,2010-03-31,2010-04-02,Estimate,2016-04-12,2016-04-14,Estimate,September 2009,,2009-09-30,April 2016,2016-04-30,October 2010,Actual,2010-10-31,May 2010,Actual,2010-05-31,,Interventional,,,Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM,Safety and Immunogenicity of Revaccination With Influenza Vaccine in Healthy Adult Subjects Aged 18 to 64 Years Who Were Previously Vaccinated With Fluzone ID or Fluzone IM,Completed,,Phase 2,1250.0,Actual,Sanofi,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 18:51:22,2023-06-15 18:51:22,INDUSTRY,,,,,
375113,375114,NCT00574704,,2007-12-14,2013-02-14,,2013-06-04,2007-12-14,2007-12-17,Estimate,2013-06-04,2013-07-11,Estimate,,,,2013-06-04,2013-07-11,Estimate,September 2006,,2006-09-30,February 2013,2013-02-28,March 2008,Actual,2008-03-31,March 2008,Actual,2008-03-31,,Interventional,,,A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis,Double Blind Placebo Controlled Study to Assess Efficacy and Safety of a Combined Allergen Vaccine (CYT005-AllQbG10) and Its Single Components in Patients With House Dust Mite Allergy,Completed,,Phase 2,40.0,Actual,Cytos Biotechnology AG,,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 15:11:47,2023-06-14 15:11:47,INDUSTRY,,,,,
375181,375182,NCT05765773,,2023-02-13,,,2023-03-09,2023-03-09,2023-03-13,Actual,,,,,,,2023-03-09,2023-03-13,Actual,"July 1, 2021",Actual,2021-07-01,February 2023,2023-02-28,"March 1, 2023",Anticipated,2023-03-01,"October 1, 2022",Actual,2022-10-01,,Interventional,,,An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older,An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac) for Adults Aged 60 Years and Older,"Active, not recruiting",,Phase 2,200.0,Actual,Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products,,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-14 15:12:36,2023-06-14 15:12:36,OTHER_GOV,,,,,
375338,375339,NCT05604690,,2022-09-15,,,2023-03-09,2022-11-01,2022-11-03,Actual,,,,,,,2023-03-09,2023-03-13,Actual,"November 3, 2022",Actual,2022-11-03,March 2023,2023-03-31,"July 27, 2023",Anticipated,2023-07-27,"June 16, 2023",Anticipated,2023-06-16,,Interventional,ITV2002,,Safety and Efficacy of Intranasal Administration of Avacc 10 Vaccine Against COVID-19 in Healthy Volunteers,"A Randomized, Double-Blind, Placebo- and OMV-Controlled Phase I Study to Evaluate the Safety, Tolerance, and Immunogenicity of the Avacc 10 Vaccine Administered Intranasally to Healthy Adult Volunteers",Recruiting,,Phase 1,36.0,Anticipated,Intravacc B.V.,,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-14 15:14:00,2023-06-14 15:14:00,INDUSTRY,,,,,
375426,375427,NCT01819155,,2013-03-22,,,2013-10-18,2013-03-22,2013-03-27,Estimate,,,,,,,2013-10-18,2013-10-22,Estimate,April 2013,,2013-04-30,June 2013,2013-06-30,September 2013,Actual,2013-09-30,September 2013,Actual,2013-09-30,,Interventional,,,Immunogenicity and Safety Trial of Adjuvanted and Non-adjuvanted Trivalent Influenza Vaccine in Tropical Africa,Assessment of the Immunogenicity and Safety of an MF59- Adjuvanted Trivalent Influenza Vaccine and a Non-adjuvanted Trivalent Influenza Vaccine Among Children in Senegal,Completed,,Phase 2,296.0,Actual,PATH,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 23:27:17,2023-06-14 23:27:17,OTHER,,,,,
375990,375991,NCT00551031,,2007-10-29,2011-10-13,2010-03-31,2016-04-12,2007-10-29,2007-10-30,Estimate,2011-10-13,2011-11-24,Estimate,2010-03-31,2010-04-02,Estimate,2016-04-12,2016-05-16,Estimate,October 2007,,2007-10-31,April 2016,2016-04-30,November 2008,Actual,2008-11-30,June 2008,Actual,2008-06-30,,Interventional,,,"Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects","Immunogenicity and Safety of Two Dosages of the Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in the Elderly Compared With Standard Fluzone® in Adults and Elderly Subjects.",Completed,,Phase 2,2098.0,Actual,Sanofi,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 00:26:57,2023-06-14 00:26:57,INDUSTRY,,,,,
376169,376170,NCT00639925,,2008-03-07,,,2013-03-13,2008-03-19,2008-03-20,Estimate,,,,,,,2013-03-13,2013-03-14,Estimate,March 2007,,2007-03-31,March 2013,2013-03-31,March 2013,Anticipated,2013-03-31,March 2013,Anticipated,2013-03-31,,Interventional,,,Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer,"Phase I Sturdy on Antiangiogenic Vaccine Therapy Using Epitope Peptide Derived From VEGFR1 and VEGFR2 With Gemcitabine in Treating Patients With Unresectable, Recurrent, or Metastatic Pancreatic Cancer",Unknown status,"Active, not recruiting",Phase 1,5.0,Actual,Fukushima Medical University,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 20:48:11,2023-06-15 20:48:11,OTHER,,,,,
376595,376596,NCT03538314,,2018-04-22,,,2022-11-16,2018-05-15,2018-05-29,Actual,,,,,,,2022-11-16,2022-11-17,Actual,"July 9, 2018",Actual,2018-07-09,November 2022,2022-11-30,October 2025,Anticipated,2025-10-31,"October 1, 2022",Actual,2022-10-01,,Interventional,,,UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma,"A Phase I, Open-label, Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in First-line Malignant Melanoma Patients Planned for Treatment With Pembrolizumab","Active, not recruiting",,Phase 1,30.0,Actual,Ultimovacs ASA,,1.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-14 15:26:34,2023-06-14 15:26:34,INDUSTRY,,,,,
376775,376776,NCT03014310,,2017-01-05,,,2020-03-19,2017-01-05,2017-01-09,Estimate,,,,,,,2020-03-19,2020-03-20,Actual,"January 9, 2017",Actual,2017-01-09,September 2019,2019-09-30,"December 19, 2018",Actual,2018-12-19,"December 19, 2018",Actual,2018-12-19,,Interventional,,,H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology,"A Phase I Cohort-Randomized, Double-Blind, Controlled Trial in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of a Monovalent Inactivated Influenza A/H5N8 Virus Vaccine Administered Intramuscularly at Different Dosages Given With or Without AS03 or MF59 Adjuvants: Assessment of Immunological Responses and Lymphocyte Interplay",Completed,,Phase 1,388.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,6.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-14 15:28:38,2023-06-14 15:28:38,NIH,,,,,
376779,376780,NCT03014076,,2017-01-04,,,2017-01-06,2017-01-06,2017-01-09,Estimate,,,,,,,2017-01-06,2017-01-09,Estimate,January 2008,,2008-01-31,January 2017,2017-01-31,January 2017,Actual,2017-01-31,January 2016,Actual,2016-01-31,,Interventional,,,Immunotherapy Vaccine and Herceptin in Breast Cancer,Phase Ib Trial of Combination Immunotherapy With HER2/Neu Peptide GP2 + GM-CSF Vaccine and Trastuzumab in Breast Cancer Patients,Completed,,Phase 1,30.0,Actual,"Cancer Insight, LLC",,2.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-14 15:28:41,2023-06-14 15:28:41,INDUSTRY,,,,,
377057,377058,NCT02034500,,2014-01-02,,,2016-06-20,2014-01-10,2014-01-13,Estimate,,,,,,,2016-06-20,2016-06-21,Estimate,March 2014,,2014-03-31,June 2016,2016-06-30,April 2015,Actual,2015-04-30,April 2015,Actual,2015-04-30,,Interventional,,,"Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults","A Phase 1, Randomized, Placebo Controlled, Single Center, Dose Escalation Study to Evaluate the Safety and Immunogenicity of 3 Vaccinations With Shigella Sonnei Vaccine (1790GAHB) Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults.",Completed,,Phase 1,52.0,Actual,GSK Vaccines Institute For Global Health S.r.l.,,10.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 00:20:54,2023-06-18 00:20:54,INDUSTRY,,,,,
377424,377425,NCT00654030,,2008-04-02,2011-08-17,,2018-03-11,2008-04-04,2008-04-07,Estimate,2013-04-08,2013-05-20,Estimate,,,,2018-03-11,2018-04-09,Actual,October 2006,,2006-10-31,March 2018,2018-03-31,November 2009,Actual,2009-11-30,November 2009,Actual,2009-11-30,,Interventional,,,Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer,Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer (NSCLC),Completed,,Phase 2,12.0,Actual,University of Kentucky,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 15:36:19,2023-06-14 15:36:19,OTHER,,,,,
377499,377500,NCT00712530,,2008-07-04,2013-02-19,,2013-02-19,2008-07-08,2008-07-10,Estimate,2013-02-19,2013-03-26,Estimate,,,,2013-02-19,2013-03-26,Estimate,January 2005,,2005-01-31,February 2013,2013-02-28,June 2006,Actual,2006-06-30,June 2006,Actual,2006-06-30,,Interventional,GIHU004,,Single DermaVir Immunization in HIV-1 Infected Patients on HAART,"A Phase I Study to Evaluate the Tolerability and Safety of LC002, a DermaVir Vaccine, in HIV-1-infected Subjects Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART)",Completed,,Phase 1,9.0,Actual,Genetic Immunity,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 15:37:31,2023-06-14 15:37:31,INDUSTRY,,,,,
377627,377628,NCT00767364,,2008-10-06,2014-03-18,,2014-06-11,2008-10-06,2008-10-07,Estimate,2014-06-11,2014-06-13,Estimate,,,,2014-06-11,2014-06-13,Estimate,July 2009,,2009-07-31,June 2014,2014-06-30,November 2013,Actual,2013-11-30,October 2012,Actual,2012-10-31,,Interventional,,,Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel Syndrome,Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel Syndrome: A Pilot Study,Completed,,Phase 1,8.0,Actual,Children's Hospital of Michigan,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 15:39:44,2023-06-14 15:39:44,OTHER,,,,,
377646,377647,NCT00784524,,2008-11-01,2017-06-21,,2019-05-15,2008-11-01,2008-11-04,Estimate,2019-05-15,2019-06-06,Actual,,,,2019-05-15,2019-06-06,Actual,September 2008,,2008-09-30,May 2019,2019-05-31,July 2014,Actual,2014-07-31,July 2014,Actual,2014-07-31,,Interventional,,,Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca,A Phase II Study of Allogeneic Large Multivalent Immunogen (LMI) Vaccine and IL-2 for the Treatment of Stable Metastatic Breast Cancer,Terminated,,Phase 2,14.0,Actual,"Masonic Cancer Center, University of Minnesota",,1.0,,Slow accrual,False,,,,True,,,,,,,,,,,,,2023-06-14 15:40:01,2023-06-14 15:40:01,OTHER,,,,,
377819,377820,NCT02873260,,2016-08-16,,,2018-03-07,2016-08-16,2016-08-19,Estimate,,,,,,,2018-03-07,2018-03-08,Actual,August 2016,Actual,2016-08-31,March 2018,2018-03-31,November 2017,Actual,2017-11-30,November 2017,Actual,2017-11-30,,Interventional,,,Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3<U+0394>30,A Phase 1 Evaluation of the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3<U+0394>30,Completed,,Phase 1,48.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 18:58:48,2023-06-15 18:58:48,NIH,,,,,
377833,377834,NCT00868218,,2009-03-23,2015-06-06,,2019-11-01,2009-03-23,2009-03-24,Estimate,2016-10-19,2016-12-13,Estimate,,,,2019-11-01,2019-11-18,Actual,March 2009,,2009-03-31,November 2019,2019-11-30,November 2013,Actual,2013-11-30,July 2010,Actual,2010-07-31,,Interventional,PANFLUVAC,Healthy adults willing to join phase I trial,Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults,Preparing for an Influenza Pandemic: A Phase I Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults,Completed,,Phase 1,60.0,Actual,University of Bergen,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 15:42:37,2023-06-14 15:42:37,OTHER,,,,,
377875,377876,NCT00896064,,2009-05-07,2017-04-21,2011-11-16,2018-06-25,2009-05-07,2009-05-11,Estimate,2017-04-21,2017-07-19,Actual,2011-11-16,2011-11-21,Estimate,2018-06-25,2018-08-17,Actual,"May 18, 2009",,2009-05-18,April 2017,2017-04-30,"August 5, 2009",Actual,2009-08-05,"August 5, 2009",Actual,2009-08-05,,Interventional,,,Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young Adults,A Study to Evaluate Safety and Immunogenicity of a Booster Dose of Two Formulations of GSK Biologicals' Pneumococcal Candidate Vaccine in Healthy Young Adults,Completed,,Phase 2,43.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-14 15:43:18,2023-06-14 15:43:18,INDUSTRY,,,,,
377942,377943,NCT00943488,,2009-07-21,2011-03-10,,2012-10-25,2009-07-21,2009-07-22,Estimate,2011-03-10,2011-04-11,Estimate,,,,2012-10-25,2012-10-31,Estimate,August 2009,,2009-08-31,March 2010,2010-03-31,March 2010,Actual,2010-03-31,March 2010,Actual,2010-03-31,,Interventional,,,CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations,A Phase II Study in Healthy Adult and Elderly Populations to Assess the Safety and Immunogenicity of an Unadjuvanted CSL H1N1 Influenza Vaccine Administered at Two Dose Levels,Completed,,Phase 2,408.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 15:44:31,2023-06-14 15:44:31,NIH,,,,,
377944,377945,NCT00943878,,2009-07-21,2011-04-14,,2012-07-26,2009-07-21,2009-07-22,Estimate,2011-04-14,2011-05-10,Estimate,,,,2012-07-26,2012-08-01,Estimate,August 2009,,2009-08-31,April 2010,2010-04-30,April 2010,Actual,2010-04-30,April 2010,Actual,2010-04-30,,Interventional,,,Sanofi H1N1 + TIV - Adults and Elderly,Effect of Administration of Licensed TIV Vaccine on the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine in Healthy Adult and Elderly Populations,Completed,,Phase 2,805.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 15:44:34,2023-06-14 15:44:34,NIH,,,,,
377983,377984,NCT00981630,,2009-09-21,2012-11-06,,2012-11-06,2009-09-21,2009-09-22,Estimate,2012-11-06,2012-12-05,Estimate,,,,2012-11-06,2012-12-05,Estimate,November 2004,,2004-11-30,November 2012,2012-11-30,November 2007,Actual,2007-11-30,February 2006,Actual,2006-02-28,,Interventional,,,Study of Live Attenuated ChimeriVax-Japanese Encephalitis Vaccine,"Randomised, Double-blind, Placebo Controlled Phase II, Dose-ranging Study of the Safety, Tolerability and Immunogenicity of Live Attenuated ChimeriVax-JE Vaccine (Lyophilised)",Completed,,Phase 2,128.0,Actual,Sanofi,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 15:45:15,2023-06-14 15:45:15,INDUSTRY,,,,,
378096,378097,NCT02247726,,2014-09-16,,2017-05-30,2022-05-25,2014-09-19,2014-09-25,Estimate,,,,2017-05-30,2017-06-06,Actual,2022-05-25,2022-05-27,Actual,September 2014,,2014-09-30,May 2022,2022-05-31,July 2016,Actual,2016-07-31,July 2016,Actual,2016-07-31,,Interventional,,,RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.,"A Phase II Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety and Immunogenicity of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum, in Healthy Third-trimester Pregnant Women and to Assess the Impact of Maternal Immunization on Infant Safety Through One Year of Life",Completed,,Phase 2,50.0,Actual,Novavax,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 15:46:47,2023-06-14 15:46:47,INDUSTRY,,,,,
378120,378121,NCT01262976,,2010-12-16,2016-12-12,2013-04-11,2017-12-05,2010-12-16,2010-12-20,Estimate,2017-12-05,2018-09-17,Actual,2013-04-11,2013-04-18,Estimate,2017-12-05,2018-09-17,Actual,"January 17, 2011",Actual,2011-01-17,November 2017,2017-11-30,"June 4, 2015",Actual,2015-06-04,"July 17, 2012",Actual,2012-07-17,,Interventional,,,Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Immunodeficiency Virus (HIV)-Positive Adults,Safety and Immunogenicity of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to HIV-positive Adults Living in a Tuberculosis Endemic Region,Completed,,Phase 2,240.0,Actual,GlaxoSmithKline,,6.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 18:59:29,2023-06-15 18:59:29,INDUSTRY,,,,,
378962,378963,NCT02364492,,2015-02-10,,,2022-03-21,2015-02-17,2015-02-18,Estimate,,,,,,,2022-03-21,2022-04-01,Actual,February 2015,Actual,2015-02-28,July 2021,2021-07-31,"November 11, 2021",Actual,2021-11-11,October 2019,Actual,2019-10-31,,Interventional,MAGTRIVACSEIN,,A Phase I Study of a Therapeutic Vaccine Candidate in Patients With Localized Breast Cancer at High-Risk of Relapse,"An Open Label First-in-Human Adjuvant Phase I Study of a Synthetic Multiple Antigenic Glycopeptide Displaying a Tri Tn Glycotop (MAG-Tn3) Plus AS15, as a Therapeutic Vaccine Candidate in Patients With Non Metastatic, HER2 Negative Localized Breast Cancer at High-Risk of Relapse",Completed,,Phase 1,20.0,Actual,Institut Pasteur,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 15:58:25,2023-06-14 15:58:25,INDUSTRY,,,,,
379108,379109,NCT00468858,,2007-05-01,2017-02-08,2015-12-28,2017-06-05,2007-05-01,2007-05-03,Estimate,2017-05-08,2017-06-06,Actual,2015-12-28,2016-02-01,Estimate,2017-06-05,2017-07-02,Actual,July 2007,,2007-07-31,June 2017,2017-06-30,April 2010,Actual,2010-04-30,April 2010,Actual,2010-04-30,,Interventional,,,A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children,"Phase II, Randomized, Double-blind, Placebo-controlled Study of Two Doses of WRAIR Live Attenuated Tetravalent Dengue Vaccine Formulations, Administered Six Months Apart, to Healthy Adults and Children",Completed,,Phase 2,636.0,Actual,U.S. Army Medical Research and Development Command,,3.0,,,False,,,,False,,,,,,,,,,,Yes,GlaxoSmithKline,2023-06-16 19:01:50,2023-06-16 19:01:50,FED,,,,,
379169,379170,NCT01231503,,2010-10-14,2015-05-04,,2018-07-17,2010-10-28,2010-11-01,Estimate,2015-05-04,2015-05-20,Estimate,,,,2018-07-17,2018-08-15,Actual,"January 13, 2011",Actual,2011-01-13,June 2018,2018-06-30,"December 23, 2014",Actual,2014-12-23,"April 30, 2014",Actual,2014-04-30,,Interventional,,,Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants,Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine 257049 When Administered on Different Schedules to Infants in Africa,Completed,,Phase 2,480.0,Actual,GlaxoSmithKline,,8.0,,,False,,,,True,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-15 19:02:37,2023-06-15 19:02:37,INDUSTRY,,,,,
379535,379536,NCT01403376,,2011-07-14,2013-01-22,,2016-01-21,2011-07-26,2011-07-27,Estimate,2013-01-22,2013-02-26,Estimate,,,,2016-01-21,2016-02-18,Estimate,September 2011,,2011-09-30,January 2016,2016-01-31,January 2012,Actual,2012-01-31,January 2012,Actual,2012-01-31,,Interventional,TERIVA,,Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide,Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide Treatment and Using a Population of Patients With Multiple Sclerosis as a Reference,Completed,,Phase 2,128.0,Actual,Sanofi,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 16:05:11,2023-06-14 16:05:11,INDUSTRY,,,,,
379665,379666,NCT01505166,,2012-01-04,2018-02-15,,2021-10-21,2012-01-05,2012-01-06,Estimate,2018-03-29,2018-05-01,Actual,,,,2021-10-21,2021-11-01,Actual,March 2012,,2012-03-31,October 2021,2021-10-31,August 2016,Actual,2016-08-31,August 2016,Actual,2016-08-31,,Interventional,FANG-CLM,Study closed to enrollment and Part 2 was not initiated.,Randomized Phase II Adjuvant Chemotherapy ± FANG in Colorectal Carcinoma With Liver Metastases,Randomized Phase II Trial of Post-operative Adjuvant Chemotherapy ± FANG Autologous Tumor Cell Vaccine in Colorectal Carcinoma With Liver Metastases,Terminated,,Phase 2,3.0,Actual,"Gradalis, Inc.",,3.0,,Terminated (Business Decision to pursue other indications),False,,,,True,,,,,,,,,,,,,2023-06-14 16:06:56,2023-06-14 16:06:56,INDUSTRY,,,,,
379679,379680,NCT01224639,,2010-10-09,2017-01-09,,2018-06-17,2010-10-19,2010-10-20,Estimate,2017-01-09,2017-02-27,Actual,,,,2018-06-17,2018-06-19,Actual,"October 11, 2010",Actual,2010-10-11,June 2018,2018-06-30,"November 9, 2011",Actual,2011-11-09,"June 9, 2011",Actual,2011-06-09,,Interventional,,The safety population included all randomized participants who received at least one dose of study vaccine and for whom post-dosing safety data was obtained.,"Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever","Phase I, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Assess the Safety and Immunogenicity of DENVax Vaccine in Healthy Adults",Completed,,Phase 1,96.0,Actual,Takeda,,6.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-15 19:04:05,2023-06-15 19:04:05,INDUSTRY,,,,,
379811,379812,NCT00397215,,2006-11-07,2012-12-19,,2019-02-12,2006-11-07,2006-11-08,Estimate,2013-03-28,2013-05-20,Estimate,,,,2019-02-12,2019-06-10,Actual,"November 17, 2006",Actual,2006-11-17,February 2019,2019-02-28,"September 14, 2009",Actual,2009-09-14,"September 14, 2009",Actual,2009-09-14,,Interventional,,,Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age,Evaluate Immunogenicity & Safety of a Single or Double-dose of the Pandemic Influenza Candidate Vaccine (GSK1562902A) Given Following a Two-administration Schedule (21 Days Apart) in Adults Over 60 Yrs,Completed,,Phase 2,437.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 19:04:26,2023-06-16 19:04:26,INDUSTRY,,,,,
379987,379988,NCT04299724,,2020-03-05,,,2020-03-06,2020-03-06,2020-03-09,Actual,,,,,,,2020-03-06,2020-03-09,Actual,"February 15, 2020",Actual,2020-02-15,March 2020,2020-03-31,"December 31, 2024",Anticipated,2024-12-31,"July 31, 2023",Anticipated,2023-07-31,,Interventional,,,Safety and Immunity of Covid-19 aAPC Vaccine,Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine,Recruiting,,Phase 1,100.0,Anticipated,Shenzhen Geno-Immune Medical Institute,,1.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-15 19:04:39,2023-06-15 19:04:39,OTHER,,,,,
380041,380042,NCT01651104,,2012-07-24,2013-07-11,,2014-04-03,2012-07-24,2012-07-26,Estimate,2013-12-19,2014-01-27,Estimate,,,,2014-04-03,2014-04-21,Estimate,July 2012,,2012-07-31,April 2014,2014-04-30,August 2012,Actual,2012-08-31,August 2012,Actual,2012-08-31,,Interventional,,Baseline analysis was performed on all enrolled subjects.,Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects,"A Phase 2, Open Label, Uncontrolled, Multicenter Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine (Fluad®), Formulation 2012/2013, When Administered to Elderly Subjects",Completed,,Phase 2,63.0,Actual,Novartis,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 16:11:55,2023-06-14 16:11:55,INDUSTRY,,,,,
380195,380196,NCT05636436,,2022-11-16,,,2023-02-01,2022-12-01,2022-12-05,Actual,,,,,,,2023-02-01,2023-02-02,Actual,"December 7, 2022",Actual,2022-12-07,February 2023,2023-02-28,"December 30, 2024",Anticipated,2024-12-30,"December 30, 2024",Anticipated,2024-12-30,,Interventional,,,Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above,"A Phase I, Single Center, Randomized, Blinded, Controlled Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above","Active, not recruiting",,Phase 1,132.0,Actual,MAXVAX Biotechnology Limited Liability Company,,11.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-14 16:13:39,2023-06-14 16:13:39,INDUSTRY,,,,,
380200,380201,NCT05463354,,2022-07-18,,,2023-01-31,2022-07-18,2022-07-19,Actual,,,,,,,2023-01-31,2023-02-02,Actual,"July 11, 2022",Actual,2022-07-11,July 2022,2022-07-31,July 2023,Anticipated,2023-07-31,February 2023,Anticipated,2023-02-28,,Interventional,,,Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster,Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster Following Primary Vaccination of Either Inactivated or mRNA or Viral Vector COVID-19 Vaccines,Recruiting,,Phase 2,450.0,Anticipated,"WestVac Biopharma Co., Ltd.",,6.0,,,False,,,,,False,False,,,False,,,,,,,,2023-06-14 16:13:42,2023-06-14 16:13:42,INDUSTRY,,,,,
380204,380205,NCT05293548,,2022-03-22,,,2023-01-31,2022-03-22,2022-03-24,Actual,,,,,,,2023-01-31,2023-02-02,Actual,"May 25, 2022",Actual,2022-05-25,January 2023,2023-01-31,August 2023,Anticipated,2023-08-31,May 2023,Anticipated,2023-05-31,,Interventional,,,"A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)","A Randomized, Controlled Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell) in Population Aged 18 Years and Above","Active, not recruiting",,Phase 2,516.0,Actual,"National Vaccine and Serum Institute, China",,2.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-14 16:13:45,2023-06-14 16:13:45,INDUSTRY,,,,,
380212,380213,NCT01018732,,2009-11-18,2011-08-09,,2015-07-14,2009-11-24,2009-11-25,Estimate,2011-08-09,2011-09-13,Estimate,,,,2015-07-14,2015-07-15,Estimate,January 2010,,2010-01-31,July 2015,2015-07-31,July 2010,Actual,2010-07-31,July 2010,Actual,2010-07-31,,Interventional,,,A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY,"A Phase 2b, Open-Label, Multi-Center Study to Evaluate the Persistence of Antibody Response and to Assess the Immune Response to a Booster Dose of MenACWY Conjugate Vaccine in Subjects Previously Vaccinated as Adolescents With Either MenACWY Conjugate Vaccine or Menomune®.",Completed,,Phase 2,155.0,Actual,Novartis,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 19:05:41,2023-06-15 19:05:41,INDUSTRY,,,,,
380374,380375,NCT00992017,,2009-10-07,2011-11-07,,2021-11-03,2009-10-07,2009-10-08,Estimate,2012-02-09,2012-03-13,Estimate,,,,2021-11-03,2021-11-05,Actual,October 2009,,2009-10-31,December 2014,2014-12-31,November 2010,Actual,2010-11-30,November 2010,Actual,2010-11-30,,Interventional,,,Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women,A Phase II Study to Assess the Safety and Immunogenicity of an Inactivated Monovalent Influenza A (H1N1) Vaccine in HIV-1 Infected Pregnant Women,Completed,,Phase 2,130.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 19:06:19,2023-06-15 19:06:19,NIH,,,,,
380378,380379,NCT02868073,,2016-08-11,,,2018-05-29,2016-08-11,2016-08-16,Estimate,,,,,,,2018-05-29,2018-05-31,Actual,"July 29, 2016",Actual,2016-07-29,May 2018,2018-05-31,"October 1, 2017",Actual,2017-10-01,"October 5, 2016",Actual,2016-10-05,,Interventional,,,"Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine","A Phase 1, Randomized, Double-Blind, Placebo-controlled, Dose-ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-vector Based Norovirus Vaccine (VXA-G1.1-NN) Expressing GI.1 VP1 and dsRNA Adjuvant Administered Orally to Healthy Volunteers",Completed,,Phase 1,66.0,Actual,Vaxart,,3.0,,,False,,,,False,,,,,,,,,,,No,,2023-06-15 19:06:22,2023-06-15 19:06:22,INDUSTRY,,,,,
380571,380572,NCT04318002,,2020-02-13,,,2022-10-21,2020-03-18,2020-03-23,Actual,,,,,,,2022-10-21,2022-10-24,Actual,"January 25, 2021",Actual,2021-01-25,October 2022,2022-10-31,July 2023,Anticipated,2023-07-31,July 2023,Anticipated,2023-07-31,,Interventional,,,Safety and Immunogenicity of RH5.1/Matrix-M in Adults and Infants Living in Tanzania,A Phase Ib Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Plasmodium Falciparum Malaria Vaccine Candidate RH5.1/Matrix-M in Healthy Adults and Infants in Tanzania,Enrolling by invitation,,Phase 1,60.0,Anticipated,University of Oxford,,6.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-14 00:14:08,2023-06-14 00:14:08,OTHER,,,,,
380622,380623,NCT01876212,,2013-06-10,2019-06-20,,2019-08-12,2013-06-10,2013-06-12,Estimate,2019-07-15,2019-08-06,Actual,,,,2019-08-12,2019-08-22,Actual,"May 16, 2014",Actual,2014-05-16,August 2019,2019-08-31,"July 31, 2019",Actual,2019-07-31,"July 11, 2018",Actual,2018-07-11,,Interventional,,,Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma,A Randomized Phase 2 Pilot Study of Type I-Polarized Autologous Dendritic Cell Vaccines Incorporating Tumor Blood Vessel Antigen (TBVA)-Derived Peptides in Combination With Dasatinib in Patients With Metastatic Melanoma,Completed,,Phase 2,15.0,Actual,University of Pittsburgh,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 16:19:04,2023-06-14 16:19:04,OTHER,,,,,
380903,380904,NCT01933776,,2013-08-28,2014-03-17,,2016-02-04,2013-08-28,2013-09-02,Estimate,2014-03-17,2014-04-21,Estimate,,,,2016-02-04,2016-03-07,Estimate,August 2013,,2013-08-31,February 2016,2016-02-29,January 2014,Actual,2014-01-31,November 2013,Actual,2013-11-30,,Interventional,,,Study of the Tdap Combined Vaccine (ADACEL) as a Booster Dose in Healthy Adults and Children in China,Clinical Safety Study of the Tdap Combined Vaccine (ADACEL) as a Booster Dose in Healthy Adults and Children in China,Completed,,Phase 1,40.0,Actual,Sanofi,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 16:22:14,2023-06-14 16:22:14,INDUSTRY,,,,,
381053,381054,NCT04930770,,2021-06-03,,,2023-02-17,2021-06-17,2021-06-18,Actual,,,,,,,2023-02-17,2023-02-21,Actual,"August 1, 2021",Anticipated,2021-08-01,February 2023,2023-02-28,"March 1, 2022",Anticipated,2022-03-01,"December 1, 2021",Anticipated,2021-12-01,,Interventional,VAX-TRES,,Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination,Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination,Withdrawn,,Phase 2,0.0,Actual,Fundacion Clinic per a la Recerca Biomédica,,1.0,,No candidates for the trial (all patients have received the third dose of the vaccine),False,,,,True,False,False,,,,,,,,,,,2023-06-14 16:24:13,2023-06-14 16:24:13,OTHER,,,,,
381758,381759,NCT05047692,,2021-09-14,,,2023-02-06,2021-09-14,2021-09-17,Actual,,,,,,,2023-02-06,2023-02-08,Actual,"September 9, 2021",Actual,2021-09-09,February 2023,2023-02-28,May 2023,Anticipated,2023-05-31,"December 2, 2022",Actual,2022-12-02,,Interventional,,,Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers,"A Dose Escalation, Multicenter, Open, Phase I Study to Assess the Safety and Immunogenicity of AdCLD-CoV19-1, a COVID-19 Preventive Vaccine in Healthy Volunteers.","Active, not recruiting",,Phase 1,40.0,Anticipated,"Cellid Co., Ltd.",,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-14 16:33:24,2023-06-14 16:33:24,INDUSTRY,,,,,
382039,382040,NCT05301504,,2022-02-24,,,2023-02-03,2022-03-24,2022-03-29,Actual,,,,,,,2023-02-03,2023-02-08,Actual,"March 30, 2022",Actual,2022-03-30,November 2022,2022-11-30,December 2023,Anticipated,2023-12-31,December 2023,Anticipated,2023-12-31,,Interventional,,,A Study in Tanzania of a New Vaccine Against Two Types of Ebola,A Phase Ib Study to Determine the Safety and Immunogenicity of a Bivalent ChAdOx1 Vectored Vaccine Against Zaire and Sudan Ebola Virus Species in Tanzanian Healthy Adult Volunteers,"Active, not recruiting",,Phase 1,76.0,Anticipated,University of Oxford,,4.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-14 16:36:44,2023-06-14 16:36:44,OTHER,,,,,
382221,382222,NCT04025580,,2019-07-18,,,2023-02-08,2019-07-18,2019-07-19,Actual,,,,,,,2023-02-08,2023-02-09,Actual,"October 2, 2019",Actual,2019-10-02,"January 31, 2023",2023-01-31,"January 31, 2023",Actual,2023-01-31,"January 31, 2023",Actual,2023-01-31,,Interventional,,,Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine,Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine,Completed,,Phase 2,90.0,Actual,National Institutes of Health Clinical Center (CC),,1.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-14 16:38:36,2023-06-14 16:38:36,NIH,,,,,
382343,382344,NCT02427750,,2015-04-13,2015-08-18,,2015-09-22,2015-04-22,2015-04-28,Estimate,2015-09-22,2015-10-19,Estimate,,,,2015-09-22,2015-10-19,Estimate,April 2015,,2015-04-30,September 2015,2015-09-30,May 2015,Actual,2015-05-31,May 2015,Actual,2015-05-31,,Interventional,,,"A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects.","A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Surface Antigen, Inactivated, Egg-Derived, Trivalent Influenza (Agrippal®) Virus Vaccine, Southern Hemisphere Formulation 2015, in Healthy Adults.",Completed,,Phase 2,126.0,Actual,Novartis,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 16:40:07,2023-06-14 16:40:07,INDUSTRY,,,,,
382458,382459,NCT02529072,,2015-08-12,2020-02-10,,2020-03-11,2015-08-18,2015-08-19,Estimate,2020-03-11,2020-03-26,Actual,,,,2020-03-11,2020-03-26,Actual,January 2016,Actual,2016-01-31,March 2020,2020-03-31,"December 30, 2019",Actual,2019-12-30,"September 15, 2017",Actual,2017-09-15,,Interventional,AVERT,,Nivolumab With DC Vaccines for Recurrent Brain Tumors,AVeRT: Anti-PD-1 Monoclonal Antibody (Nivolumab) in Combination With DC Vaccines for the Treatment of Recurrent Grade III and Grade IV Brain Tumors,Completed,,Phase 1,6.0,Actual,Duke University,,2.0,,,False,,,,True,,,,,,,,,,,Undecided,,2023-06-14 16:41:33,2023-06-14 16:41:33,OTHER,,,,,
382462,382463,NCT02532036,,2015-08-18,2020-08-14,,2020-08-14,2015-08-20,2015-08-25,Estimate,2020-08-14,2020-08-31,Actual,,,,2020-08-14,2020-08-31,Actual,September 2015,,2015-09-30,November 2018,2018-11-30,"October 4, 2018",Actual,2018-10-04,"October 4, 2018",Actual,2018-10-04,,Interventional,,,MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) Infection,A Phase I Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine MVA85A Administered by the Aerosol Inhaled Route and the Intramuscular Route in Healthy Adult Volunteers Who Are Latently Infected With Mycobacterium Tuberculosis,Terminated,,Phase 1,2.0,Actual,University of Oxford,,3.0,,Poor recruitment,False,,,,False,,,,,,,,,,,,,2023-06-14 16:41:37,2023-06-14 16:41:37,OTHER,,,,,
382523,382524,NCT02585700,,2015-10-13,2017-05-11,,2018-07-16,2015-10-22,2015-10-23,Estimate,2018-07-16,2019-01-15,Actual,,,,2018-07-16,2019-01-15,Actual,November 2015,,2015-11-30,October 2015,2015-10-31,March 2016,Actual,2016-03-31,March 2016,Actual,2016-03-31,,Interventional,,,"A Study of a Seasonal Trivalent Split, Inactivated Influenza Vaccine","A Phase 1 Double Blinded, Randomized, Placebo-Controlled Study to Examine the Safety and Immunogenicity of a Seasonal Trivalent Split, Inactivated Influenza Vaccine Produced by Torlak in Healthy Adult Volunteers in Serbia",Completed,,Phase 1,60.0,Actual,"Institute of Virology, Vaccines and Sera, Torlak",,2.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-14 16:42:39,2023-06-14 16:42:39,OTHER,,,,,
382660,382661,NCT00942071,,2009-07-16,,,2012-11-28,2009-07-17,2009-07-20,Estimate,,,,,,,2012-11-28,2012-11-29,Estimate,August 2008,,2008-08-31,November 2012,2012-11-30,November 2012,Actual,2012-11-30,November 2012,Actual,2012-11-30,,Interventional,,,A Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NP+M1 in Healthy Adults,A Phase I Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NP+M1 in Healthy Adults,Completed,,Phase 1,58.0,Actual,University of Oxford,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 19:06:18,2023-06-16 19:06:18,OTHER,,,,,
382698,382699,NCT05409300,,2022-03-28,,,2023-02-15,2022-06-07,2022-06-08,Actual,,,,,,,2023-02-15,2023-02-16,Actual,"April 25, 2022",Actual,2022-04-25,February 2023,2023-02-28,July 2024,Anticipated,2024-07-31,August 2023,Anticipated,2023-08-31,,Interventional,CovicompareG,,Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea,Phase II Trial Evaluating the Immunogenicity and Safety of BBIBP-CorV Vaccine in Adults in Guinea,Recruiting,,Phase 2,200.0,Anticipated,"ANRS, Emerging Infectious Diseases",,1.0,,,False,,,,False,False,False,,,,,,,,,Yes,,2023-06-14 16:44:28,2023-06-14 16:44:28,OTHER_GOV,,,,,
383101,383102,NCT00965263,,2009-08-24,2017-08-03,,2017-11-06,2009-08-24,2009-08-25,Estimate,2017-11-06,2017-12-11,Actual,,,,2017-11-06,2017-12-11,Actual,March 2003,,2003-03-31,September 2017,2017-09-30,August 2009,Actual,2009-08-31,July 2009,Actual,2009-07-31,,Interventional,,"Overall, 10 volunteers participated in this study.",Therapeutic Cocaine Vaccine: Human Laboratory Study,Tests of a Therapeutic Cocaine Vaccine,Completed,,Phase 2,15.0,Actual,New York State Psychiatric Institute,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 19:15:26,2023-06-15 19:15:26,OTHER,,,,,
383319,383320,NCT01171989,,2010-07-27,2017-02-28,2010-12-23,2020-01-03,2010-07-28,2010-07-29,Estimate,2017-02-28,2017-04-11,Actual,2010-12-23,2010-12-30,Estimate,2020-01-03,2020-01-21,Actual,"August 18, 2010",Actual,2010-08-18,January 2020,2020-01-31,"December 3, 2010",Actual,2010-12-03,"December 3, 2010",Actual,2010-12-03,,Interventional,,,Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose,Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose in 12-18 Months Old Healthy Children,Completed,,Phase 2,391.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=137,Yes,IPD is available via the Clinical Study Data Request site (click on the link provided below),2023-06-15 19:16:10,2023-06-15 19:16:10,INDUSTRY,,,,,
383546,383547,NCT04301154,,2020-03-02,,,2022-04-20,2020-03-05,2020-03-10,Actual,,,,,,,2022-04-20,2022-04-27,Actual,"February 18, 2022",Actual,2022-02-18,April 2022,2022-04-30,"October 31, 2023",Anticipated,2023-10-31,"October 31, 2023",Anticipated,2023-10-31,,Interventional,HVRRICANE,,Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth,"Phase I, Proof of Concept, Open-Label, Randomized Clinical Trial to Evaluate the Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth",Recruiting,,Phase 1,25.0,Anticipated,Henry M. Jackson Foundation for the Advancement of Military Medicine,,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-14 16:53:50,2023-06-14 16:53:50,OTHER,,,,,
383630,383631,NCT02888418,,2016-08-11,,,2016-08-30,2016-08-30,2016-09-05,Estimate,,,,,,,2016-08-30,2016-09-05,Estimate,October 2016,,2016-10-31,August 2016,2016-08-31,December 2017,Anticipated,2017-12-31,October 2017,Anticipated,2017-10-31,,Interventional,,,Safety and Immunogenicity Study of Human Papilloma Virus Vaccine in Women Aged 9 to 30 and Men Aged 9 to 17,"Random, Double Blind, Placebo Controlled Phase I Clinical Trials to Estimate the Safety and Preliminary Immunogenicity of Tetravalent Recombinant Human Papilloma Virus Vaccine (6,11,16,18 Type)(Hansenula Polymorpha) in Women of 9 to 30 Years Old and Men of 9 to 17 Years Old",Unknown status,Not yet recruiting,Phase 1,135.0,Anticipated,Beijing Chaoyang District Centre for Disease Control and Prevention,,6.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 19:17:31,2023-06-15 19:17:31,OTHER,,,,,
383656,383657,NCT02873286,,2016-08-09,2020-08-11,,2020-09-01,2016-08-16,2016-08-19,Estimate,2020-09-01,2020-09-22,Actual,,,,2020-09-01,2020-09-22,Actual,September 2016,Actual,2016-09-30,September 2020,2020-09-30,December 2018,Actual,2018-12-31,December 2018,Actual,2018-12-31,,Interventional,,Full Analysis Set,RSV-MVA-BN Vaccine Phase II Trial in = 55 Year Old Adults,"A Randomized, Single-blind, Placebo Controlled, Dose-ranging Phase II Trial in = 55 Year Old Adults to Evaluate the Safety and Immunogenicity of the Recombinant MVA-BN-RSV Vaccine",Completed,,Phase 2,420.0,Actual,Bavarian Nordic,,5.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-14 16:55:20,2023-06-14 16:55:20,INDUSTRY,,,,,
383796,383797,NCT00623753,,2008-02-18,,,2017-04-24,2008-02-25,2008-02-26,Estimate,,,,,,,2017-04-24,2017-04-26,Actual,May 2007,,2007-05-31,September 2011,2011-09-30,January 2008,Actual,2008-01-31,January 2008,Actual,2008-01-31,,Interventional,,,"Evaluate Tolerability of a Multi-envelope, Prime-boost HIV Vaccine in Healthy Adults","Evaluate Tolerability and Safety of Multi-Envelope, Prime-boost HIV Vaccine (DVP) in Healthy Adults",Terminated,,Phase 1,3.0,Actual,St. Jude Children's Research Hospital,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 19:18:09,2023-06-15 19:18:09,OTHER,,,,,
383802,383803,NCT01168401,,2010-07-21,2017-05-04,,2018-04-27,2010-07-22,2010-07-23,Estimate,2018-04-27,2018-11-23,Actual,,,,2018-04-27,2018-11-23,Actual,"September 3, 2010",Actual,2010-09-03,April 2018,2018-04-30,"January 9, 2013",Actual,2013-01-09,"January 1, 2013",Actual,2013-01-01,,Interventional,,Modified Intent to Treat (mITT) population included all participants who received at least 1 dose of study product.,Bivalent Norovirus Vaccine Study,"Phase 1, Randomized Controlled Dose Escalation, Safety and Immunogenicity Study of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine Adjuvanted With Monophosphoryl Lipid A (MPL) and Aluminum Hydroxide [Al(OH)3] in Adults",Completed,,Phase 1,102.0,Actual,Takeda,,2.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-15 19:18:13,2023-06-15 19:18:13,INDUSTRY,,,,,
383920,383921,NCT01165203,,2010-07-15,2017-05-11,2013-04-11,2018-03-30,2010-07-15,2010-07-19,Estimate,2017-05-11,2017-06-07,Actual,2013-04-11,2013-04-18,Estimate,2018-03-30,2018-04-30,Actual,"September 30, 2010",Actual,2010-09-30,October 2017,2017-10-31,"May 14, 2013",Actual,2013-05-14,"July 6, 2012",Actual,2012-07-06,,Interventional,,,Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects,Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A in Adult HIV-infected Subjects,Completed,,Phase 2,123.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 19:18:43,2023-06-15 19:18:43,INDUSTRY,,,,,
384203,384204,NCT00958243,,2009-08-12,2011-07-13,,2018-04-25,2009-08-12,2009-08-13,Estimate,2011-07-13,2011-08-09,Estimate,,,,2018-04-25,2018-05-23,Actual,August 2009,,2009-08-31,April 2018,2018-04-30,April 2010,Actual,2010-04-30,November 2009,Actual,2009-11-30,,Interventional,,,A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA,"A Phase II, Multicenter, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population",Completed,,Phase 2,473.0,Actual,Seqirus,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 19:20:01,2023-06-15 19:20:01,INDUSTRY,,,,,
384238,384239,NCT03498300,,2018-04-07,2019-11-24,,2020-03-11,2018-04-07,2018-04-13,Actual,2020-03-11,2020-03-24,Actual,,,,2020-03-11,2020-03-24,Actual,"May 9, 2018",Actual,2018-05-09,March 2020,2020-03-31,"April 13, 2019",Actual,2019-04-13,"April 13, 2019",Actual,2019-04-13,,Interventional,,,Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Tdap in Pregnant Thai Women,"Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Reduced-antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine (Tdap) in Pregnant Thai Women",Completed,,Early Phase 1,129.0,Actual,Mahidol University,,2.0,,,False,,,,,True,False,,,True,,,,,,Undecided,,2023-06-14 17:03:08,2023-06-14 17:03:08,OTHER,,,,,
384630,384631,NCT04943718,,2021-06-13,,,2021-06-26,2021-06-26,2021-06-29,Actual,,,,,,,2021-06-26,2021-06-29,Actual,"July 15, 2021",Anticipated,2021-07-15,June 2021,2021-06-30,"June 13, 2024",Anticipated,2024-06-13,"June 13, 2023",Anticipated,2023-06-13,,Interventional,,,Personalized Vaccine for Patients With Recurrent Malignant Glioma,"Personalized Vaccine for Patients With Recurrent Malignant Glioma: a Single-arm, Single-center, Open-labeled Study",Recruiting,,Phase 1,10.0,Anticipated,"Xuanwu Hospital, Beijing",,1.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-19 03:42:53,2023-06-19 03:42:53,OTHER,,,,,
384678,384679,NCT04100772,,2019-09-18,,,2022-10-28,2019-09-20,2019-09-24,Actual,,,,,,,2022-10-28,2022-10-31,Actual,"May 18, 2020",Actual,2020-05-18,October 2022,2022-10-31,"August 23, 2022",Actual,2022-08-23,"June 23, 2021",Actual,2021-06-23,,Interventional,PICTPCV13i,,Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above,"A Randomized,Blind, Positive-controlled Phase I Clinical Trial to Preliminary Evaluate the Safety and Immunogencity of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT) in Healthy People Aged 6 Weeks and Above",Completed,,Phase 1,237.0,Actual,CanSino Biologics Inc.,,8.0,,,False,,,,False,False,False,,,,,,,,,No,"In order to maintain the rights of the subject, do not open the IPD",2023-06-14 17:09:14,2023-06-14 17:09:14,INDUSTRY,,,,,
384810,384811,NCT00000630,,1999-11-02,,,2021-10-26,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-26,2021-10-27,Actual,,,,October 2021,2021-10-31,December 1992,Actual,1992-12-31,,,,,Interventional,,,Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn),Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn),Completed,,Phase 1,35.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 17:10:30,2023-06-14 17:10:30,NIH,,,,,
384850,384851,NCT00001026,,1999-11-02,,,2021-10-28,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-28,2021-11-04,Actual,,,,October 2021,2021-10-31,December 1994,Actual,1994-12-31,,,,,Interventional,,,"A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals","A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals",Completed,,Phase 1,56.0,,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 17:11:04,2023-06-14 17:11:04,NIH,,,,,
384851,384852,NCT00001044,,1999-11-02,,,2021-10-28,2001-08-30,2001-08-31,Estimate,,,,,,,2021-10-28,2021-11-04,Actual,,,,October 2021,2021-10-31,May 1995,Actual,1995-05-31,,,,,Interventional,,,"A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.","A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.",Completed,,Phase 1,80.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 17:11:04,2023-06-14 17:11:04,NIH,,,,,
384891,384892,NCT00001512,,1999-11-03,,,2017-06-30,1999-11-03,1999-11-04,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"September 9, 1996",,1996-09-09,"March 5, 2010",2010-03-05,"March 5, 2010",Actual,2010-03-05,"March 5, 2010",Actual,2010-03-05,,Interventional,,,Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines,Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines,Completed,,Phase 1,42.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 17:11:26,2023-06-14 17:11:26,NIH,,,,,
384936,384937,NCT00001992,,1999-11-02,,,2005-06-23,2001-08-30,2001-08-31,Estimate,,,,,,,2005-06-23,2005-06-24,Estimate,,,,August 1992,1992-08-31,,,,,,,,Interventional,,,A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers,A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers,Completed,,Phase 1,,,NIH AIDS Clinical Trials Information Service,,,,,False,,,,,,,,,,,,,,,,,2023-06-14 17:11:52,2023-06-14 17:11:52,INDUSTRY,,,,,
385010,385011,NCT00002232,,1999-11-02,,,2005-06-23,2001-08-30,2001-08-31,Estimate,,,,,,,2005-06-23,2005-06-24,Estimate,,,,June 1999,1999-06-30,,,,,,,,Interventional,,,"A Study of GENEVAX-HIV, a Possible Vaccine","GENEVAX-HIV (APL 400-003), a Candidate DNA Vaccine: A Pilot Study of GENEVAX-HIV Given by Intramuscular or Intradermal Administration in HIV Seronegative Volunteers",Completed,,Phase 1,,,NIH AIDS Clinical Trials Information Service,,,,,False,,,,,,,,,,,,,,,,,2023-06-14 17:12:23,2023-06-14 17:12:23,INDUSTRY,,,,,
385060,385061,NCT00002454,,1999-11-01,,,2011-07-23,2004-02-26,2004-02-27,Estimate,,,,,,,2011-07-23,2011-07-26,Estimate,December 1971,,1971-12-31,January 2002,2002-01-31,,,,,,,,Interventional,,,Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx,Phase II Study of Immunotherapy With Autogenous Papilloma Vaccine in Patients With Recurrent Juvenile Papilloma of the Larynx,Unknown status,"Active, not recruiting",Phase 2,,,National Cancer Institute (NCI),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 17:12:50,2023-06-14 17:12:50,NIH,,,,,
385245,385246,NCT00624975,,2008-02-19,,,2012-07-30,2008-02-27,2008-02-28,Estimate,,,,,,,2012-07-30,2012-08-01,Estimate,November 2008,,2008-11-30,July 2012,2012-07-31,July 2012,Actual,2012-07-31,July 2012,Actual,2012-07-31,,Interventional,,,Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants,"A Multi-site, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Immunogenicity of Trehalose-reformulated Peru-15 (Choleragarde)Vaccine Given Simultaneously With Measles Vaccine in Healthy Indian and Bangladeshi Infants",Terminated,,Phase 2,74.0,Actual,International Vaccine Institute,,2.0,,one of site was not able to get an approval from the national regulatory authority.,False,,,,True,,,,,,,,,,,,,2023-06-15 19:22:58,2023-06-15 19:22:58,OTHER,,,,,
385333,385334,NCT04313127,,2020-03-15,,,2021-08-02,2020-03-17,2020-03-18,Actual,,,,,,,2021-08-02,2021-08-04,Actual,"March 16, 2020",Actual,2020-03-16,May 2020,2020-05-31,"February 20, 2021",Actual,2021-02-20,"January 20, 2021",Actual,2021-01-20,,Interventional,CTCOVID-19,,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,"A Single-center,Open-label,Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old",Completed,,Phase 1,108.0,Actual,CanSino Biologics Inc.,,3.0,,,False,,,,True,False,False,,,,,,Data will be available beginning 3 months and ending one year following article publication,"Data access requests will be reviewed by the sponsor,investigator and collaborators on the basis of scientific merit. To gain access, data requestors will need to sign a data access agreement.",http://www.jshealth.com/,Yes,"We support data sharing of the individual participant data. The individual participant data that underlie the results reported in this article, after deidenti<U+FB01>cation (text, tables, figures, and appendixes) will be shared. Individual participant data will be available beginning 3 months and ending one year following article publication. Supporting clinical documents including study protocol, statistical analysis plan (SAP), and the informed consent form (ICF) will be available immediately following publication for at least one year. Supporting clinical documents access information will be available at http://www.jshealth.com/. Researchers who provide a scientifically sound proposal will be allowed to access to the individual participant data. Proposals should be directed to jszfc@vip.sina.com or cw0226@foxmail.com.",2023-06-15 19:23:00,2023-06-15 19:23:00,INDUSTRY,,,,,
385382,385383,NCT04529538,,2020-08-24,,,2023-02-28,2020-08-26,2020-08-27,Actual,,,,,,,2023-02-28,2023-03-01,Actual,"March 26, 2021",Actual,2021-03-26,February 2023,2023-02-28,"February 17, 2023",Actual,2023-02-17,"February 17, 2023",Actual,2023-02-17,,Interventional,,,Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines,"A First-in-human, Phase 1, Randomized, Observer-blind, Controlled Study to Assess the Safety and Immunogenicity of Novel Live Attenuated Type 1 and Type 3 Oral Poliomyelitis Vaccines in Healthy Adults",Completed,,Phase 1,205.0,Actual,PATH,,8.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-14 17:16:01,2023-06-14 17:16:01,OTHER,,,,,
385535,385536,NCT05461131,,2022-07-13,,,2023-05-08,2022-07-13,2022-07-15,Actual,,,,,,,2023-05-08,2023-05-09,Actual,"June 20, 2022",Actual,2022-06-20,May 2023,2023-05-31,"September 1, 2023",Anticipated,2023-09-01,"July 1, 2023",Anticipated,2023-07-01,,Interventional,CHAMPION-1,,Pertussis Challenge Study in Adults Vaccinated With BPZE1,"A Phase 2b, Placebo-Controlled, Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy Adults to Assess Protection Against Colonization Following Challenge With Virulent Wild-Type Bordetella Pertussis",Recruiting,,Phase 2,44.0,Anticipated,ILiAD Biotechnologies,,2.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-18 00:26:51,2023-06-18 00:26:51,INDUSTRY,,,,,
385747,385748,NCT00004032,,1999-12-10,,,2013-01-22,2003-08-22,2003-08-25,Estimate,,,,,,,2013-01-22,2013-01-23,Estimate,October 1997,,1997-10-31,January 2013,2013-01-31,,,,April 2004,Actual,2004-04-30,,Interventional,,,Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer,Intraperitoneal (IP) Autologous Therapeutic Tumor Vaccine AUT-OV-ALVAC-h.B7.1 Plus IP rIFN-gamma for Patients With Ovarian Cancer. A Pilot Study,Completed,,Phase 1,12.0,Actual,National Cancer Institute (NCI),,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 17:19:55,2023-06-14 17:19:55,NIH,,,,,
385759,385760,NCT00004104,,1999-12-10,,,2016-03-30,2004-07-16,2004-07-19,Estimate,,,,,,,2016-03-30,2016-03-31,Estimate,June 1998,,1998-06-30,March 2016,2016-03-31,,,,July 2000,Actual,2000-07-31,,Interventional,,,Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma,Phase II Trial of the Effects of Interferon Alfa-2b on the Immunogenicity of a Polyvalent Melanoma Antigen Vaccine in Patients With Stage III Malignant Melanoma,Completed,,Phase 2,,,NYU Langone Health,,,,,False,,,,,,,,,,,,,,,,,2023-06-14 17:20:03,2023-06-14 17:20:03,OTHER,,,,,
386214,386215,NCT00128219,,2005-08-05,2009-08-03,,2015-01-15,2005-08-05,2005-08-09,Estimate,2010-07-01,2010-07-05,Estimate,,,,2015-01-15,2015-01-27,Estimate,July 2003,,2003-07-31,August 2009,2009-08-31,December 2008,Actual,2008-12-31,December 2008,Actual,2008-12-31,,Interventional,,,Prevention of GBS Colonization Via Immunity,"A Phase II Randomized, Double-Blinded, Comparative Clinical Trial for a Group B Streptococcus Serotype III-Tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Acquisition of GBS Type III",Completed,,Phase 2,667.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 00:15:46,2023-06-14 00:15:46,NIH,,,,,
386328,386329,NCT00375726,,2006-09-12,,,2010-12-13,2006-09-12,2006-09-13,Estimate,,,,,,,2010-12-13,2010-12-14,Estimate,October 2006,,2006-10-31,December 2010,2010-12-31,September 2008,Actual,2008-09-30,September 2008,Actual,2008-09-30,,Interventional,,,Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults,"Phase 1 Study of the Safety and Immunogenicity of rDEN3/4delta30(ME), a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3",Completed,,Phase 1,58.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 17:25:25,2023-06-14 17:25:25,NIH,,,,,
386418,386419,NCT00382980,,2006-09-28,,,2010-08-26,2006-09-28,2006-10-02,Estimate,,,,,,,2010-08-26,2010-08-27,Estimate,October 2006,,2006-10-31,September 2008,2008-09-30,September 2007,Actual,2007-09-30,September 2007,Actual,2007-09-30,,Interventional,,,Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults,"A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Clinical Trial of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Immunization With Inactivated, Vero Cell-Culture Derived Influenza A/H5N1 Vaccine Given Alone or With Aluminum Hydroxide to Healthy Young Adults",Completed,,Phase 1,308.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,6.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 17:26:22,2023-06-14 17:26:22,NIH,,,,,
386459,386460,NCT00385320,,2006-10-06,,,2019-12-26,2006-10-06,2006-10-09,Estimate,,,,,,,2019-12-26,2019-12-27,Actual,"May 31, 2001",Actual,2001-05-31,December 2019,2019-12-31,"April 30, 2003",Actual,2003-04-30,"April 30, 2003",Actual,2003-04-30,,Interventional,,,Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 Months,"To Assess the Efficacy, Immuno & Safety of 2 Doses of GSK HRV Vaccine at Different Virus Concentrations in Healthy Infants Aged 2 Months & Previously Uninfected With HRV, Concurrently Given With DTPw-HBV, Hib.",Completed,,Phase 2,2640.0,Actual,GlaxoSmithKline,,,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=3349,Yes,IPD is available via the Clinical Study Data Request site (click on the link provided below),2023-06-14 17:26:40,2023-06-14 17:26:40,INDUSTRY,,,,,
386970,386971,NCT01040325,,2009-12-25,,,2012-03-13,2009-12-28,2009-12-29,Estimate,,,,,,,2012-03-13,2012-03-14,Estimate,December 2009,,2009-12-31,January 2012,2012-01-31,December 2010,Actual,2010-12-31,June 2010,Actual,2010-06-30,,Interventional,,,Traveler's Diarrhea (TD) Vaccine Asia Efficacy Study,"A Phase Two, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System in Travelers to Asia",Completed,,Phase 2,723.0,Actual,"Intercell USA, Inc.",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 19:07:14,2023-06-16 19:07:14,INDUSTRY,,,,,
387522,387523,NCT05284812,,2022-02-21,,,2023-05-06,2022-03-09,2022-03-17,Actual,,,,,,,2023-05-06,2023-05-09,Actual,"February 10, 2022",Actual,2022-02-10,May 2023,2023-05-31,"December 31, 2024",Anticipated,2024-12-31,"June 30, 2024",Anticipated,2024-06-30,,Interventional,,,A Phase <U+2161> Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02),"A Phase <U+2161> Study on the Safety, Tolerability and Immunogenicity of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried",Recruiting,,Phase 2,200.0,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,7.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-18 00:28:02,2023-06-18 00:28:02,INDUSTRY,,,,,
387543,387544,NCT00603811,,2008-01-04,,,2014-09-22,2008-01-28,2008-01-29,Estimate,,,,,,,2014-09-22,2014-09-23,Estimate,September 2007,,2007-09-30,September 2014,2014-09-30,October 2008,Actual,2008-10-31,October 2008,Actual,2008-10-31,,Interventional,,,Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults,"A Multicenter, Double-blind, Randomized, Escalating Dose-ranging Study to Investigate the Safety and Immunogenicity of the VAX102 Influenza Vaccine in Healthy Adults",Completed,,Phase 1,60.0,Actual,VaxInnate Corporation,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 19:27:38,2023-06-15 19:27:38,INDUSTRY,,,,,
388174,388175,NCT05293223,,2021-11-24,,,2023-03-11,2022-03-16,2022-03-24,Actual,,,,,,,2023-03-11,2023-03-14,Actual,"October 1, 2021",Actual,2021-10-01,March 2023,2023-03-31,"April 15, 2023",Anticipated,2023-04-15,"November 15, 2022",Actual,2022-11-15,,Interventional,FH-63,,Phase IIB Study of Recombinant Novel Coronavirus Vaccine,An Open-label Clinical Trial Phase IIB to Evaluate the Immunogenicity and Safety of Recombinant Novel Coronavirus Vaccine in Participants Aged 18 Years and Above That Previously Received One Dose of Sputnik V,"Active, not recruiting",,Phase 2,450.0,Anticipated,Fundación Huésped,,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-14 17:43:14,2023-06-14 17:43:14,OTHER,,,,,
388213,388214,NCT05178901,,2021-12-06,,,2023-03-10,2022-01-04,2022-01-05,Actual,,,,,,,2023-03-10,2023-03-14,Actual,"January 10, 2022",Actual,2022-01-10,March 2023,2023-03-31,January 2024,Anticipated,2024-01-31,June 2023,Anticipated,2023-06-30,,Interventional,,,A Phase 1 Study to Evaluate Safety & Immunogenicity of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects,"A Phase 1 Randomized, Single Center, Double-Blind, Placebo-Controlled, Dose-Response and Open-Label or Single Blind Booster Study to Evaluate the Safety and Immunogenicity of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects",Recruiting,,Phase 1,60.0,Anticipated,Public Health Vaccines LLC,,6.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-14 17:43:42,2023-06-14 17:43:42,INDUSTRY,,,,,
388519,388520,NCT05004181,,2021-08-05,,,2023-05-08,2021-08-05,2021-08-13,Actual,,,,,,,2023-05-08,2023-05-09,Actual,"August 25, 2021",Actual,2021-08-25,May 2023,2023-05-31,October 2023,Anticipated,2023-10-31,October 2023,Anticipated,2023-10-31,,Interventional,,,Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants,A Phase II Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Monovalent and Multivalent RNA-based Vaccines in Healthy Subjects,"Active, not recruiting",,Phase 2,1383.0,Actual,BioNTech SE,,12.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-18 00:28:57,2023-06-18 00:28:57,INDUSTRY,,,,,
388692,388693,NCT01829373,,2013-04-08,,,2013-04-10,2013-04-10,2013-04-11,Estimate,,,,,,,2013-04-10,2013-04-11,Estimate,October 2011,,2011-10-31,April 2013,2013-04-30,February 2013,Actual,2013-02-28,June 2012,Actual,2012-06-30,,Interventional,,,Lung Cancer Vaccine Plus Oral Dietary Supplement,Lung Cancer Immunotherapy With Vaccine 1650-G and Yeast Derived ß-Glucan,Completed,,Phase 1,5.0,Actual,University of Kentucky,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 23:34:15,2023-06-14 23:34:15,OTHER,,,,,
388844,388845,NCT01216332,,2010-10-05,2016-08-12,,2019-04-29,2010-10-05,2010-10-07,Estimate,2019-04-29,2019-05-03,Actual,,,,2019-04-29,2019-05-03,Actual,October 2010,,2010-10-31,April 2019,2019-04-30,May 2013,Actual,2013-05-31,May 2013,Actual,2013-05-31,,Interventional,,"Four subjects were excluded from the data analysis (from the high dose group), because they were given the second dose of TIV outside the study window period",Standard Versus High-Dose Trivalent Inactivated Flu Vaccine in Pediatric Acute Lymphoblastic Leukemia Patients,"Randomized, Double Blind, Comparison of Standard Dose Trivalent Inactivated Influenza Vaccine Versus High Dose Trivalent Inactivated Influenza Vaccine in Pediatric Patients With Acute Lymphoblastic Leukemia",Completed,,Phase 1,50.0,Actual,Vanderbilt University Medical Center,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 19:30:41,2023-06-15 19:30:41,OTHER,,,,,
388866,388867,NCT01385215,,2011-04-25,,,2012-12-05,2011-06-29,2011-06-30,Estimate,,,,,,,2012-12-05,2012-12-06,Estimate,April 2011,,2011-04-30,December 2012,2012-12-31,June 2011,Actual,2011-06-30,June 2011,Actual,2011-06-30,,Interventional,,,Strategies for Enhancing Mucosal Immunity to Influenza Vaccine,Strategies for Enhancing Mucosal Immunity to Influenza Vaccine,Completed,,Early Phase 1,60.0,Actual,Duke University,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 17:50:22,2023-06-14 17:50:22,OTHER,,,,,
388950,388951,NCT04896086,,2021-05-20,,,2023-05-08,2021-05-20,2021-05-21,Actual,,,,,,,2023-05-08,2023-05-09,Actual,"May 24, 2021",Actual,2021-05-24,"May 5, 2023",2023-05-05,"January 25, 2024",Anticipated,2024-01-25,"January 25, 2024",Anticipated,2024-01-25,,Interventional,,,"First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV, in Healthy Adults","VRC 325 (000410): A Phase I Open-Label Clinical Trial to Evaluate the Dose, Safety, Tolerability and Immunogenicity of Mosaic Quadrivalent Influenza Vaccine With and Without Adjuplex Compared With a Licensed Inactivated Seasonal QIV, In Healthy Adults","Active, not recruiting",,Phase 1,35.0,Actual,National Institutes of Health Clinical Center (CC),,8.0,,,False,,,,,True,False,,,,,,,,,No,.Only aggregate data will be shared.,2023-06-18 00:29:18,2023-06-18 00:29:18,NIH,,,,,
389011,389012,NCT01386489,,2011-06-30,,,2019-12-13,2011-06-30,2011-07-01,Estimate,,,,,,,2019-12-13,2019-12-16,Actual,"June 17, 2011",,2011-06-17,"March 19, 2014",2014-03-19,"March 19, 2014",Actual,2014-03-19,"March 9, 2014",Actual,2014-03-09,,Interventional,,,Immune Responses to Two Experimental HIV Vaccines in Healthy Adults,"VRC 016: A Phase 1b Open-Label, Randomized Clinical Trial to Evaluate Early Innate and Adaptive Immune Responses to the Investigational HIV-1 Vaccines: VRC-HIVADV014-00-VP and VRC-HIVDNA016-00-VP in Ad5 Seronegative Healthy Adults",Completed,,Phase 1,36.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 17:51:21,2023-06-14 17:51:21,NIH,,,,,
389012,389013,NCT01386502,,2011-06-30,,,2017-06-30,2011-06-30,2011-07-01,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"June 15, 2011",,2011-06-15,"October 31, 2011",2011-10-31,"October 31, 2011",Actual,2011-10-31,,,,,Interventional,,,CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors,Phase I Trial of Escalating Doses of Anti-PD1 Monoclonal Antibody (CT-011) in Combination With p53 Vaccine in Adults With Advanced Solid Tumors,Withdrawn,,Phase 1,0.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 17:51:22,2023-06-14 17:51:22,NIH,,,,,
389059,389060,NCT01026246,,2009-12-03,,,2013-03-28,2009-12-03,2009-12-04,Estimate,,,,,,,2013-03-28,2013-03-29,Estimate,June 2010,,2010-06-30,May 2012,2012-05-31,March 2012,Actual,2012-03-31,March 2012,Actual,2012-03-31,,Interventional,,,EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults,"Phase I, Double-Blinded, Placebo-Controlled Dosage-Escalation Study of the Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults",Completed,,Phase 1,60.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 19:10:18,2023-06-16 19:10:18,NIH,,,,,
389205,389206,NCT04799431,,2021-03-11,,,2023-05-05,2021-03-11,2021-03-16,Actual,,,,,,,2023-05-05,2023-05-09,Actual,"May 3, 2023",Actual,2023-05-03,May 2023,2023-05-31,"May 3, 2023",Actual,2023-05-03,"May 3, 2023",Actual,2023-05-03,,Interventional,,,Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer,A Pilot Study of a Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Adenocarcinoma,Withdrawn,,Phase 1,0.0,Actual,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,1.0,,Study never started,False,,,,True,True,False,,,,,,,,,No,,2023-06-18 00:29:35,2023-06-18 00:29:35,OTHER,,,,,
389483,389484,NCT01391494,,2011-07-11,,,2012-04-26,2011-07-11,2011-07-12,Estimate,,,,,,,2012-04-26,2012-04-27,Estimate,February 2011,,2011-02-28,January 2011,2011-01-31,June 2011,Actual,2011-06-30,June 2011,Actual,2011-06-30,,Interventional,,,"A Safety Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Adults, Children and Infants","A Phase I Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Adults, Children and Infants",Completed,,Phase 1,288.0,Actual,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,15.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 17:54:57,2023-06-14 17:54:57,OTHER,,,,,
389614,389615,NCT00283283,,2006-01-24,2016-12-22,,2021-02-10,2006-01-24,2006-01-27,Estimate,2020-06-18,2020-06-19,Actual,,,,2021-02-10,2021-02-12,Actual,November 2004,Actual,2004-11-30,February 2021,2021-02-28,May 2006,Actual,2006-05-31,November 2004,Actual,2004-11-30,,Interventional,,FCSR didn't report baseline demographics per arm they were presented by age group.,Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine,Clinical Study to Compare the Immune Response of Half Dose Trivalent Inactivated Influenza Vaccine (TIV) to Full Dose,Completed,,Phase 2,1316.0,Actual,U.S. Army Medical Research and Development Command,,8.0,,,False,,,,False,,,,,,,,,,,No,,2023-06-14 00:20:48,2023-06-14 00:20:48,FED,,,,,
390135,390136,NCT02564523,,2015-09-29,2022-02-09,2020-02-10,2022-02-09,2015-09-29,2015-09-30,Estimate,2022-02-09,2022-03-07,Actual,2020-02-10,2020-02-17,Actual,2022-02-09,2022-03-07,Actual,"November 6, 2015",Actual,2015-11-06,February 2022,2022-02-28,"February 12, 2019",Actual,2019-02-12,"February 12, 2019",Actual,2019-02-12,,Interventional,,,"Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults","A Randomized, Observer-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults, Including Elderly Subjects, HIV-infected Subjects, and Healthy Children in Two Age Strata in Africa",Completed,,Phase 2,1075.0,Actual,Janssen Vaccines & Prevention B.V.,,3.0,,,False,,,,True,,False,,,,,,,,,,,2023-06-14 18:00:55,2023-06-14 18:00:55,INDUSTRY,,,,,
390183,390184,NCT05273528,,2022-03-01,,,2022-03-01,2022-03-01,2022-03-10,Actual,,,,,,,2022-03-01,2022-03-10,Actual,"January 11, 2022",Actual,2022-01-11,March 2022,2022-03-31,"January 6, 2023",Anticipated,2023-01-06,"January 6, 2023",Anticipated,2023-01-06,,Interventional,Omicron,,The Immunogenicity and Safety of V-01-351/V-01D Bivalence Vaccine,"A Single Arm, Open Label Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of V-01-351/V-01D Bivalence Vaccine in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines","Active, not recruiting",,Phase 2,20.0,Actual,Livzon Pharmaceutical Group Inc.,,1.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-14 18:01:32,2023-06-14 18:01:32,INDUSTRY,,,,,
390318,390319,NCT05262673,,2022-02-21,,,2022-03-07,2022-02-21,2022-03-02,Actual,,,,,,,2022-03-07,2022-03-08,Actual,"March 1, 2022",Anticipated,2022-03-01,March 2022,2022-03-31,"December 31, 2025",Anticipated,2025-12-31,"December 31, 2024",Anticipated,2024-12-31,,Interventional,,,NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL,NGS-MRD Evaluation of Antigen-specific T Cells and DC Vaccine Combination Targeting B-cell Acute Lymphoblastic Leukemia,Recruiting,,Phase 1,10.0,Anticipated,Shenzhen Geno-Immune Medical Institute,,1.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-14 18:02:51,2023-06-14 18:02:51,OTHER,,,,,
390417,390418,NCT05075122,,2021-07-21,,,2022-03-08,2021-09-29,2021-10-12,Actual,,,,,,,2022-03-08,2022-03-09,Actual,"August 2, 2021",Actual,2021-08-02,March 2022,2022-03-31,February 2025,Anticipated,2025-02-28,August 2024,Anticipated,2024-08-31,,Interventional,FOCUS,,Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab,Phase 2 Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic PD-L1 Positive (CPS=1) Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab,Recruiting,,Phase 2,75.0,Anticipated,Martin-Luther-Universität Halle-Wittenberg,,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-14 18:03:52,2023-06-14 18:03:52,OTHER,,,,,
390444,390445,NCT04954131,,2021-07-06,,,2022-02-22,2021-07-06,2021-07-08,Actual,,,,,,,2022-02-22,2022-03-10,Actual,"August 10, 2021",Actual,2021-08-10,February 2022,2022-02-28,"November 15, 2022",Anticipated,2022-11-15,"November 15, 2021",Actual,2021-11-15,,Interventional,,,Immunogenicity and Safety Study of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adultsin China,"A Multi-center, Double-blind, Randomized, Controlled, Phase 2 Study to Evaluate the Immunogenicity and Safety of CpG 1018/Alum-adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Individuals Aged 18 Years and Older in China","Active, not recruiting",,Phase 2,766.0,Actual,"Zhejiang Clover Biopharmaceuticals, Inc.",,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-14 18:04:12,2023-06-14 18:04:12,INDUSTRY,,,,,
390710,390711,NCT04563273,,2020-06-19,,,2023-05-06,2020-09-22,2020-09-24,Actual,,,,,,,2023-05-06,2023-05-09,Actual,"October 21, 2020",Actual,2020-10-21,May 2023,2023-05-31,"October 30, 2022",Actual,2022-10-30,"October 30, 2022",Actual,2022-10-30,,Interventional,,,Clinical Study of BCG Vaccine for Intradermal Injection,"Randomized, Blinded, Placebo-Controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of BCG Vaccine for Intradermal Injection in 6-65 Year Olds",Completed,,Phase 1,160.0,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,4.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-18 00:30:20,2023-06-18 00:30:20,INDUSTRY,,,,,
390915,390916,NCT03359239,,2017-11-27,,,2023-05-12,2017-11-29,2017-12-02,Actual,,,,,,,2023-05-12,2023-05-16,Actual,"May 8, 2019",Actual,2019-05-08,May 2023,2023-05-31,"October 12, 2021",Actual,2021-10-12,"October 12, 2021",Actual,2021-10-12,,Interventional,,,Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer,"Pilot Study of Atezolizumab Plus PGV001, a Multipeptide Personalized Neoantigen Vaccine, in Patients With Locally Advanced or Metad or Metastatic Urothelial Cancer",Completed,,Phase 1,10.0,Actual,Icahn School of Medicine at Mount Sinai,,1.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-14 18:09:09,2023-06-14 18:09:09,OTHER,,,,,
391067,391068,NCT02427581,,2015-04-22,,,2022-03-09,2015-04-27,2015-04-28,Estimate,,,,,,,2022-03-09,2022-03-10,Actual,"September 29, 2015",Actual,2015-09-29,March 2022,2022-03-31,"December 31, 2025",Anticipated,2025-12-31,"December 31, 2025",Anticipated,2025-12-31,,Interventional,,,Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy,A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy,Withdrawn,,Phase 1,0.0,Actual,Washington University School of Medicine,,1.0,,Drugs not available,False,,,,True,True,False,,,,,,,,,No,,2023-06-14 18:11:12,2023-06-14 18:11:12,OTHER,,,,,
391314,391315,NCT01399424,,2011-07-20,,,2017-06-30,2011-07-20,2011-07-21,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"July 16, 2011",,2011-07-16,"April 25, 2012",2012-04-25,"April 25, 2012",Actual,2012-04-25,"April 25, 2012",Actual,2012-04-25,,Interventional,,,Shigella Sonnei OSPC-rDT Conjugate Vaccine,Shigella Sonnei OSPC-rDT Conjugate Vaccine,Withdrawn,,Phase 1,0.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 18:14:04,2023-06-14 18:14:04,NIH,,,,,
391337,391338,NCT01399853,,2011-07-19,,,2012-05-29,2011-07-19,2011-07-22,Estimate,,,,,,,2012-05-29,2012-05-31,Estimate,July 2011,,2011-07-31,May 2012,2012-05-31,May 2012,Actual,2012-05-31,November 2011,Actual,2011-11-30,,Interventional,,,A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants,A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants,Completed,,Phase 2,1200.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,10.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 18:14:21,2023-06-14 18:14:21,NETWORK,,,,,
391397,391398,NCT01400672,,2011-07-19,,,2020-03-16,2011-07-21,2011-07-22,Estimate,,,,,,,2020-03-16,2020-03-18,Actual,"July 17, 2012",Actual,2012-07-17,March 2020,2020-03-31,"October 8, 2018",Actual,2018-10-08,"March 7, 2016",Actual,2016-03-07,,Interventional,,,Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma,Imiquimod/BTIC Lysate-Based Vaccine Immunotherapy for Diffuse Intrinsic Pontine Glioma in Children and Young Adults,Terminated,,Phase 1,8.0,Actual,"Masonic Cancer Center, University of Minnesota",,1.0,,Treatment ineffective; Extreme toxicity,False,,,,True,,,,,,,,,,,,,2023-06-14 18:14:54,2023-06-14 18:14:54,OTHER,,,,,
391513,391514,NCT05284799,,2022-03-10,,,2022-12-15,2022-03-10,2022-03-17,Actual,,,,,,,2022-12-15,2022-12-16,Actual,"May 9, 2022",Actual,2022-05-09,December 2022,2022-12-31,"December 9, 2022",Actual,2022-12-09,"July 19, 2022",Actual,2022-07-19,,Interventional,,,Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.,"Phase 2a, Randomized, Double-blind (Double-dummy), Controlled, Parallel-group Study to Evaluate the Immunogenicity and the Safety of the Concomitant Administration of OVX836 Influenza Vaccine and a Quadrivalent Inactivated Influenza Vaccine Given Intramuscularly as 2 Separate Injections in the Same Arm, in Comparison to Co-administration of Quadrivalent Inactivated Influenza Vaccine and Placebo and to Co-administration of OVX836 and Placebo Given Intramuscularly in Healthy Subjects.",Completed,,Phase 2,180.0,Actual,Osivax,,3.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-15 19:37:25,2023-06-15 19:37:25,INDUSTRY,,,,,
391565,391566,NCT01403285,,2011-07-21,,,2014-05-16,2011-07-26,2011-07-27,Estimate,,,,,,,2014-05-16,2014-05-19,Estimate,August 2011,,2011-08-31,May 2014,2014-05-31,April 2014,Actual,2014-04-30,April 2014,Actual,2014-04-30,,Interventional,,,Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma,A Phase 1 Trial of Peptide-Based Glioma Vaccine IMA950 in Patients With Glioblastoma (GBM),Terminated,,Phase 1,6.0,Actual,Immatics Biotechnologies GmbH,,,,Due to poor accrual. This decision was taken without any safety reasons. Since beginning of the study (June 2011) only six patients were enrolled.,False,,,,True,,,,,,,,,,,,,2023-06-14 18:16:34,2023-06-14 18:16:34,INDUSTRY,,,,,
391830,391831,NCT01406509,,2011-07-26,,,2012-04-17,2011-07-29,2011-08-01,Estimate,,,,,,,2012-04-17,2012-04-19,Estimate,August 2011,,2011-08-31,April 2012,2012-04-30,December 2011,Actual,2011-12-31,November 2011,Actual,2011-11-30,,Interventional,,,"Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Children","A Phase I Clinical Trial for Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Children",Completed,,Phase 1,40.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 18:19:07,2023-06-14 18:19:07,NETWORK,,,,,
391908,391909,NCT01407497,,2011-08-01,,,2013-12-03,2011-08-01,2011-08-02,Estimate,,,,,,,2013-12-03,2013-12-04,Estimate,August 2011,,2011-08-31,December 2013,2013-12-31,August 2013,Actual,2013-08-31,March 2013,Actual,2013-03-31,,Interventional,,,Safety and Immunogenicity Study of a DNA Priming and MVA Boosting Strategy of HIV Vaccine,A Phase I Trial to Assess Safety and Immunogenicity of i.d. DNA Priming and i.m. MVA Boosting in Healthy Volunteers in Mozambique and to Develop Further HIV Vaccine Trial Capacity Building in Mozambique,Completed,,Phase 1,25.0,Actual,"Instituto Nacional de Saúde, Mozambique",,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 18:19:46,2023-06-14 18:19:46,OTHER_GOV,,,,,
391947,391948,NCT01258595,,2010-12-10,2011-09-19,,2016-04-12,2010-12-10,2010-12-13,Estimate,2011-09-19,2011-10-27,Estimate,,,,2016-04-12,2016-05-16,Estimate,November 2010,,2010-11-30,April 2016,2016-04-30,April 2011,Actual,2011-04-30,March 2011,Actual,2011-03-31,,Interventional,,,A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age,Safety and Immunogenicity of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age,Completed,,Phase 2,300.0,Actual,Sanofi,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 19:38:20,2023-06-15 19:38:20,INDUSTRY,,,,,
392372,392373,NCT01414504,,2011-08-02,,,2012-09-14,2011-08-10,2011-08-11,Estimate,,,,,,,2012-09-14,2012-09-17,Estimate,December 2009,,2009-12-31,September 2012,2012-09-30,September 2012,Actual,2012-09-30,September 2011,Actual,2011-09-30,,Interventional,PCVFU,,Pneumococcal Conjugate Vaccine Followup,Pneumococcal Conjugate Vaccine Followup: Investigation of Serotype-specific Antibody Persistence and B Cell Memory at Age 3-5 Years Following 23valent Pneumococcal Polysaccharide Vaccine at Age 9 Months in PNG Children Previously Primed With 7valent Pneumococcal Conjugate Vaccine,Completed,,Phase 2,280.0,Actual,Papua New Guinea Institute of Medical Research,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 18:24:24,2023-06-14 18:24:24,OTHER_GOV,,,,,
392389,392390,NCT01123941,,2010-05-13,2012-02-29,,2013-12-16,2010-05-13,2010-05-14,Estimate,2012-05-14,2012-06-13,Estimate,,,,2013-12-16,2014-01-17,Estimate,May 2010,,2010-05-31,December 2013,2013-12-31,November 2010,Actual,2010-11-30,June 2010,Actual,2010-06-30,,Interventional,,,Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old),"A Phase I, Randomized, Single-Blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Adult Subjects 18 to 40 Years of Age.",Completed,,Phase 1,50.0,Actual,Novartis,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 19:39:16,2023-06-15 19:39:16,INDUSTRY,,,,,
392513,392514,NCT01416038,,2011-08-09,,,2017-04-20,2011-08-11,2011-08-12,Estimate,,,,,,,2017-04-20,2017-04-21,Actual,December 2011,Actual,2011-12-31,April 2017,2017-04-30,May 2013,Actual,2013-05-31,May 2013,Actual,2013-05-31,,Interventional,,,"Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer","Phase 1-2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer",Completed,,Phase 1,19.0,Actual,"ImmunoVaccine Technologies, Inc. (IMV Inc.)",,3.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-14 18:25:35,2023-06-14 18:25:35,INDUSTRY,,,,,
392542,392543,NCT00996034,,2009-10-14,2012-09-12,,2015-11-19,2009-10-15,2009-10-16,Estimate,2015-11-19,2015-12-24,Estimate,,,,2015-11-19,2015-12-24,Estimate,September 2009,,2009-09-30,November 2015,2015-11-30,February 2011,Actual,2011-02-28,February 2011,Actual,2011-02-28,,Interventional,,,Nicotine Vaccination and Nicotinic Receptor Occupancy,123I-5-IA SPECT Imaging of Nicotinic Receptors and Effects of Nicotine Vaccine,Completed,,Phase 2,14.0,Actual,Yale University,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 19:39:44,2023-06-15 19:39:44,OTHER,,,,,
392814,392815,NCT01419925,,2011-08-17,,,2014-05-12,2011-08-17,2011-08-18,Estimate,,,,,,,2014-05-12,2014-05-13,Estimate,August 2011,,2011-08-31,May 2014,2014-05-31,January 2012,Actual,2012-01-31,January 2012,Actual,2012-01-31,,Interventional,,,A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers,"A Phase II Multicenter, Randomized, Placebo Controlled Study to Assess the Safety and Immunogenicity of an IM Influenza Vaccine (Multimeric-001) Followed by Administration of TIV to Elderly Volunteers.",Completed,,Phase 2,120.0,Actual,BiondVax Pharmaceuticals ltd.,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 18:28:18,2023-06-14 18:28:18,INDUSTRY,,,,,
393064,393065,NCT01423825,,2011-08-24,,,2021-10-13,2011-08-24,2011-08-26,Estimate,,,,,,,2021-10-13,2021-10-14,Actual,August 2011,,2011-08-31,October 2021,2021-10-31,July 2013,Actual,2013-07-31,July 2013,Actual,2013-07-31,,Interventional,,,"Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)","A Phase 1 Placebo-Controlled Study Extension to HVTN 073 / SAAVI 102, to Evaluate the Safety and Immunogenicity of Novartis Sub C gp140 Vaccine With MF59 Adjuvant, as a Boost Following SAAVI DNA-C2 Vaccine and SAAVI MVA-C Vaccine, in HIV Uninfected Healthy Adult Participants in South Africa and the United States",Completed,,Phase 1,27.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 18:30:55,2023-06-14 18:30:55,NIH,,,,,
393716,393717,NCT01434680,,2011-09-14,2013-07-18,,2017-03-13,2011-09-14,2011-09-15,Estimate,2014-02-24,2014-03-26,Estimate,,,,2017-03-13,2017-04-25,Actual,September 2011,,2011-09-30,March 2017,2017-03-31,November 2012,Actual,2012-11-30,November 2012,Actual,2012-11-30,,Interventional,,,Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers,"A Phase 2, Randomized, Comparative, Multicenter Observer-Blind Study Evaluating the Safety and Immunogenicity of the New Liquid Formulation of Novartis Meningococcal C Conjugate Vaccine and of the Novartis Lyophilized Meningococcal C Conjugate Vaccine Manufactured at Two Different Sites, in Healthy Toddlers",Completed,,Phase 2,992.0,Actual,Novartis,,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 00:22:01,2023-06-14 00:22:01,INDUSTRY,,,,,
393747,393748,NCT01428596,,2011-09-01,,,2020-06-08,2011-09-02,2011-09-05,Estimate,,,,,,,2020-06-08,2020-06-09,Actual,September 2010,,2010-09-30,June 2020,2020-06-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,,Interventional,GCHT01,,Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects,A Phase I Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Replication-defective HIV-1 Vaccine (HIVAX) in HIV-1 Infected Subjects Receiving Highly Active Antiretroviral Therapy,Unknown status,"Active, not recruiting",Phase 1,30.0,Anticipated,GeneCure Biotechnologies,,3.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-14 18:38:30,2023-06-14 18:38:30,INDUSTRY,,,,,
394110,394111,NCT00624182,,2008-02-19,,,2015-06-22,2008-02-19,2008-02-26,Estimate,,,,,,,2015-06-22,2015-06-23,Estimate,February 2008,,2008-02-29,June 2015,2015-06-30,December 2016,Anticipated,2016-12-31,April 2016,Anticipated,2016-04-30,,Interventional,,,Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer,"Phase 1 Study of Gemcitabine With Vaccine Therapy Targeting Tumor Antigen, URLC10, For The Patients With Unresectable or Recurrent Bile Duct Cancer",Suspended,,Phase 1,9.0,Anticipated,Akita University Hospital,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 19:42:37,2023-06-15 19:42:37,OTHER,,,,,
394143,394144,NCT01434381,,2011-09-10,,,2014-02-10,2011-09-13,2011-09-14,Estimate,,,,,,,2014-02-10,2014-02-11,Estimate,August 2011,,2011-08-31,February 2014,2014-02-28,August 2013,Actual,2013-08-31,August 2013,Actual,2013-08-31,,Interventional,,,Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark),"Open Label Phase 1 Study in Malaria Naive Adults of the Safety and Immunogenicity of Pfs25-EPA/Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum",Completed,,Phase 1,30.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 18:42:18,2023-06-14 18:42:18,NIH,,,,,
394156,394157,NCT00961883,,2009-08-17,,,2013-09-04,2009-08-17,2009-08-19,Estimate,,,,,,,2013-09-04,2013-09-06,Estimate,August 2009,,2009-08-31,September 2013,2013-09-30,,,,January 2013,Actual,2013-01-31,,Interventional,,,"Safety of and Immune Response to Prime/Boost Vaccine Regimens in Healthy, HIV-1 Uninfected, Ad5 Seronegative Adults","A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Heterologous Prime/Boost Vaccine Regimens (NYVAC-B/rAd5 vs. rAd5/NYVAC-B) in Healthy, HIV-1 Uninfected, Ad5 Seronegative Adult Participants",Completed,,Phase 1,80.0,Actual,HIV Vaccine Trials Network,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 19:13:38,2023-06-16 19:13:38,NETWORK,,,,,
394196,394197,NCT01435135,,2011-09-08,,,2020-11-02,2011-09-14,2011-09-15,Estimate,,,,,,,2020-11-02,2020-11-03,Actual,April 2012,Actual,2012-04-30,November 2020,2020-11-30,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,,Interventional,,,Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144,"Randomized, Double Blind Evaluation of Late Boost Strategies for HIV-uninfected Participants in the HIV Vaccine Efficacy Trial RV 144: ""Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming With VaxGen gp120 B/E (AIDSVAX B/E) Boosting in HIV-uninfected Thai Adults""",Unknown status,"Active, not recruiting",Phase 2,162.0,Anticipated,U.S. Army Medical Research and Development Command,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 18:42:50,2023-06-14 18:42:50,FED,,,,,
394217,394218,NCT01435499,,2011-09-08,,,2016-05-23,2011-09-14,2011-09-16,Estimate,,,,,,,2016-05-23,2016-05-24,Estimate,September 2011,,2011-09-30,May 2016,2016-05-31,March 2016,Actual,2016-03-31,January 2013,Actual,2013-01-31,,Interventional,,,Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma,A Feasibility and Toxicity Study of a Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Secreting Allogeneic Melanoma Vaccine Administered Alone or in Combination With Cyclophosphamide in Subjects With Surgically Resected At-Risk Melanoma,Completed,,Phase 1,21.0,Actual,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 18:43:05,2023-06-14 18:43:05,OTHER,,,,,
394274,394275,NCT01436422,,2011-09-16,,,2015-08-19,2011-09-16,2011-09-19,Estimate,,,,,,,2015-08-19,2015-08-20,Estimate,August 2011,,2011-08-31,August 2015,2015-08-31,March 2014,Actual,2014-03-31,March 2014,Actual,2014-03-31,,Interventional,,,Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine,A Phase 1 Evaluation of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine Admixtures TV003 and TV005 in Healthy Flavivirus-Naïve Adult Subjects,Completed,,Phase 1,112.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 18:43:33,2023-06-14 18:43:33,NIH,,,,,
394977,394978,NCT01438606,,2011-09-19,,,2021-10-13,2011-09-20,2011-09-22,Estimate,,,,,,,2021-10-13,2021-10-15,Actual,October 2011,,2011-10-31,October 2021,2021-10-31,,,,January 2013,Actual,2013-01-31,,Interventional,,,"Evaluating the Safety of and Immune Response to the VSV-Indiana HIV Vaccine in Healthy, HIV-Uninfected Adults","A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of VSV-Indiana HIV Gag Vaccine Given Intramuscularly in Healthy, HIV-1-Uninfected Adult Participants",Completed,,Phase 1,60.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,10.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 18:49:44,2023-06-14 18:49:44,NIH,,,,,
395131,395132,NCT00290147,,2006-02-09,2017-03-02,,2017-05-23,2006-02-09,2006-02-10,Estimate,2017-03-02,2017-04-14,Actual,,,,2017-05-23,2017-06-20,Actual,January 2006,,2006-01-31,May 2017,2017-05-31,April 2009,Actual,2009-04-30,December 2006,Actual,2006-12-31,,Interventional,,,Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine,"An Open-Label, Dose Escalation, Phase I Safety, and Immunogenicity Trial of a Dengue Serotype 1 (DEN-1) Premembrane (prM) and Envelope (E) DNA Vaccine (D1ME100) in Healthy Adults Volunteers",Completed,,Phase 1,22.0,Actual,U.S. Army Medical Research and Development Command,,2.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-14 00:22:57,2023-06-14 00:22:57,FED,,,,,
395204,395205,NCT01441167,,2011-09-24,,,2018-07-03,2011-09-24,2011-09-27,Estimate,,,,,,,2018-07-03,2018-07-05,Actual,"September 14, 2011",,2011-09-14,"June 5, 2013",2013-06-05,"June 5, 2013",Actual,2013-06-05,"June 5, 2013",Actual,2013-06-05,,Interventional,,,Experimental PfSPZ Vaccine in Adults Without Malaria,"VRC 312: A Phase 1, Open-Label, Dose-Escalation Clinical Trial With Experimental Challenge to Evaluate Intravenous Administration of the PfSPZ Vaccine in Malaria-Naive Adults",Completed,,Phase 1,64.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-14 18:51:20,2023-06-14 18:51:20,NIH,,,,,
395205,395206,NCT01441193,,2011-09-26,,,2016-03-03,2011-09-26,2011-09-27,Estimate,,,,,,,2016-03-03,2016-03-04,Estimate,September 2011,,2011-09-30,March 2016,2016-03-31,February 2014,Actual,2014-02-28,February 2014,Actual,2014-02-28,,Interventional,,,A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002),"A Phase I, Open Label, Safety and Immunogenicity Vaccine Trial Based on the Association of Recombinant HIV-1 Biologically Active Tat and V2-deleted Env Proteins in HIV Uninfected Healthy Adult Volunteers.",Terminated,,Phase 1,11.0,Actual,Istituto Superiore di Sanità,,4.0,,"Enrollments were suspended due to delta-V2 Env unavailability, following the EMA/CHMP/BWP/534898/2008 guideline, not allowing the use of a retest date",False,,,,True,,,,,,,,,,,,,2023-06-14 18:51:20,2023-06-14 18:51:20,OTHER,,,,,
395351,395352,NCT01443117,,2011-09-27,,,2021-10-28,2011-09-27,2011-09-29,Estimate,,,,,,,2021-10-28,2021-11-01,Actual,,,,October 2021,2021-10-31,,,,August 2014,Anticipated,2014-08-31,,Interventional,,,Evaluating the Safety and Immune Response to Two Pneumococcal Vaccines in HIV-Infected Pregnant Women,"Administration of Polysaccharide or Conjugated Pneumococcal Vaccines to HIV-Infected Pregnant Women: Safety and Magnitude, Persistence, and Transplacental Transfer of Vaccine-Serotype Pneumococcal Anti-Capsular Antibodies",Withdrawn,,Phase 2,0.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 18:52:40,2023-06-14 18:52:40,NIH,,,,,
395414,395415,NCT01443663,,2011-09-28,,,2016-02-05,2011-09-28,2011-09-30,Estimate,,,,,,,2016-02-05,2016-02-09,Estimate,October 2011,,2011-10-31,February 2016,2016-02-29,March 2013,Actual,2013-03-31,September 2012,Actual,2012-09-30,,Interventional,,,Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine,"Immunogenicity and Safety Study of a 45 Micrograms Dose of Inactivated, Unadjuvanted H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H5N1 and H7N3 Influenza Vaccines and in H5 and Live Attenuated Vaccine Naïve Individuals",Completed,,Phase 1,69.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 18:53:02,2023-06-14 18:53:02,NIH,,,,,
395444,395445,NCT00973895,,2009-09-05,,,2017-06-30,2009-09-05,2009-09-09,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"August 6, 2009",,2009-08-06,"September 3, 2010",2010-09-03,"September 3, 2010",Actual,2010-09-03,"September 3, 2010",Actual,2010-09-03,,Interventional,,,"VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years Old","VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years Old",Completed,,Phase 1,20.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-16 19:15:33,2023-06-16 19:15:33,NIH,,,,,
395473,395474,NCT01444482,,2011-08-19,,,2011-09-29,2011-09-29,2011-09-30,Estimate,,,,,,,2011-09-29,2011-09-30,Estimate,May 2011,,2011-05-31,September 2011,2011-09-30,,,,November 2011,Anticipated,2011-11-30,,Interventional,,,Study of Parenterally Administrated Adjuvanted Seasonal Influenza Vaccine in Healthy Elderly Volunteers,A Phase I Single Blinded Randomised Exploratory Trial in Elderly Volunteers to Assess and Compare Safety and Immunogenicity of Adjuvanted Seasonal Influenza Vaccine (Investigational Vaccine) to Standard Seasonal Influenza Vaccine.,Unknown status,"Active, not recruiting",Phase 1,110.0,Actual,Isconova AB,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 18:53:31,2023-06-14 18:53:31,INDUSTRY,,,,,
395516,395517,NCT01445002,,2011-09-26,,,2013-01-10,2011-09-30,2011-10-03,Estimate,,,,,,,2013-01-10,2013-01-14,Estimate,October 2011,,2011-10-31,January 2013,2013-01-31,October 2012,Actual,2012-10-31,March 2012,Actual,2012-03-31,,Interventional,,,Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy,"Safety and Dose Finding Study Based on the Effects of Three Subcutaneous Injections of BM32, a Recombinant Hypoallergenic Grass Pollen Vaccine, on Responses to Allergen Challenge by Skin Testing and in the Vienna Challenge Chamber (VCC) as Well as Immunological Response in Subjects Know to Suffer From Grass-pollen Induced Allergic Rhinitis",Completed,,Phase 2,79.0,Actual,Biomay AG,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 18:53:50,2023-06-14 18:53:50,INDUSTRY,,,,,
395553,395554,NCT00427908,,2007-01-26,2017-05-04,2012-08-02,2018-05-08,2007-01-26,2007-01-29,Estimate,2018-05-08,2018-06-04,Actual,2012-08-02,2012-08-07,Estimate,2018-05-08,2018-06-04,Actual,"February 7, 2007",Actual,2007-02-07,May 2018,2018-05-31,"December 3, 2007",Actual,2007-12-03,"December 3, 2007",Actual,2007-12-03,,Interventional,,,Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612,Evaluate Non-Inferiority and Persistence of the Immune Response of GSK Biologicals' Meningococcal Vaccine 134612 Versus Meningitec or Mencevax ACWY in Healthy Subjects (1-10 Years of Age),Completed,,Phase 2,613.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 19:32:51,2023-06-16 19:32:51,INDUSTRY,,,,,
395581,395582,NCT03934541,,2019-04-29,2022-02-08,,2022-06-15,2019-04-29,2019-05-02,Actual,2022-04-20,2022-05-12,Actual,,,,2022-06-15,2022-07-06,Actual,"August 26, 2019",Actual,2019-08-26,June 2022,2022-06-30,"May 26, 2021",Actual,2021-05-26,"February 5, 2021",Actual,2021-02-05,,Interventional,,,"Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants","A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants",Completed,,Phase 1,24.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-16 19:15:46,2023-06-16 19:15:46,NIH,,,,,
395585,395586,NCT01445743,,2011-09-23,,,2014-02-12,2011-09-30,2011-10-04,Estimate,,,,,,,2014-02-12,2014-02-14,Estimate,September 2011,,2011-09-30,February 2014,2014-02-28,February 2014,Actual,2014-02-28,August 2012,Actual,2012-08-31,,Interventional,,,Immunogenicity and Safety of an Acellular DPT Vaccine During Pregnancy,"Immunogenicity and Safety of an Acellular DPT Vaccine in Pregnant Women in Nuevo Leon, Mexico",Completed,,Phase 2,204.0,Actual,Hospital Universitario Dr. Jose E. Gonzalez,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 18:54:14,2023-06-14 18:54:14,OTHER,,,,,
395666,395667,NCT01446926,,2011-10-03,,,2018-01-09,2011-10-03,2011-10-05,Estimate,,,,,,,2018-01-09,2018-01-10,Actual,September 2011,,2011-09-30,January 2018,2018-01-31,June 2013,Actual,2013-06-30,March 2013,Actual,2013-03-31,,Interventional,,,"Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants","Safety and Immunogenicity of Pneumococcal Protein Vaccine (PPrV) in Healthy Adults, Toddlers and Infants in Bangladesh",Completed,,Phase 1,280.0,Actual,Sanofi,,11.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 18:55:09,2023-06-14 18:55:09,INDUSTRY,,,,,
396678,396679,NCT02684383,,2016-02-16,,,2016-11-29,2016-02-16,2016-02-18,Estimate,,,,,,,2016-11-29,2016-11-30,Estimate,,,,November 2016,2016-11-30,July 2016,Actual,2016-07-31,July 2016,Actual,2016-07-31,,Interventional,,,"Evaluation of the Safety and Immunogenicity of rDEN3<U+0394>30, a Live Attenuated Monovalent Dengue Virus Vaccine","A Phase 1 Evaluation of the Safety and Immunogenicity of rDEN3<U+0394>30, a Live Attenuated Monovalent Dengue Virus Vaccine",Completed,,Phase 1,14.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 20:49:35,2023-06-15 20:49:35,NIH,,,,,
397009,397010,NCT01477580,,2011-11-18,,,2019-01-11,2011-11-18,2011-11-22,Estimate,,,,,,,2019-01-11,2019-01-15,Actual,"July 23, 2012",Actual,2012-07-23,January 2019,2019-01-31,"December 11, 2014",Actual,2014-12-11,"January 23, 2014",Actual,2014-01-23,,Interventional,,,Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001),"A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Tetravalent Recombinant Subunit Dengue Vaccine (V180) in Healthy Adults",Completed,,Phase 1,98.0,Actual,Merck Sharp & Dohme LLC,,13.0,,,False,,,,True,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2023-06-14 19:09:00,2023-06-14 19:09:00,INDUSTRY,,,,,
397142,397143,NCT01479296,,2011-11-22,,,2021-10-13,2011-11-22,2011-11-24,Estimate,,,,,,,2021-10-13,2021-10-15,Actual,December 2011,,2011-12-31,October 2021,2021-10-31,"November 27, 2017",Actual,2017-11-27,May 2013,Actual,2013-05-31,,Interventional,,,"Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults",A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans,Completed,,Phase 1,90.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 19:10:21,2023-06-14 19:10:21,NIH,,,,,
397300,397301,NCT01859325,,2013-05-16,2018-03-09,,2020-02-24,2013-05-17,2013-05-21,Estimate,2018-03-09,2018-04-09,Actual,,,,2020-02-24,2020-03-03,Actual,"May 10, 2013",Actual,2013-05-10,May 2018,2018-05-31,"February 26, 2017",Actual,2017-02-26,"February 26, 2017",Actual,2017-02-26,,Interventional,,,Therapeutic Vaccine for HIV,"A Phase I Randomized, Double-Blind, Placebo-Controlled Study of a Multi-Antigen DNA Vaccine Prime Delivered by In Vivo Electroporation, rVSV Booster Vaccine in HIV-Infected Patients Who Began Antiretroviral Therapy During Acute/Early Infection",Completed,,Phase 1,33.0,Actual,National Institutes of Health Clinical Center (CC),,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-14 00:23:42,2023-06-14 00:23:42,NIH,,,,,
397376,397377,NCT01482052,,2011-11-23,,,2013-01-11,2011-11-28,2011-11-30,Estimate,,,,,,,2013-01-11,2013-01-14,Estimate,November 2011,,2011-11-30,January 2013,2013-01-31,January 2013,Actual,2013-01-31,January 2013,Actual,2013-01-31,,Interventional,,,"Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis","A Double-Blind, Randomized, Controlled, Two Arm Phase 1 Clinical Trial of the Safety and Immunogenicity of Group A, C, Y & W-135 Meningococcal Polysaccharide DT Conjugate Vaccine: NmVac4-A/C/Y/W-135-DT",Completed,,Phase 1,60.0,Actual,JN-International Medical Corporation,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 19:12:14,2023-06-14 19:12:14,INDUSTRY,,,,,
397496,397497,NCT01483274,,2011-11-03,,,2017-05-08,2011-11-30,2011-12-01,Estimate,,,,,,,2017-05-08,2017-05-09,Actual,March 2015,,2015-03-31,May 2017,2017-05-31,June 2015,Actual,2015-06-30,June 2015,Actual,2015-06-30,,Interventional,AML,,Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation,Pharmacologic Upregulation of Cancer Testis Antigens Followed by Vaccine Therapy for Patients With Relapsed Acute Myelogenous Leukemia (AML) Following Allogeneic Stem Cell Transplantation,Withdrawn,,Phase 1,0.0,Actual,University of Louisville,,2.0,,Adult patient population barriers.,False,,,,True,,,,,,,,,,,,,2023-06-14 19:13:02,2023-06-14 19:13:02,OTHER,,,,,
397576,397577,NCT01484548,,2011-11-29,,,2014-02-24,2011-11-30,2011-12-02,Estimate,,,,,,,2014-02-24,2014-02-26,Estimate,January 2012,,2012-01-31,February 2014,2014-02-28,May 2013,Actual,2013-05-31,August 2012,Actual,2012-08-31,,Interventional,,,Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers,"A Phase 1, Randomized Clinical Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of The LEISH-F3 + GLA-SE Vaccine Compared To The LEISH-F3 Protein Alone In Healthy Adult Subjects",Completed,,Phase 1,36.0,Actual,Access to Advanced Health Institute (AAHI),,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 19:13:50,2023-06-14 19:13:50,OTHER,,,,,
397610,397611,NCT02948829,,2016-10-26,2021-03-26,,2023-04-26,2016-10-26,2016-10-28,Estimate,2021-03-26,2021-04-26,Actual,,,,2023-04-26,2023-05-24,Actual,"April 3, 2017",Actual,2017-04-03,April 2023,2023-04-30,"December 14, 2020",Actual,2020-12-14,"October 16, 2017",Actual,2017-10-16,,Interventional,,Safety Set included all enrolled participants who received at least 1 dose of TDV.,Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children,"An Open Label, Phase 2 Study to Investigate Cell-mediated Immunity and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Healthy Children Aged 4 to 16 Years",Completed,,Phase 2,200.0,Actual,Takeda,,1.0,,,False,,,,True,False,False,,,,,,,"IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.",https://vivli.org/ourmember/takeda/,Yes,"Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.",2023-06-13 23:17:39,2023-06-13 23:17:39,INDUSTRY,,,,,
397652,397653,NCT01485406,,2011-12-01,,,2021-02-08,2011-12-01,2011-12-05,Estimate,,,,,,,2021-02-08,2021-02-10,Actual,"December 12, 2011",Actual,2011-12-12,February 2021,2021-02-28,"March 15, 2012",Actual,2012-03-15,"March 15, 2012",Actual,2012-03-15,,Interventional,,,Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers,Safety and Immunogenicity Study of GSK Biologicals' Pneumococcal Vaccine 2830930A When Administered as a Single Dose in Healthy Toddlers Aged 12-23 Months,Completed,,Phase 1,61.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (copy the URL below to your browser),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=20770,Yes,IPD for this study is available via the Clinical Study Data Request site.,2023-06-14 19:14:26,2023-06-14 19:14:26,INDUSTRY,,,,,
397737,397738,NCT01486329,,2011-12-02,,,2015-06-05,2011-12-05,2011-12-06,Estimate,,,,,,,2015-06-05,2015-06-08,Estimate,December 2011,,2011-12-31,June 2015,2015-06-30,December 2014,Actual,2014-12-31,October 2014,Actual,2014-10-31,,Interventional,,,"VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer","VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer to Examine Safety, Tolerability, and Immune Response to the Investigational VEGFR-2 DNA Vaccine VXM01",Completed,,Phase 1,72.0,Actual,Vaximm GmbH,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 19:14:59,2023-06-14 19:14:59,INDUSTRY,,,,,
397974,397975,NCT01487876,,2011-09-22,,,2011-12-07,2011-12-07,2011-12-08,Estimate,,,,,,,2011-12-07,2011-12-08,Estimate,September 2011,,2011-09-30,September 2011,2011-09-30,December 2012,Anticipated,2012-12-31,August 2012,Anticipated,2012-08-31,,Interventional,,,Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients,A Randomized Controlled Trial of Dual-plasmid HBV DNA Vaccine Mediated by in Vivo Electroporation in Chronic Hepatitis B Patients Under Lamivudine Chemotherapy,Unknown status,Recruiting,Phase 2,240.0,Anticipated,The 458 Hospital of Chinese PLA,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 19:16:12,2023-06-14 19:16:12,OTHER,,,,,
398125,398126,NCT01489618,,2011-12-08,,,2016-02-23,2011-12-08,2011-12-09,Estimate,,,,,,,2016-02-23,2016-02-24,Estimate,June 2009,,2009-06-30,February 2016,2016-02-29,March 2013,Actual,2013-03-31,March 2013,Actual,2013-03-31,,Interventional,EVAD,,"""Prime Boost"" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency","Randomised, Multicentric, Phase ii Study of the Immunogenicity of a ""Prime Boost"" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency",Terminated,,Phase 2,45.0,Actual,"Institut National de la Santé Et de la Recherche Médicale, France",,2.0,,End of production,False,,,,True,,,,,,,,,,,,,2023-06-14 19:17:27,2023-06-14 19:17:27,OTHER_GOV,,,,,
398283,398284,NCT02274415,,2014-09-22,,,2022-09-06,2014-10-22,2014-10-24,Estimate,,,,,,,2022-09-06,2022-09-09,Actual,"September 16, 2013",Actual,2013-09-16,October 2017,2017-10-31,"April 10, 2019",Actual,2019-04-10,"September 18, 2017",Actual,2017-09-18,,Interventional,DREVAC,,Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells Disease,Study of the Immunogenicity of a Prime Boost Vaccination Strategy Combining Conjugated Anti-pneumococcal and Polysaccharide Anti-pneumococcal Vaccine Compared to Polysaccharide Anti -Pneumococcal Vaccine Alone in Patients With Sickle Cells Disease,Completed,,Phase 2,116.0,Actual,Assistance Publique - Hôpitaux de Paris,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-13 23:20:54,2023-06-13 23:20:54,OTHER,,,,,
398406,398407,NCT00985673,,2009-09-24,2011-12-21,,2018-07-04,2009-09-24,2009-09-28,Estimate,2011-12-21,2012-01-30,Estimate,,,,2018-07-04,2018-08-01,Actual,"October 1, 2009",,2009-10-01,September 2016,2016-09-30,"December 29, 2010",Actual,2010-12-29,"December 28, 2009",Actual,2009-12-28,,Interventional,,,Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults,A Study to Evaluate the Safety and Immunogenicity of an A/California/7/2009 (H1N1)V-like Vaccine GSK2340274A or GSK2340273A Co-administered With Trivalent Inactivated Seasonal Influenza Vaccine in Adults 19 to 40 Years of Age,Completed,,Phase 2,611.0,Actual,GlaxoSmithKline,,6.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-13 23:21:23,2023-06-13 23:21:23,INDUSTRY,,,,,
398462,398463,NCT01492985,,2011-11-24,,,2019-07-02,2011-12-13,2011-12-15,Estimate,,,,,,,2019-07-02,2019-07-05,Actual,July 2013,Actual,2013-07-31,February 2018,2018-02-28,"April 8, 2017",Actual,2017-04-08,October 2016,Actual,2016-10-31,,Interventional,,,Lipopeptide Immunisation With GTU-multiHIV Trial,Evaluation of a Therapeutic Immunization Strategy Associating a DNA Vaccine (GTU-MultiHIV B) Followed by a Lipopeptide Vaccine (LIPO-5) in the Control of Viral Replication Following Antiretroviral Treatment Interruption in HIV-1 Infected Patients With a CD4 Cell Count = 600/mm3,Completed,,Phase 2,103.0,Actual,"ANRS, Emerging Infectious Diseases",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 19:19:41,2023-06-14 19:19:41,OTHER_GOV,,,,,
398475,398476,NCT01493154,,2011-11-21,,,2018-11-20,2011-12-13,2011-12-15,Estimate,,,,,,,2018-11-20,2018-11-23,Actual,April 2012,,2012-04-30,November 2018,2018-11-30,October 2015,Actual,2015-10-31,October 2015,Actual,2015-10-31,,Interventional,,,Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients,A Phase I Clinical Trial Assessing the Safety and Feasibility of Administration of pNGVL4a-CRT/E7(Detox) DNA Vaccine Using the Intramuscular TriGridTM Delivery System in Combination With Cyclophosphamide in HPV-16 Associated Head and Neck Cancer Patients,Terminated,,Phase 1,2.0,Actual,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,4.0,,Study Funding Terminated,False,,,,True,,,,,,,,,,,,,2023-06-14 19:19:47,2023-06-14 19:19:47,OTHER,,,,,
398577,398578,NCT01494740,,2011-12-15,,,2011-12-16,2011-12-16,2011-12-19,Estimate,,,,,,,2011-12-16,2011-12-19,Estimate,December 2009,,2009-12-31,October 2009,2009-10-31,January 2010,Actual,2010-01-31,January 2010,Actual,2010-01-31,,Interventional,,,Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants,Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants,Completed,,Phase 2,312.0,Actual,Shanghai Institute Of Biological Products,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 19:20:50,2023-06-14 19:20:50,INDUSTRY,,,,,
398721,398722,NCT01496989,,2011-12-19,,,2013-08-30,2011-12-21,2011-12-22,Estimate,,,,,,,2013-08-30,2013-09-02,Estimate,December 2011,,2011-12-31,August 2013,2013-08-31,,,,March 2013,Actual,2013-03-31,,Interventional,,,Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers,"A Phase 1 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate Safety and Immunogenicity of a Multiantigen HIV (HIV-MAG) pDNA Vaccine With or Without Human IL-12 pDNA GENEVAX® IL-12) and Ad35-GRIN/ENV Vaccine in HIV-Uninfected, Healthy Volunteers",Completed,,Phase 1,75.0,Anticipated,International AIDS Vaccine Initiative,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 19:22:18,2023-06-14 19:22:18,NETWORK,,,,,
398772,398773,NCT01497769,,2011-12-20,,,2013-07-01,2011-12-20,2011-12-22,Estimate,,,,,,,2013-07-01,2013-07-02,Estimate,September 2011,,2011-09-30,July 2013,2013-07-31,April 2013,Actual,2013-04-30,October 2012,Actual,2012-10-31,,Interventional,,,"Safety of Tuberculosis Vaccine, MVA85A, Administered by the Aerosol Route and the Intradermal Route",A Phase I Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine MVA85A Administered by the Aerosol Inhaled Route and the Intradermal Route in Healthy BCG-vaccinated Adult Subjects,Completed,,Phase 1,24.0,Actual,University of Oxford,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 19:22:49,2023-06-14 19:22:49,OTHER,,,,,
398821,398822,NCT01498718,,2011-12-21,,,2016-03-23,2011-12-21,2011-12-23,Estimate,,,,,,,2016-03-23,2016-03-24,Estimate,December 2011,,2011-12-31,March 2016,2016-03-31,April 2013,Actual,2013-04-30,April 2013,Actual,2013-04-30,,Interventional,,,Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone,"Double-Blind, Randomized Phase 1b Study of 2011/12 Influenza Investigational DNA Vaccine, VRC-FLUDNA061-00-VP, Followed by 2012/13 Trivalent Inactivated Vaccine (TIV) Compared to 2012/13 TIV Alone in Healthy Adults",Completed,,Phase 1,131.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 19:23:21,2023-06-14 19:23:21,NIH,,,,,
399037,399038,NCT00992836,,2009-10-08,2011-08-23,,2021-11-03,2009-10-08,2009-10-09,Estimate,2012-01-05,2012-02-09,Estimate,,,,2021-11-03,2021-11-05,Actual,October 2009,,2009-10-31,December 2014,2014-12-31,August 2010,Actual,2010-08-31,August 2010,Actual,2010-08-31,,Interventional,,,Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth,A Phase II Study to Assess the Safety and Immunogenicity of an Inactivated Swine-Origin H1N1 Influenza Vaccine in HIV-1 Perinatally Infected Children and Youth,Completed,,Phase 2,155.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 19:53:34,2023-06-15 19:53:34,NIH,,,,,
399099,399100,NCT01502345,,2011-12-23,,,2013-01-30,2011-12-29,2011-12-30,Estimate,,,,,,,2013-01-30,2013-01-31,Estimate,January 2012,,2012-01-31,January 2013,2013-01-31,January 2013,Actual,2013-01-31,January 2013,Actual,2013-01-31,,Interventional,HTNV/PUUV,,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines","Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines, pWRG/HTN-M(x) and pWRG/PUU-M(s2), for Prevention of Hemorrhagic Fever With Renal Syndrome Administered to Healthy Adult Volunteers Using the TDS-IM Electroporation Delivery Device",Completed,,Phase 1,31.0,Actual,U.S. Army Medical Research and Development Command,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 19:25:53,2023-06-14 19:25:53,FED,,,,,
399100,399101,NCT01502358,,2011-12-15,,,2016-11-03,2011-12-28,2011-12-30,Estimate,,,,,,,2016-11-03,2016-11-04,Estimate,December 2011,,2011-12-31,April 2015,2015-04-30,December 2013,Actual,2013-12-31,December 2013,Actual,2013-12-31,,Interventional,TVDV,,Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease,"A Phase 1 Study To Evaluate The Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue (Serotype 1, 2, 3, and 4) Plasmid DNA Vaccine (TVDV) Formulated With and Without Vaxfectin®",Completed,,Phase 1,40.0,Actual,U.S. Army Medical Research and Development Command,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 19:25:54,2023-06-14 19:25:54,FED,,,,,
399129,399130,NCT01502735,,2011-12-16,,,2015-04-21,2011-12-29,2012-01-02,Estimate,,,,,,,2015-04-21,2015-04-22,Estimate,December 2011,,2011-12-31,April 2015,2015-04-30,September 2013,Actual,2013-09-30,September 2013,Actual,2013-09-30,,Interventional,DENV-1 PIV,,Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease,A Phase 1 Trial of the Walter Reed Army Institute of Research (WRAIR) Dengue Virus Serotype-1 Purified Inactivated Vaccine (DENV-1 PIV) in Flavivirus Antibody Naïve Adults,Completed,,Phase 1,20.0,Actual,U.S. Army Medical Research and Development Command,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 19:26:10,2023-06-14 19:26:10,FED,,,,,
399478,399479,NCT01506570,,2012-01-05,,,2015-08-19,2012-01-09,2012-01-10,Estimate,,,,,,,2015-08-19,2015-08-20,Estimate,December 2011,,2011-12-31,August 2015,2015-08-31,September 2013,Actual,2013-09-30,September 2013,Actual,2013-09-30,,Interventional,,,Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine,A Phase 1 Evaluation of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine Admixtures TV003 and TV005 in Healthy Flavivirus-experienced Adult Subjects,Completed,,Phase 1,58.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 19:29:06,2023-06-14 19:29:06,NIH,,,,,
399649,399650,NCT01509144,,2012-01-04,,,2014-05-20,2012-01-09,2012-01-12,Estimate,,,,,,,2014-05-20,2014-05-21,Estimate,January 2012,,2012-01-31,May 2014,2014-05-31,October 2013,Actual,2013-10-31,June 2013,Actual,2013-06-30,,Interventional,,,EuroNeut41: Safety & Immunogenicity of Immunisations With HIV Vaccine,"Phase 1, Randomised, Single-centre, Observer-blind Clinical Trial of Safety and Immunogenicity of Nasal-prime and Intramuscular Boost Immunisation With EN41-FPA2 HIV Vaccine in Healthy Female Volunteers",Completed,,Phase 1,48.0,Actual,PX'Therapeutics,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 19:30:55,2023-06-14 19:30:55,INDUSTRY,,,,,
399673,399674,NCT00980447,,2009-09-17,,,2010-02-05,2009-09-18,2009-09-21,Estimate,,,,,,,2010-02-05,2010-02-08,Estimate,October 2009,,2009-10-31,February 2010,2010-02-28,December 2009,Actual,2009-12-31,December 2009,Actual,2009-12-31,,Interventional,,,"Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults","A Multicenter, Non-Blinded, Dose Escalation Study to Evaluate the Immunogenicity, Safety and Optimal Dose of Three Doses Regimen of Recombinant Influenza H5N1 Vaccine, After Two Vaccinations Given 3 Weeks Apart, in Healthy Young Adults.",Completed,,Phase 2,90.0,Actual,UMN Pharma Inc.,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 19:17:10,2023-06-16 19:17:10,INDUSTRY,,,,,
399978,399979,NCT01512277,,2012-01-09,,,2013-08-26,2012-01-13,2012-01-19,Estimate,,,,,,,2013-08-26,2013-08-27,Estimate,September 1998,,1998-09-30,August 2013,2013-08-31,September 1999,Actual,1999-09-30,March 1999,Actual,1999-03-31,,Interventional,Bilhvax1a,,"Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis",Phase 1 Study Evaluating Safety and Immunological Criteria of Efficacy of the Recombinant Vaccine Candidate Bilhvax Against Schistosomiasis,Completed,,Phase 1,24.0,Actual,"University Hospital, Lille",,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 19:33:18,2023-06-14 19:33:18,OTHER,,,,,
400035,400036,NCT01512706,,2012-01-15,,,2012-04-26,2012-01-15,2012-01-19,Estimate,,,,,,,2012-04-26,2012-04-27,Estimate,July 2011,,2011-07-31,June 2011,2011-06-30,February 2012,Actual,2012-02-29,January 2012,Actual,2012-01-31,,Interventional,,,"A Phase II, Safety and Efficacy Study of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants","A Phase II Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants",Completed,,Phase 2,660.0,Actual,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,15.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 19:33:36,2023-06-14 19:33:36,OTHER,,,,,
400077,400078,NCT01513135,,2012-01-17,,,2016-03-03,2012-01-19,2012-01-20,Estimate,,,,,,,2016-03-03,2016-03-04,Estimate,March 2012,,2012-03-31,March 2016,2016-03-31,July 2014,Actual,2014-07-31,May 2014,Actual,2014-05-31,,Interventional,ISS T-003,,"A Phase Il of a Therapeutic, Recombinant, Biologically Active HIV-1 Tat Protein Vaccine in HIV-Infected, Anti-Tat Negative, ARV-Treated Adult Volunteers","A Phase Il, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Immunogenicity and Safety of a Therapeutic, Recombinant, Biologically Active HIV-1 Tat Protein Vaccine in HIV-Infected, Anti-Tat Negative, ARV-Treated Adult Volunteers",Completed,,Phase 2,200.0,Actual,Istituto Superiore di Sanità,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 19:33:56,2023-06-14 19:33:56,OTHER,,,,,
400382,400383,NCT03769194,,2018-12-06,2021-05-05,,2022-12-14,2018-12-06,2018-12-07,Actual,2021-06-28,2021-06-30,Actual,,,,2022-12-14,2023-01-10,Actual,"December 17, 2018",Actual,2018-12-17,December 2022,2022-12-31,"October 2, 2020",Actual,2020-10-02,"December 18, 2019",Actual,2019-12-18,,Interventional,,,"Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.","Immunogenicity and Safety Study of VLA15, A Multivalent Recombinant OspA (Outer Surface Protein A) Based Vaccine Candidate Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. A Randomized, Controlled, Observer-blind Phase 2 Study.",Completed,,Phase 2,572.0,Actual,Pfizer,,4.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-14 00:17:21,2023-06-14 00:17:21,INDUSTRY,,,,,
400621,400622,NCT01518478,,2011-12-14,,,2017-02-27,2012-01-23,2012-01-26,Estimate,,,,,,,2017-02-27,2017-03-01,Actual,November 2011,,2011-11-30,February 2017,2017-02-28,March 2012,Actual,2012-03-31,February 2012,Actual,2012-02-29,,Interventional,,,Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot,An Open Label Study in Adults With Atopic Dermatitis to Assess Variability in Immune Response to Fluzone® Intradermal Vaccine,Completed,,Early Phase 1,40.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 19:37:26,2023-06-14 19:37:26,NIH,,,,,
400872,400873,NCT00640861,,2008-03-20,,,2018-10-29,2008-03-20,2008-03-21,Estimate,,,,,,,2018-10-29,2018-10-31,Actual,"August 28, 2008",Actual,2008-08-28,October 2018,2018-10-31,"April 21, 2015",Actual,2015-04-21,"April 21, 2015",Actual,2015-04-21,,Interventional,,,Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer,MUC1/HER-2/Neu Peptide Based Immunotherapeutic Vaccines for Breast Adenocarcinomas,Completed,,Early Phase 1,45.0,Anticipated,Mayo Clinic,,,,,False,,,,True,,,,,,,,,,,,,2023-06-15 20:50:21,2023-06-15 20:50:21,OTHER,,,,,
401079,401080,NCT01522820,,2012-01-25,,,2016-10-03,2012-01-30,2012-02-01,Estimate,,,,,,,2016-10-03,2016-10-04,Estimate,March 2012,,2012-03-31,October 2016,2016-10-31,July 2016,Actual,2016-07-31,July 2016,Actual,2016-07-31,,Interventional,,,Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors,A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors,Completed,,Phase 1,18.0,Actual,Roswell Park Cancer Institute,,5.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 19:40:18,2023-06-14 19:40:18,OTHER,,,,,
401244,401245,NCT01525004,,2011-10-14,,,2016-08-12,2012-01-30,2012-02-02,Estimate,,,,,,,2016-08-12,2016-08-16,Estimate,September 2011,,2011-09-30,August 2016,2016-08-31,December 2012,Actual,2012-12-31,June 2012,Actual,2012-06-30,,Interventional,,,Standard Dose Versus High-Dose Inactivated Flu Vaccine in Pediatric Solid Organ Transplant Patients,"Randomized, Double Blind, Comparison of Standard Dose Trivalent Inactivated Influenza Vaccine in Pediatric Solid Organ Transplant Patients",Completed,,Phase 1,38.0,Actual,Vanderbilt University,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 19:41:49,2023-06-14 19:41:49,OTHER,,,,,
401787,401788,NCT01531322,,2011-08-12,,,2018-09-06,2012-02-08,2012-02-10,Estimate,,,,,,,2018-09-06,2018-09-07,Actual,October 2011,,2011-10-31,September 2018,2018-09-30,January 2012,Actual,2012-01-31,January 2012,Actual,2012-01-31,,Interventional,,,A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects,"A Phase 1 Open-label Study to Assess the Safety and Tolerability of a Single Dose of 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Adults, Children and Infants",Completed,,Phase 1,72.0,Actual,Pfizer,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 19:46:26,2023-06-14 19:46:26,INDUSTRY,,,,,
401800,401801,NCT01531530,,2011-10-26,,,2021-04-27,2012-02-08,2012-02-13,Estimate,,,,,,,2021-04-27,2021-04-30,Actual,July 2011,,2011-07-31,April 2021,2021-04-30,September 2012,Actual,2012-09-30,September 2012,Actual,2012-09-30,,Interventional,,,"Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP","Safety, Clinical Tolerance, and Immunogenicity of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set, Live, Oral Shigella Flexneri 2a Vaccine Manufactured Using cGMP",Completed,,Phase 1,26.0,Actual,"University of Maryland, Baltimore",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 19:46:34,2023-06-14 19:46:34,OTHER,,,,,
401898,401899,NCT01532960,,2012-02-08,,,2020-05-07,2012-02-14,2012-02-15,Estimate,,,,,,,2020-05-07,2020-05-08,Actual,July 2012,,2012-07-31,May 2020,2020-05-31,September 2015,Actual,2015-09-30,September 2015,Actual,2015-09-30,,Interventional,Breast 41,,Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer,A Pilot Study of the Immunogenicity of a 9-Peptide Breast Cancer Vaccine Plus Poly-ICLC in Stage I-IV Breast Cancer,Terminated,,Phase 1,11.0,Actual,University of Virginia,,1.0,,"Futility for immune responses to the vaccine. Also, a component of study drug was in short supply.",False,,,,True,,,,,,,,,,,,,2023-06-14 19:47:28,2023-06-14 19:47:28,OTHER,,,,,
401988,401989,NCT01534468,,2012-02-13,,,2015-12-14,2012-02-13,2012-02-16,Estimate,,,,,,,2015-12-14,2015-12-15,Estimate,March 2012,,2012-03-31,December 2015,2015-12-31,March 2014,Actual,2014-03-31,March 2014,Actual,2014-03-31,,Interventional,,,Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy Adults,"Evaluation of Priming by Pandemic Live Attenuated Influenza Vaccine (LAIV) on the Subsequent Response to Inactivated H7N7 Vaccine in Healthy Adults: A Non-Randomized, Open Label Study",Completed,,Phase 1,45.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 19:48:33,2023-06-14 19:48:33,NIH,,,,,
402069,402070,NCT01536054,,2011-12-30,,,2020-03-25,2012-02-15,2012-02-20,Estimate,,,,,,,2020-03-25,2020-03-27,Actual,"August 20, 2012",Actual,2012-08-20,March 2020,2020-03-31,"April 21, 2015",Actual,2015-04-21,"April 21, 2015",Actual,2015-04-21,,Interventional,,,"Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer","A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing ALVAC(2)-NY-ESO-1(M)/TRICOM Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube, and Primary Peritoneal Cancer",Completed,,Phase 1,7.0,Actual,Roswell Park Cancer Institute,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 19:49:27,2023-06-14 19:49:27,OTHER,,,,,
402207,402208,NCT00381615,,2006-09-27,2015-02-04,,2015-09-11,2006-09-27,2006-09-28,Estimate,2015-09-11,2015-10-09,Estimate,,,,2015-09-11,2015-10-09,Estimate,September 2006,,2006-09-30,September 2015,2015-09-30,August 2008,Actual,2008-08-31,July 2007,Actual,2007-07-31,,Interventional,,Analysis was performed on all enrolled subjects.,"Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study","A Phase 2, Open Label, Multi-Center, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine±OMV, When Administered to Healthy Infants at 2, 4, 6 and/or 12 Months of Age",Completed,,Phase 2,147.0,Actual,Novartis,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 19:18:14,2023-06-16 19:18:14,INDUSTRY,,,,,
402313,402314,NCT01538979,,2012-02-07,,,2015-12-17,2012-02-24,2012-02-27,Estimate,,,,,,,2015-12-17,2015-12-18,Estimate,March 2012,,2012-03-31,December 2015,2015-12-31,March 2015,Actual,2015-03-31,December 2014,Actual,2014-12-31,,Interventional,,,Phase II Study of Grass Pollen Allergy Vaccine BM32,"Phase IIb Study on the Safety and Efficacy of BM32, a Recombinant Hypoallergenic Vaccine for Immunotherapy of Grass Pollen Allergy",Completed,,Phase 2,181.0,Actual,Biomay AG,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 19:51:54,2023-06-14 19:51:54,INDUSTRY,,,,,
402495,402496,NCT00869713,,2009-03-25,,,2022-02-16,2009-03-25,2009-03-26,Estimate,,,,,,,2022-02-16,2022-03-04,Actual,September 2009,Actual,2009-09-30,February 2022,2022-02-28,May 2021,Actual,2021-05-31,February 2019,Actual,2019-02-28,,Interventional,RVF,,"Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated","Long-Term Open-Label Primary Vaccination and Booster Dose Study of the Safety and Immunogenicity of Rift Valley Fever Vaccine, Inactivated, Dried (TSI-GSD 200) in At-Risk Adults",Completed,,Phase 2,98.0,Actual,U.S. Army Medical Research and Development Command,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 00:24:52,2023-06-14 00:24:52,FED,,,,,
402658,402659,NCT01543464,,2012-02-08,,,2018-03-16,2012-03-02,2012-03-05,Estimate,,,,,,,2018-03-16,2018-03-19,Actual,May 2012,,2012-05-31,March 2018,2018-03-31,September 2016,Actual,2016-09-30,September 2016,Actual,2016-09-30,,Interventional,,,Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients,"Combination of IDO/Survivin Peptide Vaccine, GM-CSF, Imiquimod and Temozolomide Chemotherapy for Patients With Metastatic Malignant Melanoma",Terminated,,Phase 2,41.0,Actual,Herlev Hospital,,1.0,,Diminished rectruitment,False,,,,True,,,,,,,,,,,,,2023-06-14 19:55:13,2023-06-14 19:55:13,OTHER,,,,,
402697,402698,NCT02837575,,2016-07-13,,,2019-02-25,2016-07-14,2016-07-19,Estimate,,,,,,,2019-02-25,2019-02-27,Actual,September 2016,,2016-09-30,February 2019,2019-02-28,December 2018,Actual,2018-12-31,April 2018,Actual,2018-04-30,,Interventional,HSV-2,,Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection",Completed,,Phase 2,261.0,Actual,Vical,,2.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-15 19:57:16,2023-06-15 19:57:16,INDUSTRY,,,,,
402800,402801,NCT01545349,,2012-02-29,,,2017-01-10,2012-03-05,2012-03-06,Estimate,,,,,,,2017-01-10,2017-01-11,Estimate,February 2012,,2012-02-29,January 2017,2017-01-31,May 2013,Actual,2013-05-31,May 2013,Actual,2013-05-31,,Interventional,LAIV,,Safety of Lactobacillus Rhamnosus GG Versus Placebo in Elderly Subjects Receiving Live Attenuated Influenza Vaccine,Double Blind Randomized Controlled Trial to Evaluate the Safety of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) Versus Placebo in Elderly Subjects Receiving Live Attenuated Influenza Vaccine,Completed,,Phase 1,30.0,Actual,Massachusetts General Hospital,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 19:56:32,2023-06-14 19:56:32,OTHER,,,,,
402926,402927,NCT01546818,,2009-06-09,,,2013-09-05,2012-03-01,2012-03-07,Estimate,,,,,,,2013-09-05,2013-09-09,Estimate,March 2012,,2012-03-31,September 2013,2013-09-30,September 2013,Actual,2013-09-30,March 2013,Actual,2013-03-31,,Interventional,,,Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients,"A Phase I, Randomized, Observer-blinded, Placebo-controlled Clinical Study to Assess the Safety, Tolerability, and Immune Response of Killed-Whole HIV-1 Vaccine (SAV001-H) Administered Intramuscularly to Chronic HIV-1 Infected Patients Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART)",Completed,,Phase 1,33.0,Actual,Sumagen,,,,,False,,,,False,,,,,,,,,,,,,2023-06-14 19:57:30,2023-06-14 19:57:30,INDUSTRY,,,,,
403035,403036,NCT01548118,,2012-02-29,,,2012-03-05,2012-03-05,2012-03-08,Estimate,,,,,,,2012-03-05,2012-03-08,Estimate,February 2012,,2012-02-29,March 2012,2012-03-31,December 2012,Anticipated,2012-12-31,October 2012,Anticipated,2012-10-31,,Interventional,,,Evaluate the Safety of Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Healthy Females,"A Blind, Randomized and Placebo-controlled Clinical Trial With Recombinant HumanPapillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Health Women-Phase I",Unknown status,Enrolling by invitation,Phase 1,160.0,Actual,"Shanghai Zerun Biotechnology Co.,Ltd",,8.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 19:58:24,2023-06-14 19:58:24,INDUSTRY,,,,,
403184,403185,NCT01549470,,2012-03-06,,,2021-10-28,2012-03-06,2012-03-09,Estimate,,,,,,,2021-10-28,2021-11-01,Actual,,,,October 2021,2021-10-31,March 2006,Actual,2006-03-31,,,,,Interventional,,,"Evaluating the Safety of and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults in Uganda","A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA009-00-VP, in Uninfected Adult Volunteers in Uganda",Completed,,Phase 1,31.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 19:59:23,2023-06-14 19:59:23,NIH,,,,,
403187,403188,NCT01549509,,2012-03-06,,,2021-10-28,2012-03-06,2012-03-09,Estimate,,,,,,,2021-10-28,2021-11-01,Actual,April 2007,,2007-04-30,October 2021,2021-10-31,October 2009,Actual,2009-10-31,April 2008,Actual,2008-04-30,,Interventional,,,"Evaluating the Safety of and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults in Uganda","A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 Recombinant Adenovirus-5 Vector Vaccine, VRC-HIVADV014-00-VP Administered Alone or Administered as a Boost to a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA009-00-VP, in Uninfected Adult Volunteers in Uganda",Completed,,Phase 1,18.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 19:59:25,2023-06-14 19:59:25,NIH,,,,,
403276,403277,NCT01457495,,2011-10-13,,,2017-06-15,2011-10-20,2011-10-24,Estimate,,,,,,,2017-06-15,2017-06-16,Actual,September 1998,,1998-09-30,June 2017,2017-06-30,September 1999,Actual,1999-09-30,September 1999,Actual,1999-09-30,,Interventional,,,Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly,Study to Assess Immunogenicity and Reactogenicity of SB Biologicals' DTPa-HBV-IPV/Hib Vaccine Given as Three-dose Primary Vaccination Course Compared to DTPa-IPV/Hib and HBV Administered Concomitantly at Separate Sites,Completed,,Phase 2,312.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-13 23:31:38,2023-06-13 23:31:38,INDUSTRY,,,,,
403838,403839,NCT01067287,,2009-07-29,,,2022-09-05,2010-02-10,2010-02-11,Estimate,,,,,,,2022-09-05,2022-09-08,Actual,March 2010,,2010-03-31,September 2022,2022-09-30,December 2023,Anticipated,2023-12-31,July 2023,Anticipated,2023-07-31,,Interventional,,,Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation,Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation,"Active, not recruiting",,Phase 2,35.0,Anticipated,Dana-Farber Cancer Institute,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-13 23:33:00,2023-06-13 23:33:00,OTHER,,,,,
404006,404007,NCT01432574,,2011-09-09,2015-04-23,,2021-09-13,2011-09-09,2011-09-13,Estimate,2015-05-28,2015-06-01,Estimate,,,,2021-09-13,2021-09-16,Actual,"February 19, 2013",Actual,2013-02-19,September 2021,2021-09-30,"November 3, 2020",Actual,2020-11-03,"May 23, 2014",Actual,2014-05-23,,Interventional,,All participants,Study of Gardasil in Mid-Adult Males (MAM),A Phase II Study of Gardasil in Human Papillomavirus Research The Mid-Adult Male Vaccine Study - The MAM STUDY,Completed,,Phase 2,150.0,Actual,H. Lee Moffitt Cancer Center and Research Institute,,1.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-14 00:25:15,2023-06-14 00:25:15,OTHER,,,,,
404164,404165,NCT05829356,,2023-04-06,,,2023-05-01,2023-04-24,2023-04-25,Actual,,,,,,,2023-05-01,2023-05-03,Actual,"April 17, 2023",Actual,2023-04-17,May 2023,2023-05-31,"February 22, 2024",Anticipated,2024-02-22,"February 22, 2024",Anticipated,2024-02-22,,Interventional,,,"Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above.","A Phase I, Parallel, Randomized, Active-controlled, Multi-center, Dose-escalation Study With Early Safety Data Reviews to Assess Safety and Immunogenicity of One Monovalent Modified Influenza mRNA Vaccine Encapsulated in LNP, in Adults Aged 18 to 49 Years and 60 Years and Above.",Recruiting,,Phase 1,225.0,Anticipated,Sanofi,,6.0,,,False,,,,False,False,False,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-14 20:07:01,2023-06-14 20:07:01,INDUSTRY,,,,,
404208,404209,NCT05799651,,2023-03-10,,,2023-04-30,2023-04-03,2023-04-05,Actual,,,,,,,2023-04-30,2023-05-03,Actual,"April 28, 2023",Actual,2023-04-28,April 2023,2023-04-30,August 2024,Anticipated,2024-08-31,November 2023,Anticipated,2023-11-30,,Interventional,,,Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults,"A Randomised, Double-Blind, Dose-Escalation Phase I Study in Healthy Adults to Assess the Safety, Tolerability and Immunogenicity of Glycovax-002, a Novel Vaccine Candidate Against COVID-19",Recruiting,,Phase 1,36.0,Anticipated,Glycovax Pharma Inc.,,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-14 20:07:17,2023-06-14 20:07:17,INDUSTRY,,,,,
404317,404318,NCT05662852,,2022-12-15,,,2023-05-01,2022-12-21,2022-12-23,Actual,,,,,,,2023-05-01,2023-05-03,Actual,"May 1, 2023",Actual,2023-05-01,May 2023,2023-05-31,"December 31, 2024",Anticipated,2024-12-31,"December 31, 2024",Anticipated,2024-12-31,,Interventional,,,Safety and Immunogenicity Study of Tdap Vaccinations for Plasma Donors,A Clinical Study of the Safety and Antibody Responses of Plasma Donors Vaccinated With a Licensed Tdap Vaccine for a Hyperimmunization Program,Enrolling by invitation,,Phase 2,100.0,Anticipated,"ABO Holdings, Inc.",,1.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-14 20:08:13,2023-06-14 20:08:13,INDUSTRY,,,,,
404605,404606,NCT05116241,,2021-10-20,,,2023-05-01,2021-11-02,2021-11-10,Actual,,,,,,,2023-05-01,2023-05-03,Actual,"October 28, 2021",Actual,2021-10-28,May 2023,2023-05-31,April 2024,Anticipated,2024-04-30,April 2024,Anticipated,2024-04-30,,Interventional,,,Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children,Phase 2b Placebo-Controlled Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy School-Age Children to Assess Immunological Response and Safety of a Single Dose BPZE1 With/Without Coadministration of Tdap (Boostrix),Recruiting,,Phase 2,600.0,Anticipated,ILiAD Biotechnologies,,3.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-14 20:10:38,2023-06-14 20:10:38,INDUSTRY,,,,,
404807,404808,NCT03041766,,2016-11-16,,,2017-12-12,2017-01-31,2017-02-03,Estimate,,,,,,,2017-12-12,2017-12-14,Actual,"December 6, 2016",Actual,2016-12-06,January 2017,2017-01-31,"June 2, 2017",Actual,2017-06-02,"April 6, 2017",Actual,2017-04-06,,Interventional,,,Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions,"Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 in Combination With the Adjuvant Glucopyranosyl Lipid A (GLA-SE) in Adults Living in Endemic Regions for S. Mansoni and S. Haematobium in Senegal. A Comparative, Randomized, Open-label Trial",Completed,,Phase 2,30.0,Actual,Oswaldo Cruz Foundation,,2.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-13 23:35:30,2023-06-13 23:35:30,OTHER,,,,,
404959,404960,NCT04239040,,2020-01-21,,,2023-05-01,2020-01-21,2020-01-23,Actual,,,,,,,2023-05-01,2023-05-03,Actual,"January 29, 2020",Actual,2020-01-29,May 2023,2023-05-31,"January 1, 2027",Anticipated,2027-01-01,"January 1, 2027",Anticipated,2027-01-01,,Interventional,,,GVAX Plus Checkpoint Blockade in Neuroblastoma,A Phase 1 Study of Combination Nivolumab and Ipilimumab With Irradiated GM-CSF Secreting Autologous Neuroblastoma Cell Vaccine (GVAX) for Relapsed or Refractory Neuroblastoma,Recruiting,,Phase 1,26.0,Anticipated,Dana-Farber Cancer Institute,,1.0,,,,,,,True,True,False,,,,,,Data can be shared no earlier than 1 year following the date of publication,DFCI - Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu,,Yes,The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2023-06-14 20:13:00,2023-06-14 20:13:00,OTHER,,,,,
405126,405127,NCT03840174,,2019-02-12,2021-10-15,,2023-05-04,2019-02-12,2019-02-15,Actual,2021-10-15,2021-11-15,Actual,,,,2023-05-04,2023-05-06,Actual,"March 8, 2019",Actual,2019-03-08,May 2023,2023-05-31,"November 7, 2019",Actual,2019-11-07,"November 7, 2019",Actual,2019-11-07,,Interventional,,,Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003),"A Phase I Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of V160 (Human Cytomegalovirus Vaccine) in Healthy Japanese Men",Completed,,Phase 1,18.0,Actual,Merck Sharp & Dohme LLC,,2.0,,,False,,,,,True,False,,,True,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2023-06-14 20:13:56,2023-06-14 20:13:56,INDUSTRY,,,,,
405265,405266,NCT00958126,,2009-08-12,2012-07-05,,2017-10-18,2009-08-12,2009-08-13,Estimate,2012-08-31,2012-10-03,Estimate,,,,2017-10-18,2017-11-21,Actual,August 2009,,2009-08-31,October 2017,2017-10-31,April 2010,Actual,2010-04-30,November 2009,Actual,2009-11-30,,Interventional,,,A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA,"A Phase II, Multicenter, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults Aged 18 Years and Older",Completed,,Phase 2,1313.0,Actual,Seqirus,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 20:01:25,2023-06-15 20:01:25,INDUSTRY,,,,,
405468,405469,NCT01556789,,2012-03-14,,,2018-05-14,2012-03-15,2012-03-16,Estimate,,,,,,,2018-05-14,2018-05-17,Actual,March 2013,,2013-03-31,September 2015,2015-09-30,September 2015,Actual,2015-09-30,May 2015,Actual,2015-05-31,,Interventional,,,Phase 1 Study of ONT-10 in Patients With Solid Tumors,"Phase 1 Study of ONT-10, a Liposomal MUC1 Cancer Vaccine, in Patients With Solid Tumors",Completed,,Phase 1,85.0,Actual,Seagen Inc.,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 20:17:36,2023-06-14 20:17:36,INDUSTRY,,,,,
405615,405616,NCT00436254,,2007-02-15,,,2023-05-05,2007-02-15,2007-02-19,Estimate,,,,,,,2023-05-05,2023-05-09,Actual,October 2001,,2001-10-31,April 2023,2023-04-30,"December 1, 2024",Anticipated,2024-12-01,March 2010,Actual,2010-03-31,,Interventional,,,Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer,A Phase I Study of a DNA Plasmid Based Vaccine Encoding the HER-2/Neu Intracellular Domain in Subjects With HER-2/Neu (HER2) Overexpressing Tumors,"Active, not recruiting",,Phase 1,66.0,Actual,University of Washington,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 00:35:15,2023-06-18 00:35:15,OTHER,,,,,
405728,405729,NCT01559831,,2012-03-19,,,2013-03-07,2012-03-20,2012-03-21,Estimate,,,,,,,2013-03-07,2013-03-08,Estimate,June 2012,,2012-06-30,March 2013,2013-03-31,March 2013,Anticipated,2013-03-31,December 2012,Anticipated,2012-12-31,,Interventional,,,Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination,Immune Responses to Revaccination After Potentially Insufficient Priming With the Japanese Encephalitis Vaccine IXIARO Batch JEV09L37,Withdrawn,,Phase 1,0.0,Actual,Valneva Austria GmbH,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 20:19:49,2023-06-14 20:19:49,INDUSTRY,,,,,
405816,405817,NCT05569239,,2022-10-03,,,2022-10-05,2022-10-05,2022-10-06,Actual,,,,,,,2022-10-05,2022-10-06,Actual,"April 1, 2023",Anticipated,2023-04-01,October 2022,2022-10-31,"July 1, 2024",Anticipated,2024-07-01,"December 1, 2023",Anticipated,2023-12-01,,Interventional,,,"Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480µg","Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of One Dose of OVX836 Influenza Vaccine 480µg, After Intramuscular Administration in Healthy Subjects Aged 18-55 Years",Not yet recruiting,,Phase 2,1500.0,Anticipated,Osivax,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-14 20:20:39,2023-06-14 20:20:39,INDUSTRY,,,,,
406075,406076,NCT01557699,,2012-03-16,2014-06-14,,2018-03-13,2012-03-16,2012-03-19,Estimate,2014-11-22,2014-12-01,Estimate,,,,2018-03-13,2018-03-14,Actual,March 2012,,2012-03-31,March 2018,2018-03-31,September 2013,Actual,2013-09-30,February 2013,Actual,2013-02-28,,Interventional,PMV-001,60 healthy adult males of 18 to 45 years,A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different Devices,"An Open-Label, Randomized, Phase I Study in Healthy Male Adults to Evaluate the Safety of a Measles Vaccine (Dry Powder)Administered by Two Devices",Completed,,Phase 1,60.0,Actual,Serum Institute of India Pvt. Ltd.,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-13 23:39:29,2023-06-13 23:39:29,INDUSTRY,,,,,
406209,406210,NCT02918006,,2016-09-26,2022-07-02,2018-07-23,2022-10-02,2016-09-26,2016-09-28,Estimate,2022-10-02,2022-10-06,Actual,2018-07-23,2018-07-26,Actual,2022-10-02,2022-10-06,Actual,"August 31, 2016",Actual,2016-08-31,October 2022,2022-10-31,"January 19, 2018",Actual,2018-01-19,"August 8, 2017",Actual,2017-08-08,,Interventional,,,A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine,"Phase 2 Randomized, Controlled, Human Influenza A (H1N1) Challenge Study Following Administration of an Oral H1N1 HA Adenoviral-Vector Based Seasonal Influenza Vaccine and dsRNA Adjuvant to Healthy Adult Volunteers",Completed,,Phase 2,179.0,Actual,Vaxart,,3.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-14 20:24:21,2023-06-14 20:24:21,INDUSTRY,,,,,
406361,406362,NCT01568515,,2012-03-22,,,2014-10-31,2012-03-29,2012-04-02,Estimate,,,,,,,2014-10-31,2014-11-04,Estimate,October 2011,,2011-10-31,October 2014,2014-10-31,August 2014,Actual,2014-08-31,August 2014,Actual,2014-08-31,,Interventional,,,Electronic Messaging to Increase Human Papillomavirus Vaccine Utilization and Adherence Among College Students,A Randomized Longitudinal Intervention Study to Assess Whether Electronic Messaging Can Increase HPV Vaccine Utilization and Adherence Among College Students in Eastern North Carolina.,Completed,,Early Phase 1,283.0,Actual,East Carolina University,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 20:25:45,2023-06-14 20:25:45,OTHER,,,,,
406508,406509,NCT01571466,,2011-11-09,,,2015-03-31,2012-04-03,2012-04-05,Estimate,,,,,,,2015-03-31,2015-04-01,Estimate,September 2011,,2011-09-30,March 2015,2015-03-31,May 2013,Actual,2013-05-31,May 2013,Actual,2013-05-31,,Interventional,2009-016578-34,,A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART,A Double-blind Phase I Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART,Completed,,Phase 1,30.0,Actual,Hospital Clinic of Barcelona,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 20:26:54,2023-06-14 20:26:54,OTHER,,,,,
406512,406513,NCT01571505,,2012-03-28,,,2017-08-30,2012-04-03,2012-04-05,Estimate,,,,,,,2017-08-30,2017-08-31,Actual,"March 1, 2012",Actual,2012-03-01,August 2017,2017-08-31,"November 30, 2016",Actual,2016-11-30,"November 30, 2016",Actual,2016-11-30,,Interventional,,,Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in INDIA (PROVIDE),Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in INDIA,Completed,,Phase 1,372.0,Actual,International Vaccine Institute,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 20:26:56,2023-06-14 20:26:56,OTHER,,,,,
406552,406553,NCT01571960,,2012-04-03,,,2021-10-13,2012-04-03,2012-04-05,Estimate,,,,,,,2021-10-13,2021-10-15,Actual,April 2012,,2012-04-30,October 2021,2021-10-31,January 2016,Actual,2016-01-31,August 2014,Actual,2014-08-31,,Interventional,,,"Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults","A Phase 1 Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-Boost Vaccine Regimen of GEO-D03 DNA and MVA/HIV62B Vaccines in Healthy, HIV-1-Uninfected Vaccinia Naive Adult Participants",Completed,,Phase 1,48.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 20:27:16,2023-06-14 20:27:16,NIH,,,,,
406650,406651,NCT02301611,,2014-11-12,,,2022-09-15,2014-11-23,2014-11-26,Estimate,,,,,,,2022-09-15,2022-09-19,Actual,January 2015,,2015-01-31,September 2022,2022-09-30,"May 11, 2022",Actual,2022-05-11,"May 11, 2022",Actual,2022-05-11,,Interventional,,,Phase IIB TL + YCWP + DC in Melanoma,"A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.",Completed,,Phase 2,184.0,Actual,"Cancer Insight, LLC",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-13 23:40:56,2023-06-13 23:40:56,INDUSTRY,,,,,
406664,406665,NCT01573312,,2012-04-05,,,2019-10-18,2012-04-05,2012-04-09,Estimate,,,,,,,2019-10-18,2019-10-21,Actual,"May 24, 2012",Actual,2012-05-24,July 2013,2013-07-31,"January 2, 2014",Actual,2014-01-02,"January 2, 2014",Actual,2014-01-02,,Interventional,,,H5N1 Vaccination With and Without AS03: Systems Biology Analysis,"A Randomized, Double-Blinded, Controlled, Phase I Study in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of Intramuscular Subvirion Inactivated Monovalent Influenza A/H5N1 Virus Vaccine Administered With and Without AS03 Adjuvant: Standard & Systems Biology Analyses",Completed,,Phase 1,20.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 20:28:19,2023-06-14 20:28:19,NIH,,,,,
407093,407094,NCT01578889,,2012-04-13,,,2021-10-13,2012-04-13,2012-04-17,Estimate,,,,,,,2021-10-13,2021-10-15,Actual,May 2012,,2012-05-31,October 2021,2021-10-31,October 2016,Actual,2016-10-31,September 2014,Actual,2014-09-30,,Interventional,,,"Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults","A Phase 1 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an IL-12 pDNA Enhanced HIV-1 Multiantigen pDNA Vaccine Delivered Intramuscularly With Electroporation, With an HIV-1 rVSV Vaccine Boost, in Healthy HIV-Uninfected Adult Participants",Completed,,Phase 1,100.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,8.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 20:32:16,2023-06-14 20:32:16,NIH,,,,,
407302,407303,NCT02820883,,2016-06-29,,,2016-09-08,2016-06-30,2016-07-01,Estimate,,,,,,,2016-09-08,2016-09-12,Estimate,June 2016,,2016-06-30,September 2016,2016-09-30,August 2016,Actual,2016-08-31,August 2016,Actual,2016-08-31,,Interventional,,,A Study of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults,"A Single-center, Dose-escalation, Open-label Pilot Study to Evaluate the Safety and Tolerability of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Aged 18-65 Years in China",Completed,,Early Phase 1,30.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,3.0,,,False,,,,True,,,,,,,,,,,Yes,,2023-06-15 20:03:47,2023-06-15 20:03:47,NETWORK,,,,,
407439,407440,NCT01592617,,2012-05-02,,,2015-08-11,2012-05-04,2012-05-07,Estimate,,,,,,,2015-08-11,2015-08-13,Estimate,May 2012,,2012-05-31,August 2015,2015-08-31,September 2015,Anticipated,2015-09-30,August 2015,Anticipated,2015-08-31,,Interventional,,,Phase II Study of S-488410 to Treat Non-small Cell Lung Cancer,Phase II Study of Peptide Cancer Vaccine S-488410 to Treat Advanced Non-Small Cell Lung Cancer,Unknown status,"Active, not recruiting",Phase 2,45.0,Anticipated,Shiga University,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 20:35:53,2023-06-14 20:35:53,OTHER,,,,,
407687,407688,NCT01823978,,2013-03-21,,,2019-10-04,2013-04-01,2013-04-04,Estimate,,,,,,,2019-10-04,2019-10-08,Actual,April 2013,,2013-04-30,November 2018,2018-11-30,September 2017,Actual,2017-09-30,May 2016,Actual,2016-05-31,,Interventional,,,Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer,A Phase I Study of BPX-201 Vaccine Plus AP1903 in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC),Completed,,Phase 1,19.0,Actual,Bellicum Pharmaceuticals,,1.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-14 23:30:39,2023-06-14 23:30:39,INDUSTRY,,,,,
407863,407864,NCT01598792,,2012-05-11,,,2016-05-17,2012-05-11,2012-05-15,Estimate,,,,,,,2016-05-17,2016-05-18,Estimate,February 2012,,2012-02-29,May 2016,2016-05-31,November 2014,Actual,2014-11-30,November 2014,Actual,2014-11-30,,Interventional,REALISTIC:,,Safety Study of Recombinant Listeria Monocytogenes(Lm)Based Vaccine Virus Vaccine to Treat Oropharyngeal Cancer,"REALISTIC: A Phase I, Dose Escalation Trial Of Recombinant Listeria Monocytogenes (Lm)-Based Vaccine Encoding Human Papilloma Virus Genotype 16 Target Antigens (ADXS11-001) In Patients With HPV-16 +ve Oropharyngeal Carcinoma",Terminated,,Phase 1,2.0,Actual,University of Liverpool,,,,Patient 2 suffered DLT post-vaccination. The vaccine manufacturers withdrew support for the study on commercial grounds.,False,,,,True,,,,,,,,,,,,,2023-06-14 20:40:16,2023-06-14 20:40:16,OTHER,,,,,
408442,408443,NCT03399578,,2018-01-08,,,2021-10-12,2018-01-12,2018-01-16,Actual,,,,,,,2021-10-12,2021-10-20,Actual,"March 14, 2018",Actual,2018-03-14,October 2021,2021-10-31,"September 17, 2021",Actual,2021-09-17,"September 17, 2021",Actual,2021-09-17,,Interventional,,,Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001),A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Vaccine ChAdOx1 MERS in UK Healthy Adult Volunteers,Terminated,,Phase 1,29.0,Actual,University of Oxford,,5.0,,"The scientific questions proposed remain relevant, but will now be addressed in a larger phase II immunogenicity trial of the ChAdOx1 MERS vaccine given at 2 doses.",False,,,,,False,False,,,,,,,,,,,2023-06-18 00:36:02,2023-06-18 00:36:02,OTHER,,,,,
408825,408826,NCT04449276,,2020-06-18,2022-04-29,,2022-04-29,2020-06-23,2020-06-26,Actual,2022-04-29,2023-01-30,Actual,,,,2022-04-29,2023-01-30,Actual,"June 18, 2020",Actual,2020-06-18,April 2022,2022-04-30,"December 21, 2021",Actual,2021-12-21,"December 21, 2021",Actual,2021-12-21,,Interventional,,,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19","COVID-19: A Phase 1, Partially Blind, Placebo-controlled, Dose Escalation, First-in-human, Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity After 1 and 2 Doses of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Healthy Adults",Completed,,Phase 1,280.0,Actual,CureVac,,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-14 20:48:50,2023-06-14 20:48:50,INDUSTRY,,,,,
409100,409101,NCT01507779,,2012-01-06,2018-08-15,,2019-02-20,2012-01-10,2012-01-11,Estimate,2019-02-20,2019-02-27,Actual,,,,2019-02-20,2019-02-27,Actual,April 2012,,2012-04-30,February 2019,2019-02-28,December 2012,Actual,2012-12-31,November 2012,Actual,2012-11-30,,Interventional,,,Safety Trial of Monovalent Whole Virus Influenza (H1N1) Vaccine,"Evaluation of The Safety and Immunogenicity of an Influenza A/H1N1 Vaccine (IVACFLU), Produced by IVAC, in Healthy Adults in Vietnam",Completed,,Phase 1,48.0,Actual,PATH,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-13 23:45:24,2023-06-13 23:45:24,OTHER,,,,,
409191,409192,NCT05873374,,2023-05-23,,,2023-05-23,2023-05-23,2023-05-24,Actual,,,,,,,2023-05-23,2023-05-24,Actual,June 2023,Anticipated,2023-06-30,May 2023,2023-05-31,April 2024,Anticipated,2024-04-30,November 2023,Anticipated,2023-11-30,,Interventional,,,"Evaluation of Safety, Tolerability, Reactogenicity, Immunogenicity of Baiya SARS-CoV-2 Vax 2 as a Booster for COVID-19","A Phase 2 Study to Evaluate the Safety, Tolerability, Reactogenicity, and Immunogenicity of Baiya SARS-CoV-2 Vax 2 Vaccine as a Booster Following Vaccination for COVID-19 in Adults Between 18 and 64 Years",Not yet recruiting,,Phase 2,75.0,Anticipated,"Baiya Phytopharm Co., Ltd.",,2.0,,,False,,,,True,False,False,,,False,,,,,,No,,2023-06-19 03:52:56,2023-06-19 03:52:56,INDUSTRY,,,,,
409214,409215,NCT01599897,,2012-05-14,,,2017-09-14,2012-05-14,2012-05-16,Estimate,,,,,,,2017-09-14,2017-09-15,Actual,August 2012,,2012-08-31,September 2017,2017-09-30,May 2014,Actual,2014-05-31,May 2014,Actual,2014-05-31,,Interventional,,,Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers,"A Phase 1, Randomized, Dose-escalation Study to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine at Two Dose Levels of the ID93 Antigen and the GLA-SE Adjuvant in Healthy Adults",Completed,,Phase 1,60.0,Actual,Access to Advanced Health Institute (AAHI),,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 20:52:50,2023-06-14 20:52:50,OTHER,,,,,
409433,409434,NCT02852005,,2016-07-28,2020-12-16,,2022-08-04,2016-07-28,2016-08-02,Estimate,2021-03-30,2021-04-01,Actual,,,,2022-08-04,2022-08-08,Actual,January 2017,Actual,2017-01-31,August 2022,2022-08-31,"October 29, 2019",Actual,2019-10-29,"August 29, 2018",Actual,2018-08-29,,Interventional,,,"Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205","A Phase 1 Clinical Trial to Evaluate the Immunogenicity of AIDSVAX B/E Bivalent gp120 Vaccine and MVA/HIV62B in Healthy, HIV-1-Uninfected Adult Participants Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205",Completed,,Phase 1,27.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,5.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-18 00:36:36,2023-06-18 00:36:36,NIH,,,,,
409889,409890,NCT00953524,,2009-08-03,2011-06-08,,2014-02-06,2009-08-04,2009-08-06,Estimate,2011-06-08,2011-07-11,Estimate,,,,2014-02-06,2014-03-10,Estimate,August 2009,,2009-08-31,February 2014,2014-02-28,December 2010,Actual,2010-12-31,March 2010,Actual,2010-03-31,,Interventional,,,A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly,Immunogenicity and Safety of Multiple Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adult and Elderly Subjects,Completed,,Phase 2,849.0,Actual,Sanofi,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 20:06:58,2023-06-15 20:06:58,INDUSTRY,,,,,
409985,409986,NCT02549833,,2015-08-20,,,2022-09-20,2015-09-11,2015-09-15,Estimate,,,,,,,2022-09-20,2022-09-22,Actual,"October 17, 2016",Actual,2016-10-17,September 2022,2022-09-30,"August 31, 2023",Anticipated,2023-08-31,"August 15, 2022",Actual,2022-08-15,,Interventional,,,Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma,Pilot Randomized Neo-adjuvant Evaluation of Poly-ICLC-Assisted Tumor Lysate Vaccines in Adult Patients With WHO Grade II Glioma,"Active, not recruiting",,Phase 1,28.0,Actual,"University of California, San Francisco",,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-19 03:49:19,2023-06-19 03:49:19,OTHER,,,,,
410108,410109,NCT00953056,,2009-08-04,2011-03-25,,2015-10-30,2009-08-05,2009-08-06,Estimate,2011-03-25,2011-04-15,Estimate,,,,2015-10-30,2015-11-01,Estimate,September 2009,,2009-09-30,October 2015,2015-10-31,March 2010,Actual,2010-03-31,March 2010,Actual,2010-03-31,,Interventional,,,"A Study of V260 in Healthy Chinese Adults, Children and Infants (V260-028)(COMPLETED)","A Double-Blind, Randomized, Placebo-Controlled, Safety and Tolerability Study of Live Pentavalent Human-Bovine Reassortant Rotavirus Vaccine in Chinese Healthy Adults, Children and Infants",Completed,,Phase 1,144.0,Actual,Merck Sharp & Dohme LLC,,6.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 20:07:30,2023-06-15 20:07:30,INDUSTRY,,,,,
410117,410118,NCT01617239,,2012-05-10,,,2014-08-19,2012-06-08,2012-06-12,Estimate,,,,,,,2014-08-19,2014-08-20,Estimate,June 2012,,2012-06-30,August 2014,2014-08-31,December 2013,Actual,2013-12-31,June 2013,Actual,2013-06-30,,Interventional,,,Clinical Study for Safety and Immunogenicity Study of Influenza Vaccine,"A Phase I, Open Label, Randomized Study in Healthy Adults to Compare Safety and Immunogenicity of Different Administration Schedules of Virosomal Influenza Vaccine",Completed,,Phase 1,84.0,Actual,Crucell Holland BV,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 20:58:55,2023-06-14 20:58:55,INDUSTRY,,,,,
410189,410190,NCT01024842,,2009-12-01,,,2016-06-07,2009-12-01,2009-12-03,Estimate,,,,,,,2016-06-07,2016-06-08,Estimate,December 2009,,2009-12-31,June 2016,2016-06-30,November 2013,Actual,2013-11-30,November 2013,Actual,2013-11-30,,Interventional,,,Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART,"HIV-CORE 001 - A Randomised Placebo-controlled Study to Evaluate the Safety and Immunogenicity of a Candidate HIV-1 Vaccine, MVA.HIVconsv, Delivered by Intramuscular Needle Injection to HIV-1 Seropositive Adult Subjects Receiving Antiretroviral Therapy (ART).",Terminated,,Phase 1,19.0,Actual,University of Oxford,,4.0,,Slow recruitment therefore study was stopped after 95% volunteers were enrolled.,False,,,,True,,,,,,,,,,,Yes,Data are presented in a manuscript submitted to a peer-reviewed journal.,2023-06-16 19:22:59,2023-06-16 19:22:59,OTHER,,,,,
410195,410196,NCT03824236,,2019-01-29,2020-04-30,,2020-08-05,2019-01-29,2019-01-31,Actual,2020-04-30,2020-05-15,Actual,,,,2020-08-05,2020-08-14,Actual,"February 5, 2019",Actual,2019-02-05,August 2020,2020-08-31,"September 26, 2019",Actual,2019-09-26,"April 30, 2019",Actual,2019-04-30,,Interventional,,,"A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults","Efficacy, Immunogenicity and Safety Study Evaluating a Fractional (Fx) Booster Dose of GSK Biologicals' Candidate Malaria Vaccine (SB257049) in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults",Completed,,Phase 2,61.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,False,True,False,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-16 19:23:00,2023-06-16 19:23:00,INDUSTRY,,,,,
410712,410713,NCT01623518,,2012-06-13,,,2014-12-01,2012-06-15,2012-06-20,Estimate,,,,,,,2014-12-01,2014-12-02,Estimate,June 2012,,2012-06-30,November 2014,2014-11-30,March 2013,Actual,2013-03-31,March 2013,Actual,2013-03-31,,Interventional,,,A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine ChAdOx1-NP+M1,A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine ChAdOx1-NP+M1,Completed,,Phase 1,15.0,Actual,University of Oxford,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 21:03:42,2023-06-14 21:03:42,OTHER,,,,,
411364,411365,NCT01632332,,2012-06-28,,,2018-10-04,2012-06-29,2012-07-02,Estimate,,,,,,,2018-10-04,2018-10-09,Actual,"July 9, 2012",Actual,2012-07-09,October 2018,2018-10-31,"July 9, 2018",Actual,2018-07-09,"March 24, 2014",Actual,2014-03-24,,Interventional,,,Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer,A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope HER-2/Neu Peptide Vaccine in Subjects Previously Treated for HER-2 Positive Breast Cancer,Completed,,Phase 1,22.0,Actual,Mayo Clinic,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 21:10:09,2023-06-14 21:10:09,OTHER,,,,,
411555,411556,NCT01634503,,2012-07-03,,,2014-02-14,2012-07-05,2012-07-06,Estimate,,,,,,,2014-02-14,2014-02-17,Estimate,November 2012,,2012-11-30,February 2014,2014-02-28,February 2014,Actual,2014-02-28,February 2014,Actual,2014-02-28,,Interventional,CIN3,,Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3,"A Single Center, Open-label, Dose-escalating, Phase <U+0399> Study to Evaluate the Safety of GX-188E Administered by Electroporation (EP) in DNA-based Therapeutic Vaccine for Patients With Cervical Intraepithelial Neoplasia Grade 3 (CIN 3)",Completed,,Phase 1,9.0,Actual,"Genexine, Inc.",,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 21:11:38,2023-06-14 21:11:38,INDUSTRY,,,,,
411619,411620,NCT00986609,,2009-09-29,,,2018-07-19,2009-09-29,2009-09-30,Estimate,,,,,,,2018-07-19,2018-07-23,Actual,"August 19, 2009",,2009-08-19,July 2018,2018-07-31,"January 21, 2016",Actual,2016-01-21,"August 29, 2013",Actual,2013-08-29,,Interventional,,,MUC1 Vaccine for Triple-negative Breast Cancer,Pilot Study of a MUCI Peptide and Poly-ICLC Vaccine for Triple-Negative Breast Cancer,Completed,,Early Phase 1,29.0,Actual,Case Comprehensive Cancer Center,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 19:23:45,2023-06-16 19:23:45,OTHER,,,,,
411962,411963,NCT01643941,,2012-07-09,,,2019-02-28,2012-07-17,2012-07-18,Estimate,,,,,,,2019-02-28,2019-03-04,Actual,August 2012,,2012-08-31,February 2019,2019-02-28,March 2014,Actual,2014-03-31,May 2013,Actual,2013-05-31,,Interventional,,,Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years,"A Phase 1/2 Placebo-controlled, Randomized, Double-blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of 3 Ascending Dose Levels Of A 4-antigen Staphylococcus Aureus Vaccine (sa4ag) And A Single Dose Level Of A 3-antigen Staphylococcus Aureus Vaccine (sa3ag) In Healthy Adults Aged 65 To <86 Years",Completed,,Phase 1,284.0,Actual,Pfizer,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 21:15:52,2023-06-14 21:15:52,INDUSTRY,,,,,
412257,412258,NCT01653249,,2012-07-26,,,2016-10-11,2012-07-26,2012-07-30,Estimate,,,,,,,2016-10-11,2016-10-12,Estimate,August 2012,,2012-08-31,October 2016,2016-10-31,July 2015,Actual,2015-07-31,July 2015,Actual,2015-07-31,,Interventional,,,A Phase I Clinical Trial of an HPV Therapeutic Vaccine,A Phase I Clinical Trial of an HPV Therapeutic Vaccine,Completed,,Phase 1,52.0,Actual,University of Arkansas,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 21:18:30,2023-06-14 21:18:30,OTHER,,,,,
412515,412516,NCT01656356,,2012-07-25,,,2012-08-07,2012-08-02,2012-08-03,Estimate,,,,,,,2012-08-07,2012-08-08,Estimate,May 2012,,2012-05-31,August 2012,2012-08-31,,,,August 2012,Actual,2012-08-31,,Interventional,,,Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers,Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers,Completed,,Phase 1,,,Mahidol University,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 21:20:40,2023-06-14 21:20:40,OTHER,,,,,
412616,412617,NCT01657526,,2012-08-02,,,2017-05-12,2012-08-02,2012-08-06,Estimate,,,,,,,2017-05-12,2017-05-15,Actual,"August 8, 2012",Actual,2012-08-08,May 2017,2017-05-31,"November 25, 2013",Actual,2013-11-25,"November 25, 2013",Actual,2013-11-25,,Interventional,,,"Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine","An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Healthy Adults",Completed,,Phase 1,48.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 21:21:34,2023-06-14 21:21:34,INDUSTRY,,,,,
412646,412647,NCT01657929,,2012-08-02,,,2014-02-24,2012-08-03,2012-08-06,Estimate,,,,,,,2014-02-24,2014-02-26,Estimate,September 2012,,2012-09-30,February 2014,2014-02-28,January 2014,Actual,2014-01-31,January 2014,Actual,2014-01-31,,Interventional,,,H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers,"A Phase 1, Randomized Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the H5-VLP + GLA-AF Pandemic Influenza Vaccine in Healthy Adult Subjects",Completed,,Phase 1,105.0,Actual,Access to Advanced Health Institute (AAHI),,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 21:21:57,2023-06-14 21:21:57,OTHER,,,,,
412691,412692,NCT00952276,,2009-08-03,2011-08-26,,2011-08-26,2009-08-03,2009-08-06,Estimate,2011-08-26,2011-10-03,Estimate,,,,2011-08-26,2011-10-03,Estimate,October 2009,,2009-10-31,August 2011,2011-08-31,March 2011,Actual,2011-03-31,December 2010,Actual,2010-12-31,,Interventional,,,A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly,Immunogenicity and Safety of Multiple Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adult and Elderly Subjects,Completed,,Phase 2,548.0,Actual,Sanofi,,5.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 20:10:28,2023-06-15 20:10:28,INDUSTRY,,,,,
412711,412712,NCT01658800,,2012-07-30,,,2015-03-05,2012-08-02,2012-08-07,Estimate,,,,,,,2015-03-05,2015-03-06,Estimate,September 2012,,2012-09-30,March 2015,2015-03-31,December 2013,Actual,2013-12-31,September 2013,Actual,2013-09-30,,Interventional,,,Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49,Phase I Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49,Completed,,Phase 1,275.0,Actual,VaxInnate Corporation,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 21:22:38,2023-06-14 21:22:38,INDUSTRY,,,,,
412730,412731,NCT01659086,,2012-08-03,,,2018-06-14,2012-08-06,2012-08-07,Estimate,,,,,,,2018-06-14,2018-06-18,Actual,"August 22, 2012",Actual,2012-08-22,June 2018,2018-06-30,"March 19, 2014",Actual,2014-03-19,"October 26, 2012",Actual,2012-10-26,,Interventional,,,Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age,An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age,Completed,,Phase 1,422.0,Actual,GlaxoSmithKline,,11.0,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-14 21:22:46,2023-06-14 21:22:46,INDUSTRY,,,,,
412912,412913,NCT01661725,,2012-08-02,,,2012-08-06,2012-08-06,2012-08-09,Estimate,,,,,,,2012-08-06,2012-08-09,Estimate,April 2006,,2006-04-30,August 2012,2012-08-31,May 2006,Actual,2006-05-31,April 2006,Actual,2006-04-30,,Interventional,,,Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 001,Phase I Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine,Completed,,Phase 1,60.0,Actual,"Hualan Biological Engineering, Inc.",,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 21:24:29,2023-06-14 21:24:29,INDUSTRY,,,,,
412913,412914,NCT01661738,,2012-08-02,,,2012-08-06,2012-08-06,2012-08-09,Estimate,,,,,,,2012-08-06,2012-08-09,Estimate,May 2006,,2006-05-31,August 2012,2012-08-31,June 2006,Actual,2006-06-30,May 2006,Actual,2006-05-31,,Interventional,,,Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 002,Phase II Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine,Completed,,Phase 2,360.0,Actual,"Hualan Biological Engineering, Inc.",,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 21:24:30,2023-06-14 21:24:30,INDUSTRY,,,,,
413136,413137,NCT01537185,,2012-02-07,2014-03-28,,2014-05-06,2012-02-22,2012-02-23,Estimate,2014-05-06,2014-06-05,Estimate,,,,2014-05-06,2014-06-05,Estimate,February 2012,,2012-02-29,February 2012,2012-02-29,April 2013,Actual,2013-04-30,October 2012,Actual,2012-10-31,,Interventional,,,Phase I Safety Trial of Streptococcus Pneumoniae Whole Cell Vaccine (SPWCV) + Alum in Healthy Adults,"A Phase 1 Randomized, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability and Immunogenicity of Inactivated Streptococcus Pneumoniae Whole Cell Vaccine Formulated With Alum (SPWCV+Alum) in Healthy Adults",Completed,,Phase 1,42.0,Actual,PATH,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-13 23:52:24,2023-06-13 23:52:24,OTHER,,,,,
413889,413890,NCT03600025,,2018-07-12,,,2021-02-16,2018-07-24,2018-07-26,Actual,,,,,,,2021-02-16,2021-02-18,Actual,"July 15, 2018",Actual,2018-07-15,July 2020,2020-07-31,"December 30, 2021",Anticipated,2021-12-30,"September 30, 2021",Anticipated,2021-09-30,,Interventional,,,Cellular Immune Responses in Typhoid Fever Patients and Vaccinees,"Investigation of Innate Immune Responses to Salmonella Typhi in Typhoid Fever in Children and Adults Patients and Vaccinees in Dhaka, Bangladesh",Unknown status,Recruiting,Phase 1,30.0,Anticipated,"International Centre for Diarrhoeal Disease Research, Bangladesh",,1.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 00:39:41,2023-06-18 00:39:41,OTHER,,,,,
413908,413909,NCT04800978,,2021-01-11,,,2021-03-14,2021-03-14,2021-03-16,Actual,,,,,,,2021-03-14,2021-03-16,Actual,"June 14, 2021",Anticipated,2021-06-14,January 2021,2021-01-31,"August 31, 2024",Anticipated,2024-08-31,"August 31, 2024",Anticipated,2024-08-31,,Interventional,,,Combination of Durvalumab and BVAC-C in Patients With HPV 16 or 18 Positive Cervical Cancer Failure to First-Line Platinum-based Chemotherapy,"An Open Label, Single Arm, Safety Lead-in, Multicenter, Investigator Initiated Trial of Combination of Durvalumab , An Immune Checkpoint Inhibitor, and BVAC-C, A Cell-based Immunotherapeutic Vaccine, in Patients With HPV 16 or 18 Positive Cervical Cancer Failure to First-Line Platinum-based Chemotherapy",Not yet recruiting,,Phase 2,37.0,Anticipated,Samsung Medical Center,,1.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-13 23:53:42,2023-06-13 23:53:42,OTHER,,,,,
414067,414068,NCT04715867,,2021-01-13,,,2022-03-27,2021-01-15,2021-01-20,Actual,,,,,,,2022-03-27,2022-03-29,Actual,"January 1, 2021",Actual,2021-01-01,December 2021,2021-12-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,,Interventional,,,Non Inferiority Trial of Locally Manufactured Rabies Vaccine 'Rabix-VC' in Bangladesh,"A Double-blind Randomized, Controlled, Non-inferiority Trial to Evaluate the Immunogenicity and Safety of New Rabies Vaccine 'Rabix-VC' on Bangladeshi Healthy Adults",Recruiting,,Phase 1,440.0,Anticipated,"International Centre for Diarrhoeal Disease Research, Bangladesh",,4.0,,,False,,,,True,False,False,,,,,,After completion of the study,Journal,,Yes,By publication in the journal,2023-06-16 19:24:29,2023-06-16 19:24:29,OTHER,,,,,
414335,414336,NCT03003195,,2016-12-19,,,2021-03-15,2016-12-21,2016-12-26,Estimate,,,,,,,2021-03-15,2021-03-18,Actual,December 2022,Anticipated,2022-12-31,March 2021,2021-03-31,December 2026,Anticipated,2026-12-31,December 2024,Anticipated,2024-12-31,,Interventional,,,The P10s-PADRE Basket Trial: Vaccination of Metastatic Cancer Patients,A Combined Phase I/II Study of a Carbohydrate Mimotope-Based Vaccine With MONTANIDE ISA 51 VG STERILE for Metastatic Cancer,Withdrawn,,Phase 2,0.0,Actual,University of Arkansas,,1.0,,Lack of Funding,False,,,,True,True,False,,,,,,,,,No,,2023-06-13 23:54:31,2023-06-13 23:54:31,OTHER,,,,,
414522,414523,NCT05155319,,2021-11-25,,,2023-02-01,2021-12-01,2021-12-13,Actual,,,,,,,2023-02-01,2023-02-03,Actual,"December 1, 2021",Actual,2021-12-01,February 2023,2023-02-28,April 2024,Anticipated,2024-04-30,"October 13, 2023",Anticipated,2023-10-13,,Interventional,EBS-UFV-001,,Universal Influenza A Vaccine in Healthy Adults,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study Evaluating Safety and Immunogenicity of Influenza A Hemagglutinin Stabilized Stem Nanoparticle Vaccine Candidate in Healthy Adults","Active, not recruiting",,Phase 1,60.0,Anticipated,Emergent BioSolutions,,6.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-16 19:24:48,2023-06-16 19:24:48,INDUSTRY,,,,,
414858,414859,NCT04785612,,2021-02-12,,,2021-09-01,2021-03-04,2021-03-08,Actual,,,,,,,2021-09-01,2021-09-02,Actual,"November 10, 2020",Actual,2020-11-10,April 2021,2021-04-30,"August 16, 2021",Actual,2021-08-16,"April 8, 2021",Actual,2021-04-08,,Interventional,,,Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults,"A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Immunogenicity and Efficacy of A Respiratory Syncytial Virus Vaccine (RSVpreF) in A Virus Challenge Model in Healthy Adults",Completed,,Phase 2,62.0,Actual,Hvivo,,2.0,,,False,,,,False,False,False,,,,,,,,,,,2023-06-13 23:55:19,2023-06-13 23:55:19,INDUSTRY,,,,,
414901,414902,NCT01323270,,2011-02-17,2014-11-21,,2022-10-26,2011-03-24,2011-03-25,Estimate,2014-11-21,2014-11-26,Estimate,,,,2022-10-26,2022-10-27,Actual,"March 18, 2011",Actual,2011-03-18,October 2022,2022-10-31,"February 19, 2013",Actual,2013-02-19,"October 8, 2012",Actual,2012-10-08,,Interventional,,,"A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.","A Phase 2, Randomized, Placebo-controlled, Single-blind Trial To Assess The Safety, Tolerability, And Immunogenicity Of Repevax(Registered) And Bivalent Rlp2086 Vaccine When Administered Concomitantly In Healthy Subjects Aged Greater Than Or Equal To 11 To <19 Years",Completed,,Phase 2,753.0,Actual,Pfizer,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 21:44:01,2023-06-14 21:44:01,INDUSTRY,,,,,
414903,414904,NCT01299480,,2011-02-15,2014-11-21,,2022-10-26,2011-02-16,2011-02-18,Estimate,2015-06-02,2015-06-04,Estimate,,,,2022-10-26,2022-10-27,Actual,"March 3, 2011",Actual,2011-03-03,October 2022,2022-10-31,"September 18, 2012",Actual,2012-09-18,"May 3, 2012",Actual,2012-05-03,,Interventional,,,"A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged =11 To <19 Years","A Phase 2, Randomized, Placebo-controlled, Single-blind Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered In Either 2- Or 3-dose Regimens In Healthy Subjects Aged Greater Than Or Equal To 11 To <19 Years",Completed,,Phase 2,1714.0,Actual,Pfizer,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 21:44:05,2023-06-14 21:44:05,INDUSTRY,,,,,
415556,415557,NCT02787109,,2016-05-23,,,2017-08-08,2016-05-26,2016-06-01,Estimate,,,,,,,2017-08-08,2017-08-10,Actual,July 2016,,2016-07-31,August 2017,2017-08-31,"July 31, 2017",Actual,2017-07-31,"July 31, 2017",Actual,2017-07-31,,Interventional,,,Safety of Chlamydia Vaccine CTH522 in Healthy Women Aged 18 to 45 Years,"A Phase I First in Human, Double-blind, Parallel, Randomised and Placebo Controlled Clinical Trial of the Safety of SSI's Adjuvanted Chlamydia Vaccine CTH522 in Healthy Women Aged 18 to 45 Years",Completed,,Phase 1,35.0,Actual,Statens Serum Institut,,3.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-15 20:14:15,2023-06-15 20:14:15,OTHER,,,,,
415612,415613,NCT00993083,,2009-10-08,,,2011-08-10,2009-10-08,2009-10-09,Estimate,,,,,,,2011-08-10,2011-08-11,Estimate,June 2009,,2009-06-30,January 2011,2011-01-31,March 2010,Actual,2010-03-31,March 2010,Actual,2010-03-31,,Interventional,,,A Study to Assess the Safety and Efficacy of a New Influenza Candidate Vaccine MVA-NP+M1 In Healthy Adults,A Phase IIA Study to Assess the Safety and Efficacy of a New Influenza Candidate Vaccine MVA-NP+M1 In Healthy Adults,Completed,,Phase 2,27.0,Actual,University of Oxford,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 19:33:18,2023-06-16 19:33:18,OTHER,,,,,
415733,415734,NCT05202561,,2022-01-19,,,2022-03-21,2022-01-19,2022-01-21,Actual,,,,,,,2022-03-21,2022-03-23,Actual,"March 10, 2022",Actual,2022-03-10,March 2022,2022-03-31,"January 19, 2024",Anticipated,2024-01-19,"January 19, 2023",Anticipated,2023-01-19,,Interventional,,,A Study of RNA Tumor Vaccine in Patients With Advanced Solid Tumors,"A Single-Arm, Open-Label, Exploratory Study to Evaluate the Safety of RNA Tumor Vaccine Injection Alone/in Combination With PD-1 Inhibitor in the Treatment of Advanced Solid Tumors With KRAS Mutation",Recruiting,,Phase 1,10.0,Anticipated,First Affiliated Hospital Bengbu Medical College,,2.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-14 21:51:42,2023-06-14 21:51:42,OTHER,,,,,
416077,416078,NCT04659941,,2020-12-08,,,2023-05-10,2020-12-08,2020-12-09,Actual,,,,,,,2023-05-10,2023-05-11,Actual,"October 1, 2020",Actual,2020-10-01,May 2023,2023-05-31,"April 1, 2024",Anticipated,2024-04-01,"October 1, 2022",Actual,2022-10-01,,Interventional,ProBCG,,Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers,Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers,"Active, not recruiting",,Phase 2,752.0,Anticipated,Universidade Federal do Rio de Janeiro,,2.0,,,False,,,,,False,False,,,False,,,,,,No,,2023-06-14 21:54:50,2023-06-14 21:54:50,OTHER,,,,,
416211,416212,NCT04440774,,2020-06-17,,,2022-03-22,2020-06-17,2020-06-22,Actual,,,,,,,2022-03-22,2022-03-23,Actual,"October 23, 2020",Actual,2020-10-23,September 2021,2021-09-30,"February 18, 2022",Actual,2022-02-18,"February 18, 2022",Actual,2022-02-18,,Interventional,,,Research Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico.,"A Single Centre, Double-blind, Double-dummy Placebo-controlled, Randomised Phase Ib Study to Evaluate the Safety & Immunogenicity of the Candidate Chikungunya Vaccine ChAdOx1 Chik & the Zika Vaccine ChAdOx1 Zika in Healthy Adults in Mexico",Completed,,Phase 1,120.0,Actual,University of Oxford,,10.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-14 21:55:56,2023-06-14 21:55:56,OTHER,,,,,
416473,416474,NCT00091273,,2004-09-07,2014-05-19,,2014-05-19,2004-09-08,2004-09-09,Estimate,2014-05-19,2014-06-20,Estimate,,,,2014-05-19,2014-06-20,Estimate,June 2004,,2004-06-30,May 2014,2014-05-31,June 2007,Actual,2007-06-30,February 2006,Actual,2006-02-28,,Interventional,,,Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer,Evaluation of Safety and Immunogenicity of a Peptide Vaccine in Patients With Epithelial Ovarian or Primary Peritoneal Cancer,Completed,,Phase 1,9.0,Actual,University of Virginia,,,,,False,,,,True,,,,,,,,,,,,,2023-06-13 23:58:28,2023-06-13 23:58:28,OTHER,,,,,
416543,416544,NCT00641017,,2008-03-05,,,2013-02-22,2008-03-19,2008-03-21,Estimate,,,,,,,2013-02-22,2013-02-25,Estimate,March 2008,,2008-03-31,February 2013,2013-02-28,July 2012,Actual,2012-07-31,July 2012,Actual,2012-07-31,,Interventional,,,Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine,"A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Human Parainfluenza Type 1 Virus Vaccine, rHPIV1 84/del170/942A, Lot PIV1 #104A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV1-Seropositive Children 15 to 59 Months of Age, and HPIV1-Seronegative Infants and Children 6 to 59 Months of Age",Completed,,Phase 1,87.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,7.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 20:51:17,2023-06-15 20:51:17,NIH,,,,,
416735,416736,NCT05656508,,2022-12-02,,,2023-04-04,2022-12-14,2022-12-19,Actual,,,,,,,2023-04-04,2023-04-06,Actual,"April 20, 2022",Actual,2022-04-20,April 2023,2023-04-30,"June 29, 2023",Anticipated,2023-06-29,"September 30, 2022",Actual,2022-09-30,,Interventional,,,ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine,"Phase 1 Study to Evaluate Safety, Tolerability and Immunogenicity of a New Recombinant Protein-based Vaccine (ARVAC CG) Against Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2), in a Population of Healthy Adult Volunteers Previously Vaccinated Against SARS-CoV-2 Virus.","Active, not recruiting",,Phase 1,80.0,Actual,Laboratorio Pablo Cassara S.R.L.,,2.0,,,False,,,,True,False,False,,,,,,Data will be available immediately following publication,"Access will be given to researchers who provide a methodologically sound proposal or whose proposed use of the data has been approved by an independent review committee identified for this purpose.

Proposals should be directed to the corresponding author of the publication.",,Yes,Data to be shared: all of the individual participant data collected during the trial after deidentification and after publication of the results,2023-06-14 22:00:36,2023-06-14 22:00:36,INDUSTRY,,,,,
416781,416782,NCT05585632,,2022-10-14,,,2023-04-04,2022-10-14,2022-10-19,Actual,,,,,,,2023-04-04,2023-04-06,Actual,"October 14, 2022",Actual,2022-10-14,April 2023,2023-04-30,"March 15, 2024",Anticipated,2024-03-15,"March 15, 2024",Anticipated,2024-03-15,,Interventional,,,"A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old","Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age","Active, not recruiting",,Phase 1,392.0,Actual,"ModernaTX, Inc.",,9.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-14 22:00:55,2023-06-14 22:00:55,INDUSTRY,,,,,
417028,417029,NCT01359150,,2011-05-11,2013-01-07,,2013-02-20,2011-05-20,2011-05-24,Estimate,2013-02-20,2013-03-29,Estimate,,,,2013-02-20,2013-03-29,Estimate,September 2011,,2011-09-30,February 2013,2013-02-28,February 2012,Actual,2012-02-29,February 2012,Actual,2012-02-29,,Interventional,,,"A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo","A Randomized, Double Blind, Placebo Controlled Phase 2 Study To Assess The Immune Response Following Administration Of Influenza And Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving Cp-690,550 Or Placebo Cp-690,550 With And Without Background Methotrexate",Completed,,Phase 2,223.0,Actual,Pfizer,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-13 23:59:44,2023-06-13 23:59:44,INDUSTRY,,,,,
417357,417358,NCT03008122,,2016-12-15,2023-01-27,,2023-03-09,2016-12-29,2017-01-02,Estimate,2023-03-09,2023-04-06,Actual,,,,2023-03-09,2023-04-06,Actual,"March 21, 2017",Actual,2017-03-21,January 2018,2018-01-31,"August 10, 2021",Actual,2021-08-10,"August 10, 2021",Actual,2021-08-10,,Interventional,,,"Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area","Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Adult Subjects Who Reside in a Flavivirus Endemic Area",Completed,,Phase 1,91.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-14 22:05:36,2023-06-14 22:05:36,NIH,,,,,
417461,417462,NCT01654263,,2012-07-19,2016-08-11,,2017-02-23,2012-07-26,2012-07-31,Estimate,2016-11-23,2017-01-23,Estimate,,,,2017-02-23,2017-03-27,Actual,"October 10, 2012",Actual,2012-10-10,"April 15, 2016",2016-04-15,"August 21, 2015",Actual,2015-08-21,"August 21, 2015",Actual,2015-08-21,,Interventional,,All participants are included in the baseline analysis population.,"A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine","A Phase IIb, Open-Label, Dose-Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine",Completed,,Phase 2,884.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,6.0,,,False,,,,,True,False,,,False,,,,,,,,2023-06-14 00:00:49,2023-06-14 00:00:49,NIH,,,,,
417648,417649,NCT03554798,,2018-05-08,2022-01-20,,2022-01-20,2018-06-12,2018-06-13,Actual,2022-01-20,2022-03-23,Actual,,,,2022-01-20,2022-03-23,Actual,"December 4, 2018",Actual,2018-12-04,January 2022,2022-01-31,"February 19, 2020",Actual,2020-02-19,"February 19, 2020",Actual,2020-02-19,,Interventional,,,A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine,A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Novel Oral Polio Type 2 (nOPV2) Vaccine Candidates in Healthy Children Aged 1 to 5 Years and in Healthy Bivalent Oral Polio Vaccine-inactivated Polio Vaccine (bOPV-IPV) Vaccinated Infants,Completed,,Phase 2,1025.0,Actual,Fidec Corporation,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-14 22:08:41,2023-06-14 22:08:41,OTHER,,,,,
417951,417952,NCT00053495,,2003-01-30,2011-01-03,,2018-08-09,2003-01-30,2003-01-31,Estimate,2011-01-14,2011-02-11,Estimate,,,,2018-08-09,2018-08-13,Actual,January 2003,,2003-01-31,August 2018,2018-08-31,November 2003,Actual,2003-11-30,June 2003,Actual,2003-06-30,,Interventional,,,"Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination","The Effect of Dose On Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults Without Previous Smallpox Vaccination",Completed,,Phase 2,353.0,Actual,Emergent BioSolutions,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 00:02:12,2023-06-14 00:02:12,INDUSTRY,,,,,
417966,417967,NCT04657198,,2020-12-01,2022-06-02,,2022-06-02,2020-12-01,2020-12-08,Actual,2022-06-02,2022-06-29,Actual,,,,2022-06-02,2022-06-29,Actual,"December 9, 2020",Actual,2020-12-09,June 2022,2022-06-30,"October 25, 2021",Actual,2021-10-25,"June 3, 2021",Actual,2021-06-03,,Interventional,,,Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study,"A Phase 2b, Open-label, Multi-center, Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 Older Adults (OA) Investigational Vaccine Administered Intramuscularly 18 Months Post-Dose 2 in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study",Completed,,Phase 2,126.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,False,True,False,,,False,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-14 22:11:04,2023-06-14 22:11:04,INDUSTRY,,,,,
418101,418102,NCT03026972,,2017-01-12,,,2022-03-09,2017-01-18,2017-01-20,Estimate,,,,,,,2022-03-09,2022-03-24,Actual,"April 16, 2018",Actual,2018-04-16,December 2019,2019-12-31,"October 30, 2019",Actual,2019-10-30,"September 4, 2018",Actual,2018-09-04,,Interventional,AEC/BC02,,A Phase <U+2160>Study of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried,A Phase <U+2160>Study of the Human Body Tolerance Research of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried,Completed,,Phase 1,25.0,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,4.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-14 22:12:44,2023-06-14 22:12:44,INDUSTRY,,,,,
418171,418172,NCT02824198,,2016-07-01,2019-05-24,2018-03-15,2022-03-15,2016-07-05,2016-07-06,Estimate,2019-05-24,2019-06-14,Actual,2018-03-15,2018-03-16,Actual,2022-03-15,2022-03-24,Actual,"July 1, 2016",Actual,2016-07-01,March 2022,2022-03-31,"January 18, 2019",Actual,2019-01-18,"March 18, 2017",Actual,2017-03-18,,Interventional,,Analysis was performed on all randomized participants.,Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule,Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Singapore,Completed,,Phase 2,118.0,Actual,Sanofi,,2.0,,,False,,,,False,True,False,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-14 22:13:33,2023-06-14 22:13:33,INDUSTRY,,,,,
418211,418212,NCT02628444,,2015-12-09,2020-12-11,,2022-03-15,2015-12-09,2015-12-11,Estimate,2021-02-03,2021-02-23,Actual,,,,2022-03-15,2022-03-24,Actual,"May 2, 2016",Actual,2016-05-02,March 2022,2022-03-31,"April 29, 2020",Actual,2020-04-29,"April 29, 2020",Actual,2020-04-29,,Interventional,,Analysis was performed on all randomized population.,Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age,"Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1-, 2-, or 3- Dose Schedules (STAGE I) Followed by a Single Booster Injection of the Same Vaccine (STAGE II) 1 or 2 Years After the Last Primary Dose in Healthy Subjects 9 to 50 Years of Age in Colombia and the Philippines",Completed,,Phase 2,1050.0,Actual,Sanofi,,9.0,,,False,,,,True,True,False,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-14 22:14:06,2023-06-14 22:14:06,INDUSTRY,,,,,
418217,418218,NCT02623725,,2015-12-03,2019-05-24,2017-11-16,2022-03-15,2015-12-03,2015-12-08,Estimate,2019-05-24,2019-06-14,Actual,2017-11-16,2017-11-20,Actual,2022-03-15,2022-03-24,Actual,"April 14, 2016",Actual,2016-04-14,March 2022,2022-03-31,"October 28, 2018",Actual,2018-10-28,"November 23, 2016",Actual,2016-11-23,,Interventional,,Analysis was performed on all randomized participants.,Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule,Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Latin America,Completed,,Phase 2,251.0,Actual,Sanofi,,2.0,,,False,,,,False,True,False,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-14 22:14:12,2023-06-14 22:14:12,INDUSTRY,,,,,
418324,418325,NCT01943825,,2013-09-12,2019-12-19,2017-04-28,2022-03-15,2013-09-12,2013-09-17,Estimate,2020-01-24,2020-02-05,Actual,2017-04-28,2017-05-01,Actual,2022-03-15,2022-03-24,Actual,"November 5, 2013",Actual,2013-11-05,March 2022,2022-03-31,"November 25, 2015",Actual,2015-11-25,"November 25, 2015",Actual,2015-11-25,,Interventional,,Analysis was performed on safety analysis set which included all participants who received at least one dose of CYD dengue vaccine or JE vaccine.,Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine,Exploration of Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity Following Various Administration Schedules With CYD Tetravalent Dengue Vaccine,Completed,,Phase 2,90.0,Actual,Sanofi,,4.0,,,False,,,,False,,,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-14 22:15:49,2023-06-14 22:15:49,INDUSTRY,,,,,
418349,418350,NCT01701999,,2012-10-03,2016-12-15,2016-09-26,2017-04-19,2012-10-04,2012-10-05,Estimate,2016-12-15,2017-02-09,Estimate,2016-09-26,2016-09-28,Estimate,2017-04-19,2017-05-16,Actual,February 2013,,2013-02-28,April 2017,2017-04-30,October 2015,Actual,2015-10-31,June 2015,Actual,2015-06-30,,Interventional,,,"Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid","Phase 2b, Two-part, Open-label, Uncontrolled Study to Evaluate Safety, Tolerability, and Immunogenicity of a Single 40-µg Dose of Recombinant Botulinum Vaccine A/B (rBV A/B) for the Production of BabyBIG® in Volunteers Previously Immunized With Pentavalent Botulinum Toxoid for Occupational Protection",Completed,,Phase 2,45.0,Actual,California Department of Public Health,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 00:02:48,2023-06-14 00:02:48,OTHER,,,,,
418354,418355,NCT01488890,,2011-12-06,2019-05-24,2014-04-08,2022-03-15,2011-12-07,2011-12-08,Estimate,2019-05-24,2019-06-14,Actual,2014-04-08,2014-05-02,Estimate,2022-03-15,2022-03-24,Actual,"December 6, 2011",Actual,2011-12-06,March 2022,2022-03-31,"September 27, 2013",Actual,2013-09-27,"September 27, 2013",Actual,2013-09-27,,Interventional,,Analysis was performed on all randomized participants.,Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine,Evaluation of the Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Administered With or Without Yellow Fever Vaccine in US Adults.,Completed,,Phase 2,390.0,Actual,Sanofi,,4.0,,,False,,,,True,True,False,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-14 22:16:14,2023-06-14 22:16:14,INDUSTRY,,,,,
418374,418375,NCT01187433,,2010-08-20,2016-09-25,2013-11-04,2022-03-10,2010-08-20,2010-08-24,Estimate,2016-09-25,2016-11-11,Estimate,2013-11-04,2013-11-27,Estimate,2022-03-10,2022-03-21,Actual,August 2010,,2010-08-31,March 2022,2022-03-31,December 2012,Actual,2012-12-31,October 2012,Actual,2012-10-31,,Interventional,,,Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America,Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in South America,Completed,,Phase 2,150.0,Actual,Sanofi,,2.0,,,False,,,,True,,,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-14 22:16:32,2023-06-14 22:16:32,INDUSTRY,,,,,
418390,418391,NCT00993447,,2009-10-09,2016-10-04,2012-04-16,2022-03-15,2009-10-09,2009-10-12,Estimate,2016-10-04,2016-11-29,Estimate,2012-04-16,2012-04-18,Estimate,2022-03-15,2022-03-24,Actual,October 2009,,2009-10-31,March 2022,2022-03-31,March 2012,Actual,2012-03-31,September 2011,Actual,2011-09-30,,Interventional,,,Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America,Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America,Completed,,Phase 2,600.0,Actual,Sanofi,,2.0,,,False,,,,True,,,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-14 22:16:47,2023-06-14 22:16:47,INDUSTRY,,,,,
418398,418399,NCT00880893,,2009-04-13,2019-04-16,,2022-03-10,2009-04-13,2009-04-14,Estimate,2019-05-23,2019-07-29,Actual,,,,2022-03-10,2022-03-21,Actual,"April 7, 2009",Actual,2009-04-07,March 2022,2022-03-31,"October 14, 2014",Actual,2014-10-14,October 2014,Actual,2014-10-31,,Interventional,,Analysis was performed on Safety analysis set which included all participants who had received at least one dose of CYD dengue or control vaccine.,Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore,Immunogenicity and Large-Scale Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Singapore,Completed,,Phase 2,1198.0,Actual,Sanofi,,2.0,,,False,,,,True,,,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-14 22:16:55,2023-06-14 22:16:55,INDUSTRY,,,,,
418524,418525,NCT03349983,,2017-11-13,,,2020-08-25,2017-11-20,2017-11-22,Actual,,,,,,,2020-08-25,2020-08-26,Actual,"January 8, 2018",Actual,2018-01-08,August 2020,2020-08-31,"June 13, 2020",Actual,2020-06-13,"June 13, 2020",Actual,2020-06-13,,Interventional,,,Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury),An Open-label Phase 1 Trial to Evaluate the Safety and Tolerability of a Modified Vaccinia Ankara (MVA) Priming Followed by Fowlpox Booster Vaccines Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-BN-Brachyury/FPV-Brachyury),Completed,,Phase 1,11.0,Actual,Bavarian Nordic,,1.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-18 00:42:05,2023-06-18 00:42:05,INDUSTRY,,,,,
418618,418619,NCT01696422,,2012-09-27,,,2019-01-15,2012-09-27,2012-10-01,Estimate,,,,,,,2019-01-15,2019-01-16,Actual,October 2013,,2013-10-31,January 2019,2019-01-31,December 2020,Anticipated,2020-12-31,April 2016,Actual,2016-04-30,,Interventional,,,"Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine","Phase II, Step-wise, Randomized, Double-blind, Controlled Clinical Trial for Safety and Immunogenicity Evaluation of a Lyophilized Formulation of Dengue 1,2,3,4 (Attenuated) Vaccine in Healthy Adults",Unknown status,"Active, not recruiting",Phase 2,300.0,Actual,Butantan Institute,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 22:18:53,2023-06-14 22:18:53,OTHER_GOV,,,,,
418954,418955,NCT01666782,,2012-08-14,2016-01-29,,2016-05-23,2012-08-14,2012-08-16,Estimate,2016-04-15,2016-05-24,Estimate,,,,2016-05-23,2016-06-24,Estimate,August 2012,,2012-08-31,May 2016,2016-05-31,December 2015,Actual,2015-12-31,June 2015,Actual,2015-06-30,,Interventional,IMMUNE,,Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy,A Randomized Pilot Study Comparing High-Dose Influenza Vaccine to Standard-Dose Influenza Vaccine in Adult Oncology Patients Less Than 65 Years Receiving Chemotherapy,Completed,,Phase 2,105.0,Actual,Rochester General Hospital,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 00:03:49,2023-06-14 00:03:49,OTHER,,,,,
419165,419166,NCT01701336,,2012-08-28,,,2013-08-28,2012-10-03,2012-10-05,Estimate,,,,,,,2013-08-28,2013-08-29,Estimate,March 2012,,2012-03-31,August 2013,2013-08-31,February 2013,Actual,2013-02-28,October 2012,Actual,2012-10-31,,Interventional,HCV004,,Study of a Novel Therapeutic Vaccine Against Hepatitis C Using Ad6NSmut and MVA-NSmut in Chronically Infected Patients,"Phase Ib Study to Assess the Safety and Immunogenicity of a Novel HCV Vaccine, Based on the Sequential Injection of Ad6NSmut and MVA-NSmut, Given in Combination With PEG-Interferon Alfa Plus Ribavirin for Re-treatment of Chronic Hepatitis C",Completed,,Phase 1,9.0,Actual,ReiThera Srl,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 22:21:55,2023-06-14 22:21:55,INDUSTRY,,,,,
419194,419195,NCT01701752,,2012-10-03,,,2013-07-26,2012-10-03,2012-10-05,Estimate,,,,,,,2013-07-26,2013-07-29,Estimate,September 2012,,2012-09-30,July 2013,2013-07-31,April 2013,Actual,2013-04-30,April 2013,Actual,2013-04-30,,Interventional,,,"Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults","A Randomised, Double Blind, Double Observer Study to Assess Repeated Administration of a Single Dose of an Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Dose of a Trivalent Inactivated Influenza Virus Vaccine in Subjects 65 to 74 Years of Age.",Completed,,Phase 1,120.0,Actual,Immune Targeting Systems Ltd,,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 22:22:12,2023-06-14 22:22:12,INDUSTRY,,,,,
419394,419395,NCT01702857,,2012-10-04,,,2017-05-22,2012-10-04,2012-10-10,Estimate,,,,,,,2017-05-22,2017-05-23,Actual,November 2012,Actual,2012-11-30,May 2017,2017-05-31,"March 23, 2017",Actual,2017-03-23,"January 20, 2017",Actual,2017-01-20,,Interventional,DPIV-002,,A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico),"A Phase I, Randomized, Placebo-Controlled, Observer-blind, Two-dose (0-28 Day Schedule) Primary Vaccination Study of WRAIR Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) in Healthy Adults in Puerto Rico",Completed,,Phase 1,100.0,Actual,U.S. Army Medical Research and Development Command,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 22:22:57,2023-06-14 22:22:57,FED,,,,,
419664,419665,NCT01705223,,2012-09-12,,,2015-05-05,2012-10-11,2012-10-12,Estimate,,,,,,,2015-05-05,2015-05-06,Estimate,August 2012,,2012-08-31,October 2014,2014-10-31,January 2015,Actual,2015-01-31,October 2014,Actual,2014-10-31,,Interventional,,,Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan),Phase IIa Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan),Completed,,Phase 2,150.0,Actual,"National Center for AIDS/STD Control and Prevention, China CDC",,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 22:24:21,2023-06-14 22:24:21,OTHER_GOV,,,,,
419769,419770,NCT01705990,,2012-10-10,,,2015-08-25,2012-10-12,2012-10-15,Estimate,,,,,,,2015-08-25,2015-08-26,Estimate,March 2013,,2013-03-31,August 2015,2015-08-31,,,,March 2015,Actual,2015-03-31,,Interventional,,,Safety and Immunogenicity Study of SeV-G(NP) HIV Vaccine Administered Intranasally and Ad35-GRIN HIV Vaccine Given Intramuscularly in Prime-Boost Regimens in HIV-Uninfected Volunteers,"A Phase I Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Trial to Evaluate the Safety and Immunogenicity of a Sendai HIV Vaccine SeV-G(NP) Given Intranasally and Ad35-GRIN Administered Intramuscularly in Prime-Boost Regimens in HIV-Uninfected, Healthy Adult Volunteers",Completed,,Phase 1,65.0,Actual,International AIDS Vaccine Initiative,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 22:24:49,2023-06-14 22:24:49,NETWORK,,,,,
419823,419824,NCT01706367,,2012-09-07,,,2014-03-05,2012-10-11,2012-10-15,Estimate,,,,,,,2014-03-05,2014-03-06,Estimate,September 2012,,2012-09-30,March 2014,2014-03-31,January 2014,Actual,2014-01-31,January 2014,Actual,2014-01-31,,Interventional,,,Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years,"A Phase 1, Placebo-Controlled, Randomized, Observer-Blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Clostridium Difficile Vaccine Administered With Or Without Adjuvant, In A 3-Dose Regimen In Healthy Adults Aged 50 To 85 Years",Completed,,Phase 1,192.0,Actual,Pfizer,,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 22:25:04,2023-06-14 22:25:04,INDUSTRY,,,,,
419959,419960,NCT01707537,,2012-10-09,,,2013-02-18,2012-10-14,2012-10-16,Estimate,,,,,,,2013-02-18,2013-02-20,Estimate,September 2012,,2012-09-30,February 2013,2013-02-28,February 2013,Actual,2013-02-28,February 2013,Actual,2013-02-28,,Interventional,OCV,,To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men,"Phase I Study to Determine the Safety and Immunogenicity of Euvichol(Oral Cholera Prevention Vaccine)in Healthy Adult Men ; Open, Non-comparative Clinical Trial",Completed,,Phase 1,20.0,Actual,"EuBiologics Co.,Ltd",,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 22:25:45,2023-06-14 22:25:45,INDUSTRY,,,,,
420198,420199,NCT01709019,,2012-10-15,,,2014-03-04,2012-10-15,2012-10-17,Estimate,,,,,,,2014-03-04,2014-03-05,Estimate,October 2012,,2012-10-31,March 2014,2014-03-31,March 2014,Actual,2014-03-31,July 2013,Actual,2013-07-31,,Interventional,,,RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly,"A Phase I Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of an RSV-F Protein Nanoparticle Vaccine, With or Without Aluminum Adjuvant, and Co-administered With a Licensed Inactivated Influenza Vaccine, in Healthy Subjects = 60 Years of Age.",Completed,,Phase 1,220.0,Actual,Novavax,,5.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 22:26:50,2023-06-14 22:26:50,INDUSTRY,,,,,
420314,420315,NCT00088985,,2004-08-04,2017-03-28,,2017-05-26,2004-08-04,2004-08-05,Estimate,2017-03-28,2017-05-09,Actual,,,,2017-05-26,2017-06-20,Actual,January 2004,,2004-01-31,May 2017,2017-05-31,October 2009,Actual,2009-10-31,October 2009,Actual,2009-10-31,,Interventional,,,"Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer",Phase II Trial Evaluating The Efficacy Of A Multiepitope Dendritic Cell Vaccine Given With Trastuzumab And Vinorelbine For The Treatment Of Women With Metastatic Breast Cancer That Express HLA-A0201,Terminated,,Phase 2,56.0,Actual,UNC Lineberger Comprehensive Cancer Center,,1.0,,Funding unavailable,False,,,,True,,,,,,,,,,,,,2023-06-14 00:08:14,2023-06-14 00:08:14,OTHER,,,,,
420394,420395,NCT00995033,,2009-10-06,,,2013-02-18,2009-10-12,2009-10-14,Estimate,,,,,,,2013-02-18,2013-02-20,Estimate,October 2009,,2009-10-31,February 2013,2013-02-28,September 2012,Actual,2012-09-30,September 2012,Actual,2012-09-30,,Interventional,,,Efficacy and Safety of NicVAX® Co-administered With Varenicline (Champix®),"A Phase 2B, Multi-Center, Randomized, Double-Blinded, Parallel-Arm , Study to Assess Efficacy and Safety of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX®) or Placebo Co-Administered With Varenicline (Champix®) as an Aid in Smoking Cessation",Completed,,Phase 2,558.0,Actual,Maastricht University Medical Center,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 19:35:24,2023-06-16 19:35:24,OTHER,,,,,
420526,420527,NCT01712425,,2012-10-04,,,2016-04-28,2012-10-19,2012-10-23,Estimate,,,,,,,2016-04-28,2016-04-29,Estimate,October 2012,,2012-10-31,April 2016,2016-04-30,October 2015,Actual,2015-10-31,October 2015,Actual,2015-10-31,,Interventional,,,Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals,Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals With Early Viral Suppression After Initiation of Antiretroviral Therapy (HAART),Completed,,Phase 1,48.0,Actual,IrsiCaixa,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 22:28:56,2023-06-14 22:28:56,OTHER,,,,,
420559,420560,NCT05033847,,2021-08-30,,,2023-01-31,2021-09-01,2021-09-05,Actual,,,,,,,2023-01-31,2023-02-02,Actual,"September 12, 2021",Actual,2021-09-12,January 2023,2023-01-31,January 2024,Anticipated,2024-01-31,November 2023,Anticipated,2023-11-30,,Interventional,,,Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above,Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above,"Active, not recruiting",,Phase 2,1800.0,Actual,"National Vaccine and Serum Institute, China",,3.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-14 00:08:43,2023-06-14 00:08:43,INDUSTRY,,,,,
420579,420580,NCT01712906,,2012-10-22,,,2013-04-26,2012-10-22,2012-10-24,Estimate,,,,,,,2013-04-26,2013-04-30,Estimate,October 2012,,2012-10-31,October 2012,2012-10-31,April 2013,Actual,2013-04-30,April 2013,Actual,2013-04-30,,Interventional,,,"A Phase I, Safety Study of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Children","A Phase II Clinical Trial for Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Children",Completed,,Phase 1,300.0,Actual,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,18.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 22:29:12,2023-06-14 22:29:12,OTHER,,,,,
421185,421186,NCT01718899,,2012-10-29,,,2016-09-26,2012-10-29,2012-10-31,Estimate,,,,,,,2016-09-26,2016-09-28,Estimate,November 2012,,2012-11-30,September 2016,2016-09-30,September 2016,Actual,2016-09-30,June 2016,Actual,2016-06-30,,Interventional,,,Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma,"A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma",Completed,,Phase 1,22.0,Actual,"OncoPep, Inc.",,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 22:33:45,2023-06-14 22:33:45,INDUSTRY,,,,,
421547,421548,NCT00267085,,2005-12-19,2009-09-24,,2012-08-01,2005-12-19,2005-12-20,Estimate,2011-01-28,2011-02-25,Estimate,,,,2012-08-01,2012-08-07,Estimate,December 2005,,2005-12-31,August 2012,2012-08-31,July 2008,Actual,2008-07-31,July 2008,Actual,2008-07-31,,Interventional,,,Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease,A Pilot Phase II Trial of a Synthetic Tumor-Specific Breakpoint Peptide Vaccine in Patients With Chronic Myeloid Leukemia (CML) and Minimal Residual Disease,Completed,,Phase 2,11.0,Actual,M.D. Anderson Cancer Center,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 00:10:35,2023-06-14 00:10:35,OTHER,,,,,
421594,421595,NCT01732198,,2012-11-19,,,2013-09-20,2012-11-21,2012-11-22,Estimate,,,,,,,2013-09-20,2013-09-23,Estimate,March 2013,,2013-03-31,September 2013,2013-09-30,April 2014,Anticipated,2014-04-30,January 2014,Anticipated,2014-01-31,,Interventional,,,"A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers","A Phase 2, Multicenter, Randomized, Double-Blind, Immunogenicity, Reactogenicity, and Safety Study of NU300 Booster Dose Compared to ActHIB®, Both Co-administered With Prevnar 13® at 12-15 Months of Age, in Healthy Toddlers Who Have Received a Primary Series of a Licensed Hib Vaccine and Prevnar 13®",Unknown status,"Active, not recruiting",Phase 2,220.0,Anticipated,Nuron Biotech Inc.,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 22:36:47,2023-06-14 22:36:47,INDUSTRY,,,,,
421749,421750,NCT01734408,,2012-11-22,,,2013-10-21,2012-11-26,2012-11-27,Estimate,,,,,,,2013-10-21,2013-10-23,Estimate,November 2012,,2012-11-30,October 2013,2013-10-31,February 2013,Actual,2013-02-28,January 2013,Actual,2013-01-31,,Interventional,,,A Booster Dose of Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children,A Booster Dose of Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children,Completed,,Phase 2,773.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,8.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 22:38:05,2023-06-14 22:38:05,NETWORK,,,,,
422388,422389,NCT02533791,,2015-08-21,,,2015-10-11,2015-08-26,2015-08-27,Estimate,,,,,,,2015-10-11,2015-10-14,Estimate,July 2015,,2015-07-31,October 2015,2015-10-31,October 2015,Actual,2015-10-31,September 2015,Actual,2015-09-30,,Interventional,,,A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization,Safety and Immunogenicity of a Booster Dose of the Recombinant Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults After Primary Immunization,Completed,,Phase 1,110.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 19:29:36,2023-06-16 19:29:36,NETWORK,,,,,
422680,422681,NCT02721043,,2016-02-16,,,2021-01-07,2016-03-22,2016-03-28,Estimate,,,,,,,2021-01-07,2021-01-11,Actual,April 2016,,2016-04-30,January 2020,2020-01-31,"June 8, 2020",Actual,2020-06-08,"November 12, 2019",Actual,2019-11-12,,Interventional,,,Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies,Study Of Pgv001 A Multi-Peptide Therapeutic Vaccine Platform For Use In The Treatment Of Malignancies In The Adjuvant Setting,Completed,,Phase 1,13.0,Actual,Icahn School of Medicine at Mount Sinai,,1.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-15 20:30:48,2023-06-15 20:30:48,OTHER,,,,,
423130,423131,NCT01827397,,2013-04-04,,,2014-05-20,2013-04-04,2013-04-09,Estimate,,,,,,,2014-05-20,2014-05-21,Estimate,April 2013,,2013-04-30,May 2014,2014-05-31,February 2014,Actual,2014-02-28,November 2013,Actual,2013-11-30,,Interventional,,,Safety & Immunogenicity of Immunisations With EN41-UGR7C HIV Vaccine,"Phase 1 Randomised, Single-centre, Observer-blind, Placebo-controlled Trial of Safety and Immunogenicity of EN41-UGR7C HIV Vaccine Candidate Administered Intramuscularly in Healthy Female Volunteers",Completed,,Phase 1,24.0,Actual,PX'Therapeutics,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 23:32:58,2023-06-14 23:32:58,INDUSTRY,,,,,
423177,423178,NCT01748747,,2012-12-10,,,2018-10-04,2012-12-10,2012-12-12,Estimate,,,,,,,2018-10-04,2018-10-09,Actual,October 2012,Actual,2012-10-31,October 2018,2018-10-31,"March 30, 2017",Actual,2017-03-30,"December 14, 2014",Actual,2014-12-14,,Interventional,,,Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery,Peptide Vaccine With Resiquimod as an Immune Modulator for Patients With Resected Melanoma: A Pilot Study,Completed,,Early Phase 1,30.0,Actual,Mayo Clinic,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 22:47:46,2023-06-14 22:47:46,OTHER,,,,,
423285,423286,NCT02718469,,2016-03-09,,,2017-04-03,2016-03-18,2016-03-24,Estimate,,,,,,,2017-04-03,2017-04-04,Actual,"December 22, 2015",Actual,2015-12-22,April 2017,2017-04-30,"September 15, 2016",Actual,2016-09-15,"September 15, 2016",Actual,2016-09-15,,Interventional,,,Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults,A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Monovalent Ebola Zaire Vaccine (rVSVN4CT1-EBOVGP1) Delivered by Intramuscular Injection in Healthy Adult Subjects,Completed,,Phase 1,38.0,Actual,Auro Vaccines LLC,,4.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-15 20:32:04,2023-06-15 20:32:04,INDUSTRY,,,,,
423407,423408,NCT01751048,,2012-12-13,,,2016-12-29,2012-12-13,2012-12-17,Estimate,,,,,,,2016-12-29,2017-01-02,Estimate,March 2013,,2013-03-31,May 2015,2015-05-31,January 2015,Actual,2015-01-31,January 2015,Actual,2015-01-31,,Interventional,,,LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine,"A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the Vaccine Candidates LEISH-F3 + GLA-SE, LEISH-F3 + MPL-SE, and LEISH-F3 + SE in Healthy Adult Subjects",Completed,,Phase 1,48.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 22:49:13,2023-06-14 22:49:13,NIH,,,,,
424387,424388,NCT00940108,,2009-07-13,2013-07-09,,2018-04-25,2009-07-14,2009-07-15,Estimate,2013-10-28,2013-11-20,Estimate,,,,2018-04-25,2018-06-28,Actual,August 2009,,2009-08-31,April 2018,2018-04-30,April 2010,Actual,2010-04-30,October 2009,Actual,2009-10-31,,Interventional,,,A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children,"A Phase II, Multicentre, Randomised, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children Aged >= 6 Months to < 9 Years.",Completed,,Phase 2,370.0,Actual,Seqirus,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 20:35:18,2023-06-15 20:35:18,INDUSTRY,,,,,
424410,424411,NCT01762930,,2012-10-16,,,2016-08-29,2013-01-06,2013-01-08,Estimate,,,,,,,2016-08-29,2016-08-31,Estimate,June 2012,,2012-06-30,August 2016,2016-08-31,December 2015,Actual,2015-12-31,December 2015,Actual,2015-12-31,,Interventional,,,Field Application of Shanchol in Adults in Bangladesh,"Study of Field Application of Oral Cholera Vaccine, Shanchol for Use in Developing Country Settings",Completed,,Phase 2,1015.0,Actual,"International Centre for Diarrhoeal Disease Research, Bangladesh",,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 22:57:16,2023-06-14 22:57:16,OTHER,,,,,
424503,424504,NCT01764126,,2012-03-16,,,2014-07-09,2013-01-07,2013-01-09,Estimate,,,,,,,2014-07-09,2014-07-10,Estimate,September 2011,,2011-09-30,January 2013,2013-01-31,February 2014,Actual,2014-02-28,February 2014,Actual,2014-02-28,,Interventional,PPR02,,Pneumococcal Protein Vaccine Safety and Immunogenicity Trial,"Safety and Immunogenicity of Pneumococcal Protein Vaccine (PPrV) in Healthy Adults, Toddlers and Infants in Bangladesh",Completed,,Phase 1,280.0,Actual,"International Centre for Diarrhoeal Disease Research, Bangladesh",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 22:58:04,2023-06-14 22:58:04,OTHER,,,,,
424514,424515,NCT01218113,,2010-10-07,2017-09-27,2013-04-11,2018-04-19,2010-10-07,2010-10-11,Estimate,2018-04-19,2018-05-21,Actual,2013-04-11,2013-04-18,Estimate,2018-04-19,2018-05-21,Actual,"November 8, 2010",Actual,2010-11-08,March 2018,2018-03-31,"November 5, 2012",Actual,2012-11-05,"November 5, 2012",Actual,2012-11-05,,Interventional,,,Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons,Efficacy and Safety of HIV Vaccine 732462 in ART-naïve HIV-1 Infected Persons,Completed,,Phase 2,191.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 20:35:47,2023-06-15 20:35:47,INDUSTRY,,,,,
424760,424761,NCT01767402,,2013-01-10,,,2013-01-10,2013-01-10,2013-01-14,Estimate,,,,,,,2013-01-10,2013-01-14,Estimate,October 2003,,2003-10-31,January 2013,2013-01-31,November 2004,Actual,2004-11-30,November 2004,Actual,2004-11-30,,Interventional,,,"Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy Adults","A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine Without or With Adjuvant, Administered at 2 Different Concentrations According to a 0-2 Month Schedule, in Healthy Adults",Completed,,Phase 1,150.0,Actual,GlaxoSmithKline,,6.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 23:00:13,2023-06-14 23:00:13,INDUSTRY,,,,,
425225,425226,NCT04188691,,2019-11-27,,,2021-04-20,2019-12-04,2019-12-06,Actual,,,,,,,2021-04-20,2021-04-22,Actual,"November 28, 2019",Actual,2019-11-28,April 2020,2020-04-30,"December 13, 2020",Actual,2020-12-13,"December 13, 2020",Actual,2020-12-13,,Interventional,,,A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine,"A Randomized, Blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenulapolymorpha) in Healthy People Aged 6 Months to 59 Years",Completed,,Phase 1,510.0,Actual,"National Vaccine and Serum Institute, China",,5.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-15 20:37:48,2023-06-15 20:37:48,INDUSTRY,,,,,
425612,425613,NCT00359619,,2006-07-18,2012-12-19,2011-02-04,2019-12-27,2006-08-01,2006-08-02,Estimate,2015-01-08,2015-02-10,Estimate,2011-02-04,2011-02-09,Estimate,2019-12-27,2020-01-02,Actual,"September 12, 2006",Actual,2006-09-12,December 2019,2019-12-31,"January 30, 2007",Actual,2007-01-30,"January 30, 2007",Actual,2007-01-30,,Interventional,,,Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine,"A Long-term, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Novel HPV Vaccine in Healthy Female Subjects Vaccinated in the Primary Study",Completed,,Phase 2,383.0,Actual,GlaxoSmithKline,,7.0,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=1524,Yes,IPD is available via the Clinical Study Data Request site (click on the link provided below),2023-06-16 19:31:09,2023-06-16 19:31:09,INDUSTRY,,,,,
426027,426028,NCT01783977,,2013-02-01,,,2021-10-13,2013-02-01,2013-02-05,Estimate,,,,,,,2021-10-13,2021-10-15,Actual,April 2013,,2013-04-30,October 2021,2021-10-31,"October 24, 2018",Actual,2018-10-24,September 2014,Actual,2014-09-30,,Interventional,,,"Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults","A Phase 1 Clinical Trial to Evaluate Safety and to Compare the Immunogenicity of 3 DNA Vaccine Prime Schedules Followed by a NYVAC Vaccine Boost in Healthy, HIV-1 Uninfected Adult Participants",Completed,,Phase 1,143.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,7.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 23:11:09,2023-06-14 23:11:09,NIH,,,,,
426153,426154,NCT01056705,,2010-01-25,,,2016-07-31,2010-01-25,2010-01-26,Estimate,,,,,,,2016-07-31,2016-08-02,Estimate,July 2009,,2009-07-31,July 2016,2016-07-31,August 2010,Actual,2010-08-31,May 2010,Actual,2010-05-31,,Interventional,Sabin IPV,,The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (IPV),The Phase <U+2161> Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains,Completed,,Phase 2,500.0,Actual,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 19:31:32,2023-06-16 19:31:32,OTHER,,,,,
426496,426497,NCT02870751,,2016-08-13,,,2018-09-10,2016-08-13,2016-08-17,Estimate,,,,,,,2018-09-10,2018-09-11,Actual,May 2016,,2016-05-31,September 2018,2018-09-30,September 2019,Anticipated,2019-09-30,December 2018,Anticipated,2018-12-31,,Interventional,ETECvacWP2,,Human Challenge Model With ST-only Enterotoxigenic Escherichia Coli,Developing A Human Challenge Model For Evaluating Vaccines Against ST-producing Enterotoxigenic Escherichia Coli,Unknown status,Recruiting,Phase 1,30.0,Anticipated,University of Bergen,,1.0,,,False,,,,True,,,,,,,,,,,Yes,Data and samples may be shared with current and future partners,2023-06-15 20:41:59,2023-06-15 20:41:59,OTHER,,,,,
426531,426532,NCT01011309,,2009-11-09,2013-09-16,,2013-11-15,2009-11-10,2009-11-11,Estimate,2013-09-16,2013-11-18,Estimate,,,,2013-11-15,2013-12-11,Estimate,October 2009,,2009-10-31,November 2013,2013-11-30,December 2011,Actual,2011-12-31,May 2011,Actual,2011-05-31,,Interventional,,,A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis,"A Phase 2, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine in the Treatment of Patients With Cutaneous Leishmaniasis",Completed,,Phase 2,45.0,Actual,Access to Advanced Health Institute (AAHI),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 20:42:24,2023-06-15 20:42:24,OTHER,,,,,
426618,426619,NCT00616291,,2008-02-14,,,2012-11-05,2008-02-14,2008-02-15,Estimate,,,,,,,2012-11-05,2012-11-06,Estimate,April 2006,,2006-04-30,November 2012,2012-11-30,July 2011,Actual,2011-07-31,July 2011,Actual,2011-07-31,,Interventional,,,"Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer",Immunotherapy of Patients With Androgen-Independent Prostate Carcinoma Using NY-ESO-1/LAGE1 Peptide Vaccine (SPORE #: 11-01-30-14),Completed,,Phase 1,14.0,Actual,Baylor College of Medicine,,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 20:42:51,2023-06-15 20:42:51,OTHER,,,,,
427008,427009,NCT01001169,,2009-10-22,2017-03-14,2010-07-02,2018-07-04,2009-10-22,2009-10-23,Estimate,2017-03-22,2017-05-02,Actual,2010-07-02,2010-07-07,Estimate,2018-07-04,2018-08-17,Actual,"October 1, 2009",,2009-10-01,July 2018,2018-07-31,"May 17, 2010",Actual,2010-05-17,"May 17, 2010",Actual,2010-05-17,,Interventional,,,Safety and Immunogenocity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Japanese Children,Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine (GSK2340274A) in Japanese Children Aged 6 Months to 17 Years,Completed,,Phase 2,60.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 20:44:20,2023-06-15 20:44:20,INDUSTRY,,,,,
427449,427450,NCT00995865,,2009-10-08,2015-10-12,,2016-04-01,2009-10-14,2009-10-15,Estimate,2016-04-01,2016-05-05,Estimate,,,,2016-04-01,2016-05-05,Estimate,January 2010,,2010-01-31,April 2016,2016-04-30,October 2010,Actual,2010-10-31,May 2010,Actual,2010-05-31,,Interventional,,,Trial of Yellow Fever Inactivated Vaccine,"Randomized, Double Blind, Controlled Phase I Trial of the Safety, Tolerability,and Immunogenicity of Graded Doses of XRX-001 Yellow Fever 17D, Inactivated Vaccine, Alum Adsorbed in Healthy Adults.",Completed,,Phase 1,60.0,Actual,GE Healthcare,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 20:46:13,2023-06-15 20:46:13,INDUSTRY,,,,,
427514,427515,NCT01812135,,2013-03-13,,,2021-07-26,2013-03-13,2013-03-15,Estimate,,,,,,,2021-07-26,2021-07-29,Actual,September 2011,,2011-09-30,March 2013,2013-03-31,December 2011,Anticipated,2011-12-31,November 2011,Anticipated,2011-11-30,,Interventional,,,Safety and Immunogenicity of EV71 Vaccine With or Without Aluminum Adjuvant in Infants,"A Double-blind and Randomized, Phase II -02 Study With Inactivated EV71 Vaccines in Healthy Infants",Withdrawn,,Phase 2,0.0,Actual,"Sinovac Biotech Co., Ltd",,3.0,,"Based on the previous study results, inactivated EV71 vaccine with aluminum adjuvant was elected to be used for the efficacy Phase III study.",False,,,,True,False,False,,,,,,,,,,,2023-06-14 23:22:44,2023-06-14 23:22:44,INDUSTRY,,,,,
427813,427814,NCT01816113,,2013-03-13,,,2017-05-05,2013-03-18,2013-03-21,Estimate,,,,,,,2017-05-05,2017-05-08,Actual,April 2013,,2013-04-30,May 2017,2017-05-31,July 2014,Actual,2014-07-31,July 2014,Actual,2014-07-31,,Interventional,,,Phase Ia Study of ChAd63/MVA PvDBP,A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Vivax Malaria Vaccine Candidates ChAd63 PvDBP Alone and With MVA PvDBP,Completed,,Phase 1,24.0,Actual,University of Oxford,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 23:25:19,2023-06-14 23:25:19,OTHER,,,,,
427993,427994,NCT01818362,,2013-03-18,,,2015-12-14,2013-03-21,2013-03-26,Estimate,,,,,,,2015-12-14,2015-12-15,Estimate,April 2013,,2013-04-30,December 2015,2015-12-31,November 2015,Actual,2015-11-30,November 2015,Actual,2015-11-30,,Interventional,,,A Phase I Study of Candidate Influenza Vaccines MVA-NP+M1 and ChAdOx1 NP+M1,A Phase I Study to Determine the Safety and Immunogenicity of Vaccination Regimens Employing the Candidate Influenza Vaccines MVA-NP+M1 and ChAdOx1 NP+M1,Completed,,Phase 1,72.0,Actual,University of Oxford,,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 23:26:46,2023-06-14 23:26:46,OTHER,,,,,
428221,428222,NCT04758962,,2021-02-08,,,2022-05-16,2021-02-16,2021-02-17,Actual,,,,,,,2022-05-16,2022-05-17,Actual,"February 15, 2021",Actual,2021-02-15,May 2022,2022-05-31,"April 19, 2022",Actual,2022-04-19,"June 4, 2021",Actual,2021-06-04,,Interventional,,,A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults,"A Phase I, First-Time-in Human (FTiH), Open-label, Dose Escalation, Non-randomized Study to Assess Safety, Reactogenicity and Immune Response of a CoV-2 SAM (LNP) Vaccine When Administered Intramuscularly on a 0, 1 Month Schedule in Healthy Adults 18 to 50 Years of Age",Completed,,Phase 1,10.0,Actual,GlaxoSmithKline,,1.0,,,False,,,,False,True,False,,,False,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2023-06-18 00:53:39,2023-06-18 00:53:39,INDUSTRY,,,,,
428269,428270,NCT01841918,,2013-01-29,,,2018-01-30,2013-04-24,2013-04-29,Estimate,,,,,,,2018-01-30,2018-01-31,Actual,January 2013,,2013-01-31,July 2017,2017-07-31,June 2013,Actual,2013-06-30,May 2013,Actual,2013-05-31,,Interventional,,,Safety and Immunogenicity of Live Attenuated Influenza H5N2,Phase II Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers,Completed,,Phase 2,150.0,Actual,Mahidol University,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 23:37:10,2023-06-14 23:37:10,OTHER,,,,,
428322,428323,NCT01842139,,2012-07-03,,,2018-03-07,2013-04-24,2013-04-29,Estimate,,,,,,,2018-03-07,2018-03-09,Actual,"December 5, 2011",Actual,2011-12-05,March 2018,2018-03-31,March 2018,Actual,2018-03-31,"February 2, 2015",Actual,2015-02-02,,Interventional,,,Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission,Randomized Phase I Study Combining Suppression of T Regulatory Cells With WT1 Vaccine Therapy for AML Patients in Complete Remission,Completed,,Phase 1,7.0,Actual,University of Chicago,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-14 23:37:18,2023-06-14 23:37:18,OTHER,,,,,
428488,428489,NCT00997607,,2009-10-16,,,2013-01-25,2009-10-16,2009-10-19,Estimate,,,,,,,2013-01-25,2013-01-28,Estimate,February 2010,,2010-02-28,January 2013,2013-01-31,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,,,Evaluating an Ebola and a Marburg Vaccine in Uganda,"A Phase IB Study to Evaluate the Safety and Immunogenicity of an Ebola DNA Plasmid Vaccine, VRC-EBODNA023-00-VP, and a Marburg DNA Plasmid Vaccine, VRC-MARDNA025-00-VP, in Healthy Adults in Kampala, Uganda",Completed,,Phase 1,108.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 19:35:49,2023-06-16 19:35:49,NIH,,,,,
428511,428512,NCT01843491,,2013-04-22,,,2015-04-28,2013-04-25,2013-04-30,Estimate,,,,,,,2015-04-28,2015-04-30,Estimate,June 2013,,2013-06-30,April 2015,2015-04-30,June 2014,Anticipated,2014-06-30,June 2014,Anticipated,2014-06-30,,Interventional,AdBa,,A Phase I Clinical Trial Immunizing Healthy Adults With the NMRC-M3V-Ad-PfCA Vaccine to Generate Biologic Reagents,A Phase I Clinical Trial Immunizing Healthy Adults With the NMRC-M3V-Ad-PfCA Vaccine to Generate Biologic Reagents for Refining Immunologic Assays Supporting the Development of the Protective Malaria Vaccine NMRC-M3V-D/Ad-PfCA (AdBa),Withdrawn,,Phase 1,0.0,Actual,U.S. Army Medical Research and Development Command,,1.0,,Did not go forward with study.,False,,,,False,,,,,,,,,,,,,2023-06-14 23:38:09,2023-06-14 23:38:09,FED,,,,,
428541,428542,NCT01061541,,2010-02-02,,,2016-09-08,2010-02-02,2010-02-03,Estimate,,,,,,,2016-09-08,2016-09-09,Estimate,August 2003,,2003-08-31,September 2016,2016-09-30,August 2004,Actual,2004-08-31,January 2004,Actual,2004-01-31,,Interventional,,,"Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix-HepB/Hib2.5 Compared to GSK Vaccine Tritanrix-HepB/Hiberix","A Phase II, Double-blind, Randomized Study to Compare the Immunogenicity, Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Tritanrix-HepB/Hib2.5 to GSK Biologicals' Tritanrix-HepB/Hiberix When Administered as a Three-dose Primary Vaccination Course to Healthy Infants at 6, 10 and 14 Weeks of Age. A Dose of Unconjugated Hib Vaccine (Plain PRP Booster) Will be Administered at the Age of 10 Months to 50% of the Subjects",Completed,,Phase 2,192.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 19:35:53,2023-06-16 19:35:53,INDUSTRY,,,,,
428723,428724,NCT02678455,,2016-02-05,,,2020-08-04,2016-02-05,2016-02-09,Estimate,,,,,,,2020-08-04,2020-08-06,Actual,March 2016,,2016-03-31,August 2020,2020-08-31,"February 5, 2020",Actual,2020-02-05,"August 10, 2017",Actual,2017-08-10,,Interventional,,,"Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh","Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine Admixture TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh",Completed,,Phase 2,192.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,Undecided,,2023-06-15 20:56:10,2023-06-15 20:56:10,NIH,,,,,
428764,428765,NCT01145508,,2010-06-15,2014-04-25,,2017-08-21,2010-06-15,2010-06-16,Estimate,2014-07-22,2014-07-23,Estimate,,,,2017-08-21,2017-09-19,Actual,August 2010,,2010-08-31,August 2017,2017-08-31,October 2015,Actual,2015-10-31,October 2012,Actual,2012-10-31,,Interventional,,All randomized patients are included in this analysis.,Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,Randomized Phase II Trial of Docetaxel With or Without PSA-TRICOM Vaccine in Patients With Castrate-Resistant Metastatic Prostate Cancer,Terminated,,Phase 2,10.0,Actual,National Cancer Institute (NCI),,2.0,,Poor accrual,False,,,,True,,,,,,,,,,,,,2023-06-15 20:56:28,2023-06-15 20:56:28,NIH,,,,,
428993,428994,NCT00918268,,2009-06-09,,,2012-04-20,2009-06-10,2009-06-11,Estimate,,,,,,,2012-04-20,2012-04-23,Estimate,June 2009,,2009-06-30,April 2012,2012-04-30,July 2009,Actual,2009-07-31,July 2009,Actual,2009-07-31,,Interventional,,,"Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2009/2010 Recommended in Northern Hemisphere in Non-elderly Adult and in Elderly Subjects","A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2009-2010, When Administered to Non-elderly Adult and Elderly Subjects",Completed,,Phase 2,130.0,Actual,Novartis,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 01:40:35,2023-06-16 01:40:35,INDUSTRY,,,,,
429167,429168,NCT01846143,,2013-04-30,,,2016-08-11,2013-05-02,2013-05-03,Estimate,,,,,,,2016-08-11,2016-08-12,Estimate,May 2013,,2013-05-31,August 2016,2016-08-31,November 2015,Actual,2015-11-30,June 2015,Actual,2015-06-30,,Interventional,Mel59,,Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies,Evaluation of the Safety and Immunogenicity of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies (Mel59),Completed,,Phase 1,15.0,Actual,University of Virginia,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 23:39:54,2023-06-14 23:39:54,OTHER,,,,,
429614,429615,NCT01165242,,2010-07-15,2017-05-11,2011-04-13,2018-05-29,2010-07-15,2010-07-19,Estimate,2017-05-11,2017-06-08,Actual,2011-04-13,2011-04-26,Estimate,2018-05-29,2018-06-26,Actual,"August 19, 2010",,2010-08-19,May 2018,2018-05-31,"July 29, 2011",Actual,2011-07-29,"February 25, 2011",Actual,2011-02-25,,Interventional,,,Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults,Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years,Completed,,Phase 2,1013.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 21:06:14,2023-06-15 21:06:14,INDUSTRY,,,,,
429633,429634,NCT01215734,,2010-10-05,2013-02-04,,2013-02-04,2010-10-05,2010-10-06,Estimate,2013-02-04,2013-03-08,Estimate,,,,2013-02-04,2013-03-08,Estimate,October 2010,,2010-10-31,February 2013,2013-02-28,September 2012,Actual,2012-09-30,April 2012,Actual,2012-04-30,,Interventional,,,Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients,"Randomized Double-Blind, Comparison of Standard Dose Trivalent Inactivated Influenza Vaccine Versus High-Dose Trivalent Inactivated Influenza Vaccine in Adult Stem Cell Hematopoetic Transplant Recipients",Completed,,Phase 1,44.0,Actual,Vanderbilt-Ingram Cancer Center,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 21:06:29,2023-06-15 21:06:29,OTHER,,,,,
429699,429700,NCT01215188,,2010-10-04,2019-04-08,,2019-04-08,2010-10-05,2010-10-06,Estimate,2019-04-08,2019-04-30,Actual,,,,2019-04-08,2019-04-30,Actual,"October 14, 2010",Actual,2010-10-14,April 2019,2019-04-30,"July 31, 2012",Actual,2012-07-31,"July 31, 2012",Actual,2012-07-31,,Interventional,,,A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003),"A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13 in Healthy Infants",Completed,,Phase 2,1152.0,Actual,Merck Sharp & Dohme LLC,,3.0,,,False,,,,True,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2023-06-15 21:07:17,2023-06-15 21:07:17,INDUSTRY,,,,,
429793,429794,NCT04170829,,2019-11-14,,,2020-11-29,2019-11-18,2019-11-20,Actual,,,,,,,2020-11-29,2020-12-01,Actual,"December 17, 2019",Actual,2019-12-17,November 2020,2020-11-30,"November 26, 2020",Actual,2020-11-26,"November 26, 2020",Actual,2020-11-26,,Interventional,,,A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate MERS-CoV Vaccine (MERS002),A Phase Ib Study to Determine the Safety and Immunogenicity of the Candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Vaccine ChAdOx1 MERS in Healthy Adult Middle Eastern Volunteers,Completed,,Phase 1,24.0,Actual,King Abdullah International Medical Research Center,,3.0,,,False,,,,,False,False,,,,,,,,,No,,2023-06-15 21:08:23,2023-06-15 21:08:23,OTHER,,,,,
429875,429876,NCT02654509,,2016-01-11,,,2020-03-16,2016-01-12,2016-01-13,Estimate,,,,,,,2020-03-16,2020-03-17,Actual,"June 3, 2008",Actual,2008-06-03,March 2020,2020-03-31,"March 18, 2018",Actual,2018-03-18,"February 16, 2016",Actual,2016-02-16,,Interventional,,,Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine,"Phase 2 Open-Label Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine, Inactivated, Dried, TSI-GSD 104, Lot 2-1-89, in Healthy Adult Subjects at Risk of Exposure to Eastern Equine Encephalitis Virus",Completed,,Phase 2,138.0,Actual,U.S. Army Medical Research and Development Command,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 21:09:07,2023-06-15 21:09:07,FED,,,,,
429904,429905,NCT00920218,,2009-06-12,2017-08-04,2011-06-01,2017-11-10,2009-06-12,2009-06-15,Estimate,2017-11-10,2017-12-12,Actual,2011-06-01,2011-06-07,Estimate,2017-11-10,2017-12-12,Actual,"July 14, 2009",Actual,2009-07-14,August 2017,2017-08-31,"March 21, 2012",Actual,2012-03-21,"April 26, 2011",Actual,2011-04-26,,Interventional,,,Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A,Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A,Completed,,Phase 2,121.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 21:09:26,2023-06-15 21:09:26,INDUSTRY,,,,,
429931,429932,NCT02658253,,2016-01-07,,,2019-11-27,2016-01-14,2016-01-18,Estimate,,,,,,,2019-11-27,2019-11-29,Actual,January 2016,,2016-01-31,May 2019,2019-05-31,"February 21, 2019",Actual,2019-02-21,"September 19, 2018",Actual,2018-09-19,,Interventional,PRIMALVAC,,Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults,"Phase Ia/Ib, Randomized, Double Blinded, Dose Escalation Trial to Evaluate the Safety and Immunogenicity in Healthy European and Burkinabe Adults of a Placental Malaria Vaccine Candidate (PRIMVAC) Formulated With Alhydrogel ® or GLA-SE",Completed,,Phase 1,68.0,Actual,"Institut National de la Santé Et de la Recherche Médicale, France",,10.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-15 21:09:43,2023-06-15 21:09:43,OTHER_GOV,,,,,
430160,430161,NCT02657161,,2016-01-11,,,2016-01-13,2016-01-13,2016-01-15,Estimate,,,,,,,2016-01-13,2016-01-15,Estimate,February 2015,,2015-02-28,January 2016,2016-01-31,July 2015,Actual,2015-07-31,July 2015,Actual,2015-07-31,,Interventional,,,Safety and Efficacy of a PIKA Rabies Vaccine Containing the PIKA Adjuvant,Phase I Study to Determine the Safety and Efficacy of a PIKA Rabies Vaccine Containing the PIKA Adjuvant,Completed,,Phase 1,37.0,Actual,Yisheng Biopharma (Singapore) Pte. Ltd.,,3.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-15 21:11:18,2023-06-15 21:11:18,INDUSTRY,,,,,
430196,430197,NCT04047979,,2019-08-06,,,2022-12-21,2019-08-06,2019-08-07,Actual,,,,,,,2022-12-21,2022-12-23,Actual,"November 14, 2019",Actual,2019-11-14,December 2022,2022-12-31,"June 30, 2024",Anticipated,2024-06-30,"December 31, 2023",Anticipated,2023-12-31,,Interventional,,,Systems Biology of Zoster Vaccine,"SHINGRIX-Systems Biology of Zoster Vaccine Recombinant, Adjuvanted",Recruiting,,Phase 2,60.0,Anticipated,Emory University,,2.0,,,False,,,,True,True,False,,,False,,,At the time of publication or 9 months after submission of the manuscript. It will be available indefinitely.,"Data will be uploaded into www.immport.org and made available to researchers with a registered account.

Type of Analysis: Any Purpose

Mode of Access: Data will be shared on www.immport.org",http://www.immport.org,Yes,"All of the individual participant data collected during the trial, after deidentification.",2023-06-15 21:11:46,2023-06-15 21:11:46,OTHER,,,,,
430307,430308,NCT02691130,,2016-02-11,,,2018-02-08,2016-02-21,2016-02-25,Estimate,,,,,,,2018-02-08,2018-02-09,Actual,November 2015,,2015-11-30,February 2018,2018-02-28,January 2017,Actual,2017-01-31,October 2016,Actual,2016-10-31,,Interventional,,,Assess the Safety and Immunogenicity of M-001 as A Standalone Influenza Vaccine and as A H5N1 Vaccine Primer in Adults,"A Multicenter, Randomized, Double-blind, Active-controlled Phase 2b Trial [Part of EU-funded UNISEC Project] to Assess the Immunogenicity & Safety of a BiondVax's Influenza Vaccine (M-001) Followed by H5N1 Vaccine in Healthy Adults",Completed,,Phase 2,224.0,Actual,BiondVax Pharmaceuticals ltd.,,3.0,,,False,,,,True,,,,,,,,,,,No,"summary of data per group will be shared, not IPD.",2023-06-15 21:12:46,2023-06-15 21:12:46,INDUSTRY,,,,,
430328,430329,NCT02647489,,2016-01-04,,,2018-06-22,2016-01-05,2016-01-06,Estimate,,,,,,,2018-06-22,2018-06-26,Actual,May 2016,,2016-05-31,October 2016,2016-10-31,"November 10, 2017",Actual,2017-11-10,"November 10, 2017",Actual,2017-11-10,,Interventional,PAMVAC,,Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously Adjuvanted,"Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Adjuvanted With Alhydrogel, GLA-SE or GLA-LSQ in Healthy Malaria-Naïve Adults and Healthy, Lifelong Malaria-Exposed, Nulligravid Adult Women",Completed,,Phase 1,66.0,Actual,University Hospital Tuebingen,,11.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 21:13:05,2023-06-15 21:13:05,OTHER,,,,,
430399,430400,NCT00651703,,2008-04-01,,,2010-11-11,2008-04-01,2008-04-03,Estimate,,,,,,,2010-11-11,2010-11-15,Estimate,April 2008,,2008-04-30,November 2010,2010-11-30,July 2010,Actual,2010-07-31,December 2009,Actual,2009-12-31,,Interventional,,,Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients,"Safety, Tolerability, and Immunogenicity of CYT004-MelQbG10 Vaccine With or Without Immunostimulating Adjuvant in HLA-A2 Positive Patients With Stage III/IV Malignant Melanoma",Completed,,Phase 2,21.0,Actual,Cytos Biotechnology AG,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 21:13:37,2023-06-15 21:13:37,INDUSTRY,,,,,
430548,430549,NCT01852266,,2013-05-08,,,2016-09-13,2013-05-08,2013-05-13,Estimate,,,,,,,2016-09-13,2016-09-15,Estimate,October 2013,,2013-10-31,September 2016,2016-09-30,,,,July 2015,Actual,2015-07-31,,Interventional,,,Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children,"A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV cps2, Lot RSV#005A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age",Completed,,Phase 1,50.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-14 23:44:04,2023-06-14 23:44:04,NIH,,,,,
430829,430830,NCT04015648,,2019-06-04,,,2022-05-17,2019-07-08,2019-07-11,Actual,,,,,,,2022-05-17,2022-05-18,Actual,"October 21, 2019",Actual,2019-10-21,November 2021,2021-11-30,"March 10, 2022",Actual,2022-03-10,"March 10, 2022",Actual,2022-03-10,,Interventional,,,Safety and Immunogenicity of a Candidate ZIKV Vaccine (ZIKA001),A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Zika Virus (ZIKV) Vaccine ChAdOx1 Zika in Healthy Adult Volunteers.,Completed,,Phase 1,24.0,Actual,University of Oxford,,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-15 21:16:51,2023-06-15 21:16:51,OTHER,,,,,
431134,431135,NCT02157051,,2014-06-03,,,2022-12-07,2014-06-04,2014-06-05,Estimate,,,,,,,2022-12-07,2022-12-09,Actual,June 2015,Actual,2015-06-30,December 2022,2022-12-31,"February 10, 2027",Anticipated,2027-02-10,"November 25, 2022",Actual,2022-11-25,,Interventional,,,Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer,A Phase I Trial of the Safety and Immunogenicity of a Multiple Antigen Vaccine (STEMVAC) in HER2 Negative Advanced Stage Breast Cancer Patients,"Active, not recruiting",,Phase 1,42.0,Actual,University of Washington,,4.0,,,False,,,,False,,,,,,,,,,,No,,2023-06-15 21:19:12,2023-06-15 21:19:12,OTHER,,,,,
431241,431242,NCT05685953,,2023-01-11,,,2023-02-16,2023-01-13,2023-01-17,Actual,,,,,,,2023-02-16,2023-02-17,Actual,"February 8, 2023",Actual,2023-02-08,February 2023,2023-02-28,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2023",Anticipated,2023-12-31,,Interventional,OpenCorona1,,"A Randomized, Phase I Study of DNA Vaccine OC-007 as a Booster Dose of COVID-19 Vaccine","A Randomized, Placebo-controlled, Double-blinded Phase I Study to Evaluate Safety and Immunogenicity of DNA Vaccine OC-007 as a Booster Dose of COVID-19 Vaccine",Recruiting,,Phase 1,16.0,Anticipated,Karolinska Institutet,,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-16 19:37:55,2023-06-16 19:37:55,OTHER,,,,,
431248,431249,NCT02883426,,2016-08-25,,,2018-05-01,2016-08-25,2016-08-30,Estimate,,,,,,,2018-05-01,2018-05-03,Actual,September 2016,,2016-09-30,May 2018,2018-05-31,,,,"January 5, 2017",Actual,2017-01-05,,Interventional,,,Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease,"Evaluation of the Safety and Immunogenicity of Live Influenza A Vaccine H3N2v (6-2) AA ca Recombinant (A/Minnesota/11/2010 (H3N2v) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H3N2v Disease",Terminated,,Phase 1,1.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,7.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 21:20:18,2023-06-15 21:20:18,NIH,,,,,
431410,431411,NCT00952419,,2009-08-03,2011-06-08,,2016-04-12,2009-08-04,2009-08-06,Estimate,2011-06-08,2011-07-11,Estimate,,,,2016-04-12,2016-04-14,Estimate,August 2009,,2009-08-31,April 2016,2016-04-30,June 2010,Actual,2010-06-30,March 2010,Actual,2010-03-31,,Interventional,,,A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years,Immunogenicity and Safety of Multiple Formulations of an A/H1N1 Pandemic Vaccine in Healthy Subjects Aged 6 Months to 9 Years,Completed,,Phase 2,474.0,Actual,Sanofi,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 21:22:00,2023-06-15 21:22:00,INDUSTRY,,,,,
432453,432454,NCT00664417,,2008-04-22,,,2012-04-16,2008-04-22,2008-04-23,Estimate,,,,,,,2012-04-16,2012-04-17,Estimate,April 2008,,2008-04-30,April 2012,2012-04-30,August 2010,Actual,2010-08-31,September 2009,Actual,2009-09-30,,Interventional,,,"Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine","Safety and Immunogenicity of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine in Healthy Adults",Completed,,Phase 1,375.0,Actual,Sanofi,,9.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 21:32:39,2023-06-15 21:32:39,INDUSTRY,,,,,
432588,432589,NCT01204658,,2010-09-16,2016-08-05,2012-11-16,2019-05-17,2010-09-16,2010-09-17,Estimate,2016-08-05,2016-09-28,Estimate,2012-11-16,2012-11-21,Estimate,2019-05-17,2019-05-29,Actual,"September 27, 2010",Actual,2010-09-27,May 2019,2019-05-31,"October 1, 2012",Actual,2012-10-01,"November 3, 2011",Actual,2011-11-03,,Interventional,,,Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants,"Safety, Reactogenicity & Immunogenicity of GSK Biologicals' Pneumococcal Vaccine 2189242A When Co-administered With DTPa-HBV-IPV/Hib Vaccine in Healthy Infants",Completed,,Phase 2,576.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months",http://clinicalstudydatarequest.com,Yes,IPD is available via the Clinical Study Data Request site (click on the link provided below),2023-06-15 21:34:31,2023-06-15 21:34:31,INDUSTRY,,,,,
432853,432854,NCT00633724,,2008-02-20,,,2013-08-13,2008-03-03,2008-03-12,Estimate,,,,,,,2013-08-13,2013-08-15,Estimate,May 2007,,2007-05-31,August 2013,2013-08-31,June 2012,Actual,2012-06-30,June 2012,Actual,2012-06-30,,Interventional,,,Multiple-Vaccine Therapy in Treating Patients With Non-small Cell Lung Cancer,Phase I Study of Multiple-vaccine Therapy Including Antiangiogenic Vaccine Using Epitope Peptide Restricted to HLA-A*2402 in Treating Patients With Unresectable or Recurrent Non-small Cell Lung Cancer,Completed,,Phase 1,9.0,Anticipated,Fukushima Medical University,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 21:36:50,2023-06-15 21:36:50,OTHER,,,,,
433006,433007,NCT02816554,,2016-06-23,,,2016-06-24,2016-06-24,2016-06-28,Estimate,,,,,,,2016-06-24,2016-06-28,Estimate,April 2015,,2015-04-30,June 2016,2016-06-30,November 2015,Actual,2015-11-30,September 2015,Actual,2015-09-30,,Interventional,,,Safety and Immunogenicity of JECEVAX in Young Children,Safety and Immunogenicity of an Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Vietnamese Children,Completed,,Phase 2,200.0,Actual,"National Institute of Hygiene and Epidemiology, Vietnam",,4.0,,,False,,,,False,,,,,,,,,,,No,"Individual data with identification removed are to be available for Ethical committee, Ministry of Health and National Foundation of Science and Technology Development to avoid misuse of data.

Public shared data will be in the form of summarised tables and figures.",2023-06-15 21:38:22,2023-06-15 21:38:22,OTHER,,,,,
433023,433024,NCT00679159,,2008-04-02,,,2010-02-08,2008-05-14,2008-05-16,Estimate,,,,,,,2010-02-08,2010-02-09,Estimate,February 2008,,2008-02-29,February 2010,2010-02-28,December 2009,Actual,2009-12-31,December 2009,Actual,2009-12-31,,Interventional,,,A Study of MVA85A in Healthy Children and Infants,"A Phase II Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Children and Infants After BCG Vaccination at Birth",Completed,,Phase 2,168.0,Actual,University of Oxford,,5.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 21:38:33,2023-06-15 21:38:33,OTHER,,,,,
433057,433058,NCT01098474,,2010-03-18,2016-11-08,2012-07-26,2019-06-11,2010-04-01,2010-04-02,Estimate,2018-11-26,2018-11-27,Actual,2012-07-26,2012-08-03,Estimate,2019-06-11,2019-06-27,Actual,"July 7, 2010",Actual,2010-07-07,June 2019,2019-06-30,"March 16, 2012",Actual,2012-03-16,"April 30, 2011",Actual,2011-04-30,,Interventional,,,Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants,Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to Healthy Infants,Completed,,Phase 2,301.0,Actual,GlaxoSmithKline,,6.0,,,False,,,,,False,False,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 21:38:55,2023-06-15 21:38:55,INDUSTRY,,,,,
433134,433135,NCT02496897,,2015-07-06,,,2019-01-08,2015-07-13,2015-07-14,Estimate,,,,,,,2019-01-08,2019-01-09,Actual,July 2015,Actual,2015-07-31,March 2018,2018-03-31,"June 5, 2018",Actual,2018-06-05,"October 13, 2017",Actual,2017-10-13,,Interventional,,,Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B,"A Phase I, Randomized, Double-blind, Placebo-controlled, Multi-centre, Ascending-dose Trial to Evaluate the Safety, Tolerability and Immunogenicity of Vaccine FP-02.2 in HBeAg-negative Hepatitis B Patients as an add-on Treatment to Entecavir or Tenofovir.",Completed,,Phase 1,60.0,Anticipated,"Altimmune, Inc.",,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-18 00:55:31,2023-06-18 00:55:31,INDUSTRY,,,,,
433589,433590,NCT00433914,,2007-02-09,2015-02-18,,2015-03-05,2007-02-09,2007-02-12,Estimate,2015-03-05,2015-03-06,Estimate,,,,2015-03-05,2015-03-06,Estimate,February 2007,,2007-02-28,March 2015,2015-03-31,July 2008,Actual,2008-07-31,December 2007,Actual,2007-12-31,,Interventional,,Analysis was performed on all enrolled subjects.,"Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants","A Phase 2, Single Blind, Single Center, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine +/- OMV, When Administered to Healthy Infants 6-8 Months Old",Completed,,Phase 2,60.0,Actual,Novartis,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 19:39:40,2023-06-16 19:39:40,INDUSTRY,,,,,
433678,433679,NCT00871741,,2009-03-26,2017-02-16,2012-11-16,2018-04-27,2009-03-26,2009-03-30,Estimate,2017-02-16,2017-04-04,Actual,2012-11-16,2012-11-21,Estimate,2018-04-27,2018-06-06,Actual,"April 1, 2009",,2009-04-01,April 2017,2017-04-30,"June 25, 2009",Actual,2009-06-25,"June 25, 2009",Actual,2009-06-25,,Interventional,,,"Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.","Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.",Terminated,,Phase 2,16.0,Actual,GlaxoSmithKline,,2.0,,Study stopped due to non-approval of IEC to proposed change in locations. Study discontinuation not due to safety/efficacy reasons related to the vaccine.,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 21:44:35,2023-06-15 21:44:35,INDUSTRY,,,,,
433756,433757,NCT02798692,,2016-06-09,,,2018-04-01,2016-06-13,2016-06-14,Estimate,,,,,,,2018-04-01,2018-04-03,Actual,June 2016,Actual,2016-06-30,March 2018,2018-03-31,March 2018,Actual,2018-03-31,May 2017,Actual,2017-05-31,,Interventional,,,Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV,"Randomized, Placebo-controlled, Double-blind Phase I Dose-escalating Trial to Evaluate the Safety and Immunogenicity of a Vaccine Against Human Cytomegalovirus",Completed,,Phase 1,54.0,Actual,Hookipa Biotech GmbH,,4.0,,,False,,,,True,,,,,,,,,,,No,,2023-06-15 21:45:40,2023-06-15 21:45:40,INDUSTRY,,,,,
434085,434086,NCT00694213,,2008-06-06,,,2019-02-25,2008-06-06,2008-06-10,Estimate,,,,,,,2019-02-25,2019-02-27,Actual,August 2007,,2007-08-31,February 2019,2019-02-28,February 2011,Actual,2011-02-28,September 2008,Actual,2008-09-30,,Interventional,,,Pandemic Influenza Plasmid DNA Vaccines (Needle-Free),"A Phase 1, Double-Blinded Study to Evaluate the Safety, Tolerability, and Immunogenicity of Pandemic Influenza Plasmid DNA Vaccines Administered With the Biojector® 2000 Needle-Free System",Completed,,Phase 1,47.0,Actual,Vical,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 21:48:25,2023-06-15 21:48:25,INDUSTRY,,,,,
434179,434180,NCT01867463,,2013-05-16,,,2018-07-03,2013-06-03,2013-06-04,Estimate,,,,,,,2018-07-03,2018-07-05,Actual,"March 27, 2013",,2013-03-27,"December 19, 2016",2016-12-19,"December 19, 2016",Actual,2016-12-19,"December 22, 2015",Actual,2015-12-22,,Interventional,,,Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine,"Double Blind Dose-Escalating Randomized Controlled Phase 1 Study in Malaria Exposed Adults of the Safety and Immunogenicity of Pfs25-EPA/ Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum in Bancoumana, Mali",Completed,,Phase 1,230.0,Actual,National Institutes of Health Clinical Center (CC),,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-14 23:54:38,2023-06-14 23:54:38,NIH,,,,,
434198,434199,NCT00697567,,2008-06-12,,,2008-06-13,2008-06-13,2008-06-16,Estimate,,,,,,,2008-06-13,2008-06-16,Estimate,September 1992,,1992-09-30,June 2008,2008-06-30,December 1997,Actual,1997-12-31,December 1997,Actual,1997-12-31,,Interventional,,,"Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant","Study in Healthy HSV Positive and HSV Negative Adults to Evaluate the Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Herpes Simplex (gD) Candidate Vaccine With or Without Adjuvant",Completed,,Phase 2,80.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 21:49:31,2023-06-15 21:49:31,INDUSTRY,,,,,
434511,434512,NCT02689726,,2015-06-29,,,2016-12-01,2016-02-18,2016-02-24,Estimate,,,,,,,2016-12-01,2016-12-02,Estimate,August 2015,,2015-08-31,October 2016,2016-10-31,August 2016,Actual,2016-08-31,August 2016,Actual,2016-08-31,,Interventional,,,"Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL","A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL",Terminated,,Phase 1,13.0,Actual,Genticel,,1.0,,Lack of efficacy in European Phase 2 study,False,,,,False,,,,,,,,,,,No,,2023-06-15 21:52:41,2023-06-15 21:52:41,INDUSTRY,,,,,
434566,434567,NCT01096056,,2010-03-29,2012-04-12,,2018-08-22,2010-03-29,2010-03-30,Estimate,2012-04-12,2012-05-10,Estimate,,,,2018-08-22,2018-09-24,Actual,"April 5, 2010",,2010-04-05,September 2016,2016-09-30,"December 13, 2010",Actual,2010-12-13,"December 13, 2010",Actual,2010-12-13,,Interventional,,,Trial to Evaluate the Safety and the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Healthy Children,Safety and Immunogenicity of GSK2186877A Candidate Seasonal Influenza Vaccine in Healthy Children 6 to 35 Months of Age.,Completed,,Phase 1,40.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 21:53:23,2023-06-15 21:53:23,INDUSTRY,,,,,
434699,434700,NCT05315362,,2022-04-06,,,2022-04-14,2022-04-06,2022-04-07,Actual,,,,,,,2022-04-14,2022-04-22,Actual,"May 1, 2022",Anticipated,2022-05-01,April 2022,2022-04-30,"May 1, 2023",Anticipated,2023-05-01,"September 1, 2022",Anticipated,2022-09-01,,Interventional,MILESTONE,,Establishing Immunogenicity and Safety of Needle-free Intradermal Delivery of mRNA COVID-19 Vaccine,Establishing Immunogenicity and Safety of Needle-free Intradermal Delivery by Solid Micro Needle Skin Patch of mRNA SARS-CoV-2 Vaccine as a Revaccination Strategy in Healthy Volunteers,Recruiting,,Phase 2,20.0,Anticipated,Leiden University Medical Center,,2.0,,,False,,,,False,False,False,,,False,,,,,,No,,2023-06-15 21:54:33,2023-06-15 21:54:33,OTHER,,,,,
434921,434922,NCT00698893,,2008-06-13,,,2017-06-01,2008-06-16,2008-06-17,Estimate,,,,,,,2017-06-01,2017-06-02,Actual,"May 1, 1992",Actual,1992-05-01,June 2017,2017-06-30,"July 1, 1992",Actual,1992-07-01,"July 1, 1992",Actual,1992-07-01,,Interventional,,,"Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults","An Open Study in Healthy Herpes Simplex Virus (HSV)-Positive Adults to Evaluate the Safety of GSK Biologicals' Candidate gD Vaccine, With or Without 3D MPL",Completed,,Phase 1,16.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 21:56:41,2023-06-15 21:56:41,INDUSTRY,,,,,
435086,435087,NCT04131595,,2019-10-16,,,2020-08-19,2019-10-17,2019-10-18,Actual,,,,,,,2020-08-19,2020-08-20,Actual,"October 7, 2019",Actual,2019-10-07,August 2020,2020-08-31,"July 22, 2020",Actual,2020-07-22,"July 22, 2020",Actual,2020-07-22,,Interventional,,,Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects,"Phase 1 Vaccination Trial to Evaluate Safety, Tolerability and Immunogenicity of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects",Completed,,Phase 1,45.0,Actual,Bavarian Nordic,,3.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-15 21:58:25,2023-06-15 21:58:25,INDUSTRY,,,,,
436107,436108,NCT00857311,,2009-03-04,2011-06-09,,2015-08-11,2009-03-05,2009-03-06,Estimate,2011-06-09,2011-07-07,Estimate,,,,2015-08-11,2015-08-25,Estimate,May 2004,,2004-05-31,August 2015,2015-08-31,May 2010,Actual,2010-05-31,January 2006,Actual,2006-01-31,,Interventional,,,MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED),"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Probe Study With an Additional Open-Label Control Arm to Evaluate the Safety and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 Gag Vaccine in Subjects With Chronic Hepatitis C Virus Infection",Completed,,Phase 1,17.0,Actual,Merck Sharp & Dohme LLC,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 22:08:03,2023-06-15 22:08:03,INDUSTRY,,,,,
436217,436218,NCT05854381,,2023-04-12,,,2023-05-02,2023-05-02,2023-05-11,Actual,,,,,,,2023-05-02,2023-05-11,Actual,June 2023,Anticipated,2023-06-30,May 2023,2023-05-31,November 2027,Anticipated,2027-11-30,November 2025,Anticipated,2025-11-30,,Interventional,,,"To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV","A Phase 1, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the HCMV-HIV Vaccine Candidate VIR-1388 in Adult Participants With Overall Good Health and Without HIV",Not yet recruiting,,Phase 1,95.0,Anticipated,"Vir Biotechnology, Inc.",,4.0,,,False,,,,,True,False,,,,,,,,,,,2023-06-15 00:00:08,2023-06-15 00:00:08,INDUSTRY,,,,,
436236,436237,NCT00703651,,2008-06-19,,,2014-01-09,2008-06-20,2008-06-23,Estimate,,,,,,,2014-01-09,2014-01-13,Estimate,September 2003,,2003-09-30,January 2014,2014-01-31,July 2006,Actual,2006-07-31,May 2006,Actual,2006-05-31,,Interventional,,,"Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults","Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route in Comparison With Intramuscular Vaccination With Vaxigrip® in Adults",Completed,,Phase 2,1150.0,Actual,Sanofi,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 22:09:11,2023-06-15 22:09:11,INDUSTRY,,,,,
436741,436742,NCT00937521,,2009-06-29,2015-02-13,,2015-03-17,2009-07-10,2009-07-13,Estimate,2015-02-13,2015-03-04,Estimate,,,,2015-03-17,2015-04-07,Estimate,July 2009,,2009-07-31,March 2015,2015-03-31,February 2012,Actual,2012-02-29,November 2010,Actual,2010-11-30,,Interventional,,,Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants,A Phase 2 Partially Observer-Blind Randomized Controlled Multicenter Dose-Ranging and Formulation-Finding Study of a New Novartis Meningococcal B Recombinant Vaccine Evaluating the Safety and Immunogenicity When Given Concomitantly With Routine Vaccines in 2-month-old Infants,Completed,,Phase 2,1507.0,Actual,Novartis,,8.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 22:14:11,2023-06-15 22:14:11,INDUSTRY,,,,,
436916,436917,NCT05241340,,2022-01-19,,,2022-02-15,2022-02-01,2022-02-15,Actual,,,,,,,2022-02-15,2022-03-03,Actual,"February 15, 2022",Actual,2022-02-15,February 2022,2022-02-28,"February 20, 2025",Anticipated,2025-02-20,"February 20, 2024",Anticipated,2024-02-20,,Interventional,RAD-VACCINE,,Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer,A Phase II Clinical Trial of Neoadjuvant Sasanlimab and Stereotactic Body Radiation Therapy as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer,Recruiting,,Phase 2,33.0,Anticipated,The Methodist Hospital Research Institute,,1.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-15 22:15:49,2023-06-15 22:15:49,OTHER,,,,,
437015,437016,NCT05432583,,2022-06-21,,,2023-05-23,2022-06-21,2022-06-27,Actual,,,,,,,2023-05-23,2023-05-24,Actual,"December 8, 2022",Actual,2022-12-08,May 2023,2023-05-31,June 2025,Anticipated,2025-06-30,June 2025,Anticipated,2025-06-30,,Interventional,,,"A Clinical Trial in Healthy Volunteers to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions","Phase I, Randomized, Observer-blinded, Placebo-controlled, 2-part, Dose Escalation and Expanded Safety Evaluation Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Prophylactic Vaccine for the Prevention of Genital Lesions Caused by Herpes Simplex Virus (HSV)-2 and Potentially HSV-1",Recruiting,,Phase 1,108.0,Anticipated,BioNTech SE,,2.0,,,False,,,,False,True,False,,,,,,,,,No,,2023-06-19 03:56:47,2023-06-19 03:56:47,INDUSTRY,,,,,
437059,437060,NCT05739292,,2023-02-12,,,2023-05-10,2023-02-12,2023-02-22,Actual,,,,,,,2023-05-10,2023-05-11,Actual,"February 28, 2023",Actual,2023-02-28,May 2023,2023-05-31,"December 30, 2023",Anticipated,2023-12-30,"October 30, 2023",Anticipated,2023-10-30,,Interventional,,,Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old,"A Single Center, Randomized, Observer-blinded, Active Comparator Phase I Study to Assess the Safety and Immunogenicity of Meningococcal (Groups A, C, W-135, X and Y) Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old","Active, not recruiting",,Phase 1,60.0,Actual,"EuBiologics Co.,Ltd",,2.0,,,False,,,,,False,False,,,,,,,,,,,2023-06-15 00:01:44,2023-06-15 00:01:44,INDUSTRY,,,,,
437201,437202,NCT05175742,,2021-12-30,,,2023-04-05,2021-12-30,2022-01-04,Actual,,,,,,,2023-04-05,2023-04-07,Actual,"August 17, 2021",Actual,2021-08-17,April 2023,2023-04-30,"March 29, 2023",Actual,2023-03-29,"March 29, 2023",Actual,2023-03-29,,Interventional,,,"PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.","A Phase 2, Randomized, Double-dummy, Observer-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Compared to Pfizer-BioNTech COVID-19 Vaccine in Healthy Seronegative Adults Aged 18 to 64 Years",Completed,,Phase 2,565.0,Actual,Providence Therapeutics Holdings Inc.,,3.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-15 22:19:14,2023-06-15 22:19:14,INDUSTRY,,,,,
437308,437309,NCT04142086,,2019-10-25,,,2022-04-22,2019-10-25,2019-10-29,Actual,,,,,,,2022-04-22,2022-04-25,Actual,"January 15, 2020",Actual,2020-01-15,April 2022,2022-04-30,"June 24, 2021",Actual,2021-06-24,"June 24, 2021",Actual,2021-06-24,,Interventional,VYF01,,Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults,"Safety, Tolerability, and Immunogenicity Dose-ranging Study of the Investigational Yellow Fever Vacine (vYF) Candidate Vaccine in Adults",Completed,,Phase 1,73.0,Actual,Sanofi,,4.0,,,False,,,,False,True,False,,,False,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-15 22:19:51,2023-06-15 22:19:51,INDUSTRY,,,,,
438103,438104,NCT00705835,,2008-06-24,,,2012-01-06,2008-06-24,2008-06-26,Estimate,,,,,,,2012-01-06,2012-01-09,Estimate,January 2003,,2003-01-31,January 2012,2012-01-31,January 2008,Actual,2008-01-31,January 2008,Actual,2008-01-31,,Interventional,,,Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel,Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel: A Trial Studying RsPMSA Doses,Completed,,Phase 1,14.0,Actual,Memorial Sloan Kettering Cancer Center,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 22:28:33,2023-06-15 22:28:33,OTHER,,,,,
438912,438913,NCT04295070,,2020-02-28,,,2021-06-08,2020-03-02,2020-03-04,Actual,,,,,,,2021-06-08,2021-06-10,Actual,"July 10, 2020",Actual,2020-07-10,June 2021,2021-06-30,"May 26, 2021",Actual,2021-05-26,"March 6, 2021",Actual,2021-03-06,,Interventional,,,Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly Volunteers,"A Phase 1, First in Human, Randomized, Double-blind, Placebo Controlled Study of the Safety, Tolerability, and Immunogenicity of the CodaVax-RSV Vaccine in Healthy Adult Volunteers",Completed,,Phase 1,36.0,Actual,"Codagenix, Inc",,3.0,,,False,,,,True,True,False,,,True,,,,,,No,,2023-06-15 22:37:43,2023-06-15 22:37:43,INDUSTRY,,,,,
439403,439404,NCT00645346,,2008-03-21,,,2011-12-07,2008-03-21,2008-03-27,Estimate,,,,,,,2011-12-07,2011-12-08,Estimate,February 2008,,2008-02-29,December 2011,2011-12-31,July 2009,Actual,2009-07-31,May 2009,Actual,2009-05-31,,Interventional,,,"A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18- 40 Years of Age","A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18- 40 Years of Age",Completed,,Phase 1,130.0,Actual,Novartis,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 22:42:51,2023-06-15 22:42:51,INDUSTRY,,,,,
439603,439604,NCT00986232,,2009-09-25,2010-01-25,,2015-03-23,2009-09-25,2009-09-29,Estimate,2010-01-25,2010-02-15,Estimate,,,,2015-03-23,2015-04-10,Estimate,April 1999,,1999-04-30,March 2015,2015-03-31,September 2000,Actual,2000-09-30,April 2000,Actual,2000-04-30,,Interventional,,,ProQuad Dose Selection Study (V221-011)(COMPLETED),"A Dose Selection Study in Healthy Children Comparing Measles Mumps, Rubella, and Varicella (ProQuad) Vaccine to M-M-R II Given Concomitantly With Process Upgrade Varicella Vaccine (PUVV) in Separate Injections",Completed,,Phase 2,1551.0,Actual,Merck Sharp & Dohme LLC,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 22:45:23,2023-06-15 22:45:23,INDUSTRY,,,,,
439610,439611,NCT00703105,,2008-06-19,,,2021-04-23,2008-06-20,2008-06-23,Estimate,,,,,,,2021-04-23,2021-04-26,Actual,October 2008,,2008-10-31,April 2021,2021-04-30,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,,Interventional,,,Ovarian Dendritic Cell Vaccine Trial,Defining the Role of CD4+CD25+ Immunoregulatory T-cells in the Treatment of Patients With Advanced Ovarian Cancer Who Receive Dendritic Cell Based Vaccine Therapies,Unknown status,Recruiting,Phase 2,36.0,Anticipated,Loyola University,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 22:45:28,2023-06-15 22:45:28,OTHER,,,,,
439620,439621,NCT00706615,,2008-06-26,,,2020-07-29,2008-06-26,2008-06-27,Estimate,,,,,,,2020-07-29,2020-07-31,Actual,July 2008,,2008-07-31,July 2012,2012-07-31,,,,April 2009,Actual,2009-04-30,,Interventional,,,Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer,A Single Arm Open-Label Phase I Study of An Injectable Replication-Incompetent Adenoviral Vector Vaccine Used to Produce An Immune Response to MUC-1 Positive Epithelial Cancer Cells in Metastatic Breast Cancer,Withdrawn,,Phase 1,0.0,Actual,Jonsson Comprehensive Cancer Center,,,,no accrual,False,,,,True,,,,,,,,,,,,,2023-06-15 22:45:36,2023-06-15 22:45:36,OTHER,,,,,
439865,439866,NCT02645032,,2015-12-22,,,2020-04-26,2015-12-31,2016-01-01,Estimate,,,,,,,2020-04-26,2020-04-28,Actual,"May 19, 2016",Actual,2016-05-19,February 2018,2018-02-28,"February 9, 2017",Actual,2017-02-09,"February 9, 2017",Actual,2017-02-09,,Interventional,,,Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine,"A Randomized, Observer-Blinded, Phase I Study to Assess the Safety and Immunogenicity of Vi-DT Conjugate Vaccine Compared to Vi-Polysaccharide (Typhim Vi®, Sanofi Pasteur) Typhoid Vaccine in Healthy Filipino Adults and Children",Completed,,Phase 1,144.0,Actual,International Vaccine Institute,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-15 22:48:05,2023-06-15 22:48:05,OTHER,,,,,
439974,439975,NCT03879694,,2019-03-13,,,2023-05-10,2019-03-14,2019-03-19,Actual,,,,,,,2023-05-10,2023-05-11,Actual,"June 17, 2019",Actual,2019-06-17,May 2023,2023-05-31,"August 17, 2024",Anticipated,2024-08-17,"August 17, 2023",Anticipated,2023-08-17,,Interventional,,,Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors,A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients With Metastatic Neuroendocrine Tumors (NETs),Recruiting,,Phase 1,14.0,Anticipated,Roswell Park Cancer Institute,,1.0,,,,,,,True,True,False,,,True,,,,,,,,2023-06-15 00:08:06,2023-06-15 00:08:06,OTHER,,,,,
440004,440005,NCT00653770,,2008-04-02,,,2010-02-08,2008-04-04,2008-04-07,Estimate,,,,,,,2010-02-08,2010-02-09,Estimate,September 2007,,2007-09-30,February 2010,2010-02-28,January 2010,Actual,2010-01-31,January 2010,Actual,2010-01-31,,Interventional,,,A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85A,"A Phase I Study to Assess the Safety and Immunogenicity of New TB Vaccine Candidates FP85A and MVA85A, in Healthy Adults Who Have Previously Been Immunized With BCG, Using a Prime-boost Delivery Schedule",Completed,,Phase 1,31.0,Actual,University of Oxford,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 22:49:30,2023-06-15 22:49:30,OTHER,,,,,
440064,440065,NCT00654316,,2008-04-02,,,2008-04-04,2008-04-04,2008-04-07,Estimate,,,,,,,2008-04-04,2008-04-07,Estimate,February 2004,,2004-02-29,March 2008,2008-03-31,November 2005,Actual,2005-11-30,November 2005,Actual,2005-11-30,,Interventional,,,Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine,A Phase I Study of the Safety and Immunogenicity of BCG (Bacille Calmette-Guerin) Vaccine Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG.,Completed,,Phase 1,11.0,Actual,University of Oxford,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 22:50:12,2023-06-15 22:50:12,OTHER,,,,,
440328,440329,NCT00978120,,2009-09-15,2012-06-27,,2012-08-08,2009-09-15,2009-09-16,Estimate,2012-06-27,2012-08-06,Estimate,,,,2012-08-08,2012-08-10,Estimate,October 2009,,2009-10-31,August 2012,2012-08-31,September 2010,Actual,2010-09-30,September 2010,Actual,2010-09-30,,Interventional,,,Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma,A Phase II Study in Patients With Asthma to Assess the Safety and Immunogenicity of an Unadjuvanted Novartis H1N1 Influenza Vaccine Administered at Two Dose Levels,Completed,,Phase 2,390.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 22:53:29,2023-06-15 22:53:29,NIH,,,,,
440554,440555,NCT00879814,,2009-04-10,2014-11-17,,2015-07-15,2009-04-10,2009-04-13,Estimate,2014-11-17,2014-11-25,Estimate,,,,2015-07-15,2015-08-06,Estimate,April 2009,,2009-04-30,July 2015,2015-07-31,July 2012,Actual,2012-07-31,July 2012,Actual,2012-07-31,,Interventional,,Safety population included all randomized participants who received at least 1 vaccination.,Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults,"A Phase 1 Randomized, Open-label, Parallel-group, Active- And Placebo-controlled Study To Assess Safety And Tolerability Of 60, 120, And 200 Mcg Meningococcal Group B Rlp2086 Vaccine In Healthy Adult Subjects",Completed,,Phase 1,48.0,Actual,Pfizer,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 22:55:54,2023-06-15 22:55:54,INDUSTRY,,,,,
440763,440764,NCT00819013,,2008-10-10,2011-11-01,,2012-01-16,2009-01-06,2009-01-08,Estimate,2011-12-12,2012-01-16,Estimate,,,,2012-01-16,2012-01-19,Estimate,July 2007,,2007-07-31,January 2012,2012-01-31,February 2009,Actual,2009-02-28,January 2009,Actual,2009-01-31,,Interventional,FLU-A,,Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults,"A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Safety, Reactogenicity, and Immunogenicity of Recombinant M2e Influenza-A Vaccine Candidate ACAM FLU-A) in Healthy Adults",Completed,,Phase 1,87.0,Actual,Sanofi,,4.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 22:57:47,2023-06-15 22:57:47,INDUSTRY,,,,,
440794,440795,NCT02864628,,2016-08-09,,,2018-08-23,2016-08-11,2016-08-12,Estimate,,,,,,,2018-08-23,2018-08-27,Actual,September 2016,Anticipated,2016-09-30,August 2018,2018-08-31,"October 27, 2017",Actual,2017-10-27,"October 27, 2017",Actual,2017-10-27,,Interventional,,,"RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.","A Partially Randomized, Partly Placebo Controlled Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA-BN® RSV Vaccine After Intranasal and Intramuscular Administration",Withdrawn,,Phase 1,0.0,Actual,Bavarian Nordic,,5.0,,Protocol was withdrawn from IND,False,,,,False,True,False,,,,,,,,,Undecided,,2023-06-15 22:58:09,2023-06-15 22:58:09,INDUSTRY,,,,,
440805,440806,NCT00662272,,2008-04-15,,,2010-03-15,2008-04-17,2008-04-21,Estimate,,,,,,,2010-03-15,2010-03-17,Estimate,June 2008,,2008-06-30,March 2010,2010-03-31,December 2009,Actual,2009-12-31,October 2008,Actual,2008-10-31,,Interventional,H-100-001,,Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant,"Randomized, Double Blind, Controlled Phase I Trial of the Safety, Tolerability and Immunogenicity of Fluzone® Inactivated Trivalent Influenza Virus Vaccine Administered With Ascending Doses of JVRS-100 Adjuvant",Completed,,Phase 1,128.0,Actual,Colby Pharmaceutical Company,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 22:58:25,2023-06-15 22:58:25,INDUSTRY,,,,,
441251,441252,NCT05104515,,2021-09-29,,,2023-03-21,2021-11-01,2021-11-03,Actual,,,,,,,2023-03-21,2023-03-22,Actual,"November 1, 2021",Actual,2021-11-01,March 2023,2023-03-31,"March 31, 2024",Anticipated,2024-03-31,"December 31, 2023",Anticipated,2023-12-31,,Interventional,,,First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine,"A Phase 1, Multicentre, Open-label, Nonrandomised, First-in-human Study of OVM-200 as a Therapeutic Vaccine in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Ovarian Cancer, and Prostate Cancer",Recruiting,,Phase 1,36.0,Anticipated,Oxford Vacmedix UK Ltd.,,1.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-15 23:02:47,2023-06-15 23:02:47,INDUSTRY,,,,,
441529,441530,NCT04075318,,2019-08-05,,,2023-03-20,2019-08-28,2019-08-30,Actual,,,,,,,2023-03-20,2023-03-22,Actual,"August 29, 2019",Actual,2019-08-29,March 2023,2023-03-31,"March 1, 2023",Actual,2023-03-01,"March 1, 2023",Actual,2023-03-01,,Interventional,,,Study of UB-312 in Healthy Participants and Parkinson's Disease Patients,"A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® PD Immunotherapeutic Vaccine (UB-312) in Healthy Participants and Participants With Parkinson's Disease",Completed,,Phase 1,138.0,Actual,United Neuroscience Ltd.,,9.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-15 23:04:51,2023-06-15 23:04:51,INDUSTRY,,,,,
441614,441615,NCT03596801,,2018-07-12,,,2023-03-21,2018-07-12,2018-07-24,Actual,,,,,,,2023-03-21,2023-03-22,Actual,"June 25, 2018",Actual,2018-06-25,March 2023,2023-03-31,December 2023,Anticipated,2023-12-31,December 2023,Anticipated,2023-12-31,,Interventional,,,"Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/<U+2206>NS1 and RSV 6120/F1/G2/<U+2206>NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children","Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-attenuated Respiratory Syncytial Virus Vaccine, RSV 6120/<U+2206>NS1, Lot RSV#018A, or RSV 6120/F1/G2/<U+2206>NS1, Lot RSV#016A, Delivered as Nose Drops to RSV-seropositive Children 12 to 59 Months of Age and RSV-seronegative Infants and Children 6 to 24 Months of Age",Recruiting,,Phase 1,75.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,6.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-15 23:05:49,2023-06-15 23:05:49,NIH,,,,,
441650,441651,NCT03462004,,2018-03-06,,,2023-03-21,2018-03-06,2018-03-12,Actual,,,,,,,2023-03-21,2023-03-22,Actual,"March 5, 2018",Actual,2018-03-05,March 2023,2023-03-31,December 2025,Anticipated,2025-12-31,December 2025,Anticipated,2025-12-31,,Interventional,,,Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein,Phase 1 Evaluation of a Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein,Suspended,,Phase 1,30.0,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,4.0,,On hold due to pandemic,False,,,,True,True,False,,,,,,,,,,,2023-06-15 23:06:01,2023-06-15 23:06:01,NIH,,,,,
441666,441667,NCT03371485,,2017-09-29,,,2023-03-20,2017-12-12,2017-12-13,Actual,,,,,,,2023-03-20,2023-03-22,Actual,"June 1, 2018",Actual,2018-06-01,March 2023,2023-03-31,"August 8, 2022",Actual,2022-08-08,"August 8, 2022",Actual,2022-08-08,,Interventional,,,AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer,A Cancer Research UK Phase I Trial of AST-VAC2 (Allogeneic Dendritic Cell Vaccine) Administered Weekly Via Intradermal Injection in Patients With Advanced Non-small Cell Lung Cancer (NSCLC),Completed,,Phase 1,9.0,Actual,Cancer Research UK,,1.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-15 23:06:10,2023-06-15 23:06:10,OTHER,,,,,
442052,442053,NCT05197712,,2022-01-15,,,2023-05-23,2022-01-15,2022-01-19,Actual,,,,,,,2023-05-23,2023-05-24,Actual,"March 28, 2022",Actual,2022-03-28,January 2023,2023-01-31,"April 10, 2024",Anticipated,2024-04-10,"May 29, 2023",Anticipated,2023-05-29,,Interventional,,,"Evaluation of the Safety, Tolerability, and Reactogenicity of the Baiya SARS-CoV-2 Vax 2 Vaccine for COVID-19 Disease","A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, and Reactogenicity of the Baiya SARS-CoV-2 Vax 2 Vaccine in Healthy Adults","Active, not recruiting",,Phase 1,24.0,Actual,"Baiya Phytopharm Co., Ltd.",,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-19 03:57:34,2023-06-19 03:57:34,INDUSTRY,,,,,
442169,442170,NCT00631995,,2008-02-29,,,2018-02-05,2008-02-29,2008-03-10,Estimate,,,,,,,2018-02-05,2018-02-06,Actual,April 2008,,2008-04-30,February 2018,2018-02-28,April 2009,Actual,2009-04-30,February 2009,Actual,2009-02-28,,Interventional,,,Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers,"Safety and Immunogenicity of a Quadrivalent Meningococcal (A, C, Y, and W-135) Tetanus Protein Conjugate Vaccine (TetraMen-T) in Toddlers",Completed,,Phase 1,360.0,Actual,Sanofi,,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 23:11:18,2023-06-15 23:11:18,INDUSTRY,,,,,
442254,442255,NCT02860650,,2016-08-04,,,2018-02-02,2016-08-04,2016-08-09,Estimate,,,,,,,2018-02-02,2018-02-05,Actual,August 2016,Actual,2016-08-31,February 2018,2018-02-28,January 2018,Actual,2018-01-31,May 2017,Actual,2017-05-31,,Interventional,,,"A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults","A Phase 1, First-in-human Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adult",Completed,,Phase 1,72.0,Actual,Janssen Vaccines & Prevention B.V.,,5.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-15 23:12:18,2023-06-15 23:12:18,INDUSTRY,,,,,
442519,442520,NCT01880411,,2013-06-13,,,2013-06-14,2013-06-14,2013-06-19,Estimate,,,,,,,2013-06-14,2013-06-19,Estimate,June 2013,,2013-06-30,June 2013,2013-06-30,June 2014,Anticipated,2014-06-30,January 2014,Anticipated,2014-01-31,,Interventional,,,"Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity PEK Fusion Protein Vaccine","Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity of a Three Dose Regimen of Escalating Doses of PEK Fusion Protein Vaccine (PEK + GPI-0100) in Patients With LSIL or HSIL",Unknown status,"Active, not recruiting",Phase 1,15.0,Anticipated,"HealthBanks Biotech Co., Ltd.",,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 00:15:41,2023-06-15 00:15:41,INDUSTRY,,,,,
442524,442525,NCT01031966,,2009-12-11,,,2012-03-28,2009-12-14,2009-12-15,Estimate,,,,,,,2012-03-28,2012-03-29,Estimate,November 2009,,2009-11-30,March 2012,2012-03-31,July 2010,Actual,2010-07-31,May 2010,Actual,2010-05-31,,Interventional,,,A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine,"A Pilot, Randomized, Open-label Study in Patients on Chronic Dialysis With End Stage Renal Disease (Esrd), to Evaluate the Enhancing Effect of Two Doses of Thymosin Alpha 1 on the Immunogenicity of h1n1sw Monovalent Vaccine",Completed,,Phase 2,120.0,Actual,sigma-tau i.f.r. S.p.A.,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 19:45:31,2023-06-16 19:45:31,INDUSTRY,,,,,
442663,442664,NCT01881581,,2013-06-16,,,2013-06-19,2013-06-16,2013-06-19,Estimate,,,,,,,2013-06-19,2013-06-20,Estimate,June 2013,,2013-06-30,June 2013,2013-06-30,August 2014,Anticipated,2014-08-31,March 2014,Anticipated,2014-03-31,,Interventional,,,Safety and Immunogenicity of Recombinant HIV Vaccines for HIV/AIDS,A Phase I Double-Blind Study to Evaluate the Safety and Immunogenicity of HIV Prime/Boost Vaccine Using DNA and MVA for HIV-1/AIDS,Unknown status,Recruiting,Phase 1,56.0,Anticipated,"Centers for Disease Control and Prevention, China",,8.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 00:16:31,2023-06-15 00:16:31,OTHER_GOV,,,,,
443946,443947,NCT01072786,,2010-02-19,,,2012-12-31,2010-02-19,2010-02-22,Estimate,,,,,,,2012-12-31,2013-01-03,Estimate,July 2010,,2010-07-31,December 2012,2012-12-31,June 2012,Actual,2012-06-30,June 2012,Actual,2012-06-30,,Interventional,,,Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine,"A Phase 1 Evaluation of the Safety and Immunogenicity of Five Admixtures of TetraVax-DV, a Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine, in Healthy Flavivirus-naïve Adult Subjects",Completed,,Phase 1,141.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 19:47:29,2023-06-16 19:47:29,NIH,,,,,
444047,444048,NCT00602784,,2008-01-04,,,2012-10-18,2008-01-15,2008-01-28,Estimate,,,,,,,2012-10-18,2012-10-19,Estimate,November 2002,,2002-11-30,October 2012,2012-10-31,September 2004,Actual,2004-09-30,May 2004,Actual,2004-05-31,,Interventional,,,Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine,"Double Blind, Randomized, Multicenter, Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine Together With Polyarginine, HCV Peptide Vaccine Alone, or Polyarginine Alone, in Patients With Chronic HCV Having Not Responded to or Relapsed From Primary Standard HCV Therapy",Completed,,Phase 2,66.0,Actual,Valneva Austria GmbH,,5.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 23:28:03,2023-06-15 23:28:03,INDUSTRY,,,,,
444168,444169,NCT00875524,,2009-04-02,2019-05-21,,2022-03-15,2009-04-02,2009-04-03,Estimate,2019-05-21,2019-07-24,Actual,,,,2022-03-15,2022-04-05,Actual,March 2009,Actual,2009-03-31,March 2022,2022-03-31,December 2014,Actual,2014-12-31,August 2014,Actual,2014-08-31,,Interventional,,The safety analysis set was defined as participants who received at least 1 dose of CYD dengue vaccine or control vaccine.,Study of ChimeriVax Tetravalent Dengue Vaccine in Healthy Subjects,Immunogenicity and Safety of ChimeriVax Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Viet Nam,Completed,,Phase 2,180.0,Actual,Sanofi,,2.0,,,False,,,,False,,,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-15 23:29:32,2023-06-15 23:29:32,INDUSTRY,,,,,
444275,444276,NCT00937404,,2009-07-09,2018-05-31,,2018-05-31,2009-07-09,2009-07-13,Estimate,2018-05-31,2018-12-17,Actual,,,,2018-05-31,2018-12-17,Actual,"August 4, 2009",Actual,2009-08-04,May 2018,2018-05-31,"November 13, 2009",Actual,2009-11-13,"November 13, 2009",Actual,2009-11-13,,Interventional,,,Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants,"An Open-label Primary Vaccination Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' Inactivated Poliomyelitis Vaccine Poliorix Administered as a Three-dose Primary Vaccination Course at 2, 3 and 4 Months of Age in Healthy Infants in China.",Completed,,Phase 1,25.0,Actual,GlaxoSmithKline,,1.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 23:30:40,2023-06-15 23:30:40,INDUSTRY,,,,,
444378,444379,NCT00432380,,2007-02-06,2017-03-23,,2019-12-27,2007-02-06,2007-02-07,Estimate,2017-09-05,2017-09-11,Actual,,,,2019-12-27,2020-01-02,Actual,"March 9, 2007",Actual,2007-03-09,December 2019,2019-12-31,"September 4, 2007",Actual,2007-09-04,"September 4, 2007",Actual,2007-09-04,,Interventional,,,A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants.,Immunogenicity and Safety of Two Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Liquid Vaccine (GSK 357941A) in Healthy Infants.,Completed,,Phase 2,375.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=273,Yes,IPD is available via the Clinical Study Data Request site (click on the link provided below),2023-06-16 19:47:45,2023-06-16 19:47:45,INDUSTRY,,,,,
444562,444563,NCT00605514,,2008-01-29,,,2017-06-30,2008-01-29,2008-01-31,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"January 25, 2008",,2008-01-25,"June 21, 2010",2010-06-21,"June 21, 2010",Actual,2010-06-21,"June 21, 2010",Actual,2010-06-21,,Interventional,,,Ebola and Marburg Virus Vaccines,"VRC 206: A Phase I Study to Evaluate the Safety and Immunogenicity of an Ebola DNA Plasmid Vaccine, VRC-EBODNA023-00-VP, and a Marburg DNA Plasmid Vaccine, VRC-MARDNA025-00-VP, in Healthy Adults",Completed,,Phase 1,20.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2023-06-15 23:33:41,2023-06-15 23:33:41,NIH,,,,,
444749,444750,NCT01889719,,2013-06-20,,,2016-02-12,2013-06-26,2013-06-28,Estimate,,,,,,,2016-02-12,2016-02-17,Estimate,January 2014,,2014-01-31,February 2016,2016-02-29,May 2015,Actual,2015-05-31,May 2015,Actual,2015-05-31,,Interventional,,,A Phase I Study to Evaluate the Safety and Immunogenicity of Heterologous Boost Immunizations With MVA-CMDR,Phase I Study to Evaluate the Safety/Immunogenicity of Boost Immunizations With MVA-CMDR in Healthy Volunteers Previously Immunized With Anti-DEC-205 Monoclonal Antibody Targeted HIV Gag p24 Vaccine Plus Poly-ICLC (RV 365 / WRAIR #2006),Completed,,Phase 1,14.0,Actual,Rockefeller University,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 00:22:28,2023-06-15 00:22:28,OTHER,,,,,
444770,444771,NCT01889836,,2013-06-10,,,2015-09-15,2013-06-28,2013-07-01,Estimate,,,,,,,2015-09-15,2015-09-16,Estimate,May 2014,,2014-05-31,September 2015,2015-09-30,December 2014,Actual,2014-12-31,December 2014,Actual,2014-12-31,,Interventional,,,Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos,Brazil's Conjugated Vaccine Project Against Meningococcal C. Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos,Completed,,Phase 1,60.0,Actual,The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 00:22:33,2023-06-15 00:22:33,OTHER,,,,,
444817,444818,NCT02616874,,2015-11-09,,,2018-01-16,2015-11-25,2015-11-30,Estimate,,,,,,,2018-01-16,2018-01-17,Actual,February 2016,,2016-02-29,January 2018,2018-01-31,"October 30, 2017",Actual,2017-10-30,September 2016,Actual,2016-09-30,,Interventional,,,Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals,An Open Label Phase I Trial to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals (BCN02-Romi),Completed,,Phase 1,15.0,Actual,IrsiCaixa,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 23:35:32,2023-06-15 23:35:32,OTHER,,,,,
445140,445141,NCT02618902,,2015-11-18,,,2021-05-10,2015-12-01,2015-12-02,Estimate,,,,,,,2021-05-10,2021-05-13,Actual,"May 30, 2017",Actual,2017-05-30,May 2021,2021-05-31,"December 31, 2021",Anticipated,2021-12-31,"November 30, 2021",Anticipated,2021-11-30,,Interventional,MS-tolDC,,"A ""Negative""Dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial","A ""Negative""Dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial",Unknown status,"Active, not recruiting",Phase 1,9.0,Actual,"University Hospital, Antwerp",,1.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-15 23:38:12,2023-06-15 23:38:12,OTHER,,,,,
445278,445279,NCT02613520,,2015-11-17,,,2018-10-10,2015-11-20,2015-11-24,Estimate,,,,,,,2018-10-10,2018-10-15,Actual,December 2015,Actual,2015-12-31,December 2017,2017-12-31,March 2017,Actual,2017-03-31,February 2017,Actual,2017-02-28,,Interventional,,,"Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and Infants","Clinical Trial to Evaluate the Safety and Immunogenicity in Age De-Escalation of Direct Venous Inoculation of a Plasmodium Falciparum Sporozoite Vaccine in Tanzanian Adults, Children, and Infants",Completed,,Phase 1,105.0,Actual,Sanaria Inc.,,23.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 23:39:40,2023-06-15 23:39:40,INDUSTRY,,,,,
445414,445415,NCT00915187,,2009-06-03,,,2011-10-18,2009-06-03,2009-06-05,Estimate,,,,,,,2011-10-18,2011-10-19,Estimate,October 2009,,2009-10-31,October 2011,2011-10-31,February 2010,Actual,2010-02-28,December 2009,Actual,2009-12-31,,Interventional,,,Safety and Immunogenicity Study of Intramuscular CCS/C-adjuvanted Influenza Vaccine in Elderly,"A Phase II Safety and Immunogenicity Study of Intramuscular CCS/C-adjuvanted Influenza Vaccine in Elderly, a Double-blind Randomized, Controlled Single Center Study",Completed,,Phase 2,130.0,Actual,NasVax Ltd,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 23:41:08,2023-06-15 23:41:08,INDUSTRY,,,,,
445525,445526,NCT02840487,,2016-07-19,,,2019-03-15,2016-07-19,2016-07-21,Estimate,,,,,,,2019-03-15,2019-03-18,Actual,"August 2, 2016",,2016-08-02,"March 14, 2019",2019-03-14,"March 14, 2019",Actual,2019-03-14,"March 14, 2019",Actual,2019-03-14,,Interventional,,,"Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults","VRC 319: A Phase I/Ib, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of A Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults",Completed,,Phase 1,80.0,Actual,National Institutes of Health Clinical Center (CC),,4.0,,,False,,,,,True,,,,,,,,,,,,2023-06-15 23:42:35,2023-06-15 23:42:35,NIH,,,,,
445546,445547,NCT02839161,,2016-07-18,,,2019-04-02,2016-07-19,2016-07-20,Estimate,,,,,,,2019-04-02,2019-04-04,Actual,January 2017,Actual,2017-01-31,April 2019,2019-04-30,"March 28, 2019",Actual,2019-03-28,"December 13, 2018",Actual,2018-12-13,,Interventional,,,Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children,"Randomized, Controlled, Phase 1 Study to Assess Safety and Immunogenicity of Co-administered Hookworm Vaccine Candidates Na-APR-1 (M74)/Alhydrogel® and Na-GST-1/ Alhydrogel® in Gabonese Children",Completed,,Phase 1,60.0,Actual,Baylor College of Medicine,,8.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 23:42:57,2023-06-15 23:42:57,OTHER,,,,,
445643,445644,NCT05229536,,2022-01-28,,,2022-02-09,2022-01-28,2022-02-08,Actual,,,,,,,2022-02-09,2022-02-25,Actual,"December 21, 2018",Actual,2018-12-21,February 2022,2022-02-28,"November 21, 2019",Actual,2019-11-21,"November 21, 2019",Actual,2019-11-21,,Interventional,,,Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months,"A Single-center, Randomized, Double-blind, Parallel Control Phase II Clinical Trial to Evaluate Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged From 3 to 35 Months",Completed,,Phase 2,720.0,Actual,"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd",,2.0,,,False,,,,False,False,False,,,,,,,,,No,,2023-06-18 00:59:53,2023-06-18 00:59:53,INDUSTRY,,,,,
445722,445723,NCT00633321,,2008-03-05,,,2011-06-07,2008-03-11,2008-03-12,Estimate,,,,,,,2011-06-07,2011-06-08,Estimate,May 2007,,2007-05-31,June 2011,2011-06-30,February 2009,Actual,2009-02-28,December 2008,Actual,2008-12-31,,Interventional,,,Study of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation,"A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study of 100 or 250 µg of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation",Completed,,Phase 2,522.0,Anticipated,Celtic Pharma Development Services,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 23:44:56,2023-06-15 23:44:56,INDUSTRY,,,,,
446139,446140,NCT01902771,,2013-07-16,,,2017-03-08,2013-07-16,2013-07-18,Estimate,,,,,,,2017-03-08,2017-03-10,Actual,"September 3, 2013",Actual,2013-09-03,March 2017,2017-03-31,"January 26, 2017",Actual,2017-01-26,"October 24, 2016",Actual,2016-10-24,,Interventional,,,Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors,A Phase I Study of Dendritic Cell Vaccine Therapy With In Situ Maturation for Pediatric Brain Tumors,Terminated,,Phase 1,1.0,Actual,University of Miami,,1.0,,Lack of Accrual,False,,,,True,True,False,,,,,,,,,,,2023-06-15 00:25:36,2023-06-15 00:25:36,OTHER,,,,,
446199,446200,NCT04336410,,2020-04-03,,,2022-04-13,2020-04-03,2020-04-07,Actual,,,,,,,2022-04-13,2022-04-15,Actual,"April 3, 2020",Actual,2020-04-03,April 2022,2022-04-30,"February 10, 2022",Actual,2022-02-10,"February 10, 2022",Actual,2022-02-10,,Interventional,,,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers",Completed,,Phase 1,120.0,Actual,Inovio Pharmaceuticals,,3.0,,,False,,,,True,True,True,True,,,,,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 10 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2023-06-15 23:50:02,2023-06-15 23:50:02,INDUSTRY,,,,,
446237,446238,NCT04810910,,2021-03-19,,,2021-11-15,2021-03-19,2021-03-23,Actual,,,,,,,2021-11-15,2021-11-16,Actual,"March 30, 2021",Actual,2021-03-30,November 2021,2021-11-30,"March 30, 2025",Anticipated,2025-03-30,"March 30, 2025",Anticipated,2025-03-30,,Interventional,,,Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy,Clinical Study of a Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy,Recruiting,,Phase 1,20.0,Anticipated,Zhejiang Provincial People's Hospital,,1.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-18 00:59:57,2023-06-18 00:59:57,OTHER,,,,,
446264,446265,NCT02831751,,2016-07-11,,,2019-10-23,2016-07-11,2016-07-13,Estimate,,,,,,,2019-10-23,2019-10-25,Actual,April 2016,,2016-04-30,October 2019,2019-10-31,January 2017,Actual,2017-01-31,July 2016,Actual,2016-07-31,,Interventional,,,"Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults","A Randomized, Observer-Blind, Multicenter, Phase 2 Study to Assess the Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults of 65 Years of Age or Older",Completed,,Phase 2,1001.0,Actual,Medicago,,4.0,,,False,,,,False,,,,,,,,,,,No,,2023-06-15 23:50:51,2023-06-15 23:50:51,INDUSTRY,,,,,
446476,446477,NCT01069575,,2010-02-16,,,2019-03-15,2010-02-16,2010-02-17,Estimate,,,,,,,2019-03-15,2019-03-19,Actual,February 2010,,2010-02-28,March 2019,2019-03-31,March 2019,Actual,2019-03-31,March 2019,Actual,2019-03-31,,Interventional,,,Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Non-small Cell Lung Cancer,"Phase I Study of Cancer Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*24 (URLC10,CDCA1,KIF20A) in Patients With Non-small Cell Lung Cancer Refractory to Standard Therapy",Completed,,Phase 1,18.0,Anticipated,Shiga University,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 19:49:44,2023-06-16 19:49:44,OTHER,,,,,
446494,446495,NCT01069653,,2010-02-16,,,2019-03-15,2010-02-16,2010-02-17,Estimate,,,,,,,2019-03-15,2019-03-19,Actual,February 2010,,2010-02-28,March 2019,2019-03-31,March 2019,Actual,2019-03-31,March 2019,Actual,2019-03-31,,Interventional,,,Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Small Cell Lung Cancer,"Phase I Study of Cancer Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*24 (CDCA1,KIF20A) in Patients With Small Cell Lung Cancer Refractory to Standard Therapy",Completed,,Phase 1,9.0,Anticipated,Shiga University,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 19:49:46,2023-06-16 19:49:46,OTHER,,,,,
446519,446520,NCT01903928,,2013-07-01,,,2019-01-21,2013-07-17,2013-07-19,Estimate,,,,,,,2019-01-21,2019-01-23,Actual,"June 20, 2013",Actual,2013-06-20,January 2019,2019-01-31,"January 19, 2015",Actual,2015-01-19,"January 19, 2015",Actual,2015-01-19,,Interventional,,,"A Study to Evaluate Safety and Tolerability of a Therapeutic Vaccine, ASP0113, in Subjects Undergoing Allogeneic Hematopoietic Cell Transplant","An Open Phase 2 Trial to Evaluate Safety of a Therapeutic Vaccine, ASP0113, in Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)",Completed,,Phase 2,9.0,Actual,Astellas Pharma Inc,,1.0,,,False,,,,True,,,,,,,,,,,No,"Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under ""Sponsor Specific Details for Astellas.""",2023-06-15 00:26:16,2023-06-15 00:26:16,INDUSTRY,,,,,
446786,446787,NCT01905215,,2013-07-11,,,2017-05-24,2013-07-18,2013-07-23,Estimate,,,,,,,2017-05-24,2017-05-30,Actual,"July 22, 2013",Actual,2013-07-22,May 2017,2017-05-31,"March 16, 2015",Actual,2015-03-16,"April 9, 2014",Actual,2014-04-09,,Interventional,,,"Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines","An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Men",Completed,,Phase 1,128.0,Actual,GlaxoSmithKline,,8.0,,,False,,,,,,,,,,,,,,,,,2023-06-15 00:27:12,2023-06-15 00:27:12,INDUSTRY,,,,,
446802,446803,NCT04148118,,2019-10-28,,,2022-05-12,2019-10-30,2019-11-01,Actual,,,,,,,2022-05-12,2022-05-18,Actual,"January 8, 2020",Actual,2020-01-08,May 2022,2022-05-31,"September 2, 2021",Actual,2021-09-02,"September 2, 2021",Actual,2021-09-02,,Interventional,IN NE-rPA,,A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults,"A Phase 1 Randomized, Observer-Blind, Active- and Placebo-Controlled Dose Comparison, Safety, Tolerability and Immunogenicity Study of Intranasal Adjuvanted Anthrax Vaccine (BW-1010; rPA + 20%W805EC) in Healthy Adult Volunteers Administered by Nasal Sprayer and Pipette With an Additional Unblinded Positive Control Arm",Completed,,Phase 1,84.0,Actual,BlueWillow Biologics,,7.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-15 23:55:54,2023-06-15 23:55:54,INDUSTRY,,,,,
447040,447041,NCT00705640,,2008-06-25,,,2016-12-15,2008-06-25,2008-06-26,Estimate,,,,,,,2016-12-15,2016-12-16,Estimate,May 2008,,2008-05-31,December 2016,2016-12-31,,,,June 2009,Actual,2009-06-30,,Interventional,Mel48,,Vaccine Therapy in Treating Patients With Advanced Melanoma,A Multipeptide Vaccine in Melanoma Patients With Evaluation of the Injection Site Microenvironment,Completed,,Phase 1,45.0,Actual,University of Virginia,,10.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 23:57:30,2023-06-15 23:57:30,OTHER,,,,,
447249,447250,NCT00842530,,2009-02-11,2019-05-21,,2022-03-10,2009-02-11,2009-02-12,Estimate,2019-07-25,2019-07-26,Actual,,,,2022-03-10,2022-04-05,Actual,February 2009,Actual,2009-02-28,March 2022,2022-03-31,February 2014,Actual,2014-02-28,September 2013,Actual,2013-09-30,,Interventional,,Safety analysis set included all participants who have received at least one injection and were analyzed according to the treatment received.,Efficacy and Safety of Dengue Vaccine in Healthy Children,Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 11 Years in Thailand,Completed,,Phase 2,4002.0,Actual,Sanofi,,2.0,,,False,,,,True,,,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-15 23:59:05,2023-06-15 23:59:05,INDUSTRY,,,,,
447292,447293,NCT00303069,,2006-03-13,2010-09-23,,2015-06-29,2006-03-13,2006-03-15,Estimate,2010-09-23,2010-10-20,Estimate,,,,2015-06-29,2015-07-22,Estimate,November 2005,,2005-11-30,June 2015,2015-06-30,July 2006,Actual,2006-07-31,July 2006,Actual,2006-07-31,,Interventional,,,V710 First-In-Man (FIM) Study (V710-001),"A Sequential-Panel, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine in Healthy Adults 18 to 55 Years of Age",Completed,,Phase 1,124.0,Actual,Merck Sharp & Dohme LLC,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 19:50:30,2023-06-16 19:50:30,INDUSTRY,,,,,
447453,447454,NCT01909752,,2013-07-24,,,2017-07-03,2013-07-24,2013-07-26,Estimate,,,,,,,2017-07-03,2017-07-06,Actual,July 2013,,2013-07-31,July 2017,2017-07-31,April 2017,Actual,2017-04-30,November 2016,Actual,2016-11-30,,Interventional,,,Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer,Randomized Phase II Trial of Cyclophosphamide With Allogeneic Non-Small Cell Lung Cancer (NSCLC) DRibble Vaccine Alone or With Granulocyte-Macrophage Colony-Stimulating Factor or Imiquimod for Adjuvant Treatment of Definitively-Treated Stage IIIA or IIIB NSCLC,Completed,,Phase 2,12.0,Actual,UbiVac,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 00:30:20,2023-06-15 00:30:20,INDUSTRY,,,,,
447644,447645,NCT03755427,,2018-11-14,,,2018-11-27,2018-11-25,2018-11-28,Actual,,,,,,,2018-11-27,2018-11-29,Actual,November 2018,Anticipated,2018-11-30,November 2018,2018-11-30,January 2020,Anticipated,2020-01-31,May 2019,Anticipated,2019-05-31,,Interventional,,,A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine,"Immunogenicity and Safety of an Alum-adjuvanted Inactivated H7N9 Influenza Vaccine: a Randomized, Blind, Placebo-controlled, a Phase II Clinical Trial",Unknown status,Not yet recruiting,Phase 2,560.0,Anticipated,Shanghai Institute Of Biological Products,,2.0,,,False,,,,True,False,False,,,,,,,,,,,2023-06-17 03:53:55,2023-06-17 03:53:55,INDUSTRY,,,,,
447770,447771,NCT00289185,,2006-02-08,2012-11-08,2009-09-03,2020-10-08,2006-02-08,2006-02-09,Estimate,2013-04-25,2013-07-08,Estimate,2009-09-03,2009-09-04,Estimate,2020-10-08,2020-10-29,Actual,"September 27, 2006",Actual,2006-09-27,October 2020,2020-10-31,"January 15, 2009",Actual,2009-01-15,"February 11, 2008",Actual,2008-02-11,,Interventional,,,"Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants","A Phase IIb Randomized, Double-blind, Controlled Study of the Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02D, a Candidate Malaria Vaccine, When Incorporated Into an Expanded Program on Immunization (EPI) Regimen That Includes DTPw/Hib in Infants Living in a Malaria-endemic Region.",Completed,,Phase 2,340.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 19:50:38,2023-06-16 19:50:38,INDUSTRY,,,,,
448280,448281,NCT05163223,,2021-04-02,,,2023-04-05,2021-12-06,2021-12-20,Actual,,,,,,,2023-04-05,2023-04-07,Actual,"February 28, 2022",Actual,2022-02-28,February 2023,2023-02-28,December 2025,Anticipated,2025-12-31,August 2025,Anticipated,2025-08-31,,Interventional,Cornerstone001,,"Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer","A Phase 2 Study to Evaluate the Efficacy and Safety of an Adjuvant Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With HER2 Low Breast Cancer (Cornerstone-001)",Recruiting,,Phase 2,146.0,Anticipated,Aston Sci. Inc.,,2.0,,,,,,,True,True,False,,,True,,,,,,No,,2023-06-16 00:07:41,2023-06-16 00:07:41,INDUSTRY,,,,,
448577,448578,NCT03503058,,2018-04-11,,,2023-04-06,2018-04-11,2018-04-19,Actual,,,,,,,2023-04-06,2023-04-07,Actual,"May 7, 2022",Actual,2022-05-07,April 2023,2023-04-30,December 2023,Anticipated,2023-12-31,July 2023,Anticipated,2023-07-31,,Interventional,,,"Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria","Safety, Tolerability, Immunogenicity and Protective Efficacy Against Naturally-Transmitted Malaria in Eastern Indonesia of Two Plasmodium Falciparum Sporozoite Vaccines, Sanaria® PfSPZ Vaccine and Sanaria® PfSPZ-CVac: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial in Healthy Indonesian Adults",Recruiting,,Phase 2,372.0,Anticipated,Sanaria Inc.,,4.0,,,False,,,,True,True,False,,,,,,,,,,,2023-06-16 00:10:46,2023-06-16 00:10:46,INDUSTRY,,,,,
448612,448613,NCT01915524,,2013-07-18,,,2016-08-04,2013-08-01,2013-08-05,Estimate,,,,,,,2016-08-04,2016-08-05,Estimate,April 2013,,2013-04-30,August 2016,2016-08-31,July 2016,Actual,2016-07-31,July 2016,Actual,2016-07-31,,Interventional,,,Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC),"An Exploratory, Open-label Phase Ib Study of RNActive®-Derived Cancer Vaccine and Local Radiation as Consolidation and Maintenance Treatment in Patients With Stage IV NSCLC and a Response or Stable Disease After First-line Chemotherapy or Therapy With an EGFR Tyrosine Kinase Inhibitor",Terminated,,Phase 1,26.0,Actual,CureVac,,1.0,,Slow recruitment in stratum 3: enrolled only 2 instead of 8 pts. within predicted time,False,,,,True,,,,,,,,,,,,,2023-06-15 00:34:28,2023-06-15 00:34:28,INDUSTRY,,,,,
448731,448732,NCT02737787,,2016-04-05,,,2023-04-06,2016-04-08,2016-04-14,Estimate,,,,,,,2023-04-06,2023-04-07,Actual,April 2016,Actual,2016-04-30,April 2023,2023-04-30,"April 6, 2023",Actual,2023-04-06,"April 6, 2023",Actual,2023-04-06,,Interventional,,,A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer,A Phase I Study of Concomitant WT1 Analog Peptide Vaccine or NY-ESO-1 Overlapping Peptides Vaccine in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission,Completed,,Phase 1,11.0,Actual,Memorial Sloan Kettering Cancer Center,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 00:11:33,2023-06-16 00:11:33,OTHER,,,,,
449447,449448,NCT00287469,,2006-02-02,2018-10-09,,2019-05-08,2006-02-02,2006-02-06,Estimate,2019-05-08,2019-05-29,Actual,,,,2019-05-08,2019-05-29,Actual,"July 9, 2001",Actual,2001-07-09,May 2019,2019-05-31,January 2005,Actual,2005-01-31,"January 19, 2004",Actual,2004-01-19,,Interventional,,,A Safety and Efficacy Study of the Hepatitis E Vaccine in Nepal.,"A Phase II, Prospective, Randomized, Double-blind, Placebo Controlled, Field Efficacy Trial of a Candidate Hepatitis E Vaccine in Nepal.",Completed,,Phase 2,2000.0,Actual,U.S. Army Medical Research and Development Command,,2.0,,,False,,,,False,True,False,,,,,,,,,,,2023-06-16 19:51:26,2023-06-16 19:51:26,FED,,,,,
449894,449895,NCT01026974,,2009-12-04,2013-05-13,,2014-09-18,2009-12-04,2009-12-07,Estimate,2014-02-07,2014-03-11,Estimate,,,,2014-09-18,2014-10-01,Estimate,February 2010,,2010-02-28,September 2014,2014-09-30,May 2012,Actual,2012-05-31,September 2010,Actual,2010-09-30,,Interventional,,,"Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine","A Phase 2, Open-Label, Single-Center, Extension Study Evaluating Antibody Persistence Compared to Naïve Children and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received a Three-Dose Series of the Novartis Vaccine as Infants in Study V72P9",Completed,,Phase 2,120.0,Actual,Novartis,,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 00:23:02,2023-06-16 00:23:02,INDUSTRY,,,,,
449965,449966,NCT02768805,,2016-04-01,,,2020-06-08,2016-05-09,2016-05-11,Estimate,,,,,,,2020-06-08,2020-06-11,Actual,"March 2, 2016",,2016-03-02,June 2020,2020-06-30,"November 26, 2016",Actual,2016-11-26,"May 17, 2016",Actual,2016-05-17,,Interventional,,,Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults,"Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Adults 18-64 Years of Age",Completed,,Phase 2,900.0,Actual,Medicago,,3.0,,,False,,,,False,,,,,,,,,,,No,,2023-06-16 00:23:51,2023-06-16 00:23:51,INDUSTRY,,,,,
450520,450521,NCT00586339,,2007-12-21,2012-02-16,,2019-12-30,2007-12-21,2008-01-04,Estimate,2012-02-16,2012-03-22,Estimate,,,,2019-12-30,2020-01-03,Actual,"January 17, 2008",Actual,2008-01-17,December 2019,2019-12-31,"July 18, 2011",Actual,2011-07-18,"July 18, 2011",Actual,2011-07-18,,Interventional,,,Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females,Evaluation of the Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in Adult Human Immunodeficiency Virus (HIV) Infected Female Subjects,Completed,,Phase 2,150.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months",https://clinicalstudydatarequest.com/Posting.aspx?ID=2198,Yes,IPD is available via the Clinical Study Data Request site (click on the link provided below),2023-06-16 00:29:33,2023-06-16 00:29:33,INDUSTRY,,,,,
450971,450972,NCT01931176,,2013-08-26,,,2015-12-14,2013-08-26,2013-08-29,Estimate,,,,,,,2015-12-14,2015-12-15,Estimate,June 2013,,2013-06-30,December 2015,2015-12-31,May 2015,Actual,2015-05-31,December 2014,Actual,2014-12-31,,Interventional,,,Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults,"A Phase 1 Evaluation of the Safety and Immunogenicity of rDEN2<U+0394>30-7169, a Live Attenuated Monovalent Dengue Virus Vaccine",Completed,,Phase 1,14.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-15 00:39:32,2023-06-15 00:39:32,NIH,,,,,
450978,450979,NCT02725437,,2016-01-29,,,2018-07-11,2016-03-28,2016-04-01,Estimate,,,,,,,2018-07-11,2018-07-13,Actual,February 2016,Actual,2016-02-29,July 2018,2018-07-31,February 2017,Actual,2017-02-28,February 2017,Actual,2017-02-28,,Interventional,,,"Clostridium Difficile Vaccine Safety, Tolerability, and Immunogenicity Study in Japanese Adults","A Phase 1, Placebo-controlled, Randomized, Observer-blinded Study To Evaluate The Safety, Tolerability, And Immunogenicity Of Two 3-dose Regimens Of Clostridium Difficile Vaccine Administered In Healthy Japanese Adults Aged 65 To 85 Years.",Completed,,Phase 1,100.0,Actual,Pfizer,,6.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 00:34:55,2023-06-16 00:34:55,INDUSTRY,,,,,
451064,451065,NCT00742885,,2008-08-27,2013-12-20,2009-05-20,2018-07-02,2008-08-27,2008-08-28,Estimate,2014-01-09,2014-02-24,Estimate,2009-05-21,2009-09-30,Estimate,2018-07-02,2018-08-20,Actual,"September 1, 2008",,2008-09-01,October 2016,2016-10-31,"March 7, 2009",Actual,2009-03-07,"March 7, 2009",Actual,2009-03-07,,Interventional,,,Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine,Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine GSK 1557484A.,Completed,,Phase 2,100.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 00:35:57,2023-06-16 00:35:57,INDUSTRY,,,,,
451345,451346,NCT02776761,,2016-05-13,,,2021-02-10,2016-05-17,2016-05-18,Estimate,,,,,,,2021-02-10,2021-02-16,Actual,"August 30, 2016",Actual,2016-08-30,February 2021,2021-02-28,"September 27, 2017",Actual,2017-09-27,"September 27, 2017",Actual,2017-09-27,,Interventional,,,"A Single-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Hantaan Puumala Virus DNA Vaccine","Hantaan Virus Plasmid DNA Vaccine (Expressing Gn and Gc Antigens; E. Coli) [HTNV Vaccine] and Puumala Virus Plasmid DNA Vaccine (Expressing Gn and Gc Antigens; E. Coli; Ajinomoto Bio-Pharma Services) [PUUV Vaccine] Administered Via Stratus Needle-free Injection System (PharmaJet, Inc.)",Completed,,Phase 1,27.0,Actual,U.S. Army Medical Research and Development Command,,3.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 00:39:12,2023-06-16 00:39:12,FED,,,,,
451391,451392,NCT02596243,,2015-11-03,,,2017-07-11,2015-11-03,2015-11-04,Estimate,,,,,,,2017-07-11,2017-07-12,Actual,August 2015,Actual,2015-08-31,July 2017,2017-07-31,August 2018,Anticipated,2018-08-31,March 2018,Anticipated,2018-03-31,,Interventional,,,Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E),"A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 2 Clinical Trial to Evaluate the Efficacy and the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation(EP) in HPV Type 16 and/or 18 Positive Patients With Biopsy-proven Cervical Intraepithelial Neoplasia Grade 2(CIN2), Grade 2/3 (CIN2/3), Grade 3(CIN3)",Unknown status,"Active, not recruiting",Phase 2,134.0,Actual,"Genexine, Inc.",,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 00:39:56,2023-06-16 00:39:56,INDUSTRY,,,,,
451487,451488,NCT00727441,,2008-08-01,2019-05-16,,2020-02-12,2008-08-01,2008-08-04,Estimate,2019-05-16,2019-06-05,Actual,,,,2020-02-12,2020-02-25,Actual,"July 2, 2008",Actual,2008-07-02,February 2020,2020-02-29,February 2019,Actual,2019-02-28,May 2015,Actual,2015-05-31,,Interventional,,,Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery,A Randomized Three-arm Neoadjuvant and Adjuvant Feasibility and Toxicity Study of a GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine Administered Either Alone or in Combination With Either a Single Intravenous Dose or Daily Metronomic Oral Doses of Cyclophosphamide for the Treatment of Patients With Surgically Resected Adenocarcinoma of the Pancreas,Completed,,Phase 2,87.0,Actual,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,3.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-16 00:41:11,2023-06-16 00:41:11,OTHER,,,,,
451659,451660,NCT00721396,,2008-07-22,2015-02-18,,2015-03-17,2008-07-23,2008-07-24,Estimate,2015-03-17,2015-03-23,Estimate,,,,2015-03-17,2015-03-23,Estimate,August 2008,,2008-08-31,March 2015,2015-03-31,July 2010,Actual,2010-07-31,July 2010,Actual,2010-07-31,,Interventional,,,"Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules","A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules.",Completed,,Phase 2,1885.0,Actual,Novartis,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 01:40:52,2023-06-16 01:40:52,INDUSTRY,,,,,
451754,451755,NCT04144179,,2019-10-28,,,2022-04-21,2019-10-28,2019-10-30,Actual,,,,,,,2022-04-21,2022-04-25,Actual,"November 6, 2019",Actual,2019-11-06,April 2022,2022-04-30,"February 24, 2020",Actual,2020-02-24,"February 24, 2020",Actual,2020-02-24,,Interventional,FBP00001,,Recombinant Influenza Vaccine Containing Different H3 Antigens in Healthy Adults 18 to 30 Years of Age,Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age,Completed,,Phase 1,150.0,Actual,Sanofi,,5.0,,,False,,,,False,True,False,,,,,,,,,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2023-06-16 00:44:04,2023-06-16 00:44:04,INDUSTRY,,,,,
451766,451767,NCT00613665,,2008-01-31,,,2013-06-10,2008-02-12,2008-02-13,Estimate,,,,,,,2013-06-10,2013-06-11,Estimate,February 2001,,2001-02-28,June 2013,2013-06-30,April 2002,Actual,2002-04-30,December 2001,Actual,2001-12-31,,Interventional,,,Safety and Immunogenicity of Chiron's Investigational H. Pylori Vaccine in Healthy Adults,"Phase I, Randomized, Controlled, Single-blind, Dose-Ranging and Schedule-Finding Study of the Safety, Tolerability, and Immunogenicity of Chiron Helicobacter Pylori Vaccine in Healthy, Helicobacter Pylori-negative Adults",Completed,,Phase 1,113.0,Actual,Novartis,,7.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 00:44:12,2023-06-16 00:44:12,INDUSTRY,,,,,
452050,452051,NCT04027036,,2019-07-17,,,2021-08-31,2019-07-18,2019-07-19,Actual,,,,,,,2021-08-31,2021-09-05,Actual,"August 6, 2020",Actual,2020-08-06,August 2021,2021-08-31,"December 20, 2021",Anticipated,2021-12-20,"December 20, 2021",Anticipated,2021-12-20,,Interventional,,,Comparison of Immunogenicity of Inactivated Poliovirus Vaccine (IPV) Administered Intramuscularly or Intradermally,Clinical Trial to Compare the Immunogenicity of the Inactivated Poliovirus Vaccine (IPV) Administered in Reduced Doses Intramuscularly or Intradermally in Infants at 2 and 4 Months of Age in the Maputo City,Enrolling by invitation,,Phase 2,360.0,Anticipated,"Instituto Nacional de Saúde, Mozambique",,2.0,,,False,,,,,False,False,,,,,,,,,Yes,,2023-06-16 00:47:31,2023-06-16 00:47:31,OTHER_GOV,,,,,
452260,452261,NCT00398138,,2006-11-09,2015-12-22,,2016-02-02,2006-11-09,2006-11-10,Estimate,2016-02-02,2016-03-02,Estimate,,,,2016-02-02,2016-03-02,Estimate,October 2006,,2006-10-31,February 2016,2016-02-29,June 2009,Actual,2009-06-30,June 2009,Actual,2009-06-30,,Interventional,,,"Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma",Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Thoracic and Myeloid Neoplasms,Completed,,Phase 1,22.0,Actual,Memorial Sloan Kettering Cancer Center,,1.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 19:57:03,2023-06-16 19:57:03,OTHER,,,,,
452441,452442,NCT00223990,,2005-09-13,2018-11-07,,2021-02-10,2005-09-13,2005-09-22,Estimate,2020-05-11,2020-05-21,Actual,,,,2021-02-10,2021-02-12,Actual,"April 8, 2005",Actual,2005-04-08,February 2021,2021-02-28,June 2007,Actual,2007-06-30,"April 26, 2006",Actual,2006-04-26,,Interventional,,,"Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine","A Dbl-blind,Randomized,Controlled,Phase IIb Field Trial in 12-47 Month-old Children in Western Kenya to Eval the Efficacy,Safety and Immunogenicity of the FMP1/AS02A Malaria Vaccine vs Rabies Vaccine",Completed,,Phase 2,400.0,Actual,U.S. Army Medical Research and Development Command,,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 19:59:38,2023-06-16 19:59:38,FED,,,,,
452696,452697,NCT01049282,,2010-01-13,,,2015-04-16,2010-01-13,2010-01-14,Estimate,,,,,,,2015-04-16,2015-04-17,Estimate,December 2008,,2008-12-31,April 2015,2015-04-30,April 2010,Actual,2010-04-30,April 2010,Actual,2010-04-30,,Interventional,THYB-03,,A Safety and Immunogenicity Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31),A Safety and Immunogenicity Phase 1 Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31) Administered in Different Antigen/Adjuvant Formulations in TST Negative and TST Positive Volunteers at 0 and 2 Months,Completed,,Phase 1,39.0,Actual,Statens Serum Institut,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 20:03:56,2023-06-16 20:03:56,OTHER,,,,,
452731,452732,NCT00370682,,2006-08-30,2017-03-08,2015-06-08,2017-05-23,2006-08-30,2006-09-01,Estimate,2017-05-23,2017-05-30,Actual,2015-06-08,2015-07-07,Estimate,2017-05-23,2017-05-30,Actual,April 2007,,2007-04-30,May 2017,2017-05-31,February 2008,Actual,2008-02-29,February 2008,Actual,2008-02-29,,Interventional,,,A Phase II Trial of a Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy Adults in Thailand,"Phase II, Randomized, Double-blind, Single Center, Controlled Study of Two Doses of Different Formulations of the WRAIR Live Attenuated Tetravalent Dengue Vaccine Compared to a Placebo Control, Administered on a 0-6 Month Schedule, to Healthy Adults",Completed,,Phase 2,120.0,Actual,U.S. Army Medical Research and Development Command,,3.0,,,False,,,,False,True,False,,,,,,,,,Yes,GSK,2023-06-16 20:04:19,2023-06-16 20:04:19,FED,,,,,
452762,452763,NCT00798304,,2008-11-25,2014-11-21,,2014-11-21,2008-11-25,2008-11-26,Estimate,2014-11-21,2014-11-26,Estimate,,,,2014-11-21,2014-11-26,Estimate,January 2009,,2009-01-31,November 2014,2014-11-30,September 2009,Actual,2009-09-30,June 2009,Actual,2009-06-30,,Interventional,,,"Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants","An Open Label, Randomized, Phase 1/2 Trial Of The Safety, Tolerability, And Immunogenicity Of Meningococcal Group B Rlp2086 Vaccine In Healthy Infants",Terminated,,Phase 2,46.0,Actual,Pfizer,,3.0,,"Following program review within Pfizer, decision was made not to go ahead with this study. This study is cancelled",False,,,,True,,,,,,,,,,,,,2023-06-16 00:49:00,2023-06-16 00:49:00,INDUSTRY,,,,,
452784,452785,NCT00239577,,2005-10-13,2017-09-21,,2019-02-18,2005-10-14,2005-10-17,Estimate,2019-02-18,2019-02-19,Actual,,,,2019-02-18,2019-02-19,Actual,"April 5, 2006",Actual,2006-04-05,February 2019,2019-02-28,"June 19, 2007",Actual,2007-06-19,"June 19, 2007",Actual,2007-06-19,,Interventional,,,A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults,"Observer-blind, Single Center, Controlled Study of 2 Doses of Various Formulations of the WRAIR Live Attenuated Tetravalent Dengue Vaccine Compared to a Placebo Control, Administered on a 0-6-month Schedule, to Healthy Adults",Completed,,Phase 2,86.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 20:04:49,2023-06-16 20:04:49,INDUSTRY,,,,,
452786,452787,NCT00262041,,2005-12-02,2013-09-09,,2018-05-17,2005-12-02,2005-12-06,Estimate,2013-09-09,2013-11-20,Estimate,,,,2018-05-17,2018-06-28,Actual,October 2004,,2004-10-31,May 2018,2018-05-31,March 2006,,2006-03-31,March 2006,Actual,2006-03-31,,Interventional,,,Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents,"A Phase 2, Randomized, Single-blind, Controlled, Multicenter Study to Compare the Safety and Immune Response of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With the Safety and Immune Response of One Dose of Licensed Meningococcal ACWY Polysaccharide Vaccine Administered to Healthy Adolescents 11 to 17 Years of Age",Completed,,Phase 2,524.0,Actual,Novartis,,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 20:04:50,2023-06-16 20:04:50,INDUSTRY,,,,,
452829,452830,NCT00365378,,2006-08-16,2010-03-22,,2015-10-22,2006-08-16,2006-08-17,Estimate,2010-03-22,2010-04-09,Estimate,,,,2015-10-22,2015-10-23,Estimate,September 1999,,1999-09-30,October 2015,2015-10-31,July 2009,Actual,2009-07-31,March 2004,Actual,2004-03-31,,Interventional,,,Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005),Study of Pilot Manufacturing Lot of HPV 16 Virus-Like Particle (VLP) Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females,Completed,,Phase 2,2409.0,Actual,Merck Sharp & Dohme LLC,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 20:05:28,2023-06-16 20:05:28,INDUSTRY,,,,,
452844,452845,NCT01048190,,2010-01-12,,,2010-01-13,2010-01-12,2010-01-13,Estimate,,,,,,,2010-01-13,2010-01-14,Estimate,August 2008,,2008-08-31,August 2008,2008-08-31,March 2009,Actual,2009-03-31,March 2009,Actual,2009-03-31,,Interventional,IPV,,The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains,The Phase I Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains,Completed,,Phase 1,130.0,Actual,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 20:05:41,2023-06-16 20:05:41,OTHER,,,,,
452912,452913,NCT03966040,,2019-05-25,,,2021-03-28,2019-05-25,2019-05-29,Actual,,,,,,,2021-03-28,2021-03-30,Actual,"May 16, 2019",Actual,2019-05-16,May 2019,2019-05-31,"May 16, 2020",Actual,2020-05-16,"December 16, 2019",Actual,2019-12-16,,Interventional,,,A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults,"A Single-center, Open-label, Phase Ib Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) With Different Dose in Healthy Adults Aged 18-70 Years in China",Completed,,Phase 1,144.0,Actual,Jiangsu Province Centers for Disease Control and Prevention,,4.0,,,False,,,,False,False,False,,,,,,within 6 months of study completion,Data access requests will be reviewed by the sponsor and requestors will be required to sign a Date Access Agreement.,,Yes,Deidentified individual participant data for all primary and secondary outcomes will be made available within 6 months of study completion.,2023-06-16 20:06:22,2023-06-16 20:06:22,NETWORK,,,,,
453234,453235,NCT02704533,,2016-03-01,,,2019-01-31,2016-03-04,2016-03-10,Estimate,,,,,,,2019-01-31,2019-02-01,Actual,"August 29, 2016",Actual,2016-08-29,January 2019,2019-01-31,December 2018,Actual,2018-12-31,"October 19, 2018",Actual,2018-10-19,,Interventional,,,Sequential Optimization of Dose and Schedule of PfSPZ Vaccine,"Sequential Optimization of Dose and Schedule of PfSPZ Vaccine, Verified by Randomized, Controlled, Double-blind Immunization and Controlled Human Malaria Infection in Malaria-naïve, Healthy Adult Volunteers in Germany",Completed,,Phase 1,45.0,Actual,Sanaria Inc.,,13.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 00:51:15,2023-06-16 00:51:15,INDUSTRY,,,,,
453389,453390,NCT00323622,,2005-09-08,2013-03-29,,2016-10-27,2006-05-08,2006-05-09,Estimate,2014-02-27,2014-03-27,Estimate,,,,2016-10-27,2016-12-09,Estimate,April 2005,,2005-04-30,October 2016,2016-10-31,May 2007,Actual,2007-05-31,May 2007,Actual,2007-05-31,,Interventional,,,Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine,"An Open Study for a 2-year Period to Confirm the Safety and Immunogenicity of the Candidate Malaria Vaccine RTS,S/AS02A in Mozambican Children Aged 1 to 4 Years at the Time of First Vaccine Dose.",Completed,,Phase 2,1737.0,Actual,GlaxoSmithKline,,8.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 20:11:34,2023-06-16 20:11:34,INDUSTRY,,,,,
453505,453506,NCT00254397,,2005-11-14,2015-10-14,,2019-09-27,2005-11-14,2005-11-16,Estimate,2019-09-27,2019-10-16,Actual,,,,2019-09-27,2019-10-16,Actual,November 2005,,2005-11-30,September 2019,2019-09-30,October 2012,Actual,2012-10-31,October 2012,Actual,2012-10-31,,Interventional,,,Melanoma Vaccine With Peptides and Leuprolide,Study of the Modulatory Activity of an LHRH-Agonist (Leuprolide) on Melanoma Peptide Vaccines as Adjuvant Therapy in Melanoma Patients,Completed,,Phase 2,98.0,Actual,M.D. Anderson Cancer Center,,4.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 20:12:46,2023-06-16 20:12:46,OTHER,,,,,
453508,453509,NCT03869333,,2019-03-04,2021-07-07,,2021-07-07,2019-03-06,2019-03-11,Actual,2021-07-07,2021-07-29,Actual,,,,2021-07-07,2021-07-29,Actual,"March 18, 2019",Actual,2019-03-18,May 2020,2020-05-31,"June 12, 2020",Actual,2020-06-12,"June 12, 2020",Actual,2020-06-12,,Interventional,,All enrolled and randomized participants,Dose Escalating Study of Intramuscular Invaplex[AR-DETOX],"A Phase 1 Double-blind, Placebo-controlled, Dose Escalating Study of Intramuscular Detoxified Shigella Flexneri 2a Artificial Invasin Complex (Invaplex[AR-DETOX]) Vaccine",Completed,,Phase 1,58.0,Actual,PATH,,4.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-16 20:12:49,2023-06-16 20:12:49,OTHER,,,,,
453973,453974,NCT01013675,,2009-11-13,,,2011-10-26,2009-11-13,2009-11-16,Estimate,,,,,,,2011-10-26,2011-10-27,Estimate,November 2009,,2009-11-30,October 2011,2011-10-31,April 2011,Actual,2011-04-30,April 2011,Actual,2011-04-30,,Interventional,,,Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly,"Randomized, Double-blind, Active -Controlled Trial to Assess Safety and Immunogenicity of Solvay's Cell-derived Influenza Vaccine, Including Revaccination, in Elderly Subjects",Completed,,Phase 2,622.0,Actual,Abbott,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 20:18:45,2023-06-16 20:18:45,INDUSTRY,,,,,
454016,454017,NCT00490529,,2007-06-20,2019-11-13,,2020-01-08,2007-06-20,2007-06-22,Estimate,2020-01-08,2020-01-13,Actual,,,,2020-01-08,2020-01-13,Actual,August 2009,,2009-08-31,January 2020,2020-01-31,"December 14, 2017",Actual,2017-12-14,"December 14, 2017",Actual,2017-12-14,,Interventional,,Includes all participants that started study procedures. Prospective participants that consented but did not receive any research procedures are not included.,Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL,"Phase 1-2 Study of a CpG-Activated Whole Cell Vaccine Followed by Autologous ""Immunotransplant"" for Mantle Cell Lymphoma",Completed,,Phase 2,59.0,Actual,Stanford University,,1.0,,,False,,,,True,True,False,,,,,,,,,No,,2023-06-16 20:19:19,2023-06-16 20:19:19,OTHER,,,,,
454082,454083,NCT00360230,,2006-07-31,2017-08-04,2009-09-03,2017-08-10,2006-08-03,2006-08-04,Estimate,2017-08-10,2018-02-19,Actual,2009-09-03,2009-09-04,Estimate,2017-08-10,2018-02-19,Actual,"August 30, 2006",Actual,2006-08-30,August 2017,2017-08-31,"May 30, 2008",Actual,2008-05-30,"August 25, 2007",Actual,2007-08-25,,Interventional,,,Partially-blind (Observer-blind) Study of Safety and Immunogenicity of Two Malaria Vaccines in Ghanaian Children,A Partially-blind (Observer-blind) Study to Evaluate the Safety and Immunogenicity of 3 Different Vaccination Schedules With 2 GSK Biologicals' Candidate Plasmodium Falciparum Vaccines in Children Aged 5 to 17 Months Living in Ghana,Completed,,Phase 2,540.0,Actual,GlaxoSmithKline,,7.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 20:20:29,2023-06-16 20:20:29,INDUSTRY,,,,,
454107,454108,NCT01055990,,2010-01-25,,,2010-01-25,2010-01-25,2010-01-26,Estimate,,,,,,,2010-01-25,2010-01-26,Estimate,October 2009,,2009-10-31,November 2009,2009-11-30,May 2010,Anticipated,2010-05-31,April 2010,Anticipated,2010-04-30,,Interventional,,,Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients,"Phase1 An Observational Clinical Trial With an Influenza A (H1N1) 2009 Monovalent,Split-virion Vaccine in Healthy Adults, Aged 18-60 Years Phase2 Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients",Unknown status,"Active, not recruiting",Phase 2,7.0,Anticipated,Shanghai Public Health Clinical Center,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 20:20:59,2023-06-16 20:20:59,OTHER_GOV,,,,,
454151,454152,NCT00775450,,2008-10-16,2011-07-14,2010-03-31,2013-12-05,2008-10-16,2008-10-20,Estimate,2011-07-14,2011-08-11,Estimate,2010-03-31,2010-04-02,Estimate,2013-12-05,2013-12-31,Estimate,October 2008,,2008-10-31,December 2013,2013-12-31,July 2009,Actual,2009-07-31,June 2009,Actual,2009-06-30,,Interventional,,,Influenza Vaccine Revaccination in Ambulatory Elderly Subjects,"Safety and Immunogenicity of Revaccination With Influenza Vaccine in Ambulatory Elderly Subjects Previously Vaccinated With Fluzone ID, Fluzone HD, and Fluzone® IM",Completed,,Phase 2,807.0,Actual,Sanofi,,5.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 00:53:05,2023-06-16 00:53:05,INDUSTRY,,,,,
454215,454216,NCT00316602,,2006-04-20,2018-11-27,,2018-12-19,2006-04-20,2006-04-21,Estimate,2018-12-19,2019-01-09,Actual,,,,2018-12-19,2019-01-09,Actual,July 2006,,2006-07-31,December 2018,2018-12-31,April 2010,Actual,2010-04-30,November 2009,Actual,2009-11-30,,Interventional,,Safety Analysis Set,A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE) Smallpox Vaccine in Subjects With Atopic Dermatitis,"A Multicenter, Open-label, Controlled Phase II Study to Evaluate Immunogenicity and Safety of MVA-BN® (IMVAMUNE) Smallpox Vaccine in 18-40 Year Old Subjects With Diagnosed Atopic Dermatitis",Completed,,Phase 2,632.0,Actual,Bavarian Nordic,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 20:22:10,2023-06-16 20:22:10,INDUSTRY,,,,,
454234,454235,NCT04552366,,2020-09-15,,,2023-05-22,2020-09-16,2020-09-17,Actual,,,,,,,2023-05-22,2023-05-24,Actual,"September 29, 2020",Actual,2020-09-29,May 2023,2023-05-31,"April 30, 2021",Actual,2021-04-30,"December 31, 2020",Actual,2020-12-31,,Interventional,,,A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults,A Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults Aged 18 Years and Older,Completed,,Phase 1,149.0,Actual,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",,6.0,,,False,,,,True,False,False,,,,,,,,,No,,2023-06-19 03:59:13,2023-06-19 03:59:13,OTHER,,,,,
454339,454340,NCT00157209,,2005-09-08,2015-07-23,,2015-10-19,2005-09-09,2005-09-12,Estimate,2015-10-19,2015-11-18,Estimate,,,,2015-10-19,2015-11-18,Estimate,August 2000,,2000-08-31,October 2015,2015-10-31,July 2012,Actual,2012-07-31,March 2006,Actual,2006-03-31,,Interventional,,Baseline analysis population included all randomized participants.,Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer),"A Multicenter Phase IIb Randomised, Controlled Study of BLP25 Liposome Vaccine for Active Specific Immunotherapy of Non-Small Cell Lung Cancer",Completed,,Phase 2,171.0,Actual,"Merck KGaA, Darmstadt, Germany",,2.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 20:23:56,2023-06-16 20:23:56,INDUSTRY,,,,,
454413,454414,NCT01060748,,2010-01-28,,,2011-03-04,2010-02-01,2010-02-02,Estimate,,,,,,,2011-03-04,2011-03-07,Estimate,March 2010,,2010-03-31,March 2011,2011-03-31,October 2010,Actual,2010-10-31,October 2010,Actual,2010-10-31,,Interventional,,,Safety and Efficacy Study of a Vaccine Against Enterotoxigenic Escherichia Coli (ETEC) to Prevent Moderate to Severe Diarrhea,"Development of a Polyvalent Vaccine Against Enterotoxigenic Escherichia Coli (ETEC)Protective Efficacy of the Deletion-Attenuated, Multi-valent ACE527 Against Challenge With a Prototype Strain of Enterotoxigenic E.Coli Expressing LT and ST Enterotoxins and CFA/I (Strain H10407) in Human Challenge Model.",Completed,,Phase 2,70.0,Actual,TD Vaccines A/S,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 20:25:24,2023-06-16 20:25:24,INDUSTRY,,,,,
454649,454650,NCT00319592,,2006-04-28,2012-07-11,,2012-08-16,2006-04-28,2006-04-27,Estimate,2012-07-11,2012-08-16,Estimate,,,,2012-08-16,2012-08-20,Estimate,May 2005,,2005-05-31,August 2012,2012-08-31,September 2006,Actual,2006-09-30,September 2006,Actual,2006-09-30,,Interventional,,,A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX,"Randomized, Double-blind, Phase II Study of the Safety, Tolerability and Immunogenicity Following Administration of Live Attenuated JE Vaccine (ChimeriVax JE) Compared With Mouse Brain-derived Inactivated JE Vaccine (JE VAX®).",Completed,,Phase 2,60.0,Actual,Sanofi,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 20:28:53,2023-06-16 20:28:53,INDUSTRY,,,,,
454805,454806,NCT01934127,,2013-08-01,,,2017-05-04,2013-08-29,2013-09-04,Estimate,,,,,,,2017-05-04,2017-05-08,Actual,"August 26, 2013",Actual,2013-08-26,May 2017,2017-05-31,"October 20, 2014",Actual,2014-10-20,"November 1, 2013",Actual,2013-11-01,,Interventional,,,Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age,An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK2789869A and GSK2789868A Administered in Adults 21 to 64 Years of Age,Completed,,Phase 1,427.0,Actual,GlaxoSmithKline,,6.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-15 00:41:39,2023-06-15 00:41:39,INDUSTRY,,,,,
454953,454954,NCT01021397,,2009-11-25,,,2012-12-31,2009-11-25,2009-11-30,Estimate,,,,,,,2012-12-31,2013-01-03,Estimate,November 2009,,2009-11-30,December 2012,2012-12-31,December 2011,Actual,2011-12-31,December 2011,Actual,2011-12-31,,Interventional,,,Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children,"Phase I Study to Determine the Safety, Infectivity, and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-Passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval",Completed,,Phase 1,12.0,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 20:33:33,2023-06-16 20:33:33,NIH,,,,,
455044,455045,NCT01022255,,2009-11-30,,,2014-01-29,2009-11-30,2009-12-01,Estimate,,,,,,,2014-01-29,2014-01-30,Estimate,January 2010,,2010-01-31,January 2014,2014-01-31,October 2013,Actual,2013-10-31,October 2013,Actual,2013-10-31,,Interventional,,,Autologous Vaccine for Follicular Lymphoma,Phase I Study of an Autologous Recombinant Idiotypic Vaccine Manufactured by magnICON® Technology for the Treatment of Patients With Relapsed or Transformed Follicular Lymphoma,Completed,,Phase 1,28.0,Actual,Icon Genetics GmbH,,1.0,,,False,,,,False,,,,,,,,,,,,,2023-06-16 20:34:37,2023-06-16 20:34:37,INDUSTRY,,,,,
455045,455046,NCT00264576,,2005-12-09,2012-12-20,,2017-02-21,2005-12-09,2005-12-13,Estimate,2012-12-20,2013-01-28,Estimate,,,,2017-02-21,2017-03-24,Actual,October 2005,,2005-10-31,December 2012,2012-12-31,May 2006,Actual,2006-05-31,December 2005,Actual,2005-12-31,,Interventional,,,Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults,"A Phase 2, Observer-Blinded, Randomized, Multicenter Study in Healthy Adults to Evaluate Safety and Tolerability and to Compare Immunogenicity of a Single Dose of Either an Investigational Trivalent Inactivated Influenza Vaccine Produced in Mammalian Cell Culture or a US-licensed Trivalent Inactivated Influenza Vaccine (Fluvirin®) Produced in Embryonated Hen Eggs",Completed,,Phase 2,613.0,Actual,Novartis,,2.0,,,,,,,False,,,,,,,,,,,,,2023-06-16 20:34:38,2023-06-16 20:34:38,INDUSTRY,,,,,
455054,455055,NCT01072734,,2010-02-19,,,2010-10-11,2010-02-19,2010-02-22,Estimate,,,,,,,2010-10-11,2010-10-13,Estimate,September 2009,,2009-09-30,October 2010,2010-10-31,February 2010,Actual,2010-02-28,January 2010,Actual,2010-01-31,,Interventional,GRIPLUP,,Auto-immunity in Lupus Patients After Influenza Vaccine,Role of CXCR4/CXCL12 Axis on the Control of Humoral Immunity and Auto-immunity in Lupus Patients After Influenza Vaccine Challenge,Completed,,Phase 2,28.0,Actual,Assistance Publique - Hôpitaux de Paris,,1.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 20:34:47,2023-06-16 20:34:47,OTHER,,,,,
455138,455139,NCT01086436,,2010-03-11,,,2017-05-18,2010-03-11,2010-03-15,Estimate,,,,,,,2017-05-18,2017-05-19,Actual,"March 13, 2010",Actual,2010-03-13,May 2017,2017-05-31,"April 16, 2010",Actual,2010-04-16,"April 16, 2010",Actual,2010-04-16,,Interventional,,,Study to Evaluate the Safety of Rotarix in Chinese Children,Reactogenicity and Safety of a Single Dose of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563) in Healthy Children,Completed,,Phase 1,50.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 20:36:01,2023-06-16 20:36:01,INDUSTRY,,,,,
455154,455155,NCT00461981,,2007-04-16,2009-05-29,,2021-09-10,2007-04-17,2007-04-18,Estimate,2010-01-12,2010-02-02,Estimate,,,,2021-09-10,2021-10-06,Actual,May 2007,,2007-05-31,January 2010,2010-01-31,February 2008,Actual,2008-02-29,December 2007,Actual,2007-12-31,,Interventional,,,A Phase 2 Study to Evaluate Immune Responses of FluMist®,"A Phase 2, Prospective, Randomized, Open-Label Study to Evaluate the Immune Responses of FluMist® Compared With Trivalent Inactivated Vaccine (TIV) in Children 12 to <36 Months of Age",Completed,,Phase 2,101.0,Actual,MedImmune LLC,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 20:36:29,2023-06-16 20:36:29,INDUSTRY,,,,,
455193,455194,NCT01069640,,2010-02-16,,,2019-03-15,2010-02-16,2010-02-17,Estimate,,,,,,,2019-03-15,2019-03-19,Actual,February 2010,,2010-02-28,March 2019,2019-03-31,March 2019,Actual,2019-03-31,March 2019,Actual,2019-03-31,,Interventional,,,Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer,Phase I Study of Cancer Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*02 (URLC10) in Patients With Non-small Cell Lung Cancer Refractory to Standard Therapy,Completed,,Phase 1,9.0,Anticipated,Shiga University,,3.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 20:36:52,2023-06-16 20:36:52,OTHER,,,,,
455436,455437,NCT00310856,,2006-04-03,2013-08-29,,2018-09-10,2006-04-03,2006-04-05,Estimate,2013-08-29,2013-11-01,Estimate,,,,2018-09-10,2018-10-09,Actual,June 2005,,2005-06-30,September 2018,2018-09-30,November 2006,Actual,2006-11-30,November 2006,Actual,2006-11-30,,Interventional,,Analysis was done for all enrolled subjects.,Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months),"A Phase 2, Partially Randomized, Open Label, Multicenter Study to Evaluate the Safety and Immunogenicity After One or Two Doses of Novartis (Formerly Chiron) Meningococcal ACWY Conjugate Vaccine Administered to Healthy Infants and Young Children",Completed,,Phase 2,175.0,Actual,Novartis,,3.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 20:39:44,2023-06-16 20:39:44,INDUSTRY,,,,,
455544,455545,NCT00262002,,2005-12-02,2013-09-02,,2014-06-16,2005-12-02,2005-12-06,Estimate,2014-06-16,2014-06-18,Estimate,,,,2014-06-16,2014-06-18,Estimate,September 2004,,2004-09-30,June 2014,2014-06-30,October 2006,Actual,2006-10-31,July 2005,Actual,2005-07-31,,Interventional,,,Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants,"A Phase II, Randomized, Open Label, Controlled, Multicenter Study to Evaluate the Safety, Immunogenicity and Induction of Immunological Memory After Two or Three Doses of Novartis (Formerly Chiron) Meningococcal ACWY Conjugate Vaccine Administered to Healthy Infants at 2, 3, 4 or 2, 4, 6 Months of Age",Completed,,Phase 2,601.0,Actual,Novartis,,7.0,,,False,,,,,,,,,,,,,,,,,2023-06-16 20:41:33,2023-06-16 20:41:33,INDUSTRY,,,,,
455674,455675,NCT03956524,,2019-05-15,,,2019-12-06,2019-05-16,2019-05-20,Actual,,,,,,,2019-12-06,2019-12-09,Actual,"March 16, 2019",Actual,2019-03-16,December 2019,2019-12-31,"August 31, 2019",Actual,2019-08-31,"August 31, 2019",Actual,2019-08-31,,Interventional,,,Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults,"An Open-label, Comparative, Clinical Phase 1 Study to Assess the Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults",Completed,,Phase 1,75.0,Actual,"EuBiologics Co.,Ltd",,3.0,,,False,,,,,False,False,,,,,,,,,No,,2023-06-16 20:43:03,2023-06-16 20:43:03,INDUSTRY,,,,,
455774,455775,NCT00129129,,2005-08-10,2012-06-15,,2018-07-26,2005-08-10,2005-08-11,Estimate,2013-12-05,2013-12-30,Estimate,,,,2018-07-26,2018-08-24,Actual,"August 1, 2004",,2004-08-01,September 2016,2016-09-30,"March 29, 2006",Actual,2006-03-29,"September 15, 2005",Actual,2005-09-15,,Interventional,,,Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine,"Evaluate Immuno and Safety of GSKBiologicals' HibMenCYTT vs Licensed Hib Conjugate Vaccine, Each Coadministered With Pediarix® and Prevnar®, in Healthy Infants. An Exploratory Control Group Will Receive Licensed Menomune® at 3 to 5 Years",Completed,,Phase 2,756.0,Actual,GlaxoSmithKline,,5.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 20:43:51,2023-06-16 20:43:51,INDUSTRY,,,,,
455808,455809,NCT01935154,,2013-08-26,,,2019-06-18,2013-08-29,2013-09-04,Estimate,,,,,,,2019-06-18,2019-06-19,Actual,August 2012,,2012-08-31,June 2019,2019-06-30,January 2017,Actual,2017-01-31,January 2017,Actual,2017-01-31,,Interventional,,,Efficacy Study of Vx001 Vaccine in NSCLC Patients,Phase II Study of Vx001 Vaccine in HLA-A*0201 Positive Patients With TERT Positive Stage IV or Recurrent Stage I-III NSCLC,Completed,,Phase 2,221.0,Actual,Vaxon Biotech,,2.0,,,False,,,,False,,,,,,,,,,,,,2023-06-15 00:42:27,2023-06-15 00:42:27,INDUSTRY,,,,,
455841,455842,NCT00741637,,2008-08-25,,,2012-03-29,2008-08-25,2008-08-26,Estimate,,,,,,,2012-03-29,2012-03-30,Estimate,July 2010,,2010-07-31,March 2012,2012-03-31,June 2011,Actual,2011-06-30,April 2011,Actual,2011-04-30,,Interventional,,,Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults,"A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Single Dose Regimen of Live Attenuated Oral Cholera Vaccine (Choleragarde®) in HIV-Seropositive Adults in Thailand",Completed,,Phase 2,32.0,Actual,International Vaccine Institute,,2.0,,,False,,,,True,,,,,,,,,,,,,2023-06-16 01:37:57,2023-06-16 01:37:57,OTHER,,,,,
455864,455865,NCT00263666,,2005-12-08,2009-02-13,,2020-11-04,2005-12-08,2005-12-09,Estimate,2009-03-12,2009-03-13,Estimate,,,,2020-11-04,2020-11-23,Actual,"March 16, 2005",Actual,2005-03-16,October 2020,2020-10-31,"February 13, 2008",Actual,2008-02-13,"February 7, 2008",Actual,2008-02-07,,Interventional,,,"A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa","A Phase II, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Reactogenicity and Immunogenicity of Three Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine",Completed,,Phase 2,100.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2023-06-16 20:44:59,2023-06-16 20:44:59,INDUSTRY,,,,,
